<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>148832</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nimhe.csip.org.uk/our-work/10-high-impact-changes-for-mental-health-services.html]]&gt;</url>
    <title>10 High Impact Changes for Mental Heath Services</title>
    <publicationDate>2006-06-20T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The high impact changes are the 10 areas of service improvement in mental health that have the greatest positive impact on service user and carer experience, service delivery, outcomes, staff and organisations.  They can be used to guide any service improvement activity through 2006 and beyond.</description>
    <body>&lt;![CDATA[ NIMHE launched the 10 High Impact Changes for Mental Health Services on 20 June 2006, underpinned by a complete publication (and executive summary) with case study evidence for the changes. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;This follows the launch of the NHS Modernisation Agency’s 10 High Impact Changes for Service Improvement and Delivery in 2004.&lt;/P&gt;
&lt;P&gt;The high impact changes are the 10 areas of service improvement in mental health that have the greatest positive impact on service user and carer experience, service delivery, outcomes, staff&amp;nbsp;and organisations.&amp;nbsp; They can be used to guide any service improvement activity through 2006 and beyond.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The 10 High Impact Changes for Mental Health Services are:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Treat home based care and support as the norm for the delivery of mental health&amp;nbsp;services. 
&lt;LI&gt;Improve flow of service users and carers across health and social care by improving access to screening and assessment. 
&lt;LI&gt;Manage variation in service user discharge processes. 
&lt;LI&gt;Manage variation in access to all mental health services. 
&lt;LI&gt;Avoid unnecessary contact for service users and provide necessary contact in the right setting.&amp;nbsp; 
&lt;LI&gt;Increase the reliability of interventions by designing care around what is known to work and that service users and carers inform and influence. 
&lt;LI&gt;&amp;nbsp;Apply a systematic approach to enable the recovery of people with long term conditions. 
&lt;LI&gt;Improve service user flow by removing queues.&amp;nbsp; 
&lt;LI&gt;Optimise service user and carer flow through the service using an integrated care pathway approach.&amp;nbsp; 
&lt;LI&gt;Redesign and extend roles in line with efficient service user and carer pathways to attract and retain an effective workforce.&lt;/LI&gt;&lt;/OL&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>317689</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealthshop.org/document.rm?id=8914]]&gt;</url>
    <title>100 ways to support recovery PDF</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>Rethink</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the first in a series of Rethink reports on mental health recovery. It identifies 100 ways in which people working across the mental health sector can support the recovery of people with mental health problems. It highlights four key tasks:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Developing a positive identity&lt;/LI&gt;
&lt;LI&gt;Framing the ‘mental illness’&lt;/LI&gt;
&lt;LI&gt;Self managing the mental illness&lt;/LI&gt;
&lt;LI&gt;Developing valued social roles&lt;/LI&gt;&lt;/OL&gt;The author Dr Mike Slade says: “&lt;EM&gt;Recovery is an idea which has developed out of the experience of people living with, and beyond, mental illness. The mental health system already helps many people to live meaningful and purposeful lives, but we can do better.&lt;/EM&gt;”]]&gt;</body>
  </document>
  <document>
    <id>326594</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/usingcareservices/healthcare/patientsurveys/mentalhealthservices.cfm]]&gt;</url>
    <title>2009 survey of mental health acute inpatient services</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>Care Quality Commission</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Care Quality Commission's 2009 survey of people who had recently had an inpatient stay for acute mental health problems was the first of its kind and collected responses from over 7,500 people. The survey asked people all about their experiences of acute inpatient mental health services along the pathway from admission to leaving hospital, including the care and treatment they received, day-to-day activities, and relationships with staff.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;Key Findings&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Most patients’ admissions began well, with 85% reporting that staff made them feel welcome on the ward.&lt;/LI&gt;
&lt;LI&gt;8% of respondents said that they had shared a sleeping area such as a room or bay with patients of the opposite sex during their most recent stay, with 92% reporting that this never happened. &lt;/LI&gt;
&lt;LI&gt;86% reported having physical health checks in hospital – but only 44% of those with physical health problems ‘definitely’ felt that enough care was taken of theses. &amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;The survey showed limited access to talking therapies, with 29% receiving these overall and less than half of those who wanted talking therapies getting them. &lt;/LI&gt;
&lt;LI&gt;Less than half (45%) said that they “always” felt safe in hospital. &amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;There was a lack of activities available for inpatients, with 35% saying that there was too little to do on weekdays and over half (54%) reporting that there were not enough activities available to them at weekends or evenings.&lt;/LI&gt;
&lt;LI&gt;Patients were often not involved in their care as much as they wanted to be, with 34% saying that they were “definitely” involved as much as they wanted to be in decisions about their care and treatment. &amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Many patients felt that they were not given understandable explanations about their care and treatment,– 48% said that the potential side effects of medicines that they were prescribed whilst in hospital were not explained to them in a way they could understand &lt;/LI&gt;
&lt;LI&gt;Only 28% said that staff on the wards “definitely” knew enough about their previous care and treatment, and 29% said they were not given information on how they could get help in a crisis after they were discharged. &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>381167</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_117488]]&gt;</url>
    <title>2009/10 National Survey of Investment in Adult Mental Health Services</title>
    <publicationDate>2010-07-16T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,FINANCE AND ACCOUNTING,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the ninth annual report presenting the results of the finance mapping exercise.&amp;nbsp; It provides details of the level of investment in mental health services for working age adults (aged 18-64) in England for 2009/10 and compares it with the reported results in previous years&lt;/P&gt;
&lt;P&gt;The data was less detailed in the first year of collection 2001/02 and some services were defined or grouped differently. This does not affect the highest level analysis e.g. total investment in year, but it could and does impact more detailed comparative analysis with later years.&amp;nbsp; Consequently, comparisons at service group level commence from 2002/03.&lt;/P&gt;
&lt;P&gt;Previous years investment have been adjusted by the GDP Deflator Figures for 31 March 2010 published by HM Treasury to reflect past investment at today’s prices.&lt;/P&gt;
&lt;H4&gt;The adult mental health analysis provides the following overall key findings:&lt;/H4&gt;
&lt;UL&gt;
&lt;LI&gt;Total investment increased from £5.892 billion in 2008/09 to £6.311 billion which is a 7.1 percent cash increase and a real increase of 5.3 percent&lt;/LI&gt;
&lt;LI&gt;Since 2001/02, the real term total investment, after allowing for inflation, has increased by £2.315 billion from £3.996 billion to £6.311 billion in 2009/10; this represents an increase of 58 percent in real terms after allowing for inflation (see Figure Four).&lt;/LI&gt;
&lt;LI&gt;The reported investment in the three priority areas (Crisis Resolution, Early Intervention and Assertive Outreach) has risen by 5 percent between 2008/09 and 2009/10, once we have added estimates of the unreported data from part of the West Midlands.&lt;/LI&gt;
&lt;LI&gt;Total investment in adult mental health services in 2009/10 (reported investment plus estimated unreported investment) was £6.311 billion or £193 per head of weighted working age population.&lt;/LI&gt;&lt;/UL&gt;
&lt;H4&gt;The analysis revealed the following about the investment between SHAs&lt;/H4&gt;
&lt;UL&gt;
&lt;LI&gt;All 10 SHAs reported real increases in investment after inflation. Six SHAs reported increases over 5 percent, whilst two SHAs&amp;nbsp;- North East and South Central reported real term increases of less than 1 percent.&lt;/LI&gt;
&lt;LI&gt;London reported a rise of 6.3 percent in real level of investment and maintained its position of the highest weighted investment per head spending SHA.&amp;nbsp; Weighted investment in adult mental health services in London was £211 per head compared to the national average of £193 per head.&lt;/LI&gt;
&lt;LI&gt;The amount invested per weighted head varies among SHAs by between 8.9 percent above, and 9.8 percent below the national average (£193)&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>385090</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.homeoffice.gov.uk/publications/consultations/cons-drug-strategy-2010/drugs-consultation?view=Binary]]&gt;</url>
    <title>2010 Drug Strategy Consultation Paper</title>
    <publicationDate>2010-08-20T00:00:00</publicationDate>
    <publisher>Home Office</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The government plans to publish a new drug strategy later this year. This targeted consultation provides an early opportunity for a wide range of partners to contribute to the development of the new strategy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Questions are asked around four key themes led by the following government departments:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Department for Education: preventing drug use&lt;/LI&gt;
&lt;LI&gt;Home Office and Ministry of Justice: strengthening enforcement, criminal justice and legal framework&lt;/LI&gt;
&lt;LI&gt;Department of Health: rebalancing treatment to support drug-free outcomes&lt;/LI&gt;
&lt;LI&gt;Department for Work and Pensions: supporting recovery to break the cycle of drug addiction&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Consultation information&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Intended audience: This consultation is aimed at a wide audience, from charities to enforcement partners, drug workers, voluntary and community sector organisations. Responses from members of the public are also welcome.&lt;/LI&gt;
&lt;LI&gt;Reference number: 2010 Drug strategy consultation paper&lt;/LI&gt;
&lt;LI&gt;Issued: 20 Aug 2010&lt;/LI&gt;
&lt;LI&gt;Opening date: 20 Aug 2010&lt;/LI&gt;
&lt;LI&gt;Closing date: 30 Sep 2010&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>213002</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=213002]]&gt;</url>
    <title>A Bright Future for All - Handouts/ Case Studies/ Appendices</title>
    <publicationDate></publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Training pack for teachers wishing to develop debate and activities on mental health promotion across their school.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;A Bright Future for All - Handouts/ Case Studies/ Appendices&lt;/pageTitle&gt;&lt;pageBody&gt;Training pack for teachers wishing to develop debate and activities on mental health promotion across their school. The pack can be used flexibly and at a pace that suits the school. It seeks to affirm work already underway, while providing guidance on what more can be done. The pack features a variety of activities, including the use of peer support and circle time, and discussions about teachers' mental well-being, and a range of handouts. &lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>213003</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=213003]]&gt;</url>
    <title>A Bright Future for All: Promoting Mental Health in Education</title>
    <publicationDate></publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,EDUCATION,EDUCATION,CHILDREN,YOUNG PEOPLE,MENTAL &amp; BEHAVIOURAL DISORDERS,SCHOOLS,EDUCATIONAL SETTINGS,POPULATION BASED &amp; PREVENTATIVE SERVICES,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,TEACHING METHODS,METHODS,SERVICES,ANALYSIS &amp; RESEARCH,POPULATIONS,GROUPS,AGE GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Main document</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;A Bright Future for All: Promoting Mental Health in Education&lt;/pageTitle&gt;&lt;pageBody&gt;This training pack is a resource for teachers to develop debate and activities on mental health promotion across their school. This pack can be used flexibly and at a pace that suits the school. It seeks to affirm work already underway, while providing guidance on what more can be done. A Bright Future for All has been developed with a number of schools and initial piloting shows that the approaches set out can make a difference, even within a few months. The pack features a variety of activities, including the use of peer support and circle time, and discussions about teachers' mental well-being, and a range of handouts.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>291080</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.newvisionformentalhealth.org.uk/A_future_vision_for_mental_health.pdf]]&gt;</url>
    <title>A future vision for mental health</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>The Future Vision Coalition</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A new vision for mental health is a discussion paper from seven national mental health organisations intended to provoke a debate on the best direction for future mental health policy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report sets out a new vision for the future of mental health and well-being in England. Based on four principles, it outlines the priorities we believe should underpin mental health policy for the next decade.&lt;/P&gt;
&lt;P&gt;The National Service Framework for Mental Health comes to an end later this year and the Department of Health has replaced it through the &lt;A href="http://newhorizons.dh.gov.uk/" target="_blank"&gt;New Horizons programme&lt;/A&gt;. This report is the result of the Future Vision Coalition's work on what the next stage of mental health policy should be.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291080</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.newvisionformentalhealth.org.uk/A_future_vision_for_mental_health.pdf]]&gt;</url>
    <title>A future vision for mental health</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>The Future Vision Coalition</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A new vision for mental health is a discussion paper from seven national mental health organisations intended to provoke a debate on the best direction for future mental health policy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report sets out a new vision for the future of mental health and well-being in England. Based on four principles, it outlines the priorities we believe should underpin mental health policy for the next decade.&lt;/P&gt;
&lt;P&gt;The National Service Framework for Mental Health comes to an end later this year and the Department of Health has replaced it through the &lt;A href="http://newhorizons.dh.gov.uk/" target="_blank"&gt;New Horizons programme&lt;/A&gt;. This report is the result of the Future Vision Coalition's work on what the next stage of mental health policy should be.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320259</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhsconfed.org/Publications/Documents/Future_vision_for_mental_health_FINAL.pdf]]&gt;</url>
    <title>A future vision for mental health</title>
    <publicationDate>2009-07-09T00:00:00</publicationDate>
    <publisher>The NHS Confederation</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ PEOPLE WITH MENTAL HEALTH ISSUES,HOW DO I INVOLVE...?,CHILD AND ADOLESCENT CONDITIONS,PATIENT AND PUBLIC INVOLVEMENT,MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,SERVICE PROVISION,STRATEGY,MENTAL HEALTH SERVICES,SERVICE SECTORS,HEALTH MANAGEMENT,PUBLIC HEALTH,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS,2009 JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=ctl00_PlaceHolderMain_RichHtmlField3__ControlWrapper_RichHtmlField style="DISPLAY: inline"&gt;
&lt;DIV style="MARGIN: 0px; FONT: 10px 'Helvetica Neue Light'; font-size-adjust: none; font-stretch: normal"&gt;
&lt;DIV style="MARGIN: 0px; FONT: 15px Helvetica; font-size-adjust: none; font-stretch: normal"&gt;&lt;SPAN style="FONT: 12px Helvetica; font-size-adjust: none; font-stretch: normal"&gt;&lt;FONT class=Apple-style-span face="'Helvetica Neue'" size=4&gt;&lt;SPAN class=Apple-style-span style="FONT-SIZE: 14px"&gt;
&lt;P&gt;This report sets out a new vision for the future of mental health and&amp;nbsp; &lt;BR&gt;well-being in England. Based on four principles, it outlines the priorities &lt;BR&gt;we believe should underpin mental health policy for the next decade.&lt;/P&gt;
&lt;P&gt;Our four principles for mental health policy are: &lt;/P&gt;
&lt;P&gt;1.&amp;nbsp; Mental health and well-being is everybody’s business. It affects every family in Britain and it can only be improved if coordinated, assertive action is taken&amp;nbsp;across Whitehall and at all levels of government. &lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Good mental health holds the key to a better quality of life in Britain. We need to promote positive mental health, prevent mental ill health and intervene early when people become unwell. &lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; People should get as much support to gain a good quality of life and fulfil their potential from mental health services as they expect to receive from physical healthcare services. Mental health care should offer hope and support for people to recover and live their lives on their own terms. &lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; We need a new relationship between mental health services and those who use them. Service users, carers and communities should be offered an active role in shaping the support available to them. With these principles at the heart of policy, we believe we can create a society in which good mental health is nurtured and in which mental ill health is managed well. &lt;BR&gt;As a consequence, our mental well-being will be a core concern of government. Effective action to promote good mental health will be taken among people of all ages and diverse backgrounds. People who experience mental distress will receive timely support to live well and have a fair and equal chance to fulfil their potential. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The actions that would be needed to make our vision a reality are summarised overleaf. &lt;/P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/DIV&gt;&lt;/DIV&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>320259</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhsconfed.org/Publications/Documents/Future_vision_for_mental_health_FINAL.pdf]]&gt;</url>
    <title>A future vision for mental health</title>
    <publicationDate>2009-07-09T00:00:00</publicationDate>
    <publisher>The NHS Confederation</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ PEOPLE WITH MENTAL HEALTH ISSUES,HOW DO I INVOLVE...?,CHILD AND ADOLESCENT CONDITIONS,PATIENT AND PUBLIC INVOLVEMENT,MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,SERVICE PROVISION,STRATEGY,MENTAL HEALTH SERVICES,SERVICE SECTORS,HEALTH MANAGEMENT,PUBLIC HEALTH,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS,2009 JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=ctl00_PlaceHolderMain_RichHtmlField3__ControlWrapper_RichHtmlField style="DISPLAY: inline"&gt;
&lt;DIV style="MARGIN: 0px; FONT: 10px 'Helvetica Neue Light'; font-size-adjust: none; font-stretch: normal"&gt;
&lt;DIV style="MARGIN: 0px; FONT: 15px Helvetica; font-size-adjust: none; font-stretch: normal"&gt;&lt;SPAN style="FONT: 12px Helvetica; font-size-adjust: none; font-stretch: normal"&gt;&lt;FONT class=Apple-style-span face="'Helvetica Neue'" size=4&gt;&lt;SPAN class=Apple-style-span style="FONT-SIZE: 14px"&gt;
&lt;P&gt;This report sets out a new vision for the future of mental health and&amp;nbsp; &lt;BR&gt;well-being in England. Based on four principles, it outlines the priorities &lt;BR&gt;we believe should underpin mental health policy for the next decade.&lt;/P&gt;
&lt;P&gt;Our four principles for mental health policy are: &lt;/P&gt;
&lt;P&gt;1.&amp;nbsp; Mental health and well-being is everybody’s business. It affects every family in Britain and it can only be improved if coordinated, assertive action is taken&amp;nbsp;across Whitehall and at all levels of government. &lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Good mental health holds the key to a better quality of life in Britain. We need to promote positive mental health, prevent mental ill health and intervene early when people become unwell. &lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; People should get as much support to gain a good quality of life and fulfil their potential from mental health services as they expect to receive from physical healthcare services. Mental health care should offer hope and support for people to recover and live their lives on their own terms. &lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; We need a new relationship between mental health services and those who use them. Service users, carers and communities should be offered an active role in shaping the support available to them. With these principles at the heart of policy, we believe we can create a society in which good mental health is nurtured and in which mental ill health is managed well. &lt;BR&gt;As a consequence, our mental well-being will be a core concern of government. Effective action to promote good mental health will be taken among people of all ages and diverse backgrounds. People who experience mental distress will receive timely support to live well and have a fair and equal chance to fulfil their potential. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The actions that would be needed to make our vision a reality are summarised overleaf. &lt;/P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/DIV&gt;&lt;/DIV&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>333155</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/cd/public/docs/controlled_drugs_third_edition.pdf]]&gt;</url>
    <title>A guide to good practice in the management of controlled drugs in primary care (England) - 3rd edition</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The guide is primarily aimed at developing good practice for the management of controlled drugs in primary care in England, but it also encompasses issues raised at the interfaces between primary, secondary and social care. This guide takes into account the significant legislative changes introduced since the publication of the first edition in December 2005.&lt;/P&gt;
&lt;P&gt;The guide should be of value in a wide range of settings where CDs are used including: &lt;/P&gt;
&lt;UL type=disc&gt;
&lt;LI&gt;GP and dental practices 
&lt;LI&gt;Pharmacies 
&lt;LI&gt;Midwifery services 
&lt;LI&gt;Out-of-hours services 
&lt;LI&gt;Patients own home 
&lt;LI&gt;Care homes 
&lt;LI&gt;Community nursing services 
&lt;LI&gt;Community palliative care services 
&lt;LI&gt;Substance misuse services 
&lt;LI&gt;Hospices 
&lt;LI&gt;Prison services 
&lt;LI&gt;Ambulance services/paramedics 
&lt;LI&gt;Intermediate care services&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>266708</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.annafreudcentre.org/ebpu/mh_ld_care_pathway_resource_pack.pdf]]&gt;</url>
    <title>A Mental Health Care Pathway for Children and Young People with Learning Disabilities: A resource pack for service planners and practitioners</title>
    <publicationDate>2007-07-27T00:00:00</publicationDate>
    <publisher>CAMHS Evidence-Based Practice Unit (2007)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ LEARNING DISABILITIES,MENTAL HEALTH,MENTAL HEALTH,DEPRESSION,CHILD AND ADOLESCENT CONDITIONS,EMOTIONAL DISORDERS,COMMISSIONING,POPULATIONS SERVED,DISEASE/CONDITION GROUPS,MENTAL HEALTH PROBLEMS,CHILDREN,YOUNG PEOPLE,PEOPLE WITH MENTAL HEALTH PROBLEMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A resource pack for services to help them become more accessible to children with learning disabilities.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This resource pack aims to assist CAMHS providers to address some of issues of accessibility to mental health services for children with learning disabilities, and to improve link-up between agencies. It also contains valuable guidance to practitioners on working with this client group. It contains&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;A step-by-step guide to the National Care Pathway developed in a Do Once and Share project in 2006. 
&lt;LI&gt;Guidance in developing local care pathways and commissioning plans 
&lt;LI&gt;Workshop session outlines and training tools 
&lt;LI&gt;Top tips for developing CAMH practitioner skills in working with children with LD 
&lt;LI&gt;Vignettes of common presentations and suggested interventions 
&lt;LI&gt;Links to resources&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>317746</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/News/Recentstories/DH_097701]]&gt;</url>
    <title>A new vision for mental health and wellbeing</title>
    <publicationDate>2009-04-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The millions of people who suffer from or might face mental illness at some point in their lives will be the focus of a new strategy, Care Services Minister Phil Hope announced today(15th April, 2009).]]&gt;</body>
  </document>
  <document>
    <id>327908</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.researchmentalhealth.org.uk/sign-today/]]&gt;</url>
    <title>A radical increase in investment to research mental health is needed</title>
    <publicationDate>2009-10-14T00:00:00</publicationDate>
    <publisher>Research Mental Health</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;A title="Mental Health Research Declaration" href="http://www.researchmentalhealth.org.uk/media/common/uploads/Mental_Health_Research_Declaration.pdf" target="_blank"&gt;&lt;STRONG&gt;declaration&lt;/STRONG&gt;&lt;/A&gt; calls for a radical increase in investment to&amp;nbsp;research mental health. It has the backing of dozens of leading scientists and public figures including Alistair Campbell, Jo Brand, Ruby Wax, Tracey Emin, Stephen Fry, Melanie C and Mercury award winner Speech Debelle.&lt;/P&gt;
&lt;P&gt;Show your support for the declaration and help us reach 10,000 sign ups to show the Government, the National Health Service, funding bodies, research institutions, the pharmaceutical industry and the third sector, why we need more investment in mental health research.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328436</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://guidance.nice.org.uk/CG90]]&gt;</url>
    <title>A summary of the NICE depression guidance.</title>
    <publicationDate></publicationDate>
    <publisher>The National Collaborating Centre for Mental Health</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Steve Pilling, Joint Director of the National Collaborating Centre for Mental Health has written a summary of the two depression guidelines published by NICE in October 2009.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;What is the new evidence? &lt;/H2&gt;
&lt;P&gt;NICE has recently published two new guidelines on depression developed by the National Collaborating Centre for Mental Health: Depression: the treatment and management of depression in adults (London: NICE, 2009; available at &lt;A href="http://www.nice.org.uk/CG90" target="_blank"&gt;www.nice.org.uk/CG90&lt;/A&gt;) and Depression in adults with a chronic physical health problem: treatment and management (London: NICE, 2009; available at &lt;A href="http://www.nice.org.uk/CG91" target="_blank"&gt;www.nice.org.uk/CG91&lt;/A&gt;). Both guidelines constitute an update of the 2004 NICE guideline on depression, which was amended in 2007 (available at &lt;A href="http://www.nice.org.uk/CG23" target="_blank"&gt;www.nice.org.uk/CG23&lt;/A&gt;). It also updates recommendations for the treatment of depression included in the NICE technology appraisal of electroconvulsive therapy (&lt;A href="http://www.nice.org.uk/TA59" target="_blank"&gt;www.nice.org.uk/TA59&lt;/A&gt;) and in a NICE review of its technology appraisal of computerised cognitive behavioural therapy (CCBT) for depression and anxiety (&lt;A href="http://www.nice.org.uk/TA97" target="_blank"&gt;www.nice.org.uk/TA97&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;A guideline on depression in people with a chronic physical health problem was developed because of the specific needs of that population, such as the challenges in identifying depression in people with long-term medical conditions, the uncertainties surrounding&amp;nbsp; the use of antidepressants (in particular drug interactions)&amp;nbsp; and engaging them in treatment. There were also some uncertainties concerning the application of evidence derived from studies of the non-physically ill to those with depression and a chronic health problem.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Why is this evidence significant?&lt;/H2&gt;
&lt;P&gt;The new guideline on depression in adults with a chronic physical health problem is significant because it seeks to improve recognition of depression, alleviate the increased burden of having both a chronic physical health problem comorbid with depression, and enhance care for this patient group by improving access to evidence-based treatments, including pharmacological and psychological interventions. This is important as depression is associated with both increased morbidity and mortality in people with chronic physical health problems. &lt;/P&gt;
&lt;P&gt;Both guidelines cover the treatment and management of subthreshold depressive symptoms (including dysthymia), which were not part of the scope of the previous guideline. Such symptoms can be disabling if they are persistent and complicate the care of the physical health problem. For persistent subthreshold depressive symptoms and mild to moderate depression, and for subthreshold symptoms that complicate the care of the physical health problem, both guidelines promote low-intensity psychosocial interventions. Such interventions include structured group physical activity programmes, individual guided self-help, computerised cognitive behavioural therapy and group-based peer support programmes. These interventions are less intensive than formal psychological interventions and can be accessed more readily and in a more flexible manner.&lt;/P&gt;
&lt;P&gt;For people with depression and a chronic physical health problem guideline there is important clarification about drug interactions for people taking an antidepressant and medication for their physical illness. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;What does it add to knowledge we already have? What is current practice and how might this evidence change that?&lt;/H2&gt;
&lt;P&gt;Although the prevalence of depression is increased in people with a chronic physical health problem, it remains under-recognised in that patient group.&amp;nbsp; The guideline provides the means to improve the detection of depression through use of a number of case identification questions. The guidelines also reinforce the value of a range of low intensity interventions, for mild to moderate depression, for people with depression including those with chronic physical health problems. The nature and flexibility of low intensity interventions make them suitable for use in a range of different settings including secondary care and by different modes of delivery (e.g. the telephone). The guidelines also provide helpful advice on drug interactions which should lead to more effective use of antidepressants (there has been concern about inadequate doses of drugs being used because of concerns about interactions) &lt;/P&gt;
&lt;P&gt;The guidelines promote the use of high-quality, well-monitored high-intensity psychological interventions (CBT, IPT, behavioural activation and couples therapy; or CBT or couples therapy for people with a chronic physical health problem). Counselling and short-term psychodynamic psychotherapy are identified as limited options for people who decline an antidepressant or a high-intensity psychological intervention , but the guideline makes it clear that healthcare professionals should discuss with the patient the uncertainty of the effectiveness of counselling and short-term psychodynamic psychotherapy in treating depression. In the new guidelines there is a strong emphasis on the use of routine outcome monitoring and supervision to ensure interventions are delivered competently;, while this is important for both psychological and pharmacological interventions&amp;nbsp; it is particularly important for the former.&lt;/P&gt;
&lt;P&gt;The guidelines also carefully reviewed the evidence for collaborative care and recommended that its use should be reserved for chronic physical health problems and moderate to severe depression which has not responded to initial high intensity psychological interventions, pharmacological treatment, or a combination of both of these.&amp;nbsp; Collaborative care typically involves case management supervised by a senior mental health professional, close collaboration between primary and secondary care services, a range of interventions consistent with those recommended in the guidelines (including patient education, psychological and pharmacological interventions, and medication management), and long term coordination of care and follow-up. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Is the new evidence likely to result in significant/minor/no change to clinical practice and current delivery of services? &lt;/H2&gt;
&lt;P&gt;The new guidelines present some implementation challenges, especially for healthcare professionals working in secondary care settings who treat people with depression and a chronic physical health problem.&amp;nbsp; There is an emphasis on identifying depression, which if successful could lead to an increase in the delivery of some aspects of care in those settings. (This may also require additional training and supervision if the interventions are to be delivered effectively). Establishing collaborative care systems will inevitably require time and resources and will lead to changes in the way care is delivered for people with depression (e.g. the introduction of stepped care systems) with greater coordination between primary and secondary care services.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Are there any potential cost savings or efficiencies to be made as a result of implementing the new evidence? &lt;/H2&gt;
&lt;P&gt;The implementation of the previous NICE guideline was significantly limited by the absence of sufficient therapists to provide the psychological therapies. The development of the Improving Access to Psychological Therapies in England and a similar programme in Scotland has begun to address this problem. The more targeted and effective use of antidepressants (for moderate and severe depression in combination with psychological interventions)&amp;nbsp; recommended in these guidelines will also improve care.&amp;nbsp; Implementation of the guidelines will therefore reduce relapse rates which will lead to a decreased&amp;nbsp; burden of disease and thereby reducing long-term costs of mental health care particularly in primary care.&amp;nbsp; &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317736</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/rss/access-justice-mental-health.htm]]&gt;</url>
    <title>Access to justice: evidence of the experience of adults with mental health problems PDF</title>
    <publicationDate>2009-05-06T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The report covers evidence on access to justice for black and minority groups, gypsies and travellers, refugees and asylum seekers, and minority groups identified by their sexuality.]]&gt;</body>
  </document>
  <document>
    <id>111323</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111323]]&gt;</url>
    <title>Access to nature</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,ENVIRONMENTAL,ENVIRONMENT,OUTCOMES,RURAL COMMUNITIES,URBAN COMMUNITIES,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SERVICES,POPULATIONS,COMMUNITIES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Access to nature&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111322:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111324:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Nature - or natural greenspace – is characterised by land, water and geological features with naturally occurring plants and animals (ref 1). Only just over one in five of the population live in a rural area and so access to nature is more likely to occur in urban or semi-urban environments.&lt;/P&gt;
&lt;P&gt;Aspects of the physical environment which have been shown to have a negative impact on mental well-being include high population density (ref 2, 3), noise (ref 4) and information and stimulus overload (ref 2).&lt;/P&gt;
&lt;P&gt;The probability of helping a stranger is inversely related to the level of environmental stimulation, which includes density of pedestrians and motor traffic (ref 2). Noise decreases the sense of connection between people and decreases the probability that people will help each other (ref 5).&lt;/P&gt;
&lt;P&gt;In a major study, Lewis and Booth found that while those living in rural areas had a much lower prevalence of mental disorder, people living in built up areas with access to gardens or green, open spaces had a lower prevalence than people in built up areas with no such access (ref 6) .&lt;/P&gt;
&lt;P&gt;(ref 7) provides several explanatory frameworks for the mental health benefits of contact with nature. These include ‘stress recovery’ – immediate psychological benefits from contact with nature (ref 8-11).&lt;/P&gt;
&lt;P&gt;And ‘attention restoration’ – longer term psychological benefits from contact with nature (ref 12, 13). &lt;/P&gt;
&lt;P&gt;Access to green, open spaces has important benefits for mental and physical health (ref 6, 14, 15). Reducing inequalities in access to green spaces and developing accessible local green spaces, for example community gardens, should be included as part of a stronger recognition of the impact of the environment on health – notably mental health and quality of life.&lt;/P&gt;
&lt;P&gt;The Communities Plan “Sustainable Communities: Building for the future” (ref 16) sets out a long-term programme of action for delivering sustainable communities in both urban and rural areas. The Plan offers a new approach to how we build and what we build.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111322:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111324:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;English Nature (2002) &lt;A href="http://www.english-nature.org.uk/pubs/publication/PDF/Annualreport11.pdf" target="_blank"&gt;Annual Report&lt;/A&gt;. (&lt;A href="http://www.english-nature.org.uk/" target="_blank"&gt;www.english-nature.org.uk&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Freeman H (ed.)(1984) Mental Health and the Environment London: Churchill Livingstone&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Brain PF (1984) Human aggression and the physical environment. in Freeman H(ed) Mental Health and the Environment 97-120&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Tarnopolsky A and Clark C (1984) Environmental noise and mental health in Freeman H (ed) Mental Health and the Environment 250-270&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Walter JA (1982) The Human Home: The myth of the sacred environment. Tring: Lion&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Lewis G and Booth M (1994) Are cities bad for your mental health? Psychological Medicine 24:913-915&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Henwood K (2002) &lt;A href="http://www.hda-online.org.uk/documents/environmentissuespaper.pdf" target="_blank"&gt;Issues in health development: Environment and health: Is there a role for environmental and countryside agencies in promoting benefits to health?&lt;/A&gt; London: Health Development Agency&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Ulrich RS (1979) Visual landscapes and psychological well being. Landscape Research 4: 17-23.&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Ulrich RS (1983) Aesthetic and affective response to natural environment. In: Altman I and Wohlwill JF (eds) Human Behaviour and Environment: advances in theory and research. Vol 6 Behaviour and the Natural Environment. New York: Plenum Press.&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Ulrich R (1984) View through a window may influence recovery from surgery. Science (4) 20-1.&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Ulrich R S, Simons R F, Losito B D, Fiorito E, Miles M A and Zelson M (1991) Stress recovery during exposure to natural and urban environments. Journal of Environmental Psychology 11: 201-30. &lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Kaplan R and Kaplan S (1989) The Experience of Nature: a psychological perspective. Cambridge: Cambridge University Press.&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Kaplan S (1995) The restorative effects of nature: toward an integrative framework. Journal of Environmental Psychology 16:169-82.&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Dalgard OS and Tambs K (1997) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/171/6/530?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074071522847_192&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=171&amp;amp;firstpage=530&amp;amp;resourcetype=1" target="_blank"&gt;Urban environment and mental health: a longitudinal study&lt;/A&gt; British Journal of Psychiatry 171:530-6&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;&lt;A href="http://www.mentality.org.uk/" target="_blank"&gt;mentality&lt;/A&gt; (2003) Nature and psychological well-being: A briefing for English Nature. London: English Nature.&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Office of the Deputy Prime Minister (2003) &lt;A href="http://www.odpm.gov.uk/stellent/groups/odpm_communities/documents/page/odpm_comm_022184.hcsp" target="_blank"&gt;Sustainable Communities: Building for the Future&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>213004</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=213004]]&gt;</url>
    <title>Actions speak louder... Tackling discrimination against people with mental illness</title>
    <publicationDate></publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>by Professor Graham Thornicroft</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Actions speak louder... Tackling discrimination against people with mental illness&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Written by Professor Graham Thornicroft, one of the world’s leading researchers in psychiatry, Actions Speak Louder sets out an agenda for change for policy makers on how to tackle discrimination.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Stigma projects the fear and anxiety felt by members of the general population onto the person with the diagnosis. People with a diagnosis do not really carry a &lt;EM&gt;mark&lt;/EM&gt; that sets them aside. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Foreword&lt;/P&gt;
&lt;P&gt;People with direct experience of mental health problems - as service users, carers or professionals - have long been aware of the impact of discrimination against people with psychiatric diagnoses. Over recent decades research by organisations like the Mental Health Foundation has confirmed that discrimination has a huge impact on people's lives. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>270348</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=270348]]&gt;</url>
    <title>Acute inpatient mental health service review</title>
    <publicationDate>2007-08-09T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Mental health care has increasingly shifted towards care and treatment in the community. This may have led to more appropriate care for those who use services, but it has also meant that standards in acute inpatient services have not always kept pace with the change. The "Mental health policy implementation guide for adult acute inpatient care provision" (Department of Health, 2002), and other policy guidance since, have sought to encourage improvement in inpatient services. The five-year review of the National Service Framework highlighted the need for continued improvement in this area and the Healthcare Commission has identified it as a priority on which to focus a service review.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Acute inpatient mental health service review&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Mental health care has increasingly shifted towards care and treatment in the community. This may have led to more appropriate care for those who use services, but it has also meant that standards in acute inpatient services have not always kept pace with the change. The "Mental health policy implementation guide for adult acute inpatient care provision" (Department of Health, 2002), and other policy guidance since, have sought to encourage improvement in inpatient services. The five-year review of the National Service Framework highlighted the need for continued improvement in this area and the Healthcare Commission has identified it as a priority on which to focus a service review.&lt;/P&gt;
&lt;P&gt;The Healthcare Commission's&amp;nbsp;service review is assessing the quality of care given by NHS providers of acute inpatient wards (sometimes called acute admission wards) and psychiatric intensive care units in England.&amp;nbsp;They will give mental health provider trusts a score, which will form part of our health check for 2006/2007.&lt;/P&gt;
&lt;P&gt;The Healthcare Commission&amp;nbsp;are assessing services against a national assessment framework. Details about how the assessment framework was developed can be found below, along with a link to a summary of the changes made to the assessment framework as a result of consultation feedback and piloting. The final version of the assessment framework and a general briefing about the mental health service review can be found by downloading the Final Assessment Framework and General Briefing PDFs.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.healthcarecommission.org.uk/serviceproviderinformation/reviewsandstudies/servicereviews/improvementreviewmethodology/adultacuteinpatientmentalhealth.cfm" target="_blank"&gt;Link to Healthcare Commission webpage on the Acute inpatient mental health service review&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>296418</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.blackwellpublishing.com/journal.asp?ref=0965-2140&amp;site=1]]&gt;</url>
    <title>Addiction</title>
    <publicationDate></publicationDate>
    <publisher>Blackwell Publishing</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"Addiction, a peer-reviewed journal, publishes top quality international research for a large and expanding readership.&amp;nbsp; It offers a lively forum for debate with editorials, commentaries, interviews with leading figures in the field, and a comprehensive book review section.&amp;nbsp; Addiction is a journal which explores the horizons.&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Editorial 
&lt;LI&gt;For debate 
&lt;LI&gt;Review 
&lt;LI&gt;Methods and techniques 
&lt;LI&gt;Research reports 
&lt;LI&gt;Letters to the editor 
&lt;LI&gt;News and notes"&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Published on a monthly basis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392204</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/genetic-causes-adhd-tested.aspx]]&gt;</url>
    <title>ADHD genes only part of the story</title>
    <publicationDate>2010-09-30T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The first direct evidence of a genetic link to attention deficit hyperactivity disorder has been found,” reported BBC News.&lt;/P&gt;
&lt;P&gt;The research behind this news compared the DNA of 366 children with attention deficit hyperactivity disorder (ADHD) and 1,047&amp;nbsp;&lt;A href="http://www.nhs.uk/news/Pages/Newsglossary.aspx#Controlgroup" target="_blank"&gt;control subjects&lt;/A&gt; not known to have the condition. It found that 14% of children with ADHD had large, rare variations in their DNA that were present in only 7% controls.&lt;/P&gt;
&lt;P&gt;Although this has been called "the first direct evidence" that ADHD is a genetic disorder, results from other genetic research and studies in twins have already highlighted the role that genetics play in ADHD. More research is now needed to confirm that the variations identified cause ADHD and to identify other variants involved. The exact causes of ADHD are not yet known, but it is currently thought that both genetic and environmental factors play a role.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372742</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/research-examines-ADHD-drug-mechanism.aspx]]&gt;</url>
    <title>ADHD mechanisms probed</title>
    <publicationDate>2010-04-19T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Children with ADHD may respond to instant rewards “in the same way as they do to medication”, says the BBC.&lt;/P&gt;
&lt;P&gt;The news is based on a study in which children with attention deficit hyperactivity disorder (ADHD) were assessed through a computer-based task that offered them extra points for less impulsive behaviour. This important study, albeit small, furthers our understanding of how ADHD affects particular brain activity and the way that interventions such as medication and motivational conditions can alter that response. The increased incentive offered in the task improved areas of brain activity that are usually affected by the disorder, having an effect similar to that of medication. However, there are some limitations, including that the behavioural response of the child does not appear to have been assessed, and that the reward scenario used may not be easily transferable to everyday life.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111329</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111329]]&gt;</url>
    <title>Adulthood</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,SERVICE DELIVERY,MENTAL HEALTH,DISEASES AND CONDITIONS,CHILDREN AND YOUNG PEOPLE,CLIENT GROUPS,ETHNICITY AND HEALTH,UNEMPLOYMENT,ENVIRONMENTAL,EDUCATION,OUTCOMES,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,DETERMINANTS,INDIVIDUAL BEHAVIOUR,PHYSICAL ACTIVITY,SOCIAL DETERMINANTS,SOCIETY,SOCIOECONOMIC FACTORS,POPULATIONS,GROUPS,LIFE EVENTS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Adulthood&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111328:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111330:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;The case for action&lt;/H2&gt;
&lt;P&gt;At any one time, one adult in six suffers from mental health problems of varying severity (ref 1). Other research suggests that one person in four will experience some kind of mental health problem in the course of a year (ref 2).&lt;/P&gt;
&lt;P&gt;Some of the most significant threats to mental health can occur during adulthood, for example unemployment, which increases risk of suicide and also the poverty which is associated with risks to mental health. A review of the published evidence on links between social position and common mental disorders found that prevalence was more marked amongst socially disadvantaged populations. More consistent associations were with unemployment, less education and low income or material standard of living. Occupational social class was the least consistent marker (ref 3).&amp;nbsp; see marginalised groups; mental health promotion and inequalities)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Life transitions such as divorce or birth of a child are common in adulthood and can undermine mental health. Caring responsibilities also carry increased risk for mental health, notably parenting and caring in later life. (see &lt;A href="nelh:111327:1" name=internalLink&gt;early years, children, families and parenting; later life&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Adulthood – summary of the evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Exercise&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The case for physical activity has been established through its impact on reduction in risk of physical ill-health such as coronary heart disease. There is also now a growing body of evidence to support the mental health benefits of physical activity in four areas: as a treatment or therapy for existing mental health problems, to improve the quality of life for people with mental health problems, to prevent the onset of mental health problems and to improve the mental well-being of the general public (ref 4).&lt;/P&gt;
&lt;P&gt;National Consensus Statements on physical activity and mental health (ref 5) show that exercise prevents clinical depression and is as effective a treatment as psychotherapeutic interventions. Exercise has also been shown to reduce anxiety, enhance mood (ref 6, 7). The evidence also points to an effect for physical activity on self-esteem, particularly in terms of physical self-perception and the strongest association for this positive affect is in children and middle-aged adults (ref 8).&lt;/P&gt;
&lt;P&gt;Evaluation of the ‘Balance for Life’ scheme found that a GP prescribed 10 week programme of exercise significantly reduced depression and anxiety and increased quality of life and self-efficacy for exercise. 68% of clinically depressed patients achieved non-clinical depression scores within three months (ref 9).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Exercise and depression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Depression is one of the most common psychiatric problems and estimates suggest that depression affects 5-10% of the populations in most developed countries (ref 10). A systematic review examined all studies with robust study design in which exercise had been used to treat clinically defined depression (ref 7). The review concluded that the evidence was strong enough to support a causal link between physical activity and reduced clinical depression.&lt;/P&gt;
&lt;P&gt;Evidence also supported the view that inactivity produces higher risk of subsequent depression; and that physical activity can be an effective medium for its treatment. Aerobic and resistance exercise may be used to treat moderate and more severe depression, usually as an adjunct to standard treatment. Finally the anti-depressant effect of exercise could be of the same magnitude as that for other psychotherapeutic interventions and no negative effects of exercise had been noted in depressed populations.&lt;/P&gt;
&lt;P&gt;However consensus does not exist on the positive impact of exercise on depression. A different systematic review aimed to determine the effectiveness of exercise as an intervention in the management of depression (ref 11). Randomised controlled trials which compared exercise with other established treatments for depression and with depression as an outcome measure were included. The reviewers concluded that the poor quality of the included studies did not allow for any association between exercise and reduction in symptoms of depression. The only possible effect noted was in the short term but its effectiveness in clinical populations was unknown.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Emotion, mood and physical activity&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Evidence from meta-analysis, narrative review, epidemiological and experimental studies supports a positive relationship between physical activity and psychological well-being. Physical activity is consistently associated with positive affect and mood (ref 12). The evidence seems to demonstrate that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;adopting a goal in exercise that is focused on personal improvement, effort and mastery has a moderate to high association with a positive mental health affect;&lt;/LI&gt;
&lt;LI&gt;a group climate in exercise settings focused on personal improvement and effort has a moderate-to-high association with positive mental health affect.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The three British epidemiological studies found a clear positive relationship between physical activity and psychological well-being. The surveys covered adolescents and adults and used clinical and non-clinical assessment tools.&lt;/P&gt;
&lt;P&gt;The five British experimental studies demonstrated that the intensity of exercise is important in determining the effects of exercise on mood. Overall there seemed to be stronger support for the effect of moderate but not high intensity exercise.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Physical activity, anxiety and stress&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is evidence to support a low-to-moderate anxiety-reducing effect of physical activity, with some studies suggesting a potentially greater effect (ref 13). There was stronger evidence to support the efficacy of acute (one-off sessions) rather than chronic (ongoing sessions) exercise interventions on reducing anxiety in mainly adult populations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventions for life transitions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is evidence that interventions focusing on social support and coping skills appear to have a powerful effect on families and individuals who are experiencing the psychological consequences of birth, care-giving, job-loss, separation or bereavement and poverty (ref 14, 15).&lt;/P&gt;
&lt;P&gt;Only one of the studies was universal prevention and targeted couples who were married and not experiencing any problems or those planning to marry. The programme focused on handling disagreements and good communications. Both of these skills are protective for mental health. At five-year follow-up intervention couples reported better relationships, fewer sexual problems and less violence and only 8% had divorced compared with 19% of controls.&lt;/P&gt;
&lt;P&gt;The remainder of the studies were selective programmes and targeted at perceived high risk groups of adults. One intervention was aimed at newly separated couples and provided advice on single parenting, housing, employment, education and legal and financial issues. At four-year follow-up there were significant differences between groups including lower levels of psychiatric symptoms in the intervention group.&lt;/P&gt;
&lt;P&gt;A study targeted at partners of women having caesarean deliveries aimed to prevent post-natal depression by providing emotional support during the birth. Bonding between parents and infants was facilitated. Outcomes supported more repaid psychological recovery from the birth than for those in the control group.&lt;/P&gt;
&lt;P&gt;Studies which reduced psychological distress and depression included one aimed at the unemployed, two aimed at people from ethnic minority groups and one aimed at widows.&lt;/P&gt;
&lt;P&gt;The unemployment study aimed to develop job-finding and coping skills and follow-up at two and a half years found that participants were earning more and experiencing fewer depressive symptoms compared with controls.&lt;/P&gt;
&lt;P&gt;Low-income patients in primary care, mainly from ethnic minority groups, who were not suffering any depressive symptoms or psychiatric disorder, were the focus of an intervention to prevent depression. One year later the intervention group had fewer depressive symptoms than those in the control group. A similar selective intervention targeted at Mexican women in the US found that effectiveness was enhanced if the intervention was administered in groups and solely for women in the middle range of initial depression scores.&lt;/P&gt;
&lt;P&gt;An intervention providing peer support to widows through one-to-one contact with other widows found that those in the programme were more likely to start new relationships and activities than controls. They also experienced fewer depressive symptoms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Spirituality and mental health&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A growing number of studies have consistently found that religious involvement is associated with positive mental health outcomes (ref 16, 17, 18) There is also evidence that demonstrates a belief in God can have a positive effect on a person’s happiness (ref 19). &lt;/P&gt;
&lt;P&gt;A systematic literature review examined the relationship between religion and mental health, social support, substance abuse and other behaviours affecting mental or social functioning. (ref 20). The review included information from more than 630 separate data-based reports focusing on religion and well-being amongst general population cohorts as well as amongst people experiencing mental distress.&lt;/P&gt;
&lt;P&gt;In 100 identified studies, religious beliefs and practices were consistently related to greater life satisfaction, happiness, positive affect, morale and other indicators of well-being. Nearly 80% of these studies reported only positive correlates between these constructs. Even where correlations were modest, they often equalled or exceeded those between well-being and other psycho-social variables such as marital status, income and social support. Only one study found a negative relationship with correlations between poor mental health and ritualism and superstition.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111328:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111330:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&lt;A href="http://www.statistics.gov.uk/" target="_blank"&gt;Office for National Statistics&lt;/A&gt; (2000) Survey of Psychiatric Morbidity Among Adults Living in Private Households. London: HMSO&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Goldberg D (1991) Filters to care. In Jenkins R and Griffiths S (eds) Indicators for Mental Health in the Population London: The Stationery Office&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Fryers T, Melzer D and Jenkins R. (2003) Social inequalities and the common mental disorders: A systematic review of the evidence. Social Psychiatry and Psychiatric Epidemiology. 38: 229 – 237.&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Fox KR (2000a) Physical activity and mental health promotion: the natural partnership. International Journal of Mental Health Promotion 2(1):4-12.&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Grant T (ed) (2000) Physical activity and mental health: national consensus statements and guidelines for practice. London: Somerset Health Authority/Health Education Authority&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Fox KR (2000b) Self-esteem, Self-perceptions and Exercise. International Journal of Sport Psychology 31:228-240&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Mutrie N (2000) The relationship between physical activity and clinically defined depression, in SJH Biddle, KR Fox and SH Boutcher (eds) Physical activity and psychological well-being London : Routledge&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Biddle SJH (2000) Emotion, mood and physical activity in Biddle SJH, Fox KR and Boutcher SH (eds) Physical Activity and Psychological Well-Being. London: Routledge&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Darbishire L and Glenister D (1998) The Balance for Life scheme: mental health benefits of GP recommended exercise in relation to depression and anxiety. Essex Health Authority.&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Weismann MM and Klerman GL (1992) Depression: Current understanding and changing trends. Annual Review of Public Health 13: 319-339&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Lawlor DA and Hopker SW (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7289/763?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Lawlor%2B&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1075108593600_960&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=322&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials&lt;/A&gt;. British Medical Journal 322: 1-8&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Biddle SJH, Fox KR, Boutcher SH and Faulkner GE (2000) The way forward for physical activity and the promotion of psychological well-being. In SJH Biddle, KR Fox and SH Boutcher (eds) Physical activity and psychological well-being London : Routledge&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Taylor A (2000) Physical activity, anxiety and stress in Biddle SJH, Fox KR and Boutcher SH (eds) Physical Activity and Psychological Well-Being. London: Routledge&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Hodgson R, Abbasi T and Clarkson J (1996) Effective mental health promotion: a literature review. Health Education Journal 55: 55-74&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Tilford S, Delaney F and Vogels M (1997) Effectiveness of mental health promotion interventions: a review. London: Health Education Authority&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Mental Health Foundation (1997) Knowing our own minds. London: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;Mental Health Foundation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Ellison C and Levin J (1998) The religion-health connection: evidence theory and future directions Health Education and Behaviour 5(6) 700-720&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Koenig HG, McCulloch ME and Larson DB (2001a) Handbook of Religion and Health. Oxford: Oxford University Press.&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Helliwell J (2001) How’s life? Combining individual and national variables to explain subjective well-being. NBER Working Paper No. w9065.&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Koenig HG (2001b) Religion and Medicine II: Religion, Mental Health and Related Behaviours. International Journal of Psychiatry in Medicine. 31 (1): 97 – 109&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317835</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/59]]&gt;</url>
    <title>Aetiology - Advanced paternal age increases risk of bipolar disorder in offspring</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does advanced paternal age increase the risk of bipolar disorder&lt;SUP&gt; &lt;/SUP&gt;in offspring?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;7 739 202 individuals were identified through linkage of the&lt;SUP&gt; &lt;/SUP&gt;Hospital Discharge Register and the Multigeneration Register.&lt;SUP&gt; &lt;/SUP&gt;From this study base of over 7 million individuals, 13 428 cases&lt;SUP&gt; &lt;/SUP&gt;(42% male) with two known biological parents and at least two&lt;SUP&gt; &lt;/SUP&gt;separate hospital admissions for bipolar disorder (using ICD&lt;SUP&gt; &lt;/SUP&gt;codes) were identified. Exclusions: people diagnosed with bipolar&lt;SUP&gt; &lt;/SUP&gt;disorder but with only one hospitalisation (to avoid inclusion&lt;SUP&gt; &lt;/SUP&gt;of people who were misdiagnosed); people diagnosed with unipolar&lt;SUP&gt; &lt;/SUP&gt;depression. Controls (67 140 people; five randomly selected&lt;SUP&gt; &lt;/SUP&gt;for each case) were people without a diagnosis of bipolar disorder&lt;SUP&gt; &lt;/SUP&gt;and matched to cases for sex and age. Controls had to be alive&lt;SUP&gt; &lt;/SUP&gt;at the date of the case’s first hospitalisation to allow&lt;SUP&gt; &lt;/SUP&gt;for an equal period of risk.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;General population, Sweden; registry data was obtained for the&lt;SUP&gt; &lt;/SUP&gt;period 1932 and 1991.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;The primary risk &lt;NOBR&gt;. .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/59" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>328856</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/125]]&gt;</url>
    <title>Aetiology - Antenatal depression predicts depression in adolescent offspring</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Does antenatal depression predict depression in adolescent offspring?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;A random sample of antenatal women from participating practices&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;was taken, and 87% (155 women) provided information on their&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;mental health during pregnancy and postnatally. This study analysed&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;the 127 mother–child pairs (82%) that provided information&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;on maternal mental health and mental health of offspring in&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;adolescence (age 16 years; mother mean age at birth 26.0 years,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;72% white British and 89% working class)&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two general practices in South London, from areas with deprivation&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;scores ranked on the 6th and 11th percentiles in 2001/2002 (lower&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;rank representing greater deprivation); study dates not reported.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Maternal depression during pregnancy, the postnatal period and&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;the following 16 years. Depressive episodes in mothers were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;assessed by GPs twice during pregnancy (between 14 and 20 weeks&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and at 36 weeks) and twice during the first postnatal year (at&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;3 and 12 months), using the Clinical Interview &lt;I&gt;&lt;NOBR&gt;. . , (Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/125" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306996</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/28]]&gt;</url>
    <title>Aetiology - Antidepressant use during first trimester not associated with risk of major congenital malformations</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does duration of antidepressant use during the first trimester of pregnancy increase the risk of major congenital malformations?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;2329 women, pregnant between 1 January 1998 and 31 December 2002, meeting the following inclusion criteria: one diagnosis of psychiatric disorder before pregnancy (ICD-9); antidepressant use for 30 days or more in the year prior to pregnancy; aged 15–45 years at the beginning of pregnancy; and live or still birth at the end of pregnancy. Women were identified using three administrative databases of the Province of Quebec (RAMQ, MED-ECHO and ISQ databases). Mailed questionnaires were used to elicit information on confounding variables such as income, education, ethnicity and lifestyle factors. Exclusion criteria: women with mental retardation, certain psychotic or non-psychotic conditions; abortion and miscarriage.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Province of Quebec, Canada; recruitment January 1998–December 2002.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Exposure to antidepressants during the first trimester of pregnancy (0–14 weeks) was assessed for cases and controls. Women filling prescriptions . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Louise Howard&lt;/P&gt;
&lt;P&gt;Section of Community Mental Health, Health Service and Population Research Department, Institute of Psychiatry, King's College London, London, UK&lt;BR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/28" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383686</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/90.extract]]&gt;</url>
    <title>Aetiology - Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is antipsychotic polypharmacy a risk factor for death from natural causes in patients with schizophrenia?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;People&lt;/H3&gt;
&lt;P id=p-2&gt;Case–control study nested in cohort of 27 633 patients aged 18–53 years, with ICD-8 and ICD-10 diagnosed schizophrenia or other psychoses (mainly non-affective). 193 ‘cases’ were selected from those who died from natural causes between 1 January 2004 and 31 December 2005. Deaths due to suicide, homicide or accident and unexplained deaths were excluded. Up to 15 age- and sex-matched controls were identified per case and had to be alive at the date of death of respective case. Their index date was defined as the date of death of their matched case. Both cases and controls were included if they had filled at least one prescription for an antipsychotic and had been hospitalised for less than 240 days during the year prior to the date of death or the index date.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Denmark; January 1996 to December 2005.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Risk factors&lt;/H3&gt;
&lt;P id=p-4&gt;Antipsychotic use; monotherapy was defined as one prescription filled for a single antipsychotic within … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/90.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>317846</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/62]]&gt;</url>
    <title>Aetiology - Attention disturbances are associated with low birth weight in an urban community but not a suburban community</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;Question:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Do psychiatric problems associated with low birth weight differ&lt;SUP&gt; &lt;/SUP&gt;according to social advantage?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;People:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;1095 children randomly sampled from newborn discharge lists&lt;SUP&gt; &lt;/SUP&gt;(1983–1985), excluding those with severe neurological&lt;SUP&gt; &lt;/SUP&gt;impairment. The first assessment was carried out at age 6 years&lt;SUP&gt; &lt;/SUP&gt;at which time 823 children participated, 717 children participated&lt;SUP&gt; &lt;/SUP&gt;at age 11 years and 713 at age 17 years.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Setting:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Two hospitals in southeast Michigan, US; assessments performed&lt;SUP&gt; &lt;/SUP&gt;1990 to 2002.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Risk factors:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Low birth weight (&lt;IMG alt="&lt;=" src="/libraryImages/Mental%20Health/contentID317846/nelhImp_0000_les.gif" border=0&gt;2500 g) versus normal birth weight; urban&lt;SUP&gt; &lt;/SUP&gt;(lower social advantage) versus suburban place of residence.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Outcomes:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Psychiatric problems: attention disturbances, internalising&lt;SUP&gt; &lt;/SUP&gt;behaviours (eg, anxiety/depression), withdrawal and externalising&lt;SUP&gt; &lt;/SUP&gt;behaviours (eg, aggression, delinquent behaviour). These three&lt;SUP&gt; &lt;/SUP&gt;areas were assessed using the Child Behaviour Checklist (rated&lt;SUP&gt; &lt;/SUP&gt;by mothers) and Teacher’s Report From (rated by teachers)&lt;SUP&gt; &lt;/SUP&gt;for each child at 6, 11 and 17 years of age. Standardised cut-offs&lt;SUP&gt; &lt;/SUP&gt;were used to determine borderline/clinical disturbance levels.&lt;SUP&gt; &lt;/SUP&gt;Odds ratios (OR) were calculated after controlling &lt;NOBR&gt;&lt;EM&gt;. . .&lt;/EM&gt;&lt;/NOBR&gt; (Abstracted)&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/62" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>306992</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/24]]&gt;</url>
    <title>Aetiology - Bidirectional association between elevated depressive symptoms and type 2 diabetes</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do symptoms of depression predict type 2 diabetes and are people with type 2 diabetes more likely to develop depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;10 048 people aged 45–84 years participating in the Multi-Ethnic Study of Atherosclerosis. Participants were separated into people without type 2 diabetes at baseline (n = 5201) and those without depressive symptoms at baseline (n = 4,847). Exclusions: clinical cardiovascular disease, or missing data on diabetes status, depressive symptoms or covariates of interest at baseline or follow-up.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Six communities from Maryland, Illinois, North Carolina, California, New York and Minnesota, USA; recruitment July 2000–August 2002.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Risk factors of interest were type 2 diabetes in people without elevated depressive symptoms at baseline, and elevated depressive symptoms in those without type 2 diabetes at baseline. (See online notes for assessment of risk factors.)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Development of type 2 diabetes or elevated depressive symptoms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&lt;BR&gt;Design: Prospective cohort study.&lt;/P&gt;
&lt;P&gt;Follow-up period: Group without type 2 diabetes . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Susan A Everson-Rose&lt;/P&gt;
&lt;P&gt;Department of Medicine and Program in Health Disparities Research, University of Minnesota, MN, USA &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/24" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321528</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/95]]&gt;</url>
    <title>Aetiology - Binge drinking while pregnant may increase risk of mental health problems in offspring</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does a binge pattern of alcohol consumption during the second and third trimesters have an effect on the mental health and cognitive outcomes of the offspring?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;BR&gt;&lt;/STRONG&gt;8240 women taking part in The Avon Longitudinal Study of Parents and Children (ALSPAC). Women with due dates between April 1991 and December 1992 were invited to take part. Only women with children from singleton births who were alive at 1 year of age, and who provided information on alcohol consumption and completed the Strengths and Difficulties Questionnaire (SDQ) were included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Avon, UK; recruitment 1990–1992.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Alcohol consumption during pregnancy (assessed using postal questionnaires). At 18 weeks’ and 32 weeks’ gestation, mothers were asked about frequency and quantity of drinking during the previous weeks (number of glasses per day). Offspring of women who drank four or more alcoholic drinks a day (binge drinking) at least once in the past 4 weeks were compared with women . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/95" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328857</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/126]]&gt;</url>
    <title>Aetiology - Cancer history may affect link between psychological distress and cancer mortality</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Does psychological distress increase the risk of death from&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;cancer?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;A nationally representative sample of 15 453 men and women (aged&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;53–65 years, 44.9% male, with a mean follow-up period&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of 7.0 (3.3) years) surveyed in 1995, 1998 and 2003 as part&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of the Scottish Health Survey. In this sample, there were 295&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;people with a history of cancer.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Scotland, UK; 1995–2006.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Psychological distress, including symptoms of anxiety, depression&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and post-traumatic stress symptoms, as assessed with the General&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Health Questionnaire (GHQ-12), with a conventional cut-off score&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of x 4 to detect psychological distress. The risk of cancer mortality&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in relation to psychological distress was calculated, with months&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;as the time scale, using the Cox proportional hazards models.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Analyses were adjusted for age, gender, socioeconomic groupings,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;marital status, body mass index, smoking, alcohol intake, physical&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;activity and survey year (1995, 1998 or 2003).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Rate of cancer mortality (ICD-9 and ICD-10 classification).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;&lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/126" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317838</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/60]]&gt;</url>
    <title>Aetiology - Combat exposure increases risk of alcohol misuse in military personnel following deployment</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;How does combat exposure affect alcohol consumption, binge drinking&lt;SUP&gt; &lt;/SUP&gt;behaviour and other alcohol related problems in US military&lt;SUP&gt; &lt;/SUP&gt;personnel?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;48 481 people enrolled in the Millennium Cohort Study. Exclusions:&lt;SUP&gt; &lt;/SUP&gt;missing demographic or other covariate data; did not answer&lt;SUP&gt; &lt;/SUP&gt;alcohol outcome questions; deployed to Iraq or Afghanistan before&lt;SUP&gt; &lt;/SUP&gt;baseline assessment; or took survey while deployed.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Military service personnel, USA; recruitment July 2001 to June&lt;SUP&gt; &lt;/SUP&gt;2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Combat exposure during deployment, defined as: personally witnessing&lt;SUP&gt; &lt;/SUP&gt;a person’s death due to war, disaster of tragic event;&lt;SUP&gt; &lt;/SUP&gt;witnessing physical abuse; or seeing dead or decomposing bodies,&lt;SUP&gt; &lt;/SUP&gt;maimed soldiers or civilians, or prisoners of war or refugees.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;New onset of heavy weekly drinking, binge drinking or alcohol&lt;SUP&gt; &lt;/SUP&gt;related problems among people with no reported alcohol outcomes&lt;SUP&gt; &lt;/SUP&gt;at baseline; increased heavy weekly drinking, binge drinking&lt;SUP&gt; &lt;/SUP&gt;or alcohol related problems among people reporting alcohol outcomes&lt;SUP&gt; &lt;/SUP&gt;at baseline. Heavy weekly drinking was defined as more than&lt;SUP&gt; &lt;/SUP&gt;14 drinks/week for &lt;NOBR&gt;&lt;EM&gt;. . &lt;/EM&gt;(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/60" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>306994</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/26]]&gt;</url>
    <title>Aetiology - Current use of SSRIs and tricyclic antidepressants may increase the risk of non-vertebral fractures in the elderly</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;BR&gt;&lt;/STRONG&gt;Do selective serotonin reuptake inhibitors (SSRIs), tricyclic depressants (TCAs) and other antidepressants increase the risk of non-vertebral fractures in the elderly?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;7983 people aged &amp;gt;=55 years participating in the Rotterdam study (mean age 77.5 years, 39% male). Exclusions: lived in study area &amp;lt;1 year and &amp;lt;5 months of pharmacy data available at baseline. Participants were followed-up until diagnosis of fracture, death or end of study (2002).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General population, Ommoord, Rotterdam, The Netherlands; recruitment 1990–1993.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Antidepressant use, as identified from pharmacy dispensing records. Antidepressants were classified as SSRIs (fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine and escitalopram), TCAs (imipramine, clomipramine, opipramol, amitriptyline, nortriptyline, doxepine, dosulepine and maprotiline) or other antidepressants (tranylcypromine, moclobemide, mianserin, trazodone, nefazodone, mirtazapine and venlafaxine). Current antidepressant use was defined as use at time of fracture; past use was defined as history of use during the study but not at the time of the fracture.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;First non-vertebral fracture (reported by . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;BR&gt;&lt;/STRONG&gt;Susan J Diem&lt;/P&gt;
&lt;P&gt;Departments of Medicine and Epidemiology, University of Minnesota, Minneapolis, Minnesota, USA&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/26" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383658</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/89.extract]]&gt;</url>
    <title>Aetiology - Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is the antidepressant venlafaxine associated with an increased risk of sudden cardiac death compared with other antidepressants?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;People&lt;/H3&gt;
&lt;P id=p-2&gt;The cohort consisted of 207 384 new users of venlafaxine, fluoxetine, citalopram or dosulepin on or after 1 January 1995; 19 268 were new users of venlafaxine. New users were identified from the UK General Practice Research Database (GPRD) and were defined as users who had not been prescribed the medication in question in the year before cohort entry (incident prescription). For inclusion, users had to be aged 18–89 years and have a recorded diagnosis of depression or anxiety. Individuals were excluded if they had a history of life threatening ventricular tachyarrhythmia, cardioversion, aborted cardiac arrest or implantation of a cardiac defibrillator before study entry; advanced cardiomyopathy (hypertrophic or dilated); or congenital conduction disorder before or during the study. In the nested case control analysis, 568 cases were identified and 14 812 matched controls were … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This is article has abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/89.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available via ATHENS login.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>301970</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/126]]&gt;</url>
    <title>Aetiology - Deployment with combat exposure increases the risk of new-onset PTSD</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does military deployment and combat exposure increase risk of&lt;SUP&gt; &lt;/SUP&gt;new onset post-traumatic stress disorder?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;50 184 (65% of total) participants of the US military millennium&lt;SUP&gt; &lt;/SUP&gt;cohort who had participated in the first follow up at 3 years&lt;SUP&gt; &lt;/SUP&gt;(between June 2004 and February 2006). Participants were active&lt;SUP&gt; &lt;/SUP&gt;duty and Reserve/National Guard personnel. "Deployers" were&lt;SUP&gt; &lt;/SUP&gt;those who had served in support of the wars in Iraq or Afghanistan&lt;SUP&gt; &lt;/SUP&gt;for &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;1 day between baseline and follow-up. "Non-deployers" were&lt;SUP&gt; &lt;/SUP&gt;those who had not served at any time before follow up. Exclusions:&lt;SUP&gt; &lt;/SUP&gt;people already deployed at baseline, or first deployed at follow-up.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Military population, USA; recruitment between July 2001 and&lt;SUP&gt; &lt;/SUP&gt;June 2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Deployment; self-reported exposure to combat; witnessed physical&lt;SUP&gt; &lt;/SUP&gt;abuse; witnessed a person’s death due to war, disaster&lt;SUP&gt; &lt;/SUP&gt;or tragic event; seeing dead or decomposing bodies; maimed soldiers&lt;SUP&gt; &lt;/SUP&gt;or civilians, refugees or prisoners of war.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Post-traumatic stress disorder (PTSD) assessed by the standardised&lt;SUP&gt; &lt;/SUP&gt;civilian checklist. &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt; &lt;BR&gt;Coady B Lapierre, PhD, LSSP&lt;BR&gt;Tarleton State University - Central Texas, Killeen, Texas, USA&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/126" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302045</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/26]]&gt;</url>
    <title>Aetiology - Early childhood factors increase risk of post-traumatic stress disorder</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do early childhood factors increase the risk for development&lt;SUP&gt; &lt;/SUP&gt;of post-traumatic stress disorder (PTSD) following a traumatic&lt;SUP&gt; &lt;/SUP&gt;event?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;All people born during the one-year period between 1972 and&lt;SUP&gt; &lt;/SUP&gt;1973 in Dunedin, New Zealand.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Dunedin, New Zealand; 1972–2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Neurodevelopmental factors including prenatal or neonatal problems&lt;SUP&gt; &lt;/SUP&gt;(as recorded by clinicians during mothers’ pregnancy),&lt;SUP&gt; &lt;/SUP&gt;IQ and motor skills. Temperament (at ages 3 and 5 years), including&lt;SUP&gt; &lt;/SUP&gt;temperament factors (including difficult, sluggish and approach);&lt;SUP&gt; &lt;/SUP&gt;behaviour (at ages 5, 7, 9 and 11 years) assessing children’s&lt;SUP&gt; &lt;/SUP&gt;antisocial, worried/fearful and hyperactive behaviour. Family&lt;SUP&gt; &lt;/SUP&gt;environment including socioeconomic status, mother’s internalising&lt;SUP&gt; &lt;/SUP&gt;symptoms (assessed at child’s age 5, 7 and 9 years), use&lt;SUP&gt; &lt;/SUP&gt;of harsh discipline (assessed at ages 7 and 9), number of residence&lt;SUP&gt; &lt;/SUP&gt;changes, &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Jonathan Bisson&lt;BR&gt;Clinical Senior Lecturer in Psychiatry, University Hospital of Wales, Cardiff, UK&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/26" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306989</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/22]]&gt;</url>
    <title>Aetiology - Elderly women with larger social networks are less likely to develop dementia</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Are social networks associated with reduced incidence of dementia in elderly women?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;2249 women aged &amp;gt;77 years without a diagnosis of dementia at baseline (see outcomes for how dementia status was determined).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Kaiser Permanente Southern California health maintenance group, USA; 2001–2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Participants’ social network size assessed using the Lubben Social Network Scale-6 (LSNS-6). The scale measured the size of the social network (people heard from or seen at least once a month), perceived support network (people who could be called on for help) and perceived confidant network (people who could be talked to about private matters). The scale provides a total score between 0 and 30; higher scores indicate a larger network. Frequency of contact with family and friends was also assessed (less than 1, 1–2, 3–6 times/week and once a day). Analyses were adjusted for potential confounding factors, such as baseline cognitive status, age, education, hormone use and the . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Robert S Wilson&lt;/P&gt;
&lt;P&gt;Rush University Medical Center, Chicago, Illinois, USA &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/22" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377677</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/57.extract]]&gt;</url>
    <title>Aetiology - Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;If cannabis causes schizophrenia, how many cannabis users need to be prevented (number needed to prevent (NNP)) in order to prevent one case of schizophrenia in England and Wales? &lt;/P&gt;
&lt;H3&gt;People:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Model estimates the NNP for England and Wales, that is number of cannabis users to be prevented; estimate of schizophrenia or psychosis incidence from the Aetiology and Ethnicity in Schizophrenia survey conducted between 1997 and 1999. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;England and Wales.&lt;/P&gt;
&lt;H3&gt;Risk factors:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Cannabis use; estimate of risk of developing psychosis with heavy and light cannabis use (compared with non-user) based on data available in a recent meta-analysis. &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;NNP is defined as the number of heavy or light cannabis users who would need to be prevented in that year in order to prevent one incident case of schizophrenia or psychosis per year (both for men and women by age). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-6&gt;Aetiology: Modelling study.&lt;/P&gt;
&lt;H3&gt;Follow-up period:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-7&gt;Twelve-month exposure data. … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words.&lt;/EM&gt; &lt;EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/2/57.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>377678</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/59.extract]]&gt;</url>
    <title>Aetiology - Frequent childhood victimisation predicts later psychiatric problems in females</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;Can childhood bullying behaviour predict long-term mental health outcomes?&lt;/P&gt;
&lt;H3&gt;People:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Participants were 5038 children born in 1981 who had information available from parents, teachers and self-reports about bullying and victimisation at the age of 8 years. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Community setting in Finland and use of medical records. Assessment of bullying behaviour was made in 1989 when participants were 8 years old. The psychiatric outcomes were measured from January 2001 to December 2005 when the participants were 13 to 24 years old. &lt;/P&gt;
&lt;H3&gt;Risk factors:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;On the basis of data on childhood bullying or victimisation, children were classified into four groups: (1) never or only sometimes bullied and were not victimised according to parents, teachers and self; (2) those who frequently bullied, but were not victimised according to parents, teachers and self; (3) those who were frequently victimised (but did not bully) according to … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/59.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;A href="http://ebmh.bmj.com/content/13/2/59.extract" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>328855</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/124]]&gt;</url>
    <title>Aetiology - Limited evidence that bullying behaviour in children may be linked to later suicidal behaviour</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Does bullying behaviour in childhood increase the risk of later&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;suicide attempt or completed suicide in young adulthood?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;5813 children who represented a selected sample of the Epidemiological&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Multicentre Child Psychiatric Study (which included all children&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;born in Finland in 1981, n = 60 007) and were assessed at the&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;age of 8 years. 91.2% of the sample (5,302) had follow-up information&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;available at age 25 years.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;School districts and municipalities of Finland.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Bullying behaviour at the age of 8 years. Questionnaires were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;completed by the child at age 8 years, teachers and parents,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and included questions on being a perpetrator of bullying or&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;a victim of bullying. Bullying or victimisation were considered&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to exist even if reported by only one informant (child, parent&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;or teacher). Confounders were childhood conduct problems (assessed&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;using the Rutter parent questionnaire) and depression (assessed&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;using the 27 item Children’s Depression Inventory).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Suicide attempts &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/124" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344677</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/30.extract]]&gt;</url>
    <title>Aetiology - Long term antidepressant use linked to increased risk of diabetes</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does antidepressant use increase the risk of developing diabetes in adults aged 30 years or over?&lt;/P&gt;
&lt;H3&gt;People:&lt;/H3&gt;
&lt;P id=p-2&gt;165 958 people with depression prescribed antidepres-sants between 1 January 1990 and 30 June 2005, as recorded in the UK General Practice Research Database. Eligible participants had to be aged at least 30 years, with no diagnosis of diabetes or treatment with oral antidiabetics or insulin, and no treatment with antidepressants in the year before study entry. Participants were followed-up until the first date of new onset diabetes, change of antidepressant, death, end of registration with the GP practice or the end of the study. Cases were matched with up to four controls for age, gender and year of study entry. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Population study, UK general practices; January 1990-June 2005.&lt;/P&gt;
&lt;H3&gt;Risk factors:&lt;/H3&gt;
&lt;P id=p-4&gt;Exposure to antidepressants classified as tricyclic and tetracyclic, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors and other antidepressants. Recent exposure was defined as a prescription in the previous 6 months; former exposure between 6 and 12 months before; past exposure between 12 and 24 months before; and non-use was no use for 2 years. Duration … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article was abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/30.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302048</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/29]]&gt;</url>
    <title>Aetiology - Maternal affective or substance disorders are risk factors for subsequent pregnancy loss</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is pre-existing maternal mental illness associated with pregnancy&lt;SUP&gt; &lt;/SUP&gt;loss?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;1960 women enrolled in the National Comorbidity Survey, 963&lt;SUP&gt; &lt;/SUP&gt;of whom (49.1%) had a DSM-III-R psychiatric diagnosis. Exclusions:&lt;SUP&gt; &lt;/SUP&gt;women with conduct disorder, antisocial personality disorder,&lt;SUP&gt; &lt;/SUP&gt;and non-affective psychosis; and women who were currently pregnant&lt;SUP&gt; &lt;/SUP&gt;or had only terminations and no previous live births or pregnancy&lt;SUP&gt; &lt;/SUP&gt;losses.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General population, USA; data first collected in the 1990s.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;DSM-III-R psychiatric diagnosis of anxiety (general anxiety&lt;SUP&gt; &lt;/SUP&gt;disorder, panic disorder, simple phobia, social phobia, agoraphobia,&lt;SUP&gt; &lt;/SUP&gt;post-traumatic stress disorder), affective (depression, dysthymia&lt;SUP&gt; &lt;/SUP&gt;or mania), or substance disorders (drug or alcohol dependence&lt;SUP&gt; &lt;/SUP&gt;or abuse; not including tobacco) whose age at onset indicated&lt;SUP&gt; &lt;/SUP&gt;that they preceded pregnancy. Other risk factors were assessed&lt;SUP&gt; &lt;/SUP&gt;and adjusted for by multivariable &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Stephen R Zubrick &lt;BR&gt;Curtin University of Technology and the Institute for Child Health Research, Perth, Australia &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/29" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301971</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/127]]&gt;</url>
    <title>Aetiology - Maternal exposure to death of a first degree relative during first trimester of pregnancy increases risk of schizophrenia in offspring</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does exposure of pregnant women to adverse life events increase&lt;SUP&gt; &lt;/SUP&gt;risk of schizophrenia in offspring?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;688 146 women giving birth in Denmark between 1 January 1973&lt;SUP&gt; &lt;/SUP&gt;and 30 June 1995 and identified through the Medical Birth Registry.&lt;SUP&gt; &lt;/SUP&gt;Civil Registration records and the National Hospital Register&lt;SUP&gt; &lt;/SUP&gt;were used to link mothers to records of their close relatives&lt;SUP&gt; &lt;/SUP&gt;to determine exposure to deaths, diagnoses of cancer, heart&lt;SUP&gt; &lt;/SUP&gt;attacks or strokes in first-degree relatives. Offspring were&lt;SUP&gt; &lt;/SUP&gt;followed from age 10 years onwards until diagnosis of schizophrenia,&lt;SUP&gt; &lt;/SUP&gt;emigration, loss to follow-up, death or end of study (30 June&lt;SUP&gt; &lt;/SUP&gt;2005).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Population study, Denmark; recruitment January 1973 to June&lt;SUP&gt; &lt;/SUP&gt;1995.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Exposure during pregnancy to death or acute myocardial infarction,&lt;SUP&gt; &lt;/SUP&gt;stroke, cancer (ICD-10 diagnosis) in spouse, other child, father,&lt;SUP&gt; &lt;/SUP&gt;mother or sibling. Exposure date was the date of death or of&lt;SUP&gt; &lt;/SUP&gt;first hospital admission that led to diagnosis. Pregnancy was&lt;SUP&gt; &lt;/SUP&gt;defined as date of last menstrual period &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Marco Procopio, Dr, MD, MRCPsych &lt;BR&gt;West Elmbridge Community Mental Health Team, Surrey &amp;amp; Borders Partnership NHS Trust, Walton on Thames, Surrey, UK &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/127" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306997</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/29]]&gt;</url>
    <title>Aetiology - Maternal use of antipsychotics in early pregnancy: little evidence of increased risk of congenital malformations</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does the use of antipsychotics in early pregnancy increase the risk of congenital malformations?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;All births recorded on the Swedish Medical Birth Register between July 1995 and the end of 2005. This included 973 767 infants from 958 729 women, of whom 2908 reported using &amp;gt;=1 antipsychotic medication early in pregnancy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;BR&gt;&lt;/STRONG&gt;Sweden; all recorded births between July 1995 and end of 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Information about all drug use was routinely collected in the first antenatal interview with a midwife and recorded in the Medical Birth Register. Antipsychotic use was subsequently split into use of dixyrazine or prochlorperazine (irrespective of use of any other antipsychotic) and use of "other antipsychotics". Dixyrazine and prochlorperazine are commonly used in the treatment of nausea and vomiting in pregnancy. Women using lithium were not included in the main analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Congenital malformations, as recorded on the Medical Birth Register, the Swedish Register of Congenital Malformations and the . . . (Abstracted)&lt;BR&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;BR&gt;Adrienne Einarson&lt;/P&gt;
&lt;P&gt;The Motherisk Program, The Hospital for Sick Children, Toronto, Canada&lt;/P&gt;
&lt;P&gt;Thomas R Einarson&lt;/P&gt;
&lt;P&gt;The Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/29" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302020</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/56]]&gt;</url>
    <title>Aetiology - More severe symptoms of depression increase coronary heart disease mortality</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does depression increase the risk of death from coronary heart&lt;SUP&gt; &lt;/SUP&gt;disease?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;660 people (57% women) without coronary heart disease (CHD)&lt;SUP&gt; &lt;/SUP&gt;who were born in 1926 or earlier, and identified through a study&lt;SUP&gt; &lt;/SUP&gt;of chronic disease epidemiology in the elderly carried out in&lt;SUP&gt; &lt;/SUP&gt;southwestern Finland from 1990–1991. Presence of CHD was&lt;SUP&gt; &lt;/SUP&gt;identified through patient history, medical records and ECG.&lt;SUP&gt; &lt;/SUP&gt;Baseline exclusions: previous myocardial infarction, angina,&lt;SUP&gt; &lt;/SUP&gt;ischemic change on the ECG, or past coronary artery bypass graft&lt;SUP&gt; &lt;/SUP&gt;or angioplasty.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Rural Finland; 1990–2002.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Severity of depression (assessed with Zung Self-rating Depression&lt;SUP&gt; &lt;/SUP&gt;Scale (ZSDS); range 20–80 points; more severe symptoms&lt;SUP&gt; &lt;/SUP&gt;of depression classified as &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;45 points). Multivariable hazards&lt;SUP&gt; &lt;/SUP&gt;ratios were calculated using Cox proportional hazard regression,&lt;SUP&gt; &lt;/SUP&gt;accounting for potential predictors of mortality (hypertension,&lt;SUP&gt; &lt;/SUP&gt;diabetes, BMI, age, medications, smoking, marital status and&lt;SUP&gt; &lt;/SUP&gt;social factors). Analyses were carried out &lt;NOBR&gt;&lt;EM&gt;. . (Abstracted).&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Brooks B Gump&lt;/P&gt;
&lt;P&gt;Associate Professor of Psychology, Department of Psychology, SUNY Oswego, NY, USA &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/56" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321525</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/93]]&gt;</url>
    <title>Aetiology - Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What factors are associated with metabolic and cardiovascular adverse events in antipsychotic treated children and adolescents?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;4140 children and adolescents (aged &amp;lt;=17 years, mean age 10.4 years; 68% male; 42% white and 41% African American; enrolled in Medicaid for a minimum of 9 months each year) prescribed one of five atypical antipsychotics or two conventional antipsychotics, and a random sample of 4500 children and adolescents not prescribed any psychotropic medication, including antipsychotics, between 1 January 1998 and 31 December 2003.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Medicaid programme, South Carolina, USA; January 1996 to December 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Use of atypical or conventional antipsychotic use, multiple antipsychotics, mood stabilisers or selective serotonin reuptake inhibitors (SSRIs) based on pharmacy claim data. Analyses were adjusted for confounders, including age, sex, ethnicity and pre-existing conditions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Prevalence and incidence of metabolic conditions (obesity, type 2 diabetes mellitus, dyslipidaemia), hypertension, cardiovascular events, cerebrovascular events and orthostatic hypotension. Outcomes were identified by looking for . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/93" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302018</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/54]]&gt;</url>
    <title>Aetiology - New use of antipsychotic drugs in elderly people with dementia may increase the mortality risk</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA,ACUTE PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does new use of antipsychotics in elderly people with dementia&lt;SUP&gt; &lt;/SUP&gt;increase the risk of all-cause mortality?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;27 259 adults aged &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;66 years with dementia who had not taken&lt;SUP&gt; &lt;/SUP&gt;antipsychotics in the year before study entry. Exclusions: psychotic&lt;SUP&gt; &lt;/SUP&gt;disorders (other than behavioural or psychological symptoms&lt;SUP&gt; &lt;/SUP&gt;of dementia) or need for palliative care; those with baseline&lt;SUP&gt; &lt;/SUP&gt;antipsychotic use.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Ontario residents aged 66 years and over with diagnosis of dementia&lt;SUP&gt; &lt;/SUP&gt;(received between April 1997 and March 2002) identified through&lt;SUP&gt; &lt;/SUP&gt;the Ontario Health Insurance Plan or Discharge Abstract Database.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;New use of atypical or conventional antipsychotic drug use (identified&lt;SUP&gt; &lt;/SUP&gt;through Ontario Drug Benefit programme). Atypical antipsychotic&lt;SUP&gt; &lt;/SUP&gt;users were separately matched to non-users and to conventional&lt;SUP&gt; &lt;/SUP&gt;antipsychotic users. Separate analyses were conducted for community&lt;SUP&gt; &lt;/SUP&gt;dwelling and non-community dwelling (residential care) people.&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Helen C Kales &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Section of Geriatric Psychiatry, Department of Psychiatry, University of Michigan; and Ann Arbor VA HSR&amp;amp;D Center of Excellence, Ann Arbor, USA &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/54" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392726</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/102.extract]]&gt;</url>
    <title>Aetiology - New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is new use of anticonvulsants associated with an increased risk of suicidal acts or violent death?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;People&lt;/H3&gt;
&lt;P id=p-2&gt;297 620 people aged over 15 years of age who began taking an anticonvulsant medication between July 2001 and December 2006 and who had been continuously enrolled in the health plan for 6 months before the first anticonvulsant prescription. &lt;EM&gt;Exclusions:&lt;/EM&gt; Receiving multiple anticonvulsant drugs or attempted suicide or medical condition that could increase the risk of suicidal acts (cancer, HIV or hospitalisation for &amp;gt;30 days) in the 6 months prior to the first anticonvulsant prescription. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;14 US states from 1 January 2004 and 3 states from 1 January 2001; the cohort was followed until 31 December 2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Risk factors&lt;/H3&gt;
&lt;P id=p-4&gt;New use of anticonvulsant medication. The most commonly prescribed anticonvulsants were gabapentin (48% of participants), topiramate (19.4%), lamotrigine (7.5%) and valproate (6.2%), and the less commonly used drugs were carbamazepine, ethosuximide, felbamate, levetiracetam, oxcarbazepine, phenytoin, pregabalin, primidone, tiagabine and zonisamide. Topiramate was chosen as the main comparator drug as it was the second most commonly used … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/102.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302019</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/55]]&gt;</url>
    <title>Aetiology - Offspring of suicide attempters at greater risk of suicide events</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS,CHILD ABUSE AND NEGLECT,SEXUAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What are the predictors of new-onset suicidal behaviour in offspring&lt;SUP&gt; &lt;/SUP&gt;of parents with mood disorders?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;365 offspring of 203 parents with a history of mood disorder.&lt;SUP&gt; &lt;/SUP&gt;Average age of offspring was 20.2 years. Exclusion criteria:&lt;SUP&gt; &lt;/SUP&gt;previous suicide attempt or emergency referral for suicidal&lt;SUP&gt; &lt;/SUP&gt;ideation in the offspring.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Parents were recruited from two in-patient units in Pittsburgh&lt;SUP&gt; &lt;/SUP&gt;and New York City; the dates of data collection are unclear.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;DSM-IV affective disorders, schizophrenia and personality disorders&lt;SUP&gt; &lt;/SUP&gt;(in children over 14 years); history of suicidal behaviour in&lt;SUP&gt; &lt;/SUP&gt;parents (assessed with Columbia University Suicide History Form&lt;SUP&gt; &lt;/SUP&gt;and the Medical Damage Lethality Rating Scale); suicide ideation&lt;SUP&gt; &lt;/SUP&gt;in parents (assessed with Scale for Suicide Ideation); aggression&lt;SUP&gt; &lt;/SUP&gt;(Brown-Goodwin Lifetime History of Aggression); history of physical&lt;SUP&gt; &lt;/SUP&gt;or sexual abuse in parents or offspring. Other risk factors&lt;SUP&gt; &lt;/SUP&gt;assessed through self-report &lt;NOBR&gt;&lt;EM&gt;. . (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;BR&gt;&lt;/STRONG&gt;Ellenor Mittendorfer Rutz&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Karolinska Institutet, Stockholm, Sweden &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/55" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328858</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/127]]&gt;</url>
    <title>Aetiology - Parental violent crime, previous violence and substance abuse predict future violence in people with schizophrenia</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;What are the risk factors for violent crime in people with schizophrenia?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;13 806 people (8891 men, 4915 women) aged 15 years or older&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;with two or more hospitalisations for schizophrenia (ICD-8,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;ICD-9 and ICD-10 criteria) between 1 January 1973 and 31 December&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;2004. Diagnoses of schizophrenia were identified from the Hospital&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Discharge Register (HDR). After the second hospital discharge,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;participants were followed until their first conviction for&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;a violent crime, emigration, death or end of follow-up.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Population study, Sweden; recruitment January 1973–December&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;2004.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Data on admissions for drug abuse or dependence and alcohol&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;abuse or dependence (ICD-8, ICD-9 and ICD-10 criteria) were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;collected from the HDR. Data on convictions for violent crime&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;before discharge from hospital were collected from the National&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Crime Register. Data on people with schizophrenia were merged&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;with the Multi-Generation Register to find information about&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;their parents. The parents were then linked to the HDR &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/127" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301993</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/91]]&gt;</url>
    <title>Aetiology - Post-traumatic stress disorder increases the risk of new drug problems in young adults</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is post-traumatic stress disorder (PTSD) associated with risk&lt;SUP&gt; &lt;/SUP&gt;of new drug problems?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;988 young adults (aged 19–24 years) who had enrolled in&lt;SUP&gt; &lt;/SUP&gt;a large cohort study while in first grade and followed through&lt;SUP&gt; &lt;/SUP&gt;primary and middle school and on into adulthood. Of the original&lt;SUP&gt; &lt;/SUP&gt;2311 participants, only those at risk of a new drug use disorder&lt;SUP&gt; &lt;/SUP&gt;(those without lifetime DSM-IV drug dependence, and who did&lt;SUP&gt; &lt;/SUP&gt;not have clinical features of DSM-IV drug abuse or dependence&lt;SUP&gt; &lt;/SUP&gt;in the previous 12 months) were included in this study. Due&lt;SUP&gt; &lt;/SUP&gt;to funding problems, not all of these 1436 people were followed&lt;SUP&gt; &lt;/SUP&gt;up and 988 were included in the final analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Participants recruited in 19 primary public schools in 5 urban&lt;SUP&gt; &lt;/SUP&gt;areas in a large city in the USA; &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Grant J Devilly, Richard Gist &lt;/P&gt;
&lt;P&gt;Department of Psychology, The University of Melbourne, Melbourne, Australia&lt;BR&gt;Kansas City, Missouri Fire Department and Department of Preventive Medicine, Kansas City University of Medicine and Biosciences, Kansas City, USA &lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/91" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306995</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/27]]&gt;</url>
    <title>Aetiology - Prolonged exposure to SRIs during pregnancy increases risks of adverse neonatal outcomes</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What are the effects of timing and duration of gestational exposure to serotonin reuptake inhibitors (SRIs) on risks of adverse neonatal outcomes?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;BR&gt;&lt;/STRONG&gt;3500 infants conceived between 1 January 1998 and 26 March 2001 whose mothers had used SRIs during pregnancy. Neonates were identified from the British Columbia Linked Health Database. Maternal mood diagnoses were obtained from Ministry of Health MSP ICD-9 codes referring to depression. These records were linked to maternal prescription records for SRI antidepressants, benzodiazepines, other antidepressants and antipsychotic medications dispensed between 1 January 1998 and 31 March 2002 (data obtained from PharmaNet).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General population, British Columbia, Canada; recruitment January 1998–March 2002.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Early gestational exposure to SRI (infants of mothers discontinuing the SRI in the first or second trimester and not resuming the SRI during pregnancy); late gestational exposure to SRI (infants of mothers with an SRI prescription during the first or second trimester and continuing to take . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Salvatore Gentile&lt;/P&gt;
&lt;P&gt;Department of Mental Health, ASL Salerno 1 Mental Health Centre n. 4, Cava de' Tirreni, Italy&lt;/P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/27" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/27" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>302049</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/30]]&gt;</url>
    <title>Aetiology - Reduced gestational age associated with an increased likelihood of depression in later life</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Are gestational age and low birth weight associated with depressive&lt;SUP&gt; &lt;/SUP&gt;symptoms in adult life?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;752 women and 619 men who were born at full term (gestational&lt;SUP&gt; &lt;/SUP&gt;age 259–294 days), selected from a larger random sample&lt;SUP&gt; &lt;/SUP&gt;of all those born at Helsinki University Central Hospital in&lt;SUP&gt; &lt;/SUP&gt;1934–44 for whom birth and child welfare records were&lt;SUP&gt; &lt;/SUP&gt;available and who could be identified by personal ID numbers&lt;SUP&gt; &lt;/SUP&gt;in Finland in 1971.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Community setting in Finland; cohort born 1934–44, date&lt;SUP&gt; &lt;/SUP&gt;of analyses not reported.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Length of gestation, birth weight, newborn length and head circumference&lt;SUP&gt; &lt;/SUP&gt;from birth records. Father’s occupation was also extracted&lt;SUP&gt; &lt;/SUP&gt;to determine social class. Analyses of the effect of body size&lt;SUP&gt; &lt;/SUP&gt;were adjusted for gender and length of gestation, and analyses&lt;SUP&gt; &lt;/SUP&gt;of length of gestation adjusted for gender and birth weight.&lt;SUP&gt; &lt;/SUP&gt;Analyses also adjusted for &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;H3&gt;Commentator: &lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Catharine R Gale &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/30" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344678</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/31.extract]]&gt;</url>
    <title>Aetiology - Schizophrenia and comorbid substance abuse substantially increases risks of violent crime</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the risk of violent crime in people with schizophrenia, and does substance abuse mediate this risk?&lt;/P&gt;
&lt;H3&gt;People:&lt;/H3&gt;
&lt;P id=p-2&gt;8003 people (5243 men, 2760 women, 4674 with unaffected full siblings) aged 15 years or older with discharges from two or more hospitalisations for schizophrenia (ICD-8, ICD-9 and ICD-10 criteria) between 1 January 1973 and 31 December 2006. Diagnoses of schizophrenia were identified from the Hospital Discharge Register (HDR). Ten age and gender matched controls were selected from the general population for each person with schizophrenia (80 025 controls). 8123 full sibling controls were compared with the 4674 people with schizophrenia with unaffected full siblings. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Population study, Sweden; recruitment January 1973-December 2006.&lt;/P&gt;
&lt;H3&gt;Risk factors:&lt;/H3&gt;
&lt;P id=p-4&gt;Data on admissions for drug abuse or dependence and alcohol abuse or dependence (ICD-8, ICD-9 and ICD-10 criteria) were collected from the HDR. Data on convictions for violent crime (see outcomes for definition) were collected from the National Crime Register for people with schizophrenia and controls. Data on people with schizophrenia were merged … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 worods. &lt;A href="http://ebmh.bmj.com/content/13/1/31.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301995</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/93]]&gt;</url>
    <title>Aetiology - Schizophrenia associated with increased risk of colon cancer but reduced risk of respiratory cancer</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Are people with schizophrenia or bipolar disorder at increased&lt;SUP&gt; &lt;/SUP&gt;risk of developing any of six common cancers?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;40 441 adults (cases; aged 25–100 years) with first record&lt;SUP&gt; &lt;/SUP&gt;of breast, colon, rectal, respiratory, prostate or gastroesophageal&lt;SUP&gt; &lt;/SUP&gt;cancer during the study period (including postmortem diagnoses),&lt;SUP&gt; &lt;/SUP&gt;plus 193 290 controls (up to 5 per case selected by incidence&lt;SUP&gt; &lt;/SUP&gt;density sampling) matched by age, sex and general practice,&lt;SUP&gt; &lt;/SUP&gt;and alive at the time of cancer diagnosis in their matching&lt;SUP&gt; &lt;/SUP&gt;case (index date). Cases and controls were selected from just&lt;SUP&gt; &lt;/SUP&gt;over 4 million people registered with general practices recorded&lt;SUP&gt; &lt;/SUP&gt;on the QRESEARCH electronic database during the study period.&lt;SUP&gt; &lt;/SUP&gt;This database contains anonymised UK primary care records for&lt;SUP&gt; &lt;/SUP&gt;a representative sample of 6% of all general practices in the&lt;SUP&gt; &lt;/SUP&gt;UK. &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Jeff J Guo &lt;/P&gt;
&lt;P&gt;University of Cincinnati Medical Center, Cincinnati, Ohio, USA &lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/93" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306991</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/23]]&gt;</url>
    <title>Aetiology - Short term use of antipsychotics increases the risk of serious adverse events in elderly people with dementia</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do antipsychotics increase the risk of serious adverse events in elderly people with dementia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;20 682 people living in the community and 20 559 nursing home residents with a diagnosis of dementia (ICD-9 and ICD-10) and &amp;gt;65 years of age. All eligible individuals resident in Ontario between 1 April 1997 and 31 March 2004 were identified and their prescription data for this period obtained. Three equally sized matched groups within the community and nursing home cohorts were selected using propensity matching: atypical antipsychotic use, conventional antipsychotic use and no antipsychotic but at least one other medication prescribed (control group). Each group in the community cohort consisted of 6894 people and each group in the nursing home residents’ cohort had 6853 members. The matched groups were similar in demographic and clinical characteristics. Exclusions: history of schizophrenia, Huntington’s disease, tics, dialysis, extrapyramidal symptoms, parkinsonism, trauma, hip/pathological fractures during 5 years prior to . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Eleonora Esposito&lt;/P&gt;
&lt;P&gt;Dipartimento di Medicina e Sanità Pubblica Sezione di Psichiatria e Psicologia Clinica, Università di Verona. WHO Collaborating Centre for Research and Training in Mental Health and Service evaluation, Verona, Italy &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/23" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317845</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/61]]&gt;</url>
    <title>Aetiology - Small for gestational age boys at increased risk of later psychiatric hospitalisation</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Is being born preterm or small for gestational age, or both,&lt;SUP&gt; &lt;/SUP&gt;associated with psychiatric hospitalisation in adolescence and&lt;SUP&gt; &lt;/SUP&gt;early adulthood?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;155 944 boys and 148 281 girls who were registered in the Swedish&lt;SUP&gt; &lt;/SUP&gt;Medical Birth Register and the Swedish Hospital Discharge Register.&lt;SUP&gt; &lt;/SUP&gt;Participants had to be alive and living in Sweden at age 13&lt;SUP&gt; &lt;/SUP&gt;years. Exclusions: children with missing values on gestational&lt;SUP&gt; &lt;/SUP&gt;length or birth weight, whose mother or father could not be&lt;SUP&gt; &lt;/SUP&gt;identified or with very high birth weights compared with length&lt;SUP&gt; &lt;/SUP&gt;of gestation.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Sweden; registry data collected on births from 1973 to 1975&lt;SUP&gt; &lt;/SUP&gt;and on discharge diagnoses from 1987 to 1996.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Preterm birth (less than 37 weeks’ gestation) or being&lt;SUP&gt; &lt;/SUP&gt;small for gestational age (SGA, birth weight less than 2 SDs&lt;SUP&gt; &lt;/SUP&gt;below the mean birth weight defined by Swedish external standards&lt;SUP&gt; &lt;/SUP&gt;from 1996), or both. Adjustments were made for medical diagnoses&lt;SUP&gt; &lt;/SUP&gt;related to delivery or pregnancy. Maternal age, &lt;NOBR&gt;&lt;EM&gt;.&lt;/EM&gt; . (Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/61" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>302046</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/27]]&gt;</url>
    <title>Aetiology - Social anxiety in middle childhood: link with behavioural inhibition when young</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER,EMOTIONAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is behavioural inhibition in early childhood a risk factor for&lt;SUP&gt; &lt;/SUP&gt;mood, disruptive behaviour or anxiety disorders in middle childhood?&lt;SUP&gt; &lt;/SUP&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;284 children aged 21 months to 6 years, whose parents had been&lt;SUP&gt; &lt;/SUP&gt;treated for DSM-III-R panic disorder or major depression without&lt;SUP&gt; &lt;/SUP&gt;panic disorder or agoraphobia, or whose parents did not have&lt;SUP&gt; &lt;/SUP&gt;major anxiety or mood disorders and had never received psychiatric&lt;SUP&gt; &lt;/SUP&gt;treatment. Main exclusions: acute psychosis or suicidal behaviour&lt;SUP&gt; &lt;/SUP&gt;in parents.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Parents with panic disorder or major depression were recruited&lt;SUP&gt; &lt;/SUP&gt;from hospital out-patient and Health Maintenance Organizations&lt;SUP&gt; &lt;/SUP&gt;settings and the control group was recruited through community&lt;SUP&gt; &lt;/SUP&gt;and hospital-based advertising; recruitment 1993–8.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Behavioural inhibition at baseline (assessed through three age-specific,&lt;SUP&gt; &lt;/SUP&gt;laboratory-based observational protocols).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Mood, disruptive behaviour or anxiety disorders in middle childhood&lt;SUP&gt; &lt;/SUP&gt;&lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Katharina Manassis &lt;/P&gt;
&lt;P&gt;Hospital for Sick Children, University of Toronto, Toronto, Canada&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/27" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392725</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/101.extract]]&gt;</url>
    <title>Aetiology - Spouses of people with incident dementia are at sixfold increased risk of developing dementia themselves</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,TREATMENT AND CARE,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is caring for a spouse with dementia associated with an increase the care giver's risk of developing dementia?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;People&lt;/H3&gt;
&lt;P id=p-2&gt;1221 married couples aged 65 or older (mean age husbands 75.7 years, wives 73.1 years) without dementia were at baseline. All participants were assessed for dementia at the start of the study and every 3 years subsequently. A screening questionnaire (Mini-Mental State Examination (3MS) or Informant Questionnaire in Cognitive decline in the Elderly (IQCODE)) was used to identify those with possible dementia. These individuals plus a 19% subsample of other participants were given an in depth clinical assessment including history taking, a brief physical evaluation, a structured neurological examination and a battery of neuropsychological of tests. At the first two screening assessments, the Dementia Questionnaire (DQ) was completed before the clinical assessment. Working diagnoses of dementia were made according to DSM-III-R criteria based on a review of all results by the assessment team, a geriatric psychiatrist and neuropsychologist. Individuals with a working dementia diagnosis had further psychiatric evaluation and laboratory studies and were reassessed after 18 months. Final consensus diagnosis was made based on all available information by a multidisciplinary consensus panel of dementia experts, with onset defined as the year in which the individual unambiguously met DSM-III-R criteria for … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/101.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317834</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/58]]&gt;</url>
    <title>Aetiology - Starting a conventional antipsychotic increases risk of death more than an atypical antipsychotic in elderly people with dementia</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Are conventional antipsychotics associated with similar rates&lt;SUP&gt; &lt;/SUP&gt;of cause specific death as atypical antipsychotics in elderly&lt;SUP&gt; &lt;/SUP&gt;people with dementia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;37 241 people (&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;65 years) who filled a prescription for an antipsychotic&lt;SUP&gt; &lt;/SUP&gt;for the first time (index prescription) between 1 January 1996&lt;SUP&gt; &lt;/SUP&gt;and 31 December 2004, including 12 882 people starting conventional&lt;SUP&gt; &lt;/SUP&gt;and 24 359 starting atypical antipsychotics. Data were acquired&lt;SUP&gt; &lt;/SUP&gt;from a comprehensive healthcare utilisation database that recorded&lt;SUP&gt; &lt;/SUP&gt;inpatient and outpatient information and pharmacy dispensing&lt;SUP&gt; &lt;/SUP&gt;for all people coming into contact with the health service during&lt;SUP&gt; &lt;/SUP&gt;the study period. Exclusion criteria: diagnosis of cancer within&lt;SUP&gt; &lt;/SUP&gt;12 months prior to the index prescription; antipsychotic prescription&lt;SUP&gt; &lt;/SUP&gt;filled within 12 months prior to the index prescription.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;General population, British Columbia, Canada; 1996 to 2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;First time antipsychotic use (conventional or atypical).&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Death within 180 days of starting antipsychotic medication and&lt;SUP&gt; &lt;/SUP&gt;cause of death (all non-cancer causes; cardiovascular; cardiovascular&lt;SUP&gt; &lt;/SUP&gt;death outside hospital; infection; &lt;NOBR&gt;&lt;EM&gt;. .&lt;/EM&gt; .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/58" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>301994</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/92]]&gt;</url>
    <title>Aetiology - Sudden infant death syndrome is associated with parental psychiatric admission</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is sudden infant death syndrome (SIDS) associated with parental&lt;SUP&gt; &lt;/SUP&gt;psychiatric admission?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;All Danish infants born between January 1973 and December 1998,&lt;SUP&gt; &lt;/SUP&gt;identified through the Civil Registration System (n = 1 439&lt;SUP&gt; &lt;/SUP&gt;982).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Denmark; January 1973 to December 1998.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;First parental inpatient admission (after age 16 years) for&lt;SUP&gt; &lt;/SUP&gt;an ICD-10 psychiatric diagnosis or alcohol- or drug-related&lt;SUP&gt; &lt;/SUP&gt;disorder occurring before their infant’s first birthday&lt;SUP&gt; &lt;/SUP&gt;or death (identified through the Psychiatric Central Register&lt;SUP&gt; &lt;/SUP&gt;from April 1969 onwards). Time dependent stratification was&lt;SUP&gt; &lt;/SUP&gt;used to categorise exposure by person-years of risk following&lt;SUP&gt; &lt;/SUP&gt;first admission. Results were adjusted according to whether&lt;SUP&gt; &lt;/SUP&gt;the mother, father or both parents had been admitted.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;SIDS and other natural or unnatural causes of death, identified&lt;SUP&gt; &lt;/SUP&gt;through the national Causes of Death Register using &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;/P&gt;
&lt;P&gt;Lena J Rane&lt;SUP&gt;&lt;/SUP&gt;, Louise M Howard&lt;SUP&gt;&lt;/SUP&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;South London and Maudsley NHS Foundation Trust, London, UK&lt;BR&gt;Institute of Psychiatry and South London and Maudsley NHS Foundation Trust, London, UK &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/92" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321529</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/96]]&gt;</url>
    <title>Aetiology - Suicide rate in young people in the UK declined from 1997 to 2003</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What was the suicide rate among young people in the UK between 1997 and 2003, and what proportion had been in contact with mental health services prior to their death?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;All young people in the UK, aged 10–19 years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General population, UK, 1 January 1997 to 31 December 2003.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Annual suicide data were obtained from the Office of National Statistics for England and Wales and from the General Register Office for Scotland and Northern Ireland. The rate of suicide per 100 000 per year was calculated using mid-year population estimates from National Statistics Online (see online notes for more details).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Coroner’s verdict of suicide or undetermined death (open verdict).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design: &lt;BR&gt;&lt;/STRONG&gt;Ecological study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There were 1722 deaths by suicide in people aged 10–19 years between 1997 and 2003. The majority (1598 cases, 93%) of these deaths were adolescents aged between 15 and 19 years with a male to female ratio of . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/96" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321523</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/92]]&gt;</url>
    <title>Aetiology - Typical and atypical antipsychotics increase risk of sudden cardiac death</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,BIPOLAR DISORDER,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DELIRIUM,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the risk of sudden cardiac death with typical and atypical antipsychotics?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;BR&gt;&lt;/STRONG&gt;279 907 Medicaid enrolees, aged 34–74 years (mean 45.7 years; 65.2% women), who were either currently taking a single antipsychotic (n = 93 307) or no antipsychotics (n = 186 600). Eligible antipsychotic users were those having at least one qualifying day of use of antipsychotic drugs during the study period. Two controls were randomly selected for each antipsychotic user, with matching for age, gender and first day of follow-up (defined as the first qualifying day for each antipsychotic user). Controls could subsequently become users of antipsychotic drugs. As well as the overall cohort, a subcohort matched for propensity scores was used in secondary analyses. Follow-up ended at the end of the study period, death, termination of Medicaid enrolment or if the participant subsequently met any of the study exclusion criteria. People could re-enter the study if . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/92" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301969</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/125]]&gt;</url>
    <title>Aetiology - Use of antidepressants in pregnancy does not increase risk of postpartum haemorrhage</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do selective serotonin reuptake inhibitors (SSRIs) and other&lt;SUP&gt; &lt;/SUP&gt;antidepressants increase risk of postpartum haemorrhage if taken&lt;SUP&gt; &lt;/SUP&gt;in late pregnancy?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;BR&gt;28 863 Canadian women aged 16–45 years who received government-funded&lt;SUP&gt; &lt;/SUP&gt;prescription cover for drugs in the 2 years prior to the delivery&lt;SUP&gt; &lt;/SUP&gt;of their baby identified through the Ontario Drug Benefit (ODB)&lt;SUP&gt; &lt;/SUP&gt;database. Cases (n = 2460) were women in this cohort with a&lt;SUP&gt; &lt;/SUP&gt;diagnosis of postpartum haemorrhage following a vaginal or caesarean&lt;SUP&gt; &lt;/SUP&gt;delivery (as reflected in the Canadian Institute for Health&lt;SUP&gt; &lt;/SUP&gt;Information Discharge Abstract Database); if haemorrhage occurred&lt;SUP&gt; &lt;/SUP&gt;in more than one pregnancy, only the first was included. Exclusions:&lt;SUP&gt; &lt;/SUP&gt;several medical conditions including alcoholism, liver disease,&lt;SUP&gt; &lt;/SUP&gt;thrombosis, malignant neoplasia, pulmonary embolism, platelet&lt;SUP&gt; &lt;/SUP&gt;defects, and hereditary bleeding disorders and exposure to particular&lt;SUP&gt; &lt;/SUP&gt;drugs (antipsychotics, anticonvulsants, anticoagulants, monoamine&lt;SUP&gt; &lt;/SUP&gt;oxidase inhibitors, more than one antidepressant, mood stabilisers,&lt;SUP&gt; &lt;/SUP&gt;antiplatelets and systemic corticosteroids). Control women (26&lt;SUP&gt; &lt;/SUP&gt;403; up to 10 for each case) were women &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Eibert R Heerdink, PhD &lt;BR&gt;Department of Pharmacoepidemiology &amp;amp; Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/125" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306993</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/25]]&gt;</url>
    <title>Aetiology - Varying effects of psychotropic medications on fracture risk in older people</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How do different psychotropic medications affect the risk of fractures in elderly people?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;People:&lt;BR&gt;&lt;/STRONG&gt;63 081 people aged 50 years and older identified through the Canadian Manitoba Health database. Cases (n = 15 792) were people with vertebral, wrist or hip osteoporotic fractures (ICD-9-CM). Controls (n = 47 289; up to three for each case) were those without osteoporotic fractures. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Exclusions:&lt;/STRONG&gt; did not have continuous health cover during the study period, resident in long term care facility, osteoporosis drug use in the year prior to fracture.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Manitoba, Canada; April 1996–March 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;BR&gt;Use of psychotropic medications. These included selective serotonin reuptake inhibitors (SSRIs), other monoamine antidepressants, benzodiazapines, typical antipsychotics, atypical antipsychotics and lithium. Use of psychotropic medications was defined as current use (&amp;lt;120 days before index date), past use (within 121–365 days before the index date) and non-use (&amp;gt;365 days before the index date). The Manitoba drug dispensing database was used as . . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;BR&gt;&lt;/STRONG&gt;Peter Vestergaard&lt;/P&gt;
&lt;P&gt;Associate Professor of Calcium Metabolic Disorders, The Osteoporotic Clinic, Aarhus, Denmark &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/25" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328852</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/123]]&gt;</url>
    <title>Aetiology - Young people leaving the UK armed forces at increased risk of suicide</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;What is the rate of suicide, timing of suicide, risk factors&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;for suicide and rate of contact with mental health services&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;among individuals leaving the UK armed forces?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;People:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;233 803 individuals leaving the British Army (59%), Naval Service&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(22%) or Royal Air Force (20%) between 1 April 1996 and 31 December&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;2005. Median age was 25 years (20–34 years) and 90% were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;male. Data were compiled by the Defence Analytical Services&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Agency (DASA). Reservists and people serving in the Gurkha regiment&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;were excluded.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Population study, UK; April 1996–December 2005.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Risk factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;The database of those who had left the armed service was linked&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;with suicide data. Survival analyses using Cox’s proportional&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;hazards models were calculated to assess the effects of age&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and length of service on suicide rate. The effect of gender,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;rank, training, marital service and length of service on suicide&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;rate were also assessed. Rate of contact with the &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/123" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;BR&gt;&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291087</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.pssru.ac.uk/pdf/dp2536.pdf]]&gt;</url>
    <title>Age Discrimination in Mental Health Services</title>
    <publicationDate>2008-06-26T00:00:00</publicationDate>
    <publisher>Personal Social Services  Research Unit</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,AGE GROUPS,SECONDARY &amp; TERTIARY SERVICES,PUBLIC HEALTH,SERVICES,MONTHLY ADDITIONS,POPULATIONS,MANAGEMENT &amp; INTERVENTIONS,GROUPS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Department commissioned two literature reviews and two research studies on the costs and benefits of eliminating age discrimination in the provision of health and social care. This was to inform decisions on whether to pursue legislation to outlaw discrimination in the provision of health and social services.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Executive summary&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Aim&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The UK government is considering the introduction of legislation to outlaw age discrimination in the provision of public services. The Department of Health commissioned a short piece of research to explore the extent of age discrimination in mental health services. Three broad issues are addressed in this report: inequalities between adult and older people’s mental health services; inequalities between adults and older people with mental health problems in their use of health and social care services; and knowledge about the likely single equalities legislation in current services and the possible costs of implementation. The report does not examine differences in outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Findings from interviews with mental health organisations&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;There is very little knowledge within mental health organisations about the new legislation. There is, however, optimism that it will help improve services for older people with mental health problems by removing some of the barriers to services, and by providing services that are at least on par with adult services.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Interviewees generally acknowledged that age discrimination exists within current mental health services, although in some cases this is indirect rather than direct discrimination, and often due to the way organisations have developed historically. Each of the areas had a separate service for working age and older adults. There was some variation in the way transition between these services was managed but new users over 65 years would always be assessed within the older people’s service.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Despite a stated belief that older people should be able to access the same services as those under 65 years, often older people’s teams did not know about services, such as supported employment or assertive outreach, which were managed by the adult teams.&lt;/P&gt;
&lt;P&gt;Ageist attitudes on the part of staff and within organisations more generally also inhibited access to the level of support experienced by younger adults. There was also a generally held view among interviewees that there were fewer services for older people and that they tended to be less well-staffed. Low levels of resources for identification and early intervention work was highlighted as having led to high levels of unmet need, particularly for older people with anxiety and depression.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>277148</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.crimereduction.homeoffice.gov.uk/drugsalcohol/drugsalcohol097.pdf]]&gt;</url>
    <title>Alcohol strategy local implementation toolkit</title>
    <publicationDate>2008-01-11T00:00:00</publicationDate>
    <publisher>HM Government</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ALCOHOL MISUSE,CHILD AND ADOLESCENT CONDITIONS,SUBSTANCE MISUSE,MENTAL HEALTH,ADULT CONDITIONS,INDIVIDUAL BEHAVIOUR,STRATEGY,TEAMWORK,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,ALCOHOL CONSUMPTION,GOVERNMENT &amp; LAW,GOVERNMENT,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This toolkit is a resource to help local teams develop strategies to address alcohol-related crime, ill health and other harm in line with Safe. Sensible. Social. The next steps in the National Alcohol Strategy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This toolkit is a resource to help local teams develop strategies to address alcohol-related crime, ill health and other harm in line with Safe. Sensible. Social. The next steps in the National Alcohol Strategy.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It is written specifically to help alcohol leads and others within local authorities, primary care trusts (PCTs), children’s services and delivery partnerships such as Crime and Disorder Reduction Partnerships (CDRPs) and Drug and Alcohol Action Teams (DAATs) – the people most likely to be responsible for developing and delivering alcohol strategies locally. It will also be useful to individual agencies tackling alcohol misuse.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The toolkit is based on the Local Alcohol Strategy Toolkit produced by London Drug and Alcohol Network and Alcohol Concern in 2004 (see &lt;A href="http://www.localalcoholstrategies.org.uk/" target="_blank"&gt;www.localalcoholstrategies.org.uk&lt;/A&gt;). It provides a step-by-step process on how to develop a local alcohol strategy, and suggests a range of activities to help with the three key strategic areas of health, community safety and children and young people.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333493</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/hunger-hormone-Alzheimers-disease.aspx]]&gt;</url>
    <title>Alzheimer's may be linked to hormone</title>
    <publicationDate>2009-12-16T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,CAUSES AND PREVENTION,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A hormone linked to appetite “could offer hope to prevent Alzheimer’s disease”, according to &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; The newspaper reported that people with the highest levels of the hormone leptin were four times less likely to develop Alzheimer’s than those with the lowest.]]&gt;</body>
  </document>
  <document>
    <id>334451</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Alzheimers-nutrient-milkshake-souvenaid.aspx]]&gt;</url>
    <title>Alzheimer's nutrient drink tested</title>
    <publicationDate>2010-01-08T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,CAUSES AND PREVENTION,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Scientists have created an “anti-Alzheimer's milkshake” that boosts memory, according to the &lt;EM&gt;Daily Mail&lt;/EM&gt;. The newspaper says that the “once-a-day miracle drink” could be available within two years.]]&gt;</body>
  </document>
  <document>
    <id>346701</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/purpose-in-life-Alzheimers.aspx]]&gt;</url>
    <title>Alzheimer's risk linked to outlook</title>
    <publicationDate>2010-03-02T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ “Elderly people with a strong sense of purpose in life face a reduced risk of developing Alzheimer's disease,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reports. The finding comes from research that assessed the outlook on life in 900 elderly people, following them for several years to see which of them developed cognitive problems.]]&gt;</body>
  </document>
  <document>
    <id>342415</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/ambidextrous-link-to-ADHD-and-mental-health.aspx]]&gt;</url>
    <title>Ambidextrous behaviour studied</title>
    <publicationDate>2010-01-26T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Ambidextrous children are “more likely to have mental health problems and difficulties in school”, according to &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The news is based on a study of 8,000 children that assessed how hand dominance was linked to behaviour, language ability and school performance at eight and 16 years. This research had a number of limitations, including the fact that only 87 children were ambidextrous. Also, rates of developmental and mental health problems were based on the results of questionnaires given to the children, parents and teachers and not on professional assessments. Without formal assessments it is not possible to determine whether the children truly had conditions such as ADHD.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296427</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/]]&gt;</url>
    <title>Annals of Internal Medicine</title>
    <publicationDate></publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"Established in 1927 by the American College of Physicians (ACP), the Annals of Internal Medicine is the leading journal for studies in internal medicine. The purpose of the journal–to promote excellence in the clinical practice of internal medicine–is supported by presentation of a wide variety of experimental and clinical subject matter in the Article, Brief Communication, Update, and Review formats. And to support the belief that physicians should also be well-informed citizens of both the medical community and society at large, Annals offers background and discussion of issues that influence both physicians and patients. This information is primarily carried in the Perspective, In the Balance, and Editorial formats. In addition, the journal presents personal narratives in the On Being a Doctor and the On Being a Patient formats that convey the feeling and the art of medicine."&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Articles 
&lt;LI&gt;Reviews 
&lt;LI&gt;Clinical Guidelines 
&lt;LI&gt;Editorials 
&lt;LI&gt;On Being a Doctor 
&lt;LI&gt;Letters 
&lt;LI&gt;Summaries for patients&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Published twice per month.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>275526</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mind.org.uk/NR/rdonlyres/A000B238-4E7E-46E3-8735-3C5E6038EBA5/0/Anotherassault.pdf]]&gt;</url>
    <title>Another assault: Mind's campaign for equal access to justice for people with mental health problems</title>
    <publicationDate>2007-11-29T00:00:00</publicationDate>
    <publisher>MIND</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,INDIVIDUAL BEHAVIOUR,MENTAL &amp; BEHAVIOURAL DISORDERS,DETERMINANTS,PUBLIC HEALTH,SOCIAL DETERMINANTS,MONTHLY ADDITIONS,2009 SEPTEMBER,ABUSE,ANTISOCIAL BEHAVIOUR,CRIME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Mind's new research exposes shockingly high levels of bullying, harassment and exploitation experienced by people with mental health problems while living in the community.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Mind's campaign for equal access to justice for people with mental health problems&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;Too often people with mental health problems are reluctant to report crimes.&lt;/P&gt;
&lt;P&gt;One victim told Mind that contact with the police exposed them to yet more discrimination and vulnerability: "The system of investigation is another assault."&lt;/P&gt;
&lt;P&gt;Mind's new research exposes shockingly high levels of bullying, harassment and exploitation experienced by people with mental health problems while living in the community.&lt;/P&gt;
&lt;P&gt;Mind believes everyone has an equal right to personal safety, and that people&amp;nbsp; experiencing mental distress have the same rights to justice as anyone else.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388531</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=388531]]&gt;</url>
    <title>Antipsychotic drugs and blood clots</title>
    <publicationDate>2010-09-22T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Antipsychotic drugs and blood clots&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;“Antipsychotic drugs taken by thousands in the UK raise the risk of dangerous blood clots,” BBC News reported. &lt;/P&gt;
&lt;P&gt;Antipsychotic medicines are mainly used to treat psychiatric illnesses such as schizophrenia and bipolar disorder. The study behind this report compared their use in over 25,000 people with blood clots in their legs or lungs and in almost 90,000 people who did not have clots. It found that there was a 32% increase in risk of a blood clot in people currently using antipsychotics. However, the overall risk of having a blood clot was still very small, even among people taking antipsychotics. Overall, people in the study had about a 0.1% chance of having a blood clot each year.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317696</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cns/dementia/merec_extra_no39.htm]]&gt;</url>
    <title>Antipsychotics increase mortality In elderly patients with dementia</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN&gt;&lt;STRONG&gt;Extended follow-up of the &lt;A href="http://www.lancet.com/journals/laneur/article/PIIS1474-4422%2808%2970295-3/abstract" target="_blank"&gt;&lt;STRONG&gt;DART-AD&lt;/STRONG&gt;&lt;/A&gt; trial found that patients with Alzheimer’s disease who continued antipsychotic medication for behavioural or psychiatric problems were more likely to die than those switched to placebo.&lt;/STRONG&gt;&lt;A href="http://www.npc.co.uk/ebt/merec/cns/dementia/merec_extra_no39.htm#REF" target="_blank"&gt;&lt;SUP&gt;1&lt;/SUP&gt;&lt;/A&gt; &lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>331067</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_109127.pdf]]&gt;</url>
    <title>Applying the NHS performance framework to mental health trusts</title>
    <publicationDate>2009-11-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document informs mental health trusts, PCTs and SHAs of the criteria against which mental health performance will be assessed. It should be read alongside 'Implementing the NHS Performance Framework'.]]&gt;</body>
  </document>
  <document>
    <id>319320</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_100710?IdcService=GET_FILE&amp;dID=197393&amp;Rendition=Web]]&gt;</url>
    <title>Approved mental health professionals, approved clinicians and best interests assessors - guidance on changes to qualifying requirements for psychologists from 1 July 2009</title>
    <publicationDate>2009-06-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The introduction of the statutory regulation of psychologists from 1 July 2009 means that the qualifying requirements are changing for psychologists wishing to be approved mental health professionals (AMHPs) and approved clinicians (ACs) under the Mental Health Act 1983 or best interest assessors under the Mental Capacity Act 2005 deprivation of liberty safeguards (MCA DOLS). The Department of Health has issued the attached guidance note explaining the changes, which take effect from 1 July 2009.]]&gt;</body>
  </document>
  <document>
    <id>296380</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://archpsyc.ama-assn.org/]]&gt;</url>
    <title>Archives of General Psychiatry</title>
    <publicationDate></publicationDate>
    <publisher>JAMA</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"Archives of General Psychiatry is published twelve times per year and features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Commentaries 
&lt;LI&gt;Original articles 
&lt;LI&gt;Reviews 
&lt;LI&gt;Corrections 
&lt;LI&gt;Letters to the editor"&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This journal is available from NLH with an Athens log-in, with a one year embargo. &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for Athens&lt;/A&gt;. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328791</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/98]]&gt;</url>
    <title>Are all antidepressants equal?</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Primary care physicians and psychiatrists manage the majority&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;of patients suffering from acute phase major depressive disorder&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;(MDD). For most patients, antidepressant treatment is the primary&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;choice of care. Second generation antidepressants (SGAs)—developed&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;following the first generation of tricyclic and monoamine oxidase&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;agents—have become the preferred drug choice because of&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;their greater tolerability, lower risk of lethality and similar&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;efficacy compared with first generation agents.&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;Clinicians prescribing SGAs face a multitude of drug choices&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;and are the target of extensive marketing campaigns by the pharmaceutical&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;industry. In 2007, three of the 20 top selling drugs in the&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;USA were antidepressants with annual sales ranging from $2.3&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;billion (venlafaxine XR (Effexor XR)) to $1.4 billion (duloxetine&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;(Cymbalta)).&lt;SUP&gt;&lt;FONT size=1&gt;1&lt;/FONT&gt;&lt;/SUP&gt; At the time of writing, 13 different SGAs have&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;been approved for the treatment of major depression in the USA&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;and Canada and two additional drugs (reboxetine, milnacipran)&lt;SUP&gt;&lt;FONT size=1&gt; &lt;/FONT&gt;&lt;/SUP&gt;are available in some &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/98" target="_blank"&gt;Full text of this article&lt;/A&gt;]&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386599</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386599]]&gt;</url>
    <title>Arthritis may block Alzheimer's</title>
    <publicationDate>2010-08-23T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Arthritis may block Alzheimer's&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A protein produced in arthritis may “protect against the development of Alzheimer's disease,” reported BBC News. US research on mice has discovered that a protein called GM-CSF, produced in rheumatoid arthritis, may trigger the immune system to destroy the protein plaques found in Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;This research used mice that had been genetically engineered to have a condition similar to Alzheimer’s. It found that these mice performed better in tests of memory and learning after they had been given a GM-CSF injection for 20 days. The protein also helped normal mice to improve their performance in the tests. After the injections, the mouse brains also contained increased levels of microglial cells, types of cells that engulf debris and foreign organisms. It is possible that these&amp;nbsp; microglial cells could combat the build-up of amyloid proteins that characterise Alzheimer’s disease.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>279979</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nta.nhs.uk/publications/documents/nta_assessing_young__people__for__substance__misuse_yp1.pdf]]&gt;</url>
    <title>Assessing young people for substance misuse</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>NHS National Treatment Agency for Substance Misuse</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,SUBSTANCE MISUSE,DETERMINANTS,WOMEN,MEN,POLICY,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,INDIVIDUAL BEHAVIOUR,SUBSTANCE MISUSE,MANAGEMENT &amp; POLICY,2008-JULY,MONTHLY ADDITIONS,POPULATIONS,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This document has been developed for service managers and practitioners delivering specialist substance misuse services to young people under the age of 18. It describes a framework for specialist substance misuse assessment, how specialist substance misuse assessment dovetails with the Common Assessment Framework (CAF) for children and young people (DfES, 2006a) and outlines the context of undertaking an assessment of young people and care planning arrangements.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Contents:&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction 
&lt;LI&gt;Parents and carers 
&lt;LI&gt;Specialist substance misuse assessment 
&lt;LI&gt;Building on assessment 
&lt;LI&gt;Responsibilities to young people 
&lt;LI&gt;Workforce support 
&lt;LI&gt;Glossary 
&lt;LI&gt;References&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This document has been developed for service managers and practitioners delivering specialist substance misuse services to young people under the age of 18. It describes a framework for specialist substance misuse assessment, how specialist substance misuse assessment dovetails with the Common Assessment Framework (CAF) for children and young people (DfES, 2006a) and outlines the context of undertaking an assessment of young people and care planning arrangements. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;It is not an assessment tool but covers the essential elements of specialist substance misuse assessment and other factors that need to be considered.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345866</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=01B1DC86-FCEA-B719-F6A8-BAEB7485B772&amp;ext=pdf]]&gt;</url>
    <title>Assessment of Effort in Clinical Testing of Cognitive Functioning for Adults</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The aims of the present document are to highlight key issues in the assessment of effort,provide guidance and suggest further reading. Specifically, the document focuses on the assessment of effort as part of a clinical assessment of cognitive function in a wide range of settings. It further aims to identify issues relevant to the interpretation of findings and the potential courses of action when an individual fails cognitive tests of effort.The primary concern of this document is the validity of cognitive symptoms and not with a broaderbased assessment of the validity of symptom complaint. The document will highlight important areas for future research.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>317659</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scie.org.uk/publications/ataglance/ataglance05.pdf]]&gt;</url>
    <title>At a glance: Mental Capacity Act 2005</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>SCIE</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ SCIE’s At a glance summaries have been developed to help you understand as quickly and easily as possible the important messages and practice advice in SCIE’s guides. These summaries will give you an overview of the messages or help direct you to parts of the guide that you may find most useful. You can also use them as training resources in teams or with individuals.]]&gt;</body>
  </document>
  <document>
    <id>285201</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_084478]]&gt;</url>
    <title>Attitudes to Mental Illness 2008 Research Report</title>
    <publicationDate>2008-05-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The latest national statistics on Attitudes to  Mental Illness produced by the Department of Health were released on 8 May 2008 according to the arrangements approved by the UK Statistics Authority.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Key points from the report:&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The general public are broadly sympathetic to people with mental health problems and community care. 
&lt;LI&gt;However, some attitudes towards people with mental health problems are worse compared to when the Department of Health first commissioned the poll in 1994, including two relating to fears of patients. 
&lt;LI&gt;On the other hand, several attitudes that had worsened over the period up until 1997 have since improved. 
&lt;LI&gt;Only two attitudes have changed significantly since last year, both an improvement – more think people with mental illness have been subject to ridicule for too long and less think it is easy to tell them from ‘normal people’.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319335</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_100345?IdcService=GET_FILE&amp;dID=197022&amp;Rendition=Web]]&gt;</url>
    <title>Attitudes to mental illness 2009 research report PDF</title>
    <publicationDate>2009-06-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The latest national statistics on Attitudes to&amp;nbsp;&amp;nbsp;Mental Illness produced by the Department of Health were released on 12 June 2009 according to the arrangements approved by the UK Statistics Authority. &lt;BR&gt;&lt;BR&gt;Since March 1993, the Department of Health has placed a set of&amp;nbsp;&amp;nbsp;questions on TNS’s Face-to-Face Consumer Omnibus about public&amp;nbsp;&amp;nbsp;attitudes towards mental illness. From 1993 to 1997 the questions were&amp;nbsp;&amp;nbsp;asked on an annual basis and then every third year up until 2003.&amp;nbsp;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;Since 2007 the survey has again been carried out annually. The surveys&amp;nbsp;&amp;nbsp;serve as a benchmark, enabling measurement of whether attitudes are improving or worsening over time. The questionnaire included a number of statements about mental illness. Respondents were asked to indicate how much they agreed or disagreed with each statement.]]&gt;</body>
  </document>
  <document>
    <id>372746</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_114902.pdf]]&gt;</url>
    <title>Attitudes to mental illness 2010 research report</title>
    <publicationDate>2010-03-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,PUBLIC HEALTH,MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;The latest national statistics on Attitudes to Mental Illness produced by the Department of Health were released on 30 March 2010 according to the arrangements approved by the UK Statistics Authority. &lt;BR&gt;&lt;BR&gt;Since March 1994, the Department of Health has placed a set of questions on TNS’s Face-to-Face Consumer Omnibus about public attitudes towards mental illness. From 1994 to 1997 the questions were asked on an annual basis and then every third year up until 2003.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Since 2007 the survey has again been carried out annually. The surveys serve as a benchmark, enabling measurement of whether attitudes are improving or worsening over time. The questionnaire included a number of statements about mental illness. Respondents were asked to indicate how much they agreed or disagreed with each statement.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key points from the report:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;People are broadly sympathetic towards people with a mental illness.&lt;/LI&gt;
&lt;LI&gt;However, some attitudes towards people with mental illness are worse compared to when the Department of Health first commissioned the poll in 1994 whilst a number have improved. Several attitudes that had worsened over the period up until 1997 have since improved.&lt;/LI&gt;
&lt;LI&gt;Attitudes to a number of statements have changed between 2009 and 2010.&lt;/LI&gt;
&lt;LI&gt;Opinions on some statements changed towards greater tolerance, for example:&lt;/LI&gt;
&lt;LI&gt;- ‘Locating mental health facilities in a residential area downgrades the neighbourhood’ - agreement with this statement decreased from 21% to 18%.&lt;/LI&gt;
&lt;LI&gt;Some opinions moved more in favour of integrating people with mental illness into the community, for example:&lt;BR&gt;- ‘Residents have nothing to fear from people coming into their neighbourhood to obtain mental health services’ – agreement with this statement increased from 62% to 66%.&lt;/LI&gt;
&lt;LI&gt;On one item though, opinions moved less in favour of integration:&lt;BR&gt;- ‘Mental hospitals are an outdated means of treating people with mental illness’ – agreement with this statement fell from 37% in 2009 to 33% in 2010.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>279989</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf]]&gt;</url>
    <title>AUDIT: The Alcohol Use Disorders Identification Test - Guidelines for Use in Primary Care</title>
    <publicationDate>2001-02-01T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ALCOHOL MISUSE,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This manual introduces the AUDIT, the Alcohol Use Disorders Identification Test, and describes how to
use it to identify persons with hazardous and harmful patterns of alcohol consumption. The AUDIT was developed by the World Health Organization (WHO) as a simple method of screening for excessive drinking and to assist in brief assessment.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;This manual introduces the AUDIT, the Alcohol Use Disorders Identification Test, and describes how to use it to identify persons with hazardous and harmful patterns of alcohol consumption. &lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The AUDIT was developed by the World Health Organization (WHO) as a simple method of screening for excessive drinking and to assist in brief assessment. It can help identify excessive drinking as the cause of the presenting illness. It provides a framework for intervention to help risky drinkers reduce or cease alcohol consumption and thereby avoid the harmful consequences of their drinking. &lt;/P&gt;
&lt;P&gt;The AUDIT also helps to identify alcohol dependence and some specific consequences of harmful drinking. It is particularly designed for health care practitioners and a range of health settings, but with suitable instructions it can be self-administered or used by non-health professionals.&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;To this end, the manual will describe:&lt;BR&gt;&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Reasons to ask about alcohol consumption 
&lt;LI&gt;The context of alcohol screening 
&lt;LI&gt;Development and validation of the AUDIT 
&lt;LI&gt;The AUDIT questions and how to use them 
&lt;LI&gt;Scoring and interpretation 
&lt;LI&gt;How to conduct a clinical screening examination 
&lt;LI&gt;How to help patients who screen positive 
&lt;LI&gt;How to implement a screening programme&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Purpose of this Manual&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;The appendices to this manual contain additional information useful to practitioners and researchers. Further research on the reliability, validity, and implementation of screening with the AUDIT is suggested using guidelines outlined in Appendix A. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259583</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/downloads/AustralianClinicalGuidelines2004.pdf]]&gt;</url>
    <title>Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa</title>
    <publicationDate>2004-07-12T00:00:00</publicationDate>
    <publisher>Australian and New Zealand Journal of Psychiatry</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,EATING DISORDERS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Royal Australian and New Zealand College of Psychiatrists is coordinating
the development of clinical practice guidelines (CPGs) in psychiatry, funded under
the National Mental Health Strategy (Australia) and the New Zealand Ministry of Health. This
CPG covers anorexia nervosa (AN).</description>
    <body>&lt;![CDATA[ 12-page article by the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Anorexia Nervosa.]]&gt;</body>
  </document>
  <document>
    <id>296421</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.informaworld.com/smpp/title~content=t768481832~db=all]]&gt;</url>
    <title>Australian and New Zealand Journal of Psychiatry</title>
    <publicationDate></publicationDate>
    <publisher>Informaworld</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"Australian and New Zealand Journal of Psychiatry is the Official Journal of The Royal Australian and New Zealand College of Psychiatrists.&lt;/P&gt;
&lt;P&gt;"The Australian and New Zealand Journal of Psychiatry is being published monthly from January 2007, ensuring rapid publication of articles of current interest. The Journal publishes original articles which describe research or report opinions of interest to psychiatrists. These contributions may be presented as original research, reviews, descriptions of patients, or letters to the editor. Editorial comments and book reviews are also published.&lt;/P&gt;
&lt;P&gt;"The Australian and New Zealand Journal of Psychiatry is the leading psychiatry journal of the Asia-Pacific region."&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Editorial 
&lt;LI&gt;Review articles 
&lt;LI&gt;Original articles 
&lt;LI&gt;Columns&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Published on a monthly basis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&amp;nbsp;&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263035</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38597&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Being There in a Crisis Update</title>
    <publicationDate>2002-02-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A briefing on the ‘Being There in a Crisis’ project. This project examined the learning from eight community-based mental health crisis services.</description>
    <body>&lt;![CDATA[ A briefing on the ‘Being There in a Crisis’ project. This project examined the learning from eight community-based mental health crisis services. The Foundation funded and supported seven crisis services over a period of three years. The Sainsbury Centre for Mental Health (SCMH) evaluated the two residential services and one other service.]]&gt;</body>
  </document>
  <document>
    <id>281350</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bestinmh.org.uk/]]&gt;</url>
    <title>Best Evidence Summaries of Topics in Mental Healthcare (BEST in MH)</title>
    <publicationDate>2008-03-04T00:00:00</publicationDate>
    <publisher>Institute of Psychiatry</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Best Evidence Summaries of Topics in Mental Healthcare (BEST in MH) is a clinical question-answering service based at the Institute of Psychiatry and funded by Guys’ and St Thomas’ Charity.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Best Evidence Summaries of Topics in Mental Healthcare (BEST in MH) is a clinical question-answering service based at the Institute of Psychiatry and funded by Guys’ and St Thomas’ Charity.&lt;/P&gt;
&lt;P&gt;We provide critically appraised summaries of guideline, systematic review and randomised controlled trial evidence in answer to questions concerning interventions or treatment in any area of mental health.&lt;/P&gt;
&lt;P&gt;We do not provide advice, give recommendations or summarise evidence from less well-conducted studies.&lt;/P&gt;
&lt;P&gt;This service is provided free of charge for all providers of mental healthcare within South London and Maudsley NHS trust and South London primary care trusts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270798</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://kc.csip.org.uk/viewdocument.php?action=viewdox&amp;pid=0&amp;doc=35065&amp;grp=1]]&gt;</url>
    <title>Best Practice Guidance for Primary Care Staff: Using the Mental Health Domains in the Quality and Outcomes Frameword (QOF)</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This guidance will also be of interest to specialist mental health trust clinicians, so that they can understand the level of care being provided by their primary care colleagues. This will improve the primary/ secondary care interface, and how care can be effectively shared between the two tiers of service.</description>
    <body>&lt;![CDATA[ &lt;P&gt;EXECUTIVE SUMMARY&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The 2006 amendment to the Quality and Outcomes Framework of the nGMS contract for primary care services introduced several new clinical domains, as&lt;BR&gt;well as amending some of the pre-existing clinical domains. The changes introduced, represent the consequences of changing clinical practice, and&lt;BR&gt;implementation of national guidelines.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The guidance provided in this paper relates to the updated mental health clinical domain, a new domain for depression and a new domain for dementia. This guidance is designed for primary care clinicians so that they can deliver high quality, evidenced based, essential services.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This guidance will also be of interest to specialist mental health trust clinicians, so that they can understand the level of care being provided by their primary care colleagues. This will improve the primary/secondary care interface, and how care can be effectively shared between the two tiers of service.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268527</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_078744]]&gt;</url>
    <title>Best Practice Guidance: Specification for adult medium-secure services</title>
    <publicationDate>2007-08-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is a best practice document with quality principles, specifications and high-level indicators for all medium-secure services. It also clarifies the performance framework underpinning the quality principles</description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a best practice document with quality principles, specifications and high-level indicators for all medium-secure services. It also clarifies the performance framework underpinning the quality principles&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;amp;dID=147448&amp;amp;Rendition=Web" target="_blank"&gt;Download Best Practice Guidance: Specification for adult medium-secure services&lt;/A&gt; (PDF, 1273K) 
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;amp;dID=147449&amp;amp;Rendition=Web" target="_blank"&gt;Download Executive summary&lt;/A&gt; (PDF, 1016K)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This document provides an overview of the context within which medium-secure services are delivered together with the high-level performance indicators. The quality principles for medium-secure services are set out in detail in the companion document Best Practice Guidance: Specification for adult medium-secure services. The specification sets out the quality principles for use by all secure commissioners to assist them in designating services.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266056</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_076511]]&gt;</url>
    <title>Best practice in managing risk: principles and guidance for best practice in the assessment and management of risk to self and others in mental health services</title>
    <publicationDate>2007-07-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This framework is a guide for mental health professionals working with service users to assess risk. It underpins risk assessment with principles of good practice for all mental health settings and provides a list of tools offering structure to risk management.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Document prepared for the National Mental Health Risk Management Programme.&lt;/P&gt;
&lt;P&gt;This framework is a guide for mental health professionals working with service users to assess risk. It underpins risk assessment with principles of good practice for all mental health settings and provides a list of tools offering structure to risk management.&lt;/P&gt;
&lt;H2&gt;Executive summary&lt;/H2&gt;
&lt;P&gt;This framework document is intended to guide mental health practitioners who work with service users to manage the risk of harm. It sets out a framework of principles that should underpin best practice across all mental health settings, and provides a list of tools that can be used to structure the often complex risk management process. The philosophy underpinning this framework is one that balances care needs against risk needs, and that emphasises:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;positive risk management; 
&lt;LI&gt;collaboration with the service user and others involved in care; 
&lt;LI&gt;the importance of recognising and building on the service user’s&lt;BR&gt;strengths; and 
&lt;LI&gt;the organisation’s role in risk management alongside the individual&lt;BR&gt;practitioner’s.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Organisations, care teams and individual practitioners should benchmark their current practice against the principles set out here, and consider ways of moving towards embedding these principles in daily practice. They should also examine the list of tools given here and consider how their practice could be improved by incorporating one or more of the tools into their risk assessment and risk management practice.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395086</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/binge-drinking-and-heart-risk.aspx]]&gt;</url>
    <title>Binge drinking 'doubles heart risk'</title>
    <publicationDate>2010-11-24T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;‘Binge drinking doubles heart risk,’ BBC News reported today. This study was in&amp;nbsp;almost 10,000 men aged 50 to 59 without heart disease from France and Northern Ireland. Most French men drank regularly (90%) compared to half of Irish men. However, Irish men were more likely to binge drink than French men (9.4% compared to 0.5%).&lt;/P&gt;
&lt;P&gt;The combined outcome of&amp;nbsp;&lt;A href="http://www.nhs.uk/conditions/heart-attack/pages/introduction.aspx" target="_blank"&gt;heart attack&lt;/A&gt; or death from heart attack over 10 years was observed in 5.3% of men from Belfast and 2.6% of men from France. Risk was doubled for&amp;nbsp;&lt;A href="http://www.nhs.uk/Livewell/alcohol/Pages/Bingedrinking.aspx" target="_blank"&gt;binge drinkers&lt;/A&gt; compared to those&amp;nbsp;men who drank&amp;nbsp;&lt;A href="http://www.nhs.uk/Livewell/alcohol/Pages/Alcoholhome.aspx" target="_blank"&gt;alcohol&lt;/A&gt; at least one day a week but did not binge drink. Compared to regular drinkers, non-drinkers also had a doubled risk of heart attack or death from heart attack, and former drinkers had an apparent tripled risk.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378340</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Binge-drinking-teens-risk-brain-damage.aspx]]&gt;</url>
    <title>Bingeing teens 'risk brain damage'</title>
    <publicationDate>2010-06-03T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Binge-drinking teenagers could be doing lasting harm to their memories,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The story is based on research on the effects of heavy alcohol consumption on the brains of seven rhesus macaque monkeys. It found that heavy alcohol use had a dramatic effect on the normal division of cells in the hippocampus, part of the brain involved in long-term memory. The researchers say this suggests that lasting damage to the brain may happen relatively early, preceding and possibly causing the neurological problems associated with alcoholism in adults.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317667</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mdf.org.uk/index.aspx?o=113922]]&gt;</url>
    <title>Biploar disorder in children and young people PDF</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>MDF The BiPolar Organisation (England)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Aimed at friends and family members of young people with bipolar disorder. Outlines some of the key issues and offers practical advice on areas such as education.]]&gt;</body>
  </document>
  <document>
    <id>388533</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=388533]]&gt;</url>
    <title>Bipolar disorder and violent crime</title>
    <publicationDate>2010-09-08T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Bipolar disorder and violent crime&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;“People with mental illness are no more likely to commit violent crimes than ordinary members of the public,” reported &lt;EM&gt;The Independent&lt;/EM&gt;. “Substance abuse is the chief cause of violent crime and increases the risk equally in people with and without mental illness,” it added.&lt;/P&gt;
&lt;P&gt;The story is based on research that looked at the risk of people with bipolar disorder committing violent crimes such as assault and robbery, compared with the general population. It found that, although bipolar disorder was associated with a higher risk of violent crime, the increase in risk was largely due to drug and alcohol abuse. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344596</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/child-genius-intelligence-bipolar-disorder.aspx]]&gt;</url>
    <title>Bipolar risk greater for bright children</title>
    <publicationDate>2010-02-04T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ “You don't have to be bipolar to be a genius – but it helps,” according to &lt;EM&gt;The Independent&lt;/EM&gt;. The newspaper said that a Swedish study of over 700,000 adults found that those who scored top grades at school were “four times more likely to develop bipolar disorder than those with average grades”.]]&gt;</body>
  </document>
  <document>
    <id>347232</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/Blurring_the_boundaries.pdf]]&gt;</url>
    <title>Blurring the boundaries: The convergence of mental health and criminal justice policy, legislation, systema and practice</title>
    <publicationDate>2010-03-31T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Health and justice services are working more closely together than ever, but with mixed results for the people who find themselves subject to both of them, according to a report published today by Sainsbury Centre for Mental Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.scmh.org.uk/publications/blurring_the_boundaries.aspx?ID=608" target="_blank"&gt;Blurring the Boundaries&lt;/A&gt;, by Max Rutherford, shows that more and more people are in touch with both mental health and criminal justice services and that the laws governing each have brought them closer together during the past 20 years.&lt;/P&gt;
&lt;P&gt;Measures that have blurred the boundaries between health and justice include the rise of 'forensic' mental health services, the creation of a mental health treatment requirement for people on community sentences and the increasing use of indeterminate prison sentences.&lt;/P&gt;
&lt;P&gt;The report finds that in many cases convergence between health and justice benefits people with mental health problems. The arrival of in-reach teams in all English prisons, for example, has for the first time brought high standards of mental health care to people who would otherwise have been neglected entirely.&lt;/P&gt;
&lt;P&gt;But there are also serious concerns about convergence. Imprisonment for Public Protection, for example, has brought a disproportionate number of people with mental health problems into prison on indeterminate sentences without proper support. The Dangerous and Severe Personality Disorder (DSPD) programme, meanwhile, costs some £60 million a year to detain just 350 people at a time despite a lack of clear evidence about its effectiveness in either improving health or reducing risk.&lt;/P&gt;
&lt;P&gt;Report author Max Rutherford said: "Convergence between health and justice can raise the standard of mental health care for some of the most excluded people in our society. The Government's pledge to extend diversion and liaison to all police stations and courts in England, for example, would make a huge difference to the lives of thousands of people, their families and their communities.&lt;/P&gt;
&lt;P&gt;"But convergence must be handled with care. A prison is no substitute for a hospital for a person in a crisis, and hospitals should not become just like prisons. Health and justice workers have quite different roles and these should not be lost in a drive to come together."&lt;/P&gt;
&lt;P&gt;Sainsbury Centre joint chief executive Sean Duggan said: "The Bradley Report last year showed how important it is for health and justice services to work together to ensure people with mental health problems who offend get the support and care they need to get their lives back on track.&lt;/P&gt;
&lt;P&gt;"Blurring the Boundaries shows that there is already a lot of convergence between the two, but it is not always working well. The DSPD programme and the burgeoning cost of medium secure hospitals show that in times of public spending constraints we need to ensure that every pound is spent wisely on services that help offenders with mental health problems to recover and rehabilitate."&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287518</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bma.org.uk/ap.nsf/AttachmentsByTitle/PDFCCSCmentalhealthsurvey08/$FILE/CCSCmentalhealthsurvey08.pdf]]&gt;</url>
    <title>BMA CCSC Psychiatry subcommittee: Survey of BMA members' views on mental health funding and patient care</title>
    <publicationDate>2008-05-30T00:00:00</publicationDate>
    <publisher>BMA</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>In this survey of UK doctors working in psychiatric services, just over half (52%) the respondents said there had been a decrease in the overall funding for mental health services.</description>
    <body>&lt;![CDATA[ &lt;P&gt;In this survey of UK doctors working in psychiatric services, just over half (52%) the respondents said there had been a decrease in the overall funding for mental health services. &lt;/P&gt;
&lt;P&gt;The survey indicates that the area most affected in the past year has been in-patient care, and that funding for day services, continuing care, and community mental health teams have also seen decreases. &lt;/P&gt;
&lt;P&gt;Secure and high dependency care and ‘access and crisis’ services were most likely to have seen increases in funding.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>375269</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/beer-belly-alzheimers-fat-risk.aspx]]&gt;</url>
    <title>Body fat 'linked to Alzheimer's'</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>NHS Choices -Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Having a “pot belly” in middle age raises the risk of Alzheimer’s disease and dementia later in life, according to the &lt;EM&gt;Daily Mail.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The news is based on research into whether total brain volume was associated with measurements such as body mass index (BMI), waist size, fat under the skin and fat around the organs. As part of the study, several hundred middle-aged participants had their body fat and brains scanned. The results suggested that a larger waist and more fat surrounding the organs were both associated with decreased brain volume. However, this early research did not examine whether any participants went on to develop Alzheimer’s or dementia. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378341</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/Bone-marrow-and-mental-illness.aspx]]&gt;</url>
    <title>Bone marrow and mental illness</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Bone marrow transplants cure mental illness – in mice”, reports &lt;EM&gt;The Guardian&lt;/EM&gt;. The newspaper says “scientists in the US claim to have used a bone marrow transplant to cure mental illness in a study that could have profound implications for patients with psychiatric problems”.&lt;/P&gt;
&lt;P&gt;The research involved genetically engineered mice that were lacking a gene called &lt;EM&gt;Hoxb8&lt;/EM&gt;. These mice groom themselves so excessively that they remove patches of fur and develop sores. This condition is similar to a human condition called trichotillomania.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395082</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/simple-early-alzheimers-test.aspx]]&gt;</url>
    <title>Brain scan is not an Alzheimer's test</title>
    <publicationDate>2010-11-12T00:00:00</publicationDate>
    <publisher>NHS Choices -Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Scientists are developing a “30-second Alzheimer’s screening test” reported &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt;&amp;nbsp;It said that such a test “could be available in as little as two years”. 
&lt;P&gt;This news was based on research that gave MRI scans to 428 healthy people in their forties to look for changes in the intensity of white matter lesions (the nerve fibres) in specific areas of the brain. The study found that these brain changes were each present in 0.4-20% of participants and that their presence in specific areas was linked to poorer performance in some cognitive tests. There were also differences in the way men and women were affected.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260824</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=260824]]&gt;</url>
    <title>Breaking down barriers - the clinical case for change</title>
    <publicationDate>2007-05-11T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A report by Professor Louis Appleby, National Director for Mental Health.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Breaking down barriers - the clinical case for change&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This report, from the National Clinical Director for Mental Health, explains why improvements in community care must continue and sets out a new phase of reform in mental health services. The report calls for the breaking down of barriers that can prevent people from rebuilding their lives and looks at how the expansion in talking therapy services, along with the move to greater community care, will help to continue a process that requires all mental health professions to re-define their role in a modern service. &lt;/P&gt;
&lt;P&gt;Employment, housing and a strong social network are as important to a person’s mental health as the treatment they receive. Louis Appleby, the National Director for Mental Health, explains why we have to continue to improve community care and break down the barriers that can prevent people from rebuilding their lives.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>282149</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.virtualward.org.uk/silo/files/briefpsychiatricratingscaleexpandedpdf.pdf]]&gt;</url>
    <title>Brief Psychiatric Rating Scale (BPRS)</title>
    <publicationDate></publicationDate>
    <publisher>Virtual Ward</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document is the expanded version (4.0) of the Brief Psychiatric Rating Scale.]]&gt;</body>
  </document>
  <document>
    <id>270430</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.gldvp.org.uk/module_images/Securing%20Safety.pdf]]&gt;</url>
    <title>Briefing of recommendations arising from the conference - Securing Safety: Supporting Women in Prison who have Experienced Violence and Abuse</title>
    <publicationDate>2007-09-13T00:00:00</publicationDate>
    <publisher>Greater London Domestic Violence Project</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,DOMESTIC VIOLENCE OR PARTNER ABUSE,DETERMINANTS,PUBLIC HEALTH,SOCIAL DETERMINANTS,PRISONS,BUILDINGS,MONTHLY ADDITIONS,SETTINGS,ABUSE,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A briefing arising from the Greater London Domestic Violence Project's November 2006 conference to highlight the needs of women offenders who are also victims of domestic abuse.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Contents&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Foreword 
&lt;LI&gt;Women in Prison: the facts 
&lt;LI&gt;Conference themes 
&lt;LI&gt;Recommendations 
&lt;LI&gt;Background 
&lt;LI&gt;References&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392207</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bap.org.uk/pdfs/BAP_Sleep_Guidelines.pdf]]&gt;</url>
    <title>British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders</title>
    <publicationDate>2010-10-21T00:00:00</publicationDate>
    <publisher>British Association for Psychopharmacology</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SLEEP PROBLEMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other&lt;BR&gt;health care practitioners. These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible&lt;BR&gt;up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment. &lt;/P&gt;
&lt;P&gt;A consensus meeting was held in London in May 2009. Those invited to attend included BAP members, representative clinicians with a strong interest in sleep&lt;BR&gt;disorders and recognized experts and advocates in the field, including a representative from mainland Europe and the USA. Presenters were asked to&lt;BR&gt;provide a review of the literature and identification of the standard of evidence in their area, with an emphasis on meta-analyses, systematic reviews&lt;BR&gt;and randomized controlled trials where available, plus updates on current clinical practice. &lt;/P&gt;
&lt;P&gt;Each presentation was followed by discussion, aimed to&lt;BR&gt;reach consensus where the evidence and/or clinical experience was considered adequate or otherwise to flag the area as a direction for future research.&lt;BR&gt;A draft of the proceedings was then circulated to all participants for comment. Key subsequent publications were added by the writer and speakers at&lt;BR&gt;draft stage. All comments were incorporated as far as possible in the final document, which represents the views of all participants although the authors&lt;BR&gt;take final responsibility for the document.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296397</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://bjp.rcpsych.org/]]&gt;</url>
    <title>British Journal of Psychiatry</title>
    <publicationDate></publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LEARNING DISABILITIES,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"Published monthly by The Royal College of Psychiatrists, this is one of the world's leading psychiatric journals. It covers all branches of the subject, with particular emphasis on the clinical aspects of each topic. In addition to a large number of authoritative papers from both the UK and around the world, the journal includes editorials, review articles, commentaries on contentious articles, short reports, a comprehensive book review section and a lively and well-informed correspondence column. A series of supplements, sent free to subscribers, provides in-depth coverage of selected areas.&lt;/P&gt;
&lt;P&gt;"The journal is essential reading for psychiatrists, clinical psychologists, and all professionals with an interest in mental health. The British Journal of Psychiatry print version is sent to all members of the Royal College of Psychiatrists, which includes most psychiatrists working in the UK. There is also a substantial international subscriber base.&lt;/P&gt;
&lt;P&gt;"All papers in this journal are peer-reviewed. No person is permitted to take any role in the peer-review of a paper in which they have an interest, defined as follows: fees or grants from, employment by, consultancy for, shared ownership in, or any close relationship with, an organisation whose interests, financial or otherwise, may be affected by the publication of the paper. Unless so stated, material in this journal does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.&lt;/P&gt;
&lt;P&gt;"Full text content is online from January 2000. Full text is made freely available 1 year after publication. There is a free archive of abstracts from 1975 and a free archive of tables of contents from 1855. The complete archive of contents between 1855 and 2000 is now also online. "&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Available from the NLH.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here&amp;nbsp;to register&amp;nbsp;for an Athens account&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379775</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/alzheimers-disease-magnet-therapy.aspx]]&gt;</url>
    <title>Can magnets ease Alzheimer's?</title>
    <publicationDate>2010-06-24T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Applying magnets to the brains of Alzheimer's disease sufferers helps them understand what is said to them”, &lt;EM&gt;The Independent&lt;/EM&gt; has claimed.&lt;/P&gt;
&lt;P&gt;The news is based on a small trial of an experimental magnetic therapy called rTMS, which some believe can reorganise brain cells and improve neurological functions. &lt;/P&gt;
&lt;P&gt;Over four weeks, five patients were given rTMS and five were given two weeks of sham treatment followed by two weeks of real rTMS. The rTMS was applied to the area of the brain known to be involved in speech and communication, which are often impaired during Alzheimer’s disease. After two weeks, those treated solely with rTMS showed improvements in sentence comprehension. Those receiving the sham treatment did not improve. The sham group then improved a similar amount after two weeks of real rTMS.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388535</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=388535]]&gt;</url>
    <title>Can men get the baby blues?</title>
    <publicationDate>2010-09-07T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Can men get the baby blues?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Depression hits one in five men after they become fathers, reported the &lt;EM&gt;Daily Mail&lt;/EM&gt;. The newspaper quoted the authors of a study as saying that this depression is “caused by extra pressures that come from having children, such as loss of sleep and increased responsibilities”.&lt;/P&gt;
&lt;P&gt;The story is based on research which looked at depression in both mothers and fathers, from the birth of their child until they were 12 years old. It found that 39% of mothers and 21% of fathers experienced a depressive episode, with the highest risk being in the first year after birth.&lt;/P&gt;
&lt;P&gt;This very large study provides some useful information about the rates of depression and the factors that may make new parents more vulnerable. It seems reasonable to suggest that the stress of new fatherhood may put men at risk of depression, and the study raises the question of whether new fathers should be screened for depression, as new mothers are. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>334453</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/new-mobile-phone-alzheimers-claim.aspx]]&gt;</url>
    <title>Can mobile phones halt Alzheimer's?</title>
    <publicationDate>2010-01-07T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,TREATMENT AND CARE,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This story is based on research that looked at the effects of exposing genetically modified mice to the same frequency of electromagnetic field that is generated by mobile phones. These genetically modified mice were created to have some characteristics of Alzheimer’s disease. This allowed the researchers to explore whether the electromagnetic field could alter the biological processes behind an Alzheimer’s-style condition.]]&gt;</body>
  </document>
  <document>
    <id>333011</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/fight-fear-phobia-therapy-test.aspx]]&gt;</url>
    <title>Can you banish fear?</title>
    <publicationDate>2009-12-10T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Humans have a six-hour window “to erase memories of fear” BBC News reported. It said that reliving a harrowing memory can trigger a brief period&amp;nbsp;during which&amp;nbsp;the mental associations of a memory can be changed from bad to good.]]&gt;</body>
  </document>
  <document>
    <id>386605</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386605]]&gt;</url>
    <title>Can you catch up on sleep?</title>
    <publicationDate>2010-08-02T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SLEEP PROBLEMS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Can you catch up on sleep?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;New research has looked at the health impact of lie-ins at the weekend. &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reports they “boost brain power”, the &lt;EM&gt;Daily Mail&lt;/EM&gt; says dragging a teenager out of bed could be detrimental to their health, while BBC News warns that&amp;nbsp;one lie-in&amp;nbsp;won't make up for poor sleep during the week.&lt;/P&gt;
&lt;P&gt;The study behind this news used a range of tests to investigate alertness and sleepiness after five consecutive nights of sleep deprivation and a single night of “recovery sleep”. When the length of this recovery sleep was increased up to the maximum of 10 hours, participants showed the greatest improvement in mental functioning. However, their&amp;nbsp;mental performance&amp;nbsp;proved to be not&amp;nbsp;as&amp;nbsp;strong as it had been prior to sleep deprivation.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>372745</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/prostate-cancer-screening-test-anxiety.aspx]]&gt;</url>
    <title>Cancer tests 'can lead to anxiety'</title>
    <publicationDate>2010-04-09T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Men could potentially be distressed by prostate cancer screening, according to BBC News. The website said that even if a tissue sample shows no signs of cancer, men can experience increased levels of distress and doctors should warn men about how testing may affect their mood.&lt;/P&gt;
&lt;P&gt;The research behind this news tracked men’s mood and anxiety from an initial blood test until three months after a tissue sample confirmed that they did not have cancer. The results showed that a small proportion of men had clinically significant levels of distress throughout testing and even after a clear result.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268529</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_078095]]&gt;</url>
    <title>Capabilities for inclusive practice</title>
    <publicationDate>2007-09-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Socially inclusive good practice guidance for the specialist mental health worker and others working with the mental health user population.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance is intended to be read by chief executives, health and social care professionals.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Executive summary&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;The National Social Inclusion Programme (NSIP) has coordinated the delivery of the action plan in the Social Exclusion Unit report Mental Health and Social Exclusion (2004). This report showed that many people with mental health problems experience exclusion and lack equal access to a range of opportunities in society, including paid employment, volunteering, housing and education. This is not only unjust but it lowers self esteem and self confidence. However, improving opportunities for people with mental health problems will enhance recovery, bring hope to people and their families, and ultimately reduce dependence as people are enabled to contribute, in multiple ways, to society and their community.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A key action in making this happen is the development of a workforce capable of delivering inclusive opportunities to people using mental health services. Working closely with the National Workforce Programme, NSIP has adapted and developed The 10 Essential Shared Capabilities (ESC) which remains valid as a framework for socially inclusive practice.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Consultation on the framework involved a representative from each of the core professional groups in the mental health workforce – nursing, occupational therapy, psychiatry, psychology and social work. A reference group including these professions discussed, reviewed and refined the work, supporting their evolution as a set of inclusion capabilities. The capabilities which include both organisational and individual dimensions, contain ideas for the ways in which they might enhance practice and add value to service development and delivery.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;To give the capabilities clear meaning and personal application to the people delivering services the organisational capabilities are mapped to the core and developmental standards of the Healthcare Commission as described in Standards for Better Health (2007), and the individual capabilities are mapped to the core dimensions of the Knowledge and Skills Framework (KSF) (2004).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317742</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/publications/docs/capacity-and-competition.pdf]]&gt;</url>
    <title>Capacity and competition policy for prsions and probation PDF</title>
    <publicationDate>2009-04-27T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The government will use this&amp;nbsp;policy to provide innovative and effective services to punish and reform offenders and improve services offered to victims and the wider public.&lt;/P&gt;
&lt;P&gt;The policy has been drawn up by the Criminal Justice Group of the Ministry of Justice and will be implemented by the National Offender Management Service, with the involvement of&amp;nbsp;the voluntary and community sector&amp;nbsp;and commercial providers.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259572</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/Psychmed/EDU/downloads/professionals/referral_routes_IoP_05.pdf]]&gt;</url>
    <title>Care pathways for eating disorders</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,EATING DISORDERS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Information for staff at King's College on how to refer people in London for treatment.]]&gt;</body>
  </document>
  <document>
    <id>317688</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealthshop.org/document.rm?id=8525]]&gt;</url>
    <title>Caring and Coping - Chapter 1 PDF</title>
    <publicationDate>2009-05-20T00:00:00</publicationDate>
    <publisher>Rethink</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Caring and Coping answers the questions most commonly asked when someone is diagnosed as seriously mentally ill.&amp;nbsp; Designed to provide a wide range of information in an easily accessible format it, offers strategies to deal with some of the more practical day to day challenges which are thrown up with a diagnosis of mental illness, such as:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;understanding the diagnosis and treatment your relative is being given, &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;your relative's rights in care and treatment&lt;/LI&gt;
&lt;LI&gt;your rights in their care&lt;/LI&gt;
&lt;LI&gt;how to cope in a crisis &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;Fully updated to include information about changes to mental health law, community support and benefits, and with a new section on the criminal justice system, it is essential reading for carers.]]&gt;</body>
  </document>
  <document>
    <id>381296</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/tart-cherry-juice-for-insomnia.aspx]]&gt;</url>
    <title>Cherry juice for insomnia</title>
    <publicationDate>2010-07-14T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SLEEP PROBLEMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Cherry juice could hold the cure to a good night’s sleep,” according to the &lt;EM&gt;Daily Mail.&lt;/EM&gt; It said that volunteers with insomnia enjoyed more sleep after drinking cherry juice than when they drank other juices.&lt;/P&gt;
&lt;P&gt;The story is based on a pilot study of 15 elderly adults with chronic insomnia that found that drinking cherry juice had a small beneficial effect on their sleep patterns. Although well designed and carefully carried out, this pilot study was small and the treatment period was only two weeks. As the authors point out, the alleged effects of cherry juice were so slight that people in the study continued to have significant sleep disturbance. Overall, this study, which was funded by a cherry juice manufacturer, cannot provide any firm evidence that cherry juice can ease insomnia.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263059</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38624&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Childhood and Adolescent Mental Health: understanding the lifetime impacts</title>
    <publicationDate>2005-01-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DISADVANTAGED GROUPS,CHILDREN,YOUNG PEOPLE,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,GOVERNMENT &amp; LAW,HEALTH SERVICES,PUBLIC SERVICES,HEALTHCARE &amp; HEALTH SERVICES,GROUPS,POPULATIONS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report of a seminar organised by the Office of Health Economics and the Mental Health Foundation.</description>
    <body>&lt;![CDATA[ A report of a seminar organised by the Office of Health Economics and the Mental Health Foundation. Child and adolescent mental health services are developing rapidly, yet they cannot meet the huge volume of demand that exists. Recent research has shown an increasing prevalence of mental health problems in children and young people. Mental health problems in children increase demands on social services, education, health and youth justice services, and families. These costs are astronomical when problems are allowed to persist into adulthood. Mental illness is costing the UK £93billion a year, and this is set to rise if we do not intervene. This report describes the findings of a high level seminar on this vital but neglected issue.]]&gt;</body>
  </document>
  <document>
    <id>313789</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_090399]]&gt;</url>
    <title>Children and young people in mind: the final report of the National CAMHS Review</title>
    <publicationDate>2008-11-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The independent CAMHS Review was commissioned to look at how mainstream and universal settings are meeting the educational, care and support of children and young people at risk of and experiencing emerging emotional, behavioural, psychological and mental health problems.&lt;/P&gt;
&lt;P&gt;The Review has looked at how CAMHS are meeting the needs of some of the most vulnerable children, with complex and challenging needs to ensure that they are delivered in a more integrated way. It has considered how we can deliver better outcomes for children with mental health problems and identified practical solutions to how those delivering, managing and commissioning services can address the challenges they face.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372737</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/Chocolate-and-depression.aspx]]&gt;</url>
    <title>Chocolate and depression</title>
    <publicationDate>2010-04-27T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The blues make you crave chocolate,” according to the &lt;EM&gt;Daily Mail,&lt;/EM&gt; while the BBC reports that “Chocolate lovers are more depressive”.&lt;/P&gt;
&lt;P&gt;The news is based on research comparing symptoms of depression with chocolate consumption levels in 931 men and women. It found that participants with high depression scores ate about 12 servings of chocolate per month. Those with low scores ate an average of 8.4 servings, and non-depressed participants ate only 5.4 servings. None were taking anti-depressants.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263041</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38605&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Choosing Mental Health: A policy agenda for mental health and public health</title>
    <publicationDate>2005-05-02T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,POLICY,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,HEALTH SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report provides an overview of Choosing Health, the Government’s public health White Paper, from a public mental health perspective.</description>
    <body>&lt;![CDATA[ This report provides an overview of Choosing Health, the Government’s public health White Paper, from a public mental health perspective.This short report provides an overview of Choosing Health, the Government’s recent public health White Paper, from a public mental health perspective. It aims to identify both the gaps and opportunities in the White Paper and to provide a framework for addressing these.Whilst the White Paper provides a major opportunity, we have a long way to go to establish a proper understanding&lt;BR&gt;of the role of mental health in public health. In the words of WHO Europe ‘there is no health without mental health’.]]&gt;</body>
  </document>
  <document>
    <id>317743</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063064?IdcService=GET_FILE&amp;dID=157521&amp;Rendition=Web]]&gt;</url>
    <title>Clinical Management of drug dependence in the adult prison settig including pyschosocial treatment as a core part PDF</title>
    <publicationDate>2006-12-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,DRUG USE DISORDERS,INDIVIDUAL BEHAVIOUR,DISADVANTAGED GROUPS,MONTHLY ADDITIONS,PUBLIC HEALTH,DETERMINANTS,SUBSTANCE MISUSE,MANAGEMENT &amp; INTERVENTIONS,PRISONS,BUILDINGS,MANAGEMENT,MANAGEMENT &amp; POLICY,GROUPS,SETTINGS,POPULATIONS,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document describes how clinical substance misuse management in prison may be developed to accord with current DH (1999) and NHS (NTA 2003) guidance. The clinical development it describes is funded by Department of Health. The guidance is accompanied by a letter of announcement and an implementation project plan.]]&gt;</body>
  </document>
  <document>
    <id>285166</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_084597]]&gt;</url>
    <title>Code of Practice: Mental Health Act 1983</title>
    <publicationDate>2008-05-07T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This revised Code of Practice has been prepared in accordance with section 118 of the Mental Health Act 1983 by the Secretary of State for Health after consulting such bodies as appeared to him to be concerned, and laid before Parliament. The Code will come into force in November 2008.</description>
    <body>&lt;![CDATA[ This revised Code of Practice has been prepared in accordance with section 118 of the Mental Health Act 1983 by the Secretary of State for Health after consulting such bodies as appeared to him to be concerned, and laid before Parliament. The Code will come into force in November 2008.]]&gt;</body>
  </document>
  <document>
    <id>328878</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.its-services.org.uk/silo/files/mental-health-act-commission--thirteenth-biennial-report-20072009--coercion-and-consent-.pdf]]&gt;</url>
    <title>Coercion and consent monitoring the Mental Health Act 2007/2009</title>
    <publicationDate>2009-07-31T00:00:00</publicationDate>
    <publisher>Mental Health Act Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report was laid before parliament on 15 July 2009. Hard copies of the report are available from The Stationary Office (TSO) at a cost of £25. The TSO website is: http://www.tsoshop.co.uk/.]]&gt;</body>
  </document>
  <document>
    <id>263113</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.drc.org.uk/pdf/FOCUS32.pdf]]&gt;</url>
    <title>Coming together: mental health, equality and human rights.</title>
    <publicationDate>2007-06-29T00:00:00</publicationDate>
    <publisher>Disability Rights Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,DISABILITIES,MENTAL &amp; BEHAVIOURAL DISORDERS,DISADVANTAGED GROUPS,PEOPLE WITH DISABILITIES,POLICY,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIETY,SOCIAL DETERMINANTS,GOVERNMENT &amp; LAW,LAW,PUBLIC SERVICES,GOVERNMENT,MANAGEMENT &amp; POLICY,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The DRC’s Mental Health Advisory Group (MHAG) believes the new Commission for Equality and Human Rights (CEHR) could significantly reduce social exclusion.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Executive summary&lt;/H2&gt;
&lt;P&gt;The DRC’s Mental Health Advisory Group (MHAG) believes the new Commission for Equality and Human Rights (CEHR) could significantly reduce social exclusion.&lt;/P&gt;
&lt;P&gt;Discrimination and inequality systematically destroy people’s mental health. People with long term mental health conditions face some of the most severe exclusion in Britain, including an 80 per cent&amp;nbsp; unemployment rate and a high likelihood of dying young, from preventable illnesses. &lt;/P&gt;
&lt;P&gt;The CEHR has the potential to break these vicious cycles that damage life chances and restrict social and economic contribution.&lt;/P&gt;
&lt;P&gt;There are big successes to build on: improvements in education and employment opportunities; more people choosing to talk openly about their experience of mental health conditions; rights to be free of discrimination under the Disability Discrimination Act (DDA); and good practice on mental health now included in guidance on disability access.&lt;/P&gt;
&lt;P&gt;The CEHR and government need to build on this by:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Promoting equality&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Ensuring that institutional discrimination is rooted out. Mental health conditions and use of mental health services should not be bars to employment, jury service, voting, or being an MP, magistrate or company director. The Disability Equality Duty should be used to close gaps of inequality between people with mental health&amp;nbsp; conditions and other citizens, with regular tracking of progress.&lt;BR&gt;&lt;STRONG&gt;Promoting human rights&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; People should be able to decide where they live and what treatment they receive (with a few rare exceptions). The purpose of health and social services should be to support people’s participation in family, community, social, educational and economic life.&lt;BR&gt;&lt;STRONG&gt;Promoting good relations&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Prejudiced and disparaging statements by politicians and the media that equate mental health conditions with violence should be challenged. Agencies, from mental health services to the Crown Prosecution Service and courts, should provide access to justice and believe people with mental health conditions who report crimes.&lt;BR&gt;&lt;STRONG&gt;Being exemplary&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The new equality commission’s own employment, service delivery and communications should be exemplary with regard to mental health and should involve people with mental health conditions across all strands of work.&lt;/P&gt;
&lt;P&gt;This paper sets out MHAG’s priorities for the CEHR in the following areas as set out in the DRC’s overall Disability Agenda:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Promoting a culture of equality and human rights 
&lt;LI&gt;Bringing an end to child poverty 
&lt;LI&gt;Increasing life chances through learning and skills 
&lt;LI&gt;Ending poverty and widening employment opportunity 
&lt;LI&gt;Increasing democratic participation and active citizenship 
&lt;LI&gt;Developing a social care system fit for the future 
&lt;LI&gt;Tackling health inequalities 
&lt;LI&gt;Meeting the future housing challenge 
&lt;LI&gt;Building stronger, safer communities&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;Download the full document in Word:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.drc.org.uk/docs/Focus32.doc" target="_blank"&gt;'Coming Together' - Word format&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>316516</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/PASAWeb/PCTzone/Yourroadmap/mentalhealthservices/]]&gt;</url>
    <title>Commercial roadmap for the procurement of mental health services: an online tool.</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3 style="MARGIN: auto 0cm"&gt;What is it?&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/H3&gt;
&lt;P&gt;The roadmap is an online resource pack for commissioners of mental health services, for all ages including child and adolescent services, containing practical tools, guidance, case studies, templates and links to support and useful web sites. It integrates commercial and procurement elements with clinical aspects to help PCTs to get the most from the provider market enabling quality, improved service needs and value for money in delivering improved outcomes.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P&gt;The roadmap helps PCTs and local authorities implement policy and guidance from the DH on world class commissioning and enabling system management. It does not replace any policy or guidance. However, it will help PCTs move towards better outcomes over the next five years as identified in Lord Darzi's Review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P&gt;The Roadmap forms part of the wider DH support to mental health commissioners as it will now deliver the Procurement for Quality workstream of the NIMHE Excellence in Commissioning Mental Health Services programme.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;H3 style="MARGIN: auto 0cm"&gt;When will it be available?&lt;o:p&gt;&lt;/o:p&gt;&lt;/H3&gt;
&lt;P&gt;The roadmap was formally launched in December to accompany the new NHS standard contract for mental health services.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P&gt;Further roadmaps which include; Community services, Ambulance services and Acute services, are currently under development and will be available in the summer.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;H3 style="MARGIN: auto 0cm"&gt;Why is it just for mental health services?&lt;o:p&gt;&lt;/o:p&gt;&lt;/H3&gt;
&lt;P&gt;Any commissioner can access the roadmap as it provides a valuable resource for all healthcare services. However, mental health services are featured because currently there are no tariffs under PBR; procurement skills and capabilities are lower and significant cost improvements were identified in the recent Comprehensive Spending Review (CSR07) financial assessments.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P&gt;This roadmap will feature mental health case studies where procurement or commerical activities have helped transform the way services are delivered. Research on the mental health provider market coupled with guidance and support in using the new standard contract and a detailed toolkit for running a mental health contracting process, provides significant help to PCTs in improving their competencies.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P&gt;Roadmaps for other healthcare categories including community services will soon be developed.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;H3 style="MARGIN: auto 0cm"&gt;What does the roadmap contain and how do you use it?&lt;o:p&gt;&lt;/o:p&gt;&lt;/H3&gt;
&lt;P&gt;The roadmap takes the form of a journey from developing a procurement strategy to help you deliver your commissioning strategy, through the contracting process to transition to safe service and contract management.&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: auto 0cm"&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260825</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=260825]]&gt;</url>
    <title>Commissioning a Brighter Future: Improving Access to Psychological Therapies</title>
    <publicationDate>2007-05-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>CSIP Choice and Access Team</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Commissioning a Brighter Future: Improving Access to Psychological Therapies&lt;/pageTitle&gt;&lt;pageBody&gt;This guidance aims to provide organisations with examples of best practice in the provision of psychological therapies.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>267342</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nta.nhs.uk/areas/young_people/Docs/YP_commissioning_guidance_consultation_draft_060807.pdf]]&gt;</url>
    <title>Commissioning Young People's Specialist Substance Misuse Treatment Services: Consultation Draft</title>
    <publicationDate>2007-08-09T00:00:00</publicationDate>
    <publisher>National Treatment Agency for Substance Misuse</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,MENTAL HEALTH,SUBSTANCE MISUSE,CHILD AND ADOLESCENT CONDITIONS,COMMISSIONING,PEOPLE WITH SUBSTANCE MISUSE PROBLEMS,SPECIALIST COMMISSIONING,DISEASE/CONDITION GROUPS,POPULATIONS SERVED,HEALTHY INDIVIDUALS,CHILDREN,YOUNG PEOPLE,MENTAL HEALTH PROBLEMS,TYPES OF COMMISSIONING,COMMISSIONING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The National Treatment Agency (NTA) has issued draft guidance to support the effective commissioning of young people’s specialist substance misuse treatments services. The guidance is targeted at both commissioners working within Drug Action Teams (DATs) and commissioners working within Children and Young People's Partnerships.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Treatment Agency (NTA) has issued draft guidance to support the effective commissioning of young people’s specialist substance misuse treatments services. The guidance is targeted at both commissioners working within Drug Action Teams (DATs) and commissioners working within Children and Young People's Partnerships.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317704</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.its-services.org.uk/silo/files/community-development-workers-for-bme-mental-health-embedding-sustainable-change.pdf]]&gt;</url>
    <title>Community Development Workers for BM mental health: embedding sustainable change PDF</title>
    <publicationDate>2009-05-12T00:00:00</publicationDate>
    <publisher>Mental Health Equalities</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN class=title&gt;Report to the National Institute for Mental Health in England National Workforce Programme and the Department of Health Programme forDelivering Race Equality in Mental Healthcare &lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>268352</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4085759]]&gt;</url>
    <title>Community Mental Health Teams - Mental Health Policy Implementation Guide</title>
    <publicationDate>2002-06-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The emphasis in this document is on identifying the functions which a CMHT in such a whole system will need to perform rather than on specifying the precise structure: local flexibility and close working relationships between all key stakeholders will enable the best arrangements to be developed in each locality.</description>
    <body>&lt;![CDATA[ The emphasis in this document is on identifying the functions which a CMHT in such a whole system will need to perform rather than on specifying the precise structure: local flexibility and close working relationships between all key stakeholders will enable the best arrangements to be developed in each locality.]]&gt;</body>
  </document>
  <document>
    <id>345870</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bpsshop.org.uk/Conducting-research-with-people-not-having-the-capacity-to-consent-to-their-participation-P709.aspx]]&gt;</url>
    <title>Conducting research with people not having the capacity to consent to their participation</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The practical guide is one of a series of documents commissioned by the Social Care Institute for Excellence, addressing different aspects of the implementation of the Mental Capacity Act (2005) and has been prepared for researchers conducting research with human participants in the United Kingdom. The Mental Capacity Act (MCA) 2005 in England and Wales and the Incapacity Act (ICA) 2000 in Scotland have established legal frameworks within Great Britain for people lacking the capacity to make decisions for themselves. Sections 30-34 of MCA 2005 and Section 51 of ICA 2000 (Scotland) refer to decisions concerning participation in research. This practical guide offers advice and examples of good practice in connection with conducting research with people lacking the capacity to consent to their participation. Reference is made throughout the document to guidance produced by different professional and research organisations within the United Kingdom.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>347126</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_114775.pdf]]&gt;</url>
    <title>Confident communities,brighter futures - A framework for developing well-being</title>
    <publicationDate>2010-03-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Sets out the argument and evidence base for prioritising well-being, and provides a systematic approach to improving mental well-being with selected evidence-based approaches and interventions that have been shown to be effective across the life course, and across key public health domains.]]&gt;</body>
  </document>
  <document>
    <id>275621</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_080913]]&gt;</url>
    <title>Consultation on guidance on 'Finding a shared vision of how people's mental health problems should be understood'</title>
    <publicationDate>2007-12-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Care Services Improvement Partnership (CSIP) has developed draft guidance for consultation on ‘Finding a shared vision of how people’s mental health problems should be understood’.  The guidance is aimed at everyone concerned with the development and delivery of services including people that use services and their carers.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Launch date: 28 November 2007&lt;/H2&gt;
&lt;H2&gt;Closing date: 5 March 2008&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Care Services Improvement Partnership (CSIP) has developed draft guidance for consultation on ‘Finding a shared vision of how people’s mental health problems should be understood’.&amp;nbsp; The guidance is aimed at everyone concerned with the development and delivery of services including people that use services and their carers.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The guidance aims to:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;identify a shared vision of how people’s mental health problems should be understood that is recognised equally by different provider groups and by service users and their carers 
&lt;LI&gt;to raise awareness of the wide variety of different approaches to assessing mental health problems and wellbeing and 
&lt;LI&gt;to build mutual understanding of these different approaches as resources for drawing together, through a shared process between service users, carers and service providers, ways of understanding a mental health problem that reflect the particular and often very different strengths and needs of individual service users.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The consultation is taking place between 28 November 07 and 05 March 08 inclusive.&amp;nbsp; We are seeking people’s views on the draft guidance in particular in relation to specific questions as well as general comments. The information which we receive back will be considered, to revise the draft and publish a final version; currently planned for May 2008.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>269015</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/publications/cp2307.htm]]&gt;</url>
    <title>Consultation on the deprivation of liberty safeguards code of practice and regulations</title>
    <publicationDate>2007-09-11T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This consultation document seeks views on a code of practice and supporting secondary legislation following the introduction of deprivation of liberty safeguards into the Mental Capacity Act 2005 by the Mental Health Act 2007. Open date: 10 September 2007. Close date: 02 December 2007.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Consultation on the deprivation of liberty safeguards code of practice and regulations &lt;/H2&gt;
&lt;P&gt;Open date: 10 September 2007&lt;/P&gt;
&lt;P&gt;Close date: 02 December 2007&lt;/P&gt;
&lt;P&gt;This consultation document seeks views on a code of practice and supporting secondary legislation following the introduction of deprivation of liberty safeguards into the Mental Capacity Act 2005 by the Mental Health Act 2007.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Consultation paper&lt;/H2&gt;
&lt;P&gt;Documents for consultation are below:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307.pdf" target="_blank"&gt;Mental Capacity Act 2005 Deprivation of Liberty Safeguards consultation&lt;/A&gt; [PDF 1.18mb, 62 pages] 
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-draft-add.pdf" target="_blank"&gt;Draft addendum to the Mental Capacity Act code of practice&lt;/A&gt; [PDF 0.41mb, 44 pages] 
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-assess.pdf" target="_blank"&gt;The assessment regulations&lt;/A&gt; [PDF 0.22mb, 8 pages] 
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-rep.pdf" target="_blank"&gt;The representative regulations&lt;/A&gt; [PDF 0.18mb, 6 pages] 
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-easy.pdf" target="_blank"&gt;Easy Read version&lt;/A&gt; [PDF 1.19mb, 44 pages] 
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-easy.pdf" target="_blank"&gt;Easy Read (Welsh version)&lt;/A&gt; [PDF 1.33mb, 44 pages] 
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-questionnaire.doc" target="_blank"&gt;Summary of questions&lt;/A&gt; [Word 0.06mb, 6 pages] 
&lt;LI&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-easy-answers.pdf" target="_blank"&gt;Easy Read answers booklet&lt;/A&gt; [PDF 2.60mb, 28 pages] 
&lt;LI&gt;
&lt;P&gt;&lt;A href="http://www.justice.gov.uk/docs/cp2307-easy-answers-w.pdf" target="_blank"&gt;Easy Read answers booklet (Welsh version)&lt;/A&gt; [PDF 2.68mb, 28 pages]&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>271342</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_079842]]&gt;</url>
    <title>Consultation on the draft revised Mental Health Act 1983 Code of Practice</title>
    <publicationDate>2007-10-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The consultation document invites your comments on the draft revised Mental Health Act 1983 Code of Practice (in light of  the Mental Health Act 2007).</description>
    <body>&lt;![CDATA[ &lt;P&gt;The consultation document invites your comments on the draft revised Mental Health Act 1983 Code of Practice (in light of&amp;nbsp; the Mental Health Act 2007).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Code provides guidance to registered medical practitioners (“doctors”), approved clinicians, managers and staff of hospitals and approved mental health practitioners (who have defined responsibilities under the provisions of the Act), on how they should proceed when undertaking duties under the Act. It should also be considered by others working in health and social services (including the independent and voluntary sectors).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The consultation starts on 25 October 2007 and ends on 24 January 2008.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111319</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111319]]&gt;</url>
    <title>Coronary heart disease</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,SOCIAL CAPITAL,DISADVANTAGED GROUPS,CARDIOVASCULAR DISEASES,CIRCULATORY DISEASES,POPULATION BASED &amp; PREVENTATIVE SERVICES,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,HEALTHCARE &amp; HEALTH SERVICES,HEALTH SERVICES,SERVICES,POPULATIONS,GROUPS,COMMUNITIES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Coronary heart disease&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111318:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111320:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Poor mental health is a risk factor for CHD. Depression, for example, quadruples the risk of CHD, even when controlling for smoking levels and obesity (ref 1). By 2020 depression will be the second only to heart disease as a major cause of disability adjusted life years (ref 2). Low social capital has a negative impact on physical and mental health. In a cross sectional ecologic study based on data from 39 states in the USA, lower levels of social trust and reciprocity were associated with higher rates of most major causes of death, including coronary heart disease (ref 3).&lt;/P&gt;
&lt;P&gt;Other factors which influence how people feel such as low job control, job insecurity, poor social networks, living in a poor neighbourhood and perceptions of relative deprivation also increase risk of CHD and influence recovery rates for myocardial infarction. Research found that while individual income is predictive of recovery from myocardial infarction, living in a poor neighbourhood results in a significant additional health deficit. An individual’s assessment of their standard of living in comparison to others is significantly associated with physical recovery (ref 4).&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111318:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111320:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Hippisley-Cox J, Fielding K and Pringle M (1998) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/316/7146/1714?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Hippisley-Cox&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074008636800_9833&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=316&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Depression as a risk factor for ischaemic heart disease in men: population based control study&lt;/A&gt; British Medical Journal 316:1714-9&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;World Health Organisation (2001) &lt;A href="http://www.who.int/whr2001/2001/" target="_blank"&gt;World Health Report&lt;/A&gt;. Geneva: WHO&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Kawachi I, Kennedy B and Lochner K (1997) Social Capital, Income Inequality and Mortality. American Journal of Public Health 87: 491-498&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;MacLeod M, Graham E and Johnston M (2001) &lt;A href="http://www.lancs.ac.uk/users/apsocsci/hvp/newsletters/8findings.htm" target="_blank"&gt;Relative deprivation and recovery from first acute myocardial infarction&lt;/A&gt;&amp;nbsp;ESRC Research Findings 8 from the Health Variations Programme University of Lancaster: Lancaster&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>276027</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcarecommission.org.uk/_db/_documents/Count_me_in-2007.pdf]]&gt;</url>
    <title>Count me in 2007: results of the 2007 national census of inpatients in mental health and learning disability services in England and Wales</title>
    <publicationDate>2007-12-07T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LEARNING DISABILITIES,MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The census aimed to provide accurate figures on the numbers of inpatients in mental health and learning disability services in England and Wales, and to encourage service providers to collect and monitor data on all ethnic groups of patients.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The census aimed to provide accurate figures on the numbers of inpatients in mental health and learning disability services in England and Wales, and to encourage service providers to collect and monitor data on all ethnic groups of patients. &lt;/P&gt;
&lt;P&gt;It was conducted on March 30 2007 and collected information on:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;31,187 inpatients in mental health wards at 257 NHS and independent healthcare organisations in England and Wales. The proportion of inpatients in independent mental health hospitals increased from 10% in 2005 to 14% in 2007. 
&lt;LI&gt;4,153 inpatients in 120 organisations providing services for those with learning disabilities in England and Wales.&amp;nbsp;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The report stresses that without accurate data the quality of care and treatment of black and minority ethnic patients cannot be monitored. It makes recommendations to the Department of Health and the Information Centre to improve the information available about patients from all ethnic backgrounds, including those in independent healthcare organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330258</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.alzheimers.org.uk/site/scripts/download.php?fileID=787]]&gt;</url>
    <title>Counting the cost: Caring for people with dementia on hospital wards</title>
    <publicationDate>2009-11-17T00:00:00</publicationDate>
    <publisher>Alzheimer's Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,MENTAL HEALTH SERVICES,ACUTE SERVICES,MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA,COMMUNITY AND DOMICILIARY SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=first&gt;People with dementia - who occupy a quarter of all hospital beds - are staying far longer in hospital than people without the condition who go in for the same treatment. &lt;/P&gt;
&lt;DIV class=byEditor&gt;
&lt;P&gt;This is costing hundreds of millions of pounds to the NHS, an Alzheimer's Society report found today (Tuesday, 17 November 2009). Based on research involving 2,400 people,Counting the Cost: caring for people with dementia on hospital wards reveals large, costly variations in the quality of care for people with dementia. &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>381576</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/about/docs/court-experience-adults-1.pdf]]&gt;</url>
    <title>Court experiences of adults with mental health conditions or learning disabilities</title>
    <publicationDate>2010-07-20T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=clear-teaser-image&gt;
&lt;P&gt;&lt;STRONG&gt;A series of reports presenting the background, findings and recommendations of a research project examining court experiences of adults with mental health conditions or learning disabilities.&lt;/STRONG&gt;&lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;The reports were carried out by Rosie McLeod, Cassie Philpin, Anna Sweeting, Lucy Joyce and Roger Evans, British Market Research Bureau (BMRB) and Liverpool John Moores University.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Report 1:&lt;/STRONG&gt;&amp;nbsp;Presents the main findings and recommendations of the project. &lt;/P&gt;
&lt;P&gt;In-depth interviews were conducted with people with mental health conditions, learning disabilities and limited mental capacity, who had been victims or witnesses in criminal proceedings, or parties in civil or family law cases. Carers, court staff and other key stakeholders also took part. This report provides an overview of findings and recommendations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reports 2-6: &lt;/STRONG&gt;Discuss in detail the findings and background for the research project&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388586</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/CR160.pdf]]&gt;</url>
    <title>CR160. Good Psychiatric Practice: Confidentiality and Information Sharing (2nd edition)</title>
    <publicationDate>2010-09-15T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal&gt;The central purpose of this document is to provide members with guidance on good practice in confidentiality. This includes advice on information sharing and on dealing with decisions on disclosure, including requests for disclosure. This comprehensive guidance develops, in depth, the outline guidance given in the College's &lt;EM&gt;&lt;A href="http://www.rcpsych.ac.uk/publications/collegereports/cr/cr154.aspx" target="_blank"&gt;Good Psychiatric Practice&lt;/A&gt;&lt;/EM&gt; report.&amp;nbsp;It has been informed by and is consistent with &lt;EM&gt;Confidentiality&lt;/EM&gt;, guidance for doctors published by the General Medical Council (GMC).&lt;/P&gt;
&lt;P class=MsoNormal&gt;The focus is on practical guidance relevant to a variety of situations and issues that confront psychiatrists and other members of multidisciplinary teams throughout the National Health Service (NHS) and independent sector. The document is supplemented by a series of appendices that provide background information and examples. Summary guidance statements are included for each area of practice.&lt;/P&gt;
&lt;P class=Pa7&gt;Since these guidelines were last issued in 2006, there have been a number of changes in health service organisation, clinical practice and public expectations, as well as a general trend towards augmenting the duty to disclose and to reducing professional privilege. Particular consideration has been given to the special issues surrounding the sensitivity of mental health information, the impact of changes in health service organisation, developments within practice (e.g. multidisciplinary and multi-agency working) and the impact of new technologies (e.g. electronic communication and computerised information systems).&lt;/P&gt;
&lt;P class=MsoNormal&gt;This report is the replacement of the original &lt;EM&gt;CR85: Good Psychiatric Practice: Confidentiality&lt;/EM&gt; from 2000,&amp;nbsp;of &lt;EM&gt;CR65: Guidance for Videotaping&lt;/EM&gt; from 1998, and of &lt;EM&gt;CR133: Good Psychiatric Practice: Confidentiality and Information Sharing&lt;/EM&gt; from 2006.&lt;/P&gt;
&lt;P class=Pa7&gt;The College recommends education and training in confidentiality at undergraduate, postgraduate and CPD levels. An online CPD module exists to support training: &lt;EM&gt;&lt;A href="http://www.psychiatrycpd.org/learningmodules/respectforconfidentiality-.aspx" target="_blank"13)"'&gt;Respect for Confidentiality - good psychiatric practice&lt;/A&gt;&lt;/EM&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263042</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38607&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Crisis Services Development Update</title>
    <publicationDate>2001-08-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update on the Mental Health Foundation’s Crisis Services Development Programme.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Update on the Mental Health Foundation's Crisis Services Development Programme.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263043</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40182&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Crisis Workbook Intro</title>
    <publicationDate>2003-05-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,MONTHLY ADDITIONS,2008-AUGUST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Intro section of workbook produced as part of our work on issues relating to the mental health of adults of working age.</description>
    <body>&lt;![CDATA[ Intro section of workbook produced as part of our work on issues relating to the mental health of adults of working age. This programme is entitled Strategies for Living, and aims to promote and encourage the development of user/survivor empowerment through research, evaluation and information gathering.]]&gt;</body>
  </document>
  <document>
    <id>267853</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.priorygroup.com/pg.asp?p=Cryingshame]]&gt;</url>
    <title>Crying Shame</title>
    <publicationDate>2007-08-15T00:00:00</publicationDate>
    <publisher>The Priory Group</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This new report from the Priory Group reveals that a shocking 72% of adults in Great Britain believe that there is a stigma associated with having a  mental illness and describe people with mental illness as unpredictable (79%), dangerous (50%)and scary (49%). Less than half (45%) of the adult population think that people with long-term mental illnesses are able to lead independent, fulfilled lives.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Mental illness is still shrouded in stigma, fear and ignorance.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This new report from the Priory Group reveals that a shocking 72% of adults in Great Britain believe that there is a stigma associated with having a mental illness and describe people with mental illness as unpredictable (79%), dangerous (50%) and scary (49%). Less than half (45%) of the adult population think that people with long-term mental illnesses are able to lead independent, fulfilled lives.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Over half of British adults (52%) agree that being diagnosed with a serious mental illness and being diagnosed with cancer are as bad as each other and 57% believe that all aspects of their lives would be negatively affected if they were diagnosed with a mental illness.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Most damningly, 77% of adults state that the media does not do a good job in educating people about mental illness and 76% say that the media does not do a good job in de-stigmatising mental illness.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Mental illness does not respect age, sex, marital status, class or region, which means that anyone, at any point in their lives, can become mentally ill. Susceptibility to mental illness is part of the human condition – no one is immune. We must stop being judgmental about people with mental illness. Mental illnesses are real illnesses, just like cancer, diabetes&lt;BR&gt;or arthritis.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Psychiatric patients are scared, and scarred, by their diagnoses. They are usually terrified at their initial consultation and feel that they are blamed for their illness in a way that other patients, say those who require orthopaedic surgery, are not.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The aim of this new report is to raise widespread awareness of the shocking stigma that still surrounds mental illness, particularly the ways in which it adversely affects treatment outcomes and employment options. The role of the media in perpetrating stigma is also examined.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317684</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.depressionalliance.org/documents/daring_to_choose_april_09.pdf]]&gt;</url>
    <title>Daring to choose - 10 ways to deliver choice for people with depression and anxiety PDF</title>
    <publicationDate>2009-05-29T00:00:00</publicationDate>
    <publisher>Depression Alliance (England)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,PATIENT AND PUBLIC INVOLVEMENT,ADULT CONDITIONS,CHRONIC MIXED ANXIETY AND DEPRESSION,PPI IN PRACTICE,HOW DO I INVOLVE...?,PEOPLE WITH MENTAL HEALTH ISSUES,INDIVIDUAL INVOLVEMENT,PATIENT CHOICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This new report gives ten recommendations for greater choice in depression and mental health services. Issued as part of Depression Awareness Week™ to help to trigger improvements for people affected by depression and anxiety, the report highlights the challenges faced by those people in getting their choice of treatment and services.]]&gt;</body>
  </document>
  <document>
    <id>327441</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.depressionalliance.org/documents/daring_to_choose_april_09.pdf]]&gt;</url>
    <title>Daring to choose - 10 ways to improve choice for people with depression and anxiety</title>
    <publicationDate>2009-09-30T00:00:00</publicationDate>
    <publisher>Depression Alliance (England)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,PATIENT AND PUBLIC INVOLVEMENT,ADULT CONDITIONS,DEPRESSION,GENERALIZED ANXIETY,PPI IN PRACTICE,HOW DO I INVOLVE...?,PEOPLE WITH MENTAL HEALTH ISSUES,INDIVIDUAL INVOLVEMENT,PATIENT CHOICE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The global burden of depression and anxiety,measured in terms of disability adjusted life-years, will rank second only to coronary heart disease by the year 2020. In the United Kingdom, nearly 10% of adults suffer from mixed depression and anxiety and a further 4.4% from generalised anxiety disorder. The total cost to the UK economy in the year 2000 was over £9 billion, including NHS costs. As a result of depression 110 million working&lt;BR&gt;days were lost and there were 2615 deaths. Depression and anxiety should be an urgent public health priority.]]&gt;</body>
  </document>
  <document>
    <id>386854</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.depressionalliance.org/PDF/daring-to-implement.pdf]]&gt;</url>
    <title>Daring to implement</title>
    <publicationDate>2010-08-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A new report highlighting the best examples of services commissioned for people with depression across the country.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>345871</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=7098E533-1143-DFD0-7E03-88C2637E1163&amp;ext=pdf]]&gt;</url>
    <title>Database of Disaster Resources</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This paper aims to help members of the BPS&amp;nbsp;gain access to relevant resources in their work with those psychologically affected by disasters and other major incidents.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>388534</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=388534]]&gt;</url>
    <title>Death risk from insomnia unclear</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SLEEP PROBLEMS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Death risk from insomnia unclear&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;“Men who find themselves unable to sleep during the small hours of the night may end up dying younger,” reported the&lt;EM&gt; Daily Mail.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This study looked at people’s insomnia and their risk of dying over a 14-year period. At the start of the study, people filled out a questionnaire on their history of insomnia and were observed for one night in a sleep laboratory. Men who reported a history of insomnia and slept for less than six hours in the lab were four times more likely to die in the follow-up period than those without insomnia who slept for six hours or more in the lab.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>105867</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=105867]]&gt;</url>
    <title>Defining Mental Health</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Defining Mental Health&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:105868:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Mental health problems are common and widely misunderstood. At any one time, one adult in six suffers from mental health problems of varying severity. (ref 1) Other research suggests that one person in four will experience some kind of mental health problem in the course of a year. (ref 2) (see &lt;A href="nelh:111329:1" name=internalLink&gt;Adulthood&lt;/A&gt;; &lt;A href="nelh:111331:1" name=internalLink&gt;marginalised groups – people with mental health problems&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;A survey of children and young people’s (aged 5 – 15) mental health found that the proportion of children and adolescents with any mental disorder was greater among boys than girls across the age range: 11% compared with 8%. (ref 3) (see &lt;A href="nelh:111328:1" name=internalLink&gt;Young people&lt;/A&gt;; &lt;A href="nelh:111327:1" name=internalLink&gt;Early years&lt;/A&gt;). &lt;BR&gt;The cost of mental illness in England adds up to £77.4 billion. (ref 4). &lt;/P&gt;
&lt;P&gt;This equates to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;£12.5 billion for care provided by the NHS, local authorities, privately funded services, family and friends;&lt;/LI&gt;
&lt;LI&gt;£23.1 billion in lost output in the economy caused by people being unable to work (paid and unpaid);&lt;/LI&gt;
&lt;LI&gt;£41.8 billion in the human costs of reduced quality of life, and loss of life, amongst those experiencing a mental health problem. (&lt;A href="http://www.scmh.org.uk/" target="_blank"&gt;www.scmh.org.uk&lt;/A&gt;)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Mental health is a contested concept which is defined in a number of different ways. There is a deficit model of mental health i.e. the absence of objectively diagnosable disease. There is a positive holistic model of mental health as a state of physical, social and mental well-being (ref 5,6).&lt;/P&gt;
&lt;P&gt;Definitions of positive mental health are still under debate but there has been a movement away from a focus solely on individual attributes such as coping skills or resilience, to one which incorporates environmental and social conditions (ref 7-10) The Carter Commission on mental health recognised that the risk of mental illness was influenced by a range of socio-economic, inter-personal and hereditary factors (ref 11).&lt;/P&gt;
&lt;P&gt;Definitions of mental health are personal and are dependant upon our individual life experiences and life context. Therefore they can be influenced by our gender, race, religious beliefs, social class, experience of family life, aspirations and beliefs etc.&lt;/P&gt;
&lt;P&gt;Mental health has been described as multifaceted with six dimensions: affective, behavioural, cognitive, socio-political, spiritual and psychological (ref 12).&lt;/P&gt;
&lt;P&gt;The Health Education Authority defined mental health in 1997 as “the emotional and spiritual resilience which enables us to survive pain, disappointment and sadness. It is a fundamental belief in our own and others’ dignity and worth”.&lt;/P&gt;
&lt;P&gt;The Mental Health Foundation has defined a mentally healthy individual as one who can:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Develop emotionally, creatively, intellectually and spiritually;&lt;/LI&gt;
&lt;LI&gt;Initiate, develop and sustain mutually satisfying personal relationships;&lt;/LI&gt;
&lt;LI&gt;Face problems, resolve them and learn from them;&lt;/LI&gt;
&lt;LI&gt;Be confident and assertive;&lt;/LI&gt;
&lt;LI&gt;Be aware of others and empathise with them;&lt;/LI&gt;
&lt;LI&gt;Use and enjoy solitude;&lt;/LI&gt;
&lt;LI&gt;Play and have fun;&lt;/LI&gt;
&lt;LI&gt;Laugh, both at themselves and at the world.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These differing models and definitions of mental health illustrate an array of individual and environmental risk and protective factors. The interaction between discrete factors and mental health outcomes is however not clearly delineated. Why a particular risk factor should result in poor mental health outcomes for one individual and not another is as yet unknown. What all these models of mental health acknowledge however is the extent to which mental health is entrenched within social relationships.&lt;/P&gt;
&lt;P&gt;A useful definition of mental health is that used by the World Health Organisation: “Mental health is a state of well-being in which the individual realises his or her own abilities, can cope with the normal stresses of life, can work productively and fruitfully and is able to make a contribution to his or her community.”&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:105868:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Office for National Statistics (2000) Survey of Psychiatric Morbidity Among Adults Living in Private Households. London: HMSO&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Goldberg D (1991) Filters to care in Indicators for Mental Health in the Population. Jenkins R and Griffiths S (ed). London. The Stationery Office.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Meltzer H, Gatward R, Goodman R and Ford T (2000) The mental health of children and adolescents in Great Britain: Summary report. London: Office for National Statistics.&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Sainsbury Centre for Mental Health (2003) The Economic and Social Costs of Mental Illness. London:&lt;A href="http://www.scmh.org.uk/wbm23.ns4/WebLaunch/LaunchMe" target="_blank"&gt;SCMH&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;World Health Organisation (1946) Constitution. New York: &lt;A href="http://www.who.int/en/" target="_blank"&gt;World Health Organisation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;World Health Organisation (1986) Ottowa Charter for Health Promotion. Ottawa: World Health Organisation&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Rutter M (1985) Resilience in the face of adversity: protective factors and resistence to psychiatric disorder. &lt;A href="http://bjp.rcpsych.org/" target="_blank"&gt;British Journal of Psychiatry&lt;/A&gt;. 147: 598-611&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Health Education Authority (1997) Mental Health Promotion: A Quality Framework. London: HEA.&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;MacDonald G and O’Hara K (1998) Ten Elements of Mental Health, Its Promotion and Demotion: Implications for Practice. Society of Health Education and Promotion Specialists.&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Secker J (1998) Current conceptualisations of mental health and mental health promotion. Health Education Research. 13 (1): 57 – 66.&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Albee GW and Ryan-Finn KD (1993) An Overview of Primary Prevention. Journal of Counselling and Development. 72: 115-123.&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Tudor K (1996) Mental Health Promotion: Paradigms and Practice. London: Routledge.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395088</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/delivering-race-equality-in-mental-health-care.pdf]]&gt;</url>
    <title>Delivering race equality in mental health care</title>
    <publicationDate>2010-11-17T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ An action plan for reform inside and outside services and The Government's response to the independent inquiry into the death of David Bennett. 2005&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>342690</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dementia2010.org/reports/Dementia2010Full.pdf]]&gt;</url>
    <title>Dementia 2010</title>
    <publicationDate>2010-02-03T00:00:00</publicationDate>
    <publisher>Alzheimer's Research Trust</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Alzheimer's Research Trust has commissioned the Health Economics Research Centre at the University of Oxford to produce a report on the economic cost of dementia to the UK, and the country's investment in research to find new treatments, preventions and cures.&lt;/P&gt;
&lt;P&gt;The Oxford team's findings are astonishing. They show dementia to be the greatest medical challenge of our time.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; * Over 820,000 people in the UK live with Alzheimer's and other dementias.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; * Dementia costs the UK economy £23 billion per year: more than cancer and heart disease combined.&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; * Dementia research is severely underfunded, receiving 12 times less support than cancer research.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>331030</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/cr155.pdf]]&gt;</url>
    <title>Dementia and people with learning disabilities</title>
    <publicationDate>2009-11-18T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ LEARNING DISABILITIES,MENTAL HEALTH,MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Guidance on the assessment, diagnosis, treatment and support of people with learning disabilities who develop dementia. Co-published by The British Psychological Society and the Royal College of Psychiatrists.&lt;/STRONG&gt; 
&lt;P class=MsoNormal&gt;The main purpose of the report is to enable those working in clinical and social care services to improve the quality of life of people with learning disabilities who develop dementia, by providing guidance to inform assessment, diagnosis, treatment and support. The guidance is aimed at clinicians in learning disability and older peoples’ mental health services and services for younger people with dementia. The main focus is on the key factors that are the elements of an excellent service, and to help those working in services evaluate how they might help the increasing numbers of people with learning disabilities who are developing dementia given improvements in life-expectancy.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;Contents:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Members of the working group&lt;/P&gt;
&lt;P class=MsoNormal&gt;Acknowledgements&lt;/P&gt;
&lt;P class=MsoNormal&gt;Foreword&lt;/P&gt;
&lt;P class=MsoNormal&gt;Purpose of this report&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;1: Context&lt;/P&gt;
&lt;P class=MsoNormal&gt;2: Epidemiology&lt;/P&gt;
&lt;P class=MsoNormal&gt;3: Baseline and monitoring&lt;/P&gt;
&lt;P class=MsoNormal&gt;4: Possible reasons for apparent decline in functioning&lt;/P&gt;
&lt;P class=MsoNormal&gt;5: Clinical presentation of dementia&lt;/P&gt;
&lt;P class=MsoNormal&gt;6: Assessment&lt;/P&gt;
&lt;P class=MsoNormal&gt;7: Decision making/telling people&lt;/P&gt;
&lt;P class=MsoNormal&gt;8: Additional health/clinical issues associated with dementia&lt;/P&gt;
&lt;P class=MsoNormal&gt;9: Conceptual understanding of the dementia process&lt;/P&gt;
&lt;P class=MsoNormal&gt;10: Philosophy of care&lt;/P&gt;
&lt;P class=MsoNormal&gt;11: Environments&lt;/P&gt;
&lt;P class=MsoNormal&gt;12: Meeting changing needs/interventions&lt;/P&gt;
&lt;P class=MsoNormal&gt;13: Medications&lt;/P&gt;
&lt;P class=MsoNormal&gt;14: End of life issues&lt;/P&gt;
&lt;P class=MsoNormal&gt;15: Capable commissioning for people with learning disabilities and dementia&lt;/P&gt;
&lt;P class=MsoNormal&gt;16: Capable workforce&lt;/P&gt;
&lt;P class=MsoNormal&gt;17: References&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;Appendix: Good Practice Standards – self assessment checklist&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327478</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/laterlife/viewResource.aspx?resid=319931&amp;code=ded7f5f2689f7a4f607afcc0fe0c03d9]]&gt;</url>
    <title>Dementia Annual Evidence Update 2009</title>
    <publicationDate>2009-09-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - later life</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Evidence - later life's&amp;nbsp;Alzheimer's Disease and Dementia Annual Evidence Update 2009 aims to provide healthcare professionals with a clear path to the most important recent evidence surrounding the five major types of dementia: Alzheimer’s; Vascular dementia; Dementia with Lewy bodies; Frontotemporal dementia; and Mixed dementias.&lt;/P&gt;
&lt;P&gt;The Dementia AEU provides bibliographies on secondary research (systematic reviews, meta analyses and guidelines) from the last 18 months for the following topics:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/LaterLife/ViewResource.aspx?resID=319933&amp;amp;pgID=1" target="_blank"&gt;Definitions, Diagnosis and Screening&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/LaterLife/ViewResource.aspx?resID=319934&amp;amp;pgID=1" target="_blank"&gt;Risk Factors and Aetiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/LaterLife/ViewResource.aspx?resID=319935&amp;amp;pgID=1" target="_blank"&gt;Pharmacological Treatments&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/LaterLife/ViewResource.aspx?resID=319937&amp;amp;pgID=1" target="_blank"&gt;Non-Pharmacological Treatments&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/LaterLife/ViewResource.aspx?resID=319939&amp;amp;pgID=1" target="_blank"&gt;Rehabilitation, Practice and Care Standards&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/LaterLife/ViewResource.aspx?resID=319942&amp;amp;pgID=1" target="_blank"&gt;Evidence on Other Dementias&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
  </document>
  <document>
    <id>330541</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Quality-of-dementia-care-in-hospitals.aspx]]&gt;</url>
    <title>Dementia care in hospitals</title>
    <publicationDate>2009-11-17T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The quality of dementia care in hospitals has featured&amp;nbsp;in many newspapers. &lt;EM&gt;The Times&lt;/EM&gt; reported that campaigners have said, “Patients with dementia are staying too long in hospital and receiving ‘disgraceful’ care that worsens their condition.” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; said that “one in three never go back to their own homes and are discharged to a nursing home instead.”]]&gt;</body>
  </document>
  <document>
    <id>296542</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.alzheimers.org.uk/outoftheshadows]]&gt;</url>
    <title>Dementia: Out of the Shadows</title>
    <publicationDate>2008-10-24T00:00:00</publicationDate>
    <publisher>Alzheimer's Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,DEMENTIA,ADULT CONDITIONS,LATER LIFE,MENTAL HEALTH,DEMENTIA,PATHOLOGY,CAUSES AND PREVENTION,DEFINITION AND TYPES,TREATMENT AND CARE,DIAGNOSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>People with dementia have spoken out about the impact and stigma a diagnosis has on their lives in a new Alzheimer's Society report called Dementia: Out of the Shadows.</description>
    <body>&lt;![CDATA[ &lt;P&gt;People with dementia have spoken out about the impact and stigma a diagnosis has on their lives in a new Alzheimer's Society report called Dementia: Out of the Shadows.&lt;/P&gt;
&lt;P&gt;People with dementia reported losing friends after a diagnosis of dementia, neighbours crossing the street as they approached and professionals dismissing symptoms as just old age.&lt;/P&gt;
&lt;P&gt;New Alzheimer's Society research also reveals that half of all UK adults believe dementia is a condition plagued by stigma. 700,000 people with dementia across the UK live with this stigma, which affects their friends, families and the professionals they rely on for help.&lt;/P&gt;
&lt;P&gt;Alzheimer's Society will lead the fight against stigma and we want to see it reduced by half in 5 years. We are calling for Government, charities, services and employers to work together and for national awareness campaigns that will bring dementia out of the shadows.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This webpage features seven You Tube videos: Four videos feature the author Terry Pratchett, and the other three feature different people describing the effects of living with dementia, stigma and diagnosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="http://www.alzheimers.org.uk/downloads/Executive_summary_Out_of_the_Shadows_07102008.pdf" target="_blank"&gt;Click this link to download the executive summary of the Dementia: Out of the Shadows report&lt;/A&gt;&lt;/H2&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="http://www.alzheimers.org.uk/downloads/Out_of_the_Shadows.pdf" target="_blank"&gt;Click this link to download the full version of the Dementia: Out of the Shadows report&lt;/A&gt;&lt;/H2&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="http://www.alzheimers.org.uk/downloads/dementia_research_2008_literature_review.pdf" target="_blank"&gt;Click this link to download the literature review&lt;/A&gt;&lt;/H2&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319733</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=319733]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Contents</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION,COMPLEMENTARY AND ALTERNATIVE MEDICINE,OCTOBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This 2009 Annual Evidence Update has focused on four key themes relating to depression:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG style="FLOAT: right" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319733/nelhImp_0000_UNITYANDSTRENGTH.jpg"&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&amp;nbsp; &lt;A href="nelh:326326:1" name=internalLink&gt;UK and International Guidelines&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;&amp;nbsp; &lt;A href="nelh:319736:1" name=internalLink&gt;Incidence and Prevalence&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp; &lt;A href="nelh:319737:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;&amp;nbsp; Treatment&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 4a. &lt;A href="nelh:319741:1" name=internalLink&gt;Pharmacological treatments&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;4b. &lt;A href="nelh:319742:1" name=internalLink&gt;Psychosocial treatments&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 4c. &lt;A href="nelh:319744:1" name=internalLink&gt;Transcanial Magnetic Stimulation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 4d. &lt;A href="http://www.library.nhs.uk/CAM/ViewResource.aspx?resID=324950&amp;amp;tabID=289" name=internalLink target="_blank"&gt;Complementary and alternative treatments&lt;/A&gt;&amp;nbsp;- &lt;EM&gt;This is a link to the Complementary and Alternative Medicine Specialist Collection&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;&amp;nbsp; &lt;A href="nelh:319745:1" name=internalLink&gt;Populations and Settings&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;&amp;nbsp; &lt;A href="nelh:324071:1" name=internalLink&gt;Genetics&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;You can download and read the following documents below:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Depression Annual Evidence Update 2009 Methodology&lt;/LI&gt;
&lt;LI&gt;Depression Annual Evidence Update 2009 Press Release&lt;/LI&gt;
&lt;LI&gt;Depression Annual Evidence Update 2009 Publicity Poster&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>319737</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=319737]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Diagnosis, Prevention and Screening</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ DEPRESSION,NOT ROUTINELY OFFERED,DEPRESSION,ADULT,SCREENING,EMERGENCY CARE,PSYCHIATRY,CLINICAL LIBRARY,MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Diagnosis, Prevention and Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319737/nelhImp_0000_DIAGNOSIS.jpg"&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bylsma LM, Morris BH, Rottenberg J. Does emotion predict the course of major depressive disorder? A review of prospective studies. British Journal Clinical Psychology 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19187578" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Colasanti V, Marianetti M, Micacchi F, Amabile GA, Mina C. Tests for the evaluation of depression in the elderly: A systematic review. Archives of Gerontology and Geriatrics 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19414202" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mann R, Hewitt CE, Gilbody SM. Assessing the quality of diagnostic studies using psychometric instruments: Applying QUADAS. Social Psychiatry and Psychiatric Epidemiology 2009; 44(4):300-307.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18836883" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herzog W, Lowe B, Mundt C et al. Validity of current somatoform disorder diagnoses: perspectives for classification in DSM-V and ICD-11. Psychopathology 2008; 41(1):4-9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17952015" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Beekman A, Cuijpers P, Mihalopoulos C, Smit F, Van Straten A. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. American Journal Psychiatry 2008; 165(10):1272-80.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18765483" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Eder M, O'Connor EA, Whitlock EP, Williams SB. Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force. Pediatrics 2009; 123(4):e716-35.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19336361" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gilbody S, Sheldon T, House A. Screening and case-finding instruments for depression: a meta-analysis. CMAJ 2008; 178(8):997-1003.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18390942" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;US Preventive Services Task Force. Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force Recommendation Statement. Pediatrics 2009; 123(4):1223-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19336383" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>324071</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=324071]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Genetics</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Genetics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID324071/nelhImp_0000_GENETICS.jpg"&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Genetics&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. International Journal of Neuropsychopharmacologium 2008; 11(8):1169-80.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18752720" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chen L, Lawlor DA, Lewis SJ et al. Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. American Journal of Medical Genetics: Part B, Neuropsychiatric Genetics 2008; 147B(6):814-21.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18205169" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 2009; 71(2):171-86.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19188531" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 2008.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18982004" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM et al. Meta-analyses of genetic studies on major depressive disorder. Molecular Psychiatry 2008; 13(8):772-85.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17938638" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Munafo MR, Durrant C, Lewis G, Flint J. Gene X environment interactions at the serotonin transporter locus. Biological Psychiatry 2009; 65(3):211-9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18691701" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Risch N, Herrell R, Lehner T et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009; 301(23):2462-71.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531786" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>326326</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=326326]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Guidelines</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Guidelines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;IMG style="FLOAT: right" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID326326/nelhImp_0000_GUIDELINES.jpg"&gt;&lt;/H2&gt;
&lt;H2&gt;Influential Guidelines from 2004-2009&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;UK Guidelines&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NICE (National Institute for Health and Clinical Excellence)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NICE first published a guideline on depression in 2004, which was updated in October&amp;nbsp;2009:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression: the treatment and management of depression in adults. 2009.&amp;nbsp;[&lt;A href="http://guidance.nice.org.uk/CG90" target="_blank"&gt;Full-text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;NICE has also published a number of other guidelines and technology appraisals that are relevant to depression:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression in children and young people : identification and management in primary, community and secondary care. 2005. [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG028NICEguideline.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Depression in adults with chronic health problems. 2009. [&lt;A href="http://guidance.nice.org.uk/CG91" target="_blank"&gt;Full-text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cognitive behavioural therapy for the management of common mental health problems. 2008. [&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cognitivebehaviouraltherapyservice/cbt.jsp" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Transcranial magnetic stimulation for severe depression. 2007. [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/IPG242GUIDANCE.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Computerised cognitive behaviour therapy for depression and anxiety: review of Technology Appraisal 51. 2006. [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA097guidance.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Department of Health&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;The competences required to deliver effective cognitive and behavioural therapy for people with depression and with anxiety disorders. 2007.&lt;BR&gt;[&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_078535.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Psychiatrists&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Psychiatric services for black and minority ethnic older people. 2009.&lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/CR156.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;British Association of Psychopharmacology&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. 2008.&lt;BR&gt;[&lt;A href="http://www.bap.org.uk/pdfs/antidepressants.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;British Occupational Health Research Foundation&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Workplace interventions for people with common mental health problems: evidence review and recommendations. 2005.&lt;BR&gt;[&lt;A href="http://www.bohrf.org.uk/downloads/cmh_rev.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical Knowledge Summaries (CKS)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression. 2005.&lt;BR&gt;[&lt;A href="http://www.cks.nhs.uk/depression#" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Map of Medicine - NHS Choices&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression. 2005.&lt;BR&gt;[&lt;A href="http://healthguides.mapofmedicine.com/choices/map/depression1.html" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Depression in children and adolescents - primary care assessment. 2005.&lt;BR&gt;[&lt;A href="http://healthguides.mapofmedicine.com/choices/map/depression_in_children_and_adolescents1.html" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;H2&gt;International Guidelines&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;American College of Physicians&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. 2008.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=12149&amp;amp;nbr=6246&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. 2008.&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Pediatrics&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Zuckerbrot RA, Cheung AH, Jensen PS, Stein RE, and Laraque D. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management. Pediatrics 2007; 120(5).&lt;BR&gt;[&lt;A href="http://pediatrics.aappublications.org/cgi/reprint/120/5/e1299.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;United States Preventive Services Task Force&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Screening and treatment for major depressive disorder in children and adolescents: U.S. Preventive Services Task Force recommendation statement. 2009.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=14294&amp;amp;nbr=7170&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>319736</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=319736]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Incidence and Prevalence</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Incidence and Prevalence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:1" name=internalLink&gt;&lt;A href="nelh:319733:0" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319736/nelhImp_0001_INCIDENCE-AND-PREVALENCE.jpg"&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Incidence and Prevalence&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bruffaerts R, Bonnewyn A, Demyttenaere K. The epidemiology of depression in Belgium. A review and some reflections for the future. Tijdschrift Voor Psychiatrie 2008; 50(10):655-65.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18951344" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cepoiu M, McCusker J, Cole MG, Sewitch M, Belzile E, Ciampi A. Recognition of depression by non-psychiatric physicians-a systematic literature review and meta-analysis. Journal of General Internal Medicine 2008; 23(1):25-36.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17968628" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gilbody S, Bower P, Torgerson D, Richards D. Cluster randomized trials produced similar results to individually randomized trials in a meta-analysis of enhanced care for depression. Journal of Clinical Epidemiology 2008; 61(2):160-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18177789" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kim D. Blues from the neighborhood? Neighborhood characteristics and depression. Epidemiologic Reviews 2008; 30:101-17.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18753674" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Landi M, BS, FL et al. Epidemiology of major depressive disorder. Quaderni Italiani Di Psichiatria 2008; 27(2):47-54).&lt;/LI&gt;
&lt;LI&gt;Tylee A. Low recognition of depression among outpatients by internists in China. EBMH Journal 2009; 12(64).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/64" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>319735</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=319735]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Methodology</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:0" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Methodology coming soon - 05.10.09&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>319741</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=319741]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Pharmacological treatments</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,CLINICAL LIBRARY,ADULT CONDITIONS,MENTAL HEALTH,PSYCHIATRY,DEPRESSION,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Pharmacological treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage3 style="FLOAT: right" src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319741/nelhImp_0000_PHARMACOLOGICAL.jpg" name=nelh_tempImage3&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Selective serotonin reuptake inhibitors or serotonin-specific reuptake inhibitor (SSRI’s)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abdollahi M, Nikfar S, Rahimi R. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Progress in Neuropsychopharmacology and Biological Psychiatry 2009; 33(1):118-27.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19028540" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Abholz HH, Schurer-Maly CC. Care of depressive patients in general practice: How, why and with how much success? A systematic review. Zeitschrift Fur Allgemeinmedizin 2008; 84(8):327-335.&lt;BR&gt;[&lt;A href="http://www.pressekatalog.de/PK/Artikel.asp?ARTID=10.1055/s-0028-1082066&amp;amp;VSRC=thieme&amp;amp;CSS=995&amp;amp;fachstichwort=englisch&amp;amp;gattung=PUP%2CFAP%2CINP&amp;amp;angebotsform=EZH%2CATK%2CABO&amp;amp;backlist=TRUE&amp;amp;Catalogswitch=3" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersson G, Cuijpers P, Van Oppen P, Van Straten A. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. Journal Clinical Psychiatry 2008; 69(11):1675-85; quiz 1839-41.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18945396" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Anderson IM, Baldwin RC, Ferrier IN et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. Journal Psychopharmacology 2008; 22(4):343-96.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18413657" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersen HF, Kennedy SH, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Current Medical Research and Opinion 2009; 25(1):161-75.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19210149" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Appelhof BC, Cooper-Kazaz R, Papakostas GI, et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. International Clinical Psychopharmacology 2009; 24(1):19-25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19092448" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Arroll B, Elley CR, Fishman T et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007954/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barbui C, Cipriani A, Furukawa TA. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008; 178(3):296-305.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18227449" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barbui C, Cipriani A. Maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. EBMH Journal 2009; 12.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/3/79" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&amp;nbsp;Barbui C, Cipriani A, Esposito E. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review&amp;nbsp; of observational studies. CMAJ 2009; 180(3):291-7.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19188627" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Baldwin DS, Goodwin G, Moller HJ et al. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. European Archives of Psychiatry and Clinical Neuroscience 2008; 258 Suppl 3:3-23.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18668279" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bauer M, Freemantle N, Moeller HJ, Tharmanathan P, Volz HP. The effect of venlafaxine compared with other antidepressants and placebo in the&amp;nbsp; treatment of major depression: a meta-analysis. European Archives Psychiatry Clinical Neuroscience 2009; 259(3):172-85.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19165525" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Becker T, Koesters M, Weinmann S. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl) 2008; 196(4):511-20; discussion 521-2.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17955213" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bonati M, Clavenna A, Usala T, Zuddas A. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. European Neuropsychopharmacology 2008; 18(1):62-73.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17662579" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brunoni AR, Fregni F, Kaptchuk TJ, Lopes M. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One 2009; 4(3):e4824.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19293925" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chuluunkhuu G, Kamae I, Nakahara N, Yanagisawa S. The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. Kobe Journal Medical Science 2008; 54(2):E147-58.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18772616" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373(9665):746-58.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19185342" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A, Furukawa TA, Geddes JR et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. Journal Clinical Psychiatry 2008; 69(11):1732-42.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19026250" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006532/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A et al. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2008.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006117/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cohen D, Hughes S. A systematic review of long-term studies of drug treated and non-drug treated depression. Journal Affective Disorders 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19249104" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cowen P, Freemantle N, Geddes J, Terao T, Whale R. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. Journal Psychopharmacology 2008.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832428" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;D’Arrigo C, Santoro V, Spina E. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics 2008; 30(7): 1206-1227.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18691982" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dekker J, Schoevers RA, Van HL. Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harvard Review of Psychiatry 2008; 16(4):225-34.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18661365" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Denberg TD, Forciea MA, Owens DK Qaseem A, Snow V. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2008; 149(10):725-33.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19017591" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Deshauer D et al. Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ 2008; 178(10):1293-301.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18458261" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dubicka B. Adolescents with SSRI-resistant depression: CBT plus antidepressant switch more effective than medication switch alone. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/110" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fava M, Papakostas GI, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biological Psychiatry 2008; 63(7):699-704.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17919460" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gartlehner G, Gaynes BN, Hansen RA et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of Internal Medicine 2008; 149(10):734-50.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19017592" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gartlehner G, Gaynes BN, Krebs EE et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. Psychosomatics 2008; 49(3):191-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18448772" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gartlehner G, Hansen RA, Thieda P et al. Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. Drug Safety 2008; 31(10):851-65.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18759509" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hansen R, Gaynes B, Thieda P et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric Services 2008; 59(10):1121-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832497" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hansen RA et al. Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Medical Decision Making 2009; 29(1):91-103.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19141788" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Joanna Moncrieff SWRH. Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews 2008.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003012/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kasper S, Moller HJ, Nelson JC, Papakostas GI. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. European Neuropsychopharmacology 2008; 18(2):122-7.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17719752" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Krishen A, Papakostas GI, Stahl SM, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Journal of Clinical Psychiatry 2008; 69(8):1287-92.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18605812" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nahas Z, Simpson AN, Simpson K, Williams N. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Human Psychopharmacology 2009; 24(5):401-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19526453" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nakagawa A, Omori IM, Watanabe N et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. Journal Clinical Psychiatry 2008; 69(9):1404-15.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19193341" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Omori I, Watanabe N, Nakagawa A et al. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. Journal Psychopharmacology 2009; 23(5):539-50.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18562407" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Tricyclic Antidepressants (TCA's)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abholz HH, Schurer-Maly CC. Care of depressive patients in general practice: How, why and with how much success? A systematic review. Zeitschrift Fur Allgemeinmedizin 2008; 84(8):327-335.&lt;BR&gt;[&lt;A href="http://www.pressekatalog.de/PK/Artikel.asp?ARTID=10.1055/s-0028-1082066&amp;amp;VSRC=thieme&amp;amp;CSS=995&amp;amp;fachstichwort=englisch&amp;amp;gattung=PUP%2CFAP%2CINP&amp;amp;angebotsform=EZH%2CATK%2CABO&amp;amp;backlist=TRUE&amp;amp;Catalogswitch=3" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Adams D, Malhi GS, Porter R et al. Clinical practice recommendations for depression. Acta Psychiatrica Scandinavica Supplementum 2009; (439):8-26.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19356154" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Arroll B, Elley CR, Fishman T et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007954/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barbui C, Cipriani A. Maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. EBMH Journal 2009; 12(79).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/3/79" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Birkenhager TK et al. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis. Journal Psychopharmacology 2009; 23(6):708-13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18562424" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A et al. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2008.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006117/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hazell P, Heathcote D, Henry DA, O’Connell D. Tricyclic drugs for depression in children and adolescents. Cochrane Database of Systematic Reviews 2008.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002317/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Serotonin-Norepinephrine Reuptake Inhibitor (SNRI's)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Andersen HF, Kennedy SH, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Current Medical Research and Opinion 2009; 25(1):161-75.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19210149" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Becker T, Koesters M, Weinmann S. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl) 2008; 196(4):511-20; discussion 521-2.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17955213" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dekker J, Schoevers RA, Van HL. Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harvard Review Psychiatry 2008; 16(4):225-34.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18661365" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Denberg TD, Forciea MA, Qaseem A, Owens DK, Snow V. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2008; 149(10):725-33.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19017591" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;D’Arrigo C, Santoro V, Spina E. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics 2008; 30(7):1206-1227.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18691982" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gaynes BN, Gartlehner G, Krebs EE et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and meta analysis. Psychosomatics 2008; 49(3):191-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18448772" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nakagawa A et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2008.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006529/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Omori IM, Nakagawa A, Watanabe N et al. Efficacy and tolerability of milnacipran in the treatment of major depression in&amp;nbsp; comparison with other antidepressants : a systematic review and meta-analysis. CNS Drugs 2008; 22(7):587-602.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18547127" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Spielmans GI. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychotherapy and Psychosomatics 2008; 77(1):12-6.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18087203" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Thase ME et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectrums 2009; 14(3):144-54.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19407711" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Monoamine Oxidase Inhibitors (MAOI's)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Amsterdam JD, Robinson DS. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. Journal of Affective Disorders 2008; 105(1-3):15-23.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17568687" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Culpepper L, Kovalick LJ. A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Primary Care Companion Journal Clinical Psychiatry 2008; 10(1):25-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18311418" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Antipsychotics&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Barbee JG. Treatment-resistant depression: adding low dose risperidone improves symptoms. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/77" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Candy B, Jones L, King M, Tookman A, Williams R. Psychostimulants for depression. Cochrane Database of Systematic Reviews 2008.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006722/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Cipriani A et al. Atypical antipsychotics are effective adjuncts for treatment resistant depression but increase discontinuation due to adverse effects. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/14" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. American Journal Geriatric Pharmacotherapy 2009; 7(1):34-59.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19281939" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatrica Scandinavia 2008;&amp;nbsp; 117(4):253-9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18190674" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Other Drug Treatments&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Annals of Pharmacotherapy 2008; 42(12):1822-31.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19033480" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ross J. Discontinuation of lithium augmentation in geriatric patients with unipolar depression: a systematic review. Canadian Journal Psychiatry 2008; 53(2):117-20.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18357930" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>319742</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=319742]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Psychosocial treatments</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Psychosocial treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319742/nelhImp_0000_PSYCHOLOGICAL.jpg"&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cognitive Behavioural Therapy (CBT)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Christensen H, Farrer L, Griffiths KM. Adherence in internet interventions for anxiety and depression. Journal of Medical Internet Research 2009; 11(2):e13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19403466" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dingle G, Oei TP. The effectiveness of group cognitive behaviour therapy for unipolar depressive disorders. Journal of Affective Disorders 2008; 107(1-3):5-21.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17716745" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dubicka B. Adolescents with SSRI-resistant depression: CBT plus antidepressant switch more effective than medication switch alone. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/110" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ebmeier KP, McDermott LM. A meta-analysis of depression severity and cognitive function. Journal of Affective Disorders 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19428120" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Eliott J, Kettler L, Venning A, Wilson A. The effectiveness of Cognitive-Behavioural Therapy with hopeful elements to prevent the development of depression in young people: a systematic review. International Journal of Evidence-Based Healthcare 2009; 7(1):15-34.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cldare/articles/DARE-12009104261/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kendall T, Munoz-Solomando A, Whittington CJ. Cognitive behavioural therapy for children and adolescents. Current Opinion Psychiatry 2008; 21(4):332-7.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18520736" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parikh SV. Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/48" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Stallard P. No long-lasting effects of classroom-based cognitive behavioural and interpersonal prevention programmes on depressive symptoms in adolescents. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/75" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weersing RV, Walker PN. Cognitive behavioural therapy for adolescents with depression. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/76" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Computer-aided Cognitive Behavioural Therapy (CCBT)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Beverley C, Ferriter M, Kaltenthaler E, Parry G. Computerised cognitive-behavioural therapy for depression: systematic review. British Journal Psychiatry 2008; 193(3):181-4.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18757972" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gilbody S, Waller R. Barriers to the uptake of computerized cognitive behavioural therapy:a systematic review of the quantitative and qualitative evidence. Psychological Medicine 2009; 39(5):705-12.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18812006" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kaltenthaler E et al. The acceptability to patients of computerized cognitive behaviour therapy for depression: a systematic review. Psychological Medication 2008; 38(11):1521-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18205964" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Other Psychological Therapies&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abholz HH, Schurer-Maly CC. Care of depressive patients in general practice: How, why and with how much success? A systematic review. Zeitschrift Fur Allgemeinmedizin 2008; 84(8):327-335 [German].&lt;BR&gt;[&lt;A href="http://www.pressekatalog.de/PK/Artikel.asp?ARTID=10.1055/s-0028-1082066&amp;amp;VSRC=thieme&amp;amp;CSS=995&amp;amp;fachstichwort=englisch&amp;amp;gattung=PUP%2CFAP%2CINP&amp;amp;angebotsform=EZH%2CATK%2CABO&amp;amp;backlist=TRUE&amp;amp;Catalogswitch=3" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersson G, Bohlmeijer E, Cuijpers P, Hollon SD, Van Straten A. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychological Medicine 2009; 1-13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19490745" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersson G, Cuijpers P, Van Oppen P, Van Straten A. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. Journal of Clinical Psychiatry 2008; 69(11):1675-85; quiz 1839-41.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18945396" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersson G, Cuijpers P, Van Oppen P, Van Straten A. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. Journal of Consulting and Clinical Psychology 2008; 76(6):909-22.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19045960" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersson G, Cuijpers P, Van Straten A, Warmerdam L. Psychological treatment of depression: a meta-analytic database of randomized studies. BMC Psychiatry 2008; 8:36.&lt;BR&gt;[&lt;A href="http://www.biomedcentral.com/1471-244X/8/36" target="_blank"&gt;Biomed Central Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersson G, Cuijpers P, Van Schaik A, Van Straten A. Psychological treatment of depression in primary care: a meta-analysis. British Journal General Practice 2009; 59(559):e51-60.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19192368" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Andersson G, Cuijpers P, Van Straten A, Warmerdam L. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the&amp;nbsp; treatment of depression: a meta-analysis. Depress Anxiety 2009; 26(3):279-88.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19031487" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bellini F, Bortolotti B, Berardi D, Menchetti M, Montaguti MB. Psychological interventions for major depression in primary care: a meta-analytic review of randomized controlled trials. General Hospital Psychiatry 2008; 30(4):293-302.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18585531" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Berner M, Frick K, Gunzler C, et al. Finding the ideal place for a psychotherapeutic intervention in a stepped care approach--a brief overview of the literature and preliminary results from the Project PREDICT. International Journal of Methods in Psychiatric Research 2008; 17 Suppl 1:S60-4.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18543364" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bonde JP. Psychosocial factors at work and risk of depression: a systematic review of the epidemiological evidence. Occupational Environmental Medicine 2008; 65(7):438-45.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18417557" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bosmans JE, De Bruijne MC, Van Schaik DJ et al. Are psychological treatments for depression in primary care cost-effective? Journal of Mental Health Policy and Economics 2008; 11(1):3-15.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18424872" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Christensen H, Griffiths KM, Gulliver A, Clack D, Kljakovic M, Wells L. Models in the delivery of depression care: a systematic review of randomised and controlled intervention trials. BMC Family Practice 2008; 9:25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18454878" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cohen D, Hughes S. A systematic review of long-term studies of drug treated and non-drug treated depression. Journal of Affective Disorders 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19249104" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cuijpers P et al.&amp;nbsp; Are individual and group treatments equally effective in the treatment of depression in adults? A meta-analysis. European Journal of Psychiatry 2008; 22(1):38-51.&lt;BR&gt;[&lt;A href="http://scielo.isciii.es/scielo.php?pid=S0213-61632008000100005&amp;amp;script=sci_arttext" target="_blank"&gt;Full text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cuijpers P, Smits N, Van Straten A, Warmerdam L. Characteristics of effective psychological treatments of depression: a metaregression analysis. Psychotherapy Research 2008; 18(2):225-36.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18815968" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Crawford MJ, Gold C, Maratos AS, Wang X. Music therapy for depression. Cochrane Database Systematic Reviews 2008; (1).&lt;BR&gt;[&lt;A href="http://www.cochrane.org/reviews/en/ab004517.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dekker J, Schoevers RA, Van HL. Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harvard Review of Psychiatry 2008; 16(4):225-34.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18661365" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ekers D, Gilbody S, Richards D. A meta-analysis of randomized trials of behavioural treatment of depression. Psychological Medicine 2008; 38(5):611-23.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17903337" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fleck MP, Berlim MT, Lafer B et al. Review of the guidelines of the Brazilian Medical Association for the treatment of depression. Revista Brasileria De Psiquiatria 2009; 31 Suppl 1:S7-S17.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19007996" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gaudiano BA. Individual behavioural therapy reduces symptoms of depression. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/108" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gold C, Kruger V, Lie SA, Solli HP. Dose-response relationship in music therapy for people with serious mental disorders: systematic review and meta-analysis. Clinical Psychology Review 2009; 29(3):193-207.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19269725" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guemes I, Guillen V, Ballesteros J. Psychotherapy versus drug therapy in depression in ambulatory care. Actas Espanolas Psiquiatria 2008; 36(5):299-306. [Spanish]&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18523896" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mottram PG, Vassilas CA, Wilson KC. Psychotherapeutic treatments for older depressed people. Cochrane Database Systematic Reviews 2008; (1).&lt;BR&gt;[&lt;A href="http://www.cochrane.org/reviews/en/ab004853.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mufson L. Group interpersonal therapy reduces depression in adolescent survivors of war. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/17" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nieuwenhuijsen K et al. Interventions to improve occupational health in depressed people. Cochrane Database Systematic Reviews 2008; (2).&lt;BR&gt;[&lt;A href="http://www.cochrane.org/reviews/en/ab006237.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schwannauer M. Depressed inpatients: treatment with psychotherapy plus pharmacotherapy superior to standard treatment. EBMH Journal 2008; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/46" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>319744</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=319744]]&gt;</url>
    <title>Depression Annual Evidence Update 2009: Transcanial Magnetic Stimulation</title>
    <publicationDate>2009-10-05T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2009: Transcanial Magnetic Stimulation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:319733:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2009 Contents Page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319744/nelhImp_0000_TMS.jpg"&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transcranial Magnetic Stimulation&lt;/STRONG&gt; &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chan P, Lam RW, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Canadian Journal of Psychiatry 2008; 53(9):621-31.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18801225" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McLoughlin DM. High frequency repetitive transcranial magnetic stimulation improves symptoms of major depression.&amp;nbsp; EBMH Journal 2009; (12).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/3/80" target="_blank"&gt;EBMH Journal&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martkn JLR. Adding repetitive transcranial magnetic stimulation to antidepressants does not improve response in people with depression. EBMH Journal 2008; (11).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/78" target="_blank"&gt;EBMH Journal&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs:&amp;nbsp; a meta-analysis. Psychological Medicine 2009; 39(1):65-75.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18447962" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386754</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386754]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Comorbidity</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Comorbidity&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Comorbidity&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Bone Metabolism&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Williams LJ, Pasco JA, Jacka FN, Henry MJ, Dodd S, Berk M. Depression and bone metabolism. A review. Psychotherapy &amp;amp; Psychosomatics 2009; 78(1):16-25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18852498" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Cancer&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Cancer Care Ontario. The management of depression in cancer patients: a clinical practice guideline. Cancer Care Ontario 2006.&lt;BR&gt;[&lt;A href="http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&amp;amp;path=/File%20Database/CCO%20Files/PEBC/pebc13-6s.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Review: depression is associated with increased cancer mortality. Evidence Based Mental Health Journal 2010; 13:41.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/2/41.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haisfield-Wolfe ME, McGuire DB, Soeken K, Geiger-Brown J, De Forge BR. Prevalence and correlates of depression among patients with head and neck cancer: a systematic review of implications for research. Oncology Nursing Forum 2009; 36(3):E107-25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19403439" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jiang X-M, Mi D et al. Mental intervention for cancer patients with depression: A systematic review of randomized controlled trials. Chinese Journal of Evidence-Based Medicine 2010; 10(3):352-355.&lt;BR&gt;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Laird BJ, Boyd AC, Colvin LA, Fallon MT. Are cancer pain and depression interdependent? A systematic review. Psycho-oncology 2009; 18(5):459-64.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18942659" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nelson CJ, Cho C, Berk AR, Holland J, Roth AJ. Are gold standard depression measures appropriate for use in geriatric cancer patients? A systematic evaluation of self-report depression instruments used with geriatric, cancer, and geriatric cancer samples. Journal of Clinical Oncology 2010; 28(2):348-57.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19996030" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009; 115(22):5349-61.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19753617" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wasteson E, Brenne E, Higginson IJ et al. Depression assessment and classification in palliative cancer patients: a systematic literature review. Palliative Medicine 2009; 23(8):739-53.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19825894" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Cardiovascular&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Allman E, Berry D, Nasir L. Depression and coping in heart failure patients: a review of the literature. Journal of Cardiovascular Nursing 2009; 24(2):106-18.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19242276" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin. Evidence Based Mental Health Journal 2010; 13: 89. &lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/3/89.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Prognosis - Developing depression after a myocardial infarction increases risk of cardiac mortality but pre-existing depression does not. Evidence Based Mental Health Journal 2009; 12:8.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/8.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Prognosis - Survival after myocardial infarction worse with first episode major depression than recurrent major depression. Evidence Based Mental Health Journal 2009; 12:106.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/106.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Chronic Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;/STRONG&gt;Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Medical Journal of Australia 2009; 190(7 Suppl):S54-60.&amp;nbsp;&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19351294" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Diabetes&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Ali S, Stone M, Skinner TC, Robertson N, Davies M, Khunti K. The association between depression and health-related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes/Metabolism Research Reviews 2010; 26(2):75-89.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20186998" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Bidirectional association between elevated depressive symptoms and type 2 diabetes. Evidence Based Mental Health Journal 2009; 12:24.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/24.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Long term antidepressant use linked to increased risk of diabetes. Evidence Based Mental Health Journal 2010; 13:30.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/1/30.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Egede LE, Ellis C. Diabetes and depression: global perspectives. Diabetes Research &amp;amp; Clinical Practice 2010; 87(3):302-12.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20181405" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS ONE 2009; 4(1):e4144.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19127292" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Current Diabetes Reviews 2009; 5(2):112-9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19442096" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Drug Use Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chaiton MO, Cohen JE, O’Loughlin J, Rehm J. A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC Public Health 2009; 9(356).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19772635" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Eating Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Araujo D, M, R et al. Binge eating disorder and depression: A systematic review. World Journal of Biological Psychiatry 2010; 11(2 PART 2):199-207.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20218783" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Luppino FS, de Wit LM, Bouvy PF et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Archives of General Psychiatry 2010; 67(3):220-9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20194822" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Epilepsy&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Ferro MA, Speechley KN. Depressive symptoms among mothers of children with epilepsy: A review of prevalence, associated factors, and impact on children. Epilepsia 2009; 50(11):2344-2354.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19694788" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and HIV/AIDS&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;New York State Department of Health. Depression and mania in patients with HIV/AIDS. New York State Department of Health 2008:23. &lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=12811&amp;amp;nbr=6613&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Hepatitis C&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Canadian Journal of Psychiatry 2009; 54(9):614-25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19751550" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Learning Disabilities&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Perez-Achiaga N, Nelson S, Hassiotis A. Instruments for the detection of depressive symptoms in people with intellectual disabilities: a systematic review. Journal of Intellectual Disabilities 2009; 13(1):55-77.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19332509" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Renal Disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Khalil AA, Frazier SK. Depressive symptoms and dietary non adherence in patients with end-stage renal disease receiving hemodialysis: a review of quantitative evidence. Issues in Mental Health Nursing 2010; 31(5):324-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20394478" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Schizophrenia&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Furtado VA, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2009; (4). &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19244590" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Suicide&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Dumesnil H, Verger P. Public awareness campaigns about depression and suicide: a review. Psychiatric Services 2009; 60(9):1203-13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19723735" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and Thyroid Function&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Williams MD, Harris R, Dayan CM, Evans J, Gallacher J, Ben-Shlomo Y. Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a meta-analysis. [Review] [35 refs]. Clinical Endocrinology 2009; 70(3):484-92.&amp;nbsp;&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18681859" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386463</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386463]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Contents</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319733/nelhImp_0000_UNITYANDSTRENGTH.jpg"&gt;The&amp;nbsp;Depression Annual Evidence Update 2010 brings together evidence-based guidelines, systematic reviews, evidence summaries, care pathways and service development literature. &lt;BR&gt;&lt;BR&gt;The Annual Evidence Update has been carried out using this methodology.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;1.&amp;nbsp; Introductory Material&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:386466:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386468:1" name=internalLink&gt;UK Guidelines&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386469:1" name=internalLink&gt;International Guidelines&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386784:1" name=internalLink&gt;Key Reports and Resources&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386471:1" name=internalLink&gt;&lt;A href="nelh:386471:1" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;A href="nelh:386471:1" name=internalLink&gt;&amp;nbsp;and Prevalence&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386472:1" name=internalLink&gt;Neuropsychology&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2.&amp;nbsp; &lt;/STRONG&gt;&lt;A href="nelh:386474:1" name=internalLink&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3.&amp;nbsp; &lt;/STRONG&gt;&lt;A href="nelh:386475:1" name=internalLink&gt;&lt;STRONG&gt;Risk Factors&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;4.&amp;nbsp; Treatment&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;U&gt;&lt;STRONG&gt;Pharmacological Treatments&lt;/STRONG&gt;&lt;/U&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:386612:1" name=internalLink&gt;Tricyclic Antidepressants (TCAs)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386610:1" name=internalLink&gt;&lt;A href="nelh:386610:1" name=internalLink&gt;Selective Serotonin Reupdate Inhibitors&lt;/A&gt;&lt;A href="nelh:386610:1" name=internalLink&gt;&amp;nbsp;(SSRIs)&lt;/A&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386611:1" name=internalLink&gt;Serotonin-norepinephrine reuptake inhibitors (SNRIs&lt;/A&gt;)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386609:1" name=internalLink&gt;Antipsychotic Drugs&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;U&gt;Other Treatments&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:386624:1" name=internalLink&gt;Electroconvulsive Therapy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386628:1" name=internalLink&gt;Transcranial Magnetic Stimulation&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386630:1" name=internalLink&gt;Other Treatments&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;U&gt;Psychosocial Treatments&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:386619:1" name=internalLink&gt;Cognitive Behavioural Therapy (CBT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386620:1" name=internalLink&gt;Computer Aided Cognitive Behavioural Therapy (CCBT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386622:1" name=internalLink&gt;Other Psychological Therapies&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/cam/viewResource.aspx?resid=387934&amp;amp;code=afb13ce127ceb7eb2a51f950bf20ff89" target="_blank"&gt;Complementary and Alternative Treatments&lt;/A&gt; - &lt;EM&gt;This is a link to the Complementary and Alternative Medicine Specialist Collection&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;5.&amp;nbsp; Populations and Settings&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:386631:1" name=internalLink&gt;Children and Adolescents&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386632:1" name=internalLink&gt;Older People&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386741:1" name=internalLink&gt;Women&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386744:1" name=internalLink&gt;Ethnicity&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:386746:1" name=internalLink&gt;Workplace&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;6.&amp;nbsp; &lt;A href="nelh:386747:1" name=internalLink&gt;Genetics&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;7.&amp;nbsp; &lt;A href="nelh:386751:1" name=internalLink&gt;Depression and Anxiety&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;8.&amp;nbsp; &lt;A href="nelh:386754:1" name=internalLink&gt;Comorbidity&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;9.&amp;nbsp; &lt;A href="nelh:386756:1" name=internalLink&gt;Dual Diagnosis&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You can download and read the following documents below:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Depression Annual Evidence Update 2010 Methodology&lt;/LI&gt;
&lt;LI&gt;Depression Annual Evidence Update 2010 Press Release&lt;/LI&gt;
&lt;LI&gt;Depression Annual Evidence Update 2010 Publicity Poster&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386751</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386751]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Depression and Anxiety</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Depression and Anxiety&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Depression and Anxiety&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Christensen H, Griffiths KM, Farrer L. Adherence in internet interventions for anxiety and depression. Journal of Medical Internet Research 2009; 11(2):E13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19403466" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Donker T, Griffiths KM, Cuijpers P, Christensen H. Psychoeducation for depression, anxiety and psychological distress: a meta-analysis. BMC Medicine 2009; 7:79.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20015347" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - A stepped care intervention is effective for elderly people with sub threshold depression or anxiety. Evidence Based Mental Health Journal 2009; 12:115.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/115.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - A stepped care programme for depressive or anxiety disorders offers good value for money. Evidence Based Mental Health Journal&amp;nbsp; 2010; 13:87. &lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/3/87.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hesse M. Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature. BMC Psychiatry 2009; 9(6).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19232121" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. Journal of Consulting and Clinical Psychology 2010; 78(2):169-183.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20350028" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lindert J, Ehrenstein OS, Priebe S, Mielck A, Brahler E. Depression and anxiety in labor migrants and refugees--a systematic review and meta-analysis. Science &amp;amp; Medicine 2009; 69(2):246-57.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19539414" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mancini M, Perna G, Rossi A, Petralia A. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: A review of the literature. Expert Opinion on Pharmacotherapy 2010; 11(7):1167-1181).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20402555" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martin A, Sanderson K, Cocker F. Meta-analysis of the effects of health promotion intervention in the workplace on depression and anxiety symptoms. Scandinavian Journal of Work, Environment &amp;amp; Health 2009; 35(1):7-18.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19065280" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van't Hof E, Cuijpers P, Stein DJ. Self-help and Internet-guided interventions in depression and anxiety disorders: a systematic review of meta-analyses. CNS Spectrums 2009; 14(2 Suppl 3):34-40.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19238128" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386474</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386474]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Diagnosis</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Diagnosis&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Allen J, Annells M. A literature review of the application of the Geriatric Depression Scale, Depression Anxiety Stress Scales and Post-traumatic Stress Disorder Checklist to community nursing cohorts. Journal of Clinical Nursing 2009; 18(7):949-59.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19284431" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Calati R, Oasi O, De Ronchi D, Serretti A. The use of the defence style questionnaire in major depressive and panic disorders: a comprehensive meta-analysis. Psychology &amp;amp; Psychotherapy: Theory, Research &amp;amp; Practice 2010; 83(Pt 1):1-13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19671241" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Diagnosis - The PHQ-9 works well as a screening but not diagnostic instrument for depressive disorder. Evidence Based Mental Health Journal 2010; 13:96. &lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/3/96.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fava GA, Tomba E. New modalities of assessment and treatment planning in depression: The sequential approach. CNS Drugs 2010; 24(6):453-465. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20443645" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 2009; 71(2):171-86.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19188531" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malhi GS, Adams D, Porter R et al. Clinical practice recommendations for depression. Acta Psychiatrica Scandinavica Supplementum 2009; (439):8-26.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19356154" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mirkhil S, Kent PM. The diagnostic accuracy of brief screening questions for psychosocial risk factors of poor outcome from an episode of pain: A systematic review. Clinical Journal of Pain 2009; 25(4):340-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19590484" target="_blank"&gt;[Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Connor AM, Bennett CL et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews 2009; (3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19588325" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Reuland DS, Cherrington A, Watkins GS, Bradford DW, Blanco RA, Gaynes BN. Diagnostic accuracy of Spanish language depression-screening instruments. Annals of Family Medicine 2009; 7(5):455-62.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19752474" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tavabie JA, Tavabie OD. Improving care in depression: qualitative study investigating the effects of using a mental health questionnaire. Quality in Primary Care 2009; 17(4):251-61.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19807958" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386756</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386756]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Dual Diagnosis</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Dual Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Dual Diagnosis&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. Journal of Clinical Psychiatry 2010; 71(3):247-54.&amp;nbsp;&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20331929" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386624</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386624]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Electroconvulsive Therapy</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Electroconvulsive Therapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Electroconvulsive Therapy&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosomatic Medicine 2009; 71(2):235-42.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19073751" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malhi GS, Adams D, Porter R et al. Clinical practice recommendations for depression. Acta Psychiatric Scandinavica Supplementum 2009; (439):8-26.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19356154" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Plakiotis C, O’Connor DW. Bifrontal ECT: A systematic review and meta-analysis of efficacy and cognitive impact. Current Psychiatry Reviews 2009; 5(3):202-217. &lt;BR&gt;[&lt;A href="http://www.ingentaconnect.com/content/ben/cpsr/2009/00000005/00000003/art00007" target="_blank"&gt;Ingenta Connect Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Waarde JA, Verwey B, Van Der Mast RC. Meta-analysis of initial seizure thresholds in electroconvulsive therapy. European Archives of Psychiatry and Clinical Neuroscience 2009; 259(8):467-474.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19381706" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zambello F, Vaona A. ECT - A critical review of meta-analyses. Rivista Di Psichiatria 2009; 44(5):337-340.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20066822" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386471</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386471]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Epidemiology and Prevalence</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Epidemiology and Prevalence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Epidemiology and Prevalence&lt;IMG style="FLOAT: right" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319736/nelhImp_0001_INCIDENCE-AND-PREVALENCE.jpg"&gt;&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Davydow DS, Gifford JM, Desai SV, Bienvenu OJ, Needham DM. Depression in general intensive care unit survivors: a systematic review. Intensive Care Med 2009; 35(5):796-809.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19165464" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Prevalence - Increase in proportion of patients on long-term medication accounts for increase in antidepressant prescribing in UK. Evidence Based Mental Health Journal 2010; 12:109. &lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/2/61.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huang CQ, Dong BR, Lu ZC, Yue JR, Liu QX. Chronic diseases and risk for depression in old age: a meta-analysis of published literature. Ageing Research Reviews 2010; 9(2):131 - 41.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19524072" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huijbregts KM, L, van der Feltz-Cornelis CM et al. Negative association of concomitant physical symptoms with the course of major depressive disorder: A systematic review. Journal of Psychosomatic Research 2010; 68(6):511-519.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20488267" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pakriev S, Kovalev J, Mozhaev M. Prevalence of depression in a general hospital in Izhevsk, Russia. Nordic Journal of Psychiatry 2009; 63(6):469-474.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19551555" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Razzouk D, Sharan P, Gallo C et al. Scarcity and inequity of mental health research resources in low-and-middle income countries: a global survey. Health Policy 2010; 94(3):211-20.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19846235" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ribeiro WS, Andreoli SB et al. Exposure to violence and mental health problems in low and middle-income countries: A literature review. Revista Brasileira De Psiquiatria 2009; 31(SUPPL. 2):S49-S57.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19967200" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;
&lt;P class=MsoNormal&gt;Steel Z, Chey T, Silove D, Marnane C, Bryant RA, van Ommeren M. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. JAMA 2009; 302(5):537-49.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19654388" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/P&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386747</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386747]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Genetics</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Genetics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID324071/nelhImp_0000_GENETICS.jpg"&gt;Genetics&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Drago A, De Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update. Human Genomics 2009; 3(3):257-74.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19403460" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genetic Medicine 2007. 9(12):819-25.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=12378&amp;amp;nbr=6407&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 2010; 15(5):473-500.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18982004" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kiyohara C, Yoshimasu K. Association between major depressive disorder and a functional polymorphism of the 5-hydroxytryptamine (serotonin) transporter gene: A meta-analysis. Psychiatric Genetics 2010; 20(2):49-58.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20016401" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Munafo MR, Durrant C, Lewis G, Flint J. Defining replication: A response to Kaufman and colleagues. Biological Psychiatry 2010; 67(4):E21-E23.&lt;BR&gt;[&lt;A href="http://www.journals.elsevierhealth.com/periodicals/bps/article/S0006-3223%2809%2901236-0/abstract" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Risch N, Herrell R, Lehner T et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009; 301(23):2462-71.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531786" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vansenne F, Bossuyt PM,&amp;nbsp; de Borgie CA. Evaluating the psychological effects of genetic testing in symptomatic patients: a systematic review. Genetic Testing and Molecular Biomarkers 2009; 13(5):555-563.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19645624" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386469</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386469]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: International Guidelines</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: International Guidelines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID326326/nelhImp_0000_GUIDELINES.jpg"&gt;International Guidelines&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;American Academy of Neurology&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66(7):996-1002.&lt;BR&gt;[&lt;A href="http://www.neurology.org/cgi/reprint/66/7/996" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Academy of Breastfeeding Medicine&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Academy of breastfeeding Medicine Protocol Committee. Use of antidepressants in nursing mothers. Breastfeeding Medicine 2008; 3(1): 44-52. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18333769" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;American College of Physicians&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. 2008.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=12149&amp;amp;nbr=6246&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. 2008.&lt;BR&gt;[Abstract not available]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;American Medical Directors Association (AMDA)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;American Medical Directors Association (AMDA). Pharmacotherapy companion to the depression clinical practice guideline. Columbia (MD): American Medical Directors Association (AMDA); 2005:24.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=7509&amp;amp;nbr=4447&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Brazilian Medical Association&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fleck MP, Berlim M et al. Revision of the guidelines of the Brazilian Medical Association for the treatment of depression (Complete version). Revista Brasileira De Psiquiatria 2009; 31(SUPPL. 1):S7-S17.&lt;BR&gt;[&lt;A href="http://www.scielo.br/pdf/rbp/v31s1/en_a03v31s1.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Cancer Care Ontario&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;G. Rodin, M. Katz, N. Lloyd, E. Green, J.A. Mackay, R. Wong, and members of the Supportive Care Guidelines Group. The management of depression in cancer patients: a clinical practice guideline. Cancer Care Ontario 2006.&lt;BR&gt;[&lt;A href="http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&amp;amp;path=/File%20Database/CCO%20Files/PEBC/pebc13-6s.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Canadian Network for Mood and Anxiety Treatments (CANMAT)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kennedy S, H,&amp;nbsp; MR et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neuro stimulation therapies. Journal of Affective Disorders 2009; 117(SUPPL. 1):S44-S53.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19656575" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lam RW, KS et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders 2009; 117(SUPPL. 1): S26-S43.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19674794" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parikh S, V,&amp;nbsp; SZ et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders 2009; 117(SUPPL. 1):S15-S25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19682749" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Patten SB, Kennedy SH et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. Journal of Affective Disorders 2009; 117(SUPPL. 1):S5-S14.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19674796" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ravindran A, V,&amp;nbsp; LR et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. Journal of Affective Disorders 2009; 117(SUPPL. 1):S54-S64.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19666194" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical Guidelines American College of Physicians&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Qaseem A, Snow V, Shekelle P, Casey DE Jr, Cross JT Jr, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians, Dallas P, Dolan NC, Forciea MA, Halasyamani L, Hopkins RH Jr, Shekelle P. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Annals International Medicine 2008; 15; 148(2):141-6.&lt;BR&gt;[&lt;A href="http://www.annals.org/content/148/2/141.abstract" target="_blank"&gt;Abstract available&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical Practice Guidelines and Protocols in British Columbiua&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Clinical Practice Guidelines and Protocols in British Columbiua 2010. Anxiety and Depression in Children and Youth - Diagnosis and Treatment. 2010.&lt;BR&gt;[&lt;A href="http://www.bcguidelines.ca/gpac/pdf/depressyouth.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Evaluation of Genomic Applications in Practice and Prevention (EGAPP)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with non psychotic depression treated with selective serotonin reuptake inhibitors. Genetic Medicine 2007; 9(12):819-25.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=12378&amp;amp;nbr=6407&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;GiaSalud&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;GiaSalud. Clinical Practice Guideline on the Management of Major Depression in Adults. GiaSalud 2009.&lt;BR&gt;[&lt;A href="http://www.guiasalud.es/GPC/GPC_424_Adults_Dep_compl_en.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Kaiser Permanente Care Management Institute&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kaiser Permanente Care Management Institute. Depression clinical practice guidelines. Oakland (CA): Kaiser Permanente Care Management Institute; 2006; 196.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=9632&amp;amp;nbr=5152&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;New York State Department of Health&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;New York State Department of Health. Depression and mania in patients with HIV/AIDS. New York State Department of Health; 2008: 23. &lt;BR&gt;[&lt;A href="http://www.guideline.gov/content.aspx?id=12811" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;New Zealand Guidelines Group&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;New Zealand Guidelines Group. Australian and New Zealand clinical practice guidelines for the treatment of Depression. New Zealand Guidelines Group 2005. &lt;BR&gt;[&lt;A href="http://www.nzgg.org.nz/guidelines/0095/Depression_Clinican_Full.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;New Zealand Guidelines Group. Depression - Information for primary health professionals. New Zealand Guidelines Group 2006.&lt;BR&gt;[&lt;A href="http://www.nzgg.org.nz/guidelines/0137/Depression___Information_for_primary_health_practitioners.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;New Zealand Guidelines Group. Identification of common mental disorders and management of depression in primary care. New Zealand Guidelines Group 2008. &lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=12994&amp;amp;nbr=6690&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Pediatrics&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Zuckerbrot RA, Cheung AH, Jensen PS, Stein RE, and Laraque D. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management. Pediatrics 2007; 120(5).&lt;BR&gt;[&lt;A href="http://pediatrics.aappublications.org/cgi/reprint/120/5/e1299.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;United States Preventive Services Task Force&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Screening for depression in primary care recommendation statement from the Canadian Task Force on preventive Healthcare. Canadian Medical Association Journal 2005; 172(1):33.&lt;BR&gt;[&lt;A href="http://www.cmaj.ca/cgi/reprint/172/1/33" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Screening and treatment for major depressive disorder in children and adolescents: U.S. Preventive Services Task Force recommendation statement. Pediatrics 2009; 123(4):1223-8.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=14294&amp;amp;nbr=7170&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;U.S. Preventive Services Task Force 2010. Screening for depression in adults. 2009. &lt;BR&gt;Abstract: U.S. Preventive Services Task Force. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. Ann International Medicine 2009 Dec 1; 151(11):784-92.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19949144" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;U.S. Department of Health &amp;amp; Human Services&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Kurlowicz L, Harvath TA. Depression. In: Capezuti E, Zwicker D, Mezey M, Fulmer T, editor(s). Evidence-based geriatric nursing protocols for best practice. 3rd ed. New York (NY): Springer Publishing Company; 2008: 57-82.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/content.aspx?id=12260" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Piven MLS. Detection of depression in the cognitively intact older adult. Iowa City (IA): University of Iowa Gerontological Nursing Interventions Research Center, Research Dissemination Core 2005; 33.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=8112&amp;amp;nbr=4519&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;University of Michigan Health System. Depression. Ann Arbor (MI): University of Michigan Health System; 2005; 20.&lt;BR&gt;[&lt;A href="http://www.guideline.gov/summary/summary.aspx?doc_id=8330&amp;amp;nbr=4662&amp;amp;ss=6&amp;amp;xl=999" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;World Federation of Societies of Biological Psychiatry (WSBP)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bauer M,&amp;nbsp; WP, C et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder. Revista De Psiquiatria Clinica 2009;&amp;nbsp; 36(SUPPL. 2):17-57.&lt;BR&gt;[&lt;A href="http://www.wfsbp.org/fileadmin/pdf/guides/guidelines290507.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386466</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386466]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Introduction</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;This guideline makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older, in primary and secondary care. This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see section 6).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Depression is a broad and heterogeneous diagnosis. Central to it is depressed mood and/or loss of pleasure in most activities. Severity of the disorder is determined by both the number and severity of symptoms, as well as the degree of functional impairment. A formal diagnosis using the ICD-10 classification system requires at least four out of ten depressive symptoms, whereas the DSM-IV system requires at least five out of nine for a diagnosis of major depression (referred to in this guideline as ‘depression’). Symptoms should be present for at least 2 weeks and each symptom should be present at sufficient severity for most of every day. Both diagnostic systems require at least one (DSM-IV) or two (ICD-10) key symptoms (low mood (In both ICD-10 and DSM-IV), loss of interest and pleasure (In both ICD-10 and DSM-IV)&amp;nbsp;or loss of energy (In ICD-10 only).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Increasingly, it is recognised that depressive symptoms below the DSM-IV and ICD-10 threshold criteria can be distressing and disabling if persistent. Therefore this updated guideline covers ‘subthreshold depressive symptoms’, which fall below the criteria for major depression, and are defined as at least one key symptom of depression but with insufficient other symptoms and/or functional) to be present.&lt;BR&gt;&lt;BR&gt;Increasingly, it is recognised that depressive symptoms below the DSM-IV and ICD-10 threshold criteria can be distressing and disabling if persistent. Therefore this updated guideline covers ‘subthreshold depressive symptoms’, which fall below the criteria for major depression, and are defined as at least one key symptom of depression but with insufficient other symptoms and/or functional&lt;BR&gt;impairment to meet the criteria for full diagnosis. Symptoms are considered persistent if they continue despite active monitoring and/or low-intensity intervention, or have been present for a considerable time, typically several months. (For a diagnosis of dysthymia, symptoms should be present for at least 2 years.) &lt;EM&gt;Both DSM-IV and ICD-10 have the category of dysthymia, which consists of depressive symptoms that are subthreshold for major depression but that persist (by definition for more than 2 years). There appears to be no empirical evidence that dysthymia is distinct from subthreshold depressive symptoms apart from duration of symptoms, and the term ‘persistent subthreshold depressive symptoms’ is preferred in this guideline.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It should be noted that classificatory systems are agreed conventions that seek to define different severities of depression in order to guide diagnosis and treatment, and their value is determined by how useful they are in practice. After careful review of the diagnostic criteria and the evidence, the Guideline Development Group decided to adopt DSM-IV criteria for this update rather than ICD-10, which was used in the previous guideline (NICE clinical guideline 23). This is because DSM-IV is used in nearly all the evidence reviewed and it provides definitions for atypical symptoms and seasonal depression. Its definition of severity also makes it less likely that a diagnosis of depression will be based solely on symptom counting. In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis. Using DSM-IV enables the guideline to target better the use of specific interventions, such as antidepressants, for more severe degrees of depression.)&lt;BR&gt;&lt;BR&gt;A wide range of biological, psychological and social factors, which are not captured well by current diagnostic systems, have a significant impact on the course of depression and the response to treatment. Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Depression often has a remitting and relapsing course, and symtpoms may persist between episodes. Where possible, the key goal of an intervention should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The guideline assumes that prescribers will use a drug’s summary of product characteristics (SPC) and the ‘British national formulary’ (BNF) to inform their decisions made with individual patients.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use. Drugs are marked with an asterisk if they do not have UK marketing authorisation for depression or the indication stated at the time of publication.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:328284:1" name=internalLink&gt;
&lt;P&gt;Information extracted from: NICE clinical guidelines - Depression - The treatment and management of depression in adults.&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386784</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386784]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Key Reports and Resources</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Key Reports and Resources&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Key Reports and Resources&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Map of Medicine&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression in children and adolescents - primary care assessment. Map of Medicine 2010. &lt;BR&gt;[&lt;A href="http://healthguides.mapofmedicine.com/choices/map/depression_in_children_and_adolescents1.html" target="_blank"&gt;View Resource&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Depression - primary care presentation. Map of Medicine 2010. &lt;BR&gt;[&lt;A href="http://healthguides.mapofmedicine.com/choices/map/depression1.html" target="_blank"&gt;View Resource&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;New Horizons - Department of Health&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Department of Health. New Horizons: towards a shared vision for mental health. 2009.&lt;BR&gt;[&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_109708.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;NHS Choices&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression. 2010.&lt;BR&gt;[&lt;A href="http://www.nhs.uk/livewell/depression/pages/depressionhome.aspx" target="_blank"&gt;View Resource&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Psychiatrists&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Improving in-patient mental health services for black and minority ethnic patients. Royal College of Psychiatrists 2010. &lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/OP71.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Looking ahead: future development of UK Mental Health Services. Royal College of Psychiatrists 2010. &lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/OP75.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mental health and the economic downturn: National priorities and NHS solutions. Royal College of Psychiatrists 2009.&lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/OP70.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;No health without mental health'. Royal College of Psychiatrists 2010. &lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/pdf/No%20Health%20-%20%20the%20evidence_%20revised%20May%2010.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Role of the consultant psychiatrists: leadership and excellence in mental health services. Royal College of Psychiatrists 2010.&lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/OP75.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;The Kings Fund&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Paying the Price: The cost of mental health care in England to 2026. The Kings Fund 2009. &lt;BR&gt;[&lt;A href="http://www.kingsfund.org.uk/document.rm?id=7665" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Other important articles&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Taylor C, Barr [Ed]. How to practice evidence-based psychiatry: Basic principles and case studies. How to Practice Evidence-Based Psychiatry: Basic Principles and Case Studies 2010;Xix:368.&lt;BR&gt;[&lt;A href="http://ajp.psychiatryonline.org/cgi/reprint/167/7/873" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van der Merwe M, Bowers L, Jones J, Simpson A, Haglund K. Locked doors in acute inpatient psychiatry: a literature review. Journal of Psychiatric &amp;amp; Mental Health Nursing 2009; 16(3):293-9.&amp;nbsp;&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19291159" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386472</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386472]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Neuropsychology</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Neuropsychology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Neuropsychology&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Douglas KM, Porter RJ. Longitudinal assessment of neuropsychological function in major depression. Australian &amp;amp; New Zealand Journal of Psychiatry 2009; 43(12):1105-18.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20001409" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Janssen DGA, Caniato RN et al. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacology 2010; 25(3):201-215.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20373471" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kessing LV, Willer IS, Knorr U. Volume of the adrenal and pituitary glands in depression. Psychoneuroendocrinology 2010.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20646833" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Poletti M. Adolescent brain development and executive functions: A prefrontal framework for developmental psychopathologies. Clinical Neuropsychiatry: Journal of Treatment Evaluation 2009; 6(4): 155-165.&lt;BR&gt;[No abstract available]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386630</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386630]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Other Treatments</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Other Treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386615:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Other Treatments&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;DiGirolamo AM, Ramirez-Zea M. Role of zinc in maternal and child mental health. American Journal of Clinical Nutrition 2009; 89(3):940S-5S.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19176735" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Griffiths KM, Calear AL, Banfield M. Systematic review on Internet Support Groups (ISGs) and depression (1): Do ISGs reduce depressive symptoms? Journal of Medical Internet Research 2009; 11(3):e40.&lt;BR&gt;[&lt;A href="http://www.jmir.org/2009/3/e40/" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Griffiths KM, Calear AL, Banfield M, Tam A. Systematic review on Internet Support Groups (ISGs) and depression (2): What is known about depression ISGs? Journal of Medical Internet Research 2009; 11(3):e41.&lt;BR&gt;[&lt;A href="http://www.jmir.org/2009/3/e41/" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hoy KE, Fitzgerald PB. Introducing magnetic seizure therapy: A novel therapy for treatment resistant depression. Australian and New Zealand Journal of Psychiatry 2010; 44(7):591-598.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/%2020560846" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386609</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386609]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Pharmacological treatment - Antipsychotics</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Pharmacological treatment - Antipsychotics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Pharmacological Treatment - Antipsychotics&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. General Hospital Psychiatry 2009; 31(5):478-83.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19703642" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Prevalence - Increased antidepressant and antipsychotic use in the USA between 1996 and 2005. Evidence Based Mental Health Journal 2010; 13:62.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/2/62.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Furtado VA, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19244590" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gentile S. Antipsychotic therapy during early and late pregnancy. a systematic review. Schizophrenia Bulletin 2010; 36(3):518-544.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18787227" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry 2009; 166(9):980-91.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19687129" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roke Y, Van Harten PN et al. Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. Journal of Child and Adolescent Psychopharmacology 2009; 19(4):403-414.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19702492" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386615</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386615]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Pharmacological Treatment - Other Drug Treatments</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Pharmacological Treatment - Other Drug Treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Pharmacological treatment - Other drug treatments&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Pharmacological&amp;nbsp;treatment - Other drug treatments&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Brunoni AR, Tadini L, Fregni F. Changes in clinical trials methodology over time: A systematic review of six decades of research in psychopharmacology. PLoS ONE 2010; 5(3):E9479. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20209133" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fleurence R, Williamson R, Jing Y et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacology Bulletin 2009; 42(3): 57-90.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19752841" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fornaro M. A systematic review on agomelatine. Italian Journal of Psychopathology 2009;&amp;nbsp; 15(3):302-309.&lt;BR&gt;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Papakostas GI, Cooper-Kazaz R, Appelhof BC et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. International Journal of Clinical Psychopharmacology 2009; 24(1):19-25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19092448" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhou R, Xu W-P et al. The efficacy and safety of mirtazapine and fluoxetine for depression: A meta-analysis. Chinese Journal of Evidence-Based Medicine 2010; 10(2):196-202.&lt;BR&gt;[No abstract available]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386610</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386610]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Pharmacological treatment - Selective Serotonin Reupdate Inhibitors (SSRIs)</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Pharmacological treatment - Selective Serotonin Reupdate Inhibitors (SSRIs)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Pharmacological treatment - SSRIs&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319741/nelhImp_0000_PHARMACOLOGICAL.jpg"&gt;Selective Serotonin Reupdate Inhibitors (SSRIs)&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Arroll B, Elley CR, Fishman T et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009; (3). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab007954.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal 2009; 180(3):291-7.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19188627" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Beaucage C, Cardinal L, Kavanagh M, Aub D. Major depression in primary care and clinical impacts of treatment strategies: a literature review [French]. Sante Mentale au Quebec 2009; 34(1):77-101.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19475195" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brunoni AR, Tadini L, Fregni F. Changes in clinical trials methodology over time: A systematic review of six decades of research in psychopharmacology. PLoS ONE 2010;&amp;nbsp; 5(3):E9479. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20209133" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS ONE [Electronic Resource] 2009; 4(3):e4824.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19293925" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bschor T, Baethge C. No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy: Review. Acta Psychiatrica Scandinavica 2010; 121(3):174-179.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19703121" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A, Brambilla P, Furukawa TA et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab004185.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A, La Ferla T, Furukawa TA et al. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009; (2). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab006117.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A, Santilli C, Furukawa TA et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009; (2).&lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab006532.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. Journal of&amp;nbsp;Clinical Psychiatry 2009; 70(9):1219-29.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19818243" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Current use of SSRIs and tricyclic antidepressants may increase the risk of non-vertebral fractures in the elderly. Evidence Based Mental Health Journal 2009; 12:26.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/26.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Long term antidepressant use linked to increased risk of diabetes. Evidence Based Mental Health Journal 2010; 13:30.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/1/30.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Prolonged exposure to SRIs during pregnancy increases risks of adverse neonatal outcomes. Evidence Based Mental Health Journal 2009; 12:27.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/27.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Are all antidepressants equal? Evidence Based Mental Health Journal 2010; 12:98-100.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/98.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal? Evidence Based Mental Health Journal 2009; 12: 101-104.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/101.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Prevalence - Increased antidepressant and antipsychotic use in the USA between 1996 and 2005. Evidence Based Mental Health Journal 2010; 13:62.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/2/62.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - &lt;BR&gt;Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder. Evidence Based Mental Health Journal 2010; 13:83. &lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/3/83.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - In adolescents with SSRI resistant depression, CBT/combined treatment is most effective in those with comorbid disorders. Evidence Based Mental Health Journal 2009; 12:108.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/108.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Review: benefits of antidepressants over placebo limited except in very severe depression. Evidence Based Mental Health Journal 2010; 13:49.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/2/49.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Review: Clinically important differences between antidepressants. Evidence Based Mental Health Journal 2009; 12:107.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/107.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Review: Maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. Evidence Based Mental Health Journal 2009; 12:79.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/79.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics – SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. Evidence Based Mental Health Journal 2009; 12:109.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/109.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303(1):47-53.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20051569" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. Journal of Clinical Psychiatry 2009; 70(3):414-22.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19254517" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hansen RA, Moore CG, Dusetzina SB, Leinwand BI, Gartlehner G, Gaynes BN. Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Medical Decision Making 2009; 29(1):91-103.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19141788" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hughes S, Cohen D. A systematic review of long-term studies of drug treated and non-drug treated depression. Journal of Affective Disorder 2009; 118(1-3):9-18.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19249104" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Janssen DGA, Caniato RN et al. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacology 2010; 25(3):201-215.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20373471" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 2010; 15(5):473-500.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18982004" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knorr U, Kessing LV.The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review. Nordic Journal of Psychiatry 2010; 64(3):153-163.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20088752" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lam RW, Kennedy SH et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders 2009; 117(SUPPL. 1):S26-S43.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19674794" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clinical Obstetrics &amp;amp; Gynecology 2009; 52(3):483-98.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19661763" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. Journal of Clinical Pharmacy &amp;amp; Therapeutics 2010; 35(2):177-89.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20456736" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malhi GS, Adams D, Porter R et al. Clinical practice recommendations for depression. Acta Psychiatrica Scandinavica Supplementum 2009; (439):8-26.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19356154" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nakagawa A, Watanabe N, Omori IM et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009; (3). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab006529.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Connor AM, Bennett CL et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews 2009; (3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19588325" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Omori I, M,&amp;nbsp; WN et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews (Online) 2010; 3.&lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab006114.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Omori IM, Watanabe N, Nakagawa A et al. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. Journal of Psychopharmacology&amp;nbsp; 2009; 23(5):539-50.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18562407" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World Journal of Biological Psychiatry 2010; 11(2 Pt 2):300-7.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20218793" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Papakostas GI, Cooper-Kazaz R, Appelhof BC et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. International Journal of Clinical Psychopharmacology 2009; 24(1):19-25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19092448" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. European Neuropsychopharmacology 2009; 19(1):34-40.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18823760" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parikh SV, Segal ZV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders 2009; 117(SUPPL.1): S15-S25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19682749" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Piek E, Van Deer Meer K, Nolen WA. Guideline recommendations for long-term treatment of depression with antidepressants in primary care- A critical review. European Journal of General Practice 2010; 16(2):106-112.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20297924" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M. Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews 2010; (3). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab007503.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rief W, Nestpriuc Y, Von Lilienfeld-Toal A et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis. Drug Safety 2009; 32(11):1041-1056.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19810776" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. Journal of Affective Disorders 2009; 118(1-3):1-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19246102" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. [References]. Psychotherapy and Psychosomatics 2009; 78(3):172-181.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19321970" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. Journal of Psychiatric Research 2010; 44(1):32-41.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19616220" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sinyor M, Levitt AJ, Cheung AH et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. Journal of Clinical Psychiatry 2010; 71(3):270-9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20122371" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. Journal of Clinical Psychiatry 2009; 70(3):344-53.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19254516" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tandt H, Audenaert K, van Heeringen C. SSRIs (selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children. [in Dutch]. Tijdschrift Voor Psychiatrie 2009; 51(6):387-93.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19517368" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Watanabe N, Omori IM, Nakagawa A et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24(1):35-53.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20030418" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. Journal of Psychopharmacology 2010; 24(4):513-20.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18832428" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yury CA, Fisher JE et al. Meta-analysis of antidepressant augmentation: Piling on in the absence of evidence. Ethical Human Psychology and Psychiatry 2009; 11(3):171-182.&lt;BR&gt;[&lt;A href="http://www.ingentaconnect.com/content/springer/ehpp/2009/00000011/00000003/art00004" target="_blank"&gt;Ingenta Connect Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zhou R, Xu W-P et al. The efficacy and safety of mirtazapine and fluoxetine for depression: A meta-analysis. Chinese Journal of Evidence-Based Medicine 2010; 10(2):196-202.&lt;BR&gt;[No abstract available]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Side Effects of Selective Serotonin Reupdate Inhibitors (SSRIs)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal 2009; 180(3):291-7.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19188627" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Chiesa A, Serretti A. Antidepressants and sexual dysfunction: Epidemiology, mechanisms and management. Italian Journal of Psychopathology 2010; 16(1):104-113.&lt;BR&gt;[No abstract available] &lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Long term antidepressant use linked to increased risk of diabetes. Evidence Based Mental Health Journal 2010; 13:30.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/1/30.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 2010; 15(5):473-500.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18982004" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lam RW, Kennedy SH et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders 2009; 117(SUPPL. 1):S26-S43.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19674794" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Australian &amp;amp; New Zealand Journal of Psychiatry 2009; 43(9):795-808.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19670052" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386611</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386611]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Pharmacological treatment - Serotonin-norepinephrine reuptake inhibitors (SNRIs)</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Pharmacological treatment - Serotonin-norepinephrine reuptake inhibitors (SNRIs)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319741/nelhImp_0000_PHARMACOLOGICAL.jpg"&gt;Pharmacological treatment - SNRIs&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Bauer M, Tharmanathan P, Volz HP et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. European Archives of Psychiatry and Clinical Neuroscience 2009; 259(3):172-185.&amp;nbsp;&lt;BR&gt;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Brunoni AR, Tadini L, Fregni F. Changes in clinical trials methodology over time: A systematic review of six decades of research in psychopharmacology. PLoS ONE 2010; 5(3):E9479.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20209133" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bschor T, Baethge C. No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy: Review. Acta Psychiatrica Scandinavica 2010; 121(3):174-179.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19703121" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Are all antidepressants equal? Evidence Based Mental Health Journal 2010; 12:98-100.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/98.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gartlehner G, Thaler K, Hansen RA, Gaynes BN. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.&amp;nbsp; Drug Safe 2009; 32(12):1159-73.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19916583" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009; (4). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab007115.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. Journal of Clinical Pharmacy &amp;amp; Therapeutics 2010; 35(2):177-89.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20456736" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mancini M, Gianni W, Rossi A, Amore M. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. Expert Opinion on Pharmacotherapy 2009; 10(5):847-60.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19351233" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Nakagawa A, Watanabe N, Omori IM et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009; (3). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab006529.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Perry R, Cassagnol M. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clinical Therapeutics 2009; 31(Pt 1):1374-404.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19698900" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Current Medical Research &amp;amp; Opinion 2010; 26(1):139-50.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19919295" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;van den Broek WW, Mulder PG, van Os E, Birkenhager TK, Pluijms E, Bruijn JA. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis. Journal of Psychopharmacology 2009; 23(6):708-13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18562424" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zerjav S,&amp;nbsp; TG,&amp;nbsp; SM, J, W. Review of duloxetine and venlafaxine in depression. Canadian Pharmacists Journal 2009; 142(3):144-152.&lt;BR&gt;[&lt;A href="http://www.cpjournal.ca/doi/abs/10.3821/1913-701X-142.3.144" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386612</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386612]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Pharmacological treatment - Tricyclic Antidepressants (TCAs)</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Pharmacological treatment - Tricyclic Antidepressants (TCAs)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Pharmacological treatments: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319741/nelhImp_0000_PHARMACOLOGICAL.jpg"&gt;Pharmacological treatments - Tricyclic Antidepressants&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Arroll B, Elley CR, Fishman T et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009; (3). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab007954.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bschor T, Baethge C. No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy: Review. Acta Psychiatrica Scandinavica 2009; 121(3):174-179.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19703121" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A, La Ferla T, Furukawa TA et al. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009; (2).&lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab006117.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Current use of SSRIs and tricyclic antidepressants may increase the risk of non-vertebral fractures in the elderly. Evidence Based Mental Health Journal 2009; 12:26.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/26.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rief W, Nestoriuc Y, Von Lilienfeld-Toal A et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis. Drug Safety 2009; 32(11):1041-1056.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19810776" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;van den Broek WW, Mulder PG, van Os E, Birkenhager TK, Pluijms E, Bruijn JA. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis. Journal of Psychopharmacology 2009; 23(6):708-13.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18562424" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Watanabe N, Omori IM, Nakagawa A et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24(1):35-53.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20030418" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Side Effects of Tricyclic Antidepressants (TCAs)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chiesa A, Serretti A. Antidepressants and sexual dysfunction: Epidemiology, mechanisms and management. Italian Journal of Psychopathology 2010; 16(1):104-113.&lt;BR&gt;[No abstract available] &lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Long term antidepressant use linked to increased risk of diabetes. Evidence Based Mental Health Journal 2010; 13:30.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/1/30.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386631</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386631]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Populations and Settings - Children and Adolescents</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Populations and Settings - Children and Adolescents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319745/nelhImp_0000_POPULATIONS.jpg"&gt;Populations and Settings - Children and Adolescents&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Attanayake V, McKay R, Joffres M, Singh S, Burkle F Jr, Mills E. Prevalence of mental disorders among children exposed to war: a systematic review of 7,920 children. Medicine, Conflict &amp;amp; Survival 2009; 25(1):4-19.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19413154" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Calear AL, Christensen H. Systematic review of school-based prevention and early intervention programs for depression. Journal of Adolescence 2010; 33(3): 429-438.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19647310" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Clavenna A, Bonati M. Adverse drug reactions in childhood: A review of prospective studies and safety alerts. Archives of Disease in Childhood 2009; 94(9): 724-728.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19531524" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DiGirolamo AM, Ramirez-Zea M. Role of zinc in maternal and child mental health. American Journal of Clinical Nutrition 2009; 89(3):940S-5S.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19176735" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dretzke J, Davenport C, et al. The clinical effectiveness of different parenting programmes for children with conduct problems: A systematic review of randomised controlled trials. Child and Adolescent Psychiatry and Mental Health 2009; 3(7).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19261188" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - In adolescents with SSRI resistant depression, CBT/combined treatment is most effective in those with comorbid disorders. Evidence Based Mental Health Journal 2009; 12:108.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/108.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jordans MJD, Tol WA et al. Systematic review of evidence and treatment approaches: Psychosocial and mental health care for children in war. Child and Adolescent Mental Health 2009; 14(1):2-14.&lt;BR&gt;[&lt;A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1475-3588.2008.00515.x/abstract" target="_blank"&gt;Wiley Online Library Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Miller EJ, Chung H. A literature review of studies of depression and treatment outcomes among U.S. College students since 1990. Psychiatric Services 2009; 60(9):1257-60.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19723743" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Poletti M. Adolescent brain development and executive functions: A prefrontal framework for developmental psychopathologies. Clinical Neuropsychiatry: Journal of Treatment Evaluation 2009; 6(4):155-165.&lt;BR&gt;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Reavley N, Jorm AF. Prevention and early intervention to improve mental health in higher education students: A review. Early Intervention in Psychiatry 2010; 4(2):132-142.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20536969" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roke Y, VHP, N et al. Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. Journal of Child and Adolescent Psychopharmacology 2009; 19(4):403-414.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19702492" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;U.S. Preventive Services Task Force 2010. Screening and treatment for major depressive disorder in children and adolescents: US preventive services task force recommendation statement 2009. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19336383" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Venning A, Kettler L, Eliott J, Wilson A. The effectiveness of Cognitive-Behavioural Therapy with hopeful elements to prevent the development of depression in young people: a systematic review. International Journal of Evidence-Based Healthcare 2009; 7(1):15-34.&lt;BR&gt;[&lt;A href="http://www.ingentaconnect.com/content/bsc/jbr/2009/00000007/00000001/art00003" target="_blank"&gt;Ingenta Connect Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weich S, Patterson J, Shaw R, Stewart-Brown S. Family relationships in childhood and common psychiatric disorders in later life: systematic review of prospective studies. British Journal of Psychiatry 2009; 194(5):392-398.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19407266" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Williams SB, O'Connor EA, Eder M, Whitlock EP. Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force. Pediatrics 2009; 123(4):e716-NaN.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19336361" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386744</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386744]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Populations and Settings - Ethnicity</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Populations and Settings - Ethnicity&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to the Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Populations and Settings - Ethnicity&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Prevalence - Low recognition of depression among outpatients by internists in China. Evidence Based Mental Health Journal 2009; 12:64. &lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/64.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Treatment - Review: befriending modestly reduces depressive symptoms in varied populations. Evidence Based Mental Health Journal 2010; 13:94. &lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/3/94.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Royal College of Psychiatrists. Improving in-patient mental health services for black and minority ethnic patients. Royal College of Psychiatrists 2010.&lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/OP71.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386632</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386632]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Populations and Settings - Older People</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Populations and Settings - Older People&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Populations and Settings - Older People&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Allen J, Annells M. A literature review of the application of the Geriatric Depression Scale, Depression Anxiety Stress Scales and Post-traumatic Stress Disorder Checklist to community nursing cohorts. Journal of Clinical Nursing 2009; 18(7):949-59.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19284431" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clinical Rehabilitation 2009; 23(10):873-87.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19675114" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chang-Quan H, Xue-Mei Z, Bi-Rong D, Zhen-Chan L, Ji-Rong Y, Qing-Xiu L. Health status and risk for depression among the elderly: a meta-analysis of published literature.&amp;nbsp; Age &amp;amp; Ageing 2010; 39(1):23-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19903775" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Colasanti V, Marianetti M, Micacchi F, Amabile GA, Mina C. Tests for the evaluation of depression in the elderly: a systematic review. Archives of Gerontology &amp;amp; Geriatrics 2010; 50(2):227-31.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19414202" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cummings Sherry M, E, Kropf NPE. Handbook of psychosocial interventions with older adults: evidence-based approaches. Handbook of Psychosocial Interventions With Older Adults: Evidence-Based Approaches 2009; Xiv:350.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~content=a923091732~db=all~jumptype=rss" target="_blank"&gt;Informa World Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Current use of SSRIs and tricyclic antidepressants may increase the risk of non-vertebral fractures in the elderly. Evidence Based Mental Health Journal 2009; 12:26.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/26.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - A stepped care intervention is effective for elderly people with sub threshold depression or anxiety. Evidence Based Mental Health Journal 2009; 12:115.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/115.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. American Journal of Geriatric Pharmacotherapy 2009; 7(1):34-59.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19281939" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huang C-Q, Dong B-R et al. Collaborative care interventions for depression in the elderly: A systematic review of randomized controlled trials. Journal of Investigative Medicine 2009; 57(2):446-455. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19174704" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huang CQ, Dong BR et al. Chronic diseases and risk for depression in old age: a meta-analysis of published literature. Research Reviews 2010; 9(2):131-41.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19524072" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mancini M, Gianni W, Rossi A, Amore M. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. Expert Opinion on Pharmacotherapy 2009; 10(5):847-60.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19351233" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clinical Therapeutics 2009; 31(5):945-61.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19539096" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Connor EA, Whitlock EP, Beil TL, Gaynes BN. Screening for depression in adult patients in primary care settings: a systematic evidence review. Annals of Internal Medicine 2009; 151(11):793-803.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19949145" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Peng XD, Huang CQ, Chen LJ, Lu ZC. Cognitive behavioural therapy and reminiscence techniques for the treatment of depression in the elderly: a systematic review. Journal of International Medical Research 2009; 37(4):975-82.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19761679" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Royal College of Psychiatrists. Links not boundaries: service transitions for people growing older with enduring or relapsing mental illness. Royal College of Psychiatrists 2009. &lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/CR153.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386741</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386741]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Populations and Settings - Women</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Populations and Settings - Women&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Populations and Settings - Women&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #18: use of antidepressants in nursing mothers. Breastfeeding Medicine 2009; 3(1):44-52.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18333769" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ammerman RT, Putnam FW, Bosse NR, Teeters AR, Van Ginkel JB. Maternal depression in home visitation: A systematic review. Aggression and Violent Behavior 2010; 15(3):191-200.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20401324" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Aetiology - Prolonged exposure to SRIs during pregnancy increases risks of adverse neonatal outcomes. Evidence Based Mental Health Journal 2009; 12:27.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/27.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gentile S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophrenia Bulletin 2010; 36(3):518-544.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18787227" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Horst RGJT, Smit JP. Antidepressants during pregnancy and lactation. Tijdschrift Voor Psychiatrie 2009; 51(5):307-314.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19434568" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lancaster CA, Gold K et al. Risk factors for depressive symptoms during pregnancy: a systematic review. American Journal of Obstetrics and Gynecology 2010; 202(1):5-14.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20096252" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clinical Obstetrics &amp;amp; Gynecology 2009; 52(3):483-98.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19661763" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Simoncelli M, Martin B-Z, Berard A. Antidepressant use during pregnancy: A critical systematic review of the literature. Current Drug Safety 2010; 5(2):153-170.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19534639" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tuccori M, Testi A, Antonioli L et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clinical Therapeutics 2009; 31(Pt 1):1426-53.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19698902" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386746</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386746]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Populations and Settings - Workplace</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Populations and Settings - Workplace&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Populations and Settings - Workplace&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Populations and Settings - Workplace&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Depressive symptoms highly prevalent after a musculoskeletal workplace injury. Evidence Based Mental Health Journal 2010; 13:45.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/2/45.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Martin A, Sanderson K, Cocker F. Meta-analysis of the effects of health promotion intervention in the workplace on depression and anxiety symptoms. Scandinavian Journal of Work, Environment &amp;amp; Health 2009; 35(1):7-18.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19065280" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schultz AB, Chen C-Y, Edington DW. The cost and impact of health conditions on presenteeism to employers: A review of the literature. PharmacoEconomics 2009;&amp;nbsp; 27(5):365-378.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19586075" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386619</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386619]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Psychosocial Treatment - Cognitive Behavioural Therapy (CBT)</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Psychosocial Treatment - Cognitive Behavioural Therapy (CBT)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319742/nelhImp_0000_PSYCHOLOGICAL.jpg"&gt;Psychosocial Treatment - Cognitive Behavioural Therapy (CBT)&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Cuijpers P, Smit F, Bohlmeijer E, Hollon SD, Andersson G. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: Meta-analytic study of publication bias. British Journal of Psychiatry 2010; 196(3): 173-178.&lt;BR&gt;[&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/196/3/173" target="_blank"&gt;British Journal of Psychiatry Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - In adolescents with SSRI resistant depression, CBT/combined treatment is most effective in those with comorbid disorders. Evidence Based Mental Health Journal 2009; 12:108.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/108.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kavanagh J, Oliver S, Lorenc T et al. School-based cognitive-behavioural interventions: a systematic review of effects and inequalities. Health Sociology Review 2009; 18(1):61-79.&lt;BR&gt;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;McNaughton JL. Brief interventions for depression in primary care: a systematic review. Canadian Family Physician 2009; 55(8):789-96.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19675262" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McPherson S, Evans C, Richardson P. The NICE Depression Guidelines and the recovery model: is there an evidence base for IAPT? Journal of Mental Health 2009; 18(5):405-15.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/935906413-2728925/content~content=a915831728~db=all~jumptype=rss" target="_blank"&gt;Informa World Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parikh S, V,&amp;nbsp; SZ et al and Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders 2009; 117(SUPPL. 1):S15-S25. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19682749" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Peng XD, Huang C]Q, Chen LJ, Lu ZC. Cognitive behavioural therapy and reminiscence techniques for the treatment of depression in the elderly: a systematic review. Journal of International Medical Research 2009; 37(4):975-82.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19761679" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Venning A, Kettler L, Eliott J, Wilson A. The effectiveness of Cognitive-Behavioural Therapy with hopeful elements to prevent the development of depression in young people: a systematic review. International Journal of Evidence-Based Healthcare 2009; 7(1):15-34.&lt;BR&gt;[&lt;A href="http://www.ingentaconnect.com/content/bsc/jbr/2009/00000007/00000001/art00003" target="_blank"&gt;Ingenta Connect Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386620</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386620]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Psychosocial Treatment - Computer Aided Cognitive Behavioural Therapy (CCBT)</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Psychosocial Treatment - Computer Aided Cognitive Behavioural Therapy (CCBT)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Psychosocial Treatment - Computer Aided Cognitive Behavioural Therapy (CCBT)&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Online cognitive behavioural therapy is effective for depression in primary care. Evidence Based Mental Health Journal 2010; 13:50.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/13/2/50.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;McNaughton JL. Brief interventions for depression in primary care: a systematic review. Canadian Family Physician 2009; 55(8):789-96.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19675262" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Waller R, Gilbody S. Barriers to the uptake of computerized cognitive behavioural therapy: A systematic review of the quantitative and qualitative evidence. Psychological Medicine 2009; 39(5):705-712.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18812006" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386622</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386622]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Psychosocial Treatment - Other Psychological Treatment</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Psychosocial Treatment - Other Psychological Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Psychosocial Treatment - Other Psychological Therapies&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clinical Rehabilitation 2009; 23(10):873-87.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19675114" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS ONE [Electronic Resource] 2009; 4(3):e4824.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19293925" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cape J, Whittington C, Bower P. What is the role of consultation-liaison psychiatry in the management of depression in primary care? A systematic review and meta-analysis. General Hospital Psychiatry 2010; 32(3):246-55.&lt;BR&gt;[&lt;A href="http://www.ghpjournal.com/article/S0163-8343%2810%2900019-8/abstract" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. Journal of Clinical Psychiatry 2009; 70(9):1219-29.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19818243" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cuijpers P, van Straten A, van Schaik A, Andersson G. Psychological treatment of depression in primary care: a meta-analysis. British Journal of General Practice 2009; 59(559):e51-60.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19192368" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cummings SME, Kropf NPE. Handbook of psychosocial interventions with older adults: evidence-based approaches. Handbook of Psychosocial Interventions With Older Adults: Evidence-Based Approaches 2009; Xiv:350.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~content=a923091732~db=all~jumptype=rss" target="_blank"&gt;Informa World Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dretzke J, Davenport C, Frew E et al. The clinical effectiveness of different parenting programmes for children with conduct problems: A systematic review of randomised controlled trials. Child and Adolescent Psychiatry and Mental Health 2009; 3(7).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19261188" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - A nurse delivered management programme for depression in people with cancer reduces depressive symptoms compared with usual care. Evidence Based Mental Health Journal 2009; 12:9.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/9.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&amp;nbsp;Evidence Based Mental Health Journal. Therapeutics - A stepped care intervention is effective for elderly people with sub threshold depression or anxiety. Evidence Based Mental Health Journal 2009; 12:115.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/115.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics – SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. Evidence Based Mental Health Journal 2009; 12:109.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/109.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Garcia-Lizana F, Munoz-Mayorga I. Telemedicine for depression: a systematic review. Perspectives in Psychiatric Care 2010; 46(2):119-27.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20377799" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Harkness EF, Bower PJ. On-site mental health workers delivering psychological therapy and psychosocial interventions to patients in primary care: Effects on the professional practice of primary care providers. Cochrane Database of Systematic Reviews 2009; (1). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab000532.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huang C-Q, Dong B-R et al. Collaborative care interventions for depression in the elderly: A systematic review of randomized controlled trials. Journal of Investigative Medicine 2009; 57(2):446-455.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19174704" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hughes S, Cohen D. A systematic review of long-term studies of drug treated and non-drug treated depression. Journal of Affective Disorders 2009; 118(1-3):9-18.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19249104" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jordans MJD, Tol WA et al. Systematic review of evidence and treatment approaches: Psychosocial and mental health care for children in war. Child and Adolescent Mental Health 2009; 14(1):2-14.&lt;BR&gt;[&lt;A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1475-3588.2008.00515.x/abstract" target="_blank"&gt;Wiley Online Library Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. Cochrane Database of Systematic Reviews 2009; (3). &lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab004366.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mead N, Lester H, Chew-Graham C, Gask L, Bower P. Effects of befriending on depressive symptoms and distress: systematic review and meta-analysis. British Journal of Psychiatry 2010; 196(2):96-101.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20118451" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Parikh S, V,&amp;nbsp; SZ et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders 2009; 117(SUPPL. 1):S15-S25.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19682749" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Patten SV, Kennedy SH et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. Journal of Affective Disorders 2009; 117(SUPPL. 1):S5-S14.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19674796" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Piqueras Bravo M, Chocron Bentata L. Systematic review: Long-term dynamic psychotherapy is more effective than other psychotherapies in the treatment of complicated mental disorders. FMC Formacion Medica Continuada En Atencion Primaria 2009; 16(5):314.&lt;BR&gt;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Smith AEM, Msetfi RM, Golding L. Client self rated adult attachment patterns and the therapeutic alliance: A systematic review. Clinical Psychology Review 2010; 30(3): 326-337.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20096978" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sturmey P. Behavioral activation is an evidence-based treatment for depression. Behav Modification 2009; 33(6):818-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19933444" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sturvan der Feltz-Cornelis CM, Van Os TWDP et al. Effect of psychiatric consultation models in primary care. A systematic review and meta-analysis of randomized clinical trials. Journal of Psychosomatic Research 2010; 68(6):521-533.ey P. Behavioral activation is an evidence-based treatment for depression. Behav Modification 2009; 33(6):818-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20488268" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386475</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386475]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Risk Factors</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Risk Factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Risk Factors&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. American Journal of Clinical Nutrition 2010; 91(3):757-70.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20130098" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal 2009; 180(3):291-7. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19188627" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Brunoni AR, Fraguas JrR, Fregni F. Pharmacological and combined interventions for the acute depressive episode: Focus on efficacy and tolerability. Therapeutics and Clinical Risk Management 2009; (1):897-910. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19956554" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Campbell LA, Kisely SR. Advance treatment directives for people with severe mental illness. Cochrane Database of Systematic Reviews 2009; (1).&lt;BR&gt;[&lt;A href="http://www2.cochrane.org/reviews/en/ab005963.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Davydow DS, Gifford JM, Desai SV, Bienvenu OJ, Needham DM. Depression in general intensive care unit survivors: a systematic review. Intensive Care Med 2009; 35(5):796-809.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19165464" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;De Berardis D, Serroni N, Cavuto M et al. The emerging role of C-reactive protein in affective and psychotic disorders. [in Italian]. Giornale Italiano Di Psicopatologia/ Italian Journal of Psychopathology 2009; 15(3):231-242.&lt;BR&gt;[No abstract available]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Review: Maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. Evidence Based Mental Health Journal 2009; 12:79.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/79.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huang CQ, Dong BR, Lu ZC, Yue JR, Liu QX. Chronic diseases and risk for depression in old age: a meta-analysis of published literature. Ageing Research Reviews 2010; 9(2):131-41.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19524072" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lancaster CA, Gold K et al. Risk factors for depressive symptoms during pregnancy: a systematic review. American Journal of Obstetrics and Gynecology 2010; 202(1):5-14. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20096252" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Liu RT, Alloy LB. Stress generation in depression: A systematic review of the empirical literature and recommendations for future study. Clinical Psychology Review 2010; 30(5): 582-593.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20478648" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Morris BH, Bylsma LM, Rottenberg J. Does emotion predict the course of major depressive disorder? A review of prospective studies. British Journal of Clinical Psychology 2009; 48(Part 3):255-74.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19187578" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;O'Connor AM, Bennett CL et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews 2009; (3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19588325" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. European Neuropsychopharmacology 2009; 19(1):34-40.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18823760" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roshanaei-Moghaddam B, Katon WJ, Russo J. The longitudinal effects of depression on physical activity. General Hospital Psychiatry 2009; 31(4):306-15.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19555789" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weich S, Patterson J, Shaw R, Stewart-Brown S. Family relationships in childhood and common psychiatric disorders in later life: systematic review of prospective studies. British Journal of Psychiatry 2009; 194(5):392-398.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19407266" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yanos PT, Stanley BS, Greene CS. Research risk for persons with psychiatric disorders: a decisional framework to meet the ethical challenge. Psychiatric Services 2009; 60(3):374-84.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19252051" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. Journal of Psychiatric Practice 2009; 15(4):289-305.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19625884" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386628</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386628]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: Transcranial Magnetic Stimulation</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: Transcranial Magnetic Stimulation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID319744/nelhImp_0000_TMS.jpg"&gt;Transcranial Magnetic Stimulation&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Review: High frequency repetitive transcranial magnetic stimulation improves symptoms of major depression. Evidence Based Mental Health Journal 2009; 12:80-81.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/80.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Therapeutics - Review: High frequency repetitive transcranial magnetic stimulation improves symptoms of treatment resistant major depression. Evidence Based Mental Health Journal 2009; 12:81.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/81.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation. Psychiatry 2009; 8(4):130-134. &lt;BR&gt;[Abstract not available]&lt;/LI&gt;
&lt;LI&gt;Kennedy S, H,&amp;nbsp; MR et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. Journal of Affective Disorders 2009; 117(SUPPL. 1):S44-S53. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19656575" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pallanti S, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review. International Journal of Clinical Psychopharmacology 2009; 24(4):163-73.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19455047" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychological Medicine 2009; 39(1):65-75.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18447962" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>386468</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386468]]&gt;</url>
    <title>Depression Annual Evidence Update 2010: UK Guidelines</title>
    <publicationDate>2010-10-04T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Depression Annual Evidence Update 2010: UK Guidelines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:386463:1" name=internalLink&gt;Back to Depression Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;IMG style="FLOAT: right" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID326326/nelhImp_0000_GUIDELINES.jpg"&gt;Influential Guidelines from 2005-2010&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;UK Guidelines&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;NICE (National Institute for Health and Clinical Excellence)&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NICE first published a guideline on depression in 2004, which was updated in October 2009:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression: the treatment and management of depression in adult. 2009. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG90NICEguideline.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;EM&gt;NICE have also published a number of other guidelines and technology appraisals that are relevant to depression:&lt;/EM&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression in children and young people : identification and management in primary, community and secondary care. 2005. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG028NICEguideline.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Depression in adults with a chronic&amp;nbsp;physical health problem: treatment and management.&amp;nbsp;2009. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG91NICEGuideline.pdf" target="_blank"&gt;Full-text&amp;nbsp;PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cognitive behavioural therapy for the management of common mental health problems. 2008. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/usingguidance/commissioningguides/cognitivebehaviouraltherapyservice/cbt.jsp" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Transcranial magnetic stimulation for severe depression. 2007. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/IPG242GUIDANCE.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Computerised cognitive behaviour therapy for depression and anxiety: review of Technology Appraisal 51. 2006. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA097guidance.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Managing long-term sickness absence and incapacity for work. 2009. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/PH19Guidance.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Rehabilitation after critical illness. 2009. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG083NICEGuideline.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Vagus nerve stimulation for treatment-resistent depression. 2009. &lt;BR&gt;[&lt;A href="http://www.nice.org.uk/nicemedia/pdf/IPG330Guidance.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Scottish Intercollegiate Guidelines Network&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Non pharmaceutical management of depression. 2010.&lt;BR&gt;[&lt;A href="http://www.sign.ac.uk/pdf/sign114.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Department of Health &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;The competences required to deliver effective cognitive and behavioural therapy for people with depression and with anxiety disorders. 2007.&lt;BR&gt;[&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_078535.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Psychiatrists&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Good psychiatric practice (third edition). 2009. &lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/publications/collegereports/cr/cr154.aspx" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Psychiatric services for black and minority ethnic older people. 2009. &lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/CR156.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Safe and appropriate care for young people on adult mental health wards. 2009. &lt;BR&gt;[&lt;A href="http://www.rcpsych.ac.uk/pdf/Safe__App_4_YP_on_IPAMH-8_jan_FINAL21.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;British Association of Psychopharmacology&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. 2008.&lt;BR&gt;[&lt;A href="http://www.bap.org.uk/pdfs/antidepressants.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;British National Formulary&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Treatment of dry mouth. 2010. &lt;BR&gt;[&lt;A href="http://bnf.org/bnf/bnf/current/29680.htm" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;British Occupational Health Research Foundation&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Workplace interventions for people with common mental health problems: evidence review and recommendations. 2005.&lt;BR&gt;[&lt;A href="http://www.bohrf.org.uk/downloads/cmh_rev.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;College of Emergency Medicine&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Guideline for the management of trycyclic antidepressant overdose. 2009. &lt;BR&gt;[&lt;A href="http://secure.collemergencymed.ac.uk/asp/document.asp?ID=5075" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical Knowledge Summaries (CKS)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression. 2010.&lt;BR&gt;[&lt;A href="http://www.cks.nhs.uk/depression#" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Map of Medicine - NHS Choices&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Depression. 2010.&lt;BR&gt;[&lt;A href="http://healthguides.mapofmedicine.com/choices/map/depression1.html" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Depression in children and adolescents - primary care assessment. 2010.&lt;BR&gt;[&lt;A href="http://healthguides.mapofmedicine.com/choices/map/depression_in_children_and_adolescents1.html" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;National Screening Committee&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Screening for&amp;nbsp;depression: a report for the UK National Screening Committee. 2010. &lt;BR&gt;[&lt;A href="http://www.screening.nhs.uk/policydb_download.php?doc=73" target="_blank"&gt;Full Text&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381298</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/Depression-and-dementia-risk.aspx]]&gt;</url>
    <title>Depression linked to dementia</title>
    <publicationDate>2010-07-07T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Having depression may nearly double the risk of developing dementia later in life,” reported BBC News. It said that a 17-year study of nearly 1,000 elderly people, found that 22% of those who were depressed at the start went on to develop dementia, compared with 17% of those who were not depressed.&lt;/P&gt;
&lt;P&gt;This is a well-designed study and was accurately reported by the BBC. It has several strengths and adds to the evidence of a link between the two conditions.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347113</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://bookshop.rcplondon.ac.uk/details.aspx?e=280]]&gt;</url>
    <title>Depression screening and management of staff on long-term sickness absence</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Royal College of Physicians</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DEPRESSION,SCREENING,POPULATION BASED &amp; PREVENTATIVE SERVICES,MONTHLY ADDITIONS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SERVICES,APRIL 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN id=ctl00_ContentPlaceHolder1_FormView1_summaryLabel&gt;
&lt;P&gt;This national comparative clinical audit measures how well NHS staff on long-term sickness absence are screened for depression by occupational health (OH) doctors and nurses. &lt;/P&gt;
&lt;P&gt;OH doctors and nurses frequently see employees who have been on long-term sickness absence. Most staff are referred by their managers. While some of these staff will already have been diagnosed with a psychological illness, others will be off sick with a physical problem.&lt;/P&gt;
&lt;P&gt;It is well documented that many people with chronic physical symptoms also develop depression. We also know that the longer an employee is off sick, the more likely this becomes; and the less likely they are to make a successful return to work. Long-term sickness absence has repercussions for the individual, their family, their employer, the benefit system and the wider economy and society as a whole.&lt;/P&gt;
&lt;P&gt;To facilitate optimum management of staff on long-term sickness absence it is important that any clinicians involved in their care screen regularly for depression; and this includes OH professionals. While there are no specific guidelines for such screening by OH professionals, there is a relevant NICE &lt;EM&gt;Guideline on the management of depression in primary and secondary care. &lt;/EM&gt;We used this national guideline to develop standards against which the care provided by OH doctors and nurses looking after NHS staff in England could be measured.&lt;/P&gt;&lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>275525</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_080714]]&gt;</url>
    <title>Deprivation of Liberty Safeguards and Mental Capacity Act 2005 local implementation networks</title>
    <publicationDate>2007-11-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Safeguards are due to be implemented in April 2009. Local Mental Capacity Act implementation networks are invited to incorporate the implementation of the Deprivation of Liberty Safeguards into their work.</description>
    <body>&lt;![CDATA[ The Safeguards are due to be implemented in April 2009. Local Mental Capacity Act implementation networks are invited to incorporate the implementation of the Deprivation of Liberty Safeguards into their work. Action: Directors of Adult Services, and NHS chief executives should read the important linked information about preparing for April 2009.]]&gt;</body>
  </document>
  <document>
    <id>283344</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_084204]]&gt;</url>
    <title>Deprivation of Liberty Safeguards implementation tool</title>
    <publicationDate>2008-04-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Department has developed an implementation tool that  local Mental Capacity Act implementation networks may wish to use when estimating the number of assessments and staff that are likely to be required in 2009 / 10.</description>
    <body>&lt;![CDATA[ The Department has developed an implementation tool that&amp;nbsp; local Mental Capacity Act implementation networks may wish to use when estimating the number of assessments and staff that are likely to be required in 2009 / 10.]]&gt;</body>
  </document>
  <document>
    <id>328881</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.its-services.org.uk/silo/files/developing-capable-practitioners-to-improve-services.pdf]]&gt;</url>
    <title>Developing capable practitioners to improve services and increase positive service user experience</title>
    <publicationDate>2008-08-08T00:00:00</publicationDate>
    <publisher>Care Services Improvement Partnership</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The purpose of this document is to explore opportunities for building flexible partnerships with a variety of health, social care and higher education institutions to meet the training and support needs of the workforce in delivering high quality care to service users with co-existing mental health and substance misuse problems. This document uses examples of existing good practice throughout the UK to demonstrate where the challenges of flexible working have been met by creative responses. Each example summarises key points that might be applied in other practice settings to benefit service and developmental improvements.]]&gt;</body>
  </document>
  <document>
    <id>268354</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=21184&amp;Rendition=Web]]&gt;</url>
    <title>Developing services for carers and families of people with mental illness</title>
    <publicationDate>2002-11-13T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The aim of this document is to help local mental health services develop support services for carers of people with mental health problems. It contains guidance on developing and sustaining mental health carer support services and also includes a sample job description for carer support workers.</description>
    <body>&lt;![CDATA[ The aim of this document is to help local mental health services develop support services for carers of people with mental health problems. It contains guidance on developing and sustaining mental health carer support services and also includes a sample job description for carer support workers.]]&gt;</body>
  </document>
  <document>
    <id>392205</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_120561.pdf]]&gt;</url>
    <title>Development of services for people with learning disabilities or mental illness in England</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,QUALITY AND MONITORING,MENTAL HEALTH SERVICES,SERVICE DELIVERY,MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,QUALITY IMPROVEMENT,LEARNING DISABILITY SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Presented to Parliament pursuant to section 11 of the Disabled Persons (Services, Consultation and Representation) Act 1986 as amended by the Health and Social Care Act 2001.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342423</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.jrf.org.uk/publications/impact-of-devolution]]&gt;</url>
    <title>Devolution’s impact on low-income people and places</title>
    <publicationDate>2010-01-13T00:00:00</publicationDate>
    <publisher>Joseph Rowntree Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,DELIRIUM,DEMENTIA,EDUCATION,ECONOMICS,ECONOMICS,UNEMPLOYMENT,ENVIRONMENTAL,ENVIRONMENT,ADULTS,COMMUNITY DEVELOPMENT,DISADVANTAGED GROUPS,POPULATION BASED &amp; PREVENTATIVE SERVICES,HEALTH ECONOMICS,REGENERATION,COMMUNITY DEVELOPMENT,OLDER PEOPLE,MONTHLY ADDITIONS,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SERVICES,GOVERNMENT,GOVERNMENT &amp; LAW,POPULATIONS,COMMUNITIES,GROUPS,AGE GROUPS,HOUSING,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ For the tenth anniversary of devolution, this Round-up and a series of reports explored trends in social and economic disadvantage as well as policy developments in four areas: housing and homelessness, employment, neighbourhood regeneration and long-term care for older people.]]&gt;</body>
  </document>
  <document>
    <id>395087</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/diabetes-drug-tested-in-dementia-study.aspx]]&gt;</url>
    <title>Diabetes drug for Alzheimer’s explored</title>
    <publicationDate>2010-11-23T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A common diabetes drug could be redeveloped as a new treatment for Alzheimer's,” reported the BBC. It said that metformin may help prevent the formation of “tau tangles”, a key brain abnormality linked to the disease.&lt;/P&gt;
&lt;P&gt;This study investigated whether metformin has any effect on the tau proteins that form these tangles. In studies of mouse cells, metformin increased the activity of an enzyme that can counteract the development of the tangles. Similar findings were also seen in live mice given the drug.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301695</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/107]]&gt;</url>
    <title>Diagnosis - Common mental disorders in primary care in India: little to distinguish five commonly used screening instruments</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effectively do five commonly used instruments screen for&lt;SUP&gt; &lt;/SUP&gt;common mental disorders in primary care in India?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;598 adults aged over 18 years attending three primary health&lt;SUP&gt; &lt;/SUP&gt;centres (PHCs) and two GP clinics in Goa in India. These were&lt;SUP&gt; &lt;/SUP&gt;a "systematic sample" of all people attending these facilities;&lt;SUP&gt; &lt;/SUP&gt;consecutive patients from the three PHCs, every fourth patient&lt;SUP&gt; &lt;/SUP&gt;from the first GP clinic and every fifth patient from the second&lt;SUP&gt; &lt;/SUP&gt;GP clinic. People requiring urgent medical attention were excluded.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Goa, India; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Test:&lt;/STRONG&gt;&lt;BR&gt;Screening properties of five different instruments were tested:&lt;SUP&gt; &lt;/SUP&gt;the Primary Health Questionnaire (PHQ), a 9-item, self-administered&lt;SUP&gt; &lt;/SUP&gt;version of the Primary Care Evaluation of Mental Disorders instrument&lt;SUP&gt; &lt;/SUP&gt;for common mental disorders; the General Health Questionnaire&lt;SUP&gt; &lt;/SUP&gt;(GHQ), a short 12-item version of this commonly used screening&lt;SUP&gt; &lt;/SUP&gt;questionnaire; the Self-Reporting Questionnaire (SRQ), a 20-item&lt;SUP&gt; &lt;/SUP&gt;questionnaire originally developed on behalf of the WHO; the&lt;SUP&gt; &lt;/SUP&gt;Kessler Psychological Distress Scale (K10), a &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Diagnostic standard:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Felicity A Goodyear-Smith, MB, ChB &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Department of General Practice &amp;amp; Primary Health Care, The University of Auckland, Auckland, New Zealand &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/107" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344530</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/10.extract]]&gt;</url>
    <title>Diagnosis - Conners’ Teacher Rating Scale has limited ability to predict DSM-IV ADHD in referred schoolchildren</title>
    <publicationDate>2010-02-09T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the predictive validity of the revised Conners’ Teacher Rating Scale (CTRS-R) for identifying children with attention deficit hyperactivity disorder (ADHD) in a clinical sample compared with the Telephone Teacher Interview (T TI-IV)?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;1038 children aged 6–12 years referred for assessment of attention, learning and behavioural problems to a pae-diatric clinic (mean age 8.8 years, 75.5% male). Children on psychotropic medications other than stimulants, attending full time treatment programmes, with premature birth, history of serious head trauma, a chronic medical condition, recent history of abuse or who were adopted were excluded.&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Outpatient paediatric clinic, Toronto, Canada; May 1996–February 2006.&lt;/P&gt;
&lt;H3&gt;Test:&lt;/H3&gt;
&lt;P id=p-4&gt;The CTRS-R, a 59 item teacher report form used to identify children with ADHD and associated behavioural difficulties. This was given to teachers by parents and completed before clinical assessment. Three subscales (L, M and N) were used to identify DSM-IV subtypes (inattentive, hyperactive/impulsive and combined, respectively). Scores were converted to T scores, scaled for age and gender, and a score of 50 taken as the mean score for the population. A cut-off T score of &amp;gt;60 … &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/10.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224612</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/6/3/78]]&gt;</url>
    <title>Diagnosis - Local adaptation of guidelines for identifying mental disorders in primary care may not improve patient outcomes</title>
    <publicationDate>2003-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Croudace T, Evans J, Harrison G et al. Impact of the ICD-10 Primary Health Care (PHC) diagnostic and management guidelines for mental disorders on detection and outcome in primary care. Cluster randomised controlled trial. Br J Psychiatry 2003 Jan;182:20–30&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does local adaptation and dissemination of the WHO ICD-I0 Primary Health Care Guidelines for Diagnosis and Management of Mental Disorders improve patient outcomes?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Cluster randomised trial. Practices were randomised in pairs after stratification by practice social deprivation score. It is unclear whether outcome assessors were blind to intervention allocation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Urban and rural primary care practises in Bristol, United Kingdom; October 1997—May 1999.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants:&lt;/STRONG&gt; Primary care practices were the unit of randomisation and analysis. 30 practices with 250 general practitioners, locums, and assistants were included. The mean practice list size was about 4200 (range 900–7300).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Half of the practices received a guideline intervention and the other half received no intervention. The intervention involved local development and dissemination of the WHO ICD-10 Primary Health Care guidelines (1996 version). General practitioners (GPs) were encouraged to adapt the WHO guidelines with colleagues from local psychiatric services. One GP from each intervention practice participated in guideline revision workshops.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main outcome measures:&lt;/STRONG&gt; The main outcomes were detection of minor psychiatric morbidity (sensitivity) at practice level and 3-month clinical outcomes among patients with 12-item General Health Questionnaire (GHQ 12) scores greater than 3 at initial screening. Secondary outcomes were quality of life, disability, patient satisfaction with care and the specificity of detection performance at practice level. The authors used a random effects model to compare outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main results&lt;/STRONG&gt;&lt;BR&gt;There were no significant differences in the sensitivity or specificity of mental health diagnoses among practices that received the guideline intervention and those that did not. There was no difference in clinical or secondary outcomes among patients at 3 months.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;Local adaptation of the WHO ICD-10 Primary Health Care Guidelines for Diagnosis and Management of Mental Disorders does not appear to influence clinician behaviour. Applying the guidelines may not improve detection rates or outcomes for primary care patients with mental disorders.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344531</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/11.extract]]&gt;</url>
    <title>Diagnosis - New Alzheimer's disease screening test performs well in UK outpatient settings</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;How effective is the TYM (‘test your memory’) cognitive test in detecting Alzheimer's disease?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;139 people attending a memory clinic: 31 people with non-Alzheimer's degenerative dementias, 108 people with Alzheimer's disease or amnestic mild cognitive impairment (85 with National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria diagnosis and 23 with amnestic mild cognitive impairment). 94 people (mean age 69 years) were included in the analysis for Alzheimer's disease as nine people with amnestic mild cognitive impairment scored poorly on the Addenbrooke's Cognitive Examination-revised (ACE-R) and were regarded as likely to progress to Alzheimer's disease. The 14 remaining people with amnestic mild cognitive impairment were analysed separately. People with cognitive problems caused by depression were excluded. 540 control participants aged 18-95 years were recruited from relatives taking people to the memory clinic, medical outpatients from two other hospitals and some dermatology outpatients. People with memory problems, a history of neurological disease or brain injury were excluded. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Three hospital outpatient departments, Cambridge; March–December 2007.&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/1/11.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224343</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/6/4/109]]&gt;</url>
    <title>Diagnosis - Nurse administered structed clinical interviews improve psychiatric diagnosis and treatment in community settings</title>
    <publicationDate>2003-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Kashner TM, Rush AJ, Surís A, et al.Impact of structured clinical interviews on physicians’ practices in community mental health settings.Psychiatr Serv 2003;54:712–718&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Do nurse-administered structured clinical interviews improve psychiatric diagnosis and treatment?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Setting:&lt;/STRONG&gt; 2 outpatient clinics, Dallas, USA.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Randomised controlled trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants:&lt;/STRONG&gt; 296 new adult psychiatric patients (aged 18–80 years) who returned for at least one follow up appointment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Nurse administered structured clinical interview held within 2 weeks of initial physician-led psychiatric assessment, versus no interview. Nurses discussed results with attending psychiatrists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Changes to diagnosis and treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main results&lt;BR&gt;&lt;/STRONG&gt;In the first 3 months after the interview people were more likely to have further tests, less likely be treated and more likely to have their diagnoses changed by their physician than people in the control group (p&amp;lt;0.001 for all). Nurse administered interviews significantly increased the likelihood of reducing medication (p=0.002) and initial dosage (p&amp;lt;0.017) at 3–6 month follow up.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;Nurse administered structured clinical interviews may help to improve diagnosing and treating of psychiatric disorders.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298041</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/107]]&gt;</url>
    <title>Diagnosis - Review: Diagnosing depression in primary care—ultra-short screening instruments may have limited use</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies. Br J Gen Pract 2007;57:144–51.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How accurate are ultra-short screening instruments for depression in primary care?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review of diagnostic studies with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, PsycINFO, EMBASE, CINAHL, Science Direct, Ingenta Select, Ovid Full text, Wiley Interscience, Web of Knowledge; search date June 2006.&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Studies of ultra-short depression screening tests (one, two or three questions) for use in primary care from published and non-peer reviewed sources. Exclusions: studies in medical patients, secondary care or nursing homes; studies of visual analogue scales or short tools (5–14 items); studies not Standards for Reporting of Diagnostic Accuracy (STARD) compliant. The meta-analysis involved using raw data to calculate the ratio of the proportion of true diagnoses to the proportion of false diagnoses. Where the ratio was significantly greater than 1, data were pooled to determine sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Ratio of true cases to false cases, sensitivity, specificity, NPV and PPV for each ultra-short test.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Twenty two analyses (12 publications) met inclusion criteria. Ultra-short depression screening instruments were significantly better at detecting depression in primary care than expected by chance (ratio of true to false diagnoses 5.5, 95% CI 5.3 to 5.6); there was significant heterogeneity in this analysis (p&amp;lt;0.001; see Notes). Pooled analysis of studies examining single-question tests (8 analyses) found that overall sensitivity was 31.9% and specificity 96%. Pooled analysis of studies of two- or three-question test instruments (14 analyses) found that overall sensitivity was 73.7% and specificity 74.7%. PPV was 55.6% for single-question tests (where prevalence of depression was 10.7%) and 38.3% for two- and three-question tests (prevalence of depression 17.6%). NPV was 92.3% for single-question tests and 93% for two- and three-question tests.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Ultra-short two- and three-question screening tests are more sensitive than ultra-short one-question screening tests. High false positive rates suggest that ultra-short tools should only be used if there are resources available for further assessment of those who screen positive.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392727</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/103.extract]]&gt;</url>
    <title>Diagnosis - Sensation seeking predicts established smoking and binge drinking in adolescents</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,SUBSTANCE MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Can sensation seeking be used to predict binge drinking and established smoking among adolescents and target adolescents for substance use interventions? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;6522 adolescents aged 10–14 years at baseline, contacted by random digit dial telephone survey. Comparing the age, sex and census region of the participants, and income groupings of their parents with the US 2000 Census data confirmed that the participants were a representative sample. Ethnicity was 62% white, 18.2% Hispanic and 13.6% black.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Telephone survey, USA; recruitment June to October 2003.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Test&lt;/H3&gt;
&lt;P id=p-4&gt;Sensation seeking was measured using a four-item scale: thrill seeking, adventure seeking, boredom susceptibility and intensity seeking. Scores for individual items ranged from one to four and were summed across items (total scores 4–16). Receiver operating characteristics (ROC) curves were used to analyse effectiveness of sensation seeking as a predictor of binge drinking and established smoking.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Diagnostic standard&lt;/H3&gt;
&lt;P id=p-5&gt;Participant report of binge drinking or established smoking at 24 months. Participants were surveyed three times at 8-month intervals. If 24-month data was not … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/103.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317796</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/44]]&gt;</url>
    <title>Diagnosis - The 3 item anxiety subscale of the Edinburgh Postpartum Depression Scale may detect postnatal depression as well as the 10 item full scale</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does the Edinburgh Postpartum Depression Scale (EPDS-3) anxiety&lt;SUP&gt; &lt;/SUP&gt;subscale perform as well as the full 10 item EPDS scale in screening&lt;SUP&gt; &lt;/SUP&gt;for postnatal depression, and how do other brief screening alternatives&lt;SUP&gt; &lt;/SUP&gt;compare?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Mothers (n = 199; 14–26 years) who made &lt;IMG border=0 alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif"&gt;1 visit to the&lt;SUP&gt; &lt;/SUP&gt;Colorado Adolescent Maternity Program with an infant &lt;IMG border=0 alt="&lt;=" src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID317796/nelhImp_0000_les.gif"&gt;6 months&lt;SUP&gt; &lt;/SUP&gt;old.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Primary care paediatric clinic for children of adolescent mothers,&lt;SUP&gt; &lt;/SUP&gt;Colorado, USA; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Test:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;EPDS-3 brief screening tool for postnatal depression. The EPDS-3&lt;SUP&gt; &lt;/SUP&gt;is a subscale of the full 10 item EPDS which includes the three&lt;SUP&gt; &lt;/SUP&gt;anxiety related items. Other brief alternatives that were compared&lt;SUP&gt; &lt;/SUP&gt;were the depressive EPDS subscale (EPDS-7) and the two items&lt;SUP&gt; &lt;/SUP&gt;of the EPDS that resemble the Patient Health Questionnaire (EPDS-2).&lt;SUP&gt; &lt;/SUP&gt;The score on each scale was multiplied by 10 and divided by&lt;SUP&gt; &lt;/SUP&gt;the number of items used, so that a cut-off of &lt;IMG border=0 alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif"&gt;10 could be used&lt;SUP&gt; &lt;/SUP&gt;for all scales. In &lt;NOBR&gt;&lt;EM&gt;. . &lt;/EM&gt;.(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/44" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>302030</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/11]]&gt;</url>
    <title>Diagnosis - The dementia screening questionnaire for individuals with intellectual disabilities has high sensitivity and specificity in adults with Down's syndrome</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How reliable is the Dementia Screening Questionnaire for Individuals&lt;SUP&gt; &lt;/SUP&gt;with Intellectual Disabilities (DSQIID)?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;179 adults with Down's syndrome and their carers who were identified&lt;SUP&gt; &lt;/SUP&gt;by contact with clinicians, and via the Leicestershire register&lt;SUP&gt; &lt;/SUP&gt;of people with intellectual disabilities. Carers who were interested&lt;SUP&gt; &lt;/SUP&gt;were sent an information sheet and the DSQIID by post, and asked&lt;SUP&gt; &lt;/SUP&gt;whether the person had other carers willing to fill in the questionnaire&lt;SUP&gt; &lt;/SUP&gt;to assess inter-rater reliability. On returning the questionnaire,&lt;SUP&gt; &lt;/SUP&gt;carers were sent another copy to assess test-retest reliability.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;UK; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Test:&lt;/STRONG&gt;&lt;BR&gt;The DSQIID. This was developed in the first phase of the study&lt;SUP&gt; &lt;/SUP&gt;using qualitative information gathered from carers of 24 adults&lt;SUP&gt; &lt;/SUP&gt;aged 48–72 years with Down's syndrome and dementia. The&lt;SUP&gt; &lt;/SUP&gt;DSQIID is completed by a carer who has known the individual&lt;SUP&gt; &lt;/SUP&gt;for &lt;NOBR&gt;&lt;EM&gt;. . (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator: &lt;BR&gt;&lt;/STRONG&gt;Trevor R Parmenter, PhD &lt;/P&gt;
&lt;P&gt;Centre for Developmental Disability Studies, University of Sydney, Sydney, Australia &lt;BR&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/12" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392730</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/104.extract]]&gt;</url>
    <title>Diagnosis - The Patient Health Questionnaire 2-item is a rapid, sensitive and specific screening tool for identifying adolescents with major depression</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is the Patient Health Questionnaire 2-item depression screen (PHQ-2) effective as a brief screening tool for depression among adolescents? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;3775 adolescents (13–17 years old) who attended a group health facility in the previous 12 months. The adolescents were randomly selected and sent a brief 10-item questionnaire, including the PHQ-2. Of those selected, 2291 (61%) completed the PHQ-2, and 281 (12%) screened positive for possible depression using the optimal PHQ-2 cut-off for major depression in adults (score =3). Based on the results of this screen, 499 adolescents were selected for telephone interview: 271 with PHQ-2 scores =3 and 228, age- and gender-matched adolescents, with PHQ-2 scores =2.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;US primary care setting; enrolment September 2007 to June 2008.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Test&lt;/H3&gt;
&lt;P id=p-4&gt;The PHQ-2 administered over the telephone. The PHQ-2 questions assess how frequently the individual had (1) a depressed mood and/or (2) lack of pleasure in usual activities in the last 2 weeks. Frequency is rated on a … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/104.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383802</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/96.extract]]&gt;</url>
    <title>Diagnosis - The PHQ-9 works well as a screening but not diagnostic instrument for depressive disorder</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Is the Patient Health Questionnaire 9 (PHQ-9) an accurate tool to screen for, diagnose and measure the severity of depressive disorder in groups that are at high risk for depressive disorder? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;A total of 664 high-risk patients aged between 18 and 70 years selected from patients enrolled at 6 health centres with 23 GPs and falling into one of 3 high-risk groups for depressive disorder: patients with unexplained somatic complaints; frequent attenders, defined as patients with consultation rates in the highest 10% in the year prior to study allocation; patients with a new mental health problem up to 3 months prior to the selection date. All participants completed the PHQ screening questionnaire. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Amsterdam; primary care patients from two academic medical centres, The Academic Medical Centre in Amsterdam and the Radbound University Nijmegen Medical centre; recruited from March 2006 through July 2007. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Test:&lt;/H3&gt;
&lt;P id=p-4&gt;The Patient Health Questionnaire-9, which evaluates the presence of one of the nine DSM-IV criteria of a depressive episode … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/96.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available via ATHENS login.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>372744</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/Alzheimers-risk-and-diet.aspx]]&gt;</url>
    <title>Diet 'affects' Alzheimer's risk</title>
    <publicationDate>2010-04-13T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Eating lots of nuts, fish and poultry while cutting down on red meat and butter could reduce the risk of Alzheimer’s disease,” reported &lt;EM&gt;The Times&lt;/EM&gt;. These findings come from a study of over 2,000 elderly people in New York.&lt;/P&gt;
&lt;P&gt;The study looked at the dietary patterns of people aged 65 and over and followed them for an average of four years. It found a lower risk of developing Alzheimer’s in people with a diet that included more salad dressing, nuts, fish, tomatoes, poultry, cruciferous vegetables, fruits and dark and green leafy vegetables, and lower intakes of high-fat dairy products, red meat, offal and butter.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388584</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.centreformentalhealth.org.uk/pdfs/Centre_for_MH_Directory_of_forensic_camhs.pdf]]&gt;</url>
    <title>Directory of services for high-risk young people</title>
    <publicationDate>2010-09-07T00:00:00</publicationDate>
    <publisher>Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This directory outlines services in England and Wales:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN&gt;National Commissioning Group (NCG) Medium Secure Units&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;SPAN&gt;Non-NCG 'forensic' in-patient units&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;SPAN&gt;Forensic Adolescent Community Treatment Service Teams (FACTS)&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;SPAN&gt;Community Based Forensic (Tier 3-4) Teams (CBFTs)&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;SPAN&gt;Other services for those with complex needs.&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It contains a summary of each service, detailing whom it's for and the contact details.&lt;/P&gt;
&lt;P&gt;The report also examines the need for a variety of services and contains a discussion on some of the key issues surrounding this topic.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395083</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/beetroot-and-dementia.aspx]]&gt;</url>
    <title>Does beetroot juice combat dementia?</title>
    <publicationDate>2010-11-04T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A daily glass of beetroot juice could combat the onset of dementia among older adults,” reported the &lt;EM&gt;Daily Express.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This news story is a based on a small study in 16 elderly people. The participants were given either a diet that was low or high in nitrates over a four-day period. Nitrates are present at high levels in beetroot and other vegetables, and converted into nitrites in the body, a chemical that is thought to increase blood flow. The participants’ blood flow to different regions of the brain was measured on a scan.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344597</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/Excessive-Internet-Use-and-Depression.aspx]]&gt;</url>
    <title>Does web addiction cause depression?</title>
    <publicationDate>2010-02-03T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ “Surfing the internet can expose a 'dark side' of the soul, with online addicts more likely to be depressed,” the &lt;EM&gt;Daily Mail&lt;/EM&gt; reported. It said that research has found that the worst affected were depressed and addicted “possibly because they are substituting the net for normal social activities”.]]&gt;</body>
  </document>
  <document>
    <id>386602</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386602]]&gt;</url>
    <title>Does yoga improve mood?</title>
    <publicationDate>2010-08-23T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Does yoga improve mood?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;“Yoga protects the brain from depression,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reported. It said that researchers have found that three sessions of yoga a week can help to keep you relaxed and prevent depression.&lt;/P&gt;
&lt;P&gt;This small trial randomly allocated 52 healthy people to either yoga or a walking exercise for 12 weeks. Assessments of the participants’ psychological state were made before and after this time, as were brain scans to look at their levels of GABA, a chemical that transmits messages in the brain and plays a role in mood and anxiety.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>331032</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Alcohol-and-heart-disease-risk.aspx]]&gt;</url>
    <title>Don't lose your head over beer claim</title>
    <publicationDate>2009-11-19T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Several newspapers reported that drinking excessive alcohol is good for the heart. &lt;EM&gt;The Independent&lt;/EM&gt; estimated that “half a dozen beers every day” could cut the risk of heart disease while The &lt;EM&gt;Daily Express&lt;/EM&gt; claimed that a bottle of wine a night can halve the odds.]]&gt;</body>
  </document>
  <document>
    <id>213020</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=213020]]&gt;</url>
    <title>Drawing on the Evidence: Advice for mental health professionals working with children and adolescents</title>
    <publicationDate></publicationDate>
    <publisher>CAMHS Evidence-Based Practice Unit (2006)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Second Edition 2006</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Drawing on the Evidence: Advice for mental health professionals working with children and adolescents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Aims&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This booklet was produced with the aim of creating an easily accessible resource that busy practitioners can have readily available as an aid to their decision-making. The first edition produced in 2002 was positively received and there were requests for an updated version.&lt;/P&gt;
&lt;P&gt;This booklet is not meant to be prescriptive. It is recognised that inferences from currently available research studies are by no means the only relevant source of information, and that broad indications from the literature may need at times to be tempered in the light of specific contexts and situations. Nevertheless, even where the practice implications of the research outlined in this booklet are considered to be impractical or inappropriate in a given context, the strong suggestions is that they make a sensible starting point for practitioner decision making. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>276872</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.jrf.org.uk/knowledge/findings/socialpolicy/2139.asp]]&gt;</url>
    <title>Drinking places: where people drink and why</title>
    <publicationDate>2008-01-07T00:00:00</publicationDate>
    <publisher>Joseph Rowntree Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The recent relaxation of the licensing laws has focused attention on binge drinking by young people in public places. This study examined alcohol consumption in two contrasting geographical areas (one urban, one rural), including attitudes to and use of alcohol across various social groupings, by age, gender, social class and faith.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The recent relaxation of the licensing laws has focused attention on binge drinking by young people in public places. This study examined alcohol consumption in two contrasting geographical areas (one urban, one rural), including attitudes to and use of alcohol across various social groupings, by age, gender, social class and faith.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The priority given to public drinking by government policy and the media has detracted attention from a much broader spectrum of the population’s routine domestic drinking practices.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 
&lt;LI&gt;Binge drinking, though technically referring to episodic heavy alcohol consumption, has come to mean high levels of street drinking by young people. This has left many people who consume high levels of alcohol in very different social circumstances feeling unwarrantedly insulated from concern. In the study, many whose home consumption far exceeded government-recommended weekly limits continued to regard their own drinking practices as unremarkable.&amp;nbsp; 
&lt;LI&gt;The research identified clear differences in tolerance thresholds and expectations of appropriate behaviour between the urban and rural areas.&amp;nbsp; 
&lt;LI&gt;Important differences in the ways that men and women in the study drank also indicate that alcohol strategies need to take account of these gender differences.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 
&lt;LI&gt;The study showed that home was increasingly where young people learned to drink. As such, young people’s drinking habits need to be understood and addressed in relation to their parents’ attitudes to and use of alcohol, and the wider changing nature of intergenerational relationships and parenting practices.&amp;nbsp;&amp;nbsp;&amp;nbsp; 
&lt;LI&gt;The study highlighted that strategies to revitalise the urban night-time economy predicated on alcohol implicitly exclude faith communities such as Muslims; this in turn contributes to social segregation.&amp;nbsp; 
&lt;LI&gt;The researchers conclude that drinking cultures are not uniform across the country, but are embedded within wider historical, socio-economic and cultural contexts. They suggest that more recognition is needed of how national alcohol strategies might be interpreted differently or have a different impact on specific locales. This is particularly pertinent in the light of the Licensing Act 2003, which has given local authorities more power to potentially dictate local licensing strategies. Geographical disparities may thus emerge in approaches to regulating and policing alcohol consumption. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317666</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mdf.org.uk/index.aspx?o=113923]]&gt;</url>
    <title>Drug Treatment of manic depression PDF</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>MDF The BiPolar Organisation (England)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This leaflet aims to explain the actions of the drugs used in manic depression and give useful information about the groups of drugs]]&gt;</body>
  </document>
  <document>
    <id>317732</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/publichealth/viewResource.aspx?resid=314343]]&gt;</url>
    <title>Drugs Annual Evidence Update</title>
    <publicationDate>2009-06-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - Public Health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This evidence update covers drugs misuse treatments in the offender population. As it is the first AEU, the period it covers is wider. Evidence is presented from January 2005 to March 2009. Other AEUs on other topics can be viewed in the &lt;SPAN class=style1&gt;&lt;A href="http://www.library.nhs.uk/publichealth/ViewResource.aspx?resID=311618" target="_blank"&gt;&lt;SPAN class=style1&gt;Annual Evidence Update archive&lt;/SPAN&gt;&lt;/A&gt;&lt;/SPAN&gt;.&lt;/P&gt;
&lt;P&gt;This AEU also coincides with the Home Office annual National Tackling Drugs Week. National Tackling Drugs Week is designed to provide local agencies and police forces with a platform to publicise the work you do to tackle drugs and reduce drug-related crime. Further details can be found by visiting the &lt;A href="http://www.drugs.homeoffice.gov.uk/communications-and-campaigns/tackling-drugs/NationalTacklingDrugsWeek/" target="_blank"&gt;National Tackling Drugs Week website&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>269267</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.turning-point.co.uk/NR/rdonlyres/9D063EC0-1DF6-4F62-8E99-CFAADC4749BD/771/DualDiagnosisGoodPracticeHandbook.pdf]]&gt;</url>
    <title>Dual Diagnosis: Good Practice Handbook</title>
    <publicationDate>2007-09-20T00:00:00</publicationDate>
    <publisher>Turning Point</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Helping practitioners to plan, organise, and deliver services for people with co-existing mental health and substance use needs.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Dual Diagnosis Good Practice Handbook&lt;/H2&gt;
&lt;P&gt;Turning Point has just released the Dual Diagnosis Good Practice Handbook - 56 pages of practical information designed to help practitioners and those involved in service design to learn from, and apply, good practice in dual diagnosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Increasingly practitioners are recognising that people using primary, secondary and social care services frequently have a combination of substance use, mental health and other needs. This handbook is the essential guide to address those issues. Whether you come into contact with people with a dual diagnosis on a regular basis, or are involved in developing or delivering suitable services for them, the Handbook will be invaluable for you. It has been supported by the Department of Health, and builds on their Good Practice Guide of 2002.&lt;/P&gt;
&lt;P&gt;The Handbook has been produced with expert insight from practitioners and agencies, including the Care Services Improvement Partnership, the National Treatment Agency, frontline practitioners and other experts in the field.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The handbook offers:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Snapshots and case studies illustrating good practice in services and projects working with dual diagnosis in a range of settings and locations 
&lt;LI&gt;Practical advice for anyone seeking to develop dual diagnosis services 
&lt;LI&gt;An overview of components of good practice, drawn from policy documents and the experiences of professionals and service users.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>381299</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/alzheimers-experimental-blood-test.aspx]]&gt;</url>
    <title>Early days for Alzheimer's test</title>
    <publicationDate>2010-07-06T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A simple blood test may soon be able to “predict Alzheimer's disease up to 10 years before symptoms appear”, says &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;. The newspaper says researchers have discovered that a rise in levels of a protein called clusterin may be an early sign of the disease.&lt;/P&gt;
&lt;P&gt;The observational and laboratory studies that lie behind this report have been well conducted and reported, and its authors have found clusterin levels are linked to cognitive decline, the severity of disease in people with Alzheimer’s and the rate of clinical progression of Alzheimer’s disease. However, the researchers do not suggest that this may be used to diagnose disease, at least not yet. In fact they say that their study does not support the clinical use of clusterin levels as a standalone biomarker for Alzheimer’s disease. These are interesting findings, but early ones that will lead to more research about protein markers of this disease rather than directly to a clinical test.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111327</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111327]]&gt;</url>
    <title>Early years, children, families &amp; parenting</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,OUTCOMES,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,YOUNG PEOPLE,CHILDREN,POPULATION BASED &amp; PREVENTATIVE SERVICES,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,SOCIOECONOMIC FACTORS,SERVICES,NURSING,HEALTHCARE &amp; HEALTH SERVICES,POPULATIONS,GROUPS,AGE GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Early years, children, families &amp; parenting&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:105872:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111328:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;The case for action:&lt;/H2&gt;
&lt;P&gt;A survey of children and young people’s mental health, between the ages of 5 and 15, found that the proportion of children and adolescents with any mental disorder was greater among boys than girls across the age range: 11% compared with 8% (ref1). Childhood mental health problems are strongly predictive of poor mental health in later life. Poor mental health in children, for example anxiety, depression and behavioural problems, is a significant risk factor for poor school outcomes, poor physical health, poor social skills and suicidal behaviour (ref 2, 3).&lt;/P&gt;
&lt;P&gt;A number of studies have identified parenting as a prime public health issue (ref 4, 5). Interventions to strengthen the relationship between infants and carers have a strong impact on both mental and physical health.&lt;/P&gt;
&lt;P&gt;Parenting has been found to be the single largest variable implicated in health outcomes for children, notably accident rates, teenage pregnancy, substance misuse, truancy, school exclusion and under-achievement, child abuse, employability, juvenile crime and mental illness (ref 6)&lt;/P&gt;
&lt;P&gt;Clinical guidance on postnatal depression and puerperal psychosis (ref 7) indicates that untreated postnatal depression is associated with detrimental affects on infant development as well as poor mental health outcomes for mothers and their children (ref 8, 9, 10).&lt;/P&gt;
&lt;P&gt;Low self-esteem has been identified as a risk factor for a broad range of psychological and behavioural problems such as crime and delinquency, substance abuse and other risk-taking behaviours, violence, poor socio-economic circumstances and suicide or attempted suicide. Research found that the most important influence on self-esteem was parenting style (ref 11). The key qualities contributing to positive self-esteem were approval and acceptance and the most damaging were sexual or physical abuse. &lt;/P&gt;
&lt;P&gt;Research points to the importance of socio-economic circumstances which create the context within which warm affectionate parenting and strong family attachment can flourish (ref 12, 13, 14).&lt;/P&gt;
&lt;P&gt;Social support from at least one warm, caring adult is protective in relation to a wide range of adversities (ref 15) These include poverty (ref 16), living in high crime neighbourhoods (ref 17), parental substance abuse and family conflict (ref 18), child abuse (ref 19) and early parental loss (ref 20). &lt;/P&gt;
&lt;P&gt;Interventions which promote resilience in children under five help those children to do well in spite of adversity (ref 21, 22, 1). Factors which strengthen resilience include family harmony, co operative relationships between parents, opportunities to succeed and internal locus of control.&lt;/P&gt;
&lt;P&gt;(see&amp;nbsp;&lt;A href="nelh:111327:1" name=internalLink&gt;Early years, children, families and parenting&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Children and families – evidence based priorities&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Interventions in the following areas have the most significant impact on improving the mental health of children and preventing or ameliorating early symptoms of mental health difficulties:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Improving parenting skills&lt;/LI&gt;
&lt;LI&gt;Strengthening child/carer relationship&lt;/LI&gt;
&lt;LI&gt;Addressing behavioural problems in infants and children&lt;/LI&gt;
&lt;LI&gt;Promotion of family mental health&lt;/LI&gt;
&lt;LI&gt;Domiciliary health visiting&lt;/LI&gt;
&lt;LI&gt;Day care and parenting support&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Early years, children, families &amp;amp; parenting – summary of the evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Effective programmes are those that work at multiple levels to strengthen the relationship between the child and the caregiver or parent and to address socio-economic factors that undermine positive parenting and family mental wellbeing.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Group-based parenting programmes for improving maternal mental health&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic review level evidence and meta-analysis supports the conclusion that group-based parenting programmes can make a significant contribution to the short-term (&amp;lt; 1 year) mental health of mothers and have a potential role to play in the promotion of their mental health (ref 5) Meta-analysis utilised outcome measures of depression, anxiety/stress, self-esteem and relationship with partner. Follow-up data supported a significant effect for the intervention group on outcome measures of self-esteem (ref 4).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pre-school development&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Good results have been achieved by programmes that address pre-school development indicators such as the development of language skills and impulse control and work to support parents in recognising, understanding and enhancing developmental milestones (ref 23) For example the Carolina Abecedarian Project combined home visits, full time day care to enhance language and cognitive development and a parent support group. The positive effects of this programme are still evident in follow up at 21 years of age (ref 24).&lt;/P&gt;
&lt;P&gt;Parents can promote language development, literacy and reading achievement by reading to pre-school children. (ref 25) A growing body of literature suggests that parent-child interactions with storybooks have both cognitive and emotional benefits for young children and are an important social context for the development of literacy. (ref 26, 27), 28, 29, 30)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Domiciliary health visiting&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Home visit programmes for first time mothers, beginning in pregnancy and continuing for two years, greatly improve the physical and mental health of children and reduce physical maltreatment. They also have significant social and economic benefits for the caregiver. Trained volunteers may be as effective as experts. Important elements include parenting support, education, work opportunities and social support (ref 12, 31, 32) Systematic review level evidence has demonstrated that home visiting is associated with improvements in:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;parenting skills;&lt;/LI&gt;
&lt;LI&gt;the quality of the home environment;&lt;/LI&gt;
&lt;LI&gt;several child behavioural problems including sleeping;&lt;/LI&gt;
&lt;LI&gt;detection and management of postnatal depression;&lt;/LI&gt;
&lt;LI&gt;enhanced quality of social support to mothers (ref 33)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Meta-analysis supports proactive interventions such as home visiting or community-based interventions in promoting family well-being, the best effect being in programmes that began ante-natally (ref 34)&lt;BR&gt;Day care and parenting support&lt;/P&gt;
&lt;P&gt;Evidence from a systematic review demonstrates that day care, combined with some home visiting and targeted parental training, has beneficial effects on children’s behavioural development and school achievement. Long-term follow-up shows a positive impact into adult life. There are also positive impacts on mothers’ education, employment and communication with their children (ref 35).&lt;/P&gt;
&lt;P&gt;Two examples of programmes in the review are the Perry Pre-school Programme (ref 36) and the High/Scope Pre-school Programme (ref 37). A key feature of the High/Scope curriculum is active learning, in which children are supported to initiate their own play and activities.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Addressing anti-social behaviour&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Persistent anti-social behaviour in children strongly increases risk of social rejection, youth offending and long term unemployment. The long term public cost from childhood for anti-social behaviour is up to ten times higher than for controls and involves many agencies (ref 38)) Parenting groups effectively reduce serious anti-social behaviour in children in real life conditions. Effective programmes combine behavioural interventions (praise, incentives, setting limits and discipline) and sympathetic support which acknowledges parents’ feelings and beliefs (ref 39).&lt;/P&gt;
&lt;P&gt;A systematic review of programmes aimed at 10 – 17 year old youth offenders found that interventions such as parent training and family therapy, as well as those that targeted a mix of family and extra-family factors such as parenting, school and peer relationships, might have a beneficial effect on reducing time spent by young people in institutions. However there was no evidence to support any positive effect on the mental health or well-being of the young people or their families (ref 40).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventions to address behaviour problems in children and young people&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Risk factors for childhood behavioural problems are closely linked with parenting style and parenting programmes aim to impart information, awareness or skills to participants on aspects of parenting. They aim both to provide a solution to child behavioural problems and to prevent progression to more serious illness.&lt;/P&gt;
&lt;P&gt;Systematic review level evidence demonstrates the positive effect of group-based parenting education programmes for children’s behaviour problems and parental mental health and this effect is sustained in the medium to long-term i.e. greater than one year (ref 41). There is also support from systematic review for the efficacy of group-based parenting programmes in improving the short-term (&amp;lt; 1 year) mental health of infants and toddlers (0 – 3yrs) although this improvement does not seem to be maintained over time (ref 42). However evidence from systematic reviews supports the efficacy of group-based parenting programmes in producing positive changes in 3 – 10 year old children’s behaviour and these seem to be maintained over time (ref 43).&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:105872:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111328:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Meltzer H, Gatward R, Goodman R and Ford T (2000) The mental health of children and adolescents in Great Britain: Summary report. London: &lt;A href="http://www.statistics.gov.uk/StatBase/Product.asp?vlnk=3983&amp;amp;Pos=&amp;amp;ColRank=1&amp;amp;Rank=272" target="_blank"&gt;Office for National Statistics&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Mental Health Foundation (1999) &lt;A href="http://www.mentalhealth.org.uk/page.cfm?pagecode=PBUP0107" target="_blank"&gt;Bright Futures – promoting children and young people’s mental health&lt;/A&gt;. London: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;Mental Health Foundation&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&lt;A href="http://www.dfes.gov.uk/mentalhealth" target="_blank"&gt;Department for Education and Skills&lt;/A&gt; (2001) Promoting children’s mental health within early years and school settings. London: The Stationery Office &lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Barlow J, Coren E and Stewart-Brown S (2002) Meta-analysis of the effectiveness of parenting programmes in improving maternal psychosocial health. British Journal of General Practice. 52: 223-233.&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Barlow J and Coren E (2002) Parent-training programmes for improving maternal psychosocial health. in &lt;A href="http://www.cochrane.org/" target="_blank"&gt;The Cochrane Library&lt;/A&gt; Issue 3: 2002 Oxford: Update Software.&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Hoghughi M (1998) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/316/7144/1545?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074167037847_3964&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=316&amp;amp;firstpage=1545&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;The importance of parenting in child health&lt;/A&gt; British Medical Journal 316, 1545&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;&lt;A href="http://www.sign.ac.uk/guidelines/fulltext/60/" target="_blank"&gt;Scottish Intercollegiate Guidelines Network&lt;/A&gt; (2002) Postnatal Depression and Puerperal Psychosis: A national clinical guideline. Edinburgh: SIGN Executive&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Murray L and Cooper PJ (1997) Effects of postnatal depression on infant development. Archives of the Diseases of Childhood 77: 99-101&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Cooper PJ and Murray L (1997) The impact of psychological treatments of postnatal depression on maternal mood and infant development. In Murray L and Cooper PJ (eds) Postpartum depression and child development. London: Guildford Press&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Field T, Healy B, Goldstein S, Perry S, Bendell D, Schanberg S et al (1988) Infants of depressed mothers show ‘depressed’ behaviour even when with non-depressed adults. Child Development 59: 1569-1579&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Emler N (2001) Self-esteem: The costs and causes of low self-worth. York: Joseph Rowntree Foundation&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Fonagy P and Higgitt A (2000) An attachment theory perspective on early influences on development and social inequalities in Osofsky J and Fitzgerald H (eds) WAIMH Handbook of Infant Mental Health 521-560 New York: John Wiley&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Heijmens Visser J, van der Ende J, Koot HM and Verhulst FC (2000) Predictors of psychopathology in young adults referred to mental health services in childhood or adolescence British Journal of Psychiatry 177:59-65&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Rutter M and Smith DJ (1995) Psychosocial Disorders in Young People Chichester: Wiley.&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Wolkow KE and Ferguson HB (2001) Community factors in the development of resiliency: considerations and future directions. Community Mental Health Journal 37 (6): 489-498&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Luther SS and Zigler E (1991) Vulnerability and competence: a review of research on resilience in childhood. American Journal of Orthopsychiatry 61: 6 – 22&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Felsman JK and Vaillant GE (1987) Resilient children as adults: a 40 year study. In EJ Anthony and BJ Cohler (eds) The invulnerable child. New York: Guildford Press&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Werner EE (1993) Risk, resilience and recovery: perspectives from the Kauai longitudinal study. Development and psychopathology 5: 503-515&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Spaccarelli S and Kim S (1995) Resilience criteria and factors associated with resilience in sexually abused girls. Child Abuse and Neglect 19 (9): 1171-1182&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Brown GW, Harris TO and Bifulco A (1986) The long term effects of early loss of a parent. In M Rutter, CE Izard and PB Read (eds) Depression in young people. New York: Guildford Press&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Titterton M, Hill M and Smart H (2002a) Mental health promotion and the early years: the evidence base: Risk, protection and resilience. Journal of Mental Health Promotion. 1 (1): 20-35.&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;Titterton M, Smart H and Hill M (2002b) Mental health promotion and the early years: the evidence base for interventions. Journal of Mental Health Promotion. 1 (4): 10-24.&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;Horacek HJ, Ramey CT, Campbell FA, Hoffman KP and Fletcher RH (1987) Predicting school failure and assessing early intervention with high-risk children Journal of the American academy of Child and Adolescent Psychiatry 26:758-763.&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp;Ramey CT, Campbell FA, Burchinal M, Skinner ML, Gardner DM and Ramey SL (2000) Persistent effects of early intervention on high risk children and their mothers Applied Developmental Science 4: 2-14.&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;Bus AG, Belsky J, van Ijzendoorn M and Crnic K (1997) Attachment and bookreading patterns: A study of mothers, fathers and their toddlers. Early Childhood Research Quarterly 12: 91-98&lt;BR&gt;26.&amp;nbsp;Baker L, Scher D and Mackler K (1997) Home and family influences on motivations for reading. Educational Psychologist 32: 69-82&lt;/P&gt;
&lt;P&gt;27.&amp;nbsp;Bus AG and van Ijzenedoorm MH (1995) Mothers reading to three year olds: the role of mother child attachment security in becoming literate. Reading Research Quarterly. 30: 998-1015.&lt;/P&gt;
&lt;P&gt;28.&amp;nbsp;DeLoache JS and Mendoza OAP (1987) Joint picturebook interactions of mothers and 1 year old children. British Journal of Developmental Psychology 5: 111-123&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp;Neuman SB (1996) Children engaging in storybook reading: The influence of access to print resources, opportunity and parental interaction. Early Childhood Research Quarterly 11: 495-513&lt;/P&gt;
&lt;P&gt;30.&amp;nbsp;Sonnenschein S, Brody G and Munsterman K (1996) The influence of family beliefs and practices on children’s early reading. In L Baker, P Afflerbach and D Reinking (eds) Developing engaged readers. Hillsdale, NJ: LEA&lt;/P&gt;
&lt;P&gt;31.&amp;nbsp;Olds DL, Eckenrode J, Henderson CR, Kitzman H, Powers J, Cole R, Sidora K, Morris P, Pettitt LM and Luckey D (1997) Long term effects of home visitation on maternal life course and child abuse and neglect: fifteen year follow up of a randomised trial &lt;A href="http://jama.ama-assn.org/" target="_blank"&gt;Journal of American Medical Association&lt;/A&gt; 278(8) 637-43&lt;/P&gt;
&lt;P&gt;32.&amp;nbsp;Hodnett ED and Roberts I (2000) Home based social support for socially disadvantaged mothers. &lt;A href="http://www.cochrane.org/" target="_blank"&gt;The Cochrane Library&lt;/A&gt;, Issue 3, Oxford:Update Software.&lt;/P&gt;
&lt;P&gt;33.&amp;nbsp;Elkan R, Kendrick D, Hewitt M, Robinson JJA, Tolley K, Blair M, Dewey M, Williams D and Brummell K (2000) &lt;A href="http://www.hta.nhsweb.nhs.uk/execsumm/summ413.htm" target="_blank"&gt;The effectiveness of domiciliary health visiting: a systematic review of international studies and a selective review of the British literature&lt;/A&gt;. &lt;A href="http://www.hta.nhsweb.nhs.uk/" target="_blank"&gt;Health Technology Assessment&lt;/A&gt;. 4 (13)&lt;/P&gt;
&lt;P&gt;34.&amp;nbsp;Macleod J and Nelson G (2000) Programs for the promotion of family wellness and the prevention of child maltreatment: a meta-analysis. Child Abuse and Neglect. 24 (9):1127-1149.&lt;/P&gt;
&lt;P&gt;35.&amp;nbsp;Zoritch B, Roberts I and Oakley A (2000) Daycare for pre-school children. Cochrane Review in &lt;A href="http://www.cochrane.org/" target="_blank"&gt;The Cochrane Library&lt;/A&gt; Issue 4, 2002. Oxford: Update Software.&lt;/P&gt;
&lt;P&gt;36.&amp;nbsp;Berrueta-Clement JR, Schweinhart LJ, Barnett WS, Epstein AS and Weikart DP (1984) Changed lives: the effects of the Perry pre-school program on youth through age 19 High/Scope Educational research Foundation, Monograph 8, High/Scope Press, Ypsilanti, USA.&lt;/P&gt;
&lt;P&gt;37.&amp;nbsp;Schweinhart LJ and Weikart DP (1992) High/Scope Perry Preschool Program outcomes in Preventing Anti-social Behaviour: Interventions from Birth through Adolescence eds J Mc Cord and RED Tremblay, 67-86 New York: Guildford Press.&lt;/P&gt;
&lt;P&gt;38.&amp;nbsp;Scott S, Spender Q and Doolan M (2001a). &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/323/7306/194?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074167142250_3986&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=323&amp;amp;firstpage=194&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Multicentre controlled trial of parenting groups for childhood antisocial behaviour in clinical practice&lt;/A&gt;. British Medical Journal 323:194.&lt;/P&gt;
&lt;P&gt;39.&amp;nbsp;Scott S, Knapp M, Henderson J and Maughan B (2001b) Financial cost of social exclusion: follow up study of antisocial children into adulthood. British Medical Journal 323:191-194.&lt;/P&gt;
&lt;P&gt;40.&amp;nbsp;Woolfenden SR, Williams K and Peat J (2002) Family and parenting interventions in children and adolescents with conduct disorder and delinquency aged 10-17. in &lt;A href="http://www.cochrane.org/" target="_blank"&gt;The Cochrane Library&lt;/A&gt;. Issue 4: 2002 Oxford: Update Software &lt;/P&gt;
&lt;P&gt;41.&amp;nbsp;Dimond C and Hyde C (1999) Parent Education Programmes for Children’s Behaviour Problems. Medium to Long-Term Effectiveness. A West Midlands Development and Evaluation Service Report. Development and Evaluation Service. Department of Public Health and Epidemiology. University of Birmingham.&lt;/P&gt;
&lt;P&gt;42.&amp;nbsp;Barlow J and Parsons J (2002) Group-based parent-training programmes for improving emotional and behavioural adjustment in 0-3 year old children. in &lt;A href="http://www.cochrane.org/" target="_blank"&gt;The Cochrane Library&lt;/A&gt; Issue 4: 2002 Oxford: Update Software&lt;/P&gt;
&lt;P&gt;43.&amp;nbsp;Barlow J and Stewart-Brown S (2000) Behavior problems and group-based parent education programs. Journal of Developmental and Behavioral Pediatrics. 21(5):356-70&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>259582</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/downloads/pdf/DiabetesManual.pdf]]&gt;</url>
    <title>Eating disorders with diabetes mellitus - information guide</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A 40-page guide written by Janet Treasure and Ulrike Schmidt (2004).]]&gt;</body>
  </document>
  <document>
    <id>317789</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/36]]&gt;</url>
    <title>Economic evaluations in evidence based healthcare</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Economic evaluations are increasingly carried out alongside&lt;SUP&gt; &lt;/SUP&gt;clinical evaluations so that the clinician is presented with&lt;SUP&gt; &lt;/SUP&gt;information on both the effectiveness and cost-effectiveness&lt;SUP&gt; &lt;/SUP&gt;of alternative treatments to inform their evidence based practice.&lt;SUP&gt; &lt;/SUP&gt;These evaluations are important on both theoretical and policy&lt;SUP&gt; &lt;/SUP&gt;grounds. An economic evaluation is made up of a number of components,&lt;SUP&gt; &lt;/SUP&gt;the most important of which are a comparison group, a stated&lt;SUP&gt; &lt;/SUP&gt;perspective, evidence of costs, evidence of effectiveness and&lt;SUP&gt; &lt;/SUP&gt;a method of combining costs and effects together. Cost-effectiveness,&lt;SUP&gt; &lt;/SUP&gt;cost-utility and cost–benefit analyses are different methods&lt;SUP&gt; &lt;/SUP&gt;of economic evaluation in common use and they are described&lt;SUP&gt; &lt;/SUP&gt;with examples.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/36" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381294</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/mdma-ecstasy-drug-treat-trauma.aspx]]&gt;</url>
    <title>Ecstasy tested for trauma therapy</title>
    <publicationDate>2010-07-19T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Ecstasy can treat trauma patients,” reported &lt;EM&gt;The Independent&lt;/EM&gt; today. It said that the drug had a ‘dramatic effect’ on people who suffered post-traumatic stress disorder (PTSD) and who did not respond to other treatments.&lt;/P&gt;
&lt;P&gt;Behind this report is a small&amp;nbsp;&lt;A href="http://www.nhs.uk/news/Pages/Newsglossary.aspx#Randomisedcontrolledtrial%28RCT%29" target="_blank"&gt;randomised controlled trial&lt;/A&gt; in 20 people with chronic, treatment-resistant PTSD. The study found that the patients showed some improvement in their symptoms when psychotherapy was combined with MDMA (ecstasy) treatment compared with psychotherapy and placebo.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271149</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nacro.org.uk/data/files/nacro-2007101000-476.pdf]]&gt;</url>
    <title>Effective mental healthcare for offenders: the need for a fresh approach</title>
    <publicationDate>2007-10-25T00:00:00</publicationDate>
    <publisher>Nacro</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,PRISONS,CUSTODIAL CENTRES,HEALTHCARE &amp; HEALTH SERVICES,BUILDINGS,HEALTH SERVICES,MONTHLY ADDITIONS,SETTINGS,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Mental health and crime policy briefing 2007.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Contents&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction page 1 
&lt;LI&gt;Background page 2 
&lt;LI&gt;Mental health needs in the offender population page 2 
&lt;LI&gt;Mentally disordered offenders page 2 
&lt;LI&gt;Recommendations for a fresh approach page 4 
&lt;LI&gt;An integrated and responsive approach page 4 
&lt;LI&gt;Listening to service users and carers page 6 
&lt;LI&gt;Enabling the police to respond effectively page 7 
&lt;LI&gt;Supporting the courts page 10 
&lt;LI&gt;Minimising unnecessary remands to prison page 11 
&lt;LI&gt;Making sentencing more responsive page 11 
&lt;LI&gt;Conclusion page 12 
&lt;LI&gt;References page 13 
&lt;LI&gt;About Nacro’s Mental Health Unit page 15&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>317691</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/338/apr02_3/b1024]]&gt;</url>
    <title>Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis</title>
    <publicationDate>2009-04-02T00:00:00</publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objective&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;To determine the effectiveness and safety of nicotine&lt;SUP&gt; &lt;/SUP&gt;replacement therapy assisted reduction to stop smoking.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Design&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;Systematic review of randomised controlled trials.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Data sources&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;Cochrane Library, Medline, Embase, CINAHL, PsychINFO,&lt;SUP&gt; &lt;/SUP&gt;Science Citation Index, registries of ongoing trials, reference&lt;SUP&gt; &lt;/SUP&gt;lists, the drug company that sponsored most of the trials, and&lt;SUP&gt; &lt;/SUP&gt;clinical experts.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Review methods&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;Eligible studies were published or unpublished&lt;SUP&gt; &lt;/SUP&gt;randomised controlled trials that enrolled smokers who declared&lt;SUP&gt; &lt;/SUP&gt;no intention to quit smoking in the short term, and compared&lt;SUP&gt; &lt;/SUP&gt;nicotine replacement therapy (with or without motivational support)&lt;SUP&gt; &lt;/SUP&gt;with placebo, no treatment, other pharmacological therapy, or&lt;SUP&gt; &lt;/SUP&gt;motivational support, and reported quit rates. Two reviewers&lt;SUP&gt; &lt;/SUP&gt;independently applied eligibility criteria. One reviewer assessed&lt;SUP&gt; &lt;/SUP&gt;study quality and extracted data and these processes were checked&lt;SUP&gt; &lt;/SUP&gt;by a second reviewer. The primary outcome, six months sustained&lt;SUP&gt; &lt;/SUP&gt;abstinence from smoking beginning during treatment, was assessed&lt;SUP&gt; &lt;/SUP&gt;by individual patient data analysis. Other outcomes were cessation&lt;SUP&gt; &lt;/SUP&gt;and reduction at end of follow-up, and adverse events.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Data synthesis&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Seven placebo controlled randomised controlled&lt;SUP&gt; &lt;/SUP&gt;trials were included (four used nicotine replacement therapy&lt;SUP&gt; &lt;/SUP&gt;gum, two nicotine replacement therapy inhaler, and one free&lt;SUP&gt; &lt;/SUP&gt;choice of therapy). They were reduction studies that reported&lt;SUP&gt; &lt;/SUP&gt;smoking cessation as a secondary outcome. The trials enrolled&lt;SUP&gt; &lt;/SUP&gt;a total of 2767 smokers, gave nicotine replacement therapy for&lt;SUP&gt; &lt;/SUP&gt;6-18 months, and lasted 12-26 months. 6.75% of smokers receiving&lt;SUP&gt; &lt;/SUP&gt;nicotine replacement therapy attained sustained abstinence for&lt;SUP&gt; &lt;/SUP&gt;six months, twice the rate of those receiving placebo (relative&lt;SUP&gt; &lt;/SUP&gt;risk (fixed effects) 2.06, 95% confidence interval 1.34 to 3.15;&lt;SUP&gt; &lt;/SUP&gt;(random effects) 1.99, 1.01 to 3.91; five trials). The number&lt;SUP&gt; &lt;/SUP&gt;needed to treat was 29. All other cessation and reduction outcomes&lt;SUP&gt; &lt;/SUP&gt;were significantly more likely in smokers given nicotine replacement&lt;SUP&gt; &lt;/SUP&gt;therapy than those given placebo. There were no statistically&lt;SUP&gt; &lt;/SUP&gt;significant differences in adverse events (death, odds ratio&lt;SUP&gt; &lt;/SUP&gt;1.00, 95% confidence interval 0.25 to 4.02; serious adverse&lt;SUP&gt; &lt;/SUP&gt;events, 1.16, 0.79 to 1.50; and discontinuation because of adverse&lt;SUP&gt; &lt;/SUP&gt;events, 1.25, 0.64 to 2.51) except nausea, which was more common&lt;SUP&gt; &lt;/SUP&gt;with nicotine replacement therapy (8.7% &lt;I&gt;v&lt;/I&gt; 5.3%; odds ratio 1.69,&lt;SUP&gt; &lt;/SUP&gt;95% confidence interval 1.21 to 2.36).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Conclusions&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;Available trials indicate that nicotine replacement&lt;SUP&gt; &lt;/SUP&gt;therapy is an effective intervention in achieving sustained&lt;SUP&gt; &lt;/SUP&gt;smoking abstinence for smokers who have no intention or are&lt;SUP&gt; &lt;/SUP&gt;unable to attempt an abrupt quit. Most of the evidence, however,&lt;SUP&gt; &lt;/SUP&gt;comes from trials with regular behavioural support and monitoring&lt;SUP&gt; &lt;/SUP&gt;and it is unclear whether using nicotine replacement therapy&lt;SUP&gt; &lt;/SUP&gt;without regular contact would be as effective.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187303</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=187303]]&gt;</url>
    <title>Equal treatment: closing the gap.</title>
    <publicationDate>2006-10-31T00:00:00</publicationDate>
    <publisher>Disability Rights Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A formal investigation into physical health inequalities experienced by people with learning disabilities and/or mental health problems.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Equal treatment: closing the gap.&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The acid test of a national health service is not whether it works for people who are generally healthy but whether it benefits those with the shortest life expectancy, the greatest problems accessing services and the biggest risk that poor health will stop them taking part in society. This investigation has revealed an inadequate response from the health services and governments in England and Wales to the major physical health inequalities experienced by some of the most socially excluded citizens: those with learning disabilities and/or mental health problems. This includes the one million people with learning disabilities, 200,000 people with schizophrenia or bipolar disorder and six million people with depression in England and Wales. &lt;/P&gt;
&lt;P&gt;It identifies practical recommendations that could make a significant difference to reducing those inequalities and to meeting the present government’s overall objectives, including to reduce premature mortality and deliver earlier, more cost-effective interventions. &lt;/P&gt;
&lt;P&gt;A step change in the delivery of health services to these groups is needed. The Disability Equality Duty (DED), in force from December 2006, is designed to provide the impetus for the public sector to improve outcomes for disabled people. This investigation provides an invaluable resource for health organisations working to meet their new duty, not least by setting out a clear evidence base for proposed actions. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345872</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=2B3429B3-1143-DFD0-7E5A-4BE3FDD763CC&amp;ext=pdf]]&gt;</url>
    <title>Ethical Practice Psychological Research Online Guidelines</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A supplementary guidance document to the Code of Ethics and Conduct, focusing on additional ethical and practice issues inherent in internet mediated research.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>383440</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/69.extract]]&gt;</url>
    <title>Evidence based mental health and Web 2.0</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=intro class="section intro"&gt;
&lt;H2&gt;Introduction: Web 1.0 versus Web 2.0&lt;/H2&gt;
&lt;P id=p-1&gt;Since its introduction in the early 1990s, the web has evolved significantly. Initially, most websites had a passive user role and either displayed static information or facilitated online transactions. However, recently the web has become more interactive and many of the most popular websites are now online applications which depend heavily on user participation. &lt;/P&gt;
&lt;P id=p-2&gt;This participatory model of web usage has come to be loosely known as ‘Web 2.0’ and the initial non-participatory web correspondingly as ‘Web 1.0’. The term has been popular since 2004&lt;SPAN class=xref-bibr&gt;1&lt;/SPAN&gt; &lt;SPAN class=xref-bibr&gt;2&lt;/SPAN&gt; and it is as much ideological as technical. Applications associated with Web 2.0 commonly facilitate the creation and exchange of user generated content. Examples include blogs, social networking sites, wikis and media sharing sites. These sorts of sites have become some of the most visited and discussed about properties on the internet. &lt;/P&gt;
&lt;P id=p-3&gt;Web 2.0 applications are predominately easy to use and free of charge and respond much more rapidly to events than do traditional media. They offer new ways for clinicians to access, share and evaluate healthcare information. Due to their interactive nature they are constantly evolving and enriching and anyone who uses them assists in their development. However, they also have limitations that need to be understood. &lt;/P&gt;
&lt;P id=p-4&gt;Healthcare professionals have yet to take full advantage of Web 2.0 technologies. In this article I will discuss and critique Web 2.0's major applications and their potential for the practice of evidence based medicine and mental health. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-2 class=section&gt;
&lt;H2&gt;Web 2.0 Applications&lt;/H2&gt;
&lt;P id=p-5&gt;Blogs, wikis and microblogs (together with Really Simple Syndication (RSS)) are reviewed first as they have had the greatest impact and share some of the same advantages and disadvantages. &lt;/P&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Blogs, RSS, wikis and microblogging&lt;/H3&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H4&gt;Blogs&lt;/H4&gt;
&lt;P id=p-6&gt;The blog was one of the earliest social software tools. Blogs are a very popular form of expression and account for 1.2% of UK internet traffic.&lt;SPAN class=xref-bibr&gt;3&lt;/SPAN&gt; They are … &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words.&lt;/EM&gt; &lt;EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/3/69.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293157</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bap.org.uk/consensus/antidepressant.pdf]]&gt;</url>
    <title>Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines</title>
    <publicationDate>2008-08-27T00:00:00</publicationDate>
    <publisher>British Association for Psychopharmacology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>On Behalf of the Consensus Meeting; endorsed by the British Association for Psychopharmacology.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A revision of the 2000 British Association for Psychopharmacology evidence based guidelines for treating depressive disorders with antidepressants was undertaken to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in May 2006. Key areas in treating depression were reviewed, and the strength of evidence and clinical implications were considered. The guidelines were drawn up after extensive feedback from participants and interested parties. A literature review is provided, which identifies the quality of evidence to inform the recommendations, the strength of which are based on the level of evidence. &lt;/P&gt;
&lt;P&gt;These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse, and stopping treatment.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296256</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/]]&gt;</url>
    <title>Evidence-Based Mental Health</title>
    <publicationDate>2008-10-20T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"An enormous amount of work goes on behind the scenes to make sure that Evidence-Based Mental Health provides you with all the information you need. We scan over 50 journals and around 25,000 articles a year so that we can identify the most important and valid 96 research articles and publish them in the journal. This means that if you read Evidence-Based Mental Health, you’ll get all the important research material you need in just 4 volumes that are published throughout the year, saving you all important time to concentrate on other things."&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Electronic pages 
&lt;LI&gt;EBMH notebook 
&lt;LI&gt;Prognosis 
&lt;LI&gt;Therapeutics 
&lt;LI&gt;Aetiology 
&lt;LI&gt;Prevalence 
&lt;LI&gt;Miscellaneous&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Published four times per year.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Available from the NLH, embargo: 1 year.&lt;/P&gt;
&lt;P&gt;You can register for an Athens log-in by following &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;this link&lt;/A&gt;. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328873</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/about/docs/research-paper-alcohol-misusing.pdf]]&gt;</url>
    <title>Evidence-based practice? The National Probation Service’s work with alcohol-misusing offenders</title>
    <publicationDate>2009-09-30T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE,INDIVIDUAL BEHAVIOUR,DISADVANTAGED GROUPS,MONTHLY ADDITIONS,PUBLIC HEALTH,DETERMINANTS,ALCOHOL CONSUMPTION,PRISONS,CUSTODIAL CENTRES,BUILDINGS,SETTINGS,POPULATIONS,GROUPS,CRIME,ANTISOCIAL BEHAVIOUR,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This process study by the Institute for Criminal Policy Research (ICPR), King’s College London, examined the National Probation Service’s work with alcohol-misusing offenders by describing and critically appraising: the procedures in place for identifying and intervening with offenders who have alcohol problems; the extent to which this work complied with the principles set out in Models of care for alcohol misusers (MoCAM); and arrangements for the commissioning and delivery of alcohol treatment requirements.]]&gt;</body>
  </document>
  <document>
    <id>395084</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/exercise-linked-to-lower-depression.aspx]]&gt;</url>
    <title>Exercise link to low depression</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Getting sweaty in your spare time means you’ll be twice as likely to stave off depression than someone who doesn’t,” the &lt;EM&gt;Daily Mirror &lt;/EM&gt;has reported. However, the newspaper says that the link only exists when people get active for their own leisure, but not when doing a physically demanding job.&lt;/P&gt;
&lt;P&gt;The news is based on a large study of Norwegian citizens, which found that higher levels of leisure-time activity (intense or light) were associated with reduced likelihood of depression, although work-based activity was not. There are some shortcomings to the research, which the researchers themselves discuss. But importantly, this study cannot prove the direction of the link, i.e. whether exercising more leads to less depressive symptoms or the equally plausible case that people who are more depressed are less likely to exercise.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397865</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/nmhdu-factfile-1.pdf]]&gt;</url>
    <title>Factfile 1 - Mental health and employment</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The first of seven factfiles published by the National Mental Health Development Unit (NMHDU) titled&amp;nbsp;&lt;EM&gt;Mental health and employment&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;The Government estimates that over five million people suffer from multiple disadvantages and 3.7 million do so persistently. Poor mental health, poor housing, worklessness and income poverty are all indicators of multiple disadvantage.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397869</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/nmhdu-factfile-2.pdf]]&gt;</url>
    <title>Factfile 2 - Mental health and housing</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The second of seven factfiles published by the National Mental Health Development Unit (NMHDU) titled&amp;nbsp;&lt;EM&gt;Mental health and housing.&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Good quality, affordable, safe housing is essential to our wellbeing. Mental health and housing are closely interlinked. Mental ill health can lead to homelessness. Homelessness, poor quality housing and housing insecurity can lead to mental health issues. Mental ill health can also make it difficult for people to find and maintain good quality housing.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397878</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/nmhdu-factfile-3.pdf]]&gt;</url>
    <title>Factfile 3 - The costs of mental ill health</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The third of seven factfiles published by the National Mental Health Development Unit (NMHDU) titled&amp;nbsp;&lt;EM&gt;The costs of mental ill health.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;‘The financial costs of the adverse effects of mental illness on people’s quality of life are estimated at £41.8 billion per annum in England. Wider costs to the national economy in terms of welfare benefits, lost productivity at work etc. amount to some £77 billion a year’&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397884</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/nmhdu-factfile-4.pdf]]&gt;</url>
    <title>Factfile 4 - Public mental health and well-being</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The fourth&amp;nbsp;of seven factfiles published by the National Mental Health Development Unit (NMHDU) titled&amp;nbsp;&lt;EM&gt;Public mental health and well-being. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Good mental health and well-being are fundamental to flourishing individuals,&lt;BR&gt;families and communities and to national economic productivity and social cohesion&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397906</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=397906]]&gt;</url>
    <title>Factfile 5 - Equalities in mental health</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The&amp;nbsp;fifth of seven factfiles published by the National Mental Health Development Unit (NMHDU) titled&amp;nbsp;&lt;EM&gt;Equalities in mental health.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;‘Inequalities are a matter of life and death, of health and sickness, of wellbeing and misery. Creating a fairer society is fundamental to improving&lt;BR&gt;the health of the whole population and ensuring a fairer distribution of good health’&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397907</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/nmhdu-factfile-6.pdf]]&gt;</url>
    <title>Factfile 6 - Stigma and discrimination in mental health</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The sixth of seven factfiles published by the National Mental Health Development Unit (NMHDU) titled&amp;nbsp;&lt;EM&gt;Stigma and discrimination in mental health. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;‘Nearly nine out of ten people (87%) with mental health problems have been affected by stigma and discrimination’&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>397909</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/nmhdu-factfile-7.pdf]]&gt;</url>
    <title>Factfile 7 - Ensuring greater access to talking therapies</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The&amp;nbsp;seventh of seven factfiles published by the National Mental Health Development Unit (NMHDU) titled&amp;nbsp;&lt;EM&gt;Ensuring greater access to talking therapies.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;‘Improving Access to Psychological Therapies: providing NICE approved, evidence based treatments for mild to moderate depression and anxiety disorders’&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388590</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/campaigns/fairdeal.aspx]]&gt;</url>
    <title>Fair Deal for Mental Health</title>
    <publicationDate>2010-09-15T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2&gt;What is Fair Deal?&lt;/H2&gt;
&lt;P&gt;Our 3 year campaign founded on the views of psychiatrists, and our networks of service users and carers covering eight priority areas:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/funding.aspx" target="_blank"&gt;&lt;STRONG&gt;F&lt;/STRONG&gt;unding&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/accesstoservices.aspx" target="_blank"&gt;&lt;STRONG&gt;A&lt;/STRONG&gt;ccess to Services&lt;/A&gt;&lt;/LI&gt;
&lt;LI style="COLOR: rgb(0,63,114)"&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/in-patientservices.aspx" target="_blank"&gt;&lt;STRONG&gt;I&lt;/STRONG&gt;n-patient Services&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/recovery.aspx" target="_blank"&gt;&lt;STRONG&gt;R&lt;/STRONG&gt;ecovery&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/discriminationstigma.aspx" target="_blank"&gt;&lt;STRONG&gt;D&lt;/STRONG&gt;iscrimination and Stigma&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/engagementwithservicesusers.aspx" target="_blank"&gt;&lt;STRONG&gt;E&lt;/STRONG&gt;ngagement with service users/carers&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/availabilityoftherapies.aspx" target="_blank"&gt;&lt;STRONG&gt;A&lt;/STRONG&gt;vailability of psychological therapies&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/linkingphysicalandmh.aspx" target="_blank"&gt;&lt;STRONG&gt;L&lt;/STRONG&gt;inking mental and physical health&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;linked by the common theme of working towards equality for people with mental health problems.&lt;/P&gt;
&lt;H2&gt;What&amp;nbsp;will happen?&lt;/H2&gt;
&lt;P style="COLOR: rgb(0,63,114)" class=ImmTextAlign_Left&gt;&lt;STRONG&gt;Involvement&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Fair Deal will centrally involve our members, and service users and carers to articulate their experience, hopes and concerns.&lt;/P&gt;
&lt;P style="COLOR: rgb(0,63,114)" class="A4 ImmTextAlign_Left"&gt;&lt;STRONG&gt;Awareness building&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=A4&gt;Fair Deal will raise awareness of our priority areas amongst Parliamentarians and national assembly representatives, across the media and with the general public.&lt;/P&gt;
&lt;P style="COLOR: rgb(0,63,114)" class="A4 ImmTextAlign_Left"&gt;&lt;STRONG&gt;Action&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=A4&gt;We will work in partnership with voluntary sector organisations and other healthcare professionals on individual projects and specific campaigns over the next 3 years.&lt;/P&gt;
&lt;H2&gt;Influence the Campaign&lt;/H2&gt;
&lt;P&gt;The Fair Deal campaign was founded on the views of psychiatrists, service users, and carers.&amp;nbsp; We want to continue this involvement and invite service providers, policy makers, politicians and journalists to take part - send us your views, experiences and case examples.&lt;/P&gt;
&lt;H2&gt;Support the Campaign&lt;/H2&gt;
&lt;P&gt;Show your support for a Fair Deal for people with mental health problems.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/testfairdealsignup.aspx" target="_blank"&gt;Sign up and receive campaign updates.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/testfairdealfeedback.aspx" target="_blank"&gt;Feed back to us&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>223701</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=223701]]&gt;</url>
    <title>Feeding Minds - The impact of food on mental health: Executive summary</title>
    <publicationDate></publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,FOOD &amp; NUTRITION,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,PROFESSIONAL PRACTICE,SERVICES,HEALTHCARE &amp; HEALTH SERVICES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>The time is now right for nutrition to become a mainstream, everyday component of mental health care</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Feeding Minds - The impact of food on mental health: Executive summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Foreword&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The brain is the platform for the mind and therefore the platform for our mental health. While our understanding of how the brain works is less advanced than our understanding of the body's other organs, much of the practical knowledge we do have of the brain has yet to be embraced and put to good use. This represents a spectrum of wasted opportunities to promote mental health and prevent mental ill-health in our society. &lt;/P&gt;
&lt;P&gt;One of the clearest examples is the role of nutrition in relation to mental health. We know that the brain is made up in large part of essential fatty acids, water and other nutrients. We know that food affects how we feel, think and behave. In fact, we know that dietary interventions may hold the key to a number of the mental health challenges our society is facing. Yet we rarely invest in developing this knowledge, and a relatively tiny - but growing - number of professionals are puting it to effective use. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344599</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/schizophrenia-psychosis-fish-oil.aspx]]&gt;</url>
    <title>Fish oil may ease psychosis</title>
    <publicationDate>2010-02-02T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Taking a daily fish oil capsule can stave off mental illness in those at highest risk,” BBC News has reported.&lt;/P&gt;
&lt;P&gt;The news comes from a study that enrolled 81 people at high risk of psychosis, and randomly assigned them to take either fish oil capsules or a dummy pill for three months. After a year, those in the fish oils group were about a&amp;nbsp;quarter less likely to have&amp;nbsp;developed a psychotic illness such as schizophrenia.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268994</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/scmh_forensic_factfile_2007.pdf]]&gt;</url>
    <title>Forensic Mental Health Services: Facts and figures on current provision</title>
    <publicationDate>2007-09-10T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,BUILDINGS,PRISONS,CUSTODIAL CENTRES,MONTHLY ADDITIONS,SETTINGS,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report by Max Rutherford and Sean Duggan</description>
    <body>&lt;![CDATA[ &lt;P&gt;Forensic mental health services provide care for people who have come into contact with the criminal justice system and have been transferred to secure NHS services.&lt;/P&gt;
&lt;P&gt;This factfile brings together figures from many sources about forensic services and shows that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fewer than half of people admitted to secure hospital stay for more than five years. 
&lt;LI&gt;Most people are admitted to secure hospitals from prison. 
&lt;LI&gt;Over one-third of people detained in 2004 had committed violent offences. 
&lt;LI&gt;About 40 people per quarter have to wait in prison for over three months before a transfer to secure hospital. 
&lt;LI&gt;Fewer than one patient in ten re-offends within two years of being discharged from secure hospital. 
&lt;LI&gt;In 2005, 26 people died while being detained in a secure hospital.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>296532</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.foresight.gov.uk/Mental%20Capital/Mental_capital_&amp;_wellbeing_Exec_Sum.pdf]]&gt;</url>
    <title>Foresight Mental Capital and Wellbeing Project (2008)</title>
    <publicationDate>2008-10-21T00:00:00</publicationDate>
    <publisher>Foresight</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PROJECTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,GEOGRAPHY,NATIONAL,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,2008-NOVEMBER,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is the final project report.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The aim of the Foresight Project on Mental Capital and Wellbeing&amp;nbsp;has been to use the best available scientific and other evidence to develop a vision for:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The opportunities and challenges facing the UK over the next 20 years and beyond, and the implications for everyone’s “mental capital” and “mental wellbeing”.&lt;/LI&gt;
&lt;LI&gt;What we all need to do to meet the challenges ahead, so that everyone can realise their potential and flourish in the future.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The Project seeks to highlight where action is most important, and how we can better allocate available resources.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.foresight.gov.uk/OurWork/ActiveProjects/Mental%20Capital/Welcome.asp" target="_blank"&gt;Click here to link to the Foresight Project on Mental Capital and Wellbeing (July 2006 - October 2008)&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291089</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bma.org.uk/ap.nsf/AttachmentsByTitle/PDFforevercool/$FILE/forevercool.pdf]]&gt;</url>
    <title>Forever cool: the influence of smoking imagery on young people</title>
    <publicationDate>2008-07-25T00:00:00</publicationDate>
    <publisher>BMA</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Forever cool: the influence of smoking imagery on young people calls on the UK Governments to introduce a range of tough measures aimed at reducing young people’s exposure to positive images of smoking.</description>
    <body>&lt;![CDATA[ Forever cool: the influence of smoking imagery on young people calls on the UK Governments to introduce a range of tough measures aimed at reducing young people’s exposure to positive images of smoking.]]&gt;</body>
  </document>
  <document>
    <id>263048</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38638&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>From Pregnancy to Early Childhood</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Mental Health Foundation commissioned this report on the basis of its National Enquiry into
the Mental Health of Children and Young People, ‘Bright Futures’. It aims to summarise a
variety of interventions designed to improve parenting, family functioning and young children’s
mental health and to promote thinking about future work rather a definitive summary of existing
knowledge.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Mental Health Foundation commissioned this report on the basis of its National Enquiry into the Mental Health of Children and Young People, ‘Bright Futures’. It aims to summarise a variety of interventions designed to improve parenting, family functioning and young children’s mental health and to promote thinking about future work rather a definitive summary of existing knowledge. This summary defines the key points from the full report, which comprises two volumes. Volume 1 is a written report and Volume 2 summarises the research in a number of tables.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=42678&amp;amp;type=Full&amp;amp;servicetype=Attachment" target="_blank"&gt;From Pregnancy to Early Childhood (Vol. 2)&lt;/A&gt; (Link to full-text PDF)&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>278017</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.socialinclusion.org.uk/publications/NSIPDSReview.pdf]]&gt;</url>
    <title>From segregation to inclusion: where are we now?</title>
    <publicationDate>2008-01-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A review of progress towards the implementation of the mental health day services commissioning guidance.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;National Review of Day Services Published - Jan 2008&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A review of mental health day services in England was published by the Department of Health and the National Social Inclusion Programme (NSIP) on 24th January.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The modernisation of day services has proven challenging in many areas since commissioning guidance was published in February 2006 . The review, entitled From segregation to inclusion: Where are we now? , looks at how things have progressed since then and identifies lessons that can be learnt from those areas where services have undergone change.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;“Over £123 million a year is spent on mental health day services” said Ben Taylor, National Day Services Lead at NSIP. “As a result it is important that they appeal to a wider range of people and are more effective at supporting them to fulfil their aspirations and take opportunities than they often have been in the past”.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The review found that the process for day services modernisation is one in which necessary challenges need to be addressed with care and it is intended that the document will help people to manage the changes. “This isn’t about throwing the baby out with the bathwater” emphasised Ben Taylor. “Day services have a vital role to play in the support and social inclusion of many people with mental health problems, but they must be supported to do it as well as possible”.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319343</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/document.rm?id=8243]]&gt;</url>
    <title>Funding adult social care in england</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Kings fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In this briefing Teresa Poole sets out how adult social care is currently funded, outlines some of the main criticisms of the current arrangements and describes the types of changes the government might consider for its reform.]]&gt;</body>
  </document>
  <document>
    <id>378338</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Gambling-addiction-and-genetics.aspx]]&gt;</url>
    <title>Gambling addiction linked to genes</title>
    <publicationDate>2010-06-11T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Gambling addiction can be inherited,” the &lt;EM&gt;Daily Mail&lt;/EM&gt; reported.&amp;nbsp;The newspaper&amp;nbsp;said, “if one of your parents is addicted to gambling the odds are high that you will be as well, research has revealed”.&lt;/P&gt;
&lt;P&gt;This study in 2,889 pairs of twins investigated the role of genetic and environmental factors in the development of gambling addiction. The researchers were particularly interested in whether these factors interact in the same way in women’s gambling addiction as in men’s.&lt;/P&gt;
&lt;P&gt;The study found that identical twins who were gamblers&amp;nbsp;were more likely to have a twin who was also a gambler than non-identical twins. The researchers suggest that this association was more to do with a&amp;nbsp;genetic link than environmental factors.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346702</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/policy/policyandparliamentary/parliamentandpublicaffairs/generalelection2010.aspx]]&gt;</url>
    <title>GENERAL ELECTION 2010: Achieving a fair deal for mental health</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In the run up to the general election The Royal College of Psychiatrists&amp;nbsp;have launched an area to find out more information about the forthcoming General Election and how the outcome will affect mental health services in the U.K.]]&gt;</body>
  </document>
  <document>
    <id>296423</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science/journal/01638343]]&gt;</url>
    <title>General Hospital Psychiatry</title>
    <publicationDate></publicationDate>
    <publisher>ScienceDirect</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"General Hospital Psychiatry will publish original articles, case reports and brief communications on: biopsychosocial approaches to medicine; liaison-consultation psychiatry; psychosomatic medicine; emergency and crisis psychiatry; the relationship of psychiatric services to general medical systems; and new directions in medical education that stress psychiatry's role in primary care, family practice, and continuing education."&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Psychiatry and Primary Care 
&lt;LI&gt;Psychiatric-Medical Comorbidity 
&lt;LI&gt;Symptom Research 
&lt;LI&gt;Emergency Psychiatry in the General Hospital 
&lt;LI&gt;Original Contributions 
&lt;LI&gt;Case Reports 
&lt;LI&gt;Letters to the Editor&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Published six times per year.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392200</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/genes-affect-alcohol-tolerance.aspx]]&gt;</url>
    <title>Genes 'affect alcohol tolerance'</title>
    <publicationDate>2010-10-21T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“'Tipsy' alcohol gene 'could help curb alcoholism'”, reads a BBC News headline. It said, “US researchers believe 10% to 20% of people have a version of the gene that may offer some protection against alcoholism.”&lt;/P&gt;
&lt;P&gt;This story is based on a study of 238 college students and their siblings, which investigated how a person’s genes might affect how well they can tolerate alcohol. It found that a region of DNA containing the CYP2E1 gene is linked with alcohol tolerance. These findings will need to be confirmed in other studies.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327438</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nature.com/ng/journal/v41/n10/abs/ng.442.html]]&gt;</url>
    <title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</title>
    <publicationDate>2009-09-28T00:00:00</publicationDate>
    <publisher>Nature Genetics</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,CAUSES AND PREVENTION,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The authors&amp;nbsp;conducted a genome-wide association study among 2,323 individuals with sporadic amyotrophic lateral sclerosis (ALS) and 9,013 control subjects and evaluated all SNPs with &lt;I&gt;P&lt;/I&gt; &amp;lt; 1.0&amp;nbsp;x 10&lt;SUP&gt;-4&lt;/SUP&gt; in a second, independent cohort of 2,532 affected individuals and 5,940 controls. Analysis of the genome-wide data revealed genome-wide significance for one SNP, rs12608932, with &lt;I&gt;P&lt;/I&gt; = 1.30 x 10&lt;SUP&gt;-9&lt;/SUP&gt;. This SNP showed robust replication in the second cohort (&lt;I&gt;P&lt;/I&gt; = 1.86 x 10&lt;SUP&gt;-6&lt;/SUP&gt;), and a combined analysis over the two stages yielded &lt;I&gt;P&lt;/I&gt; = 2.53 x 10&lt;SUP&gt;-14&lt;/SUP&gt;. The rs12608932 SNP is located at 19p13.3 and maps to a haplotype block within the boundaries of &lt;I&gt;UNC13A&lt;/I&gt;, which regulates the release of neurotransmitters such as glutamate at neuromuscular synapses. Follow-up of additional SNPs showed genome-wide significance for two further SNPs (rs2814707, with &lt;I&gt;P&lt;/I&gt; = 7.45&amp;nbsp;x 10&lt;SUP&gt;-9&lt;/SUP&gt;, and rs3849942, with &lt;I&gt;P&lt;/I&gt; = 1.01 x 10&lt;SUP&gt;-8&lt;/SUP&gt;) in the combined analysis of both stages. These SNPs are located at chromosome 9p21.2, in a linkage region for familial ALS with frontotemporal dementia found previously in several large pedigrees.]]&gt;</body>
  </document>
  <document>
    <id>275468</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://website.scmh.org.uk/80256FBD004F6342/vWeb/pcKHAL796MYK]]&gt;</url>
    <title>Getting the Basics Right - Developing a primary care mental health service in prisons</title>
    <publicationDate>2007-11-22T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SECONDARY &amp; TERTIARY SERVICES,PUBLIC HEALTH,BUILDINGS,PRISONS,SERVICES,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS,SETTINGS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This policy paper looks at ways in which this could be achieved and makes policy recommendations to help the NHS build up a primary care mental health service in every English prison.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Most primary care in prisons is able only to address people’s physical health problems. As a result, prisoners with common mental health conditions frequently go untreated.&lt;/P&gt;
&lt;P&gt;Government policy since 2001 has been for prisoners to receive health care that is ‘equivalent’ to that which they would get outside. A good quality primary care mental health service in prison would devote more time to addressing prisoners’ needs.&lt;/P&gt;
&lt;P&gt;This policy paper looks at ways in which this could be achieved and makes policy recommendations to help the NHS build up a primary care mental health service in every English prison.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325074</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/news/acute-care--getting-the-medicines-right-published/?keywords=Getting+the+medicines+right%3A+medicines+management+in+adult+and+older+adult+acute+mental+health+wards]]&gt;</url>
    <title>Getting the medicines right: medicines management in adult and older adult acute mental health wards</title>
    <publicationDate>2009-07-31T00:00:00</publicationDate>
    <publisher>The National Mental Health Development Unit</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The document provides:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;An evaluation of specific pharmacy led medicines management schemes proposed for adult and older adult acute mental health wards. &lt;/LI&gt;
&lt;LI&gt;Recommendations about the suitability of those medicines management schemes for adult and older adult acute mental health wards. &lt;/LI&gt;
&lt;LI&gt;Key messages from service users and carers arising from the consultation, and a 5-stage model framework for getting medicines management right on acute mental health wards.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>325053</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/publications/collegereports/cr/cr154.aspx]]&gt;</url>
    <title>Good Psychiatric Practice (Third edition)</title>
    <publicationDate>2009-05-31T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=ImmTextAlign_Left&gt;&lt;EM&gt;Good Psychiatric Practice (third edition)&amp;nbsp;&lt;/EM&gt;sets out standards of practice for psychiatrists. It is aligned to the General Medical Council’s (GMC’s) &lt;EM&gt;Good Medical Practice&lt;/EM&gt; (2006), the standards for all medical practitioners. In this edition, the GMC standards are followed by the additional standards required for good psychiatric practice. Repetition of standards is avoided where possible. &lt;EM&gt;Good Medical Practice&lt;/EM&gt; (2006) is not reproduced in full in this document and is available at &lt;A href="http://www.gmc-uk.org/guidance/good_medical_practice/index.asp" target="_blank"&gt;www.gmc-uk.org/guidance/good_medical_practice/index.asp&lt;/A&gt;.&lt;/P&gt;
&lt;P class=ImmTextAlign_Left&gt;CR154 replaces the second edition of &lt;EM&gt;Good Psychiatric Practice&lt;/EM&gt; (CR125). The document has been revised with the GMC’s approach to revalidation in mind. The standards set out in &lt;EM&gt;Good Psychiatric Practice&lt;/EM&gt; are those psychiatrists will need to meet for recertification in the UK. Reference is also made to legal principles relevant to the UK. The standards of practice do, however, apply to members of the Royal College of Psychiatrists, or other psychiatrists, whatever their grade, whatever the clinical setting and wherever they are practising.&lt;/P&gt;
&lt;P class=ImmTextAlign_Left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa61&gt;&lt;STRONG&gt;CR154 covers the following areas:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=Pa61&gt;The duties of a doctor registered with the GMC&lt;/LI&gt;
&lt;LI class=Pa61&gt;Core attributes – good psychiatrists&lt;/LI&gt;
&lt;LI class=Pa61&gt;Good clinical care&lt;/LI&gt;
&lt;LI class=Pa61&gt;Maintaining good practice&lt;/LI&gt;
&lt;LI class=Pa61&gt;Teaching, training, appraising and assessing&lt;/LI&gt;
&lt;LI class=Pa61&gt;Relationships with patients&lt;/LI&gt;
&lt;LI class=Pa61&gt;Consent&lt;/LI&gt;
&lt;LI class=Pa61&gt;Confidentiality&lt;/LI&gt;
&lt;LI class=Pa61&gt;Working with colleagues&lt;/LI&gt;
&lt;LI class=Pa61&gt;Working with management&lt;/LI&gt;
&lt;LI class=Pa61&gt;Research&lt;/LI&gt;
&lt;LI class=Pa61&gt;Probity&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>317749</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/CR154.pdf]]&gt;</url>
    <title>Good psychiatric practice (third edition) PDF</title>
    <publicationDate>2009-05-14T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=ImmTextAlign_Left&gt;&lt;EM&gt;Good Psychiatric Practice (third edition)&amp;nbsp;&lt;/EM&gt;sets out standards of practice for psychiatrists. It is aligned to the General Medical Council’s (GMC’s) &lt;EM&gt;Good Medical Practice&lt;/EM&gt; (2006), the standards for all medical practitioners. In this edition, the GMC standards are followed by the additional standards required for good psychiatric practice. Repetition of standards is avoided where possible. &lt;EM&gt;Good Medical Practice&lt;/EM&gt; (2006) is not reproduced in full in this document and is available at &lt;A href="http://www.gmc-uk.org/guidance/good_medical_practice/index.asp" target="_blank"&gt;www.gmc-uk.org/guidance/good_medical_practice/index.asp&lt;/A&gt;.&lt;/P&gt;
&lt;P class=ImmTextAlign_Left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=ImmTextAlign_Left&gt;CR154 replaces the second edition of &lt;EM&gt;Good Psychiatric Practice&lt;/EM&gt; (CR125). The document has been revised with the GMC’s approach to revalidation in mind. The standards set out in &lt;EM&gt;Good Psychiatric Practice&lt;/EM&gt; are those psychiatrists will need to meet for recertification in the UK. Reference is also made to legal principles relevant to the UK. The standards of practice do, however, apply to members of the Royal College of Psychiatrists, or other psychiatrists, whatever their grade, whatever the clinical setting and wherever they are practising.&lt;/P&gt;
&lt;P class=ImmTextAlign_Left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa61&gt;&lt;STRONG&gt;CR154 covers the following areas:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=Pa61&gt;The duties of a doctor registered with the GMC&lt;/LI&gt;
&lt;LI class=Pa61&gt;Core attributes – good psychiatrists&lt;/LI&gt;
&lt;LI class=Pa61&gt;Good clinical care&lt;/LI&gt;
&lt;LI class=Pa61&gt;Maintaining good practice&lt;/LI&gt;
&lt;LI class=Pa61&gt;Teaching, training, appraising and assessing&lt;/LI&gt;
&lt;LI class=Pa61&gt;Relationships with patients&lt;/LI&gt;
&lt;LI class=Pa61&gt;Consent&lt;/LI&gt;
&lt;LI class=Pa61&gt;Confidentiality&lt;/LI&gt;
&lt;LI class=Pa61&gt;Working with colleagues&lt;/LI&gt;
&lt;LI class=Pa61&gt;Working with management&lt;/LI&gt;
&lt;LI class=Pa61&gt;Research&lt;/LI&gt;
&lt;LI class=Pa61&gt;Probity&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>374956</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/Green-exercise-and-mental-health.aspx]]&gt;</url>
    <title>'Green exercise' and mental health</title>
    <publicationDate>2010-05-04T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Five minutes exercising in the countryside boosts mental health,” reported &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;. It said a study has found that “exercising in wilderness areas or near water tended to have the biggest impact on mental state” and that “the greatest health changes were seen in the young and the mentally-ill”.&lt;/P&gt;
&lt;P&gt;This news report is based on research that pooled the results of 10 studies from the University of Essex on the effect of outdoor exercise in green environments on self-esteem and mood. It has a number of limitations, including the fact that all the studies came from the same institution, and more robust results may have been achieved by systematically searching for and pooling all research addressing the same question. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287522</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_084919]]&gt;</url>
    <title>Guidance for GPs, other clinicians and health professionals on the care of gender variant people</title>
    <publicationDate>2008-05-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SEXUAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This publication is written by a team from the Gender Identity Research and Education Society which includes doctors and trans people. It provides an overview of care and discussion of the issues involved in treating those experiencing gender variant conditions.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This publication is written by a team from the Gender Identity Research and Education Society which includes doctors and trans people. It provides an overview of care and discussion of the issues involved in treating those experiencing gender variant conditions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316034</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098828?IdcService=GET_FILE&amp;dID=192560&amp;Rendition=Web]]&gt;</url>
    <title>Guidance on IMHAs’ access to records</title>
    <publicationDate>2009-05-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Department of Health has been asked for advice on whether section 130B of the Mental Health Act 1983 allows independent mental health advocates (IMHAs) to see information in patients’ records which would not be disclosed directly to the patient and, if so, whether IMHAs may share that information with patients.]]&gt;</body>
  </document>
  <document>
    <id>345865</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=69F25E9C-C686-9D12-450E-D4FB9AC51723&amp;ext=pdf]]&gt;</url>
    <title>Guidance on Mental Health Act for the Approved Clinician Peer Review Panel</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This guidance is for the Approved Clinician Peer Review Panel members who are considering submissions made by registered psychologists for approval as approved clinician under the Mental Health Act 1983. This panel has, explicitly, an advisory and formative function and is neither regulatory nor summative in purpose. Approval and judgement of competency resides solely within the powers of the statutory approving authority.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>333442</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_110256.pdf]]&gt;</url>
    <title>Guidance on the consumption of alcohol by children and young people. A report by the Chief Medical Officer</title>
    <publicationDate>2009-12-17T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILD AND ADOLESCENT CONDITIONS,SUBSTANCE MISUSE,MENTAL HEALTH,INDIVIDUAL BEHAVIOUR,YOUNG PEOPLE,CHILDREN,HEALTH PROTECTION,POPULATION BASED &amp; PREVENTATIVE SERVICES,MONTHLY ADDITIONS,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,ALCOHOL CONSUMPTION,HEALTH SERVICES,SERVICES,HEALTHCARE &amp; HEALTH SERVICES,POPULATIONS,AGE GROUPS,GROUPS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In April 2008 the Chief Medical Officer was asked by the Secretaries of State for Health and for Children, Schools and Families to prepare guidance on the consumption of alcohol by children and young people.&lt;/P&gt;
&lt;P&gt;Over the last decade, public concern about the impact of alcohol on health and society has steadily mounted.&lt;/P&gt;
&lt;P&gt;Particular concern has centred on the level and pattern of drinking among children and young people and its consequences on health, crime, violence and antisocial behaviour.&lt;/P&gt;
&lt;P&gt;The key role of the Chief Medical Officer is to provide, for the Government and the public, advice without fear or favour. The best scientific evidence has been sought and used as the basis not just for presenting the facts, but also for making well-founded policy recommendations.&lt;/P&gt;
&lt;P&gt;The work to support the Department of Health in producing this report has been carried out by Professor Mark Bellis and his team at the Centre for Public Health, Liverpool John Moores University.&lt;/P&gt;
&lt;P&gt;This guidance was published initially in draft form as part of a consultation on advice and information for children, young people and alcohol, being facilitated in England by the Department for Children, Schools and Families. The findings from this consultation have been collated and utilised in the development of this final version of the Chief Medical Officer’s guidance.&lt;/P&gt;
&lt;P&gt;How to use this document&lt;/P&gt;
&lt;P&gt;This document is organised into the following sections:&lt;/P&gt;
&lt;P&gt;Section 2: Nature and extent of the problem&lt;BR&gt;provides an overview of drinking patterns and some of their consequences in young people in the UK.&lt;/P&gt;
&lt;P&gt;Section 3: Guidance for the consumption of alcohol by children and young people presents each guideline followed by the rationale, the underpinning scientific evidence and implications. Links are made from the evidence to Section 4 and Section 5.&lt;/P&gt;
&lt;P&gt;Section 4: Review of current policy, guidance and practice contains a summary of relevant information which relates to the guidance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319338</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2009/9789241547543_eng.pdf]]&gt;</url>
    <title>Guidelines for the psychosocially Assisted Pharmacological Treatment of Opioid Dependence PDF</title>
    <publicationDate></publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DRUG USE DISORDERS,ADULT CONDITIONS,MENTAL HEALTH,DETERMINANTS,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,SUBSTANCE MISUSE,MONTHLY ADDITIONS,2009 AUGUST]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT lang=JA face=FrutigerLT-Light size=2&gt;&lt;FONT lang=JA face=FrutigerLT-Light size=2&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;/FONT&gt;These guidelines were developed in response to a resolution from the United Nations Economic and Social Council (ECOSOC), which invited the World Health Organization (WHO), in collaboration with the United Nations Office on Drugs and Crime (UNODC), “to develop and publish minimum requirements and international guidelines on psychosocially assisted pharmacological treatment of persons dependent on opioids”[1].&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;In accordance with WHO policy, the recommendations in these guidelines are based on systematic reviews of the available literature and consultation with a range of experts from different regions of the world.&lt;BR&gt;&lt;/P&gt;&lt;FONT lang=JA face=FrutigerLT-Light size=2&gt;&lt;FONT lang=JA face=FrutigerLT-Light size=2&gt;&lt;/FONT&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>292626</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.handsonscotland.co.uk/index.html]]&gt;</url>
    <title>HandsOnScotland</title>
    <publicationDate>2008-08-22T00:00:00</publicationDate>
    <publisher>HeadsUpScotland</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,BEREAVEMENT AND LOSS,BULLYING,CHILD ABUSE AND NEGLECT,CONDUCT DISORDER,DEPRESSIVE DISORDER,SELF-HARM,EMOTIONAL DISORDERS,EATING DISORDERS,SCHOOL REFUSAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>HandsOnScotland is an online resource for anybody working with children and young people. The website provides practical information and techniques on how to respond helpfully to children and young people's troubling behaviour.</description>
    <body>&lt;![CDATA[ &lt;P&gt;HandsOnScotland is an online resource for anybody working with children and young people. The website provides practical information and techniques on how to respond helpfully to children and young people's troubling behaviour. For more information please visit the website at &lt;A href="http://www.handsonscotland.co.uk/" target="_blank"&gt;www.handsonscotland.co.uk&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The website was commissioned by the Scottish government through HeadsUpScotland and was developed by Playfield Institute (NHS Fife) in partnership with Barnardo's and the University of Dundee. Please note that even though the site was developed in Scotland and has Scotland in the web address, it would be useful for workers throughout who work with children and young people.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125611</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/page.aspx?o=303910]]&gt;</url>
    <title>Health and social inequalities in English adolescents: exploring the importance of school, family and neighbourhood</title>
    <publicationDate></publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILD AND ADOLESCENT CONDITIONS,SCHOOL REFUSAL,EMOTIONAL DISORDERS,CONDUCT DISORDER,BULLYING,MENTAL HEALTH,REPORTS,YOUNG PEOPLE,COMMUNITY CHILD HEALTH,MENTAL HEALTH,CHILD HEALTH,ADOLESCENCE,PUBLICATIONS,SPECIALTIES,DETERMINANTS,PUBLIC HEALTH,SOCIAL DETERMINANTS,GROUPS,POPULATIONS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Research into children's health and health behaviours and the factors influencing them is essential for the development of effective health education and health promotion policy. 
&lt;P&gt;Health Behaviour in School-Aged Children (HBSC) is a WHO study carried out in a large number of countries in Europe and North America. It aims to gain new insight into adolescent health behaviours, health and lifestyles in their social context. &lt;/P&gt;
&lt;P&gt;This report uses data from the HBSC study carried out in England in 2002 to investigate the influence of a range of social indicators on the health and health-related behaviour of children aged 11-15. Specifically it explores the relative importance of school, family and neighbourhood across a number of health indicators in order to further our understanding of how best to promote the healthy development of young people now and for the future. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>279699</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/PDF/!removed--WAA%20Nat%20Report%20final%20for%20Leads%2010%2012.pdf]]&gt;</url>
    <title>Healthcare Commission: National Audit of Violence 2006-7</title>
    <publicationDate>2008-02-14T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DOMESTIC VIOLENCE OR PARTNER ABUSE,DEPRESSION,DEMENTIA,ACUTE PSYCHOTIC DISORDERS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>More than half of nurses on mental health wards report being physically assaulted at work. The figure rises to almost three-quarters for mental health nurses working on wards for patients with  disorders such as dementia.</description>
    <body>&lt;![CDATA[ &lt;P&gt;More than half of nurses on mental health wards report being physically assaulted at work. The figure rises to almost three-quarters for mental health nurses working on wards for patients with&amp;nbsp; disorders such as dementia.&lt;/P&gt;
&lt;P&gt;The findings were published in the second national audit of violence in mental health services conducted on behalf of the Healthcare Commission by the Royal College of Psychiatrists.&lt;/P&gt;
&lt;P&gt;There are about 30,000 in-patients in mental health units in NHS and independent organisations in England and Wales.&amp;nbsp; The audit involved 211 units at 69 of those organisations and for the first time looked separately at services for working-age adults and wards for people over 65. &lt;/P&gt;
&lt;P&gt;The Commission and the Royal College joined forces to highlight the high levels of violence on mental health wards, saying the impact on staff and patient can be “constant and intolerable”.&lt;/P&gt;
&lt;P&gt;They said that improvements had been made to the way violence is managed on wards for people of working age, particularly in providing effective alarm systems, reporting incidents and having an appropriate mix of skills among the staff team.&lt;/P&gt;
&lt;P&gt;But the Commission and the Royal College said more improvements were needed, particularly on wards for older people, where physical environments, activities for patients, training and staffing levels were particularly poor.&lt;/P&gt;
&lt;P&gt;Sixty-four per cent of nurses in wards for older people said they had been physically assaulted, compared to 46% of nurses on wards for adults of working age. Some described serious injury such as fractures, dislocations and black eyes.&lt;/P&gt;
&lt;P&gt;When looking specifically at wards for older people with organic disorders such as dementia, the number of nurses reporting physical assaults rose to 73%. But patients on wards for older people were less likely to be physically assaulted.&lt;/P&gt;
&lt;P&gt;Six per cent of patients on wards for older people reported being physically assaulted, 14% said they had been threatened or made to feel unsafe and 29% had been made to feel upset or distressed. On wards for working-age adults, these figures were 18%, 34% and 45% respectively. &lt;/P&gt;
&lt;P&gt;Dr Paul Lelliott from the Royal College of Psychiatrists commented: “Those working on psychiatric wards, and in particular the nurses, are the unsung heroes of mental healthcare. Their every working day is a challenge and this audit once again highlights the danger to their personal safety.&amp;nbsp; Despite this, ward staff continue to provide care to the most severely ill people in a professional and compassionate manner. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;“The re-audit involving wards for adults of working age shows that improvements can be made.&amp;nbsp; We have learnt from working with hundreds of wards involved in the audit over the past five years that good leadership is the single most important ingredient for quality and safety. Mental health services must give ward managers the authority to manage their wards effectively and must ensure that they have the resources they need to create as safe an environment as possible.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;“The Royal College of Psychiatrists is committed to continuing its work with inpatient units throughout the United Kingdom through its accreditation system for psychiatric wards.&amp;nbsp; This publicly recognises excellence in this most challenging of environment and encourages all wards to constantly work to improve the quality of care they provide and their safety.”&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Anna Walker, chief executive of the Healthcare Commission, said: “This audit reveals worrying levels of violence against nursing staff in mental health units, particularly on wards for people with disorders such as dementia. It is a testament to the commitment and compassion of nurses that such a high number of patients in their wards say they are treated with dignity and respect. &lt;/P&gt;
&lt;P&gt;“The report highlights areas where if acted on, we know can make a difference in reducing levels of violence. Services need to concentrate on giving people meaningful activities in an environment that is designed to ensure that patients, staff and visitors are as safe as possible. They should ensure that staff have the proper training and skills and that patients get good continuity of care, without the overuse of bank and agency staff. Finally, they should have proper systems to report and manage incidents when they do happen.&lt;/P&gt;
&lt;P&gt;“We urge all organisations to look at these areas. We will be checking on performance through our assessments, including the annual health check ratings. We will also carry out this year a national study of mental health services for older people.&lt;/P&gt;
&lt;P&gt;“Leaders of mental health providers must check that they are not allowing a culture to develop that accepts daily violence as part of the norm. I doubt any patient in an acute hospital bed would put up with physical violence and there’s no reason why patients or staff in mental health services should either.”&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333119</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_109772.pdf]]&gt;</url>
    <title>Healthy children, safer communities - a strategy to promote the health and well-being of children and young people in contact with the youth justice system</title>
    <publicationDate>2009-12-08T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,MENTAL HEALTH SERVICES,PRISON HEALTH,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,CONDUCT DISORDER,SCHOOL REFUSAL,SUBSTANCE MISUSE,COMMISSIONING,SERVICE SECTORS,MENTAL HEALTH SERVICES,POPULATIONS SERVED,CHILDREN,YOUNG PEOPLE,PEOPLE WITH MENTAL HEALTH PROBLEMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This cross government strategy aims to help tackle youth crime and anti-social behaviour, and contribute to community safety in England. It sets out a strategic approach to inform the work of the Healthy Children, Safer Communities Programme Board to fulfil the vision that children and young people will be safer, healthier and stay away from crime.]]&gt;</body>
  </document>
  <document>
    <id>396222</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_122252.pdf]]&gt;</url>
    <title>Healthy lives, healthy people: our strategy for public health in England</title>
    <publicationDate>2010-11-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This White Paper sets out the Government’s long-term vision for the future of public health in England. The aim is to create a ‘wellness’ service (Public Health England) and to strengthen both national and local leadership.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>276025</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nao.org.uk/publications/0708/helping_people_through_mental.aspx]]&gt;</url>
    <title>Helping people through mental health crisis: the role of Crisis Resolution and Home Treatment services</title>
    <publicationDate>2007-12-07T00:00:00</publicationDate>
    <publisher>National Audit Office</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Published by the National Audit Office (NAO), this report on Crisis Resolution and Home Treatment (CRHT) found that services are being limited by a lack of input from specialist health and social care professionals, variations in staffing levels across the country and too few admissions to hospital being assessed by CRHT teams.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Published by the National Audit Office (NAO), this report on Crisis Resolution and Home Treatment (CRHT) found that services are being limited by a lack of input from specialist health and social care professionals, variations in staffing levels across the country and too few admissions to hospital being assessed by CRHT teams. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The report found that CRHT services have been implemented across most areas of the country, and where they are working they are making a significant impact. However the report also found wide variations between areas in the extent to which teams are staffed and resourced. Only three regions achieved the DH estimate for a fully-functioning service of 14 or more whole-time-equivalent CRHT staff per 150,000 population. The NAO has also published a report from a survey of clinicians who refer patients to CRHT services. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387439</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0012244;jsessionid=8533E130CBFA5AF255D9D284582F0B47.ambra02]]&gt;</url>
    <title>Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial</title>
    <publicationDate></publicationDate>
    <publisher>Alzheimer's Research Trust</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A new randomised controlled trial suggests high doses of B vitamins may halve the rate of brain shrinkage in older people experiencing some of the warning signs of Alzheimer's disease.]]&gt;</body>
  </document>
  <document>
    <id>378413</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/document.rm?id=8687]]&gt;</url>
    <title>How patients choose and how providers respond</title>
    <publicationDate>2010-06-03T00:00:00</publicationDate>
    <publisher>The Kings Fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN&gt;
&lt;P&gt;The policy of offering patients a choice in where they receive hospital treatment was intended to create competition between providers, encouraging efficiency and responsiveness to patients’ preferences and ultimately to drive up the quality of care. So has the policy met those aims?&lt;/P&gt;
&lt;P&gt;Since January 2006, patients requiring a referral to a specialist have been entitled to a choice of four or five providers. And from April 2008 that choice has been extended to any eligible NHS or independent sector provider in England – so-called ‘free choice’. &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Patient choice: how patients choose and how providers respond&lt;/EM&gt; considers how choice of provider is operating in practice and its impact on hospital providers. More specifically, the report aims to answer the following questions.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;How do patients experience choice?&lt;/LI&gt;
&lt;LI&gt;What factors are important to patients when choosing between providers?&lt;/LI&gt;
&lt;LI&gt;How do GPs support choice?&lt;/LI&gt;
&lt;LI&gt;How are providers responding to choice?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The study was conducted in four areas in England and included questionnaires sent to patients and interviews with patients, GPs and Providers. The results showed that choice was important to the majority of patients but just under half recalled being offered a choice. There were differences in patient, and GP and provider views on who thought choice was important, who was offered a choice and who chose to travel beyond their local hospital for treatment.&lt;/P&gt;
&lt;P&gt;Data from choices made in hypothetical and real situations showed that patients valued aspects of quality when choosing a hospital. However in practice, most patients chose to be treated by their local provider and few consulted published performance information on quality to help them choose, instead relying on past experience and their GP’s advice. &amp;nbsp;&lt;/P&gt;
&lt;P&gt;While the threat of patients choosing a different hospital led some providers to focus more on reputation, there was little evidence of direct competition for patients’ custom and choice has not so far acted as a lever to improve quality.&lt;/P&gt;
&lt;P&gt;The information about how patient choice is working in practice will be invaluable to those seeking to implement the policy at national and local level.&lt;/P&gt;&lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>317703</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealth.org.uk/information/wellbeing-podcasts/?entryid24=71078]]&gt;</url>
    <title>How to overcome fear and anxiety podcast</title>
    <publicationDate>2009-04-30T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN class=oDataFormAnswerText&gt;&lt;SPAN class=oDataFormAnswerTextStyle&gt;The how to overcome fear and anxiety podcast has been released for Mental Health Action Week 2009. The podcast outlines ways to overcome fear and anxiety and is also available in written form.&lt;/SPAN&gt;&lt;/SPAN&gt;]]&gt;</body>
  </document>
  <document>
    <id>259569</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/Psychmed/EDU/downloads/professionals/detect_ed_guide_IoP_05.pdf]]&gt;</url>
    <title>How to pick up eating disorders</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A guide for those who work with young people, eg teachers, youth workers, etc.]]&gt;</body>
  </document>
  <document>
    <id>259575</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/downloads/pdf/TreatmentQuestionsAN.pdf]]&gt;</url>
    <title>How, when and why: Treatment questions in Anorexia Nervosa</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A PDF article written for General Practitioners.]]&gt;</body>
  </document>
  <document>
    <id>269092</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/mental_health/emergencies/guidelines_iasc_mental_health_psychosocial_june_2007.pdf]]&gt;</url>
    <title>IASC Guidelines on Mental Health and Psychosocial Support in Emergency Settings</title>
    <publicationDate>2007-09-14T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION,GENERALIZED ANXIETY,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Inter-Agency Standing Committee (IASC) Guidelines on Mental Health and Psychosocial Support in Emergency Settings clearly state that protecting and promoting mental health and psychosocial well-being is the responsibility of all humanitarian agencies and workers. Until now, many people involved in emergency response have viewed mental health and psychosocial well-being as the sole responsibility of psychiatrists and psychologists.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The guidelines lay out the essential first steps in protecting or promoting people's mental health and psychosocial well-being in the midst of emergencies. They identify useful practices and flag potentially harmful ones, and clarify how different approaches complement one another.&lt;/P&gt;
&lt;P&gt;“The new guidelines present a major step forward to much better protect the mental health and psychosocial well-being of displaced persons using an integrated approach in collaboration with all partners” said Ms Ruvendrini Menikdiwela, Deputy Director, Division for International Protection Services at the Office of the United Nations High Commissioner of Refugees.&lt;/P&gt;
&lt;P&gt;The guidelines have a clear focus on social interventions and supports. They emphasize the importance of building on local resources such as teachers, health workers, healers, and women’s groups to promote psychosocial well-being. They focus on strengthening social networks and building on existing ways community members deal with distress in their lives.&lt;/P&gt;
&lt;P&gt;The guidelines include attention to protection and care of people with severe mental disorders, including severe trauma-induced disorders, as well as access to psychological first aid for those in acute distress.&lt;/P&gt;
&lt;P&gt;See &lt;A href="http://www.who.int/mediacentre/news/releases/2007/pr46/en/index.html" target="_blank"&gt;news webpage&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291523</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_086566]]&gt;</url>
    <title>Implementation of the Mental Health Act 2007: transitional arrangements</title>
    <publicationDate>2008-07-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>From 3 November 2008, major changes are being made to the Mental Health Act 1983 as a result of amendments made to it by the Mental Health Act 2007.  This guidance explains the transitional provisions associated with those changes.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Executive summary&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;From 3 November 2008, major changes are being made to the Mental Health Act 1983 (“the Act”), as a result of amendments made to it by the Mental Health Act 2007.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This guidance explains the transitional provisions associated with those changes. These relate to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Applications for detention under Part 2 of the Act;&lt;/LI&gt;
&lt;LI&gt;Detention under Part 3 of the Act&lt;/LI&gt;
&lt;LI&gt;Arrangements for the renewal of detention;&lt;/LI&gt;
&lt;LI&gt;Consent to treatment under Part 4 of the Act;&lt;/LI&gt;
&lt;LI&gt;Guardianship;&lt;/LI&gt;
&lt;LI&gt;Tribunals;&lt;/LI&gt;
&lt;LI&gt;Applications to the County Court about the appointment of acting nearest relatives;&lt;/LI&gt;
&lt;LI&gt;Approved mental health professionals; and&lt;/LI&gt;
&lt;LI&gt;Approved clinicians.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please note in particular that the Mental Health Act 1983 Approved Clinician (General) Directions made on 31 July 2008 revoke the Mental Health Act 1983 Approved Clinician Directions 2008 (made on 7 May 2008) and now incorporate Directions on the transitional arrangements for approved clinicians.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Further guidance for strategic health authorities and employers on their responsibilities around approving and employing approved clinicians and responsible clinicians is being produced separately and will be available soon.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This guidance covers the transitional arrangements only. It applies to England.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Hospital managers, local social services authorities and strategic health authorities will need to ensure that they and their staff are familiar with these transitional arrangements in order to apply the changes correctly.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377553</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/Implementing_recovery_methodology.pdf]]&gt;</url>
    <title>Implementing Recovery: A methodology for organisational change</title>
    <publicationDate>2010-04-27T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;SPAN id=ctl00_centreColumn_Publicationview1_PublicationDataList_ctl00_BlurbLabel1&gt;The principles of recovery now underpin developments in mental health services in a number of countries. In England, they figure prominently in New Horizons and have received widespread support from the major professional bodies. This paper presents a practical methodology to help mental health services and their local partners become more recovery-oriented in their organisation and practices, and thereby to support these processes more effectively.&lt;/SPAN&gt;&amp;nbsp;]]&gt;</body>
  </document>
  <document>
    <id>275520</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nacro.org.uk/data/files/nacro-2008102700-355.pdf]]&gt;</url>
    <title>Implementing the Mental Health Act 2007</title>
    <publicationDate>2007-11-29T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is the microsite for CSIP/NIMHE's implementation programme for the forthcoming changes to the Mental Health Act 1983 in England.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Implementing the Mental Health Act 2007&lt;/H2&gt;
&lt;P&gt;This is the microsite for CSIP/NIMHE's implementation programme for the forthcoming changes to the Mental Health Act 1983 in England.&lt;/P&gt;
&lt;P&gt;We have been tasked by the Department of Health to have a key role in:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;informing those involved in mental health care of the proposed changes and the impact they may have 
&lt;LI&gt;supporting implementation by service providers, directly and by signposting sources of information 
&lt;LI&gt;and providing opportunties to influence national policy&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The Mental Health Act 2007 received Royal Assent on 19 July 2007 and can be downloaded here. The assumption for the final implementation of the amendments is October 2008 (see the Commencement Plan).&lt;/P&gt;
&lt;P&gt;Draft Revised Code of Practice and Secondary Legislation&lt;/P&gt;
&lt;P&gt;The Government has launched two formal consultation exercises on the draft revised Code of Practice and draft secondary legislation in the light of the Mental Health Act 2007.&lt;/P&gt;
&lt;P&gt;NHS bodies and local social services authorities should be aware of the proposals and are invited to comment. See here.&lt;/P&gt;
&lt;P&gt;The programme has five key workstreams: Training, Workforce, Advocacy, Administration and Supervised Community Treatment. These underpin the eight regional leads, who are the first point of contact for their localities.&lt;/P&gt;
&lt;P&gt;It is intended that this site will build into a valuable portal for everyone involved in implementing the amendments. Please check back regularly for updates and new resources.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324796</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18976728]]&gt;</url>
    <title>Improving access to child and adolescent mental health services</title>
    <publicationDate>2009-08-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This joint DH/DCSF guide states how the 18 weeks referral to treatment standard, (NHS Operating Framework for 2009/10) applies to non-emergency consultant-led CAMHS services and pathways. This guide does not set any new standards or targets. It shows how accessible low-wait CAMHS can be achieved and provides good practice examples.]]&gt;</body>
  </document>
  <document>
    <id>283065</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_084065]]&gt;</url>
    <title>Improving Access to Psychological Therapies (IAPT) Commissioning Toolkit</title>
    <publicationDate>2008-04-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This  commissioning  toolkit is designed to help PCTs improve or establish stepped care psychological therapies following NICE guidelines. The toolkit is structured around the commissioning cycle and is specifically linked to the World Class Commissioning competencies. It brings together a wide range of existing tools and guides and includes positive practice examples throughout.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Improving Access to Psychological Therapies (IAPT) programme has one principal aim - to help PCTs implement NICE Guidelines for people suffering from depression and anxiety disorders. &lt;/P&gt;
&lt;P&gt;The Government is committed to improving access to psychological therapies and announced additional funding to increase services over the next three years. &lt;/P&gt;
&lt;P&gt;This Commissioning Toolkit is designed to help PCTs improve or establish stepped care psychological therapies following NICE guidelines. &lt;/P&gt;
&lt;P&gt;The toolkit is structured around the commissioning cycle and is specifically linked to the World Class Commissioning competencies.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;It brings together a wide range of existing tools and guides and includes positive practice examples throughout.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260938</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=260938]]&gt;</url>
    <title>Improving Access to Psychological Therapies: Specification for the commissioner-led Pathfinder programme</title>
    <publicationDate>2007-05-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Improving Access to Psychological Therapies: Specification for the commissioner-led Pathfinder programme&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The 'Specification for the commissioner-led Pathfinder programme' was launched by the Secretary of State for Health Patricia Hewitt on 10th May 2007 at the National Improving Access to Psychological Therapies conference at the Oval cricket ground.&lt;/P&gt;
&lt;P&gt;The Department of Health seeks to extend the Improving Access to Psychological Therapies (IAPT) programme in 2007/08 to build on the early successes of the two IAPT demonstration sites launched in 2006 in Doncaster and Newham.&lt;/P&gt;
&lt;P&gt;In 2006/07, the IAPT demonstration sites’ core purpose was to collect evidence of delivery in order to develop a business case for national roll-out of the IAPT service model.&lt;/P&gt;
&lt;P&gt;It is important that we build on the success of the demonstration sites and continue to develop our evidence base. To address this, the Department now seeks to extend the scope and range of the IAPT programme in 2007/08 to support the case for further service expansion by demonstrating that the benefits of the new service can&lt;BR&gt;be replicated across the country.&lt;/P&gt;
&lt;P&gt;This will be achieved through establishing a number of IAPT Pathfinders in 2007/08. We envisage the establishment of up to 10 Pathfinder sites, which will use redesign techniques to implement a defined care pathway, service specification and service framework.&lt;/P&gt;
&lt;P&gt;The approach to the IAPT Pathfinder programme will be based on the following core principles:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;flexible, evidence-based service models within a defined national IAPT stepped care framework of evidence-based interventions;&lt;/LI&gt;
&lt;LI&gt;working with and harnessing local innovation; and&lt;/LI&gt;
&lt;LI&gt;moving towards a standard national IAPT outcome framework.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Modest additional resources (approximately £200,000) will be available to primary care trusts (PCTs) that successfully bid to become IAPT Pathfinder sites. These nonrecurrent funds will be sufficient to provide project management, data collection support and pump-prime some service capacity. Pathfinder sites will use these resources and the support of the national IAPT network to develop local services and contribute to an assessment of further capacity requirements.&lt;/P&gt;
&lt;P&gt;The new Pathfinder sites will be confirmed in July 2007 and will commence implementation of the new service from September 2007.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395092</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_121603]]&gt;</url>
    <title>Improving care for people with long term conditions: 'at a glance' information sheets for healthcare professionals</title>
    <publicationDate>2010-11-17T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Department has produced a series of information sheets for doctors,nurses, those delivering personal health budgets, allied health professionals, health trainers and anyone supporting individuals with long term conditions. The information sheets cover a range of topics including care planning, care co-ordination, managing need and assessment of risk, motivating people to self care, goal setting and action planning and end of life care.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344601</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/OP71.pdf]]&gt;</url>
    <title>Improving In-patient Mental Health Services for Black and Minority Ethnic Patients</title>
    <publicationDate>2010-02-25T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report forms an important addition to ongoing and important discussions about improving care and treatment for people from Black and minority ethnic communities, and indeed all communities.]]&gt;</body>
  </document>
  <document>
    <id>266053</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nao.org.uk/publications/0607/support_for_people_with_dement.aspx]]&gt;</url>
    <title>Improving services and support for people with dementia</title>
    <publicationDate>2007-07-02T00:00:00</publicationDate>
    <publisher>National Audit Office</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,NEUROLOGICAL CONDITIONS,MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,TREATMENT AND CARE,DEMENTIA,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report by the comptroller and auditor general.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Contents:&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Summary 
&lt;LI&gt;Part One: Dementia presents a significant and urgent challenge to health and social care 
&lt;LI&gt;Part Two: Services in England could do better on early diagnosis and intervention 
&lt;LI&gt;Part Three: Management of community care following diagnosis is disjointed and often ineffective 
&lt;LI&gt;Part Four: There are opportunities to improve the quality and cost-effectiveness of the system's response to dementia 
&lt;LI&gt;Appendices 
&lt;LI&gt;Glossary 
&lt;LI&gt;Endnotes&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>277847</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.publications.parliament.uk/pa/cm200708/cmselect/cmpubacc/228/228.pdf]]&gt;</url>
    <title>Improving Services and Support for People with Dementia: Sixth report of session 2007-08</title>
    <publicationDate>2008-01-14T00:00:00</publicationDate>
    <publisher>House of Commons</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,DIAGNOSIS,MENTAL HEALTH,ADULT CONDITIONS,LATER LIFE,DEMENTIA,PATHOLOGY,CAUSES AND PREVENTION,DEFINITION AND TYPES,TREATMENT AND CARE,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report, together with formal minutes, oral and written evidence.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Contents&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Report Page 
&lt;LI&gt;Summary 
&lt;LI&gt;Conclusions and Recommendations 
&lt;LI&gt;1 The prevalence and cost of dementia and the development of a&lt;BR&gt;Departmental strategy diagnosis and early intervention 
&lt;LI&gt;2 Diagnosis and early intervention 
&lt;LI&gt;3 Access to and quality of support services 
&lt;LI&gt;4 Acute hospital admission and care home experiences 
&lt;LI&gt;Formal Minutes 
&lt;LI&gt;Witnesses 
&lt;LI&gt;List of written evidence 
&lt;LI&gt;List of Reports from the Committee of Public Accounts 2007–08&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;On the basis of a report by the Comptroller and Auditor General (C&amp;amp;AG), we examined the prevalence and costs of dementia, diagnosis and early intervention, access to and quality of support services, and experiences of people with dementia in hospital and care homes. We took evidence from witnesses from the Department of Health and the NHS.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394985</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_122094.pdf]]&gt;</url>
    <title>Improving services for women and child victims of violence: the Department of Health Action Plan</title>
    <publicationDate>2010-11-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,DOMESTIC VIOLENCE OR PARTNER ABUSE,CHILD ABUSE AND NEGLECT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This action plan sets out how the Department in partnership with others will take action by Spring 2011 to address many of the issues that came out of the Taskforce work&lt;/P&gt;
&lt;P&gt;It aims to lay the foundations for embedding high quality evidence based practice within the NHS in response to violence and abuse and is set around four key themes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Awareness-raising&lt;BR&gt;
&lt;LI&gt;Workforce, education and training&lt;BR&gt;
&lt;LI&gt;Improving quality of services&lt;BR&gt;
&lt;LI&gt;Evidence and Information&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>338971</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_111187.pdf]]&gt;</url>
    <title>Improving the health and well-being of people with long term conditions. World class services for people with long term conditions: information tool for commissioners</title>
    <publicationDate>2010-01-14T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The main aim of the information tool is to share a common vision of what a good service for people with LTCs, and to provide some practical suggestions for commissioners to help them achieve that vision.]]&gt;</body>
  </document>
  <document>
    <id>296747</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dcsf.gov.uk/CAMHSreview/downloads/e-INTERIM%20REPORT%20-%20FINAL.pdf]]&gt;</url>
    <title>Improving the mental health and psychological well-being of children and young people: National CAMHS Review Interim Report</title>
    <publicationDate>2008-10-28T00:00:00</publicationDate>
    <publisher>CAMHS</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The National CAMHS Review was announced in December 2007 in the National Children’s Plan. It is an independent review, sponsored by the Department for Children, Schools and Families and the Department of Health.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The National CAMHS Review was announced in December 2007 in the National Children’s Plan. It is an independent review, sponsored by the Department for Children, Schools and Families and the Department of Health.&lt;/P&gt;
&lt;P&gt;The Review is considering progress to date since the publication of the National Service Framework for Children, Young People and Maternity Services, particularly Standard Nine, and Every Child Matters. It is also considering how services can be improved further to meet the educational, health and social care needs of all children and young people at risk of, or experiencing, mental health problems.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295156</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/In_the_dark_summary.pdf]]&gt;</url>
    <title>In The Dark: The mental health implications of Imprisonment for Public Protection (summary)</title>
    <publicationDate>2008-09-18T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DETERMINANTS,OUTCOMES,UNEMPLOYMENT,EDUCATION,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,BUILDINGS,PRISONS,MONTHLY ADDITIONS,GROUPS,SETTINGS,POPULATIONS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>IPP is a sentence for people whose crimes are not serious enough for life imprisonment but whom the courts think are dangerous. They cannot be released until the Parole Board thinks they are no longer dangerous.

This report finds that IPP prisoners are much more likely than other prisoners to have mental health problems. Being on IPP appears to be making this worse because of the uncertainty and hopelessness it creates.</description>
    <body>&lt;![CDATA[ &lt;P&gt;IPP is a sentence for people whose crimes are not serious enough for life imprisonment but whom the courts think are dangerous. They cannot be released until the Parole Board thinks they are no longer dangerous.&lt;/P&gt;
&lt;P&gt;This report finds that IPP prisoners are much more likely than other prisoners to have mental health problems. Being on IPP appears to be making this worse because of the uncertainty and hopelessness it creates.&lt;/P&gt;
&lt;P&gt;In the Dark looks at the sentencing process, what information is given to prisoners and the courses they can do as well as the prisoners' mental health needs and the impact of mental ill health on the IPP process. It makes recommendations for health and criminal justice services.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.scmh.org.uk/pdfs/In_the_dark_summary.pdf" target="_blank"&gt;Download the In the dark summary (533 KB)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.scmh.org.uk/pdfs/In_the_dark_commissioners_summary.pdf" target="_blank"&gt;Download the In the dark summary for commissioners (552 KB)&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>285155</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mind.org.uk/NR/rdonlyres/B8ACA0C3-C16C-45DE-886D-84F0745A1C9D/0/Mw08reportWeb.pdf]]&gt;</url>
    <title>In the red: debt and mental health</title>
    <publicationDate>2008-05-12T00:00:00</publicationDate>
    <publisher>MIND</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Research by Mind shows that debt is not just a financial problem but can have a serious impact on a person's mental health in terms of anxiety and stress, depression, self-harm and suicidal thoughts, as well as adding to wider social exclusion problems.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Key findings&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;How much debt were respondents in?&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Respondents owed an average of £3,250 on credit or store cards.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;In the previous 12 months:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Respondents had borrowed an average of £3,257. 
&lt;LI&gt;70 per cent of people had been unable to pay a bill at the final reminder. 
&lt;LI&gt;50 per cent reported missing two or more consecutive payments with at least one bill. 
&lt;LI&gt;78 per cent of those with problem debt had been threatened with legal or court action. 
&lt;LI&gt;51 per cent of those with problem debt had been contacted by bailiffs or debt collectors.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Living standards of those with problem debt (see 'definitions')&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Almost 50 per cent were living on a weekly household income of £200 or less, defined by the Government as 'living on the poverty line'. 
&lt;LI&gt;56 per cent had gone without food due to a shortage of money. 
&lt;LI&gt;51 per cent had gone without heating. 
&lt;LI&gt;92 per cent reported not being able to socialise. 
&lt;LI&gt;87 per cent needed to borrow money or use a credit card to pay for food or other everyday spending. 
&lt;LI&gt;71 per cent ran out of money every week or most weeks.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Creditors' responses to those with problem debt&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;63 per cent did not tell creditors about their mental health problem because they didn't think they would understand. 
&lt;LI&gt;47 per cent chose not to tell because they thought creditors would not believe them.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Of the 37 per cent who did tell creditors:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;83 per cent had been harassed about debt repayments despite informing the organisation of their mental health problems. 
&lt;LI&gt;79 per cent felt their mental health problems were not taken into account when a decision was made about their financial difficulties. 
&lt;LI&gt;74 per cent felt they were treated unsympathetically and insensitively by staff after telling the organisation.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Link to Mind's MONEY website: &lt;A href="http://www.mind.org.uk/money/" target="_blank"&gt;Money and mental health&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327449</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/document.rm?id=8457]]&gt;</url>
    <title>Independant sector treatment centres</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>The Kings Fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Independent sector treatment centres (ISTCs) provide services to NHS patients but are owned and run by organisations outside the NHS. This briefing paper explains why ISTCs were introduced, and how they are funded, staffed and regulated. It assesses their impact so far, including the quality of their services and whether they provide good value for money. Finally, it examines what their future may be now that the contracts ISTC providers hold with the Department of Health are beginning to expire.]]&gt;</body>
  </document>
  <document>
    <id>282207</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=10605]]&gt;</url>
    <title>Independent investigation of serious patient safety incidents in mental health services: good practice guidance</title>
    <publicationDate>2008-03-13T00:00:00</publicationDate>
    <publisher>National Patient Safety Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The National Patient Safety Agency (NPSA) has launched guidance aimed at improving and standardising the approach to independent investigations into serious patient safety incidents in mental health services. It describes the three main stages of the independent investigation process, examining the initial service management review, internal NHS mental health trust investigations and strategic health authority independent investigations.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This document describes the three main stages of the independent investigation process.&lt;/P&gt;
&lt;P&gt;It examines the initial service management review, internal NHS mental health trust investigations and Strategic Health Authority independent investigations.&lt;/P&gt;
&lt;P&gt;It also looks at how NHS organisations can support the victims of serious incidents and how to support staff.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317745</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098828?IdcService=GET_FILE&amp;dID=192560&amp;Rendition=Web]]&gt;</url>
    <title>Independent mental health advocates: supplementary guidance on access to patient records under section 130B of the Mental Health Act 1983 PDF</title>
    <publicationDate>2009-05-05T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Department of Health has been asked for advice on whether section 130B of the Mental Health Act 1983 allows independent mental health advocates (IMHAs) to see information in patients’ records which would not be disclosed directly to the patient and, if so, whether IMHAs may share that information with patients.]]&gt;</body>
  </document>
  <document>
    <id>263054</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/publications/?EntryId=47662&amp;char=I]]&gt;</url>
    <title>Indications of Public Health in the English Regions</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,PUBLIC HEALTH,INDICATORS,METHODS,NATIONAL,REGIONAL VARIATIONS,LOCAL AUTHORITY AREAS,AREAS,GEOGRAPHY,PLACES,ANALYSIS &amp; RESEARCH,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report on mental health in the series on Indications of Public Health in the English Regions will provide a useful reference document for the wide range of agencies and  individuals involved in public mental health and wellbeing.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report on mental health in the series on Indications of Public Health in the English Regions will provide a useful reference document for the wide range of agencies and&amp;nbsp; individuals involved in public mental health and wellbeing.&lt;/P&gt;
&lt;P&gt;It brings together for the first time a variety of sources of data, reminding readers that within our National Service Framework, there is far more to modern mental health services than GP appointments and hospital admissions. Our service users are increasingly benefiting from a spectrum of care, the majority of which is delivered in the community and as close to home as possible. The mental health workforce comprises new types of staff working in new ways to improve the experience of service users and carers.&lt;/P&gt;
&lt;P&gt;This report has been produced jointly by the North East Public Health Observatory (NEPHO) and the National Mental Health Observatory (MHO) on behalf of the Association of Public Health Observatories (APHO) and in collaboration with the National Institute for Mental Health in England (NIMHE), the Healthcare Commission, the Mental Health Foundation and the Prescription Pricing Division of the NHS Business Services Authority.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267828</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nwph.net/nwpho/Publications/Alcohol_Indications.pdf]]&gt;</url>
    <title>Indications of Public Health in the English Regions: 8 - Alcohol</title>
    <publicationDate>2007-08-21T00:00:00</publicationDate>
    <publisher>The North West Public Health Observatory</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ALCOHOL MISUSE,MENTAL HEALTH,ADULT CONDITIONS,PUBLIC HEALTH,DETERMINANTS,ALCOHOL CONSUMPTION,INDIVIDUAL BEHAVIOUR,LIFESTYLE,SOCIAL DETERMINANTS,METHODS,ANALYSIS,MEASUREMENT,INDICATORS,REGIONAL VARIATIONS,GEOGRAPHY,HEALTH REGIONS,ANALYSIS &amp; RESEARCH,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The North West Public Health Observatory has published a report Indications of Public Health in the English Regions: 8 for the Chief Medical Officer which examines the impact of harmful drinking on individuals, their families and the wider community.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Executive Summary&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;As part of the series of Indications of Public Health in the English Regions commissioned from the Association of Public Health Observatories (APHO) by the Chief Medical Officer (CMO) for England, the North West Public Health Observatory (NWPHO) has published this report on alcohol. The topic of alcohol has been an emerging issue across Europe for a number of years. In 2006, the United Kingdom rated third highest across 25 EU member states for the number of drinks consumed in one sitting, with 24% of residents drinking five or more drinks on a day when they drink alcoholic beverages. The UK also has one of the highest rates of admission to hospital or an emergency room due to alcohol use in 15-16 year olds across EU countries.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Alcohol leads to a range of public health problems. Acute conditions, such as alcoholic poisoning, violence and accidents as well as the more chronic effects, such as alcohol-induced pancreatitis, chronic liver disease and stomach cancer all potentially lead to reduced health and wellbeing and at worst, loss of life. Alcohol affects all of society, from the burden on the NHS in terms of hospital admission and treatment in primary care, the economic burden due to loss of employment and reduced capacity to work, through to other negative effects of alcohol on the social and behavioural welfare of communities.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This Regional Indications report is produced alongside the new national strategy Safe. Sensible. Social: The next steps in the National Alcohol Strategy which was published in June 2007. The strategy outlines a coordinated response across a wide range of community groups, public sector agencies, commercial businesses and the media. Several next steps are highlighted that will continue the Government’s commitment to reduce the harms and costs that alcohol has on the health and wellbeing of England’s population.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324893</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_104948.pdf]]&gt;</url>
    <title>Information sharing and mental health</title>
    <publicationDate>2009-09-09T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This Department of Health guidance sets out some of the issues relating to the exchange of information between mental health trusts and outside organisations and individuals.&amp;nbsp;It sets out when, why and how information can safely be exchanged for the benefit of the individual and the public.]]&gt;</body>
  </document>
  <document>
    <id>291060</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/informed-gender-practice.pdf]]&gt;</url>
    <title>Informed Gender Practice: Mental health acute care that works for women (July 2008)</title>
    <publicationDate>2008-07-25T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The guidance is aimed at multi-disciplinary teams who work with inpatients, their managers and commissioners of acute inpatient services. It should also be of value to community based staff, to women with experience of using acute care and to user groups that advocate for their interests.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Women and men’s needs&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This guidance describes why and in what way women’s needs are different from men’s and how this affects their experiences on the ward, acknowledging the diversity of women who will become inpatients. The needs of men are not specifically addressed, although the need for informed gender practice for men is acknowledged and there is transferability in many of the points made.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Who is the guidance for?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The guidance is aimed at multi-disciplinary teams who work with inpatients, their managers and commissioners of acute inpatient services. It should also be of value to community based staff, to women with experience of using acute care and to user groups that advocate for their interests.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;What does the guidance do?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The guidance encourages all staff to take an approach that promotes understanding of a woman’s journey.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Core principles&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The core principles of informed gender practice are equality, knowledge and commitment and relationships. The multi-disciplinary team must have a shared understanding of the ways that gender inequality can harm mental health – especially through a woman’s experience of violence and abuse – and be willing to address these as part of recovery.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346700</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Injection-for-curing-goldfish-fears.aspx]]&gt;</url>
    <title>Injection for curing 'fish fears'</title>
    <publicationDate>2010-03-23T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PHOBIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ “Scientists have created fearless goldfish,” the &lt;EM&gt;Daily Mirror&lt;/EM&gt; reported. &lt;EM&gt;The Daily Telegraph &lt;/EM&gt;and&lt;EM&gt;&amp;nbsp;Daily Mail &lt;/EM&gt;also cover the same study, saying that an injection may be able to “cure phobias”. The&amp;nbsp;&lt;EM&gt;Mirror&lt;/EM&gt; reports that experts aim to use the method (an injection of local anaesthetic into the brain) “to help cure people of common phobias, such as fear of flying, of heights or of spiders”.]]&gt;</body>
  </document>
  <document>
    <id>317737</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/publications/docs/intensive-help-vulnerable-people.pdf]]&gt;</url>
    <title>Intensive help for vulnerable people: applying case management models in the justice system PDF</title>
    <publicationDate>2009-05-06T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,DISADVANTAGED GROUPS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,LAW,GOVERNMENT &amp; LAW,CUSTODIAL CENTRES,PRISONS,BUILDINGS,MONTHLY ADDITIONS,SETTINGS,GROUPS,POPULATIONS,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Case management is a structured process aimed at coordinating services and support on behalf of an individual. The study assesses whether case management models could be used to deliver better outcomes for individuals in civil, criminal and family justice.]]&gt;</body>
  </document>
  <document>
    <id>317754</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=CE6B3CDA-0473-71EF-E6E9-0DFBBD149C48&amp;ext=pdf]]&gt;</url>
    <title>Interim Supplementary Guidance for Chartered Psychologists seeking approval and acting as Approved Clinicians (2009)</title>
    <publicationDate>2009-04-20T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The aim of the &lt;EM&gt;Reference Guide &lt;/EM&gt;is to facilitate understanding of the provisions of the Mental Health Act 1983 (as it is amended by the MHA 2007) and the associated secondary legislation. It replaces the Memorandum on the Act last published by the Department of Health and the Welsh Office in 1998. The &lt;EM&gt;Reference Guide &lt;/EM&gt;is about the Act as it applies in England. There are a number of differences in the way it applies in Wales.]]&gt;</body>
  </document>
  <document>
    <id>268353</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_072730]]&gt;</url>
    <title>International experiences of using community treatment orders</title>
    <publicationDate>2007-03-07T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is a review of research into international experiences of using community treatment orders.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a review of research into international experiences of using community treatment orders.&lt;/P&gt;
&lt;P&gt;The Government is introducing supervised community treatment (SCT) to allow more patients to live safely, under supervision, in the community instead of in hospital. SCT will help more patients to rebuild their lives in the community and help to reduce the risk that a minority of patients pose to themselves and the public.&lt;/P&gt;
&lt;P&gt;We commissioned the Institute of Psychiatry to undertake this literature review of the research available from the many countries in the world, which use different forms of SCT (often known as community treatment orders) to ensure we were up to date with the evidence. We would like to thank the authors for a thorough piece of work. The overall conclusion is a fair one -&amp;nbsp; that it is very difficult to secure reliable evidence in this area, and that as result there is very little conclusive evidence to demonstrate that SCT is either effective or ineffective.&lt;/P&gt;
&lt;P&gt;This situation reflects, at least in part, the problem of doing gold standard trials in this area. This is a difficult area to research and, although some studies have reported positive findings, these findings can not be regarded as reliable. More research will be needed.&lt;/P&gt;
&lt;P&gt;We are encouraged by reports from clinicians, carers and patients&amp;nbsp; in other countries that community treatment orders are of benefit and where they have made criticisms we hope to learn from these. We are confident that SCT, with its range of checks and balances, will be well received in England and Wales.&lt;/P&gt;
&lt;P&gt;The review highlights that there is a gap in current research. Future work needs to focus on who benefits from SCT, the effect of compliance with treatment and key outcomes.&amp;nbsp; The Government has awarded 2 major funding grants of around £1 million to fill this gap and support the successful implementation of SCT in England and Wales.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296400</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/4294/home]]&gt;</url>
    <title>International Journal of Geriatric Psychiatry</title>
    <publicationDate></publicationDate>
    <publisher>Wiley InterScience</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The International Journal of Geriatric Psychiatry features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Review articles 
&lt;LI&gt;Research articles 
&lt;LI&gt;Research letters 
&lt;LI&gt;Current awareness&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;This journal is published every month.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt;&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>70699</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=70699]]&gt;</url>
    <title>Introduction to acute psychotic disorders</title>
    <publicationDate>2004-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Acute psychotic disorders - F23.9 Includes first-episode psychosis, acute schizophrenia-like psychosis, acute delusional psychosis and other acute and transient psychotic disorders. (Clinical term: Acute and transient psychotic disorders Eu23)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to acute psychotic disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Acute psychotic disorders - F23.9 Includes first-episode psychosis, acute schizophrenia-like psychosis, acute delusional psychosis and other acute and transient psychotic disorders. (Clinical term: Acute and transient psychotic disorders Eu23). 
&lt;H2&gt;&lt;BR&gt;Presenting complaints &lt;/H2&gt;
&lt;P&gt;Patients might experience:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;hallucinations, eg hearing voices when no one is around, seeing visions &lt;/LI&gt;
&lt;LI&gt;strange beliefs or fears &lt;/LI&gt;
&lt;LI&gt;apprehension, confusion &lt;/LI&gt;
&lt;LI&gt;perceptual disturbances. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Families and other agencies (eg schools, social workers, probation and housing services) might ask for help with behaviour changes that cannot be explained, including strange or frightening behaviour (eg withdrawal, suspiciousness, self-neglect and threats). 
&lt;P&gt;Young adults, particularly when experiencing their first episode of psychosis, may present with persistent changes in functioning, behaviour or personality (eg multiple physical complaints, withdrawal or deterioration in social, academic or occupational performance), but without florid psychotic symptoms. 
&lt;H2&gt;&lt;BR&gt;Diagnostic features &lt;/H2&gt;
&lt;P&gt;Recent onset of:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;hallucinations (false or imagined sensations, eg hearing voices when no-one is around, seeing visions) &lt;/LI&gt;
&lt;LI&gt;delusions (firmly held ideas that are often false and not shared by others in the patient’s social, cultural or ethnic group, eg patient believes they are being poisoned by neighbours, receiving messages from television, or being looked at by others in some special way) &lt;/LI&gt;
&lt;LI&gt;disorganized or strange speech &lt;/LI&gt;
&lt;LI&gt;agitation or bizarre behaviour&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;extreme and labile emotional states. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These symptoms may be preceded by a period of deteriorating social, occupational and academic functioning. 
&lt;H2&gt;&lt;BR&gt;Differential diagnosis &lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Physical disorders that can cause psychotic symptoms include:&lt;BR&gt;- drug-induced psychosis&amp;nbsp; (especially stimulants such as amphetamine or cocaine)&lt;BR&gt;- alcoholic hallucinosis&lt;BR&gt;- infectious or febrile illness&lt;BR&gt;- Epilepsy - G40, G41 (or other organic intracranial pathology).&lt;/LI&gt;
&lt;LI&gt;Refer to Delirium for other potential causes.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;To exclude organic conditions it may be useful to perform urine and blood investigations. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family &lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Agitation and strange behaviour can be symptoms of a mental disorder. &lt;/LI&gt;
&lt;LI&gt;Acute episodes often have a good prognosis, (ref 1) and it is important to remain positive in view of the proven benefits of treatments and support from various agencies. &lt;/LI&gt;
&lt;LI&gt;The long-term course of the illness can be difficult to predict from an acute episode. &lt;/LI&gt;
&lt;LI&gt;The sooner psychotic symptoms are identified and treated, the better the outcome. &lt;/LI&gt;
&lt;LI&gt;Advise patient and family about the importance of medication, how it works and possible side-effects.&lt;/LI&gt;
&lt;LI&gt;Continued treatment may be needed for several months after symptoms resolve. &lt;/LI&gt;
&lt;LI&gt;Psychotic illness is no-one's fault and has nothing to do with parenting.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;If the patient requires treatment under the Mental Health Act, advise family about related legal issues. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family &lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Ensure the safety of the patient and those caring for them:&lt;BR&gt;- family or friends should be available for the patient if possible&lt;BR&gt;- ensure that the patient's basic needs (eg food, drink and accommodation) are met. &lt;/LI&gt;
&lt;LI&gt;Minimize stress and stimulation: do not argue with psychotic thinking (you may disagree with the patient's beliefs but do not try to argue they are wrong). &lt;/LI&gt;
&lt;LI&gt;Avoid confrontation or criticism, unless it is necessary to prevent harmful or disruptive behaviour (ref 2). &lt;/LI&gt;
&lt;LI&gt;If there is a significant risk of suicide, violence or neglect, admission to hospital or close observation in a secure place may be required.&amp;nbsp; If the patient refuses treatment, legal measures may be needed. &lt;/LI&gt;
&lt;LI&gt;The DVLA must be notified in all cases. Advise patient to inform DVLA: driving should cease during the acute illness (cars and motorbikes) and until patient has been stable and well for at least 3 years with insight into their condition (LGV/PSV driver) (ref 3) &lt;/LI&gt;
&lt;LI&gt;Encourage resumption of normal activities as soon as possible.&lt;/LI&gt;
&lt;LI&gt;It is important to offer psychological and social support to both patient and family/carer. This may include advice about benefits and housing. Specific referral for family intervention may also be appropriate. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication &lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Antipsychotic medication can reduce psychotic symptoms over 10-14 days. Where access to a specialist is speedy and symptoms relatively mild, especially for a first referral, the specialist may prefer to see the patient unmedicated. &lt;/LI&gt;
&lt;LI&gt;If you decide to treat prior to the patient seeing a specialist, then the first-line treatment should be an atypical antipsychotic (ref 4-8). Examples include olanzapine (5-10 mg a day) if sedation is required or risperidone (4-V6 mg per day) which is relatively non-sedating (BNF section 4.2.1). The use of a typical drug (eg haloperidol) as first-line treatment is no longer recommended. Patients experiencing a first episode of psychosis require lower doses of medication and should be prescribed an atypical drug (ref 9). In a case of relapse where the patient has previously responded to a drug, restart that drug. The dose should be the lowest possible for the relief of symptoms (ref 10). &lt;/LI&gt;
&lt;LI&gt;Anti-anxiety medication may also be used for the short term in conjunction with neuroleptics to control acute agitation (BNF section 4.1.2). Examples include&amp;nbsp; diazepam (5-V10 mg up to four times a day) or lorazepam (1-V2 mg up to four times a day). If required, diazepam can be given rectally or lorazepam IM (although this must be kept refrigerated).&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;In a first episode, continue antipsychotic medication for at least 6 months after symptoms resolve (ref 11). Close supervision is usually needed in order to encourage patient agreement.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Be alert to the risk of co-morbid use of street drugs (eg amphetamines) and alcohol. &lt;/LI&gt;
&lt;LI&gt;Monitor for side-effects of medication: &lt;BR&gt;- acute dystonias or spasms may be managed with oral or injectable antiparkinsonian drugs (BNF section 4.9.2), eg procyclidine (5 mg three times per day) or orphenadrine (50 mg three times per day)&lt;BR&gt;- Parkinsonian symptoms (eg tremor, akinesia) may be managed with oral antiparkinsonian drugs (BNF section 4.9.2), eg procyclidine (5 mg three times per day) or orphenadrine (50 mg three times per day). Withdrawal of antiparkinsonian drugs should be attempted after 2-3 months without symptoms, as these drugs&amp;nbsp; are liable to misuse and may impair memory. &lt;BR&gt;- Akathisia (severe motor restlessness) may be managed with dosage reduction or beta-blockers (eg with propranolol [30-80 mg a day]) (BNF section 2.4). Switching to a low-potency antipsychotic (eg olanzapine or quetiapine) may help&lt;BR&gt;- Tardive dyskinesia is a particularly important side-effect to monitor for. It is associated with longer term use of traditional antipsychotic medication, is severely disabling and can be irreversible&lt;BR&gt;- Other side-effects, eg weight gain and sexual dysfunction, are under-reported and are important reasons for poor adherence. Quetiapine (an atypical antipsychotic) is least likely to elevate serum prolactin and lead to weight gain and should be considered when these side-effects become troublesome. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;More detail on antipsychotic drugs and their differing side-effect profiles can be found in the Maudsley Prescribing Guidelines and the UKPPG (ref 12,13) 
&lt;H2&gt;&lt;BR&gt;Referral &lt;/H2&gt;
&lt;P&gt;Referral should be made under the following conditions:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;As an emergency, if the risk of suicide, violence or neglect is considered significant. &lt;/LI&gt;
&lt;LI&gt;Urgently for ALL first episodes to the early intervention service, to confirm the diagnosis and arrange care planning and appointment of key worker. A home visit may be required. Specific interventions for people experiencing their first episode of psychosis, including specific psychoeducation of the patient and family, (ref 14,15) is one of the requirements of the National Service Framework for Mental Health (ref 16) &lt;/LI&gt;
&lt;LI&gt;For ALL relapses, to review the effectiveness of the care plan, unless there is an established previous response to treatment and it is safe to manage the patient at home. &lt;/LI&gt;
&lt;LI&gt;If&amp;nbsp; there is non-adherence with treatment, treatment resistance, problematic side-effects, failure of community treatment, or concerns about co-morbid drug and alcohol misuse. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Particularly on relapse, referral may be to the Community Mental Health Team or to a member of it, such as a community mental health nurse (community psychiatric nurse [CPN]), as well as to a psychiatrist. &lt;/P&gt;
&lt;P&gt;If there is fever, rigidity and/or labile blood pressure, stop antipsychotic medication and refer immediately to the on-call physician for investigation of neuroleptic malignant syndrome. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Special considerations in children and adolescents &lt;/H2&gt;
&lt;P&gt;Acute disturbance in children and teenagers is usually due to causes other than psychosis, and anxiety symptoms may masquerade as hallucinations or delusions. The diagnosis of psychosis should be made by a specialist and the appropriate specialist referral will usually be to the Child and Adolescent Mental Health Service. 
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Rethink (formerly the National Schizophrenia Fellowship) &lt;BR&gt;England: 020 8974 6814 (Advice line: 10am–3pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:advice@rethink.org" target="_blank"&gt;advice@rethink.org&lt;/A&gt;; website: &lt;A href="http://www.rethink.org/" target="_blank"&gt;http://www.rethink.org&lt;/A&gt;&lt;BR&gt;Scotland: 0131 557 8969&lt;BR&gt;Northern Ireland: 02890 402 323&lt;BR&gt;Monthly social groups for clients with schizophrenia living in the community and support for relatives. &lt;/P&gt;
&lt;P&gt;Schizophrenia Association of Great Britain 01248 354 048&lt;BR&gt;Email: &lt;A href="mailto:info@sagb.co.uk" target="_blank"&gt;info@sagb.co.uk&lt;/A&gt;; website: &lt;A href="http://www.sagb.co.uk/" target="_blank"&gt;http://www.sagb.co.uk&lt;/A&gt;&lt;BR&gt;Offers information and support to sufferers, relatives, friends, carers and medical workers. 
&lt;P&gt;MINDinfoLINE 08457 660 163 (Helpline 9.15am–5.15pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:info@mind.org.uk" target="_blank"&gt;info@mind.org.uk&lt;/A&gt;; website: &lt;A href="http://www.mind.org.uk/" target="_blank"&gt;http://www.mind.org.uk&lt;/A&gt;&lt;BR&gt;Information service for matters relating to mental health. 
&lt;P&gt;SANELine 08457 678000 (Helpline 12noon–2.00am)&lt;BR&gt;Website: &lt;A href="http://www.sane.org.uk/" target="_blank"&gt;http://www.sane.org.uk&lt;/A&gt;&lt;BR&gt;A helpline offering information and advice on all aspects of mental health for those experiencing illness, or for their families or friends. 
&lt;P&gt;Hearing Voices Network 0161 228 3896 (10.30am–3pm, Monday–Wednesday, Friday)&lt;BR&gt;Website: &lt;A href="http://www.hearing-voices.org.uk/" target="_blank"&gt;http://www.hearing-voices.org.uk&lt;/A&gt;&lt;BR&gt;Self-help groups to allow people to explore their voice-hearing experiences. 
&lt;P&gt;Mental Health Care &lt;BR&gt;Website: &lt;A href="http://www.mentalhealthcare.org.uk/" target="_blank"&gt;http://www.mentalhealthcare.org.uk&lt;/A&gt;&lt;BR&gt;This site provides mental health information and research news from the Institute of Psychiatry and the South London and Maudsley NHS Trust in partnership with Rethink. 
&lt;P&gt;The Mental Health Foundation produces the information booklet Understanding Schizophrenia. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW, UK. Tel: 020 7802 0304. Website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;. 
&lt;P&gt;Living With Schizophrenia: a Holistic Approach to Understanding, Preventing and Recovering from Negative Symptoms by John Watkins. South Yarra, Australia: Hill of Content Publishing (now Michelle Anderson Publishing), 1996. 
&lt;P&gt;Working with Voices by R Coleman and M Smith. Handsell Publishing, Gloucester, UK, 1997 Workbook to help voice-hearers manage their voices. 
&lt;P&gt;Hearing Voices: A Common Human Experience by John Watkins. South Yarra, Australia: Hill of Content Publishing (now Michelle Anderson Publishing),1998. 
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; World Health Organization. Schizophrenia: An International Follow-up Study. Chichester: John Wiley &amp;amp; Sons, 1979. (AIV) Large outcome study with two-year follow-up, showed that only 10-15% of patients did not recover from their illness in that two-year period. Another shorter-term follow-up study (Lieberman J, Jody D, Geisler S et al. Time course and biologic correlates of treatment response in first episode schizophrenia. Arch Gen Psychiatry 1993, 50: 369-376) showed that 83% of first-episode psychotic patients treated with antipsychotic medication remitted by one year post-inpatient admission. 
&lt;P&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Kavanagh DJ. Recent developments in expressed emotion and schizophrenia. Br J Psychiatry 1992, 160: 601-620. (AIII) Family support and education, which promotes a more supportive family environment, can reduce relapse rates substantially. 
&lt;P&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Driver and Vehicle Licensing Agency. At a Glance Guide to Medical Aspects of Fitness to Drive. URL &lt;A href="http://www.dvla.gov.uk/" target="_blank"&gt;http://www.dvla.gov.uk&lt;/A&gt;. Further information is available from The Senior Medical Adviser, DVLA, Driver Medical Unit, Longview Road, Morriston, Swansea SA99 ITU, Wales. 
&lt;P&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Atypical antipsychotics appear to be better tolerated, with fewer extrapyramidal side-effects, than typical drugs at therapeutic doses. Even at low doses, extrapyramidal side-effects are commonly experienced with typical drugs. Whether or not atypicals improve the long-term outcome has yet to be established. Risperidone, amisulpride and possibly olanzapine have a dose-related effect. Selected references: 
&lt;P&gt;&lt;STRONG&gt;5 &lt;/STRONG&gt;American Psychiatric Association. Practice guidelines: schizophrenia. Am J Psychiatry 1997, 154(Suppl 4): 1-49. (BII) This reports 60% of patients receiving acute treatment with typical antipsychotic medication, develop significant extrapyramidal side-effects. 
&lt;P&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Mir S, Taylor D. Issues in schizophrenia. Pharmaceut J 1998, 261: 55-58. (CV) This work reviews evidence on efficacy, safety and patient tolerability of atypical antipsychotics. 
&lt;P&gt;&lt;STRONG&gt;7 &lt;/STRONG&gt;Duggan L, Fenton M, Dardennes RM et al. Olanzapine for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 1999. (CI) Twenty-one studies were analysed. Olanzapine was found to be an effective antipsychotic that produced fewer movement side-effects. It did tend to cause more weight gain than the older drugs, however. 
&lt;P&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Hunter RH, Joy CB, Kennedy E et al. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software (C1) Twenty-three studies were analysed. Risperidone might be equally clinically effective as relatively high doses of haloperidol. It causes fewer adverse effects than the side-effect-prone haloperidol. 
&lt;P&gt;&lt;STRONG&gt;9 &lt;/STRONG&gt;National Institute for Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Clinical Guideline 1. December 2002. URL &lt;A href="http://www.nice.org.uk/" target="_blank"&gt;http://www.nice.org.uk&lt;/A&gt;. (AI) 
&lt;P&gt;&lt;STRONG&gt;10&amp;nbsp;&lt;/STRONG&gt;Bollini P, Pampallona S, Orza MJ. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med 1994, 24: 307-316. (AI) For most patients, higher than moderate doses of antipsychotic drugs bring increased side-effects but no additional therapeutic gains. 
&lt;P&gt;&lt;STRONG&gt;11 &lt;/STRONG&gt;Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bull 1995, 21(4): 567-577. (AI) This paper produces overwhelming evidence that continuing maintenance therapy reduces risk of relapse. The authors conclude that it is appropriate to taper or discontinue medication within six months to a year for first-episode patients who experience a full remission of symptoms. 
&lt;P&gt;&lt;STRONG&gt;12 &lt;/STRONG&gt;Taylor D, McConnell D, McConnel H, Kerwin R. The Bethlem and Maudsley NHS Trust Prescribing Guidelines 2001. London: Martin Dunitz Ltd, 2000. 
&lt;P&gt;&lt;STRONG&gt;13 &lt;/STRONG&gt;United Kingdom Psychiatric Pharmacy Group (UKPPG). URL &lt;A href="http://www.ukppg.co.uk/" target="_blank"&gt;http://www.UKPPG.co.uk&lt;/A&gt;. 
&lt;P&gt;&lt;STRONG&gt;14 &lt;/STRONG&gt;Mental Health Commission. Early Intervention in Psychosis: Guidance Note. Wellington, New Zealand, 1999. 
&lt;P&gt;&lt;STRONG&gt;15 &lt;/STRONG&gt;Falloon I, Coverdale J, Laidlaw T et al. Family management in the prevention of morbidity of schizophrenia: social outcome of a 2-year longitudinal study. Psychol Med 1997, 17: 59-66. (AII) Involvement of the family is vital. Education is important for engaging individuals and families in treatment and promoting recovery. Psychological therapies may be helpful. 
&lt;P&gt;&lt;STRONG&gt;16 &lt;/STRONG&gt;Department of Health. National Service Framework for Mental Health. London: HMSO, 1999.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79020</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79020]]&gt;</url>
    <title>Introduction to adjustment disorder</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADJUSTMENT DISORDER,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Adjustment disorder - F43.2 (including acute stress reaction) (Clinical term: Adjustment disorders Eu43.2)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to adjustment disorder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Adjustment disorder - F43.2 (including acute stress reaction) (Clinical term: Adjustment disorders Eu43.2)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Patients feel overwhelmed or unable to cope. &lt;/LI&gt;
&lt;LI&gt;There may be stress-related physical symptoms such as insomnia, headache, abdominal pain, chest pain and palpitations. &lt;/LI&gt;
&lt;LI&gt;Patients may report symptoms of acute anxiety or depression.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Use of alcohol or other substances may increase. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Acute reaction to a recent stressful or traumatic event. &lt;/LI&gt;
&lt;LI&gt;Extreme distress resulting from a recent event, or preoccupation with the event. &lt;/LI&gt;
&lt;LI&gt;Symptoms may be primarily somatic. &lt;/LI&gt;
&lt;LI&gt;Other symptoms may include: &lt;BR&gt;- low or sad mood&amp;nbsp;&lt;BR&gt;- anxiety&lt;BR&gt;-&amp;nbsp;worry&amp;nbsp;&lt;BR&gt;- feeling unable to cope.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Acute reaction usually lasts from a few days to several weeks.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;P&gt;Acute symptoms may persist or evolve over time. Patients should be followed up after 1-2 weeks. If significant symptoms persist, consider an alternative diagnosis. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32#&lt;/LI&gt;
&lt;LI&gt;Generalized anxiety - F41.1 &lt;/LI&gt;
&lt;LI&gt;Panic disorder - F41.0&lt;/LI&gt;
&lt;LI&gt;Chronic mixed anxiety and depression - F41.2 &lt;/LI&gt;
&lt;LI&gt;Unexplained somatic complaints - F45 &lt;/LI&gt;
&lt;LI&gt;Bereavement and loss - Z63 &lt;/LI&gt;
&lt;LI&gt;Post-traumatic stress disorder - F43.1 &lt;/LI&gt;
&lt;LI&gt;Dissociative (conversion) disorder - F44&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Stressful events often have mental and physical effects. The acute state is a natural reaction to events. &lt;/LI&gt;
&lt;LI&gt;Stress-related symptoms usually last only a few days or weeks.&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Elicit and explain patient’s concerns (this is important for preventing somatic symptoms from continuing). &lt;/LI&gt;
&lt;LI&gt;Review and reinforce positive steps the patient has taken to deal with the stress. &lt;/LI&gt;
&lt;LI&gt;Identify steps the patient can take to modify the situation that produced the stress. If the situation cannot be changed, discuss coping strategies. &lt;/LI&gt;
&lt;LI&gt;Identify relatives, friends and community resources able to offer support. &lt;/LI&gt;
&lt;LI&gt;Encourage a return to usual activities within a few weeks. &lt;BR&gt;Short-term rest and relief from stress may help the patient. Consider short-term sickness certification. &lt;/LI&gt;
&lt;LI&gt;Encourage the patient to acknowledge the personal significance of the stressful event. &lt;/LI&gt;
&lt;LI&gt;Offering a further consultation with a member of the primary-care team, to see how the situation develops, can be valuable in helping the patient through the episode.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;Most acute stress reactions will resolve without the use of medication. Skilled GP advice and reassurance is as effective as benzodiazepines (ref 2). However, if severe anxiety symptoms occur, consider using anti-anxiety drugs for up to 3 days. If the patient has severe insomnia, use hypnotic drugs for up to 3 days. Doses should be as low as possible. (BNF sections 4.1.1 and 4.1.2.) &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Usually self-limiting. Routine referral to secondary mental health services is advised if:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;symptoms persist and general referral criteria are met. &lt;BR&gt;unsure of the diagnosis.&lt;/LI&gt;
&lt;LI&gt;Consider recommending a practice counsellor or voluntary/non-statutory counselling (ref 3 &amp;amp; 4) services in all other cases where symptoms persist.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;BACP (British Association for Counselling and Psychotherapy) 0870 443 5252. &lt;BR&gt;Website: &lt;A href="http://www.counselling.co.uk/" target="_blank"&gt;http://www.counselling.co.uk&lt;/A&gt;&lt;BR&gt;Provides advice on sources of individual counselling and family therapy in the UK.&lt;/P&gt;
&lt;P&gt;The Samaritans National phone number 08457 909 090 (helpline 24-hours a day)&lt;BR&gt;Email: &lt;A href="mailto:jo@samaritans.org" target="_blank"&gt;jo@samaritans.org&lt;/A&gt;; website: &lt;A href="http://www.samaritans.org.uk/" target="_blank"&gt;http://www.samaritans.org.uk&lt;/A&gt;&lt;BR&gt;Offers confidential emotional support to any person who is despairing or suicidal. &lt;/P&gt;
&lt;P&gt;Victim Support 0845 30 30 900 (Support line 9am–9pm, Monday–Friday; 9am–7pm, Saturday/Sunday; 9am–5pm, bank holidays)&lt;BR&gt;Email: &lt;A href="mailto:contact@victimsupport.org.uk" target="_blank"&gt;contact@victimsupport.org.uk&lt;/A&gt;; website: &lt;A href="http://www.victimsupport.com/" target="_blank"&gt;http://www.victimsupport.com&lt;/A&gt; &lt;BR&gt;Provides emotional support and practical information for anyone who has suffered the effects of crime, regardless of whether the crime has been reported.&lt;/P&gt;
&lt;P&gt;Citizens Advice Bureau (see local telephone directory)&lt;BR&gt;Main website: &lt;A href="http://www.citizensadvice.org.uk/" target="_blank"&gt;http://www.citizensadvice.org.uk&lt;/A&gt; (gives directory of all offices and advice by email); Advice Guide website: &lt;A href="http://www.adviceguide.org.uk/" target="_blank"&gt;http://www.adviceguide.org.uk&lt;/A&gt;&lt;BR&gt;Provides a wide range of free and confidential advice and help. Subjects include social security benefits, housing, family and personal matters, money advice and consumer complaints. &lt;/P&gt;
&lt;P&gt;Relate 01788 573 241/0845 456 1310&lt;BR&gt;Email: &lt;A href="mailto:enquiries@relate.org.uk" target="_blank"&gt;enquiries@relate.org.uk&lt;/A&gt;; website: &lt;A href="http://www.relate.org.uk/" target="_blank"&gt;http://www.relate.org.uk&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Counselling for adults with relationship difficulties, whether married or not.&lt;/P&gt;
&lt;P&gt;International Stress Management Association (ISMA) UK 0700 780 430 (helpline)&lt;BR&gt;Email: &lt;A href="mailto:stress@isma.org.uk" target="_blank"&gt;stress@isma.org.uk&lt;/A&gt;; website: &lt;A href="http://www.isma.org.uk/" target="_blank"&gt;http://www.isma.org.uk&lt;/A&gt;&lt;BR&gt;Promotes knowledge and best practice in the prevention and reduction of acute stress.&lt;/P&gt;
&lt;P&gt;Coping with stress at work. Talking Life, 1A Grosvenor Road, Hoylake, Wirral CH47 3BS, UK. Tel: 0151 632 0662; website: &lt;A href="http://www.talkinglife.co.uk/" target="_blank"&gt;http://www.talkinglife.co.uk&lt;/A&gt;&lt;BR&gt;This is a tape teaching you to recognize stress symptoms. It includes a relaxation exercise.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Consensus (BV). As people reacting to stresses such as unemployment or divorce are at high risk of developing a mental disorder, studies on prevention in high-risk groups may be relevant. These support the offering of social support and problem-solving. [NHS Centre for Reviews and Dissemination. Mental health promotion in high-risk groups. Effect Health Care Bull 1997, 3(3): 1-10.] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Catalan J, Gath D, Edmonds G, Ennis J. The effects of not prescribing anxiolytics in general practice. Br J Psychiatry 1984, 144: 593-602. (BII) GP advice and reassurance is as effective as administration of benzodiazepines. The mean time spent by the GP for giving advice and reassurance was 12 minutes, compared with 10.5 minutes for giving a prescription. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Roth AD, Fonagy P. What Works For Whom? A Critical Review of Psychotherapy Research. New York: Guilford Press, 1996. (CII) The efficacy of counselling in primary-care settings is difficult to assess because of the methodological problems of available research. It seems more appropriate for milder presentations of disorders, however, than for more severe presentations, and evidence is better for counselling focused on a particular client group (eg relationship or bereavement counselling). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Bower P, Rowland N, Mellor Clark J et al. Effectiveness and cost-effectiveness of counselling in primary care (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (B1) Seven studies were analysed. Results showed that counselling is significantly more effective than 'usual care' in the short- but not the long-term. Satisfaction with counselling was high. Patients had a mix of 'emotional disorders'. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79021</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79021]]&gt;</url>
    <title>Introduction to alcohol misuse</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,ALCOHOL MISUSE,PRIMARY CARE SERVICES,GUIDELINES,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,INDIVIDUAL BEHAVIOUR,ALCOHOL CONSUMPTION,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES,SERVICES,FRAMES OF REFERENCE,HEALTH SERVICES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Alcohol misuse - F10 (Clinical term: Mental and behavioural disorders due to use of alcohol Eu10)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to alcohol misuse&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Alcohol misuse - F10 (Clinical term: Mental and behavioural disorders due to use of alcohol Eu10)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Patients may present with:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;depressed mood &lt;/LI&gt;
&lt;LI&gt;nervousness &lt;/LI&gt;
&lt;LI&gt;insomnia &lt;/LI&gt;
&lt;LI&gt;physical complications of alcohol use (eg ulcer, gastritis, liver disease, hypertension) &lt;/LI&gt;
&lt;LI&gt;accidents or injuries due to alcohol use &lt;/LI&gt;
&lt;LI&gt;poor memory or concentration &lt;/LI&gt;
&lt;LI&gt;evidence of self-neglect (eg poor hygiene) &lt;/LI&gt;
&lt;LI&gt;failed treatment for depression.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;There may also be:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;legal and social problems due to alcohol use (eg marital problems, domestic violence, child abuse or neglect, missed work) &lt;/LI&gt;
&lt;LI&gt;signs of alcohol withdrawal (eg sweating, tremors, sickness, hallucinations [usually visual] seizures)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients may sometimes deny or be unaware of alcohol problems. Family members may request help before patient does (eg because patient is irritable at home or missing work). Problems may also be identified during routine health promotion screening.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Harmful alcohol use:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;/STRONG&gt;heavy alcohol use (e.g. &amp;gt;28 units per week for men and &amp;gt;21 units per week for women)&lt;/LI&gt;
&lt;LI&gt;overuse of alcohol has caused physical harm (e.g. liver disease, gastrointestinal bleeding), psychological harm (e.g. depression or anxiety), or has led to harmful social consequences (e.g. loss of job or breakdown of a relationship).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Alcohol dependence is present when three of the following are present:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;a strong desire or compulsion to use alcohol &lt;/LI&gt;
&lt;LI&gt;difficulty controlling alcohol use &lt;/LI&gt;
&lt;LI&gt;withdrawal symptoms (e.g. anxiety, tremors, sweating) when drinking is ceased &lt;/LI&gt;
&lt;LI&gt;tolerance (e.g. drinks large amounts of alcohol without appearing intoxicated) &lt;/LI&gt;
&lt;LI&gt;continued alcohol use despite harmful consequences &lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;neglect of other activities due to alcohol.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Blood tests such as gamma-glutamyl transferase (GGT) and mean corpuscular volume (MCV) can help identify heavy drinkers. Administering the CAGE or AUDIT questionnaire may also help diagnosis.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;P&gt;Symptoms of anxiety or depression may occur with heavy alcohol use. Alcohol use can also mask other disorders, e.g. agoraphobia, social phobia and generalized anxiety.&amp;nbsp; Assess and manage symptoms of depression or anxiety if symptoms continue after a period of abstinence. &lt;/P&gt;
&lt;P&gt;Drug misuse may also co-exist with this condition. Presentation of other psychiatric disorders should trigger inquiry about alcohol and drug misuse history.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Alcohol dependence is an illness with serious consequences. &lt;/LI&gt;
&lt;LI&gt;Ceasing or reducing alcohol use will bring mental and physical benefits.&lt;/LI&gt;
&lt;LI&gt;Drinking during pregnancy may harm the baby. &lt;/LI&gt;
&lt;LI&gt;Goal-setting needs to be negotiated and matched to individual needs and assessment, as well as overall pattern of drinking and dependence. &lt;/LI&gt;
&lt;LI&gt;For most patients with alcohol dependence, physical complications of alcohol abuse or psychiatric disorder, abstinence from alcohol is the preferred goal (ref 1). Sometimes, abstinence is also necessary for social crises, to regain control over drinking or because of failed attempts at reducing drinking. Because abrupt abstinence can cause withdrawal symptoms, medical supervision is necessary &lt;/LI&gt;
&lt;LI&gt;In some cases of harmful alcohol use, controlled or reduced drinking is a reasonable goal, or a reasonable starting goal where the alcohol-dependent patient is unwilling or unable to quit. &lt;/LI&gt;
&lt;LI&gt;As in many chronic behavioural disorders, relapses are common. Controlling or ceasing drinking often requires several attempts. Outcome depends on the motivation and confidence of the patient.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;(ref 2, 3)&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;In assessing patients with alcohol or other type of addictive behaviour, the framework of cycles of change can be helpful in assessing the patient’s readiness for change. A patient may be:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;precontemplative (ie not considering any change) &lt;/LI&gt;
&lt;LI&gt;contemplative (ie considering change or prepared to change behaviour), or &lt;/LI&gt;
&lt;LI&gt;in an action phase where they are actually in the process of change. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Of course, because of the relapsing nature of these disorders, patients might shift from an action phase, back to a precontemplative change and then move through the phases of change. Assessment can be a prompt for some to move into a contemplative or action phase.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;For all patients:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;discuss costs and benefits of drinking from the patient's perspective &lt;/LI&gt;
&lt;LI&gt;feedback information about health risks, including the results of GGT and MCV &lt;/LI&gt;
&lt;LI&gt;emphasize personal responsibility for change &lt;/LI&gt;
&lt;LI&gt;give clear advice to change and discuss alternative strategies to alter drinking pattern &lt;/LI&gt;
&lt;LI&gt;assess and manage physical health problems and nutritional deficiencies (eg vitamin B) &lt;/LI&gt;
&lt;LI&gt;consider options for&amp;nbsp; problem-solving or targeted counselling to deal with life problems related to alcohol use &lt;/LI&gt;
&lt;LI&gt;brief interventions in primary care settings are effective with hazardous drinking (ref 4).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;If there is no evidence of physical or psychological harm due to drinking and the patient is not dependent, a controlled drinking programme is a reasonable goal:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;negotiate a clear goal for decreased use (e.g. no more than two drinks per day,&amp;nbsp; with two alcohol-free days per week). &lt;/LI&gt;
&lt;LI&gt;discuss strategies to avoid or cope with high-risk situations (e.g. social situations&amp;nbsp; and stressful events) &lt;/LI&gt;
&lt;LI&gt;introduce self-monitoring procedures (e.g. a drinking diary) and safer drinking behaviour (e.g. time restrictions, drinking more slowly, interspersing with non-alcoholic drinks). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;For patients with physical or mental illness and/or dependency, or failed attempts at controlled drinking, an abstinence programme is indicated.&lt;/STRONG&gt; &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;For patients willing to stop now:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;set a definite day to quit &lt;/LI&gt;
&lt;LI&gt;discuss symptoms and management of alcohol withdrawal &lt;/LI&gt;
&lt;LI&gt;discuss strategies to avoid or cope with high-risk situations (e.g. social situations&amp;nbsp; and stressful events) &lt;/LI&gt;
&lt;LI&gt;make specific plans to avoid drinking (e.g. ways to face stressful events without&amp;nbsp; alcohol, ways to respond to friends who still drink) &lt;/LI&gt;
&lt;LI&gt;help patients to identify family members or friends who will support ceasing&amp;nbsp; alcohol use &lt;/LI&gt;
&lt;LI&gt;consider options for support after withdrawal.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;For patients not willing to stop or reduce now, a harm-reduction programme is indicated:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;do not reject or blame &lt;/LI&gt;
&lt;LI&gt;clearly point out medical and social problems caused by alcohol&lt;/LI&gt;
&lt;LI&gt;consider thiamine preparations &lt;/LI&gt;
&lt;LI&gt;make a future appointment to re-assess health and alcohol use.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;For patients who do not succeed, or who relapse:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;identify and give credit for any success&lt;/LI&gt;
&lt;LI&gt;discuss the situations that led to relapse &lt;/LI&gt;
&lt;LI&gt;return to earlier steps above &lt;/LI&gt;
&lt;LI&gt;avoid blame or criticism &lt;/LI&gt;
&lt;LI&gt;be aware of the patient’s sense of failure or self-criticism and give support if needed.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Self-help organizations voluntary and non-statutory agencies are often helpful for patients, families and other people involved (ref 5).&lt;/P&gt;
&lt;P&gt;Doctors have a responsibility to inform patients that they are obligated to inform the DVLA if they have been given a diagnosis of alcohol misuse or dependency; licence restoration only after a period free from alcohol problems and satisfactory medical reports (ref.6). This advice should be documented in the medical records. &lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;(ref 3) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Detoxification:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;/STRONG&gt;For patients with mild withdrawal symptoms, frequent monitoring, support, reassurance, adequate hydration and nutrition are sufficient treatment without medication (ref 7). &lt;/LI&gt;
&lt;LI&gt;Patients with a moderate withdrawal syndrome may require benzodiazepines and vitamins in addition. Most can be detoxified, with a good outcome, as outpatients or at home (ref 8).&amp;nbsp; Community detoxification should only be undertaken by practitioners with appropriate training and supervision. &lt;/LI&gt;
&lt;LI&gt;Patients at risk of a complicated withdrawal syndrome (e.g. with a history of fits or delirium tremens, very heavy use and high tolerance, significant polydrug use, benzodiazepine dependence, severe co-morbid medical or psychiatric disorder) who lack social support or are a significant suicide risk may require specialist input and likely inpatient detoxification, which should be carried out in liaison with specialist alcohol services. &lt;/LI&gt;
&lt;LI&gt;Chlordiazepoxide (Librium; 10 mg) is recommended.&amp;nbsp; The initial dose should be titrated against withdrawal symptoms, within a range of 5–40 mg four times a day.&amp;nbsp; (BNF section 4.10.) This requires close, skilled supervision. &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The following regimen is commonly used, although the dose level and length of treatment will depend on the severity of alcohol dependence and individual patient factors (e.g. weight, sex and liver function): &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Days 1 and 2:&lt;/STRONG&gt;&amp;nbsp;20–30 mg qds &lt;BR&gt;&lt;STRONG&gt;Days 3 and 4:&lt;/STRONG&gt;&amp;nbsp;15 mg qds&lt;BR&gt;&lt;STRONG&gt;Day 5:&lt;/STRONG&gt; &amp;nbsp;10 mg qds &lt;BR&gt;&lt;STRONG&gt;Day 6:&lt;/STRONG&gt; &amp;nbsp;10 mg bd&lt;BR&gt;&lt;STRONG&gt;Day 7:&lt;/STRONG&gt;&amp;nbsp;10 mg nocte &lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Naltrexone may decrease alcohol consumption in people with alcohol dependency but their compliance with treatment appears problematic (ref 9).&lt;/LI&gt;
&lt;LI&gt;Chlomethiazole is not recommended for outpatient detoxification under any circumstances (ref 10). &lt;/LI&gt;
&lt;LI&gt;Dispensing should be daily or involve the support of family members to prevent the risk of misuse or overdose. Confirm abstinence by checking the breath for alcohol, or using a saliva test or breathalyser for the first 3-5 days. &lt;/LI&gt;
&lt;LI&gt;Thiamine (150 mg per day in divided doses) should be given orally for 1 month (ref 11). As oral thiamine is poorly absorbed, transfer patient immediately to a general hospital or clinic with appropriate resuscitation facilities for parenteral supplementation if any one of the following is present: ataxia, confusion, memory disturbance, delirium tremens, hypothermia and hypotension, ophthalmoplegia or unconsciousness. &lt;/LI&gt;
&lt;LI&gt;Daily supervision is essential in the first few days, then advisable thereafter, to adjust dose of medication, assess whether the patient has returned to drinking, check for serious withdrawal symptoms and maintain support.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Supporting abstinence&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Anxiety and depression often co-occur with alcohol misuse. The patient may have been using alcohol to self-medicate. If symptoms of anxiety or depression increase or remain after a period of abstinence of &amp;gt;2-3 weeks.&amp;nbsp; Selective serotonin re-uptake inhibitor (SSRI) antidepressants are preferred to tricyclics because of the risk of tricyclic–alcohol interactions (fluoxetine, paroxetine and citalopram do not interact with alcohol). Other newer drugs such as venlafaxine and mirtazepine can also be considered (BNF section 4.3.3.) For anxiety, benzodiazepines should be avoided because of their high potential for abuse (ref 12) (BNF section 4.1.2.) &lt;/LI&gt;
&lt;LI&gt;Disulfiram (Anatabuse) produces an aversive reaction including flushing, headaches, palpitations and nausea if combined with alcohol. Extreme reactions can produce hypotension, cardiac arrythmias and collapse, resulting in several contraindications and limiting its use. It is more effective if supervised. (BNF section 4.10) (ref 13) &lt;/LI&gt;
&lt;LI&gt;Acamprosate may help to maintain abstinence from alcohol as an adjunct to psychosocial treatment in some cases.&lt;/LI&gt;
&lt;LI&gt;Naltrexone has a similar profile to Acamprosate, but is not currently licensed for this indication in the UK.&lt;BR&gt;For information on brief interventions for people whose drinking behaviour puts them at risk of becoming dependent, see Alcohol Concern's Brief Intervention Guidelines (ref 14).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Consider referral:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;to non-statutory Alcohol Advice and Counselling Agency, if available, and if no psychiatric illness is present &lt;/LI&gt;
&lt;LI&gt;to a specialist NHS alcohol service if the patient has alcohol dependence and requires an abstinence-based group programme or has an associated psychiatric disorder, or if there are no appropriately trained practitioners available in primary care &lt;/LI&gt;
&lt;LI&gt;for general or specialist hospital inpatient detoxification if the patient does not meet the criteria for community detoxification. &lt;/LI&gt;
&lt;LI&gt;to targeted counselling, if available, to deal with the social consequences of drinking (e.g. relationship counselling) &lt;/LI&gt;
&lt;LI&gt;non-urgently to secondary mental health services if there is a severe mental illness (see relevant disorder), or if symptoms of mental illness persist after detoxification and abstinence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;If available, specific, social skills training (ref 15) and community-based treatment packages (ref 16) both may be effective in reducing drinking.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Al-Anon Family Groups UK and Eire 020 7403 0888 (24-hour helpline)&lt;BR&gt;Website: &lt;A href="http://www.al-anonuk.org.uk/" target="_blank"&gt;http://www.al-anonuk.org.uk&lt;/A&gt;&lt;BR&gt;Understanding and support for families and friends of alcoholics whether still drinking or not.&lt;BR&gt;&lt;BR&gt;Alcoholics Anonymous 0845 769 7555 (24-hour helpline)&lt;BR&gt;Website: &lt;A href="http://www.alcoholics-anonymous.org.uk/" target="_blank"&gt;http://www.alcoholics-anonymous.org.uk&lt;/A&gt; &lt;BR&gt;Helpline and support groups for men and women trying to achieve and maintain sobriety and help other alcoholics to get sober.&lt;BR&gt;&lt;BR&gt;National Association for Children of Alcoholics 0117 924 8005&lt;BR&gt;Email: &lt;A href="mailto:help@nacoa.org.uk" target="_blank"&gt;help@nacoa.org.uk&lt;/A&gt;; Website: &lt;A href="http://www.nacoa.org.uk/" target="_blank"&gt;http://www.nacoa.org.uk&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;Drinkline National Alcohol Helpline 0800 917 8282 (11am–7pm, Monday–Friday)&lt;BR&gt;&lt;BR&gt;Secular Organisations for Sobriety (SOS) 020 8698 9332/020 8291 5572 (helpline)&lt;BR&gt;A non-religious self-help group.&lt;BR&gt;&lt;BR&gt;Northern Ireland Community Addiction Service 02890 664 434&lt;BR&gt;&lt;BR&gt;Alcohol Focus Scotland 0141 572 6700&lt;BR&gt;Email:jacklaw@alcohol-focus-scotland.org.uk; website: &lt;A href="http://www.alcohol-focus-scotland.org.uk/" target="_blank"&gt;http://www.alcohol-focus-scotland.org.uk&lt;/A&gt; &lt;BR&gt;Formerly the Scottish Council on Alcohol, initiates and supports actions to promote a healthy approach to the use of alcohol. &lt;BR&gt;&lt;BR&gt;Health Education Authority 020 7430 0850&lt;BR&gt;&lt;BR&gt;Health Development Agency (HDA) 020 7430 0850 &lt;BR&gt;Recorded alcohol information is also available on freephone 0500 801802&lt;BR&gt;Email: &lt;A href="mailto:communications@hda-online.org.uk" target="_blank"&gt;communications@hda-online.org.uk&lt;/A&gt;; website: &lt;A href="http://www.hda-online.org.uk/" target="_blank"&gt;http://www.hda-online.org.uk&lt;/A&gt; &lt;BR&gt;Produces leaflets on sensible drinking. &lt;BR&gt;&lt;BR&gt;Health Education Board for Scotland 0131 536 5500&lt;BR&gt;Website: &lt;A href="http://www.hebs.scot.nhs.uk/" target="_blank"&gt;http://www.hebs.scot.nhs.uk&lt;/A&gt;&lt;BR&gt;Provides leaflets to support brief interventions for people at risk of becoming dependent on alcohol.&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Alcohol, Alcohol and Depression, Alcohol and Other Drug Misuse&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Rosenberg H. Prediction of controlled drinking by alcoholics and problem drinkers. Psychol Bull 1993, 113: 129-139. (BII) This is a qualitative review of the literature. Successful achievement of controlled drinking is associated with less severe dependence and a belief that controlled drinking is possible. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; NHS Centre for Reviews and Dissemination. Brief interventions and alcohol use. Effect Health Care Bull 1993, 1: 1-12. (AI) Brief interventions, including assessing drinking and related problems, motivational feedback and advice, are effective. They are most successful for less severely affected patients. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Slattery J, Chick J, Cochrane M et al. Prevention of Relapse in Alcohol Dependence. Health Technology Assessment Report 3. Glasgow: Health Technology Board for Scotland, 2003. URL &lt;A href="http://www.htbs.co.uk/" target="_blank"&gt;http://www.htbs.co.uk&lt;/A&gt;. (A1) This study looked at treatments for individuals with alcohol dependence. Psychological treatments are effective but brief psychological treatments have no effect. Acamprosate and naltrexone showed significant beneficial effects. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002, 97(3): 265-277. (A1) Three hundred and sixty-one studies were analysed. There is strong evidence for the use of psychological treatments and the drugs acamprosate and naltrexone in treatment of alcohol use disorders. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; McCrady B, Irvine S. Self-help groups. In: Hester R, Miller W (eds.) Handbook of Alcoholism Treatment Approaches: Effective Alternatives. 2nd edition. New York: Allyn and Bacon, 2003. (AIV) This chapter discusses the characteristics of patients who are good candidates for Alcoholics Anonymous (AA). Several studies show AA to be an important support in remaining alcohol-free to patients who are willing to attend. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Driver and Vehicle Licensing Agency. At a Glance Guide to Medical Aspects of Fitness to Drive. URL &lt;A href="http://www.dvla.gov.uk/" target="_blank"&gt;http://www.dvla.gov.uk&lt;/A&gt;. Further information is available from The Senior Medical Adviser, &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; American Psychiatric Association. Practice Guidelines: Substance Use Disorders, 1996. (BIV) Where patients have mild to moderate withdrawal symptoms, general support, reassurance and frequent monitoring is sufficient treatment for two thirds of them, without pharmacological treatment. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Collins MN, Burns T, Van den Berk PA, Tubman GF. A structured programme for out-patient alcohol detoxification. Br J Psychiatry 1990, 156: 871-874. (BIV) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. (B1) Nineteen studies were analysed. Naltrexone may decrease alcohol consumption in people with alcohol dependency but their compliance with treatment appears problematic. It should be given with psychological intervention. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Duncan D, Taylor D. Chlormethiazole or chlordiazepoxide in alcohol detoxification. Psychiatr Bull 1996, 20: 599-601. (AIV) This paper describes randomized controlled trials that show chlordiazepoxide and chlomethiazole to be of equal efficacy; however, chlordiazepoxide is a safer alternative (there is a risk of fatal respiratory depression with alcohol and chlomethiazole) and chlomethiazole is no longer recommended for outpatient use. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Cook CC, Hallwood PM, Thomson AD. B vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Alcohol Alcoholism 1998, 33(4): 317-336. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Kranzler H, Burleson J, Del Boca F et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994, 51: 720-731. (BII) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; Hughes JC, Cook CC. The efficacy of disulfiram: a review of outcome studies Addiction 1997, 92(4): 381-395. (C1) Thirty-eight studies were analysed. Support for the general use of oral disulfiram is equivocal, mostly leading to reduced quantity of alcohol consumed and a reduced number of drinking days. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; Alcohol Concern. Brief Interventions Guidelines. London, 1997. Available from Alcohol Concern, Waterbridge House, 32-36 Loman Street, London SE1 OEE, UK. Tel: +44 20 7928 7377. URL &lt;A href="http://www.alcoholconcern.org.uk/" target="_blank"&gt;http://www.alcoholconcern.org.uk&lt;/A&gt;. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; Holder H, Longabaugh R, Miller W, Rubonis A. The cost effectiveness of treatment for alcoholism: a first approximation. J Stud Alcohol 1991, 52: 517-540. (AI) Treatments aim to improve self-control and social skills - for example, relationship skills, assertiveness and drink refusal. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; Hunt G, Axrin N. A community reinforcement approach to alcoholism. Behav Res Ther 1973, 11: 91-104. (AI) This approach uses behavioural principles and includes training in job finding, support in developing alcohol free social and recreational activities, and an alcohol-free social club.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79024</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79024]]&gt;</url>
    <title>Introduction to attention-deficit / hyperactivity disorder</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,SPECIALTIES,ATTENTION DEFICIT AND HYPERKINETIC DISORDERS,CHILD HEALTH,COMMUNITY CHILD HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Attention-deficit/hyperactivity disorder (ADHD) (most popular term for hyperkinetic disorder - F90)* (Clinical term: Attention deficit disorder Eu97)     
*ADHD is a term taken from DSM-IV. In its US definition it is a much broader category.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to attention-deficit / hyperactivity disorder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Attention-deficit/hyperactivity disorder (ADHD) (most popular term for hyperkinetic disorder - F90)* (Clinical term: Attention deficit disorder Eu97)&amp;nbsp;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;*ADHD is a term taken from DSM-IV. In its US definition it is a much broader category. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Most commonly presents in childhood as a result of complaints by parents or teachers about problems in behaviour and for learning.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;All of the following:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Six of nine features of inattention: careless with detail; fail to sustain attention; appears not to listen; does not finish instructed tasks; poor self-organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; seems forgetful. &lt;/LI&gt;
&lt;LI&gt;Three of five features of hyperactivity: fidgets; leaves seat when should be seated; runs/climbs excessively and inappropriately; noisy in play; persistent motor activity unmodified by social context &lt;/LI&gt;
&lt;LI&gt;One of four features of impulsivity: blurts out answers before question completed; fails to wait turn or queue; interrupts others’ conversation or games; talks excessively for social context. &lt;/LI&gt;
&lt;LI&gt;Pattern of behaviour pervasive across at least two types of situation; information about school. behaviour is therefore very valuable. &lt;/LI&gt;
&lt;LI&gt;Onset no later than age 7. &lt;/LI&gt;
&lt;LI&gt;Causing significant distress or impaired functioning. &lt;/LI&gt;
&lt;LI&gt;Not better explained by another psychiatric disorder.&lt;BR&gt;Excitability, impatience and defiant angry outbursts are common, but as these have many other causes, they do not establish the diagnosis by themselves.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Normal boisterousness or dreaminess &lt;/LI&gt;
&lt;LI&gt;Conduct or oppositional disorders - F91. &lt;/LI&gt;
&lt;LI&gt;Learning disability (mental retardation) - F70. &lt;/LI&gt;
&lt;LI&gt;Disinhibited attachment disorder.&lt;/LI&gt;
&lt;LI&gt;Depressive - F32#, especially in adolescent boys. &lt;/LI&gt;
&lt;LI&gt;Emotional disorders with onset specific to childhood - F93. &lt;/LI&gt;
&lt;LI&gt;Hearing impairment and epileptic seizures should be asked about.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Co-morbidity is common:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;developmental disorders (of reading, motor co-ordination, speech and language) &lt;/LI&gt;
&lt;LI&gt;antisocial behaviour &lt;/LI&gt;
&lt;LI&gt;illicit substance use &lt;/LI&gt;
&lt;LI&gt;emotional and mood disorders &lt;/LI&gt;
&lt;LI&gt;tic disorders and Tourette’s syndrome &lt;/LI&gt;
&lt;LI&gt;autistic spectrum disorder.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;It is essentially a syndrome with various causes, predominantly genetic but including low birth weight, serious early neglect, and fetal alcohol exposure. &lt;/LI&gt;
&lt;LI&gt;It is not directly a result of upbringing, but a child’s behaviour may make it difficult for parents to be positive and supportive. &lt;/LI&gt;
&lt;LI&gt;Manifestations at school may differ from the picture at home. &lt;/LI&gt;
&lt;LI&gt;Recognizing co-morbidity can avoid some of the arguments that may otherwise arise about diagnosis.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1,2)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treat as a chronic disorder. &lt;/LI&gt;
&lt;LI&gt;If you suspect a child has the condition, refer. &lt;/LI&gt;
&lt;LI&gt;Maintain consistency and structure: routines, stated expectations of behaviour, family rules (ref 3). Allowing the child to race around in an ungoverned way in an attempt to diminish hyperactivity will not work. In contrast structured exercise might be helpful, particularly in improving sleep. &lt;/LI&gt;
&lt;LI&gt;Ensure the child has adequate sleep. &lt;/LI&gt;
&lt;LI&gt;Establish constructive communication with school to:&lt;BR&gt;-&amp;nbsp;ensure teachers are informed&lt;BR&gt;-&amp;nbsp;detect special educational needs&lt;BR&gt;-&amp;nbsp;monitor progress (particularly if child is on medication). &lt;BR&gt;Keep confrontations to a minimum. &lt;/LI&gt;
&lt;LI&gt;Make a positive effort to have enjoyable interactions with child: play and praise&lt;/LI&gt;
&lt;LI&gt;Positive interactions should outweigh negative interactions. This should be the basis for any disciplinary intervention; for example the 1-2-3 rule: &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;1.&amp;nbsp;Instruct the child to do something or desist&lt;BR&gt;2.&amp;nbsp;Threat that if not complied with, the child will go to time out &lt;BR&gt;3.&amp;nbsp;Time out - child placed out of communicative contact for one minute per year of age. &lt;/P&gt;
&lt;P&gt;Set realistic expectations, short-term goals, and praise success. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Some children will become more excitable and active with certain foods. These vary from child to child, and parents will usually have identified them. Colouring and preservative exclusion can often be helpful, but radical exclusion diets should only be used under supervision from a paediatric dietician. &lt;/LI&gt;
&lt;LI&gt;There have been anecdotal reports of helpful change with some dietary additives for example fish oils, evening primrose oil, zinc, with no evidence of harmful effects; some can be prescribed.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Medication should always be considered in severe cases; this should follow a specialist assessment. &lt;/LI&gt;
&lt;LI&gt;Stimulant medication (methylphenidate, dexamphetamine) is the most effective means of controlling core symptoms (ref 4,5). It should only be initiated at specialist secondary care level (the paediatrician or child and adolescent psychiatrist). Primary care has an important role in supporting treatment and families. Shared care protocols vary but primary care tasks typically include the following:&lt;BR&gt;- repeat prescriptions&lt;BR&gt;-&amp;nbsp;checking height and weight and entering these on a growth chart&lt;BR&gt;-&amp;nbsp;adjusting doses within narrow limits&lt;BR&gt;-&amp;nbsp;reporting and managing adverse effects&lt;BR&gt;-&amp;nbsp;encouraging child’s positive view of treatment (not as coercion). &lt;/LI&gt;
&lt;LI&gt;Specialists are responsible for clear monitoring, supervision and dosage recommendation. &lt;/LI&gt;
&lt;LI&gt;Stimulant drugs are controlled and need to be prescribed in the doctor’s writing using words and figures to describe dosage and numbers of tablets to be prescribed. They do not, however, lead to dependence in children for whom they are prescribed. &lt;/LI&gt;
&lt;LI&gt;Extended-release preparations are often preferred to avoid the necessity of drugs being given at school. &lt;/LI&gt;
&lt;LI&gt;Second-line drugs include imipramine, bupropion, atomoxetine, risperidone and melatonin. At the time of writing these are not necessarily licensed but may still be appropriate under specialist supervision.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;ADHD should be considered in any child with hyperactive behaviour or inattentiveness reported by teachers. The diagnosis can be difficult in young children and where there is co-morbidity. Many localities have a specialist ADHD clinic; otherwise there may be a choice between a paediatric clinic and Child and Adolescent Mental Health Services.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;ADDISS (The Attention Deficit Disorder Information and Support Service) 020 8906 9068&lt;BR&gt;Website: &lt;A href="http://www.addiss.co.uk/" target="_blank"&gt;http://www.addiss.co.uk&lt;/A&gt;&lt;BR&gt;Advice, support, local self-help groups, conferences and literature.&lt;/P&gt;
&lt;P&gt;CHADD (Children and Adults with ADHD) &lt;A href="http://www.chadd.org/" target="_blank"&gt;http://www.chadd.org&lt;/A&gt;&lt;BR&gt;This is an American support group and a good source of information for parents.&lt;/P&gt;
&lt;P&gt;The Mental Health Foundation produces the information booklet All About ADHD. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW; tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Attention deficit disorder and hyperactivity&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1 &lt;/STRONG&gt;Hill P, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001, 84: 404-409. The authors suggest a good-practice protocol with a checklist. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Jensen PS, Hinshaw SP, Swanson JM et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatrics 2001, 22(1): 60-73. (AII) This is a randomized controlled trial. Results indicated that medication (usually methylphenidate) and combination interventions were substantially superior to behavioural and community care interventions for attention-deficit hyperactivity disorder symptoms. High-quality medication treatment characterized by careful, yet adequate, dosing, three-times-daily methylphenidate administration, monthly follow-up visits and communication with schools conveyed substantial benefits to those children that received it. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; A Cochrane Review will be available soon. Zwi M, Pindoria S, Joughin C. Parent training interventions in attention-deficit/hyperactivity disorder (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; National Institute for Clinical Excellence. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention-Deficit/Hyperactivity Disorder in Childhood. Technology appraisal guidance No.13, 2000; URL &lt;A href="http://www.nice.org.uk/" target="_blank"&gt;http://www.nice.org.uk&lt;/A&gt;. (AI) Services specializing in attention-deficit/hyperactivity disorder (ADHD) should ensure that methylphenidate is used as part of a comprehensive treatment programme for children with a diagnosis of severe ADHD. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Ramchandani P, Joughin C, Zwi M. Attention deficit hyperactivity disorder in children. Clinical Evidence 2002, 8: 280-290. (AI) Methylphendate alone or combined with behavioural treatments and dexamphetamine are beneficial for ADHD.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79799</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79799]]&gt;</url>
    <title>Introduction to bereavement and loss</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,PALLIATIVE AND SUPPORTIVE CARE,DEATH,BEREAVEMENT AND LOSS,SURGERY,NARRATIVES,PLACE OF DEATH,DEATH RITES &amp; RITUALS,BEREAVEMENT,WILLS,FUNERALS,PERIOPERATIVE MANAGEMENT,POST-DEATH,PERIOPERATIVE DEATH,UNEXPECTED OUTCOMES,COMPLICATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Bereavement and loss - Z63 (Clinical term: Grief reaction E2900).</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to bereavement and loss&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Bereavement and loss - Z63 (Clinical term: Grief reaction E2900).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;An acute grief reaction is a normal, understandable reaction to loss. Patients present in different ways, but typically they:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;feel overwhelmed by loss &lt;/LI&gt;
&lt;LI&gt;are preoccupied with the loss &lt;/LI&gt;
&lt;LI&gt;may present with somatic symptoms following loss.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Individual grief experiences vary enormously; they depend on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the type of loss (eg a loved one, health, social status and lifestyle through the loss of a job, or the breakdown of a relationship) &lt;/LI&gt;
&lt;LI&gt;the nature of the loss (expected versus unexpected, traumatic loss, concurrent multiple stressful events, multiple losses) &lt;/LI&gt;
&lt;LI&gt;the individual suffering the loss (eg coping strategies, age, spiritual health, previous experience of loss) and their social context (eg family systems, access to support, cultural context). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Grief may precipitate or exacerbate other psychiatric conditions. It can also become pathological, eg it can be absent, delayed (grief reaction triggered some time after loss) or chronic (intrusive and fixed emotions of grief).&amp;nbsp; Broadly speaking difficulties arise when the response becomes unusually dysfunctional to the individual and those around them.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Besides the emotional response to loss, symptoms resembling depression can occur:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;low or sad mood &lt;/LI&gt;
&lt;LI&gt;disturbed sleep &lt;/LI&gt;
&lt;LI&gt;loss of appetite &lt;/LI&gt;
&lt;LI&gt;loss of interest &lt;/LI&gt;
&lt;LI&gt;restlessness &lt;/LI&gt;
&lt;LI&gt;guilt or self-criticism about actions not taken by the person before the death of the loved one &lt;/LI&gt;
&lt;LI&gt;transient hallucinations of the deceased person such as hearing their voice &lt;/LI&gt;
&lt;LI&gt;thoughts of joining the deceased.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The patient may:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;withdraw from usual activities and social contacts &lt;/LI&gt;
&lt;LI&gt;find it difficult to think of the future &lt;/LI&gt;
&lt;LI&gt;increase his/her use of drugs or alcohol.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patient presentation can be obvious, but it can also be hidden. Adverse reactions to loss may only be revealed after careful questioning.&amp;nbsp; It may be possible to identify certain individuals who are at particular risk (eg social isolation, history of mental illness, previous unresolved grief). Assessing the impact of the loss and the coping strategies available is important in guiding management. Taking time, perhaps over a couple of appointments, may be necessary. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32# Knowing when to use the medical model for depression can be difficult and it is important not to medicalize the problem. That said, disabling depressive symptoms that become protracted (about 4-6 months) or severe (eg retardation, overwhelming guilt, hopelessness, suicidal ideation) may be helped by treatment for depression.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Generalized anxiety - F41.1&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Sleep problems - F51.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Everybody grieves differently. &lt;/LI&gt;
&lt;LI&gt;Important losses are often followed by intense sadness, crying, anger, disbelief, anxiety, guilt or irritability.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Bereavement typically includes preoccupation with the deceased (including hearing or seeing the person). &lt;/LI&gt;
&lt;LI&gt;A desire to discuss the loss is normal and beneficial. &lt;/LI&gt;
&lt;LI&gt;Inform patients, especially those at greater risk of developing an abnormal grief reaction, of local agencies, which offer bereavement counselling and aim to help guide people through their normal grief (ref 1).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 2)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If a loss can be predicted, lead the patient and their family through the challenges facing them with appropriately paced and guided discussion, shared understanding based on the patient’s world view and optimal physical care. &lt;/LI&gt;
&lt;LI&gt;Enable the bereaved person to talk about the deceased and the circumstances of the death. This can provide them with a useful narrative about their loss which will help them in the future. &lt;/LI&gt;
&lt;LI&gt;Answer questions to enable the bereaved to understand what happened at the time of death. &lt;/LI&gt;
&lt;LI&gt;Encourage free expression of feelings about the loss (including feelings of sadness, guilt or anger). In bereavement, be prepared to hear and acknowledge any expressions of anger directed at health professionals, including yourself. Sensitive management of this anger can be crucial. &lt;/LI&gt;
&lt;LI&gt;Offer reassurance that recovery will take time (grief has to run its course). Some reduction in burdens (eg work or social commitments) may be necessary. &lt;/LI&gt;
&lt;LI&gt;Explain that intense grieving will fade slowly and that reminders of the loss may continue to provoke feelings of loss and sadness. &lt;/LI&gt;
&lt;LI&gt;Social structures (eg families) are vulnerable at times of bereavement. Group coping strategies can increase or decrease subsequent individual morbidity and group functioning. &lt;/LI&gt;
&lt;LI&gt;Take into account the cultural context of the loss.&lt;/LI&gt;
&lt;LI&gt;Listening and giving a sense of ‘being there’ for the patient may be all that is needed.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;There is no ‘catch-all’ advice for the patient and family but the following might be helpful:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Do cry if the need is there and don’t be surprised if you cry more than normal, even if it is in unusual places. &lt;/LI&gt;
&lt;LI&gt;Do accept help from others but don’t let people pressure you to do things that don’t feel right or before you are ready. &lt;/LI&gt;
&lt;LI&gt;Don’t feel guilty if you do not always feel upset. There will be many occasions when you need to carry on with everyday things. &lt;/LI&gt;
&lt;LI&gt;Do remember that children and young people need to grieve as well. Let the teachers and school know. &lt;/LI&gt;
&lt;LI&gt;Do remember that people react to grief in different ways; within a family this can be difficult. &lt;/LI&gt;
&lt;LI&gt;Do take care of yourself and try to eat sensibly and rest.&lt;/LI&gt;
&lt;LI&gt;Do try and keep life as normal as possible, with some sort of routine. Do, if you can, avoid any major changes in the first year, such as moving house. &lt;/LI&gt;
&lt;LI&gt;Do take things a day at a time when you are feeling low, but be ready, as time passes, to try new things and meet people.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;Avoid medication if possible. If the grief reaction becomes abnormal, seek advice on the use of antidepressants.&lt;/P&gt;
&lt;P&gt;Disturbed sleep is to be expected.&amp;nbsp; If severe insomnia occurs, short-term use of hypnotic drugs may be helpful but use should be limited to 2 weeks. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;If the patient is failing to respond to the measures outlined above, or symptoms are severe and persistent, or patients are particularly at risk, then more formal grief counselling may help and can be arranged via:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;practice counsellor &lt;/LI&gt;
&lt;LI&gt;Cruse Bereavement Care (adult bereaved) &lt;/LI&gt;
&lt;LI&gt;Compassionate Friends (for those bereaved through the loss of a child) &lt;/LI&gt;
&lt;LI&gt;hospice bereavement services (for those bereaved of hospice patients) &lt;/LI&gt;
&lt;LI&gt;Relate (for those who are suffering through the loss of a relationship).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Referral to secondary mental-health services is advised:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;if the patient is severely depressed, threatening suicide (never be afraid to ask), or showing psychotic features &lt;/LI&gt;
&lt;LI&gt;non-urgently, if symptoms have not subsided by 1 year despite bereavement counselling.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Refer bereaved people with a learning disability to a specialist disability team or specialist learning disability counsellor.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Cruse Bereavement Care 0870 167 1677 (Helpline 9.30am–5.00pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:info@crusebereavementcare.org.uk" target="_blank"&gt;info@crusebereavementcare.org.uk&lt;/A&gt;; website: &lt;A href="http://www.crusebereavementcare.org.uk/" target="_blank"&gt;http://www.crusebereavementcare.org.uk&lt;/A&gt;&lt;BR&gt;Offers support, information, training and direct telephone help to anyone who has been affected by a death. Over 150 branches throughout the UK.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Compassionate Friends 0117 953 9639 (Helpline 10am–4pm, 6.30pm–10.30pm)&lt;BR&gt;Email: &lt;A href="mailto:info@tcf.org.uk" target="_blank"&gt;info@tcf.org.uk&lt;/A&gt;; website: &lt;A href="http://www.tcf.org.uk/" target="_blank"&gt;http://www.tcf.org.uk&lt;/A&gt;&lt;BR&gt;Organization of bereaved parents offering friendship and understanding to others after the death of a child.&lt;/P&gt;
&lt;P&gt;Stillbirth and Neonatal Death Society (SANDS) 020 7436 5881 (Helpline 10am–3pm)&lt;BR&gt;Email: &lt;A href="mailto:support@uk-sands.org" target="_blank"&gt;support@uk-sands.org&lt;/A&gt;; website: &lt;A href="http://www.uk-sands.org/" target="_blank"&gt;http://www.uk-sands.org&lt;/A&gt;&lt;BR&gt;Provides support for parents and families whose baby is stillborn, or dies shortly after birth.&lt;/P&gt;
&lt;P&gt;Foundation for the Study of Infant Deaths (FSID) 0870 787 0554 (helpline) &lt;BR&gt;Email: &lt;A href="mailto:fsid@sids.org.uk" target="_blank"&gt;fsid@sids.org.uk&lt;/A&gt;; website: &lt;A href="http://www.sids.org.uk/" target="_blank"&gt;http://www.sids.org.uk&lt;/A&gt;&lt;BR&gt;National helpline, local parent groups and befrienders to bereaved families who have suffered a cot death.&lt;/P&gt;
&lt;P&gt;Papyrus 01706 214 449&lt;BR&gt;Website: &lt;A href="http://www.papyrus-uk.org/" target="_blank"&gt;http://www.papyrus-uk.org&lt;/A&gt;&lt;BR&gt;Self-help for parents of young people who have committed suicide. &lt;/P&gt;
&lt;P&gt;Relate 01788 573 241&lt;BR&gt;Website: &lt;A href="http://www.relate.org.uk/" target="_blank"&gt;http://www.relate.org.uk&lt;/A&gt;&lt;BR&gt;Counselling for adults with relationship difficulties, whether married or not.&lt;/P&gt;
&lt;P&gt;Growthhouse.org &lt;A href="http://www.growthhouse.org/" target="_blank"&gt;http://www.growthhouse.org&lt;/A&gt;&lt;BR&gt;This is an award winning website for those facing the end of life and bereavement.&lt;BR&gt;&lt;BR&gt;Coping with Bereavement. The Royal College of Psychiatrists. Talking Life, 1A Grosvenor Rd, Hoylake, Wirral CH47 3BS. Tel: 0151 632 0662. website: &lt;A href="http://www.talkinglife.co.uk/" target="_blank"&gt;http://www.talkinglife.co.uk&lt;/A&gt;&lt;BR&gt;A programme on tape of practical advice and support to people of all ages who have been bereaved.&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Bereavement, Sleeping well, Bereavement information pack: for those bereaved by suicide or other sudden death.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Raphael B. Preventive intervention with the recently bereaved. Arch Gen Psychiatry 1997, 34: 1450-1454. (BIII) This work demonstrates that 'high-risk' bereaved people who receive counselling have fewer symptoms of lasting anxiety and tension than those who do not. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Kato PM, Mann T. A synthesis of psychological interventions for the bereaved. Clin Psychol Rev 1999, 19(3): 275-296. (C1) Fourteen studies were analysed. A slight improvement is seen for individual therapies.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79029</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79029]]&gt;</url>
    <title>Introduction to bereavement and loss in childhood</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD HEALTH,SPECIALTIES,MENTAL HEALTH,PALLIATIVE AND SUPPORTIVE CARE,AGE-RELATED ISSUES,DEATH,POPULATIONS AND SETTINGS,BEREAVEMENT AND LOSS,CHILD AND ADOLESCENT CONDITIONS,SURGERY,FUNERALS,WILLS,DEATH RITES &amp; RITUALS,BEREAVEMENT,PLACE OF DEATH,NARRATIVES,PERIOPERATIVE MANAGEMENT,POST-DEATH,COMPLICATIONS,UNEXPECTED OUTCOMES,PERIOPERATIVE DEATH]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Bereavement and loss in childhood - Z63.4 (Clinical term: Grief reaction E2900)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to bereavement and loss in childhood&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Bereavement and loss in childhood - Z63.4 (Clinical term: Grief reaction E2900)Bereavement and loss in childhood - Z63.4 (Clinical term: Grief reaction E2900)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presentation&lt;/H2&gt;
&lt;P&gt;Reaction of children over the age of 10 to the death of a parent or other close family member is similar to that of adults. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Adolescents may develop a depressive disorder and may self-medicate with alcohol or non-prescribed drugs. If depressed, they need assessment for suicidality. Children of normal intelligence who have reached the age of five to seven are capable of comprehending a concept of death that includes the ideas of irreversibility, non-functionality (dead people cannot move, breathe, eat, see, hear, feel) and universality. &lt;/LI&gt;
&lt;LI&gt;Children may not express grief directly but indirectly through play and behaviour. Anger may predominate. They might believe their parent will return, and seem indifferent or unfeeling to others. &lt;/LI&gt;
&lt;LI&gt;They are capable of expressing grief and taking part in community mourning rituals but will often need help and encouragement to do so. &lt;/LI&gt;
&lt;LI&gt;If the death was violent and witnessed by the child, such as in an accident, or where there was also a perceived threat to their own life, post-traumatic stress symptoms are likely to interfere with the normal grief process. &lt;/LI&gt;
&lt;LI&gt;Children younger than four years are unable to understand the reasons for their parent's disappearance and may attribute it to their own 'bad' behaviour. &lt;/LI&gt;
&lt;LI&gt;They may react to loss by predominantly somatic symptoms or a mixture of somatic and behavioural symptoms. These are usually non-specific and include sleeping and eating problems, complaints of abdominal pain and headache, as well as an increase in oppositional or withdrawn behaviour. &lt;/LI&gt;
&lt;LI&gt;Separation anxiety is likely to be present which may present as School refusal.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Children will also be affected by the grief reaction of their surviving parent, which rarely may lead to neglect. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for carers and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Bereavement in childhood is a risk factor for later difficulties (separation anxiety disorder, anxiety, depression or other emotional disorders during childhood and adolescence, and depressive disorder in adult life). The risk can be reduced by good early management and therapeutic intervention, if indicated.&lt;/LI&gt;
&lt;LI&gt;Multiple losses such as moving house or school or repeat changes of carer should be avoided. If unavoidable, try to prepare the child, and enable them to keep contact with previous attachment figures for a time after any move. &lt;/LI&gt;
&lt;LI&gt;Children over five, if well supported, might benefit by seeing the dead parent, because this helps them to understand about the non-functionality of death. (They do not benefit from seeing a mutilated or unrecognizable parent.) &lt;/LI&gt;
&lt;LI&gt;They also are helped by attending the funeral, providing they wish to, and the surviving parent agrees. &lt;BR&gt;•&amp;nbsp;Agencies such as Cruse Bereavement Care offer bereavement support and counselling and publish book lists and pamphlets for children and adolescents. &lt;/LI&gt;
&lt;LI&gt;Family therapy has been shown to improve children’s functioning after bereavement. This might be available from the local Child and Adolescent Mental Health Service (CAMHS), and other agencies. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;(ref 1, 2)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If attending a parent with a terminal illness, consider with the family when and what to tell the child and who should do it. &lt;/LI&gt;
&lt;LI&gt;Explain directly to the child what is happening or has happened to their parent or other family member and answer questions they may have. Reassure them that they will be looked after. &lt;/LI&gt;
&lt;LI&gt;Anticipate that young children may have distorted or immature thinking, eg they might think it was their fault or that their parent/family member will return soon. &lt;/LI&gt;
&lt;LI&gt;Ascertain child’s worries about the health of the remaining parent and any siblings, and reassure. &lt;/LI&gt;
&lt;LI&gt;Encourage participation in the funeral, as appropriate. &lt;/LI&gt;
&lt;LI&gt;Encourage the family to talk about the dead person, share their sorrow together and remember good times. They should help children keep mementos of the dead person, perhaps in a memory box. &lt;/LI&gt;
&lt;LI&gt;Discourage families from giving explanations to the child that are developmentally inappropriate; for example, discourage the explanation that ‘Mummy has gone to heaven’. If a religious explanation is desired, it is better to say 'Mummy’s soul having gone to be with God in heaven. Her body doesn’t work any more and has to be buried or cremated’. &lt;/LI&gt;
&lt;LI&gt;Advise the family to maintain child’s normal routines as far as possible (eg school, nursery). &lt;/LI&gt;
&lt;LI&gt;Reassure the family that most bereaved children recover from the loss with good support; children are resilient. &lt;/LI&gt;
&lt;LI&gt;Ensure that the child’s school is aware of their bereavement and is supportive. &lt;/LI&gt;
&lt;LI&gt;Anticipate anniversary reactions – the first Christmas, birthday and anniversary of the death. Monitor the child’s progress for the next year. &lt;/LI&gt;
&lt;LI&gt;Bereavement support or counselling for child and family (perhaps including family therapy) should be considered in each case as a preventive intervention. &lt;/LI&gt;
&lt;LI&gt;Some charities run groups and/or camps for bereaved children (eg Winston’s Wish in Gloucestershire), again as a preventive intervention. &lt;/LI&gt;
&lt;LI&gt;If the bereavement was a violent, traumatic one, watch for post-traumatic stress symptoms (flashbacks, high arousal, avoidance) and arrange appropriate referral if these persist. Traumatic bereavement giving rise to PTSD is best treated early with cognitive behavioural therapy. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;There is rarely a place for medication with children. &lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Refer to voluntary agency for bereavement counselling for child and parent. Cruse Bereavement Care or the Child Bereavement Network can give details of local services. &lt;/LI&gt;
&lt;LI&gt;Refer to CAMHS if the child or adolescent is showing symptoms or signs of continuing dysfunction (eg school refusal, continuing separation anxiety, persistent somatic or other behavioural problems, parasuicidal behaviour, PTSD). &lt;/LI&gt;
&lt;LI&gt;If health services were involved with the person who died (eg a hospice), these can be very helpful &lt;/LI&gt;
&lt;LI&gt;If family therapy is indicated, CAMHS, some Social Services departments or training institutes might be the appropriate source.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Cruse Bereavement Care&amp;nbsp;&amp;nbsp; 020 8939 9530, Youthline 0808 808 1677 &lt;BR&gt;Website: &lt;A href="http://www.crusebereavementcare.org.uk/" target="_blank"&gt;http://www.crusebereavementcare.org.uk&lt;/A&gt;&lt;BR&gt;Voluntary bereavement care with 150 branches throughout the UK. Offers support, training, direct telephone help to children and young people (of 12–18 years) through the Youthline; publications, help in finding local counselling. The website has a useful guide to ‘Helping children’.&lt;/P&gt;
&lt;P&gt;Child Bereavement Trust 01494 446 648. &lt;BR&gt;Website: &lt;A href="http://www.childbereavement.org.uk/" target="_blank"&gt;http://www.childbereavement.org.uk/&lt;/A&gt;&lt;BR&gt;Offers training for counselling bereaved children and advice on where to obtain help in UK. The website has advice sheets for parents and young people and a list of useful resources, including videos for young people.&lt;/P&gt;
&lt;P&gt;Child Bereavement Network 0115 911 8070&lt;BR&gt;Website: &lt;A href="http://www.ncb.org.uk/cbn/index.htm" target="_blank"&gt;http://www.ncb.org.uk/cbn/index.htm&lt;/A&gt;&lt;BR&gt;This site has an online directory of accessible specialist bereavement support services throughout the UK.&lt;/P&gt;
&lt;P&gt;Winston’s Wish 0845 203 0405&lt;BR&gt;Website: &lt;A href="http://www.winstonswish.org.uk/" target="_blank"&gt;http://www.winstonswish.org.uk&lt;/A&gt;&lt;BR&gt;This is an organization supporting bereaved children and young people, and offering guidance and information to anyone concerned about a child after bereavement. &lt;/P&gt;
&lt;P&gt;SAMM (Support after Murder and Manslaughter) 020 7735 3838&lt;BR&gt;Email: &lt;A href="mailto:enquiries@samm.org.uk" target="_blank"&gt;enquiries@samm.org.uk&lt;/A&gt;; website: &lt;A href="http://www.samm.org.uk/" target="_blank"&gt;http://www.samm.org.uk&lt;/A&gt;&lt;BR&gt;A helpline and useful publications, including some for carers.&lt;/P&gt;
&lt;P&gt;SOBS (Survivors of Bereavement by Suicide) 0870 241 3337 (9am–9pm, daily)&lt;BR&gt;Website: &lt;A href="http://www.uk-sobs.org.uk/" target="_blank"&gt;http://www.uk-sobs.org.uk&lt;/A&gt; &lt;BR&gt;This site offers emotional and practical support to those affected by suicide. Provides a factsheet entitled Understanding Childhood Bereavement.&lt;BR&gt;Institute of Family Therapy 020 7391 9150&lt;BR&gt;Website: &lt;A href="http://www.instituteoffamilytherapy.org.uk/" target="_blank"&gt;http://www.instituteoffamilytherapy.org.uk&lt;/A&gt;&lt;BR&gt;Offers family therapy and training in family therapy.&lt;/P&gt;
&lt;P&gt;BACP (British Association for Counselling and Psychotherapy) 0870 443 5252&lt;BR&gt;Email: &lt;A href="mailto:bacp@bacp.co.uk" target="_blank"&gt;bacp@bacp.co.uk&lt;/A&gt;; website: &lt;A href="http://www.counselling.co.uk/" target="_blank"&gt;http://www.counselling.co.uk&lt;/A&gt;&lt;BR&gt;Will advise on sources of individual counselling and family therapy in the UK.&lt;BR&gt;A leaflet is available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Death in the family - helping children to cope&lt;/P&gt;
&lt;P&gt;When Someone Very Special Dies and When Something Terrible Happens (traumatic bereavement) by M Heegaard. Cruse Bereavement Care, 126 Sheen Road, Richmond, Surrey TW9 1UR; tel: 020 8939 9530.&lt;BR&gt;Work books for children.&lt;/P&gt;
&lt;P&gt;Beyond the Rough Rock. Supporting a Child who has been Bereaved Through Suicide by D Crossley and J Stokes, 2002. Winston’s Wish, The Clara Burgess Centre, Gloucestershire Hospital, Great Western Road, Gloucester GL1 3NN; tel: 0845 203 0405.&lt;BR&gt;Book to help children.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1 &lt;/STRONG&gt;Black D. Bereavement. In: Rutter M, Taylor E (eds.) Child and Adolescent Psychiatry, 4th edn. Oxford: Blackwell Science, 2002: pp. 299-308. This is a review of treatments and interventions. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Harris-Hendriks J, Black D, Kaplan T. When Father Kills Mother - Guiding Children Through Trauma and Grief, 2nd edn. London: Routledge, 2000. This is a comprehensive review of the effects of traumatic bereavement on children and details of treatments.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79036</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79036]]&gt;</url>
    <title>Introduction to bipolar disorder</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,BIPOLAR DISORDER,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Bipolar disorder - F31 (Clinical term: Bipolar affective disorder Eu31)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to bipolar disorder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Bipolar disorder - F31 (Clinical term: Bipolar affective disorder Eu31)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Patients may have a period of depression, mania, mixed manic and depressive symptoms, or unusual or abnormal behaviour, with the pattern described below. &lt;/P&gt;
&lt;P&gt;Referral may be made by others due to the patient’s lack of insight.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Periods of mania with:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;increased energy and activity&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;elevated mood or irritability &lt;/LI&gt;
&lt;LI&gt;rapid speech&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;loss of inhibitions, including financial and sexual inhibitions &lt;/LI&gt;
&lt;LI&gt;decreased need for sleep&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;increased importance of self &lt;/LI&gt;
&lt;LI&gt;delusions, hallucinations, disturbed or illogical thinking.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;The patient may be easily distracted. &lt;BR&gt;&lt;BR&gt;The patient may also have periods of depression with:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;low or sad mood &lt;/LI&gt;
&lt;LI&gt;loss of interest or pleasure &lt;/LI&gt;
&lt;LI&gt;disturbed sleep &lt;/LI&gt;
&lt;LI&gt;poor concentration or irritability&lt;/LI&gt;
&lt;LI&gt;guilt or low self-worth &lt;/LI&gt;
&lt;LI&gt;disturbed appetite &lt;/LI&gt;
&lt;LI&gt;fatigue or loss of energy &lt;/LI&gt;
&lt;LI&gt;suicidal thoughts or acts &lt;/LI&gt;
&lt;LI&gt;delusions, hallucinations, disturbed or illogical thinking.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Either type of episode may predominate. Episodes may alternate frequently or may be separated by periods of normal mood. Psychotic phases include strange or illogical beliefs, or disturbed or illogical thinking. &lt;BR&gt;&lt;BR&gt;Mixed states are very common; even if criteria for mixed states are not met, depressive symptoms are very common in manic episodes and associated manic symptoms can occur in bipolar depression.&lt;BR&gt;Lesser degrees of mania and hypomania can be missed on a brief interview and collateral information from relatives is vital.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Alcohol misuse - F10 or Drug use disorder - F11# can cause similar symptoms. &lt;/LI&gt;
&lt;LI&gt;Chronic psychotic disorders - F20# (psychotic subtype, schizoaffective disorder or schizophrenia) or major Depression - F32#, especially where psychotic symptoms are present.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;/STRONG&gt;Unexplained changes in mood and behaviour can be symptoms of an illness. &lt;/LI&gt;
&lt;LI&gt;Effective treatments are available. Long-term treatment can help prevent future episodes. &lt;/LI&gt;
&lt;LI&gt;If left untreated, manic episodes may become disruptive or dangerous. Manic episodes often lead to loss of job, legal problems, financial problems or high-risk sexual behaviour. When the first, milder symptoms of mania or hypomania occur, referral is often indicated and the patient should be encouraged to see their GP straight away. &lt;/LI&gt;
&lt;LI&gt;Inform patients who are on lithium of the signs of lithium toxicity &lt;/LI&gt;
&lt;LI&gt;Manic symptoms can be followed by depressive symptoms; the patient’s GP should be informed of major changes in the patient’s mood and the occurrence of suicidal ideas.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Remain optimistic and emphasize the patient’s strengths and abilities rather than deficits. &lt;/LI&gt;
&lt;LI&gt;In acute manic or depressive episodes, refer urgently to secondary care. &lt;/LI&gt;
&lt;LI&gt;During depression, assess risk of suicide. (Has the patient frequently thought of death or dying?&amp;nbsp; Does the patient have a specific suicide plan?&amp;nbsp; Have they made serious suicide attempts in the past?&amp;nbsp; Can the patient be sure not to act on suicidal ideas?) Ask about risk of harm to others. &lt;/LI&gt;
&lt;LI&gt;During manic periods:&lt;BR&gt;-&amp;nbsp;avoid confrontation unless necessary to prevent harmful or dangerous acts&lt;BR&gt;-&amp;nbsp;advise caution about impulsive or dangerous behaviour&lt;BR&gt;-&amp;nbsp;close observation by family members is often needed&lt;BR&gt;-&amp;nbsp;if agitation or disruptive behaviour are severe, hospitalization may be required&lt;BR&gt;-&amp;nbsp;suicide is not unknown, especially in mixed states. Identify early warning signs with the patient and family&lt;/LI&gt;
&lt;LI&gt;During depressed periods, consult management guidelines for depression.&lt;/LI&gt;
&lt;LI&gt;Describe illness and possible future treatments. &lt;/LI&gt;
&lt;LI&gt;Encourage the family to consult, even if the patient is reluctant.&lt;/LI&gt;
&lt;LI&gt;Women with bipolar disorder who are planning pregnancy or to become pregnant should seek early advice about control and prevention of the illness and use of medication ante- and postnatally. The risk of relapse is high postnatally.&amp;nbsp; Specialist advice is indicated. &lt;/LI&gt;
&lt;LI&gt;Work with patient and family to identify early warning symptoms of mood swings, in order to avoid major relapse. &lt;/LI&gt;
&lt;LI&gt;The treatment plan should include recognition of early warning signs and the agreed management of crises should be clearly recorded in the medical records; a copy of the plan should be given to the patient, and with the patient’s permission, to the family/carers. &lt;/LI&gt;
&lt;LI&gt;For patients able to identify early symptoms of a forthcoming `high' (sleep disturbance is the most important warning sign for mania), advise:&lt;BR&gt;-&amp;nbsp;planning for a good night's sleep &lt;BR&gt;-&amp;nbsp;avoid taking major decisions&lt;BR&gt;-&amp;nbsp;taking steps to limit capacity to spend money (eg give credit cards to a friend)&lt;BR&gt;-&amp;nbsp;avoiding stimulating or stressful situations (eg parties) (ref 1)&lt;/LI&gt;
&lt;LI&gt;Therapeutic alliances build on respect and feeling valued; encourage the patient to build relationships with key members of the practice team, eg by seeing the same doctor or nurse at each appointment. Use the relationship to discuss the treatment plan, including medication. &lt;/LI&gt;
&lt;LI&gt;DVLA must be notified in all cases. Advise patient to inform DVLA: driving should cease during the acute illness (cars and motorbikes) and until patient has been stable and well for at least 3 years with insight into their condition (LGV/PSV driver) (ref 2) &lt;/LI&gt;
&lt;LI&gt;Cognitive behavioural therapy may be of benefit in relapse prevention of mania and the treatment of depressive episodes.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;If the patient displays psychotic symptoms, increasing agitation, excitement or disruptive behaviour, antipsychotic medication may be needed initially (ref 3) (BNF section 4.2.) Antipsychotic medication has a specific antimanic action. The doses should be the lowest possible for the relief of symptoms (ref 4). If antipsychotic medication causes acute dystonic reactions (eg muscle spasms) or marked extrapyramidal symptoms (eg stiffness or tremors), antiparkinsonian medication (BNF section 4.9), eg procyclidine, 5 mg orally up to three times a day, may be helpful. Routine use is not necessary. Atypical antipsychotics, eg olanzapine, are now widely used and usually obviate the need for antiparkinsonian medication. &lt;/LI&gt;
&lt;LI&gt;Benzodiazepines may also be used in the short term with or without antipsychotic medication and mood stabilizers to control acute agitation (ref 5) (BNF section 4.1.2) and re-establish a normal sleep pattern. Examples include diazepam (5-10 mg up to four times a day) or lorazepam (1-2 mg up to four times a day).&amp;nbsp; If required, diazepam can be given rectally, or lorazepam IM (although it must be kept refrigerated).&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Lithium can help relieve mania (ref 6,7,8,9) and depression (ref 10,11,12) and can prevent episodes from recurring (ref 13,14,15). One usually commences or stops taking lithium only with specialist advice. Some GPs are confident about restarting lithium treatment after a relapse.&amp;nbsp; Alternative mood-stabilizing medications include carbamazepine and sodium valproate (ref 16). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;If lithium is prescribed: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;it takes several days to show effects and is probably slower to act than the antipsychotics - there should be a clear agreement between the referring GP and the specialist as to who is monitoring lithium treatment. Lithium monitoring is ideally carried out using an agreed protocol. If carried out in primary care, monitoring should be done by a suitably trained person.&lt;/LI&gt;
&lt;LI&gt;levels of lithium in the blood should be measured frequently, when adjusting the dose, and every three months in stable patients, 10-14 hours post-dose (desired blood level is 0.4-1.0 mmol/L [BNF section 4.2.3]; locally recommended levels may vary slightly. If blood levels are &amp;gt;1.5 mmo/L or there is diarrhoea and vomiting, stop the lithium immediately. If there are other signs of lithium toxicity (eg tremors, diarrhoea, vomiting, nausea or confusion) stop lithium and check blood level. Renal and thyroid function should be checked every 2-3 months when adjusting the dose, and every 12 months in stable patients (ref 17).&lt;/LI&gt;
&lt;LI&gt;Never stop lithium abruptly (except in the presence of toxicity) - relapse rates are twice as high under these conditions (ref.15, 18). Lithium should be continued for at least six months after symptoms resolve (longer-term use is usually necessary to prevent recurrences). Lithium should be tapered off over at least four weeks, and rebound mania is substantially reduced if the patient is co-prescribed an atypical antipsychotic.&lt;/LI&gt;&lt;/UL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Antidepressant medication is often needed during phases of depression but can precipitate mania when used alone. If the patient becomes hypomanic, stop the antidepressant. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;
&lt;P&gt;Referral to secondary mental health services is advised:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;as an emergency if very vulnerable, eg if there is significant risk of suicide or disruptive behaviour &lt;/LI&gt;
&lt;LI&gt;urgently if significant symptoms continue or escalate despite treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Non-urgent referral or advice from specialist worker is recommended:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;for assessment, care planning and allocation of key worker under the Care Programme Approach &lt;/LI&gt;
&lt;LI&gt;before starting lithium &lt;/LI&gt;
&lt;LI&gt;for medication review and for other treatment strategies, eg cognitive behavioural therapy &lt;/LI&gt;
&lt;LI&gt;because of lithium’s teratogenicity, for preconceptual counselling or contraception advice; for all women with a history of bipolar disorder to plan prevention and management of high risk (up to 50%) of puerperal psychosis.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;The Manic Depression Fellowship (MDF) &lt;BR&gt;England: 020 7793 2600&lt;BR&gt;Email: &lt;A href="mailto:mdf@mdf.org.uk" target="_blank"&gt;mdf@mdf.org.uk&lt;/A&gt;; website: http://, website: &lt;A href="http://www.mdf.org.uk/" target="_blank"&gt;http://www.mdf.org.uk&lt;/A&gt;&lt;BR&gt;Scotland: 0141 560 2050; Email: &lt;A href="mailto:manic@globalnet.co.uk" target="_blank"&gt;manic@globalnet.co.uk&lt;/A&gt;&lt;BR&gt;Wales: 01633 244 244; Email: &lt;A href="mailto:mdf.wales@btclick.com" target="_blank"&gt;mdf.wales@btclick.com&lt;/A&gt;;, website: &lt;A href="http://www.manicdepressionwales.org.uk/" target="_blank"&gt;http://www.manicdepressionwales.org.uk&lt;/A&gt;&lt;BR&gt;Advice, support, local self-help groups and publications list for people with a manic depressive illness.&lt;/P&gt;
&lt;P&gt;A leaflet is available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Manic depressive illness&lt;/P&gt;
&lt;P&gt;Overcoming Mood Swings by Jan Scott. Constable &amp;amp; Robinson, 2001&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Inside Out: A Guide to Self-Management of Manic Depression. Available from the Manic Depression Fellowship, Castle Works, 21 St George’s Road, London SE1 6ES. Tel: 020 7793 2600&lt;/P&gt;
&lt;P&gt;Living Without Depression and Manic Depression: a Workbook for Maintaining Mood Stability by Mary Ellen Copeland. New Harbinger Press, USA&lt;/P&gt;
&lt;P&gt;New Hope for People with Bipolar Disorder by Jan Fawcett. Crown Publications 2000, Victoria, Canada&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Manic Depression Fellowship. Inside Out: A Guide to Self-Management of Manic Depression. London, 1995. Available from the Manic Depression Fellowship, 8-10 High Street, Kingston-upon-Thames, London KT1 1EY, UK. This advice is based on self-management training, 7-12 sessions of which have been shown to increase time between manic episodes. See Perry A, Tarrier N, Morris R et al. Randomised control trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br Med J 1999, 318: 149-152. (BII) Teaching patients to recognise early symptoms of manic relapse and seek early treatment is associated with important clinical improvements in time to first manic relapse, social functioning, and employment. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Driver and Vehicle Licensing Agency. At a Glance Guide to Medical Aspects of Fitness to Drive. URL &lt;A href="http://www.dvla.gov.uk/" target="_blank"&gt;http://www.dvla.gov.uk&lt;/A&gt;. Further information is available from The Senior Medical Adviser, DVLA, Driver Medical Unit, Longview Road, Morriston, Swansea SA99 ITU, Wales. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Chou JC-Y. Recent advances in treatment of acute mania. J Clin Psychopharm 1991, 11: 3-21. (BII) Antipsychotics are effective in mania, and they appear to have a more rapid effect than lithium. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Rifkin A, Doddi S, Karajgi B et al. Dosage of haloperidol for mania. Br J Psychiatry 1994, 165: 113-116. (BII) Doses of haloperidol over 10 mg a day in management of mania confer no benefit. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; American Psychiatric Association. Practice Guidelines: Bipolar Disorder. Washington, DC, 1996. (AII) Four randomized control trials show that benzodiazepines are effective, in place of, or in conjunction with, a neuroleptic in sedating acutely agitated, manic patients. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Cookson J. Lithium: balancing risks and benefits. Br J Psychiatry 1997, 171: 113-119. (BIII) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Dali I. Mania. Lancet 1997, 349: 1157-1160. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Bowden C, Brugger A, Swann A et al. Efficacy of divolproex versus lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994, 271: 918-924. (CII) This is a randomized controlled trial. Lithium is as effective as valproate and more effective than placebo.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; A Cochrane Review will soon be available: Bhagwagar Z, Goodwin G, Geddes J. Lithium for acute mania (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Zornberg G, Pope H Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993, &lt;BR&gt;13: 397-408. (BIII) A review of nine controlled studies shows a high response rate to lithium for acute bipolar depression. Response may take six to eight weeks to become evident, however. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; A Cochrane Review will soon be available. Gijsman HJ, Rendell J, Geddes J, Nolen WA, Goodwin GM. Antidepressants for bipolar depression (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; A Cochrane Review will soon be available. Bhagwagar Z, Goodwin G and Geddes J. Lithium for bipolar depression (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; Goodwin G. Lithium revisited: a re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995, 167: 573-574. (BIII) Trials show prophylactic use of lithium to be effective, although most trials have had methodological flaws. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; Berghofer A, Kossmann B, Muller-Oerlinghausen B. Course of illness and pattern of recurrence in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996, 93: 349-354. The prophylactic effect of lithium can be maintained over at least 10 years. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; Burgess S, Geddes J, Hawton K, Townsend E, Jamieson K, Goodwin G. Lithium or maintenance treatment of mood disorders (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. (A1) Nine studies were analysed. Lithium was more effective than placebo in preventing relapse in bipolar disorder. Caution should be exercised in abruptly stopping lithium therapy in patients who have been taking it successfully for some time, because of the high risk of relapse. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; Macritchie K, Geddes J, Scott J et al. Valproate for acute mood episodes in bipolar disorder (Cochrane Review). In: The Cochrane Library, Issue I. Oxford: Update Software, 2003. (A1) Ten studies were analysed. No significant difference in efficacy was seen between valproate and lithium or between valproate and carbamazepine. Valproate might be less effective in reducing manic symptoms than olanzapine but it could cause less sedation and weight gain. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; Schou M. Effects of long-term lithium treatment on kidney function: an overview. J Psychiatry Res 1988, 22: 287-296. This is a qualitative literature review. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994, 164(2): 149-152. (BIII) Fourteen studies were analysed. More than 50% of new episodes of illness occurred within three months of treatment cessation. Lithium should not be introduced for the prophylactic treatment of bipolar illness unless or until the doctor and patient understand that it must be used for a minimum of two years. If after two years there is no worthwhile benefit, it is more likely that harm, in the form of premature recurrence of mania, will be done.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79046</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79046]]&gt;</url>
    <title>Introduction to bullying</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,SERVICE DELIVERY,CLIENT GROUPS,CHILDREN AND YOUNG PEOPLE,ETHNICITY AND HEALTH,MENTAL HEALTH,BULLYING,CHILD AND ADOLESCENT CONDITIONS,CHILD HEALTH,COMMUNITY CHILD HEALTH,SPECIALTIES,DISEASES AND CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Bullying (clinical term: 13ZF.)

Bullying is defined as the intentional, unprovoked abuse of power by one or more children to inflict pain or cause distress to another child on repeated occasions. It occurs in social groups with clear power relationships and low supervision, to some extent in all schools, and often without apparent provocation.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to bullying&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Bullying (clinical term: 13ZF.)&lt;/P&gt;
&lt;P&gt;Bullying is defined as the intentional, unprovoked abuse of power by one or more children to inflict pain or cause distress to another child on repeated occasions. It occurs in social groups with clear power relationships and low supervision, to some extent in all schools, and often without apparent provocation.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Bullying can have a major impact on the physical and mental health of victims, as well as on their education. It is perceived as stressful by those who experience it (ref 1).&lt;BR&gt;Victims of bullying may present with a variety of psychosomatic symptoms or mental health problems, including the following: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;sleeping difficulties &lt;/LI&gt;
&lt;LI&gt;bed wetting &lt;/LI&gt;
&lt;LI&gt;feeling sad &lt;/LI&gt;
&lt;LI&gt;headaches &lt;/LI&gt;
&lt;LI&gt;stomach aches &lt;/LI&gt;
&lt;LI&gt;irritability, poor concentration &lt;/LI&gt;
&lt;LI&gt;depression, suicidal ideation, deliberate self-harm &lt;/LI&gt;
&lt;LI&gt;somatic symptoms &lt;/LI&gt;
&lt;LI&gt;anxiety &lt;/LI&gt;
&lt;LI&gt;social dysfunction.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Health professionals seeing school children who present with any of these should consider bullying as a possible contributory factor. &lt;/P&gt;
&lt;P&gt;There is some evidence to suggest that bullying can have long-term mental health effects (ref 2, 3). Former victims of bullying are more likely than non-victimized peers to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;be depressed &lt;/LI&gt;
&lt;LI&gt;be anxious &lt;/LI&gt;
&lt;LI&gt;be lonely &lt;/LI&gt;
&lt;LI&gt;have low self-esteem &lt;/LI&gt;
&lt;LI&gt;feel less comfortable with the opposite sex.&lt;BR&gt;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Compared with other children, ‘passive victims’ of bullying tend to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;be cautious &lt;/LI&gt;
&lt;LI&gt;be sensitive &lt;/LI&gt;
&lt;LI&gt;be quiet &lt;/LI&gt;
&lt;LI&gt;be more anxious and insecure &lt;/LI&gt;
&lt;LI&gt;have fewer friends &lt;/LI&gt;
&lt;LI&gt;feel unhappy and lonely &lt;/LI&gt;
&lt;LI&gt;have low self-esteem &lt;/LI&gt;
&lt;LI&gt;have a negative view of themselves and their situation &lt;/LI&gt;
&lt;LI&gt;look upon themselves as failures &lt;/LI&gt;
&lt;LI&gt;feel stupid, ashamed and unattractive. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;A smaller group - ‘proactive victims’ - is characterized by a combination of anxious and aggressive reaction patterns. These children have concentration difficulties, may be overactive and often behave in ways that cause irritation and tension around them. Their behaviour frequently provokes other children who retaliate in a negative fashion. Although any child can be bullied, it is more likely to occur to the following vulnerable children. Those who:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;are shy or lacking in close friends at school &lt;/LI&gt;
&lt;LI&gt;come from an overprotective family environment or a family experiencing crisis or distress &lt;/LI&gt;
&lt;LI&gt;come from a different racial or ethnic group from the majority&lt;/LI&gt;
&lt;LI&gt;differ in some obvious respect from the majority, eg by stammering, having a physical disability or being of short stature &lt;/LI&gt;
&lt;LI&gt;have special educational needs &lt;/LI&gt;
&lt;LI&gt;provoke their peers by their inappropriate behaviour &lt;/LI&gt;
&lt;LI&gt;have Asperger syndrome or other autistic spectrum disorder.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Bullying is more common in boys and in the youngest pupils in a school. &lt;/LI&gt;
&lt;LI&gt;The commonest type of bullying is general name-calling, followed by being physically hit, being threatened and having rumours spread about the bullied individual. &lt;/LI&gt;
&lt;LI&gt;Research suggests an incidence of about one in five for being bullied (with higher figures for children who attend remedial classes or who are of Asian origin) and up to one in ten for bullying others. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Encourage the child to tell their parents and teacher. Reassure them they were right to tell and that the adults will try to work together to keep them safe. &lt;/LI&gt;
&lt;LI&gt;In the first instance, bullying should be dealt with by approaching the school directly to inform it of the problem. Consider involving a school or practice counsellor (ref 4). &lt;/LI&gt;
&lt;LI&gt;Encourage parents to raise the issue with school, possibly against the child’s wishes, if the problem persists. &lt;/LI&gt;
&lt;LI&gt;Bullying interventions in schools include:&lt;BR&gt;-&amp;nbsp;the setting up of whole-school policies&lt;BR&gt;-&amp;nbsp;curriculum-based strategies&lt;BR&gt;-&amp;nbsp;intervening in bullying situations by working directly with pupils involved in bully/victim problems&lt;BR&gt;-&amp;nbsp;setting up school tribunals or ‘bully courts’&lt;BR&gt;-&amp;nbsp;assertiveness training for victims&lt;BR&gt;-&amp;nbsp;making changes to playgrounds&lt;BR&gt;-&amp;nbsp;peer-led interventions (eg peer counseling&lt;BR&gt;-&amp;nbsp;working with lunch-time supervisors.&lt;/LI&gt;
&lt;LI&gt;Being bullied is one of the stressors most strongly associated with suicidal behaviour in adolescents. Both bullies and victims are at increased risk of suicide (ref 5). Bullies need help too.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;
&lt;P&gt;Bullying by fellow pupils is a primary responsibility of the school; every school should have an anti-bullying policy.&lt;BR&gt;&lt;BR&gt;Referral to a specialist Child and Adolescent Mental Health Service is advised if the child or adolescent:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;is severely depressed &lt;/LI&gt;
&lt;LI&gt;has suicidal thoughts &lt;/LI&gt;
&lt;LI&gt;is self-harming &lt;/LI&gt;
&lt;LI&gt;shows social withdrawal &lt;/LI&gt;
&lt;LI&gt;refuses to eat &lt;/LI&gt;
&lt;LI&gt;is severely anxious or has insomnia &lt;/LI&gt;
&lt;LI&gt;is developing school refusal.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Anti-Bullying Campaign 020 7378 1446&lt;BR&gt;Provides help if a child is being bullied or if a child is a bully.&lt;/P&gt;
&lt;P&gt;Childwatch 01482 325 552 &lt;BR&gt;Website: &lt;A href="http://www.childwatch.org.uk/" target="_blank"&gt;http://www.childwatch.org.uk&lt;/A&gt;&lt;BR&gt;Advice for children on bullying and abuse that occurs at home and at school.&lt;/P&gt;
&lt;P&gt;ChildLine 0800 1111 (24-hour helpline) &lt;BR&gt;Website: &lt;A href="http://www.childline.org.uk/" target="_blank"&gt;http://www.childline.org.uk&lt;/A&gt;&lt;BR&gt;Telephone service for all children and young people providing confidential counselling, support and advice on any issue. Parents can also write to ChildLine. &lt;/P&gt;
&lt;P&gt;Kidscape 020 7730 3300 &lt;BR&gt;Website: &lt;A href="http://www.kidscape.org.uk/childrenteens/childrenteensindex.shtml" target="_blank"&gt;http://www.kidscape.org.uk/childrenteens/childrenteensindex.shtml&lt;/A&gt;&lt;BR&gt;This is a charity set up to protect children from danger – whether from peers, adults they know or complete strangers.&lt;/P&gt;
&lt;P&gt;NSPCC (National Society for the Prevention of Cruelty to Children) 0808 800 5000 (helpline)&lt;BR&gt;Website: &lt;A href="http://www.nspcc.org.uk/html/home/needadvice/bullying.htm" target="_blank"&gt;http://www.nspcc.org.uk/html/home/needadvice/bullying.htm&lt;/A&gt;&lt;BR&gt;Charity specializing in child protection and the prevention of cruelty to children.&lt;/P&gt;
&lt;P&gt;Bullying Online &lt;A href="http://www.bullying.co.uk/" target="_blank"&gt;http://www.bullying.co.uk&lt;/A&gt;&lt;BR&gt;Gives help and advice for parents and pupils in dealing with school bullying.&lt;/P&gt;
&lt;P&gt;The Bullying Project &lt;A href="http://www.bullying.org/" target="_blank"&gt;http://www.bullying.org&lt;/A&gt;&lt;BR&gt;Provides online mentoring support programmes, as well as educational resources.&lt;BR&gt;A leaflet is available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): The emotional cost of bullying&lt;/P&gt;
&lt;P&gt;Tackling Bullying: Listening to the Views of Children and Young People. Summary Report by Christine Oliver and Mano Candappa of the Thomas Coram Research Unit, Department for Education and Skills, 2003. Available from ChildLine, 45 Folgate Street, London E1 6GL; tel: 020 7650 3200; website: &lt;A href="http://www.dfes.gov.uk/bullying/" target="_blank"&gt;http://www.dfes.gov.uk/bullying/&lt;/A&gt;.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Sharp S. How much does bullying hurt? The effects of bullying on the personal well being and educational progress of secondary aged students. Education Child Psychol 1995, 12(2): 81-88. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Hawker D, Boulton M. Twenty years' research on peer victimisation and psychosocial maladjustment: a meta-analytic review of cross-sectional studies. J Child Psychol Psychiatry 2000, 42(4): 441-455. (CI) This is a meta-analysis of cross-sectional studies. Results suggest that victimization is most strongly related to depression, and least strongly to anxiety. There was no evidence that victimization is more strongly related. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Deater-Decker K. Recent research examining the role of peer relations in the development of psychopathology. J Child Psychol Psychiatry 2001, 42(5): 565-580.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Dawkins J. Bullying in schools: Doctors' responsibilities. Br Med J 1995, 310: 274-275. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Kaltiala-Heino R, Rimpela M, Marttunen M, Rimpela A, Rantanen P. Bullying, depression and suicidal ideation in Finnish adolescents. Br Med J 1999, 319: 348-51. (CV) Adolescents who are being bullied and those who are bullies are at an increased risk of depression and suicide. The need for psychiatric intervention should be considered not only for victims of bullying but also for bullies.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79078</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79078]]&gt;</url>
    <title>Introduction to child abuse and neglect</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,COMMUNITY CHILD HEALTH,MENTAL HEALTH,CHILD PROTECTION,SPECIALTIES,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,CHILD ABUSE AND NEGLECT]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Child abuse and neglect - Z61.4, Z61.5, Z61.6* (Clinical term: Child abuse ZV612) *This is the coding for sexual and physical abuse; neglect and emotional abuse are not specifically coded under the current ICD-10 classification.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to child abuse and neglect&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Child abuse and neglect - Z61.4, Z61.5, Z61.6* (Clinical term: Child abuse ZV612) *This is the coding for sexual and physical abuse; neglect and emotional abuse are not specifically coded under the current ICD-10 classification.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Abuse is not usually presented as the problem. Instead, children present with complaints that are the sequelae of abuse or neglect. Most of these are psychological or behavioural, some are physical.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Recognition and diagnostic features&lt;/H2&gt;
&lt;P&gt;Four forms of maltreatment are recognized: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;neglect - the persistent failure to meet a child’s physical and psychological needs by lack of supervision or provision (N) &lt;/LI&gt;
&lt;LI&gt;physical abuse and non-accidental injury (which includes fabricated or induced illness) (PA) &lt;/LI&gt;
&lt;LI&gt;sexual abuse (CSA)&lt;/LI&gt;
&lt;LI&gt;emotional abuse (EA).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Different forms may lead to different sequelae, but there is often co-occurrence of more than one form. All forms include some element of emotional maltreatment, but emotional abuse may occur on its own.&lt;BR&gt;&lt;BR&gt;Children with disabilities are particularly vulnerable. Children of all ages may experience abuse and neglect.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Physical neglect and emotional abuse often continue from early childhood &lt;/LI&gt;
&lt;LI&gt;Physical abuse in infancy may cause serious injury and occasionally death or lasting disability. Later in childhood, it is associated more with inappropriate and harsh punishment.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Sexual abuse is more common in adolescence and in girls, although young boys are also abused.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Child abuse and neglect are recognized by: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ill-treatment that the child receives (including both omission and commission). Neglect and emotional abuse are observable forms of ill treatment &lt;/LI&gt;
&lt;LI&gt;harm arising from the abuse or neglect.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;During routine or unrelated medical examinations, children may be found to have signs of the results of child abuse and neglect. Occasionally, an injured child may be brought for treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Signs of physical harm:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Multiple superficial injuries of varying ages, for which no reasonable explanation is give - for example&amp;nbsp; bruises (which may resemble the shape of the article used to inflict the bruise), abrasions, cuts or cigarette burns (PA). &lt;/LI&gt;
&lt;LI&gt;Fractures - rib, metaphyseal and spiral fracture; skull in non-ambulant children (PA). &lt;/LI&gt;
&lt;LI&gt;Retinal and subdural haemorrhages in non-ambulant children (PA). &lt;/LI&gt;
&lt;LI&gt;Failure to thrive and short stature (EA; N). &lt;/LI&gt;
&lt;LI&gt;Poisoning, asphyxiation (PA - induced illness). &lt;/LI&gt;
&lt;LI&gt;Delayed or no immunizations (N). &lt;/LI&gt;
&lt;LI&gt;Untreated medical conditions (N). &lt;/LI&gt;
&lt;LI&gt;Sexually-transmitted diseases (CSA).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Indicators of psychological harm:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32# (CSA)&lt;/LI&gt;
&lt;LI&gt;Anxiety (recent onset) (EA; CSA). &lt;/LI&gt;
&lt;LI&gt;Low self-esteem (PA; EA; CSA). &lt;/LI&gt;
&lt;LI&gt;Post-traumatic stress disorder - F43 (adult) (CSA)&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Conduct or oppositional-defiant disorder - F91 (PA) (EA) &lt;/LI&gt;
&lt;LI&gt;Sexualized behaviour inappropriate to age and stage of development (CSA). &lt;/LI&gt;
&lt;LI&gt;Deliberate self-harm (CSA). &lt;/LI&gt;
&lt;LI&gt;Substance misuse - F10, F11# (CSA). &lt;/LI&gt;
&lt;LI&gt;Educational underachievement (N; EA). &lt;/LI&gt;
&lt;LI&gt;Social isolation (EA).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Recognition of sexual abuse ultimately relies most strongly on the child’s verbal disclosures or descriptions. The reliability and credibility of a child’s descriptions are often closely scrutinized and challenged, despite the fact that false allegations are rare. Most cases of child sexual abuse have no physical signs and, when found, are rarely conclusive proof of abuse, being regarded as (only) compatible with the child’s account of sexual abuse.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;Child abuse and neglect is often disputed or denied by the parents or alleged abusers. There may well be a delay in presentation of the child to a doctor, and the history/explanation might be inconsistent, changing and not compatible with the injury or child’s development.&lt;/P&gt;
&lt;P&gt;Some forms of ill-treatment are readily observable:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Neglect with lack of supervision leading to accidents or lack of hygiene and provision of basic care &lt;/LI&gt;
&lt;LI&gt;Emotional abuse, including frequent negativity towards, and excessive punishment of, the child.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;What may be in dispute is the extent to which these forms of parent-child interaction are actually harming the child and qualify for the term 'abuse'. &lt;/P&gt;
&lt;P&gt;None of the list of possible presentations is caused exclusively by child abuse or neglect, although some patterns of physical injury (eg certain fractures, bruises, retinal and subdural haemorrhages, genital and perianal signs) are strongly suggestive or typical of abuse. They require immediate intervention to safeguard the child, and expert validation.&lt;/P&gt;
&lt;P&gt;It is important to exclude likely alternative explanations for the child’s difficulties. Mental ill-health of the parent or suspected abuser, or their mental ill-health, substance abuse or domestic violence are risk factors for child abuse and neglect. However, not all troubled adults are responsible for child abuse and neglect.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Everyone, particularly those in a professional role, has a responsibility to report any concerns. &lt;/LI&gt;
&lt;LI&gt;Professionals must work together in partnership with the family to protect the child(ren); there may be a need to override confidentiality in the interests of interdisciplinary communication. &lt;/LI&gt;
&lt;LI&gt;The child is not responsible for the abuse. &lt;/LI&gt;
&lt;LI&gt;Child protection procedures and the statutory centrality of Social Services should be explained.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sharing information and reporting:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Follow local ACPC (Area Child Protection Committee) guidelines &lt;/LI&gt;
&lt;LI&gt;If in doubt about possible child abuse and neglect, discuss with health visitor and named or designated doctor in the primary care team &lt;/LI&gt;
&lt;LI&gt;If suspicious or likely child abuse and neglect, report to Social Services.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Immediate treatment:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Few children require immediate medical or psychiatric treatment. Exceptions are those who have been seriously injured, infected with a sexually-transmitted disease, are pregnant, or those acutely traumatized by the abuse. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Multidisciplinary response:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The first step is to determine whether the child and other children in the family need immediate protection. The closer the relationship between the non-abusing caregiver(s) and the (suspected) abuser, the more precarious the position of the child. The term 'close' includes love, fear or dependency. &lt;/LI&gt;
&lt;LI&gt;This requires a multidisciplinary assessment, led by Social Services usually in collaboration with other agencies - health, police, voluntary organizations (eg NSPCC). &lt;/LI&gt;
&lt;LI&gt;A strategy discussion may be followed by a Child Protection Conference (CPC).&amp;nbsp; It is important that the GP attends the CPC or sends a report of salient information about the child and family&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;ensuring protection may require an emergency protection order and placing of the child's name on the Child Protection Register with a protection plan and sometimes through court proceedings &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Supporting the child and family:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Acknowledge the crisis and distress that investigation and intervention cause to the child and family. &lt;/LI&gt;
&lt;LI&gt;Acknowledge that there may be conflicting interests between the needs of the child and those of the parents.&lt;/LI&gt;
&lt;LI&gt;Explain that in law (Children Act 1989) the child's welfare is paramount. &lt;/LI&gt;
&lt;LI&gt;Facilitate meaningful contact for the child with trusted and familiar persons who are supportive of the child's needs. &lt;/LI&gt;
&lt;LI&gt;Support the child who discloses abuse not to feel responsible for the abuse or guilty about disclosing it. Beyond the needs of the medical history taking, do not question the child about the concern and do not make unrealistic promises.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Actively support the non-abusing parent(s), who is often very distressed and who may feel torn between the abuser and child. &lt;/LI&gt;
&lt;LI&gt;Help the parents to accept that acknowledging responsibility for the maltreatment is a difficult, painful but necessary process in order to achieve positive change for the child and family.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The GP must ensure treatment is provided for children whose names are not on the Child Protection Register and for whom there is therefore no protection plan. &lt;/LI&gt;
&lt;LI&gt;A comprehensive treatment plan includes help for the child, the non-abusing caregiver(s), siblings and the abuser. &lt;/LI&gt;
&lt;LI&gt;Parents may require parenting work and considerable social support. Such help often needs to be maintained for long periods, as change may not be sustained after a short but intensive course of intervention. &lt;/LI&gt;
&lt;LI&gt;Many abused children require educational remediation for their associated educational underachievement &lt;/LI&gt;
&lt;LI&gt;Treatment for the child depends on the nature of the maltreatment and the sequelae; there is no unitary post-abuse syndrome, not even following specific forms such as sexual abuse. Treatment needs to be based on an individual's needs at any given time and may be given in groups or individually. &lt;/LI&gt;
&lt;LI&gt;Group therapy is not appropriate where a case is subject to a criminal inquiry that may result in criminal court proceedings (ref 2). &lt;/LI&gt;
&lt;LI&gt;Cognitive behavioural therapy is effective for PTSD and sexualized behaviour &lt;/LI&gt;
&lt;LI&gt;Treatment should be given for Depressive disorder - F32, Substance misuse - F10, F11 and Deliberate self-harm which often develop in adolescence. &lt;/LI&gt;
&lt;LI&gt;As well as emotional and behavioural difficulties, some maltreated children undergo social disruption as part of the necessary protection process. They experience considerable difficulties arising from separations and impermanence and require active support through this process &lt;/LI&gt;
&lt;LI&gt;Some children require more intensive psychotherapy for the effects of the abuse. &lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Liaison and referral&lt;/H2&gt;
&lt;P&gt;Treating agencies include social services, family centres, child and adolescent mental health services, adult mental health and substance misuse services, and voluntary agencies (eg the NSPCC).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;NSPCC (National Society for the Protection of Children) 0808 800 5000 (24-hour child protection helpline)&lt;BR&gt;Email: &lt;A href="mailto:help@nspcc.org.uk" target="_blank"&gt;help@nspcc.org.uk&lt;/A&gt;; website: &lt;A href="http://www.nspcc.org.uk/" target="_blank"&gt;http://www.nspcc.org.uk&lt;/A&gt;&lt;BR&gt;This is a charity specializing in child protection and the prevention of cruelty to children.&lt;/P&gt;
&lt;P&gt;ChildLine 0800 1111 (24-hour helpline)&lt;BR&gt;Website: &lt;A href="http://www.childline.org.uk/" target="_blank"&gt;http://www.childline.org.uk&lt;/A&gt;&lt;BR&gt;A telephone service for all children and young people providing confidential counselling, support and advice on any issue. Parents can also write to ChildLine. &lt;/P&gt;
&lt;P&gt;Like it is&lt;BR&gt;Email: &lt;A href="mailto:likeitis@stopes.org.uk" target="_blank"&gt;likeitis@stopes.org.uk&lt;/A&gt;; website: &lt;A href="http://www.likeitis.org.uk/" target="_blank"&gt;http://www.likeitis.org.uk&lt;/A&gt;&lt;BR&gt;Sex education for young people.&lt;/P&gt;
&lt;P&gt;Youth2Youth 020 8896 3675&lt;BR&gt;Email: &lt;SPAN style="COLOR: rgb(31,73,125); FONT-STYLE: normal; FONT-FAMILY: Arial"&gt;&lt;A href="mailto:talk@youth2youth.co.uk" target="_blank"&gt;talk@youth2youth.co.uk&lt;/A&gt;&lt;/SPAN&gt;; website: &lt;A href="http://www.youth2youth.co.uk/" target="_blank"&gt;http://www.youth2youth.co.uk&lt;/A&gt;&lt;BR&gt;Telephone, email and online chat line run by young people for young people.&lt;/P&gt;
&lt;P&gt;Ask Brook 020 7284 6040&lt;BR&gt;Email: &lt;A href="mailto:admin@brookcentres.org.uk" target="_blank"&gt;admin@brookcentres.org.uk&lt;/A&gt;; website: &lt;A href="http://www.brook.org.uk/" target="_blank"&gt;http://www.brook.org.uk&lt;/A&gt;&lt;BR&gt;Provides free and confidential sexual health advice and contraception to young people up to the age of 25 &lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Domestic Violence: It’s Affects on Children, Child Abuse and Neglect: the Emotional Effects&lt;BR&gt;A leaflet is available from the Royal College of General Practitioners (&lt;A href="http://www.rcgp.org.uk/" target="_blank"&gt;http://www.rcgp.org.uk&lt;/A&gt;): Domestic Violence in Families with Children&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Bannon MJ, Carter YH. The Role of Primary Care in the Protection of Children from Abuse and Neglect. A joint position paper with the Royal College of Paediatrics and Child Health and endorsed by the NSPCC. London: RCGP Publications, 2003. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Home Office/CPS/Department of Health Practice. Guidance Provision of Therapy for Child Witnesses Prior to a Criminal Trial. URL &lt;A href="http://www.doh.gov.uk/scg/therapy/therapybooklet.htm" target="_blank"&gt;http://www.doh.gov.uk/scg/therapy/therapybooklet.htm&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>82617</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=82617]]&gt;</url>
    <title>Introduction to chronic (persistent) psychotic disorders</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Includes schizophrenia, schizoaffective disorders, schizotypal disorder, persistent delusional disorders, induced delusional disorder, other non-organic psychotic disorders.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to chronic (persistent) psychotic disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Chronic (persistent) psychotic disorders* - F29# (Clinical term: Schizophrenia Eu20). Includes schizophrenia, schizoaffective disorders, schizotypal disorder, persistent delusional disorders, induced delusional disorder, other non-organic psychotic disorders&lt;/P&gt;
&lt;P&gt;* Chronic psychosis has become a pejorative term: persistent psychosis embraces the possibility of recovery.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Many patients will have an established history of psychosis; others, however, may be unknown to specialized services, particularly those with more insidious presentations or those who have disengaged or are homeless.&lt;/P&gt;
&lt;P&gt;Patients may present with the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;difficulties with thinking or concentrating (eg they think that the television is talking to them, or that their thoughts are being read) &lt;/LI&gt;
&lt;LI&gt;reports of hearing voices or seeing visions &lt;/LI&gt;
&lt;LI&gt;strange beliefs (eg having supernatural powers or being persecuted) &lt;/LI&gt;
&lt;LI&gt;extraordinary physical complaints (eg strange sensations or having unusual objects inside their body) &lt;/LI&gt;
&lt;LI&gt;problems or questions related to antipsychotic medication &lt;/LI&gt;
&lt;LI&gt;problems in managing work, studies or relationships &lt;/LI&gt;
&lt;LI&gt;physical health care problems (eg weight, respiratory or cardiac problems) &lt;/LI&gt;
&lt;LI&gt;lack of energy or motivation and an inability to feel emotion &lt;/LI&gt;
&lt;LI&gt;depression or suicidal thinking.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Families might seek help because of apathy, withdrawal, poor hygiene, or strange behaviour.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Persistent problems with the following features:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;social withdrawal and/or poor social integration &lt;/LI&gt;
&lt;LI&gt;low motivation, interest or self-neglect &lt;/LI&gt;
&lt;LI&gt;disordered thinking (exhibited by strange or disjointed speech).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Periodic episodes of:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;depression (co-existing depression is a common, and is sometimes a serious consequence of persistent psychosis; there is a serious risk of suicide) &lt;/LI&gt;
&lt;LI&gt;agitation or restlessness &lt;/LI&gt;
&lt;LI&gt;bizarre behaviour &lt;/LI&gt;
&lt;LI&gt;hallucinations (false or imagined perceptions, eg hearing voices) &lt;/LI&gt;
&lt;LI&gt;delusions (firm beliefs that are often false, eg patient is related to royalty, receiving messages from the television, being followed or persecuted) &lt;/LI&gt;
&lt;LI&gt;intense fear, anxiety and distress.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It can be difficult to ask patients about strange thoughts and hallucinations. Useful questions include, ‘Have you had the feeling lately that people are talking or plotting about you, or trying to hurt you?’, ‘Is there anything special about you that would make anyone want to do that?’ ‘Have there been times lately when you have heard noises or voices or seen strange things when no one else was about and there was nothing else to explain it?’&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32# (if low or sad mood, pessimism and/or feelings of guilt; co-morbid depression is common). &lt;/LI&gt;
&lt;LI&gt;Bipolar disorder - F31 (if symptoms of mania excitement, elevated mood, exaggerated self-worth is prominent). &lt;/LI&gt;
&lt;LI&gt;Alcohol misuse - F10 or Drug use disorders - F11#. Chronic intoxication or withdrawal from alcohol or other substances (stimulants, hallucinogens) can cause psychotic symptoms. &lt;/LI&gt;
&lt;LI&gt;Patients with persistent psychosis might misuse drugs and/or alcohol.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Agitation and strange behaviour can be symptoms of a mental disorder. &lt;/LI&gt;
&lt;LI&gt;Symptoms may come and go over time. &lt;/LI&gt;
&lt;LI&gt;Medication should be part of an overall holistic and multi-axial approach to care and can help by reducing current difficulties and the risk of relapse. &lt;/LI&gt;
&lt;LI&gt;Stable living conditions (eg stable accommodation, adequate income, daily work or activities) are a pre-requisite for effective rehabilitation and recovery. &lt;/LI&gt;
&lt;LI&gt;It is important for family/carers to work with the doctors to learn to recognise early warning signs of relapse and for an advance agreement to be established with the patient and family/carers on how crises should be managed. &lt;/LI&gt;
&lt;LI&gt;Voluntary organizations can provide valuable information, support and self-management courses to the patient and carers.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Remain optimistic and emphasize the patient’s strengths and abilities rather than deficits. &lt;/LI&gt;
&lt;LI&gt;Recovery often takes place in small steps and, for the patient, being engaged in an activity that is meaningful to them might be as important as symptom control. &lt;/LI&gt;
&lt;LI&gt;Discuss a treatment plan with the patient, in line with NICE good practice; (ref 1) provide information on the condition, treatment choices and informed discussion. The treatment plan should include recognition of early warning signs and the agreed management of crises should be clearly recorded in the medical records. A copy of the plan should be given to the patient and, with their permission, to the family/carers. &lt;/LI&gt;
&lt;LI&gt;Explain that drugs help prevent relapse, and discuss information on effects and side-effects with the patient. &lt;/LI&gt;
&lt;LI&gt;The DVLA must be notified in all cases. Advise patient to inform DVLA: driving should cease until patient has been stable and well for at least three years and has insight into his/her condition (LGV/PSV driver) (ref 2) &lt;/LI&gt;
&lt;LI&gt;Support patient to function in the areas that are important to him/her (eg work, recreation, relationships). &lt;/LI&gt;
&lt;LI&gt;It is important proactively to offer patients the same health promotion and prevention measures as the general population (eg smoking cessation, weight control, screening for diabetes and sexual health). &lt;/LI&gt;
&lt;LI&gt;Substance misuse (seen in over 30% of cases) will increase the chance of relapse. &lt;/LI&gt;
&lt;LI&gt;Psychological therapies for both the patient and family/carers might help prevent relapse, promote recovery, and are increasingly available in local services. Encourage the patient to engage with psychological therapies where available (eg cognitive behavioural therapy, family therapy, problem-solving interventions). &lt;/LI&gt;
&lt;LI&gt;Family interventions or problem-solving work might help improve patient and carer health. &lt;/LI&gt;
&lt;LI&gt;Therapeutic alliances build on respect and feeling valued. Encourage the patient to build relationships with key members of the practice team, for example by seeing the same doctor or nurse at each appointment. Use the relationship to discuss the treatment plan including medication advantages of medication and to review the effectiveness of the care plan.&lt;/LI&gt;
&lt;LI&gt;Acute psychotic disorder - F23. Advise on the management of agitated or excited states. &lt;/LI&gt;
&lt;LI&gt;If care is shared with the Community Mental Health Team, agree who is to do what. &lt;/LI&gt;
&lt;LI&gt;Support of the carer is essential for effective treatment and rehabilitation. An assessment of the patient’s needs and those of the carer (under the Carer’s Recognition and Services Act) can be requested from the local Social Services department.&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Antipsychotic medication may reduce psychotic symptoms (BNF section 4.2.1). &lt;/LI&gt;
&lt;LI&gt;Some patients remain stable on the older medications (eg trifluoperazine, chlorpromazine). If effective and well tolerated, NICE guidance suggests the drug should be continued (ref 1). If ineffective or poorly tolerated, NICE guidance suggests an atypical medication should be considered (ref 1). &lt;/LI&gt;
&lt;LI&gt;Atypical antipsychotics, for example olanzapine (5–10 mg a day) or risperidone (2-4 mg per day), should be considered as a first-line treatment (ref 1). &lt;/LI&gt;
&lt;LI&gt;Inform the patient that continued medication helps reduce risk of relapse. In general, antipsychotic medication should be continued for at least one year. &lt;/LI&gt;
&lt;LI&gt;The dose should be the lowest possible for relief of symptoms and effective daily functioning. &lt;/LI&gt;
&lt;LI&gt;If, after team support, the patient is reluctant or erratic in taking medication, injectable long-acting antipsychotic medication could be considered in order to ensure continuity of treatment and reduce risk of relapse (ref 3).&amp;nbsp; It should be reviewed at 4-6 monthly intervals, and a weight gain and physical annual heath check is essential to decrease the risk of cardiac and respiratory effects of medication and a sedentary lifestyle. Doctors and nurses who give depot injections in primary care need training to do so (ref 4). If available, specific counselling about medication is also helpful (ref 5). As part of the ‘shared care plan’, decide who is to contact the patient should he/she fail to attend an appointment. &lt;/LI&gt;
&lt;LI&gt;Discuss the potential side-effects with the patient. Common motor side-effects, particularly with older antipsychotics, include the following: &lt;BR&gt;-&amp;nbsp;Acute dystonias or spasms and parkinsonian symptoms (eg tremor and akinesia), which can be managed with antiparkinsonian drugs (eg orphenadrine [50 mg three times a day] ); (BNF section 4.9) &lt;BR&gt;-&amp;nbsp;withdrawal of antiparkinsonian drugs should be attempted after 2-3 months without symptoms, as these drugs are liable to misuse and may impair memory.&lt;BR&gt;-&amp;nbsp;Akathisia (severe motor restlessness) can be managed with dosage reduction, or beta-blockers (eg propranolol at 30–80 mg a day) (BNF section 2.4). A change in medication might be necessary&lt;BR&gt;-&amp;nbsp;Tardive dyskinesia is a particularly important side-effect for which to monitor. It is associated with longer-term use of traditional antipsychotic medication, is severely disabling and can be irreversible.&lt;/LI&gt;
&lt;LI&gt;Other side-effects can include glucose intolerance, weight gain, galactorrhoea and photosensitivity. Patients suffering from drug-induced photosensitivity are eligible for sunscreen on prescription. &lt;/LI&gt;
&lt;LI&gt;Avoid poly-pharmacy, particularly concurrent prescribing of typical and atypical antipsychotics, and prescribing in excess of BNF guidelines.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;
&lt;P&gt;Referral to secondary mental health services is advised:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Urgently:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;if there are signs of relapse (unless there is an established previous response to treatment and it is safe to manage the patient at home) &lt;/LI&gt;
&lt;LI&gt;if there is a risk to self or others. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Non-urgently:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;if there is a poor response to treatment &lt;/LI&gt;
&lt;LI&gt;to clarify diagnosis and ensure most appropriate treatment, including family interventions and cognitive behavioural therapy for psychosis &lt;/LI&gt;
&lt;LI&gt;if there is non-compliance with treatment, problematic side-effects, failure of community treatment or breakdown of living arrangements (eg threat of loss of home).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients with complex mental-health, occupational, social and financial needs are normally managed by specialist services, under the Care Programme Approach and shared care with primary healthcare teams once stable. &lt;/P&gt;
&lt;P&gt;Community Mental Health Services should be able to provide concordance therapy, (ref 5) family interventions, (ref 6) cognitive behaviour therapy (ref 7) and rehabilitative facilities. &lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Special considerations in children and adolescents&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;In younger teenagers, psychosis is less common than in adults, and in prepubertal children it is decidedly rare. When it does occur, however, it often takes a particularly severe and persistent form. &lt;/LI&gt;
&lt;LI&gt;For children and teenagers, family-based management and specialist education are particularly important. &lt;/LI&gt;
&lt;LI&gt;Only atypical antipsychotics should be used and depot preparations are seldom necessary or appropriate. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Child and Adolescent Mental Health Services should usually be the specialist advisors for children and teenagers.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Rethink (formerly the National Schizophrenia Fellowship)&lt;BR&gt;England: 020 8974 6814 (Advice line: 10am–3pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:advice@rethink.org" target="_blank"&gt;advice@rethink.org&lt;/A&gt;; website: &lt;A href="http://www.rethink.org/" target="_blank"&gt;http://www.rethink.org&lt;/A&gt;&lt;BR&gt;Scotland: 0131 557 8969&lt;BR&gt;Northern Ireland: 02890 402 323&lt;BR&gt;Monthly social groups for clients with schizophrenia living in the community and relatives support.&lt;/P&gt;
&lt;P&gt;Schizophrenia Association of Great Britain 01248 354 048&lt;BR&gt;Email: &lt;A href="mailto:info@sagb.co.uk" target="_blank"&gt;info@sagb.co.uk&lt;/A&gt;; website: &lt;A href="http://www.sagb.co.uk/" target="_blank"&gt;http://www.sagb.co.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Offers information and support to sufferers, relatives, friends, carers and medical workers.&lt;/P&gt;
&lt;P&gt;MINDinfoLINE 08457 660 163 (9.15am–5.15pm, Monday–Friday).&lt;BR&gt;Email: &lt;A href="mailto:info@mind.org.uk" target="_blank"&gt;info@mind.org.uk&lt;/A&gt;; website: &lt;A href="http://www.mind.org.uk/" target="_blank"&gt;http://www.mind.org.uk&lt;/A&gt;&lt;BR&gt;Information service for matters relating to mental health.&lt;/P&gt;
&lt;P&gt;SANELine 08457 678 000 (helpline 12noon–2.00am)&lt;BR&gt;Website: &lt;A href="http://www.sane.org.uk/" target="_blank"&gt;http://www.sane.org.uk&lt;/A&gt;&lt;BR&gt;Helpline offering information and advice on all aspects of mental health for those experiencing illness or their families or friends.&lt;/P&gt;
&lt;P&gt;Hearing Voices Network 0161 228 3896 (10.30am–3pm, Monday–Wednesday, Friday)&lt;BR&gt;Self-help groups to allow people to explore their voice-hearing experiences.&lt;/P&gt;
&lt;P&gt;The UK NHS Portal for Schizophrenia&lt;BR&gt;Website: &lt;A href="http://www.nelmh.org/home_schizophrenic.asp?c=10" target="_blank"&gt;http://www.nelmh.org/home_schizophrenic.asp?c=10&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;This is a web-based information resource for people with schizophrenia and their carers. The site contains a number of user-friendly sections: Evidence-based treatment summaries; What is schizophrenia? How is schizophrenia diagnosed? Managing schizophrenia; Living with schizophrenia; Support for carers; and Legal issues.&lt;/P&gt;
&lt;P&gt;IRIS (Initiative to Reduce the Impact of Schizophrenia) 01922 858 044&lt;BR&gt;Website: &lt;A href="http://www.iris-initiative.org.uk/" target="_blank"&gt;http://www.iris-initiative.org.uk&lt;/A&gt;&lt;BR&gt;In conjunction with Rethink, IRIS has developed clinical guidelines for practitioners and consumers.&lt;/P&gt;
&lt;P&gt;Mental Health Care &lt;A href="http://www.mentalhealthcare.org.uk/" target="_blank"&gt;http://www.mentalhealthcare.org.uk&lt;/A&gt;&lt;BR&gt;This site provides mental health information and research news from the Institute of Psychiatry and the South London and Maudsley NHS Trust in partnership with Rethink.&lt;/P&gt;
&lt;P&gt;The Mental Health Foundation produces the information booklet Understanding Schizophrenia. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW, UK. Tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Living With Schizophrenia: a Holistic Approach to Understanding, Preventing and Recovering from Negative Symptoms by John Watkins. Hill of Content Publishing, 1996.&lt;/P&gt;
&lt;P&gt;Working with Voices by R Coleman and M Smith. Handsell Publishing, 1997&lt;BR&gt;This is a workbook to help voice hearers manage their voices.&lt;/P&gt;
&lt;P&gt;Human Voices: A Common Human Experience by John Watkins. Hill of Content Publishing, 1998&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; National Institute for Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Clinical Guideline 1. December 2002. URL &lt;A href="http://www.nice.org.uk/" target="_blank"&gt;http://www.nice.org.uk&lt;/A&gt;. (AI) &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2 &lt;/STRONG&gt;Driver and Vehicle Licensing Agency. At a Glance Guide to Medical Aspects of Fitness to Drive. URL &lt;A href="http://www.dvla.gov.uk/" target="_blank"&gt;http://www.dvla.gov.uk&lt;/A&gt;. Further information is available from The Senior Medical Adviser, DVLA, Driver Medical Unit, Longview Road, Morriston, Swansea SA99 ITU, Wales. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Adams CE, Eisenbruch M. Depot fluphenazine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (CI) The use of depot fluphenazine continues to be based on clinical judgement rather than on evidence from methodical evaluation within trials. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;4 &lt;/STRONG&gt;Kendrick T, Millar E, Burns T, Ross F. Practice nurse involvement in giving depot neuroleptic injections: development of a patient assessment and monitoring checklist. Prim Care Psychiatry 1998, 4(3): 149-154 (AIV) Of the 25% of people with schizophrenia who have no specialist contact, many have a practice nurse as their only regular professional contact. Levels of knowledge of schizophrenia and its treatment of those nurses was often no better than a lay person's. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;5 &lt;/STRONG&gt;Kemp R, Kirov G, Everitt B, David A. A randomised controlled trial of compliance therapy: 18-month followup. Br J Psychiatry 1998, 172: 413-419. (AII) Patients who received specific counselling regarding their attitudes towards their illness and drug treatment were five times more likely to take medication without prompting compared with controls.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;6&lt;/STRONG&gt;&amp;nbsp; Pharoah FM, Mari JJ, Streiner D. Family intervention for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Thirteen studies were analysed. Families receiving this intervention, which promotes a more supportive family environment, can expect the family member with schizophrenia to relapse less and to be in hospital less. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;7 &lt;/STRONG&gt;Cormac I, Jones C, Campbell C, Silveira da Mota Neto J. Cognitive behaviour therapy for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Thirteen studies were analysed. Four small trials show that cognitive behaviour therapy is associated with substantially reduced risk of relapse.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>82618</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=82618]]&gt;</url>
    <title>Introduction to chronic mixed anxiety and depression</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC MIXED ANXIETY AND DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Chronic mixed anxiety and depression - F41.2 (Clinical term: Mixed anxiety and depressive disorder Eu41.2)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to chronic mixed anxiety and depression&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Chronic mixed anxiety and depression - F41.2 (Clinical term: Mixed anxiety and depressive disorder Eu41.2)&lt;/P&gt;
&lt;P&gt;Many people in the community report significant levels of depression and/or anxiety that do not meet the diagnostic criteria for either depressive episode or the anxiety disorders. There are a variety of ways of classifying this group within ICD-10, including dysthymia, mixed anxiety and depression.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;One or more physical symptoms (eg pains, poor sleep, fatigue), and various anxiety and depressive symptoms, present for more than six months.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Low or sad mood. &lt;/LI&gt;
&lt;LI&gt;Loss of interest or pleasure. &lt;/LI&gt;
&lt;LI&gt;Prominent anxiety or worry. &lt;/LI&gt;
&lt;LI&gt;Multiple associated symptoms for example:&lt;BR&gt;-&amp;nbsp;disturbed sleep&amp;nbsp;&lt;BR&gt;-&amp;nbsp;disturbed appetite&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;BR&gt;- tremor&amp;nbsp;&amp;nbsp;&lt;BR&gt;- suicidal thoughts or self-harm&lt;BR&gt;- fatigue or loss of energy&amp;nbsp;&amp;nbsp; &lt;BR&gt;-&amp;nbsp;dry mouth&lt;BR&gt;-&amp;nbsp;palpitations&amp;nbsp;&amp;nbsp; &lt;BR&gt;-&amp;nbsp;tension and restlessness&lt;BR&gt;-&amp;nbsp;poor concentration&amp;nbsp; &lt;BR&gt;-&amp;nbsp;irritability &lt;BR&gt;-&amp;nbsp;dizziness&amp;nbsp;&amp;nbsp; &lt;BR&gt;-&amp;nbsp;sexual dysfunction.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;If more severe depression or anxiety are present. &lt;/LI&gt;
&lt;LI&gt;If marked fear/anxiety in particular situations (eg crowds, enclosed spaces, travel). &lt;/LI&gt;
&lt;LI&gt;If history of manic episodes (eg excitement, elevated mood, rapid speech&lt;/LI&gt;
&lt;LI&gt;If somatic symptoms predominate without an adequate physical explanation&lt;/LI&gt;
&lt;LI&gt;If drinking heavily or using drugs&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Anxiety and depression have many physical and mental effects that are likely to be worse at times of personal stress. Aim to help the patient reduce symptoms. &lt;/LI&gt;
&lt;LI&gt;The problems are not due to weakness or laziness. &lt;/LI&gt;
&lt;LI&gt;Regular structured visits can be helpful - state their frequency and include arranged visits to other professionals if necessary.&amp;nbsp;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;If physical symptoms are present, discuss their link to mental distress.&lt;/LI&gt;
&lt;LI&gt;Advise relaxation methods to relieve physical symptoms&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Cut down caffeine intake (coffee, tea, stimulant drinks). &lt;/LI&gt;
&lt;LI&gt;Discuss ways to challenge negative thoughts or exaggerated worries.&lt;/LI&gt;
&lt;LI&gt;Encourage simple cognitive strategies and structured problem-solving between appointments:&lt;BR&gt;-&amp;nbsp;Identify events that trigger undue worry (eg a young woman presents with worry, tension, nausea and insomnia which began after her son was diagnosed with asthma. Her anxiety worsens when he has asthma episodes)&lt;BR&gt;-&amp;nbsp;List as many solutions as possible (eg meet the nurse to learn about asthma management; discuss concerns with parents of other asthmatic children; write down a management plan for asthma episodes).&lt;BR&gt;-&amp;nbsp;List the pros and cons of each possible solution. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;At appointments, help the patient to:&lt;BR&gt;-&amp;nbsp;choose their preferred approach&lt;BR&gt;-&amp;nbsp;work out the steps necessary to achieve the plan&lt;BR&gt;-&amp;nbsp;set a date to review the plan; identify and encourage whatever seems to be working. &lt;/LI&gt;
&lt;LI&gt;Assess risk of suicide. &lt;/LI&gt;
&lt;LI&gt;Encourage use of self-help books, tapes and/or leaflets, and voluntary organizations (ref 1).&lt;/LI&gt;
&lt;LI&gt;These patients risk developing more severe disorders and should be monitored regularly.&lt;/LI&gt;&lt;/OL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Medication is a secondary treatment of uncertain value. &lt;/LI&gt;
&lt;LI&gt;If prescribed, medication should be simple, reviewed regularly, and only continued if definitely helping. &lt;/LI&gt;
&lt;LI&gt;Avoid multiple psychotropics. &lt;/LI&gt;
&lt;LI&gt;Can try a tricyclic or SSRI antidepressant if depression or anxiety are marked (ref 2) (BNF section 4.3.). &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Stress/anxiety management, (ref 3) problem-solving, (ref 4) cognitive behaviour therapy or counselling (ref 5,6) might help and be given in primary care or the voluntary sector. It is unusual to refer for psychological treatment unless the disorder becomes severe.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Refer to secondary mental healthcare as an emergency if suicide risk is significant&lt;/P&gt;
&lt;P&gt;Consider recommending voluntary/non-statutory/self-help organizations.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Depression Alliance&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;England: 020 8768 0123 &lt;BR&gt;Wales: 029 2069 2891 (10am–4pm, Monday–Friday)&lt;BR&gt;Scotland: 0131 467 3050&lt;BR&gt;Website: &lt;A href="http://www.depressionalliance.org/" target="_blank"&gt;http://www.depressionalliance.org&lt;/A&gt;&lt;BR&gt;Provides information and support groups.&lt;/P&gt;
&lt;P&gt;Aware Defeat Depression Ltd. (local groups) 02871 260 602&lt;BR&gt;Email: &lt;A href="mailto:info@aware-ni.org" target="_blank"&gt;info@aware-ni.org&lt;/A&gt;; website: &lt;A href="http://www.aware-ni.org/" target="_blank"&gt;http://www.aware-ni.org&lt;/A&gt; &lt;BR&gt;Provides information leaflets, lectures and runs support groups for sufferers and relatives.&lt;/P&gt;
&lt;P&gt;The Samaritans 08457 909090 (24-hour helpline; see telephone directory for local branches)&lt;BR&gt;Website: &lt;A href="http://www.samaritans.org.uk/" target="_blank"&gt;http://www.samaritans.org.uk&lt;/A&gt;&lt;BR&gt;The Samaritans offer confidential emotional support to any person who is despairing or suicidal. &lt;/P&gt;
&lt;P&gt;SANEline 0845 767 8000 (12pm–2am)&lt;BR&gt;Website: &lt;A href="http://www.sane.org.uk/" target="_blank"&gt;http://www.sane.org.uk&lt;/A&gt;&lt;BR&gt;This is a helpline offering information and advice on all aspects of mental health for those experiencing illness or their families or friends.&lt;/P&gt;
&lt;P&gt;First Steps to Freedom 01926 851 608 (24-hour helpline)&lt;BR&gt;Email: &lt;A href="mailto:info@firststeps.demon.co.uk" target="_blank"&gt;info@firststeps.demon.co.uk&lt;/A&gt;; website: &lt;A href="http://www.first-steps.org/" target="_blank"&gt;http://www.first-steps.org&lt;/A&gt;&lt;BR&gt;CITA (Council for Involuntary Tranquilliser Addiction) 0151 949 0102&amp;nbsp; (helpline 10am–1pm, Monday–Friday; emergency weekend number available)&lt;BR&gt;Offers advice on withdrawing from tranquilisers and help with anxiety and depression.&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Worries and Anxieties, Anxiety &amp;amp; Phobias, Anxiety&lt;BR&gt;Helping You Cope: A Guide To Starting And Stopping Tranquillisers and Sleeping Tablets by the Mental Health Foundation: now out of print, but available online: &lt;A href="http://www.mentalhealth.org.uk/page.cfm?pagecode=PBBF" target="_blank"&gt;http://www.mentalhealth.org.uk/page.cfm?pagecode=PBBF&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Anxiety, Phobias and Panic Attacks: Your Questions Answered by Elaine Sheehan, Vega Books, 2002 &lt;BR&gt;Information and advice on types of anxiety and the treatments available, including self-help strategies and what to expect.&lt;/P&gt;
&lt;P&gt;Living With Fear, 2nd edition, by Isaac M Marks. McGraw Hill, 2001. Tel: 01628 252 700; Email: &lt;A href="mailto:orders@mcgraw-hill.co.uk" target="_blank"&gt;orders@mcgraw-hill.co.uk&lt;/A&gt;.&amp;nbsp; &lt;BR&gt;This is a self-help manual.&lt;/P&gt;
&lt;P&gt;Managing Anxiety and Depression by Nicholas Holdsworth and Roger Paxton. London: The Mental Health Foundation, 1999. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW. Tel: 7802 0304. &lt;A href="http://ww.mentalhealth.org.uk/" target="_blank"&gt;http://ww.mentalhealth.org.uk&lt;/A&gt;&lt;BR&gt;Restoring the Balance: A Self-Help Program for Managing Anxiety and Depression by Fred Yates. London: The Mental Health Foundation, 2000. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW, UK. Tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;.&lt;BR&gt;This is a self-help CD-ROM for people with mild to moderate anxiety and depression.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Consensus, plus some, usually small, trials. For example, Donnan P, Hutchinson A, Paxton R et al. Self-help materials for anxiety: a randomized controlled trial in general practice. Br J Gen Pract 1990; 40: 498-501. (BV). Audiotape and booklet is given to patients with chronic anxiety. Intervention led to reduced scores for depression, as well as for anxiety.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Lima M, Moncrieff J. Drugs versus placebo for the treatment of dysthymia (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Fifteen studies were analysed. There is some evidence of efficacy of most antidepressants in dysthymia (chronic, mild depressive syndrome) that has been present for at least two years.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; McLean J, Pietroni P. Self care - who does best? Soc Sci Med 1990, 30(5): 591-596. (BIII) This describes a controlled trial of a general-practice-based class teaching self-care skills, relaxation, stress management, medication, nutrition and exercise. Significant improvements were seen and maintained after one year. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Catalan J, Gath DH, Anastasiades P et al. Evaluation of a brief psychological treatment for emotional disorders in primary care. Psychol Med 1991, 21: 1013-1018. (BII) This paper describes a small randomized control trial. Patients - selected for high symptom scores - did significantly better with problem-solving therapy than with routine care. Other patients - with lower symptom scores -who were not treated showed similar improvement to the treated group. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Roth AD, Fonagy P. What Works For Whom? A Critical Review of Psychotherapy Research. New York: Guilford Press, 1996. (CII) This work concludes that the efficacy of counselling in primary-care settings is difficult to assess because of the methodological problems of available research. Counselling seems more appropriate for milder than for more severe disorders, and evidence seems better for counselling focused on a particular client group (eg relationship or bereavement counselling).&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Bower P, Rowland N, Mellor Clark J et al. Effectiveness and cost-effectiveness of counselling in primary care (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (B1) Seven studies were analysed. Results showed that counselling is significantly more effective than 'usual care' in the short- but not the long-term. Satisfaction with counselling was high. Patients had a mix of 'emotional disorders'.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79058</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79058]]&gt;</url>
    <title>Introduction to conduct disorder (including oppositional-defiant disorder)</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CHILD AND ADOLESCENT CONDITIONS,CONDUCT DISORDER,MENTAL HEALTH,EDUCATION AND SCHOOLS,INDIVIDUAL BEHAVIOUR,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PERSONALITY DISORDERS,YOUNG PEOPLE,CHILDREN,SPECIALTIES,COMMUNITY CHILD HEALTH,CHILD HEALTH,DETERMINANTS,PUBLIC HEALTH,MONTHLY ADDITIONS,POPULATIONS,GROUPS,AGE GROUPS,2009 SEPTEMBER,ANTISOCIAL BEHAVIOUR]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Conduct disorder (including oppositional-defiant disorder) - F91# (Clinical term: Conduct disorders Eu91) 

All children are defiant at times and it is a normal part of adolescence to do the opposite of what one is told. Oppositional-defiant disorder mainly applies to children whose functioning at home and at school is impaired by constant conflict with adults and other children. Conduct disorder mainly applies to adolescents whose behaviour goes to antisocial extremes; many are excluded from school or in trouble with the law.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to conduct disorder (including oppositional-defiant disorder)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Conduct disorder (including oppositional-defiant disorder) - F91# (Clinical term: Conduct disorders Eu91) Conduct disorder (including oppositional-defiant disorder) - F91# (Clinical term: Conduct disorders Eu91) All children are defiant at times and it is a normal part of adolescence to do the opposite of what one is told. &lt;BR&gt;&lt;BR&gt;Oppositional-defiant disorder mainly applies to children whose functioning at home and at school is impaired by constant conflict with adults and other children. Conduct disorder mainly applies to adolescents whose behaviour goes to antisocial extremes; many are excluded from school or in trouble with the law.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;In younger children: marked tantrums, defiance, fighting, and bullying. &lt;/LI&gt;
&lt;LI&gt;In older children and adolescents: serious law breaking such as stealing, damage to property, assault. &lt;/LI&gt;
&lt;LI&gt;Can be confined only to school or only to home.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;A pattern of repetitive, persistent and excessive antisocial, aggressive or defiant behaviour lasting six months or more. &lt;/LI&gt;
&lt;LI&gt;These features must be out of keeping with the child’s development level, norms of peer group behaviour, and cultural context (eg isolated tantrums in a three-year-old should not be regarded as abnormal). &lt;/LI&gt;
&lt;LI&gt;In younger children (say, three to eight year-olds), the behaviours are characteristic of the oppositional-defiant type of conduct disorder: angry outbursts, loss of temper, refusal to obey commands and rules, destructiveness, hitting, but without the presence of serious law-breaking. &lt;/LI&gt;
&lt;LI&gt;In older children and adolescents (say, nine to 18 years olds), the behaviours are characteristic of conduct disorder per se: vandalism, cruelty to people and animals, bullying, lying, stealing outside the home, truancy, drug and alcohol misuse, and criminal acts, plus all the features of the oppositional-defiant type.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;P&gt;Co-existent disorders are common and do not rule out the diagnosis; they are easily missed so should be carefully checked for:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Attention-deficit/hyperactivity disorder - F90. &lt;/LI&gt;
&lt;LI&gt;Hyperactivity. &lt;/LI&gt;
&lt;LI&gt;Depressive disorder - F32#. &lt;/LI&gt;
&lt;LI&gt;Specific reading retardation (dyslexia). &lt;/LI&gt;
&lt;LI&gt;Generalized Learning disability (mental retardation) - F70. &lt;/LI&gt;
&lt;LI&gt;Autism spectrum disorders - F84. &lt;/LI&gt;
&lt;LI&gt;Adjustment reaction (this follows a clear stressor, such as parental divorce, bereavement, trauma, abuse, or change of caregiver).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Parenting problems are commonly associated and include a lack of positive joint activities with the child, insufficient praise, inconsistent discipline, harsh punishments, hostility, rejection or emotional abuse, sexual abuse, and poor monitoring of the whereabouts of older children.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;The child is likely to be temperamentally different from their siblings, and cannot easily control their actions. &lt;/LI&gt;
&lt;LI&gt;Antisocial behaviour is learned and can be corrected (unlearned). &lt;/LI&gt;
&lt;LI&gt;The long-term prognosis is not good without intervention (they do not ‘grow out of it’) but is good with appropriate management, especially parent behavioural management training (ref 1-3)&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Promote daily play and positive joint activities between parent and child for at least 10 minutes per day, despite both sides’ initial reluctance. &lt;/LI&gt;
&lt;LI&gt;Encourage praise and rewards for specific, agreed desired behaviours. If appropriate, monitor with a chart. Negotiate rewards with the child and change target behaviours every two to six weeks and rewards more often. &lt;/LI&gt;
&lt;LI&gt;Set clear house rules and give short specific commands about the desired behaviour, not prohibitions about undesired behaviour (eg 'Please walk slowly', rather that 'Don’t run'). &lt;/LI&gt;
&lt;LI&gt;Provide consistent and calm consequences for misbehaviour. Many unwanted behaviours can be ignored, and will then stop (but may increase when this technique is first tried). Distracting the child from an unwanted behaviour is likely to be more effective than saying, 'Don’t do it'. If neither ignoring nor distraction is appropriate, ‘time out’ (to avoid the unwanted behaviour receiving positive reinforcement) may be effective. This can involve leaving the child alone to calm down or sending them to a quiet, boring ‘time out’ room (or other space in the house) for no more than one minute per year of age, and 10 minutes maximum. Avoid getting into arguments or explanations with the child, as this merely provides additional attention for the misbehaviour. &lt;/LI&gt;
&lt;LI&gt;Reorganize the child’s day to prevent trouble. Examples include asking a neighbour to look after the child while going to the supermarket, ensuring that activities are available for long car journeys, and arranging activities in separate rooms for siblings who are prone to fight. &lt;/LI&gt;
&lt;LI&gt;Monitor the whereabouts of teenagers. Telephone the parents of friends whom they say they are visiting. &lt;/LI&gt;
&lt;LI&gt;Liaise with school and suggest similar principles are applied. Parents should put pressure on the child’s school to look hard for specific learning difficulties such as dyslexia.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;No drugs are effective. Methylphenidate is effective for co-morbid hyperkinetic disorder and may reduce conduct problems in children with both problems &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;If problems are mainly or exclusively at school, parents should request that the school involves educational services, such as the Educational Psychology Service (for assessment of specific learning difficulty), the Educational Welfare Service (for attendance problems) or local behaviour support teams. Some schools employ school counsellors or specialized teachers who may be skilled in anger management training. &lt;/LI&gt;
&lt;LI&gt;Referral to a local Child and Adolescent Mental Health Service (CAMHS) should be considered for cases that fail to improve, where the behaviour is leading to major impairment, or where co-existing problems such as hyperkinetic disorder or autism spectrum disorder are suspected. &lt;/LI&gt;
&lt;LI&gt;For adolescents with law-breaking behaviour (delinquency), youth-offending teams can often provide an intensive intervention package for the duration of the court’s involvement. This may include parenting groups for behavioural management training. &lt;/LI&gt;
&lt;LI&gt;For preschool children, health visitors are often trained to educate parents in behavioural management techniques. Local parent support agencies such as Sure Start may be able to provide more intensive input. &lt;/LI&gt;
&lt;LI&gt;Social Services must be involved in cases of suspected abuse (of any sort), when a young person’s behaviour is beyond the control of parents, and with adopted children. They may not have the resources to help in more straightforward cases. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;National Family and Parenting Institute 020 7424 3460&lt;BR&gt;Email: &lt;A href="mailto:info@nfpi.org" target="_blank"&gt;info@nfpi.org&lt;/A&gt; website: &lt;A href="http://www.nfpi.org/" target="_blank"&gt;http://www.nfpi.org&lt;/A&gt;&lt;BR&gt;Details of the most studied form of parent managements training are on: &lt;A href="http://www.incredibleyears.com/" target="_blank"&gt;http://www.incredibleyears.com&lt;/A&gt;&lt;BR&gt;Leaflet available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;):&lt;BR&gt;Behavioural problems and conduct disorder&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Kazdin A. Psychosocial treatments for conduct disorder in children. J Child Psychol Psychiatry 1997, 38: 161-178. (CII) This is a literature review. Promising treatments include problem-solving skills training, parent management training, functional family therapy and multisystemic therapy. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Scott S, Spender Q, Doolan M et al. Multicentre controlled trial of parenting groups for child antisocial behaviour in clinical practice. Br Med J 2001, 323: 194-197. (CIII) Parenting groups effectively reduce serious antisocial behaviour in children in real-life conditions. Follow-up is needed to see if the children's poor prognosis is improved and criminality prevented. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Woolfenden SR, Williams K, Peat J. Family and parenting interventions in children and adolescents with conduct disorder and delinquency aged 10-17 (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Eight trials were analysed. Current evidence suggests that family and parenting interventions for juvenile delinquents and their families have beneficial effects on reducing time spent in institutions. This has an obvious benefit to the participant and their family, and may result in a cost saving for society.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79125</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79125]]&gt;</url>
    <title>Introduction to deliberate self-harm</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH,CHILD HEALTH,SPECIALTIES,SELF HARM,CHILD AND ADOLESCENT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Deliberate self-harm - X60 - X84 (Clinical term: self-harm in children and adolescents U2…)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to deliberate self-harm&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Deliberate self-harm - X60 - X84 (Clinical term: self-harm in children and adolescents U2…)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Deliberate self-harm in children and adolescents usually presents with a deliberate overdose of tablets or cutting. It occasionally presents with other methods of self-harm, such as attempted hanging, strangulation, burning or running in front of a car.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Assessment&lt;/H2&gt;
&lt;P&gt;The diagnosis of deliberate self-harm in primary care settings is usually straightforward. However, some children and adolescents who have harmed themselves may try to conceal their true intent, claiming for instance that an overdose was accidental. Many others will conceal self-harm from parents and the practitioner. &lt;/P&gt;
&lt;P&gt;Assessment is directed to four main issues:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;assessment and management of the current episode. &lt;/LI&gt;
&lt;LI&gt;identification and management of associated problems. &lt;/LI&gt;
&lt;LI&gt;identification and promotion of the child and family's resources. &lt;/LI&gt;
&lt;LI&gt;prevention of repetition.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment and management of the current episode&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;All children and adolescents who have taken an overdose should receive prompt medical attention. &lt;/LI&gt;
&lt;LI&gt;Suicidal intent should be assessed. Circumstances suggesting a high intent include the use of very dangerous methods, precautions to avoid discovery, and final acts such as leaving a note or giving possessions away. &lt;/LI&gt;
&lt;LI&gt;The triggers of the current episode should be identified. These include arguments with family members, disciplinary crises at home or school, rows with peers, and breaking up with a boyfriend or girlfriend. &lt;/LI&gt;
&lt;LI&gt;Cutting often occurs when the young person experiences strong feelings of tension, and the young person might report that cutting provides some temporary relief. Most young people who cut themselves have long-standing problems such as low self-esteem or substance abuse.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Identification and management of associated problems&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Self-harm in adolescents is associated with depression, drug or alcohol abuse, behavioural problems, and physical illness. &lt;/LI&gt;
&lt;LI&gt;There is often an association with family difficulties, including parental discord and violence, parental depression or substance abuse, role models of suicidal behaviour in the family, abuse of all kinds, and bereavement. &lt;/LI&gt;
&lt;LI&gt;Other associated problems include bullying at school, peer role models of self-harm, models of self-harm in the media, and educational difficulties.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Identification and promotion of the child and family's resources&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Factors in the child that protect them from self-harm, or from repetition of self-harm include being particularly good at something (eg a sport), positive peer relationships, good school attendance and academic achievement, and positive plans for the future. &lt;/LI&gt;
&lt;LI&gt;Family factors that reduce the risk of self-harm include a close relationship with at least one positive role model, parenting styles that encourage rather than punish, and clear methods for communication within the family.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention of repetition&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;This should begin with an assessment of the risk factors for frequent repetition or suicide - male gender, older age, use of dangerous methods, severe mental health problems (such as depression), high suicidal intent during the index episode of self-harm, and continuing suicidal intent. &lt;/LI&gt;
&lt;LI&gt;Factors suggesting there is continuing suicidal intent include a clear statement that the young person intends to harm themselves again (such a statement should always be taken seriously), depression, unresolved personal or family problems (particularly if these appeared to precipitate previous self-harm), hopelessness, clear suicidal plans, easy access to dangerous methods, and frequent previous attempts. &lt;/LI&gt;
&lt;LI&gt;Assessment of mental state and continuing suicidal intent will usually require that the young person be interviewed without the parent. &lt;/LI&gt;
&lt;LI&gt;There is no evidence that encouraging children and adolescents to talk with professionals about suicidal feelings and suicidal plans precipitates self-harm. &lt;/LI&gt;
&lt;LI&gt;The risk of repetition and suicide is not static, but changes over time, and may require regular assessment.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Deliberate self-harm should always be taken seriously, even if the actual intent to die seems to have been low. &lt;/LI&gt;
&lt;LI&gt;Take whatever steps are necessary to prevent the young person gaining access to methods of harming themselves again (eg parents should clear old tablets out of the medicine cupboard, lock away essential medicines and hide sharp knives). &lt;/LI&gt;
&lt;LI&gt;Do not make the adolescent feel guilty or reject them because of the self-harming behaviour. This will simply make matters worse. &lt;/LI&gt;
&lt;LI&gt;Although many families want to draw a veil over the episode, it can often be important to talk about it. The young person needs to feel that their behaviour is being listened to and understood, not devalued or ridiculed. &lt;/LI&gt;
&lt;LI&gt;Parents should create an atmosphere for listening if the young person wants to talk; parents should be around, but not hover.&lt;/LI&gt;
&lt;LI&gt;Helplines, such as the Samaritans, and local emergency services are available 24 hours a day.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Assessment of suicidal thinking and planning is an important part of the mental-state examination of any young person who presents with emotional or behavioural difficulties. &lt;/LI&gt;
&lt;LI&gt;Underlying mental health problems, particularly depression and substance misuse, need to be assessed and managed. &lt;/LI&gt;
&lt;LI&gt;Risk of repetition should be reviewed regularly, particularly in patients who are at high risk of further self-harm.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;Medication is not usually required by adolescents who self-harm, but if the young person has major depression then an SSRI can be prescribed.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;All children and adolescents who have taken an overdose should be referred to hospital for medical evaluation, admission and subsequent evaluation by a mental health professional. &lt;/LI&gt;
&lt;LI&gt;Urgent referral to secondary mental health services should be considered when there is a high risk of further self-harm or completed suicide. All children and adolescents who engage in serious methods of self-harm (eg attempted hanging), or who use methods suggesting high suicidal intent, should be referred. &lt;/LI&gt;
&lt;LI&gt;Consider referral for psychological therapies, as appropriate.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Self Harm Alliance 01242 578 820 (Helpline 6pm–7pm, Tuesday, Sunday; 11am–1pm, Thursday)&lt;BR&gt;Email: &lt;A href="mailto:selfharmalliance@aol.com" target="_blank"&gt;selfharmalliance@aol.com&lt;/A&gt;; website: &lt;A href="http://www.selfharmalliance.org/" target="_blank"&gt;http://www.selfharmalliance.org&lt;/A&gt;&lt;BR&gt;Helpline, produces monthly newsletters, provides postal and email support and offers an advocacy service.&lt;/P&gt;
&lt;P&gt;ChildLine 0800 1111 (24-hour helpline) &lt;BR&gt;Website: &lt;A href="http://www.childline.org.uk/" target="_blank"&gt;http://www.childline.org.uk&lt;/A&gt;&lt;BR&gt;Telephone service for all children and young people providing confidential counselling, support and advice on any issue. Parents can also write to ChildLine. &lt;/P&gt;
&lt;P&gt;Change our Minds &lt;A href="http://www.changeourminds.com/" target="_blank"&gt;http://www.changeourminds.com&lt;/A&gt;&lt;BR&gt;A website run by the Samaritans, targeted at a younger audience.&lt;/P&gt;
&lt;P&gt;Self Injury and Related Issues (SIARI)&lt;BR&gt;Email: &lt;A href="mailto:jan@siari.uk" target="_blank"&gt;jan@siari.uk&lt;/A&gt;; website: &lt;A href="http://www.siari.co.uk/" target="_blank"&gt;http://www.siari.co.uk&lt;/A&gt;&lt;BR&gt;Forum for self-harmers.&lt;/P&gt;
&lt;P&gt;Suicide Information and Education Centre (Canada) &lt;A href="http://www.suicideinfo.ca/" target="_blank"&gt;http://www.suicideinfo.ca&lt;/A&gt;&lt;BR&gt;Library, resources and specific youth links.&lt;BR&gt;A leaflet is available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Fact Sheet 30: Deliberate Self Harm in Young People.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79089</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79089]]&gt;</url>
    <title>Introduction to delirium</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DELIRIUM]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Delirium - F05 (Clinical term: Other mental disorders due to brain damage and dysfunction caused by physical disease Eu05)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to delirium&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Delirium - F05 (Clinical term: Other mental disorders due to brain damage and dysfunction caused by physical disease Eu05)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Families may request help because patient is suddenly more confused or becomes either much quieter or agitated and disturbed. &lt;/LI&gt;
&lt;LI&gt;Patients may appear uncooperative, fearful or tearful. &lt;/LI&gt;
&lt;LI&gt;Delirium occurs in many older patients hospitalized for physical conditions.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Acute onset, usually over hours or days, of:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;confusion (patient appears disoriented for time and place, may misidentify people and have a poor grasp of situations and surroundings) &lt;/LI&gt;
&lt;LI&gt;impairment of memory &lt;/LI&gt;
&lt;LI&gt;disturbance of conscious level with reduced ability to focus or shift attention and markedly diminished attention span. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;May be accompanied by:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;agitation (hyperactive delirium) or, more commonly, apathy (hypoactive delirium) &lt;/LI&gt;
&lt;LI&gt;changes in mood, eg fearfulness, sadness &lt;/LI&gt;
&lt;LI&gt;perplexity and sometimes apathy &lt;/LI&gt;
&lt;LI&gt;illusions (misperceptions of normal stimuli) &lt;/LI&gt;
&lt;LI&gt;suspiciousness&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;disturbed sleep (reversal of sleep pattern) &lt;/LI&gt;
&lt;LI&gt;disturbed thinking, often reflected in incoherent speech &lt;/LI&gt;
&lt;LI&gt;hallucinations (can occur in any sensory modality but visual hallucinations are most common) &lt;/LI&gt;
&lt;LI&gt;autonomic features (eg sweating, tachycardia, tachypnoea).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Symptoms often develop rapidly and may change from hour to hour. They are characteristically worse at night.&lt;/P&gt;
&lt;P&gt;Delirium may occur in patients with previously normal mental function but is more common in those with previous degenerative brain disorder. Delirium may occur in patients with previously normal mental function or in those with dementia. People with chronic physical illnesses are also more vulnerable to delirium, and in these groups it might be precipitated by apparently innocuous things, including minor infections, changes to any drug treatment and changes in environment.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;Acute psychotic disorders - F23 (if symptoms persist, delusions and disordered thinking predominate, and no physical cause is identified).&lt;BR&gt;&lt;BR&gt;Delirium in the setting of dementia could be missed if the pre-existing dementia is not recognized. Some features of quiet delirium occur in acute dysphasias (stroke) and depression, and of hyperactive delirium in acute psychotic episodes or mania.&amp;nbsp; &lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Strange behaviour or speech and sudden confusion can be symptoms of a medical illness, especially if the patient is elderly or has dementia. &lt;/LI&gt;
&lt;LI&gt;Seek help urgently if patient becomes confused.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to family&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Delirium is a medical emergency with appreciable mortality. &lt;/LI&gt;
&lt;LI&gt;Hospitalization might be required because of agitation or the physical illness that is causing delirum. Patients may need to be admitted to a medical ward in order to diagnose and treat the underlying disorder. In an emergency, where there is risk to life and safety, a medically ill patient may be taken to a general hospital for treatment under common law, without using the Mental Health Act. In such a case, a medical doctor may make this decision without involvement of a psychiatrist. &lt;/LI&gt;
&lt;LI&gt;Take measures to prevent the patient from harming themselves or others (eg remove unsafe objects, restrain if necessary). &lt;/LI&gt;
&lt;LI&gt;Supportive contact with familiar people can reduce confusion. &lt;/LI&gt;
&lt;LI&gt;Provide frequent reminders of time and place and minimize distracting stimuli to reduce confusion. &lt;/LI&gt;
&lt;LI&gt;Keep lighting levels bright to minimize visual illusions. &lt;/LI&gt;
&lt;LI&gt;Keep up fluid and food intake as much as possible&amp;nbsp; (ref 2) &lt;/LI&gt;
&lt;LI&gt;Try and encourage mobility (ref 3) &lt;/LI&gt;
&lt;LI&gt;Try and encourage a restful sleep at night. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 4)&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Avoid use of sedative or hypnotic medications (eg benzodiazepines) except for the treatment of alcohol or sedative withdrawal. &lt;/LI&gt;
&lt;LI&gt;Antipsychotic medication in low doses (BNF section 4.2.1) might sometimes be needed to control agitation, psychotic symptoms or aggression. Beware of drug side-effects (drugs with anticholinergic action and antiparkinsonian medication can exacerbate or cause delirium) and drug interactions.&lt;/LI&gt;
&lt;LI&gt;When drugs are required because of severe behavioural disturbance or risk to self and/or others, low-dose risperidone is the usual drug of first choice, except in alcohol or drug withdrawal states or in patients with liver disease in might be helpful. &lt;/LI&gt;
&lt;LI&gt;If Lewy body dementia is suspected, benzodiazepines are preferred to antipsychotics. because the latter can be fatal (ref 5).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Referral to secondary mental health services is rarely indicated. Referral to a physician is nearly always indicated if:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the cause is unclear &lt;/LI&gt;
&lt;LI&gt;the cause is clear and treatable but carers are unable to support the patient or they are living alone &lt;/LI&gt;
&lt;LI&gt;drug or alcohol withdrawal or overdose or another underlying condition necessitating inpatient medical care is suspected.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Rabins PV. Psychosocial and management aspects of delirium. Int Psychoger 1991, 3(2): 319-324. (BV) This is a review of 21 papers, concluding that the evidence base is very thin. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Inouye SK, Bogardus ST Jr, Charpentier PA et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999, 340: 669-676. (CIII) Intervention was associated with significant improvement in the degree of cognitive impairment among patients with cognitive impairment at admission, and with a reduction in the rate of use of sleep medication among all patients. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; A Cochrane Review will soon be available. Britton A, Russell R. Multidisciplinary team interventions for delirium in patients with chronic cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software Issue 4, 2003. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Rummans TA, Evans JM, Krahn LE, Fleming KC. Delirium in elderly patients: evaluation and management. Mayo Clinic Proc 1995, 70(10): 989-998. (BV). This reviews 55 papers, concluding that the evidence base is thin. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Ballard C, Grace J, McKeith I et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998, 351: 1032-1033. (CV) This is a case-register study. Other interventions should be explored before the use of neuroleptics in patients with dementia, particularly in those with dementia with Lewy bodies.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79103</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79103]]&gt;</url>
    <title>Introduction to dementia</title>
    <publicationDate>2005-03-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,NEUROLOGICAL CONDITIONS,PSYCHIATRIC,SYMPTOM MANAGEMENT,ALZHEIMER’S DISEASE,LATER LIFE,ADULT CONDITIONS,MENTAL HEALTH,DEMENTIA,DEFINITION AND TYPES,PALLIATIVE AND SUPPORTIVE CARE,CONDITIONS,NERVOUS SYSTEM DISEASES,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Dementia - F03 (Clinical term: Dementia in Alzheimer’s disease Eu00.)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to dementia&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Dementia - F03 (Clinical term: Dementia in Alzheimer’s disease Eu00.)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Patients may complain of forgetfulness, decline in mental functioning (eg getting muddled making phone calls, deciding which bus to catch, sorting out change at the checkout), difficulty finding words (especially names and nouns) or feeling depressed, but may be unaware of memory loss.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Families may ask for help initially because of failing memory, disorientation, and change in personality or behaviour. In the later stages of the illness, they may seek help because of distressing or dangerous behaviour (eg aggression, wandering, incontinence or leaving the gas on unlit). &lt;/LI&gt;
&lt;LI&gt;Dementia may also be diagnosed during consultations for other problems, as relatives might confuse early dementia with natural ageing. &lt;/LI&gt;
&lt;LI&gt;Changes in behaviour and functioning (eg poor personal hygiene or social interaction) in an older patient should raise the possibility of a diagnosis of dementia.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Decline in memory for recent events, thinking, judgement, orientation and language. &lt;/LI&gt;
&lt;LI&gt;Patients may have become apparently apathetic or disinterested, but might also appear alert and appropriate, despite deterioration in memory and other cognitive function. &lt;/LI&gt;
&lt;LI&gt;Decline in everyday function (eg dressing, washing and cooking). &lt;/LI&gt;
&lt;LI&gt;Changes in personality or emotional control - patients may become easily upset, tearful or irritable, as well as apathetic, and have persecutory delusions. &lt;/LI&gt;
&lt;LI&gt;Common with advancing age (5% over 65 years; 20% over 80 years); very rare in youth or middle age.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Dementia has a number of causes. The most common include Alzheimer’s disease (60% of cases) characterized by a gradual progression; vascular dementia (20%) with a classically step-wise progression; and Lewy body dementia (15%) with fluctuating cognition, visual hallucinations and parkinsonism, but the clinical picture is often not clear cut.&lt;/P&gt;
&lt;P&gt;Owing to the problems inherent in taking a history from people with dementia, it is very important that information about the level of current functioning and possible decline in functioning is obtained from an informant (eg spouse, child or other carer), together with the use of formal memory tests and assessment of activities of daily living (ref 1).&lt;/P&gt;
&lt;P&gt;Tests of memory and thinking include the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The ability to repeat the names of three common objects (eg apple, table, penny) immediately, and recall them after three minutes. &lt;/LI&gt;
&lt;LI&gt;The ability accurately to identify the day of the week, the month and the year. &lt;/LI&gt;
&lt;LI&gt;The ability to give their name and full, postal address. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;Examine and investigate for treatable causes of dementia. Common causes of cognitive worsening in the elderly are as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Delirium - F05. (Sudden increases in confusion, wandering attention or agitation will usually indicate a physical illness [eg acute infectious illness] or toxicity from medication). &lt;/LI&gt;
&lt;LI&gt;Acute psychosis - F23.9 &lt;/LI&gt;
&lt;LI&gt;Chronic (persistent) psychosis - F20#. &lt;/LI&gt;
&lt;LI&gt;Depression - F32#. (Depression may cause memory and concentration problems similar to those of dementia, especially in older patients, if low or sad mood is prominent, or if the impairment is patchy and has developed rapidly.) &lt;/LI&gt;
&lt;LI&gt;Common organic causes of impairment include metabolic and endocrine disorders, neoplasms, any drug treatments. &lt;BR&gt;Helpful tests in distinguishing an organic cause include MSU, FBC, vitamin B12, folate, LFTs, TFTs, U and E, Ca2+and glucose.&amp;nbsp;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;/STRONG&gt;Dementia is frequent in old age but is not inevitable. &lt;/LI&gt;
&lt;LI&gt;Memory loss and confusion may cause behaviour problems, for example agitation, suspiciousness, emotional outbursts, apathy, disinhibition in aggression, inappropriate sexual behaviour, and an inability to take part in normal social interaction. &lt;/LI&gt;
&lt;LI&gt;Memory loss usually proceeds slowly, but the course and long-term prognosis vary with the disease causing dementia. Discuss diagnosis, likely progress and prognosis with the patient and family. &lt;/LI&gt;
&lt;LI&gt;Physical illness or other stress can increase confusion. &lt;/LI&gt;
&lt;LI&gt;The patient will have great difficulty in learning new information. Avoid placing patient in unfamiliar places or situations. &lt;/LI&gt;
&lt;LI&gt;Membership of a support group and information on dementia for the family can aid caring, although some carers might find this distressing in the short term.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Always give information about local services in addition to general advice about dementia.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 2)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Regularly review the patient’s ability to perform daily tasks safely, behavioural problems and general physical condition. &lt;/LI&gt;
&lt;LI&gt;If memory loss is mild, consider use of memory aids or reminders. &lt;/LI&gt;
&lt;LI&gt;Encourage the patient to make full use of remaining abilities. &lt;/LI&gt;
&lt;LI&gt;Encourage maintainance of the patient's physical health and fitness through good diet and exercise, plus swift treatment of intercurrent physical illness. &lt;/LI&gt;
&lt;LI&gt;Make sure the patient and family understand that the condition may impair the ability to drive. If the patient is incapable of understanding this advice, the GP should inform the DVLA immediately. In early dementia when sufficient skills are retained and progression is slow, a licence may be issued subject to annual review (car and motorbike drivers only) (ref 3). &lt;/LI&gt;
&lt;LI&gt;Regularly assess risk (balancing safety and independence), especially at times of crisis. As appropriate, discuss arrangements for support in the home, community or day care programmes, or residential placement.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Review how the carer is managing, especially if they live with the patient. Consider ways to reduce stress on those caring for the patient (eg self-help groups, home help, day care and respite care). Contact with other families caring for relatives with dementia may be helpful, although this can be distressing at first. An assessment of the patient's needs and those of the carer (under the Carer's Recognition and Services Act) can be requested from the local Social Services Department. Carers may need continuing support after the patient has entered residential care or has died. &lt;/LI&gt;
&lt;LI&gt;Discuss planning of legal and financial affairs with family members, including information on seeking ‘power of attorney’ and ‘enduring power of attorney’. Attendance allowance and a discount on council tax bills can usually be claimed. An allowance (Invalid Carers Allowance) can also be obtained by carers. An information sheet is available from the Alzheimer's Society and further information and help can be obtained through local Social Services. &lt;/LI&gt;
&lt;LI&gt;Non-pharmacological methods of dealing with difficult behaviour can be adopted.&amp;nbsp; For example, carers may be able to deal with repetitive questioning if they are given the information that this is because of the dementia affecting the patient's memory.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Antipsychotic medication in very low doses (BNF section 4.2.1) might sometimes be needed to manage some behavioural problems (eg aggression or restlessness). Behavioural problems change with the course of the dementia; therefore, withdraw medication every few months on a trial basis to see if it is still needed, and discontinue if it is not. Beware of drug side-effects (eg parkinsonian symptoms, anticholinergic effects) and drug interactions (avoid combining with tricyclic antidepressants, alcohol, anticonvulsants or L-dopa preparations.). Antipsychotics should be avoided in Lewy body dementia (ref 4).&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Avoid using sedative or hypnotic medications (eg benzodiazepines) if possible. If other treatments have failed and severe management problems remain, use very cautiously and for no more than two weeks; they may increase confusion.&lt;/LI&gt;
&lt;LI&gt;Aspirin in low doses can be prescribed in vascular dementia to attempt to slow deterioration. &lt;/LI&gt;
&lt;LI&gt;In Alzheimer's disease, consider referring to secondary care for assessment and initiation of anticholinesterase drugs, which may postpone the onset of more severe symptoms but do not affect the eventual outcome of the disease. NICE recommends that donepezil, rivastigmine and galantamine should be made available as part of the management of some people with mild-to-moderate Alzheimer’s disease (ref 5). These drugs should be started by specialists and the patient assessed every six months by specialists or their GP following shared protocols. &lt;/LI&gt;
&lt;LI&gt;Memantine, which acts on the glutamate neuroreceptors, has been licensed in the UK for moderate to severe Alzheimer’s disease, but the clinical evidence for its effectiveness is currently sparse (ref 6,7).&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Referral&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Refer early to a specialist for assessment and possible treatment with anticholinesterase treatment in the case of early Alzheimer’s. &lt;/LI&gt;
&lt;LI&gt;Consider referral to Social Services for practical help: needs assessment, formal care planning, home help, day care and help with placement and benefits.&lt;/LI&gt;
&lt;LI&gt;Refer to a physician if complex medical co-morbidity or sudden worsening of dementia. &lt;/LI&gt;
&lt;LI&gt;Refer to psychiatric services if there are intractable behavioural problems, unusually complex family relationships or if depressive or psychotic episode occurs.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;/STRONG&gt;Alzheimer’s Society 0845 300 0336 (helpline)&lt;BR&gt;Email: &lt;A href="mailto:helpline@alzheimers.org.uk" target="_blank"&gt;helpline@alzheimers.org.uk&lt;/A&gt;; website: &lt;A href="http://www.alzheimers.org.uk/" target="_blank"&gt;http://www.alzheimers.org.uk&lt;/A&gt;&lt;BR&gt;Provides support to people with all forms of dementia -not just Alzheimer’s - their family and friends, and supports research on education and training for primary care.&lt;/P&gt;
&lt;P&gt;Age Concern &lt;A href="http://www.ace.org.uk/" target="_blank"&gt;http://www.ace.org.uk&lt;/A&gt;&lt;BR&gt;England: 0800 009 966 (Information line 7am–7pm, seven days a week); Email: &lt;A href="mailto:ace@ace.org.uk" target="_blank"&gt;ace@ace.org.uk&lt;/A&gt; &lt;BR&gt;Northern Ireland: 02890 245 729; Email: &lt;A href="mailto:info@ageconcernni.org" target="_blank"&gt;info@ageconcernni.org&lt;/A&gt;&lt;BR&gt;Wales: 029 2037 1566; Email: &lt;A href="mailto:enquiries@accymru.org.uk" target="_blank"&gt;enquiries@accymru.org.uk&lt;/A&gt;&lt;BR&gt;Scotland: 0131 220 3345; Email: &lt;A href="mailto:enquiries@acscot.org.uk" target="_blank"&gt;enquiries@acscot.org.uk&lt;/A&gt;&lt;BR&gt;Provides information and advice relating to older people.&lt;/P&gt;
&lt;P&gt;Help the Aged &lt;A href="http://www.helptheaged.org.uk/" target="_blank"&gt;http://www.helptheaged.org.uk&lt;/A&gt;&lt;BR&gt;England: 020 7278 1114; Email: &lt;A href="mailto:info@helptheaged.org.uk" target="_blank"&gt;info@helptheaged.org.uk&lt;/A&gt;&lt;BR&gt;Wales: 02920 346 550; Email: &lt;A href="mailto:infocymru@helptheaged.org.uk" target="_blank"&gt;infocymru@helptheaged.org.uk&lt;/A&gt;&lt;BR&gt;Scotland: 0131 551 6331; Email: &lt;A href="mailto:infoscot@helptheaged.org.uk" target="_blank"&gt;infoscot@helptheaged.org.uk&lt;/A&gt;&lt;BR&gt;Northern Ireland: 02890 230 666; Email: &lt;A href="mailto:infoni@helptheaged.org.uk" target="_blank"&gt;infoni@helptheaged.org.uk&lt;/A&gt;&lt;BR&gt;Provides advice and support to older people&lt;/P&gt;
&lt;P&gt;Carers UK 0808 808 7777 (helpline 10am–12noon and 2–4pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:info@ukcarers.org.uk" target="_blank"&gt;info@ukcarers.org.uk&lt;/A&gt;, website: &lt;A href="http://www.carersonline.org.uk/" target="_blank"&gt;http://www.carersonline.org.uk&lt;/A&gt;&lt;BR&gt;Formerly the National Carers Association. Provides information and advice on all aspects of care for both carers and professionals.&lt;/P&gt;
&lt;P&gt;Counsel and Care 020 7485 1566 (10.30am–4pm, Monday–Friday)&lt;BR&gt;Website: &lt;A href="http://www.counselandcare.org.uk/" target="_blank"&gt;http://www.counselandcare.org.uk&lt;/A&gt;&lt;BR&gt;Advice and information on home and residential care for older people.&lt;/P&gt;
&lt;P&gt;Crossroads Association 0845 450 0350&lt;BR&gt;Email: &lt;A href="mailto:communications@crossroads.org.uk" target="_blank"&gt;communications@crossroads.org.uk&lt;/A&gt;; website: &lt;A href="http://www.crossroads.org.uk/" target="_blank"&gt;http://www.crossroads.org.uk&lt;/A&gt;&lt;BR&gt;Regional centres throughout the UK, providing practical support and help for carers, including respite care, day centres, befriending and night care. There is also a scheme for young carers.&lt;/P&gt;
&lt;P&gt;Benefits Enquiry Line 0800 882 200 &lt;BR&gt;Advice and information for people with disabilities and their carers about benefits and assistance with claim form completion.&lt;/P&gt;
&lt;P&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;):&lt;BR&gt;Memory and Dementia, Alzheimer’s disease and dementia, Drug Treatment of Alzheimer’s.&lt;/P&gt;
&lt;P&gt;The Mental Health Foundation produces the information booklets All About Dementia and Because You Care (which includes suggestions to carers about how to deal with difficult behaviour in people with dementia). Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW, UK. Tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Alzheimer’s at your Fingertips, 2nd edition, by Harry Cayton, Nori Graham and J Warner. Class Publishing, 2002.&lt;BR&gt;For patients and carers, this book answers commonly asked questions about all types of dementia.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; World Health Organization. Schizophrenia: An International Follow-up Study. Chichester: John Wiley &amp;amp; Sons, 1979. (AIV) Large outcome study with two-year follow-up, showed that only 10-15% of patients did not recover from their illness in that two-year period. Another shorter-term follow-up study (Lieberman J, Jody D, Geisler S et al. Time course and biologic correlates of treatment response in first episode schizophrenia. Arch Gen Psychiatry 1993, 50: 369-376) showed that 83% of first-episode psychotic patients treated with antipsychotic medication remitted by one year post-inpatient admission. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Eccles M, Clark J, Livingstone M et al. North of England evidence-based guidelines development project: guidelines for the primary-care management of dementia. Br Med J 1998, 317: 802-808. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Driver and Vehicle Licensing Agency. At a Glance Guide to Medical Aspects of Fitness to Drive. URL &lt;A href="http://www.dvla.gov.uk/" target="_blank"&gt;http://www.dvla.gov.uk&lt;/A&gt;. Further information is available from The Senior Medical Adviser, DVLA, Driver Medical Unit, Longview Road, Morriston, Swansea SA99 ITU, Wales. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Ballard C, Grace J, McKeith I et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998, 351: 1032-1033. (CV) This is a case-register study. Other interventions should be explored before the use of neuroleptics in patients with dementia, particularly in those with dementia with Lewy bodies. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; National Institute for Clinical Excellence. Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease (Technology appraisal guidance 19). London: NICE, 2001. URL &lt;A href="http://www.nice.org.uk/" target="_blank"&gt;http://www.nice.org.uk&lt;/A&gt;. (AI) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Areosa Sastre A, Sherriff F. Memantine for dementia (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. (BI) Seven studies were analysed. Results are awaited from two large trials, but those to date suggest a small beneficial effect from 20 or 30 mg/day of memantine on cognitive function measured at 6 and 28 weeks and on global function in patients with mild to moderately severe Alzheimer's disease, vascular and mixed dementia. 259 References 05-WHO-(Refs)-resize-cpp 19/1/2004 2:33 pm Page 259 &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348(14): 1333-1341. (BII) Memantine reduced clinical deterioration in moderate to severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available. It was not associated with a significant frequency of adverse events.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>82256</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=82256]]&gt;</url>
    <title>Introduction to depression</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Depression - F32# (Clinical term: Depressive episode Eu32)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to depression&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Depression - F32# (Clinical term: Depressive episode Eu32)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;The patient may present initially with one or more physical symptoms, such as pain or ‘tiredness all the time’.&amp;nbsp; Further enquiry may reveal low mood, loss of interest or irritability.&lt;/P&gt;
&lt;P&gt;A wide range of presenting complaints may accompany or conceal depression. These include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;anxiety or insomnia &lt;/LI&gt;
&lt;LI&gt;worries about social problems, eg financial or marital difficulties &lt;/LI&gt;
&lt;LI&gt;increased drug or alcohol use &lt;/LI&gt;
&lt;LI&gt;(in a new mother) constant worries about her baby or fear of harming the baby.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Low or sad mood. &lt;/LI&gt;
&lt;LI&gt;Loss of interest or pleasure.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;At least four of the following associated symptoms are present:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;disturbed sleep&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;disturbed appetite&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;guilt or low self-worth&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;pessimism or hopelessness about the future &lt;/LI&gt;
&lt;LI&gt;fatigue or loss of energy&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;agitation or slowing of movement or speech &lt;/LI&gt;
&lt;LI&gt;diurnal mood variation &lt;/LI&gt;
&lt;LI&gt;poor concentration &lt;/LI&gt;
&lt;LI&gt;suicidal thoughts or acts &lt;/LI&gt;
&lt;LI&gt;loss of self-confidence &lt;/LI&gt;
&lt;LI&gt;sexual dysfunction.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Symptoms of anxiety or nervousness and physical aches and pains are also frequently present.&lt;/P&gt;
&lt;P&gt;Some groups are at higher risk, for example: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;those with adverse life events and social difficulties (eg the unemployed, single parents, the homeless, those living in care, those experiencing social isolation) &lt;/LI&gt;
&lt;LI&gt;those with a past history of depression and other psychiatric disorders &lt;/LI&gt;
&lt;LI&gt;those with chronic physical disorders &lt;/LI&gt;
&lt;LI&gt;women who have experienced recent childbirth &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;It may be helpful to ask the following questions:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;During the past month, have you been bothered by little interest and pleasure in daily activities? &lt;/LI&gt;
&lt;LI&gt;During the past month, have you been bothered by feeling down, depressed and hopeless?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;A negative answer to either of these questions makes depression unlikely.&lt;/P&gt;
&lt;P&gt;A negative answer to either of these questions makes depression unlikely.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Acute psychotic disorder - F23 (if hallucinations [eg hearing voices] or delusions [eg strange or unusual beliefs] are present).&lt;/LI&gt;
&lt;LI&gt;Bipolar disorder - F31 (if patient has a history of manic episodes [eg excitement, rapid speech and elevated mood]). &lt;/LI&gt;
&lt;LI&gt;Alcohol misuse - F10 or Drug use disorder - F11 (if heavy alcohol or drug use is present). &lt;/LI&gt;
&lt;LI&gt;Chronic mixed anxiety and depression - F41.2 &lt;/LI&gt;
&lt;LI&gt;Postnatal depression - F53 &lt;/LI&gt;
&lt;LI&gt;Bereavement - Z63 &lt;/LI&gt;
&lt;LI&gt;Adjustment disorder - F43.2 &lt;/LI&gt;
&lt;LI&gt;Unexplained somatic complaints - F45 &lt;/LI&gt;
&lt;LI&gt;Generalized anxiety - F41.1&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Some medications might produce symptoms of depression (eg beta-blockers, other antihypertensives, H2 blockers, oral contraceptives and corticosteroids). &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Depression is a common illness and effective treatments are available. &lt;/LI&gt;
&lt;LI&gt;Depression is not weakness or laziness. &lt;/LI&gt;
&lt;LI&gt;Depression can affect a person’s ability to cope. &lt;/LI&gt;
&lt;LI&gt;Emotional and practical support from family and friends are very valuable. &lt;/LI&gt;
&lt;LI&gt;Recommend information leaflets or audiotapes to reinforce the information &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Assess suicidal intent. The belief that enquiring about suicidal ideation may prompt some people to consider self-harm is not supported by research findings or clinical experience. Placed in the context of asking people about symptoms of depression, such questions feel less awkward for the interviewer, for example 'It sounds as if you have been feeling very down recently; has there ever been a time when you have felt as though you couldn’t be bothered carrying on? Have you ever felt that life was not worth living/that you would be better off if you were dead? Have you ever thought of harming yourself in any way?' Close supervision by family or friends or hospitalization may be needed. &lt;/LI&gt;
&lt;LI&gt;Consider high-risk groups, for example older people, men, those with physical illness, substance abuse, a family history of suicide and those who have previously demonstrated self-harm. &lt;/LI&gt;
&lt;LI&gt;Identify current life problems or social stresses, including precipitating factors. Focus on small, specific steps patients might take towards reducing or improving management of these problems. Avoid major decisions or life changes. &lt;/LI&gt;
&lt;LI&gt;Plan short-term activities which give the patient enjoyment or build confidence. Exercise may be helpful (ref 2) &lt;/LI&gt;
&lt;LI&gt;If appropriate, advise reduction in caffeine intake (ref 3) and drug and alcohol use (ref 4) &lt;/LI&gt;
&lt;LI&gt;Support the development of good sleep patterns and encourage a balanced diet (ref 5) &lt;/LI&gt;
&lt;LI&gt;Encourage patient to resist pessimism and self-criticism, not to act on pessimistic ideas (eg ending a marriage or leaving a job), and not to concentrate on negative or guilty thoughts. &lt;/LI&gt;
&lt;LI&gt;If physical symptoms are present, discuss the link between these and mood &lt;/LI&gt;
&lt;LI&gt;Involve the patient in discussing the advantages and disadvantages of available treatments. Inform them that medication usually works more quickly than psychotherapies (ref 6, 7). Arrange another appointment to monitor progress one to two later, whether or not on medication. &lt;/LI&gt;
&lt;LI&gt;After improvement, plan with the patient the action to be taken if signs of relapse occur. &lt;/LI&gt;
&lt;LI&gt;Patients might find it helpful to keep a mood diary, rating mood changes between 1 and 10 and noting down any external influencing factors. This can be practically useful in identifying patterns.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;P&gt;Consider antidepressant drugs if sad mood or loss of interest are prominent for at least two weeks, preferably four weeks, and if four weeks or more of the following symptoms are present (every day for most of the day), accompanied by significant impairment of functioning:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;fatigue or loss of energy&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;disturbed sleep&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;guilt or self-reproach&lt;/LI&gt;
&lt;LI&gt;poor concentration &lt;/LI&gt;
&lt;LI&gt;thoughts of death or suicide &lt;/LI&gt;
&lt;LI&gt;disturbed appetite &lt;/LI&gt;
&lt;LI&gt;agitation or slowing of movement and speech.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;There is no evidence that people with recent onset of only few or very mild depressive symptoms respond to antidepressants (ref 8). There is evidence that persistent mild depression, lasting two years or more, responds to antidepressants (ref 9).&lt;/P&gt;
&lt;P&gt;Consider delaying medication until the second or subsequent visit because there is a high rate of spontaneous recovery (see again within a week to reassess).&lt;/P&gt;
&lt;P&gt;There is no evidence to suggest that any antidepressant is more effective than others; (ref 10, 11) however, their side-effect profiles differ, and therefore some drugs will be more acceptable to particular patients than others (BNF section 4.3).&lt;BR&gt;Choice of medication:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If the patient has responded well to a particular drug in the past, use that drug again. &lt;/LI&gt;
&lt;LI&gt;If the patient is older or physically ill, use medication with fewer anticholinergic and cardiovascular side-effects. &lt;/LI&gt;
&lt;LI&gt;If the patient is suicidal, avoid tricyclics and consider dispensing a few days' supply at a time. &lt;/LI&gt;
&lt;LI&gt;If the patient is anxious or unable to sleep, use a drug with more sedative effects, but warn of drowsiness and problems driving.&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;If the patient is unwilling to give up alcohol, choose one of the SSRI antidepressants that do not interact with alcohol (eg fluoxetine, paroxetine and citalopram; BNF section 4.3.3).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Explain to the patient that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the medication must be taken every day (poor adherence is very common, particularly in pregnancy and breastfeeding); &lt;/LI&gt;
&lt;LI&gt;the drug is not addictive in that higher and higher doses are not required, but withdrawal symptoms may occur if drugs are stopped suddenly; &lt;/LI&gt;
&lt;LI&gt;improvement in mood will start two to three weeks after starting the medication; &lt;/LI&gt;
&lt;LI&gt;side-effects occur from the beginning but usually fade in seven to ten days with SSRIs; they may be more persistent with tricyclic antidepressants; &lt;/LI&gt;
&lt;LI&gt;individuals vary in their reaction to different drugs, including absorption time, which will influence the appropriateness and timing of taking drugs with a sedative profile. &lt;/LI&gt;
&lt;LI&gt;Stress that the patient should consult the doctor before stopping the medication. The drug should never be stopped abruptly (withdrawal symptoms may then occur). All antidepressants should be withdrawn slowly, preferably over 4 weeks in weekly decrements.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Continue full-dose antidepressant medication for at least four to six months after the condition improves to prevent relapse (ref 12,13, 14, 15).&amp;nbsp; Review regularly - at least monthly - during this time to monitor response, side-effects and adherence. Consider, jointly with the patient, the need for further continuation beyond four to six months. If the patient has had several episodes of major depression, consider carefully long-term, prophylactic treatment (ref 16). Obtain a second opinion at this point.&lt;/P&gt;
&lt;P&gt;If sleep problems are very severe, consider a sedative antidepressant, for example a tricyclic. &lt;/P&gt;
&lt;P&gt;If using tricyclic medication, build up over seven to ten days to the effective dose (eg dothiepin: start at 50-75 mg and build to 150 mg nocte; or imipramine: start at 25-50 mg each night and build to 100-150 mg ) (ref 17). It is reasonable to treat with doses of between 75 and 100 mg a day if the patient is responding (ref 18, 19).&lt;/P&gt;
&lt;P&gt;Withdraw antidepressant medication slowly, and monitor for withdrawal reactions and to ensure remission is stable. Gradual reduction of SSRIs can be achieved by using syrup in reducing doses or taking a tablet on alternate days. &lt;/P&gt;
&lt;P&gt;Hypericum perforata (known as St John's Wort and available from health food stores) is efficacious for mild to moderate symptoms of depression, both acute and chronic, but not significant major depression (ref 21). GPs should enquire whether patient is taking St John's Wort because it is widely available and might interact with prescribed medication and diet (eg oral contraceptives, warfarin). (ref 22-24) Over-the-counter formulations are very variable in dosage.&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;The following structured therapies, delivered by appropriately trained practitioners, are effective for some people with depression: (ref 25,26,27)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cognitive behavioural therapy (CBT) &lt;/LI&gt;
&lt;LI&gt;Behaviour therapy &lt;/LI&gt;
&lt;LI&gt;Interpersonal therapy &lt;/LI&gt;
&lt;LI&gt;Structured problem-solving.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients with chronic, relapsing depression might benefit more from CBT or a combination of CBT and antidepressants than from medication alone (ref 28, 29, 30, 31). Counselling might be helpful, especially in milder cases and if focused on specific psychosocial problems related to the depression (eg relationships, bereavement) (ref 32, 33). In the short term, it may have some advantages over normal GP care and patients like it, but after 12 weeks there are no benefits (ref 32, 33).&lt;/P&gt;
&lt;P&gt;Referral to secondary mental health services is advised:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;as an emergency if there is a significant risk of suicide or danger to others, psychotic symptoms or severe agitation &lt;/LI&gt;
&lt;LI&gt;as a non-emergency, if significant depression persists despite treatment&amp;nbsp; in primary care. (Antidepressant therapy has failed if the patient remains symptomatic after a full course of treatment at an adequate dosage. If there is no clear improvement after four weeks with the first drug, it should be changed to another class of drug.)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;If drug or alcohol misuse is also a problem, see guidelines for these disorders.&lt;/P&gt;
&lt;P&gt;Recommend voluntary/non-statutory services in all other cases where symptoms persist, where the patient has a poor or non-existent support network, or where social or relationship problems are contributing to the depression (ref 9).&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Depression Alliance&amp;nbsp; &lt;A href="http://www.depressionalliance.org/" target="_blank"&gt;http://www.depressionalliance.org&lt;/A&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;England: 020 8768 0123 &lt;BR&gt;Wales: 029 2069 2891 (10am-4pm, Monday-Friday)&lt;BR&gt;Scotland: 0131 467 3050&lt;BR&gt;Provides information and self-help groups.&lt;BR&gt;&lt;BR&gt;Aware Defeat Depression Ltd 02871 260602&lt;BR&gt;Email: &lt;A href="mailto:info@aware-ni.org" target="_blank"&gt;info@aware-ni.org&lt;/A&gt;; website: &lt;A href="http://www/aware-ni.org" target="_blank"&gt;http://www/aware-ni.org&lt;/A&gt;&lt;BR&gt;Provides information leaflets, lectures and runs support groups for sufferers and relatives.&lt;BR&gt;&lt;BR&gt;Samaritans 08457 909090 (24-hr helpline) &lt;BR&gt;Email: &lt;A href="mailto:jo@samaritans.org" target="_blank"&gt;jo@samaritans.org&lt;/A&gt;; website: &lt;A href="http://www.samaritans.org.uk/" target="_blank"&gt;http://www.samaritans.org.uk&lt;/A&gt;&lt;BR&gt;Offers confidential emotional support to any person who is despairing or suicidal. &lt;BR&gt;&lt;BR&gt;Calm 0800 585858 (helpline 5pm-3am)&lt;BR&gt;Helpline for young men who are depressed or suicidal.&lt;BR&gt;&lt;BR&gt;SAD (Seasonal Affective Disorder) Association 01903 814942&lt;BR&gt;Website: &lt;A href="http://www.sada.org.uk/" target="_blank"&gt;http://www.sada.org.uk&lt;/A&gt; &lt;BR&gt;Information about seasonal affective disorder (SAD). Offers advice and support to members.&lt;BR&gt;&lt;BR&gt;UK Register of Counsellors&amp;nbsp;&amp;nbsp; 01788 568739&lt;BR&gt;Provides a list of BAC-accredited counsellors.&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Antidepressants,&amp;nbsp;&amp;nbsp; Depression&lt;BR&gt;The Mental Health Foundation produces the information booklet All About Depression.&amp;nbsp; Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW UK. Tel: 7802 0304. website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;Overcoming Depression by Paul Gilbert. Constable &amp;amp; Robinson, 2000&lt;BR&gt;Self-help book. &lt;BR&gt;&lt;BR&gt;Overcoming Depression by Chris Williams. Arnold Publishing, 2001&lt;BR&gt;Self-help book (also available as a CD-ROM; see below).&lt;BR&gt;&lt;BR&gt;Mind over Mood by Dennis Greenberger and Christine Padesky. New York, Guilford Press, 1995&lt;BR&gt;Self-help manual designed to be used as an adjunct to therapy (a clinician’s guide is also available).&lt;BR&gt;&lt;BR&gt;The Feeling Good Handbook by David D Burns. Avon Books, 1989 &lt;BR&gt;A self-help manual.&lt;BR&gt;&lt;BR&gt;Depression – the Way Out of your Prison, 2nd edn by Dorothy Rowe. London: Routledge, 1996 &lt;BR&gt;An explanatory book.&lt;BR&gt;&lt;BR&gt;Coping with Depression. Talking Life, 1A Grosvenor Rd, Hoylake, Wirral CH47 3BS, UK. Tel: 0151 632 0662 &lt;A href="http://www.talkinglife.co.uk/" target="_blank"&gt;http://www.talkinglife.co.uk&lt;/A&gt;&lt;BR&gt;Tape programme, produced with The Royal College of Psychiatrists’ Defeat Depression initiative, describes strategies for coping with all types of depression using cognitive techniques. &lt;BR&gt;&lt;BR&gt;Overcoming Depression. University of Leeds Media Innovations Ltd, 3 Gemini Business Park, Sheepscar Way, Leeds LS7 3JB, UK. Tel: 0113 262 1600; website: &lt;A href="http://www.calipso.co.uk/" target="_blank"&gt;http://www.calipso.co.uk&lt;/A&gt;&lt;BR&gt;A CD-ROM self-help package.&lt;BR&gt;&lt;BR&gt;Beating the Blues. Ultrasis UK Ltd, 4th Floor, 13/17 Long Lane, London EC1A 9PN. Tel: 020 7600 6777; website: &lt;A href="http://www.ultrasis.com/" target="_blank"&gt;http://www.ultrasis.com&lt;/A&gt;&lt;BR&gt;Interactive multi-media programme designed for use in primary care setting, with practitioner assessment and progress review each week. &lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; NICE will publish a guideline on the management of depression in February 2004. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. Br Med J 2001, 322: 763-767. (BI) Fourteen studies were analysed. The effectiveness of exercise in reducing symptoms of depression cannot be determined because of a lack of good-quality research on clinical populations with adequate follow-up. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Greden JF. Anxiety or caffeinism: a diagnosis dilemma. Am J Psychiatry 1974, 131: 1089-1092. (AV) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Schuckit M. Alcohol and major depressive disorder: a clinical perspective. Acta Psychiatrica Scand 1994, 377: 28-32. (AIV)&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Wallin M, Rissanen A. Food and mood: relationship between food, serotonin and affective disorders. Acta Psychiatr Scand 1994, 377(Suppl): 36-40. (CV) Quoted in Guidelines for the Treatment and Management of Depression by Primary Health Care Professionals. National Health Committee of New Zealand, 1996. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Schulberg H, Katon W, Simon G, Rush AJ. Best clinical practice: guidelines for managing major depression in primary care. J Clin Psychiatry 1999, 60(Suppl 7): 19-24. (BII) The authors conclude that recovery rates for an acute episode of major depression in primary care are similar for guideline-driven pharmacotherapy and depression-specific psychotherapies, such as interpersonal therapy and problem-solving treatments. Medication takes four to six weeks to show effect and psychotherapies six to eight weeks. Another conclusion from this paper is that recent randomized controlled trials conducted in primary care show a 50-60% response rate to all classes of antidepressants in primary-care patients. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Lave J, Frank R, Schulberg H, Kamlet M. Cost-effectiveness of treatments for major depression in primary-care practice. Arch Gen Psychiatry 1998, 55(7): 645-51. (BII) The authors describe a high-quality randomized control trial comparing standardized treatment by nortriptyline, interpersonal psychotherapy and primary physician's usual care (n &amp;gt;90 for each group) for major depression in primary care. Both standardized therapies were better than usual care, and more expensive. Those taking drugs did slightly better with respect to both quality of life and economic outcomes. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Paykel E, Hollyman J, Freeling P, Sedgwick P. Prediction of therapeutic benefit from amitriptyline in mild depression:a gernal practice,placebo-controlled trial. J Affective Disord 1988,14:83-95.(BIII)&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Lima M, Moncrieff J. Drugs versus placebo for the treatment of dysthymia (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI). Fifteen studies were looked at. There is some evidence of efficacy of most antidepressants in dysthymia (chronic, mild depressive syndrome) that has been present for at least 2 years.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Schulberg H, Katon W, Simon G, Rush AJ. Best clinical practice: guidelines for managing major depression in primary care. J Clin Psychiatry 1999, 60(Suppl 7): 19-24. (BII) The authors conclude that recovery rates for an acute episode of major depression in primary care are similar for guideline-driven pharmacotherapy and depression-specific psychotherapies, such as interpersonal therapy and problem-solving treatments. Medication takes four to six weeks to show effect and psychotherapies six to eight weeks. Another conclusion from this paper is that recent randomized controlled trials conducted in primary care show a 50-60% response rate to all classes of antidepressants in primary-care patients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; NHS Centre for Reviews and Dissemination, University of York. The treatment of depression in primary care. Effect Health Care 1993, March(5):1-12.(AIII)&lt;BR&gt;Effective strategies to improve the detection and appropriateness of treatment of depression in primary care are available.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Prien R, Kupfer D. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986, 143: 18-23. (BII) The authors conclude that patients treated for a first episode of uncomplicated depression, who respond well to an antidepressant, should receive a full therapeutic dose for at least 16-20 weeks after achieving full remission. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; A Cochrane Review will soon be available. Carney S, Geddes JR, Furukawa T et al. Duration of treatment with antidepressants in depressive disorder (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software Issue 4, 2003.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; Reimherr F, Amsterdam J, Quitkin F et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998, 155: 1247-1253. (BIII) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; A Cochrane Review will soon be available. Cipriani A, Brambilla P, Barbui C, Hotopf M. Fluoxetine versus other types of pharmacotherapy for depression (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software Issue 4, 2003. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; Kupfer D, Frank E, Perel J et al. Five-year outcomes for maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry 1998, 59: 279-288. 260 References 05-WHO-(Refs)-resize-cpp 19/1/2004 2:33 pm Page 260 This is a study carried out by psychiatric patients. There are no comparable clinical trials of the efficacy of maintenance treatment in reducing recurrence of depression in primary care. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; Donoghue J. Sub-optimal use of tricyclic antidepressants in primary care: Editorial. Acta Psychiatrica Scand 1998, 98(6): 429-431. (CV) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side-effects of low dosage tricyclic antidepressants in depression: systematic review. Br Med J 2002, 325: 991-995. (AI) Treatment of depression in adults with low dose tricyclics is justified.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; A Cochrane Review will soon be available. Furukawa T, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; Linde K, Mulrow CD. St John's wort for depression (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Twenty-seven studies were analysed. St John's Wort demonstrated beneficial effects in mild and moderate depressive disorders. St John's Wort extracts have fewer short-term side-effects than older antidepressants; however, the preparations available on the market could vary considerably in their pharmaceutical quality. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; Thiede HM, Walper A. Inhibition of MAO and CoMT by Hypericum extracts and hypericin. J Geriat Psychiatr Neurol 1994, 7(Suppl 1): S54-S56. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; Interactions with tyramine-containing foods (eg beans, some cheeses, yeast, bovril, bananas, pickled herrings), are theoretically possible. However, there is, to date, an absence of spontaneous reports of these problems occurring. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001, 15: 2163-75. (BIII) Interactions between herbal medicines and synthetic drugs exist and can have serious clinical consequences. Healthcare professionals should ask their patients about the use of herbal products and consider the possibility of herb-drug interactions. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; DeRubeis RJ, Crits-Cristoph P. Empirically supported individual and group psychological treatments for adult mental disorders. J Consulting Clin Psychol 1998, 66(1): 37-52. (BI) This work supports cognitive behaviour therapy, behaviour therapy and structured problem-solving. Studies reviewed are based in secondary care. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; Churchill R, Hunot V, Corney R et al. A systematic review of controlled trials of the effectiveness and cost effectiveness of brief psychological treatments for depression. Health Technol Assess 2001, 5(35): 1-173. (AI) Brief psychological treatments, particularly those derived from cognitive/behavioural models, are beneficial in the treatment of people with depression managed outside the hospital setting. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem-solving treatment with amitriptyline and placebo for major depression in primary care. Br Med J 1995, 310: 441-445. (AII) Where the therapies have been compared with each other, none appears clearly superior to the others. More variance in outcomes may be due to the strength of the therapeutic relationship, rather than to the treatment method used. Problem-solving is the easiest therapy to learn and can be provided by GPs and primary-care nurses. Brief cognitive behaviour therapy is difficult to deliver, even using trained therapists (Scott J. Editorial: Psychological treatments for depression - an update. Br J Psychiatry 1995, 167: 289-292). Evidence for the effectiveness of therapies in depression in primary care tends to be weaker than in major depressive disorder in secondary care. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; Thase M, Greenhouse J, Frank E et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997, 54: 1009-1015. (CIV) Combined therapy was not significantly more effective than psychotherapy alone in patients with milder depression; a highly significant advantage was observed in more severe recurrent depressions. Poorer outcomes were also observed in women and older patients. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; A Cochrane Review will soon be available. Churchill R, Wessely S, Lewis G. Combinations of pharmacotherapy and psychotherapy for depression (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; Evans M, Hollon S, De Rubeis R et al. Differential relapse following cognitive therapy and pharmacotherapy of depression. Arch Gen Psychiatry 1992, 49: 802-808. (BII) It appears that providing cognitive therapy during acute treatment prevents relapse. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; A Cochrane Review will soon be available. Churchill R, Wessely S, Lewis G. Antidepressants alone versus psychotherapy alone for depression (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; Roth AD, Fonagy P. What Works For Whom? A Critical Review of Psychotherapy Research. New York: Guilford Press, 1996. (CII) The efficacy of counselling in primary-care settings is difficult to assess because of the methodological problems of available research. It seems more appropriate for milder presentations of disorders, however, than for more severe presentations, and evidence is better for counselling focused on a particular client group (eg relationship or bereavement counselling). &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; Bower P, Rowland N, Mellor Clark J et al. Effectiveness and cost-effectiveness of counselling in primary care (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (B1) Seven studies were analysed. Results showed that counselling is significantly more effective than 'usual care' in the short- but not the long-term. Satisfaction with counselling was high. Patients had a mix of 'emotional disorders'. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; Ostler KJ, Thompson C, Kinmonth ALK et al. Influence of socio-economic deprivation on the prevalence and outcome of depression in primary care: the Hampshire Depression Project. Br J Psychiatry 2001, 178(1): 12-17. The authors show a strong link between high indices of deprivation and poor prognosis for depression in primary care.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>82620</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=82620]]&gt;</url>
    <title>Introduction to depressive disorder in adolescents</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,SPECIALTIES,DEPRESSION,CHILD HEALTH,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Depressive disorder in adolescents - F32#* (Clinical term: Depressive episode Eu32) * The current ICD-10 classification does not distinguish between adults and adolescents.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to depressive disorder in adolescents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Depressive disorder in adolescents - F32#* (Clinical term: Depressive episode Eu32) * The current ICD-10 classification does not distinguish between adults and adolescents.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Introduction&lt;/H2&gt;
&lt;P&gt;Depressive disorder in pre-adolescents is very rare and difficult to distinguish from the intense emotional reactions and misery that are common in small children. All cases of suspected depressive disorder in pre-adolescents should be referred. This guideline is concerned with depressive disorder in adolescents.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Adolescents usually present with symptoms of depressive disorder such as depression, suicidality or sleep disturbance. Depressive disorder can also present with its complications (eg school refusal) or with co-morbid problems (eg behavioural difficulties). Adolescents frequently present with physical symptoms, such as headaches or abdominal pain. Irritability can also be a symptom of depression.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Depression is diagnosed using the same criteria as in adults.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Low or sad mood is present most days.&lt;/LI&gt;
&lt;LI&gt;Loss of interest or pleasure is present most days.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;As well as several of the following associated symptoms:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Hopelessness &lt;/LI&gt;
&lt;LI&gt;Poor concentration &lt;/LI&gt;
&lt;LI&gt;Poor or excessive sleep for developmental stage &lt;/LI&gt;
&lt;LI&gt;Weight loss (or failure to gain weight normally) or excessive weight gain &lt;/LI&gt;
&lt;LI&gt;Suicidal thoughts or acts &lt;/LI&gt;
&lt;LI&gt;Low self-esteem &lt;/LI&gt;
&lt;LI&gt;Loss of energy &lt;/LI&gt;
&lt;LI&gt;Agitation or slowing of movement or speech.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;To qualify for a diagnosis of depressive disorder, these symptoms should lead to significant suffering or impairment and should persist for at least one month.&lt;/P&gt;
&lt;P&gt;Several factors increase the risk of depression, and their presence should alert the practitioner to the possibility of this diagnosis. These include being in care, recent bereavement, family breakdown, and adolescents with shy personalities who have peer relationship problems.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Anxiety disorder (Depressive disorder should only be diagnosed if the symptoms are clearly prominent and not part of an anxiety disorder). &lt;/LI&gt;
&lt;LI&gt;Normal adolescent emotionality (Depressive disorder should only be diagnosed if there is social impairment, or there are serious symptoms such as a suicidal attempt). &lt;/LI&gt;
&lt;LI&gt;Conduct disorder - F91# (depressive disorder should only be diagnosed if the symptoms are clearly prominent and not part of the behavioural disorder). &lt;/LI&gt;
&lt;LI&gt;Drug use - F11# (diagnose depression as secondary if it occurs only in conjunction with heavy substance abuse [eg misuse of marijuana]). &lt;/LI&gt;
&lt;LI&gt;Bipolar disorder - F31 (adult) (in referred samples about 1 in 20 adolescents with severe depression go on to develop bipolar disorder; the risk is higher if there are features of psychotic depression and a family history of bipolar disorder).&lt;BR&gt;Some medications used by adolescents, eg preparations for acne, oral contraceptives and corticosteroids, can be associated with depression. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;A wide range of problems can occur in conjunction with depression, which makes the diagnosis more difficult. Symptoms of general or separation anxiety (fear of being away from a major attachment figure) are frequently present. Other co-morbidities include behavioural problems, substance misuse, school attendance problems and family difficulties.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;The adolescent is not making the symptoms up. What look like laziness or crossness can be symptoms of depression. &lt;/LI&gt;
&lt;LI&gt;Depression can affect relationships within the family and the ability to do school work or to go to school. &lt;/LI&gt;
&lt;LI&gt;Effective treatments are available for depression, and there is a good chance of recovery. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Identify current life problems or stresses and try to reduce them. &lt;/LI&gt;
&lt;LI&gt;Try to keep the adolescent active by planning enjoyable activities with them. &lt;/LI&gt;
&lt;LI&gt;If the depression is not severe, encourage the adolescent to go to school. &lt;/LI&gt;
&lt;LI&gt;Encourage the adolescent to take exercise, to get to bed early and to eat a balanced diet. &lt;/LI&gt;
&lt;LI&gt;If the adolescent has made a suicidal attempt, the parent should be encouraged to secure medication and sharp objects. Offer the patient and family an emergency telephone number. &lt;/LI&gt;
&lt;LI&gt;Involve both patient and family in discussing the advantages and disadvantages of psychological and physical treatments. Many adolescents and families are worried about taking antidepressant medication, so respect this decision and continue to monitor. &lt;/LI&gt;
&lt;LI&gt;Individual psychological treatments, such as cognitive behavioural therapy and interpersonal therapy, are the treatment of first choice, if available. &lt;/LI&gt;
&lt;LI&gt;Family therapy has not been found to be effective, but might be indicated if family problems are obviously contributing to the adolescent’s depression. &lt;/LI&gt;
&lt;LI&gt;Response to the initial treatment usually occurs within eight weeks. If it has not, consider a second line of treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;In general, medication is not the first-line treatment. &lt;/LI&gt;
&lt;LI&gt;Consider antidepressants, however, if the depression is so severe that psychological treatment is unlikely to work by itself, if non-medical treatments have failed or are not available. &lt;/LI&gt;
&lt;LI&gt;Tricyclic antidepressants should be avoided - there is little evidence they are effective in adolescent depression and they are dangerous in overdose. &lt;/LI&gt;
&lt;LI&gt;SSRIs are the first-line antidepressants.&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Start with half the adult dose and increase slowly, as adherence is particularly poor in this age group and perceived side-effects are the most common reason for not taking medication. &lt;/LI&gt;
&lt;LI&gt;Explain that the medication must be taken every day, that improvement in symptoms takes three to four, and that there may be some mild side-effects but that these usually fade within two weeks.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Referral may be necessary if structured psychological therapies are not available in primary care.&lt;/P&gt;
&lt;P&gt;Referral to a Child and Adolescent Mental Health Service is advised:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;in an emergency, when there is a high risk of self-harm, psychotic symptoms, or refusal to drink &lt;/LI&gt;
&lt;LI&gt;if depression persists despite initial treatment in primary care &lt;/LI&gt;
&lt;LI&gt;if the depression occurs in the context of complex family or social difficulties &lt;/LI&gt;
&lt;LI&gt;if the cause of the depression is likely to include abuse &lt;/LI&gt;
&lt;LI&gt;if the depression is co-morbid with severe behavioural disorder or substance abuse.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Young Minds Trust 020 7336 8445&lt;BR&gt;Parent information service: 0800 018 2138; website: &lt;A href="http://www.youngminds.org.uk/" target="_blank"&gt;http://www.youngminds.org.uk&lt;/A&gt;&lt;BR&gt;Aims to improve the mental health of all children and young people. Produces a range of leaflets for parents and young people. &lt;/P&gt;
&lt;P&gt;Change our Minds &lt;A href="http://www.changeourminds.com/" target="_blank"&gt;http://www.changeourminds.com&lt;/A&gt;&lt;BR&gt;A website run by the Samaritans targeted at a younger audience.&lt;BR&gt;A leaflet is available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Depression in children and young people&lt;/P&gt;
&lt;P&gt;So Young, So Sad, So Listen by P Graham and C Hughes. Gaskell Press, 1995. &lt;BR&gt;A book discussing childhood depression.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; NICE will publish a guideline on the management of depression in children and adolescents in March 2005.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79073</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79073]]&gt;</url>
    <title>Introduction to dissociative (conversion) disorder</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DISSOCIATIVE (CONVERSION) DISORDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Dissociative (conversion) disorder - F44 [Clinical term: Dissociative (conversion) disorders Eu44]</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to dissociative (conversion) disorder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Dissociative (conversion) disorder - F44 [Clinical term: Dissociative (conversion) disorders Eu44]&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Patients exhibit unusual or dramatic physical symptoms, such as seizures, amnesia, trance, loss of sensation, visual disturbances, paralysis, aphonia, identity confusion and ‘possession’ states. There is no evidence that the patient is intentionally producing the symptom.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Physical symptoms that are unusual in presentation and not consistent with known disease.&lt;/P&gt;
&lt;P&gt;Onset is often sudden and related to psychological stress or difficult personal circumstances.&lt;/P&gt;
&lt;P&gt;In acute cases, symptoms may:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;be dramatic and unusual &lt;/LI&gt;
&lt;LI&gt;change from time to time &lt;/LI&gt;
&lt;LI&gt;be related to attention from others.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;In more chronic cases, patients might appear inappropriately calm in view of the seriousness of the complaint.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;Carefully consider physical conditions that might cause symptoms. A full history and physical (including neurological) examination are essential. Early symptoms of neurological disorders (eg multiple sclerosis) may resemble conversion symptoms.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Unexplained somatic complaints - F45.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Depression - F32# (atypical depression may present in this way).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Physical or neurological symptoms often have no clear physical cause. Symptoms can be brought about by stress. &lt;/LI&gt;
&lt;LI&gt;Symptoms usually resolve rapidly (from hours to a few weeks), leaving no permanent damage.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Encourage the patient to acknowledge recent stresses or difficulties (although it is not necessary for the patient to link the stresses to current symptoms).&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Advise the patient to take a brief rest and relief from stress, then return to usual activities. &lt;/LI&gt;
&lt;LI&gt;Give positive reinforcement for improvement. Try not to reinforce symptoms. Encourage problem-solving for current stresses and difficulties. &lt;/LI&gt;
&lt;LI&gt;Advise against prolonged rest or withdrawal from activities.&lt;/LI&gt;
&lt;LI&gt;Discuss plan with patient’s family (but care is required because in some instances family problems may have precipitated the episode).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;Avoid anxiolytics or sedatives.&lt;/P&gt;
&lt;P&gt;In more chronic cases with depressive symptoms, antidepressant medication may be helpful.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Non-urgent referral to secondary mental health services is advised if confident of the diagnosis:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;if symptoms persist &lt;/LI&gt;
&lt;LI&gt;if symptoms are recurrent or severe &lt;/LI&gt;
&lt;LI&gt;if the patient is prepared to discuss a psychological contribution to symptoms.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;If unsure of the diagnosis, consider referral to a physician before referral to secondary mental health services.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;BACP (British Association for Counselling and Psychotherapy) 0870 443 5252&lt;BR&gt;Website: &lt;A href="http://www.counselling.co.uk/" target="_blank"&gt;http://www.counselling.co.uk&lt;/A&gt;.&lt;BR&gt;Provides advice on sources of individual counselling and family therapy in the UK.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79085</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79085]]&gt;</url>
    <title>Introduction to domestic violence or partner abuse</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DOMESTIC VIOLENCE OR PARTNER ABUSE,ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DETERMINANTS,PUBLIC HEALTH,SOCIAL DETERMINANTS,MONTHLY ADDITIONS,DOMESTIC VIOLENCE,2009 SEPTEMBER,ABUSE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to domestic violence or partner abuse&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Patients may be fearful and reluctant to disclose domestic violence and abuse. Professionals should be particularly sensitive and empathetic in their approach.&lt;/P&gt;
&lt;P&gt;The patient may present with:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;physical injuries: bruising, cuts, burns, broken bones &lt;/LI&gt;
&lt;LI&gt;increased rate or severity of injuries, especially located on the abdomen, during pregnancy &lt;/LI&gt;
&lt;LI&gt;physical complaints: headaches, chronic pain, pelvic inflammatory disease, pelvic pain, sexual dysfunction &lt;/LI&gt;
&lt;LI&gt;psychiatric symptoms: depression, anxiety, suicidality, post-traumatic stress disorder, alcohol or drug abuse &lt;/LI&gt;
&lt;LI&gt;comments about relationship problems or jealousy by the partner &lt;/LI&gt;
&lt;LI&gt;complaints of being hit or harmed by the partner&lt;/LI&gt;
&lt;LI&gt;fearfulness &lt;/LI&gt;
&lt;LI&gt;a partner who insists on being present at appointments; a partner who intimidates or controls the patient&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic pointers&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Dysjunction between physical signs and reported mechanism and history of injury should increase the index of suspicion. &lt;/LI&gt;
&lt;LI&gt;Physical, sexual or emotional abuse perpetrated by a spouse or partner. Both men and women can be victims, but female victims of male partners experience more severe injury and greater depression. (Partner abuse also occurs in gay and lesbian relationships.) &lt;/LI&gt;
&lt;LI&gt;Behavioural changes such as hypervigilence, submissive behaviour in the presence of the abuser, partner speaks or responds on behalf of patient.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Co-existing conditions&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Domestic violence is associated with high rates of mental health problems, which also need to be assessed and treated:&lt;BR&gt;-&amp;nbsp;Self-harm and Depression - F32# are among the most common mental health sequelae of partner abuse (ref 1). Living with violence can exacerbate a predisposition to depression, but a woman’s first exposure to abuse can also cause subsequent depression. Depression may improve as time passes after abuse&lt;BR&gt;- Battered women are nearly four times more likely to suffer from Post-traumatic stress disorder - F43.1, directly related to the experience of partner violence.&lt;BR&gt;- Alcohol misuse - F10 and Drug use disorders - F11# occur in higher rates in abused women, with evidence that it may be a consequence and not just an association with partner violence&lt;BR&gt;- &amp;nbsp;Higher levels of Generalized anxiety - F41.1 and Phobic disorders - F40 occur, as well as worse long-term physical health. &lt;/LI&gt;
&lt;LI&gt;Children witnessing domestic violence might present with symptoms related to this experience. For example, young children might experience tummy aches, difficulty in sleeping, regression tantrums, and enuresis; boys might present with aggression, disobedience, truancy or substance misuse, girls with withdrawal from others, anxiety and depression, low self-esteem, vague physical symptoms. Girls are more likely to develop eating disorders or deliberate self-harm tendencies. Schooling might be affected and children can exhibit symptoms of Post-traumatic stress disorder (nightmares, flash backs, easily startled). &lt;/LI&gt;
&lt;LI&gt;Children living in the home are also at higher risk of being assaulted or abused by the perpetrator. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;P&gt;Domestic violence is a universal problem: one in four British women and one in seven men are physically assaulted by a partner in their lives (ref 2). Rates are higher if forms of emotional abuse are included.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The effects of domestic violence go beyond physical injury. &lt;/LI&gt;
&lt;LI&gt;The risk of attack is increased for women when they try to leave. The woman should have safety awareness and be encouraged to seek appropriate support. Children who witness or experience domestic violence are also directly affected and are at risk.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;General management and advice to patient&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Assess immediate risk.&lt;/STRONG&gt; Ask if patient feels she or her children might be in danger when she returns home today. Detailed risk assessment questions are probably not appropriate within primary care consultations. However, encourage the woman to protect herself and her children. Reassure her that seeking help does not mean that her children will be taken in to care. Encourage her to talk to the children about how they feel. &lt;/LI&gt;
&lt;LI&gt;Abused women report that they feel they can confide in their GP, yet often feel ashamed to disclose their situation. Most women experiencing partner abuse are not recognized within primary care (ref 3). Although there is debate about routine screening, (ref 4) having a low threshold for asking direct questions about domestic violence is necessary to identify cases. &lt;/LI&gt;
&lt;LI&gt;The higher prevalence of current or past abuse in women with mental health problems is a compelling reason for asking about abuse routinely in such cases. &lt;/LI&gt;
&lt;LI&gt;In the absence of visible injury, the practitioner can lead up to explicit enquiry about abuse with a statement like, 'Because conflict or violence is so common in the lives of women, we have begun to ask routinely about abuse in relationships'. If the presenting complaint is anxiety or depression, exploration of stressors should include enquiry about partner abuse. The following questions (HARK) - humiliation, afraid, rape, kick) can be used to ask about past abuse:&lt;BR&gt;-&amp;nbsp;&lt;STRONG&gt;Humiliation&lt;/STRONG&gt;: Within the past year, have you been humiliated or emotionally abused in other ways by your partner, ex-partner or anyone close to you?&lt;BR&gt;-&amp;nbsp;&lt;STRONG&gt;Afraid&lt;/STRONG&gt;: Within the past year have you been afraid of your partner, ex-partner or anyone close to you?&lt;BR&gt;-&amp;nbsp;&lt;STRONG&gt;Rape&lt;/STRONG&gt;: Within the past year have you been raped or forced to have any kind of sexual activity by your partner, ex-partner or anyone close to you?&lt;BR&gt;-&amp;nbsp;&lt;STRONG&gt;Kick&lt;/STRONG&gt;: Within the past year, have you been kicked, hit, slapped or otherwise physically hurt by your partner, ex-partner or anyone close to you? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;If the answer to any of these questions is 'yes', with the woman's permission summarize information in the medical record, including a description of the abuse and any related symptoms. A more detailed record can be made at a subsequent consultation. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Documentation&lt;/STRONG&gt;. Good records might prove invaluable in future legal proceedings, as well as in alerting other colleagues with whom the woman might consult. &lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Confidentiality&lt;/STRONG&gt; is crucial; accidental access to the record by the partner can place the woman at greater risk - information should not be entered into hand-held records (eg antenatal or child health records), and care should be taken in entering an identifiable term on a computer summary that might be visible to the partner if he attends a consultation. &lt;/LI&gt;
&lt;LI&gt;After disclosure, or in the absence of disclosure if the practitioner still suspects abuse, give a contact number for local agencies that provide advocacy. Evaluations of advocacy projects in the UK are positive and, generally, abused women find referral to advocacy acceptable (ref 5). &lt;/LI&gt;
&lt;LI&gt;Cognitive behaviour therapy interventions are effective in improving the mental health of abused women (ref 6). &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;After disclosure of a history of partner abuse by a patient and contact with an advocacy agency, further follow-up for mental health sequelae by the primary care clinician is recommended. This might result in referral to a therapist. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Contact the Police Domestic Violence Officer to discuss safety and options.&lt;/P&gt;
&lt;P&gt;Women's Aid Federation&lt;BR&gt;National Domestic Violence helpline (24hr)&lt;BR&gt;England: 08457 023 468&lt;BR&gt;Wales: 029 2039 0874 &lt;BR&gt;Northern Ireland: 01232 249 041/358 &lt;BR&gt;Scotland: 0131 221 0401&lt;BR&gt;Website: &lt;A href="http://www.womensaid.org.uk/" target="_blank"&gt;http://www.womensaid.org.uk&lt;/A&gt;&lt;BR&gt;Support, advice, information and referrals for women experiencing domestic violence. &lt;/P&gt;
&lt;P&gt;Zero Tolerance 0800 028 3398 (helpline)&lt;BR&gt;Website: &lt;A href="http://www.domesticviolenceprevention.com/" target="_blank"&gt;http://www.domesticviolenceprevention.com&lt;/A&gt; &lt;BR&gt;Support, advice and information for women experiencing domestic violence.&lt;BR&gt;Rape Crisis Federation 020 7837 1600 (24-hour helpline)&lt;BR&gt;Website: &lt;A href="http://www.rapecrisis.co.uk/" target="_blank"&gt;http://www.rapecrisis.co.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Victim Support 0845 30 30 900 (Support line 9am¡V9pm, Monday - Friday; 9am-7pm, Saturday/Sunday; 9am-5pm, bank holidays; see telephone directory for local branch)&amp;nbsp; &lt;BR&gt;Provides emotional support and practical information for anyone who has suffered the effects of crime, regardless of whether the crime has been reported.&lt;/P&gt;
&lt;P&gt;Refuge 0870 599 5443 (24-hour national crisis line)&lt;BR&gt;Offers support, information and referrals. It runs its own refuges in London and the South East. &lt;/P&gt;
&lt;P&gt;Kiran ¡X Asian Women's Aid 020 8558 1986; Email: &lt;A href="mailto:kiranawa@talk21.com" target="_blank"&gt;kiranawa@talk21.com&lt;/A&gt;&lt;BR&gt;Advice, support and refuge for Asian women, and women from other cultures (eg Turkey, Iran, Morocco and Malaysia, etc.)&lt;/P&gt;
&lt;P&gt;Everyman Project&lt;BR&gt;1a Waterlow Road, Archway, London N19 5NJ.&lt;BR&gt;Telephone: 0207 263 8884&lt;BR&gt;Fax: 0207 113 2324.&lt;BR&gt;Email - &lt;A href="mailto:everymanproject@btinternet.com" target="_blank"&gt;everymanproject@btinternet.com&lt;/A&gt;&lt;BR&gt;Web Site: &lt;A href="http://www.rapecrisis.co.uk/" target="_blank"&gt;&lt;FONT color=#0000ff&gt;http://&lt;/FONT&gt;&lt;/A&gt;&lt;A href="http://www.everymanproject.co.uk/" target="_blank"&gt;&lt;FONT color=#0000ff&gt;www.everymanproject.co.uk&lt;/FONT&gt;&lt;/A&gt;&lt;BR&gt;Helpline on 0207 263 8884 6.30pm to 9.00pm on Tuesdays and Wednesdays.&lt;BR&gt;Counselling, support and advice to men who are violent or concerned about their violence, and anyone affected by that violence.&lt;/P&gt;
&lt;P&gt;Relate 01788 573 241/456 1310&lt;BR&gt;Website: &lt;A href="http://www.relate.org.uk/" target="_blank"&gt;http://www.relate.org.uk&lt;/A&gt;&lt;BR&gt;Counselling for adults with relationship difficulties, whether married or not.&lt;/P&gt;
&lt;P&gt;Parentline 01702 559 900 (helpline)&lt;BR&gt;Offers help and advice to parents on bringing up children and teenagers.&lt;/P&gt;
&lt;P&gt;The Suzy Lamplugh Trust Website: &lt;A href="http://www.suzylamplugh.org.uk/" target="_blank"&gt;http://www.suzylamplugh.org.uk&lt;/A&gt;&lt;BR&gt;Works to minimize the damage caused to individuals and to society by aggression in all its forms.&lt;BR&gt;For legal advice (eg child custody, restraining injunctions):&lt;/P&gt;
&lt;P&gt;The National Council for Civil Liberties 020 7378 8659 (advice line)&lt;/P&gt;
&lt;P&gt;Citizens' Advice Bureau (see telephone directory for local branch)&lt;/P&gt;
&lt;P&gt;Rights of Women 020 7251 6575&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Fact sheet 18, for parents and teachers. Domestic violence - its effects on children.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Golding JM. Intimate partner violence as a risk factor for mental disorders: a meta-analysis. J Family Violence 1999, 14: 99-132. (CIV) This is a literature review of 38 studies. Existing research is consistent with the hypothesis that intimate partner violence increases the risk for mental health problems such as depression, suicidality, Post-traumatic stress disorder and drug abuse. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Home Office. Domestic Violence: Finding from a new British Crime Survey self completion questionnaire. London: Home Office Research Studies, 1999. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Richardson J, Coid J, Petruckevitch A et al. Identifying domestic violence: cross-sectional study in primary care. Br Med J 2002, 324: 274-277 (CIV) This is a survey and review of medical records. Health professions should be aware of domestic violence, but the case for screening has not been made. One in six subjects surveyed objected to screening. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Ramsay J, Richardson J, Carter YH et al. Should health professionals screen women for domestic violence? Systematic review. Br Med J 2002, 325: 314 (CIV) Twenty studies in surveys and interventions studies were reviewed. Most subject were in favour of screening. None of the studies measured quality of life, mental health outcomes or potential harm from screening programmes. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Burton S, Regan L, Kelly L. Supporting Women and Challenging Men: Lessons From the Domestic Violence Intervention Project. Bristol: Policy Press, 1998 (CIV) Women benefit from the combination of forms of support, with support groups being the most effective in combating shame, self-blame and the destruction of self-belief, which can strongly inhibit a woman's attempts to end violence. Although two in three men dropped out of the programme, there was a substantial impact on attitudes and behaviour for most men who did complete it. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Abel E. Psychosocial treatments for battered women: a review of the empirical research. Res Social Work Practice 2000, 10: 55-77.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79072</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79072]]&gt;</url>
    <title>Introduction to drug use disorders</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS,DETERMINANTS,OUTCOMES,ALL CAUSES OF MORBIDITY &amp; MORTALITY,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,SUBSTANCE MISUSE,MANAGEMENT &amp; INTERVENTIONS,PROFESSIONAL PRACTICE,INFORMATION,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Drug use disorders - F10 - F19#  (F10 alcohol, F11 -opioids, F12 - cannabinoids, F13 - sedatives or hypnotics, F14.- cocaine, F15 - other stimulants, including caffeine, F16 - hallucinogens, F18 - volatile solvents,  F19 -  multiple drug use and use of other psychoactive substances) (Clinical term: Mental and behavioural disorders due to use of opioids – Eu11)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to drug use disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Drug use disorders - F10 - F19#&amp;nbsp; (F10 alcohol, F11 -opioids, F12 - cannabinoids, F13 - sedatives or hypnotics, F14.- cocaine, F15 - other stimulants, including caffeine, F16 - hallucinogens, F18 - volatile solvents,&amp;nbsp; F19 -&amp;nbsp; multiple drug use and use of other psychoactive substances) (Clinical term: Mental and behavioural disorders due to use of opioids – Eu11)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Patients may have depressed mood, nervousness or insomnia.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Patients might present with a direct request for help to withdraw from or to stabilize their drug use. &lt;/LI&gt;
&lt;LI&gt;Patients might present in a state of intoxication or withdrawal, or with physical complications of their drug use (eg abscesses or thromboses). &lt;/LI&gt;
&lt;LI&gt;Patients may present with social or legal consequences of their drug use (eg debt or prosecution). &lt;/LI&gt;
&lt;LI&gt;Occasionally, covert drug use may manifest itself as bizarre, unexplained behaviour.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Signs of drug withdrawal include the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Opioids: nausea, sweating, restlessness, goose bumps, diarrhoea (cold turkey), hallucinations &lt;/LI&gt;
&lt;LI&gt;Sedatives: anxiety, tremors, insomnia, hallucinations (rare). &lt;/LI&gt;
&lt;LI&gt;Stimulants (cocaine, crack, amphetamine, ecstasy): depression, moodiness, irritability.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The family may request help before the patient (eg because the patient is irritable at home or missing work).&lt;/P&gt;
&lt;P&gt;Whatever their motivation for seeking help, the aim of treatment is to assist the patient to remain healthy until, if motivated to do so and with appropriate help and support, they can achieve a drug-free life.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Drug use has caused physical harm (eg injuries while intoxicated), psychological harm (eg symptoms of mental disorder due to drug use), or has led to harmful social consequences (eg loss of job, severe family problems, criminality).&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Habitual and/or harmful or chaotic drug use. &lt;/LI&gt;
&lt;LI&gt;Difficulty controlling drug use. &lt;/LI&gt;
&lt;LI&gt;Strong desire to use drugs. &lt;/LI&gt;
&lt;LI&gt;Tolerance (can use large amounts of drugs without appearing intoxicated). &lt;/LI&gt;
&lt;LI&gt;Withdrawal (eg anxiety, tremors or other withdrawal symptoms after stopping use).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Diagnosis is aided by the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;History: including reason for presentation, past and current (ie in the past 4 weeks) drug use, routes of use, past medical and psychiatric history, social (and especially child care) responsibilities, forensic history and past contact with treatment services. Poly-drug use/misuse/abuse is common and current and previous history should be elicited. &lt;/LI&gt;
&lt;LI&gt;Examination: motivation, physical (needle tracks or complications, eg thrombosis or viral illness), mental state &lt;/LI&gt;
&lt;LI&gt;Investigations (haemoglobin, LFTs including gamma-glutamyl transferase [GGT], urine drug screen, Hepatitis B and C).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Alcohol misuse - F10 often co-exists. Poly-drug use is very common. &lt;/LI&gt;
&lt;LI&gt;Symptoms of anxiety or depression may also occur with heavy drug use. &lt;/LI&gt;
&lt;LI&gt;Psychotic disorders - F23, F20#. &lt;/LI&gt;
&lt;LI&gt;Acute organic syndromes. &lt;/LI&gt;
&lt;LI&gt;Presentation of other psychiatric disorders should trigger inquiry about alcohol and drug misuse history.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Drug misuse can be a chronic behavioural disorder. Controlling or stopping use often requires several attempts. Relapse is common. &lt;/LI&gt;
&lt;LI&gt;Abstinence should be seen as the long-term goal. Harm reduction (especially reducing intravenous drug use) might be a more realistic goal in the short- to medium-term. &lt;/LI&gt;
&lt;LI&gt;Stopping or reducing drug use can result in psychological, social and physical benefits. &lt;/LI&gt;
&lt;LI&gt;Using some drugs during pregnancy risks harming the baby (ref 1). &lt;/LI&gt;
&lt;LI&gt;For intravenous drug-users, there is a risk of contracting and/or transmitting HIV infection, hepatitis or other infections carried by body fluids. Discuss appropriate precautions (eg use condoms and do not share needles, syringes, spoons, water or any other injecting equipment).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;Advice should be given according to the patient’s motivation and willingness to change (ref 2). For many patients with chronic, relapsing opioid dependence, the treatment of choice is maintenance on long-acting opioids (ref 3,4,5).&lt;/P&gt;
&lt;P&gt;In assessing patients with alcohol or other type of addictive behaviour, the framework of cycles of change can be helpful in assessing the patient’s readiness for change. A patient may be:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;pre-contemplative, ie not considering any change &lt;/LI&gt;
&lt;LI&gt;contemplative, ie considering change or prepared to change behaviour, or &lt;/LI&gt;
&lt;LI&gt;in an action phase where they are actually in the process of change. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Of course, because of the relapsing nature of these disorders, patients may shift from an action phase back to a pre-contemplative phase and then move through the phases of change. Assessment can be a prompt for some to move into a contemplative or action phase.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;For all patients:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Discuss costs and benefits of drug use from the patient's perspective. &lt;/LI&gt;
&lt;LI&gt;Feedback information about health risks, including the results of investigations. &lt;/LI&gt;
&lt;LI&gt;Emphasize personal responsibility for change. &lt;/LI&gt;
&lt;LI&gt;Give clear advice to change. &lt;/LI&gt;
&lt;LI&gt;Assess and manage physical health problems (eg anaemia, chest problems) and nutritional deficiencies. &lt;/LI&gt;
&lt;LI&gt;Consider options for&amp;nbsp; problem-solving, or targeted counselling, to deal with life problems related to drug use. &lt;/LI&gt;
&lt;LI&gt;Goal setting needs to be negotiated and matched to individual needs and assessment, as well as overall pattern of drinking and dependence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;For patients not willing to stop or change drug use now:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Do not reject or blame. &lt;/LI&gt;
&lt;LI&gt;Advise on harm-reduction strategies (eg if the patient is injecting, advise on needle exchange, not injecting alone, not mixing alcohol, benzodiazepines and opiates).&lt;/LI&gt;
&lt;LI&gt;Clearly point out medical, psychological and social problems caused by drugs.&lt;/LI&gt;
&lt;LI&gt;Make a future appointment to re-assess health (eg well-woman checks, immunization) and discuss drug use.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;If reducing drug use is a reasonable goal (or if a patient is unwilling to quit):&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Negotiate a clear goal for decreased use and regularly review progress. &lt;/LI&gt;
&lt;LI&gt;Discuss strategies to avoid or cope with high-risk situations (eg social situations, stressful events).&lt;/LI&gt;
&lt;LI&gt;Introduce self-monitoring procedures (eg diary of drug use) and safer drug-use behaviours (eg time restrictions, slowing down rate of use). &lt;/LI&gt;
&lt;LI&gt;It is useful to set agreed rights and responsibilities for both patient and healthcare team. This may include a contract, which you both sign, clearly setting out your and the patient’s responsibilities and the consequences of non-adherence. &lt;/LI&gt;
&lt;LI&gt;Consider options for referral to appropriate statutory or voluntary services for increased support, eg counselling and/or rehabilitation.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;If maintenance on substitute drugs is considered a reasonable goal (or if a patient is unwilling to quit):&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Negotiate a clear goal for less harmful behaviour. Help the patient develop a hierarchy of aims (eg reducing injecting behaviour, stopping illicit use and maintenance on prescribed, substitute drugs). &lt;/LI&gt;
&lt;LI&gt;Discuss strategies to avoid or cope with high-risk situations (eg social situations or stressful events). &lt;/LI&gt;
&lt;LI&gt;Consider withdrawal symptoms and how to avoid or reduce them. Provide information on the recognition and management of methadone toxicity. &lt;/LI&gt;
&lt;LI&gt;Consider options for referral to appropriate statutory or voluntary (including NAO services) for increased support, eg counselling and/or rehabilitation.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;For patients willing to stop now:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Set a definite day to quit.&lt;/LI&gt;
&lt;LI&gt;Consider withdrawal symptoms and how to manage them. &lt;/LI&gt;
&lt;LI&gt;Emphasize importance of planning ahead to cope with difficulties (see below). If patient is unclear what their coping strategies are, consider deferring ‘quit date’ and work on coping strategies. &lt;/LI&gt;
&lt;LI&gt;Discuss strategies to avoid or cope with high-risk situations (eg social situations or stressful events). &lt;/LI&gt;
&lt;LI&gt;Make specific plans to avoid drug use (eg how to respond to friends who still use drugs). &lt;/LI&gt;
&lt;LI&gt;Identify family or friends who will support stopping drug use. &lt;/LI&gt;
&lt;LI&gt;Consider options for referral to appropriate statutory or voluntary (including NAO services) for increased support, eg counselling or rehabilitation or both.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;For patients who do not succeed or who relapse:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Identify and give credit for any success. &lt;/LI&gt;
&lt;LI&gt;Discuss situations which led to relapse. &lt;/LI&gt;
&lt;LI&gt;Return to earlier steps.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Self-help organizations are often helpful.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;To withdraw a patient from benzodiazepines, convert to a long-acting drug such as diazepam and reduce gradually (eg by 2 mg a fortnight) over a period of two to six months (BNF section 4.1). Benzodiazepine prescribing should be undertaken with caution, and long-term prescribing is now rarely initiated (ref 6,7).&lt;/P&gt;
&lt;P&gt;Withdrawal from stimulants or cocaine is distressing and may require medical supervision under a shared-care scheme. &lt;/P&gt;
&lt;P&gt;Both long-term maintenance of a patient on substitute opiates (eg methadone) and withdrawal from opiates should be done as part of a shared-care scheme (ref 8). A multidisciplinary approach is essential and should include drug counselling/therapy (ref 9) and possible future rehabilitation needs (ref 10). The doctor signing the prescription is solely responsible for prescribing; this cannot be delegated. Doctors prescribing methadone should be familiar with the Department of Health’s document entitled Drug Misuse and Dependence:&amp;nbsp; Guidelines on Clinical Management (ref 11). &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Careful assessment, including urine or saliva analysis and, where possible, dose assessment is essential before prescribing any substitute medication, including methadone. Dosages will depend on the results of this assessment.&lt;/LI&gt;
&lt;LI&gt;For long-term maintenance or stabilization prior to gradual withdrawal, the dose should be titrated up to that needed both to block withdrawal symptoms and block craving for opiates (ref 12). &lt;/LI&gt;
&lt;LI&gt;For gradual withdrawal, after a period of stabilization, the drug can be slowly tapered (eg by 5 mg a fortnight). &lt;/LI&gt;
&lt;LI&gt;Daily dispensing (using blue FP 10 prescription forms) and, where available, supervised ingestion are recommended, especially in the first three months of treatment. Record exact details of the prescription, frequency and chemist in case the patient presents to a colleague. &lt;/LI&gt;
&lt;LI&gt;In the UK, Methadone Mixture BNF at 1 mg/ml is the most often-used substitute medication for opioid addiction (ref 13) (BNF section 4.10). Newer drugs have become available (eg buprenorphine [ref 14]) and can be considered as alternatives to methadone. &lt;/LI&gt;
&lt;LI&gt;Withdrawal from opiates for patients whose drug use is already well controlled can be managed with lofexidine (ref 15,16) (BNF section 4.10). &lt;/LI&gt;
&lt;LI&gt;Wherever possible, treatment should be undertaken in the context of shared care.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Help with life problems, employment and social relationships is an important component of treatment (ref 17).&lt;BR&gt;&lt;BR&gt;Shared care between all agencies (non-statutory agencies, NHS mental health and drug misuse services) and professionals involved is essential. Clarity on who is responsible for prescribing and for the physical care of the patient is crucial.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Narcotics Anonymous UK 020 7730 0009&lt;BR&gt;Email: &lt;A href="mailto:helpline@ukna.org" target="_blank"&gt;helpline@ukna.org&lt;/A&gt;; website: &lt;A href="http://www.ukna.org/" target="_blank"&gt;http://www.ukna.org&lt;/A&gt;&lt;BR&gt;A network of recovering addicts supporting each other to live without drugs.&lt;/P&gt;
&lt;P&gt;CITA (Council for Involuntary Tranquilliser Addiction) 0151 949 0102 (helpline 10.00am–1.00pm, Monday–Friday; emergency weekend number available)&lt;BR&gt;Offers advice on withdrawing from tranquillisers and help with anxiety and depression.&lt;/P&gt;
&lt;P&gt;ADFAM National 020 7928 8900 (helpline 10am–5pm, Monday, Wednesday–Friday; 10am–6.45pm, Tuesday)&lt;BR&gt;Website: &lt;A href="http://www.adfam.org.uk/" target="_blank"&gt;http://www.adfam.org.uk&lt;/A&gt;&lt;BR&gt;Confidential support and information for families and friends of drug users.&lt;/P&gt;
&lt;P&gt;National Drugs Helpline/Talk to Frank 0800 776 600 (24-hour)&lt;BR&gt;Website: &lt;A href="http://www.talktofrank.com/" target="_blank"&gt;http://www.talktofrank.com&lt;/A&gt;&lt;BR&gt;Provides free, confidential advice, including information on local services.&lt;BR&gt;Release 020 7603 8654 (24-hour helpline), 020 7729 9904 (advice line, 10 am–6 pm), 0808 8000 800 (Drugs in School helpline, 10 am–6 pm)&lt;BR&gt;Email:info@release.org.uk; website: &lt;A href="http://www.release.org.uk/" target="_blank"&gt;http://www.release.org.uk&lt;/A&gt;.&lt;BR&gt;Advice, support and information to drug users and their friends and families on all aspects of drug use and drug-related legal problems.&lt;/P&gt;
&lt;P&gt;National Institute on Drug Abuse (NIDA) Website: &lt;A href="http://www.nida.nih.gov/" target="_blank"&gt;http://www.nida.nih.gov&lt;/A&gt;&lt;BR&gt;A useful American site with lots of information and leaflets to download.&lt;BR&gt;Families Anonymous 020 7498 4680 (1pm–5pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:office@famanon.org.uk" target="_blank"&gt;office@famanon.org.uk&lt;/A&gt;, website: &lt;A href="http://www.famanon.org.uk/" target="_blank"&gt;http://www.famanon.org.uk&lt;/A&gt;&lt;BR&gt;Runs self-help groups in the UK for families and friends of those with a drug problem.&lt;/P&gt;
&lt;P&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Alcohol and other drug misuse, Drug and alcohol misuse&lt;/P&gt;
&lt;P&gt;Coping with Tranquilliser Addiction, produced in association with CITA. Talking Life, 1A Grosvenor Rd, Hoylake, Wirral CH47 3BS, UK. Tel 0151 632 0662; website: &lt;A href="http://www.talkinglife.co.uk/" target="_blank"&gt;http://www.talkinglife.co.uk&lt;/A&gt;.&lt;BR&gt;Self-help cassette.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Kaltenbach K, Finnegan L. Children of maternal substance misusers. Curr Opin Psychiatry 1997, 10: 220-224. Most harm to children is indirect, for example via ill health of the mother, poor antenatal care or cigarette smoking. There is a smaller risk of direct harm caused by heroin - growth retardation - and cocaine and amphetamines. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Miller W, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behaviour. New York: Guilford Press, 1991. (AV) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Gossop M, Stewart D, Marsden J. NTORS at One Year: The National Treatment Outcome Research Study. Change in Substance Use, Health and Criminal Behaviour One Year After Intake. London: Department of Health, 1998. (A1) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Ward J, Mattick R, Hall W. Maintenance Treatment and Other Opioid Replacement Therapies. London: Harwood Academic Press, 1997. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Jeffries V, Gabbay M, Carnwath T. Treatments for Opiate Users in Primary Care. Monograph for Enhancing Shared Care Project, Chapel Road, Sale, Manchester M33 7FD, UK. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Lader M, Russell J. Guidelines for the prevention and treatment of benzodiazepine dependence: summary of a report from the Mental Health Foundation. Addiction 1993, 88(12): 1707-1708. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Royal College of Psychiatrists. Benzodiazepines: Risks, Benefits and Dependence - A Re-Evaluation. London: The Royal College of Psychiatrists, UK. URL &lt;A href="http://www.rcpsych.ac.uk/publications/cr/cr59.htm" target="_blank"&gt;http://www.rcpsych.ac.uk/publications/cr/cr59.htm&lt;/A&gt;. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; The Task Force to Review Services for Drug Misusers. Report of an Independent Review of Drug Treatment Services in England. London: DoH, 1995. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; American Psychiatric Association. Practice Guidelines: Substance Use Disorders. Washington DC, 1996. (BII) This publication reports a large randomized controlled trial replicated in a controlled trial comparing drug counselling, drug counselling plus supportive psychotherapy, and drug counselling plus cognitive behaviour therapy for methadone maintenance patients. Those with moderate to high depression or other psychiatric symptoms did better with either therapy in addition to drug counselling. For patients with low levels of psychiatric symptoms, all three treatments were equally effective. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Khantzian E. The primary-care therapist and patient needs in substance abuse treatment. Am J Drug Alcohol Abuse 1988, 14: 159-167. The authors review studies of relapse prevention through, for example, encouraging improved social and other relationships and activities. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Department of Health, The Scottish Office, The Welsh Office and DHSS Northern Ireland. Drug Misuse and Dependence: Guidelines on Clinical Management, 1999. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Amato L, Davoli M, Ferri M, Ali R. Methadone at tapered doses for the management of opioid withdrawal (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Tapered methadone seems to be useful and causes fewer side-effects than other medicated detoxification methods. Moreover, the rate of completion is higher. However, relapse rates are high. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; Marsch LC. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour and criminality: a meta-analysis. Addiction 1998, 93: 515-532. (A1) This is a systematic review of 11 studies. Results demonstrate a consistent, statistically significant relationship between methadone maintenance treatment and the reduction of illicit opiate use, HIV risk behaviours and drug- and property-related criminal behaviour. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (BI) Buprenorphine is an effective intervention for use in the maintenance treatment of heroin dependence, but it is not more effective than methadone at adequate doses. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (BI) Ten studies compared a treatment regimen based on an alpha2-adrenergic agonist, with one based on reducing doses of methadone. Participants stay in treatment longer with methadone regimens, which may provide greater opportunity for psychosocial intervention. Methadone regimes may be preferable for withdrawal in outpatient settings where the risk of relapse to heroin use is high. Methadone might also facilitate transfer to maintenance treatment, should completion of withdrawal become unlikely. For those who are well prepared for withdrawal and seeking earlier resolution of withdrawal symptoms, alpha2-adrenergic agonist treatment may be preferred. Clonidine and lofexidine appear equally effective for inpatient settings, but the lower incidence of hypotension makes lofexidine more suited to use in outpatient settings. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; Brown AS, Fleming PM. A naturalistic study of home detoxification from opiates using lofexidine. J Psychopharmacol 1998, 12: 93-96. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; McLellan AT, Arndt IO, Metzger DS. The effects of psychosocial services in substance abuse treatment. JAMA 1993, 269: 1953-1959. (BII) Patients who received employment help, psychiatric care and family therapy had better outcomes than those who received counselling, who in turn had better outcomes than those who received methadone only.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79106</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79106]]&gt;</url>
    <title>Introduction to eating disorders</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Eating disorders in children and adolescents - F50* (F98.2 refers only to infants and early childhood). (Clinical term: Eating disorders Eu50) * The current ICD-10 classification does not distinguish between adults and children and adolescent</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to eating disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Eating disorders in children and adolescents - F50* (F98.2 refers only to infants and early childhood). (Clinical term: Eating disorders Eu50) * The current ICD-10 classification does not distinguish between adults and children and adolescent&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;The family may ask for help because of the patient's loss of weight, refusal to eat, vomiting or amenorrhea. The family unit is often under considerable stress by the time help is sought. &lt;/LI&gt;
&lt;LI&gt;Patients may present with symptoms of binge-eating and purging or laxative abuse.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Depressive disorder - F32 (often occurs along with bulimia or anorexia). &lt;/LI&gt;
&lt;LI&gt;Physical illness (eg tuberculosis, acquired immune deficiency disease, endocrine disorders, inflammatory bowel disease and hyperthyroidism) may cause weight loss, but it can usually be distinguished by the lack of a distorted body image and a desire to put on weight. &lt;/LI&gt;
&lt;LI&gt;Food refusal - refusal of food which does not involve preoccupation with body shape or weight and which is best viewed as oppositional behavioural difficulties that often resolve with time. &lt;/LI&gt;
&lt;LI&gt;Selective eating - children consume an extremely narrow range of food, but are generally of appropriate height and weight, indicating that their energy intake is probably sufficient. Sometimes this occurs as part of Asperger syndrome. &lt;/LI&gt;
&lt;LI&gt;Food avoidance emotional disorder - this term is applied to emotional disorders in which food avoidance is prominent, eg certain cases of depression, obsessive-compulsive disorder or school refusal, but which do not fulfil the diagnostic criteria for anorexia nervosa. &lt;/LI&gt;
&lt;LI&gt;Functional dysphagia - a rare condition in which the history is of a traumatic episode of choking or difficulty swallowing, followed by food avoidance which is usually selective and which may lead to weight loss. &lt;/LI&gt;
&lt;LI&gt;Pervasive refusal syndrome - profound and pervasive refusal to eat, drink, walk, talk, or engage in any form of self-care.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Routine laboratory investigations should include serum electrolytes, liver enzymes, full blood count, renal function, glucose, full protein and albumin.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;In children and adolescents, some eating disorders (anorexia nervosa and pervasive refusal syndrome) represent potentially life-threatening conditions that impede physical, emotional and behavioural growth and development. &lt;/LI&gt;
&lt;LI&gt;If treated soon after onset, child and adolescent eating disorders have a relatively good prognosis; however, if not treated they may become chronic conditions by adulthood. &lt;/LI&gt;
&lt;LI&gt;In severe cases of pre-pubertal anorexia nervosa, the medical consequences may be irreversible. For example growth retardation; delayed puberty may result in sterility and incomplete development of secondary sex characteristics; and impaired acquisition of peak bone mass during the second decade of life may result in osteoporosis in adulthood.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;/STRONG&gt;(ref 1)&lt;BR&gt;&lt;BR&gt;Eating disorders are serious conditions with a high lifetime mortality, mainly from suicide.&lt;/P&gt;
&lt;P&gt;The GP can undertake early simple steps to treat eating disorder with the help of the practice nurse, counsellor and/or dietician.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anorexia nervosa&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Family involvement is essential for any intervention with children and adolescents (ref 2) &lt;/LI&gt;
&lt;LI&gt;The patient, parents and other family members need information and education about the disorder.&lt;/LI&gt;
&lt;LI&gt;Expect denial from the patient. Encourage and empower parents to be in charge concerning the child's health, eating and safety. Emphasis should be placed on empowering parents as controllers of the patient's food intake. &lt;/LI&gt;
&lt;LI&gt;Weigh the patient weekly and chart their weight. Set manageable goals in agreement with the patient and their family; for example, aim for a 0.5 kg weight increase per week. For patients who are denying the illness, setting the task of gaining weight can often be usefully presented as ‘diagnostic’- someone who is not suffering from an eating disorder should be able to gain weight relatively easily. &lt;/LI&gt;
&lt;LI&gt;Older adolescents might benefit from individual support. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Bulimia nervosa&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Family involvement and providing information and education are equally important as they are in anorexia nervosa (ref 2). &lt;/LI&gt;
&lt;LI&gt;Older adolescents might benefit from individual support and the use of appropriate self-help literature. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Antidepressant medication (eg fluoxetine up to 60 mg daily) usually helps to reduce the frequency of bingeing and vomiting in some patients with bulimia nervosa, but it is not a cure (BNF 4.3.3). &lt;/LI&gt;
&lt;LI&gt;No psychoactive medication has proven effective with anorexia nervosa. Antidepressant medication may be beneficial for children and adolescents with concurrent depressive disorder.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;
&lt;P&gt;Young people with eating disorders are at risk of other mental health problems, including suicide; therefore liaison with the Child and Adolescent Mental Health Service (CAMHS) is always recommended.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anorexia nervosa&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If there is lack of a rapid improvement in eating patterns and weight, refer to the CAMHS, or to the more specialist Children and Adolescent Eating Disorder Service, if locally available. Intensive treatments of early-onset anorexia nervosa can prevent many of the more severe consequences from occurring. In addition, evidence indicates that treatment outcomes are more favourable when eating disorders are treated soon after their onset. &lt;/LI&gt;
&lt;LI&gt;Refer for urgent assessment if there has been rapid weight loss or the body mass index (BMI) of the patient is low. The BMI cut-offs need to be adjusted for growth. Specialist intervention might prevent the need for inpatient treatment even in individuals who are seriously underweight.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Bulimia nervosa&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Consider referral to CAMHS or a specialist Eating Disorder Service if there is a lack of progress in primary care or if more specific treatments (eg cognitive behavioural therapy or family therapy) are not available. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Eating Disorders Association (EDA) 0845 634 7650 (Youthline [for under 19s] 4.00pm–6.30pm, weekdays)&lt;BR&gt;Email: &lt;A href="mailto:info@edauk.com" target="_blank"&gt;info@edauk.com&lt;/A&gt;; website: &lt;A href="http://www.edauk.com/" target="_blank"&gt;http://www.edauk.com&lt;/A&gt;&lt;BR&gt;Self-help support groups for sufferers, their relatives and friends. Assists in putting people in touch with sources of help in their own area.&lt;/P&gt;
&lt;P&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Anorexia and Bulimia, Changing Minds: Anorexia and Bulimia, Understanding Eating Disorders in Young People, and Worries about Weight.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Robin A, Gilroy M, Dennis AB. Treatment of eating disorders in children and adolescents. Clin Psychol 1998, 18(4): 421-446. (CIV) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Eisler I, Le Grange D, Asen E. Family interventions. In: Treasure J, Schmidt U, van Furth E (eds.) Handbook of Eating Disorders. Chichester: John Wiley and Sons, 2003.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79106</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79106]]&gt;</url>
    <title>Introduction to eating disorders</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Eating disorders in children and adolescents - F50* (F98.2 refers only to infants and early childhood). (Clinical term: Eating disorders Eu50) * The current ICD-10 classification does not distinguish between adults and children and adolescent</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to eating disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Eating disorders in children and adolescents - F50* (F98.2 refers only to infants and early childhood). (Clinical term: Eating disorders Eu50) * The current ICD-10 classification does not distinguish between adults and children and adolescent&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;The family may ask for help because of the patient's loss of weight, refusal to eat, vomiting or amenorrhea. The family unit is often under considerable stress by the time help is sought. &lt;/LI&gt;
&lt;LI&gt;Patients may present with symptoms of binge-eating and purging or laxative abuse.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Depressive disorder - F32 (often occurs along with bulimia or anorexia). &lt;/LI&gt;
&lt;LI&gt;Physical illness (eg tuberculosis, acquired immune deficiency disease, endocrine disorders, inflammatory bowel disease and hyperthyroidism) may cause weight loss, but it can usually be distinguished by the lack of a distorted body image and a desire to put on weight. &lt;/LI&gt;
&lt;LI&gt;Food refusal - refusal of food which does not involve preoccupation with body shape or weight and which is best viewed as oppositional behavioural difficulties that often resolve with time. &lt;/LI&gt;
&lt;LI&gt;Selective eating - children consume an extremely narrow range of food, but are generally of appropriate height and weight, indicating that their energy intake is probably sufficient. Sometimes this occurs as part of Asperger syndrome. &lt;/LI&gt;
&lt;LI&gt;Food avoidance emotional disorder - this term is applied to emotional disorders in which food avoidance is prominent, eg certain cases of depression, obsessive-compulsive disorder or school refusal, but which do not fulfil the diagnostic criteria for anorexia nervosa. &lt;/LI&gt;
&lt;LI&gt;Functional dysphagia - a rare condition in which the history is of a traumatic episode of choking or difficulty swallowing, followed by food avoidance which is usually selective and which may lead to weight loss. &lt;/LI&gt;
&lt;LI&gt;Pervasive refusal syndrome - profound and pervasive refusal to eat, drink, walk, talk, or engage in any form of self-care.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Routine laboratory investigations should include serum electrolytes, liver enzymes, full blood count, renal function, glucose, full protein and albumin.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;In children and adolescents, some eating disorders (anorexia nervosa and pervasive refusal syndrome) represent potentially life-threatening conditions that impede physical, emotional and behavioural growth and development. &lt;/LI&gt;
&lt;LI&gt;If treated soon after onset, child and adolescent eating disorders have a relatively good prognosis; however, if not treated they may become chronic conditions by adulthood. &lt;/LI&gt;
&lt;LI&gt;In severe cases of pre-pubertal anorexia nervosa, the medical consequences may be irreversible. For example growth retardation; delayed puberty may result in sterility and incomplete development of secondary sex characteristics; and impaired acquisition of peak bone mass during the second decade of life may result in osteoporosis in adulthood.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;/STRONG&gt;(ref 1)&lt;BR&gt;&lt;BR&gt;Eating disorders are serious conditions with a high lifetime mortality, mainly from suicide.&lt;/P&gt;
&lt;P&gt;The GP can undertake early simple steps to treat eating disorder with the help of the practice nurse, counsellor and/or dietician.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anorexia nervosa&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Family involvement is essential for any intervention with children and adolescents (ref 2) &lt;/LI&gt;
&lt;LI&gt;The patient, parents and other family members need information and education about the disorder.&lt;/LI&gt;
&lt;LI&gt;Expect denial from the patient. Encourage and empower parents to be in charge concerning the child's health, eating and safety. Emphasis should be placed on empowering parents as controllers of the patient's food intake. &lt;/LI&gt;
&lt;LI&gt;Weigh the patient weekly and chart their weight. Set manageable goals in agreement with the patient and their family; for example, aim for a 0.5 kg weight increase per week. For patients who are denying the illness, setting the task of gaining weight can often be usefully presented as ‘diagnostic’- someone who is not suffering from an eating disorder should be able to gain weight relatively easily. &lt;/LI&gt;
&lt;LI&gt;Older adolescents might benefit from individual support. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Bulimia nervosa&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Family involvement and providing information and education are equally important as they are in anorexia nervosa (ref 2). &lt;/LI&gt;
&lt;LI&gt;Older adolescents might benefit from individual support and the use of appropriate self-help literature. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Antidepressant medication (eg fluoxetine up to 60 mg daily) usually helps to reduce the frequency of bingeing and vomiting in some patients with bulimia nervosa, but it is not a cure (BNF 4.3.3). &lt;/LI&gt;
&lt;LI&gt;No psychoactive medication has proven effective with anorexia nervosa. Antidepressant medication may be beneficial for children and adolescents with concurrent depressive disorder.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;
&lt;P&gt;Young people with eating disorders are at risk of other mental health problems, including suicide; therefore liaison with the Child and Adolescent Mental Health Service (CAMHS) is always recommended.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anorexia nervosa&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If there is lack of a rapid improvement in eating patterns and weight, refer to the CAMHS, or to the more specialist Children and Adolescent Eating Disorder Service, if locally available. Intensive treatments of early-onset anorexia nervosa can prevent many of the more severe consequences from occurring. In addition, evidence indicates that treatment outcomes are more favourable when eating disorders are treated soon after their onset. &lt;/LI&gt;
&lt;LI&gt;Refer for urgent assessment if there has been rapid weight loss or the body mass index (BMI) of the patient is low. The BMI cut-offs need to be adjusted for growth. Specialist intervention might prevent the need for inpatient treatment even in individuals who are seriously underweight.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Bulimia nervosa&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Consider referral to CAMHS or a specialist Eating Disorder Service if there is a lack of progress in primary care or if more specific treatments (eg cognitive behavioural therapy or family therapy) are not available. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Eating Disorders Association (EDA) 0845 634 7650 (Youthline [for under 19s] 4.00pm–6.30pm, weekdays)&lt;BR&gt;Email: &lt;A href="mailto:info@edauk.com" target="_blank"&gt;info@edauk.com&lt;/A&gt;; website: &lt;A href="http://www.edauk.com/" target="_blank"&gt;http://www.edauk.com&lt;/A&gt;&lt;BR&gt;Self-help support groups for sufferers, their relatives and friends. Assists in putting people in touch with sources of help in their own area.&lt;/P&gt;
&lt;P&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Anorexia and Bulimia, Changing Minds: Anorexia and Bulimia, Understanding Eating Disorders in Young People, and Worries about Weight.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Robin A, Gilroy M, Dennis AB. Treatment of eating disorders in children and adolescents. Clin Psychol 1998, 18(4): 421-446. (CIV) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Eisler I, Le Grange D, Asen E. Family interventions. In: Treasure J, Schmidt U, van Furth E (eds.) Handbook of Eating Disorders. Chichester: John Wiley and Sons, 2003.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79863</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79863]]&gt;</url>
    <title>Introduction to eating disorders</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH,CHILD HEALTH,EATING DISORDERS,SPECIALTIES,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Eating disorders - F50 (Clinical term: Eating disorders Eu50)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to eating disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Eating disorders - F50 (Clinical term: Eating disorders Eu50)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;The family may ask for help because of the patient’s loss of weight, refusal to eat, vomiting or amenorrhoea. Earlier stages may include levels of dietary restriction that cause alarm within the family.&lt;/P&gt;
&lt;P&gt;The patient may engage in extreme dietary restriction, binge eating, and various forms of extreme weight-control behaviour, such as self-induced vomiting, driven exercising or laxative misuse. &lt;/P&gt;
&lt;P&gt;Both anorexia nervosa and bulimia nervosa may present as physical disorders:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Non-specific symptoms: abdominal pain, bloating, constipation, cold intolerance, light-headedness, hair, nail or skin changes. &lt;/LI&gt;
&lt;LI&gt;Food allergy/intolerance and chronic fatigue syndromes sometimes precede the development of an eating disorder and may cause diagnostic confusion. &lt;/LI&gt;
&lt;LI&gt;Amenorrhoea, fertility problems, gastrointestinal and oropharyngeal problems. &lt;/LI&gt;
&lt;LI&gt;Low mood, anxiety/irritability.&lt;BR&gt;Although the range of physical presenting complaints is large, in practice the most important task for the practitioner in primary care is to be alert to the possibility of an eating disorder and to enquire further in a sensitive manner.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Common features are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;unreasonable fear of being fat or gaining weight &lt;/LI&gt;
&lt;LI&gt;self-evaluation almost exclusively based on shape and weight &lt;/LI&gt;
&lt;LI&gt;extensive efforts to control/reduce weight (eg strict dieting, vomiting, use of purgatives, excessive exercise) &lt;/LI&gt;
&lt;LI&gt;denial that weight or eating habits are a problem (anorexia nervosa) &lt;/LI&gt;
&lt;LI&gt;obsessional symptoms &lt;/LI&gt;
&lt;LI&gt;relationship difficulties &lt;/LI&gt;
&lt;LI&gt;increasing withdrawal &lt;/LI&gt;
&lt;LI&gt;school and work problems.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients with &lt;STRONG&gt;anorexia nervosa&lt;/STRONG&gt; typically show:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;severe dietary restriction despite very low weight (body mass index &amp;lt;17.5 kg/m2) &lt;/LI&gt;
&lt;LI&gt;morbid fear of fatness &lt;/LI&gt;
&lt;LI&gt;distorted body image (ie an unreasonable belief that one is overweight) &lt;/LI&gt;
&lt;LI&gt;amenorrhoea. &lt;/LI&gt;
&lt;LI&gt;A proportion of patients binge and purge.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients with &lt;STRONG&gt;bulimia nervosa&lt;/STRONG&gt; typically show:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;binge-eating (ie discrete episodes of uncontrolled overeating) &lt;/LI&gt;
&lt;LI&gt;purging (attempts to eliminate food by self-induced vomiting or via diuretic or laxative use) &lt;/LI&gt;
&lt;LI&gt;strict dieting and other compensatory measures such as excessive exercise &lt;/LI&gt;
&lt;LI&gt;self-evaluation based on shape and weight.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;A patient may show both anorexic and bulimic patterns at different times. In addition, full criteria for anorexia or bulimia nervosa are not fulfilled by 30-50% of patients with clinically significant eating disorders (these patients are said to have atypical eating disorders or eating disorders not otherwise specified [EDNOS]). &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Physical illness (eg malabsorption syndrome, chronic inflammatory intestinal diseases, tumours, tuberculosis, vasculitis and diabetes mellitus) may cause weight loss or vomiting, although it is not self-induced. &lt;/LI&gt;
&lt;LI&gt;There may be co-existing problems such as Depression - F32#, Generalized anxiety - F41.1, Obsessive-compulsive disorder - F42, Drug use disorders - F11# or Self-harm.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The differential diagnosis of weight loss is large, but when an appropriate history is taken with corroboration, it is unusual for diagnostic difficulty to occur. It is important not to delay diagnosis by over-investigation and referral, which may render the doctor complicit with the anorexic denial of the patient.&lt;/P&gt;
&lt;P&gt;Medical consequences of severe weight loss include impaired attention and concentration, impaired visuo-spatial abilities and poor memory, hypotension, bradycardia, ECG alterations, arrhythmias, mitral valve prolapse, bone marrow suppression, osteoporosis, low glucose, amenorrhoea, muscle weakness, impaired gastric emptying, constipation.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Medical complications of purging include dental problems, salivary-gland swelling, upper and lower gastrointestinal bleeding, dehydration and electrolyte imbalance, cardiac arrhythmias and epileptic seizures. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Purging and severe starvation may cause serious physical harm. Anorexia nervosa can be life-threatening. &lt;/LI&gt;
&lt;LI&gt;Purging and severe dieting are ineffective ways of achieving lasting weight-control. &lt;/LI&gt;
&lt;LI&gt;Information leaflets, self-help books and self-help organizations such as the Eating Disorders Association may be helpful in explaining the diagnosis and available treatment options, providing information about what practical steps the person can take to overcome their difficulties and putting patients and their families in touch with other patients. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1,2)&lt;/P&gt;
&lt;P&gt;The GP can undertake straightforward steps to treat eating disorders with the help of the practice counsellor, practice nurse and/or a dietician, although most cases will be referred on for specialist treatment.&lt;/P&gt;
&lt;P&gt;It is important to support the family and to engage them constructively in management.&lt;/P&gt;
&lt;P&gt;In &lt;STRONG&gt;anorexia nervosa&lt;/STRONG&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;It is helpful to see the patient without, as well as with, the family. &lt;/LI&gt;
&lt;LI&gt;Expect denial and ambivalence. Elicit the patient's concerns about the negative effects of the eating problem on aspects of their life. Ask the patient about the benefits that their eating has for them (eg the feeling of being in control, feeling safe, being able to get care and attention from family). Don't try to force the patient to change if he/she is not ready. &lt;/LI&gt;
&lt;LI&gt;Educate the patient about food and weight. &lt;/LI&gt;
&lt;LI&gt;Weigh the patient regularly and chart his/her weight. Set manageable goals in agreement with the patient (eg aim for a 0.5 kg weight increase per week [this requires a calorie intake of about 2500 kcal per day]). A supportive family member may be able to help the patient achieve this. Consultation with a dietician may be helpful to establish normal calorie and nutrient intake and regular patterns of eating. If after four to eight weeks this approach is not succeeding, refer the patient to a specialist. &lt;/LI&gt;
&lt;LI&gt;A return to normal eating habits may be a distant goal. &lt;BR&gt;•&amp;nbsp;Encourage the family to be patient and consistent.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;In &lt;STRONG&gt;bulimia nervosa&lt;/STRONG&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Use a collaborative approach. &lt;/LI&gt;
&lt;LI&gt;Ask the patient to obtain one of the readily available cognitive behavioural self-help books (see below) (ref 3). These provide reliable sources of information and specific guidance for overcoming the eating disorder. Encourage the patient to follow the advice contained in the book and see them at one to two week intervals to oversee their use of the book. If after eight weeks this approach is not succeeding, refer the patient to a specialist. &lt;/LI&gt;
&lt;LI&gt;Discuss the patient’s biased beliefs about weight, shape and eating (eg carbohydrates are fattening) and encourage review of rigid views about body image (eg patients believe no one will like them unless they are very thin). Do not simply state that the patient's view is wrong.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 1, 2) &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;In bulimia nervosa, antidepressants (eg fluoxetine at 60 mg mane) are effective in reducing binging and vomiting in a proportion of cases (ref 4); however, compliance with medication may be poor, and long-term benefit uncertain (BNF section 4.3). Any beneficial effects will be evident within two to four weeks. If after eight weeks this approach is not succeeding, refer the patient to a specialist. &lt;/LI&gt;
&lt;LI&gt;No pharmacological treatment for anorexia nervosa has been established to date (ref 5). Psychiatric conditions (eg depression) may co-occur and may respond to pharmacological treatment, although effectiveness may be reduced while at low weight. &lt;/LI&gt;
&lt;LI&gt;Order blood tests for urea and electrolytes with patients who are vomiting frequently or regularly misusing laxatives.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Refer to secondary mental health services for non-urgent assessment if there is a lack of progress in primary care, despite the above measures described. If available, consider family therapy for anorexic patients (under 18 years),&amp;nbsp; (ref 6) individual psychotherapy for anorexic patients over 18,(ref 7) and cognitive behavioural therapy (ref 8,9) for those with bulimia nervosa.&lt;/P&gt;
&lt;P&gt;Consider non-statutory/voluntary services/self-help organizations, such as the Eating Disorders Association. &lt;/P&gt;
&lt;P&gt;Refer for urgent assessment (if possible, to secondary mental health services with expertise in eating disorders) if physically unwell (ref 10).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Eating Disorders Association (EDA) 01603 621 414 (helpline: 9am–6.30pm)&lt;BR&gt;Email: &lt;A href="mailto:info@edauk.com" target="_blank"&gt;info@edauk.com&lt;/A&gt;; website: &lt;A href="http://www.edauk.com/" target="_blank"&gt;http://www.edauk.com&lt;/A&gt;.&lt;BR&gt;Self-help support groups for sufferers, their relatives and friends. It assists in putting people in touch with sources of help in their own area.&lt;/P&gt;
&lt;P&gt;Centre for Eating Disorders (Scotland) 0131 668 3051 (helpline)&lt;BR&gt;Psychotherapy for individuals, self-help manuals and information packs.&lt;/P&gt;
&lt;P&gt;Anorexia Bulimia Careline (Northern Ireland)&amp;nbsp; 02890 614 440 (helpline)&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Anorexia and Bulimia, Changing Minds: Anorexia and Bulimia, and Worries about Weight.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bulimia nervosa and binge eating disorders:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bulimia Nervosa – A Cognitive Therapy Programme for Clients by Myra Cooper et al. Jessica Kingsley, 2000.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Bulimia and Binge Eating by P Cooper. Constable &amp;amp; Robinson, London, 1995.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Overcoming Binge Eating by Christopher Fairburn. New York: Guilford Press, 1995.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Overcoming Bulimia. University of Leeds Media Innovations Ltd, 3 Gemini Business Park, Sheepscar Way, Leeds LS7 3JB. Tel: 0113 262 1600; website &lt;A href="http://www.calipso.co.uk/" target="_blank"&gt;http://www.calipso.co.uk&lt;/A&gt;.&lt;BR&gt;A CD-ROM self-help package.&lt;/P&gt;
&lt;P&gt;The Mental Health Foundation produces the information booklet All About Bulimia Nervosa. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW. Tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anorexia nervosa:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Overcoming Anorexia Nervosa. A Self-Help Guide Using Cognitive Behavioural Techniques by Christopher Freeman. London: Constable &amp;amp; Robinson, 2002.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Getting Better Bit(e) by Bit(e) by Ulrike Schmidt and Janet Treasure. Psychology Press, 1997.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Anorexia Nervosa – The Wish to Change, 2nd edition, by AH Crisp et al. Psychology Press, 1996.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Overcoming Anorexia. University of Leeds Media Innovations Ltd, 3 Gemini Business Park, Sheepscar Way, Leeds LS7 3JB. Tel: 0113 262 1600; website: &lt;A href="http://www.calipso.co.uk/" target="_blank"&gt;http://www.calipso.co.uk&lt;/A&gt;.&lt;BR&gt;A CD-ROM self-help package. Available early 2004.&lt;/P&gt;
&lt;P&gt;Anorexia Nervosa: A Survival Guide for Families, Friends and Sufferers by Janet Treasure. Psychology Press, 1997.&lt;BR&gt;The Mental Health Foundation produces the information booklet All About Anorexia Nervosa. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW. Tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; NICE will publish a guideline on the management of eating disorders in January 2004. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Fairburn CG, Harrison PJ. Eating disorders. Lancet 2003, 361: 407-416. (AI) This is an up-to-date evidence-based review of all aspects of eating disorders including their management. A specific form of cognitive behaviour therapy is the most effective treatment for patients with eating disorders, although few patients seem to receive it in practice. Treatment of anorexia nervosa and atypical eating disorders has received remarkably little research attention. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; A Cochrane review will soon be available. Schmidt U, Perkins S, Winn S et al. Self-help and guided self-help for eating disorders (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI). Sixteen studies were analysed. The use of a single antidepressant agent was clinically effective for the treatment of bulimia nervosa compared with placebo, with an overall greater remission rate but a higher dropout rate. No differential effect regarding efficacy and tolerability among the various classes of antidepressants could be demonstrated. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Treasure J, Schmidt U. Anorexia nervosa. Clinical Evidence 2002, 8: 903-913. (AI) No evidence was found of beneficial effects for tricyclic antidepressants or SSRIs&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Russell GFM, Szmukler GI, Dare C, Eisler I. An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Arch Gen Psychiatr 1987, 44: 1047-1056. (CIII) Patients with anorexia nervosa with onset at or before age 18 and of less than three year's duration did better with family therapy than individual therapy. Moreover, older patients did better with individual therapy. However, a major UK review, while supporting these recommendations, states that there are currently no high quality reviews of psychological treatments for anorexia nervosa (Gloaguen V, Cottraux J, Cucherat M et al. A meta-analysis of the effects on cognitive therapy in depressed patients. J Affect Disord 1998, 49: 59-72). &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; A Cochrane review will soon be available. Hay P, Bacaltchuk J, Claudino A, Ben-Tovim D. Individual psychotherapy in the outpatient treatment of adults with anorexia nervosa (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Bacaltchuk J, Hay P, Trefiglio R. Antidepressants versus psychological treatments and their combination for bulimia nervosa (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software (AI) Seventeen studies were looked at. Using a more conservative statistical approach, combination treatments were superior to single psychotherapy. Psychotherapy appeared to be more acceptable to subjects. When antidepressants were combined with psychological treatments, acceptability of the latter was significantly reduced. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Hay PJ, Bacaltchuk J. Psychotherapy for bulimia nervosa and binging (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Thirty-four studies were analysed. There is small body of evidence supporting the efficacy of cognitive behaviour therapy in bulimia nervosa and similar syndromes. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Eating Disorders Special Interest Group, Royal College of Psychiatry. Primary Care Protocol for the Management of Adults with Eating Disorders. URL &lt;A href="http://www.rcpsych.ac.uk/college/sig/eatdis.htm" target="_blank"&gt;http://www.rcpsych.ac.uk/college/sig/eatdis.htm&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79863</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79863]]&gt;</url>
    <title>Introduction to eating disorders</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH,CHILD HEALTH,EATING DISORDERS,SPECIALTIES,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Eating disorders - F50 (Clinical term: Eating disorders Eu50)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to eating disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Eating disorders - F50 (Clinical term: Eating disorders Eu50)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;The family may ask for help because of the patient’s loss of weight, refusal to eat, vomiting or amenorrhoea. Earlier stages may include levels of dietary restriction that cause alarm within the family.&lt;/P&gt;
&lt;P&gt;The patient may engage in extreme dietary restriction, binge eating, and various forms of extreme weight-control behaviour, such as self-induced vomiting, driven exercising or laxative misuse. &lt;/P&gt;
&lt;P&gt;Both anorexia nervosa and bulimia nervosa may present as physical disorders:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Non-specific symptoms: abdominal pain, bloating, constipation, cold intolerance, light-headedness, hair, nail or skin changes. &lt;/LI&gt;
&lt;LI&gt;Food allergy/intolerance and chronic fatigue syndromes sometimes precede the development of an eating disorder and may cause diagnostic confusion. &lt;/LI&gt;
&lt;LI&gt;Amenorrhoea, fertility problems, gastrointestinal and oropharyngeal problems. &lt;/LI&gt;
&lt;LI&gt;Low mood, anxiety/irritability.&lt;BR&gt;Although the range of physical presenting complaints is large, in practice the most important task for the practitioner in primary care is to be alert to the possibility of an eating disorder and to enquire further in a sensitive manner.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Common features are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;unreasonable fear of being fat or gaining weight &lt;/LI&gt;
&lt;LI&gt;self-evaluation almost exclusively based on shape and weight &lt;/LI&gt;
&lt;LI&gt;extensive efforts to control/reduce weight (eg strict dieting, vomiting, use of purgatives, excessive exercise) &lt;/LI&gt;
&lt;LI&gt;denial that weight or eating habits are a problem (anorexia nervosa) &lt;/LI&gt;
&lt;LI&gt;obsessional symptoms &lt;/LI&gt;
&lt;LI&gt;relationship difficulties &lt;/LI&gt;
&lt;LI&gt;increasing withdrawal &lt;/LI&gt;
&lt;LI&gt;school and work problems.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients with &lt;STRONG&gt;anorexia nervosa&lt;/STRONG&gt; typically show:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;severe dietary restriction despite very low weight (body mass index &amp;lt;17.5 kg/m2) &lt;/LI&gt;
&lt;LI&gt;morbid fear of fatness &lt;/LI&gt;
&lt;LI&gt;distorted body image (ie an unreasonable belief that one is overweight) &lt;/LI&gt;
&lt;LI&gt;amenorrhoea. &lt;/LI&gt;
&lt;LI&gt;A proportion of patients binge and purge.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients with &lt;STRONG&gt;bulimia nervosa&lt;/STRONG&gt; typically show:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;binge-eating (ie discrete episodes of uncontrolled overeating) &lt;/LI&gt;
&lt;LI&gt;purging (attempts to eliminate food by self-induced vomiting or via diuretic or laxative use) &lt;/LI&gt;
&lt;LI&gt;strict dieting and other compensatory measures such as excessive exercise &lt;/LI&gt;
&lt;LI&gt;self-evaluation based on shape and weight.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;A patient may show both anorexic and bulimic patterns at different times. In addition, full criteria for anorexia or bulimia nervosa are not fulfilled by 30-50% of patients with clinically significant eating disorders (these patients are said to have atypical eating disorders or eating disorders not otherwise specified [EDNOS]). &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Physical illness (eg malabsorption syndrome, chronic inflammatory intestinal diseases, tumours, tuberculosis, vasculitis and diabetes mellitus) may cause weight loss or vomiting, although it is not self-induced. &lt;/LI&gt;
&lt;LI&gt;There may be co-existing problems such as Depression - F32#, Generalized anxiety - F41.1, Obsessive-compulsive disorder - F42, Drug use disorders - F11# or Self-harm.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The differential diagnosis of weight loss is large, but when an appropriate history is taken with corroboration, it is unusual for diagnostic difficulty to occur. It is important not to delay diagnosis by over-investigation and referral, which may render the doctor complicit with the anorexic denial of the patient.&lt;/P&gt;
&lt;P&gt;Medical consequences of severe weight loss include impaired attention and concentration, impaired visuo-spatial abilities and poor memory, hypotension, bradycardia, ECG alterations, arrhythmias, mitral valve prolapse, bone marrow suppression, osteoporosis, low glucose, amenorrhoea, muscle weakness, impaired gastric emptying, constipation.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Medical complications of purging include dental problems, salivary-gland swelling, upper and lower gastrointestinal bleeding, dehydration and electrolyte imbalance, cardiac arrhythmias and epileptic seizures. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Purging and severe starvation may cause serious physical harm. Anorexia nervosa can be life-threatening. &lt;/LI&gt;
&lt;LI&gt;Purging and severe dieting are ineffective ways of achieving lasting weight-control. &lt;/LI&gt;
&lt;LI&gt;Information leaflets, self-help books and self-help organizations such as the Eating Disorders Association may be helpful in explaining the diagnosis and available treatment options, providing information about what practical steps the person can take to overcome their difficulties and putting patients and their families in touch with other patients. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1,2)&lt;/P&gt;
&lt;P&gt;The GP can undertake straightforward steps to treat eating disorders with the help of the practice counsellor, practice nurse and/or a dietician, although most cases will be referred on for specialist treatment.&lt;/P&gt;
&lt;P&gt;It is important to support the family and to engage them constructively in management.&lt;/P&gt;
&lt;P&gt;In &lt;STRONG&gt;anorexia nervosa&lt;/STRONG&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;It is helpful to see the patient without, as well as with, the family. &lt;/LI&gt;
&lt;LI&gt;Expect denial and ambivalence. Elicit the patient's concerns about the negative effects of the eating problem on aspects of their life. Ask the patient about the benefits that their eating has for them (eg the feeling of being in control, feeling safe, being able to get care and attention from family). Don't try to force the patient to change if he/she is not ready. &lt;/LI&gt;
&lt;LI&gt;Educate the patient about food and weight. &lt;/LI&gt;
&lt;LI&gt;Weigh the patient regularly and chart his/her weight. Set manageable goals in agreement with the patient (eg aim for a 0.5 kg weight increase per week [this requires a calorie intake of about 2500 kcal per day]). A supportive family member may be able to help the patient achieve this. Consultation with a dietician may be helpful to establish normal calorie and nutrient intake and regular patterns of eating. If after four to eight weeks this approach is not succeeding, refer the patient to a specialist. &lt;/LI&gt;
&lt;LI&gt;A return to normal eating habits may be a distant goal. &lt;BR&gt;•&amp;nbsp;Encourage the family to be patient and consistent.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;In &lt;STRONG&gt;bulimia nervosa&lt;/STRONG&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Use a collaborative approach. &lt;/LI&gt;
&lt;LI&gt;Ask the patient to obtain one of the readily available cognitive behavioural self-help books (see below) (ref 3). These provide reliable sources of information and specific guidance for overcoming the eating disorder. Encourage the patient to follow the advice contained in the book and see them at one to two week intervals to oversee their use of the book. If after eight weeks this approach is not succeeding, refer the patient to a specialist. &lt;/LI&gt;
&lt;LI&gt;Discuss the patient’s biased beliefs about weight, shape and eating (eg carbohydrates are fattening) and encourage review of rigid views about body image (eg patients believe no one will like them unless they are very thin). Do not simply state that the patient's view is wrong.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 1, 2) &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;In bulimia nervosa, antidepressants (eg fluoxetine at 60 mg mane) are effective in reducing binging and vomiting in a proportion of cases (ref 4); however, compliance with medication may be poor, and long-term benefit uncertain (BNF section 4.3). Any beneficial effects will be evident within two to four weeks. If after eight weeks this approach is not succeeding, refer the patient to a specialist. &lt;/LI&gt;
&lt;LI&gt;No pharmacological treatment for anorexia nervosa has been established to date (ref 5). Psychiatric conditions (eg depression) may co-occur and may respond to pharmacological treatment, although effectiveness may be reduced while at low weight. &lt;/LI&gt;
&lt;LI&gt;Order blood tests for urea and electrolytes with patients who are vomiting frequently or regularly misusing laxatives.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Refer to secondary mental health services for non-urgent assessment if there is a lack of progress in primary care, despite the above measures described. If available, consider family therapy for anorexic patients (under 18 years),&amp;nbsp; (ref 6) individual psychotherapy for anorexic patients over 18,(ref 7) and cognitive behavioural therapy (ref 8,9) for those with bulimia nervosa.&lt;/P&gt;
&lt;P&gt;Consider non-statutory/voluntary services/self-help organizations, such as the Eating Disorders Association. &lt;/P&gt;
&lt;P&gt;Refer for urgent assessment (if possible, to secondary mental health services with expertise in eating disorders) if physically unwell (ref 10).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Eating Disorders Association (EDA) 01603 621 414 (helpline: 9am–6.30pm)&lt;BR&gt;Email: &lt;A href="mailto:info@edauk.com" target="_blank"&gt;info@edauk.com&lt;/A&gt;; website: &lt;A href="http://www.edauk.com/" target="_blank"&gt;http://www.edauk.com&lt;/A&gt;.&lt;BR&gt;Self-help support groups for sufferers, their relatives and friends. It assists in putting people in touch with sources of help in their own area.&lt;/P&gt;
&lt;P&gt;Centre for Eating Disorders (Scotland) 0131 668 3051 (helpline)&lt;BR&gt;Psychotherapy for individuals, self-help manuals and information packs.&lt;/P&gt;
&lt;P&gt;Anorexia Bulimia Careline (Northern Ireland)&amp;nbsp; 02890 614 440 (helpline)&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Anorexia and Bulimia, Changing Minds: Anorexia and Bulimia, and Worries about Weight.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bulimia nervosa and binge eating disorders:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bulimia Nervosa – A Cognitive Therapy Programme for Clients by Myra Cooper et al. Jessica Kingsley, 2000.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Bulimia and Binge Eating by P Cooper. Constable &amp;amp; Robinson, London, 1995.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Overcoming Binge Eating by Christopher Fairburn. New York: Guilford Press, 1995.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Overcoming Bulimia. University of Leeds Media Innovations Ltd, 3 Gemini Business Park, Sheepscar Way, Leeds LS7 3JB. Tel: 0113 262 1600; website &lt;A href="http://www.calipso.co.uk/" target="_blank"&gt;http://www.calipso.co.uk&lt;/A&gt;.&lt;BR&gt;A CD-ROM self-help package.&lt;/P&gt;
&lt;P&gt;The Mental Health Foundation produces the information booklet All About Bulimia Nervosa. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW. Tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anorexia nervosa:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Overcoming Anorexia Nervosa. A Self-Help Guide Using Cognitive Behavioural Techniques by Christopher Freeman. London: Constable &amp;amp; Robinson, 2002.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Getting Better Bit(e) by Bit(e) by Ulrike Schmidt and Janet Treasure. Psychology Press, 1997.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Anorexia Nervosa – The Wish to Change, 2nd edition, by AH Crisp et al. Psychology Press, 1996.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Overcoming Anorexia. University of Leeds Media Innovations Ltd, 3 Gemini Business Park, Sheepscar Way, Leeds LS7 3JB. Tel: 0113 262 1600; website: &lt;A href="http://www.calipso.co.uk/" target="_blank"&gt;http://www.calipso.co.uk&lt;/A&gt;.&lt;BR&gt;A CD-ROM self-help package. Available early 2004.&lt;/P&gt;
&lt;P&gt;Anorexia Nervosa: A Survival Guide for Families, Friends and Sufferers by Janet Treasure. Psychology Press, 1997.&lt;BR&gt;The Mental Health Foundation produces the information booklet All About Anorexia Nervosa. Publications, The Mental Health Foundation, 7th Floor, 83 Victoria Street, London SW1H 0HW. Tel: 020 7802 0304; website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; NICE will publish a guideline on the management of eating disorders in January 2004. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Fairburn CG, Harrison PJ. Eating disorders. Lancet 2003, 361: 407-416. (AI) This is an up-to-date evidence-based review of all aspects of eating disorders including their management. A specific form of cognitive behaviour therapy is the most effective treatment for patients with eating disorders, although few patients seem to receive it in practice. Treatment of anorexia nervosa and atypical eating disorders has received remarkably little research attention. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; A Cochrane review will soon be available. Schmidt U, Perkins S, Winn S et al. Self-help and guided self-help for eating disorders (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI). Sixteen studies were analysed. The use of a single antidepressant agent was clinically effective for the treatment of bulimia nervosa compared with placebo, with an overall greater remission rate but a higher dropout rate. No differential effect regarding efficacy and tolerability among the various classes of antidepressants could be demonstrated. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Treasure J, Schmidt U. Anorexia nervosa. Clinical Evidence 2002, 8: 903-913. (AI) No evidence was found of beneficial effects for tricyclic antidepressants or SSRIs&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Russell GFM, Szmukler GI, Dare C, Eisler I. An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Arch Gen Psychiatr 1987, 44: 1047-1056. (CIII) Patients with anorexia nervosa with onset at or before age 18 and of less than three year's duration did better with family therapy than individual therapy. Moreover, older patients did better with individual therapy. However, a major UK review, while supporting these recommendations, states that there are currently no high quality reviews of psychological treatments for anorexia nervosa (Gloaguen V, Cottraux J, Cucherat M et al. A meta-analysis of the effects on cognitive therapy in depressed patients. J Affect Disord 1998, 49: 59-72). &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; A Cochrane review will soon be available. Hay P, Bacaltchuk J, Claudino A, Ben-Tovim D. Individual psychotherapy in the outpatient treatment of adults with anorexia nervosa (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Bacaltchuk J, Hay P, Trefiglio R. Antidepressants versus psychological treatments and their combination for bulimia nervosa (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software (AI) Seventeen studies were looked at. Using a more conservative statistical approach, combination treatments were superior to single psychotherapy. Psychotherapy appeared to be more acceptable to subjects. When antidepressants were combined with psychological treatments, acceptability of the latter was significantly reduced. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Hay PJ, Bacaltchuk J. Psychotherapy for bulimia nervosa and binging (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Thirty-four studies were analysed. There is small body of evidence supporting the efficacy of cognitive behaviour therapy in bulimia nervosa and similar syndromes. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Eating Disorders Special Interest Group, Royal College of Psychiatry. Primary Care Protocol for the Management of Adults with Eating Disorders. URL &lt;A href="http://www.rcpsych.ac.uk/college/sig/eatdis.htm" target="_blank"&gt;http://www.rcpsych.ac.uk/college/sig/eatdis.htm&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79789</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79789]]&gt;</url>
    <title>Introduction to emotional disorders with onset specific to childhood</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,SPECIALTIES,CHILD HEALTH,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EMOTIONAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Emotional disorders with onset specific to childhood - F93 (Clinical term: Emotional disorders with onset specific to childhood Eu93)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to emotional disorders with onset specific to childhood&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Emotional disorders with onset specific to childhood - F93 (Clinical term: Emotional disorders with onset specific to childhood Eu93)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Introduction&lt;/H2&gt;
&lt;P&gt;Children may experience a number of different emotional disorders. This guideline concerns anxiety disorders and symptoms that are specific to childhood, and is intended for use with children aged 10 years and younger. For anxious adolescents and adult-type emotional disorders that may also be seen in childhood (including obsessive-compulsive disorder and post-traumatic stress disorder), refer to the adult guidelines: Obsessive compulsive disorder, and Post-traumatic stress disorder).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Anxiety symptoms in childhood can take a number of forms. Most children experiencing anxiety difficulties will demonstrate behavioural, cognitive or somatic features. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Behavioural features&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Avoidance of feared activities, eg reluctance to go to school or to go swimming; feared objects, eg animals. &lt;/LI&gt;
&lt;LI&gt;Clinginess or reluctance to separate from trusted adults. This can include refusal to sleep alone. &lt;/LI&gt;
&lt;LI&gt;Withdrawal. This can take the form of shyness in the presence of strangers or large groups of people. In some cases, a more general withdrawal from people and situations is seen, and in severe cases, children may become mute &lt;/LI&gt;
&lt;LI&gt;Tantrums/tearfulness/other outward displays of distress, when asked to engage in a feared activity or to separate from a parent &lt;/LI&gt;
&lt;LI&gt;General irritability.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Cognitive features&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Many children, especially those of school age, will be able to report cognitive symptoms of anxiety. In particular, they (or more often their parents) report that they worry about feared catastrophes. These worries are often unrealistic, but the child may not recognize this. &lt;BR&gt;Somatic features. &lt;/P&gt;
&lt;P&gt;Many anxious children report a range of somatic symptoms, including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;palpitations &lt;/LI&gt;
&lt;LI&gt;stomach aches, headaches, other aches and pains with no obvious organic cause &lt;/LI&gt;
&lt;LI&gt;breathlessness &lt;/LI&gt;
&lt;LI&gt;difficultly getting to sleep &lt;/LI&gt;
&lt;LI&gt;nausea &lt;/LI&gt;
&lt;LI&gt;feeling wobbly or 'jelly legs' &lt;/LI&gt;
&lt;LI&gt;'butterflies'.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Some may present their anxiety in an entirely physical form, although with further sensitive questioning, evidence of behavioural and cognitive symptoms of anxiety is usually also present. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Depressive disorder - F32# often co-exists with anxiety and can be very difficult to distinguish in this age group. Marked sleep disturbance, disturbed appetite, dysphoric mood, or tearfulness in the absence of direct anxiety provocation could indicate that a child is depressed. &lt;/LI&gt;
&lt;LI&gt;Obsessive-compulsive disorder (OCD) - F42 (adult), indicated by the presence of marked rituals or compulsive behaviours. Most children have phases of ritualized behaviour, which can usually be distinguished from OCD by the degree of distress caused if a ritual is interrupted, and the number of rituals present at any one stage. &lt;/LI&gt;
&lt;LI&gt;Post-traumatic stress disorder - F43.1 (adult) if the onset of anxiety was preceded by an extremely distressing experience. &lt;/LI&gt;
&lt;LI&gt;Maltreatment - children who have experienced physical, emotional or sexual abuse are at high risk of developing emotional difficulties; this possibility should always be borne in mind. Concern should be raised when anxiety onset occurs over a short period subsequent to relatively normal development and when no other explanation (eg change of school/family circumstances) is apparent. &lt;/LI&gt;
&lt;LI&gt;Physical illness - it is important to exclude an organic cause for emotional difficulties, particularly where the child presents with mostly physical symptoms. When physical symptoms occur only in specific situations (eg severe headaches on weekdays, but symptom free at weekends and during school holidays), this is a good indication that they might be anxiety-related. It is then usually safe to conclude that symptoms have a psychological origin. &lt;/LI&gt;
&lt;LI&gt;Normal behaviour - it is often difficult to diagnose anxiety disorder in young children, because a moderate level of anxiety is normative at certain developmental stages. For example, most toddlers show some anxiety when separated from their primary caregiver; a large minority of pre-school and infant school-aged children will express fears of the dark, animals, monsters/ghosts and the like. These worries should not, on their own, raise too much concern, unless they are causing marked distress for the parent or child, or they interfere with the child’s ability to engage in developmentally important activities (eg a child who is unable to sleep in their own bed because they are afraid of the dark). &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to parents and carers&lt;/H2&gt;
&lt;P&gt;GPs wishing to manage a case themselves should attempt to determine the factors that might be maintaining or causing the anxiety. Multiple factors should be investigated:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Is an external problem causing the child to be anxious, for example bullying at school or academic difficulties? This should be addressed in the first instance. &lt;/LI&gt;
&lt;LI&gt;Is the parent anxious? Anxious children very often have an anxious parent. It is thought that children can learn to be anxious from their parents. Advise parents to minimize their own displays of fear or worry when the child is present. A referral to adult mental health services might also be appropriate. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Does the parent allow the child to avoid feared activities? &lt;BR&gt;-&amp;nbsp;Gently explain that the child needs to learn to cope with their fear, and should not be allowed to avoid feared activities.&lt;BR&gt;-&amp;nbsp;Expose a child with a severe phobia to their fear in a number of graded steps; do not suddenly force them to cope with their fear unsupported. If the practitioner does not feel confident in helping the family to develop this ‘hierarchy’, a referral to specialist services should be made.&lt;BR&gt;-&amp;nbsp;Encourage parents to display a calm and confident appearance when their child is being exposed to their fear. If they appear upset at their child’s distress, the child will pick this up and will then become more distressed. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;How are brave behaviours being encouraged in the family? Encourage parents to praise and give small rewards for displaying brave behaviour, for example a shy child might be told 'If you go into the shop and ask the lady for some sweets, then I will give you the money to pay for them', 'If the child does not approach the assistant,&amp;nbsp; do not provide sweets on that occasion. School-age children respond well to star charts. The rules for using star charts for brave behaviour are as follows:&lt;BR&gt;-&amp;nbsp;Only focus on one or two behaviours at a time&lt;BR&gt;-&amp;nbsp;Have one star chart per behaviour&lt;BR&gt;-&amp;nbsp;Negotiate rules for the star chart, for example ‘sleeping in own bed for one night = one star; four stars = trip to the swimming pool’&lt;BR&gt;-&amp;nbsp;Ignore mistakes and failures – do not ever mark them on the star chart. Simply carry on awarding stars when they are earned. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Does the parent have good basic parenting skills? Are they consistent and gentle in their use of discipline, or do they shout a lot, or use smacking? Do they use praise and reward to encourage desirable behaviour? There is evidence that many parents of anxious children have impaired parenting skills. If basic advice on these issues is not adequate to change parenting practice (and it is often very difficult for parents to change), attendance at a parenting class may be helpful. Most communities now have access to parenting classes. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Does the child have a relatively healthy lifestyle? In particular, parents should be encouraged to:&lt;BR&gt;-&amp;nbsp;monitor their child’s caffeine intake&lt;BR&gt;-&amp;nbsp;make sure that their child eats regularly&lt;BR&gt;-&amp;nbsp;establish regular daily routines for their child.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The practitioner should do the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Reassure parents that anxiety often passes, and by following the advice given above, there is a strong likelihood of a good outcome. &lt;/LI&gt;
&lt;LI&gt;Educate parents about their child’s anxiety. It is often helpful to explain the fight/flight response and its role in causing distressing physical symptoms. Parents often fail to push their child to expose to their fear, because the physical symptoms that this elicits are so worrying. Strongly emphasize that these symptoms are not harmful to the child.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;Medication is not advised for this age group.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Referral to specialist mental health services should be considered in the following circumstances:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;When the child has multiple symptoms of anxiety; for example, he/she is very afraid of dogs and distressed by separation from parents. &lt;/LI&gt;
&lt;LI&gt;When anxiety threatens to interfere with education; for example, the child is very reluctant to go to school, and the parent is not managing to maintain full attendance. &lt;/LI&gt;
&lt;LI&gt;When symptoms are threatening the achievement of other developmentally important goals; for example, a shy child who is reluctant to mix with other children. &lt;/LI&gt;
&lt;LI&gt;When the child or parent is very distressed by the symptom(s). &lt;/LI&gt;
&lt;LI&gt;Where there are co-morbid behaviour problems. &lt;/LI&gt;
&lt;LI&gt;Where there is felt to be risk of significant harm to the child or other person. Refer to specialist services as an emergency. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Catching anxiety problems early may have long-term benefits. Therefore, where good mental health services are available, the GP should consider referring all cases of anxiety to specialist services, no matter how minor. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Child Anxiety Network (CAN)&lt;BR&gt;&lt;A href="http://childhoodanxietynetwork.org/" target="_blank"&gt;http://childhoodanxietynetwork.org&lt;/A&gt;&lt;BR&gt;A US-based resource for parents, teachers and health workers regarding childhood anxiety disorders.&lt;/P&gt;
&lt;P&gt;Helping your Anxious Child: A Step by Step Guide for Parents by RM Rapee, S Spence, V Cobham and Wignall. New Harbinger Publications, 2000. A self-help book for parents.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79787</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79787]]&gt;</url>
    <title>Introduction to generalized anxiety</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Generalized anxiety - F41.1 (Clinical term: Generalized anxiety disorder Eu41.1)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to generalized anxiety&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Generalized anxiety - F41.1 (Clinical term: Generalized anxiety disorder Eu41.1)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Tension-related symptoms, e.g. headache, pounding heart, insomnia, complaint of `stress’. Enquiry reveals prominent anxiety.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Multiple, persistent and uncued anxiety or tension including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;autonomic arousal (eg dizziness, sweating, fast or pounding heart, dry mouth, stomach pains) &lt;/LI&gt;
&lt;LI&gt;mental tension (eg undue worry, feeling tense or nervous, poor concentration, sense of forboding) &lt;/LI&gt;
&lt;LI&gt;physical tension (eg restlessness, headaches, tremors, cannot relax, chest pain or constriction).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Symptoms may last for months and recur regularly, and are often worsened by stressful events in those prone to worry. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Co-existing disorders&lt;/H2&gt;
&lt;P&gt;If disorders below are the most prominent feature (see appropriate guidelines), treat accordingly. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32# &lt;/LI&gt;
&lt;LI&gt;Panic disorder - F41.0 &lt;/LI&gt;
&lt;LI&gt;Phobic disorders - F40 &lt;/LI&gt;
&lt;LI&gt;Post-traumatic stress disorder - F43.1 &lt;/LI&gt;
&lt;LI&gt;Alcohol misuse - F10 or Drug use disorders - F11 - F19&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Certain physical conditions (eg thyrotoxicosis), medications (eg methylxanthines, beta-agonists) or street drugs (stimulants) may cause anxiety symptoms.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Anxiety has both physical and mental effects. &lt;/LI&gt;
&lt;LI&gt;The ability to reduce anxiety can be learned (ref 1)&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 2)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Explain the link between physical and psychological symptoms of anxiety. &lt;/LI&gt;
&lt;LI&gt;Encourage use of relaxation methods daily to reduce anxiety.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Cut down caffeine consumption (coffee, tea, stimulant drinks). &lt;/LI&gt;
&lt;LI&gt;Avoid using alcohol, tobacco, street drugs to cope with anxiety.&lt;/LI&gt;
&lt;LI&gt;Tell about practice or non-statutory resources for problem-solving, relaxation, yoga. &lt;/LI&gt;
&lt;LI&gt;Regular physical exercise is often helpful. &lt;/LI&gt;
&lt;LI&gt;Use self-help publications to develop psychosocial strategies to cope with anxiety &lt;/LI&gt;
&lt;LI&gt;Encourage engagement in activities that are pleasurable or have previously reduced anxiety. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Encourage simple cognitive strategies:&lt;BR&gt;-&amp;nbsp;identify undue worries (eg when daughter is five minutes late from school, mother worries that she may have had an accident)&lt;BR&gt;-&amp;nbsp;discuss ways to question these undue worries when they occur (eg when the mother starts to worry about daughter, could tell herself, “I’m starting to be caught up in worry again.&amp;nbsp; She’s only a few minutes late and should be home soon. I won't call her school to check unless she's an hour late”. Explore alternative explanations. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Structured problem-solving methods can ease current life problems that contribute to anxiety: (ref 3) &lt;BR&gt;-&amp;nbsp;identify triggers of undue worry (eg a woman presents with worry, tension, nausea and insomnia which began after her son was diagnosed with asthma and worsens when he has asthmatic episodes). Ask the patient to:&lt;BR&gt;-&amp;nbsp;list every solution they can think of (eg meet the nurse to learn about asthma management, read leaflets about it, discuss concerns with other parents of asthmatic children, write down a management plan for son’s asthma episodes) &lt;BR&gt;list the pros and cons of each possible solution (try this between appointments)&lt;BR&gt;help the patient to choose their preferred approach (not necessarily the first that comes to mind)&lt;BR&gt;-&amp;nbsp;help the patient to work out the steps necessary to achieve the plan&lt;BR&gt;- set a date to review the plan. Work out and encourage what is working.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 2)&lt;/P&gt;
&lt;P&gt;Longer-term outcome seems better after psychosocial than drug treatment. Medication is a secondary treatment in managing generalized anxiety. (ref 1, 4) ay be used if significant anxiety persists despite the&amp;nbsp; measures described above.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Anti-anxiety medication (ref 5, 6, 7) (BNF section 4.1.2.): avoid short-acting benzodiazepines; they should not be used for less than 2 weeks.&lt;/LI&gt;
&lt;LI&gt;Antidepressant drugs (BNF section 4.3), eg tricyclics or SSRIs, may help, especially if depression is present (ref 8,9). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Discontinuation should be gradual over a month.&lt;BR&gt;Beta-blockers may reduce physical symptoms such as tremor in particular settings (ref 10).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;
&lt;P&gt;Liaison or non-urgent referral to secondary mental-health services is advised if anxiety is sufficiently severe or enduring to interfere with social or work functioning.&lt;/P&gt;
&lt;P&gt;Consider cognitive/behavioural therapy or anxiety management (ref 5,6,7). Self-care classes and ‘assisted bibliotherapy’ can also be effective in primary care for milder anxiety (ref 11,12).&lt;/P&gt;
&lt;P&gt;Resources for patients and families&lt;BR&gt;No Panic 01952 590 545 (helpline 10 am–10 pm); 0808 808 0545 (gives numbers of volunteers for the day)&lt;BR&gt;Website: &lt;A href="http://www.no-panic.co.uk/" target="_blank"&gt;http://www.no-panic.co.uk&lt;/A&gt;.&lt;BR&gt;Helpline, information booklets, local self-help groups (including telephone recovery groups) for people with anxiety, phobias obsessions, panic.&lt;/P&gt;
&lt;P&gt;Triumph Over Phobia (TOP) UK 01225 330 353&lt;BR&gt;Email: &lt;A href="mailto:triumphoverphobia@compuserve.com" target="_blank"&gt;triumphoverphobia@compuserve.com&lt;/A&gt;; website: &lt;A href="http://www.triumphoverphobia.com/" target="_blank"&gt;http://www.triumphoverphobia.com&lt;/A&gt;.&lt;BR&gt;Structured self-help groups for sufferers from phobias or obsessive-compulsive disorder. It produces self-help materials.&lt;BR&gt;Stresswatch Scotland 01563 528 910 (helpline 10am–1pm, Monday–Friday, excluding Wednesday) &lt;BR&gt;Advice, information, materials on panic, anxiety, stress phobias. &lt;/P&gt;
&lt;P&gt;The Mental Health Foundation produces the information booklet All About Anxiety. Publications, The Mental Health Foundation, 83 Victoria Street, London SW1H 0HW. Tel: 020 7802 0304. website: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;http://www.mentalhealth.org.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Mind Publications produces the booklet How To Cope With Panic Attacks. MIND, Granta House, 15-19 Broadway, London E15 4BQ, Tel: 020 8519 2122, and The Mental Health Foundation, 83 Victoria Street, London, SW1H 0HW Tel: 020 7802 0300. &lt;BR&gt;Living with Fear, 2nd edition, by Isaac M Marks. McGraw Hill, 2001. Tel: 01628 252 700; Email: &lt;A href="mailto:orders@mcgraw-hill.co.uk" target="_blank"&gt;orders@mcgraw-hill.co.uk&lt;/A&gt;. &lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Overcoming Anxiety: a Self-Help Guide Using CBT by Helen Kinnerly. Constable and Robinson, 1997.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Learn to Relax by Mike George. Duncan Baird, 1998.&lt;BR&gt;Relaxation exercises (also available as a cassette).&lt;/P&gt;
&lt;P&gt;Coping with Anxiety. Talking Life, 1A Grosvenor Rd, Hoylake, Wirral CH47 3BS. Tel: 0151 632 0662; website: &lt;A href="http://www.talkinglife.co.uk/" target="_blank"&gt;http://www.talkinglife.co.uk&lt;/A&gt;.&lt;BR&gt;A cassette package describing three strategies for relieving anxiety. &lt;/P&gt;
&lt;P&gt;Overcoming Anxiety. University of Leeds Media Innovations Ltd, 3 Gemini Business Park, Sheepscar Way, Leeds LS7 3JB. Tel: 0113 262 1600; website: &lt;A href="http://www.calipso.co.uk/" target="_blank"&gt;http://www.calipso.co.uk&lt;/A&gt;.&lt;BR&gt;A CD-ROM self-help package.&lt;/P&gt;
&lt;P&gt;Fear Fighter &lt;A href="http://www.fearfighter.com/" target="_blank"&gt;http://www.fearfighter.com&lt;/A&gt; &lt;BR&gt;Self-help guidance plus option of live helpline advice if you get stuck. &lt;BR&gt;Yoga and meditation classes, as part of adult education programmes, are provided at most Colleges of Further Education.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Shear K, Schulberg H. Anxiety disorders in primary care. Bull Menninger Clinic 1995, 59(2; Suppl A): 73-82. (BI) Studies of psychoeducation and minimal intervention in primary care show much promise as first-line interventions for anxiety disorders in primary care. More severely ill patients require more specialist intervention.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; NICE will publish a guideline on Anxiety (generalized) in June 2004. (AI) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Hawton K, Kirk J. Problem-solving. In: Hawton K, Salkovskis PM, Kirk J, Clark DM (eds.) Cognitive Therapy for Psychiatric Problems: A Practical Guide. Oxford: Oxford University Press, 1989: 406-426. (AII) &lt;BR&gt;4 Catalan J, Gath D, Edmonds G, Ennis J. The effects of not prescribing anxiolytics in general practice. Br J Psychiatry 1984, 144: 593-602. (BII) GP advice and reassurance is as effective as administration of benzodiazepines. The mean time spent by the GP for giving advice and reassurance was 12 minutes, compared with 10.5 minutes for giving a prescription. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Gould RA, Otto MW, Pollack MH, Yap L. Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behaviour Ther 1997, 28(2): 285-305. (BI) This paper discusses the effectiveness of different treatments for anxiety. Buspirone had a much lower effect size than either benzodiazepines or antidepressants, and its onset is slow (up to four weeks). However, problems with dependence and withdrawal are minimal compared with benzodiazepines. Cognitive behaviour therapy (CBT) and anxiety management were the most efficacious psychological treatments; each was equally efficacious in the short term. Gains of CBT and anxiety management were maintained at six months. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Lader MH, Bond AJ. Interaction of pharmacological and psychological treatments of anxiety. Br J Psychiatry 1998, 173(Suppl 34): 165-8. Firm conclusions are not possible. Observations suggest using benzodiazepines for treating anxiety initially, as these produce rapid symptomatic improvement; then psychological treatments can take over. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; A Cochrane review will soon be available. Gale C, Kapczinski F, Busnello JV et al. Benzodiazepines for generalized anxiety (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Kapczinski F, Lima MS, Souza, JS, Schmitt, R. Antidepressants for generalized anxiety disorder (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software (AI) Fifteen studies were examined. Antidepressants are superior to placebo in treating general anxiety disorder (GAD) and are tolerated by GAD patients. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; A Cochrane review will soon be available. Kapczinski F, Ribeiro L, Quevedo J et al. 5HT-1 agonists for generalized anxiety (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Tyrer P. Use of beta-blocking drugs in psychiatry and neurology. Drugs 1980, 20: 300-308. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Kupshik G, Fisher C. Assisted bibliotherapy: effective, efficient treatment for moderate anxiety problems. Br J Gen Pract 1999, 49: 47-8. (BIII) Learning self-help skills through reading, supported by contact with a clinician, significantly improved symptoms. More patients improved with more clinician contact, especially if less educated. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Bower P, Richards D, Lovell, K. The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review. Br J Gen Pract 2001, 51: 838-845. (AI) Self-help treatments may have the potential to improve the overall cost-effectiveness of mental health service provision.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79788</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79788]]&gt;</url>
    <title>Introduction to obsessive-compulsive disorder</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OBSESSIVE COMPULSIVE DISORDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Obsessive-compulsive disorder (OCD) - F42 (Clinical term: Obsessive compulsive disorder Eu42)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to obsessive-compulsive disorder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Obsessive-compulsive disorder (OCD) - F42 (Clinical term: Obsessive compulsive disorder Eu42)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Commonly concern avoidance and thoughts of 'contamination' by objects or situations, and repetitive, cleaning and washing rituals to dispel the contamination. &lt;/LI&gt;
&lt;LI&gt;Also common are intrusive thoughts of doubt and repetitive checking to prevent harm to self or others, or urges to obtain order or precision or follow a strictly personal routine.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Patients often conceal their symptoms (because of their perceived silly or shameful nature) for fear of ridicule or other unpleasant consequences and so seek help only many years after their problem began.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Obsessions: recurrent intrusive, unwanted, non-sensical thoughts, images or impulses that the patient knows are ‘silly’ but cannot banish. The obsessions relate to the presenting complaint and usually cause anxiety or other discomfort. &lt;/LI&gt;
&lt;LI&gt;Compulsions: repetitive rituals performed to reduce anxiety from obsessions by warding off the imagined dreaded consequences. Common rituals are repetitive checking, washing or cleaning, or repetitive rearranging and ordering of objects. Other compulsive behaviours include hoarding of objects and extreme slowness in carrying out every day activities. &lt;/LI&gt;
&lt;LI&gt;Most patients have both obsessive thoughts and compulsive rituals. &lt;/LI&gt;
&lt;LI&gt;Most patients have or have had insight into their obsessions and compulsions (although this can depend on when you ask them and how anxious they are) and regard them as ‘silly’ and resist them. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Symptoms should last for at least two weeks and the patient should have insight into at least one of the symptoms (ie obsessions or compulsions) as being excessive or unreasonable.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Phobias -F40 phobics fear phobic objects more directly than the imagined consequences characteristically seen in OCD. &lt;/LI&gt;
&lt;LI&gt;Hypochondriasis - the fear is of an illness rather than contamination per se. &lt;/LI&gt;
&lt;LI&gt;Depression - F32# common co-existent condition. &lt;/LI&gt;
&lt;LI&gt;Generalized anxiety - F41.1 worries are less stereotyped than in obsessions. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Other conditions in which stereotyped repetitive behaviour may be seen are:&lt;BR&gt;-&amp;nbsp;Eating disorders - F50&lt;BR&gt;- Autism spectrum disorders - F84&lt;BR&gt;- Tourettes syndrome&lt;BR&gt;- Psychosis - F23, F20&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Patients and their relatives need to understand (as the symptoms can be bizarre and non-sensical) that OCD is well known and can be overcome by systematic self-help involving exposure and ritual prevention. &lt;/LI&gt;
&lt;LI&gt;Patients often pressure their families to participate in their rituals (eg cleaning, checking, etc.) and to give reassurance about their doubts. &lt;/LI&gt;
&lt;LI&gt;Such demands can be very frequent and insistent and can become a source of conflict and stress within the family. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Patients and their relatives can understand the problem better and how to help it by reading and implementing a self-help manual. &lt;/LI&gt;
&lt;LI&gt;The doctor should explain to them together that giving reassurance or help with rituals may transiently relieve the patient’s anxiety but worsens their problems. &lt;/LI&gt;
&lt;LI&gt;The doctor can help the patient and family start treatment by agreeing that if the patient seeks reassurance or help with rituals the family will reply 'The doctor says no answer'. &lt;/LI&gt;
&lt;LI&gt;Exposure to stimuli triggering obsessional thoughts and response prevention (ie prevention of performance of rituals) is effective (ref 2-4) and the improvement lasts longer than that observed with drug treatment (ref 5,6) &lt;/LI&gt;
&lt;LI&gt;Cognitive therapy involves correcting faulty interpretations and beliefs about thoughts and their consequences (2-4, 7) and is as effective as behaviour therapy (ref 8).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 1) &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Drug treatment might be indicated where patients are unwilling to engage in behaviour or cognitive therapy, or where expertise to deliver such therapies is not available. &lt;/LI&gt;
&lt;LI&gt;Clomipramine and SSRIs (eg fluoxetine, fluvoxamine, sertraline and citalopram) are effective in the treatment of OCD. An adequate trial of treatment usually requires moderate to maximum BNF dose and a duration of about 12 weeks (ref 6) (BNF 4.3.1 and 4.3.3). &lt;/LI&gt;
&lt;LI&gt;Discontinuation of drug after improvement often results in relapse within weeks so long-term maintenance treatment with medication may be required (ref 6).&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Referral&lt;/H2&gt;
&lt;P&gt;These particularly apply where there are co-existing disorders.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Special considerations for children and adolescents&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;In children, care needs to be taken to distinguish between normal rituals, which are common up to the age of about 10 years, and OCD. &lt;/LI&gt;
&lt;LI&gt;Parents are often involved in maintaining the rituals by providing reassurance. &lt;/LI&gt;
&lt;LI&gt;Children and adolescents may not recognize the excessive or unreasonable nature of their thoughts and rituals and may not wish to engage in therapy. &lt;/LI&gt;
&lt;LI&gt;Very few drug treatments are licensed for children in the UK. &lt;/LI&gt;
&lt;LI&gt;In children cognitive behaviour therapy has been shown to be as effective as clomipramine (ref 9).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Resources for patient and families&lt;/H2&gt;
&lt;P&gt;OCD Action 020 7226 4000 (9.30am–5pm, Tuesday, Wednesday, 11am–5pm, Thursday)&lt;BR&gt;Email: &lt;A href="mailto:info@ocdaction.org.uk" target="_blank"&gt;info@ocdaction.org.uk&lt;/A&gt;; website: &lt;A href="http://www.ocdaction.org.uk/" target="_blank"&gt;http://www.ocdaction.org.uk&lt;/A&gt; &lt;BR&gt;Provides information, advice and support for people with obsessive compulsive disorder and related disorders such as body dysmorphic disorder and trichotillomania&lt;/P&gt;
&lt;P&gt;Triumph over Phobia 01225 330 353&amp;nbsp;&amp;nbsp; &lt;BR&gt;Email: &lt;A href="mailto:triumphoverphobia@compuserve.com" target="_blank"&gt;triumphoverphobia@compuserve.com&lt;/A&gt;; website: &lt;A href="http://www.triumphoverphobia.com/" target="_blank"&gt;http://www.triumphoverphobia.com&lt;/A&gt;&lt;BR&gt;Structured self-help groups for sufferers from phobias or obsessive-compulsive disorder. Produces self-help materials.&lt;/P&gt;
&lt;P&gt;Living with Fear, 2nd edition, by Isaac M Marks. McGraw-Hill, 2001. Tel 01628 252700; Email: &lt;A href="mailto:orders@mcgraw-hill.co.uk" target="_blank"&gt;orders@mcgraw-hill.co.uk&lt;/A&gt;&amp;nbsp; &lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Getting Control: Overcoming Your Obsessions and Compulsions by Lee Baer. Brown &amp;amp; Co, 1991.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;The Imp of the Mind: Exploring the Silent Epidemic of Obsessive Bad Thoughts by Lee Baer. Penguin &amp;amp; Dutton Books, 2001.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Obsessive-Compulsive Disorder - the Facts, 2nd edition, by Padmal de Silva and Stanley Rachman. Oxford University Press, 1998.&lt;/P&gt;
&lt;P&gt;Understanding Obsessions and Compulsions. A Self-Help Manual by F Tallis. Sheldon Press, 1992.&lt;/P&gt;
&lt;P&gt;Obsessive Compulsive Disorder by Stuart Montgomery and Joseph Zohar. Martin Dunitz, 1999.&lt;/P&gt;
&lt;P&gt;Overcoming Obsessive Compulsive Disorder by David Veale and Rob Willson. Robinson, 2005.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; NICE will publish a guideline on the management of Obsessive-compulsive disorder in February 2005. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Greist JH, Marks IM, Baer L et al. Behaviour therapy for obsessive compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry 2002, 63: 138-145 (CII) This is a randomized controlled trial. Computer-guided behaviour therapy was effective for patients with Obsessive compulsive disorder, although clinician-guided behaviour therapy was even more effective. Systematic relaxation was ineffective. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Freeston MH, Ladouceur R. The cognitive-behavioural treatment of obsessions. In: Caballo VE (ed) International Handbook of Cognitive and Behavioural Treatment of Psychological Disorders. Oxford: Pergamon, 1998: 127-160. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Salkovskis PM, Kirk J. Obsessional disorders. In: Hawton K, Salkovskis PM, Kirk J, Clark M (eds.) Cognitive Behaviour Therapy for Psychiatric Disorders. Oxford: Oxford University Press, 1988: 129-168. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Stern R, Drummond L. The Practice of Behavioural and Cognitive Psychotherapy. Cambridge: Cambridge University Press, 1991&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Marks IM. Fears, Phobias and Rituals. New York: Oxford University Press, 1987. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Soomro GM. Obsessive compulsive disorder. Clinical Evidence 2002, 8: 991-1002. (AI) This is a review. Selective serotonin reuptake inhibitors, behaviour therapy, cognitive therapy and combined treatment (fluvoxamine and behaviour therapy) are beneficial in Obsessive-compulsive disorder. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Cottraux J, Note I, Yao SN et al. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in Obsessive-compulsive disorder. Psychother Psychosom 2001, 70(6): 288-297. (BII) This is a randomized controlled trial. Cognitive therapy and behaviour therapy were equally effective for patients with Obsessive-compulsive disorder.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; de Haan E, Hodgduin KA, Buitecaar JK et al. Behavior therapy versus clomipramine for the treatment of obsessive-compulsive disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 1998, 37(10): 1022-1029. (CII) This is a randomized controlled trial. Behaviour therapy is shown to be a good alternative to drug treatment.&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79798</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79798]]&gt;</url>
    <title>Introduction to panic disorder</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PANIC DISORDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Panic disorder - F41.0 (Clinical term: Panic disorder [episodic paroxysmal anxiety] Eu41.0)
</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to panic disorder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Panic disorder - F41.0 (Clinical term: Panic disorder [episodic paroxysmal anxiety] Eu41.0)&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;One or more unexplained sudden physical symptoms (eg chest pain, dizziness, shortness of breath) or intense fear of impending collapse, heart attack or stroke.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Spontaneous episodes of severe anxiety that start suddenly, rise rapidly, and last from a few minutes to an hour. Such panic ‘attacks’ occur with physical sensations such as palpitations, chest pain, sense of choking, churning stomach, dizziness, feelings of unreality, or impending disaster (losing control, going mad, sudden death, heart attack). The patient fears further panics and avoids places where they have occurred. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;P&gt;Many medical conditions can cause panic-like symptoms (eg arrhythmia, cerebral ischaemia, coronary disease, asthma, thyrotoxicosis) and can also co-exist with panic. History and physical examination should exclude many of these. Investigate any physical symptoms until confident there is no physical cause. Repeating investigations can increase anxiety and should be avoided. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Drugs may induce panic, as may withdrawal from drugs such as benzodiazepines. &lt;/LI&gt;
&lt;LI&gt;Phobic disorders - F40 (when panics occur in particular situations). &lt;/LI&gt;
&lt;LI&gt;Depression -F32# (if low or sad mood is present). Depression may co-exist with panic.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Panics are common and can be treated. &lt;/LI&gt;
&lt;LI&gt;Anxiety often causes frightening physical symptoms (eg chest pain, dizziness, shortness of breath) which do not indicate physical illness and will pass when anxiety subsides. Explain how the body's arousal causes these symptoms and how anxiety about them can create a vicious cycle. &lt;/LI&gt;
&lt;LI&gt;Panic causes frightening thoughts (eg fear of dying, that one is going mad or will lose control) and vice versa. These pass when anxiety subsides. &lt;/LI&gt;
&lt;LI&gt;Mental and physical anxiety reinforce each other. &lt;/LI&gt;
&lt;LI&gt;Withdrawing from or avoiding situations where panics occur may give immediate relief (‘a quick fix’) but worsen the problem in the long run.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Advise the patient to learn to spot early warning signs of impending panic and do the following at their start: &lt;BR&gt;-&amp;nbsp;If it is practical to do so, stay where you are until the panic passes, which may take up to an hour (eg if you’re in a car on a busy road, pull over and park where it is safe to do so; if panic starts on a train platform as your train comes in, get onto the train and complete your journey). Do not rush to a place of ‘safety’.&amp;nbsp;&lt;BR&gt;-&amp;nbsp;Tell yourself that the frightening thoughts and sensations are a sign of panic and will eventually pass. Note the time passing on your watch. It may feel like an eternity but it will usually only last a few minutes. Focus thinking on something visible and non-threatening (eg if in a supermarket, look at booklets there).&lt;BR&gt;- Breathing too rapidly (hyperventilation) can worsen panic. Start slow deep breathing, counting slowly one-two-three on each breath in and on each breath out.&amp;nbsp; &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Notice what you fear during a panic (eg that you’re having a heart attack) and challenge it (eg remind yourself, ‘This is not a heart attack; it is a panic that will pass in a few minutes’). &lt;/LI&gt;
&lt;LI&gt;Alternatively, some patients improve by thinking the very worst and trying hard to faint on the spot, which they won’t be able to do (paradoxical intention). &lt;/LI&gt;
&lt;LI&gt;Cut down caffeine intake (coffee, tea, street drugs). &lt;/LI&gt;
&lt;LI&gt;Avoid using alcohol or cigarettes to cope with anxiety. &lt;/LI&gt;
&lt;LI&gt;Self-help groups, books, tapes or leaflets may help people manage panic and overcome fears (ref 2) &lt;/LI&gt;
&lt;LI&gt;A few minutes of cognitive behavioural therapy advice improves panic patients enduringly. (ref 2)&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 3)&lt;/P&gt;
&lt;P&gt;Most patients benefit from the measures described above and need no medication, unless their mood is very low.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If there is marked depression, tricyclics or SSRIs may help after some weeks (ref 4,5) (BNF section 4.3).&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;It is best to face fears without medication or alcohol or street drugs.&amp;nbsp; If the feared situation is rare (eg flying for someone who flies rarely), occasional short-term beta-blockers might help. &lt;/LI&gt;
&lt;LI&gt;Relapse is higher after discontinuation of an antidepressant or SSRI157,(ref 6,7) or a benzodiazepine (ref 8) than after discontinuation of pill placebo or of cognitive behaviour therapy. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Avoid unnecessary medical referral and investigations for physical symptoms if the diagnosis is clear.&lt;/P&gt;
&lt;P&gt;Consider self-help/voluntary/non-statutory services.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Triumph Over Phobia (TOP) UK 01225 330 353&lt;BR&gt;Email: &lt;A href="mailto:triumphoverphobia@compuserve.com" target="_blank"&gt;triumphoverphobia@compuserve.com&lt;/A&gt;; website: &lt;A href="http://www.triumphoverphobia.com/" target="_blank"&gt;http://www.triumphoverphobia.com&lt;/A&gt;.&lt;BR&gt;Structured self-help groups for sufferers from phobias or obsessive-compulsive disorder. It produces self-help materials.&lt;/P&gt;
&lt;P&gt;No Panic 01952 590 545 (helpline 10am¡V10pm), 0808 808 0545 (gives numbers of volunteers for the day) &lt;BR&gt;Website: &lt;A href="http://www.no-panic.co.uk/" target="_blank"&gt;http://www.no-panic.co.uk&lt;/A&gt;&lt;BR&gt;Helpline, information booklets, local self-help groups (including telephone recovery groups) for people with anxiety, phobias obsessions and panic.&lt;/P&gt;
&lt;P&gt;Social Anxiety UK&lt;BR&gt;Website: &lt;A href="http://www.social-anxiety.org.uk/" target="_blank"&gt;http://www.social-anxiety.org.uk&lt;/A&gt;.&lt;BR&gt;Information and support for sufferers of social anxiety and related problems. The site has a chat room and details of local meetings across the UK.&lt;/P&gt;
&lt;P&gt;First Steps to Freedom 01926 851 608 (24-hour helpline) &lt;BR&gt;Email: &lt;A href="mailto:info@firststeps.demon.co.uk" target="_blank"&gt;info@firststeps.demon.co.uk&lt;/A&gt;; website: &lt;A href="http://www.first-steps.org/" target="_blank"&gt;http://www.first-steps.org&lt;/A&gt;&lt;BR&gt;Runs self-help groups.&lt;/P&gt;
&lt;P&gt;Stresswatch Scotland 01563 528 910 (helpline 10am-1pm, Monday-Friday, excluding Wednesday)&lt;BR&gt;Advice, information, materials on panic, anxiety, stress and phobias.&amp;nbsp; &lt;BR&gt;Living with Fear, 2nd edition, by Isaac Marks. McGraw-Hill, 2001. Tel: 01628 252 700; Email: &lt;A href="mailto:orders@mcgraw-hill.co.uk" target="_blank"&gt;orders@mcgraw-hill.co.uk&lt;/A&gt;. &lt;BR&gt;Self-help manual. &lt;/P&gt;
&lt;P&gt;Overcoming Panic- A Self-Help Guide Using CBT by Derrick Silove and Vijaya Manicavasagar. Constable &amp;amp; Robinson, 1997.&lt;BR&gt;Self-help manual.&lt;/P&gt;
&lt;P&gt;Who's Afraid.....? Coping With Fear, Anxiety and Panic Attacks by&amp;nbsp; Alice Neville. Arrow Books, 1991.&lt;BR&gt;Mind Publications produces the booklet How To Cope With Panic Attacks. MIND, Granta House, 15-19 Broadway, London E15 4BQ, tel: 020 8519 2122, and The Mental Health Foundation, 83 Victoria Street, London SW1H 0HW tel: 020 7802 0300. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Marson AG, Williamson PR, Hutton JL et al.; on behalf of the epilepsy monotherapy trialists. Carbamazepine versus valproate monotherapy for epilepsy (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Eight studies were analysed. There was some evidence to support the policy of using carbamazepine as the first treatment of choice in partial epilepsies, but no evidence to support the choice of valproate in generalized epilepsies. Confidence intervals were too wide to confirm equivalence, however. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Swinson RP, Soulios C, Cox BJ, Kuch K. Brief treatment of emergency-room patients with panic attacks. Am J Psychiatry 1992, 149: 944-946. (BIII) People presenting to Accident and Emergency with panic who went on to have psychoeducation and exposure instructions improved significantly more at follow-up compared with controls.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Kumar S, Oakley-Browne. Panic disorder. Clinical Evidence 2002, 8: 1003-1009. (AI) Selective-serotonin reuptake inhibitors and tricyclic antidepressants are effective in Panic disorder. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998, 155(Suppl): 1-26. (AII) Tricyclic antidepressants (TCAs), selective serotonin re-uptake inhibitors, monoamine oxidase inhibitors and benzodiazepines had roughly comparable short-term efficacy in patients with panic disorder. Benzodiazepines help in the very short term if very rapid control of symptoms is critical. TCA side-effects might be problematic. Discontinuation of medication commonly leads to relapse, so longer-term use is recommended - 2-18 months -after which period, the relapse rate is unknown. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; A Cochrane review will be available soon. Mendes HA, Lima MS, Hotopf MH. Serotonin reuptake inhibitors and new generation antidepressants for panic disorder (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Barlow DH, Gorman JM, Shear KM et al. Cognitive behavioural therapy, imipramine or their combination for panic disorder: a RCT. JAMA 2000, 283: 2529-2536. (BII) Combining imipramine and cognitive behaviour therapy (CBT) appears to confer limited advantage acutely but more substantial advantage by the end of maintenance. Each treatment worked well immediately following treatment and during maintenance; CBT appeared durable in follow-up. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Haug TT, Blomhoff S, Hellstrom K et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 2003, 101: 312-318. (BII) Exposure therapy alone yielded a further improvement during follow-up, whereas exposure therapy combined with sertraline and sertraline alone showed a tendency towards deterioration after the completion of treatment. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Marks I, Swinson P, Basoglu M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993, 162: 776-787. (BII) Where agoraphobic fear and avoidance is present, with panic, exposure - a behavioural treatment - proved to be twice as effective as alprazolam.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>82263</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=82263]]&gt;</url>
    <title>Introduction to personality disorders</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Personality (behavioural) disorders - F60 (Clinical term: Disorders of adult personality and behaviour Eu60). 
Some people find the term 'Personality disorder' inflammatory, and it is therefore perhaps preferable to talk to the patient about their ‘personality difficulties’.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to personality disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Personality (behavioural) disorders - F60 (Clinical term: Disorders of adult personality and behaviour Eu60). &lt;/P&gt;
&lt;P&gt;Some people find the term 'Personality disorder' inflammatory, and it is therefore perhaps preferable to talk to the patient about their ‘personality difficulties’.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Patients may present in a variety of ways:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Constantly worrying or displaying excessive dependence on the primary care team &lt;/LI&gt;
&lt;LI&gt;Repeated consultations, including for unexplained physical symptoms &lt;/LI&gt;
&lt;LI&gt;Threatening self-harm or aggressive behaviour &lt;/LI&gt;
&lt;LI&gt;Intense and superficial relationships &lt;/LI&gt;
&lt;LI&gt;With complaints of another mental disorder: depression, anxiety, eating disorders and addictions are all more prevalent &lt;/LI&gt;
&lt;LI&gt;Impulsive or threatening behaviours, eg repeated self-harm.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These patients are usually difficult with multiple social problems; and they may have a previous history of problematic dealings with the health service. They are more likely to attend in a crisis but may then fail to re-attend for follow-up appointments. &lt;/P&gt;
&lt;P&gt;Alternatively, the patient may come to the attention of the primary care team because of the impact their behaviour is having on others:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Family and carers may express concern about the patient’s behaviour (eg threatening behaviour, self-harm). &lt;/LI&gt;
&lt;LI&gt;Through their antisocial behaviour, in which case they may be referred by the Criminal Justice System.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Maladaptive patterns of behaviour, thinking and control of emotions. &lt;/LI&gt;
&lt;LI&gt;Disturbance is enduring and not limited to episodes of mental illness. &lt;/LI&gt;
&lt;LI&gt;Disorder leads to considerable personal distress and/or significant problems in occupational and social functioning. &lt;/LI&gt;
&lt;LI&gt;Early manifestations (eg conduct disorder) may appear in childhood, but Personality disorder should not be diagnosed in someone under the age of 18.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;ICD-10 recognizes nine subcategories of Personality disorder, each with its own set of diagnostic criteria. They fall into three groups:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Group A: Paranoid and schizoid; characterized by oddness, difficulty mixing with others and paranoid thinking &lt;/LI&gt;
&lt;LI&gt;Group B: Dissocial, emotionally unstable (impulsive type and borderline type) and histrionic; characterized by problems with impulse control, affect regulation and relationship instability &lt;/LI&gt;
&lt;LI&gt;Group C: Anankastic, anxious and dependent; characterized by anxiety, excessive dependency on others and obsessional behaviour.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;Although other mental disorders can occur in the context of a personality disorder, a primary diagnosis of personality disorder should only be made in the absence of mental illness. If possible, obtain an informant’s account of the patient’s personality. &lt;/P&gt;
&lt;P&gt;Consider the following, particularly when behaviour is ‘out of character’:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32# &lt;/LI&gt;
&lt;LI&gt;Acute to chronic (persistent) psychotic disorder - F23, F20# &lt;/LI&gt;
&lt;LI&gt;Anxiety disorders &lt;/LI&gt;
&lt;LI&gt;Drug use disorders - F10 - F19#; these commonly occur in people with dissocial and emotionally unstable personality disorders &lt;/LI&gt;
&lt;LI&gt;A medical condition causing personality change (eg head injury, acute&lt;BR&gt;confusional state, Dementia – F03#.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Mental illness and addictions occurring in people with personality disorders are treatable.&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Modification of problematic behaviour is possible, but the patient must be motivated to change his/her behaviour. &lt;/LI&gt;
&lt;LI&gt;Specialist treatment consists of a combination of psychological treatments (including group and individual psychotherapies) reinforced by drug therapy at critical times. &lt;/LI&gt;
&lt;LI&gt;Treatment of any sort (including for associated conditions) requires the patient’s active involvement. The relationship with the professional concerned is crucial.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1) &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Consistency and continuity in approach, basic problem-solving techniques, and assistance in containing psychological stress form the foundation for the clinical approach to these patients. &lt;/LI&gt;
&lt;LI&gt;Difficulties with others can be minimized, if the person is taught to avoid situations that lead them into conflict with others (eg avoiding group living if mixing with others makes them anxious). &lt;/LI&gt;
&lt;LI&gt;Ensure that both the patient and others involved in their care understand the treatment plan and aims. &lt;/LI&gt;
&lt;LI&gt;The practitioner needs to be very clear about his/her role and its boundaries. &lt;/LI&gt;
&lt;LI&gt;The practitioner needs to communicate effectively with others in their team. If several health professionals are involved in the patient’s care, ensure that a consistent approach is adopted. &lt;/LI&gt;
&lt;LI&gt;Professional disputes about patient care (which commonly occur with this patient group) can be minimized by holding regular meetings with those involved with the patient.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Establish a clear protocol for how all members of the team will respond to the patient during a crisis. Crisis contacts should be brief, focused and goal-oriented. If possible, give the patient some responsibility for resolving the crisis. &lt;/LI&gt;
&lt;LI&gt;Treat co-morbid conditions. &lt;/LI&gt;
&lt;LI&gt;Focus on immediate, everyday problems. The aim is not to cure the personality disorder but to help the patient deal with everyday life. Behavioural disturbances associated with Personality disorder tend to improve with advancing age. &lt;/LI&gt;
&lt;LI&gt;Specialist treatment of personality disorders consists of a combination of psychological treatments reinforced by drug therapy. &lt;/LI&gt;
&lt;LI&gt;Personality-disordered patients can be supported by a primary care team in conjunction with input from specialist psychiatric services where appropriate. The support generally needs to be long-term and the style of consultation needs to be adapted to the type of personality disorder that the patient has.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;P&gt;Medication, while of some benefit, is not the mainstay of treatment. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Antidepressant medication: SSRIs have a growing evidence base in the management of impulsive behaviour (ref 2). &lt;/LI&gt;
&lt;LI&gt;Low-dose atypical antipsychotic medication: may help to reduce paranoid ideation and the level of arousal experienced by some personality-disordered patients. However, the long-term effectiveness is not yet established. &lt;/LI&gt;
&lt;LI&gt;Mood stabilizers: may help to ease the affective instability experienced by those with an emotionally unstable personality disorder.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Be mindful of the possibility of overdose in this group of patients.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Referral to a community mental health team for an assessment can be helpful under the following circumstances:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;For diagnostic clarification &lt;/LI&gt;
&lt;LI&gt;If there is a risk of harm to self or others &lt;/LI&gt;
&lt;LI&gt;For treatment of co-morbid mental illness&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;For specialist treatment of the underlying personality disorder&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The referral might, however, be unsuccessful either because the patient does not want to be referred, does not attend for assessment or fails to co-operate with the treatment offered. Increasingly, it is the case that community mental health teams (whose main remit is to deal with severe mental illness) do not have the resources or expertise to manage personality-disordered patients. The need for specialist psychiatric services for this group of patients has recently been acknowledged by the Department of Health (ref 1).&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Borderline &lt;A href="http://www.bpdcentral.com/" target="_blank"&gt;http://www.BPDcentral.com&lt;/A&gt; &lt;BR&gt;This site is mainly for families of people with Borderline personality disorder.&lt;/P&gt;
&lt;P&gt;Borderline UK &lt;A href="http://www.borderlineuk.co.uk/" target="_blank"&gt;http://www.borderlineuk.co.uk&lt;/A&gt;&lt;BR&gt;A national user-led network of people within the UK who have been diagnosed with Borderline personality disorder. The site provides detailed information on Borderline personality disorder.&lt;/P&gt;
&lt;P&gt;Borderline Personality Disorder Research Foundation &lt;A href="http://www.borderlineresearch.org/" target="_blank"&gt;http://www.borderlineresearch.org&lt;/A&gt;&lt;BR&gt;Provides details of research and other information&lt;/P&gt;
&lt;P&gt;Understanding Personality Disorders. Available from MIND Publications, 15-19 Broadway, London E15 4BQ, tel: 020 8519 2122. &lt;BR&gt;Leaflet with straightforward explanations. Useful for family members, staff and others.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; UK Department of Health guidelines on personality disorder. Personality Disorder: No Longer a Diagnosis of Exclusion. Policy Implementation Guidance for the Development of Services for People with Personality Disorder. URL &lt;BR&gt;&lt;A href="http://www.doh.gov.uk/mentalhealth/personalitydisorder.htm" target="_blank"&gt;http://www.doh.gov.uk/mentalhealth/personalitydisorder.htm&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; World Health Organization. Schizophrenia: An International Follow-up Study. Chichester: John Wiley &amp;amp; Sons, 1979. (AIV) Large outcome study with two-year follow-up, showed that only 10-15% of patients did not recover from their illness in that two-year period. Another shorter-term follow-up study (Lieberman J, Jody D, Geisler S et al. Time course and biologic correlates of treatment response in first episode schizophrenia. Arch Gen Psychiatry 1993, 50: 369-376) showed that 83% of first-episode psychotic patients treated with antipsychotic medication remitted by one year post-inpatient admission.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>82257</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=82257]]&gt;</url>
    <title>Introduction to phobic disorders</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PHOBIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Phobic disorder - F40 Includes: agoraphobia, social phobia and specific phobia. (Clinical code: Phobic anxiety disorders Eu40)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to phobic disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Phobic disorder - F40 Includes: agoraphobia, social phobia and specific phobia. (Clinical code: Phobic anxiety disorders Eu40)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Patients may fear and/or avoid activities such as going outside their home, shopping, visiting friends, or other situations that trigger panic. &lt;BR&gt;&lt;BR&gt;While in or thinking about the feared situation, patients may complain of palpitations, dizziness, inability to breathe properly, or other physical symptoms of anxiety.&lt;/P&gt;
&lt;P&gt;Ask: 'Is there anything you tend to avoid or fear more than most people do?'&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Unreasonably strong fear and/or avoidance of people, places, or events.&lt;/P&gt;
&lt;P&gt;Commonly feared/avoided situations include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;leaving home, or being alone at home &lt;/LI&gt;
&lt;LI&gt;crowds or public places &lt;/LI&gt;
&lt;LI&gt;travelling by bus, train, plane or car &lt;/LI&gt;
&lt;LI&gt;open spaces &lt;/LI&gt;
&lt;LI&gt;performing in public&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;social events &lt;/LI&gt;
&lt;LI&gt;other, such as animals, darkness, heights, blood, etc.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Panic disorder - F41.0 (if panics are prominent and not brought on by anything in particular). &lt;/LI&gt;
&lt;LI&gt;Depression - F32# (if low or sad mood is prominent).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Patients can treat their phobia successfully. &lt;/LI&gt;
&lt;LI&gt;Avoiding feared situations feeds the fear. &lt;/LI&gt;
&lt;LI&gt;By facing the fear systematically, one overcomes it.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Does the patient understand the problem and want to deal with it? &lt;/LI&gt;
&lt;LI&gt;Encourage the patient and his/her relatives to read and follow self-exposure instructions from an appropriate manual or website. &lt;/LI&gt;
&lt;LI&gt;Suggest that the patient list all situations that he/she fears and avoids although other people do not. &lt;/LI&gt;
&lt;LI&gt;Help the patient to plan progressively more challenging exposure steps so he/she can gradually get used to each feared situation in turn&lt;BR&gt;- Find a first small step towards whatever frightens him/her (eg if afraid of leaving home, take a short walk away from home with a relative).&lt;BR&gt;- Practice this small step of facing a feared situation for an hour each day until it becomes boring rather than frightening. &lt;BR&gt;- Say that success involves learning to experience and stay with panic. While performing the step say to yourself: 'If I face my panic (in whatever place frightens me) by remaining there rather than running away, and practice slow, deep breathing, then the fear will start to die down within 30-60 minutes'. &lt;BR&gt;- The patient should not leave the feared situation until the fear starts to subside.&amp;nbsp; &lt;BR&gt;- Once doing that step feels fairly comfortable, go on to a slightly more difficult step and repeat the procedure (eg spend a longer time away from home; then do this alone).&lt;BR&gt;- If exposure to real feared situation(s) is hard to arrange, the patient should instead write and read, or tape record and listen to, long scenarios of exposure to that situation(s).&lt;BR&gt;- The patient should take no alcohol, anti-anxiety medication or street drugs for at least four hours before practicing these steps. &lt;/LI&gt;
&lt;LI&gt;The patient should ask a friend or relative to help plan his/her exercises to face and overcome the fear. Self-help groups can assist in this. &lt;/LI&gt;
&lt;LI&gt;The patient should keep a diary of the ‘face-the-fear’ exercises described above, to fine-tune step-by-step management. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;By facing their fear systematically, many patients will need no medication (ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where patients only meet their real phobic situation rarely (eg flying or speaking in public), occasional short-term anti-anxiety or beta-blocker drugs can help (ref 2-6). Regular use is undesirable and fear is likely to return when the drug is stopped.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;If exposure is refused or fails after a daily hourly trial for four weeks, or depression is also present, tricyclic or SSRI medication may be indicated.&amp;nbsp; &lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Triumph Over Phobia (TOP UK) 01225 330 353&lt;BR&gt;Email: &lt;A href="mailto:triumphoverphobia@compuserve.com" target="_blank"&gt;triumphoverphobia@compuserve.com&lt;/A&gt;.&lt;BR&gt;Structured self-help groups for sufferers from phobias or Obsessive-compulsive disorder. It produces self-help materials.&lt;/P&gt;
&lt;P&gt;Stresswatch Scotland 01563 528 910 (helpline 10am–1pm, Monday–Friday, excluding Wednesday)&lt;BR&gt;Advice, information, materials on panic, anxiety, stress and phobias.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Fear Fighter &lt;A href="http://www.fearfighter.com/" target="_blank"&gt;http://www.fearfighter.com&lt;/A&gt;.&lt;BR&gt;Self-help guidance plus option of live helpline advice if you get stuck.&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Anxiety and Phobias, and Social Phobias.&lt;/P&gt;
&lt;P&gt;Living With Fear, 2nd edition, by Isaac Marks. McGraw Hill, 2001, tel: 01628 252700, Email: &lt;A href="mailto:orders@mcgraw-hill.co.uk" target="_blank"&gt;orders@mcgraw-hill.co.uk&lt;/A&gt;.&lt;BR&gt;Self-help manual. &lt;/P&gt;
&lt;P&gt;Painfully Shy: How to Overcome Social Anxiety by B Markway. Griffin, 2001&lt;/P&gt;
&lt;P&gt;Triumph Over Shyness: Conquering Shyness &amp;amp; Social Anxiety by M Stein. McGraw–Hill, 2003&lt;BR&gt;Available as an e book, which can be download from Amazon.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1 &lt;/STRONG&gt;Marson AG, Williamson PR, Hutton JL et al.; on behalf of the epilepsy monotherapy trialists. Carbamazepine versus valproate monotherapy for epilepsy (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Eight studies were analysed. There was some evidence to support the policy of using carbamazepine as the first treatment of choice in partial epilepsies, but no evidence to support the choice of valproate in generalized epilepsies. Confidence intervals were too wide to confirm equivalence, however. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Tyrer P. Use of beta-blocking drugs in psychiatry and neurology. Drugs 1980, 20: 300-308. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Benzodiazepines are effective in many cases in suppressing panic in the short term. They are not effective for chronic panics or phobias - there is no evidence that any gains continue when drugs are withdrawn, and there is some evidence that they do not. Where patients are doing exposure therapy by gradually facing the fear, there is some evidence that benzodiazepines actually interfere with maintenance of longer-term gains. Selected references (BII): &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998, 155(Suppl): 1-26. (AII) Tricyclic antidepressants (TCAs), selective serotonin re-uptake inhibitors, monoamine oxidase inhibitors and benzodiazepines had roughly comparable short-term efficacy in patients with panic disorder. Benzodiazepines help in the very short term if very rapid control of symptoms is critical. TCA side-effects might be problematic. Discontinuation of medication commonly leads to relapse, so longer-term use is recommended - 2-18 months -after which period, the relapse rate is unknown. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Marks I, Swinson P, Basoglu M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993, 162: 776-787. (BII) Where agoraphobic fear and avoidance is present, with panic, exposure - a behavioural treatment - proved to be twice as effective as alprazolam.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; A Cochrane review will be available soon. van der Linden GJH, van Balkom JLM, Zung-dirwayi N, Stein DJ. Pharmacotherapy for social phobia (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software.&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79121</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79121]]&gt;</url>
    <title>Introduction to postnatal disorders</title>
    <publicationDate>2005-02-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Postnatal depression - F53 (Closest equivalent clinical term: Neurotic depression of reactive type Eu204)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to postnatal disorders&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Postnatal depression - F53 (Closest equivalent clinical term: Neurotic depression of reactive type Eu204)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Women may present with one of three distinct syndromes - in descending order of severity:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Baby blues - normally occurs in the week after birth, and tends to be mild. Women with baby blues do not usually present, because the condition is short-lived, but it can develop into postnatal depression. A new mother presenting with depression should never be dismissed as having ‘just the baby blues’. &lt;/LI&gt;
&lt;LI&gt;Postnatal depression - presents with mild/moderate to severe depression, usually 4-12 weeks after birth but may be up to six months after the birth. &lt;/LI&gt;
&lt;LI&gt;Puerperal psychosis - pronounced disturbance of mood, presenting in the first few weeks after birth.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Baby blues:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Emotional lability, crying, irritatability, tiredness, feelings of inadequacy.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Postnatal depression:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;tearfulness, which may be worse at particular times of the day &lt;/LI&gt;
&lt;LI&gt;irritability, agitation, poor concentration &lt;/LI&gt;
&lt;LI&gt;anxiety (the mother may be afraid to be alone with the baby) &lt;/LI&gt;
&lt;LI&gt;sleep difficulties (even if baby is sleeping) &lt;/LI&gt;
&lt;LI&gt;appetite disturbance &lt;/LI&gt;
&lt;LI&gt;guilt &lt;/LI&gt;
&lt;LI&gt;ambivalence about the baby &lt;/LI&gt;
&lt;LI&gt;low self-esteem, indecisiveness &lt;/LI&gt;
&lt;LI&gt;exhaustion and general inability to cope &lt;/LI&gt;
&lt;LI&gt;thoughts of self-harm and suicide &lt;/LI&gt;
&lt;LI&gt;vague physical symptoms.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Risk factors include a previous history of depression or postnatal depression, poor relationship with partner, adverse social circumstances, an unplanned pregnancy, perinatal death.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Puerperal psychosis:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;pronounced disturbance of mood - either consistently low or high, or fluctuating unpredictably between the two, and sometimes interspersed with periods of normal mental state &lt;/LI&gt;
&lt;LI&gt;extreme irritatability &lt;/LI&gt;
&lt;LI&gt;delusions (often taking the form of irrational preoccupations concerning the baby) and hallucinations &lt;/LI&gt;
&lt;LI&gt;onset within the first few weeks after birth.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Risk factors include a previous or family history of psychosis, and young age.&lt;/P&gt;
&lt;P&gt;In different cultures, pregnancy and childbirth are associated with widely differing traditions and rituals, as well as differences in the concept of depression.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Panic disorder - F41.0. &lt;/LI&gt;
&lt;LI&gt;Generalized anxiety - F41.1.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Depression following childbirth is essentially the same condition as depression at any other time.&lt;/P&gt;
&lt;P&gt;There is a risk that normal physical or emotional changes following childbirth may be mistaken for depression or alternatively may mask depressive symptoms.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Baby blues affects up to 50% of new mothers and is usually self-limiting. &lt;/LI&gt;
&lt;LI&gt;Postnatal depression is common, affecting 10-15% of new mothers; puerperal psychosis is a much rarer condition (0.5-1% of all births). &lt;/LI&gt;
&lt;LI&gt;It can be very difficult for new mothers to admit that they are not coping or feeling depressed at a time they perceive should be happy. &lt;/LI&gt;
&lt;LI&gt;Mothers may be concerned that if they are honest about their feelings their baby will be taken into care. &lt;/LI&gt;
&lt;LI&gt;Mothers with postnatal depression do not usually harm their babies; babies may be at risk from mothers suffering from puerperal psychosis. &lt;/LI&gt;
&lt;LI&gt;Emotional and practical support from family and friends is very valuable (ref 1) &lt;/LI&gt;
&lt;LI&gt;The outcome for most mothers with postnatal depression is very good, provided they receive appropriate care. &lt;/LI&gt;
&lt;LI&gt;If untreated, postnatal depression may be prolonged and can have an effect on mother-baby attachment and in turn on the child’s educational, emotional and behavioural experiences.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Postnatal depression:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;The Edinburgh Postnatal Depression Scale (EPDS) is an effective tool for screening and monitoring progress; (ref 2) it is not a diagnostic tool. &lt;/LI&gt;
&lt;LI&gt;If available, non-directive counselling, interpersonal psychotherapy and cognitive behavioural therapy are effective (ref 3-5). &lt;/LI&gt;
&lt;LI&gt;Postnatal groups run by health visitors and mental health nurses are effective. &lt;/LI&gt;
&lt;LI&gt;Provision of social support, eg a home help or child care, may be helpful.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Puerperal psychosis:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Very close monitoring of mother and baby is essential, which usually requires admission, preferably to a specialist unit. &lt;/LI&gt;
&lt;LI&gt;Medication is always required. &lt;/LI&gt;
&lt;LI&gt;Psychological therapies are likely to be helpful after the acute phase. &lt;/LI&gt;
&lt;LI&gt;Electroconvulsive therapy may occasionally be necessary..&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Antidepressants: the response in mothers suffering postnatal depression is usually good (ref 6). Antidepressants should continue to be taken for up to 6 months after recovery. &lt;/LI&gt;
&lt;LI&gt;SSRIs are the treatment of choice. Fluoxetine is contraindicated in breastfeeding mothers (BNF 4.3.3). &lt;/LI&gt;
&lt;LI&gt;Antipsychotic medication and mood stabilizers may be needed for puerperal psychosis. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;UL&gt;
&lt;LI&gt;Preconceptual referral is recommended for women:&lt;BR&gt;-&amp;nbsp;with a history of bipolar disorder or other psychosis, including a previous puerperal episode, who have a high risk of puerperal psychosis&lt;BR&gt;- taking any mood stabilizers or long-term antipsychotics (ref 7) &lt;/LI&gt;
&lt;LI&gt;Refractory cases of depression should be referred to the community mental health team. &lt;/LI&gt;
&lt;LI&gt;In severe cases, referral to inpatient services may be necessary, ideally to a specialist mother and baby unit (babies should not be admitted to general psychiatric wards).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;The Association for Post Natal Illness (APNI) 020 7386 0868 &lt;BR&gt;Email: &lt;A href="mailto:info@apni.org" target="_blank"&gt;info@apni.org&lt;/A&gt;; website: &lt;A href="http://www.apni.org/" target="_blank"&gt;http://www.apni.org&lt;/A&gt;&lt;BR&gt;Provides information on postnatal depression. APNI will put affected mothers in touch with others who have had similar experiences.&lt;/P&gt;
&lt;P&gt;National Childbirth Trust (NCT) 0870 444 8707&lt;BR&gt;Website: &lt;A href="http://www.nctpregnancyandbabycare.com/" target="_blank"&gt;http://www.nctpregnancyandbabycare.com&lt;/A&gt;&lt;BR&gt;Provides information and support on all aspects of pregnancy and childbirth, with local groups around the country.&lt;/P&gt;
&lt;P&gt;Meet-a-Mum Association (MAMA) 01525 217 064&lt;BR&gt;Email: &lt;A href="mailto:meet-a-mum.assoc@blueyonder.co.uk" target="_blank"&gt;meet-a-mum.assoc@blueyonder.co.uk&lt;/A&gt;; website: &lt;A href="http://website:www.MAMA.org.uk/" target="_blank"&gt;http://website:www.MAMA.org.uk&lt;/A&gt;&lt;BR&gt;Local self-help groups for pregnant women and those with young children.&lt;/P&gt;
&lt;P&gt;Fathers Direct &lt;A href="http://www.fathersdirect.com/" target="_blank"&gt;http://www.fathersdirect.com&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The Samaritans 08457 909090 (helpline: 24-hour, everyday)&lt;BR&gt;Email: &lt;A href="mailto:jo@samaritans.org" target="_blank"&gt;jo@samaritans.org&lt;/A&gt;; website: &lt;A href="http://www.samaritans.org.uk/" target="_blank"&gt;http://www.samaritans.org.uk&lt;/A&gt;&lt;BR&gt;Offer confidential emotional support to any person who is despairing or suicidal.&lt;/P&gt;
&lt;P&gt;Depression Alliance &lt;A href="http://www.depressionalliance.org/" target="_blank"&gt;http://www.depressionalliance.org&lt;/A&gt;&lt;BR&gt;England: 020 8768 0123 &lt;BR&gt;Wales: 029 2069 2891 (10am-4pm Mon-Fri 10am - 4pm, Monday - Friday)&lt;BR&gt;Scotland: 0131 467 3050&lt;BR&gt;Provides information and self-help groups.&lt;/P&gt;
&lt;P&gt;Aware Defeat Depression Ltd 02871 260 602&lt;BR&gt;Email: &lt;A href="mailto:info@aware-ni.org" target="_blank"&gt;info@aware-ni.org&lt;/A&gt;; website:&amp;nbsp; &lt;A href="http://www.aware-ni.org/" target="_blank"&gt;http://www.aware-ni.org&lt;/A&gt; &lt;BR&gt;Provides information leaflets, lectures and runs support groups for sufferers of depression and their relatives.&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Postnatal Depression - Help is at Hand, Mental Illness after Childbirth.&lt;/P&gt;
&lt;P&gt;Postnatal Depression: Facing the Paradox of Loss, Happiness and Motherhood by Paula Nicholson. Wiley, 2001&lt;/P&gt;
&lt;P&gt;Maternal Distress and Postnatal Depression: The Myth of Madonna by J Littlewood and N McHugh. Macmillan, 1997&lt;/P&gt;
&lt;P&gt;Coping with Postnatal Depression by Fiona Marshall. Sheldon Press, SPCK Mail Order, 36 Steep Hill, Lincoln LN2 1LU, UK.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Ray KL, Hodnett ED. Caregiver support for postpartum depression (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (CI) Women with postpartum (postnatal) depression who are supported by caregivers are less likely to remain depressed, although the most effective support from caregivers remains unknown. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Harris B, Huckle P, Thomas R et al. The use of rating scales to identify postnatal depression. Br J Psychiatry 1989, 154: 813-817 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive behavioural therapy in the treatment of postnatal depression. Br Med J 1997, 314: 932. (BII) Both fluoxetine and cognitive-behavioural counselling given as a course of therapy are effective treatments for non-psychotic depression in postnatal women. After an initial session of counselling, additional benefit results from either fluoxetine or further counselling &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Holden JM, Sagovsky R, Cox JL. Counselling in a general practice setting: a controlled study of health visitor intervention in treatment of postnatal depression. Br Med J 1989, 298: 223-6. (BII) Counselling by health visitors is valuable in managing non-psychotic postnatal depression. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; O'Hara M, Stuart S, Gorman L, Wenzel A. Efficacy of interpersonal psychotherapy for postnatal depression. Arch Gen Psychiatry 2000, 57: 1039-1045. (BII) Interpersonal psychotherapy is an efficacious treatment for postpartum depression. It reduced depressive symptoms and improved social adjustment, and represents an alternative to pharmacotherapy, particularly for women who are breastfeeding. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Hoffbrand S, Howard L, Crawley H. Antidepressant treatment for post-natal depression (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software Ltd (CI) One study was examined. Women with postnatal depression can be treated effectively with fluoxetine, which is as effective as a course of cognitive-behavioural counselling in the short-term. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Altshuler LL, Cohen L, Szuba MP et al. Pharmaceutical management of psychiatric illness during pregnancy. Am J Psychiatry 1996, 153: 592-606. (BI) This is a review. The use of psychotropic medications during pregnancy is appropriate in many clinical situations and should include thoughtful weighing of risk of prenatal exposure with risk of relapse following drug discontinuation.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79793</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79793]]&gt;</url>
    <title>Introduction to post-traumatic stress disorder</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to post-traumatic stress disorder&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Physical symptoms (eg various pains, poor sleep or fatigue) and various anxiety and depressive symptoms linked to a particular trauma, of more than a month’s duration. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32# (if showing preoccupation with and rumination about a past traumatic event that emerged during a depressive episode). &lt;/LI&gt;
&lt;LI&gt;Phobic disorders - F40 (if patient avoids particular objects, situations or activities after a traumatic event, but has no non-phobic distress). &lt;/LI&gt;
&lt;LI&gt;Adjustment disorder - F43.2 (if the patient only partly fulfils criteria or the problem followed an event that was not especially traumatic). &lt;/LI&gt;
&lt;LI&gt;Generalized anxiety - F41.1 (if there are no intrusions and/or avoidance).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Traumatic events often have psychological effects. For the majority, symptoms subside with no intervention. (refer to Psychological responses to traumatic stress: what to expect)&lt;/LI&gt;
&lt;LI&gt;Once symptoms have continued for over a month, treatment can be effective. &lt;/LI&gt;
&lt;LI&gt;The patient needs support and understanding, not to be told to ‘snap out of it’.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Educate the patient and family about PTSD to help them understand the patient’s altered attitude and behaviour. &lt;/LI&gt;
&lt;LI&gt;Most people find it helpful to discuss the event unhurriedly with sympathetic friends and family. Explain that avoidance of cues associated with the trauma strengthens and maintains fears and distress. Encourage the patient to face avoided activities and situations gradually. &lt;/LI&gt;
&lt;LI&gt;Ask about suicide risk.&lt;/LI&gt;
&lt;LI&gt;Avoid using alcohol, tobacco or street drugs to cope with anxiety. &lt;/LI&gt;
&lt;LI&gt;Single session intervention is not needed for everyone after a trauma (ref 2). &lt;/LI&gt;
&lt;LI&gt;Provide a few sessions of cognitive behaviour therapy from about a month after the trauma benefit patients (ref 3-6) &lt;/LI&gt;
&lt;LI&gt;The evidence for a benefit from eye movement desensitization and reprocessing remains controversial (ref 7). &lt;/LI&gt;
&lt;LI&gt;Other psychological therapies, including group and psychodynamic therapies, are of unknown effectiveness (ref 8).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;The long-term outcome appears better after psychosocial approaches than after drug treatment.&lt;/P&gt;
&lt;P&gt;Antidepressants might help, especially if depression is prominent (ref 8). Drugs for PTSD are generally needed in higher doses and for longer than when used for depression.&amp;nbsp; Improvement may take up to eight weeks to manifest.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;If available, consider behaviour therapy (exposure) or cognitive techniques (ref 3-6).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Medical Foundation for the Care of Victims of Torture &lt;BR&gt;Website: &lt;A href="http://www.torturecare.org.uk/" target="_blank"&gt;http://www.torturecare.org.uk&lt;/A&gt; &lt;BR&gt;Provides survivors of torture with medical treatment, social assistance and psychotherapeutic support.&lt;/P&gt;
&lt;P&gt;CombatStress 01372 841 600&lt;BR&gt;Email: &lt;A href="mailto:contactus@combatstress.org.uk" target="_blank"&gt;contactus@combatstress.org.uk&lt;/A&gt;; website: &lt;A href="http://www.combatstress.com/" target="_blank"&gt;http://www.combatstress.com&lt;/A&gt;.&lt;BR&gt;Supports men and women discharged from the armed services and merchant navy who suffer from mental health problems, including post-traumatic stress disorder. Has a regional network of welfare officers who visit people at home or in hospital.&lt;/P&gt;
&lt;P&gt;Refugee Support Centre 020 7820 3606&lt;BR&gt;Counsels refugees, asylum seekers. Gives training and information to health and social care professionals on psychosocial needs of refugees.&lt;/P&gt;
&lt;P&gt;Victim Support 0845 3030 900 (support line 9 am–9pm, Monday–Friday; 9am–7pm, Saturday and Sunday; 9am–5pm, bank holidays)&lt;BR&gt;Email: &lt;A href="mailto:contact@victimsupport.org.uk" target="_blank"&gt;contact@victimsupport.org.uk&lt;/A&gt;; website: &lt;A href="http://www.victimsupport.org.uk/" target="_blank"&gt;http://www.victimsupport.org.uk&lt;/A&gt;&lt;BR&gt;Provides emotional support and practical information for anyone who has suffered the effects of crime, regardless of whether the crime has been reported.&lt;/P&gt;
&lt;P&gt;Rape Crisis Federation 0115 900 3560 (9am–5pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:info@rapecrisis.co.uk" target="_blank"&gt;info@rapecrisis.co.uk&lt;/A&gt;; website: &lt;A href="http://www.rapecrisis.co.uk/" target="_blank"&gt;http://www.rapecrisis.co.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Women against Rape 020 7482 2496 &lt;BR&gt;Email: &lt;A href="mailto:war@womenagainstrape.net" target="_blank"&gt;war@womenagainstrape.net&lt;/A&gt;; website: &lt;A href="http://www.womenagainstrape.net/" target="_blank"&gt;http://www.womenagainstrape.net&lt;/A&gt;&lt;BR&gt;Fear Fighter &lt;A href="http://www.fearfighter.com/" target="_blank"&gt;http://www.fearfighter.com&lt;/A&gt;&lt;BR&gt;Self-help guidance plus the option of live helpline advice, if you get stuck.&lt;/P&gt;
&lt;P&gt;Living With Fear by Isaac Marks, 2nd edition. McGraw Hill, 2001, tel: 01628 252 700; Email: &lt;A href="mailto:orders@mcgraw-hill.co.uk" target="_blank"&gt;orders@mcgraw-hill.co.uk&lt;/A&gt;.&lt;BR&gt;Self-help manual. Includes help with fear and avoidance symptoms of PTSD.&lt;/P&gt;
&lt;P&gt;Overcoming Traumatic Stress by Claudia Herbert and Ann Wetmore. London: Robinson Publishing, 1999.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1 &lt;/STRONG&gt;NICE will publish a guideline on the management of Post-traumatic stress disorder in January 2005. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Rose S, Bisson J, Wessley S. Psychological debriefing for preventing post traumatic stress disorder (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. (AI). The routine use of single-session debriefing given to non-selected trauma victims cannot be recommended at present. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Bisson JI.Early interventions following traumatic events. Psychiatric Ann 2003, 33: 37-44. (BI) The authors review randomized controlled trials and conclude that the evidence base does not support routine early intervention but that multiple session cognitive behavioural early interventions might help. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Foa EB, Keane TM, Friedman MJ (eds.) Effective Treatments for PTSD. New York: Guildford Press, 2000. This work summarizes evidence for a wide variety of treatment approaches for Post-traumatic stress disorder. Cognitive therapy and exposure therapy emerge as the psychological treatments with the best evidence for efficacy.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Bisson JI., Andrew M. Psychological treatment of Post-traumatic stress disorder (PTSD) (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Marks I, Lovell K, Noshirvani H et al. Treatment of Post-traumatic stress disorder by exposure and/or cognitive restructuring: a controlled study. Arch Gen Psychiatry 1998, 55: 317-25. (BII) This randomized control trial shows that exposure, cognitive restructuring, or both combined, were equally effective in Post-traumatic stress disorder and better than relaxation without exposure. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Shepherd J, Stein K, Milne R. Eye movement desensitization and reprocessing in the treatment of Posttraumatic stress disorder: a review of an emerging therapy. Psychol Med 2000, 30(4): 863-871. (AI) This is a systematic review of 16 studies. Eye movement desensitization and reprocessing might be as effective as imaginal exposure therapy and more effective than relaxation techniques in Post-traumatic stress disorder but it is unclear if it is the technique or the imaginal exposure component that is effective. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Stein DJ, Zungu-Dirwayi N, Van der Linden GJ, Seedat S. Pharmacotherapy for post-traumatic stress disorder (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Fifteen studies were examined. The research base is limited but there is increasing evidence that drugs can help in Post-traumatic stress disorder. Sertraline and paroxetine have been the most researched and have been shown to be effective. There is good evidence for the efficacy of fluoxetine and some evidence for tricyclic antidepressants and monoamine oxidase inhibitors. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79795</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79795]]&gt;</url>
    <title>Introduction to school refusal</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,EDUCATION AND SCHOOLS,MENTAL HEALTH,CHILD HEALTH,COMMUNITY CHILD HEALTH,SPECIALTIES,CHILD AND ADOLESCENT CONDITIONS,SCHOOL REFUSAL]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to school refusal&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Presentation&lt;/H2&gt;
&lt;P&gt;The commonest ages of presentation are at five and 11 (because of school transitions), and 14 -15 (because of accumulating social and academic pressures).&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The child is reluctant to leave home and attend school. There are often physical complaints, such as abdominal pain, headache, sore throat, often with no signs of physical illness. The symptoms are typically worse on weekday mornings and absent at weekends and holidays. Some children complain of anxiety symptoms that include a racing heart, shaking; sweating, difficulty breathing, butterflies in the tummy or nausea, pins and needles. All symptoms are likely to be interpreted as signs of physical illness; the clue is that they subside during school holidays or on Friday evenings, or are present only in the morning. Attempts by the parents to insist on attendance result in heightened distress, or temper outbursts. &lt;/LI&gt;
&lt;LI&gt;The child may express fears about the school environment (usually bullying, social ostracism or difficulty with school work), or they may be fearful about leaving the home because of worries such as family illness, death or disability, or maternal depression with threats of self-harm. Often, the child cannot voice these fears, and then they can only be guessed at. &lt;/LI&gt;
&lt;LI&gt;There is often a history of separation difficulties on first starting school. &lt;/LI&gt;
&lt;LI&gt;Background family factors include ineffectual organization and discipline, often with an absent or uninvolved father, emotional over-involvement with the child, with excessive anxiety about physical symptoms and difficulties seeking or using help from teachers when school problems first emerge. &lt;/LI&gt;
&lt;LI&gt;There may be an underlying depressive disorder or generalized anxiety. School refusal can be an expression of a particular fear or phobia or a manifestation of generalized anxiety. Pointers to this can include social withdrawal or avoidance. In depressive disorder, symptoms such as loss of interest and enjoyment may pre-date the school attendance problem. Some children with an anxiety disorder show no symptoms so long as they are off school. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;Truancy is the wilful avoidance of school without parental knowledge and is less likely to present in primary care. In contrast, the whereabouts of school refusers’ whereabouts are usually known to parents. Some children have features of both these conditions.&lt;/P&gt;
&lt;P&gt;A third possibility is that parents might wilfully keep their child away from school for reasons of their own. Genuine illness such as asthma or migraine may be combined with a school refusal picture. This can be due to the main caregiver having a specific reason to be anxious, such as having had a relative who died from asthma, or from a brain tumour. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for parents and carers&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;The outcome is best in younger children and those who have been out of school for a short time. &lt;/LI&gt;
&lt;LI&gt;A change of school is usually unhelpful because the problems tend to recur in the new setting. &lt;/LI&gt;
&lt;LI&gt;Parents need to work together and agree a firm and consistent approach to their child’s difficulties. &lt;/LI&gt;
&lt;LI&gt;It is crucially important for there to be good communication with the school&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to parents and carers&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Provide a rapid consultation to exclude physical illness and give reassurance about fitness for school. &lt;/LI&gt;
&lt;LI&gt;Explore with the child and parents the source of the child’s anxieties about attending school/leaving home, and deal with these as far as possible. &lt;/LI&gt;
&lt;LI&gt;Exclude an underlying depression that might need treatment or referral.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The following steps will enable many children to return to school successfully:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Establish parental agreement for the goal of the child’s return to school. &lt;/LI&gt;
&lt;LI&gt;Encourage the parents to make close links with a key member of the school staff, to work out and support school return plans and deal with issues such as bullying or academic difficulties. &lt;/LI&gt;
&lt;LI&gt;The child’s return to school may need to be in small steps with consolidation of success at each stage. &lt;/LI&gt;
&lt;LI&gt;The plans usually involve parents taking the child to school until confidence is restored, and the father’s involvement in this is often crucial to success. &lt;/LI&gt;
&lt;LI&gt;Encourage parents to take a firm and consistent line over keeping to the school return plans. There may be an upsurge of distress from their child to start with, which needs to be managed calmly, and praise given when the child succeeds.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Once the child is back in school, they may experience a recurrence of some anxiety about returning to school after holidays or illnesses. Prompt action is needed to ensure the attendance problem does not recur.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;In general, school refusal should be managed without medication. &lt;/LI&gt;
&lt;LI&gt;A depressive disorder might require antidepressants.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Co-existent physical illness such as migraine may require its own dietary or pharmacological treatment. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Liaison and referral&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;If parents feel the child is too ill to attend school, and will not accept the reassurance of the primary care team, referral to a paediatrician for reassurance can be helpful. &lt;/LI&gt;
&lt;LI&gt;Referral to the Educational Social Worker (Educational Welfare Officer) will be needed for children with persistent school attendance problems. It is their role to link with the school and other sources of help as necessary. Sometimes parents are threatened with court proceedings; an early approach by the parent to this service can make this less likely. &lt;/LI&gt;
&lt;LI&gt;Parents can ask the school to refer their child to an educational psychologist or special needs teacher within the school to look for possible undetected academic difficulties. &lt;/LI&gt;
&lt;LI&gt;The local Child and Adolescent Mental Health Services (CAMHS) might be needed to assess the child’s level of depression or anxiety, or to help parents establish authority and control. &lt;/LI&gt;
&lt;LI&gt;In some areas, a local tutorial unit may provide a valuable halfway house between school and the social isolation of staying at home that is more acceptable to the young person than returning to a large school. &lt;/LI&gt;
&lt;LI&gt;Home tutors can play a useful role with persistent school refusers by helping them to make the transition between home and school, or between home and tutorial unit, then tutorial unit and school. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for parents and carers&lt;/H2&gt;
&lt;P&gt;Advisory Centre for Education (ACE) 0808 800 5793 (general advice line)&lt;BR&gt;Website: &lt;A href="http://www.ace-ed.org.uk/" target="_blank"&gt;http://www.ace-ed.org.uk&lt;/A&gt;&lt;BR&gt;Independent advice centre for parents, offering free advice on many topics including exclusion from school, bullying, special educational needs and school admission appeals.&lt;/P&gt;
&lt;P&gt;Young Minds Parent information line 0800 018 2138 &lt;BR&gt;Website: &lt;A href="http://www.youngminds.org.uk/" target="_blank"&gt;http://www.youngminds.org.uk&lt;/A&gt;&lt;BR&gt;Produces books and leaflets about young people’s mental health and offers seminars and training.&lt;/P&gt;
&lt;P&gt;A leaflet is available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Factsheet 9: Children Who Do Not Go To School.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79790</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79790]]&gt;</url>
    <title>Introduction to self-harm</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,SELF-HARM,OUTCOMES,SELF HARM,MENTAL &amp; BEHAVIOURAL DISORDERS,INJURIES,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,INFORMATION,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Self Harm - X60-X84 (Clinical term: Self-harm U2…)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to self-harm&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Self Harm - X60-X84 (Clinical term: Self-harm U2…)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;The majority of people who present either to Accident and Emergency or to primary care following non-fatal self-harm do so after:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;an overdose &lt;/LI&gt;
&lt;LI&gt;an episode of self-cutting &lt;/LI&gt;
&lt;LI&gt;other more violent forms of deliberate self-harm such as asphyxiation or self-poisoning using car exhaust fumes (these suggest a high degree of suicidal intent).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Best practice suggests that GPs should try to contact and assess their patients when notified that they have self-harmed, although current evidence does not yet show that this significantly reduces repetition rates.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Assessment&lt;/H2&gt;
&lt;P&gt;There are three assessment tasks:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To assess and manage the current episode &lt;/LI&gt;
&lt;LI&gt;To identify and manage any associated conditions &lt;/LI&gt;
&lt;LI&gt;To prevent a repetition of the self-harm.&lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;Assessing and managing the current episode&lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;Prompt attention to any medical sequelae, including long-term physical damage, eg liver damage from overdose. &lt;/LI&gt;
&lt;LI&gt;Identify relevant/ongoing trigger(s) (note that precipitating events that surround episodes of self-harm are poor predictors of suicide risk, making the notion of a ‘suicidal gesture’ following interpersonal crisis difficult to sustain). &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Assessment of suicidal intent, including:&lt;BR&gt;- deliberate isolation at time of self-harm&lt;BR&gt;- precautions made against discovery&lt;BR&gt;- &amp;nbsp;‘final acts’ in anticipation of death, eg giving possessions away, making a&amp;nbsp; will&lt;BR&gt;- communication of intent before the attempt and self-report of motivation&amp;nbsp; for self-harm (to solve a problem or escape a situation)&lt;BR&gt;-&amp;nbsp;patient’s perceptions of barriers/incentives, eg “I could never actually kill myself because of the children” (generic, therefore safer) or “I’ll kill myself if she doesn’t come back by next Monday” (specific, therefore riskier). &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Assessment of background history, including past and current contact with mental health services, social problems and substance misuse problems. &lt;/LI&gt;
&lt;LI&gt;Note that socio-demographic groups at increased risk include men, those aged 15-25 or over 55, those who are widowed, separated or divorced, those who are socially isolated, unemployed, those with a family history of suicide and a previous history of self-harm. &lt;/LI&gt;
&lt;LI&gt;Note that rates of suicide are particularly high in the period following discharge from psychiatric hospital, release from prison, and in the months following an episode of non-fatal self-harm. (The suicide rate increases 100-fold in the year following an episode of self-harm). Patients who regularly present with self-harm have an even higher rate of eventual suicide. &lt;/LI&gt;
&lt;LI&gt;Note that the most important risk factor for suicide is the presence of depression, drug/alcohol abuse, or other mental health problems (see below). &lt;/LI&gt;
&lt;LI&gt;Identify current life problems, social stresses and precipitating factors. Episodes often occur in the context of multiple social difficulties and interpersonal problems. It is therefore important to assess the nature and extent of unresolved problems and how the patient would cope with future crises (see below). Focus on small, specific steps patients might take towards reducing or improving management of these problems. Avoid major decisions or life changes. &lt;/LI&gt;
&lt;LI&gt;Support the family. It is likely to be very distressing to discover that a family member is self-harming. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Identification and management of any associated conditions&lt;/STRONG&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mental disorders, most commonly Depression - F32#, Alcohol misuse - F10 or Drug use disorders - F11 - F19#, but also psychoses. &lt;/LI&gt;
&lt;LI&gt;Bereavement and loss - Z63. &lt;/LI&gt;
&lt;LI&gt;Painful, disabling or life-threatening physical illnesses. &lt;/LI&gt;
&lt;LI&gt;Being the victim or perpetrator of violence.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention of repeated self-harm&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This requires a thorough assessment of suicidal intent:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Does the patient think that life is not worth living? &lt;/LI&gt;
&lt;LI&gt;Does the patient have a sense of hopelessness? &lt;/LI&gt;
&lt;LI&gt;Does the patient have a suicide plan and the (immediate) means to carry it out? &lt;/LI&gt;
&lt;LI&gt;Is the patient likely to act on the plan?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The belief that enquiring about suicidal ideation may prompt some people to consider self-harm is not supported by research findings or clinical experience. Placed in the context of asking people about symptoms of depression such questions feel less awkward for the interviewer, eg “It sounds as if you have been feeling very down recently; has there ever been a time when you have felt as though you couldn’t be bothered carrying on? Have you ever felt that life was not worth living/that you would be better off if you were dead? Have you ever thought of harming yourself in any way?”.&lt;/P&gt;
&lt;P&gt;Some people self-harm by repeatedly cutting or, more rarely, burning themselves. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cutting usually occurs when the person is experiencing strong feelings such as tension or frustration. Patients often report that cutting provides temporary relief from distress.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Patients usually deny having thoughts of suicide. &lt;/LI&gt;
&lt;LI&gt;Some patients lead ordinary lives and do not experience self-cutting as a major problem; for others it is part of a wider problem that includes long-standing feelings of low self-esteem and deep-rooted sadness and is associated with other forms of self-harm such as alcohol abuse or drug problems.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Patient confidentiality may be particularly sensitive when patients present with self-harm. It may be necessary (and appropriate) to override patient confidentiality when life is at risk. &lt;/LI&gt;
&lt;LI&gt;It can come as a great shock to family members that a relative is experiencing thoughts of self-harm. &lt;/LI&gt;
&lt;LI&gt;Feelings of self-harm are common among people who experience mental distress and only a small proportion of people with suicidal thoughts actually act on them. &lt;/LI&gt;
&lt;LI&gt;The family should take any possible specific steps to reduce the opportunity for further self-harm, for example, by removing weapons, drugs, etc. &lt;/LI&gt;
&lt;LI&gt;Patients and family members may be reassured by being told about helplines and local services that are available 24 hours a day, eg the Samaritans.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Assessment of suicidal ideation is an important part of the mental state examination of anyone who presents with a mental health problem. &lt;/LI&gt;
&lt;LI&gt;Any underlying mental disorder needs to be treated. &lt;/LI&gt;
&lt;LI&gt;Patients who, as a result of assessment, are considered at risk of further self-harm should be reviewed regularly by the GP. &lt;/LI&gt;
&lt;LI&gt;Psychological treatments may help the person make sense of their difficulties without feeling the need to self-harm (ref 2). The approach that therapists usually use involves paying attention to how a person is feeling rather than concentrating directly on whether or not they are harming themselves. &lt;/LI&gt;
&lt;LI&gt;Clinicians managing complex or protracted cases of self-harm should consider seeking peer support or supervision.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;Medication needs to be given as required for any underlying psychiatric disorder. &lt;/P&gt;
&lt;P&gt;Use of antidepressants such as SSRIs, selective noradrenalin reuptake inhibitors (SNRIs) and lofepramine is recommended for all those who have depressive symptoms and are felt to be at risk of suicide as they are relatively safe in overdose.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Those with active suicidal intent or continuing suicidal ideation may need to be referred to specialist medical services. &lt;/LI&gt;
&lt;LI&gt;Where a mental disorder has been diagnosed, refer to the relevant guidelines for that disorder. &lt;/LI&gt;
&lt;LI&gt;Consider referral for psychological therapies, as appropriate. &lt;/LI&gt;
&lt;LI&gt;It has been argued that because of the rates of underlying mental disorder and greater risk of subsequent suicide in the elderly, all elderly people who present to primary care services following deliberate self-harm should be referred to secondary care services.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Self Injury and Related Issues (SIARI)&lt;BR&gt;Email: &lt;A href="mailto:jan@siari.uk" target="_blank"&gt;jan@siari.uk&lt;/A&gt;; website: &lt;A href="http://www.siari.co.uk/" target="_blank"&gt;http://www.siari.co.uk&lt;/A&gt;&lt;BR&gt;Forum for self-harmers.&lt;/P&gt;
&lt;P&gt;The Samaritans&amp;nbsp; 08457 909 090 (24-hour helpline, everyday) &lt;BR&gt;Email: &lt;A href="mailto:jo@samaritans.org" target="_blank"&gt;jo@samaritans.org&lt;/A&gt;; website: &lt;A href="http://www.samaritans.org.uk/" target="_blank"&gt;http://www.samaritans.org.uk&lt;/A&gt;&lt;BR&gt;Offers confidential emotional support to any person who is despairing or suicidal.&lt;/P&gt;
&lt;P&gt;Cruse Bereavement Care 020 8940 4818 (for details of local services)&lt;BR&gt;Helpline: 0870 167 1677 (9.30am-5.00pm, Monday–Friday)&lt;BR&gt;Email: &lt;A href="mailto:info@crusebereavementcare.org.uk" target="_blank"&gt;info@crusebereavementcare.org.uk&lt;/A&gt;; website: &lt;A href="http://www.crusebereavementcare.org.uk/" target="_blank"&gt;http://www.crusebereavementcare.org.uk&lt;/A&gt;&lt;BR&gt;Offers support, information, training and direct telephone help to anyone who has been affected by a death. &lt;/P&gt;
&lt;P&gt;Bereavement Information Pack for those affected by a suicide. A copy of the booklet can be purchased from the Royal College of Psychiatrist, Book Sales, 17 Belgrave Square, London SW1X 8PG.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; NICE will publish a guideline on the management of self-harm in March 2004. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Hawton K, Townsend E, Arensman E et al. Psychosocial and pharmacological treatments for deliberate self harm (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. (AI) Twenty-three studies were analysed. Promising results were found for problem-solving therapy, provision of a card to allow emergency contact with services, depot flupenthixol for recurrent repeaters of self-harm and long-term psychological therapy for female patients with borderline personality disorder and recurrent self-harm&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79413</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79413]]&gt;</url>
    <title>Introduction to sexual disorders (female)</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,SEXUAL DISORDERS,FEMALE,DETERMINANTS,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,SEXUAL HEALTH,POPULATIONS,GENDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Sexual disorders (female) - F52 (Clinical term: Sexual dysfunction, not caused by organic disorder or disease Eu52)
Clinical judgements about sexual dysfunction should take into account the individual’s ethnic, cultural, religious and social background, which may influence sexual desire, expectations and attitudes about performance.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to sexual disorders (female)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Sexual disorders (female) - F52 (Clinical term: Sexual dysfunction, not caused by organic disorder or disease Eu52)&lt;BR&gt;&lt;BR&gt;Clinical judgements about sexual dysfunction should take into account the individual’s ethnic, cultural, religious and social background, which may influence sexual desire, expectations and attitudes about performance.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Patients may be reluctant to discuss sexual matters. They may instead complain of physical symptoms, depressed mood or relationship problems. It is important to be aware that patients with sexual problems may have a history of sexual abuse/assault (in childhood or later).&lt;/LI&gt;
&lt;LI&gt;Patients may present sexual problems during a routine cervical-smear test, well-woman clinic or when discussing contraception.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Sexual dysfunction can cause marked distress and interpersonal difficulty. Common sexual disorders presenting in women are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;lack or loss of sexual desire, sexual aversion &lt;/LI&gt;
&lt;LI&gt;sexual arousal disorder (inability to attain/maintain an adequate physiological response to sexual excitement) &lt;/LI&gt;
&lt;LI&gt;sexual pain disorders:&lt;BR&gt;-&amp;nbsp;vaginismus (involuntary spasm of vaginal muscles on attempted penetration accompanied by a fear or phobia the phobia can rarely occur without the spasm)&lt;BR&gt;-&amp;nbsp;dyspareunia (recurrent genital pain associated with sexual intercourse - superficial vulval, vaginal or deep pelvic) &lt;/LI&gt;
&lt;LI&gt;orgasmic disorder (delay in, or absence of, orgasm or climax).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Distinguish between lifelong versus acquired, generalized versus situational, psychological versus combined factors.&lt;/P&gt;
&lt;P&gt;When the sexual dysfunction can be better accounted for by another axis 1 disorder, or is due to the direct physiological effects of a substance/medication, or a general medical condition; that is:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If low or sad mood is prominent, refer to Depression - F32#.&amp;nbsp; Depression may cause low desire, or may result from sexual and relationship problems. &lt;/LI&gt;
&lt;LI&gt;Relationship problems. If persistent discord in the relationship is the primary problem, relationship counselling should precede specific psychosexual treatment of the sexual dysfunction. &lt;/LI&gt;
&lt;LI&gt;Gynaecological disorders (vulval pain disorders [eg vulval vestibulitis], vaginal infections, pelvic infections [salpingitis] and other pelvic lesions [eg tumours or cysts]), although vaginismus rarely has a physical cause. &lt;/LI&gt;
&lt;LI&gt;Side-effects of medication, alcohol or drugs (eg SSRI antidepressants, oral contraceptives and beta-blockers).&amp;nbsp; &lt;BR&gt;•&amp;nbsp;Physical illnesses that affect the sexual physiology - vascular, neurological or endocrine systems - might contribute (eg atherosclerosis, multiple sclerosis, diabetes). &lt;BR&gt;•&amp;nbsp;Note that more than one sexual dysfunction can co-exist.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Lack or loss of sexual desire&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Sexual desire varies at differing times in an individual’s life and varies widely between individuals. Research shows that at any one time 30-40% of women will claim low sexual desire. Loss of or low sexual desire has many causes, including relationship problems, earlier traumas (eg sexual abuse/assault), fear of pregnancy, postnatal problems, loss and bereavement, physical and psychiatric illnesses, stress (including long working hours) and many more. Women with low/no libido do not usually initiate sexual activity or may only engage in it reluctantly when it is initiated by a partner.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General management and advice to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Discuss patient’s beliefs about sexual relations. Check whether the patient and/or the partner have unreasonable expectations. Ask the patient about traumatic sexual and relationship experiences and negative attitudes to sex. Accept that this may take more than one appointment.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;If possible, see partners together as well as individually. Try to find out if this is a problem for the woman or the relationship. If the latter, consider a difference in sexual need rather than dysfunction. Suggest development of an understanding and acceptance of what each partner wants during intimacy and help them to communicate these wants. Suggest introducing this communication into intimacy in a planned way (ie ‘I would like this…’). &lt;/P&gt;
&lt;P&gt;Over several weeks, encourage patient and partner to practise pleasurable physical contact without intercourse, commencing with non-genital touching and moving through mutual genital stimulation to a gradual return to full intercourse. Partners must take it in turns to be active and passive in terms of touching and to initiate/go second (‘sensate focus’ therapy).&lt;/P&gt;
&lt;P&gt;Consider ways of building self-esteem (eg exercise, education) and advise time and space to herself.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Sexual arousal disorder&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The essential feature is an inability to achieve or maintain an adequate lubrication-swelling response of sexual excitement. It is often accompanied by sexual desire disorder and orgasmic disorder. Women may have little or no subjective sense of sexual arousal. Resulting problems include painful intercourse, sexual avoidance and relationship discord.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General management and advice to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Advise similar strategies as in management of low sexual desire (‘sensate focus’ therapy) and anorgasmia, including self-pleasuring manually/with a vibrator and the use of sexual fantasy.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Vaginismus&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Vaginismus is an involuntary spasm of the pubococcygeal muscles, accompanied by intense fear of penetration and anticipation of pain. Sexual responses (eg desire, pleasure) may not be impaired unless penetration is attempted or anticipated. It is found more often in younger women than older ones, in women with negative attitudes to sex, and those with a history of previous sexual abuse/assault. Once vaginismus is established, it is usually chronic but it can be overcome with specific psychosexual therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General management and advice to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The patient needs to gain confidence and control over vaginal muscle spasm. Exercises (systematic desensitization) involving vaginal muscle relaxation (reverse Kegels) and the systematic introduction of graded trainers (fingers, tampons or vaginal dilators) are successful if coupled with addressing the fear or phobia. Control can then be shared with a partner. Treatment often requires long-term therapy but has a promising outcome. Avoidance of practice and low motivation are common problems.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Dyspareunia&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There are many physical causes, both of deep and superficial dyspareunia. Women typically seek treatment in general medical settings. Genital abnormalities are rarely found on examination. Exclude treatable causes. Pain can occur before, during and after intercourse. In some cases, however, anticipation, poor lubrication and muscle tension are significant factors. Even where there has been a physical cause and it has resolved, anticipation of pain may frequently maintain the dyspareunia. The use and understanding of pain cycles is very helpful and often the secret to success.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General management and advice to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Treat any physical cause. Check if patient experiences desire/arousal/lubrication.&amp;nbsp; Relaxation, good arousal, prolonged foreplay and careful penetration may overcome psychogenic problems. Referral to a gynaecologist or GUM clinic or psychosexual service is advisable if simple measures are unsuccessful.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Anorgasmia&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Previous trauma, restrictive upbringing and negative attitudes to sex may have led to an inhibition of the normal sexual response. Many women are unable to experience orgasm during intercourse but can often achieve it by clitoral stimulation. Women may achieve sexual satisfaction without an orgasm.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General management and advice to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Discuss the couple's beliefs and attitudes. Encourage self-pleasuring, manually or using a vibrator, and the use of sexual fantasy. The couple should be helped to communicate openly and to reduce any unrealistic expectations. Self-help books, leaflets or educational videos may be useful.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Patients can refer themselves to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Relate &lt;/LI&gt;
&lt;LI&gt;BASRT (British Association for Sexual and Relationship Therapy) - registered psychosexual therapists &lt;/LI&gt;
&lt;LI&gt;Brook Advisory Centres&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Family planning clinics &lt;/LI&gt;
&lt;LI&gt;Genito-urinary medicine (GUM) clinics.&lt;BR&gt;Consider referral to a psychosexual specialist if patient and doctor are unable to enter into a programme of treatment or if primary care treatment has failed.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Relate 0845 1304 010/4561 310 (helpline)&lt;BR&gt;Website: &lt;A href="http://www.relate.org.uk/" target="_blank"&gt;http://www.relate.org.uk&lt;/A&gt;&lt;BR&gt;Counselling for adults with relationship difficulties, whether married or not.&lt;/P&gt;
&lt;P&gt;BASRT (British Association for Sexual and Relationship Therapy) 020 8543 2707&lt;BR&gt;Email: &lt;A href="mailto:info@basrt.org.uk" target="_blank"&gt;info@basrt.org.uk&lt;/A&gt;; website: &lt;A href="http://www.basrt.org.uk/" target="_blank"&gt;http://www.basrt.org.uk&lt;/A&gt;&lt;BR&gt;Registered therapists are multidisciplinary, and work in the NHS as well as privately.&lt;/P&gt;
&lt;P&gt;Brook Advisory Centres 020 7617 8000 (24-hour helpline)&lt;BR&gt;Email: &lt;A href="mailto:admin@brookcentres.org.uk" target="_blank"&gt;admin@brookcentres.org.uk&lt;/A&gt;; website: &lt;A href="http://www.brook.org.uk/" target="_blank"&gt;http://www.brook.org.uk&lt;/A&gt;&lt;BR&gt;Free counselling and confidential advice on contraception and sexual matters, especially for young people (under 25).&lt;/P&gt;
&lt;P&gt;AVERT &lt;A href="http://www.avert.org.uk/" target="_blank"&gt;http://www.avert.org.uk&lt;/A&gt;&lt;BR&gt;Includes useful lesbian and young people’s sections, which give basic information on homosexuality and sexual health.&lt;/P&gt;
&lt;P&gt;Lovelife &lt;A href="http://www.lovelife.uk.com/" target="_blank"&gt;http://www.lovelife.uk.com&lt;/A&gt;&lt;BR&gt;Designed for 16–24-year-olds, includes a list of GUM and family planning clinics around the country.&lt;/P&gt;
&lt;P&gt;Dr Miriam Stoppard’s Everywoman’s Life Guide by Miriam Stoppard. Profile Pursuit Ltd, 2002&lt;/P&gt;
&lt;P&gt;Embarrassing Problems: Straight-Talking Good Advice by M Stern. Health Press, 1995&lt;/P&gt;
&lt;P&gt;Painful Sex: A Guide to Causes, Treatment and Prevention by M Goldsmith. Thorsons, 1995&lt;/P&gt;
&lt;P&gt;Becoming Orgasmic: A Sexual Growth Program for Women by JR Heiman and J LoPiccolo, Prentice-Hall, 1988. Self-help exercises for anorgasmia.&lt;/P&gt;
&lt;P&gt;A Woman's Guide to Overcoming Sexual Fear and Pain by Aurelie Jones Goodwin, New Harbinger Publications, 1997&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79412</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79412]]&gt;</url>
    <title>Introduction to sexual disorders (male)</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ SEXUAL DISORDERS,MENTAL HEALTH,ADULT CONDITIONS,MALE,PUBLIC HEALTH,DETERMINANTS,SEXUAL HEALTH,INDIVIDUAL BEHAVIOUR,GENDER,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Sexual disorders (male) - F52 (Clinical term: Sexual dysfunction, not caused by organic disorder or disease Eu52)
Clinical judgements about sexual dysfunction should take into account the individual’s ethnic, cultural, religious, and social background, which may influence sexual desire, expectations, and attitudes about performance. Sexual problems in non-Western patients are often somatized; expectations may be unrealistic and psychological explanations and therapies may not be readily accepted.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to sexual disorders (male)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Sexual disorders (male) - F52 (Clinical term: Sexual dysfunction, not caused by organic disorder or disease Eu52)&lt;BR&gt;&lt;BR&gt;Clinical judgements about sexual dysfunction should take into account the individual’s ethnic, cultural, religious, and social background, which may influence sexual desire, expectations, and attitudes about performance. Sexual problems in non-Western patients are often somatized; expectations may be unrealistic and psychological explanations and therapies may not be readily accepted.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Patients may be reluctant to discuss sexual matters. They may instead complain of physical symptoms, depressed mood or relationship problems.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Sexual dysfunction may cause marked distress and interpersonal difficulty.&lt;/P&gt;
&lt;P&gt;Common sexual disorders in men are as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;erectile dysfunction or impotence &lt;/LI&gt;
&lt;LI&gt;premature ejaculation &lt;/LI&gt;
&lt;LI&gt;retarded ejaculation or orgasmic dysfunction (intravaginal ejaculation is greatly delayed or absent but can often occur normally during masturbation) &lt;/LI&gt;
&lt;LI&gt;lack or loss of sexual desire. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Distinguish between lifelong versus acquired, generalized versus situational, and sexual dysfunction caused by psychological versus combined factors.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis and co-existing conditions&lt;/H2&gt;
&lt;P&gt;When the sexual dysfunction can be better accounted for by another axis 1 disorder, or is caused by the direct psychological effects of a substance/medication, or a general medical condition; that is:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Depression - F32#. &lt;/LI&gt;
&lt;LI&gt;Problems in relationships with partners frequently co-exist and may contribute to sexual disorder, especially those of desire. Where there is persistent discord in the relationship, relationship counselling should precede specific treatment of the sexual dysfunction. &lt;/LI&gt;
&lt;LI&gt;Specific organic pathology is a rare cause of orgasmic dysfunction or premature ejaculation. &lt;/LI&gt;
&lt;LI&gt;Physical factors frequently contribute to erectile dysfunction, including diabetes, hypertension, alcohol abuse, smoking, medication (eg antidepressants, antipsychotics, diuretics and beta-blockers), multiple sclerosis and spinal injury. (Important clue: inability to achieve erection at any time - nocturnal, morning, masturbation, etc.) &lt;/LI&gt;
&lt;LI&gt;Patients may have unreasonable expectations of their own performance. &lt;/LI&gt;
&lt;LI&gt;Note that more than one sexual dysfunction can co-exist.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Erectile dysfunction (failure of genital response; impotence)&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Erectile dysfunction is the persistent or recurrent inability to attain or maintain an adequate erection. It is often a temporary response to stress or loss of confidence and responds to psychosexual treatment, especially if morning erections occur. It is frequently associated with sexual anxiety, fear of failure, concerns about sexual performance, and a decreased subjective sense of sexual excitement and pleasure. It may also be caused by physical factors (problems with the blood vessels or nerves) or by medication. &lt;/P&gt;
&lt;P&gt;General management and advice to patient and partner (ref 1)&lt;BR&gt;Advise patient and partner to refrain from attempting intercourse for several weeks.&amp;nbsp; Encourage them to practise pleasurable physical contact without intercourse during that time, commencing with non-genital touching and moving through mutual genital stimulation to a gradual return to full intercourse at the end of that period. Partners must take it in turns to be active and passive in terms of touching, and to initiate/go second ('sensate focus' therapy).&lt;/P&gt;
&lt;P&gt;Progression along this continuum should be guided by the return of consistent, reliable erections. A book containing self-help exercises might be helpful. Inform patient and partner of the possibilities of physical treatment by penile rings, vacuum devices, intracavernosal injections and medication.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Oral: sildenafil 50-100 mg taken on an empty stomach 40-60 in before intercourse enhances erections in 80% of patients, whether the cause is psychogenic or neurological (ref 2,3,4,5). Beware danger of interaction with cardiac nitrates (BNF section 7.4.5). &lt;/LI&gt;
&lt;LI&gt;Recent developments include two new phosphodiesterase type (ref 6, 7). &lt;/LI&gt;
&lt;LI&gt;Intraurethral: MUSE (prostaglandin E1) 125-1000 mg inserted 10 min before intercourse produces erections in 40-50% of patients (ref 8) (BNF section 7.4.5). &lt;/LI&gt;
&lt;LI&gt;Intracavernosal: prostaglandin E1 5-20 mg injected 10 min before intercourse produces erections in 80-90% of patients,(ref 9) but long-term acceptability is low.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These medications are less effective in predominantly vasculogenic cases. See current NHS Executive guidelines for prescription of the above, either privately or on the NHS.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Premature ejaculation&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Persistent or recurrent onset of ejaculation and orgasm with minimal sexual stimulation before, on or shortly after penetration and before the person wishes it. Most young men learn to delay orgasm with sexual experience and ageing, but some continue to ejaculate prematurely. Premature ejaculation is typically seen in young men and is present from their first attempts at intercourse. When onset occurs later in life, it is often caused by a decreased frequency of sexual activity, intense performance anxiety with a new partner, or loss of ejaculatory control related to erectile dysfunction. It may also occur in men who have stopped regular use of alcohol.&lt;/P&gt;
&lt;P&gt;Control of ejaculation is possible and can enhance sexual pleasure for both partners.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General advice and management to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Reassure the patient that ejaculation can be delayed by learning new approaches during masturbatory training (eg the squeeze or stop–start technique). &lt;BR&gt;Medication&lt;/P&gt;
&lt;P&gt;In some cases, delay can also be achieved with clomipramine or SSRI medication (paroxetine, sertraline) or clomipramine, but relapse is very common on cessation.&amp;nbsp; Local anaesthetic sprays, if used cautiously, can delay ejaculation. Durex Performa is a new condom coated with a small amount of anaesthetic cream.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Orgasmic dysfunction or retarded ejaculation&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Persistent or recurrent delay in/absence of orgasm, following the normal excitement phase. The man typically feels aroused at the beginning, but thrusting gradually becomes a chore and less pleasurable.&lt;/P&gt;
&lt;P&gt;This is a more difficult condition to treat; however, if ejaculation can be brought about in some way (eg through masturbation) the prognosis is better. Can be secondary to medication (eg antidepressants) or regular alcohol use.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General management and advice to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Consider the patient’s age and whether stimulation is adequate in focus, intensity and duration. Recommend exercises, such as self-pleasuring and penile stimulation with body oil, use of vibrator or masturbation close to the point of orgasm, plus use of sexual fantasy, followed by vaginal penetration shortly before ejaculatory ‘point of no return’. Continue practice, and on repeated attempts try to penetrate progressively sooner.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Lack or loss of sexual desire&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Essential information for patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The level of sexual desire varies widely between individuals. It may merely represent different expectations. Lack or loss of sexual desire has many causes, including stress and relationship problems, physical and psychiatric illnesses, bereavement or other losses, medication (SSRIs) and, rarely, hormonal deficiencies. Men with low/absent sexual desire typically do not usually initiate sexual activity or may only engage in it reluctantly when it is initiated by his partner.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General management and advice to patient and partner&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Encourage stress reduction, balanced assertiveness and co-operation between partners and fostering intimacy through increased communication and shared pleasurable activities. ‘Sensate focus’ may be helpful in re-introducing structured but ‘safe’, non-performance-related sexual activity. Educational leaflets, books or videos might be helpful.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Patients can refer themselves to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Relate &lt;/LI&gt;
&lt;LI&gt;BASRT (British Association for Sexual and Relationship Therapy)-registered psychosexual therapist &lt;/LI&gt;
&lt;LI&gt;Family planning clinics &lt;/LI&gt;
&lt;LI&gt;Genito-urinary medicine clinics.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Consider referral if patient and doctor are unable to enter into a programme of treatment or if primary care treatment has failed:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;to a urologist for erectile dysfunction, if unresponsive to medication and counselling &lt;/LI&gt;
&lt;LI&gt;to a psychosexual specialist, if problem is predominantly psychogenic.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Relate&amp;nbsp; 0845 1304 010/4561 310 (helpline)&lt;BR&gt;Website: &lt;A href="http://www.relate.org.uk/" target="_blank"&gt;http://www.relate.org.uk&lt;/A&gt;&lt;BR&gt;Counselling for adults with relationship difficulties, whether married or not.&lt;/P&gt;
&lt;P&gt;BASRT (British Association for Sexual and Relationship Therapy) 020 8543 2707&lt;BR&gt;Email: &lt;A href="mailto:info@basrt.org.uk" target="_blank"&gt;info@basrt.org.uk&lt;/A&gt;; website: &lt;A href="http://www.basrt.org.uk/" target="_blank"&gt;http://www.basrt.org.uk&lt;/A&gt;&lt;BR&gt;Registered therapists are multidisciplinary and work in the NHS as well as privately.&lt;/P&gt;
&lt;P&gt;The Impotence Association 020 8767 7791 (helpline)&lt;BR&gt;Email: &lt;A href="mailto:theia@btinternet.com" target="_blank"&gt;theia@btinternet.com&lt;/A&gt;; website: &lt;A href="http://www.impotence.org.uk/" target="_blank"&gt;http://www.impotence.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Brook Advisory Centres 020 7617 8000 (24-hour helpline)&lt;BR&gt;Free counselling and confidential advice on contraception and sexual matters for young people (under 25).&lt;/P&gt;
&lt;P&gt;AVERT &lt;A href="http://www.avert.org.uk/" target="_blank"&gt;http://www.avert.org.uk&lt;/A&gt;&lt;BR&gt;Includes useful gay and young people’s sections, which give basic information about homosexuality and sexual health.&lt;/P&gt;
&lt;P&gt;Lovelife &lt;A href="http://www.lovelife.uk.com/" target="_blank"&gt;http://www.lovelife.uk.com&lt;/A&gt;&lt;BR&gt;Designed for 16–24 year olds. Includes a list of GUM and family planning clinics around the country.&lt;/P&gt;
&lt;P&gt;Impotence: A Guide for Men of All Ages by W Dinsmore and P Kell. RSM Press, 2002&lt;/P&gt;
&lt;P&gt;Embarrassing Problems: Straight-Talking Good Advice by M Stern. Health Press Ltd, 1998&lt;/P&gt;
&lt;P&gt;Men and Sex by B Zilbergeld. Fontana, 1980 &lt;/P&gt;
&lt;P&gt;Self-help exercises for erectile dysfunction and premature ejaculation.&lt;/P&gt;
&lt;P&gt;Sexual Happiness by M Yaffe and E Fenwick. Dorling Kindersley, 1986&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Ralph D, McNicholas T; for the Erectile Dysfunction Alliance. UK Management Guidelines for Erectile Dysfunction. Br Med J 2000, 321: 499-503. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Montorsi F, Salonia A, Deho F et al. Pharmacological management of erectile dysfunction. Br J Urol Int 2003, 91(5): 446-454. (CI) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Vitezic D, Pelcic-Mrsic J. Erectile dysfunction: oral pharmacotherapy options. Int J Clin Pharmacol Ther 2002, 40(9): 393-403. (AI) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Werneke U, Crowe M. Review of patients with erectile dysfunction attending the Maudsley Psychosexual Clinic in 1999: the impact of sildenafil. Sex Relation Ther 2002, 17(4): 171-185. (CIV) Sildenafil has a very satisfactory efficacy/safety profile in all patient categories. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; A Cochrane Review will be available soon. Fink H, Wilt T, MacDonald R et al. Sildenafil for erectile dysfunction (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Kuan J, Brock G. Selective phosphodiesterase type 5 inhibition using Tadalafil for the treatment of erectile dysfunction. Expert Opin Invest Drugs 2002, 11(11): 1605-1613. (AI) This is a review. Tadalafil is likely to play an important role in the management of erectile dysfunction across a broad spectrum of aetiologies, once past the ongoing regulatory review process. Side-effects are generally mild to moderate. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; A Cochrane Review will be available soon. Urciuoli R, Cantisani TA, Carlini M et al. Prostaglandin E1 for treatment of erectile dysfunction (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Padma-Natham H, Hellstrom WJG, Kaiser RE et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997, 336: 1-7. (AII) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Linet OI, Ogrine FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996, 334: 873-877. (AII)&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79796</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79796]]&gt;</url>
    <title>Introduction to sleep problems</title>
    <publicationDate>2005-03-02T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SLEEP PROBLEMS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Sleep problems - F51 (Clinical term: Non-organic sleep disorders Eu51)
</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to sleep problems&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Sleep problems - F51 (Clinical term: Non-organic sleep disorders Eu51)&lt;/P&gt;
&lt;H2&gt;&lt;EM&gt;Insomnia&lt;/EM&gt;&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Difficulty falling asleep. &lt;/LI&gt;
&lt;LI&gt;Recurrent waking during the night.&lt;/LI&gt;
&lt;LI&gt;Feeling unrefreshed (ie easily exhausted or fatigued) by sleep. &lt;/LI&gt;
&lt;LI&gt;Falling asleep at inappropriate times during the day.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Insomnia is associated with:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;complaints of poor memory and concentration &lt;/LI&gt;
&lt;LI&gt;irritability &lt;/LI&gt;
&lt;LI&gt;prone to accidents at work &lt;/LI&gt;
&lt;LI&gt;underperformance at work, or educational problems in young people &lt;/LI&gt;
&lt;LI&gt;psychosocial difficulties &lt;/LI&gt;
&lt;LI&gt;impairment &lt;/LI&gt;
&lt;LI&gt;reduced quality of life &lt;/LI&gt;
&lt;LI&gt;more frequent use of health services due to general ill health &lt;/LI&gt;
&lt;LI&gt;chronic dependence on hypnotic medication and sometimes alcohol as a (ineffective) means of ‘sleeping’ better.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;It is essential that the cause of insomnia be identified rather than attempting to treat the problem symptomatically, as treatment depends on cause.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Transient insomnia&lt;/STRONG&gt; (several days duration; commonplace) may result from worry about an anticipated event, upset related to a family dispute, unfamiliar sleeping environment, brief illness, withdrawal from hypnotic drugs. &lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Short-term insomnia&lt;/STRONG&gt; (several weeks) might result from longer illness and worries about being ill, financial problems or difficulties at work, bereavement (may become prolonged if not resolved), psychiatric disorder with fluctuating course.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Chronic insomnia&lt;/STRONG&gt; (months or years) may result from:&lt;BR&gt;- persistent psychological problems, especially stress&lt;BR&gt;- poor sleep hygiene, eg sleeping environment not conducive to sleep (including snoring or restless bed partner), excessive intake of caffeine or overuse of nicotine or alcohol, especially at night&lt;BR&gt;- physical disorders that disturb sleep, eg painful conditions, respiratory disorders&lt;BR&gt;- psychiatric disorders, including Depression - F32#, Generalized anxiety - F41.1, psychotic states&lt;BR&gt;- medication, including some bronchodilators, decongestants, antidepressants and stimulants&lt;BR&gt;- other sleep disorders, including Restless legs syndrome&lt;BR&gt;- conditioned insomnia where original cause no longer applies but bed has become associated with being awake.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Assessment should include a full sleep history from patient (also bed partner, family, etc if possible), examination of mental state and review of medical, psychiatric and family histories. Screening sleep questionnaires and a sleep diary can be valuable.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Temporary sleep problems are common and do not require treatment. &lt;/LI&gt;
&lt;LI&gt;People vary in the amount of sleep they need. &lt;/LI&gt;
&lt;LI&gt;If insomnia lasts more than a few days, advice should be sought and the cause identified (most causes are treatable). &lt;/LI&gt;
&lt;LI&gt;Generally avoid self-medication with over-the-counter or someone else’s medication; using alcohol to sleep better; taking sleeping pills for more than a few days (and preferably not at all); lying awake in bed for long periods. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 1-3)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Encourage the patient to practise good sleep hygiene: &lt;BR&gt;-&amp;nbsp;Keep to regular hours for going to bed and getting up in the morning, including at weekends&lt;BR&gt;- Make plans or think about problems before retiring to bed&lt;BR&gt;- Keep a pen and pad next to the bed for writing down troublesome thoughts which can then be reviewed&lt;BR&gt;- Avoid caffeine and alcohol in the evenings&lt;BR&gt;- Avoid daytime naps.&lt;/LI&gt;
&lt;LI&gt;Daytime exercise can help the patient to sleep regularly, but evening exercise may contribute to insomnia. &lt;/LI&gt;
&lt;LI&gt;Behavioural treatment is safer and more effective than medication (eg cognitive therapy, stimulus control, sleep restriction, relaxation). &lt;/LI&gt;
&lt;LI&gt;Self-help leaflets, books and groups may be useful.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Sleep diaries are often useful in assessment and monitoring of progress. &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Address underlying psychosocial, psychiatric or physical conditions. &lt;/LI&gt;
&lt;LI&gt;Make changes to medication, as appropriate. &lt;/LI&gt;
&lt;LI&gt;A brief, time-limited use of hypnotic medication may sometimes be useful. &lt;/LI&gt;
&lt;LI&gt;Hypnotic medication may be used occasionally. Risk of dependence increases significantly after 14 days of use. &lt;/LI&gt;
&lt;LI&gt;Melatonin is only justified for jetlag&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Most cases will be dealt with in primary care.&lt;/P&gt;
&lt;P&gt;Depending on likely cause of insomnia, referral may be appropriate to general medicine, neurology or psychiatry.&lt;/P&gt;
&lt;P&gt;Referral for behavioural interventions may be useful where locally available.&lt;/P&gt;
&lt;P&gt;Refer to a sleep disorders clinic, if available, if diagnosis is uncertain or treatment has failed. &lt;/P&gt;
&lt;H2&gt;&lt;EM&gt;&lt;BR&gt;Excessive daytime sleepiness (EDS)&lt;/EM&gt;&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Prolonged overnight sleep. &lt;/LI&gt;
&lt;LI&gt;Falling asleep during the day. &lt;/LI&gt;
&lt;LI&gt;Feeling constantly tired, exhausted or fatigued. &lt;/LI&gt;
&lt;LI&gt;Poor memory and concentration. &lt;/LI&gt;
&lt;LI&gt;Irritability or depression.&lt;/LI&gt;
&lt;LI&gt;Automatic behaviour in a sleepy state. &lt;/LI&gt;
&lt;LI&gt;Periods of sleepiness alternating with normal periods.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Excessive daytime sleepiness is associated with:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Poor occupational or school performance &lt;/LI&gt;
&lt;LI&gt;Increased accident rate (including road traffic accidents) &lt;/LI&gt;
&lt;LI&gt;Impaired marital relationships and social activities &lt;/LI&gt;
&lt;LI&gt;Misdiagnosis as laziness, depression, intellectual decline.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;It is important to distinguish between sleepiness and fatigue without prominent sleepiness, which may be caused by physical disorders (eg anaemia) or primary psychiatric disorder.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Chronic lack of sleep. &lt;/LI&gt;
&lt;LI&gt;Circadian rhythm sleep disorder, including irregular sleep-wake schedule or shift work. &lt;/LI&gt;
&lt;LI&gt;Disrupted (poor quality) sleep caused by obstructive sleep apnoea (common); caffeine, alcohol or nicotine excess; other non-prescribed drugs (including withdrawal phase). &lt;/LI&gt;
&lt;LI&gt;Increased sleep tendency, eg narcolepsy (characterized by sleep attacks and cataplexy), over-sedation by medication. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Assessment should include sleep histories and a general review. Sleep questionnaires, sleep diary or actigraphy can be valuable. &lt;/P&gt;
&lt;P&gt;Polysomnography is often needed, including respiratory measures. Other specific interventions may be appropriate, eg toxicology screen.&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Medical advice should be sought for sleepiness affecting everyday functioning. &lt;/LI&gt;
&lt;LI&gt;Underlying condition can usually be treated if correctly diagnosed. &lt;/LI&gt;
&lt;LI&gt;Do not use stimulant drugs to stay awake.&lt;/LI&gt;
&lt;LI&gt;Avoid driving or other potentially hazardous activities until sleepiness is corrected.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;Chronotherapy (retiming of sleep phase) may be appropriate for circadian rhythm sleep disorders.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Stimulant drugs are appropriate for narcolepsy.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Continuous positive airway pressure for obstructive sleep apnoea.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Drug treatment should be reserved for specialist recommendation.&lt;/P&gt;
&lt;H2&gt;&lt;EM&gt;&lt;BR&gt;Parasomnias&lt;/EM&gt;&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Some parasomnias (recurrent episodes of disturbed behaviour, experiences or physiological change occurring exclusively or predominantly in relation to sleep) are subtle, others are dramatic and frightening to experience or witness.&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;Primary parasomnias:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pre-sleep period or sleep onset: sleep starts (sudden jerk or sensation often alarming); rhythmic movements, eg headbanging, rocking &lt;/LI&gt;
&lt;LI&gt;Early in the night in light non-rapid eye movement (NREM) sleep: teeth grinding, periodic limb movements (repetitive jerky movements) &lt;/LI&gt;
&lt;LI&gt;Early in the night in deep NREM sleep: confusional arousals (mainly in young children), sleepwalking, sleep (night) terrors &lt;/LI&gt;
&lt;LI&gt;Later in the night in REM (ie dreaming) sleep: nightmares, REM sleep behaviour disorder (in which dreams are acted out) &lt;/LI&gt;
&lt;LI&gt;On waking: sleep paralysis &lt;/LI&gt;
&lt;LI&gt;At various times during sleep: sleep talking, sleep-related eating disorders.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary parasomnias:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Physical: nocturnal epilepsy, awakenings associated with sleep-related breathing difficulties &lt;/LI&gt;
&lt;LI&gt;Psychiatric: panic attacks, post-traumatic stress disorder, pseudoparasomnias (when the person is actually awake).&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;The various parasomnias are often confused with each other and all dramatic parasomnias can mistakenly be called ‘nightmares’ or ‘night terrors’.&lt;/P&gt;
&lt;P&gt;Assessment:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Requires precise description of subjective and objective changes from start to finish of parasomnia, together with timing and circumstances in which they occur &lt;/LI&gt;
&lt;LI&gt;Audio-visual recording is very valuable &lt;/LI&gt;
&lt;LI&gt;Polysomnography with audio-visual recording is required in complicated cases &lt;/LI&gt;
&lt;LI&gt;A family history may be instructive, eg sleepwalking/sleep terrors &lt;/LI&gt;
&lt;LI&gt;A physical and psychiatric review is important.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Many parasomnias of childhood improve spontaneously but protection may be necessary in the meantime (eg in sleepwalking). &lt;/LI&gt;
&lt;LI&gt;It is important to have the correct diagnosis. &lt;/LI&gt;
&lt;LI&gt;It should not be assumed that something is psychiatrically wrong with the person.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 4)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ensure the correct diagnosis on which treatment depends.&lt;/LI&gt;
&lt;LI&gt;Good sleep hygiene generally helps.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Referral&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Most common parasomnias should be identifiable in primary care, if assessed thoroughly. &lt;/LI&gt;
&lt;LI&gt;Refer to a sleep disorders clinic in complicated cases or uncertainty about type of parasomnia or significance.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Special considerations in children and adolescents&lt;/H2&gt;
&lt;P&gt;Parental factors feature prominently in the cause, management and prognosis of children’s sleep problems.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Children and adolescents have the same basic sleep problems as adults but the underlying causes differ in certain ways, eg sleeplessness is often the result of parenting practices where the child has failed to acquire good sleep habits or has developed unsatisfactory ones. &lt;/LI&gt;
&lt;LI&gt;The clinical manifestations of basically the same disorder can be different in young and adult patients, eg obstructive sleep apnoea in children is usually caused by large tonsils and adenoids, is not particularly limited to being overweight, and instead of sleepiness, it may result in overactivity and learning and behaviour problems. &lt;/LI&gt;
&lt;LI&gt;Medication plays even less of a role in treatment. Behavioural approaches are particularly important, although they require effective involvement of parents. &lt;/LI&gt;
&lt;LI&gt;Prognosis is better than in adults, where the condition may have become well established and complicated by the long-term consequences of the sleep disturbance.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;British Sleep Society&lt;BR&gt;Email: &lt;A href="mailto:Martin.King@papworth_tr.anglex.nhs.uk" target="_blank"&gt;Martin.King@papworth_tr.anglex.nhs.uk&lt;/A&gt;; website: &lt;A href="http://www.british-sleep-society.org.uk/" target="_blank"&gt;http://www.british-sleep-society.org.uk&lt;/A&gt;&lt;BR&gt;UKAN (Narcolepsy Association UK) 020 7721 8904&lt;BR&gt;Email: &lt;A href="mailto:infor@narcolepsy.org.uk" target="_blank"&gt;infor@narcolepsy.org.uk&lt;/A&gt;; website: &lt;A href="http://www.narcolepsy.org.uk/" target="_blank"&gt;http://www.narcolepsy.org.uk&lt;/A&gt;&lt;BR&gt;Provides help for those suffering from narcolepsy.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Leaflets available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Sleeping well, Tiredness.&lt;/P&gt;
&lt;P&gt;Coping with Sleep Problems and Coping with Children’s Sleep Problems. The Royal College of Psychiatrists. Talking Life, 1A Grosvenor Rd, Hoylake, Wirral CH47 3BS; tel: 0151 632 0662; website: &lt;A href="http://www.talkinglife.co.uk/" target="_blank"&gt;http://www.talkinglife.co.uk&lt;/A&gt;.&lt;BR&gt;Advice, information and strategies on tape for coping with insomnia (sleeplessness) and other disorders that lead to excessive daytime sleepiness. They present practical strategies to help parents cope with the sleep difficulties of their babies and young children.&lt;/P&gt;
&lt;P&gt;Understanding Sleep Disorders in Adults by G Stores. Family Doctor Publications / British Medical Association, 2003. A guide for the general public to sleep disorders in adults.&lt;/P&gt;
&lt;P&gt;Solve Your Child’s Sleep Problems by R Ferber. Dorling Kindersley, 1986.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Kupfer DJ, Reynolds CF. Management of insomnia. N Engl J Med 1997, 336: 341-346. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Ancoli-Israel S. Insomnia in the elderly: a review for the primary-care practitioner. Sleep 2000, 23(Suppl 1): S23-S30. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Edinger JD, Wohlgemuth WK. The significance and management of persistent primary insomnia: the past, present and future of behavioural insomnia therapies. Sleep Med Rev 1999, 3: 101-118. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Stores G. Dramatic parasomnias. J R Soc Med 2001, 94: 173-176.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>79797</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=79797]]&gt;</url>
    <title>Introduction to substance misuse in young people</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CHILD AND ADOLESCENT CONDITIONS,SUBSTANCE MISUSE,MENTAL HEALTH,DETERMINANTS,YOUNG PEOPLE,COMMUNITY CHILD HEALTH,MENTAL HEALTH,CHILD HEALTH,SPECIALTIES,SUBSTANCE MISUSE,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,INDIVIDUAL BEHAVIOUR,SUBSTANCE MISUSE,MANAGEMENT &amp; POLICY,INFORMATION,FRAMES OF REFERENCE,2008-JULY,MONTHLY ADDITIONS,POPULATIONS,GROUPS,AGE GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Substance misuse in young people - F10, F11#* (Clinical term: Mental and behavioural disorders due to use of alcohol Eu10, Mental and behavioural disorders due to use of opioids Eu11) * The current ICD-10 classification code does not distinguish between adults and children and adolescents, nor does the clinical term code. 
</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to substance misuse in young people&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Substance misuse in young people - F10, F11#* (Clinical term: Mental and behavioural disorders due to use of alcohol Eu10, Mental and behavioural disorders due to use of opioids Eu11) * The current ICD-10 classification code does not distinguish between adults and children and adolescents, nor does the clinical term code. &lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Introduction&lt;/H2&gt;
&lt;P&gt;Substance misuse in young people should be considered in the context of 'normal' adolescent risk-taking and experimentation: 65% of young people (aged under 18) will experiment with illegal drugs; 96% of this experimentation is with cannabis and only 4% go on to regular abuse and long-term problems. Polydrug use is common as part of the 'club scene' in older adolescents, so a variety of substances - legal and illegal - are used on a sporadic basis.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;P&gt;Presentation is often at the instigation of others (parents, teachers, social services, criminal justice), often precipitated by physical, psychological or social 'events'. Young people's advisory services may suggest GP consultation to a young person where they feel significant medical problems may arise.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;P&gt;May be divided into physical, psychological and social features but the patient will usually present with a mixture of these.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Physical:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;respiratory symptoms caused by smoking &lt;/LI&gt;
&lt;LI&gt;peri-oral and peri-nasal lesions caused by inhalation or snorting &lt;/LI&gt;
&lt;LI&gt;physical injuries incurred during intoxication &lt;/LI&gt;
&lt;LI&gt;agitation after polydrug or prolonged use &lt;/LI&gt;
&lt;LI&gt;needle tracks, thrombosis or abscesses owing to intravenous use &lt;/LI&gt;
&lt;LI&gt;withdrawal syndromes.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Psychological:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;mood changes: depression on withdrawal of stimulants, irritability as part of withdrawal syndrome &lt;/LI&gt;
&lt;LI&gt;acute mental disorders, psychosis, confusion, etc &lt;/LI&gt;
&lt;LI&gt;deliberate self-harm or suicide attempt.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Social:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;deteriorating educational performance &lt;/LI&gt;
&lt;LI&gt;family conflict &lt;/LI&gt;
&lt;LI&gt;crime: petty associated with intoxication; theft to provide funds; ‘dealing’ as part of more serious association with drug culture.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Substance misuse is defined as use that is medically, legally or socially unacceptable (therefore potentially subject to changing levels of acceptability). This might apply to ‘legal’ substances such as tobacco in a young person over 16 if there is potential physical or social harm caused by its use.&lt;/P&gt;
&lt;P&gt;Risk factors for substance misuse include the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Living in an area of high ‘usage’ &lt;/LI&gt;
&lt;LI&gt;‘Social’ factors. For example, parental conflict, separation, divorce; physical or sexual abuse; neglect; poor monitoring or supervision; family history of substance misuse &lt;/LI&gt;
&lt;LI&gt;‘Psychological’ factors, such as psychological distress, psychiatric disorder, conduct and emotional disorder &lt;/LI&gt;
&lt;LI&gt;‘Exclusion’ factors, such as unemployment, truancy and criminal activities.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Harmful use is a subclassification of misuse, where actual physical or psychological harm ensues (for example blood-borne virus infections with needle use; overdose and death with solvent use; cardiovascular disease [embolus etc]; injuries during intoxication; and social exclusion). Not all misuse leads to harm but the risk of this is significant, even at first use of some substances. &lt;/P&gt;
&lt;P&gt;Dependence is diagnosed if at least three of the following criteria have been present in the preceding 12 months:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Narrowing of the substance repertoire &lt;/LI&gt;
&lt;LI&gt;Persistent substance use, despite evidence of its harmful consequences &lt;/LI&gt;
&lt;LI&gt;Difficulties in controlling the use of the substance &lt;/LI&gt;
&lt;LI&gt;Neglect of interests and an increased amount of time taken to obtain the substance or recover from its effects &lt;/LI&gt;
&lt;LI&gt;Evidence of tolerance such that higher doses are required to achieve the same effect&lt;/LI&gt;
&lt;LI&gt;Compulsion: a strong desire to take the substance &lt;/LI&gt;
&lt;LI&gt;A withdrawal syndrome when substance use ceases or is reduced. The young person might also report the use of substances to relieve the withdrawal symptoms.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;P&gt;Substance misuse may be a ‘symptom’ of an underlying psychological problem. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Deliberate self-harm - intoxication or overdose may not be accidental; an underlying suicidal intent should be suspected because substance use is strongly linked to suicide. &lt;/LI&gt;
&lt;LI&gt;Mood disorder. &lt;/LI&gt;
&lt;LI&gt;Anxiety disorder. &lt;/LI&gt;
&lt;LI&gt;Eating disorders - F50. &lt;/LI&gt;
&lt;LI&gt;Psychotic disorder - F20#. &lt;/LI&gt;
&lt;LI&gt;Personality disorders - F60 – 69 (adult). &lt;/LI&gt;
&lt;LI&gt;Attention-deficit/hyperactivity disorder - F90. &lt;/LI&gt;
&lt;LI&gt;Acute or chronic confusional state.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for parents and carers&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Although substance misuse in young people is very common and often ‘on–off’, it is occasionally fatal and should be taken seriously. &lt;/LI&gt;
&lt;LI&gt;Substance misuse in young people can be a ‘symptom’ of an underlying psychological problem that itself requires treatment.&lt;/LI&gt;
&lt;LI&gt;If identified early, there is less likelihood of progression to a more severe condition, as well as social, psychological and physical consequences. &lt;/LI&gt;
&lt;LI&gt;Even if the problem has progressed, there is benefit in reducing or stopping and in social ‘interventions’. &lt;/LI&gt;
&lt;LI&gt;Engagement and retention in treatment and family support are key, even if the long-term goal of abstinence cannot be immediately achieved. &lt;/LI&gt;
&lt;LI&gt;Voluntary organizations and drug services and agencies provide valuable support and are often the most appropriate source of help.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Confidentiality and access to services for young people need specific consideration. Local services will have well-formulated policies on confidentiality about which the primary care team needs to be aware. &lt;/LI&gt;
&lt;LI&gt;Instil positive expectations of success and offer support and encouragement. &lt;/LI&gt;
&lt;LI&gt;Assess motivation for psychological change. &lt;/LI&gt;
&lt;LI&gt;Give advice on cessation and harm reduction (eg ‘safe levels’ of drinking). &lt;/LI&gt;
&lt;LI&gt;Confirmatory urine/saliva analysis, information (from professionals, family and friends), regular monitoring and review of compliance represent satisfactory co-operation with agreed treatment options and plan. &lt;/LI&gt;
&lt;LI&gt;Discuss a referral plan with the young person and family and obtain their support for it, within the confines of medical confidentiality and consent. &lt;/LI&gt;
&lt;LI&gt;Management options include counselling, motivational enhancement, cognitive behavioural therapy, family therapy and group therapy. The choice depends on the nature and extent of the problem and which approach appears most appropriate and suitable for a particular young person and their family.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;A diagnosis of definite clinical dependence is necessary for prescribing. Only exceptionally should GPs prescribe - with specialist advice, support and supervision. Almost all medications are not licensed for patients under 18.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;P&gt;Community drug and alcohol services for young people are usually the initial source of help. Early referral for specialist assessment or admission may be necessary for the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Severe physical illness &lt;/LI&gt;
&lt;LI&gt;Co-morbid severe mental illness&lt;/LI&gt;
&lt;LI&gt;Abuse of multiple substances &lt;/LI&gt;
&lt;LI&gt;Frequent relapses of substance misuse &lt;/LI&gt;
&lt;LI&gt;Unstable social circumstances, living alone, homelessness.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;DrugScope 020 7928 1211&lt;BR&gt;Email: &lt;A href="mailto:services@drugscope.org.uk" target="_blank"&gt;services@drugscope.org.uk&lt;/A&gt;; website: &lt;A href="http://www.drugscope.org.uk/" target="_blank"&gt;http://www.drugscope.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;ChildLine 0800 1111 (24-hour helpline)&lt;BR&gt;Website: &lt;A href="http://www.childline.org.uk/" target="_blank"&gt;http://www.childline.org.uk&lt;/A&gt;&lt;BR&gt;Telephone service for all children and young people providing confidential counselling, support and advice on any issue. Parents can also write to ChildLine. &lt;/P&gt;
&lt;P&gt;Drinkline National Alcohol Helpline 0800 917 8282 (11am–7pm, Monday–Friday)&lt;BR&gt;Website: &lt;A href="http://www.wrecked.co.uk/" target="_blank"&gt;http://www.wrecked.co.uk&lt;/A&gt;&lt;BR&gt;For young people. Provides confidential information, help and advice about drinking.&lt;/P&gt;
&lt;P&gt;HIT &lt;A href="http://www.hit.org.uk/" target="_blank"&gt;http://www.hit.org.uk&lt;/A&gt;&lt;BR&gt;Leaflets are available from the Royal College of Psychiatrists (&lt;A href="http://www.rcpsych.ac.uk/" target="_blank"&gt;http://www.rcpsych.ac.uk&lt;/A&gt;): Factsheet 34: Mental Health and Growing Up, Second Edition: Drug and alcohol misuse, and Factsheet 35 (for parents and teachers): Mental Health and Growing Up, Second Edition: Alcohol and Drugs - What Parents Need to Know.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>82262</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=82262]]&gt;</url>
    <title>Introduction to unexplained somatic complaints</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,UNEXPLAINED SOMATIC COMPLAINTS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Unexplained somatic complaints - F45 (Clinical term: Somatoform disorders Eu45)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Introduction to unexplained somatic complaints&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Unexplained somatic complaints - F45 (Clinical term: Somatoform disorders Eu45)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Presenting complaints&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Any physical symptom may be present.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Symptoms may vary widely across cultures. &lt;/LI&gt;
&lt;LI&gt;Complaints may be single or multiple and may change over time.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Diagnostic features&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Physical symptoms which persist and remain unexplained following adequate examination, investigations and explanation by the doctor. &lt;/LI&gt;
&lt;LI&gt;Commonly, frequent medical visits in spite of negative investigations. &lt;/LI&gt;
&lt;LI&gt;Symptoms of depression and anxiety are common. The likelihood of psychiatric disorder (anxiety or depression) increases with increasing number of unexplained somatic symptoms (ref 1).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Some patients may be primarily concerned with obtaining relief from physical symptoms.&amp;nbsp; Others may be worried about having a physical illness and be unable to believe that no physical condition is present (hypochondriasis).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Differential diagnosis&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Alcohol misuse - F10. &lt;/LI&gt;
&lt;LI&gt;Drug use disorders - F11 - F19#, eg seeking narcotics for relief of pain. &lt;/LI&gt;
&lt;LI&gt;If low or sad mood is prominent, see Depression - F32#.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Generalized anxiety - F41.1, if anxiety symptoms are prominent. &lt;/LI&gt;
&lt;LI&gt;Panic disorder - F41.0 (misinterpretation of the somatic signs associated with panic). &lt;/LI&gt;
&lt;LI&gt;Chronic mixed anxiety and depression - F41.2. &lt;/LI&gt;
&lt;LI&gt;Acute psychotic disorders - F23 (if strange beliefs about symptoms are present (eg belief that organs are decaying).&lt;/LI&gt;
&lt;LI&gt;An organic cause. Take a multiaxial approach. While it is important not to over-investigate, it is important to keep the physical side under review as an organic problem may emerge.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Essential information for patient and family&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Stress often produces or exacerbates physical symptoms. &lt;/LI&gt;
&lt;LI&gt;Focus should be on managing the symptoms, not on discovering their cause. &lt;/LI&gt;
&lt;LI&gt;A cure might not always be possible; the goal should be to live the best life possible even if symptoms continue.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;General management and advice to patient and family&lt;/H2&gt;
&lt;P&gt;(ref 2)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Acknowledge that the patient’s physical symptoms are real to the patient. &lt;/LI&gt;
&lt;LI&gt;Ask about the patient’s beliefs (what is causing the symptoms?) and fears (what do they fear may happen?) &lt;/LI&gt;
&lt;LI&gt;Be explicit early on about considering psychological issues. The exclusion of illness and exploration of emotional aspects should happen in parallel. Investigations should have a clear indication. It may be helpful to say to the patient, “I think this result is going to be normal”. &lt;/LI&gt;
&lt;LI&gt;Avoid blanket reassurance; offer appropriate explanation (eg not all headaches indicate a brain tumour). Advise patients not to focus on medical worries. &lt;/LI&gt;
&lt;LI&gt;Discuss emotional stresses that were present when the symptoms arose.&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Explain the links between stress and physical symptoms and how a vicious cycle can develop, eg ‘Stress can cause a tightening of the muscles in the gut.&amp;nbsp; This can lead to the development of abdominal pain or worsening of existing pain. The pain aggravates the tightening of the gut muscles’. A diagram may be helpful. &lt;/LI&gt;
&lt;LI&gt;Relaxation methods can help relieve symptoms related to tension (eg headache, neck or back pain).&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Encourage exercise and enjoyable activities. The patient need not wait until all symptoms are gone before returning to normal routines. &lt;/LI&gt;
&lt;LI&gt;Treat associated depression, anxiety, drug or alcohol problems. &lt;/LI&gt;
&lt;LI&gt;For patients with more chronic complaints, time-limited appointments that are regularly scheduled can prevent more frequent, urgent visits (ref 3) &lt;/LI&gt;
&lt;LI&gt;Structured problem-solving methods may help patients to manage current life problems or stresses which contribute to symptoms (ref 4). &lt;/LI&gt;
&lt;LI&gt;Help the patient to: &lt;BR&gt;- identify the problem &lt;BR&gt;- list as many solutions as possible&amp;nbsp; &lt;BR&gt;- list the pros and cons of each possible solution. (The patient should do this perhaps between appointments.)&lt;BR&gt;- support the patient in choosing their preferred approach&lt;BR&gt;- help the patient to work out the steps necessary to achieve the plan&lt;BR&gt;- set a date to review the plan. Identify and reinforce things that are working.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Medication&lt;/H2&gt;
&lt;P&gt;Avoid unnecessary diagnostic testing or prescription of new medication for each new symptom. Rationalize polypharmacy.&lt;BR&gt;Where depression is also present, an antidepressant may be indicated)&lt;/P&gt;
&lt;P&gt;Even in the absence of clinical depression, a therapeutic trial of antidepressant medication may be helpful (ref 5).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Referral&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Patients are best managed in primary health-care settings.&amp;nbsp; Consistency of approach within the practice is essential. Seeing the same person is helpful. Consider referral to a partner for a second opinion. Documenting discussions with colleagues can reduce stress by sharing responsibility within the primary care team. &lt;/LI&gt;
&lt;LI&gt;Non-urgent referral to secondary mental health services is advised on grounds of functional disability, especially if the patient is unable to work, and duration of symptoms, i.e. if the patient has had the symptoms for a long time. &lt;/LI&gt;
&lt;LI&gt;Cognitive behaviour therapy or interpersonal therapy, if available, may help some patients, though willingness of patients to participate is sometimes poor (ref 6-8). &lt;/LI&gt;
&lt;LI&gt;Refer to a liaison psychiatrist, if available, for those who persist in their belief that they have a physical cause for their symptoms, despite good evidence to the contrary. &lt;/LI&gt;
&lt;LI&gt;Avoid multiple referrals to medical specialists. Documented discussions with appropriate medical specialists may be helpful from time to time as, in some cases, underlying physical illness eventually emerges. &lt;/LI&gt;
&lt;LI&gt;After each specialist referral the GP should review with the patient’s understanding of their illness in the light of the specialist consultation. (The more doctors a patient sees, the greater the likelihood of apparent inconsistencies which commonly serve to increase the patient’s distress as well as their uncertainty about the reliability of the account offered by doctors and others.)&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Resources for patients and families&lt;/H2&gt;
&lt;P&gt;Depression Alliance&amp;nbsp; &lt;BR&gt;England 020 8768 0123 &lt;BR&gt;Website: &lt;A href="http://www.depressionalliance.org/" target="_blank"&gt;www.depressionalliance.org&lt;/A&gt;&lt;BR&gt;Wales 029 2069 2891 (10am-4pm Mon-Fri)&lt;BR&gt;Scotland 0131 467 3050&lt;BR&gt;Provides information and self-help groups.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Mayou R, Farmer A. ABC of psychological medicine. Functional somatic symptoms and syndromes. Br Med J 2002, 325: 265-268 &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Goldberg R, Dennis H, Novack M, Gask L. The recognition and management of somatization: what is needed in primary care training. Psychosomatics 1992, 33(1): 55-61. (BV) &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Smith GR, Rost K, Kashner M. A trial of the effect of a standardised psychiatric consultation on health outcomes and costs in somatising patients. Arch Gen Psych 1995, 52(3): 238-243. (BII) &lt;BR&gt;4 Hawton K, Kirk J. Problem-solving. In: Hawton K, Salkovskis PM, Kirk J, Clark DM (eds.) Cognitive Therapy for Psychiatric Problems: A Practical Guide. Oxford: Oxford University Press, 1989: 406-426. (AII) &lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff HL. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med 1998; 60(4): 503-9&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Speckens A, Van Hemert A, Spinhoven P et al. Cognitive behavioural therapy for medically unexplained physical symptoms: a randomized controlled trial. Br Med J 1995, 311: 1328-1332. (BII) Six to 16 sessions of cognitive behaviour therapy were conducted in medical outpatients. Intervention was found to be effective and acceptable to patients, and gains were maintained at 12-month follow-up. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; Kashner TM, Rost K, Cohen B et al. Enhancing the health of somatization disorder patients: effectiveness of short-term group therapy. Psychosomatics 1995, 36: 924-932. (BII) Randomized controlled trial of 70 patients in primary care offered eight sessions of group therapy. Improvement, both physical and emotional, were maintained. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Guthrie E. Emotional disorder in chronic illness: psychotherapeutic interventions. Br Med J 1996, 168(30): 265-273.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388588</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/publications/docs/investigating-disclosures-sexual-offenders.pdf]]&gt;</url>
    <title>Investigating disclosures made by sexual offenders</title>
    <publicationDate>2010-09-14T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SEXUAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=clear-teaser-image&gt;
&lt;P&gt;&lt;STRONG&gt;Preliminary findings from the first phase of research into using mandatory polygraph testing in the management of sexual offenders in the community.&lt;/STRONG&gt;&lt;/P&gt;&lt;/DIV&gt;&lt;!-- clear-teaser-image --&gt;&lt;BR&gt;
&lt;P&gt;The National Offender Management Service is piloting the use of mandatory polygraph testing for sexual offenders managed in the community in the East and West Midlands over a three-year period from April 2009.&lt;/P&gt;
&lt;P&gt;This exploratory research provides an in depth understanding of the nature of disclosures and the processes by which disclosures are made and used under normal (pre-polygraph) supervision arrangements, so that the impact of the polygraph can later be properly assessed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320661</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/Investigation_into_West_London_Mental_Health_NHS_Trust_FINAL_200907171608.pdf]]&gt;</url>
    <title>Investigation into West London Mental Health NHS Trust</title>
    <publicationDate>2009-07-21T00:00:00</publicationDate>
    <publisher>Care Quality Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,QUALITY AND MONITORING,HEALTH AND SAFETY,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The investigation into West London Mental Health NHS Trust focuses on the trust's response to sucides and other serious untoward incidents within the trust.]]&gt;</body>
  </document>
  <document>
    <id>291102</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.choiceforum.org/carers.pdf]]&gt;</url>
    <title>Involving carers in out of area treatments: a good practice guide</title>
    <publicationDate>2008-07-25T00:00:00</publicationDate>
    <publisher>CSIP</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This guide has drawn on three main sources: Carers who have described their experiences, wishes and needs in relation to OATs; service commissioners who have set out what they think could andvshould happen when people are placed out of area; good practice demonstrated or aspired to by service providers.</description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;LI&gt;Section 1 Introduction - This section describes what is meant by OATs and provides some background information.&lt;/LI&gt;
&lt;LI&gt;Section 2 7 Key Principles - This section sets out the 7 key principles on which the guide is based. &lt;/LI&gt;
&lt;LI&gt;Section 3 For Carers- This section sets out what carers should be able to expect in terms of involvement when someone is placed out of area.&lt;/LI&gt;
&lt;LI&gt;Section 4 For Care Coordinators - This section provides a checklist of measures that care coordinators can take to effectively involve carers in OATs.&lt;/LI&gt;
&lt;LI&gt;Section 5 For Service Commissioners - This section provides a checklist of measures that service commissioners can take to effectively involve carers in OATs.&lt;/LI&gt;
&lt;LI&gt;Section 6 For Service Providers - This section provides a checklist of measures that service providers can take to effectively involve carers in OATs.&lt;/LI&gt;
&lt;LI&gt;Section 7 What helps?- This section is based on the experience of OATs carers and provides additional suggestions on what might help to involve them.&lt;/LI&gt;
&lt;LI&gt;Section 8 Developing the Guide - This section describes how the guide was developed&lt;/LI&gt;
&lt;LI&gt;Section 9 Glossary of Terms - This section explains some of the more technical language in the guide. Words or phrases which appear in the glossary are asterisked the first time they appear in the text.&lt;/LI&gt;
&lt;LI&gt;Section 10 More Information - This section lists other useful sources of information concerning OATs and carers.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>263055</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38623&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Is Anybody There?</title>
    <publicationDate>2001-04-02T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report on friendship and mental health, based on a survey of 543 people, looks at the experiences of people with mental health problems and those who support friends with mental health problems.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A report on friendship and mental health, based on a survey of 543 people, looks at the experiences of people with mental health problems and those who support friends with mental health problems. It illustrates the importance of personal relationships, in particular friendships, and contains recommendations for government and policy makers, media and educational campaigns, mental and other health professionals.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38619&amp;amp;type=Full&amp;amp;servicetype=Attachment" target="_blank"&gt;Is Anybody There? Update&lt;/A&gt; (Link to full-text PDF) &lt;/P&gt;
&lt;P&gt;This update briefing summarises the main findings of a survey investigating friendship and mental health. This formed part of a campaign for Mental Health Action Week, April 2001. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296429</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://springerlink.metapress.com/content/104757/]]&gt;</url>
    <title>Journal of Autism and Developmental Disorders</title>
    <publicationDate></publicationDate>
    <publisher>Springer Netherlands</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"Journal of Autism and Developmental Disorders covers all the severe psychopathologies in childhood, including autism and childhood schizophrenia. Its original articles discuss experimental studies on the biochemical, neurological, and genetic aspects of a disorder; the implications of normal development for deviant processes; and interaction between disordered behavior of individuals and social or group factors. The journal features research and case studies involving the entire spectrum of interventions, including behavioral, biological, educational, and community aspects. Coverage extends to advances in the diagnosis and classification of disorders."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Published on a monthly basis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&amp;nbsp;&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296403</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://psycnet.apa.org/index.cfm?fa=browsePA.volumes&amp;jcode=ccp]]&gt;</url>
    <title>Journal of Consulting and Clinical Psychology</title>
    <publicationDate></publicationDate>
    <publisher>American Psychological Association</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"Journal of Consulting and Clinical Psychology examines the treatment and care of diverse patient groups. Featured articles deal with the development, validity, and use of diagnostic techniques and treatments for disordered behavior.&lt;/P&gt;
&lt;P&gt;"The journal also publishes studies of various populations with a clinical interest, such as medical patients, ethnic minorities, persons with serious mental illness, and community samples.&lt;/P&gt;
&lt;P&gt;"Readers will find studies with a cross-cultural or demographic focus for treating behavior disorders; studies of personality and its assessment and development in relation to clinical dysfunction and treatment; and studies of gender, age, ethnicity, or sexual orientation that have a clear bearing on diagnosis, assessment, and treatment."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Six issues are published per year.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296426</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://jnnp.bmj.com/]]&gt;</url>
    <title>Journal of Neurology, Neurosurgery, and Psychiatry with Practical Neurology</title>
    <publicationDate></publicationDate>
    <publisher>BMJ</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"The Journal of Neurology, Neurosurgery, and Psychiatry publishes original articles, short reports, editorials, commentaries and more; covering the whole field of clinical neurological practice, neurosurgery &amp;amp; neuropsychiatry. Emphasis is given to common disorders such as cerebrovascular disease, multiple sclerosis, Parkinson's disease, peripheral neuropathy, epilepsy, and subarachnoid haemorrhage."&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Editorial commentaries 
&lt;LI&gt;Papers 
&lt;LI&gt;Short reports 
&lt;LI&gt;Letters 
&lt;LI&gt;Historical notes 
&lt;LI&gt;Neurological pictures 
&lt;LI&gt;Neurology of body systems 
&lt;LI&gt;Corrections&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Published on a monthly basis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296416</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/journal/117995531/home]]&gt;</url>
    <title>Journal of the American Geriatrics Society</title>
    <publicationDate></publicationDate>
    <publisher>Wiley InterScience</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;"The Journal of the American Geriatrics Society is a comprehensive and reliable source of monthly research and information about common diseases and disorders of older adults."&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Clinical investigations 
&lt;LI&gt;Brief reports 
&lt;LI&gt;Brief methodological reports 
&lt;LI&gt;Progress in Geriatrics 
&lt;LI&gt;Education and Training 
&lt;LI&gt;Models of Geriatric Care, Quality Improvement adn Program Dissemination 
&lt;LI&gt;Special article 
&lt;LI&gt;Editorials 
&lt;LI&gt;Letters to the editor&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Published on a monthly basis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>334284</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_110786.pdf]]&gt;</url>
    <title>Keeping Children and Young People in Mind: The Government's full response to the independent review of CAMHS</title>
    <publicationDate>2010-01-07T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,QUALITY AND MONITORING,MENTAL HEALTH SERVICES,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The full Government response to the final report of the independent CAMHS Review, setting out progress to date and plans for the future of children and young people's mental health. The response also gives examples of the outcomes expected from a good service as an aid for commissioners, providers and practitioners.]]&gt;</body>
  </document>
  <document>
    <id>325084</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhsconfed.org/Publications/Documents/MHN_factsheet_August_2009_FINAL_2.pdf]]&gt;</url>
    <title>Key facts and trends in mental health PDF</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>The NHS Confederation</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This fact sheet outlines some of the key available data relating to mental health, including:&lt;BR&gt;• key trends in morbidity and behaviour&lt;BR&gt;• wider societal changes and challenges&lt;BR&gt;• NHS budget and spending trends&lt;BR&gt;• service activity&lt;BR&gt;• quality, safety and user experience&lt;BR&gt;• staffing levels and staff satisfaction.]]&gt;</body>
  </document>
  <document>
    <id>381297</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/head-size-and-Alzheimers-disease.aspx]]&gt;</url>
    <title>Large heads give ‘dementia benefit’</title>
    <publicationDate>2010-07-13T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Having a big head may protect against dementia,” reported the BBC. The news report said that research in 270 patients with Alzheimer’s disease found that a larger head size (as a marker of brain size) was linked to better performance in cognitive tests, even when patients had the same amount of brain loss assessed by MRI scan.&lt;/P&gt;
&lt;P&gt;This was a preliminary study that requires further research in a larger group of people. It is important to highlight that brain size is largely determined by genes and it is not clear whether it is possible to influence brain size during childhood sufficiently to promote greater brain function resilience following brain loss in later life.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111330</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111330]]&gt;</url>
    <title>Later Life</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DEPRESSION,SOCIAL SUPPORT,CARERS,ADULTS,DETERMINANTS,PUBLIC HEALTH,SOCIETY,SOCIAL DETERMINANTS,GROUPS,COMMUNITIES,POPULATIONS,AGE GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Later Life&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111329:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111331:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;The case for action:&lt;/H2&gt;
&lt;P&gt;One in five people is aged over 60, life expectancy is growing and by 2025 20% of the population in industrialised countries will be aged 65 and over (ref 1). As a consequence mental health promotion programmes have the potential to make a significant difference to the health and wellbeing of such a large population cohort.&lt;/P&gt;
&lt;P&gt;Within broader gerontological literature the notion of successful and productive ageing is seen as considerably more than the prevention or amelioration of physical and mental illness. Although there is lack of clarity about what constitutes ‘successful ageing’ it seems evident that it involves a complex process of adaptation to physical, social, interpersonal and psychological changes that accompany ageing (ref 2).&lt;/P&gt;
&lt;P&gt;Standard 8 of the National Service Framework for Older People (ref 3) focuses on the promotion of health and active life in older age and states that ‘ The health and well-being of older people is (to be) promoted through a co-ordinated programme of action led by the NHS with support from councils.’ The aim is to extend the healthy life expectancy of older people. However the age discrimination that informs attitudes to those in later life can impede the design and delivery of appropriate services (ref 4).&lt;/P&gt;
&lt;P&gt;Good mental health and wellbeing are as important for older people as for any other age group and may also confer additional benefits, because of the links between positive mental health and good physical health, notably in relation to reduced risk of cardiovascular disease (ref 5, 6). Emotional well-being also protects against stroke, with sustained low mood and depression increasing the risk of stroke (ref 7, 8). Men and women who scored highest in a survey on emotional health were twice as likely to be alive by the study’s end. The link between subjective feelings of happiness and good health held even after controlling for chronic disease, smoking, drinking habits, weight, sex and education (ref 9).&lt;/P&gt;
&lt;P&gt;An estimated 15% of people over the age of 65 years are experiencing depression, 5% severely. (ref 10, 11). Mild depression has been reported to be 69% higher among older people than the general population because of less social contact and low self-esteem (ref 12). Elderly people from ethnic minorities may be at particular risk in suffering from dementia and depression (ref 13).&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Mental health promotion in later life – summary of the evidence&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Targeting depression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Programmes and initiatives which target depression and its impact on morbidity and mortality are especially relevant in later life because depression is a very common problem (ref 14). There is an association between depression and negative affect on physical health (ref 15, 16) and increased risk of suicide (ref 17). &lt;/P&gt;
&lt;P&gt;Social support has been shown to be effective in countering depression. An overview of home visits by public health nurses with all groups in Canada showed reduced levels of care required for the elderly (ref 18). A telephone based support service provided through the social work service in the USA concluded that this sort of outreach strategy was moderately effective in targeting older adults with depressive symptomatology, social isolation and unmet needs. (ref 19).&lt;/P&gt;
&lt;P&gt;Suicide is strongly related to untreated depression and specialist services can play a positive role in identifying and preventing elderly suicide. An evaluation of one such initiative in the USA, the Centre for Elderly Suicide Prevention, concluded that community agencies with specialised programmes for older adults showed promise (ref 20).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Social activity and social wellbeing&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Much social gerontological research and practice has been guided by a hypothesis that there is a positive link between social activity and social wellbeing amongst older people.&lt;/P&gt;
&lt;P&gt;(ref 21) In the face of role losses, older individuals need to substitute other roles or activities. The resulting positive social interaction may enable individuals to keep their self-esteem intact with resulting favourable impact on subjective wellbeing (ref 22).&lt;/P&gt;
&lt;P&gt;A meta-analysis on social activity/subjective wellbeing found that social activity was positively and significantly related to subjective wellbeing (ref 23). The analysis found that informal activities and activities with friends were not related consistently more strongly to subjective well-being than were formal activities or those with neighbours. However scope and frequency of social activity did have an impact on subjective wellbeing.&lt;/P&gt;
&lt;P&gt;Good personal support networks, for example friendship or a confiding relationship, and opportunities for social and physical activities protect mental health and enable people at any age to recover from stressful life events like bereavement or financial problems (ref 24). This can be particularly effective for those in later life whose social networks may have been reduced, through bereavement or relocation. Access to information and practical help can play an important role in reducing feelings of exclusion and isolation.&lt;/P&gt;
&lt;P&gt;People with a small primary support group (3 people or less) are at greatest risk of mental health problems (ref 25). Social support reduces death rates, susceptibility to infection and depression, notably in older people (ref 26). &lt;/P&gt;
&lt;P&gt;Walking and regular social activities are positively associated with successful ageing. Involvement in social activities provides significant protection against morbidity, as well as good quality of life (ref 27).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Health promotion interventions targeting social isolation and loneliness&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic review evidence suggests that effective interventions to combat social isolation and loneliness among older people tend to be long-term group activities that are aimed at a specific target group,include an element of participant control and utilise a multi-faceted approach (ref 28).&lt;/P&gt;
&lt;P&gt;Causes of social isolation and loneliness were identified through the literature, by questioning experts in the field and by asking older people themselves. Identified causes were physical disability, e.g. loss of mobility, deterioration of eyesight, loss of hearing, social, e.g. bereavement, loss of home, loss of family, break-up of community, environmental, e.g. poor housing, lack of transport, lack of local services, psychological e.g. fear of crime, fear of traffic, motivation, locus of control and financial i.e. poverty.&lt;/P&gt;
&lt;P&gt;Effective interventions were characterised by group activities that targeted specific groups of participants, utilised more than one intervention method and aimed to deliver across a broad range of outcomes and allowed participants some level of control.&lt;/P&gt;
&lt;P&gt;The evidence base is not strong enough to support a positive effect for befriending schemes and their impact on measures of loneliness for older people. Very few studies were identified that utilised befriending as a counter to loneliness and social isolation.&lt;/P&gt;
&lt;P&gt;However there is limited but positive evidence that self-help groups provide an effective approach to ameliorating the impact of loneliness and social isolation for older people (ref 29). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Support for carers of people with dementia&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic review level evidence did not support any consistently positive effect of educational or support interventions for dementia caregivers in any of the outcome measures associated with psychological well-being or reduction in caregiver burden. Some of the interventions did seem to produce consistent improvements in caregivers’ knowledge of the presenting illness, but the increased knowledge appeared unrelated to psychological or social outcomes (ref 30).&lt;/P&gt;
&lt;P&gt;However there seems to be an indication that studies conducted from 1990 onwards have benefited from increased knowledge and awareness about carers and their needs. In terms of improvements in psychological well-being there is a moderate improvement over time. Thirteen interventions aiming to improve psychological well-being were evaluated among nine studies that were conducted pre-1990. Five (38%) of these interventions reported success in improving psychological well-being. However from 1990 onwards, twelve out of twenty four (50%) interventions that were evaluated among twenty studies reported statistically significant improvements in well-being.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Domiciliary home visiting for elderly people and their carers&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is limited but positive evidence that home visiting is associated with a reduction in caregiver stress, reductions in carers’ psychological symptoms and enhanced well-being. There was no significant effect of home visiting on psychological symptoms, well-being or quality of life amongst the elderly (ref 31). &lt;/P&gt;
&lt;P&gt;The studies reported some positive outcomes i.e. reduction in stress, improved coping strategies and better social support deriving from a group-based intervention. Increased knowledge about the care-giver’s role, competencies and sense of control were also noted. One further study on support given to carers of elderly people with dementia found that although levels of depression and anxiety did not improve after the intervention, home-visited carers did demonstrate improvements in their quality of life and found their care-giver role less problematic.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Providing opportunities to volunteer&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Numerous programmes have been established since the 1960s that link older volunteers with people who may benefit from their service. However no studies had previously addressed the efficacy of such programmes for either older volunteers or the people with whom they work.&lt;/P&gt;
&lt;P&gt;Meta-analysis provides evidence that interventions which provide opportunities for older people to do voluntary work improves mental health in those who volunteer and also reduces depression in older people who receive services such as visits or peer counselling from an older volunteer. (ref 32).&lt;/P&gt;
&lt;P&gt;The majority of the studies described volunteer programmes which utilised face-to-face or direct helping between the volunteer and the client. The majority of the volunteers in the programmes were white, female or not married. Mean age was 71 years.&lt;/P&gt;
&lt;P&gt;Nearly three-quarters of the older volunteers scored higher on quality of life measures than did their non-volunteer counterparts. Nine of every ten clients ‘counselled’ by older volunteers experienced more improvement on outcome measures such as diminished depression than their average counterpart who did not receive services from an older volunteer.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111329:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111331:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Kinsella K (1996) Demographic aspects in Ebrahim S and Kalache A (eds) Epidemiology in Old Age. London. BMJ Publishing.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Godfrey M (1999) Preventive strategies for older people: mapping the literature on effectiveness and outcomes. Anchor Research.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Department of Health (2001) The &lt;A href="http://www.dh.gov.uk/assetRoot/04/07/12/83/04071283.pdf" target="_blank"&gt;National Service Framework for Older People&lt;/A&gt;. London: Department of Health&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Roberts E, Robinson J and Seymour L (2002) &lt;A href="http://www.kingsfund.org.uk/publications/booksales/index.cfm?fuseaction=products.productDetail&amp;amp;productID=2558" target="_blank"&gt;Old habits die hard:tackling age discrimination in health and social care&lt;/A&gt;. London: Kings Fund&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Hippisley-Cox J, Fielding K and Pringle M (1998) Depression as a risk factor for ischaemic heart disease in men: population based case control study. British Medical Journal 316: 1714-9&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Bosma H, Marmot MG and Hemmingway H (1997) Low job control and risk of coronary heart disease in Whitehall II (prospective cohort) study. &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/314/7080/558" target="_blank"&gt;British Medical Journal&lt;/A&gt; &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/314/7080/558" target="_blank"&gt;314:558&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Jonas BS and Mussolino ME (2000) Symptoms of Depression as a Prospective Risk Factor for Stroke. Psychosomatic Medicine 62(4):463-472.&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Ostir GV, Markides KS, Peek MK and Goodwin JS (2001) The association between emotional well-being and the incidence of stroke in older adults. Psychosomatic Medicine 63:210-215.&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Goodwin JS (2000) Glass half full attitude promotes health in old age. Journal of the American Geriatrics Society 48: 473-478.&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Banerjee S, Shamash K, Alastair J D M Macdonald, and Anthony H Mann (1996) Randomised controlled trial of effect of intervention by psychogeriatric team on depression in frail elderly people at home &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/313/7064/1058" target="_blank"&gt;British Medical Journal&lt;/A&gt; 313: 1058-1061&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Bennett KM (1997) Customary physical activity and gender as precursors for late life personal disturbance British Journal of Clinical Psychology 173: 4-7&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;&lt;A href="http://www.audit-commission.gov.uk/" target="_blank"&gt;Audit Commission&lt;/A&gt; (2000) Forget me not: mental health services for older people Abingdon&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;McCracken CFM, Boneham MA, Copeland JRM, Williams KE, Wilson K, Scott A, McKibbin P and Cleave N (1997) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/171/3/269?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=mccracken&amp;amp;title=prevalence&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1073911772292_1285&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;journalcode=bjprcpsych" target="_blank"&gt;Prevalence of dementia and depression among elderly people in black and ethnic minorities&lt;/A&gt;. British Journal of Psychiatry 171:269-273&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Han H (2000) Depressive symptoms and self-rated health in community dwelling older adults: a longitudinal study Dissertation abstracts international: The Sciences and Engineering 61,4b 1863&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Beck DA and Koenig HG (1996) Minor depression – a review of the literature International Journal of Psychiatry in Medicine 26,2 177-209&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Bruce ML (2001) Depression and disability in late life: directions for future research American Journal of Geriatric Psychiatry 9,2 102-112&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Pearson JL and Brown GK (2000) Suicide prevention in late life: direction for science and practice Clinical Psychology Review 20,6:685-705&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Ciliska D, Hayward S, Thomas H, Mitchell A, Dobbins M, Underwood J, Rafael A and Martin E (1996) A systematic overview of the effectiveness of home visiting as a delivery strategy for public health nursing interventions Canadian Journal of Public Health 87,3 193-198&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Morrow HN, Becker KS and Judy L (1998) Evluating an intervention for the elderly at increased risk of suicide Research on Social Work Practice 8,1 28&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Fiske A and Arbore P (2000) Future directions in late life suicide prevention Omega: Journal of Death and Dying 42,1 37-53&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Dowd JJ (1980) Stratification among the Aged. Monterey, CA:Brooks/Cole&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;Lemon BW, Bengston VL and Peterson JA (1972) An exploration of the ativity theory of aging: activity types and life satisfaction among in-movers to a retirement community. Journal of Gerontology 33:109-125&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;Okun MA, Stock WA, Haring MJ and Witter RA (1984) The social activity/subjective well-being relation:a quantitative synthesis. Research on Aging. 6(1): 45-65.&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp;Cooper H, Arber S, Fee L and Ginn J (1999) The Influence of Social Support and Social Capital on Health. London: Health Education Authority&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;Brugha TS, Wing JK, Brewin CR, MacCarthy B and Lasage A (1993) The relationship of social network deficits in social functioning in long term psychiatric disorders Social Psychiatry and Psychiatric Epidemiology 28:218-224&lt;/P&gt;
&lt;P&gt;26.&amp;nbsp;Cohen S (ed) (1997) Measuring stress: a guide for health and social scientists Oxford University Press, Oxford&lt;/P&gt;
&lt;P&gt;27.&amp;nbsp;Health Development Agency (2002) Pre-retirement health checks and plans: literature review. London: Health Development Agency&lt;/P&gt;
&lt;P&gt;28.&amp;nbsp;Cattan M and White M (1998) &lt;A href="http://www.rhpeo.org/ijhp-articles/1998/13/index.htm" target="_blank"&gt;Developing Evidence Based Health Promotion for Older People: a systematic review and survey of health promotion interventions targeting social isolation and loneliness among older people&lt;/A&gt;. Internet Journal of Health Promotion.&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp;Godfrey M (1999) Preventive strategies for older people: mapping the literature on effectiveness and outcomes. Anchor Research.&lt;/P&gt;
&lt;P&gt;30.&amp;nbsp;Cooke DD, McNally L, Mulligan KT, Harrison MJG and Newman SP (2001) Psychosocial interventions for caregivers of people with dementia: a systematic review. Aging &amp;amp; Mental Health 5 (2): 120-135&lt;/P&gt;
&lt;P&gt;31.&amp;nbsp;Elkan R, Kendrick D, Hewitt M, Robinson JJA, Tolley K, Blair M, Dewey M, Williams D and Brummell K (2000) The effectiveness of domiciliary health visiting: a systematic review of international studies and a selective review of the British literature. Health Technology Assessment. 4 (13)&lt;/P&gt;
&lt;P&gt;32.&amp;nbsp;Wheeler FA, Gorey KM and Greenblatt B (1998) The beneficial effects of volunteering for older volunteers and the people they serve:a meta-analysis. International Journal of Aging and Human Development. 47(1):69-79.&lt;/P&gt;
&lt;P&gt;McClelland KA (1982) Self-conception and life satisfaction: integrating aged subculture and activity theory. Journal of Gerontology 37: 723-732&lt;/P&gt;
&lt;P&gt;Oxman TE et al (1992) Social support and depressive symptoms in the elderly American Journal of Epidemiology 135:356-368&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322817</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=322817]]&gt;</url>
    <title>Launch of a national learning package to support the refocused Care Programme Approach (CPA) in mental health</title>
    <publicationDate>2009-08-13T00:00:00</publicationDate>
    <publisher>The Centre for Clinical and Academic Workforce Innovation</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Launch of a national learning package to support the refocused Care Programme Approach (CPA) in mental health&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The Centre for Clinical and Academic Workforce Innovation (CCAWI) at the University of Lincoln has been commissioned by the Department of Health to produce a learning resource to support the mental health workforce to implement the refocused CPA. The first stage of the project is complete and is available free at &lt;A href="http://www.lincoln.ac.uk/ccawi/CPA.htm" target="_blank"&gt;http://www.lincoln.ac.uk/ccawi/CPA.htm&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;CCAWI is working in partnership with the Care Programme Approach Association (CPAA), the Mental Health Foundation and Linking Voices, a service user and carer organisation based in Lincolnshire. The learning resource promotes a CPA that is fully integrated into everyday practice and is consistent with core values and recent policy initiatives, including best practice guidance in risk management.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;The learning materials are designed for all mental health workers with maximum benefit being achieved through inter-professional and multi-agency learning. The main learning pathway will prepare care co-ordinators and this will incorporate a work based assessment scheme using identified competences.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;The care co-ordinator pathway consists of a trainer’s manual, a trainee’s manual, a work-based assessment scheme, a multi-media DVD of narratives of service users, carers and practitioners to support the programme and an example of a module specification that could be adapted to fit local university regulations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;The resource is designed to be used flexibly according to the needs and resources of organisations and participants. It consists of nine units of learning that stand alone or may be delivered together as a complete programme. The units reflect recent changes to policy and guidance including refocusing the CPA (DH 2008), guidance on risk management (2007) and the personalisation agenda (DH 2008a).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;An additional online learning pathway is being produced to support those who need to know about the CPA but who are not Care Co-ordinators. This will be available in August.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;The next stage of the project is to develop an on-line training needs analysis that directs individuals to the most appropriate learning pathway based on their role, experience and knowledge in relation to the CPA. There will also be a series of roll out stakeholder conferences throughout England from October to December that are designed to support the local implementation of the resource.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;For further information / enquiries email:&amp;nbsp; &lt;A href="mailto:cpa@lincoln.ac.uk" target="_blank"&gt;cpa@lincoln.ac.uk&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381696</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_117832.pdf]]&gt;</url>
    <title>Liberating the NHS: Report on the arms-length bodies review</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,LEARNING DISABILITIES,HEALTH,POLICY,SERVICE SECTORS,OTHER SECTORS,CENTRAL GOVERNMENT,HEALTH AND SOCIAL CARE,MENTAL HEALTH SERVICES,PRIMARY CARE SERVICES,ACUTE SERVICES,MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,HEALTH &amp; WELLBEING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;The Department of Health has conducted a review of its arm’s-length bodies (ALBs)&lt;/P&gt;
&lt;P&gt;The report of the review, which follows the publication of the White Paper, Equity and excellence: Liberating the NHS, sets out our proposals for ALBs in the health and social care sector. These proposals form part of the cross-Government strategy to increase accountability and transparency, and to reduce the number and cost of quangos.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263058</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=43570&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Life's Labours Lost</title>
    <publicationDate>2003-10-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A study of the experiences of people who have lost their occupation following mental health problems. This research is part of the Foundation's Strategies for Living project.</description>
    <body>&lt;![CDATA[ A study of the experiences of people who have lost their occupation following mental health problems. This research is part of the Foundation's Strategies for Living project.]]&gt;</body>
  </document>
  <document>
    <id>317752</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/CR153.pdf]]&gt;</url>
    <title>Links not boundaries: service transitions for people growing older with enduring or relapsing mental illness PDF</title>
    <publicationDate>2009-01-02T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document updates Council Report CR110: &lt;EM&gt;Caring for People who enter Old Age with Enduring or Relapsing Mental Illness (‘Graduates’)&lt;/EM&gt;. It has been produced by a working party including representatives from the Faculties of Old Age Psychiatry, General and Community Psychiatry, and Rehabilitation Psychiatry, from the Faculty of Old Age Psychiatry Consumer Group and a Mental Health Nurse. 
&lt;P class=MsoNormal&gt;The Report makes a series of recommendations aimed at improving the care of people who are growing old with enduring or relapsing mental illness and who face the possibility of moving between psychiatric services, most commonly from general and community (or rehabilitation) psychiatry to the psychiatry of old age.&lt;/P&gt;
&lt;P class=MsoNormal&gt;The recommendations fall into six main areas:&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=ListParagraphCxSpFirst&gt;The use of transition protocols&lt;/LI&gt;
&lt;LI class=ListParagraphCxSpMiddle&gt;Assessment&lt;/LI&gt;
&lt;LI class=ListParagraphCxSpMiddle&gt;The process of transition&lt;/LI&gt;
&lt;LI class=ListParagraphCxSpMiddle&gt;The care plan&lt;/LI&gt;
&lt;LI class=ListParagraphCxSpMiddle&gt;Monitoring&lt;/LI&gt;
&lt;LI class=ListParagraphCxSpLast&gt;Commissioning&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;Making the transition between services can be a difficult and worrying time for users and their families. Organisations are advised to consider these recommendations, which have been produced after wide debate to which many people have contributed, and to review their policies and procedures in order to try to improve the experiences of families using their service.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>269072</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealth.org.uk/EasysiteWeb/getresource.axd?AssetID=49331&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Listen Up! Report - Person-centred approaches to help young people experiencing mental health and emotional problems</title>
    <publicationDate>2007-09-13T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,PATIENT AND PUBLIC INVOLVEMENT,YOUNG PEOPLE,HOW DO I INVOLVE...?,PEOPLE WITH MENTAL HEALTH ISSUES,CHILD AND ADOLESCENT CONDITIONS,OUTCOMES,EDUCATION,EDUCATION,MENTAL &amp; BEHAVIOURAL DISORDERS,CARERS,VOLUNTARY ORGANISATIONS,CHILDREN,YOUNG PEOPLE,EDUCATIONAL SETTINGS,SERVICE PROVISION,HEALTH MANAGEMENT,SERVICE DELIVERY,MENTAL HEALTH SERVICES,COMMISSIONING,NHS ACTIVITIES,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,CARE,HEALTH SERVICES,PROFESSIONAL PRACTICE,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES,GROUPS,ORGANISATIONS,POPULATIONS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Listen Up! makes the case for fundamental change in the basic service model for young people. It calls on commissioners to designate a lead agency and person to co-ordinate the commissioning of services for young people aged 16-25.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Listen Up! makes the case for fundamental change in the basic service model for young people. It calls on commissioners to designate a lead agency and person to co-ordinate the commissioning of services for young people aged 16-25.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;It also calls for the provision of long-term funding to voluntary sector organisations, and for statutory youth mental health services in general to learn from the voluntary sector’s example of person-centred provision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The report is primarily aimed at those who commission and fund services for children and young people, as well as those working within the voluntary and community sectors and statutory sector who are setting up or developing services for young people with mental health and emotional problems.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mentalhealth.org.uk/our-work/service-development/cyp/listen-up/" target="_blank"&gt;See also the Listen Up! Webpage for more information about the project.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263060</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38741&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Listening to Children</title>
    <publicationDate>1998-07-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>By Clare Armstrong, Malcolm Hill &amp; Jenny Secker. Centre for the Child &amp; Society, University of Glasgow.</description>
    <body>&lt;![CDATA[ Report of a study undertaken by the Centre for Child and Society at the University of Glasgow to evaluate children’s understanding of mental health and mental illness, examines and assesses language and attitudes, as well as perceptions of professionals and seeking help.]]&gt;</body>
  </document>
  <document>
    <id>378348</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/OP75.pdf]]&gt;</url>
    <title>Looking Ahead: Future Development of UK Mental Health Services</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,INNOVATION AND IMPROVEMENT,CHANGE MANAGEMENT,ENGAGEMENT,ORGANISATIONS,LEADING IMPROVEMENT,SERVICE REDESIGN,PERSONALISATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=mainContent&gt;
&lt;P class=A1&gt;This report is being launched at the College's International Congress (June 2010) where hard copies will be available.&amp;nbsp; Otherwise, for the present, this document is available online only.&lt;/P&gt;
&lt;P class=A1&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=A1&gt;&lt;STRONG&gt;Recommendations from a Royal College of Psychiatrists’ enquiry.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=A1&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa10&gt;In the 60 years of the National Health Service (NHS) there has probably never been unanimity of view on the design of mental health services. Every generation has brought its priorities, trends and pendulum swings; every crisis has brought its reactions – and sometimes its overreactions. The College identified that there exists not only a need, but also an opportunity, for service redesign in mental health.&lt;/P&gt;
&lt;P class=Default&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa11&gt;This report draws on evidence given during hearings held in February 2010, a number of written responses submitted to the enquiry’s evidence committee, and presentations delivered at a one-day seminar held in March 2010. Although exhaustive neither in its scope nor in the breadth of those from whom it sought evidence, the enquiry nevertheless represents a serious effort to consider service redesign in mental healthcare and to give voice to the people who work at the heart of our mental health services. The document aims to identify areas for future service development that reflect the needs and aspirations of users of mental health services, those who care for them and also the people who deliver those services.&lt;/P&gt;
&lt;P class=Pa11&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa11&gt;The document is a distillation of the views of a broad church, comprising more than 50 psychiatrists, psychologists, nurses, occupational therapists, social workers, commissioners, trust chief executives, academics, health economists, voluntary sector organisation chief executives, service users, carers, medical directors and national mental health programme leads.&lt;/P&gt;
&lt;P class=A1&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=A1&gt;&lt;STRONG&gt;The report then examines the following topics, giving recommendations on each:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=Pa9&gt;Creating efficiencies and improving productivity through redesigned services and care pathways&lt;/LI&gt;
&lt;LI class=Pa9&gt;Consultant expertise at the beginning of the pathway&lt;/LI&gt;
&lt;LI class=Pa9&gt;Standardised outcomes&lt;/LI&gt;
&lt;LI class=Pa9&gt;Investing to save through the development of family mental healthcare&lt;/LI&gt;
&lt;LI class=Pa9&gt;Out-of-area treatments&lt;/LI&gt;
&lt;LI class=Pa9&gt;Mental health of older people&lt;/LI&gt;
&lt;LI class=Pa9&gt;In-patient care&lt;/LI&gt;
&lt;LI class=Pa9&gt;Statutory and voluntary sector partnerships&lt;/LI&gt;
&lt;LI class=Pa9&gt;Housing&lt;/LI&gt;
&lt;LI class=Pa9&gt;Employment and mental health&lt;/LI&gt;
&lt;LI class=Pa9&gt;Substance misuse&lt;/LI&gt;
&lt;LI class=Pa9&gt;Relationship between physical and mental health&lt;/LI&gt;
&lt;LI class=Pa9&gt;Psychological therapies&lt;/LI&gt;
&lt;LI class=Pa9&gt;Peer support&lt;/LI&gt;&lt;/UL&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>317738</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.justice.gov.uk/publications/docs/bradley-mental-health-cjs-gov-response-grid.pdf]]&gt;</url>
    <title>Lord Bradley report on people with mental health problems or learning disabilities in the Criminal justice system: a government response PDF</title>
    <publicationDate>2009-04-30T00:00:00</publicationDate>
    <publisher>Ministry of Justice</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DISABILITIES,LEARNING DISABILITIES,PUBLIC HEALTH,BUILDINGS,PRISONS,MONTHLY ADDITIONS,SETTINGS,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In December 2007 the&amp;nbsp;Lord Chancellor and&amp;nbsp;Secretary of State for Justice, Jack Straw, invited Lord Keith Bradley to lead an independent inquiry into diversion of offenders with mental health problems or learning disabilities away from prison into other more appropriate services.&lt;/P&gt;
&lt;P&gt;Lord Bradley's&amp;nbsp;report has been welcomed by ministers across government, including Department of Health, Ministry of Justice, Home Office and Department for Children, Schools and Families, who recognise the need for reform in this area and the necessity for more joined up services to strengthen capacity and take forward this work.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263061</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38748&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>'Lost and Locked In': Patients' Perspectives on Leave udner Section 37/41</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This research study focused on leave for patients in a secure setting detained under a section 37/41 of the Mental Health Act 1983- a Home Office order under which patients are severely restricted in the amount and type of leave from hospital they are entitled to.</description>
    <body>&lt;![CDATA[ This research study focused on leave for patients in a secure setting detained under a section 37/41 of the Mental Health Act 1983- a Home Office order under which patients are severely restricted in the amount and type of leave from hospital they are entitled to. It aimed to find out how patients understand the system of gaining leave, how they feel about this system and what they see as the benefits and disadvantages of having leave.]]&gt;</body>
  </document>
  <document>
    <id>274299</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhsconfed.org/issues/publications.cfm]]&gt;</url>
    <title>Maintaining the momentum towards excellent services for children and young people's mental health</title>
    <publicationDate>2007-11-09T00:00:00</publicationDate>
    <publisher>The NHS Confederation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Aims to raise awareness among board members about the challenges facing child and adolescent mental health services.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;This report aims to:&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;raise awareness amongst the board members of both commissioning and providing organisations about the challenges facing child and adolescent mental health services (CAMHS), and to highlight the present window of opportunity for leaders to respond to these challenges 
&lt;LI&gt;illustrate the long-term benefits of comprehensively meeting the mental health needs of children and young people, both to the individuals and families concerned, and to public services and the economy as a whole over that individual’s lifetime 
&lt;LI&gt;show both commissioners and providers what they can actively do, under existing governance arrangements, to ensure that the recent momentum of progress in CAMHS is not lost, and that their area builds upon these foundations.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>111308</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111308]]&gt;</url>
    <title>Making connections:related policy</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Making connections:related policy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111325:1" name=internalLink&gt;previous&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;Making connections: Early years, children, families and parenting&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Early Years Development and Childcare Partnerships&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;These partnerships are locality based agencies which aim to make links between all local organisations, companies and individuals to promote positive childcare facilities. They link childminders, play-schools, day nurseries and nursery placements. The Early Years and Childcare Development Partnerships are responsible for drafting the Early Years and Childcare Development Plans and they work with Sure Start Programmes and Early Excellence Centres where available. &lt;A href="http://www.dfes.gov.uk/eydcp" target="_blank"&gt;www.dfes.gov.uk/eydcp&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sure Start&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Sure Start aims to improve the health and well-being of families and children before and from birth, so children are ready to flourish when they go to school – by:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;setting up local Sure Start programmes to improve services for families with children under four and&lt;/LI&gt;
&lt;LI&gt;spreading good practice learned from local programmes to everyone involved in providing services for young children.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Sure Start programmes work with parents-to-be, parents and children to promote the physical, intellectual and social development of babies and young children. They are particularly centred initially on disadvantaged children or children living in disadvantaged areas. Each Sure Start programme is different, as they are designed to meet local needs. There are now 342 Sure Start programmes running in disadvantaged areas, and by 2004, there will be 500 active Sure Start programmes.www.surestart.gov.uk&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Children’s Fund&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Children's Fund aims to tackle child poverty and social exclusion. The Fund will support services to identify children and young people (5-13 years) who are showing early signs of disturbance and provide them and their families with the support they need. The fund will be rolled out nationally and by 2003/4 funding will be available in all areas of England. The Children’s Fund Local Network will work with local communities to improve the lives of the most vulnerable children. The Fund aims to build a bridge for consistent provision between Sure Start and Connexions.www.cypu.gov.uk&lt;/P&gt;
&lt;H2&gt;Making connections: young people and schools&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Connexions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Connexions aims to ensure success through learning and a smooth transition to adulthood and working life for every young person. Working alongside its partners, Connexions must provide teenagers with (or connect them to) the support they need to benefit fully from formal and informal learning. This may involve tackling barriers to learning, advice on career and learning goals. Connexions will be delivered through Connexions Partnerships working with a network of Personal Advisers locally. Partnerships will include schools, colleges of further education, local authorities, careers services, Training and Enterprise Councils (TECs), youth services, social services, and the voluntary sector. &lt;A href="http://www.connexions.gov.uk/" target="_blank"&gt;www.connexions.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Healthy Schools Programme&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Healthy Schools Programme is a key part of the Government’s drive to improve standards of health and education and to tackle health inequalities. Its aim is to make children, teachers, parents and communities more aware of the opportunities that exist in schools for improving health. Emotional health and wellbeing is one key area which schools participating in the Healthy Schools Standard can concentrate on. &lt;A href="http://www.wiredforhealth.gov.uk/" target="_blank"&gt;www.wiredforhealth.gov.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;There is also a new PSHE (Personal, Social and Health Education) website area on TeacherNet is a dedicated learning and development resource for teachers of PSHE and Citizenship - &lt;A href="http://www.teachernet.gov.uk/pshe" target="_blank"&gt;www.teachernet.gov.uk/pshe&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Excellence in Cities – Learning Support Units and Learning Mentors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Excellence in Cities recognises the special characteristics of city schools and includes Excellence Clusters and Excellence Challenge. It sets out a package of measures to build on existing policies to raise standards in city schools focusing on the needs of individual pupils. There are 6 key strands: extended opportunities for gifted and talented pupils, learning mentors for all pupils who need them; learning support units; a network of new city learning centres; more Beacon and specialist schools; and EiC Action Zones. &lt;A href="http://www.dfes.gov.uk/" target="_blank"&gt;www.dfes.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Millennium Volunteering&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Millennium volunteering is a national initiative to encourage young people (aged 16-25 years) to get involved in their local community and to make a sustained commitment to volunteering. Recognition is given through awards. &lt;A href="http://www.mvonline.gov.uk/" target="_blank"&gt;www.mvonline.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Emotional Behavioural Disorders&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Guidance on the management of and support for children with emotional behavioural disorders has emerged from the Department for Education and Skills. The Department has established an internal programme to improve behaviour within schools, a large element of which involves the promotion of mental health in schools, both primary and secondary. It builds on the guidance published in 2001 and is planned to run for three years. (&lt;A href="http://www.dfes.gov.uk/" target="_blank"&gt;www.dfes.gov.uk&lt;/A&gt;)&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Making connections: workplace&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;New Deal Schemes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There are a number of New Deal schemes in place to help particular groups back to work including New Deal for Lone Parents, New Deal for Partners, New Deal for Young People, New Deal for People Aged 25+, New Deal for Older People and New Deal for Disabled People. New Deal is part of the Government’s Welfare to Work programme. The schemes provide individual tailored help and support, with personal advisers who review individual’s job plans, circumstances, benefits, training and help them back into the job market. &lt;A href="http://www.newdeal.gov.uk/" target="_blank"&gt;www.newdeal.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Work-Life Balance&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Work-Life Balance scheme is run by the DTI. It aims to engage employers and employees to identify flexible approaches to work and additional responsibilities such as caring for children or older people or contributing to the local community. The guidance outlines the impact that a poor work-life balance can have on mental health, through increased stress and unease. The Work-Life Balance Challenge Fund provides consultatncy advice and support to employers. &lt;A href="http://www.dti.gov.uk/work-lifebalance" target="_blank"&gt;www.dti.gov.uk/work-lifebalance&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Working Together&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Working Together – Securing a Quality Workforce for the NHS is the first human resources framework for the NHS. It outlines plans for the recruitment and retention of an effective workforce with the diversity, skills and capacity to deliver a quality NHS service. It reiterates the Government's commitment to equality of opportunity by setting a number of priority areas for local action, including equality in the workplace and achieving a more representative workforce.&lt;/P&gt;
&lt;P&gt;Investment and Reform for NHS Staff: Taking forward the NHS Plan sets out how workforce issues will be addressed to deliver the NHS Plan.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Improving Working Lives&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Improving Working Lives Standard sets a model of good HR practice against which NHS Employers and their staff can measure the organisation's HR management and against which NHS employers will be kite-marked. NHS organisations will be required to achieve accreditation against the Standard by April 2003, demonstrating they are improving the working lives of staff.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Vital Connection&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Vital Connection is the Equalities Framework for the NHS, launched in 2000. It introduces a package of indicators, standards and monitoring arrangements on disability, tackling harassment and achieving a representative workforce and broad training on equality and diversity. It commits the NHS to deliver the Government’s commitments on equality and social inclusion.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Looking Beyond Labels&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Looking Beyond Labels is a Department of Health led campaign to promote positive working opportunities for people with disabilities, including people with mental health problems, in the NHS. It has been implemented to support the NHS meeting the requirements of the Disability Discrimination Act.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Mental Health and Employment in the NHS (2002)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Mental Health and Employment in the NHS provides guidance and advice to NHS employers on the retention and future employment of people who have experienced or are experiencing mental health problems. The guidance endorses best practice in terms of adherence to relevant policies such as the Disability Discrimination Act, recruitment, retention, pre-employment health assessments, occupational health, human resources practice and the development of an appropriate culture for mental health workforce.&lt;/P&gt;
&lt;H2&gt;Making connections: related policy initiatives&lt;/H2&gt;
&lt;H2&gt;Local authorities&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Modernisation of Local Government&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A wide range of initiatives which form part of the government’s programme of constitutional reform and democratic renewal are relevant to mental health promotion. Neighbourhood renewal, urban regeneration, sustainable development and improving the quality of life of communities are linked by underpinning aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;develop new roles for local authorities as community leaders&lt;/LI&gt;
&lt;LI&gt;promote the economic, social and environmental well being of an area and the local community&lt;/LI&gt;
&lt;LI&gt;improve involvement and consultation locally&lt;/LI&gt;
&lt;LI&gt;develop a vision and a plan for the local area with the local community&lt;/LI&gt;
&lt;LI&gt;develop and deliver services that enhance well being and quality of life.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Social Exclusion Unit&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Social Exclusion Unit was set up to reduce social exclusion by producing ‘joined-up solutions to joined-up problems’. The Unit defines social exclusion as what can happen when people or areas suffer from a combination of linked problems such as unemployment, poor skills, low incomes, poor housing, high crime environments, bad health and family breakdown. The Unit announced their Mental Health and Social Exclusion programme in March 2003 to address the barriers to opportunity faced by adults with mental health problems. A national consultation addressed two questions:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;what more can be done to enable more adults with mental health problems to enter and retain work&lt;/LI&gt;
&lt;LI&gt;what more can be done to ensure that adults with mental health problems have the same opportunities for social participation and access to services as the general population&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Further information can be found on &lt;A href="http://www.socialexclusionunit.gov.uk/" target="_blank"&gt;www.socialexclusionunit.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Neighbourhood Renewal and Urban Regeneration&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The aim of neighbourhood renewal is to improve people’s lives in the most deprived areas by lifting standards of employment, educational attainment, housing and health and lowering crime rates. This approach to regeneration aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;attack the core problems of deprived areas, like weak economies and poor schools;&lt;/LI&gt;
&lt;LI&gt;harness the power of all sectors to work in partnership;&lt;/LI&gt;
&lt;LI&gt;focus existing services and resources explicitly on deprived areas; and&lt;/LI&gt;
&lt;LI&gt;gives local residents and community groups a central role in turning their neighbourhoods around.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The National Renewal Unit is responsible for:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;monitoring and supporting mainstream services to focus on deprivation&lt;/LI&gt;
&lt;LI&gt;managing the national neighbourhood renewal fund and the NDC fund&lt;/LI&gt;
&lt;LI&gt;fostering the development of effective strategies through local strategic partnerships that provide leadership&lt;/LI&gt;
&lt;LI&gt;developing community capacity to encourage community self-help and&lt;/LI&gt;
&lt;LI&gt;leading and mobilising participation by the voluntary and business sectors.&lt;BR&gt;&lt;A href="http://www.neighbourhood.gov.uk/" target="_blank"&gt;www.neighbourhood.gov.uk&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;New Deal for Communities&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;New Deal for Communities aims to tackle multiple deprivation in the most deprived neighbourhoods. Programmes will be delivered through partnerships formed by local people, community and voluntary organisations, public agencies, local authorities and business. Programmes will tackle the routes of social exclusion and will need to address five key areas: unemployment, improving health, tackling crime, raising educational achievement and improving housing and the physical environment &lt;A href="http://www.neighbourhood.gov.uk/" target="_blank"&gt;www.neighbourhood.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Community Strategies and Local Strategic Partnerships&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Local Government Act 2000 set out the context for community leadership and local strategic partnerships, covering a broad new requirement to improve economic, social and environmental well being and a duty to prepare a community strategy. The Local Strategic Partnership is a body of stakeholders who will develop ways to involve local people in shaping the future of their neighbourhood and in how services are provided.&lt;/P&gt;
&lt;P&gt;The Local Strategic Partnership will:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;deliver community strategies&lt;/LI&gt;
&lt;LI&gt;bring together plans, partnerships and initiatives for mainstream public service providers&lt;/LI&gt;
&lt;LI&gt;work with local authorities to develop local public service agreements (including targets on tackling deprivation)&lt;/LI&gt;
&lt;LI&gt;develop and deliver local neighbourhood renewal strategies.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The community strategies must connect with the local communities and demonstrate clear and co-ordinated partnership working with all the bodies that provide local services, as well as local authority leadership. &lt;A href="http://www.neighbourhood.gov.uk/partnerships" target="_blank"&gt;www.neighbourhood.gov.uk/partnerships&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Best Value and Local Public Service Agreements&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Best Value is an assessment of the services and information provided by Local Authorities to local communities. The statutory duty aims to improve services and their quality through regular monitoring and reporting encouraging good practice and sharing between authorities and supporting a closer engagement between local government and local people. The national standards frameworks also link to Local Public Service Agreements.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Quality of Life&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Quality of life indicators are voluntary. They are designed to help local authorities and their partners in Local Strategic Partnerships (LSPs) to monitor their community strategies. They cover three broad areas of economic, social and environmental well being and are intended to complement best value performance indicators (BVPIs).&lt;BR&gt;The quality of life indicators can be used to :&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Identify key objectives within community strategies&lt;/LI&gt;
&lt;LI&gt;Monitor progress against those objectives and local priorities set within community strategies&lt;/LI&gt;
&lt;LI&gt;Foster partnerships working across all agencies involved in local areas&lt;/LI&gt;
&lt;LI&gt;Facilitate comparisons between different areas&lt;/LI&gt;
&lt;LI&gt;Paint a picture of and monitor changes to the quality of life in a local area &lt;BR&gt;&lt;A href="http://www.audit-commission.gov.uk/" target="_blank"&gt;www.audit-commission.gov.uk&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sustainable Development&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Sustainable development is about ensuring a better quality of life for everyone. A new scheme launched in early 2003 - Sustainable Communities: Building for the future - sets out a long-term programme of action for delivering sustainable communities in both urban and rural areas. Among other things the report addresses the quality of public spaces. &lt;A href="http://www.odpm.gov.uk/" target="_blank"&gt;www.odpm.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111325:1" name=internalLink&gt;previous&lt;/A&gt;&amp;gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>260391</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=138280&amp;Rendition=Web]]&gt;</url>
    <title>Making decisions: The Independent Mental Capacity Advocate (IMCA) Service</title>
    <publicationDate>2007-05-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Helping people who are unable to make some decisions for themselves. There is a new law that can help - The Mental Capacity Act 2005.</description>
    <body>&lt;![CDATA[ This booklet is one of a series of six on the Mental Capacity Act published by the Mental Capacity Implementation Programme (MCIP). MCIP is a joint government programme between the Department of Health, the Department for Constitutional Affairs, the Public Guardianship Office and the Welsh Assembly Government that has been established to implement the organisation, process and procedures to launch the Mental Capacity Act in 2007. This booklet provides information on the Independent Mental Capacity Advocate (IMCA) service established by the Mental Capacity Act. It is not a statutory Code of Practice issued under the Mental Capacity Act 2005 and is not a guide to how the law will apply to specific situations.]]&gt;</body>
  </document>
  <document>
    <id>282206</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/Making_recovery_a_reality_policy_paper.pdf]]&gt;</url>
    <title>Making Recovery a Reality</title>
    <publicationDate>2008-03-17T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This paper looks at the principles of recovery, the skills required and obstacles to implementing recovery-orientated practice.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;This paper looks at the principles of recovery, the skills required and obstacles to implementing recovery-orientated practice.&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mental health services need to change radically to focus on recovery. They need to demonstrate success in helping service users to get their lives back and giving service users the chance to make their own decisions about how they live their lives.&lt;/P&gt;
&lt;P&gt;Recovery turns mental health services' priorities on their heads. Traditional services wait until a person's illness is cured before helping them to get their life back. Recovery-focused services aim from day one to help people to build a life for themselves. The medical care they give is in support of that bigger purpose.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;]]&gt;</body>
  </document>
  <document>
    <id>328792</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/101]]&gt;</url>
    <title>Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In this issue of &lt;I&gt;Evidence-Based Mental Health&lt;/I&gt;, Gartlehner and&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Gaynes&lt;SUP&gt;&lt;FONT size=2&gt;1&lt;/FONT&gt;&lt;/SUP&gt; comment &lt;B&gt;&lt;I&gt;(see page 98)&lt;/I&gt;&lt;/B&gt; on our recently published systematic&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;review&lt;SUP&gt;&lt;FONT size=2&gt;2&lt;/FONT&gt;&lt;/SUP&gt; that investigated the comparative efficacy and acceptability&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of 12 new generation antidepressants &lt;B&gt;&lt;I&gt;(see page 107)&lt;/I&gt;&lt;/B&gt;. In their&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;view, methodological shortcomings limit the validity of our&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;results and the conclusions reached. In this commentary, our&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;aim is to explain the rationale for doing this systematic review,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;outline its main findings and address the points raised by Gartlehner&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and Gaynes.&lt;SUP&gt;&lt;FONT size=2&gt;1&lt;/FONT&gt;&lt;/SUP&gt; Scientific debate can illuminate and clarify complex&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;analyses and we are, therefore, delighted to respond to their&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;critique. While we consider that some of the issues raised are&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;substantive and merit reasoned response, we also believe that&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;some of their criticisms seem rather overstated. We understand&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;that Gartlehner and Gaynes too have published an analysis comparing&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;antidepressants and we note that this is now the third &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;[&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/101" target="_blank"&gt;Full text of this article&lt;/A&gt;]&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263062</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40132&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Making the link between mental health and youth homelessness</title>
    <publicationDate>2006-07-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH,OUTCOMES,YOUNG PEOPLE,CHILDREN,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,NHS ACTIVITIES,COMMISSIONING,MENTAL HEALTH SERVICES,SERVICE DELIVERY,HEALTH MANAGEMENT,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,SOCIOECONOMIC FACTORS,SOCIETY,HEALTHCARE &amp; HEALTH SERVICES,SERVICES,PUBLIC SERVICES,CARE,HEALTH SERVICES,GOVERNMENT &amp; LAW,AGE GROUPS,POPULATIONS,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report calls for joined up commissioning of integrated services across sectors, to speed up access to specialist mental health and drug and alcohol services when needed by young people.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Increasing numbers of young homeless people with mental health problems are not getting adequate support because services rarely work together to provide the necessary help. This report calls for joined up commissioning of integrated services across sectors, to speed up access to specialist mental health and drug and alcohol services when needed by young people.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38621&amp;amp;type=Full&amp;amp;servicetype=Attachment" target="_blank"&gt;Mental Health Needs of Homeless Young People&lt;/A&gt; (Link to full-text PDF)&lt;/P&gt;
&lt;P&gt;This report draws on current research into young homeless people as a specific subset of the homeless population. It examines their mental health needs and discusses approaches to meeting those needs. The basic premise of the review is that insecure accommodation is injurious to both mental and physical health. Improved accommodation options will result in better health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259577</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/professionals/AcuteRisk.shtml]]&gt;</url>
    <title>Management of Acute Medical Risk and Refeeding in Anorexia Nervosa</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ In-patient treatment in a specialised unit skilled in refeeding should be considered if the person with anorexia nervosa falls into the high, acute risk category. Information for General Practitioners.]]&gt;</body>
  </document>
  <document>
    <id>287526</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.aomrc.org.uk/aomrc/admin/reports/docs/MHdoc.pdf]]&gt;</url>
    <title>Managing Urgent Mental Health Needs in the Acute Trust: A guide by practitioners, for managers and commissioners in England and Wales</title>
    <publicationDate>2008-05-30T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide from the Academy of Medical Royal Colleges.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Executive summary&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The current provision of mental health services to people attending the Emergency Department of General hospitals or those admitted to medical and surgical wards are extremely variable across the country. Yet, these departments have high levels of activity and encounter some of the most seriously ill people at greatest risk. This situation is unacceptable.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There has been no incentive to commission or develop services in these areas as it does not feature on the ‘must do’ agenda for mental health or acute services. On the contrary, and for the same reason, the services that do exist have been under considerable threat during times of recent change in the NHS. This situation must be addressed as it is not in the best interests of an NHS ambitious to be more effective and efficient. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Good management of mental health problems can make a significant contribution to the effectiveness and efficiency of acute hospitals and improve the outcome for patients.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There is an urgent need to develop national standards that inform the commissioning of services, thereby guaranteeing that people in need receive prompt assessment and management by appropriately trained professionals. These professionals will need dedicated time to fulfil these responsibilities and will have expertise working in General hospitals. The existing specialty of liaison psychiatry is best placed to form the basis of this development.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317669</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mdf.org.uk/index.aspx?o=113688]]&gt;</url>
    <title>Manic Depression - bipolar disorder</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>MDF The BiPolar Organisation (England)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ General description of the condition, describing symptoms of depression and elation, treatments, and the types of help available.]]&gt;</body>
  </document>
  <document>
    <id>317668</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mdf.org.uk/index.aspx?o=113921]]&gt;</url>
    <title>Manic Depression - Information for family and friends PDF</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>MDF The BiPolar Organisation (England)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A comprehensive guide for those who have to cope with manic depression in a relative or friend.]]&gt;</body>
  </document>
  <document>
    <id>111332</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111332]]&gt;</url>
    <title>Marginalised groups - black and minority ethnic groups</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,DISEASES AND CONDITIONS,MENTAL HEALTH,ETHNICITY AND HEALTH,MENTAL HEALTH,ENVIRONMENTAL,OUTCOMES,EDUCATION,MENTAL &amp; BEHAVIOURAL DISORDERS,ETHNIC GROUPS,DETERMINANTS,PUBLIC HEALTH,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,INFORMATION,MANAGEMENT &amp; POLICY,GROUPS,CULTURAL IDENTITY,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Marginalised groups - black and minority ethnic groups&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111331:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111333:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Mental health promotion can play a key role in promoting a wide range of health and social benefits for people from black and minority ethnic communities, for example more accessible services, increased employment opportunities, more social inclusion. They are amongst the most socially excluded people in society, being more likely than others to live in deprived neighbourhoods, be poor, be unemployed, experience ill health, and live in overcrowded and unpopular housing. People from black and minority ethnic communities experience the added jeopardy of widespread racial harassment and racist crime that also impacts on their mental health and well being.&lt;/P&gt;
&lt;P&gt;There is immense diversity within each community and each individual within an ethnic group is unique and different, with individual differences sometimes outweighing group differences in extent and importance (ref 1). Individual experiences may sometimes be over simplified, or assumptions wrongly made that people have similar views, experiences or needs because they belong to a particular black or minority ethnic group.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Evidence based priorities:&lt;/H2&gt;
&lt;P&gt;Tackling racism is likely to be the most effective route to improving the mental health of Black and Minority Ethnic groups. Cumulative exposure to racism and racial discrimination is a key risk factor for mental health problems, notably for depression and is particularly damaging for people who are already vulnerable, such as mental health service users (ref 2).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Racism affects mental well being in two main ways:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;It contributes to mental distress and can lead to feelings of isolation, fear, intimidation, low self-esteem and anger. Depression may be caused by feelings of rejection, loss, helplessness, hopelessness and an inability to have control over external forces. (ref 3, 4). Research has found that many black people regard racism and its effects as a major contributing factor to the prevalence of mental health problems. (ref 5 Alexander 1999)&lt;/LI&gt;
&lt;LI&gt;It can act as a barrier to the access and provision of appropriate services. Black and minority ethnic groups may feel excluded from services because of direct discrimination, for example the attitudes of staff towards them, or through indirect discrimination such as being unable to access services because of language barriers. Racial harassment of staff and patients by staff and patients is a widespread problem in the NHS (ref 6 , 7),&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Mental illness prevalence data varies considerably for different populations and between migrants and those born in the UK. Prevalence variation may reflect:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;different patterns of help-seeking&lt;/LI&gt;
&lt;LI&gt;over-diagnosis&lt;/LI&gt;
&lt;LI&gt;mis-diagnosis&lt;/LI&gt;
&lt;LI&gt;failure to identify psychological problems&lt;/LI&gt;
&lt;LI&gt;racism within mental health services&lt;/LI&gt;
&lt;LI&gt;lack of culturally appropriate services&lt;/LI&gt;
&lt;LI&gt;socio-economic factors e.g. deprivation, unemployment and the impact of racism.&lt;BR&gt;(ref 8 , 9)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;A study in Camberwell, South London, based on contact with psychiatric services over a ten year period, found that the incidence of schizophrenia in non-white ethnic minorities increased significantly as the proportion of such minorities in the local population fell (ref 10, 11).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Mental health services&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Although mental health services have received more attention than mental health promotion, ongoing concerns about appropriate, accessible and culturally sensitive services are relevant to mental health promotion because of the impact of poor services on the mental health of those who use them, their carers and the wider community. Some of these issues are addressed in two publications by the Sainsbury Centre for Mental Health: Cultural Sensitivity Proforma (in draft) and Breaking the Circles of Fear (2002) both available via &lt;A href="http://www.scmh.org.uk/" target="_blank"&gt;www.scmh.org.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;During 2003 the Government published Inside Outside: Improving Mental Health Services for Black and Minority Ethnic Communities in England (ref 12). There had previously been no national strategy or policy specifically intended to improve the mental health of minority ethnic groups or the care and treatment they receive from mental health services. Inside Outside is the first step and anticipates a National Plan for Ethnicity and Mental Health as part of the Government’s Modernisation Programme. Inside Outside sets out three overarching strategic objectives:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;reducing and eliminating ethnic inequalities in mental health service experience and outcome&lt;/LI&gt;
&lt;LI&gt;developing a Mental Health Workforce that is capable of delivering effective mental health services in a multicultural context&lt;/LI&gt;
&lt;LI&gt;enhancing and building on the capacity within black and minority ethnic communities and in the voluntary sector for dealing with mental health and mental ill health.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Black and Minority Ethnic Groups – summary of the evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is a very limited evidence base on the effectiveness of mental health promotion among black and minority ethnic communities in the UK. Mental health promotion recognises that often the process of promotion is as important as the outcome itself. Therefore mental health promotion practice should be inclusive, it should value diversity, support appropriate methods of consultation, development and evaluation with all members of the local community.&lt;/P&gt;
&lt;P&gt;Promoting mental health for different Black and Minority Ethnic groups raises a number of complex issues. There are well-documented cultural differences in the way in which psychological distress is presented, perceived and interpreted, and different cultures may develop different responses for coping with psychological stressors (ref 13). Differences in case finding methods may also account for differences in diagnosis (ref 14).&lt;/P&gt;
&lt;P&gt;The evidence base on risk and protective factors for mental health and mental illness is largely drawn from research on White European or North American populations. Mental health promotion interventions which emphasise individualism may not be appropriate for all cultures and belief systems.&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Holistic community services&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Needs assessment with Black and Minority Ethnic communities has frequently demonstrated a strong demand for services which offer a holistic approach, promote greater community involvement in decision making and recognise the impact of racism on people’s experiences of everyday life (ref 5)&lt;/P&gt;
&lt;P&gt;For African and Caribbean young men, priorities include building partnerships involving arts, creativity, spirituality and alternative therapies, and integrating these with education, training and employment opportunities, to form the basis of a holistic approach. (ref 15).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Support networks/ self help&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;People with a small support group (3 people or less) are at greatest risk of mental health problems (ref 16). Social support reduces death rates, susceptibility to infection and depression, notably in older people (ref 17, 18).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Spirituality&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;People from black and minority ethnic communities in the UK are more likely than the white majority to be practising their religious faith. In one study a higher proportion of African Caribbean people affirmed a religious (predominantly Christian) belief than that of the white population or other minority ethnic communities (ref 19). South Asian women, have also been identified as using prayer as a major coping strategy for depression (ref 20).&lt;/P&gt;
&lt;P&gt;Research has shown that religious involvement is associated with positive mental health outcomes (ref 21). A growing number of studies also emphasise the importance of spiritual beliefs and the value of support from faith communities for people with mental health problems (ref 19, 22). Other studies have found a resistance to spiritual issues within mental health services, where religious beliefs are sometimes interpreted as symptoms of illness (ref 23-25).&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Refugees and Asylum seekers&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Reducing isolation and dependence, locating suitable accommodation and promoting opportunities for work and education should underpin mental health promotion strategies for refugees and asylum seekers. Building partnerships to address hostility and racism is also crucial. In a study of Iraqui asylum seekers, depression was more closely linked with poor social support than with a history of torture (ref 26). Burnett and Peel, (ref 27) in a review of the issues, identify support for people within their own communities and opportunities for developing links and friendships with the host community as crucial to promoting health and well-being.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Alcohol and substance misuse&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Substance misuse is a significant risk factor for mental health problems. Strategies to tackle this should take account of the fact that choice and pattern of substance use is heavily influenced by religious, cultural and historical factors (ref 28).&lt;/P&gt;
&lt;P&gt;Indian-born men have more than twice the prevalence rates of alcohol related disorders than White men and alcohol related admissions accounted for 25% of all psychiatric admissions in this group in 1981 (ref 29).&lt;/P&gt;
&lt;P&gt;Brief interventions in primary care may be effective in reducing excessive alcohol consumption. (ref 30). However, screening in general practice does not seem to be an effective precursor to brief interventions targeting excessive alcohol use (ref 31, 32). Effective interventions should be adapted for different groups. See: primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Self harm and suicide&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Deliberate self-harm is much more common among Asian women. Rates of attempted and completed suicide are much higher, notably in younger Asian women, whereas in Asian men and African-Caribbean men the rates are lower than the national average. Among Asian women, attempted suicide is less likely to be related to untreated mental health problems (ref 33-37).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Primary care&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Strengthening the delivery of mental health promotion in primary care is particularly important because of the poor recognition of psychological distress in all ethnic minorities in primary care. Black and minority ethnic patients are also under-represented within counselling and psychotherapeutic interventions. See: &lt;A href="nelh:111326:1" name=internalLink&gt;primary care&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Primary care has a role in strengthening access to self help and support networks by ensuring better links between primary health care and sources of information and support within different black and minority ethnic communities. Effective interventions include the promotion of self-help, advocacy, neighbourhood and voluntary activities, as well as structures that facilitate community planning and local decision-making in the provision of services (ref 38-40).&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Schools&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;School interventions can make an important contribution to reducing the impact of wider inequalities, but schools can also reinforce inequality. More children from ethnic minorities are likely to experience bullying than white children and black children, particularly boys, are much more likely to be excluded from school (ref 41). Schools are often the first port of call for refugees and asylum seekers, making it particularly important for parents and carers from these groups to be included e.g. via support groups for parents.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111331:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111333:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Fernando, S. (2002) Mental health, race and culture. Second Edition Hampshire: Palgrave&lt;BR&gt;&lt;BR&gt;2.&amp;nbsp;Jackson JS, Brown TN, Williams DR et al (1996) Racism and the physical and mental health status of African Americans: a thirteen year national panel study Ethnicity and Disease 6:109-122&lt;BR&gt;&lt;BR&gt;3.&amp;nbsp;Gray P. (1999) Ethnicity: An agenda for mental health (eds. Bhugra, D. &amp;amp; Bahl, V.) Gaskell: London&lt;BR&gt;&lt;BR&gt;4.&amp;nbsp;Sashidharan, S &amp;amp; Francis, E. (1993) in Race and health in contemporary Britain (ed. Ahmad, W.I) Open University Press: Buckingham&lt;BR&gt;&lt;BR&gt;5.&amp;nbsp;Alexander Z (1999) Study of Black, Asian and Ethnic Minority Issues Department of Health&lt;BR&gt;&lt;BR&gt;6.&amp;nbsp;Rawaf, S. &amp;amp; Bahl, V (1998) Assessing health needs of people from minority ethnic groups Royal College of Physicians &amp;amp; Faculty of Public Health Medicine: London&lt;BR&gt;&lt;BR&gt;7.&amp;nbsp;NHS Executive (1998) Tackling Racial Harassment in the NHS London:NHSE&lt;BR&gt;&lt;BR&gt;8.&amp;nbsp;Fernando S (1998) Part 1: Background in Forensic Psychiatry, Race and Culture (eds Fernando S, Ndegwa D and Wilson M) London:Routledge&lt;BR&gt;&lt;BR&gt;9.&amp;nbsp;Bhugra D, Leff J, Mallett R et al (1997) Incidence and outcome of schizophrenia in Whites, African-Caribbeans and Asians in London Psychological Medicine 27 791-795&lt;BR&gt;&lt;BR&gt;10.&amp;nbsp;Boydell J, van Os J, McKenzie K, Allardyce J, Goel R, McCreadie RG, Murray RM (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/323/7325/1336?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074161546619_1928&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=323&amp;amp;firstpage=1336&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment &lt;/A&gt;British Medical Journal 323:1336&lt;BR&gt;&lt;BR&gt;11.&amp;nbsp;Sharpley MS, Hutchinson G, Murray RM, McKenzie K (2001) &lt;A href="http://bjp.rcpsych.org/cgi/content/full/178/40/s60?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074162291342_429&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=178&amp;amp;firstpage=60&amp;amp;resourcetype=1" target="_blank"&gt;Understanding the excess of psychosis among the African-Caribbean population in England: review of current hypotheses&lt;/A&gt; British Journal of Psychiatry 178 (supplement 40) 60-68&lt;BR&gt;&lt;BR&gt;12.&amp;nbsp;NIMHE (2003) Inside Outside: Improving mental health services for Black and Minority Ethnic Communities in England. Leeds.&lt;A href="http://www.nimhe.org.uk/" target="_blank"&gt; NIMHE&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;13.&amp;nbsp;Bhugra D and Cochrane R (eds) 2001 Psychiatry in Multicultural Britain London: Gaskell&lt;BR&gt;&lt;BR&gt;14.&amp;nbsp;Cheng ATA (2001) &lt;A href="http://bjp.rcpsych.org/cgi/content/full/179/1/1?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074161735824_344&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=179&amp;amp;firstpage=1&amp;amp;resourcetype=1" target="_blank"&gt;Case definition and culture: are people all the same?&lt;/A&gt; British Journal of Psychiatry 179:1-3&lt;BR&gt;&lt;BR&gt;15.&amp;nbsp;&lt;A href="http://www.mentality.org.uk/" target="_blank"&gt;mentality&lt;/A&gt; (2002) Mellow Works: A Evaluation of the Impact and Influence of the Mellow Campaign. London: mentality&lt;BR&gt;&lt;BR&gt;16.&amp;nbsp;Brugha TS, Wing JK, Brewin CR, MacCarthy B and Lasage A (1993) The relationship of social network deficits in social functioning in long term psychiatric disorders Social Psychiatry and Psychiatric Epidemiology 28:218-224&lt;BR&gt;&lt;BR&gt;17.&amp;nbsp;Cohen S (ed) (1997) Measuring stress: a guide for health and social scientists Oxford University Press, Oxford&lt;BR&gt;&lt;BR&gt;18.&amp;nbsp;Oxman TE et al (1992) Social support and depressive symptoms in the elderly American Journal of Epidemiology 135:356-368&lt;BR&gt;&lt;BR&gt;19.&amp;nbsp;Faulkner A (2000) &lt;A href="http://www.mentalhealth.org.uk/page.cfm?pagecode=PBUP0203" target="_blank"&gt;Strategies for Living: Report of user led research into people’s strategies for living with mental distress&lt;/A&gt;. London: Mental Health Foundation&lt;BR&gt;&lt;BR&gt;20.&amp;nbsp;Beliappa J (1991) Illness or Distress? Alternative models of mental health. London: Confederation of Indian Organisations&lt;BR&gt;&lt;BR&gt;21.&amp;nbsp;Ellison C and Levin J (1998) The religion-health connection: evidence theory and future directions Health Education and Behaviour 5(6) 700-720&lt;BR&gt;&lt;BR&gt;22.&amp;nbsp;Mental Health Foundation (2002) &lt;A href="http://www.mentalhealth.org.uk/page.cfm?pagecode=PRNR0234" target="_blank"&gt;Taken Seriously: The Somerset Spirituality Project&lt;/A&gt; London: Mental Health Foundation&lt;BR&gt;&lt;BR&gt;23.&amp;nbsp;Friedli L (2000) A matter of faith: religion and mental health International Journal of Mental Health Promotion 2(2) 7-13&lt;BR&gt;&lt;BR&gt;24.&amp;nbsp;Asian Health Development Project (1999) Mental health: an Islamic Perspective Unpublished Report (Asian Health Development Project, Holy Trinity Community Centre, Dean Street, Ashton under Lyne OL6 7HD&lt;BR&gt;&lt;BR&gt;25.&amp;nbsp;Clay C (1999) Religion, spirituality and mental health Unpublished dissertation Warwickshire&lt;BR&gt;&lt;BR&gt;26.&amp;nbsp;Gorst-Unsworth C, Goldenberg E. &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/172/1/90?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074161969422_356&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=172&amp;amp;firstpage=90&amp;amp;resourcetype=1" target="_blank"&gt;Psychological sequelae of torture and organised violence suffered by refugees from Iraq. Trauma-related factors compared to social factors in exile&lt;/A&gt;. Br J Psychiatry 1998; 172: 90-94&lt;BR&gt;&lt;BR&gt;27.&amp;nbsp;Burnett A and Peel M (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7285/544?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074161648006_1952&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=322&amp;amp;firstpage=544&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Health needs of asylum seekers and refugees&lt;/A&gt; British Medical Journal 322:544-547&lt;BR&gt;&lt;BR&gt;28.&amp;nbsp;Wanigaratne S, Unnithan S and Strang J (2001) Substance misuse and ethnic minorities: issues for the UK in Bhugra and Cochrane (eds) Psychiatry in Multicultural Britain 243-263 London:Gaskell&lt;BR&gt;&lt;BR&gt;29.&amp;nbsp;Cochrane R and Bal S (1989) Mental Hospital admission rates of immigrants to England Social Psychiatry and Psychiatric Epidemiology 24:2-12&lt;BR&gt;&lt;BR&gt;30.&amp;nbsp;Ashenden, R., Silagy, C and Weller, D. (1997) A systematic review of the effectiveness of promoting lifestyle change in general practice Family Practice, 14: 160-175.&lt;BR&gt;&lt;BR&gt;31.&amp;nbsp;Beich A, Gannik D and Malterud K (2002) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/325/7369/870?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074161151946_1775&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=325&amp;amp;firstpage=870&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Screening and brief intervention for excessive alcohol use: qualitative interview study of the experiences of general practitioners&lt;/A&gt;. British Medical Journal. 325: 870-874&lt;BR&gt;&lt;BR&gt;32.&amp;nbsp;Beich A, Thorsen T and Rollnick S (2003) Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis. British Medical Journal. 327: 536-541.&lt;BR&gt;&lt;BR&gt;33.&amp;nbsp;Glover G (1989) The pattern of psychiatric admissions of Caribbean-born immigrants in London Social Psychiatry and Psychiatric Epidemiology 24:49-56&lt;BR&gt;&lt;BR&gt;34.&amp;nbsp;Bhugra D and Bahl V (eds) (1999) Ethnicity: an agenda for mental health &lt;A href="http://www.doh.gov.uk/mentalhealth" target="_blank"&gt;Department of Health&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;35.&amp;nbsp;Bhugra D, Desai M and Baldwin D (1999a) Attempted suicide in West London I: rates across ethnic communities Psychological Medicine 29:1125-1130&lt;BR&gt;&lt;BR&gt;36.&amp;nbsp;Bhugra D, Desai M et al (1999b) Attempted suicide in West London II: intergroup comparisons Psychological Medicine 29:1131-1139&lt;BR&gt;&lt;BR&gt;37.&amp;nbsp;Soni Raleigh V and Balarajan R (1992) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/161/3/365?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074162361035_446&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=161&amp;amp;firstpage=365&amp;amp;resourcetype=1" target="_blank"&gt;Suicide and self-burning among Indians and West Indians in England and Wales&lt;/A&gt; British Journal of Psychiatry 161:365-368&lt;BR&gt;&lt;BR&gt;38.&amp;nbsp;Stark W (1998) Empowerment and self-help initiatives – enhancing the quality of psycho-social care in Jenkins and Ustun (eds) Preventing mental illness: mental health promotion in primary care London&lt;BR&gt;&lt;BR&gt;39.&amp;nbsp;Whelan (1993) The role of social support in mediating the psychological consequences of economic stress Sociology of Health and Illness 15:86-101&lt;BR&gt;&lt;BR&gt;40.&amp;nbsp;Rosengren et al (1993) Stressful life events, social support and mortality in men born in 1933 &lt;A href="http://bmj.bmjjournals.com/" target="_blank"&gt;British Medical Journal&lt;/A&gt; 307:1102-5&lt;BR&gt;&lt;BR&gt;41.&amp;nbsp;National Society for the Prevention of Cruelty to Children (1999) Protecting children from racism and racial abuse&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>111331</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111331]]&gt;</url>
    <title>Marginalised groups - people with mental health problems</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,OUTCOMES,ENVIRONMENTAL,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,DETERMINANTS,SOCIAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; POLICY,INFORMATION,POPULATIONS,GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Marginalised groups - people with mental health problems&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111330:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111332:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Estimates of the prevalence of mental health problems in the population vary. Different measurements include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;One person in four will experience some kind of mental health problem in the course of a year (ref 1).&lt;/LI&gt;
&lt;LI&gt;10-25% of the general population annually present with mental health problems, usually to primary care. Within this figure 2-4% will have a severe mental illness and a smaller number within this group will have a severe and enduring mental illness (ref 2).&lt;/LI&gt;
&lt;LI&gt;Estimates for the number of people with a severe and enduring mental illness vary from 0.3-1.5% of the adult population. (ibid)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Evidence based priorities:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;People with mental health problems consistently identify stigma, discrimination and exclusion as major barriers to health, welfare and quality of life (ref 3-5). Exclusion from mainstream opportunities, notably employment, and lack of control, influence and participation in how mental health services are designed and delivered are a particular cause for concern.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;People with mental health problems – summary of the evidence&lt;/H2&gt;
&lt;P&gt;People with mental health problems will benefit from the same range of mental health promotion opportunities as everyone else. The following interventions focus on evidence of effectiveness in addressing discrimination and reducing inequalities. Other interventions e.g. strengthening opportunities for creativity and social support have a protective effect on mental health and should be available to people with existing mental health problems.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Physical health care&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Research in many countries has reliably confirmed that psychiatric patients have high rates of physical illness, much of which goes undetected and results in increased rates of chronic morbidity and mortality (ref 6-8). People who use mental health services, in particular those with a diagnosis of schizophrenia or bipolar disorder, are at increased risk for a range of physical illnesses, including coronary heart disease, diabetes, infections and respiratory disease. They are almost twice as likely to die from coronary heart disease as the general population and four times more likely to die from respiratory disease (ref 9-12).&lt;/P&gt;
&lt;P&gt;Due to the higher levels of morbidity from a range of factors, people who use mental health services should have routine physical health checks, annually at the very least (ref 13). Prescribed medication should also be reviewed regularly so that any side effects can be monitored. Primary care is an appropriate setting within which these interventions can be undertaken (ref 14).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Depression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Depression is often described as the common cold of mental health disorders and has an estimated point prevalence of between 15-30% in the UK (ref 15) 60-70% of adults will at some time in their lives experience depression or worry of sufficient severity to influence their daily activities. (ref 16 Mann 1992) It is suggested that more than half of those who attend their general practice may have some symptoms of depression (ref 17). &lt;/P&gt;
&lt;P&gt;The vast majority of depressed patients do not require hospitalisation and in the UK 90% of depression is managed in primary care (ref 16). Nevertheless there are significant direct and indirect costs associated with depression such as cost of treatment and working days lost (ref 18, 19).&lt;/P&gt;
&lt;P&gt;Wulsin et al (ref 20) conducted a systematic review of the literature on depression. The studies linking depression to early death were poorly controlled, but did suggest that depression substantially increased mortality risk, especially by unnatural causes and cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Non-pharmacological treatments for depression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In response to patient preference, combined with problems in non-compliance with medication, failure to respond to medication and contraindications to pharmacotherapy, psychological treatments have become increasingly available as an alternative intervention for people with depression (ref 21, 22).&lt;/P&gt;
&lt;P&gt;National Consensus Statements on physical activity and mental health (Grant 2000) show that exercise prevents clinical depression and is as effective a treatment as psychotherapeutic interventions. Exercise has also been shown to reduce anxiety, enhance mood and improve self esteem (ref 23-24).&lt;/P&gt;
&lt;P&gt;A systematic review examined the effectiveness and cost-effectiveness of brief psychological treatments for depression (ref 25). The review found that patients receiving any variant of psychotherapy were significantly more likely to improve to a degree where they were no longer considered clinically depressed, exhibited fewer symptoms post-treatment and experienced greater symptom reduction from baseline than those receiving treatment as usual. Cognitive behavioural therapy showed more of an effect than interpersonal, psychodynamic or supportive therapies. Individual approaches were also more likely to produce a positive outcome than group approaches.&lt;/P&gt;
&lt;P&gt;Several meta-analyses have examined the effect of non-pharmacological treatments for depression. One treatment method exposed to meta-analysis was bibliotherapy (ref 26). In bibliotherapy the patient takes a standardised treatment in book form home and works through it independently. Contact with a health professional is kept to a minimum, usually by telephone. The meta-analyses clearly indicated that bibliotherapy for mild to moderate depression is as effective as individual or group therapy. A note of caution was expressed however due to the limited number of studies and the small experimental groups comprised of non-clinical populations.&lt;/P&gt;
&lt;P&gt;A meta-analysis reviewed the effects of cognitive therapy (CT) in depressed patients (ref 27). Forty-eight high quality controlled trials were included in the analysis and at post-test cognitive therapy appeared significantly more effective than waiting lists, antidepressants or other miscellaneous therapies for people with mild to moderate depression. Review of eight follow-up studies comparing CT with antidepressants suggested that CT may prevent relapses in the long term. On average only 29.5% of the patients treated with CT relapsed versus 60% of those treated with antidepressants.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Pre-vocational training and supported employment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A systematic review assessed the effects of pre-vocational training and supported employment for people with severe mental illness against each other and also against standard care in hospital and in the community (ref 28). Eighteen randomised controlled trials of reasonable quality provided the data from which the reviewers concluded that supported employment is more effective than pre-vocational training in helping severely mentally ill people to obtain competitive employment. Clients in supported employment also earned more and worked more hours than those in pre-vocational training.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Exercise&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is robust evidence to support the mental health benefits of physical activity in four areas: as a treatment or therapy for existing mental health problems, to improve quality of life for people with mental health problems, to prevent onset of mental health problems and to improve the mental well-being of the general public (ref 23). Exercise is an effective adjunct for some of the negative symptoms of schizophrenia, as well as for depression and anxiety. Exercise can also be a helpful coping strategy for symptoms like hallucinations (ref 29).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Creative activity&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A growing number of studies confirm that creative activity has positive mental health benefits. These may relate to the development of self-expression and self-esteem, to opportunities for social contact and participation, or to providing a sense of purpose, a sense of meaning and improved quality of life (ref 30, 31). These findings are significant because low self-esteem is a risk factor for depression, suicidal behaviour, eating disorders and being bullied (ref 32).&lt;/P&gt;
&lt;P&gt;Studies have shown the positive impact of writing, reading and music. Writing as a therapy has a significant impact on standard measures of disease severity over a four-month period (ref 33, 34). One study showed that psychiatric patients who participated in arts projects had fewer readmissions than those who did not (ref 35).&lt;/P&gt;
&lt;P&gt;Art therapy is one of the creative therapies that can be used in addition to medication for helping people with schizophrenia. Art therapy in Britain developed primarily within adult psychiatric units and is one of the only forms of therapy designed to cater for the needs of more disturbed people. It is unique in that materials are used to engage with clients in psychodynamic therapy (ref 36).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Social Support&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Active participation in user groups has a wide range of benefits (ref 37-40). People with a small primary support group (3 people or less) are at greatest risk of mental health problems (ref 41). Social support reduces death rates, susceptibility to infection and depression (ref 42, 43).&lt;/P&gt;
&lt;P&gt;Good personal support networks, for example friendship or a confiding relationship, protect mental health and enable people to recover from stressful life events like bereavement or financial problems. Interventions include the promotion of self-help, advocacy, neighbourhood and voluntary activities, as well as structures which facilitate community planning and local decision making in the provision of services.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Spirituality&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Religious involvement is associated with positive mental health outcomes (ref 44). A growing number of studies also emphasise the importance of spiritual beliefs and the value of support from faith communities for people with mental health problems (ref 45).&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111330:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111332:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;1.&amp;nbsp;Goldberg D (1991) Filters to care. In Jenkins R and Griffiths S (eds) Indicators for Mental Health in the Population London: The Stationery Office.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Sainsbury Centre for Mental Health (1998) Keys to Engagement: Review of Care for People with severe mental illness who are hard to engage with services. London: SCMH&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Dunn S (1999) Creating accepting communities: report of the MIND inquiry into social exclusion and mental health problems London: &lt;A href="http://www.mind.org.uk/" target="_blank"&gt;Mind&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Department of Health (2001) Making it happen: a guide to delivering mental health promotion London. Department of Health.&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Mental Health Foundation (2000) Strategies for living: report of user led research into people’s strategies for living with mental distress London: Mental Health Foundation&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Koran LM, Sox HC, Marton KI, Moltzen S, Sox CH, Kraemer HC et al (1989) Medical evaluation of psychiatric patients. 1. Results in a state mental health system. Archives of General Psychiatry 46: 733-740&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Makikyro T, Karvonen JT, Hakko H, Nieminen P, Joukamen M, Isohanni M et al (1998) Co-morbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28 year follow-up of the 1966 northern Finland general population birth cohort. Public Health 112: 221-228&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Lawrence D, Holman CDJ and Jablensky AV (2001) Preventable Physical Illness in People with Mental Illness Perth: &lt;A href="http://www.dph.uwa.edu.au/" target="_blank"&gt;The University of Western Australia&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Phelan M, Stradins L and Morrison S (2001) Physical health of people with severe mental illness &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7284/443?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074090383375_7437&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=322&amp;amp;firstpage=443&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;British Medical Journal&lt;/A&gt; 322 p443-444&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Harris EC and Barraclough B (1998) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/173/1/11?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074089471979_2677&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=173&amp;amp;firstpage=11&amp;amp;resourcetype=1" target="_blank"&gt;Excess mortality of mental disorder&lt;/A&gt; British Journal of Psychiatry 173 p.11-53&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Barr W (2001) Physical health of people with severe mental illness &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/323/7306/231?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Barr&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074083966044_4632&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=323&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;British Medical Journal&lt;/A&gt; &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/323/7306/231?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Barr&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074083966044_4632&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=323&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;323: 321-322&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Brown S, Inskip H, Barraclough B (2000) Causes of the excess mortality of schizophrenia British Journal of Psychiatry 177 p212-217&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Cohen A and Hove M (2001) Physical health of the severe and enduing mentally ill – a training pack for GP educators &lt;A href="http://www.scmh.org.uk/" target="_blank"&gt;Sainsbury Centre for Mental Health &amp;amp; Department of Health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;mentality (2003) Not all in the mind: The physical health of people with mental health problems. London: mentality&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Hotopf M, Lewis G and Normand C (1996) The treatment of depression: ealuation and cost-effectiveness. PHP Dept Pubtn No. 20. London: London School of Hygiene and Tropical Medicine.&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Mann A (1992) In: Jenkins R, Newton J and Young R (eds) The Prevention of Anxiety and Depression. London: HMSO&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Freeling P and Tylee A (1992) In: Handbook of Affective Disorders.Edinburgh: Churchill Livingstone.&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Croft-Jeffreys C and Wilkinson G (1989) Estimated cost of neurotic disorder in UK practice. Psychological Medicine 19:549-559&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Stoudemire A, Frank R and Hedemark N (1986) The economic burden of depression. General Hospital Psychiatry 8:394-397&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Wulsin LR, Vaillant GE and Wells VE (1999) A Systematic Review of the Mortality of Depression. Psychosomatic Medicine. 61:6-17&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Simon GE, VonKorff M, Wagner EH and Barlow W (1993) Patterns of anti-depressant use in community practice. General Hospital Psychiatry 15:399-400&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;Scott J (1995) Psychological treatments for depression. British Journal of Psychiatry 167:289-2&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;Fox KR (2000) Self-esteem, self-perceptions and exercise International Journal of Sport Psychology 31:228-240&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp;Mutrie N (2000) The relationship between physical activity and clinically defined depression, in SJH Biddle, KR Fox and SH Boutcher (eds) Physical activity and psychological well-being London : Routledge&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A and Wessely S (2001) A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. &lt;A href="http://www.hta.nhsweb.nhs.uk/" target="_blank"&gt;Health Technology Assessment&lt;/A&gt;. Vol 5. No 35.&lt;/P&gt;
&lt;P&gt;26.&amp;nbsp;Cuijpers P (1997) Bibliotherapy for unipolar depression: a meta analysis. Journal of Behaviour Therapy and Experimental Psychiatry, 28:139-147&lt;/P&gt;
&lt;P&gt;27.&amp;nbsp;Gloaguen V, Cottraux J, Cucherat M and Blackburn I-M (1998) A meta analysis of the effects of cognitive therapy in depressed patients. Journal of Affective Disorders. 49 (1):59-72.&lt;/P&gt;
&lt;P&gt;28.&amp;nbsp;Crowther R, Marshall M, Bond G and Huxley P (2002) &lt;A href="http://www.cochrane.org/cochrane/revabstr/AB003080.htm" target="_blank"&gt;Vocational rehabilitation for people with severe mental illness&lt;/A&gt;. (Cochrane Review) in The Cochrane Library, Issue 3, 2002. Oxford:Update Software&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp;Faulkner G and Biddle S (1999) Exercise as an adjunct treatment for schizophrenia: a review of the literature Journal of Mental Health 8,5:441-457&lt;/P&gt;
&lt;P&gt;30.&amp;nbsp;Huxley P (1997) Arts on prescription: an evaluation Stockport&lt;/P&gt;
&lt;P&gt;31.&amp;nbsp;Oliver JPJ, Huxley PJ, Bridges K and Mohammed H (1996) Quality of Life and Mental Health Services London: Routledge&lt;/P&gt;
&lt;P&gt;32.&amp;nbsp;Emler N (2001) Self-esteem: The costs and causes of low self-worth. York: Joseph Rowntree Foundation&lt;/P&gt;
&lt;P&gt;33.&amp;nbsp;Smyth JM et al (1999) Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis: a randomized trial. &lt;A href="http://jama.ama-assn.org/" target="_blank"&gt;Journal of the American Medical Association&lt;/A&gt; 281:1304-1309.&lt;/P&gt;
&lt;P&gt;34.&amp;nbsp;Spiegel D (1999) Healing words: emotional expression and disease outcome.&lt;/P&gt;
&lt;P&gt;35.&amp;nbsp;Colgan S, Bridges K and Faragher B (1991) A tentative START to community care Psychiatric Bulletin 15:596-8&lt;/P&gt;
&lt;P&gt;36.&amp;nbsp;Deco S (1998) Art psychotherapy groups. In Skaife S and Huet V (eds) Between pictures and words London: Routledge&lt;/P&gt;
&lt;P&gt;37.&amp;nbsp;Barnes M and Shardlow P (1997) From passive recipient to active citizen: participation in mental health user groups. Journal of Mental Health 6 (3): 289 – 300.&lt;/P&gt;
&lt;P&gt;38.&amp;nbsp;Stark W (1998) Empowerment and self-help initiatives – enhancing the quality of psycho-social care in Jenkins and Ustun (eds) Preventing mental illness: mental health promotion in primary care London&lt;/P&gt;
&lt;P&gt;39.&amp;nbsp;Whelan R (1993) The role of social support in mediating the psychological effects of economic stress Sociology of Health and Illness 15:86-101&lt;/P&gt;
&lt;P&gt;40.&amp;nbsp;Rosengren et al (1993) Stressful life events, social support and mortality in men born in 1933 British Medical Journal 307:1102-5&lt;/P&gt;
&lt;P&gt;41.&amp;nbsp;Brugha TS, Wing JK, Brewin CR, MacCarthy B and Lasage A (1993) The relationship of social network deficits in social functioning in long term psychiatric disorders Social Psychiatry and Psychiatric Epidemiology 28:218-224&lt;/P&gt;
&lt;P&gt;42.&amp;nbsp;Cohen S (ed) (1997) Measuring stress: a guide for health and social scientists Oxford University Press, Oxford&lt;/P&gt;
&lt;P&gt;43.&amp;nbsp;Oxman TE et al (1992) Social support and depressive symptoms in the elderly American Journal of Epidemiology 135:356-368&lt;/P&gt;
&lt;P&gt;44.&amp;nbsp;Ellison C and Levin J (1998) The religion-health connection: evidence theory and future directions Health Education and Behaviour 5(6) 700-720&lt;/P&gt;
&lt;P&gt;45.&amp;nbsp;Mental Health Foundation (2002) Taken Seriously: The Somerset Spirituality Project. London &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;Mental Health Foundation&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>392222</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/CR162.pdf]]&gt;</url>
    <title>MARSIPAN: Management of Really Sick Patients with Anorexia Nervosa</title>
    <publicationDate>2010-10-20T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,EATING DISORDERS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal&gt;The Management of Really Sick Patients with Anorexia Nervosa (MARSIPAN) working group arose out of concerns that a number of patients with severe anorexia nervosa were being admitted to general medical units and sometimes deteriorating and dying on those units because of psychiatric problems, such as non-adherence to nutritional treatment, and medical complications, such as re-feeding syndrome. Sometimes overzealous application of National Institute for Health and Clinical Excellence (NICE) guidelines led to death from underfeeding syndrome. It seems there are also worrying variations in practice.&lt;/P&gt;
&lt;P class=MsoNormal&gt;This report aims to clarify the situation and provides recommendations and unambiguous guidelines on the management of this patient group in a number of settings, in order to help reduce the number of avoidable deaths of patients with severe anorexia nervosa. It provides:&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=MsoNormal&gt;Advice on physical assessment.&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;Advice to the primary care team and criteria for admission to both medical units and specialist eating disorder units as well as non-specialist psychiatric units, and criteria for transfer between those services.&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;Advice on the required members of the in-patient medical team.&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;Medical, nutritional and psychiatric management of patients with severe anorexia nervosa in medical units, including the appropriate use of mental health legislation.&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;Advice for commissioners on required services for this group of very ill patients.&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;This is a joint report from the Royal College of Psychiatrists and the Royal College of Physicians (London).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259579</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/professionals/maudsleymethod/index.shtml]]&gt;</url>
    <title>Maudsley Method</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Maudsley method refers to the form of family therapy developed in 1970-1980 at the Maudsley Hospital and evaluated under the team led by Professor Gerald Russell (including Dr C Dare, Dr I Eisler and Dr G Szmukler).]]&gt;</body>
  </document>
  <document>
    <id>381293</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.audit-commission.gov.uk/SiteCollectionDocuments/Downloads/20100623mentalhealthbriefing.pdf]]&gt;</url>
    <title>Maximising resources in adult mental health</title>
    <publicationDate>2010-06-23T00:00:00</publicationDate>
    <publisher>Audit Commission</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,INNOVATION AND IMPROVEMENT,EVALUATION,ECONOMIC]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=subbox&gt;
&lt;P&gt;In the first in a series of new efficiency briefings, we ask what scope there is for improving the efficiency of the acute care pathway in adult mental health, while maximising quality. &lt;/P&gt;
&lt;P&gt;Data shows there is wide variation between the use of inpatient beds and bed-days, and spending on crisis resolution and home treatment teams. And the data is only the starting point. Mental health trusts and primary care trusts need to work together to understand the detail behind the headline figures.&lt;/P&gt;
&lt;P&gt;Our series of ‘Delivering more for less’ efficiency briefings look at areas of the NHS where our analysis of local and national data shows that potential efficiency savings could be made. &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>105872</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=105872]]&gt;</url>
    <title>Measuring Mental Health</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,ENVIRONMENTAL,SOCIAL CAPITAL,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,SERVICES,MANAGEMENT &amp; POLICY,METHODS,INDICATORS,MEASUREMENT,POPULATIONS,ANALYSIS &amp; RESEARCH,COMMUNITIES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Measuring Mental Health&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:105869:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111327:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Identifying indicators of mental health poses a predicament for mental health promotion. As a rule there has been a focus on measures to detect mental ill health and on negative symptoms such as sadness, anxiety or pessimism. &lt;/P&gt;
&lt;P&gt;The reliability and utility of diagnostic criteria have been challenged on the grounds that they are not sufficiently culturally sensitive (ref 1, 2). There are also concerns that diagnoses like depression or anxiety disorder medicalise forms of distress which may be a normal response to traumatic events. Finally clinical definitions of mental illness like schizophrenia or bi-polar disorder describe a range of symptoms and provide a framework for understanding mental distress that has been challenged both by the mental health user/survivor movement as well as by professionals working within psychiatry (ref 3, 4). &lt;/P&gt;
&lt;P&gt;There are a number of well-validated instruments designed to measure positive aspects of mental health in individuals. These include the Psychological Wellbeing Scale, the Sense of Coherence Scale the Affect Balance Scale and the Affectometer. Key elements of these tools include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;agency&lt;/LI&gt;
&lt;LI&gt;capacity to learn, grow and develop&lt;/LI&gt;
&lt;LI&gt;feeling loved, trusted, understood and valued&lt;/LI&gt;
&lt;LI&gt;interest in life&lt;/LI&gt;
&lt;LI&gt;autonomy&lt;/LI&gt;
&lt;LI&gt;self-acceptance and self-esteem&lt;/LI&gt;
&lt;LI&gt;optimism and hopefulness&lt;/LI&gt;
&lt;LI&gt;resilience (ref 5)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Quality of life indicators developed by the Audit Commission are relevant, at least in part, to mental health outcomes for individuals and communities (ref 6). They include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the percentage of people satisfied with their neighbourhood as a place to live&lt;/LI&gt;
&lt;LI&gt;quality and amount of natural environment&lt;/LI&gt;
&lt;LI&gt;cultural, recreational and leisure services available&lt;/LI&gt;
&lt;LI&gt;opportunities to participate in local planning and decision making&lt;/LI&gt;
&lt;LI&gt;percentage of people who consider that their neighbourhood is getting worse&lt;/LI&gt;
&lt;LI&gt;percentage of respondents concerned about noise&lt;/LI&gt;
&lt;LI&gt;area of parks and green open spaces per 1,000 head of population&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Finally indicators are emerging which explore the relationship between social capital and health. These include formal and informal social networks, group membership, generalised trust, reciprocity and civic engagement. (&lt;A href="http://www.statistics.gov.uk/socialcapital" target="_blank"&gt;www.statistics.gov.uk/socialcapital&lt;/A&gt;) &lt;/P&gt;
&lt;P&gt;In areas where neighbourhood renewal programmes are well-developed, or where community strategies are in process of implementation, some of the following indicators are coming into more common useage:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;feeling safe&lt;/LI&gt;
&lt;LI&gt;trusting unfamiliar others&lt;/LI&gt;
&lt;LI&gt;participation&lt;/LI&gt;
&lt;LI&gt;influencing local decisions&lt;/LI&gt;
&lt;LI&gt;believing the local neighbourhood is improving&lt;/LI&gt;
&lt;LI&gt;access to social support&lt;/LI&gt;
&lt;LI&gt;employment&lt;/LI&gt;
&lt;LI&gt;meaningful activity&lt;/LI&gt;
&lt;LI&gt;support for parents&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Outcome measures for interventions that promote mental health can be drawn from some or all of these indicators. For example, interventions that facilitate the capacity to learn – an individual indicator – may also include measures of participation – a social capital indicator.&lt;/P&gt;
&lt;P&gt;There is still undue emphasis on mental health promotion outcome measures derived from experimental research. The imposition of a hierarchy of evidence, particularly one which focuses almost exclusively on evaluation outcomes from randomised controlled trials (RCTs), has been challenged. Commentators have questioned whether such an approach can provide a sufficiently comprehensive view of the effect of complex social interventions and have offered innovative models for measuring the mental health impact of such interventions (ref 7, 8). &lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:105869:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111327:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Bhugra D and Bahl V (eds) (1999) Ethnicity: an agenda for mental health. London: Department of Health.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Bhui, K. (2001) Over-representation of Black people in secure psychiatric facilities. British Journal Psychiatry, 178 (6) 575.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Bracken P and Thomas P (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7288/724?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074166751119_3896&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=322&amp;amp;firstpage=724&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Postpsychiatry: a new direction for mental health&lt;/A&gt;. British Medical Journal. 322: 724-727. &lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Bhugra D and Cochrane R (eds) (2001) Psychiatry in multicultural Britain. London: Gaskell.&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Stewart-Brown S (2002) Measuring the parts most measures do not reach: a necessity for evaluation in mental health promotion. Journal of Mental Health Promotion. 1 (2): 4 – 9.&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Audit Commission (2003) Quality of Life: A Good Practice Guide to Communicating Quality of Life Indicators. London: &lt;A href="http://www.audit-commission.gov.uk/" target="_blank"&gt;Audit Commission&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Peersman G, Harden A and Oliver S (1998) Effectiveness of health promotion interventions in the workplace: a review. London: Health Education Authority.&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Barry M (2002) Challenges and opportunities in strengthening the evidence base for mental health promotion. Promotion &amp;amp; Education. IX (2): 44 – 48.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>263064</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38628&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Medicines &amp; Good Mental Health in Later Life</title>
    <publicationDate>2001-10-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report on a UK survey of the availability of community-based pharmaceutical care for older people with mental health needs.</description>
    <body>&lt;![CDATA[ A report on a UK survey of the availability of community-based pharmaceutical care for older people with mental health needs.]]&gt;</body>
  </document>
  <document>
    <id>386604</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386604]]&gt;</url>
    <title>Meditation 'changes the brain'</title>
    <publicationDate>2010-08-17T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Meditation 'changes the brain'&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;“Meditation is proven to be the serene way to get smarter,” reported the &lt;EM&gt;Daily Mail&lt;/EM&gt;.&amp;nbsp;It&amp;nbsp;said scientists found&amp;nbsp;that even a short course of meditation “strengthens connections between the regions of the brain that regulate our emotional responses”.&lt;/P&gt;
&lt;P&gt;The study in question compared the brains scans of people who received 11 hours of meditative sessions over a period of a month to those of people who were shown basic relaxation techniques. People who received meditation sessions were found to have more changes in the white matter of the brain in an area called the corona radiata.&lt;/P&gt;
&lt;P&gt;The study was relatively small (45 people), and only included healthy young adults. It did not look at whether these brain changes were linked to changes in behaviour, intelligence or emotions.&amp;nbsp;Overall, this study may further our understanding of the effects meditation can have on the cells of the brain, but it does not further our understanding of any mental health benefits.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381301</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/meeting-the-psychological-and-emotional-needs-of-people-who-are-homeless.pdf]]&gt;</url>
    <title>Meeting the psychological and emotional needs of homeless people</title>
    <publicationDate>2010-05-31T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMDU)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide describes effective ways of recognising and meeting the psychological and emotional needs of people who have experienced homelessness, are sleeping rough or living in insecure accommodation, in particular young people and rough sleepers with histories of complex trauma/personality disorder. The guide outlines the national policy context, the research evidence which informs developing practice, and explores the issues for service providers and commissioners.&lt;/P&gt;
&lt;P&gt;The guide describes the common psychological problems associated with complex trauma and offers examples of treatment models available. The case studies describe a variety of existing services for rough sleepers and young people which address emotional and psychological problems. These illustrate the wide range of techniques and approaches that are commissioned across the country and contact details are provided.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392202</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/memory-drug-studied-in-mice.aspx]]&gt;</url>
    <title>Memory drug studied in mice</title>
    <publicationDate>2010-10-13T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;EM&gt;Daily Express&lt;/EM&gt; reports today of a “drug to stop memory loss”. It said that a British team of researchers have made an amazing breakthrough and are a step closer to an “anti-ageing drug for the brain”.&lt;/P&gt;
&lt;P&gt;Underpinning this news report is a study that tested a new drug in mice. The study found that mice that received the drug had better spatial memory than control mice when they were&amp;nbsp;tested in a maze.&lt;/P&gt;
&lt;P&gt;These findings do not mean that a treatment or a cure for dementia has been found. This is good research within its own right, and well documented by the researchers in their research paper. However, this is still early-stage research in animals. As there was no long-term follow-up of the animals and its effects on other types of memory, the findings have little immediate relevance to the health of people with dementia. The &lt;EM&gt;Daily Express’s&lt;/EM&gt; front-page report is not justified by this research.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381295</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/memory-problems-and-pear-shape.aspx]]&gt;</url>
    <title>Memory gone pear shaped?</title>
    <publicationDate>2010-07-15T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Pear-shaped women face increased risks of mental problems and memory loss in later life,” reported &lt;EM&gt;The Sun.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The story is based on a study in 8,745 postmenopausal women aimed at determining if body mass index (BMI) and hip-waist ratio (HWR), were associated with cognitive function. It found that in women with a higher BMI, those who were 'pear-shaped' (low HWR) tended to&amp;nbsp;have slightly lower scores of cognitive function than their 'apple shaped' (high HWR) counterparts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293443</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085476]]&gt;</url>
    <title>Mental Capacity Act 2005: Deprivation of liberty safeguards - Code of Practice to supplement the main Mental Capacity Act 2005 Code of Practice</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Code of Practice contains guidance on the deprivation of liberty safeguards. It is particularly intended to provide guidance for professionals involved in administering and delivering the safeguards, who are under a duty to have regard to the Code. The Code is also intended to provide information for people who are, or could become, subject to the deprivation of liberty safeguards, and for their families, friends and carers, as well as for anyone who believes that someone is being deprived of their liberty unlawfully.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The deprivation of liberty safeguards Code of Practice was laid in draft before Parliament by the Lord Chancellor on 13 June 2008, in accordance with sections 42 and 43 of the Mental Capacity Act 2005. The Code was subject to the negative Parliamentary process, and successfully completed its 40 day laying period on 22 July.&lt;/P&gt;
&lt;P&gt;The final version of the Code was published on 26 August 2008. It is available in hard copy from The Stationery Office Bookshop.&lt;/P&gt;
&lt;P&gt;The deprivation of liberty safeguards have been introduced into the Mental Capacity Act 2005 by the Mental Health Act 2007. It is planned that the safeguards will come into force in April 2009.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The safeguards provide a framework for approving the deprivation of liberty for people who lack the capacity to consent to treatment or care in either a hospital or care home that, in their own best interests, can only be provided in circumstances that amount to a deprivation of liberty. The safeguards legislation contains detailed requirements about when and how deprivation of liberty may be authorised. It provides for an assessment process that must be undertaken before deprivation of liberty may be authorised and detailed arrangements for renewing and challenging the authorisation of deprivation of liberty.&lt;/P&gt;
&lt;P&gt;The Code of Practice contains guidance on the deprivation of liberty safeguards. It is particularly intended to provide guidance for professionals involved in administering and delivering the safeguards, who are under a duty to have regard to the Code. The Code is also intended to provide information for people who are, or could become, subject to the deprivation of liberty safeguards, and for their families, friends and carers, as well as for anyone who believes that someone is being deprived of their liberty unlawfully.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>263065</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40153&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Mental Capacity Act Briefing</title>
    <publicationDate>2005-10-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Executive Briefing setting the Mental Capacity Act 2005 in context, explaining the key implications and assessing some of its shortcomings.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Executive Briefing setting the Mental Capacity Act 2005 in context, explaining the key implications and assessing some of its shortcomings. Essential reading for anyone involved in the provision of care for people with impaired decision-making abilities.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40157&amp;amp;type=Full&amp;amp;servicetype=Attachment" target="_blank"&gt;Mental Capacity Act Summary Briefing&lt;/A&gt; (Link to full-text PDF)&lt;/P&gt;
&lt;P&gt;2 page summary briefing setting the Mental Capacity Act 2005 in context, explaining the key implications and assessing some of its shortcomings. Essential reading for anyone involved in the provision of care for people with impaired decision-making abilities.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270316</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Bulletins/theweek/DH_078749]]&gt;</url>
    <title>Mental Health Act 2007 (Commencement No. 3) Order 2007: action for NHS bodies and local social services authorities</title>
    <publicationDate>2007-09-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Mental Health Act 2007 (Commencement No. 3) Order 2007 brings into effect a number of amendments to the Mental Health Act 1983 and the Mental Capacity Act 2005.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;The changes&lt;/H2&gt;
&lt;P&gt;The Mental Health Act 2007 (Commencement No. 3) Order 2007 brings into effect a number of amendments to the Mental Health Act 1983 and the Mental Capacity Act 2005.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Most of the provisions come into force on 1 October 2007 but two, relating to civil partners as nearest relative (section 26) and consent for young people aged 16 or 17 (section 43), come into force on later dates to allow service providers time to prepare for the change.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Action&lt;/H2&gt;
&lt;P&gt;NHS bodies and local social services authorities will need to identify patients who are likely to be affected by the changes to the law on civil partners as nearest relatives and consent for young people aged 16 or 17 and make arrangements to ensure that they are implemented immediately they come into effect: &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Civil partners as nearest relative&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Starting on Saturday 1 December civil partners will have the same status as a husband or wife when determining a patient’s nearest relative.&amp;nbsp; This change is brought in by section 26 of the Mental Health Act 2007 which amends section 26 and section 27 of the Mental Health Act 1983. The past actions of the previous nearest relative are to be treated in the same way as in any of the other circumstances in which a nearest relative is replaced by another person who is subsequently placed higher in the list of nearest relatives. The responsibilities of hospital managers, Approved Social Workers and Local Social Services Authorities to the new nearest relative are to be undertaken according to the legal requirements of the 1983 Act.&lt;/P&gt;
&lt;P&gt;As a result of this amendment, a number of people will become the nearest relative of their civil partners in place of the person who was previously the nearest relative, especially if the civil partnership is less than 6 months old. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284099</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_084351]]&gt;</url>
    <title>Mental Health Act 2007 (Commencement No. 5 and Transitional Provisions) Order 2008 - guidance on transfers between places of safety</title>
    <publicationDate>2008-04-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Mental Health Act 2007 (Commencement No. 5 and Transitional Provisions)  Order 2008 - S.I. No. 2008/800 (C.39) - brings section 44 of the Mental Health Act 2007 (the 2007 Act) on places of safety into effect on 30 April 2008.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Mental Health Act 2007 (Commencement No. 5 and Transitional Provisions)&amp;nbsp; Order 2008 - S.I. No. 2008/800 (C.39) - brings section 44 of the Mental Health Act 2007 (the 2007 Act) on places of safety into effect on 30 April 2008.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Under sections 135 and 136 of the Mental Health Act 1983 (the 1983 Act) a police officer may remove a person who is believed or appears to be suffering from a mental disorder to a place of safety. Section 44 of the 2007 Act amends these sections of the 1983 Act to allow a person to be taken from one place of safety to one or more other places of safety during the 72 hour maximum overall period during which they may be detained under either of these two sections. They may be taken between places of safety by a police officer, an approved social worker (until approved social workers are replaced in this role by approved mental health professionals in due course) or someone authorised by either of them.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Section 44 of the 2007 Act comes into force on 30 April 2008.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS bodies and local social services authorities will need to ensure that their staff are aware of the change and that it is reflected in local policies.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296534</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089408]]&gt;</url>
    <title>Mental Health Act 2007 : guidance on the extension of victims' rights under the Domestic Violence, Crime and Victims Act 2004</title>
    <publicationDate>2008-10-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>As a result of the Mental Health Act 2007, from 3 November 2008 victims’ rights under the Domestic Violence Crime and Victims Act 2004 will be extended to victims of offenders who are detained, or on supervised community treatment, as unrestricted patients under Part 3 of the Mental Health Act 1983. This will involve new duties on hospital managers, responsible clinicians, approved mental health professionals and on NHS bodies who fund treatment of such patients in the independent sector.</description>
    <body>&lt;![CDATA[ As a result of the Mental Health Act 2007, from 3 November 2008 victims’ rights under the Domestic Violence Crime and Victims Act 2004 will be extended to victims of offenders who are detained, or on supervised community treatment, as unrestricted patients under Part 3 of the Mental Health Act 1983. This will involve new duties on hospital managers, responsible clinicians, approved mental health professionals and on NHS bodies who fund treatment of such patients in the independent sector.]]&gt;</body>
  </document>
  <document>
    <id>276030</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.symmetricsd.co.uk/survey/surveyhome.asp?qnid=1&amp;page=2]]&gt;</url>
    <title>Mental Health Act 2007 implementation Self Assessment Tool</title>
    <publicationDate>2007-12-07T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The ISAT (Implementation Self Assessment Tool) will be of most interest to organizations providing services to patients detained under the legislation plus those providing services for children and young people (CYP) aged under 18 on a voluntary or detained basis. However, it also provides a useful framework for health and social care commissioners and others with an interest in implementation of the new legislation.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Mental Health Act 2007 Implementation Self Assessment Tool (ISAT)&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;Produced by the Care Services Improvement Partnership (CSIP), the aim of the ISAT is to help organisations providing services under the Act to prepare for a timely and effective implementation of the new legislation. The tool will be useful to service commissioners. Although its primary target is health and social care service providers, some of the standards relate solely to commissioners. More generally the tool should help commissioners develop service specifications and support performance management.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>297190</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Mentalhealth/DH_089882]]&gt;</url>
    <title>Mental Health Act 2007: Key Documents</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>From 3 November 2008 most of the remaining provisions of the Mental Health Act 2007 – with the exception of deprivation of liberty safeguards, advocacy and age-appropriate environments for those under 18 – come into force and the Mental Health Act 1983 is amended.</description>
    <body>&lt;![CDATA[ &lt;P&gt;From 3 November 2008 most of the remaining provisions of the Mental Health Act 2007 – with the exception of deprivation of liberty safeguards, advocacy and age-appropriate environments for those under 18 – come into force and the Mental Health Act 1983 is amended. &lt;/P&gt;
&lt;P&gt;The following documents and webpages are relevant to these changes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Mentalhealth/DH_078743" target="_blank"&gt;Mental Health Act 2007 - overview&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.opsi.gov.uk/acts/acts2007/ukpga_20070012_en_1" target="_blank"&gt;Mental Health Act 2007 (opens new window)&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Mentalhealth/DH_063423" target="_blank"&gt;Mental Health Act 1983 as amended by the 2007 Act – updated 28 August 2007&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_084597" target="_blank"&gt;Revised Code of Practice to the Mental Health Act 1983&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088162" target="_blank"&gt;Reference guide&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Mentalhealth/DH_077359" target="_blank"&gt;Secondary legislation&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377559</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/mh_employment_key_opportunities.pdf]]&gt;</url>
    <title>Mental Health and Employment - key opportunities to pt policy into practice</title>
    <publicationDate>2010-04-15T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN id=ctl00_centreColumn_Publicationview1_PublicationDataList_ctl01_BlurbLabel1&gt;This paper aims to make sense of what the new policy set out in New Horizons, Working our way to better mental health, Realising ambitions and Work, Recovery and Inclusion means in practice and pick out the key commitments and opportunities as we see them.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;It follows on from our summary of the policies and looks at how employment and other services can put these opportunities into practice.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>280063</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083066]]&gt;</url>
    <title>Mental health and ill health in doctors</title>
    <publicationDate>2008-02-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report looks at mental health and ill health in doctors and the factors that influence them. It outlines ways in which the NHS can provide appropriate services and encourage doctors and other health care workers to seek early advice and support for mental health problems.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;This publication sets out the findings and recommendations of the working group set up to consider what steps might make it less likely that doctors would suffer from mental ill health and easier for them to seek help early.&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We know that many doctors are affected by mental ill health – particularly depression and alcohol or drug problems. We also know that they do not ask for treatment early, if at all. The system, as it is currently organised, may militate against their being able to do this easily. There are too many worries about confidentiality and potential impact on career and colleagues for many doctors to do what they would tell their patients to do. The combined forces of stigma, shame and secrecy make it particularly difficult for individuals, organisations and policy makers to address mental ill health in doctors.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;After the publication of the Daksha Emson Inquiry Report, the National Director for Mental Health, Professor Louis Appleby, established a group that worked with key organisations to consider what steps might make it less likely that doctors would become unwell and easier for them to seek help early. The group focused on doctors, but many of the problems and recommendations described in this report are also relevant to other health workers. The group limited its work to mental health and ill health; other conditions were not considered.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This report and its recommendations are the result of their findings. It is for local and national organisations to consider and determine how they can take forward the issues raised.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330388</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/OP70.pdf]]&gt;</url>
    <title>Mental Health and the Economic Downturn: National priorities and NHS solutions</title>
    <publicationDate>2009-11-12T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal&gt;Produced by the Royal College of Psychiatrists, Mental Health Network, NHS Confederation &amp;amp; London School of Economics and Political Science.&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;In September 2009 a 1-day meeting on mental health and the economic downturn was held in London. The meeting was convened by the Royal College of Psychiatrists, the Mental Health Network, NHS Confederation and the London School of Economics and Political Science. The meeting explored the impact the downturn was having on mental health as well as where some of the solutions may lie for those working at a local and national level in service provision and policy.&lt;/P&gt;
&lt;P class=MsoNormal&gt;This report builds on the outcomes of that meeting. It outlines the challenges facing the sector and sets out how policy makers, organisational leaders and health and social care professionals should respond.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;STRONG&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=MsoNormal&gt;Executive summary&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;Introduction&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;The extent of the challenge&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;National priorities&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;NHS solutions&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;Conclusion&lt;/LI&gt;
&lt;LI class=MsoNormal&gt;References&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>396326</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/document.rm?id=8841]]&gt;</url>
    <title>Mental Health and The Productivity Challenge: Improving quality and value for money</title>
    <publicationDate>2010-12-02T00:00:00</publicationDate>
    <publisher>The Kings Fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,QUALITY AND MONITORING,FINANCE AND FUNDING,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,COMMISSIONING,SERVICE SECTORS,MENTAL HEALTH SERVICES,ASSESSMENT AND PLANNING,QUALITY IMPROVEMENT,COST EFFECTIVENESS,COMMISSIONING PROCESS,INNOVATION AND IMPROVEMENT,EVALUATION,PERFORMANCE INDICATORS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class="content_block press_release_content_block"&gt;
&lt;H2 class=sIFR-replaced&gt;&lt;SPAN id=sIFR_replacement_4_alternate class=sIFR-alternate&gt;Summary&lt;/SPAN&gt;&lt;/H2&gt;
&lt;P&gt;The NHS is facing a significant financial challenge and needs to make substantial improvements in productivity if it is to provide high-quality services without additional&amp;nbsp; funding. Spending on mental health accounts for around 10 per cent of the overall health budget and so the mental health sector has a key role in responding to this challenge.&lt;/P&gt;
&lt;P&gt;The King’s Fund and &lt;A href="http://www.centreformentalhealth.org.uk/" target="_blank"&gt;Centre for Mental Health&lt;/A&gt;, with the support of the Royal College of Psychiatrists and the NHS Confederation’s Mental Health Network, have worked together to explore how mental health services could be delivered in a different and more cost-effective way. The consensus from their work, including an expert seminar and a review of evidence, is that there is scope for mental health services not only to improve their own productivity but also to support productivity improvements in other parts of the NHS.&lt;/P&gt;
&lt;P&gt;Mental health and the productivity challenge: Improving quality and value for money focuses on four main areas:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;immediate priorities for improving productivity in existing mental health services 
&lt;LI&gt;what mental health services can offer to improve productivity in the NHS as a whole 
&lt;LI&gt;the economic benefits beyond the NHS of improved mental health care 
&lt;LI&gt;the longer-term challenge of building a preventive and empowering mental health system.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The report suggests that there are real opportunities to change the way mental health services are delivered in order to achieve more within existing budgets. &lt;/P&gt;
&lt;P&gt;Of the improvement areas highlighted in the report, we consider that the following are the most promising targets for immediate attention:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;reducing unnecessary bed use in acute and secure psychiatric wards 
&lt;LI&gt;establishing systems to review the use of highly expensive out-of-area treatments 
&lt;LI&gt;improving workforce productivity 
&lt;LI&gt;strengthening the interface between mental and physical health care, particularly for older people and people with long-term conditions.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Many case studies and practical examples are included to illustrate these conclusions, and there are recommendations for action that involve everyone in the health service. &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>276193</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.fphm.org.uk/resources/AtoZ/ps_mental_health_and_work.pdf]]&gt;</url>
    <title>Mental Health and Work</title>
    <publicationDate>2007-12-13T00:00:00</publicationDate>
    <publisher>Faculty of Public Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,BUILDINGS,WORKPLACE,MONTHLY ADDITIONS,SETTINGS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Britain's bosses are unaware of the scale of mental ill health in their workplaces or the enormous financial toll it can take, according to a new Position Statement issued by the Faculty of Public Health (FPH). The Faculty of Public Health recognises that mental health is a major public health issue. Mental health and work – a position statement is the first of a series of statements that they will be issuing on mental health issues over the next few months.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Britain's bosses are unaware of the scale of mental ill health in their workplaces or the enormous financial toll it can take, according to a new Position Statement issued by the Faculty of Public Health (FPH). The Faculty of Public Health recognises that mental health is a major public health issue. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mental health and work – a position statement is the first of a series of statements that they will be issuing on mental health issues over the next few months.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319365</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2009/9789241563567_eng.pdf]]&gt;</url>
    <title>Mental Health aspects of women's reproductive health: a global review of the literature PDF</title>
    <publicationDate>2009-06-25T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A report from the world health organisation.]]&gt;</body>
  </document>
  <document>
    <id>276235</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://website.scmh.org.uk/80256FBD004F6342/vWeb/pcKHAL79TMF9]]&gt;</url>
    <title>Mental Health at Work: Developing the business case</title>
    <publicationDate>2007-12-14T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,POLICY,PUBLIC HEALTH,MANAGEMENT &amp; POLICY,WORKPLACE,BUILDINGS,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS,SETTINGS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Policy paper.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Because of mental ill health among their staff businesses across Britain are losing £1,000 a year for every person they employ, says a report published by the Sainsbury Centre for Mental Health. Mental health at work: developing the business case finds that the total cost to UK employers of mental ill health among their staff is over £25 billion. That is equivalent to £1,000 per employee in the workforce. Mental health at work finds that simple steps to improve the management of mental health in the workplace should enable employers to save 30 per cent or more of these costs - at least £8 billion a year. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>223715</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=223715]]&gt;</url>
    <title>Mental Health Bill [HL]</title>
    <publicationDate></publicationDate>
    <publisher>House of Lords</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Amendments to Mental Health Act 1983.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mental Health Bill [HL]&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;A href="http://www.publications.parliament.uk/pa/ld200607/ldbills/001/07001.i-iv.html" target="_blank"&gt;Mental Health Bill [House of Lords]&lt;/A&gt;&amp;nbsp;(click here for a link to the web site)&lt;/H2&gt;
&lt;P&gt;The latest mental health bill covers a number of areas, such as amendments to the definitions of mental disorder, treatment and the nomination of nearest relatives as patient's representatives. The main innovation, however, is the introduction of supervised community treatment. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>313776</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/publications/mental%20health/NHS%20specialist%20mental%20health%20services/MHMDS09/MHBulletin%202003-2008_FINAL2.pdf]]&gt;</url>
    <title>Mental Health Bulletin: second report on experimental statistics from Mental Health Minimum Dataset (MHMDS) annual returns, 2003-2008.</title>
    <publicationDate>2009-03-24T00:00:00</publicationDate>
    <publisher>NHS The Information Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This is the second national report on NHS services for people with severe and enduring mental health problems (secondary or specialist mental health services) using information from the Mental Health Minimum Dataset (MHMDS). It provides experimental statistics at a national level on the number of people who use these services, how many of them are detained in hospital and some of the ways in which their care is managed, including how long people spend in hospital. Trust level results by provider and commissioner are available online only at &lt;A href="http://www.mhmdsonline.ic.nhs.uk/" target="_blank"&gt;http://www.mhmdsonline.ic.nhs.uk&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The MHMDS is the only dataset that covers services provided in the community and in hospital, including outpatient services. The data are also unique in linking, for each anonymous individual patient, records of contact with different parts of the service and with different providers. The MHMDS has the potential to answer questions not only about what services are being used, but also about whether they are helping to improve people’s lives.&lt;BR&gt;The experimental statistics published in October 2008 showed providers and commissioners of these services for the first time the kind of analyses which could be produced using the MHMDS. The data for this second report had already been submitted before the first was published and this second report simply updates the analyses presented in the first, rather than extending them. However, the role of the MHMDS as the main source of information about specialist mental health services has been established and will be developed.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The report includes information for 2003-2008 and the results show that during the year 2007-2008:&lt;BR&gt;• During 2007-2008 nearly 1.2 million people (1,190,542) were in contact with NHS specialist mental services for adults – this is a rate of access for the population of England of about one person in fifty.&lt;BR&gt;• The number of people in contact with these services rose by 39,282 (3.4%) from 1,151,260 in 2006-07 to 1,190,542 in 2007-08). Women accounted for 56% of the total number of people in 2007-2008 (for whom gender was recorded) and for 70% of this increase (from 631,378 to 659,245 for women and from 517,373 to 528,372 for men). This increase is consistent with the findings from the 2007 Adult Psychiatric Morbidity Survey which showed women’s mental health worsening, with more of them diagnosed with depression, anxiety or suicidal thoughts than in previous surveys.&lt;BR&gt;• About one in eleven of people using secondary mental health services (8.9%) spent time as an inpatient in mental hospital in 2007-2008. 52% of this group (54,635) were men and 48% (50,934) were women. One in three inpatients spent time compulsorily detained under the Mental Health Act in the same year.&lt;BR&gt;The other ten in eleven people (91.1%) who did not spend any time as an inpatient during 2007-2008 were treated as outpatients and by community mental health services. 56% of this group (551,504) were women and 44% were men (428,776) and women outnumbered men by 122,728.&lt;BR&gt;• The proportion of mental health service users who spent time in hospital in 2007-2008 was higher for some black and minority ethnic groups than for the White group:&lt;BR&gt;o 18.9% of service users in the Black or Black British group spent time in hospital&lt;BR&gt;o 14.3% of the Mixed group&lt;BR&gt;o 11.5% of the Asian or Asian British group.&lt;BR&gt;o 9.7% of the White group&lt;/P&gt;
&lt;P&gt;• The data do not show whether this is because some ethnic groups have higher prevalence of severe mental illness requiring hospital treatment or whether people from these black and minority ethnic (BME) groups are less likely to seek early help from the NHS services. The 2007 Adult Psychiatric Morbidity Survey shows some variations by ethnicity for rates of treated and untreated psychiatric conditions.&lt;BR&gt;• Once again the most recent figures also seem consistent with the findings of the National Mental Health and Ethnicity Census (Count Me In) regarding the over-representation of some BME groups amongst detained patients.&lt;BR&gt;• In 2007-2008 5,020 records (out of 108,551 that included a hospital stay) showed a hospital stay exceeding a year. Over half of all records that included a hospital stay showed an average length of stay of less than a month (56,189 out of 108,551 records).&lt;BR&gt;• The number of people who spent time in hospital reduced by more than 800 (from 106,561 in 2006-2007 to 105,719 in 2007-2008) and this is consistent with a slight fall in the number of admissions, by 4,010 (from 130,387 in 2006-07 to 126,377 in 2007-08) and a fall of nearly 200 in the estimated number of beds occupied each day (from 22,091 in 2006-07 to 21,924 in 2007-08).&lt;BR&gt;• The 2007-08 data suggest that over 500 young people under the age of 16 spent time as inpatients on adult wards. The number of people aged under 16 in the admitted category was compared with Hospital Episodes Statistics (HES) Finished Episodes data. These show over 500 Finished Episodes for patients aged under 16 in 2007-2008 under the Adult Mental Illness Main Specialty, so there is some consistency between MHMDS and HES reporting of young people being treated on adult wards. However, these figures are not consistent with other data returned directly to the Department of Health by Primary Care Trusts (PCTs). This discrepancy is being addressed with trusts as part of the process of moving from ‘experimental’ to ‘official’ statistics and further investigation will be carried out into possible causes.&lt;/P&gt;
&lt;P&gt;The results are presented as ‘experimental statistics’ because there are still issues with the collection and coverage of the data. The NHS Information Centre is working with partners to resolve these issues. Also, the design and methodology of the analysis are new and the most useful form for regular national statistics from the MHMDS has not yet been finalised.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266199</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://website.scmh.org.uk/80256FBD004F6342/vWeb/pcKHAL74HHC6]]&gt;</url>
    <title>Mental Health Care in Prisons: Briefing</title>
    <publicationDate>2007-06-26T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,PRISONS,BUILDINGS,MONTHLY ADDITIONS,SETTINGS,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This 8-page briefing paper provides an overview of the mental health care available in prisons.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The quality of mental health care available in our prisons is frequently poor.&lt;/P&gt;
&lt;P&gt;This briefing paper provides an overview of the mental health care available in prisons. It examines how mental health problems are identified in prison, how prison inreach teams work, transfers to NHS care, alternatives to prison, and what care is available to prisoners after their release.&lt;/P&gt;
&lt;P&gt;It also makes recommendations for improvements and introduces the Sainsbury Centre for Mental Health's criminal justice work.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332616</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_109698.pdf]]&gt;</url>
    <title>Mental health clinical costing standards 2009/2010</title>
    <publicationDate>2009-12-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,FINANCE AND FUNDING,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Best practice guidance for organisations using and implementing Patient Level Costing and Information Systems (PLICS) in a mental health setting.]]&gt;</body>
  </document>
  <document>
    <id>270428</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/mental_health/policy/en/]]&gt;</url>
    <title>Mental health Improvements for Nations Development: The WHO MIND Project</title>
    <publicationDate>2007-10-11T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,ETHNIC GROUPS,DISADVANTAGED GROUPS,LANGUAGE,MENTAL &amp; BEHAVIOURAL DISORDERS,ETHNICITY,POPULATION BASED &amp; PREVENTATIVE SERVICES,POLICY,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,SOCIETY,SOCIOECONOMIC FACTORS,INDIVIDUAL BEHAVIOUR,SUBSTANCE MISUSE,SERVICES,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES,LAW,HEALTH SERVICES,PROFESSIONAL PRACTICE,GOVERNMENT &amp; LAW,INTERNATIONAL ISSUES,GEOGRAPHY,POPULATIONS,GROUPS,SETTINGS,CULTURAL IDENTITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Mental and neurological disorders such as depression, schizophrenia, epilepsy and substance abuse, among others, cause immense suffering for those affected, amplifies people's vulnerability and can lead individuals into a life of poverty. Despite the worldwide availability of cost-effective treatments the vast majority of people are left without access to the treatment they need.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Mental health Improvements for Nations Development: The WHO MIND Project&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Towards concrete changes in people's daily lives&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Mental and neurological disorders such as depression, schizophrenia, epilepsy and substance abuse, among others, cause immense suffering for those affected, amplifies people's vulnerability and can lead individuals into a life of poverty. Despite the worldwide availability of cost-effective treatments the vast majority of people are left without access to the treatment they need. Instead of getting the help and support they require to lead productive lives, many people are subject to stigma, discrimination and human rights violations and are denied the basic life opportunities given to other citizens. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Mental health improvements are central to nations' development&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;By treating many of the debilitating mental disorders and by promoting mental health, people will experience major improvements in their lives. They will be able to work and rise out of poverty, provide their children with the right social and emotional environment to flourish, participate productively in community life, and contribute to the economy of their country. In order to achieve this countries need to put in place human rights oriented mental health policies, strategic plans and laws to ensure that effective treatment, prevention and promotion programs are made available to all people who need them.&lt;/P&gt;
&lt;H2&gt;THE 4 CORE THEMATIC AREAS OF WHO MIND &lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;ACTION IN COUNTRIES: Nations at Work&lt;/H2&gt;
&lt;P&gt;The ultimate goal of the World Health Organisation's work with countries is to reduce the treatment gap - allowing more people with mental disability to receive effective and humane treatment and care so that they and their families are able o live productive lives in the community.&lt;/P&gt;
&lt;P&gt;In this web space, you will find examples of the excellent work being carried out in countries to improve the lives of people with mental disorders.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.who.int/mental_health/policy/country/en/index.html" target="_blank"&gt;More on country work for mental health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;MENTAL HEALTH POLICY, PLANNING &amp;amp; SERVICE DEVELOPMENT: Integration for better services&lt;/H2&gt;
&lt;P&gt;Mental health policy and action plans are important because they coordinate, through a common vision, all programmes and services related to mental health. Without this type of organization, mental disorders are likely to be treated in an inefficient and fragmented manner.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.who.int/mental_health/policy/services/en/index.html" target="_blank"&gt;More on policies, plans and service development for mental health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;MENTAL HEALTH, HUMAN RIGHTS &amp;amp; LEGISLATION: Denied citizens: Including the excluded&lt;/H2&gt;
&lt;P&gt;Too many people with mental disability are exposed to a wide range of human rights violations both within psychiatric institutions and in the community. Developing mental health legislation which respects human rights and setting up bodies to monitor human rights conditions in mental health facilities are two important steps towards stopping these violations.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.who.int/mental_health/policy/legislation/en/index.html" target="_blank"&gt;More on legislation and human rights protection for mental health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;MENTAL HEALTH, POVERTY &amp;amp; DEVELOPMENT: Mental health core to development&lt;/H2&gt;
&lt;P&gt;By treating and preventing mental disorders we can: reduce premature mortality; improve outcomes for many debilitating and chronic 'physical ' health problems; reduce violence and injuries; and improve social and economic development.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.who.int/mental_health/policy/development/en/index.html" target="_blank"&gt;More on links between poverty, development &amp;amp; mental health&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111322</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111322]]&gt;</url>
    <title>Mental health in communities</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,ENVIRONMENTAL,MENTAL &amp; BEHAVIOURAL DISORDERS,SOCIAL CAPITAL,CAPACITY BUILDING,DISADVANTAGED GROUPS,ETHNIC GROUPS,PUBLIC HEALTH,DETERMINANTS,SOCIAL DETERMINANTS,CULTURAL IDENTITY,COMMUNITIES,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mental health in communities&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111321:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111323:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Current frameworks for mental health promotion no longer concentrate only on the prevention of individual mental illness. Rather enhancing a sense of well-being or promoting positive mental health are also seen as key goals (ref 1). An emphasis on public mental health widens its application onto the mental health needs of the whole population rather than individuals. Public mental health also extends to enhancing the mental health of organisations and communities with a view to fostering a mentally healthy society.&lt;/P&gt;
&lt;P&gt;This approach is coherent with the view that mental health is not simply a characteristic of individuals. Whole communities, including faith communities, ethnic communities and communities of identity, can feel marginalised, fearful and unable to participate fully. These feelings impact on mental and physical health (ref 2, 3). Perceptions of racial discrimination are a significant factor in the poor health of Black and Minority Ethnic Groups, over and above socio-economic factors (ref 4) and lack of trust in unfamiliar others is a risk factor for psychological problems (ref 5).&lt;/P&gt;
&lt;P&gt;Community interventions which focus on building social capital or structural interventions which widen participation in education offer opportunities for promoting the health of communities. (ref 6, 7).&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111321:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111323:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Department of Health (2001) Making it happen: a guide to delivering mental health promotion London. Department of Health.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Ferrie JE, Shipley MJ, Marmot M et al (1998) An uncertain future: the health effects of threats to employment security in white collar men and women American Journal of Public Health 88:1030-6&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Marmot M, Ferrie J, Newman K and Stansfeld S (2001) The contribution of job insecurity to socio-economic inequalities &lt;A href="http://www.lancs.ac.uk/users/apsocsci/hvp/newsletters/11findings.htm" target="_blank"&gt;ESRC Research Findings 11 from the Health Variations Programme &lt;/A&gt;Lancaster: University of Lancaster&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Nazroo JY and Karlsen S (2001) Ethnic inequalities in health: social class, racism and identity &lt;A href="http://www.lancs.ac.uk/users/apsocsci/hvp/newsletters/10findings.htm" target="_blank"&gt;ESRC Research Findings 10 from the Health Variations Programme&lt;/A&gt; Lancaster: Lancaster University&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Berry HL and Rickwood DJ (2000) Measuring social capital at the individual level: personal social capital, values and psychological distress International Journal of Mental Health Promotion 2,3 35-44&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;East of England Faiths Leadership Conference (2003) &lt;A href="http://www.eeflc.org.uk/faith.pdf" target="_blank"&gt;Faith in Action: A Report on Faith Communities and Social Capital in the East of England&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Cameron M, Edmans T, Greatley A and Morris D (2003) Community Renewal and Mental Health: Strengthening the Links. London: &lt;A href="http://www.kingsfund.org.uk/index.cfm" target="_blank"&gt;Kings Fund&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>374954</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/armed-forces-wellbeing-military-health.aspx]]&gt;</url>
    <title>Mental health in the armed forces</title>
    <publicationDate>2010-05-13T00:00:00</publicationDate>
    <publisher>NHS Choices -Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Medical services face a tidal wave of servicemen suffering from mental trauma as a result of the wars in Iraq and Afghanistan”, reported &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;. Other newspapers reporting the same study said that alcohol abuse is a bigger problem.&lt;/P&gt;
&lt;P&gt;This news is based on a survey of nearly 10,000 personnel in the UK armed forces, which&amp;nbsp;looked at whether being deployed in Iraq or Afghanistan affects mental health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291475</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=291475]]&gt;</url>
    <title>Mental Health Journals available from NLH</title>
    <publicationDate>2008-08-04T00:00:00</publicationDate>
    <publisher>Mental Health Specialist Library</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>This is a list of the journals relevant to mental health practitioners which are available from the NLH homepage.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mental Health Journals available from NLH&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Access the current contents pages of the top mental health journals: &lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://ebmh.bmj.com/current.dtl" target="_blank"&gt;Evidence-Based Mental Health&lt;/A&gt; (from BMJ) – Available via My Journals, embargo: 1 year&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.bmj.com/current.dtl" target="_blank"&gt;British Medical Journal&lt;/A&gt; (from BMJ)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://archpsyc.ama-assn.org/current.dtl" target="_blank"&gt;Archives of General Psychiatry&lt;/A&gt; (from AMA) – Available via My Journals, embargo: 1 year&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://jama.ama-assn.org/current.dtl" target="_blank"&gt;Journal of the American Medical Association&lt;/A&gt; (from AMA)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://ajp.psychiatryonline.org/current.dtl" target="_blank"&gt;American Journal of Psychiatry&lt;/A&gt; (from EBSCO, via CINAHL)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://bjp.rcpsych.org/current.shtml" target="_blank"&gt;British Journal of Psychiatry&lt;/A&gt; (from EBSCO, via CINAHL)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www3.interscience.wiley.com/journal/4294/home" target="_blank"&gt;International Journal of Geriatric Psychiatry&lt;/A&gt; (from EBSCO, via CINAHL)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://psycnet.apa.org/index.cfm?fa=browsePA.volumes&amp;amp;jcode=ccp" target="_blank"&gt;Journal of Consulting and Clinical Psychology&lt;/A&gt; (from EBSCO, via CINAHL)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www3.interscience.wiley.com/journal/117995531/home" target="_blank"&gt;Journal of the American Geriatrics Society&lt;/A&gt; (from EBSCO, via CINAHL)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www3.interscience.wiley.com/journal/117967480/home" target="_blank"&gt;Addiction&lt;/A&gt; (from EBSCO, via CINAHL)&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Other&amp;nbsp;medical journals available from NLH (links are&amp;nbsp;to the current contents pages):&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://content.nejm.org/current.shtml" target="_blank"&gt;New England Journal of Medicine&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.informaworld.com/smpp/title~db=all~content=g902176360~tab=toc" target="_blank"&gt;Australian and New Zealand Journal of Psychiatry&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.sciencedirect.com/science/journal/01638343" target="_blank"&gt;General Hospital Psychiatry&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://jnnp.bmj.com/" target="_blank"&gt;Journal of Neurology, Neurosurgery, and Psychiatry&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://pediatrics.aappublications.org/current.shtml" target="_blank"&gt;Pediatrics&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.annals.org/current.shtml" target="_blank"&gt;Annals of Internal Medicine&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://springerlink.metapress.com/content/104757/?Content+Status=Accepted" target="_blank"&gt;Journal of Autism and Developmental Disorders&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://psychservices.psychiatryonline.org/current.dtl" target="_blank"&gt;Psychiatric Services&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;*These are all journals which are available through Athens. You can register for Athens by following &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;this link&lt;/A&gt;.*&lt;/H2&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>263069</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38668&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Mental Health Needs of Young Offenders update</title>
    <publicationDate>2002-05-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,OUTCOMES,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,CHILDREN,YOUNG PEOPLE,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,HEALTHCARE &amp; HEALTH SERVICES,HEALTH SERVICES,PUBLIC SERVICES,LAW,BUILDINGS,PRISONS,CUSTODIAL CENTRES,GOVERNMENT &amp; LAW,POPULATIONS,SETTINGS,GROUPS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In 2000 the Mental Health Foundation established a vulnerable young people project to explore the mental health needs of four key groups of young people identified as being at risk of developing mental health difficulties.These being young offenders, children with emotional and behavioural difficulties, looked after children and homeless young people.This project forms part of the Mental Health Foundation’s ongoing programme of work on children and young people’s mental health .&lt;/P&gt;
&lt;P&gt;Research on current policy and practice with respect to the mental health needs of each group was commissioned by the Mental Health Foundation. The focus of the research was on England but the issues and findings will be relevant to interested parties across the UK. Full reports have been prepared for each group and issued for consultation. A combined final report will be published in the spring of 2003.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This update reports on a research carried out by the Policy Research Bureau,&lt;BR&gt;commissioned by the Mental Health Foundation, on a review of existing research literature on the mental health of young offenders.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266075</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.acd?AssetID=38625&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Mental Health of Looked-After Children</title>
    <publicationDate>2002-08-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DISADVANTAGED GROUPS,CARERS,CHILDREN,YOUNG PEOPLE,POLICY,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,HEALTH SERVICES,CARE,POPULATIONS,GROUPS,HOUSEHOLDS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report looks at work that is addressing the mental health needs of looked-after children, who are a particularly vulnerable group. The report also presents areas of concern and proposals for change.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report looks at work that is addressing the mental health needs of looked-after children, who are a particularly vulnerable group. The report also presents areas of concern and proposals for change.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40171&amp;amp;type=Full&amp;amp;servicetype=Attachment" target="_blank"&gt;Mental Health of Looked-After Children Summary - Full-text PDF&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Summary of report looking at work that is addressing the mental health needs of looked-after children, who are a particularly vulnerable group. The report also presents areas of concern and proposals for change.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266117</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38735&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Mental Health of Young Offenders</title>
    <publicationDate>2002-08-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH,OUTCOMES,YOUNG PEOPLE,CHILDREN,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,CARE,PUBLIC SERVICES,LAW,HEALTH SERVICES,INFORMATION,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES,CUSTODIAL CENTRES,PRISONS,GOVERNMENT &amp; LAW,BUILDINGS,AGE GROUPS,GROUPS,SETTINGS,POPULATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report reviews existing literature on the mental health needs of young offenders and addresses issues of prevalence, types of disorders, and relevant interventions.</description>
    <body>&lt;![CDATA[ This report reviews existing literature on the mental health needs of young offenders and addresses issues of prevalence, types of disorders, and relevant interventions. The report has an English focus but the issues raised will be of relevance to interested partners across the UK, even though youth justice arrangements vary.]]&gt;</body>
  </document>
  <document>
    <id>213022</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=213022]]&gt;</url>
    <title>Mental Health Policy Implementation Guide: Community Development Workers for Black and Minority Ethnic Communities</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,COMMUNITY DEVELOPMENT,ETHNIC GROUPS,POPULATION BASED &amp; PREVENTATIVE SERVICES,POLICY,COMMUNITY DEVELOPMENT,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SERVICES,MANAGEMENT &amp; POLICY,GROUPS,CULTURAL IDENTITY,COMMUNITIES,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Final Handbook (November 2006)</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mental Health Policy Implementation Guide: Community Development Workers for Black and Minority Ethnic Communities&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Preface&lt;/P&gt;
&lt;P&gt;Community Development Workers (CDWs) will work with and support communities including the Black and Minority Ethnic (BME) voluntary sector, help build capacity within them, and ensure the views of the minority communities are taken into account by the statutory sector during planning and delivery of services.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>289685</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=289685]]&gt;</url>
    <title>Mental Health Specialist Collection: Content Development Strategy November 2009</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mental Health Specialist Collection: Content Development Strategy November 2009&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The Mental Health Specialist&amp;nbsp;Collection Content Development Strategy contains the following information:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;SCOPE OF THIS STRATEGY&amp;nbsp;4&lt;/LI&gt;
&lt;LI&gt;PURPOSE/AIMS OF THE MENTAL HEALTH SPECIALIST COLLECTION&amp;nbsp;4&lt;/LI&gt;
&lt;LI&gt;TARGET AUDIENCE&amp;nbsp;4&lt;/LI&gt;
&lt;LI&gt;KEY STAKEHOLDERS&amp;nbsp;4&lt;BR&gt;a. Core team&amp;nbsp;4&lt;BR&gt;b. Core groups&amp;nbsp;5&lt;BR&gt;c. External reference group (ERG)&amp;nbsp;5&lt;/LI&gt;
&lt;LI&gt;TAXONOMY&amp;nbsp;5&lt;BR&gt;a. Adult conditions&amp;nbsp;5&lt;BR&gt;b. Child and adolescent conditions&amp;nbsp;6&lt;BR&gt;c. Mental health promotion&amp;nbsp;6&lt;/LI&gt;
&lt;LI&gt;TYPES OF INFORMATION INCLUDED IN THE COLLECTION&amp;nbsp;6&lt;BR&gt;a. Guidance and Pathways&amp;nbsp;6&lt;BR&gt;b. Evidence&amp;nbsp;7&lt;BR&gt;c. Reference&amp;nbsp;7&lt;BR&gt;d. Education and CPD&amp;nbsp;7&lt;BR&gt;e. Patient information&amp;nbsp;7&lt;/LI&gt;
&lt;LI&gt;SELECTION CRITERIA AND QUALITY CONTROL&amp;nbsp;7&lt;/LI&gt;
&lt;LI&gt;SEARCH STRATEGIES&amp;nbsp;8&lt;/LI&gt;
&lt;LI&gt;ANNUAL EVIDENCE UPDATES&amp;nbsp;8&lt;BR&gt;a.&amp;nbsp;Sources to search&amp;nbsp;8&lt;BR&gt;APPENDIX 1: SOURCES OF EVIDENCE&amp;nbsp;10&lt;BR&gt;APPENDIX 2 – LIDA INSTRUMENT&amp;nbsp;16&lt;BR&gt;APPENDIX 3 – COCHRANE SCHIZOPHRENIA SEARCH STRATEGIES&amp;nbsp;29&lt;BR&gt;APPENDIX 4 – DEPRESSION PUBMED SEARCH STRATEGY&amp;nbsp;34&lt;BR&gt;APPENDIX 5 - MENTAL HEALTH SC PROPOSED TAXONOMY (&lt;A href="http://www.library.nhs.uk/MENTALHEALTH" target="_blank"&gt;WWW.LIBRARY.NHS.UK/MENTALHEALTH&lt;/A&gt;)&amp;nbsp;37&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>289385</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=289385]]&gt;</url>
    <title>Mental Health Specialist Library: Promotional materials</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Mental Health Specialist Library</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Download the MHSL promotional materials here.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Mental Health Specialist Library: Promotional materials&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Download the MHSL leaflet and poster to use in your organisations and networks to promote the library:&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;H2&gt;Free&lt;/H2&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;H2&gt;Reliable&lt;/H2&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;H2&gt;Evidence-based&lt;/H2&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>319364</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.euro.who.int/document/e92227.pdf]]&gt;</url>
    <title>Mental Health, resilience and inequalities</title>
    <publicationDate>2009-06-25T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,MONTHLY ADDITIONS,DETERMINANTS,PUBLIC HEALTH,PSYCHOLOGICAL DETERMINANTS,SOCIAL DETERMINANTS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report explores the wealth of evidence that mental health influences a very wide range of outcomes for individuals and communities. These include healthier lifestyles; better physical health; improved recovery from illness; fewer limitations in daily living; higher educational attainment; greater productivity, employment and earnings; better relationships with adults and with children; more social cohesion and engagement and improved quality of life.&lt;/P&gt;
&lt;P&gt;These outcomes are not just or necessarily a consequence of the absence of mental illness, but are associated with the presence of positive mental health, sometimes referred to as ‘wellbeing’. Improving mental health is a worthwhile goal in itself: most people value a sense of emotional and social wellbeing; in addition, good mental health has many other far reaching benefits.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260302</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074490]]&gt;</url>
    <title>Mental Health: New Ways of Working for Everyone</title>
    <publicationDate>2007-04-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Progress Report: April 2007</description>
    <body>&lt;![CDATA[ &lt;P&gt;172-page document on developing and sustaining a capable and flexible workforce, launched by Professor Louis Appleby.&lt;/P&gt;
&lt;P&gt;Produced by the National Institute for Mental Health in England (NIMHE) National Workforce Programme, the report builds on previous guidance and promotes a model where ‘distributed responsibility’ is shared amongst team members and no longer be delegated by a single professional such as the consultant.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325539</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;o=11991]]&gt;</url>
    <title>Mental wellbeing of children in secondary education</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance is for all those who have a responsibility for the social and emotional wellbeing of young people in secondary education. This includes teachers, support staff, governors and professionals with public health as part of their remit working in education (including the independent sector), local authorities, the NHS and the wider public, voluntary and community sectors.&lt;/P&gt;
&lt;P&gt;It focuses on interventions to support all young people aged 11-19 who attend any education establishment.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293478</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhhe.heacademy.ac.uk/]]&gt;</url>
    <title>MHHE: Mental health in higher education</title>
    <publicationDate>2008-09-02T00:00:00</publicationDate>
    <publisher>Mental health in higher education</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Mental Health in Higher Education (mhhe) aims to increase networking and the sharing of approaches to learning and teaching about mental health across the disciplines in UK higher education.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Use this website to access information, exchange resources, share ideas and to keep up to date with news and developments.&lt;/P&gt;
&lt;P&gt;There is a growing resource about learning and teaching mental health in the past few years. You can find some of these resources here so as to prevent reinventing the wheels, or to get inspired and develop better teaching resources.&lt;/P&gt;
&lt;P&gt;Sometimes you may wonder how mental health is taught in other subjet areas or in different institutions. You may also want to develop an innovative idea of teaching with colleagues who share similar interests, or you may want to spark off a debate about issues you encountered in daily teaching aout mental health. This website is a portal for you to connect with other mental health educators across UK. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383438</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/65.full.pdf]]&gt;</url>
    <title>Misconceptions about gene–environment interactions in psychiatry</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Misunderstandings surrounding the study of gene–environment interactions are very common. Given the large increase in the number of studies examining interactions in recent years, this raises serious concerns about the value of time and resources spent in these endeavours. In this article we discuss why, despite frequent claims to the contrary, studies of gene–environment interactions are very unlikely to enhance our understanding of disease aetiology or prevention.]]&gt;</body>
  </document>
  <document>
    <id>105869</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=105869]]&gt;</url>
    <title>Models of mental health promotion</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,ENVIRONMENTAL,EDUCATION,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,SOCIAL CAPITAL,CAPACITY BUILDING,POPULATION BASED &amp; PREVENTATIVE SERVICES,POLICY,PUBLIC HEALTH,DETERMINANTS,SOCIAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,SERVICES,COMMUNITIES,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Models of mental health promotion&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:105868:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:105872:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Mental health promotion does have a role to play in preventing mental health problems, but it also has a much wider range of health, social and economic benefits. Current frameworks for mental health promotion no longer concentrate solely on the prevention of mental illness.&lt;/P&gt;
&lt;P&gt;There are several complementary models of mental health promotion which acknowledge individual and broader socio-economic determinants on mental health. A common feature is the need to broaden mental health promotion programmes and interventions beyond those targeting the individual. For example, community interventions which focus on building social capital or policy level interventions which widen participation in education have also been identified as the domain of mental health promotion.&lt;/P&gt;
&lt;P&gt;Such a ‘public mental health’ approach supports the enhancement of well-being or the promotion of ‘positive mental health’ as laudable goals. The application of this approach reflects a public health ethos which looks beyond individuals to the physical, social and environmental context for health (ref 1).&lt;/P&gt;
&lt;P&gt;The logical end point of this approach is the design and delivery of interventions and programmes to promote the mental health of organizations and communities with a view to fostering a ‘mentally healthy society’.&lt;/P&gt;
&lt;P&gt;Mental health promotion functions at three interconnected levels.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Individual - increasing emotional resilience through interventions designed to promote self-esteem, life and coping skills, e.g. communicating, negotiating, relationship and parenting skills;&lt;/LI&gt;
&lt;LI&gt;Community – increasing social support, social inclusion and participation, improving neighbourhood environments, anti-bullying strategies at school, workplace health, community safety, childcare and self-help networks.&lt;/LI&gt;
&lt;LI&gt;Structural/policy - developing initiatives to reduce discrimination and inequalities, to promote access to education, meaningful employment, affordable housing, health, social and other services which support those who are vulnerable (ref 1, 2)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The principles of effective mental health promotion interventions have been described as those which include the following approaches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The intervention aims to influence a combination of several risk or protective factors;&lt;/LI&gt;
&lt;LI&gt;It involves the social network of the target group;&lt;/LI&gt;
&lt;LI&gt;It intervenes at a range of different times rather than once only;&lt;/LI&gt;
&lt;LI&gt;It involves a combination of intervention methods (ref 3)&lt;BR&gt;Key principles of effective practice include programmes that aim to:&lt;/LI&gt;
&lt;LI&gt;Reduce anxiety&lt;/LI&gt;
&lt;LI&gt;Enhance control&lt;/LI&gt;
&lt;LI&gt;Facilitate participation&lt;/LI&gt;
&lt;LI&gt;Promote social inclusion (ref 1)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Principles that are considered to underpin effective interventions include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;non-stigmatising provision – often open access&lt;/LI&gt;
&lt;LI&gt;needs-led programmes – based on mapping, current provision and priorities&lt;/LI&gt;
&lt;LI&gt;effective methods of consultation with local communities and ownership&lt;/LI&gt;
&lt;LI&gt;engagement with users – in the broadest sense – can be the whole community&lt;/LI&gt;
&lt;LI&gt;delivery in partnership – pan sector approach to provision&lt;/LI&gt;
&lt;LI&gt;utilising appropriate approaches – eg. peer led (age specific), culturally relevant (ref 4)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Mental health promotion can also contribute significantly to health improvement for people living with mental health problems and has a key role to play in challenging discrimination and increasing understanding of mental health issues. (see &lt;A href="nelh:111331:1" name=internalLink&gt;marginalised groups - people with mental health problems&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;Mental health promotion interventions and programmes should be as broad-based as possible and not limited purely to high risk groups. People at high risk will only ever be a small percentage of the whole population, so that programmes restricted to this target group undermine the potential of mental health promotion to reduce the prevalence of common mental health problems in the population at large.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:105868:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:105872:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Department of Health (2001) Making it happen: a guide to developing mental health promotion London: Department of Health&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Health Education Authority (1997) Mental Health Promotion: A Quality Framework. London: HEA.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Bosma MWM and Hosman CMH (1990) Preventie op waarde geschat. Nijmegen: Beta&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Sainsbury Centre for Mental Health and mentality (2004) Briefing on Standard One of the National Service Framework for Mental Health: Mental Health Promotion. London. &lt;A href="http://www.scmh.org.uk/8025694D00337EF1/vWeb/fsCPIR4PDJ8T" target="_blank"&gt;SCMH&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>259580</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/professionals/MotivationalInt.shtml]]&gt;</url>
    <title>Motivational Interviewing</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Motivational interviewing for Eating Disorders, by Prof Janet Treasure, Dr Ulrike Schmidt and Gill Todd, Eating Disorder South London and Maudsley NHS Trust.]]&gt;</body>
  </document>
  <document>
    <id>329925</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Multi-tasking-test-for-Alzheimers.aspx]]&gt;</url>
    <title>Multi-tasking test for Alzheimer's</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,DEMENTIA,DIAGNOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ “A multi-tasking test can help avoid confusion between symptoms of depression and early Alzheimer’s,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reported. It said that people with Alzheimer’s often have mildly impaired reasoning and memory, which can&amp;nbsp;easily be mistaken for signs of depression. This can&amp;nbsp;lead to&amp;nbsp;them being wrongly diagnosed.]]&gt;</body>
  </document>
  <document>
    <id>154901</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.npcrdc.ac.uk/Publications/PCMHWs.pdf]]&gt;</url>
    <title>National Evaluation of Primary Care Mental Health Workers</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>National Primary Care Research &amp; Development Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is a summary of the final report of the National Evaluation of Graduate Primary Care Mental Health Workers (PCMHWs) carried out by the National Primary Care Research and Development Centre (NPCRDC) at The University of Manchester.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Report conclusions:&lt;/H2&gt;&lt;FONT face=Helvetica size=3&gt;
&lt;P align=left&gt;Fewer graduate PCMHWs were employed than originally planned and many initially reported an intention to apply to clinical psychology training. In the initial survey, approximately two-thirds managed patients and this figure rose to over 90% by follow-up. Access to the graduate PCMHWs was often restricted with half of patients being reviewed beforehand by a specialist mental health professional. Types of patients seen and interventions provided were generally in line with current guidelines. The integration of graduate PCMHWs into primary care was a significant predictor of their clinical role. At follow-up, graduate PCMHWs were more satisfied with various aspects of the job but remuneration remained a source of dissatisfaction for most. More than half reported an intention to leave their post within the next six months, though many indicated that they would remain within the NHS.&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296539</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.skillsforhealth.org.uk/~/media/Resource-Library/PDF/XMod_update_%20July_09-PT.ashx]]&gt;</url>
    <title>National Occupational Standards (NOS) for Psychological Therapies.</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Skills for Health</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Skills for Health (SfH) are developing National Occupational Standards (NOS) for Psychological Therapies. The development of NOS in this area will make a timely and significant contribution to a number of UK initiatives in this area.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Skills for Health (SfH) are developing National Occupational Standards (NOS) for Psychological Therapies. The development of NOS in this area will make a timely and significant contribution to a number of UK initiatives in this area.&lt;/P&gt;
&lt;P&gt;The project will focus on the delivery of Psychological Therapy and will focus on four therapy areas covering adults and children:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cognitive Behaviour Therapy 
&lt;LI&gt;Psychodynamic Psychoanalytic Therapy 
&lt;LI&gt;Systemic and Family Therapy 
&lt;LI&gt;Humanistic Person-centred / Process Experiential (working title)&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>322035</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_103351]]&gt;</url>
    <title>National oversight group annual report 2008-09</title>
    <publicationDate>2009-07-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ First annual report of the National Oversight Group for High Secure Services, which brings together significant stakeholders to provide oversight for the high secure services on behalf of the Secretary of State for Health.]]&gt;</body>
  </document>
  <document>
    <id>259628</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nimhe.csip.org.uk/our-work/suicide-prevention/annual-report-on-progress-2006.html?keywords=National%20Suicide%20Prevention%20Strategy%20for%20England]]&gt;</url>
    <title>National Suicide Prevention Strategy for England</title>
    <publicationDate>2007-04-16T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Annual report on progress 2006</description>
    <body>&lt;![CDATA[ This 28-page report shows that good progress is being made towards meeting the Government target to reduce suicide by 20 per cent by 2010, but more can be done to bring down the suicide rate further. It sets out the achievements of the last 12 months and shows the lowest overall rate of suicide amongst the general population on record, a fall in suicide rates amongst young men, a fall in the rate of self-inflicted deaths in prisons to 70 in 2005/6, a 17 per cent reduction compared with last year and a fall in the number of suicides amongst mental health in-patients from 217 in 1997 to 154 in 2004. The report also says that more needs to be done to reduce the number of people in contact with mental health services who take their own lives.]]&gt;</body>
  </document>
  <document>
    <id>291524</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nacro.org.uk/data/files/nacro-2006042400-283.pdf]]&gt;</url>
    <title>National Suicide Prevention Strategy for England - annual report on progress 2005</title>
    <publicationDate>2008-08-05T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This is the fifth annual report of progress since the national suicide prevention strategy for England was launched. The National Institute for Mental Health in England, part of the Care Services Improvement Partnership (CSIP), is responsible for implementation of the strategy in partnership with a range of agencies and organisations committed to supporting delivery of the strategy goals and objectives.]]&gt;</body>
  </document>
  <document>
    <id>266887</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nta.nhs.uk/areas/treatment_planning/docs/nta_needs_assessment_guidance.pdf]]&gt;</url>
    <title>Needs assessment guidance for adult drug treatment</title>
    <publicationDate>2007-08-31T00:00:00</publicationDate>
    <publisher>National Treatment Agency for Substance Misuse</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,DRUG USE DISORDERS,DETERMINANTS,DISADVANTAGED GROUPS,SERVICE PROVISION,PEOPLE WITH MENTAL HEALTH PROBLEMS,DISEASE/CONDITION GROUPS,MENTAL HEALTH PROBLEMS,POPULATIONS SERVED,ASSESSMENT AND PLANNING,NEEDS ASSESSMENT,COMMISSIONING,HEALTH MANAGEMENT,NHS ACTIVITIES,NEEDS ASSESSMENT,PUBLIC HEALTH,SUBSTANCE MISUSE,INDIVIDUAL BEHAVIOUR,LIFESTYLE,SOCIAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,COMMISSIONING PROCESS,2008-AUGUST,MONTHLY ADDITIONS,POPULATIONS,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The new needs assessment guidance issued by the National Treatment Agency (NTA) is designed to assist commissioners and local partnership to build on the advances made in 07/08 in terms of depth and uniformity of approach to needs assessment, and in the evidence base on which decisions are made for treatment planning.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report contains information about needs assessments and&amp;nbsp;treatment system mapping. &lt;/P&gt;
&lt;P&gt;A range of health needs assessment (HNA) approaches have been suggested since the early 1990s and each has its place in the comprehensive needs assessment approach required for formulating plans that reduce the harms associated with drug use. In broad terms, these are:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Epidemiology and research – the collection, analysis and interpretation of data (both qualitative and qualitative); to generate hypotheses and answer them 
&lt;LI&gt;Corporate – determining and balancing the views of a range of local and regional stakeholders; building their commitment to the resulting action plans 
&lt;LI&gt;Comparative – assessing existing provision against service standards, national targets and other comparable areas.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Combined, these provide a robust and systematic process for the production of an evidencebased adult drug treatment plan. The needs assessment should be seen as a strategic process – owned and understood by stakeholders – and is an integral part of treatment planning, implementation and performance management.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327444</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.screening.nhs.uk/getdata.php?id=9449]]&gt;</url>
    <title>New consultation - depression</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>UK National Screening Committee</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The draft evaluation of depression screening against the UK NSC criteria.&lt;/P&gt;
&lt;P&gt;This paper uses evidence published up to June 2009 to update the review by Gilbody et al (2006) of the performance of screening for depression against the UK National Screening Committee Criteria for appraising the viability, effectiveness and appropriateness of a screening programme (National Screening Committee 2003).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327432</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Healthcare/Mentalhealth/NewHorizons/index.htm]]&gt;</url>
    <title>New Horizons in Mental Health - what do you think?</title>
    <publicationDate>2009-10-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Government wants to help everyone to have better mental health. The New Horizons consultation aims to help come up with an approach to make services for adults with mental health problems better in the future, and to help everyone have better mental health.]]&gt;</body>
  </document>
  <document>
    <id>332576</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_109708.pdf]]&gt;</url>
    <title>New Horizons: a shared vision for mental health</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DEPRESSION,QUALITY IMPROVEMENT,MONTHLY ADDITIONS,QUALITY AND MONITORING,SERVICE SECTORS,POLICY,MENTAL HEALTH SERVICES,HEALTH MANAGEMENT,DETERMINANTS,PUBLIC HEALTH,PSYCHOLOGICAL DETERMINANTS,INNOVATION AND IMPROVEMENT,ORGANISATIONAL DEVELOPMENT,ORGANISATIONS,2010,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;New Horizons is a cross-government programme of action with the twin aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;improve the mental health and well-being of the population&lt;/LI&gt;
&lt;LI&gt;improve the quality and accessibility of services for people with poor mental health.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;New Horizons sets out an intention across a wide range of agencies to move towards a society where people understand that their mental well-being is as important as their physical health if they are to live their lives to the full. It describes some of the factors that affect well-being and some everyday strategies for preserving and boosting it. It also sets out the benefits, including economic benefits, of doing so.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321412</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_103144]]&gt;</url>
    <title>New Horizons: towards a shared vision for mental health - consultation</title>
    <publicationDate>2009-07-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,QUALITY AND MONITORING,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION,QUALITY IMPROVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Over the last 18 months, the Department of Health has been talking to a wide range of people and organisations about their ideas for better mental well-being and better mental health care as part of the New Horizons programme. New Horizons exists in order to advance the aims of improving the mental health and well-being of the population as well as improving the quality and acessibility of services for people with poor mental health. The New Horizons consultation document reflects what has been heard so far.&lt;/P&gt;
&lt;P&gt;This consultation document sets out a new vision for targeting the root causes of mental illness and supporting the local development of higher quality, more personalised services. It explores both the prevention of mental illness and earlier intervention when things go wrong. It also looks at how services can become more innovative and work more effectively together. Key themes include prevention; tackling stigma; early interventions; personalised care; innovation; value for money; multi-agency commissioning / collaboration and strengthening transitional care.&lt;/P&gt;
&lt;P&gt;While New Horizons describes some clear ideas that have emerged during discussions with a wide range of people it is not a final document. There are a number of important questions still to be resolved and the response to these and the rest of the proposals will have a strong influence on the final version. There is also a link to the online questionnaire regarding the consultation document in the other 'links section' below. &lt;/P&gt;
&lt;P&gt;The consultation closes on 15 October 2009.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;Target audience&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;PCT CEs, NHS Trust CEs, SHA CEs, Care Trust CEs, Foundation Trust CEs, Medical Directors, Directors of PH, Directors of Nursing, local authority CEs, Directors of Adult SSs, PCT Chairs, NHS Trust Board Chairs, Special HA CEs, Directors of Finance, allied health professionals, GPs, communications leads, emergency care leads, Directors of Children’s SSs, public health leads and specialists, National Mental Health Development Unit&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270743</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_079102]]&gt;</url>
    <title>New Ways of Working for Everyone - A best practice implementation guide</title>
    <publicationDate>2007-10-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The guide sets out how health and social care organisations could take a strategic approach to the implementation of New Ways of Working.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The purpose of this best practice implementation guide, produced by the National Institute for Mental Health in England (NIMHE) National Workforce Programme (NWP), is to set out how health and social care organisations could take a strategic approach to the implementation of New Ways of Working (NWW). Until now, NWW has been addressed by some&amp;nbsp; practitioners and teams and has been discussed at Board level in some Trusts.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In this guide, we aim to help and support organisations in addressing how NWW can be approached across the whole system. As NHS Trusts are the largest single employers of mental health professionals at this time, they have been identified here as the primary audience in the first instance.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;A draft of this guide was presented to the NWW for Everyone national conference which took place on 25 April 2007, as well as the subsequent regional conferences organised by the Care Services Improvement Partnership (CSIP)/NIMHE development centres. It has been prepared with the help of feedback from a number of sources, including the conference delegates and those who responded to the call for comments set out on the NWW website at &lt;A href="http://www.newwaysofworking.org.uk/" target="_blank"&gt;www.newwaysofworking.org.uk&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>331316</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=331316]]&gt;</url>
    <title>NHS Evidence - mental health newsletter archive</title>
    <publicationDate>2009-11-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;NHS Evidence - mental health newsletter archive&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Below you will find previous issues of the monthly newsletter:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;2010&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence-mentalhealth.cmail4.com/T/ViewEmail/y/B72DB5A7A536AAFF/6211EDF9F1969DCA9A8E73400EDACAB4" target="_blank"&gt;December 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence-mentalhealth.cmail2.com/T/ViewEmail/y/33CDC6A260F09D0C/66CAB537633863D40F8C96E86323F7F9" target="_blank"&gt;November 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence-mentalhealth.cmail2.com/T/ViewEmail/y/33CDC6A260F09D0C/66CAB537633863D40F8C96E86323F7F9" target="_blank"&gt;October 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence-mentalhealth.cmail5.com/T/ViewEmail/y/72CC207D37352FE3/6211EDF9F1969DCA9A8E73400EDACAB4" target="_blank"&gt;Special Issue: Depression Annual Evidence Update 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence-mentalhealth.cmail1.com/T/ViewEmail/y/2182F84AB34C76A8/6211EDF9F1969DCA9A8E73400EDACAB4" target="_blank"&gt;September 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail1.com/T/ViewEmail/y/16A3D26653DFE7C6/66CAB537633863D40F8C96E86323F7F9" target="_blank"&gt;August 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail5.com/T/ViewEmail/y/537A28592BB85625/6211EDF9F1969DCA9A8E73400EDACAB4" target="_blank"&gt;July 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail4.com/T/ViewEmail/y/F9A9036E29A1EC2C/F87E6001ADB813DFC68C6A341B5D209E" target="_blank"&gt;June 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail3.com/T/ViewEmail/y/CB62948B1CBA368C/F87E6001ADB813DFC9C291422E3DE149" target="_blank"&gt;May 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail2.com/T/ViewEmail/y/27FD241E158BA22B/F87E6001ADB813DFC9C291422E3DE149" target="_blank"&gt;Special Issue: Schizophrenia Annual Evidence Update 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail5.com/T/ViewEmail/y/3AF1BB5D273B8AF4/F87E6001ADB813DFC9C291422E3DE149" target="_blank"&gt;April 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail4.com/T/ViewEmail/y/53F8AC7ABE9ECBA0/57668FE93442E4E9D9767B6002735221" target="_blank"&gt;March 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail3.com/T/ViewEmail/y/901BB5DCB1437A3E/6211EDF9F1969DCA9A8E73400EDACAB4" target="_blank"&gt;February 2010&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail4.com/T/ViewEmail/y/E85719A249721E7E/6211EDF9F1969DCA9A8E73400EDACAB4" target="_blank"&gt;January 2010&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;2009&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail1.com/T/ViewEmail/y/144DA18C2C064B9A/57668FE93442E4E9D9767B6002735221" target="_blank"&gt;December 2009&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.cmail1.com/T/ViewEmail/y/8457950CFF620B8A/66CAB537633863D40F8C96E86323F7F9" target="_blank"&gt;November 2009&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://nhsevidence.createsend.com/T/ViewEmail/y/BC9B1D4CBFE80B31" target="_blank"&gt;October 2009&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387228</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=387228]]&gt;</url>
    <title>NHS Evidence - mental health promotional leaflet</title>
    <publicationDate>2010-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;NHS Evidence - mental health promotional leaflet&lt;/pageTitle&gt;&lt;pageBody&gt;NHS Evidence - mental health have produced a promotional leaflet. The leaflet is available to download in portable document format [PDF].&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>289430</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/publicationspdfs/Updates/MentalHlthweb.pdf]]&gt;</url>
    <title>NHS HTA Themed Update: Mental Health</title>
    <publicationDate>2008-06-02T00:00:00</publicationDate>
    <publisher>HTA</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The latest Health Technology Assessment (HTA) Themed Update focuses on the work of the National Institute for Health Research (NIHR) HTA programme in the area of mental health. As well as featuring some of the latest trials that the HTA programme has commissioned and funded, the Themed Update contains details of newly published research, and news and views from opinion leaders in the field.</description>
    <body>&lt;![CDATA[ The latest Health Technology Assessment (HTA) Themed Update focuses on the work of the National Institute for Health Research (NIHR) HTA programme in the area of mental health. As well as featuring some of the latest trials that the HTA programme has commissioned and funded, the Themed Update contains details of newly published research, and news and views from opinion leaders in the field, such as Professor Til Wykes.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>333120</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/@sta/@perf/documents/digitalasset/dh_109889.pdf]]&gt;</url>
    <title>NHS Stop Smoking Services: service and monitoring guidance 2010/11</title>
    <publicationDate>2009-12-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document provides best practice guidance relevant to the provision of all NHS stop smoking interventions and sets out fundamental quality principles for the delivery of services which can be used to inform the development of local commissioning arrangements. It also includes full details of the data reporting requirements for NHS Stop Smoking Services.]]&gt;</body>
  </document>
  <document>
    <id>280062</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_079644]]&gt;</url>
    <title>NHS Stop Smoking Services: service and monitoring guidance, October 2007/08 - updated</title>
    <publicationDate>2008-02-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This updated guidance is intended for everyone involved in managing, commissioning or delivering NHS stop smoking services. It has been developed by means of a collaboration with representatives from SHAs, PCTs, the Information Centre and academics from the field of smoking cessation.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This updated guidance is intended for everyone involved in managing, commissioning or delivering NHS stop smoking services. It has been developed by means of a collaboration with representatives from SHAs, PCTs, the Information Centre and academics from the field of smoking cessation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386823</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsOnDraftRecommendationsForPsychosisWithCoexistingSubstanceMisuse.jsp]]&gt;</url>
    <title>NICE consults on draft recommendations for psychosis with co-existing substance misuse</title>
    <publicationDate>2010-08-18T00:00:00</publicationDate>
    <publisher>NICE</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NICE is currently developing a clinical guideline on the assessment and management of psychosis with co-existing substance misuse in adults and young people. As part of this process, draft recommendations have been published on the NICE website today (10 August) for public consultation.&lt;/P&gt;
&lt;P&gt;Psychosis is used to describe a group of severe mental health disorders characterised by the presence of delusions and hallucinations that disrupt a person’s perception, thoughts, emotions and behaviour. The main forms of psychosis are schizophrenia, bipolar disorder or other affective psychoses.&lt;/P&gt;
&lt;P&gt;Dr Fergus Macbeth, Director of the Centre for Clinical Practice at NICE, said: "Approximately 40% of people who have been diagnosed with psychosis have also misused a substance at some point in their lifetime. This is at least double the rate seen in the general population. When these two conditions co-exist, patients can spend twice as long in hospital, compared with those who do not misuse substances. They experience poorer physical health, are less likely to take prescribed medication and more likely to ‘drop out’ of services. However, less than a fifth of people who have coexisting psychosis and substance misuse receive treatment for their substance misuse.&lt;/P&gt;
&lt;P&gt;"The aim of this guideline is to help ensure that people diagnosed with a form of psychosis who also misuse substances can be identified and treated effectively for both conditions. The draft recommendations are now available for public consultation. Anyone wishing to submit comments should visit our website for more information on the consultation process."&lt;/P&gt;
&lt;P&gt;Draft recommendations issued for consultation include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Recognition of psychosis with coexisting substance misuse in adults and young people: Healthcare professionals in all healthcare settings, including primary care, secondary mental health care services, CAMHS and accident and emergency departments, and those in prisons and criminal justice mental health liaison schemes, should routinely ask adults and young people with known or suspected psychosis about their use of alcohol and/or prescribed and non-prescribed (including illicit) drugs.&lt;/LI&gt;
&lt;LI&gt;Secondary care mental health services:&lt;/LI&gt;&lt;/UL&gt;
&lt;OL&gt;
&lt;LI&gt;Do not exclude adults and young people with psychosis and coexisting substance misuse from age-appropriate mental healthcare because of their substance misuse.&lt;/LI&gt;
&lt;LI&gt;Do not exclude adults and young people with psychosis and coexisting substance misuse from age-appropriate substance misuse services because of a diagnosis of psychosis.&lt;/LI&gt;&lt;/OL&gt;
&lt;UL&gt;
&lt;LI&gt;Substance misuse services: Healthcare professionals working in substance misuse services should be competent to: recognise the signs and symptoms of psychosis; undertake a full mental health needs and risk assessment; know how and when to refer to secondary mental health services.&lt;/LI&gt;
&lt;LI&gt;Inpatient mental health services: All inpatient services should ensure that they have policies and procedures for promoting a therapeutic environment free from drugs and alcohol that have been developed together with service users and carers. These should include: search procedures, visiting arrangements, planning and reviewing leave, drug and alcohol testing, disposal of legal and illicit substances, and other security measures. Soon after admission, provide all service users, and their families, carers and significant others, with information about the policies and procedures.&lt;/LI&gt;
&lt;LI&gt;Specific issues for young people with psychosis and coexisting substance misuse: Those providing and commissioning services should ensure that:&lt;/LI&gt;&lt;/UL&gt;
&lt;OL&gt;
&lt;LI&gt;age-appropriate mental health services are available for young people with psychosis and coexisting substance misuse and&lt;/LI&gt;
&lt;LI&gt;transition arrangements to adult mental health services are in place where appropriate.&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
  </document>
  <document>
    <id>285312</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/media/410/E9/ImplUptakeReportAtypicalAntipsychotics.pdf]]&gt;</url>
    <title>NICE Implementation Uptake Report: atypical antipsychotic drugs for the treatment of schizophrenia</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>NHS The Information Centre</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NICE implementation uptake reports provide information on national trends and activity associated with technologies recommended in NICE guidance.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Overview&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;This is an update to a previous report. Since the last assessment, the numbers of prescriptions for atypical antipsychotic drugs dispensed in the community in England has continued to increase (figure 1). In the 12 months to March 2007, atypicals accounted for 67% of all antipsychotic prescriptions. The NICE guidance, published in June 2002, suggested that the adoption of atypical antipsychotic drugs would reach a level of at least 65% atypicals.&lt;BR&gt;Local organisations should consider referring to the NICE audit criteria produced for this guidance to help ensure that atypical antipsychotic drugs are prescribed appropriately for people with schizophrenia.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392203</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/alzheimers-disease-drugs.aspx]]&gt;</url>
    <title>NICE updates Alzheimer's drugs guidance</title>
    <publicationDate>2010-10-07T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Hundreds of thousands more patients in the early stages of Alzheimer's disease could get drug treatments following a U-turn by the health watchdog,” BBC News reported.&lt;/P&gt;
&lt;P&gt;Widespread news coverage has been given to new draft guidance from NICE for the treatment of Alzheimer’s disease. If the draft decision is upheld, the guidance would update previous recommendations for the NHS provision of the drugs donepezil, galantamine and rivastigmine for people in the early stages of the disease.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260922</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=260922]]&gt;</url>
    <title>NIMHE Mental Health Promotion Update: March 2007</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,SOCIAL SUPPORT,SOCIAL CAPITAL,DISADVANTAGED GROUPS,GOOD PRACTICE,POPULATION BASED &amp; PREVENTATIVE SERVICES,COMMUNITY DEVELOPMENT,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,FRAMES OF REFERENCE,MANAGEMENT &amp; POLICY,SERVICES,BUILDINGS,TECHNOLOGY,SCIENCE &amp; TECHNOLOGY,PRISONS,POPULATIONS,ANALYSIS &amp; RESEARCH,GROUPS,SETTINGS,COMMUNITIES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;NIMHE Mental Health Promotion Update: March 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This edition of the NIMHE Mental Health Promotion Update has articles on: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mind Bloggling,&amp;nbsp; an innovative web-based project which has been designed to give people experieincing mental ill health a voice&lt;/LI&gt;
&lt;LI&gt;Working for Health: Good Practice, Ideas &amp;amp; Suggestions from Working for Health Conferences held in May 2006 &amp;amp; December 2006&lt;/LI&gt;
&lt;LI&gt;A Strategy for Building a World-Class Third Sector in the London Thames Gateway, November 2006&lt;/LI&gt;
&lt;LI&gt;North West Mental Health Workplace Project&lt;/LI&gt;
&lt;LI&gt;Initiatives, such as Healthy Hearts &amp;amp; Minds in St Helens and Halton, Health Improvement Podcasts as a way of reaching people with health information, and Improving access to talking therapies&lt;/LI&gt;
&lt;LI&gt;The National Social Inclusion Programme&lt;/LI&gt;
&lt;LI&gt;Social Inclusion not Social Intrusion! Using Service Users' Perspectives to Promote Well-Being &amp;amp; Social Inclusion&lt;/LI&gt;
&lt;LI&gt;Coping in Prison - A mental health promotion group reaching prisoners in Oxfordshire&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>327907</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/pdf/No%20Health%20without%20mental%20health%20the%20Evidence.pdf]]&gt;</url>
    <title>'No health without mental health’</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=Verdana size=3&gt;&lt;FONT face=Verdana size=3&gt;
&lt;P align=left&gt;The aim of this report is to draw attention to the close links between physical and mental well being. The report is primarily concerned with mental health problems that are associated with, or arise from, physical illness, and the general interface between mental and physical health.&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>266759</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcarecommission.org.uk/_db/_documents/Community_mental_health_full_report.pdf]]&gt;</url>
    <title>No voice, no choice: A joint review of adult community mental health services in England</title>
    <publicationDate>2007-07-30T00:00:00</publicationDate>
    <publisher>Commission for Social Care Inspection</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The pace of change and improvement in community mental healthcare has been variable and service users are often too little involved in their care, according to a review carried out by the Healthcare Commission and the Commission for Social Care Inspection. It said that although services had improved, some people still had little or no access to care and treatment and many were given little information about their care plan, medication or care co-ordinator. There was also patchy access to effective psychological treatments, help with finding employment and physical health checks.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;In summary&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;It is clear that care reforms have not permeated all LIT communities across the country equally. Our findings on how well people using services are involved in the care that they receive remains of particular concern.&lt;BR&gt;Independence is as important an issue for people who experience mental health problems as it is for cardiac or diabetes patients, but sadly, the gaps in the provision of services highlighted in the 2004 Mental Health and Social Exclusion report remain.&lt;/P&gt;
&lt;P&gt;Providers and commissioners of services must ensure that they continue to improve. Using the key findings of this review as a benchmark to&lt;BR&gt;measure progress, and taking forward our recommendations, will help to make these improvements. However, good partnerships with other agencies, particularly those in the voluntary sector, are key to implementing these recommendations and to meeting the various&lt;BR&gt;needs of local communities.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Summary of Key Findings&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;The Care Programme Approach:&lt;/EM&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Many people who use services were not fully involved with decisions about their own care. 
&lt;LI&gt;Too few people are being offered or are receiving a written copy of their care plan. 
&lt;LI&gt;People are not always aware of who their care co-cordinator is. 
&lt;LI&gt;Not enough care reviews are being carried out. 
&lt;LI&gt;Too few people are involved in decisions about their medication. 
&lt;LI&gt;More focus is needed on physical health. 
&lt;LI&gt;People need help with employment. 
&lt;LI&gt;Problems with dual diagnosis.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;EM&gt;Delivering equality needs more emphasis&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Direct payments&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The provision of out-of-hours crisis services varies widely&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Greater access to key talking therapies is needed&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>279967</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nta.nhs.uk/publications/documents/nta_non_medical_prescribing_1207.pdf]]&gt;</url>
    <title>Non-medical prescribing, patient group directions and minor ailment schemes in the treatment of drug misusers</title>
    <publicationDate>2007-12-03T00:00:00</publicationDate>
    <publisher>NHS National Treatment Agency for Substance Misuse</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Drug treatment guidance publication.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Executive summary&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;Non-medical prescribing (particularly nurse and pharmacist prescribing), patient group directions (PGDs) and minor ailment schemes (MAS) are all part of a range of NHS reforms designed to improve patients’ access to medicines, develop workforce capability, utilise skills more effectively and ensure provision of more accessible and effective patient care. Successful implementation requires robust clinical governance mechanisms and teamworking, as well as access to specialist pharmaceutical support. Commissioners, managers and practitioners can now explore the potential of all these different mechanisms as ways of improving access to medicines for drug misusers.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342392</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.sign.ac.uk/pdf/sign114.pdf]]&gt;</url>
    <title>Non-pharmaceutical management of depression</title>
    <publicationDate>2010-01-29T00:00:00</publicationDate>
    <publisher>Scottish Intercollegiate Guidelines Network (SIGN)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Depression is a significant health problem which affects men and women of all ages and social backgrounds.The personal, social and economic consequences are substantial.&lt;/P&gt;
&lt;P&gt;Depression is associated with sickness absence and prevents many people seeking, maintaining or returning to employment. Prescribed antidepressant medication is the most common treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;WHY WE NEED A GUIDELINE&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Depression Alliance Scotland proposed the development of this guideline based on feedback from service users who were seeking information about interventions other than prescribed antidepressants which could be helpful in managing their depression.&lt;/P&gt;
&lt;P&gt;The Scottish Integrated Care Pathway (ICP) for depression sets standards for appropriate care and treatment of people with depression. It states that for those who choose a non-pharmacological approach, or for whom medication is not effective, there should be the offer of a brief depressionfocused psychological intervention.&lt;/P&gt;
&lt;P&gt;There is a need for accessible and robust evidence based information about the alternatives to prescribed antidepressants to be available to both GPs and service users.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;REMIT&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This guideline provides an assessment of, and presents the evidence base for, the efficacy of non-pharmaceutical therapies, encompassing psychological therapies, structured exercise and lifestyle interventions, and a range of alternative and complementary treatments, many of which are not routinely available within the NHS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;TARGET USERS OF THE GUIDELINE&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This guideline will be of particular interest to those developing mental health services, health care professionals in primary and secondary care (eg GPs, community psychiatric nurses, clinical psychologists and psychiatrists) and patients with depression and their carers.&lt;/P&gt;
&lt;P&gt;It may also be helpful to voluntary organisations and exercise professionals working in exercise referral schemes, public or private fitness centres, and physical activity promotion. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>375276</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpch.ac.uk/doc.aspx?id_Resource=6567]]&gt;</url>
    <title>Not Just a Phase: A Guide to the Participation of Children and Young People in Health Services</title>
    <publicationDate>2010-04-30T00:00:00</publicationDate>
    <publisher>Royal College of Paediatrics and Child Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Not Just a Phase has been developed and published by the Young People's Health Special Interest Group of the Royal College of Paediatrics and Child Health.&amp;nbsp;It&amp;nbsp;provides information to ensure the safe, meaningful and ethical participation of children and young people within the delivery of quality child health services and practically demonstrates how we can contribute towards creating a culture of participation.&lt;/P&gt;
&lt;P&gt;The executive sumamary reads:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Participation is defined as the process by which individuals and/or groups of individuals can influence the decision making process and bring about change.&lt;/LI&gt;
&lt;LI&gt;Participation involves a continuum from involvement of individual young people in decisions affecting their dailylife to the engagement of large groups of young people in making strategic decisions about the use of substantial healthcare resources.&lt;/LI&gt;
&lt;LI&gt;Children and young people’s right to participate in matters affecting their lives is laid out in the United Nations Convention on the Rights of the Child (UNCRC), a legally binding International convention.&lt;/LI&gt;
&lt;LI&gt;Participation of children, young people and their families in the design and development of services is government health policy.&lt;/LI&gt;
&lt;LI&gt;There are different degrees of children and young people’s participation and it is important to be aware of the pitfalls of non-participation such as tokenism, manipulation and decoration.&lt;/LI&gt;
&lt;LI&gt;The research evidence base for children and young people’s participation is limited. Future research efforts should concentrate on important health outcomes and consider the cost effectiveness of different methods of participation. Consideration should be given to how interventions such as participation impact on health&lt;BR&gt;inequality.&lt;/LI&gt;
&lt;LI&gt;Participation has the potential to reduce health inequalities; however this requires an understanding of existing power imbalances, barriers affecting the involvement of children and young people from diverse backgrounds and a range of experience, and an invested commitment to address the inequalities.&lt;/LI&gt;
&lt;LI&gt;The ethos, culture and environment in which children and young people participate should be safe, ageappropriate and accessible for children and young people with a range of abilities.&lt;/LI&gt;
&lt;LI&gt;Safeguarding children and young people, respecting their confidentiality and ensuring their wellbeing at all times is paramount to the success of any participation initiative and strategy.&lt;/LI&gt;
&lt;LI&gt;There are a number of key steps in planning a participation initiative. Children and young people should be involved in the planning. Youth workers have skills and expertise in facilitating the meaningful participation of children and young people.&lt;/LI&gt;
&lt;LI&gt;Service leaders should develop a culture of participation within their organisation.&lt;/LI&gt;
&lt;LI&gt;The participation of children and young people should be evaluated systematically and the outcomes shared with key stakeholders. The contribution that children and young people make should be valued and any successes celebrated.&lt;/LI&gt;
&lt;LI&gt;Children and young people can participate in many different ways, including commissioning services, designing the built healthcare environment, recruiting and selecting staff, governance of health services and developing healthcare research.&lt;/LI&gt;
&lt;LI&gt;There are many different methods by which children and young people can participate in health services including questionnaires and surveys, focus and advisory groups, interactive media, youth councils and forums or as mystery shoppers, young inspectors and young researchers.&lt;/LI&gt;
&lt;LI&gt;The participation of children and young people contributes to the quality of health services for children and young people, it improves the health of children and young people and it’s fun!&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>266118</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38633&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Out at Work</title>
    <publicationDate>2002-04-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report based on a survey of over 400 people with personal experience of mental health problems.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Report based on a survey of over 400 people with personal experience of mental health problems. It examines their experiences in seeking work, the attitudes of colleagues, support available within the workplace, the impact of work on mental health and the ways in which people left or lost jobs.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38634&amp;amp;type=Full&amp;amp;servicetype=Attachment" target="_blank"&gt;Out at Work Briefing&amp;nbsp;- Update series&lt;/A&gt; (Published April 2002 - Link to full-text PDF)&lt;/P&gt;
&lt;P&gt;Update briefing on the findings of the 'Out at Work' survey. The majority of people with mental health problems who responded to this survey are still not in paid employment, in either a full-time or part-time capacity. A number of reasons were given, including the effects of medication, the difficulties of losing benefits and discrimination.The decision as to whether or not to ‘come out’ as a mental health service user is for many people fraught with difficulty.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291421</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.policyexchange.org.uk/images/publications/pdfs/Out_of_sight__out_of_mind.pdf]]&gt;</url>
    <title>Out of Sight, Out of Mind: The state of mental healthcare in prison</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Policy Exchange</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report on mental healthcare in prisons.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Our prison population is at its highest ever. Of the 82,000 prisoners in England and Wales it is estimated that nine out of ten have one or more mental health disorders. Although treatment of mental illness in prison has improved over the past decade, mental healthcare is not given the attention it deserves. The rates of mental illness among prisoners suggest that the Prison Service has become a catch-all social and mental healthcare service, as well as a breeding ground for poor mental health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327904</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_093677.pdf]]&gt;</url>
    <title>Outcomes compendium: helping you select the right tools for best mental health care practice in your field</title>
    <publicationDate>2009-01-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;The compendium provides information on available outcomes measures tools for use in mental health services. It provides an evidence based evaluation of existing measure to support informed choice. It is designed to support clinicians engaged in service delivery and development who wish to gauge clinical effectiveness and recovery in a balanced, culturally appropriate and ethical manner.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Please note: The PDF file below is primarily structured for hard copy print, and as such accessibility in parts of the document is not logically structured. The content within the document is nevertheless fully accessible..&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327430</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103756.pdf]]&gt;</url>
    <title>Pandemic influenza and the Mental Health Act 1983: consultation on proposed changes to the Mental Health Act 1983 and its associated secondary legislation</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;You are invited to comment on proposals for temporary amendments to the Mental Health Act 1983 which may be required in the event of the severe staff shortages that may be expected during an influenza pandemic.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;You are invited to say whether you think these proposals are likely to be helpful.&amp;nbsp; Please let us know if there are any significant issues which you think we should have included, or if we have included anything unnecessary.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289771</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085925]]&gt;</url>
    <title>Pandemic influenza: guidance on preparing mental health services in England</title>
    <publicationDate>2008-07-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,VIRAL,GUIDELINES,ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,INFLUENZA,RESPIRATORY DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,GUIDELINES,TEAMWORK,STAFF USE,RESPIRATORY,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,FRAMES OF REFERENCE,HEALTH SERVICES,SERVICES,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This document is designed to assist mental health trusts and other specialist mental health service providers in developing their plans for responding to an influenza pandemic.</description>
    <body>&lt;![CDATA[ This document is designed to assist mental health trusts and other specialist mental health service providers in developing their plans for responding to an influenza pandemic. This document details a national approach, setting out the key planning assumptions and principles, roles and responsibilities that should inform the development of local plans.]]&gt;</body>
  </document>
  <document>
    <id>345973</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.its-services.org.uk/silo/files/paths-to-personalisation.pdf]]&gt;</url>
    <title>Paths to Personalisation in mental health</title>
    <publicationDate>2010-03-16T00:00:00</publicationDate>
    <publisher>The National Mental Health Development Unit</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,POLICY,SERVICE SECTORS,MENTAL HEALTH SERVICES,SERVICE DELIVERY,SERVICE MODERNISATION,MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,COMMISSIONING,POPULATIONS SERVED,DISEASE/CONDITION GROUPS,MENTAL HEALTH PROBLEMS,PEOPLE WITH MENTAL HEALTH PROBLEMS,TYPES OF COMMISSIONING,PERSONALISED COMMISSIONING,INNOVATION AND IMPROVEMENT,ENGAGEMENT,PERSONALISATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Published today by the NMHDU Personalisation in Mental Health Programme, this guide has been produced to help all those involved understand how things will need to be done differently to make personalisation a reality for people with mental health needs. This is a whole system guide, so hopefully it will give some information, guidance and signposts for people, whoever and wherever they are. The guide provides information about what personalisation means for mental health services and supports, offers examples of what needs to be in place to make things work, and provides pointers to good practice and sources of advice and information.]]&gt;</body>
  </document>
  <document>
    <id>266119</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=45814&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Pathways to Policy</title>
    <publicationDate>2007-04-02T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This toolkit enables NGOs and user groups to promote the voice of service users in the development of mental health policy.</description>
    <body>&lt;![CDATA[ This toolkit enables NGOs and user groups to promote the voice of service users in the development of mental health policy. Drawing on the experiences of a 5-year programme, the toolkit provides a framework for establishing a mental health policy “forum” to enable people experiencing mental distress to have a genuine voice in policy-making. It provides a step-by-step guide to user groups to working in partnership with other stakeholders to prioritise local mental health issues, develop action plans and raise awareness.]]&gt;</body>
  </document>
  <document>
    <id>345863</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/therapeutics/cns/schiz/resources/pda_schizophrenia.pdf]]&gt;</url>
    <title>Patient decision aid: Antipsychotic drugs</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This patient decision aid is intended to assist healthcare professionals in consultations with patients with mental health problems such as schizophrenia in whom treatment with antipsychotic drugs is being considered.]]&gt;</body>
  </document>
  <document>
    <id>317707</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/document.rm?id=7664]]&gt;</url>
    <title>Paying the price: The cost of mental health care in England 2026 PDF</title>
    <publicationDate>2009-05-14T00:00:00</publicationDate>
    <publisher>Kings fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Recognising the significance of mental health in terms of both expenditure and the overall health of the population, the Kings Fund commissioned a review to look at current and projected needs for mental health services and their related costs to 2026.]]&gt;</body>
  </document>
  <document>
    <id>287510</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/publications/kings_fund_publications/paying_the_price.html]]&gt;</url>
    <title>Paying the Price: The Cost of Mental Health Care in England to 2026</title>
    <publicationDate>2008-05-30T00:00:00</publicationDate>
    <publisher>King's Fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ DEPRESSIVE DISORDER,EMOTIONAL DISORDERS,GENERALIZED ANXIETY,PERSONALITY (BEHAVIOURAL) DISORDERS,EATING DISORDERS,ACUTE PSYCHOTIC DISORDERS,CHILD AND ADOLESCENT CONDITIONS,DEPRESSION,DEMENTIA,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,BIPOLAR DISORDER,MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,ECONOMICS,DETERMINANTS,ECONOMICS,MENTAL &amp; BEHAVIOURAL DISORDERS,COSTING,COSTS,PUBLIC HEALTH,GEOGRAPHY,NATIONAL,HEALTHCARE &amp; HEALTH SERVICES,HEALTH SERVICES,MONTHLY ADDITIONS,SETTINGS,MANAGEMENT &amp; INTERVENTIONS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Recognising the significance of mental health in terms of both expenditure and the overall health of the population, the King’s Fund commissioned a review. This report presents current and projected needs for mental health services and their related costs. It gives details on a number of specific disorders, including depression, schizophrenic disorders and dementia. Paying the Price suggests that without the right level and type of investment we will all pay the price – not just in wasted resources but also in wasted lives. This report should be used to encourage informed debate about the future nature and shape of mental health support.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report from the King's Fund, the results of a year-long study into the costs of meeting the mental health needs of the nation over the next two decades, reveals that mental illness in England cost £50 billion in 2007.&amp;nbsp; Almost half, £22.5 billion represents money spent on direct NHS and social care services to support people with mental disorders. The rest, £26.1 billion, represents the estimated cost to the economy of earnings lost because of the thousands of people unable to work due to their mental illness.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Although it finds that the prevalence of most mental disorders, including schizophrenia, is likely to remain stable over the next 20 years, it predicts a huge increase in dementia - up by almost two-thirds (61 per cent) from 582,827 to 937,636 due to an ageing population.&amp;nbsp; As a result of this, and above inflation rises in health care costs, the bill for mental health services is expected to grow from £22.5 billion to £47 billion.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The report contains chapters on eight different specific disorders: depression, anxiety disorders, schizophrenic disorders, bipolar and related conditions, eating disorders, personality disorder, disorders affecting children and adolescents, and dementia. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="http://www.kingsfund.org.uk/document.rm?id=7681" target="_blank"&gt;Download summary&lt;/A&gt; (68kb)&lt;/H2&gt;
&lt;LI&gt;
&lt;H2&gt;&lt;A href="http://www.kingsfund.org.uk/document.rm?id=7665" target="_blank"&gt;Download in full&lt;/A&gt; (3717kb)&lt;/H2&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>111318</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111318]]&gt;</url>
    <title>Physical health</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,DISADVANTAGED GROUPS,PATIENTS,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,PRIMARY CARE SERVICES,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SERVICES,HEALTH SERVICES,HEALTHCARE &amp; HEALTH SERVICES,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Physical health&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111317:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111319:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;Physical health of people with severe and enduring mental health problems&lt;/H2&gt;
&lt;P&gt;People with severe and enduring mental health problems are one of the most vulnerable groups, with a considerably raised risk of physical illness and premature mortality from natural causes, including coronary heart disease, diabetes, infections and respiratory disease (ref 1-4). &lt;/P&gt;
&lt;P&gt;A person with schizophrenia, can expect to live for ten years less than someone without a mental health problem and around half of this excess mortality is caused by physical health problems (ref 5). People with mental health problems are almost twice as likely to die from coronary heart disease as the general population and four times more likely to die from respiratory diseases (ref 6). Smoking-related fatal disease is much commoner than in the general population, notably among people with schizophrenia (ref 7, 8). Depression increases the risk of stroke and emotional wellbeing protects against stroke (ref 9).&lt;/P&gt;
&lt;P&gt;Some research suggests that people with mental health problems are much less likely to be offered health promotion interventions, in spite of a much higher attendance at primary care. (ref 10, 11). There is scope for considerable improvement in the detection and treatment of physical illness in this group. Annual health checks and providing the same level of health promotion/prevention support as received by the general population could make a significant contribution to the reduction of health inequalities (ref 12, 13).&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111317:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111319:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Phelan M, Stradins L and Morrison S (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7284/443" target="_blank"&gt;Physical health of people with severe mental illness&lt;/A&gt; British Medical Journal 322 p443-444&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Harris EC and Barraclough B (1998) Excess mortality of mental disorder &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/173/1/11?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=Harris&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074006943030_3230&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=173&amp;amp;resourcetype=1" target="_blank"&gt;British Journal of Psychiatry&lt;/A&gt;&amp;nbsp;&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/173/1/11?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=Harris&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074006943030_3230&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=173&amp;amp;resourcetype=1" target="_blank"&gt;173 p.11-53&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Barr W (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/323/7306/231?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Barr&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074007203153_8918&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=323&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Physical health of people with severe mental illness &lt;/A&gt;British Medical Journal 323, p321-322&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Lawrence D, Holman CDJ and Jablensky AV (2001) Preventable Physical Illness in People with Mental Illness Perth: &lt;A href="http://www.dph.uwa.edu.au/" target="_blank"&gt;The University of Western Australia&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Brown S, Inskip H, Barraclough B (2000) Causes of the excess mortality of schizophrenia &lt;A href="http://bjp.rcpsych.org/" target="_blank"&gt;British Journal of Psychiatry&lt;/A&gt;&amp;nbsp;177 p212-217&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Mortenson PB and Juel K (1993) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/163/2/183?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;title=Mortality%2Band%2Bcauses%2Bof%2Bdeath&amp;amp;andorexacttitle=phrase&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074006496528_3193&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;journalcode=bjprcpsych" target="_blank"&gt;Mortality and causes of death in first admitted schizophrenic patients&lt;/A&gt; British Journal of Psychiatry 163 183-9&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Addington J, el-Guebaly N, Campbell W et al (1998) Smoking cessation treatment for patients with schizophrenia American Journal of Psychiatry 155(7) p974-979&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;McNeill A (2001) Smoking and mental health: a literature review &lt;A href="http://www.ash.org.uk/" target="_blank"&gt;Action on Smoking and Health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Ostir Glenn V, Markides KS, Peek MK, Goodwin JS (2001) The association between emotional well-being and the incidence of stroke in older adults Psychosomatic Medicine 63:210-215&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Burns and Cohen (1998) Items of service payments for general practitioner care of severely mentally ill patients: does the money matter? British Journal of General Practice 48 p1415-1416&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Cohen A and Phelan M (2001) The Physical Health of Patients with Mental Illness: a neglected area. Mental Health Promotion Update 2:15-16&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Cohen A and Hove M (2001) Physical health of the severe and enduing mentally ill – a training pack for GP educators &lt;A href="http://www.scmh.org.uk/" target="_blank"&gt;Sainsbury Centre for Mental Health &amp;amp; Department of Health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;mentality (2003) Not all in the mind: the physical health of people with mental health problems. London: &lt;A href="http://www.mentality.org.uk/" target="_blank"&gt;mentality&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317751</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/publications/collegereports/op/op67.aspx]]&gt;</url>
    <title>Physical Health in mental health</title>
    <publicationDate>2009-01-02T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=mainContent&gt;
&lt;P class=Default&gt;&lt;STRONG&gt;This report is available online-only.&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI class=Default&gt;General health morbidity among people with mental health problems is high.&lt;/LI&gt;
&lt;LI class=Pa17&gt;There is a need for good-quality general healthcare for psychiatric patients, whether in community settings or in-patient care.&lt;/LI&gt;
&lt;LI class=Pa21&gt;There is a need for clarity about the responsibility of the psychiatrist in general healthcare, working in partnership and collaboration with primary healthcare and other specialist colleagues.&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=Pa16&gt;There is a growing body of evidence that many psychiatrists lack the skills required to provide for the general healthcare of people with mental health problems. This situation may have arisen for good reason – psychiatrists have sought to specialise in mental health matters, regarding physical healthcare as the province of other clinicians. However, as medical practitioners, psychiatrists clearly have a role to play in the management of the general health problems of people with mental health problems. This entails an understanding of the complex interactions between mental health and general health, and an appropriate level of competence in the prevention, detection and treatment of general health problems in their patients, including awareness of the indications for specialist referral.&lt;/P&gt;
&lt;P class=Pa22&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa22&gt;&lt;STRONG&gt;Overall aim&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=Pa22&gt;The overall aim of the Scoping Group was to explore a range of issues concerning the general health of people with mental health problems, with a view to making recommendations to the Council of the Royal College of Psychiatrists on matters concerning clinical practice, training and the identification of other priorities in physical healthcare.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>315289</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/OP67.pdf]]&gt;</url>
    <title>Physical health in mental health - final report of a scoping document [PDF]</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PEOPLE WITH HIV OR AIDS,DISADVANTAGED GROUPS,ETHNIC GROUPS,PATIENTS,PEOPLE WITH DISABILITIES,PUBLIC HEALTH,PROFESSIONAL PRACTICE,HEALTH SERVICES,HEALTHCARE &amp; HEALTH SERVICES,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS,POPULATIONS,GROUPS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ There is a growing body of evidence that many psychiatrists lack the skills required to provide for the general healthcare of people with mental health problems.]]&gt;</body>
  </document>
  <document>
    <id>268366</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=14907&amp;Rendition=Web]]&gt;</url>
    <title>Policy briefing: NHS investment in mental health services (2005/06)</title>
    <publicationDate>2006-05-17T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This policy briefing outlines the key findings from a one-off survey of Strategic Health Authorities carried out by the Department of Health in December 2005. The survey was undertaken to establish whether NHS organisations had maintained their agreed investment levels during 2005/6.</description>
    <body>&lt;![CDATA[ This policy briefing outlines the key findings from a one-off survey of Strategic Health Authorities carried out by the Department of Health in December 2005. The survey was undertaken to establish whether NHS organisations had maintained their agreed investment levels during 2005/6.]]&gt;</body>
  </document>
  <document>
    <id>344600</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/pdf/PS01_2010x.pdf]]&gt;</url>
    <title>Position statement on sexual orientation</title>
    <publicationDate>2010-02-24T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SEXUAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Royal College of Psychiatrists clarify their position on sexual orientation.]]&gt;</body>
  </document>
  <document>
    <id>260774</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_066059]]&gt;</url>
    <title>Positive Steps: Supporting race equality in mental healthcare</title>
    <publicationDate>2007-02-21T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Positive Steps guide was produced with the help of mental health care staff and community workers and offers advice and support for better responding to the needs of BME patients. The guide - which highlights good practice that already exists in the mental healthcare system - is part of the Government's five-year action plan (Delivering Race Equality in Mental Health Care) to further improve services for these patients. The guide also incorporates key mental health issues and religious and cultural needs for different ethnic groups, using needs for South Asian, African and Caribbean groups as examples. It also includes an extensive list of useful contacts, organisations and resources.]]&gt;</body>
  </document>
  <document>
    <id>298062</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/128]]&gt;</url>
    <title>Prevalence - A third of men and 15% of women discharged from medium secure forensic psychiatry services in the UK re-offend</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ALCOHOL MISUSE,BIPOLAR DISORDER,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DEPRESSION,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;BR&gt;&lt;/STRONG&gt;Coid J, Hickey N, Kahtan N, et al. Patients discharged from medium secure forensic psychiatry services: reconvictions and risk factors. Br J Psychiatry 2007;190:223–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How common is reconviction following discharge from medium secure psychiatry services and do any factors predict re-offence?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Cohort study.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Medium secure forensic psychiatry services in 7 of 14 regional health authorities in the UK; all admissions between 1989 and 1993.&lt;BR&gt;Population: 1344 people initially admitted to medium secure forensic psychiatry services (in 7 of the 14 regional health authorities) in the UK and later released into the community. People admitted to these services but then placed in private sector or other National Health Service secure units were also included. The majority (60%) had been admitted with a primary diagnosis of schizophrenia/schizoaffective disorder. Other primary diagnoses included personality disorder (14%), depression (7%), and mania (8%). Most people had a comorbid diagnosis of alcohol or drug dependence or misuse, or antisocial personality disorder. Follow-up was from date of discharge to 31 December 1998 (end of the study), date of death, or date of leaving the country, whichever occurred first.&lt;BR&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt; Data on convictions during the follow-up period were retrieved through the Offenders Index at the Home Office. Convictions were only counted if they occurred while the person was in the community (not in another psychiatric institution). Incidence rates were determined using Cox regression hazard models for specific offences.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Convictions for any of sexual offences, arson, burglary, theft, fraud, deception, robbery or grave offences (homicide, serious wounding, rape, buggery, arson, robbery and aggravated burglary) determined from the Offenders Index at the Home Office.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;BR&gt;&lt;/STRONG&gt;People were followed up for an average of 6.2 years. About 34% of men and 15% of women were convicted of a criminal offence of some kind during follow-up. This equated to an incidence of 46.8 offences per 100 person-years for men, and 16.3 offences per 100 person-years for women. Among men, about 20% were convicted of acquisitive offences (such as burglary), 18% of violent offences and 12% were convicted of grave offences. Among women, about 7% were convicted of acquisitive offences, 6% of grave offences and 5% of violent offences. Any reconviction was more common in men, those younger at first court appearance, those spending less than two years in a secure unit, those with &amp;gt;=1 or &amp;gt;=6 previous convictions, alcohol dependence, personality disorder, mania and those who had not been sectioned (see table).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;About a third of men, and one in seven women discharged from medium secure forensic psychiatry services re-offend.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302050</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/31]]&gt;</url>
    <title>Prevalence - An estimated 3.4% of adults have adult attention-deficit hyperactivity disorder</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How common is adult attention-deficit hyperactivity disorder&lt;SUP&gt; &lt;/SUP&gt;(ADHD)?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;11 422 adults (18–44 years old) from households randomly&lt;SUP&gt; &lt;/SUP&gt;selected in multistage household sampling, and interviewed as&lt;SUP&gt; &lt;/SUP&gt;part of the World Health Organization World Mental Health Survey&lt;SUP&gt; &lt;/SUP&gt;Initiative.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Ten countries in Europe (Belgium, France, Germany, Italy, Spain,&lt;SUP&gt; &lt;/SUP&gt;The Netherlands), the Americas (USA, Mexico, Colombia), and&lt;SUP&gt; &lt;/SUP&gt;the Middle East (Lebanon); interviews conducted 2001–3.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Face-to-face interviews were conducted in two parts. The first&lt;SUP&gt; &lt;/SUP&gt;part assessed participants for core diagnoses. All people meeting&lt;SUP&gt; &lt;/SUP&gt;diagnostic criteria plus a random sample of other participants&lt;SUP&gt; &lt;/SUP&gt;were given part II of the interview, which assessed other diagnoses&lt;SUP&gt; &lt;/SUP&gt;of interest, including adult ADHD. The interview assessed childhood&lt;SUP&gt; &lt;/SUP&gt;ADHD based on the Diagnostic Interview Schedule for DSM-IV (DIS);&lt;SUP&gt; &lt;/SUP&gt;people retrospectively meeting criteria for childhood ADHD were&lt;SUP&gt; &lt;/SUP&gt;asked whether they &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;STRONG&gt;Commentator: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Johannes Thome, MD, PhD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Institute of Life Science, The School of Medicine, Swansea University, Swansea, UK&amp;nbsp;&lt;/FONT&gt;&lt;FONT size=2&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/31" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306999</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/30]]&gt;</url>
    <title>Prevalence - Antipsychotic prescriptions for children and adolescents in the UK increased from 1993 to 2005</title>
    <publicationDate></publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What are the trends in antipsychotic medication prescription for people 18 years and younger in the UK?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;Children and adolescents (0–18 years) registered on the General Practice Research Database (GPRD), with &amp;gt;=1 year data recorded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;384 UK general practices included in the GPRD; data were extracted for the period January 1 1992–31 December 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Information on prescriptions was extracted from the GPRD, which holds de-identified patient information regarding consultations (eg, prescriptions, clinical notes, referrals, test results) and demographic data from participating general practices in the UK. Cases were children and adolescents prescribed at least one antipsychotic medication.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Prevalence of antipsychotic prescriptions (users per 1000 patient years) by age group (0–6, 7–12, 13–18 years) and by type of antipsychotic prescribed (typical or atypical) from 1993 to 2005; condition for which medication was prescribed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&lt;BR&gt;Design: Repeated cross sectional study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main Results:&lt;/STRONG&gt;&lt;BR&gt;The prescription of all antipsychotic drugs increased between 1993 and 2005 (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Mark Olfson&lt;/P&gt;
&lt;P&gt;Columbia University and New York State Psychiatric Institute, New York, New York, USA &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/30" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302051</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/32]]&gt;</url>
    <title>Prevalence - Autism and prenatal exposure to storms</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is the prevalence of autism linked to prenatal exposure to hurricanes&lt;SUP&gt; &lt;/SUP&gt;and storms?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;All children in utero and born between 1980 and 1995 in Louisiana&lt;SUP&gt; &lt;/SUP&gt;identified through records from the National Centre for Health&lt;SUP&gt; &lt;/SUP&gt;Statistics in Maryland.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Louisiana, USA.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Children born in the time period of interest diagnosed with&lt;SUP&gt; &lt;/SUP&gt;DSM-III-R or IV autistic disorder since 1990 were identified&lt;SUP&gt; &lt;/SUP&gt;from records held at Louisiana’s Department of Health&lt;SUP&gt; &lt;/SUP&gt;and Hospitals (DHH). Data on storms affecting Louisiana between&lt;SUP&gt; &lt;/SUP&gt;1980 and 1995 were collected from the National Weather Service.&lt;SUP&gt; &lt;/SUP&gt;The severity of the exposure depended on the impact the storm&lt;SUP&gt; &lt;/SUP&gt;had on the area (parish) and how vulnerable the residents of&lt;SUP&gt; &lt;/SUP&gt;that parish were to the storm’s effects. Being in utero&lt;SUP&gt; &lt;/SUP&gt;in New Orleans when a hurricane centre passed through the city&lt;SUP&gt; &lt;/SUP&gt;was considered to be a high exposure; intermediate exposure&lt;SUP&gt; &lt;/SUP&gt;was &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Diana E Schendel, PhD &lt;/P&gt;
&lt;P&gt;National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, USA &lt;BR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/32" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383698</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/93.extract]]&gt;</url>
    <title>Prevalence - Binge drinking frequent among adults aged 50 years and older</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,ALCOHOL MISUSE,HEALTH &amp; WELLBEING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the prevalence of, and correlates for, at-risk alcohol use and binge drinking among adults aged 50 years and older?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P id=p-2&gt;10,953 adults (46% men, 54% women) aged 50 years and older. Approximately 40% were aged more than 65 years.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;National Survey on Drug Use and Health; data taken from surveys performed in 2005 and 2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Assessment:&lt;/H3&gt;
&lt;P id=p-4&gt;The sampling frame of the National Survey on Drug Use and Health covers roughly 98% of the US population aged 12 years or older. Multistage methods are used to collect a representative sample of household residents, civilians residing on military bases and residents of shelters, college dormitories, rooming houses, migratory workers camps and halfway houses. People excluded from the sample include those in institutions (eg, prisons, hospitals, nursing homes) and homeless people not living in shelters. Respondents were interviewed privately at their residence; 68,308 respondents (76%) completed the survey in 2005 and 67,802 (74%) in 2006. Survey results from 2005 and 2006 were combined to increase power. Social and demographic variables examined included age, sex, race, educational levels, marital status, employment status and annual income. Psychological distress was measured … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/93.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>223991</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/8/2/56]]&gt;</url>
    <title>Prevalence - Boys in late adolescence have a low rate of use of mental health services</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;BR&gt;&lt;/STRONG&gt;Sourander A, Multimaki P, Santalahti P, et al. Mental health service use among 18-year-old adolescent boys: a prospective 10-year follow-up study. J Am Acad Child Adolesc Psychiatry 2004;43:1250–8.&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What is the uptake rate of mental health services among 18 year old boys and what are the factors that predict service use?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Prospective cohort study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Finland; 1989–1999.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 2316 Finnish 18 year old boys attending military call-up. Participants were part of a 10 year follow up study of a representative sample of Finnish children born in 1981 (the Epidemiological Multicentre Child Psychiatric Study in Finland).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt; Participants were first assessed at age 8 using self-report (the Children’s Depression Inventory), parent reports (Rutter A2 Scale) and teacher reports (Rutter B2 Scale). Children with a score of 13 or above on the Rutter A2 scale, or 9 or above on the Rutter B2 scale were classified as having behavioural problems. At military call-up, participants completed a questionnaire assessing mental health service use in the previous year. Univariate and multivariate logistic regression were used to analyse associations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Self-reported use of mental health services in the previous year.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Follow up period:&lt;/STRONG&gt; 10 years.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;BR&gt;&lt;/STRONG&gt;In the previous year, 2.1% of participants (48/2316) had used mental health services; seven respondents (0.3%) had received psychiatric inpatient care. Boys who were considered by their teachers to have behavioural problems at age 8 were significantly more likely to have utilised mental health services at age 18 (OR 2.6, CI 95% 1.3 to 5.1; multivariate analysis). Parental or self-report of behavioural problems at age 8 did not significantly predict service use (figures not presented).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;BR&gt;&lt;/STRONG&gt;The rate of use of mental health services in 18 year old Finnish boys is considerably lower than the estimated prevalence of psychopathology in adolescents. Education services have a crucial role in identifying children at risk of future mental health problems.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302021</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/57]]&gt;</url>
    <title>Prevalence - Depression: greater effect on overall health than angina, arthritis, asthma or diabetes</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How do people rate the effects of depression on their overall&lt;SUP&gt; &lt;/SUP&gt;health status in comparison to angina, arthritis, asthma and&lt;SUP&gt; &lt;/SUP&gt;diabetes?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;245 404 inhabitants of 60 countries.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Global study representing people from 60 countries (26 from&lt;SUP&gt; &lt;/SUP&gt;the European region, 15 from the African region, six from the&lt;SUP&gt; &lt;/SUP&gt;Americas, four from the eastern Mediterranean region, five from&lt;SUP&gt; &lt;/SUP&gt;the southeast Asia region and four from the western Pacific&lt;SUP&gt; &lt;/SUP&gt;region); time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Face-to-face interviews were conducted with the majority of&lt;SUP&gt; &lt;/SUP&gt;participants in their home countries using the standardised&lt;SUP&gt; &lt;/SUP&gt;WHO World Health Survey (WHO WHS) that collected demographic&lt;SUP&gt; &lt;/SUP&gt;information and used 16 health-related questions assessing eight&lt;SUP&gt; &lt;/SUP&gt;health domains (including vision, mobility, cognition, pain,&lt;SUP&gt; &lt;/SUP&gt;etc) to derive an overall health score. The overall health score&lt;SUP&gt; &lt;/SUP&gt;ranged from 0 (worst health) to &lt;NOBR&gt;&lt;EM&gt;. . (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Leonard E Egede &lt;/P&gt;
&lt;P&gt;Medical University of South Carolina, Charleston, USA &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/57" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298037</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/95]]&gt;</url>
    <title>Prevalence - Ethnic minority groups, particularly African-Caribbean and Black African groups, are at increased risk of psychosis in the UK</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ETHNICITY AND HEALTH,DISEASES AND CONDITIONS,MENTAL HEALTH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Fearon P, Kirkbride JB, Morgan C, et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP study. Psychol Med 2006;36:1541–50.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Is there an increased risk of psychotic illness in ethnic minority groups in the UK?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Longitudinal study.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; General population in Southeast London, Nottingham, and Bristol, UK; September 1997 to August 1999.&lt;BR&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 1 029 802 people aged 16–64 years living in the three study areas.&lt;BR&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt; People presenting to mental health services for the first time with delusions, hallucinations, thought disorder, or negative symptoms of schizophrenia were referred for assessment interview. Patient information systems for London and Nottingham were additionally searched for relevant psychotic diagnostic codes. Interviewees were assessed with the PSE SCAN v.2.0. Case notes of people unable to be interviewed were assessed with the Item Group Checklist of the SCAN interview. Sociodemographic factors were assessed with a specially designed questionnaire. Ethnicity was determined by three separate assessors based on self-description of ethnicity, place of birth, and parents’ place of birth. Classifications were White British, Black African, African-Caribbean, Asian, Mixed or White Other. Consensus diagnoses (ICD-10) were made by clinicians blinded to ethnicity.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; ICD-10 psychosis (including schizophrenia and other psychoses).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;568 people were diagnosed with psychotic illness during the 1.6 million person-years of follow-up. Psychosis incidence was higher in all British ethnic minority groups than in the White British group (see tableGo). Schizophrenia and mania were highest in African-Caribbeans (schizophrenia incidence per 100 000 persons per year: 70.7 in African-Caribbeans vs 7.2 in White British; incidence rate ratio (IRR) 9.1, 95% CI 6.6 to 12.6; mania incidence per 100 000 persons per year: 15.5 in African-Caribbeans vs 2.2 in White British; IRR 8.0, 95% CI 4.3 to 14.8), and second highest in Black-Africans (schizophrenia incidence per 100 000 persons per year: 40.3; IRR vs White British: 5.8, 95% CI 3.9 to 8.4; mania incidence per 100 000 persons per year: 12.3; IRR vs White British: 6.2, 95% CI 3.1 to 12.1).&lt;BR&gt;&lt;STRONG&gt;&amp;nbsp;&lt;BR&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;The incidence of psychoses in the UK is higher in ethnic minority groups than the White British group, and is highest in African-Caribbean and Black African groups.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301972</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/128]]&gt;</url>
    <title>Prevalence - Global WHO survey: poor physical and mental health more prevalent among women who have experienced intimate partner violence</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ DOMESTIC VIOLENCE OR PARTNER ABUSE,ADULT CONDITIONS,MENTAL HEALTH,DETERMINANTS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,SOCIAL DETERMINANTS,MONTHLY ADDITIONS,POPULATIONS,ABUSE,DOMESTIC VIOLENCE,2009 SEPTEMBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is intimate partner violence and domestic violence linked to&lt;SUP&gt; &lt;/SUP&gt;physical and mental health problems in women?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;19 568 inhabitants of 10 countries who had ever had a partner.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Global study representing people from 10 countries (15 sites)&lt;SUP&gt; &lt;/SUP&gt;in the WHO multi-country study on women’s health and domestic&lt;SUP&gt; &lt;/SUP&gt;violence against women; interviews carried out 2000–2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Interviews were conducted in person by female interviewers in&lt;SUP&gt; &lt;/SUP&gt;a community setting using a standardised questionnaire. Women&lt;SUP&gt; &lt;/SUP&gt;were asked whether they had experienced physical or sexual violence&lt;SUP&gt; &lt;/SUP&gt;at the hand of a current or previous partner at any time in&lt;SUP&gt; &lt;/SUP&gt;their life or in the previous 12 months. Women responding yes&lt;SUP&gt; &lt;/SUP&gt;were then asked for details of the incidents. Other questions&lt;SUP&gt; &lt;/SUP&gt;included self-rated health and whether they experienced any&lt;SUP&gt; &lt;/SUP&gt;of the following physical symptoms in the previous 4 weeks:&lt;SUP&gt; &lt;/SUP&gt;difficulty walking or with daily activities, pain, memory loss,&lt;SUP&gt; &lt;/SUP&gt;dizziness and vaginal discharge. The Self Report Questionnaire&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;. . (Abstracted).&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;BR&gt;Amy E Bonomi, PhD, MPH &lt;BR&gt;Human Development and Family Science, The Ohio State University, Columbus, Ohio, USA Nancy Glass, PhD, MPH, RN &lt;BR&gt;Center for Global Health, Johns Hopkins University, Baltimore, Maryland, USA &lt;/NOBR&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/128" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377682</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/63.extract]]&gt;</url>
    <title>Prevalence - HIV-positive young people at high risk of psychiatric disorders</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;What is the rate of psychiatric and substance abuse disorders in HIV-positive young people and are these disorders associated with HIV status? &lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Young people, aged between 9 and 16 years with perinatal exposure to HIV, recruited from medical centres providing family-focused care to HIV-affected families. 340 care givers and young person pairs, 206 HIV-positive and 134 HIV-negative young people were included (51% female, 54% African Americans and mean age 12.2 years). Among the care givers 87% were female, 46% were HIV positive and 50% were the biological parents. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Four medical centres in New York, USA; dates are not reported.&lt;/P&gt;
&lt;H3&gt;Assessment:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Data were obtained from the baseline interview of the Child and Adolescent Self-Awareness and Health (CASAH) project, a large US longitudinal study of psychosocial determinants of behaviour in HIV-infected and HIV-exposed youths. Young people and their care givers were interviewed separately but simultaneously in two interviews over a 4-week period. The first interview included a psychiatric assessment, the Diagnostic Interview Schedule for Children, and care givers and young people were asked about the presence or absence of symptoms … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/63.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302027</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/63]]&gt;</url>
    <title>Prevalence - Incidence of schizophrenia lower in people with type I diabetes</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the incidence of schizophrenia in people with type 1&lt;SUP&gt; &lt;/SUP&gt;diabetes in Finland?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;All individuals born 1950–9 in Finland (896 175 people)&lt;SUP&gt; &lt;/SUP&gt;identified through the National Population Register. Of these,&lt;SUP&gt; &lt;/SUP&gt;5009 were found to have type 1 diabetes based on the Social&lt;SUP&gt; &lt;/SUP&gt;Insurance Institution of Finland register.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General population, Finland; followed up from 1969–91.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Diagnoses of type 1 diabetes and of schizophrenia (ICD-8 or&lt;SUP&gt; &lt;/SUP&gt;DSM-III-R) during follow-up were identified through the Social&lt;SUP&gt; &lt;/SUP&gt;Insurance Institution of Finland register, the National Hospital&lt;SUP&gt; &lt;/SUP&gt;Discharge Register, and the Pension Register. A broad concept&lt;SUP&gt; &lt;/SUP&gt;of schizophrenia was used, which included schizoaffective, schizophreniform,&lt;SUP&gt; &lt;/SUP&gt;and schizotypal personality disorders. To control for reduced&lt;SUP&gt; &lt;/SUP&gt;sensitivity in the registers, the rate of false positives was&lt;SUP&gt; &lt;/SUP&gt;assessed in a subsample of 906 individuals in whom DSM-IV &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;H3&gt;Commentators:&lt;/H3&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Ruud van Winkel, Marc De Hert &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;University Psychiatric Center Catholic University Leuven, Kortenberg, Belgium&lt;BR&gt;Department of Psychiatry and Neuropsychology, EURON, South Limburg Mental Health Research and Teaching Network, Maastricht University, Maastricht, The Netherlands &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/63" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302024</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/60]]&gt;</url>
    <title>Prevalence - Increase in out-based physician diagnoses of bipolar disorder in youth in the USA</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How do patterns of outpatient visits with a diagnosis of bipolar&lt;SUP&gt; &lt;/SUP&gt;disorder differ between 1994 and 2003 for youths and adults?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;Representative sample of people visiting out-based physicians&lt;SUP&gt; &lt;/SUP&gt;in the USA. Data were collected through the National Ambulatory&lt;SUP&gt; &lt;/SUP&gt;Medical Care Survey (NAMCS), an annual survey which samples&lt;SUP&gt; &lt;/SUP&gt;a nationally representative group of visits to doctors engaged&lt;SUP&gt; &lt;/SUP&gt;in direct patient care.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Out-based physicians across the USA; 1994–2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;As part of the NAMCS, for one week during the year selected&lt;SUP&gt; &lt;/SUP&gt;physicians completed a questionnaire about each patient visit&lt;SUP&gt; &lt;/SUP&gt;(collecting demographic, clinical and treatment characteristics).&lt;SUP&gt; &lt;/SUP&gt;To look at temporal trends in visits with a diagnosis of bipolar&lt;SUP&gt; &lt;/SUP&gt;disorder, researchers pooled data for the following years: 1994–5,&lt;SUP&gt; &lt;/SUP&gt;1996–7, 1998–9, 2000–1, and 2002–3.&lt;SUP&gt; &lt;/SUP&gt;Trends were compared in two different &lt;NOBR&gt;&lt;EM&gt;. . (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Joseph C Blader &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Stony Brook State University of New York, Stony Brook, New York, USA &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/60" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377679</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/61.extract]]&gt;</url>
    <title>Prevalence - Increase in proportion of patients on long-term medication accounts for increase in antidepressant prescribing in UK</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;What factors have contributed to the recent increase in the prescription of antidepressants in the UK?&lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Participants were 189 851 people from the general practice research database (GPRD) and who had experienced their first episode of depression between 1993 and 2005. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;UK. The sample was selected from the GPRD, which contains anonymised primary care records of over 3 million patients registered in the UK. A total of 170 practices contributed data for the full duration of the study. &lt;/P&gt;
&lt;H3&gt;Assessment:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;The participants comprised first ever diagnoses of depression between 1993 and 2005 without an associated prescription for antidepressants or with a first ever antidepressant prescription for depression that was diagnosed 180 days before or 90 days after the prescribing event. The cohort of patients being followed in 1993 comprised the incident cases of first ever depression episode in that year whereas the cohort in the following years was cumulative and included patients from earlier years. The cohorts of later years therefore contained a mixture incident cases, prevalent cases and new episodes. The patients … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/61.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377680</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/62.extract]]&gt;</url>
    <title>Prevalence - Increased antidepressant and antipsychotic use in the USA between 1996 and 2005</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,BIPOLAR DISORDER,CHRONIC MIXED ANXIETY AND DEPRESSION,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;Have the prevalence and the sociodemographic and clinical patterns of antidepressant medication treatment changed between 1996 and 2005 in the USA? &lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Two samples considered to be representative of the US non-institutionalised civilian population were selected in 1996 (n=18 993) and 2005 (n=28 445). &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Households in the USA.&lt;/P&gt;
&lt;H3&gt;Assessment:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Respondents to the 1996 and 2005 Medical Expenditure Panel Surveys that were =6 years and that had reported receiving at least one antidepressant prescription during that calendar year.&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Change in the rate of antidepressant use, the clinical interventions received and the number of antidepressant prescriptions per person between 1996 and 2005 survey (adjusted rate ratio) in different population subgroups. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-6&gt;Cross-sectional study.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-9 class="section results"&gt;
&lt;H2&gt;Main results&lt;/H2&gt;
&lt;P id=p-7&gt;The use of antidepressants increased between 1996 and 2005 … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/62.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>301998</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/95]]&gt;</url>
    <title>Prevalence - Increased risk of sexual offending in men with psychotic disorders</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC MIXED ANXIETY AND DEPRESSION,DOMESTIC VIOLENCE OR PARTNER ABUSE,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How common are lifetime sexual offences in men with psychotic&lt;SUP&gt; &lt;/SUP&gt;disorders?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;345 508 people (171 949 women; 173 559 men) born in Denmark&lt;SUP&gt; &lt;/SUP&gt;between 1 January 1944 and 31 December 1947. Exclusions: men&lt;SUP&gt; &lt;/SUP&gt;and women who died or emigrated before age 44 years; men whose&lt;SUP&gt; &lt;/SUP&gt;only recorded hospitalisations occurred when they were transferred&lt;SUP&gt; &lt;/SUP&gt;to hospital by police after an arrest. Due to the low number&lt;SUP&gt; &lt;/SUP&gt;of arrests in women, only men were included in the final analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General population, Denmark; data obtained from Danish national&lt;SUP&gt; &lt;/SUP&gt;registers in 1991.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;People who had been hospitalised with a diagnosis of psychotic&lt;SUP&gt; &lt;/SUP&gt;disorder according to ICD-8 were identified using the Danish&lt;SUP&gt; &lt;/SUP&gt;Psychiatric Register at the Institute for Psychiatric Demography&lt;SUP&gt; &lt;/SUP&gt;in Aarhus, Denmark. Type of psychotic disorder (schizophrenia,&lt;SUP&gt; &lt;/SUP&gt;schizoaffective disorder, psychosis associated with organic&lt;SUP&gt; &lt;/SUP&gt;&lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Seena Fazel, Niklas Långström, &lt;BR&gt;Clinical Senior Lecturer in Forensic Psychiatry, Department of Psychiatry, University of Oxford, UK&lt;BR&gt;Associate Professor, Centre for Violence Prevention, Karolinska Institutet, Stockholm, Sweden &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/95" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298038</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/96]]&gt;</url>
    <title>Prevalence - Lifetime prevalence of psychotic disorders in Finland is 3.1%</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,BIPOLAR DISORDER,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007;64:19–28.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How common are psychotic disorders, including schizophrenia and bipolar I disorder, in the Finnish population?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Cross-sectional study.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Eighty areas (160 municipalities, including the 15 biggest towns) in Finland; 2000–4.&lt;BR&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 8028 people aged over 30 years randomly selected using a two-stage stratified cluster sampling procedure to be nationally representative.&lt;BR&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt; Initial screening for psychotic disorders consisted of a health examination and interview using the Composite International Diagnostic Interview (CIDI) in 2000–1. People meeting any of the following criteria were selected for diagnostic confirmation: physician or self-reported possible or definite psychotic disorder; lifetime episode of elevated mood lasting at least 4 days plus at least three manic symptoms (CIDI section F); any clinically relevant positive psychotic symptom or at least three lifetime positive psychotic symptoms (CIDI section G); symptoms of formal thought disorder, negative symptoms, hallucinations or catatonic symptoms (CIDI section P); receiving treatment or disability pension for severe psychotic or mental disorders (using the following national registers: National Hospital Discharge Register, Medication Reimbursement Register of the Finnish Social Insurance Institution, Pension Register of the Finnish Centre for Pensions); interview comments suggestive of psychosis; receiving medication; use of mood-stabilising medication or lithium (not for epilepsy or other somatic disorders) from 1996 through 2002 (Finnish National Prescription Register of the National Insurance Institution). People identified were re-interviewed (Structured Clinical Interview for DSM-IV Axis I Disorders, Global Assessment of Functioning, and the Social and Occupational Functioning Assessment Scale) and had neurological assessment between 2002 and 2004. Final diagnoses were made (DSM-IV-TR criteria) by three experienced clinicians based on interview data and case notes.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Lifetime prevalence of any psychotic disorder, specific affective (includes bipolar disorder with and without psychotic features, and major depressive disorder with psychotic features) or non-affective (includes schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, psychotic disorder not otherwise specified) psychotic disorders; concordance between individual screening tools and DSM-IV diagnoses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;The overall lifetime prevalence of any psychotic disorder was 3.06%. The lifetime prevalence of non-affective psychotic disorders was 1.94%; 0.59% for affective psychotic disorders; 0.42% for substance-induced psychotic disorders; and 0.21% for psychotic disorders resulting from a general medical condition. Bipolar I disorder (with or without psychotic features) had a lifetime prevalence of 0.24%, and schizophrenia a prevalence of 0.87%. National registers were the most sensitive predictors of a diagnosis of any psychotic disorder (sensitivity 86%). The subscales of the CIDI interview were not sensitive predictors of disorder (combined sensitivity of all subsections 43.5%; individual scale sensitivity ranged from 12% to 41%). Both self and physician report of psychosis lacked sensitivity (27% and 24% respectively).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;The lifetime prevalence of psychotic disorders is high in the Finnish population, about 3.1%. Using multiple national registers, including hospital and treatment records, is the most sensitive way to identify those with psychoses. Physician report, self-report and CIDI interview are not sensitive measures of psychotic disorder when used individually.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317848</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/64]]&gt;</url>
    <title>Prevalence - Low recognition of depression among outpatients by internists in China</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;What is the prevalence and recognition rate of depressive disorders&lt;SUP&gt; &lt;/SUP&gt;in Shenyang, China?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;5312 sequential patients (mean age 48.1±17.7 years; 60%&lt;SUP&gt; &lt;/SUP&gt;female) being treated in the internal medicine outpatient department&lt;SUP&gt; &lt;/SUP&gt;of participating hospitals. Only people aged 15 years or older&lt;SUP&gt; &lt;/SUP&gt;and who were physically able to complete the interview were&lt;SUP&gt; &lt;/SUP&gt;included.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;23 general hospitals, Shenyang, China; interviews carried out&lt;SUP&gt; &lt;/SUP&gt;November 2004 to January 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Prior to participants seeing the internists, interviews were&lt;SUP&gt; &lt;/SUP&gt;conducted by trained psychiatrists who administered the Chinese&lt;SUP&gt; &lt;/SUP&gt;version of the 12 item General Health Questionnaire (GHQ-12).&lt;SUP&gt; &lt;/SUP&gt;The results of the GHQ-12 were used to classify participants&lt;SUP&gt; &lt;/SUP&gt;as being at low risk, moderate risk or high risk for mental&lt;SUP&gt; &lt;/SUP&gt;disorders. The Structured Clinical Interview for DSM-IV-TR Axis&lt;SUP&gt; &lt;/SUP&gt;1 Disorders (SCID) was administered to all high risk, 10% of&lt;SUP&gt; &lt;/SUP&gt;low risk and 40% of moderate risk participants. Participants&lt;SUP&gt; &lt;/SUP&gt;then saw the internists who were blind to the SCID diagnosis&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;.&lt;/EM&gt; . (Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/64" target="_blank"&gt;Full text of this article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>302022</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/58]]&gt;</url>
    <title>Prevalence - Major depressive disorder is common in the elderly population of Yoruba-speaking regions of Nigeria</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How common is major depressive disorder in the elderly population&lt;SUP&gt; &lt;/SUP&gt;in Yoruba-speaking areas of Nigeria?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;2152 adults (aged &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;65 years) selected by multi-stage probability&lt;SUP&gt; &lt;/SUP&gt;sampling of households. 1897 were analysed after exclusion of&lt;SUP&gt; &lt;/SUP&gt;those with dementia.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Eight Yoruba-speaking states in the south-west and south-central&lt;SUP&gt; &lt;/SUP&gt;regions of Nigeria; interviews conducted November 2003 to August&lt;SUP&gt; &lt;/SUP&gt;2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Face-to-face interviews were conducted using the World Mental&lt;SUP&gt; &lt;/SUP&gt;Health Survey section of the composite international diagnostic&lt;SUP&gt; &lt;/SUP&gt;interview. Diagnoses of major depressive disorder (MDD) were&lt;SUP&gt; &lt;/SUP&gt;made using DSM-IV criteria and verified by review of the survey&lt;SUP&gt; &lt;/SUP&gt;by a clinical psychiatrist. Persons diagnosed as having dementia&lt;SUP&gt; &lt;/SUP&gt;by a cognitive screen were excluded. The Quick Inventory of&lt;SUP&gt; &lt;/SUP&gt;Depressive Symptomatology Self-Report (QIDS-SR) was used to&lt;SUP&gt; &lt;/SUP&gt;rate the worst month of depressive symptoms over the past year&lt;SUP&gt; &lt;/SUP&gt;in those with MDD, and to classify &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;BR&gt;&lt;/STRONG&gt;Mark Tomlinson &lt;BR&gt;Health Systems Research Unit, Medical Research Council, Cape Town, South Africa &lt;BR&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/58" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302023</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/59]]&gt;</url>
    <title>Prevalence - Major depressive disorder: afternoon and evening diurnal mood variation is common</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How common is diurnal mood variation (DMV) and how do patients&lt;SUP&gt; &lt;/SUP&gt;with classic DMV (morning worsening) differ from those without&lt;SUP&gt; &lt;/SUP&gt;it or from those with afternoon or evening worsening?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;3744 outpatients aged 18–75 years with non-psychotic major&lt;SUP&gt; &lt;/SUP&gt;depressive disorder (score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;14 on HAM-D-17) who were also enrolled&lt;SUP&gt; &lt;/SUP&gt;in the STAR*D (Sequenced Treatment Alternatives to Relieve Depression)&lt;SUP&gt; &lt;/SUP&gt;study. People with schizophrenia, schizoaffective disorder,&lt;SUP&gt; &lt;/SUP&gt;bipolar disorder, anorexia nervosa, obsessive compulsive disorder&lt;SUP&gt; &lt;/SUP&gt;or bulimia nervosa were excluded.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Primary and psychiatric care sites in the public and private&lt;SUP&gt; &lt;/SUP&gt;sectors; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;Clinicians used their judgement and the DSM-IV-TR diagnostic&lt;SUP&gt; &lt;/SUP&gt;checklist to diagnose depression. Participants were assessed&lt;SUP&gt; &lt;/SUP&gt;at baseline with the Inventory of Depressive &lt;I&gt;&lt;NOBR&gt;. . (Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;H3&gt;Commentator:&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;/H3&gt;
&lt;P&gt;Greg Murray &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Senior Lecturer and Clinical Psychologist Coordinator, MPsych (Clinical Psychology), Swinburne University of Technology, Australia &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/59" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224042</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/8/1/28]]&gt;</url>
    <title>Prevalence - Mental disorders are highly prevalent in Germany</title>
    <publicationDate>2005-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Jacobi F, Wittchen HU, Holting C, et al. Prevalence, comorbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004;34:597–611.&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What is the prevalence of mental disorders and comorbidity in German adults, and what are their associated factors and treatment rates?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Cross sectional study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; 113 communities across Germany; June 1998 to October 1999.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 4181 adults, aged 18–65 years, randomly drawn from population registries (113 randomly selected communities and 130 sampling units). People who were hospitalised for the entire recruitment period were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt; The Mental Health Supplement (GHS-MHS) was a subsection of the German National Health Interview and Examination Survey (GHSCS) (n = 7124). Individuals who screened positive in a 12 item questionnaire in the core survey, and 50% of those screening negative, were contacted for a structured clinical interview. Participants were assessed for a wide range of DSM-IV disorders, their comorbidity and correlation with other factors. Data were weighted for 50% negative response exclusion, sex, age, and community. Prevalence estimates and odds ratios (using logistical regression) were calculated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Mental disorders (DSM-IV), including psychotic disorders, substance abuse, depression, bipolar mood disorder, anxiety disorders, and somatic and eating disorders. Subthreshold diagnoses were noted. Post-traumatic stress disorder and antisocial personality disorder were not assessed. Healthcare usage was assessed and reported as "at least minimal intervention". Information was obtained via structured computer assisted clinical interviews (M-CIDI) by clinically trained personnel.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Follow up period:&lt;/STRONG&gt; 12 months.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;The 12 month prevalence for any mental disorder was 31%. Anxiety, depression, and somatoform disorders were most common (any mood disorder: 11.9%; unipolar depression: 10.7%; any anxiety disorder: 14.5%; phobias: 12.6%; any somatoform disorder: 11.0%). Eating disorders, obsessive-compulsive disorder, and illegal drug abuse had the lowest rates (0.3%, 0.7%, and 0.7%). Prevalence of possible psychosis was 2.6%. Comorbidity rates ranged from 44% (alcohol abuse) to 94% (generalised anxiety), with 60.5% of individuals with mental disorders having a single diagnosis. Most disorders emerged at a young age (median age for lifetime disorders was 20 years); depression and psychosis started later (medians of 31 and 37 years). Increased rates of mental illness were associated with being female, single, low social class, or of poor health. Forty per cent of participants received "at least minimal intervention" and this rate depended on comorbidity (single disorder 30%, 76% for high comorbidity).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Mental disorders are highly prevalent in the adult German population with rates similar to other national studies. Disorders start early in life and are often comorbid.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NOTES&lt;/STRONG&gt;&lt;BR&gt;Response rate of the GHSCS was 61.4% (n = 7124). After exclusion of subjects &amp;gt;65 years and 50% of screen negatives, the sample size for the GHS-MHS was 4773. A response rate of 87.6% resulted in a total of 4181 participants in the GHS-MHS. The paper also reported selected one month and lifetime prevalence rates.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302026</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/62]]&gt;</url>
    <title>Prevalence - Metabolic syndrome common in people with psychotic disorders, particularly in users of high potency antipsychotics</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the prevalence of metabolic syndrome in people with&lt;SUP&gt; &lt;/SUP&gt;psychotic disorders or using antipsychotic medications?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;Subset of 5434 people (aged over 30 years) enrolled in the Health&lt;SUP&gt; &lt;/SUP&gt;2000 Study who had available measurements relating to metabolic&lt;SUP&gt; &lt;/SUP&gt;syndrome that were taken after fasting for 4 hours.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Primary care settings across 80 municipalities in Finland; recruitment&lt;SUP&gt; &lt;/SUP&gt;September 2000 to June 2001.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt;&lt;BR&gt;People who were screened positive for a possible psychotic disorder&lt;SUP&gt; &lt;/SUP&gt;(reported a diagnosis, showed signs of psychotic or manic symptoms&lt;SUP&gt; &lt;/SUP&gt;during health examination) were interviewed using the research&lt;SUP&gt; &lt;/SUP&gt;version of the Structured Clinical Interview for DSM-IV-TR to&lt;SUP&gt; &lt;/SUP&gt;diagnose psychotic disorders. Diagnoses were classified as schizophrenia,&lt;SUP&gt; &lt;/SUP&gt;other non-affective psychotic disorders (including schizophreniform&lt;SUP&gt; &lt;/SUP&gt;and schizoaffective disorder), and affective psychosis (bipolar&lt;SUP&gt; &lt;/SUP&gt;I disorder and major depressive disorder with psychotic symptoms).&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;. . (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Shubulade Smith &lt;/P&gt;
&lt;P&gt;Institute of Psychiatry, London, UK &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/62" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392733</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/106.extract]]&gt;</url>
    <title>Prevalence - Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What is the prevalence of negative symptoms in outpatients treated with antipsychotics for schizophrenia, schizophreniform or schizoaffective disorder? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;1452 outpatients with schizophrenia spectrum disorders, aged 18–74 years, participating in the CLAMORS (Cardiovascular, Lipid and Metabolic Outcomes Research in Schizophrenia) study. Outpatients meeting &lt;EM&gt;Diagnostic and Statistical Manual, Fourth Edition&lt;/EM&gt; criteria for schizophrenia, schizophreniform or schizoaffective disorder, and who had received oral antipsychotic treatment with risperidone, olanzapine, quetiapine, ziprasidone, amisulpride or haloperidol, for 12 weeks or longer, were included. Outpatients treated with two or more antipsychotics, and those who were admitted to hospital at the time of evaluation, were excluded. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Multicentre (91 outpatient centres) study carried out from May 2004 to April 2005.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Assessment&lt;/H3&gt;
&lt;P id=p-4&gt;Negative symptoms and clinical severity were assessed using five items from the schizophrenia Postive and Negative Syndrome Scale (PANSS) negative symptoms subscale (blunted affect, emotional withdrawal, poor rapport, social withdrawal and verbal fluency). A PANSS symptom severity score of &amp;gt;3 on an item indicated a negative symptom being present (scale 1–7, where 1 = symptom absent and 7 = symptom extremely … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/106.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307001</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/31]]&gt;</url>
    <title>Prevalence - People admitted to psychiatric hospitals commonly lack the mental capacity to make treatment decisions</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What proportion of people admitted to psychiatric hospitals have the mental capacity to make decisions on treatment?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;350 people consecutively admitted for psychiatric care. Exclusions: no written informed consent; change in choice or resistance to assessment; residence outside catchment area or transferred from other inpatient facilities.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Three general adult psychiatric wards serving an inner city area, Maudsley Hospital, London, UK; February 2006–June 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment:&lt;BR&gt;&lt;/STRONG&gt;Information on patient’s presenting problems, diagnosis and treatment plan were obtained from medical records. The clinical researcher ascertained whether the main decision about treatment was stabilisation with drugs, admission to a place of safety or further assessment. Decision about a patient’s mental capacity was based on a clinical assessment and the McArthur competence assessment tool for treatment. The McArthur tool consists of an interview in which the interviewer assesses the participant’s ability to understand, appreciate, reason and express choice about their decision. The assessment is made as . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Scott Y H Kim&lt;/P&gt;
&lt;P&gt;University of Michigan, Ann Arbor, Michigan, USA &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/31" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317847</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/63]]&gt;</url>
    <title>Prevalence - Pervasive behavioural problems are common in children born at less than 26 weeks of gestation</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;Question:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does being born at less than 26 weeks of gestation (extremely&lt;SUP&gt; &lt;/SUP&gt;preterm) increase pervasive behavioural problems at 6 years&lt;SUP&gt; &lt;/SUP&gt;of age?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Population:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;All children born &lt;IMG border=0 alt="&lt;=" src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID317847/nelhImp_0000_les.gif"&gt;25 weeks of gestation in UK and Ireland between&lt;SUP&gt; &lt;/SUP&gt;March and December 1995. 241 of 308 eligible children responded;&lt;SUP&gt; &lt;/SUP&gt;of these 200 had complete reports from teachers and parents.&lt;SUP&gt; &lt;/SUP&gt;They were compared with reports for 148 age matched control&lt;SUP&gt; &lt;/SUP&gt;children.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Setting:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;UK and Ireland; children born between March and December 1995.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Assessment:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Behavioural problems, including emotional symptoms, conduct&lt;SUP&gt; &lt;/SUP&gt;problems, hyperactivity, peer problems and prosocial behaviours,&lt;SUP&gt; &lt;/SUP&gt;were assessed at age 6 years by teacher and parent completed&lt;SUP&gt; &lt;/SUP&gt;Strengths and Difficulties Questionnaires (SDQ). Clinical pervasive&lt;SUP&gt; &lt;/SUP&gt;behaviour was defined as behaviour in the clinical range reported&lt;SUP&gt; &lt;/SUP&gt;by both the parent and teacher. Cognitive ability was assessed&lt;SUP&gt; &lt;/SUP&gt;using the Kaufman Assessment Battery for Children unless the&lt;SUP&gt; &lt;/SUP&gt;child had disability or cognitive impairment, in which case&lt;SUP&gt; &lt;/SUP&gt;the Griffiths Scale of Mental Development or &lt;NOBR&gt;. .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/63" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>298036</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/94]]&gt;</url>
    <title>Prevalence - Prevalence of clinically diagnosed mental ill-health in adults with intellectual disabilities is around 40%</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Cooper SA, Smiley E, Morrison J, et al. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 2007;190:27–35.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What is the prevalence of mental ill-health in adults with intellectual disabilities?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Cross-sectional study.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Greater Glasgow Health Board area, Scotland; 2002–4.&lt;BR&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 1023 adults (&amp;gt;=16 years old) with intellectual disabilities, identified through social work services, local authorities, local specialist health services, the Health Board, the Scottish Executive Statistical Department, and primary healthcare services. Adults with IQ scores between 70 and 80 with complex health needs were excluded.&lt;BR&gt;&lt;STRONG&gt;Assessment:&lt;/STRONG&gt; Initial assessment included: review of case notes; the Psychiatric Assessment Schedule for Adults with Developmental Disabilities (PAS-ADD); C21st Health Check (assessment of developmental level, physical and mental health, problem behaviours and autistic-spectrum disorders); physical health assessments and blood tests. Participants were referred for full psychiatric assessment if a mental health problem was suspected. Full psychiatric assessment included: review of case notes; comprehensive consultant-level assessment; the Present Psychiatric State for Adults with Learning Disabilities (PPS-LD), plus instruments to detect psychopathology associated with learning disabilities, autistic spectrum disorders, hyperkinetic disorders, and problem behaviours; the Test for Severe Impairment; and the Vineland Scale. The assessment included at least one face-to-face interview with the participant and their main carer and with close relatives if possible.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Mental ill-health, defined by four criteria: (1) diagnosis by psychiatrist; (2) Diagnostic Criteria in adults with Learning Disabilities/mental retardation (DC-LD); (3) ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research (ICD-10-DCR); (4) DSM-IV-TR.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;The prevalence of mental ill-health in adults with intellectual disabilities varied depending on assessment measure (40.9% with clinical diagnosis; 35.2% with DC-LD; 16.6% with ICD-10-DCR; 15.7% with DSM-IV-TR). The prevalence was lower with ICD-10-DCR and DSM-IV-TR, which were developed for diagnosis of mental illness in the general population, whereas a higher prevalence was found with clinical diagnosis and DC-LD, which take into account the intellectual disabilities in this population. The most common mental illness identified by clinical diagnosis and DC-LD was problem behaviour (22.5% with clinical diagnosis; 18.7% with DC-LD; 0.1% with ICD-10-DCR; 0.1% with DSM-IV-TR). The most common mental illness identified by ICD-10-DCR and DSM-IV-TR was affective disorder (4.8% with ICD-10-DCR; 3.6% with DSM-IV-TR; 6.6% with clinical diagnosis; 5.7% with DC-LD).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;The prevalence of mental ill-health in adults with intellectual disabilities is around 40% using assessment measures that are specifically aimed at this population.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392731</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/105.extract]]&gt;</url>
    <title>Prevalence - Review: cognitive impairment present in people with affective psychoses</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What are the characteristics and level of cognitive impairment in people with affective psychoses (APs)?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-2&gt;Effect size (Cohen's d) of difference in cognitive abilities measured over eight domains using a variety of reliable tests: general intelligence (current IQ, premorbid IQ); mental speed (symbol coding, Trail making A); memory (verbal learning, delayed recall); visual memory recall; executive function (Wisconsin Card Sorting Test (WCST)) categories, WCST perseverations, Trail making B, Stroop interference); verbal fluency (category fluency, letter fluency); sustained attention (continuous performance test (CPT)) and working memory (digit span backwards); effect of moderator variables on cognitive performance (gender, age, education, symptomatic status, age of onset and duration of illness). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources&lt;/H3&gt;
&lt;P id=p-4&gt;PubMed, PsycINFO, EMBASE and Scopus were searched from 1987 to May 2009 for comparative studies. Reference lists of identified studies were hand searched. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis&lt;/H3&gt;
&lt;P id=p-5&gt;Reviewers appraised studies and selected trials in adults comparing cognitive abilities in people with psychotic major depression (MDP) or psychotic bipolar disorder (BDP; ICD-9, ICD-10, DSM-III, DSM-III-R … &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/105.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328860</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/128-a]]&gt;</url>
    <title>Prevalence - Review:Prevalence of adult ADHD declines with age</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;What is the prevalence of adult attention deficit hyperactivity&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;disorder (ADHD) and which factors have an effect?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Prevalence of ADHD in adults (DSM-IV criteria).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review with meta-analysis.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;MEDLINE, PsycLit and EMBASE were searched (search dates not&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;given) for population based studies. Reference lists of identified&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;studies were hand searched.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;English language studies were appraised and population based&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;studies providing prevalence data for adult ADHD (DSM-IV criteria)&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;were selected. Studies researching prevalence of ADHD in special&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;groups (eg, people with bipolar or panic disorder) were excluded,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;as were family studies, follow-up studies and studies not using&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;DSM-IV criteria to diagnose adult ADHD. A mixed effect meta-regression&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;was applied to estimate the prevalence of ADHD and to assess&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;the impact of demographic variables on the estimates of prevalence.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Main results&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Six studies met inclusion criteria and were included in the&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;meta-analysis. Prevalence of adult ADHD varied greatly (table&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;1). The pooled prevalence &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/128-a" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111326</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111326]]&gt;</url>
    <title>Primary care</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DEPRESSION,PATIENTS,DISADVANTAGED GROUPS,POPULATION BASED &amp; PREVENTATIVE SERVICES,PRIMARY CARE SERVICES,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SERVICES,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Primary care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111334:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111306:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;The case for action&lt;/H2&gt;
&lt;P&gt;Primary care is a critical setting within which to promote mental health for a number of reasons. About one in four people suffers from a diagnosable mental health problem each year and about 90% of those people turn up at the GP surgery (ref 1). &lt;/P&gt;
&lt;P&gt;People present to primary care with mental health problems in a variety of ways. Typically problems in primary care are a mixture of social, psychological, medical, emotional, financial and family difficulties&amp;nbsp;(ref 2). An appropriate response would include a psycho-bio-social rather than a purely medical approach (ref 3).&lt;/P&gt;
&lt;P&gt;Primary care trusts now have public health responsibilities which strengthen their role in promoting mental health at a population level and not just on an individual patient-based level. PCTs are key players in Local Strategic Partnerships and are required to develop a range of alliances with other statutory agencies as well as the voluntary sector and the broader public (ref 4).&lt;/P&gt;
&lt;P&gt;There are new opportunities to develop services at the interface between primary care and local populations, to reach out to socially excluded groups such as refugees, homeless people and those with substance misuse problems, and to address inequalities in access to services such as talking treatments. Exercise, arts and education referrals, ‘walking for health’ schemes, increasing benefit uptake, protocols for shared care with user/survivor networks and referrals to self-help and voluntary groups are key aspects of the primary care role to strengthen mental health within communities (ref 5).&lt;/P&gt;
&lt;P&gt;Mental health is now included in quality of care awards in the new GP contract (ref 6). This will facilitate GP practices establishing registers of people with severe and enduring mental health problems and provide an opportunity to offer targeted physical health checks.&lt;/P&gt;
&lt;P&gt;Recruitment of primary care mental health graduate workers (ref 7) as well as primary care gateway workers (ref 8) will enhance the provision of accurate, needs-based mental health prevention and promotion services.&lt;/P&gt;
&lt;H2&gt;Primary Care – summary of the evidence&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Detecting, treating and preventing depression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The World Health Organisation estimates that next to ischaemic heart disease, major depression will be the world’s second most debilitating disease by 2020 (ref 9). Depression is the third most common reason for consultation in UK general practice (ref 10). Up to half of cases of depression or anxiety may go undiagnosed in primary care (ref 11). Different research found that general practitioners fail to detect only one in seven, rather than one in two, cases of treatable depression or anxiety (ref 12). A prospective cohort study in Germany compared routine depression screening of patients in primary care versus selective evaluation of suspected cases of depression (ref 13). They found that the sensitivity of family doctors’ unaided clinical diagnosis was 65% but this improved to 93% when a wellbeing screening tool was used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Managing peri and post natal depression:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Training midwives, health visitors and practice nurses to detect mental health problems can improve early identification of perinatal depression. In some localities, primary care offers an integrated service that addresses the emotional needs of pregnant women, aiming to improve early detection of perinatal anxiety and depression (ref 14, 15).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Depression in the over 60s&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A systematic review examined trials of treatments for depression in primary care patients over the age of 60 (ref 16). Only two of the identified studies exclusively focused on the over 60s, a further three studies included the over 60s and there was an emphasis on severe rather than moderate depression. All the trials involved the use of medication. The reviewers concluded that there was little evidence of effectiveness for a range of different treatments for depression in the over 60s. No studies had addressed measures of efficacy of non-pharmacological interventions, such as cognitive or behavioural therapy or psychotherapy. This was deemed to be a serious omission. Given the greater amount of medication that older people regularly take for other conditions, there is more likelihood of drug interactions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Self-help for depression and anxiety&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Access to effective psychological therapies in primary care is problematic because of the small number of trained professionals and high demand for care. It has been suggested that self-help treatments based on proven psychological therapies may provide a method by which access can be improved. A systematic review scrutinised the current evidence, from randomised controlled trials and controlled before and after studies, of efficacy of self-help treatments for anxiety and depression in primary care (ref 17). The reviewers conclude that there is preliminary evidence that self-help packages may offer some clinical advantages over routine primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Counselling: Clinical and cost-effectiveness&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Counselling has become an almost routine component of primary care service provision (ref 18) A systematic review examined the clinical and cost effectiveness of counselling in primary care&amp;nbsp;(ref 19). Seven trials were included in the review and the conclusion drawn was that in the short-term the counselling group showed greater effectiveness than the ‘usual care’ group and the counselling service attracted high satisfaction ratings from patients. However positive effect was not sustained in the long-term. The limited economic analysis seemed to show that counselling was no more costly than usual care. The evidence from the review supports the provision of counselling as a useful addition to primary care provision alongside other mental health treatments. However there is no clarity on which patients might benefit most from counselling or other psychological therapies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reducing alcohol consumption&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Brief interventions in primary care may be effective in reducing excessive alcohol consumption (ref 20) However, screening in general practice does not seem to be an effective precursor to brief interventions targeting excessive alcohol use (ref 21,22).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Facilitating access to voluntary sector resources&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Facilitation between primary care and the voluntary sector improves psycho-social outcomes. Findings from a randomised controlled trial in Avon with 26 general practices, found that people who were referred from primary care to a liaison organisation had better mental health scores (e.g. less anxiety), found it easier to carry out everyday activities and had more positive feelings about general health and ‘quality of life’ than those who were not referred (ref 23).&lt;/P&gt;
&lt;P&gt;A ‘family support co-ordinator’ employed to work from a General Practice base in Hackney, London, was well received by vulnerable families. This approach combined referral facilitation with practical and emotional support to help families build their own resources and find ways around problems. An evaluation of the service suggested that combining practical and emotional support enabled people to get the help they wanted. The offering of protected time and independent help provided from a general practice base was convenient and non-stigmatising&amp;nbsp; (ref 24).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Support networks/ self help:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;People with a small primary support group (3 people or less) are at greatest risk of mental health problems (ref 25). Social support reduces death rates, susceptibility to infection and depression, notably in older people (re 26,27).&lt;/P&gt;
&lt;P&gt;Primary care has a role in strengthening access to self help and support networks by ensuring better links between primary health care and sources of information and support in the community. Effective interventions include the promotion of self-help, advocacy, neighbourhood and voluntary activities, as well as structures that facilitate community planning and local decision-making in the provision of services (ref 28-30).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Exercise&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A number of trials suggest that patients respond positively to GP advice to take more exercise (ref 31). National Consensus Statements on physical activity and mental health (ref 32) show that exercise prevents clinical depression and is as effective in treatment as other psychotherapeutic interventions. Exercise also reduces anxiety, enhances mood and improves self esteem (ref 33, 34). Regular exercise improves cognitive functioning, reduces mental health problems and improves the mental health of older people (ref 35). Evaluation of the Balance for Life scheme in Essex found that the 10 week programme of exercise that GP’s prescribed for patients significantly reduced depression and anxiety, increased overall quality of life and self-efficacy for exercise. 68% of clinically depressed patients had depression scores that became non-clinical within three months (ref 36).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Prescription for learning&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Strengthening the links between primary care and education has been under researched, although there is good evidence of the physical and mental health benefits of involvement in learning (ref 37). Research from the Basic Skills Agency shows that around 7 million adults with poor basic skills will class themselves as long term sick, rather than being classed as unemployed. Prescriptions for Learning, led by the National Organisation for Adult Learning, in partnership with the Nottingham Health Action Zone, uses a learning adviser in primary care settings to provide learning support for patients with poor basic skills. &lt;A href="http://www.niace.org.uk/" target="_blank"&gt;www.niace.org.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Promoting the mental health of mothers and children&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Thurrock Community Mothers programme, now replicated nationally, uses the expertise of trained volunteers with experience of mothering, to support local parents. There is equal emphasis on developing the skills of the Community Mother volunteers themselves and many move on to other employment opportunities. Community mother programmes have demonstrated positive socio-economic and health improvements for children, parents and volunteers, and have also been successful with traveller communities (ref 38-40). Other approaches include parenting groups for parents of children at local day nurseries.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111334:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111306:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;McCulloch A (2003) &lt;A href="http://www.scmh.org.uk/8025695100388752/GenerateFrameset1?OpenAgent&amp;amp;doc=wpASTN5F9KJ7" target="_blank"&gt;Introduction in Primary Solutions: An independent policy review on the development of primary care mental health services&lt;/A&gt;. London: Sainsbury Centre for Mental Health&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Department of Health (2001a) &lt;A href="http://www.dh.gov.uk/assetRoot/04/05/89/10/04058910.pdf" target="_blank"&gt;Workforce Action Team Special Report on Primary Care Mental Health&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Dowrick C (2001) Advances in psychiatric treatment in primary care. Advances in psychiatric treatment 7: 1-8&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Department of Health (2001b) &lt;A href="http://www.dh.gov.uk/assetRoot/04/05/87/26/04058726.pdf" target="_blank"&gt;Shifting the balance of power within the NHS: securing delivery&lt;/A&gt;. London: Department of Health&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Gask L, Rogers A, Roland M, Bower P and Morris D (2003) &lt;A href="http://www.npcrdc.man.ac.uk/Publications/mentalhealth-handbook.pdf" target="_blank"&gt;A practical guide to the National Service Framework for Mental Health in primary care.&lt;/A&gt; (2nd edition)&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;SCMH (2003) &lt;A href="http://www.scmh.org.uk/8025695100388752/GenerateFrameset1?OpenAgent&amp;amp;doc=wpPCHN4ULFWD" target="_blank"&gt;Investing in General Practice – The new General Medical Services Contract for GPs&lt;/A&gt;. Briefing 21&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Department of Health (2003) &lt;A href="http://www.dh.gov.uk/assetRoot/04/01/95/31/04019531.pdf" target="_blank"&gt;Fast-forwarding Primary Care Mental Health: Graduate primary care mental health workers&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Department of Health (2002) &lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4006795&amp;amp;chk=uC5BV%2B" target="_blank"&gt;Fast-forwarding Primary Care Mental Health: ‘Gateway Workers’&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Murray CJ and Lopez AD (1996) (eds) The global burden of disease .A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;NHS Centre for Reviews and Dissemination (2002) Improving the recognition and management of depression in primary care. Effective Health Care Bulletin Vol. 7, No.5 University of York&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Goldberg D and Huxley P (1992) Common mental disorders. London: Routledge&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Kessler D, Bennewith O, Lewis G and Sharp D (2002) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/325/7371/1016?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074858114085_3868&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=325&amp;amp;firstpage=1016&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Detection of depression and anxiety in primary care: follow up study&lt;/A&gt;. British Medical Journal 325: 1016-1017&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Henkel V, Mergl R, Kohnen R, Maier W, Moller H-J and Hegerl U (2003) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/326/7382/200?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074857896586_3792&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=326&amp;amp;firstpage=200&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Identifying depression in primary care: a comparison of different methods in a prospective cohort study&lt;/A&gt;. British Medical Journal 326: 200-201&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Hodnett ED (2000) Support during pregnancy for women at increased risk Cochrane Review The Cochrane Library Issue 3, Oxford: Update Software&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Cooper PJ and Murray L (1998) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/316/7148/1884?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074856976893_3409&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=316&amp;amp;firstpage=1884&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Post natal depression: clinical review&lt;/A&gt; British Medical Journal 316:1884-1886&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Freudenstein U, Jagger C, Arthur A and Donner-Banzhoff, N (2001) Treatments for late life depression in primary care: a systematic review. Family Practice, 18 (3):321-327.&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Bower P, Richards D and Lovell K (2001a) The clinical and cost-effectiveness of self-help treatments for anxiety and depression in primary care: a systematic review. British Journal of General Practice 51: 838-845&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Bower P and Sibbald B (2002) &lt;A href="http://www.cochrane.org/cochrane/revabstr/AB000532.htm" target="_blank"&gt;On-site mental health workers in primary care:effects on professional practice&lt;/A&gt;. Oxford: The Cochrane Library. Issue 4.&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Bower P, Rowland N, Mellor Clark J, Heywood P, Godfrey C and Hardy R (2001b) &lt;A href="http://www.cochrane.org/cochrane/revabstr/AB001025.htm" target="_blank"&gt;Effectiveness and cost effectiveness of counselling in primary care&lt;/A&gt;. Oxford: The Cochrane Library. Issue 3. 2002&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Ashenden R, Silagy C and Weller D (1997) A systematic review of effectiveness of promoting lifestyle change in general practice Family Practice 14:160-175&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Beich A, Gannik D and Malterud K (2002) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/325/7369/870?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074856557621_3209&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=325&amp;amp;firstpage=870&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Screening and brief intervention for excessive alcohol use: qualitative interview study of the experiences of general practitioners&lt;/A&gt;. British Medical Journal. 325: 870-874&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;Beich A, Thorsen T and Rollnick S (2003) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/327/7414/536?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074856609622_3243&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=327&amp;amp;firstpage=536&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis&lt;/A&gt;. British Medical Journal. 327: 536-541.&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;Grant C, Goodenough T, Harvey I and Hine C (2000) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/320/7232/419?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074857836841_3769&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=320&amp;amp;firstpage=419&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;A randomised controlled trial and economic evaluation of a referrals facilitator between primary care and the voluntary sector&lt;/A&gt;&amp;nbsp;British Medical Journal 320:419-23&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp;Goodhart C, Layzell S, Cook A and Graffy J (1999) Family support in General Practice. Journal of the Royal Society of Medicine. 92 (10): 525-528.&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;Brugha TS, Wing JK, Brewin CR, MacCarthy B and Lasage A (1993) The relationship of social network deficits in social functioning in long term psychiatric disorders Social Psychiatry and Psychiatric Epidemiology 28:218-224&lt;/P&gt;
&lt;P&gt;26.&amp;nbsp;Cohen S (ed) (1997) Measuring stress: a guide for health and social scientists Oxford University Press, Oxford&lt;/P&gt;
&lt;P&gt;27.&amp;nbsp;Oxman TE et al (1992) Social support and depressive symptoms in the elderly American Journal of Epidemiology 135:356-368&lt;/P&gt;
&lt;P&gt;28.&amp;nbsp;Stark W (1998) Empowerment and self-help initiatives – enhancing the quality of psycho-social care in Jenkins and Ustun (eds) Preventing mental illness: mental health promotion in primary care London&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp;Whelan R (1993) The role of social support in mediating the psychological effects of economic stress Sociology of Health and Illness 15:86-101&lt;/P&gt;
&lt;P&gt;30.&amp;nbsp;Rosengren et al (1993) Stressful life events, social support and mortality in men born in 1933 &lt;A href="http://bmj.bmjjournals.com/" target="_blank"&gt;British Medical Journal&lt;/A&gt; 307:1102-5&lt;/P&gt;
&lt;P&gt;31.&amp;nbsp;Killoran A, Fentem P and Caspersen C (eds) (1994) Moving on: international perspectives on promoting physical activity Health Education Authority: London&lt;/P&gt;
&lt;P&gt;32.&amp;nbsp;Grant T (ed) (2000) Physical activity and mental health: national consensus statements and guidelines for practice Somerset Health Authority/Health Education Authority London&lt;/P&gt;
&lt;P&gt;33.&amp;nbsp;Fox KR (2000) Self esteem, self perceptions and exerciseInternational Journal of Sport Psychology 31:228-240&lt;/P&gt;
&lt;P&gt;34.&amp;nbsp;Mutrie N (2000) The relationship between physical activity and clinically defined depression Physical activity and psychological well-being SJH Biddle, KR Fox and SH Boutcher (eds) Routledge, London&lt;/P&gt;
&lt;P&gt;35.&amp;nbsp;Etnier JL, Salazar W, Landers DM, Petruzzello SJ, Han M and Nowell P (1997) The influence of physical fitness and exercise upon cognitive functioning: a meta analysis Journal of Sport and Exercise Psychology19:249-277&lt;/P&gt;
&lt;P&gt;36.&amp;nbsp;Darbishire L and Glenister D (1998) The Balance for Life scheme: mental health genefits of GP recommended exercise in relation to depression and anxiety Essex&lt;/P&gt;
&lt;P&gt;37.&amp;nbsp;Challis M (1996) Andragogy and the accreditation of prior learning. International Journal of Lifelong Education. 15 (1)&lt;/P&gt;
&lt;P&gt;38.&amp;nbsp;Johnson Z and Molloy B (1995) The Community Mothers Programme: empowerment of parents by parents Journal of Children and Society 9,2:73-85&lt;/P&gt;
&lt;P&gt;39.&amp;nbsp;Fitzpatrick P, Molloy B and Johnson Z (1997) Community mothers programme: extension to the traveller community in Ireland Journal of Epidemiology and Community Health 51:299-303&lt;/P&gt;
&lt;P&gt;40.&amp;nbsp;Johnson Z, Howell F and Molloy B (1993) The Community Mothers programme: randomised controlled trial of non-professional intervention in parenting &lt;A href="http://bmj.bmjjournals.com/" target="_blank"&gt;British Medical Journal&lt;/A&gt;&amp;nbsp;306:1449-1452&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cohen A and Hove M (2001) Physical health of the severe and enduing mentally ill – a training pack for GP educators Sainsbury Centre for Mental Health &amp;amp;Department of Health&lt;/P&gt;
&lt;P&gt;Crowther R, Bond G, Huxley P, Marshall M (2000) &lt;A href="http://www.cochrane.org/cochrane/revabstr/ab003080.htm" target="_blank"&gt;Vocational rehabilitation for people with severe mental disorders&lt;/A&gt; (Protocol for a Cochrane Review) The Cochrane Library, Issue 3, Oxford&lt;/P&gt;
&lt;P&gt;Health Education Authority (2000) Art for health: a review of good practice in community based arts projects and interventions which have an impact on health and well-being HEA: London&lt;/P&gt;
&lt;P&gt;Matarasso F (1997) Use or ornament? The social impact of participation in the arts Comedia: Stroud&lt;/P&gt;
&lt;P&gt;Smyth, JM et al, (1999) Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis: a randomised trial JAMA: 281: 1304-1309&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>291091</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.primarycarecontracting.nhs.uk/uploads/primary_care_service_frameworks/primary_care_service_framework_-_alcohol_v9_final.pdf]]&gt;</url>
    <title>Primary Care Service Framework: Alcohol Services in Primary Care</title>
    <publicationDate>2008-07-25T00:00:00</publicationDate>
    <publisher>NHS Primary Care Contracting</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This ‘enhanced service’ framework should be read in conju nction with the supportive statements for commissioning on
the Primary Care Contracting website – 33Hwww.pcc.nhs.uk/204.php – and the additional supportive notes at the end of
this document.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This ‘enhanced service’ framework should be read in conjunction with the supportive statements for commissioning on the Primary Care Contracting website – 33Hwww.pcc.nhs.uk/204.php – and the additional supportive notes at the end of this document. A complementary suite of practical resources is also available on this website to support commissioners, providers and other stakeholders with local service design and development. These additional practical tools or pointers have all been successfully used to improve the health of people with alcohol problems and have been shared by PCTs and providers of primary care alcohol services. Primary Care Contracting is grateful for all those organisations that were willing to share their learning across the NHS.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This document provides examples of good practice around alcohol services in primary care and can be adapted and used as a basis for an enhanced service via a schedule within a local primary care contract or Service Level Agreement. This will hopefully avoid duplication of effort and speed up the commissioning process. It would be appropriate to adapt or include local information in the relevant sections. Legal advice or support for local contractual arrangements may need to be considered.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266135</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=42418&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Primary Concernts</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Primary Concerns asserts that people with mental health problems should be receiving the same level of treatment for their physical health needs as others.</description>
    <body>&lt;![CDATA[ Primary Concerns asserts that people with mental health problems should be receiving the same level of treatment for their physical health needs as others. This need for equality is deemed crucial because people with severe and enduring mental health problems often have worse physical health outcomes. The report says that Practice Based Commissioning, which enables primary care practices to save money by providing hospital services direct rather than paying for secondary care services, needs to extend to mental health in order to provide a range of services and treatments to patients. This would require commissioning training for GPs and other primary care staff, and the introduction of a national tariff for mental health.]]&gt;</body>
  </document>
  <document>
    <id>388566</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.centreformentalhealth.org.uk/pdfs/prison_mental_health_vision_reality.pdf]]&gt;</url>
    <title>Prison Mental Health: Vision and Reality</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>Royal College of Nursing and Nacro, the crime reduction charity,</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,MENTAL HEALTH SERVICES,PRISON HEALTH,MENTAL HEALTH,ADULT CONDITIONS,PUBLIC HEALTH,OUTCOMES,POPULATIONS,SETTINGS,GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,DISADVANTAGED GROUPS,BUILDINGS,PRISONS,MONTHLY ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The need for better mental health care in prisons has been evident for some time. Prisoners have dramatically higher rates of mental health problems compared to the general population.&lt;/P&gt;
&lt;P&gt;This publication, developed jointly with the &lt;A href="http://www.rcn.org.uk/" target="_blank"&gt;Royal College of Nursing&lt;/A&gt; and &lt;A href="http://www.nacro.org.uk/" target="_blank"&gt;Nacro, the crime reduction charity&lt;/A&gt;, aims to examine what has been achieved in prison mental health over recent years from a number of different personal perspectives and individual observations of working in England. It looks at the specific achievements of inreach teams and of efforts to divert offenders from custody.&lt;/P&gt;
&lt;P&gt;It also looks more broadly at the rapid growth of the prison population during the same period and the treatment of offenders with mental health problems outside as well as inside prison.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>276241</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081260]]&gt;</url>
    <title>Procedure for the transfer of prisoners to and from hospital under sections 47 and 48 of the Mental Health Act (1983)</title>
    <publicationDate>2007-12-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,ADJUSTMENT DISORDER,ALCOHOL MISUSE,BEREAVEMENT AND LOSS,BIPOLAR DISORDER,CHRONIC MIXED ANXIETY AND DEPRESSION,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DEMENTIA,DEPRESSION,DISSOCIATIVE (CONVERSION) DISORDER,DOMESTIC VIOLENCE OR PARTNER ABUSE,DRUG USE DISORDERS,EATING DISORDERS,GENERALIZED ANXIETY,OBSESSIVE COMPULSIVE DISORDER,PANIC DISORDER,PERSONALITY (BEHAVIOURAL) DISORDERS,PHOBIC DISORDERS,POST-TRAUMATIC STRESS DISORDER,POSTNATAL DISORDERS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The revised and updated 'Procedure for the Transfer of Prisoners to and from Hospital under Sections 47 and 48 of the Mental Health Act 1983' aims to help colleagues to work together more effectively to secure and sustain significant improvements in any unacceptable delays.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The revised and updated 'Procedure for the Transfer of Prisoners to and from Hospital under Sections 47 and 48 of the Mental Health Act 1983' aims to help colleagues to work together more effectively to secure and sustain significant improvements in any unacceptable delays.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The procedure is a result of wide national consultation and explains each stage of the transfer process, providing clear guidance for key stakeholders to enable timely transfer. In particular, the procedure highlights the vital role of safe and effective commissioning by responsible commissioners. A list of useful contacts and their details is also provided for further support.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We encourage those involved in the process of transferring prisoners to and from hospital under Sections 47 and 48 of the Mental Health Act 1983 to use this document to support them in their work to enable prisoners to access timely care and treatment as afforded by service users accessing mental health services in the community.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328905</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Processed-food-and-low-mood.aspx]]&gt;</url>
    <title>Processed food and low mood</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Eating a diet high in processed foods increases the risk of depression,” BBC News reported.&lt;/P&gt;
&lt;P&gt;This report is based on data from a long-running study of middle-aged civil servants. An analysis found that eating processed foods was associated with depression five years later, even after other social and health factors were taken into account.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302028</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/10]]&gt;</url>
    <title>Prognosis - About a third of young women are estimated to fully recover from social phobia within 18 months</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PHOBIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the rate of recovery from social phobia and what are&lt;SUP&gt; &lt;/SUP&gt;the prognostic factors predicting recovery?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;91 women (mean age 22 years) with DSM-IV social phobia (meeting&lt;SUP&gt; &lt;/SUP&gt;all 8 criteria at baseline) from a total sample of 1396 German&lt;SUP&gt; &lt;/SUP&gt;women aged 18–24 years recruited in the Dresden Prediction&lt;SUP&gt; &lt;/SUP&gt;Study, which collected information on the incidence, prevalence&lt;SUP&gt; &lt;/SUP&gt;and course of psychiatric disorders in a randomly selected sample&lt;SUP&gt; &lt;/SUP&gt;from the community.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Community setting, Dresden, Germany; enrolment 1996.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;Socio-demographic factors; psychosocial factors (including daily&lt;SUP&gt; &lt;/SUP&gt;hassles and life satisfaction); comorbid psychiatric disorders;&lt;SUP&gt; &lt;/SUP&gt;characteristics of social phobia (severity, age at onset, avoidance&lt;SUP&gt; &lt;/SUP&gt;behaviour, impairment). Prognostic factors were assessed in&lt;SUP&gt; &lt;/SUP&gt;face-to-face interviews using the Diagnostic Interview for Psychiatric&lt;SUP&gt; &lt;/SUP&gt;Disorders (F-DIPS) and other measures such as the Symptoms Checklist&lt;SUP&gt; &lt;/SUP&gt;90-Revised, Anxiety Sensitivity Index, and Marburger Health&lt;SUP&gt; &lt;/SUP&gt;Study Mental Health Questionnaire, administered by trained doctors&lt;SUP&gt; &lt;/SUP&gt;or final year psychology &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Ina Marteinsdottir, PhD, MD &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Institution for Neuroscience, Uppsala, Sweden &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/10" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383446</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/75.extract]]&gt;</url>
    <title>Prognosis - Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Do angiotensin receptor blockers protect against or slow the progression of dementia and Alzheimer's disease?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P id=p-2&gt;Participants were 819 491 older adults (98% male; aged =65 as of October 2002) with cardiovascular disease. More than 11 500 were taking angiotensin receptor blockers (ARBs), &amp;gt;91 000 were taking the angiotensin-converting enzyme (ACE) inhibitor lisinopril and &amp;gt;696 000 were taking other cardiovascular drugs (which included ß blockers and calcium channel antagonists, and excluded ARBs, ACE inhibitors and statins). The study included those without a diagnosis of dementia or Alzheimer's disease at baseline (2001–2002) as well as those with these diagnoses.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Administrative database of the US Veteran Affairs; data collected October 2001 to September 2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors:&lt;/H3&gt;
&lt;P id=p-4&gt;Use of angiotensin receptor blockers, lisinopril, combinations of these or other cardiovascular medications. Lisinopril was selected as a comparator, as ACE inhibitors are a similar drug class to ARBs and share indications, and lisinopril has the largest group of users of the ACE inhibitors. … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/75.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>392736</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/109.extract]]&gt;</url>
    <title>Prognosis - Anhedonia predicts adverse cardiac events in people with acute coronary syndromes</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Does anhedonia and/or depressed mood predict recurrent major adverse cardiac events (MACEs) in people with acute coronary syndromes (ACS)? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;Consecutive sample of 453 people (58% male, mean age 61 years, range 25–93 years) hospitalised for ACS: 21% with acute myocardial infarction with ST-segment elevation, 33% with acute myocardial infarction without ST-segment elevation and 46% with unstable angina. To be included, participants had to either be not depressed (scoring 0–4 on the Beck Depression Inventory, BDI) or have at least mild depression (scoring =10 on the BDI). People scoring 5–9 on the BDI were excluded to delineate clearly between depressed and non-depressed people. Main exclusions were terminal illness, cognitive impairment and alcohol or substance abuse, being unavailable for follow-up or screening not completed in the first week.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Cardiac units in three university hospitals, New York and Connecticut, USA; recruitment May 2003 to June 2005.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;Anhedonia and depressed mood (clinical or patient assessed), depressive symptoms severity (BDI score &amp;lt;5 vs =10), major depressive episodes (MDEs). Participants had a semistructured diagnostic interview 1 week after admission for ACS. The interview assessed anhedonia, depressed mood and Diagnostic … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/109.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302005</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/41]]&gt;</url>
    <title>Prognosis - Attention deficit hyperactivity disorder is associated with poorer academic performance</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is attention deficit hyperactivity disorder (ADHD) associated&lt;SUP&gt; &lt;/SUP&gt;with poorer academic outcomes?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;From a large birth cohort for whom school records were available&lt;SUP&gt; &lt;/SUP&gt;through a contractual agreement with the city, 370 adolescents&lt;SUP&gt; &lt;/SUP&gt;fulfilling criteria for ADHD (mean age 10.4 years; 75% male),&lt;SUP&gt; &lt;/SUP&gt;and 740 age and gender matched controls (two for each case)&lt;SUP&gt; &lt;/SUP&gt;without ADHD or any other psychiatric disorder were selected.&lt;SUP&gt; &lt;/SUP&gt;Medical records for these participants were available through&lt;SUP&gt; &lt;/SUP&gt;the Rochester Epidemiology Project. DSM-IV exclusion criteria:&lt;SUP&gt; &lt;/SUP&gt;severe mental retardation, developmental disorder, schizophrenia&lt;SUP&gt; &lt;/SUP&gt;or other psychiatric disorder.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Rochester, Minnesota, USA. Participants enrolled in the January&lt;SUP&gt; &lt;/SUP&gt;1976 to December 1982 birth cohort.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;ADHD.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Reading achievement (percentile rank on the California Achievement&lt;SUP&gt; &lt;/SUP&gt;Score, measured every 2 years to mean age 13 years), absenteeism&lt;SUP&gt; &lt;/SUP&gt;(percentage days absent per school grade level for &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Kapil Sayal &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Senior Lecturer in Child &amp;amp; Adolescent Psychiatry, Institute of Mental Health and University of Nottingham, Nottingham, UK &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/41" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344526</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/9.extract]]&gt;</url>
    <title>Prognosis - Attention problems in primary school affect education achievements at high school</title>
    <publicationDate>2010-02-09T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Which childhood behavioural problems predict lower scores on academic tests and diminish educational achievement at age 17 years? &lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P id=p-2&gt;1095 children born between 1983 and 1985. Children were selected randomly from birth records at one urban and one suburban hospital in Detroit. Exclusions: mental retardation, blindness or severe neurological impairment. 823 (75%) were assessed after initial exclusions. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Detroit, USA; time period studied 1983–2000.&lt;/P&gt;
&lt;H3&gt;Prognostic factors:&lt;/H3&gt;
&lt;P id=p-4&gt;Children were initially assessed when they were 6 years old with the Wechsler Intelligence Scale for Children-Revised; Full-scale IQ to measure cognitive ability; and the three subscales from the Teacher Rating Form- namely, attention problems subscale (measuring attention deficit hyperactivity disorder), internalising behaviour composite scale (assessing withdrawn, anxious or depressed behaviour plus somatic complaints), and externalising behaviour composite scale (assessing delinquent and aggressive behaviour). The final assessment was at age 17 years when academic behaviour was assessed...&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/1/9.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321481</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/74]]&gt;</url>
    <title>Prognosis - Child bipolar I disorder is associated with manic episodes in adulthood</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does child bipolar I disorder continue into adulthood and what are the characteristics of subsequent episodes?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;115 consecutively ascertained children (7–16 years old) with first episode DSM-IV bipolar I disorder (mixed or manic phase) of duration &amp;gt;=2 weeks, displaying elation and/or grandiosity; and Children’s Global Assessment Scale (CGAS) score &amp;lt;=60. Exclusion criteria: IQ &amp;lt;=70; major medical or neurological disorder; pervasive developmental disorder; schizophrenia; pregnant or substance use disorder at baseline; adopted.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;University medical school research unit, USA; enrolment September 1995 to December 1998.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;Age, gender, illness characteristics and comorbidity (age at onset, CGAS score, psychosis, grandiose delusions, daily cycling, major depressive disorder, dysthymia, attention deficit/hyperactivity disorder, conduct disorder), referring centre (paediatric or psychiatric), parental warmth and tension/hostility (Psychosocial Schedule for School Age Children-Revised) and select mental health diagnoses in first degree relatives.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Manic episodes and substance use disorder during adulthood, recovery (8 consecutive weeks without meeting DSM-IV mania criteria), remission . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words.&amp;nbsp;&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/3/74" target="_blank"&gt;Full text of the article&lt;/A&gt;&lt;/EM&gt;&lt;EM&gt;&amp;nbsp;is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392751</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/110.extract]]&gt;</url>
    <title>Prognosis - Children with ADHD at increased risk of adolescent ADHD, ODD, anxiety or depression and functional impairment</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What are the adolescent outcomes of childhood attention-deficit hyperactivity disorder (ADHD)?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;169 adolescents who had been identified as being at high risk of ADHD in childhood (94 met full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) ADHD criteria, 75 met subthreshold criteria), and a matched group of 163 peers who had been identified as being at low risk of ADHD in childhood (matched for gender, race, poverty status and age). Children were defined as being at high risk if they were diagnosed or being treated for ADHD, or had behaviour problems and elevated scores (1.5 SD above the norm) on the Swanson, Nolan and Pelham IV ADHD screening measure. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;One school in North Florida, USA; data collected between 1998 and 2008.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;ADHD in childhood. High-risk children were given an ADHD diagnostic assessment at waves 2, 4 and 6, and low-risk children at wave 6 only (Diagnostic Interview Schedule for Children, version 4 used at wave 2; Kiddie-SADS-Present and Lifetime Version at subsequent waves). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Psychopathology (Vanderbilt ADHD Diagnostic Parent Rating Scale (VADPRS)); functioning (Columbia Impairment Scale score &amp;gt;14 indicated functional impairment); quality of life (Child Health Questionnaire … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/110.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328794</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/105]]&gt;</url>
    <title>Prognosis - Cognitive decline fastest in people with Alzheimer’s disease compared with other dementias</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Are there differences in demographic features, cognitive decline&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and survival among people with vascular dementia, Alzheimer’s&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;disease or Alzheimer’s disease with cerebrovascular disease?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;970 of 3545 consecutive patients who were: diagnosed with "probable"&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;vascular dementia (VaD; neuroepidemiology branch of the US National&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Institute of Neurological Disorders and Stroke and the Association&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Internationale pour la Recherche et l’Enseignement en&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Neurosciences criteria); "probable" or "definite" Alzheimer’s&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;disease (AD; National Institute of Neurologic and Communicative&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Disorders and Stroke and the AD and Related Disorders Association&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;criteria); or Alzheimer’s disease with cerebrovascular&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;disease (AD+CVD; clinical criteria for possible AD as for AD&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;alone, plus clinical or brain imaging evidence of CVD). In addition,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;participants had to be examined at least twice for a minimum&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of 1 year, and have had a Dementia Rating Scale (DRS) measurement&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;during the year of the first visit. The 2575 excluded patients&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;did not meet the above inclusion &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/4/105" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392754</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/112.extract]]&gt;</url>
    <title>Prognosis - Depression in older people is associated with increased risk of developing dementia</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,CAUSES AND PREVENTION,DEMENTIA,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is depression associated with an increased risk of dementia in older people?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;949 older adults (average age 79 years; 63.6% women), from the Framingham Heart Study, who did not have dementia at the start of the current study. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Framingham, Massachusetts, USA; 1990–2008.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;Depression (score =16 on the Center for Epidemiologic Studies Depression Scale (CES-D); supplementary analyses also included people taking antidepressants). Analyses were adjusted for age, gender, education, homocysteine levels and APOE e4 genotype.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Dementia. Participants were assessed using the mini-mental state examination (MMSE) in every biennial examination to screen for possible dementia. Participants whose MMSE score fell below age- and education-adjusted cut-offs underwent neurological and neuropsychological testing. Participants classified as having dementia satisfied DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria, had dementia severity =1.0 on the Clinical Dementia Rating Scale and exhibited symptoms of dementia for at least 6 months. Alzheimer's disease (AD) was confirmed using criteria of the National Institute of Neurological and Communicative Disorders and … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/112.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306946</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/8]]&gt;</url>
    <title>Prognosis - Developing depression after a myocardial infarction increases risk of cardiac mortality but pre-existing depression does not</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does the association between depression and cardiac mortality differ between people with pre- and post-myocardial infarction depression? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;588 adults (mean age 60.0 (SD 11.1) years; 70% male) admitted to hospital with suspected myocardial infarction (MI) who were found to meet WHO criteria for MI plus two of the following on screening: characteristic ECG changes, history of typical chest pain or serial increase in creatine phosphokinase (CPK) to twice or more the normal limits. Exclusion criteria were: serious comorbidities, too unwell to complete assessment, aged 80 years or older, limited spoken English or lived outside the catchment area. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Four inner city hospitals, UK; screening October 1997–November 1999. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;The main factor of interest was depression and its time of onset, either pre-MI or post-MI. At baseline, participants completed the Hospital Anxiety and Depression Scale (HADS) on their mental state in the week before the MI and then again at 12 months after . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Elisabeth J Martens, Peter de Jonge&lt;BR&gt;Centre of Research on Psychology in Somatic Diseases, Department of Medical Psychology, Tilburg University and Department of Psychiatry, University of Groningen, Tilburg, Groningen, The Netherlands&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/8" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317792</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/43]]&gt;</url>
    <title>Prognosis - Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;What are the remission and recovery rates in people with schizophrenia,&lt;SUP&gt; &lt;/SUP&gt;and what predicts these rates?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;392 people (mean age 37.9 years, 50% male) with schizophrenia&lt;SUP&gt; &lt;/SUP&gt;(DSM-IV), aged 18 years or older, who had never received antipsychotic&lt;SUP&gt; &lt;/SUP&gt;treatment. Participants were moderately ill with a mean Clinical&lt;SUP&gt; &lt;/SUP&gt;Global Impressions-Severity of Illness scale (CGI-Schizophrenia;&lt;SUP&gt; &lt;/SUP&gt;CGI-SCH) score of 4.4, and had a short history of illness (median&lt;SUP&gt; &lt;/SUP&gt;0.6 years). Initial treatment was with atypical antipsychotics&lt;SUP&gt; &lt;/SUP&gt;for 92% and with conventional antipsychotics for the remaining&lt;SUP&gt; &lt;/SUP&gt;8%.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Outpatient setting, Germany; recruitment January–December&lt;SUP&gt; &lt;/SUP&gt;2001.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;I&gt;Predictors at baseline:&lt;/I&gt; duration of illness, age, gender, symptomatic&lt;SUP&gt; &lt;/SUP&gt;status (CGI-SCH); functional variables, quality of life/subjective&lt;SUP&gt; &lt;/SUP&gt;wellbeing (Subjective Wellbeing under Neuroleptic Treatment&lt;SUP&gt; &lt;/SUP&gt;Scale, SWN-K). &lt;I&gt;Predictors in the early course of treatment:&lt;/I&gt;&lt;SUP&gt; &lt;/SUP&gt;(first 3 months) subjective wellbeing, symptomatic remission&lt;SUP&gt; &lt;/SUP&gt;and functional remission. &lt;I&gt;Predictors during the course of treatment:&lt;/I&gt;&lt;SUP&gt; &lt;/SUP&gt;substance use disorder (SUD) during follow-up (not present at&lt;SUP&gt; &lt;/SUP&gt;baseline); remitted SUD (SUD at baseline &lt;NOBR&gt;&lt;EM&gt;. .&lt;/EM&gt; .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/43" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>377596</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/42.extract]]&gt;</url>
    <title>Prognosis - Girls with ADHD have an increased risk of psychopathology in young adulthood</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2&gt;Question:&lt;/H2&gt;
&lt;P&gt;What is the prevalence of psychopathology in girls with and without attention-deficit hyperactivity disorder (ADHD) followed into young adulthood?&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A total of 262 girls aged between 6 and 18 years were recruited from various from various psychiatric and paediatric sources. Out of these, 140 girls had DSM-III-R ADHD, and 122 did not (controls). Exclusion criteria: being adopted, nuclear family not available for participation, major sensorimotor disabilities, psychosis, autism, full-scale IQ&amp;lt;80, or inadequate ability with the English language.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;USA; time period not stated.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;Prognostic factors:&lt;/H2&gt;
&lt;P&gt;Diagnosis of ADHD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Lifetime and previous-year DSM-IV psychopathology, including composite categories of antisocial disorders, mood disorders, anxiety disorders, developmental disorder, and substance-dependence disorders. Diagnoses were assessed in interviews with the participants and their mothers using the Structured Clinical Interview for DSM-IV and modules of the DSM-IV modified Schedule for Affective Disorders and Schizophrenia for School-Age Children – Epidemiologic Version. Assessments were made blinded to original diagnoses.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Methods&lt;BR&gt;Design:&lt;/H2&gt;
&lt;P&gt;Longitudinal case–control study.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/2/42.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321473</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/73]]&gt;</url>
    <title>Prognosis - Harsh parenting, insufficient income and infant aggression predict preschool peer victimisation</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,BULLYING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What are the trajectories of peer victimisation in preschool and what are the predictors of these trajectories?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;1970 children (49% female) born in Quebec between October 1997 and July 1998, who were taking part in the Quebec Longitudinal Study of Child Development, selected by stratified sampling from the Quebec Birth Registry. Participants were assessed at average ages of 4.5 and 16.6 months, and 2.4, 3.4, 4.1, 5.1, 6.2 and 7.2 years. Children with data from at least one maternally rated peer victimisation assessment between the ages of 3.4 and 6.2 years were included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Quebec, Canada; 1997–2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prognostic factors:&lt;BR&gt;&lt;/STRONG&gt;Family level factors were assessed at age 5 months, including family adversity (single parent family, low parental education and age at birth of first child, and insufficient income) and harsh reactive parenting (assessed using three self-rated items from the Parental Cognitions and Conduct Toward the Infant Scale). Child level factors assessed at age 17 . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words.&amp;nbsp;&lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/73" target="_blank"&gt;&lt;EM&gt;Full text&amp;nbsp;of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;&amp;nbsp;is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383445</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/74.extract]]&gt;</url>
    <title>Prognosis - High mortality and reduced quality of life in people who have presented to hospital for self-harm in the UK</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What is the long-term morbidity and quality of life for patients who engage in self-harm?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;150 individuals (average age 28.4 years; 39% male, 61% female) who had presented to hospital with an episode of self-harm in 1997 (94% with self-poisoning, 4% self-injury, 4% both; 31.3% first episode of self-harm, 63.3% had =1 previous episodes). These individuals were initially selected to be a representative sample of self-harm patients presenting to one hospital, as part of the WHO/EURO Multicentre Study on Parasuicide. They were then traced and contacted about 6 years later to take part in the current study.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;UK; original recruitment from one hospital in 1997.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;Self-harm. The study focused on describing outcomes in the cohort rather than identifying prognostic factors. It compared mortality the cohort with the age and sex match general English population based on 1997 interim life-tables and EuroQoL quality of life with local population norms from the Health Survey for England 1996. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Mortality, death by suicide (based on death certificate or open verdicts judged to be suicide by a panel of psychiatrists), repetition of self-harm, psychiatric diagnoses (ICD-10 version of … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/74.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383443</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/73.extract]]&gt;</url>
    <title>Prognosis - Moderate or high physical activity lowers the risk of cognitive impairment in older people</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,HEALTH &amp; WELLBEING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is physical activity associated with preventing or delaying cognitive decline in the older people?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;3903 people aged =55 years identified from a statutory health insurance fund database.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;General community, Bavaria, Germany; enrolment 2001–2003.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;Physical activity at baseline, classed as no activity, moderate activity (activity &amp;lt;3 times a week) and high activity (activity = 3 times a week). Activities included were strenuous activities such as walking, hiking, bicycling, swimming, gardening or other exercise.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Cognitive function assessed using the 6CIT, a shortened form of the Blessed Information Memory Concentration Scale (http://www.strokecenter.org/trials/scales/somct.html). The 6CIT includes six questions; scores of =7 are considered normal and those &amp;gt;7 indicate cognitive impairment. Candidate covariates in multivariate analyses included age, body mass index, gender, smoking, history of ischemic heart disease and/or stroke, hypertension, diabetes, hyperlipidaemia, … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/3/73.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301976</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/73]]&gt;</url>
    <title>Prognosis - Mortality in people with dementia taking antipsychotics higher than in those taking other psychiatric medications</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEMENTIA,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is there a difference in mortality rate in the year after starting&lt;SUP&gt; &lt;/SUP&gt;a new antipsychotic for neuropsychiatric symptoms of dementia&lt;SUP&gt; &lt;/SUP&gt;and other psychiatric drugs?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;10 615 older adults (over 65 years old) diagnosed with dementia&lt;SUP&gt; &lt;/SUP&gt;in fiscal years 2002 or 2003 who started outpatient psychiatric&lt;SUP&gt; &lt;/SUP&gt;medication within 6 months of being diagnosed with dementia.&lt;SUP&gt; &lt;/SUP&gt;Exclusions: using psychiatric medication in 6 months prior to&lt;SUP&gt; &lt;/SUP&gt;dementia diagnosis; receiving lithium; having a seizure disorder.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;National Department of Veterans Affairs (VA) data registries,&lt;SUP&gt; &lt;/SUP&gt;USA; fiscal years 2001–5.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;Type of psychiatric medication: antipsychotic (conventional,&lt;SUP&gt; &lt;/SUP&gt;atypical, or both) or other. Analyses were adjusted for potential&lt;SUP&gt; &lt;/SUP&gt;confounders, including: age, gender, use of cholinesterase inhibitors,&lt;SUP&gt; &lt;/SUP&gt;delirium diagnosis present at time of first prescription filling,&lt;SUP&gt; &lt;/SUP&gt;date of starting psychiatric medication, schizophrenia &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;James Warner &lt;/P&gt;
&lt;P&gt;St Charles Hospital, Central North West London Foundation NHS Trust, London, UK &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/73" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317791</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/42]]&gt;</url>
    <title>Prognosis - One-third of the excess death rate in 15–54 year olds in Scotland due to problem drug use</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;How does problem drug use contribute to excess death rate in&lt;SUP&gt; &lt;/SUP&gt;Scotland compared with England?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;1033 drug users, aged 15–54 years, starting a new treatment&lt;SUP&gt; &lt;/SUP&gt;episode and recruited into the Drug Outcomes Research in Scotland&lt;SUP&gt; &lt;/SUP&gt;study (88% had used heroin in the 3 months prior to recruitment).&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;33 drug treatment agencies, Scotland. Recruitment from 2001&lt;SUP&gt; &lt;/SUP&gt;to 2002.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Problem drug use. The number of deaths in the study population&lt;SUP&gt; &lt;/SUP&gt;(Scottish problem drug users) was determined and used to calculate&lt;SUP&gt; &lt;/SUP&gt;a crude death rate per 1000 person years. The standardised mortality&lt;SUP&gt; &lt;/SUP&gt;ratio (SMR) was calculated by dividing this rate by the rate&lt;SUP&gt; &lt;/SUP&gt;for the European standard population. The SMR was combined with&lt;SUP&gt; &lt;/SUP&gt;data on the prevalence of problem drug use in Scotland and England&lt;SUP&gt; &lt;/SUP&gt;to estimate the total number of deaths in drug users in each&lt;SUP&gt; &lt;/SUP&gt;country. The SMR for the drug users was also used for England&lt;SUP&gt; &lt;/SUP&gt;as age and gender &lt;NOBR&gt;&lt;EM&gt;. . .&lt;/EM&gt;&lt;/NOBR&gt; (Abstracted)&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/42" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>392752</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/111.extract]]&gt;</url>
    <title>Prognosis - Opiate substitute treatment is associated with increased overall survival among injecting drug users</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What is the rate of long-term cessation of intravenous drug and survival in injecting drug users, and is it influenced by opiate substitution treatment and other factors? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;794 people (average age 26.7 years) with a history of injecting drug use presenting between 1980 and 2007. Follow-up data could be obtained for 655 (82%) of these individuals, and they contributed 10 390 person-years of data. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Single primary care facility, Edinburgh, UK; 1980–2007.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;Taking intravenous drugs and having opiate substitute treatment. Gender, age at first injection, year of first injection (before or after 1986), HIV status, periods in prison, history of overdose requiring treatment at an accident and emergency department, self-harm, problem drinking and referrals for serious mental health issues were included as covariates in the analyses. Data were obtained from primary care records and from a questionnaire on lifetime injecting drug use and current health status. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Long-term cessation of intravenous drug use and mortality. Long-term cessation was defined as at least … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/111.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301668</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/105]]&gt;</url>
    <title>Prognosis - Partial syndromes of eating disorders in adolescence are associated with adverse health outcome in adulthood</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Orginal article:&lt;/STRONG&gt;&lt;BR&gt;Patton GC, Coffey C, Carlin JB, et al. Prognosis of adolescent partial syndromes of eating disorder. Br J Psychiatry 2008;192:294–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What impact do partial syndromes of eating disorder in adolescence have on health and social adjustment in young adulthood? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;2032 students selected using a two-stage cluster sample and followed up regularly into young adulthood. In the first wave, one class from each of 44 schools was selected at random. A second class was randomly selected 6 months later (wave 2). The average age of participants at the start of study was 14.5 years. Follow-up was at subsequent 6-month intervals during the remaining school years (waves 3–6) and at two stages in young adulthood (wave 7, aged 20–21 years; wave 8, aged 24–25 years). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Victoria, Australia; August 1992 to March 2003. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;Partial syndrome of eating disorder based on DSM-IV criteria for anorexia or bulimia on the Branched Eating Disorders Test. See online notes for further details on how anorexia and bulimia were defined. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Depression or anxiety (assessed on the Revised Clinical...(abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Phillipa J Hay, FRANZCP, MD, DPhil &lt;BR&gt;School of Medicine University of Western Sydney, Sydney, Australia &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/105" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383452</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/78.extract]]&gt;</url>
    <title>Prognosis - Past or current drug or alcohol use disorders increase the likelihood of a switch from depressive to manic, mixed or hypomanic states in patients with bipolar disorder</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE,BIPOLAR DISORDER,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;How does comorbid substance abuse affect recovery from major depressive episodes in patients with bipolar disorder?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;A total of 3,750 adults with &lt;EM&gt;DSM-IV&lt;/EM&gt; bipolar I or bipolar II disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Analyses included 2,154 participants who experienced a depressive episode during the study and completed at least one follow-up visit after the onset of this episode. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Multiple centres, USA; 1999 to 2005.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;Current or past alcohol or drug use disorder (assessed using the Mini-International Neuropsychiatric Interview).&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Time to remission from depressive episode (no more than two syndromal features of depression for at least 8 weeks); switch to a manic, hypomanic or mixed episode (meeting full &lt;EM&gt;DSM-IV&lt;/EM&gt; criteria on any follow-up visit). &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV id=methods class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-8 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-6&gt;Cohort study.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-9 class=subsection&gt;
&lt;H3&gt;Follow up period&lt;/H3&gt;
&lt;P id=p-7&gt;24 months from the start of a depressive episode.&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV id=results class="section results"&gt;
&lt;H2&gt;Main results&lt;/H2&gt;
&lt;P id=p-8&gt;Of the participants who experienced depressive episodes, 8% had a current alcohol use disorder and 32.2% had a past alcohol use disorder, 7.3% had a current drug use … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/78.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHEN accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>298040</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/106]]&gt;</url>
    <title>Prognosis - Poor insight increases relapse and re-admission to hospital in people with non-affective psychosis</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;BR&gt;&lt;/STRONG&gt;Drake RJ, Dunn G, Tarrier N, et al. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J Clin Psychiatry 2007;68:81–6.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does insight influence prognosis in people with non-affective psychosis?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Prospective cohort study.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Day patient and in-patient units in three geographical areas in England; July 1996 to September 1998.&lt;BR&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 257 people aged 16–65 years with first admission for DSM-IV schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder or psychotic disorder not otherwise specified.&lt;BR&gt;Prognostic factors: Insight at baseline assessed using the Birchwood Insight Scale (BIS; higher score indicates greater insight, score range 0–16). Analyses were stratified by centre, and adjusted for potential confounders (age, gender, ethnic group, diagnosis, years in full-time education, substance misuse, duration of untreated psychosis, overall and negative symptoms at baseline, social functioning at baseline).&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Symptoms (Positive and Negative Syndrome Scale (PANSS); higher score indicates greater symptom severity); social functioning (Social Functioning Scale (SFS)); relapse (worsening of positive symptoms lasting &amp;gt;=2 weeks and resulting in a change in management); rehospitalisation.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Eighteen months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Insight at baseline was lower in people with non-affective psychosis who subsequently relapsed (mean difference in BIS score 10.3, 95% CI 0.32 to 2.66; p = 0.013) or were re-admitted to hospital (mean difference in BIS score 10.2, 95% CI 0.84 to 3.40; p = 0.001), than those who did not. After adjustment for confounders, people with greater insight at baseline were less likely to relapse (for each additional BIS point estimated HR 0.943, 95% CI 0.892 to 0.996; p = 0.035) or to be re-admitted (for each additional BIS point estimated HR 0.934, 95% CI 0.876 to 0.996; p = 0.036). Before adjustment for confounders, greater insight at baseline predicted less severe overall symptoms at 18 months (Pearson correlation between BIS score and final PANSS total score: –0.172, 95% CI –0.322 to –0.013), but there was no significant correlation between insight at baseline and social functioning at 18 months (data not reported). After adjustment for confounders, there was no significant correlation between baseline insight and overall symptoms (regression coefficient –0.363, 95% CI –0.931 to +0.205) or social functioning (regression coefficient +0.699, 95% CI –0.628 to +2.026).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;In people with non-affective psychosis, poor insight is associated with relapse and re-admission to hospital. However, insight is not independently associated with symptoms or social function.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>297929</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/73]]&gt;</url>
    <title>Prognosis - Predictors of symptomatic remission in people with schizophrenia identified</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006;67:1690–7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What are the predictors of remission in outpatients with schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Prospective cohort study.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; European Schizophrenia Outpatient Health Outcomes study, Germany; recruitment January to December 2001.&lt;BR&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 2960 adult outpatients with DSM-IV schizophrenia either switching to or beginning a new antipsychotic (mean age 42 years; 49% male). Exclusions: IQ &amp;lt;=70, other DSM-IV schizophrenia spectrum disorders, bipolar I disorder, or psychotic disorder.&lt;BR&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt; Baseline predictors: age; gender; illness duration; symptoms (Clinical Global Impressions-Severity of Illness (CGI)-Schizophrenia scale overall severity score subscale scores). Functional predictors included occupational status, independent living and subjective wellbeing (Subjective Wellbeing Under Neuroleptic Treatment Scale (SWN-K)). Antipsychotic treatment factors included first antipsychotic, neurological side effects, and atypical or typical initial antipsychotic medication. Early treatment predictors were: symptomatic remission, functional remission (being employed, active student, household head, and living independently) and adequate subjective wellbeing (SWN-K score &amp;gt;=80) at 3 months. Predictors throughout treatment were: comorbid DSM-IV substance use disorder; non-compliance with antipsychotic medication.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Symptomatic remission (CGI-Schizophrenia score &amp;lt;=3 overall and on subscales), complete remission (symptomatic and functional), and adequate subjective wellbeing. At minimum, remission criteria had to be met for last 6 months of study.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Two years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;At 2 years, 47% of participants achieved symptomatic remission and 13% achieved complete remission. Baseline predictors for symptomatic remission included less severe symptoms, being employed, living independently, better subjective wellbeing, receiving a first course of antipsychotics, and first-line treatment with an atypical antipsychotic (see &lt;A href="http://ebmh.bmj.com/supplemental" target="_blank"&gt;http://ebmh.bmj.com/supplemental&lt;/A&gt; for table). Early symptomatic remission and adequate wellbeing during treatment predicted symptomatic remission at 2 years. Non-compliance with antipsychotics and persistent substance use disorder throughout treatment predicted non-remission. Baseline prognostic factors for complete remission included younger age (&amp;lt;30 years vs &amp;gt;=40 years), being employed and living independently, a first course of antipsychotics or first-line treatment with atypical antipsychotics. Early treatment predictors of complete remission were early symptomatic and functional remission, and early adequate wellbeing.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Despite antipsychotic medication, only about half of people with schizophrenia achieve symptomatic remission, and few achieve complete remission. Better initial function, less severe symptoms, receiving a first course of antipsychotic treatment, use of a first-line atypical antipsychotic and early treatment response increase likelihood of symptomatic remission at 2 years.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392735</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/108.extract]]&gt;</url>
    <title>Prognosis - Prescribing preferred medications improves adherence in people with severe mental illness</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What is the effect of psychiatric advance directives on type of medications prescribed and adherence to prescribed medications?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population&lt;/H3&gt;
&lt;P id=p-2&gt;Adults (aged 18–65 years) with schizophrenia or schizoaffective disorder (63%), bipolar disorder (25%) or major depressive disorder with psychotic features (12%), participating in a randomised controlled trial comparing the effects of preparing a psychiatric advanced directive (PAD) with giving general information about PAD. Of the 239 participants randomised to preparing a PAD, only 123 participants completing both a PAD plus a follow-up interview at 12 months were included in this study.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Outpatients from county-based programmes, North Carolina, USA; time period studied October 2004 to September 2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors&lt;/H3&gt;
&lt;P id=p-4&gt;Medication preferences described in the PAD: participants identified medications they would either request for treatment or refuse to take during a psychiatric crisis. Forward-selected stepwise logistic regression was used to identify factors associated with medication adherence at 12 months. Possible predictor variables included diagnosis, age, sex, race and history of hospitalisation in the past 12 months, Brief … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/108.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302004</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/40]]&gt;</url>
    <title>Prognosis - Problems identifying odours predicts mild cognitive impairment in the elderly</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does impaired odour identification predict the development of&lt;SUP&gt; &lt;/SUP&gt;mild cognitive impairment in elderly people?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;589 community-dwelling elderly people (average age 79.9 years;&lt;SUP&gt; &lt;/SUP&gt;77% female) participating in the Rush Memory and Ageing Project&lt;SUP&gt; &lt;/SUP&gt;(a study of risk factors for common chronic conditions) who&lt;SUP&gt; &lt;/SUP&gt;agreed to annual evaluations and brain donation at death. Exclusions:&lt;SUP&gt; &lt;/SUP&gt;baseline mild cognitive impairment (MCI) or dementia.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Rush University Medical Centre, Chicago and University of Pennsylvania,&lt;SUP&gt; &lt;/SUP&gt;US; ongoing study commenced in 1997.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;Ability to identify familiar odours assessed by score on the&lt;SUP&gt; &lt;/SUP&gt;12-item Brief Smell Identification Test (shortened form of the&lt;SUP&gt; &lt;/SUP&gt;test). A microcapsule was scratched and adults had to match&lt;SUP&gt; &lt;/SUP&gt;the smell with one of four options.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Mild cognitive impairment (MCI) that did not fulfil dementia&lt;SUP&gt; &lt;/SUP&gt;criteria. Adults were assessed annually &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Kaarin J Anstey &lt;/P&gt;
&lt;P&gt;Ageing Research Unit, Centre for Mental Health Research, Australian National University, Canberra, Australia &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/40" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301975</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/72]]&gt;</url>
    <title>Prognosis - Prognostic factors for progression to psychosis in high risk youth</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How common is conversion to psychosis in high risk youths, what&lt;SUP&gt; &lt;/SUP&gt;factors predict this risk?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;370 people (mean age 18 years) with prodromal psychotic symptoms&lt;SUP&gt; &lt;/SUP&gt;(according to Structured Interview for Prodromal Syndromes (SIPS)&lt;SUP&gt; &lt;/SUP&gt;criteria) who had been referred by school counsellors or community-based&lt;SUP&gt; &lt;/SUP&gt;mental health professionals. The main SIPS criteria include:&lt;SUP&gt; &lt;/SUP&gt;onset or worsening in the preceding 12 months of attenuated&lt;SUP&gt; &lt;/SUP&gt;positive thoughts in one or more of five categories (grandiosity,&lt;SUP&gt; &lt;/SUP&gt;unusual thought, paranoia/suspicion, disorganised communication,&lt;SUP&gt; &lt;/SUP&gt;or perceptual abnormalities; rated from 0 (none) to 6 (fully&lt;SUP&gt; &lt;/SUP&gt;psychotic state), score of 3–5 indicates a prodromal state);&lt;SUP&gt; &lt;/SUP&gt;onset in previous 3 months of brief intermittent psychotic symptoms&lt;SUP&gt; &lt;/SUP&gt;not meeting DSM-IV threshold for psychotic disorder; or the&lt;SUP&gt; &lt;/SUP&gt;combination of deterioration of &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;30% on the General Assessment&lt;SUP&gt; &lt;/SUP&gt;of &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Alison Yung &lt;/P&gt;
&lt;P&gt;ORYGEN Research Centre and the University of Melbourne, Parkville, Australia &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/72" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383448</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/76.extract]]&gt;</url>
    <title>Prognosis - Review: ADHD impairs quality of life, but children and young people with ADHD perceive less impairment than parents</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the impact of ADHD and its management on quality of life (QoL) of children?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-2&gt;Quality of life (QoL) as assessed by the parent or child/adolescent using any instrument. The included studies used mainly generic instruments including: the Child Health Questionnaire, Pediatric Quality of Life Inventory, Youth Quality of Life Instrument-Research Version, the Munich Quality of Life Questionnaire for Children, the Dutch Child AZL TNO Quality of Life, the TNO AZL Child Quality of Life, the EuroQoL Five-Dimension Questionnaire, standard gamble interviews and the Global Impression of Perceived Difficulties. The only disorder-specific measure used was the ADHD Impact Module. &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV id=methods class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P id=p-4&gt;Ovid MEDLINE (R), Cochrane database of systematic reviews, ACP Journal Club, DARE, CCTR, CMR, HTA, NHSEED, EMBASE and PsychINFO were searched for the period between 1988 and April 2008. Hand-searches of reference lists of identified papers and reviews was also carried out. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P id=p-5&gt;Studies published in peer-reviewed journals providing empirical data on the QoL of children or adolescents with ADHD were included. All abstracts and the full texts of the selected papers were assessed by two authors. Data were extracted by one … &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/76.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>317790</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/41]]&gt;</url>
    <title>Prognosis - Review: positive psychological well-being reduces the risk of mortality in both ill and healthy populations</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does positive psychological well-being reduce the risk of mortality&lt;SUP&gt; &lt;/SUP&gt;in healthy and already ill populations?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Risk of mortality.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Medline, PsycINFO; Web of Science and PubMed were searched for&lt;SUP&gt; &lt;/SUP&gt;articles between database inception and January 2008. Reference&lt;SUP&gt; &lt;/SUP&gt;lists from found articles were also hand searched for additional&lt;SUP&gt; &lt;/SUP&gt;studies.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;Prospective cohort studies investigating the relationship between&lt;SUP&gt; &lt;/SUP&gt;positive psychological factors and mortality in both healthy&lt;SUP&gt; &lt;/SUP&gt;and already ill populations (with follow-up periods of &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;1 year&lt;SUP&gt; &lt;/SUP&gt;for ill populations) were included. Studies looking at the effect&lt;SUP&gt; &lt;/SUP&gt;of either positive affect (state measures) or positive disposition&lt;SUP&gt; &lt;/SUP&gt;(trait measures) were included. Exclusions: psychological well-being&lt;SUP&gt; &lt;/SUP&gt;determined by self-rated health or functional status; reversed&lt;SUP&gt; &lt;/SUP&gt;indicators of negative affect; or mortality outcomes of suicide,&lt;SUP&gt; &lt;/SUP&gt;injury or accident. Effect sizes were measured using hazard&lt;SUP&gt; &lt;/SUP&gt;ratios (HR) or relative risks and the data were analysed using&lt;SUP&gt; &lt;/SUP&gt;random effects modelling because..(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/41" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301671</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/106]]&gt;</url>
    <title>Prognosis - Risk of death from natural causes increased in people with psychiatric admissions</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is the risk of mortality from natural causes in people with psychiatric admissions elevated compared to people without psychiatric admissions?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;BR&gt;All Danish adults (about 4.1 million people) aged &amp;gt;=15 years registered with the Civil Registration System (a register of all births, deaths, immigrations and emigrations) between 1973 and 1993. All citizens have a unique registration number that allows linkage between different databases.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General population, Denmark; time period studied January 1973 to December 1993.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;BR&gt;Psychiatric admissions, identified through the Psychiatric Centre Register, which includes all admissions since 1969. Admissions were separated into 11 diagnostic categories based on ICD-8 coding of their primary diagnosis: schizophrenia, affective psychoses, non-affective psychoses, neurosis, psychopathy/personality disorders, alcoholism, drug abuse, organic psychoses, presenile/senile/vascular dementia, learning difficulty or other non-psychotic conditions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Death from natural causes, identified through the National Causes of Death Register. Natural causes of death were grouped into 9 broad groups based on ICD-8 coding: cancer.... (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Francesco Amaddeo, MD, PhD, Professor of Psychiatry&lt;/P&gt;
&lt;P&gt;Section of Psychiatry and Clinical Psychology, Department of Medicine and Public Health, University of Verona, Verona, Italy &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/106" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298039</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/105]]&gt;</url>
    <title>Prognosis - Severe mental illness increases the risk of death from coronary heart disease or stroke</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,BIPOLAR DISORDER,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Osborn DPJ, Levy G, Nazareth I, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry 2007;64:242–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Are people with severe mental health illness at increased risk of death from coronary heart disease, stroke or cancer?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Retrospective cohort study.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; General Practice Research Database (GPRD), covering 741 practices in the UK; June 1987 to April 2002.&lt;BR&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt; 46 136 people with &amp;gt;=1 diagnosis of severe mental illness (SMI) made after age 18 years and 300 426 people who had never been diagnosed with SMI (6 selected randomly for each person with SMI) identified from the GPRD. SMI was defined as bipolar disorder, schizophrenia, schizoaffective disorder, delusional disorder or other non-organic psychoses (identified based on Read and Oxford Medical Information System codes); people with organic psychoses (for example, alcohol, drug-induced) were excluded. Only people with at least 6 months’ data of sufficient quality were included.&lt;BR&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt; Severe mental illness. Hazard ratios (HRs) were calculated using Cox regression, and adjusted for patient age, sex, period in which data were collected (1987–92; 1992–7; 1997–2002), smoking and social deprivation. Analyses were stratified by age because HRs were found to vary significantly by age group.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Deaths from coronary heart disease (CHD), stroke, and the seven most common cancers in the UK (respiratory, colorectal, breast, prostate, stomach, oesophageal and pancreas). Read and OXMIS codes used to search the GPRD for these conditions (and synonyms).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Compared to people without SMI, people with SMI were at an increased risk of death from CHD between the ages of 18–49 years (adjusted HR 2.88, 95% CI 1.77 to 4.70), and 50–75 years (adjusted HR 1.76, 95% CI 1.54 to 2.01), but not at 75 years and above (adjusted HR 1.04, 95% CI 0.91 to 1.18). People with SMI were also at increased risk of death from stroke between the ages of 50–75 years (adjusted HR 1.83, 95% CI 1.45 to 2.31), and at 75 years and over (adjusted HR 1.33, 95% CI 1.16 to 1.52), but not between 18–49 years (adjusted HR 2.39, 95% CI 0.92 to 6.17). There was no significant association between SMI and risk of death from a common cancer at any age (18–49 years: adjusted HR 1.04, 95% CI 0.60 to 1.82; 50–75 years: adjusted HR 1.10, 95% CI 0.93 to 1.29; &amp;gt;=75 years: adjusted HR 0.89, 95% CI 0.73 to 1.07).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;The risk of mortality from coronary heart disease is increased in people with severe mental illness in the 18–75 years age group. Mortality from stroke is increased in people with severe mental illness aged 50 years and above. Having a severe mental illness does not increase the risk of death from the seven most common cancers in the UK.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328795</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/106]]&gt;</url>
    <title>Prognosis - Survival after myocardial infarction worse with first episode major depression than recurrent major depression</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Is the association with cardiac mortality different between&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;people with a first episode of major depression (MD) and recurrent&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;MD?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Population:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;1328 people post-myocardial infarction (MI) from the Enhancing&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Recovery in Coronary Heart Disease (ENRICHD) clinical trial.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;370 participants were diagnosed with first episode of MD, 550&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;participants had recurrent MD and 408 people were free of depression.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Exclusion criteria: cognitive impairment, other major psychiatric&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;disorders, other life threatening medical illnesses, imminent&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;risk of suicide, too ill to participate, taking antidepressants&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;for less than 14 days (for participants with depression only)&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;or exemption from their cardiologist.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Coronary care units at eight ENRICHD clinical trial sites, USA;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;recruitment October 1996–October 1999.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Prognostic factors:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Depression was diagnosed using the Depression Interview and&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Structured Hamilton which uses DSM-IV criteria to diagnose current&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;depressive episodes and the Hamilton Rating Scale for Depression&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to determine depression severity. Only people meeting full DSM-IV&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;criteria for depression for &amp;gt; 14 &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; &lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/106" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383449</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/77.extract]]&gt;</url>
    <title>Prognosis - The EPOS prediction model improves ability to predict transition to first episode psychosis in individuals at high risk</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does combining the ultra-high-risk (UHR) and basic symptom-based criterion cognitive disturbances (COGDIS) improve ability to predict transition to first episode psychosis? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P id=p-2&gt;Two hundred and forty-five help-seeking adolescents and young adults (ages 16 to 35) predicted by UHR and COGDIS criteria to be in a putatively prodromal state of psychosis. Exclusion criteria: previous psychotic episode lasting longer than a week or prodromal symptoms arising from general medical disorder, or drug or alcohol dependence. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Six early detection outpatient centres in Germany, Finland, the Netherlands and the UK; screening April 2002 to April 2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Prognostic factors:&lt;/H3&gt;
&lt;P id=p-4&gt;Symptoms (SIPS, BSABS-P and Beck Depression Inventory [BDI]), functioning (Global Assessment of Functioning, GAF-M) and sociodemographic factors. Individual factors were initially assessed using the Cox proportional hazard model, and significant factors were entered into the multivariate Cox regression analysis. The effect of treatment with antidepressants or antipsychotics was also assessed. The prognostic scores based on the final model were used to stratify the participants into four risk groups, from lowest (group I) to highest (group IV) risk. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-5&gt;Transition to psychosis. Full-blown psychotic symptoms were defined as any single item on the positive subscale of SIPS with a score … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/77.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>266136</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38640&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Promoting Engagement Project Update</title>
    <publicationDate>2002-05-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,PATIENT AND PUBLIC INVOLVEMENT,CHILD AND ADOLESCENT CONDITIONS,HOW DO I INVOLVE...?,PEOPLE WITH MENTAL HEALTH ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on identifying why seemingly effective early interventions for children with/or at risk of developing mental health problems sometimes fail to reach those who need them most.</description>
    <body>&lt;![CDATA[ Update briefing on identifying why seemingly effective early interventions for children with/or at risk of developing mental health problems sometimes fail to reach those who need them most.]]&gt;</body>
  </document>
  <document>
    <id>331022</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://guidance.nice.org.uk/PH22/Guidance/pdf/English]]&gt;</url>
    <title>Promoting mental wellbeing at work (Guidance for employers on promoting mental wellbeing through productive and healthy working conditions)</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,PUBLIC HEALTH,MONTHLY ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The guidance is for those who have a direct or indirect role in, and responsibility for, promoting mental wellbeing at work. This includes all employers and their representatives, irrespective of the size of the business or organisation and whether they are in the public, private, or voluntary sectors. It may also be of interest to professionals working in human resources or occupational health, employees, trade unions representatives and members of the public.]]&gt;</body>
  </document>
  <document>
    <id>111325</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111325]]&gt;</url>
    <title>Promoting our own mental health</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,OUTCOMES,EDUCATION,ENVIRONMENTAL,GENERAL PUBLIC,MENTAL &amp; BEHAVIOURAL DISORDERS,DETERMINANTS,PUBLIC HEALTH,SOCIAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,PSYCHOLOGICAL DETERMINANTS,INFORMATION,MANAGEMENT &amp; POLICY,POPULATIONS,GROUPS,COMMUNITIES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Promoting our own mental health&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111324:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111308:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Mental health is about how people think and feel. How we think and feel affects our overall health and well-being and quality of life. Many factors influence mental health – housing, jobs, schools, transport, the environment – as well as they way we live our lives. This section gives information about what you can do to look after your own mental health and the mental health of others.&lt;/P&gt;
&lt;P&gt;Everyone has mental health needs. From time to time, most of us feel stressed, anxious, worried or afraid. We may also have experiences that are very difficult to cope with, such as losing our job or the end of a relationship. Being bullied, sexual or racial harassment, experiencing discrimination because of a mental health problem, not having a voice because we’re too young, too old or simply different, can all have an impact on our mental health.&lt;/P&gt;
&lt;P&gt;Doing something positive can make all the difference – for ourselves and for others.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accepting ourselves&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Our beliefs, background, culture, religion, sexuality and experiences make us who we are. Everyone is entitled to respect, including you.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accepting others&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;It’s easy to feel threatened by people who are different. You’ll feel better and learn more if you can accept others. Everyone has something to offer.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Talking about it&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Most people feel isolated and overwhelmed by their problems sometimes – it can help to share your feelings. If you feel there is no one to talk to, you could call a helpline.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Being a good listener&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Good listening is a skill. Rather than offering advice, it can help to let the person work things out as they talk. Hear them out - avoid making judgements, check from time to time that you’ve understood.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Keeping in touch with friends&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Friends are important, especially at difficult times. You don’t have to be strong and struggle on alone. Be there – and let others be there for you. Be a good friend and neighbour - keep in touch.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Getting involved&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Meeting new people and getting involved in things can make all the difference – for you and others. Joining a club or offering your services as a volunteer to a charity can be rewarding and help you feel less alone.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Drinking in moderation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Drinking alcohol to deal with problems will only make things worse. It’s best to drink in moderation and avoid binges. If you’re worried about your drinking speak to your doctor.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Taking care with Drugs&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Illegal drugs can trigger mental health problems. If you have a drugs problem, talk to someone about it.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Learning new skills&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Learning a new skill can increase your confidence – whether it's for pleasure, to make new friends or to improve your chances of a job.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Doing something creative&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;All kinds of creative things can help if you are anxious or low. They can also increase your confidence. Music, writing, painting, drawing, poetry, cooking, gardening – experiment to find something you enjoy.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Relaxing&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Try and make time for yourself. Fit things into your day that help you unwind – reading, listening to music, prayer or meditation – whatever you enjoy or find relaxing.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Keeping active&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Regular exercise really helps if you’re feeling depressed or anxious. It can give you more energy too. Find something you enjoy – a team sport, swimming, walking, or dancing.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Asking for help&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Everyone needs help from time to time - from friends and family, a support group, faith community or from your local doctor or community mental health team. It’s OK to ask for help, even though it can feel difficult.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Surviving&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;When times are difficult, it is sometimes all we can do to survive. Take one day at a time and don’t be too hard on yourself. Take time out if you need it. If you have a long-term mental health problem, try to plan the care you need with your keyworker and others for when you’re less well.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111324:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111308:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>296432</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ps.psychiatryonline.org/index.dtl]]&gt;</url>
    <title>Psychiatric Services</title>
    <publicationDate></publicationDate>
    <publisher>American Psychiatric Publishing, Inc.</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Journals.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Promotional summary of aims and objectives:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Psychiatric Services, established in 1950, is published monthly by the American Psychiatric Association for mental health professionals and others concerned with treatment and services for persons with mental illnesses and mental disabilities, in keeping with APA's objectives to improve care and treatment, to promote research and professional education in psychiatric and related fields, and to advance the standards of all psychiatric services and facilities.&lt;/P&gt;
&lt;P&gt;Features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;This Month's Highlights 
&lt;LI&gt;Taking Issue 
&lt;LI&gt;Articles 
&lt;LI&gt;Columns 
&lt;LI&gt;Brief Reports 
&lt;LI&gt;Frontline Reports 
&lt;LI&gt;Letters 
&lt;LI&gt;Book Reviews 
&lt;LI&gt;News &amp;amp; Notes&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Published on a monthly basis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Available from the NLH.&lt;/P&gt;
&lt;P&gt;&lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for an Athens account&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325051</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/publications/collegereports/cr/cr156.aspx]]&gt;</url>
    <title>Psychiatric services for black and minority ethnic older people</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal&gt;This document looks at the mental health needs of Black and Minority Ethnic (BME) older people and the psychiatric services offered to this group, focussing on the main changes that have occurred since the original college report (CR103) published in 2001. The main areas covered include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Definition of BME older people.&lt;/LI&gt;
&lt;LI&gt;Demographic changes.&lt;/LI&gt;
&lt;LI&gt;Review of influential publications and policy pertaining to the mental health of BME groups in general and those specifically relevant to BME older people.&lt;/LI&gt;
&lt;LI&gt;Research involving psychiatric aspects of BME older people.&lt;/LI&gt;
&lt;LI&gt;Current examples of good practice.&lt;/LI&gt;
&lt;LI&gt;Revision of recommendations as a result of this review.&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal&gt;The progress of developing and improving services for BME older people with mental health problems in actual practice has been slow with only a&amp;nbsp;few examples of good practice since the recommendations made in CR103 in 2001. Thus the original recommendations of CR103 are retained and five &lt;SPAN&gt;additional recommendations are made.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;Professor Ajit Shah and Dr Simon Adelman, the authors of the report, said, “With a growing BME elderly population, the time is now right to build on previous work to further develop culturally appropriate and sensitive mental health services for older people from BME groups.”&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&lt;SPAN&gt;This report replaces &lt;EM&gt;CR103. Psychiatric services for Black and minority ethnic elders&lt;/EM&gt; from 2001.&lt;/SPAN&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345875</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=26BAC924-C904-7904-145D-01F6BBDFE7B6&amp;ext=pdf]]&gt;</url>
    <title>Psychological Health and Well-Being: A New Ethos for Mental Health</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A report of the Working Group on Psychological Health and Well-Being. The National Service Framework for Mental Health - NSF - (Department of Health, 1999) outlined a clear and positive framework for the provision of mental health care. With a 10-year timeframe for implementation of the original NSF, however, it is appropriate to consider what a new service framework should contain.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>345874</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=4E424D3B-DA2A-24A9-FEF7-1FE0AFF417BA&amp;ext=pdf]]&gt;</url>
    <title>Psychological Health: Connecting Communities A new Horizons strategy for local well-being service networks: A discussion paper</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ John Hanna's paper provides a detailed explanation of the proposed Connecting Communities model,describing a basic local network, the function of each focal service’s Connecting Communities Network (CCN) champion, the technologically supported network assessment and referral system and audit/outcome measurement relating to both intra-service efficacy and inter-service/network reciprocality.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>268304</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38641&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Psychological Therapies Update</title>
    <publicationDate>2000-01-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on two studies funded by the Mental Health Foundation which were concerned with the long-term evaluation of psychological therapies, and methods of improving access to psychotherapy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Update briefing on two studies funded by the Mental Health Foundation which were concerned with the long-term evaluation of psychological therapies, and methods of improving access to psychotherapy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345876</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=5D9841DC-9D60-BD84-8985-239A25A72A89&amp;ext=pdf]]&gt;</url>
    <title>Psychologists Working as Expert Witnesses</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guildelines and procedure for England and Wales. The report is part of a quinquennial review cycle and supersedes the following individual reports: Psychologists as Expert Witness (1998) and Psychologists and the New Rules of Civil Procedure (1999) and the August 2007, Psychologists as Expert Witnesses:Guidelines and Procedure for England and Wales.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>317699</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nccmh.org.uk/downloads/Psychosis/PsychosisSubstanceMisuseFinalScope.pdf]]&gt;</url>
    <title>Psychosis with Substance misuse PDF (scope)</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>NCCMH</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=Arial&gt;
&lt;P align=left&gt;This scope details how The Department of Health have asked NICE: "To develop a clinical guideline for the assessment and management of severe mental illness in conjunction with problematic substance misuse."&lt;/P&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>327459</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103189.pdf]]&gt;</url>
    <title>Psychosocial care for NHS staff during an influenza pandemic</title>
    <publicationDate>2009-07-31T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;The purpose of the guidance is to set out the psychosocial care strategy that NHS and social care organisations need to have in place for supporting staff resilience. The guidance emphasises the need to manage the psychosocial resilience in NHS staff who are working over a sustained period on flu pandemic.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;It will ensure that appropriate staff are available to work during the indeterminate period of the flu pandemic&lt;/LI&gt;
&lt;LI&gt;It will support staff to achieve a swift recovery phase back to normal services&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;As the NHS Operating Framework requires all NHS organisations to have robust plans to respond to a flu pandemic in place by the end of 2008. The guidance advises the following actions to facilitate that process for the immediate future and beyond:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Identifies the factors that influences physical, psychosocial and mental health of staff to enable organisations pre-empt through forward planning&lt;/LI&gt;
&lt;LI&gt;The psychosocial guidance document suggests actions to support and monitor the various levels of the strategy.&lt;/LI&gt;
&lt;LI&gt;Within the framework for delivering psychosocial care for staff reaffirms the importance of preparation and aims to assure that staff will be resilient.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>268306</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38643&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Psychotherapy Research Initiative</title>
    <publicationDate>2000-02-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing describing the Psychotherapy Research Initiative, funded by the Mental Health Foundation. The Initiative address the following key questions: How can we measure and compare the effectiveness of different psychological therapies? And how can we ensure that they are being delivered by competent, well-trained therapists?</description>
    <body>&lt;![CDATA[ Update briefing describing the Psychotherapy Research Initiative, funded by the Mental Health Foundation. The Initiative address the following key questions: How can we measure and compare the effectiveness of different psychological therapies? And how can we ensure that they are being delivered by competent, well-trained therapists?]]&gt;</body>
  </document>
  <document>
    <id>236093</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=236093]]&gt;</url>
    <title>Public health interventions to promote positive mental health and prevent mental health disorders among adults: Evidence briefing</title>
    <publicationDate>2007-01-29T00:00:00</publicationDate>
    <publisher>National Institute for Health and Clinical Excellence</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,MENTAL HEALTH PROMOTION,OUTCOMES,ADULTS,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SERVICES,AGE GROUPS,POPULATIONS,ANALYSIS &amp; RESEARCH,GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Public health interventions to promote positive mental health and prevent mental health disorders among adults: Evidence briefing&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This evidence briefing defines adult mental health and looks at ways of promoting mental health, along with the methodological issues involved. &lt;/P&gt;
&lt;P&gt;The contents includes:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Methods&lt;/LI&gt;
&lt;LI&gt;Evidence Base papers&lt;/LI&gt;
&lt;LI&gt;Findings&lt;/LI&gt;
&lt;LI&gt;Discussion&lt;/LI&gt;
&lt;LI&gt;Gaps in the evidence base and recommendations for research&lt;/LI&gt;
&lt;LI&gt;References&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;This briefing aims to:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;identify all relevant systematic reviews, syntheses, meta-analyses and review-level papers on nonpharmacological interventions to promote positive mental health and prevent mental health disorders in adults aged over 16&lt;/LI&gt;
&lt;LI&gt;review these papers and highlight effective ways to promote positive mental health and prevent mental health disorders either by reducing the risk factors for adults with no diagnosed mental disorder (primary prevention) or by preventing relapse (secondary prevention) in people previously diagnosed with a mental disorder, particularly those in disadvantaged and vulnerable groups&lt;/LI&gt;
&lt;LI&gt;identify cost-effectiveness data for nonpharmacological interventions that aim to promote positive mental health and prevent mental health disorders in adults&lt;/LI&gt;
&lt;LI&gt;highlight any gaps in the evidence and make recommendations for future research.&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>268308</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38644&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Pull Yourself Together! Update</title>
    <publicationDate>2000-04-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on the findings of a piece of research to identify sources of discrimination experienced by people living with mental distress. This research was launched as part of a campaign during Mental Health Action Week (April 2000).</description>
    <body>&lt;![CDATA[ Update briefing on the findings of a piece of research to identify sources of discrimination experienced by people living with mental distress. This research was launched as part of a campaign during Mental Health Action Week (April 2000).]]&gt;</body>
  </document>
  <document>
    <id>224367</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/6/4/128]]&gt;</url>
    <title>Qualitative - Stigma alone does not explain non-disclosure of psychological symptoms in general practice</title>
    <publicationDate>2003-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Prior L, Wood F, Lewis G, Pill R.Stigma revisited, disclosure of emotional problems in primary care consultations in Wales.Soc Sci Med 2003;56:2191–2200&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Do people fail to disclose psychological symptoms to general practitioners for fear of stigma, or for other reasons?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Qualitative focus group study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Primary care practices, Wales.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants:&lt;/STRONG&gt; 127 people aged 18–70 from rural, urban and valley practices. Participants were selected from 3 age groups (15 women, 17 men aged 18–25; 18 women, 16 men aged 35–45 and 32 women, 29 men aged 50–70).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data collection and analysis:&lt;/STRONG&gt; Data were generated from 4 focus group exercises: discussion of fictional situations and emotional states; ranking of importance of physical and emotional symptoms; ranking of importance of sources of help for common mental disorders and finally, suitability of different questionnaires for ascertaining cases in primary care.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main Results&lt;/STRONG&gt;&lt;BR&gt;Concerns about stigma were not the only reasons given for non-disclosure. Other reasons for non-disclosure may include a perception that psychological symptoms are less worrisome than physical symptoms; that psychological symptoms should be dealt with by the individual, rather than a health professional, or that psychological symptoms are not a "health problem" but a "part of life".&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;Health professionals need to be aware that, as well as fear of stigma, psychological symptoms may not be reported due to differences in importance lay people and professionals ascribe to these symptoms when describing illness.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322060</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bps.org.uk/media-centre/press-releases/releases$/british-journal-of-clinical-psychology$/psychologists-investigate-cognitive-failings-of-eatign-disorder-sufferers.cfm]]&gt;</url>
    <title>Quantitative evidence for distinct cognitive impairment in anorexia nervosa and bulimia nervosa</title>
    <publicationDate>2009-07-22T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Sufferers of eating disorders have problems with certain mental tasks; this is the finding of a comprehensive overview of studies examining the link between cognitive deficits and eating disorders, published online in the Journal of Neuropsychology today, 22nd July 2009.]]&gt;</body>
  </document>
  <document>
    <id>275466</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://website.scmh.org.uk/80256FBD004F6342/vWeb/pcKHAL77SH5N]]&gt;</url>
    <title>Race Equality Training in Mental Health Services In England: Does One Size Fit All?</title>
    <publicationDate>2007-10-08T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Race Equality Training in Mental Health Services in England is based on a survey of participants, providers and commissioners of training. The report finds that in the absence of any professional body to set standards for race equality training, providers have a wide range of skills and experience. Only one quarter of participants had received any training from a service user in mental health.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Race Equality Training in Mental Health Services in England is based on a survey of participants, providers and commissioners of training. The report finds that in the absence of any professional body to set standards for race equality training, providers have a wide range of skills and experience. Only one quarter of participants had received any training from a service user in mental health.&lt;/P&gt;
&lt;P&gt;The report calls for fundamental changes in the delivery of race equality training. It calls for national quality standards and guidance on the qualification and accreditation of trainers. It says training should be evaluated for its impact on staff knowledge and skills, and services should be monitored for delivering training that works.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347118</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Rats-addicted-to-junk-food.aspx]]&gt;</url>
    <title>Rats addicted to 'junk food'</title>
    <publicationDate>2010-03-29T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Junk food may be addictive in the same way as heroin or cocaine,” &lt;EM&gt;The Independent&lt;/EM&gt; reported. It said researchers have found that a high-calorie diet of fatty, sugary food leads to compulsive overeating in rats and causes changes to the brain similar to those in humans who are addicted to the drugs.&lt;/P&gt;
&lt;P&gt;The study behind this news report is a well-conducted laboratory study in rats. The researchers found that rats with extended access to a high-fat, high-sugar diet had changes in the area of the brain associated with reward and developed compulsive eating habits.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388585</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.centreformentalhealth.org.uk/pdfs/Centre_for_MH_Promoting_mh_in_secure_settings.pdf]]&gt;</url>
    <title>Reaching out, reaching in - Promoting mental health and emotional wellbeing in secure settings</title>
    <publicationDate>2010-09-07T00:00:00</publicationDate>
    <publisher>Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Promoting mental health and emotional wellbeing in secure settings&lt;/H3&gt;
&lt;P&gt;This study was commissioned by the Department of Health to review current levels and standards of mental health provision in the young people's secure estate in England.&lt;/P&gt;
&lt;P&gt;This paper suggests that there is an urgent need for all secure units to develop an integrated, whole system and comprehensive approach to supporting the mental health and wellbeing of the young people in their care and, no less important, to ensure that any improvements made while in custody are supported and maintained following release.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317735</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mind.org.uk/NR/rdonlyres/FA0823A3-D193-4B74-AE99-EBE17AA39975/6684/chance.pdf]]&gt;</url>
    <title>Reassessing risk in mental health PDF</title>
    <publicationDate>2009-05-22T00:00:00</publicationDate>
    <publisher>MIND</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=FrutigerLT-Light&gt;
&lt;P align=left&gt;This report is based on a roundtable discussion held in March 2007. This report captures some key issues discussed at the seminar, and what Mind believes were some of the most interesting proposals for change. The views of participants varied and it should not be assumed that all individual participants would agree with all of its recommendations.&lt;/P&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>321653</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_101788?IdcService=GET_FILE&amp;dID=199424&amp;Rendition=Web]]&gt;</url>
    <title>Recognising complexity: commissioning guidance for personality disorder services</title>
    <publicationDate>2009-07-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance for commissioners in the NHS, criminal justice system, local authorities and others, which provides information and suggestions on best practice when considering services and systems for people with personality disorders.]]&gt;</body>
  </document>
  <document>
    <id>275467</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://website.scmh.org.uk/80256FBD004F6342/vWeb/pcKHAL77VCWM]]&gt;</url>
    <title>Recruitment and mental health: A report by Employers' Forum on Disability and Sainsbury Centre for Mental Health</title>
    <publicationDate>2007-10-10T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report describes what employers and government could do differently that would make it easier to recruit people with mental health problems.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Mental ill health is common and can affect anyone of any age, gender, ethnicity or social group. Three in ten employees will experience mental health problems during a year.&lt;/P&gt;
&lt;P&gt;The majority of people with mental health problems are willing and able to work. Despite this, an estimated one million people are out of work.&lt;/P&gt;
&lt;P&gt;This report describes what employers and government could do differently that would make it easier to recruit people with mental health problems. You can download it below.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268309</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40196&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Redesigning Mental Health Day Services</title>
    <publicationDate>2005-01-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This toolkit has been produced by The London Development Centre (CSIP), in association with the Mental Health Foundation. The toolkit provides support for commissioners, voluntary and statutory providers and service users, to remodel their day services to promote increased opportunities for social inclusion.</description>
    <body>&lt;![CDATA[ This toolkit has been produced by The London Development Centre (CSIP), in association with the Mental Health Foundation. The toolkit provides support for commissioners, voluntary and statutory providers and service users, to remodel their day services to promote increased opportunities for social inclusion.]]&gt;</body>
  </document>
  <document>
    <id>111306</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111306]]&gt;</url>
    <title>Reducing inequalities</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,DETERMINANTS,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,REGENERATION,POPULATION BASED &amp; PREVENTATIVE SERVICES,POLICY,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SOCIOECONOMIC FACTORS,SOCIAL DETERMINANTS,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; POLICY,SERVICES,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Reducing inequalities&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111326:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111317:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Mental health is a cross cutting theme which impacts on the achievement of a number of targets for reducing health inequalities. The failure to address the importance of psycho-social factors may have contributed to the limited success of a range of past public health initiatives, notably those concerned with neighbourhood renewal, regeneration and health at work, as well as smoking, sexual health and obesity. How people think and feel, individually and collectively, has a profound impact on public health. There is evidence that the chronic stress of deprivation, exclusion, fear of crime, racism, injustice and perceived powerlessness damages the nervous system, the cardio-vascular and the immune systems, influencing cholesterol levels, blood pressure, blood clotting, immunity and growth in childhood. (See: &lt;A href="nelh:111331:1" name=internalLink&gt;marginalised groups – people with severe and enduring mental health problems&lt;/A&gt;.)&lt;/P&gt;
&lt;P&gt;The following section summarises some of the links between mental health promotion and reducing inequalities.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111326:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111317:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322118</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_103643?IdcService=GET_FILE&amp;dID=202707&amp;Rendition=Web]]&gt;</url>
    <title>Reference guide to consent for examination or treatment, second edition 2009</title>
    <publicationDate>2009-08-04T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ LEARNING DISABILITIES,AUTISM,ADVOCACY &amp; EMPOWERMENT,CHALLENGING BEHAVIOUR,DAY SERVICES &amp; EMPLOYMENT,HEALTH,PERSON CENTRED SERVICES,LEARNING DISABILITY POLICY,PROFOUND &amp; MULTIPLE DISABILITIES,CONSENT,VULNERABLE ADULTS &amp; ABUSE,PARENTS WITH DISABILITIES,HOUSING,EYES AND VISION,MENTAL HEALTH,SUPPORTING FAMILY CARERS,INTRODUCTION: WHAT IS LEARNING DISABILITY?,MENTAL HEALTH,LATER LIFE,AGEISM,ADULT CONDITIONS,DEMENTIA,FALLS,SCREENING AND SURVEILLANCE,STROKE,CHILD AND ADOLESCENT CONDITIONS,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,LOW VISION,PARKINSON'S DISEASE,HEALTH &amp; WELLBEING,NSF FOR OLDER PEOPLE,EDUCATION,COMMUNICATION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This document updates that issued in 2001 and provides a guide to the legal framework that all health professionals need to take account of in obtaining valid consent for any examination, treatment or care that they propose to undertake.]]&gt;</body>
  </document>
  <document>
    <id>295143</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088162]]&gt;</url>
    <title>Reference guide to the Mental Health Act 1983</title>
    <publicationDate>2008-09-17T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The aim of this guide is to set out the main provisions of the Act and the associated secondary legislation, as they will stand at 3 November 2008 (which is when the majority of the amendments made by the Mental Health Act 2007 take effect).</description>
    <body>&lt;![CDATA[ &lt;P&gt;The aim of this guide is to set out the main provisions of the Act and the associated secondary legislation, as they will stand at 3 November 2008 (which is when the majority of the amendments made by the Mental Health Act 2007 take effect).&lt;/P&gt;
&lt;P&gt;The reference guide replaces the Memorandum on Parts I to VI, VIII and X of the Act last published by the Department of Health and the Welsh Office in 1998 (but the reference guide is only about the Act as it applies in England).&lt;/P&gt;
&lt;P&gt;The reference guide is published by TSO (The Stationery Office). &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088162?IdcService=GET_FILE&amp;amp;dID=148162&amp;amp;Rendition=Web" target="_blank"&gt;Download Reference guide to the Mental Health Act 1983 (PDF, 1676K)&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282681</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083647]]&gt;</url>
    <title>Refocusing the care programme approach: Policy and positive practice guidance</title>
    <publicationDate>2008-03-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Following the national consultation, Reviewing the Care programme Approach (CPA), and having considered the issues identified, this guidance updates policy and sets out positive practice guidance for trusts and commissioners to review local practice to refocus CPA within mental health services.</description>
    <body>&lt;![CDATA[ Following the national consultation, Reviewing the Care programme Approach (CPA), and having considered the issues identified, this guidance updates policy and sets out positive practice guidance for trusts and commissioners to review local practice to refocus CPA within mental health services.]]&gt;</body>
  </document>
  <document>
    <id>268310</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38646&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Reform of the Mental Health Act Update</title>
    <publicationDate>2000-05-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on the Mental Health Foundation’s response to the Nov 1999 Green Paper ‘Reform of the Mental Health Act 1983 - Proposals for Consultation’.</description>
    <body>&lt;![CDATA[ Update briefing on the Mental Health Foundation’s response to the Nov 1999 Green Paper ‘Reform of the Mental Health Act 1983 - Proposals for Consultation’.]]&gt;</body>
  </document>
  <document>
    <id>259578</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/professionals/RelapseForm.shtml]]&gt;</url>
    <title>Relapse management</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Relapse management form for General Practitioners.]]&gt;</body>
  </document>
  <document>
    <id>346699</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Relaxation-therapy-for-anxiety.aspx]]&gt;</url>
    <title>Relaxation therapy for anxiety</title>
    <publicationDate>2010-03-11T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC MIXED ANXIETY AND DEPRESSION,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Having a massage is no better at beating stress than home relaxation techniques like breathing deeply and listening to soothing music,” reports &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;This news is based on a trial on the effectiveness of therapeutic massage in treating generalised anxiety disorder (GAD), compared to thermotherapy (a heat-based treatment)&amp;nbsp;or relaxation room therapy. After 12 weeks, anxiety scores improved in all three groups.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>273453</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealthfirstaid.csip.org.uk/silo/files/feb-08-exec-summary-early-detection-report.pdf]]&gt;</url>
    <title>Report on Early detection and intervention for young people at risk of psychosis</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>National Institute for Mental Health in England</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,BIPOLAR DISORDER,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report compiled by Sophie Parker, Paul French, Aoiffe Kilcommons &amp; David Shiers</description>
    <body>&lt;![CDATA[ &lt;H2&gt;&amp;nbsp;Contents&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Executive summary 
&lt;LI&gt;Introduction 
&lt;LI&gt;Everybody’s business 
&lt;LI&gt;Rationale for intervening earlier 
&lt;LI&gt;A specialist service model 
&lt;LI&gt;Summary 
&lt;LI&gt;Acknowledgements 
&lt;LI&gt;Appendix - Service implementation guide 
&lt;LI&gt;References&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The drive to detect and intervene earlier in the care pathway of an individual with an emerging psychosis is supported by increasingly robust evidence. It is timely, in the light of this evidence and the rapidly changing configuration of mental health services specialising in early intervention, to consider how the key players in the early part of the pathway work together.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This report will explore some of the development challenges for specialist services, illustrating how this emerging evidence base can be translated into the real world by providing examples of good practice in specialist services. In particular we examine how the primary care / specialist interface needs to change if we are to realise the potential benefits of the research evidence.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;General Practitioners are critical pathway players in the interface with specialist services. Working with experts from the Royal College of General Practice, the Royal College of Psychiatry and the British Psychological Society we have created a specific guidance for general practitioners. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>274301</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_080689]]&gt;</url>
    <title>Research evidence on the effectiveness of self care support</title>
    <publicationDate>2007-11-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This document provides an evidence base on the effectiveness of self care support, such as information, self care support devices, self care skills training and self care support networks in the care of people with long term health conditions, short term ailments and among those taking initiatives to stay healthy.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;This report contains a Summary of Studies on Mental Health Conditions, including: Alzheimer's, Amnesia, Dementia, Behavioural disorder, Bi-polar disorder, Chronic fatigue syndrome, Depression, Eating disorders, Insomnia, and Schizophrenia. (See p.68)&lt;/H2&gt;
&lt;P&gt;This document provides an evidence base on the effectiveness of self care support, such as information, self care support devices, self care skills training and self care support networks in the care of people with long term health conditions, short term ailments and among those taking initiatives to stay healthy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266201</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/scmh_research_priorities_literature_review_final_report.pdf]]&gt;</url>
    <title>Research Priorities for Service User and Carer-Centred Mental Health Services</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Overview report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R &amp; D. January 2007.</description>
    <body>&lt;![CDATA[ &lt;P&gt;There is very little work that sets out the research priorities for developing patient and carer focused services.&amp;nbsp;The Sainsbury Centre for&amp;nbsp;Mental Health&amp;nbsp;carried out these two projects to identify the research priorities for the next five years. They were funded by the National Collaborating Centre for Service, Delivery and Organisation (SDO).&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;A literature review for patient and carer-centre mental health research priorities. 
&lt;LI&gt;Patient and carer-centred mental health research priorities for the medium to long term: A consultation exercise&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;The research priorities that emerged from the literature review:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Patient-carer centred care 
&lt;LI&gt;Service user involvement 
&lt;LI&gt;Carer-centred care, carer involvement and support 
&lt;LI&gt;Marginalised groups 
&lt;LI&gt;General priorities&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The research priorities that emerged from the consultation were:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;GPs &amp;amp; primary care 
&lt;LI&gt;Prevention &amp;amp; mental health promotion 
&lt;LI&gt;Non- medication based interventions 
&lt;LI&gt;Social inclusion &amp;amp; the role of mental health &amp;amp; social care services 
&lt;LI&gt;Services for people in crisis 
&lt;LI&gt;Person-centred care planning 
&lt;LI&gt;User &amp;amp; carer involvement in service planning &amp;amp; delivery 
&lt;LI&gt;Supporting &amp;amp; empowering family members &amp;amp; carers 
&lt;LI&gt;Medication &amp;amp; side effects 
&lt;LI&gt;Care pathways &amp;amp; transitions between services 
&lt;LI&gt;Workforce issues 
&lt;LI&gt;Mental health in the criminal justice system&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;There were also common themes for services, including marginalised groups, service user and carer involvement in planning and service delivery and workforce issues.&lt;/P&gt;
&lt;P&gt;You can read the full reports and an overview below.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.scmh.org.uk/80256FBD004F3555/vWeb/flKHAL733J4J/$file/scmh_research_priorities_literature_review_final_report.pdf" target="_blank"&gt;Download Literature Review Report&lt;/A&gt; (PDF, 184 KB)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.scmh.org.uk/80256FBD004F3555/vWeb/flKHAL733J4B/$file/scmh_research_priorities_consultation_final_report.pdf" target="_blank"&gt;Download Consultation Report&lt;/A&gt; (PDF, 336 KB)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.scmh.org.uk/80256FBD004F3555/vWeb/flKHAL733J4P/$file/scmh_research_priorities_overview_report.pdf" target="_blank"&gt;Download Overview Report &lt;/A&gt;(PDF, 100 KB)&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392211</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealthshop.org/products/rethink_publications/annual_review_20091.html]]&gt;</url>
    <title>Rethink - Annual review 2009/10 – Real voices, real change</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>Rethink</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Rethink have published their annual review for 2009/2010.]]&gt;</body>
  </document>
  <document>
    <id>386828</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/CR161x.pdf]]&gt;</url>
    <title>Revalidation and Guidance for Psychiatrists (CR161)</title>
    <publicationDate>2010-08-18T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=Pa14&gt;Revalidation is the process by which doctors will have to demonstrate to the General Medical Council (GMC) that they are up to date and fit to practise and that they are complying with the relevant professional standards. Revalidation will have two elements, relicensing and recertification.&lt;/P&gt;
&lt;P class=Pa13&gt;The report defines relicensing and recertification, gives the aims of revalidation, and goes on to explain in detail how psychiatrists will be able to evidence meeting revalidation standards.&lt;/P&gt;
&lt;H3&gt;Contents&lt;/H3&gt;
&lt;UL&gt;
&lt;LI class=Pa10&gt;Introduction&lt;/LI&gt;
&lt;LI class=Pa10&gt;Aims of revalidation&lt;/LI&gt;
&lt;LI class=Pa10&gt;How psychiatrists will be able to evidence meeting revalidation standards&lt;/LI&gt;
&lt;LI class=Pa10&gt;Evidence that will be reviewed at appraisal&lt;/LI&gt;
&lt;LI class=Pa10&gt;&lt;EM&gt;Good Medical Practice&lt;/EM&gt; and &lt;EM&gt;Good Psychiatric Practice&lt;/EM&gt;&lt;/LI&gt;
&lt;LI class=Pa10&gt;Responsible officers&lt;/LI&gt;
&lt;LI class=Pa10&gt;Remediation&lt;/LI&gt;
&lt;LI class=Pa10&gt;Frequently asked questions&lt;/LI&gt;
&lt;LI class=Pa10&gt;Summary of the revalidation process&lt;/LI&gt;
&lt;LI class=Pa10&gt;References&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=Pa10&gt;&lt;STRONG&gt;Appendices&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI class=Pa11&gt;Case-based discussion – specialist doctor&lt;/LI&gt;
&lt;LI class=Pa11&gt;Guidance for case-based discussion&lt;/LI&gt;
&lt;LI class=Pa11&gt;Multisource feedback colleague structured reflective template&lt;/LI&gt;
&lt;LI class=Pa11&gt;Multisource feedback patient structured reflective template&lt;/LI&gt;
&lt;LI class=Pa11&gt;Criteria and indicators of best practice in clinical audit&lt;/LI&gt;
&lt;LI class=Pa11&gt;Audit &lt;EM&gt;pro forma&lt;/EM&gt;&lt;/LI&gt;
&lt;LI class=Pa11&gt;Complaint report structured reflective template&lt;/LI&gt;
&lt;LI class=Pa11&gt;Serious untoward incident audit structured reflective template&lt;/LI&gt;
&lt;LI class=Pa11&gt;General Medical Council domains for revalidation, including specialty standards for &lt;EM&gt;Good Psychiatric Practice&lt;/EM&gt; (3rd edn)&lt;/LI&gt;
&lt;LI class=Pa11&gt;&amp;nbsp;Summary of possible supportive evidence for meeting specialist standards&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301990</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/88]]&gt;</url>
    <title>Review -  Screening and intervention for alcohol misuse in emergency rooms reduces alcohol-related injuries</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS,INDIVIDUAL BEHAVIOUR,POPULATION BASED &amp; PREVENTATIVE SERVICES,SCREENING,MONTHLY ADDITIONS,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,ALCOHOL CONSUMPTION,SERVICES,2009 OCTOBER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=-1&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the evidence for emergency room based interventions for alcohol use?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Frequency or quantity of alcohol consumption, frequency of heavy drinking consumption, and consequences during follow-up (for example, alcohol-related injuries).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;BR&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, PsychINFO, CCTR, DARE, CDSR, ACP Journal Club, Global Health, SWAB, Current Contents Connect and Web of Science, were searched between January 1996 and July 2007.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Intervention studies published in a peer-reviewed journal examining the effectiveness of emergency room treatment (including counselling, motivational interviewing, pharmacological treatment or advice) on an alcohol-related outcome. The Centers for Disease Control and Prevention Guide to Community Preventative Services Data Collection Instrument criteria and the Cochrane Effective Practise and Organisation of Care Review Group Data Collection Checklist were used to . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Mike J Crawford&lt;/P&gt;
&lt;P&gt;Department of Psychological Medicine, Imperial College London, UK&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/88" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&amp;nbsp;&lt;BR&gt;&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302038</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/19]]&gt;</url>
    <title>Review - Adding Chinese herbal medicine to antipsychotics may improve some outcomes in schizophrenia, but more high quality trials are needed</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is Chinese herbal medicine an effective treatment for schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Global state (Clinical Global Impression scale), mental state (Brief Psychiatric Rating Scale, Scale for Assessment of Negative Symptoms), leaving the study early, adverse effects.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Design: Systematic review and meta-analysis.&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Cochrane Schizophrenia Group’s trial register, including searches of MEDLINE, CINAHL, BIOSIS Inside, EMBASE, CENTRAL and PsycINFO; Chinese Medical Literature Analysis and Retrieval System, China National Knowledge Infrastructure Database, Chinese Biomedical Database, and the Allied Complementary Medicine Database were searched in 2003. Hand searches of journals and conference proceedings were also carried out.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Randomised controlled trials (RCTs) in people with schizophrenia or related psychosis (any diagnostic criteria), using any Chinese herbal medicine in comparison with any other therapy. Trials were excluded if there was . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ursula Werneke, MD, MSc, MRCPsych&lt;/P&gt;
&lt;P&gt;Sunderby Hospital, Luleå, Sweden &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words.&lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/19" target="_blank"&gt; Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302033</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/14]]&gt;</url>
    <title>Review - Atypical antipsychotics are effective adjuncts for treatment resistant depression but increase discontinuation due to adverse effects</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;BR&gt;&lt;/STRONG&gt;How effective are atypical antipsychotics as adjunctive therapy for treatment resistant depression? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Primary outcome: remission rates using the Hamilton Rating Scale for Depression (HAM-D) or Montgomery-Asberg Depression Rating Scale (MADRS). Secondary outcomes: discontinuation rates and response rates. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design: Systematic review with meta-analysis. &lt;BR&gt;Data sources:&lt;/STRONG&gt; Studies in any language were searched for in MEDLINE, PubMed, the Cochrane database and EMBASE from inception; as well as abstracts of multinational psychiatric meetings since 2000, and the clinical trial registries of antipsychotic manufacturers or direct contact with manufacturers not having such registries. The search date was not reported. &lt;/P&gt;
&lt;P&gt;Study selection and analysis: Double-blind, randomised, placebo-controlled trials of an antipsychotic as an adjunct to an antidepressant for treatment resistant depression using and assessing either the HAM-D or MADRS as their primary outcome . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;BR&gt;A Cipriani, MD, M Dieterich, MD, C Barbui, MD &lt;/P&gt;
&lt;P&gt;University of Verona, Verona, Italy &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/14" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302025</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/61]]&gt;</url>
    <title>Review - Black and minority ethnic people are more likely to be detained under the Mental Health Act 1983—no clear evidence why</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,ETHNICITY,PUBLIC HEALTH,MONTHLY ADDITIONS,POPULATIONS,CULTURAL IDENTITY,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;BR&gt;&lt;/STRONG&gt;Compared with White people, how frequently are people from Black and Minority Ethnic groups detained under the Mental Health Act 1983?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Rates of compulsory detention under the Mental Health Act.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, CINAHL, PsycINFO, ASSIA, SIGLE, HMIC, Web of Science, Cochrane database and the National Research Register; 1984 to April 2005. CD-ROM for the British National Bibliography was also searched for relevant literature.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: English language studies relating to compulsory detention under the Mental Health Act 1983 and including terms related to mental illness or forensic psychiatry, and with inclusion of &amp;gt;=2 ethnic groups (any non-White). Odds of compulsory detention of people from Black and Minority Ethnic (BME) groups compared with White groups were combined using a fixed effects meta-analysis. . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Elizabeth Cantor-Graae&lt;/P&gt;
&lt;P&gt;Department of Clinical Sciences, Lund University, Malmö, Sweden &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words. Full text of the article is available for users with ATHENS accounts.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302047</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/28]]&gt;</url>
    <title>Review - Cannabis use increases the risk of psychotic outcomes</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ACUTE PSYCHOTIC DISORDERS,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does cannabis use increase the risk of psychotic or affective mental health problems?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Psychosis and affective mental health problems&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;BR&gt;Design: Systematic review of longitudinal studies.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, CINAHL, PsycINFO, ISI Web of Knowledge, ISI Proceedings, ZETOC, BIOSIS, LILACS and MEDCARIB; searched from database inception to September 2006.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Population-based longitudinal studies or nested case-control studies assessing cannabis use and subsequent psychotic or affective mental health problems were included. The following were explicitly excluded: cohort studies of people with metal illness or substance-use problems, cohorts in prison populations, randomised controlled trials of cannabis for medical use. The presence of delusions, hallucinations or thought disorder was a requirement for all psychosis outcomes. Affective outcomes included mood or bipolar disorder, affective disorder, depression anxiety, neurosis, mania or suicide ideation and . . . (Abstracted)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Stéphane Potvin1, Mohamed Ben Amar2&lt;/P&gt;
&lt;P&gt;University of Sherbrooke, Sherbrooke, Canada&lt;BR&gt;University of Montreal, Montreal, Canada&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/28" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301984</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/81]]&gt;</url>
    <title>Review - Children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective and safe are antipsychotics for children and adolescents with early onset schizophrenia spectrum disorders?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Any efficacy outcome (symptoms, response, time to discontinuation), adverse events.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;BR&gt;Design: Systematic review.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE (searched 1970–2007), hand search of reference lists and conference abstracts, as well as contact with investigators in the field and drug manufacturers.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Double-blind randomised controlled trials (RCTs) of antipsychotics for early onset schizophrenia spectrum disorders were included. Trials had to include 15 or more participants (children and adolescents) and last for at least 4 weeks.&lt;BR&gt;MAIN RESULTS:&lt;/P&gt;
&lt;P&gt;Ten RCTs, three of first generation antipsychotics (FGAs) and seven of second generation antipsychotics (SGAs), met inclusion criteria. Average age of participants ranged from about 9–16 years. Most of the trials were small . . (Abstracted)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ginger Nicol, John Newcomer&lt;/P&gt;
&lt;P&gt;Washington University School of Medicine, Department of Psychiatry, St Louis, USA&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/81" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301707</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/113]]&gt;</url>
    <title>Review - Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEMENTIA,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective are cholinesterase inhibitors and memantine for&lt;SUP&gt; &lt;/SUP&gt;dementia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Cognitive and global functioning, behaviour, and quality of&lt;SUP&gt; &lt;/SUP&gt;life measures such as activities of daily living and caregiver&lt;SUP&gt; &lt;/SUP&gt;burden. Secondary outcomes: mortality, rate of institutionalisation,&lt;SUP&gt; &lt;/SUP&gt;and adverse events.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;FONT face=Arial color=#cc3300 size=4&gt;&lt;/FONT&gt;&lt;STRONG&gt;Method:&lt;BR&gt;&lt;!-- null --&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, Pre-MEDLINE, EMBASE, PsycINFO, Cochrane Central Register&lt;SUP&gt; &lt;/SUP&gt;of Controlled Trials, Allied and Complementary Medicine Database,&lt;SUP&gt; &lt;/SUP&gt;CINAHL and AgeLine were searched from January 1986 to November&lt;SUP&gt; &lt;/SUP&gt;2006 for English language articles. Reference lists of identified&lt;SUP&gt; &lt;/SUP&gt;studies were hand searched.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; RCTs of cholinesterase inhibitors or memantine in people with&lt;SUP&gt; &lt;/SUP&gt;major dementia (including Alzheimer’s, vascular and Parkinson’s&lt;SUP&gt; &lt;/SUP&gt;dementia) compared to placebo or another drug. Measures of cognition&lt;SUP&gt; &lt;/SUP&gt;were the Alzheimer’s Disease Assessment Scale (ADAS; cognitive&lt;SUP&gt; &lt;/SUP&gt;and non-cognitive subscales), Severe Impairment Battery (SIB),&lt;SUP&gt; &lt;/SUP&gt;and Mini-Mental State Examination. The validated measure of&lt;SUP&gt; &lt;/SUP&gt;global functioning was the clinician-based impression of change&lt;SUP&gt; &lt;/SUP&gt;with caregiver input (CIBIC-plus). Heterogeneity was investigated&lt;SUP&gt; &lt;/SUP&gt;&lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Hanna Kaduszkiewicz, MD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Institute of Primary Medical Care, Center of Psychosocial Medicine, University Medical Center Hamburg- Eppendorf, Hamburg, Germany &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;Falk Hoffmann, MPH &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Centre for Social Policy Research, Division Health Economics, Health Policy and Outcomes Research, University of Bremen, Bremen, Germany &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/113" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301979</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/76]]&gt;</url>
    <title>Review - Cognitive behavioural therapy for adolescents with depression</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;FONT size=-1&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is cognitive behavioural therapy (CBT) for adolescent depression and what factors explain the observed changes in meta-analytic effect sizes over time?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Effectiveness of CBT; differences in estimates of efficacy of cognitive behavioural therapy for adolescents; moderator variables (treatment duration, nature of sample, type of control group, setting, methodological rigor, therapist vocation, severity of depression at baseline).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;&lt;/STRONG&gt;&lt;STRONG&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Medical and psychological databases (PsycINFO and MEDLINE) were searched from January 1980 to September 2006. A hand search of reference lists of studies of CBT was also carried out.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Published, peer-reviewed randomised controlled trials (RCTs) of CBT in people aged 12–18 years with depression (DSM-III or later, Researcher Diagnostic . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;V Robin Weersing, Patrick N Walker&lt;/P&gt;
&lt;P&gt;SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA &lt;/P&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;FONT size=-1&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/76" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&amp;nbsp;&lt;/P&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>301867</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/117]]&gt;</url>
    <title>Review - Cognitive remediation improves cognitive functioning in schizophrenia</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;BR&gt;&lt;/STRONG&gt;Is cognitive remediation an effective treatment for schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Overall cognition, verbal and visual learning and memory, speed of processing, attention/vigilance, reasoning/problem solving and social cognition. Many different neuropsychological assessment tools were used for measurement of each cognitive domain.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE and PsycINFO (search date not given) were searched for English language articles.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Randomised controlled trials examining psychosocial interventions aimed at improving cognitive function in people with schizophrenia, schizoaffective disorder, or schizophreniform disorder. Neuropsychological tests of general effects had to be included and were assigned to cognitive domains (described by the Measurement and Treatment Research to Improve Cognition in Schizophrenia) of verbal and non-verbal working memory, verbal and visual learning and memory, speed of processing, attention/vigilance, reasoning/problem solving and social cognition. Effect sizes were determined using post-treatment group means (and SD), ANCOVA, MANCOVA or pre-post difference scores. Fixed effect models were . . . (Abstracted)&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary:&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Til Wykes, PhD, FBPS&lt;/P&gt;
&lt;P&gt;Centre for Recovery in Severe Psychosis, Institute of Psychiatry, King's College London, London, UK &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/117" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301698</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/108]]&gt;</url>
    <title>Review - Individual behavioural therapy reduces symptoms of depression</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective are behavioural therapies for depression?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Depressive symptoms (either self-rated—eg, Beck Depression&lt;SUP&gt; &lt;/SUP&gt;Inventory, or clinician rated—eg, Hamilton Depression&lt;SUP&gt; &lt;/SUP&gt;Rating Scale).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;FONT face=Arial color=#cc3300 size=4&gt;&lt;/FONT&gt;&lt;STRONG&gt;Method:&lt;BR&gt;&lt;!-- null --&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, PsycINFO, Cochrane Library, DARE, CINAHL, AMED&lt;SUP&gt; &lt;/SUP&gt;and the British Nursing Index were searched from inception to&lt;SUP&gt; &lt;/SUP&gt;January 2006 for randomised controlled trials (RCTs). Reference&lt;SUP&gt; &lt;/SUP&gt;lists of identified studies were hand searched.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Two reviewers appraised studies and selected RCTs of behavioural&lt;SUP&gt; &lt;/SUP&gt;therapy in adults (aged &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;16 years) with a primary diagnosis of&lt;SUP&gt; &lt;/SUP&gt;depression. Treatments could be delivered in a community or&lt;SUP&gt; &lt;/SUP&gt;inpatient setting. Behavioural therapy had to be individual,&lt;SUP&gt; &lt;/SUP&gt;time limited, and based on changing the behavioural consequences&lt;SUP&gt; &lt;/SUP&gt;of environmental or cognitive triggers. Comparator treatments&lt;SUP&gt; &lt;/SUP&gt;could include cognitive behavioural therapy (CBT) or cognitive&lt;SUP&gt; &lt;/SUP&gt;therapy, brief psychotherapies, supportive counselling, treatment&lt;SUP&gt; &lt;/SUP&gt;as usual, waiting list or other inactive control. Two reviewers&lt;SUP&gt; &lt;/SUP&gt;rated study quality and extracted data. Authors were &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Brandon A Gaudiano, PhD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Alpert Medical School of Brown University and Butler Hospital, Providence, Rhode Island, USA &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/108" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301705</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/112]]&gt;</url>
    <title>Review - Insufficient evidence on Huperzine A for Alzheimer’s</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=-1&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective and safe is Huperzine A for Alzheimer’s disease?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Changes in cognitive function (eg, from scores on Mini Mental State Examination (MMSE), Hasegawa Dementia Scale (HDS), or ADAS-Cog), changes to global clinical assessment (eg, from scores on Clinical Dementia Rating (CDR) or Clinician Interview-Based Impression (CIBIC-Plus)), all cause mortality, adverse events.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;Data sources: The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, CBM, AMED and relevant websites were searched in February 2006. Relevant journals and reference lists of studies were hand searched; unpublished material was identified by contacting experts in the field.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: All RCTs of Huperzine A in adults with Alzheimer’s disease (AD) of any severity were included. Participants had to be diagnosed with AD using standard criteria (ICD-9 or -10, DSM III, III-R or IV, or National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer’s . . . [Full text of this article]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Tiffany W Chow, MD, MSc&lt;/P&gt;
&lt;P&gt;Clinician-Scientist, Rotman Research Institute, Baycrest and Assistant Professor, University of Toronto Department of Medicine, Neurology Division and Department of Psychiatry, Geriatric Psychiatry Division, Toronto, Canada &lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/112" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302040</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/21]]&gt;</url>
    <title>Review - More high quality studies needed to determine the effects on patient outcomes of psychiatric care guideline implementation</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What are the effects of implementation of psychiatric guidelines on patient and provider outcomes?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Provider performance or patient outcomes.&lt;BR&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;Design: Systematic review.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, Cochrane Trials Register, CINAHL and PsycINFO were searched in March 2006. Reference lists of guidelines and other publications and websites were searched to identify English and non-English studies. A hand search of a selection of journals published between 1996 and 2005 was also performed.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Randomised controlled trials (RCTs), non-randomised comparative studies, and before-and-after studies examining the effects of implementing psychiatric guidelines on either service provider performance or patient outcomes in a primary care or professional mental health setting were included. Exclusions: non-adult studies; specific diagnostic guidelines (for example, ICD-10 primary care guidelines); studies of more than one guideline; guidelines as only . . . (Abstracted)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Amy H Cheung&lt;/P&gt;
&lt;P&gt;Department of Psychiatry, University of Toronto, Toronto, Canada&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/21" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301708</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/114]]&gt;</url>
    <title>Review - Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is paliperidone (risperidone’s active metabolite) an effective&lt;SUP&gt; &lt;/SUP&gt;treatment for schizophrenia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Several outcomes were assessed by the review including death&lt;SUP&gt; &lt;/SUP&gt;(suicide and natural causes), mental state, cognitive and social&lt;SUP&gt; &lt;/SUP&gt;functioning, behaviour, quality of life and adverse effects.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;H3&gt;Method: &lt;/H3&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Cochrane Schizophrenia Group’s Register was searched up&lt;SUP&gt; &lt;/SUP&gt;to December 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; RCTs examining effects of any dose of adjunct paliperidone (oral&lt;SUP&gt; &lt;/SUP&gt;or intramuscular) in people with schizophrenia or schizophrenia-like&lt;SUP&gt; &lt;/SUP&gt;illness (using any diagnostic criteria), regardless of age or&lt;SUP&gt; &lt;/SUP&gt;sex. Studies were rated to determine risk of bias; those rated&lt;SUP&gt; &lt;/SUP&gt;as at high risk of bias were not included in the review. Studies&lt;SUP&gt; &lt;/SUP&gt;with more than 50% dropout were excluded as were studies using&lt;SUP&gt; &lt;/SUP&gt;rating scales that had not been described in a peer-reviewed&lt;SUP&gt; &lt;/SUP&gt;journal. A conservative intention-to-treat analysis was used,&lt;SUP&gt; &lt;/SUP&gt;where dropouts were assumed to have had the negative outcome&lt;SUP&gt; &lt;/SUP&gt;(except death). Risk ratios &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt; &lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentary:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Christian Dolder, PharmD, BCPS &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Wingate University School of Pharmacy, Wingate, North Carolina, USA &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/114" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302017</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/53]]&gt;</url>
    <title>Review - Psychological interventions for caregivers of people with dementia</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEMENTIA,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Are psychological interventions effective for family caregivers of people with dementia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Quantitative outcome measures of caregiver psychological health, including depression, distress, and burden.&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design: Systematic review.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; "Electronic databases" were searched in July 2003, including a hand search of reference lists. The Cochrane Library was also searched and an additional hand search of four journals was also conducted.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: All primary research studies with quantitative outcome measures of caregiver psychological health. Search terms were broad and most studies were included. Exclusions: studies in caregivers of people without dementia; studies only reporting outcomes in the person with dementia; interventions involving medication or not based on an explicit psychological model (for example, aromatherapy). Depending on research quality, each study was assigned an . . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;James Warner&lt;/P&gt;
&lt;P&gt;St Charles’s Hospital, London, UK&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. Full text of the article is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301982</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/79]]&gt;</url>
    <title>Review - Psychosocial and psychological interventions reduce postpartum depressive symptoms</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective are psychosocial and psychological interventions compared with usual care for treating postpartum depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Primary outcomes were recovery and reduction in depressive symptoms, as defined and measured in the individual trials.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Cochrane Collaboration Depression, Anxiety, and Neurosis Controlled Trials registers (searched August 2007), the Cochrane Pregnancy and Childbirth Review Group trials register, CENTRAL, MEDLINE (1966–2006), EMBASE (1980–2006), CINAHL (1982–2006), and hand searches of reference lists, and contact with experts in the field.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Randomised controlled trials comparing psychosocial or psychological interventions with usual care for reducing symptoms of postpartum depression were included. Women could be identified using self report measures or by diagnostic interview during the 12 months after delivery. Usual care consisted of . . (Abstracted)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Kathryn M Abel&lt;/P&gt;
&lt;P&gt;Centre for Women's Mental Heath, University of Manchester, Manchester, UK&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/79" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302013</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/49]]&gt;</url>
    <title>Review - Psychotherapy for adolescents with depression: initial but no sustainable benefits</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is psychotherapy an effective way to treat children and adolescents with depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Risk of response, defined as score below the threshold for diagnosis of depression on whichever scale the study used—"operationalized criteria" or "a validated depression severity measure". Secondary outcomes were cost and safety of treatment.&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Cochrane CENTRAL, MEDLINE, CINAHL, PsycINFO, EMBASE, PSYNDEX, LILACS, conference proceedings and hand searches of journals; performed by searching the Cochrane Collaboration Depression, Anxiety and Neurosis Registers on 17 December 2004. Additional supplementary search of CENTRAL, MEDLINE, PsycINFO and EMBASE was carried out, and from the selected papers, reference lists were examined and lead authors contacted for further data on other trials.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Individual or cluster randomised controlled . . . (Abstracted)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Sally N Merry&lt;/P&gt;
&lt;P&gt;Werry Centre for Child and Adolescent Mental Health, University of Auckland, Auckland, New Zealand&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/49" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301992</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/90]]&gt;</url>
    <title>Review - Psychotherapy may be beneficial for people with hypochondriasis</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is psychotherapy effective for people suffering from hypochondriasis? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Hypochondrial cognition or behaviour rated by a validated hypochondriasis or health anxiety scale (Health Anxiety Inventory, Health Anxiety Questionnaire, Whitley Index, Somatic Symptom Index or Illness Attitudes Scale), or appropriate visual analogue scale. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;Design: Systematic review with meta-analysis. &lt;BR&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, PsycINFO, AMED, CINAHL, CENTRAL, Cochrane Trials register, ISI Web of Knowledge and WorldCat Dissertations were searched in August 2007. Reference lists of retrieved articles were also searched to identify additional studies and experts in the field contacted to identify unpublished trials. &lt;/P&gt;
&lt;P&gt;Study selection and analysis: Randomised controlled trials (RCTs) comparing individual or group psychotherapy with placebo, waiting list, treatment as usual or no treatment in adults (aged 18–75 years) diagnosed with hypochondriasis (ICD-10, DSM-IV . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Theo K Bouman &lt;/P&gt;
&lt;P&gt;Department of Clinical and Developmental Psychology, University of Groningen, The Netherlands &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/90" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301967</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/124]]&gt;</url>
    <title>Review - Short stay hospitalisation does not increase readmissions compared with long stay</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is planned short stay hospitalisation compared with long stay (standard) hospitalisation for people with severe mental illness?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Death, service outcomes (including hospital readmission), global and mental function.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; The Cochrane Schizophrenia group trial register was searched in July 2007. In addition, reference lists of relevant papers were hand searched, papers citing included studies were identified using SciSearch, and authors of the main studies were contacted to identify unpublished research.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: RCTs comparing planned short-term versus long-term/standard hospitalisation for people with schizophrenia, related disorders or any "severe/chronic mental disorders/illnesses" were included. RCTs randomising all acute psychiatric admissions were not included in the meta-analyses. Studies where more than 50% of participants were lost to follow-up were excluded from analyses. In intention-to-treat analyses people leaving studies early were assumed to have had a negative outcome, except for in the mortality analyses. Two . . . [Full text of this article]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Sara Bressi Nath, PhD, MSW&lt;/P&gt;
&lt;P&gt;Bryn Mawr College, Graduate School of Social Work and Social Research, Bryn Mawr, Pennsylvania, USA &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/124" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301966</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/123]]&gt;</url>
    <title>Review - Substance use disorders respond to psychosocial interventions</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;How effective are psychosocial treatments for the management of cannabis, cocaine, opiate and polysubstance abuse and dependence?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Self-reported abstinence (maximum number days/weeks, mean percent of days abstinent during treatment, percentage of sample abstinent &amp;gt;=3 weeks during treatment, percentage of sample with post treatment abstinence), post-treatment score on the Addiction Severity Index, and toxicology (mean number and percent of negative screens during treatment, percent of sample demonstrating abstinence).&lt;/P&gt;
&lt;P&gt;Methods:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design: Systematic review with meta-analysis.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PsycINFO and MEDLINE (searched from date of inception to March 2005), and search of the Cochrane Central Register of Controlled Trials (first quarter of 2005).&lt;/P&gt;
&lt;P&gt;Study selection and analysis: All English-language RCTs of any individual psychosocial interventions for any substance abuse (excluding alcohol or nicotine abuse/dependence) compared to a control (eg, waiting list, treatment as usual). Trials had to include only participants aged &amp;gt;=18 years and be in a nonintensive outpatient setting with no more than . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Michael Farrell, Dr, MRCP, MRCPsych&lt;/P&gt;
&lt;P&gt;Reader in Addiction Psychiatry, Institute of Psychiatry, Kings College London, London, UK&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/123" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268311</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38630&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Review of Mental Health Legislation in the UK</title>
    <publicationDate>2002-11-04T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A summary of Mental Health Legislation in the UK.</description>
    <body>&lt;![CDATA[ A summary of Mental Health Legislation in the UK.]]&gt;</body>
  </document>
  <document>
    <id>377595</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/41.extract]]&gt;</url>
    <title>Review: depression is associated with increased cancer mortality</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2&gt;Question:&lt;/H2&gt;
&lt;P&gt;Are there associations between depression and mortality of cancer patients and do these vary dependent on the study characteristics?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;RR ratio for depression and cancer mortality.&lt;/P&gt;
&lt;H2&gt;Methods:&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Systematic review and meta analysis.&lt;/P&gt;
&lt;H3&gt;Date Sources:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Medline, Cochrane Data Base, PsychLit, and PSYNDEX were searched for relevant studies.&lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Criteria for inclusion in the meta analysis were studies including cancer patients or prospective community-based studies reporting cancer mortality; depressive disorders diagnosed according to ICD-10 &lt;EM&gt;DSM-III&lt;/EM&gt;, &lt;EM&gt;III-R&lt;/EM&gt; or IV; or depressive symptoms assessed with self-rating scales or interviewer ratings. Also, statistics could be calculated or estimated for associations between depression and mortality. RR were calculated for each study and pooled using random-effects models. Heterogeneity was assessed using the Q statistic. Analyses were carried out to look at the effects of potential moderator variables.&lt;/P&gt;
&lt;H2&gt;Main Results&lt;/H2&gt;
&lt;P&gt;A total of 76 studies met inclusion criteria (176 863 … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/2/41.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105868</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=105868]]&gt;</url>
    <title>Risk and protective factors for mental health</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,EDUCATION,ENVIRONMENTAL,UNEMPLOYMENT,SOCIAL CAPITAL,SOCIAL SUPPORT,MENTAL &amp; BEHAVIOURAL DISORDERS,DISADVANTAGED GROUPS,DETERMINANTS,PUBLIC HEALTH,SOCIAL DETERMINANTS,SOCIETY,SOCIOECONOMIC FACTORS,POPULATIONS,GROUPS,GENDER,COMMUNITIES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Risk and protective factors for mental health&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:105867:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:105869:1" name=internalLink&gt;&lt;A href="nelh:105869:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Mental health is embedded within social and socio-economic relationships and so also are the risk and protective factors for mental health. Risk factors for poor mental health are myriad and include a family history of psychiatric disorder, violence, childhood neglect, family breakdown, and unemployment. Bereavement, financial strain and long-term caring are risk factors across the life cycle and especially in later life (ref 1).&lt;/P&gt;
&lt;P&gt;Gender has a significant impact on risk and protective factors for mental health. Rates of suicide are four times as high in men as in women and the difference is increasing (ref 2). However women are at greatly increased risk of depression and anxiety, eating disorders and self-harm. (ref 3, 4). As with other health indicators, there is a strong correlation between deprivation and poor mental health.&lt;/P&gt;
&lt;P&gt;Psychological protective factors for mental well-being include feeling respected, valued and supported, together with a sense of hopefulness about the future and they exert an influence on how individuals respond to stressful or traumatic life events (ref 5, 6). Individual psychological characteristics are influenced by wider socio-economic factors, such as parenting, schools, employment, housing and financial security.&lt;/P&gt;
&lt;P&gt;The social environment also plays a part in promoting mental well-being. Social capital, which consists of the informal and formal networks, customs and relationships that make up our individual and community interactions, can serve to protect mental health (ref 7). Perceived levels of trust, tolerance and participation are critical protective factors.&lt;/P&gt;
&lt;P&gt;For example, a study found that of trust in friends, family and community, only lack of trust in community predicted psychological distress. In other words, the extent to which people believe that unfamiliar others are trustworthy was an important factor determining levels of distress. (ref 8).&lt;/P&gt;
&lt;P&gt;A framework developed by the Health Education Authority emphasised the importance of social and environmental factors in determining mental health (ref 9). In addition to genetic inheritance the three key areas influencing mental health were identified as:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Healthy social support, economic and cultural structures;&lt;/LI&gt;
&lt;LI&gt;Strong social networks and social inclusion;&lt;/LI&gt;
&lt;LI&gt;Emotional resilience&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:105867:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:105869:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Milne A, Hatzidimitriadou E, Chryssanthopoulou C and Owen T (2001) Caring in Later Life: Reviewing the Role of Older Carers. London. &lt;A href="http://www.helptheaged.org.uk/default.htm" target="_blank"&gt;Help the Aged&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Meltzer H, Gill B, Pettigrew M and Hinds K (1996) The prevalence of psychiatric morbidity among adults living in private households OPCS surveys of psychiatric morbidity in Great Britain Report 1 HMSO London: HMSO&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Piccinelli M and Wilkinson G (2000) Gender differences in depression. The British Journal of Psychiatry 177: 486-492&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Department of Health (2002) &lt;A href="http://www.dh.gov.uk/assetRoot/04/07/54/87/04075487.pdf" target="_blank"&gt;Women’s Mental Health: Into the Mainstream: Strategic Development of Mental Health Care for Women&lt;/A&gt; London: Department of Health&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Pollock LR and Williams JM (1998) Problems solving suicidal behaviour. Suicide and Life Threatening Behaviour 28 (4): 375-387&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Williams JMG and Pollock LR (2001) Psychological aspects of the suicidal process In K. van Heeringen (Ed.) Understanding Suicidal Behaviour. Chichester: John Wiley&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Putnam R (1993) The prosperous community: social capital and public life. American Prospect 13:35-42.&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Berry HL and Rickwood DJ (2000) Measuring social capital at the individual level: personal social capital, values and psychological distress. International Journal of Mental Health Promotion 2 (3): 35-44&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Health Education Authority (1997) Mental Health Promotion: A Quality Framework. London: HEA.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>378347</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/OP74.pdf]]&gt;</url>
    <title>Role of the Consultant Psychiatrists: Leadership and excellence in mental health services</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal&gt;The pace of change in modern mental healthcare has increased exponentially over the past few years. The role of the consultant psychiatrist within a multidisciplinary team has been debated in a way that might have been unthinkable in the past. As a profession we must look outwards, work with stakeholders, face the challenges related to changing expectations, and contribute to the debate with a positive, robust and well-evidenced response. Defensiveness and retreat into past certainties will not do.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa10&gt;The consultant psychiatrist, because of the nature of their medical training, represents the only professional able to integrate biological, psychological and social elements of healthcare into care packages to manage and alleviate mental illness, and to understand the complex interactions between mental and physical health.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa9&gt;The role and the responsibilities of the consultant psychiatrist within the multidisciplinary team are still unique. This report clearly sets out the unique benefits that a consultant psychiatrist brings to patient care, team leadership and service development.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa10&gt;Consultant time is expensive and, particularly in the current financial climate, commissioners who spend scarce resources need to understand the value of what they buy. Otherwise they will, understandably, look to buy something which costs less and ‘appears’ to do the same job.&lt;/P&gt;
&lt;P class=Pa10&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal&gt;This report should bring clarity and confidence to our fellow professionals, to our patients and their carers, and to all others who have an interest in these matters.&lt;/P&gt;
&lt;P class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=Pa10&gt;It should be read in conjunction with &lt;EM&gt;&lt;A href="http://www.rcpsych.ac.uk/publications/collegereports/cr/cr154.aspx" target="_blank"&gt;Good Psychiatric Practice (3&lt;SUP&gt;rd&lt;/SUP&gt; edition)&lt;/A&gt;&lt;/EM&gt;, which sets out standards of practice for psychiatrists, and &lt;EM&gt;&lt;A href="http://www.rcpsych.ac.uk/training/curriculum2009.aspx" target="_blank"&gt;A Competency Based Curriculum for Specialist Training in Psychiatry&lt;/A&gt;&lt;/EM&gt;. Both documents define the skills, knowledge and attitudes necessary for psychiatrists to be able to fulfil their roles as physicians.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328790</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/97]]&gt;</url>
    <title>Schizophrenia and NICE: all quiet on the community front?</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Although the concept of psychotic illness was known to the healers&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of his age, Sun Tzu did not have mental illness in mind when&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;he penned those words two and a half thousand years ago. His&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;maxim nonetheless remains true of both our responses to war&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and to schizophrenia. They have much in common. Both are universally&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;associated with images of horror and darkness. Both carry an&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;awful cost—1% of the human population will suffer a psychotic&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;breakdown, often in young adulthood. Both are ever changing.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;War has altered beyond recognition since 1911 when Bleuler first&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;coined the term "schizophrenia" to describe a shattering of&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;the mind. When the Captains of American psychiatry met last&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;year to consider their future nomenclatures, they came close&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to dropping the S word altogether. Over here, our top brass—their&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;chateaus &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/97" target="_blank"&gt;&lt;EM&gt;Full text of this article&lt;/EM&gt;&lt;/A&gt;&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344930</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344930]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Antipsychotics - 1st Generation (Typical)</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Antipsychotics - 1st Generation (Typical)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Early clinical studies established that antipsychotic medications are effective in the treatment of acute schizophrenic episodes,&amp;nbsp;although they proved to be more effective at alleviating positive symptoms than negative symptoms such as alogia or affective blunting. However, no consistent difference between the FGAs was demonstrated in terms of antipsychotic efficacy or effects on individual symptoms, syndromes or schizophrenia subgroups. Accordingly, the choice of drug for an individual was largely dependent on differences in side-effect profiles. The limitations of these first-generation antipsychotic drugs included heterogeneity of response in acute episodes, with a proportion of individuals showing little improvement, and a range of undesirable acute and long-term side-effects.&lt;/P&gt;
&lt;P&gt;First generation antipsychotics include benperidol, chlorpromazine hydrochloride, flupentixol, fluphenazine hydrochloride, haloperidol, levomepromazine, pericyazine, perphenazine, pimozide, prochlorperazine, promazine hydrochloride, sulpiride, trifluoperazine, zuclopenthixol acetate and zuclopenthixol dihydrochloride. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19900962" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 2009; 35(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18417466" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drymalski WM, Campbell TC. A review of Motivational Interviewing to enhance adherence to antipsychotic medication in patients with schizophrenia: Evidence and recommendations. Journal of Mental Health 2009; 18(1):6-15.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~db=all~content=a904724736~tab=content" target="_blank"&gt;Informaworld Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia. Evidence Based Mental Health Journal 2009.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/13.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Antipsychotic prescriptions for children and adolescents in the UK increased from 1993 to 2005. Evidence Based Mental Health Journal 2009.&amp;nbsp;&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/30.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Typical and atypical antipsychotics increase risk of sudden cardiac death. Evidence Based Mental Health Journal 2009; 12.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/92.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fenton M, Rathbone J, Reilly J. Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001944/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haddad P, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. The British Journal of Psychiatry 2009; 195 (SUPPL 52):S20-S28.&lt;BR&gt;[&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/195/52/S20" target="_blank"&gt;BJPsych Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huf G, Alexander J, Allen MH, Raveendran NS. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Systematic Reviews 2009; (3).&lt;BR&gt;[&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005146/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irving CB, Adams CE, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003082/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kennedy E KADS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database of Systematic Reviews 2009; (4). &lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004027/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia:&amp;nbsp; a meta-analysis. Lancet 2009; 373(9657).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19058842" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 2009; 39(11).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19338710" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabinowitz J, Levine SZ, Barkai O, Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophrenia Bulletin 2009; 35(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18303093" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rathbone J MT. Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001949/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). Clinical Evidence (Online) 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19445748" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19946012" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 2009; 113(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19524406" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Side Effects of Antipsychotics&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Conventional or typical antipsychotic agents (more recently called first-generation antipsychotics or FGAs) are associated with a high incidence and broad range of side effects, including lethargy, sedation, weight gain and sexual dysfunction. Movement disorders, such as parkinsonism, akathisia, dystonia, often referred to as acute extrapyramidal side effects (EPS), are common and can be disabling and distressing. A serious long-term side effect is tardive dyskinesia, which develops in around 20% of people receiving first-generation antipsychotic drugs. This is a late-onset EPS, characterised by abnormal involuntary movements of the lips, jaw, tongue and facial muscles, and sometimes the limbs and trunk. Although a person who develops tardive dyskinesia is usually unaware of the movements, they are clearly noticed by others, and the condition has long been recognised as a severe social handicap.&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bushe CJ, Bradley AJ, Doshi S, Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. International Journal of Clinical Practice 2009; 63(12).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19840151" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Non-pharmacological interventions reduce antipsychotic induced weight gain. Evidence Based Mental Health Journal 2009; (2).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/52.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evidence Based Mental Health Journal 2009; (2).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/50.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guilera G, Pino O, Gomez-Benito J, Rojo J, Emilio. Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials. The European Journal of Psychiatry 2009; 23(2):77-89.&lt;BR&gt;[&lt;A href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;amp;pid=S0213-61632009000200002&amp;amp;lng=es&amp;amp;nrm=iso" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roke Y, Van Hartern PN et al. Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. Journal of Child and Adolescent Psychopharmacology 2009; 19(4):403-414.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19702492" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychological Medicine 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19656426" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344940</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344940]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Antipsychotics - 2nd Generation (Atypical)</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Antipsychotics - 2nd Generation (Atypical)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;/H2&gt;
&lt;P&gt;The search for better-tolerated and more effective drugs eventually generated a series of second-generation drugs, characterised by a lower liability for extrapyramidal symptoms.&lt;/P&gt;
&lt;P&gt;Second generation antipsychotics include amisulpride, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, sertindole and zotepine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Adib Essali, Nahla Al-Haj Haasan, Chunbo Li, John Rathbone. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000059/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: A systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19900962" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophrenia Bulletin 2009; 35(2):458-468).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18436527" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003729/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Berk M, Rathbone J, Mandriota-Carpenter SL. Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002304/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006324/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. International Journal of Clinical Practice 2009; 63(12).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19840150" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. International Journal of Clinical Practice 2009; 63(8).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19624791" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 2009; 35(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18417466" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;DeSilva P, Fenton M, Rathbone J. Zotepine for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001948/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drymalski WM, Campbell TC. A review of Motivational Interviewing to enhance adherence to antipsychotic medication in patients with schizophrenia: Evidence and recommendations. Journal of Mental Health 2009; 18(1):6-15.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~db=all~content=a904724736~tab=content" target="_blank"&gt;Informaworld Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran SO. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001359/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clinical Therapeutics 2009; 31(Pt 1):1345-59.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19698898" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia. Evidence Based Mental Health Journal 2009.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/13.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Antipsychotic prescriptions for children and adolescents in the UK increased from 1993 to 2005. Evidence Based Mental Health Journal 2009.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/30.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence Based Mental Health Journal 2009.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/51.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Insufficient evidence to guide use of drugs for clozapine induced hypersalivation. Evidence Based Mental Health Journal 2009.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/12.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Lamotrigine may be an effective treatment for clozapine resistant schizophrenia. Evidence Based Mental Health Journal 2009; (12)&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/111.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia. Evidence Based Mental Health Journal 2009; (12).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/112.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Second generation antipsychotics are a heterogeneous drug class. Evidence Based Mental Health Journal 2009; (12).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/90.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Typical and atypical antipsychotics increase risk of sudden cardiac death. Evidence Based Mental Health Journal 2009; (12).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/92.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fernandez Sanchez A, Pinto-Meza A, Maria Haro J. Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral pharmaceutical forms of atypical and conventional antipsychotics used in Spain for treating patients with schizophrenia. Revista De Psiquiatria y Salud Mental 2009; 2(1):5-28.&lt;BR&gt;[&lt;A href="http://www.elsevier.es/watermark/ctl_servlet?_f=10&amp;amp;pident_articulo=13135774&amp;amp;pident_usuario=0&amp;amp;pcontactid=&amp;amp;pident_revista=286&amp;amp;ty=67&amp;amp;accion=L&amp;amp;origen=elsevier&amp;amp;web=www.elsevier.es&amp;amp;lan=en&amp;amp;fichero=286v02n01a13135774pdf001_2.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005237/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. Journal of Clinical Psychiatry 2009; 70(5).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19389331" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004027/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmid F, Lewis R, Kissling W, Leucht S. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006752/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PSS, Kissling W, Leucht S. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006627/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HGG, Kissling W, Leucht S. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Databases of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006569/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry 2009; 14(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18180760" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia:&amp;nbsp; a meta-analysis. Lancet 2009; 373(9657).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19058842" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009; 166(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19015230" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007474/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 2009; 39(11).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19338710" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Omori IM, Wang J. Sulpiride versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007811/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pani L, Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opinion on Drug Delivery 2009; 6(3):319-331.&lt;BR&gt;[&lt;A href="http://informahealthcare.com/doi/abs/10.1517/17425240902780158" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rabinowitz J, Levine SZ, Barkai O, Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophrenia Bulletin 2009; 35(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18303093" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). Clinical Evidence (Online) 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19445748" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sparshatt A, Taylor D, Patel MX, Kapur S. Amisulpride - Dose, plasma concentration, occupancy and response: Implications for therapeutic drug monitoring. Acta Psychiatrica Scandinavica 2009; 120(6):416-428.&lt;BR&gt;[&lt;A href="http://www3.interscience.wiley.com/journal/122476628/abstract" target="_blank"&gt;Wiley Interscience Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica 2009; 119(6).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19245679" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23(6).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19480467" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19946012" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 2009; 113(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19524406" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Side Effects of Antipsychotics&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Conventional or typical antipsychotic agents (more recently called first-generation antipsychotics or FGAs) are associated with a high incidence and broad range of side effects, including lethargy, sedation, weight gain and sexual dysfunction. Movement disorders, such as parkinsonism, akathisia, dystonia, often referred to as acute extrapyramidal side effects (EPS), are common and can be disabling and distressing. A serious long-term side effect is tardive dyskinesia, which develops in around 20% of people receiving first-generation antipsychotic drugs. This is a late-onset EPS, characterised by abnormal involuntary movements of the lips, jaw, tongue and facial muscles, and sometimes the limbs and trunk. Although a person who develops tardive dyskinesia is usually unaware of the movements, they are clearly noticed by others, and the condition has long been recognised as a severe social handicap.&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Non-pharmacological interventions reduce antipsychotic induced weight gain. Evidence Based Mental Health Journal 2009; (2).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/52.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evidence Based Mental Health Journal 2009; (2).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/50.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bushe CJ, Bradley AJ, Doshi S, Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. International Journal of Clinical Practice 2009; 63(12).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19840151" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guilera G, Pino O, Gomez-Benito J, Rojo J, Emilio. Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials. The European Journal of Psychiatry 2009; 23(2):77-89.&lt;BR&gt;[&lt;A href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;amp;pid=S0213-61632009000200002&amp;amp;lng=es&amp;amp;nrm=iso" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roke Y, Van Hartern PN et al. Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. Journal of Child and Adolescent Psychopharmacology 2009; 19(4):403-414.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19702492" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychological Medicine 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19656426" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344962</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344962]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Comorbidity</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Comorbidity&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Schizophrenia has a number of comorbid conditions. These include impairment of cognitive function, depression, obsessive-compulsive behavior and aggressive behaviour.&lt;/P&gt;
&lt;P&gt;We cover &lt;A href="nelh:344963:1" name=internalLink&gt;&lt;A href="nelh:344963:1" name=internalLink&gt;&lt;A href="http://www.library.nhs.uk/mentalHealth/ViewResource.aspx?resID=310279&amp;amp;pgID=1" target="_blank"&gt;dual diagnosis&lt;/A&gt;&lt;/A&gt;&lt;/A&gt; (schizophrenia and substance misuse) separately.&lt;/P&gt;
&lt;P style="TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0cm 0cm 12pt; mso-pagination: none; mso-list: l0 level1 lfo1; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 12pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA. How Prevalent Are Anxiety Disorders in Schizophrenia? A Meta-Analysis and Critical Review on a Significant Association. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19959704" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophrenia Res 2009; 114(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19695837" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cunill R, Castells X, Simeon D. Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. Journal of Clinical Psychiatry 2009; 70(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19192458" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Duggan L, Brylewski J. Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000030/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fazel S, Gulati G, Linsell L, Geddes JR, Grann M. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med 2009; 6(8).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19668362" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ferron JC et al. A review of research on smoking cessation interventions for adults with schizophrenia spectrum disorders. Mental Health and Substance Use: Dual Diagnosis 2009; 2(1):64-79.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~content=a907739376~db=all~jumptype=rss" target="_blank"&gt;Informaworld Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Furtado VA, Srihan V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005377/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gustafsson C, Ojehagen A, Hansson L et al. Effects of psychosocial interventions for people with intellectual disabilities and mental health problems: a survey of systematic reviews. Research on Social Work Practice 2009; 19(3): 281-291.&lt;BR&gt;[&lt;A href="http://rsw.sagepub.com/cgi/content/abstract/19/3/281" target="_blank"&gt;Sage Journals Online Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hesdorffer DC, Rauch SL, Tamminga CA. Long-term psychiatric outcomes following traumatic brain injury: a review of the literature. Journal of Head Trauma Rehabilitation 2009; 24(6): 452-9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19940678" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oud MJ, Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Family Practice 2009; 10: 32.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19426545" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344947</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344947]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Complementary and Alternative Therapies</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,COMPLEMENTARY AND ALTERNATIVE MEDICINE,SCHIZOPHRENIA,CONDITIONS A-Z,CONDITIONS S,APRIL 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Complementary and Alternative Therapies&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Agarwal V, Abhijnhan A, Raviraj P. Ayurvedic medicine for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006867/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Complementary medicines in mental health. Evidence Based Mental Health Journal 2009; 12(1).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/1.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gold C, Solli HP, Kruger V, Lie SA. Dose-response relationship in music therapy for people with serious mental disorders: systematic review and meta-analysis. Clinical Psychology Review 2009; 29(3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19269725" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hollywell C, Walker J. Private prayer as a suitable intervention for hospitalised patients: A critical review of the literature. Journal of Clinical Nursing 2009; 18(5):637-651.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19077024" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Izquierdo de Santiago A, Khan M. Hypnosis for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004160/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lee MS, Shin BC, Ronan P, Ernst E. Acupuncture for schizophrenia: a systematic review and meta-analysis. International Journal of Clinical Practice 2009; 63(11).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19832819" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roine E, Roine RP, Rasanen P, Vuori I, Sintonen H, Saarto T. Cost-effectiveness of interventions based on physical exercise in the treatment of various diseases: a systematic literature review. International Journal of Technology Assessment Health Care 2009; 25(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19845974" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. International Journal of Neuropsychopharmacology 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19775502" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Xia J Grant TJ. Dance therapy for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006868/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344877</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344877]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Contents</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,CLINICAL LIBRARY,PSYCHIATRY,MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,SCHIZOPHRENIA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Contents&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;The Schizophrenia Annual Evidence Update 2010 brings together evidence-based guidelines, systematic reviews, evidence summaries, care pathways and service development literature.&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;The Annual Evidence Update has been carried out using &lt;A href="nelh:344972:1" name=internalLink&gt;this methodology&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Contents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Introductory Material&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:345136:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344920:1" name=internalLink&gt;Epidemiology and pathology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344922:1" name=internalLink&gt;Incidence and prevalence&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344924:1" name=internalLink&gt;UK treatment guidelines and international guidelines&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344926:1" name=internalLink&gt;Key reports and resources&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;2. &lt;A href="nelh:344927:1" name=internalLink&gt;Risk factors&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;3. &lt;A href="nelh:344928:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;4. Treatment&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:344934:1" name=internalLink&gt;Early intervention&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344930:1" name=internalLink&gt;Antipsychotics - 1st generation (typical)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344940:1" name=internalLink&gt;Antipsychotics - 2nd generation (atypical)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344941:1" name=internalLink&gt;Depot antipsychotic injections&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344946:1" name=internalLink&gt;Other drug treatments&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344947:1" name=internalLink&gt;Complementary and alternative therapies&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344948:1" name=internalLink&gt;Psychosocial interventions&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:344949:1" name=internalLink&gt;Other treatments&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;5. &lt;A href="nelh:344951:1" name=internalLink&gt;Prognosis&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;6. &lt;A href="nelh:344952:1" name=internalLink&gt;Populations and settings&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. &lt;A href="nelh:344962:1" name=internalLink&gt;Comorbidity&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;8. &lt;A href="nelh:344963:1" name=internalLink&gt;Dual diagnosis&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;9. &lt;A href="nelh:344965:1" name=internalLink&gt;Health economics&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;10. &lt;A href="nelh:344969:1" name=internalLink&gt;Health service provision&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/mentalhealth/DuetsSubmissionForm.aspx" target="_blank"&gt;If you have an unanswered mental health question, please complete the Database of Uncertainties about the Effects of Treatments form (DUETs).&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;Please &lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/mentalHealth/ContactUs.aspx" target="_blank"&gt;&lt;STRONG&gt;contact us&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt; if you have any comments to make about the Schizophrenia Annual Evidence Update 2010.&lt;/STRONG&gt; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344941</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344941]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Depot Antipsychotic Injections</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Depot Antipsychotic Injections&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Abhijnhan A, Adams CE, David A, Ozbilen M. Depot fluspirilene for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001718/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Citrome L. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. International Journal of Clinical Practice 2009; 64(2):216-39.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19886879" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;David A, Quraishi SN, Rathbone J. Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001717/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dinesh M, David A, Quraishi. Depot pipotiazine palmitate and undecylenate for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001720/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fernandez Sanchez A, Pinto-Meza A, Maria Haro J. Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral pharmaceutical forms of atypical and conventional antipsychotics used in Spain for treating patients with schizophrenia. Revista De Psiquiatria y Salud Mental 2009; 2(1):5-28.&lt;BR&gt;[&lt;A href="http://www.elsevier.es/watermark/ctl_servlet?_f=10&amp;amp;pident_articulo=13135774&amp;amp;pident_usuario=0&amp;amp;pcontactid=&amp;amp;pident_revista=286&amp;amp;ty=67&amp;amp;accion=L&amp;amp;origen=elsevier&amp;amp;web=www.elsevier.es&amp;amp;lan=en&amp;amp;fichero=286v02n01a13135774pdf001_2.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fleischhacker WW. Second-generation antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry 2009; 195(Suppl. 52):S29-S36.&lt;BR&gt;[&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/195/52/S29" target="_blank"&gt;BJPsych Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. British Journal of Psychiatry 2009; 195(Suppl. 52):S20-S28.&lt;BR&gt;[&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/195/52/S20" target="_blank"&gt;BJPsych Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Waddell L, TM. Attitudes of patients and mental health staff to antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry 2009; 195(Suppl.52):S43-S50.&lt;BR&gt;[&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/195/52/S43" target="_blank"&gt;BJPsych Abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344928</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344928]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Diagnosis</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The wide variation in presentation, course and outcome in schizophrenia may reflect an underlying variation in the nature of the disorder, or even that schizophrenia is a cluster of different disorders with variable courses and outcomes. Equally, this variation may result from a complex interaction between biological, social, psychological, cultural and economic factors. Several models to explain this heterogeneity have been proposed, although none has been widely accepted. Moreover, prior to the establishment of diagnostic systems such as the Diagnostic and Statistical Manual of Mental Disorders and the International Statistical Classification of Diseases and Related Health Problems, large variations in the incidence and prevalence of the disorder were reported. While DSM, ICD and similar systems have improved the reliability and consistency of diagnosis, considerable controversy exists as to whether a diagnosis of schizophrenia really represents a single underlying disorder.&amp;nbsp; &lt;BR&gt;&amp;nbsp;&lt;BR&gt;Both ICD-10 and DSM-IV agree on the symptom clusters that confirm a diagnosis of schizophrenia. There are three main domains, including: psychotic symptoms such as certain types of auditory hallucinations (hearing voices), delusions (‘paranoia’, ‘telepathy’) and thought disorder (incomprehensible speech); negative symptoms such as poor self care, reduced motivation, reduced ability to experience pleasure, alogia (reduced production of thought) and affective blunting (lack of emotional expression); reduced social functioning and the rarer symptom of catatonia. ICD-10 requires that at least one such diagnostic symptom from one of the 3 domains should be clearly present for 1 month. ICD-10 also confirms the diagnosis if two of these symptoms have been present in a less clear manner over the same time frame. The diagnosis is not made in the presence of prominent mood symptoms such as depression or mania. In DSM-IV there is agreement with ICD-10 that diagnostic symptoms need to be present for at least 1 month. It also stipulates that there should be evidence of ongoing symptoms persisting for at least 6 months. &lt;/P&gt;
&lt;P&gt;The uncertainty about diagnosis, and consequently its limited predictive validity, raises a number of important issues for service users. First, many clinicians in both primary and secondary care are reluctant to give this diagnosis, sometimes making it more difficult for people and their families to receive help early on. Second, some service users are reluctant to accept the diagnosis, and may reject suggestions that schizophrenia is an illness in need of treatment. Third, to receive a diagnosis of schizophrenia, with the stigma that this entails, seems to some a heavy price to pay given the diagnostic uncertainties that exist. Finally, some people diagnosed with schizophrenia object to receiving compulsory treatment for what they regard as no more than a putative illness.&amp;nbsp; &lt;BR&gt;&amp;nbsp;&lt;BR&gt;That there are genuine problems with the diagnosis and classification of schizophrenia is not at question. However, for many people so diagnosed, the frequently painful and frightening experiences of schizophrenia and the disability often associated with it, with or without the diagnosis. Moreover, to improve treatments and services for this group of people would be difficult without an operational diagnostic category with which to undertake research, and to allocate resources on the basis of proven need. Despite this practical requirement for diagnostic categories, caution is necessary, to avoid making overly simplistic prognostications for individual service users. Professionals also have a duty to provide good, clear and honest information regarding schizophrenia, and about the treatments and services available.&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bora E, Yucel M, Pantelis C. Theory of mind impairment in schizophrenia: meta-analysis. Schizophrenia Research 2009; 109(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19195844" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chang W-C, Chan SSM, Chung DWS. Diagnostic stability of functional psychosis: A systematic review. Hong Kong Journal of Psychiatry 2009; 19(1):30-41.&lt;BR&gt;[&lt;A href="http://findarticles.com/p/articles/mi_6882/is_1_19/ai_n31484084/" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cohen AS, Brown LA, Minor KS. The psychiatric symptomatology of deficit schizophrenia: A meta-analysis. Schizophrenia Research 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19887305" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dominguez Mde G, Viechtbauer W, Simons CJ, Van Os J, Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychology Bulletin 2009; 135(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19210058" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Farooq S, Large M, Nielssen O, Waheed W. The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis. Schizophrenia Research 2009; 109(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19233621" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23(3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19413446" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pappa S, Dazzan P. Spontaneous movement disorders i&lt;BR&gt;n antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychological Medicine 2009; 39(7).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19000340" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. The Journal of Clinical Psychiatry 2009; 70(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19026265" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344963</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344963]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Dual Diagnosis</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Dual Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;&lt;SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 12pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;
&lt;OL&gt;
&lt;LI&gt;Carra G, Johnson S. Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review. Social Psychiatry and Psychiatric Epidemiology 2009; 44(6):429-47.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19011722" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cleary M, Hunt GE, Matheson S, Walter G. Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: Systematic review. Journal of Advanced Nursing 2009; 65(2):238-258.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19016921" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Edward K-L, Munro I. Nursing considerations for dual diagnosis in mental health.&amp;nbsp; International Journal of Nursing Practice 2009; 15(2):74-79.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19335524" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hjorthoj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders--a systematic review. Addictive Behaviors 2009; 34(10):6-7.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19268481" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J. Prevalence of alcohol use disorders in schizophrenia-a systematic review and meta-analysis. Acta Psychiatrica Scandinavica 2009; 120(2):85-96.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19374633" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19386576" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: Systematic review of comparative studies. British Journal of Psychiatry 2009; 194(6):491-499).&lt;BR&gt;[&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/194/6/491" target="_blank"&gt;BJPsych Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344934</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344934]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Early Intervention</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Early Intervention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;De Koning MB, Bloemen O et al. Early intervention in patients at ultra high risk of psychosis: Benefits and risks. Acta Psychiatrica Scandinavica 2009; 119(6):426-442.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19392813" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NIMHE. Report on early detection and intervention for young people at risk of psychosis. NIMHE 2008.&lt;BR&gt;[&lt;A href="http://jan-net.co.uk/archive/early-intervention-in-psychosis-full-reportpdf-.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. The British Journal of Psychiatry 2009; 195(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19794194" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344920</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344920]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Epidemiology and Pathology</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Epidemiology and Pathology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. People admitted to psychiatric hospitals commonly lack the mental capacity to make treatment decisions. Evidence Based Mental Health Journal 2009.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/31.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Large M, Smith G, Nielssen O. The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis. Schizophrenia Research 2009; 112(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19457644" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oud MJ, Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Family Practice 2009; 10.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19426545" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychological Medicine 2009; 39(7).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19000340" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophrenia Research 2009; 113(2-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19608386" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. British Journal of Psychiatry 2009; 195(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19794194" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Richard-Devantoy S, Olie JP, Gourevitch R. Risk of homicide and major mental disorders: A critical review. Encephale 2009; 35(6).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20004282" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sirdifield C, Gojkovic D, Brooker C, Ferriter M. A systematic review of research on the epidemiology of mental health disorders in prison populations: A summary of findings. Journal of Forensic Psychiatry &amp;amp; Psychology 2009; 20(suppl 1): 78-101.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~content=a909964411~db=all~order=page" target="_blank"&gt;Informaworld Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Startup M, Bucci S, Langdon R. Delusions of reference: A new theoretical model. Cognitive Neuropsychiatry 2009; 14(2):110-126.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~content=a910442134~db=all~jumptype=rss" target="_blank"&gt;Informaworld Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychological Medicine 2009; 39(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18606047" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Snellenberg JX, de Candia T. Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Archives General Psychiatry 2009; 66(7).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19581566" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wang Y, Cui J, Chan RC et al. Meta-analysis of prospective memory in schizophrenia: nature, extent, and correlates. Schizophrenia Research 2009; 114(1-3):64-70.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19713081" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 2009; 113(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19524406" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Yanos PT, Stanley BS, Greene CS. Research risk for persons with psychiatric disorders: a decisional framework to meet the ethical challenge. Psychiatric Services 2009; 60(3).&lt;BR&gt;[&lt;A href="http://psychservices.psychiatryonline.org/cgi/content/abstract/60/3/374" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344965</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344965]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Health Economics</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Health Economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fernandez Sanchez A, Pinto-Meza A,&amp;nbsp; Maria Haro J. Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral pharmaceutical forms of atypical and conventional antipsychotics used in Spain for treating patients with schizophrenia. Revista De Psiquiatria y Salud Mental 2009; 2(1):5-28.&lt;BR&gt;[&lt;A href="http://www.elsevier.es/watermark/ctl_servlet?_f=10&amp;amp;pident_articulo=13135774&amp;amp;pident_usuario=0&amp;amp;pcontactid=&amp;amp;pident_revista=286&amp;amp;ty=67&amp;amp;accion=L&amp;amp;origen=elsevier&amp;amp;web=www.elsevier.es&amp;amp;lan=en&amp;amp;fichero=286v02n01a13135774pdf001_2.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Kisely SR, Campbell LA, Preston NJ. Compulsory community and involuntary outpatient treatment for people with severe mental disorders. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004408/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Konnopka A, Klingberg S, Wittorf A, Konig HH. The cost of schizophrenia in Germany: a systematic review of the literature. Psychiatrishe Praxis 2009; 36(5):211-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19437382" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roine E, Roine RP, Rasanen P, Vuori I, Sintonen H, Saarto T. Cost-effectiveness of interventions based on physical exercise in the treatment of various diseases: a systematic literature review. International Journal of Technology Assessment in Health Care 2009; 25(4):427-54.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19845974" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344969</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344969]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Health Service Provision</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Health Service Provision&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Alwan N, Johnstone P, Zolese G. Length of hospitalisation for people with severe mental illness. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000384/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bhoopathi PSS, Sheoran R. Educational games for mental health professionals. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001471/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Devantoy RS, Olie JP, Gourevitch R. Risk of homicide and major mental disorders: A critical review. Encephale 2009; 35(6):521-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20004282" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Limited evidence to support specialist mental health services as alternatives to inpatient care for young people with severe mental health disorders. Evidence Based Mental Health Journal 2009; 12 (4).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/117.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Hickling FW, Abel W, Garner P, Rathbone J. Open general medical wards versus specialist psychiatric units for acute psychoses. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003290/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irving CB, Adams CE, Rice K. Crisis intervention for people with severe mental illnesses. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001087/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kisely SR, Campbell LA, Preston NJ. Compulsory community and involuntary outpatient treatment for people with severe mental disorders. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004408/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Knaup C, Koesters M, Schoefer D, Becker T, Puschner B. Effect of feedback of treatment outcome in specialist mental healthcare: Meta-analysis. British Journal of Psychiatry 2009; 195(1):15-22.&lt;BR&gt;[&lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/195/1/15" target="_blank"&gt;BJPsych Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Lamb CE. Alternatives to admission for children and adolescents: providing intensive mental healthcare services at home and in communities: what works? Current Opinion Psychiatry 2009; 22(4):345-50.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19461516" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leff HS, Chow CM et al. Does one size fit all? What we can and can't learn from a meta-analysis of housing models for persons with mental illness. Psychiatric Services 2009; 60(4):473-482.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19339322" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Lohonen J, Isohanni M, Nieminen P, Miettunen J. Coverage of the bibliographic databases in mental health research. Nordic Journal of Psychiatry 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19883199" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Macpherson R, Edwards TR, Chilvers R, David C, Elliott HJ. Twenty-four hour care for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004409/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mansouri N, Gharaee B, Shariat SV et al. The change in attitude and knowledge of health care personnel and general population following trainings provided during integration of mental health in primary health care in Iran: A systematic review. International Journal of Mental Health Systems 2009; 25(3):1.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19555504" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Shek E, Stein AT, Shansis FM, Marshall M, Crowther R, Tyrer P. Day hospital versus outpatient care for people with schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003240/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344922</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344922]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Incidence and Prevalence</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Incidence and Prevalence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:1" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Schizophrenia is a relatively common illness, and it is certainly the most common form of psychotic disorder. The mean incidence of schizophrenia reported in epidemiological studies, when the diagnosis is limited to core criteria and corrected for age, is 0.11 per 1000 (range 0.07–0.17 per 1000); if broader criteria are used, this figure doubles to 0.24 per 1000 (range 0.07–0.52 per 1000). Average rates for men and women are similar, although the mean age of onset is about 5 years greater in women (hence a lower female rate in adolescence), with a second smaller peak after the menopause. The lifetime prevalence of schizophrenia is between 0.4% and 1.4%. The National Survey of Psychiatric Morbidity in the UK found a population prevalence of probable psychotic disorder of 5 per 1000 in the age group 16–74 years.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Attanayake V, McKay R, Joffres M, Singh S, Burkle F Jr, Mills E. Prevalence of mental disorders among children exposed to war: a systematic review of 7,920 children. Medicine, Conflict and Survival 2009; 25(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19413154" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chan RC, Xu T, Heinrichs RW, Yu Y, Gong QY. Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: A systematic review and meta-analysis. Neuroscience Biobehavioural Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19925825" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chan RC, Xu T, Heinrichs RW, Yu Y, Wang Y. Neurological Soft Signs in Schizophrenia: A meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19377058" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Maniglio R. Severe mental illness and criminal victimization: a systematic review. Acta Psychiatrica Scandinavica 2009; 119(3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19016668" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Michalczuk R, Mitchell A. Monetary incentives for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007626/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Oud MJ, Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Family Practice 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19426545" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. Journal of Clinical Psychopharmacology 2009; 29(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19512975" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345136</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=345136]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Introduction</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="http://www.library.nhs.uk/mentalHealth/ViewResource.aspx?resID=344877" target="_blank"&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;Schizophrenia is a major psychiatric disorder, or cluster of disorders, characterised by psychotic symptoms that alter a person’s perception, thoughts, affect, and behaviour. Each person with the disorder will have a unique combination of symptoms and experiences. Typically there is a prodromal period often characterised by some deterioration in personal functioning. This includes memory and concentration problems, unusual behaviour and ideas, disturbed communication and affect, and social withdrawal, apathy and reduced interest in daily activities. These are sometimes called ‘negative symptoms’. The prodromal period is usually followed by an acute episode marked by hallucinations, delusions, and behavioural disturbances. These are sometimes called ‘positive symptoms’, and are usually accompanied by agitation and distress. Following resolution of the acute episode, usually after pharmacological, psychological and other interventions, symptoms diminish and often disappear for many people, although sometimes a number of negative symptoms may remain. This phase, which can last for many years, may be interrupted by recurrent acute episodes, which may need additional intervention. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Although this is a common pattern, the course of schizophrenia varies considerably. Some people may have positive symptoms very briefly while others may experience them for many years. Others have no prodromal period, the disorder beginning suddenly with an acute episode. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Over a lifetime, about 1% of the population will develop schizophrenia. The first symptoms tend to start in young adulthood, but can occur at any age, usually at a time when people are trying to make the transition to independent living. The symptoms and behaviour associated with schizophrenia can have a distressing impact on family and friends. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The diagnosis of schizophrenia is still associated with considerable stigma, fear and limited public understanding. The first few years after onset can be particularly upsetting and chaotic, and there is a higher risk of suicide. Once an acute episode is over, there are often other problems such as social exclusion, with reduced opportunities to get back to work or study, and problems making new relationships.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Recently, there has been a new emphasis in services on early detection and intervention, a focus on long-term recovery and promoting people’s choices about the management of their condition. There is evidence that most people will recover, although some will have persisting difficulties or remain vulnerable to future episodes. Not everyone will accept help from statutory services. In the longer term, most people will find ways to manage acute problems, and compensate for any remaining difficulties. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Carers, relatives and friends of people with schizophrenia are important both in the process of assessment and engagement, and in the long-term successful delivery of effective treatments. This guideline uses the term ‘carer’ to apply to everyone who has regular close contact with the person with schizophrenia, including advocates, friends or family members, although some family members may choose not to be carers.&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Information extracted from: &amp;nbsp;&lt;A href="http://www.nice.org.uk/Guidance/CG82" target="_blank"&gt;NICE clinical guieline - Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. March 2009&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344926</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344926]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Key Reports and Resources</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Key Reports and Resources&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Key Reports&lt;/H2&gt;
&lt;H3&gt;Department of Health&lt;/H3&gt;
&lt;OL&gt;
&lt;LI&gt;New Horizons - Department of Health. New Horizons: towards a shared vision for mental health. Department of Health 2009. [&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_109708.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Based Mental Health Journal&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Schizophrenia and NICE: all quiet on the community front?&amp;nbsp;Evidence Based Mental Health Journal 2009.&amp;nbsp;[&lt;A href="http://ebmh.bmj.com/content/12/4/97.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;National Collaborating Centre for Mental Health&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;National Collaborating Centre for Mental Health. Psychosis with substance misuse. National Collaborating Centre for Mental Health 2009. [&lt;A href="http://www.nccmh.org.uk/downloads/Psychosis/PsychosisSubstanceMisuseFinalScope.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;The Kings Fund&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. The cost of mental health care in England to 2026. The Kings Fund 2008. [&lt;A href="http://www.kingsfund.org.uk/document.rm?id=7664" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;H2&gt;Other Useful Reports&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Castagnini A, Berrios GE. Acute and transient psychotic disorders (ICD-10 F23): A review from a European perspective. European Archives of Psychiatry and Clinical Neuroscience 2009; 259(8):433-443.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19381705" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Edwards SJ, Clarke MJ, Wordsworth S, Borrill J. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. International Journal of Clinical Practice 2009; 63(6):841-854.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19490195" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;No authorship indicated. NASMHPD report outlines capacity-building plan for physical health monitoring in the mental health system. Psychiatric Services 2009; 60(1):131.&lt;BR&gt;[&lt;A href="http://psychservices.psychiatryonline.org/cgi/content/full/60/1/131" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;H2&gt;Resources&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Map of Medicine. Chronic persistent schizophrenia. Map of Medicine 2008. [&lt;A href="http://healthguides.mapofmedicine.com/choices/map/chronic_schizophrenia1.html" target="_blank"&gt;Access to resource&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Map of Medicine. Suspected schizophrenia. Map of Medicine 2008. [&lt;A href="http://healthguides.mapofmedicine.com/choices/map/schizophrenia1.html" target="_blank"&gt;Access to resource&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;NHS Choices. Schizophrenia - understanding schizophrenia. NHS Choices&amp;nbsp; 2010. [&lt;A href="http://www.nhs.uk/pathways/schizophrenia/pages/landing.aspx" target="_blank"&gt;Access to resource&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;New Horizons - Department of Health. New Horizons 2009. [&lt;A href="http://www.newhorizons.dh.gov.uk/" target="_blank"&gt;Access to resource&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344972</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344972]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Methodology</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;The Schizophrenia Annual Evidence Update 2010 presents the results of extensive literature searches carried out to identify systematic reviews, evidence based summaries, meta-analyses and UK Treatment and International Guidelines relating to Schizophrenia published in 2009.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344946</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344946]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Other Drug Treatments</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Other Drug Treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Barnes TRE, Soares-Weiser K, Bacaltchuk J. Central action beta-blockers versys placebo for neuroleptic-induced acute akathisia. Cochrane Database of Systematic Reviews 2010;(3).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001946/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bellon A, Le Pen G, Matricon J et al. Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia. Expert Opinion on Drug Discovery 2009; 4(3):257-278.&lt;BR&gt;[&lt;A href="http://www.ingentaconnect.com/content/apl/edc/2009/00000004/00000003/art00005" target="_blank"&gt;Ingenta Connect Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Cgeine MV, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database of Systematic Reviews 2009, (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000234/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Chua WLLC, Izquierdo de Santiago A et al. Estrogen for schziophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004719/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Brief interventions, gradual dose reduction and psychological interventions increase benzodiazepine cessation compared with routine care. Evidence Based Mental Health Journal 2009; 12.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/91.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Lamotrigine may be an effective treatment for clozapine resistent schizophrenia. Evidence Based Mental Health Journal 2009; 12.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/111.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Huf G, Alexander J, Allen MH, Raveendran NS. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Systematic Reviews 2009; (3).&lt;BR&gt;[&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005146/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jung XT, Newton R. Cochrane Reviews of non-medication-based psychotherapeutic and other interventions for schizophrenia, psychosis, and bipolar disorder: A systematic literature review. International Journal of Mental Health Nursing 2009; 18(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19594644" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor-induced akathisia. Journal of the American Pharmacists Association 2009; 49(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19289334" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kumar A, Strech D. Zuclopenthixol Dihydrochloride for schizophrenia. Schizophrenia Bulletin 2009; 35(5):855-856.&lt;BR&gt;[&lt;A href="http://schizophreniabulletin.oxfordjournals.org/cgi/content/extract/sbp077v1" target="_blank"&gt;Schizophrenia Bulletin Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001258/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. Journal of Clinical Psychopharmacology 2009; 29(2):141-6.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19512975" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Paranthaman Sethupathi B, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systemtic Reviews 2010; (3).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000205/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rathbone J, Deeks JJ, Soares-Weiser K. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000203/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003727/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tiihonen J Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003730/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2009; 109(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19186030" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006391/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Xiaomeng L, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007778/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344949</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344949]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Other Treatments</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Other Treatments&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Arnone D, Cavanagh J, Gerber D, Lawrie SM, Ebmeier KP, McIntosh AM. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. British Journal of Psychiatry 2009; 195(3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19721106" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Campbell LA, Kisely SR. Advance treatment directives for people with severe mental illness. Cochrane Database of Systematic Reviews 2010; 3.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005963/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 2009; 35(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18417466" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health. Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia. Evidence Based Mental Health 2009.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/55.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophrenia Research 2009; 108(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19138833" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Galderisi S, Mucci A, Volpe U, Boutros N. Evidence-based medicine and electrophysiology in schizophrenia. Clinical EEG and Neuroscience 2009; 40(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19534300" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irving CB, Mumby-Croft R, Joy LA. Polyunsaturated fatt acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews 2010; 3.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001257/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kantrowitz JT, Citrome L, Javitt DC. A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophrenia. Clinical Therapeutics 2009; 31(Pt 1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19698899" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). Clinical Evidence (Online) 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19445748" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2010; 3.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000076/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tungpunkom P, Nicol M. Life skills programmes for chronic mental ilnesses. Cochrane Database of Systematic Reviews 2010, 3.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000381/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Varga E, Tenyi T, Simon M, Fekete S, Herold R. Exploration of mentalizing skills with functional imaging methods in schizophrenia: a systematic review. Psychiatric Hungarian 2009; 24(2).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19667422" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344952</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344952]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Populations and Settings</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Populations and Settings&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Children and Adolescents&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Antipsychotic prescriptions for children and adolescents in the UK increased from 1993 to 2005. Evidence Based Mental Health Journal 2009; 12(1).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/30.extract" target="_blank"&gt;EBMH Journal&amp;nbsp;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Individual placement and support improves employment of young people with first episode psychosis. Evidence Based Mental Health Journal 2009; 12(2).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/53.extract" target="_blank"&gt;EBMH Journal&amp;nbsp;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Schizophrenia in either parent increases risk of infant mortality.&amp;nbsp; Evidence Based Mental Health Journal 2009; 12(3).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/94.extract" target="_blank"&gt;EBMH Journal&amp;nbsp;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004027/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. British Journal of Psychiatry 2009; 195(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19794194" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Roke Y, VHP, N et al. Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. Journal of Child and Adolescent Psychopharmacology 2009; 19(4): 403-414.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19702492" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Criminal Behaviour&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Fazel S, Yu R. Psychotic Disorders and Repeat Offending: Systematic Review and Meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19959703" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Maniglio R. Severe mental illness and criminal victimization: a systematic review. Acta Psychiatrica Scandinavica 2009; 119(3): 180-91.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19016668" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Sirdifield C, Gojkovic D, Brooker C, Ferriter M.&amp;nbsp; A systematic review of research on the epidemiology of mental health disorders in prison populations: A summary of findings. Journal of Forensic Psychiatry &amp;amp; Psychology 2009; 20(Suppl1):S78-S101.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~content=a909964411~db=all~order=page" target="_blank"&gt;Informaworld Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Women&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Digirolamo A, M,&amp;nbsp; R-ZM. Role of zinc in maternal and child mental health. American Journal of Clinical Nutrition 2009; 89(3): 940S-945S. &lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19176735" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia. Evidence Based Mental Health Journal 2009; 12(2).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/55.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Schizophrenia in either parent increases risk of infant mortality.&amp;nbsp; Evidence Based Mental Health Journal 2009; 12(3).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/94.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breastfeeding: A review of the evidence. Pediatrics 2009; 124(4): E547-E556.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19736267" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Irving CB SM. Mother and baby units for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4).&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006333/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Matevosyan NR. Reproductive health in women with serious mental illness: A review. Sexuality and Disability 2009; 27(2): 109-118.&lt;BR&gt;[&lt;A href="http://www.springerlink.com/content/q63208p224674201/" target="_blank"&gt;Springer Link Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Selten JP, Frissen A, Lensvelt-Mulders G, Morgan VA. Schizophrenia and 1957 pandemic of influenza: Meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19959706" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wildgust HJ, Kohen D. Impact of hyperprolactinaemia on the general health of patients with schizophrenia. Effects of Psychotropic Drugs 2009; 116-128.&lt;BR&gt;[&lt;A href="http://content.karger.com/ProdukteDB/produkte.asp?Doi=189779" target="_blank"&gt;Abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Caregivers&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chien WT, Norman I. The effectiveness and active ingredients of mutual support groups for family caregivers of people with psychotic disorders: a literature review. International Journal of Nursing Studies 2009; 46(12).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19481205" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mattila E, Leino K, Paavilainen E, Astedt-Kurki P. Nursing intervention studies on patients and family members: a systematic literature review. Scandinavian Journal of Caring Sciences 2009; 23(3): 611-622.&lt;BR&gt;[&lt;A href="http://www3.interscience.wiley.com/journal/122464716/abstract" target="_blank"&gt;Wiley Interscience Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Taylor TL, Killaspy H, Wright C et al. A systematic review of the international published literature relating to quality of institutional care for people with longer term mental health problems. BMC Psychiatry 2009; 9.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19735562" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Workplace&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Corbiere M, Shen J, Rouleau M, Dewa CS. A systematic review of preventive interventions regarding mental health issues in organizations. Work: Journal of Prevention, Assessment &amp;amp; Rehabilitation 2009; 33(1):81-116.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19597288" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;] &lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344951</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344951]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Prognosis</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Prognosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Historically, many psychiatrists and other healthcare professionals have taken a pessimistic view of the prognosis for schizophrenia, regarding it as a severe, intractable and often deteriorating lifelong illness. This negative view has failed to find confirmation from long-term follow-up studies, which have demonstrated considerable variations in long-term outcome. While it is estimated that around three quarters of people with schizophrenia will suffer recurrent relapse and some continued disability, the findings of follow-up studies over periods of 20 to 40 years suggest that there is a moderately good long-term global outcome in over half of people with schizophrenia, with a smaller proportion having extended periods of remission of symptoms without further relapses. It should also be noted that some people who never experience complete recovery from their experiences nonetheless manage to sustain an acceptable quality of life if given adequate support and help.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Crowther R, Marshall M, Bond GR, Huxley P. Vocational rehabilitation for people with severe mental illness. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003080/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia. Evidence Based Mental Health Journal 2009; 12(2).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/43.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Parental violent crime, previous violence and substance abuse predict future violence in people with schizophrenia. Evidence Based Mental Health Journal 2009; 12(4).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/4/127.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Farooq S, Large M, Nielssen O, Waheed W. The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis. Schizophrenia Research 2009; 109(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19233621" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Fazel S, Yu R. Psychotic disorders and repeat offending: systematic review and meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19959703" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Phillips LJ, Francey SM, Edwards J, McMurray N.&amp;nbsp; Strategies used by psychotic individuals to cope with life stress and symptoms of illness: a systematic review. Anxiety Stress Coping 2009; 22(4).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19333796" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). Clinical Evidence (Online) 2009; 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19445748" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19946012" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weinmann S. More high quality studies needed to determine the effects on patient outcomes of psychiatric care guideline implementation.&amp;nbsp; Evidence Based Mental Health Journal 2009; 11.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/11/1/21.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 2009; 113(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19524406" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344948</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344948]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Psychosocial Interventions</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Psychosocial Interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NICE guidance suggests 3 types of psychological and psychosocial intervention for people with schizophrenia and their families:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Offer cognitive behavioural therapy (CBT) to all people with schizophrenia. This can be started either during the acute phase&amp;nbsp;or later, including in inpatient settings.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Offer family intervention to all families of people with schizophrenia who live with or are in close contact with the service user. This can be started either during the acute phase or later, including in inpatient settings.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Consider offering arts therapies to all people with schizophrenia, particularly for the alleviation of negative symptoms. This can be started either during the acute phase or later, including in inpatient settings.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;OL&gt;
&lt;LI&gt;Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: A systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19900962" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Drymalski WM, Campbell TC. A review of motivational interviewing to enhance adherence to antipsychotic medication in patients with schizophrenia: Evidence and recommendations. Journal of Mental Health 2009; 18(1):6-15.&lt;BR&gt;[&lt;A href="http://www.informaworld.com/smpp/content~db=all~content=a904724736~tab=content" target="_blank"&gt;Informaworld Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Brief interventions, gradual dose reduction and psychological interventions increase benzodiazepine cessation compared with routine care. Evidence Based Mental Health Journal 2009; 12.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/91.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. CBT does not improve relapse rates in peopled with recently relapsed psychosis. Evidence Based Mental Health Journal 2009; 12(14).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/1/14.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Long term psychodynamic psychotherapy improves outcomes in people with complex mental disorders. Evidence Based Mental Health 2009; 12.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/56.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Non-pharmacological interventions reduce antipsychotic induced weight gain. Evidence Based Mental Health Journal 2009; 12.&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/2/52.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Jordans MJD, Tol WA et al. Systematic review of evidence and treatment approaches: Psychosocial and mental health care for children in war. Child and Adolescent Mental Health 2009; 14(1):2-14.&lt;BR&gt;[&lt;A href="http://www3.interscience.wiley.com/journal/121640809/abstract" target="_blank"&gt;Wiley Interscience Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Malmberg L, Fenton M, Rathbone J. Individual psychodynamic psychotherapy&amp;nbsp;and psychoanalysis for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001360/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database of Systematic Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000088/frame.html" target="_blank"&gt;Cochrane Abstract&lt;/A&gt;] &lt;/LI&gt;
&lt;LI&gt;Sablier J, Stip E, Franck N. Cognitive remediation and cognitive assistive technologies in schizophrenia. Encephale 2009; 35(2):160-167. [Article in French]&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19393385" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). Clinical Evidence (Online) 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19445748" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van Os J. Schizophrenia treatment: Content versus delivery. Acta Psychiatrica Scandinavica 2009; 119(Suppl. 438):29-32.&lt;BR&gt;[&lt;A href="http://www3.interscience.wiley.com/journal/121557095/abstract" target="_blank"&gt;Wiley Interscience&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ventegodt S, Merrick J. A review of side effects and adverse events of non-drug medicine (Nonpharmaceutical complementary and alternative medicine): Psychotherapy, mind-body medicine and clinical holistic medicine. Journal of Complementary and Integrative Medicine 2009; 6(1):16.&lt;BR&gt;[&lt;A href="http://www.bepress.com/jcim/vol6/iss1/16/" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Wobrock T, Soyka M. Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opinion Pharmacotherapy 2009; 10(3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19191675" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344927</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344927]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: Risk Factors</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: Risk Factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The possible causes of schizophrenia are not well understood. Research has attempted to determine the causal role of biological, psychological and social factors. The evidence does not point to any single cause. Increasingly, it is thought that schizophrenia and related psychoses result instead from a complex interaction of multiple factors. Much of the research evidence on the aetiology of schizophrenia is consistent with the long-standing 'stress-vulnerability' model. This paradigm suggests that individuals possess different levels of vulnerability to schizophrenia, which are determined by a combination of biological, social and psychological factors. It is proposed that vulnerability results in the development of problems only when environmental stressors are present. If there is great vulnerability, relatively low levels of stress might be sufficient to cause problems. If there is less vulnerability, problems develop only with higher levels of stress. The model is consistent with a wide variety of putative causes of the disorder, as well as the differential relapse and readmission rates observed among people with schizophrenia.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This section has been&amp;nbsp;divided up into&amp;nbsp;4 categories:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Genetic Risk Factors&lt;/LI&gt;
&lt;LI&gt;Neuropsychological Risk Factors&lt;/LI&gt;
&lt;LI&gt;Cognitive Risk Factors&lt;/LI&gt;
&lt;LI&gt;Other Risk Factors&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Genetic Risk Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bousman CA, Glatt SJ, Everall IP, Tsuang MT. Genetic association studies of methamphetamine use disorders: A systematic review and synthesis. American Journal of Medical Genetics Part B 2009; 150B(8).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19219857" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dinan TG. MicroRNAs as a target for novel antipsychotics: a systematic review of an emerging field. International Journal of Neuropsychopharmacology 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19849891" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Gong YG, Wu CN, Xing QH, Zhao XZ, Zhu J, He L. A two-method meta-analysis of Neuregulin 1(NRG1) association and heterogeneity in schizophrenia. Schizophrenia Research 2009; 111(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19362450" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Maher BS, Reimers MA, Riley BP, Kendler KS. Allelic Heterogeneity in Genetic Association Meta-Analysis: An Application to DTNBP1 and Schizophrenia. Human Heredity 2009; 69(2):71-79.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19996605" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophrenia Research 2009; 113(2-3):181-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19608386" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tan GM, Arnone D, McIntosh AM, Ebmeier KP. Meta-analysis of magnetic resonance imaging studies in chromosome 22q11.2 deletion syndrome (velocardiofacial syndrome). Schizophrenia Research 2009; 115(2-3):173-81.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19819113" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Zai CC, Tiwari AK, Basile V et al. Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Progress in Neuropsychopharmacology &amp;amp; Biological Psychiatry 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19778569" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Important&amp;nbsp;review articles relating to Genetic Risk&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Psychiatric GWAS Consortium Coordinating Committe, Cichon S, Craddock N, Daly M et al. Genomewide association studies: history, rationae, and prospects fpr psychiatric disorders. American Journal of Psychiatry 2009; 166(5):540-56. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19339359" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;The role of genetics in the etiology of schizophrenia. The Psychiatric clinics of North America 2010 33(1):35-66.&amp;nbsp;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20159339" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Neuropsychological Risk Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Broyd SJ, Demanuele C, Debener S et al. Default-mode brain dysfunction in mental disorders: A systematic review. Neuroscience and Biobehavioral Reviews 2009; 33(3):279-296.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18824195" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Dominguez Mde G, Viechtbauer W, Simons CJ, Van Os J, Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychological Bull 2009; 135(1):157-71.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19210058" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophrenia Research 2009; 108(1-3).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19128945" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. Psychological Medicine 2009; 39(6):889-905.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18945379" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Goulet K, Deschamps B, Evoy F, Trudel JF. Use of brain imaging (computed tomography and magnetic resonance imaging) in first-episode psychosis: Review and retrospective study. Canadian Journal of Psychiatry 2009; 54(7):493-501.&lt;BR&gt;[&lt;A href="http://www.biomedsearch.com/nih/Use-brain-imaging-computed-tomography/19660172.html" target="_blank"&gt;Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23(3):315-36.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19413446" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 2009; 39(11):1763-77.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19338710" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Van der Meer L, Costafreda S, Aleman A, David AS. Self-reflection and the brain: A theoretical review and meta-analysis of neuroimaging studies with implications for schizophrenia. Neuroscience and Biobehavioral Reviews 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20015455" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Varga E, Tenyi T, Simon M, Fekete S, Herold R. Exploration of mentalizing skills with functional imaging methods in schizophrenia: a systematic review [Article in Hungarian]. Psychiatria Hungarica 2009; 24(2);108-23.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19667422" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI style="TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0cm 0cm 12pt; mso-pagination: none; mso-list: l0 level1 lfo1; mso-layout-grid-align: none" class=MsoNormal&gt;Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophrenia Research 2009; 113(2-3):189-99.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19628375" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Cognitive Risk Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bonnot O, Anderson GM, Cohen D, Willer JC, Tordjman S. Are patients with schizophrenia insensitive to pain? A reconsideration of the question. The Clinical Journal of Pain 2009; 25(3):244-252.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19333176" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Bora E, Yucel M, Pantelis C. Cognitive impairment in affective psychoses: a meta-analysis. Schizophrenia Bulletin 2010; 36(1).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19767349" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Doughty OJ, Done DJ. Is semantic memory impaired in schizophrenia? A systematic review and meta-analysis of 91 studies. Cognitive Neuropsychiatry 2009; 14(6).&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19894144" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Guilera G, Pino O, Gomez-Benito J, Rojo J, Emilio. Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials. The European Journal of Psychiatry 2009; 23(2):77-89.&lt;BR&gt;[&lt;A href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;amp;pid=S0213-61632009000200002&amp;amp;lng=es&amp;amp;nrm=iso" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Marronaro M, Riccardi I, Pacifico R et al. Cognitive remediation: Beyond psychosis? Italian Journal of Psychopathology 2009; 15(1):13-24.&lt;BR&gt;[&lt;A href="http://www.gipsicopatol.it/italiano/rivista/2009/vol15-1/Rossi.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. Journal of Clinical Psychiatry 2009; 70(1):104-12.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19026265" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Other Risk Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Dekker N, Linszen DH, De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 2009; 42(6):350-360.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19752588" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Devantoy RS, Olie JP, Gourevitch R. Risk of homicide and major mental disorders: A critical review [article in french]. Encephale 2009; 35(6):521-30.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20004282" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Douglas KS, Guy LS, Hart SD. Psychosis as a risk factor for violence to others: a meta-analysis. Psychological Bulletin 2009; 135(5):679-706.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19702378" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Evidence Based Mental Health Journal. Typical and atypical antipsychotics increase risk of sudden cardiac death.&amp;nbsp; Evidence Based Mental Health Journal 2009; 12(3).&lt;BR&gt;[&lt;A href="http://ebmh.bmj.com/content/12/3/92.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophrenia Research 2009; 113(2-3):181-8.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19608386" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Selten JP, Frissen A, Lensvelt-Mulders G, Morgan VA. Schizophrenia and 1957 Pandemic of Influenza: Meta-analysis. Schizophrenia Bulletin 2009.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19959706" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Tenback DE, Van Harten PN, Van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Movement Disorders 2009; 24(16):2309-15.&lt;BR&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19645070" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344924</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=344924]]&gt;</url>
    <title>Schizophrenia Annual Evidence Update 2010: UK Treatment Guidelines and International Guidelines</title>
    <publicationDate>2010-04-12T00:00:00</publicationDate>
    <publisher>NHS Evidence - mental health</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schizophrenia Annual Evidence Update 2010: UK Treatment Guidelines and International Guidelines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;A href="nelh:344877:0" name=internalLink&gt;Back to Schizophrenia Annual Evidence Update 2010: Contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Influential Guidelines from 2005-2010&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;UK Treatment Guidelines&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;British National Formulary&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;British National Formulary. &lt;A href="nelh:313810:1" name=internalLink&gt;Treatment of dry mouth&lt;/A&gt;. British National Formulary 2009. [&lt;A href="http://bnf.org/bnf/bnf/current/login.htm?uri=http%3A%2F%2Fbnf.org%2Fbnf%2Fbnf%2Fcurrent%2F29680.htm" target="_blank"&gt;Payment required to access Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;British Psychological Society&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;British Psychological Society. &lt;A href="nelh:277077:1" name=internalLink&gt;Best interests guidance on determining the best interests of asults who lack the capacity to make a decision (or decisions) for themselves&lt;/A&gt;. British Psychological Society 2007. [&lt;A href="http://www.bps.org.uk/downloadfile.cfm?file_uuid=448A2D24-1143-DFD0-7E4B-5FA0B872E9C1&amp;amp;ext=pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;CKS&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;CKS. &lt;A href="nelh:105221:1" name=internalLink&gt;Schizophrenia&lt;/A&gt;. CKS 2010.[&lt;A href="http://www.cks.nhs.uk/schizophrenia" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Department of Health&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Department of Health. &lt;A href="nelh:156272:1" name=internalLink&gt;Choosing health:supporting the physical health needs of people with severe mental illness - commissioning framework&lt;/A&gt;. Department of Health 2006. [&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4138290.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;General Medical Council&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;General Medical Council. &lt;A href="nelh:287158:1" name=internalLink&gt;Consent: patients and doctors making decisions together&lt;/A&gt;. General Medical Council 2008. [&lt;A href="http://www.gmc-uk.org/static/documents/content/Consent_2008.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;National Institute for Health and Clinical Excellence (NICE)&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/MENTALHEALTH/ViewResource.aspx?resID=30348&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=PUBLICATION_DATE" target="_blank"&gt;Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care&lt;/A&gt;.National Institute for Health and Clinical Excellence. NICE clinical guideline 82 2009. [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG82NICEGuideline.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/MENTALHEALTH/ViewResource.aspx?resID=285312&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=PUBLICATION_DATE&amp;amp;catID=8601" target="_blank"&gt;NICE Implementation Uptake Report: atypical antipsychotic drugs for the treatment of schizophrenia&lt;/A&gt;. National Institute for Health and Clinical Excellence. Service Guidance 2008. [&lt;A href="http://www.nice.org.uk/media/410/E9/ImplUptakeReportAtypicalAntipsychotics.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&amp;nbsp;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Safety First&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Patient Satefy First. &lt;A href="nelh:316323:1" name=internalLink&gt;The how to guide for reducing harm from high risk medicines&lt;/A&gt;. Patient Safety First 2008. [&lt;A href="http://www.patientsafetyfirst.nhs.uk/ashx/Asset.ashx?path=/How-to-guides-2008-09-19/Medicines 1.1_17Sept08.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Nursing&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Royal College of Nursing. &lt;A href="nelh:78466:1" name=internalLink&gt;Violence: the short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments&lt;/A&gt;. Royal College of Nursing 2006. [&lt;A href="http://www.nice.org.uk/nicemedia/pdf/cg025niceguideline.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Psychiatrists&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Royal College of Psychiatrists. &lt;A href="nelh:155609:1" name=internalLink&gt;Consensus statement on high-dose antipsychotic medication&lt;/A&gt;. Royal College of psychiatrists 2006. [&lt;A href="http://www.rcpsych.ac.uk/files/pdfversion/CR138.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;International Guidelines&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Australia and New Zealand&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Summary Australian and new Zealand clinical practice guideline for the&amp;nbsp;treatment of schizophrenia. [&lt;A href="http://www.nzgg.org.nz/guidelines/0094/APY_535.pdf" target="_blank"&gt;Full Text&amp;nbsp;PDF&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Rosenberg S, hickie IB, Mendoza J. National mental health reform: less talk, more action. Medical Journal of&amp;nbsp;Australia 2009; 190(4). [&lt;A href="http://www.mja.com.au/public/issues/190_04_160209/ros10709_fm.html" target="_blank"&gt;Full Text&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Canada&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Canadian psychiatric Association. Treatment of schizophrenia. The Canadian Journal of Psychiatry 2005. [&lt;A href="https://ww1.cpa-apc.org/Publications/Clinical_Guidelines/schizophrenia/november2005/cjp-cpg-suppl1-05_full_spread.pdf" target="_blank"&gt;Full Text PDF&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Guideline Implementation&lt;/H2&gt;
&lt;OL&gt;
&lt;LI&gt;Weinmann S. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/21" target="_blank"&gt;Review - More high quality studies needed to determine the effects on patient outcomes of psychiatric care guideline implementation&lt;/A&gt;. Evidence Based Mental Health Journal 2008; 11:21. [&lt;A href="http://ebmh.bmj.com/content/11/1/21.extract" target="_blank"&gt;EBMH Journal Abstract&lt;/A&gt;]&lt;/LI&gt;
&lt;LI&gt;Weinmann S, Hoerger S, Erath M, Kilian R, Gaebel W, Becker T. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18642975" target="_blank"&gt;Implementation of a schizophrenia practice guideline: clinical results&lt;/A&gt;. Journal of&amp;nbsp;Clinical Psychiatry 2008; 69(8):1299-306. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18642975" target="_blank"&gt;Pubmed Abstract&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325072</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/SchizophreniaGeneticsFound.aspx]]&gt;</url>
    <title>Schizophrenia genes identified</title>
    <publicationDate>2009-07-02T00:00:00</publicationDate>
    <publisher>Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Scientists have unlocked “the secrets of schizophrenia”, according to &lt;EM&gt;The Independent&lt;/EM&gt;. The newspaper says that research has identified thousands of tiny genetic variations which together could account for more than one-third of the inherited risk of schizophrenia.]]&gt;</body>
  </document>
  <document>
    <id>111333</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111333]]&gt;</url>
    <title>Schools</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,EDUCATION,OUTCOMES,ENVIRONMENTAL,EDUCATION,MENTAL &amp; BEHAVIOURAL DISORDERS,CHILDREN,YOUNG PEOPLE,POPULATION BASED &amp; PREVENTATIVE SERVICES,SCHOOLS,EDUCATIONAL SETTINGS,PUBLIC HEALTH,DETERMINANTS,SOCIAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; POLICY,INFORMATION,SERVICES,POPULATIONS,GROUPS,AGE GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Schools&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111332:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111334:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;The case for action&lt;/H2&gt;
&lt;P&gt;School has a significant influence on the behaviour and development of all children and young people (ref 1, 2). The importance of school as a setting for promoting the mental health of children has been acknowledged by the Department for Education and Skills in their guidelines Promoting children’s mental health within early years and school settings (ref 3).&lt;/P&gt;
&lt;P&gt;Poor achievement and poor school performance are risk factors for substance abuse, unwanted teenage pregnancy, conduct problems and involvement in crime. (ref 1, 3, 4). Educational achievement increases self-esteem and confidence, employment opportunities, life opportunities and social support. School is also crucial source of friends and social networks.&lt;/P&gt;
&lt;P&gt;Schools can strengthen the ability of young people to cope successfully with transition and change. School interventions can make an important contribution to reducing the impact of wider inequalities (ref 5).&lt;/P&gt;
&lt;P&gt;There is increasing evidence that schools can promote all children’s mental health, and intervene effectively with those children experiencing problems. There is also evidence that strategies to promote mental health impact on individual children’s learning and behaviour, staff performance and morale, and the overall ethos and success of the school. (see &lt;A href="nelh:111328:1" name=internalLink&gt;young people&lt;/A&gt;; &lt;A href="nelh:111308:1" name=internalLink&gt;making connections – young people &amp;amp; schools&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Evidence based priorities:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is evidence for the value of a ‘social competence’ approach, which focuses on the promotion of generic skills designed to increase resilience, promote self-esteem and enable children and young people to avoid risk and attain/maintain health promoting behaviour. The key components of the ‘social competence’ model are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Self-management&lt;/LI&gt;
&lt;LI&gt;Problem solving&lt;/LI&gt;
&lt;LI&gt;Communication&lt;/LI&gt;
&lt;LI&gt;Resisting negative social influences&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Methods associated with increased effectiveness include cognitive/behavioural approaches, interactive interventions and, to a much lesser extent, peer education. There is a strong case for reviewing materials and resources used in school-based health promotion to assess the extent to which they are based on these approaches.&lt;/P&gt;
&lt;H2&gt;School as a setting for promoting mental health – summary of the evidence&lt;/H2&gt;
&lt;P&gt;Successful programmes are those that involve parents and the wider community, strengthen school attachment and address the ethos and culture of the school as a whole. This should include a generic focus on skills that increase mental and social well-being and mechanisms for identifying and supporting at risk and vulnerable children.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Health promoting schools&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is limited but promising evidence that a health promoting schools approach can impact positively on aspects of mental and social well-being such as self-esteem and bullying (ref 6).&amp;nbsp; Interventions were targeted at 5 – 16 year olds and addressed a wide range of topics including substance abuse, sexual health, food and nutrition and health related exercise. There was some evidence that this approach is able to impact positively on aspects of mental and social well-being such as self-esteem and bullying which have previously proved difficult to influence.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Health promotion in schools&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is evidence from a review of reviews to show that school health promotion initiatives that make changes to the school’s environment and attempt to involve parents and the wider community provide a more effective framework within which to promote mental health than those that use a curriculum based approach only (ref 6).&lt;/P&gt;
&lt;P&gt;Most of the interventions used curriculum-based approaches only, but some utilised an environmental approach which included changes to the school’s ethos or involvement of families and community participation. Programmes using this approach were more likely to be successful than those which did not. The interventions covered a wide range of health promotion topics. There was evidence that stress management and life skills training had a positive impact in interventions addressing psychological aspects of health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Universal approaches to mental health promotion in schools&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Systematic review level evidence demonstrates that universal school mental health promotion programmes can be effective. Long-term interventions that aim to promote positive mental health and involve changes to the school climate are likely to be more successful than brief class-based mental illness prevention programmes (ref 4).&lt;/P&gt;
&lt;P&gt;Most of the included studies showed some positive impact on mental health. The most robustly positive evidence was obtained for schools that adopted a whole-school approach, were implemented continuously for more than one year and were mental health promoting rather than mental illness preventing. Programmes that aimed to improve children’s behaviour and were limited to the classroom were less likely to be effective.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Universal and targeted primary prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Primary prevention describes either universal approaches aimed at whole groups such as all 10 year olds; or targeted or indicated approaches aimed at those deemed to be at risk such as children in transition from primary to secondary school.&lt;/P&gt;
&lt;P&gt;Review evidence from the US suggests that primary universal and targeted interventions are effective in preventing mental disorders in school-aged children (5 – 18 yrs) especially if programmes commence in the pre-school years and are targeted at risk and protective factors rather than specific problem behaviours (ref 7). &lt;/P&gt;
&lt;P&gt;Programmes included those on violence prevention, skills training, changes to the school environment and multi-component programmes involving children and families. Reviewers concluded that short-term preventive interventions produced time-limited benefits with at risk groups whereas multi-year programmes were more likely to foster enduring benefits. Ongoing intervention starting at pre-school and in the early primary school years may be necessary to reduce future morbidity.&lt;/P&gt;
&lt;P&gt;A meta-analysis of outcome research on primary prevention mental health programmes for children and adolescents came to similar conclusions (ref 8). The 177 studies included in the review were mainly aimed at younger children and only just over one in ten programmes involved adolescents 13 years or older. Programmes varied between individual, person-centred approaches such as problem-solving; environment-centred approaches such as modifications to the school environment; or those which addressed transitions such as divorce in the family or school entry.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Cognitive Behavioural Therapy for Depression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Indicated prevention of depression in high school adolescents through cognitive behavioural therapy has significant positive results (ref 9).&lt;/P&gt;
&lt;P&gt;A universal school based programme to prevent depression (RAP), focussing on a cognitive approach to life skills and problem solving resulted in significantly lower levels of depression and hopelessness (ref 10).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Eating disorder prevention programmes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Everybody’s Different Program in Australia which focussed on improving self-esteem was effective in reducing body dissatisfaction in young people and altering weight control behaviour in girls (ref 11). This is most significant because a history of severe or moderate dieting is the single most important predictor for anorexia.&lt;/P&gt;
&lt;P&gt;A systematic review described two programmes which combined media literacy and an advocacy approach that was associated with some reduction in the acceptance of society’s ideals about body appearance (ref 12). One programme used a psychoeducation approach and one other adopted a focus on self-esteem. The choice of subject group in the included studies varied from primary through to secondary school and involved either males and females combined, or females on their own. The most common intervention mode was cognitive behavioural, i.e. targeting eating attitudes and behaviours.&lt;/P&gt;
&lt;P&gt;Overall the results of the review offered insufficient evidence for targeting specific age groups or gender mixes or to support the effectiveness of any specific type of eating disorder prevention programme for children and adolescents.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Peer relationships&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Problems with children’s peer relationships have significant implications for later psychological adjustment and well-being, hence the importance of techniques for improving children’s abilities to relate to their peers (ref 13). Meta analysis demonstrated the relative effectiveness of three methods of social skills training with socially isolated children: coaching, interpersonal cognitive problem-solving and modelling (ref 14. There was a significant improvement in children’s levels of social interaction and problem-solving. Programmes delivered by psychologists or their assistants were more effective than those delivered by teachers.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Anti-bullying&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Anti-bullying schemes which involve the whole school, parents and the community e.g. the Campaign against Bully-Victim Problems, are effective and have significant long term impacts on criminal behaviour, alcohol abuse, depression and suicidal behaviour (ref 15, 16). (see also: &lt;A href="nelh:111328:1" name=internalLink&gt;young people&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;The importance of involving key adults in the wider community to prevent bullying has been noted by the World Health Organisation (ref 17). This judgment corroborates one of the basic principles of effective health promoting schools, i.e. involvement of the families and communities which the school serves.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Suicide prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Suicide prevention programmes in schools are not proven to be effective and there is some evidence that they may increase risk for vulnerable young people, particularly boys (ref 6, 18, 19).&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Rutter M and Smith DJ (1995) Psychosocial Disorders in Young People Chichester: Wiley.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Weare K (2000) Developing Mental, Emotional and Social Health: A Whole School Approach. London: Routledge.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&lt;A href="http://www.dfes.gov.uk/mentalhealth/" target="_blank"&gt;Department for Education and Skills&lt;/A&gt; (2001) Promoting children’s mental health within early years and school settings. London: The Stationery Office&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Wells J, Barlow J and Stewart-Brown S (2001) A systematic review of universal approaches to mental health promotion in schools Health Services Research Unit, University of Oxford, Institute of Health Sciences&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Acheson D (1998) Independent Inquiry into Inequalities in Health Report. London: The Stationery Office.&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Lister-Sharp D, Chapman S, Stewart-Brown S, Sowden A (1999) Health promoting schools and health promotion in schools: two systematic reviews London: &lt;A href="http://www.hta.nhsweb.nhs.uk/execsumm/summ322.htm" target="_blank"&gt;Health Technology Assessment&lt;/A&gt;&amp;nbsp;No 22&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Greenberg MT, Domitrovich C and Bumbarger B (2001) The Prevention of Mental Disorders in School-aged Children: Current State of the Field. Prevention &amp;amp; Treatment. Volume 4. Article 1.&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Durlak JA &amp;amp; Wells AM (1997) Primary prevention mental health programs for children and adolescents: a meta-analytic review American Journal of Community Psychology 25:115-152&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Clarke GN, Hawkins W, Murphy M, Sheeber LS, Lewinsohn PM and Seeley JR (1995) Targeted prevention of unipolar depressive disorder in an at risk sample of high school adolescents: a randomised trial of a group cognitive intervention Journal of American Academy of Child and Adolescent Psychiatry 34:312-321&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Dadds M, Spence S, Holland DE, Barrett PM and Laurens KR (1997) Prevention and early intervention for anxiety disorders: a controlled trail Journal of Consulting and Clinical Psychology 65:627-635&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;O’Dea J and Abraham S (1999) Improving the body image, eating attitudes and behaviours of young male and female adolescents: a new educational approach which focuses on self-esteem Journal of Abnormal Psychology 99 3-15&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Pratt BM and Woolfenden SR (2002) &lt;A href="http://www.update-software.com/abstracts/ab002891.htm" target="_blank"&gt;Interventions for preventing eating disorders in children and adolescents&lt;/A&gt;&amp;nbsp;(Cochrane Review). In: &lt;A href="http://www.update-software.com/cochrane/" target="_blank"&gt;The Cochrane Library&lt;/A&gt;, Issue 4,2002. Oxford: Update Software&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Asher SR and Coie JD (eds) (1990) Peer Rejection in Childhood. Cambridge: Cambridge University Press&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Erwin PG (1994) Effectiveness of social skills training with children: a meta-analytic study. Counselling Psychology Quarterly 7(3):305-310.&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Olweus D (1993) Bullying at school: what we know and what we can do London: Blackwell&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Olweus D (1995) Bullying or peer abuse at school: facts and interventions. Current Directions in Psychological Science. 4:196-200&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;&lt;A href="http://www.who.org/" target="_blank"&gt;World Health Organisation&lt;/A&gt; (1998) Violence &lt;A href="http://www.who.int/school_youth_health/media/en/93.pdf" target="_blank"&gt;Prevention: An Important Element of a Health Promoting School: WHO Information Series on School Health&lt;/A&gt;. Document 3. Geneva:WHO&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Ploeg J, Ciliska D, Dobbins M, Hayward S, Thomas H, Underwood J (1996) A systematic overview of the effectiveness of public health nursing interventions: an overview of adolescent suicide prevention programes Quality of Nursing Worklife Research Unit, McMaster University, University of Toronto&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Harden A, Rees R, Shepherd J, Brunton G, Oliver S and Oakley A (2001) Young people and mental health: a systematic review of research on barriers and facilitators. London:&lt;A href="http://eppi.ioe.ac.uk/" target="_blank"&gt;EPPI-Centre&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>327458</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/seeing-double-meeting-the-challenge-of-dual-diagnosis.pdf]]&gt;</url>
    <title>Seeing double: Meeting the challenge of dual diagnosis</title>
    <publicationDate>2009-09-30T00:00:00</publicationDate>
    <publisher>The National Mental Health Development Unit</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,COLLABORATIVE WORKING,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A third of mental health users, half of substance misuse service users and 70 per cent of prisoners are subject to dual diagnosis.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The report, published by the NHS Confederation and the National Mental Health Development Unit, looks at the challenges posed to the NHS by people who have either developed problems with alcohol or drugs because of a pre-existing mental health condition, or have had a mental health condition caused by misusing alcohol or drugs.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It addresses the way provision of services for mental health and drug and alcohol misuse have developed separately and looks at how stronger links between the two, along with better workforce development and awareness, can provide a better service and potentially save money.&lt;BR&gt;The report references research, which has shown service users with a dual diagnosis typically use NHS services more and cost more.&lt;/P&gt;
&lt;P&gt;The report cites a study of services in South London, which found a greater proportion of patients with dual diagnosis used the support of community psychiatric nurses, inpatient care and emergency clinics.&lt;/P&gt;
&lt;P&gt;Their analysis found dual diagnosis patients had significantly higher core' psychiatric service costs (a difference of £1,362) and non-accommodation service costs (£1,360) than patients without a dual diagnosis.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268315</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=43587&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Self Help Groups</title>
    <publicationDate>2004-10-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The work presented in this report reflects a collaboration between the Mental Health Foundation and Rethink.</description>
    <body>&lt;![CDATA[ The work presented in this report reflects a collaboration between the Mental Health Foundation and Rethink. Findings from a symposium held for members of self-help groups for people who experience mental distress are presented together with selected findings from the self-help literature. The report includes also the results of a mapping exercise carried out by the Mental Health Foundation in December 2003, which sought to estimate the number of self-help groups in England for people who experience mental distress.]]&gt;</body>
  </document>
  <document>
    <id>381300</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/pdf/PS03-2010.pdf]]&gt;</url>
    <title>Self-harm, suicide and risk: a summary</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>The Royal College of Psychiatrists</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This College report examines the issues of self-harm, suicide and risk in detail. It was produced by a working group, chaired by Lord John Alderdice. It was compiled with the help of expert evidence from health professionals, third sector providers, policy professionals, service users and carers as well as members of the Royal College of Psychiatrists. It takes the current research picture into consideration, as well as surveys of College members and current government guidelines and initiatives. This position statement is a summary of some of the key findings and recommendations from the report.]]&gt;</body>
  </document>
  <document>
    <id>285160</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/medicines_management/safety/selfadmin/library/sig_sam_in_mh.php]]&gt;</url>
    <title>Service Improvement Guide: Self administration of medicines in Mental Health Trusts</title>
    <publicationDate>2008-05-07T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This guide is intended to help support the implementation of medicines self-administration by service users in Mental Health Trusts. It provides ideas and practical suggestions, drawing on the experiences of trusts taking part in the hospital medicines management collaborative hosted by the National Prescribing Centre (NPC).</description>
    <body>&lt;![CDATA[ This guide is intended to help support the implementation of medicines self-administration by service users in Mental Health Trusts. It provides ideas and practical suggestions, drawing on the experiences of trusts taking part in the hospital medicines management collaborative hosted by the National Prescribing Centre (NPC).]]&gt;</body>
  </document>
  <document>
    <id>267834</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/cr145.pdf]]&gt;</url>
    <title>Sexual boundary issues in psychiatric settings</title>
    <publicationDate>2007-08-23T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This revision of the original College Report CR52: Sexual Abuse and Harassment in Psychiatric Settings (Royal College of Psychiatrists, 1996) has led to a review within a wider remit, taking into account major developments in the legal framework within which patients are treated and encompassing a broader discussion on sexuality. Issues of capacity and consent are relevant for all areas of care, and psychiatric professionals have to balance principles of autonomy and protection. Particularly relevant in this context are the Human Rights Act (1998), the Sexual Offences Act (2003),the Mental Capacity Act (2003), and additional legislation regarding standards of care for both adults and children.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Executive summary and recommendations&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;Revision of the original College report Sexual Abuse and Harassment in Psychiatric Settings (Royal College of Psychiatrists, 1996) led to a review with a wider remit, to take into account major developments in the legal framework in which patients are treated and to encompass a broader discussion on sexuality. Issues of capacity and consent are relevant for all areas of care and psychiatric professionals have to balance principles of autonomy and protection. Particularly relevant in the context are the&amp;nbsp;human Rights Act 1998, the Sexual Offences Act 2003, the Mental Capacity Act 2003 and additional legislation regarding standards of care for both adults and children.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The area is one of high risk in terms of likelihood and impact because of the vulnerability of the patient group. Recommendations are made in the&amp;nbsp;light of the Kerr/Haslam inquiry (Department of Health, 2005), the Patient Safety Observatory Report 2 (National Patient Safety Agency, 2006) and the government report Safeguarding Patients (Department of Health, 2007).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Recommendations&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Wards must have appropriate design and sufficient space to allow&lt;BR&gt;patients to be cared for in safety, privacy and a reasonable degree of comfort. 
&lt;LI&gt;Sufficient numbers of qualified staff must be on duty at all times. 
&lt;LI&gt;All staff should be in regular supervision. This will include discussion of attitudes and behaviour. Supervision may also provide a safe space in which they are able to acknowledge lack of skill and to voice anxieties and concerns about themselves and others. 
&lt;LI&gt;Trusts should have evidence bases and protocols for treatments. They should be aware of therapies being undertaken by all staff, through supervision, appraisals and job plans. A register of treatments is a useful mechanism for recording treatments and approved protocols; it could also include chaperone requirements, and specify training and supervision requirements for each treatment. 
&lt;LI&gt;Clinical supervisors and managers must develop an understanding of the causes and recognition of sexual abuse and should be aware of the situations in which abuse is more likely to occur. 
&lt;LI&gt;Staff induction programmes should include clear instructions about&lt;BR&gt;what behaviour is acceptable and what is unacceptable. 
&lt;LI&gt;Each psychiatric unit must have developed an accepted philosophy, with ensuing policy and procedures, to cover the appropriate expression of sexuality among in-patients. The policy will address human rights, legality, capacity and consent, contraception and cultural variances. 
&lt;LI&gt;Each unit must have a policy with respect to allegations of sexual&lt;BR&gt;harassment, sexual abuse and rape, whether this be by another&lt;BR&gt;patient, by a staff member or by a visitor to the ward. The policy will address the duties of staff, immediate action, evidence, support to the complainant, when and how to involve the police and/or social services, incident reporting and investigation, and disciplinary procedures. 
&lt;LI&gt;There should be regular audit concerning the numbers of incidents,&lt;BR&gt;complaints and allegations, patient attitudes to policies, and staff&lt;BR&gt;attitudes, knowledge of and adherence to policies. 
&lt;LI&gt;Employment policies must ensure that all staff, clinical and nonclinical, permanent or temporary, have no previous record of sexual impropriety. 
&lt;LI&gt;Senior management must support training in the prevention,&lt;BR&gt;recognition and management of abusive and potentially abusive&lt;BR&gt;situations. There should be ongoing multidisciplinary educational&lt;BR&gt;programmes for staff, to raise awareness and confidence in dealing&lt;BR&gt;with issues related to the expression of sexuality. Staff should receive specific training in the recognition of abuse and the handling of allegations of abuse and harassment. 
&lt;LI&gt;Patient information should be readily available, including information about what to expect in assessment and treatment, how to access support and advice, and how to make a complaint.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319342</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.kingsfund.org.uk/document.rm?id=8296]]&gt;</url>
    <title>Shaping PCT Provider Services</title>
    <publicationDate>2009-06-18T00:00:00</publicationDate>
    <publisher>Kings fund</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Finding the right place and organisational form for community health services has been a conundrum that the National Health Service (NHS) has puzzled over for more than a quarter of a century. Since leaving local authority control in 1974, community health services have been lodged in numerous temporary homes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The organisation of community health services is now back on the agenda following Lord Darzi’s NHS Next Stage Review (Darzi 2008; Department of Health 2008b). Darzi’s diagnosis was clear: community health services have a vital role to play in delivering care closer to people’s homes, but they are not yet fit for purpose. Better information, stronger management and more expert commissioning are all needed if community health services are to realise their potential.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The inadequacies of primary care trust (PCT) provision are fundamentally intertwined with those relating to PCT commissioning. The management of significant provider arms has distracted PCT boards from their core commissioning role (and the recent national assessment of PCTs’ world class commissioning competencies has demonstrated that there is a need for urgent improvement). The commissioning role of PCTs is now rightly taking precedence over that of provision.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>262932</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://kc.csip.org.uk/viewresource.php?action=viewdocument&amp;doc=99725&amp;grp=586]]&gt;</url>
    <title>Shift - Action on Stigma: Feedback Report</title>
    <publicationDate>2007-06-27T00:00:00</publicationDate>
    <publisher>Shift</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Action on Stigma is a Department of Health initiative that aims to build on the good work already undertaken by many organisations to improve mental health in the workplace.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Action on Stigma is a Department of Health initiative that aims to build on the good work already undertaken by many organisations to improve mental health in the workplace.&lt;/P&gt;
&lt;P&gt;Following the publication of the Action on Stigma discussion document, a listening exercise was launched to seek the views of employers, people with mental health problems and other stakeholders.&lt;/P&gt;
&lt;P&gt;This report sets out the findings from the listening exercise and how these will help inform the future work of the Action on Stigma programme. &lt;/P&gt;
&lt;P&gt;The report is available in as a PDF or Word document:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://kc.csip.org.uk/viewdocument.php?action=viewdox&amp;amp;pid=0&amp;amp;doc=35018&amp;amp;grp=586" target="_blank"&gt;Action on Stigma feedback report (PDF)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://kc.csip.org.uk/viewdocument.php?action=viewdoc&amp;amp;pid=0&amp;amp;doc=3501&amp;amp;grp=586" target="_blank"&gt;Action on Stigma feedback report (Microsoft Word)&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>279864</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://kc.csip.org.uk/viewdocument.php?action=viewdox&amp;pid=0&amp;doc=37653&amp;grp=584]]&gt;</url>
    <title>Shift: What's the Story - Reporting on mental health and suicide</title>
    <publicationDate>2008-02-18T00:00:00</publicationDate>
    <publisher>Shift</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ADULT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This handbook is packed with useful facts, figures and contacts. It is designed to help you do your job when covering these stories, whether you’re a print, broadcast or magazine journalist.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This handbook is packed with useful facts, figures and contacts. It is designed to help you do your job when covering these stories, whether you’re a print, broadcast or magazine journalist.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The handbook also contains tips on how best to avoid causing needless offence - or worse - to your many readers and viewers affected by mental health problems. They apply whether you are covering a murder, a suicide or in fact wherever mental health crops up in the news, which can be pretty much anywhere. Our aim is to help you cover these stories properly and, at the same time, improve public understanding and avoid adding to the problems faced by people with mental health problems.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://kc.csip.org.uk/viewdocument.php?action=viewdox&amp;amp;pid=0&amp;amp;doc=37653&amp;amp;grp=584" target="_blank"&gt;Download a PDF version of What's the Story?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://homepage.mac.com/shiftstigma/whatsthestory.rtf" target="_blank"&gt;Download an RTF version of What's the Story?&lt;/A&gt; (suitable for Word and other word processors)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://shift.org.uk/mediahandbook" target="_blank"&gt;Visit Shift's What's the Story&lt;/A&gt; website for more information &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287515</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/short-changed.pdf]]&gt;</url>
    <title>Short-changed - Spending on prison mental health care</title>
    <publicationDate>2008-05-30T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report, published by the Sainsbury Centre for Mental Health (SCMH), states that prison mental health services in England face a postcode lottery in funding and get only one-third of the money they need.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Summary&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Last year, £20.8 million was spent on mental health care in prisons through inreach teams. This is 11% of total prison health care spending or just over £300 for each member of the prison population.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Prison inreach teams aim to provide the specialist mental health services to people in prison that are provided by community-based mental health teams for the population at large. But inreach teams have been hindered by limited resourcing, constraints imposed by the prison environment, difficulties in ensuring continuity of care and wide variations in local practice.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Government policy for prison health care is based on the principle of equivalence. This means that standards of care for people in prison should be the same as those available in the community at large, relative to need.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The level of need for mental health care in prisons is particularly high, because of the much greater prevalence of mental illness, especially severe mental illness, among prisoners than among people of working age in the general population.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;While more is spent per head on mental health care in prisons than in the wider community, this is not nearly enough to accommodate this much higher level of need.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The resources currently available for mental health care in prisons are only about a third of the amount required to deliver the policy objective of equivalence.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Spending on prison mental health care also varies widely across the country. In London and in the North East, Yorkshire and Humber, the NHS spends more than twice as much per prisoner than it does in the East Midlands and the South West. This variation cannot be explained by different levels of need or costs: it amounts to a postcode lottery in prison mental health care.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Major investment is needed in the overall level of provision for mental health care in prisons and in its geographical allocation if equivalence is ever to be achieved.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291093</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/short-changed.pdf]]&gt;</url>
    <title>Short-changed: Spending on Prison Mental Health Care</title>
    <publicationDate>2008-07-25T00:00:00</publicationDate>
    <publisher>Sainsbury Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,BUILDINGS,PRISONS,MONTHLY ADDITIONS,GROUPS,SETTINGS,POPULATIONS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report, published by the Sainsbury Centre for Mental Health (SCMH) , states that prison mental health services in England face a postcode lottery in funding and get only one-third of the money they need.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Last year, £20.8 million was spent on mental health care in prisons through inreach teams. This is 11% of total prison health care spending or just over £300 for each member of the prison population.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Prison inreach teams aim to provide the specialist mental health services to people in prison that are provided by community-based mental health teams for the population at large. But inreach teams have been hindered by limited resourcing, constraints imposed by the prison environment, difficulties in ensuring continuity of care and wide variations in local practice.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Government policy for prison health care is based on the principle of equivalence. This means that standards of care for people in prison should be the same as those available in the community at large, relative to need.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333162</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/pdf/Significant%20Harm%20intercollegiate%20statement%20Dec09.pdf]]&gt;</url>
    <title>Significant harm - the effects of administrative detention on the health of children, young people and their families</title>
    <publicationDate>2009-12-10T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,CHILD ABUSE AND NEGLECT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal&gt;The Royal Colleges of Paediatrics and Child Health, General Practitioners and Psychiatrists and the UK Faculty of Public Health have published a new policy statement and recommendations on the harms to the physical and mental health of children and young people in the UK who are subjected to administrative immigration detention.&lt;/P&gt;
&lt;P class=MsoNormal&gt;The three Royal Colleges and the UK Faculty of Public Health believe that the administrative immigration detention of children, young people and their families is harmful and unacceptable and call on the Government to see this issue as a matter of priority and stop detaining children without delay.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333012</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/psychosis-risk-smoking-skunk-hash-cannbis-compared.aspx]]&gt;</url>
    <title>Skunk linked to psychosis</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Smokers of the strong ‘skunk’ variety of cannabis are seven times more likely to experience psychosis, according to the &lt;EM&gt;Daily Mail.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>328877</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2009/9789241597937_eng.pdf]]&gt;</url>
    <title>Smoke-free movies: from evidence to action</title>
    <publicationDate>2009-10-31T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report emphasizes the need for enforceable policies to severely restrict smoking imagery in movies. It is backed by evidence indicating a causal link between exposure to movie smoking depictions and youth smoking initiation. The report summarizes current knowledge, as well as approaches to ensure that movies that are marketed to youth do not contain tobacco imagery.]]&gt;</body>
  </document>
  <document>
    <id>111320</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111320]]&gt;</url>
    <title>Smoking</title>
    <publicationDate></publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,SMOKING CESSATION,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,SOCIOECONOMIC FACTORS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,SERVICES,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Smoking&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111319:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111321:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Smoking prevalence is significantly higher among people with mental health problems than among the general population, some studies showing rates to be as high as 80% among people with schizophrenia (ref 1). People with depression are more likely to smoke and to have difficulty when they try to stop. (Ibid) People with psychotic disorders who live in institutions are particularly vulnerable. Over 70% of this group smoke including 52% who are heavy smokers (ref 2). &lt;/P&gt;
&lt;P&gt;Explanations offered to account for such high smoking rates include social exclusion and deprivation, the impact of time in institutional settings that allow smoking and use cigarettes as currency and the possible use of nicotine as self-medication both to counter the effects of illness and the side-effects of prescribed medication (ref 1, 3). &lt;/P&gt;
&lt;P&gt;A case control study of substance misuse in schizophrenia revealed that even though problem use of drugs and alcohol by people with schizophrenia was greater than in the general population, tobacco use was far and away the greatest problem (ref 4). &lt;/P&gt;
&lt;P&gt;Almost half of mental health service users want to quit, but there evidence reveals that smoking cessation information and services are not reaching this group (ref 1, 5, 6). Current services are not addressing the special needs of one of the most vulnerable groups of smokers. For example, within primary care, health promotion data for people with severe and enduring mental health problems (e.g. smoking behaviour) is much less likely to be recorded than for the general population (ref 5, 7).&lt;/P&gt;
&lt;P&gt;Parallel guidance on physical health assessment and treatment, from the National Institute for Mental Health in England (ref 8,9), should make a contribution to alleviating this neglected area of health care. The information is targeted at health and social care professionals and also at mental health service users.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111319:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111321:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;McNeill A (2001) Smoking and mental health: a literature review &lt;A href="http://www.ash.org.uk/" target="_blank"&gt;Action on Smoking and Health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Meltzer H, Gill B, Petticrew M et al (1995) Economic activity and social functioning of adults with psychiatric disorders (OPCS Surveys of Psychiatric Morbidity in Great Britain: Report 3) London: HMSO&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Health Development Agency (2001) Where do we go from here? Tobacco control policies in psychiatric and long-stay settings. London: HDA&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;McCreadie R (2002) Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. &lt;A href="http://bjp.rcpsych.org/" target="_blank"&gt;British Journal of Psychiatry&lt;/A&gt; 181: 321-325&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;mentality (2003) Not all in the mind: the physical health of people with mental health problems. London: &lt;A href="http://www.mentality.org.uk/" target="_blank"&gt;mentality&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Dean J, Todd G, Morrow H, and Sheldon K (2001) Mum, I used to be good looking…Look at me now: The physical health needs of adults with mental health problems: The perspectives of users, carers and front-line staff. International Journal of Mental Health Promotion 3 (4 ): 16-24&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Cohen A and Hove M (2001) Physical health of the severe and enduing mentally ill – a training pack for GP educators &lt;A href="http://www.scmh.org.uk/" target="_blank"&gt;Sainsbury Centre for Mental Health &amp;amp; Department of Health&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;National Institute for Mental Health (England) (2004a) Physical health needs of people with mental health problems: Guidance for health and social care professionals. Leeds: &lt;A href="http://www.nimhe.org.uk/" target="_blank"&gt;NIMHE&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;National Institute for Mental Health (England) (2004b) What you can expect. Physical health needs of people with mental health problems: Guidance for mental health service users. Leeds: &lt;A href="http://www.nimhe.org.uk/" target="_blank"&gt;NIMHE&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>372740</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/smoking-down-to-your-genes.aspx]]&gt;</url>
    <title>Smoking is 'down to your genes'</title>
    <publicationDate>2010-04-26T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Genes determine why some smoke,” according to &lt;EM&gt;The Independent&lt;/EM&gt;, which said that smokers may be able to blame their genes for their addiction.&lt;/P&gt;
&lt;P&gt;The news is based on research that identified genetic variants linked to the likelihood of smoking and the number of cigarettes people smoke a day. The well-conducted analysis of several studies has confirmed the associations between smoking behaviour and three genetic variants, two of which had not been identified before. The research also highlighted a complicated causal relationship between the presence of these variants, smoking behaviour and lung cancer,&amp;nbsp;which the study authors say needs untangling.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381289</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/default.asp?sID=1172577414129&amp;sPublicationID=1279784404203&amp;sDocID=6325]]&gt;</url>
    <title>Smoking, drinking and drug use among young people in England in 2009</title>
    <publicationDate>2010-07-22T00:00:00</publicationDate>
    <publisher>NHS Information Centre for Health and Social Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report contains results from an annual survey of secondary school pupils in years 7 to 11 (mostly aged 11 to 15). 7,674 pupils in 247 schools in England completed questionnaires in the autumn term of 2009.&lt;/P&gt;
&lt;P&gt;The National Centre for Social Research (NatCen) and the National Foundation for Educational Research (NFER) carried out the survey on behalf of The NHS Information Centre for health and social care, the Home Office and the Department for Education (formerly the Department for Children, Schools and Families). This is the most recent survey in a series that began in 1982. Each survey since 1998 has included a core set of questions on smoking, drinking and drug use and, since 2000 the remainder of the questions have focused in alternate years on smoking and drinking or on drug use. The emphasis of the 2009 survey is on drug use.&lt;/P&gt;
&lt;P&gt;The survey report presents information on the percentage of pupils who have ever smoked, tried alcohol or taken drugs. The report explores the attitudes and beliefs of school children towards smoking, drinking and drug use and where children obtain cigarettes, alcohol and drugs. Relationships between smoking, drinking and drug use are explored along with the links between smoking, drinking and drug use with other factors such as age, gender, ethnicity, previous truancy or exclusion. &lt;/P&gt;
&lt;H3&gt;Key facts&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;22 per cent of pupils reported ever having taken drugs, 15 per cent had taken drugs in the last year and 8% had taken drugs in the last month, a decrease from 29 per cent, 20 per cent and 12 per cent respectively in 2001 (the first year in which the current method of measuring drug use was used). 
&lt;LI&gt;Less than one in ten pupils thought that it would be OK for someone of their age to try drugs or take them regularly; for example, they were slightly more tolerant of cannabis use (9 per cent thought it OK to try once, 5 per cent to take once a week) than sniffing glue (9 per cent once, 3 per cent once a week) and cocaine was seen as the least acceptable of the drugs (3 per cent thought it OK to try once, 1 per cent to take once a week). Almost all pupils thought their families would either try to stop them from taking drugs (84 per cent) or would try to persuade them to stop (15 per cent). There was a strong relationship between drug use and families' attitudes: those who thought their families would try to stop them taking drugs were less likely to have taken drugs than those who thought their families would take a more lenient view. 
&lt;LI&gt;Three in ten (29 per cent) pupils have tried smoking at least once, the lowest percentage since the survey began in 1982 when 53 per cent of pupils had tried smoking. The prevalence of regular smoking has declined from its peak of 13 per cent in 1996 to 6 per cent in 2007 and has remained at 6 per cent in 2008 and 2009. 
&lt;LI&gt;51 per cent of pupils have tried alcohol at least once and 18 per cent drank alcohol in the last week, a decrease from the peak of 26 per cent in 2001. The percentage of pupils between 11 and 15 who have never drunk alcohol has risen in recent years from 39 per cent in 2003 to 49 per cent in 2009. 
&lt;LI&gt;The survey sample represents an estimated population of 3.1 million young people aged between 11 and 15. Findings indicate that in England in 2009 around 180,000 11 to 15 years olds were regular smokers, around 540,000 drank alcohol in the last week, around 250,000 had taken drugs (including glue, gas and other volatile substances) in the last month and around 450,000 had taken drugs in the last year.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>111324</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111324]]&gt;</url>
    <title>Social exclusion and health</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DISADVANTAGED GROUPS,PUBLIC HEALTH,DETERMINANTS,SOCIAL DETERMINANTS,SOCIOECONOMIC FACTORS,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Social exclusion and health&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111323:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111325:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Since the early 1980s there has been increasing recognition that the health of individuals and communities is closely linked to and affected by social and economic deprivation (ref 1,2 3). On almost every count people with mental health problems are among the most excluded groups in society and they consistently identify stigma, discrimination and exclusion as major barriers to health, welfare and quality of life (ref 4 -6). &lt;/P&gt;
&lt;P&gt;Having a diagnosis frequently results in direct socio-economic consequences such as bad housing, lack of meaningful activity and limited financial resources. The socio-economic circumstances of adults with mental health problems aged 16-74 means that in comparison to people without mental health problems they are more likely to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;fall behind with bills&lt;/LI&gt;
&lt;LI&gt;live in a rented home&lt;/LI&gt;
&lt;LI&gt;experience problems with daily living&lt;/LI&gt;
&lt;LI&gt;have experienced a major life event such as divorce or bereavement&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;(ref 7)&lt;/P&gt;
&lt;P&gt;There are strong links between poor housing and mental and physical ill health. Six in ten homeless people suffer some sort of mental distress, 20% have a severe mental illness and people who sleep rough are 35 times more likely to kill themselves than the general population. (ref 8).&lt;/P&gt;
&lt;P&gt;Unemployment affects those with long-term mental disorders more than any other groups of people with disabilities. Only 13% are in employment in comparison to over a third of people with disabilities generally (ref 9). Inability to gain employment results in significant poverty for people with mental health problems (ref 10).&lt;/P&gt;
&lt;P&gt;The impact of inequality falls disproportionately on some groups of mental health service users more than others. Gender inequalities in income and wealth, in combination with women’s role as mothers and carers, make them particularly susceptible to poverty, which is associated with mental and physical ill health (ref 11).&lt;/P&gt;
&lt;P&gt;Social exclusion and deprivation both have a significant impact on the physical and mental health of refugees and asylum seekers. In a study of Iraqi asylum seekers, depression was more closely linked with poor social support than with a history of torture. (ref 12). Burnett and Peel in a review of the issues (ref 13), identify support for people within their own communities and opportunities for developing links and friendships with the host community as crucial to promoting health and well-being.&lt;/P&gt;
&lt;P&gt;Those in later life who have mental health problems face age discrimination, negative stereotyping, isolation and low income. This combination of factors maintains their social exclusion and increases their vulnerability to poor physical health (ref 14,15,16).&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111323:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111325:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Department of Health and Social Security (1980) Inequalities in Health: Report of a Research Working Group chaired by Sir Douglas Black. London: DHSS&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Whitehead M (1987) The Health Divide: Inequalities in Health in the 1980s. London: Health Education Council&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Department of Health (1998) &lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4006902&amp;amp;chk=j2Tt7C" target="_blank"&gt;A First Class Service&lt;/A&gt; London. Department of Health.&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Dunn S (1999) &lt;A href="http://www.mind.org.uk/News%2Bpolicy%2Band%2Bcampaigns/Policy/Creatingacceptingcommunities.htm" target="_blank"&gt;Creating accepting communities: report of the MIND inquiry into social exclusion and mental health problems&lt;/A&gt;&amp;nbsp;London: Mind&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Department of Health (2001) Making it happen: a guide to delivering mental health promotion London. Department of Health.&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Mental Health Foundation (2000) Strategies for living London: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;MHF&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;ONS (2000) &lt;A href="http://www.statistics.gov.uk/STATBASE/Product.asp?vlnk=9324" target="_blank"&gt;Psychiatric morbidity among adults living in private households: 2000 Summary report&lt;/A&gt;. London: Office for National Statistics&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Crisis (1999) Pressure Points. London: &lt;A href="http://www.crisis.org.uk/" target="_blank"&gt;Crisis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;ONS (1998) Labour Force Survey 1997/98. London: Office for National Statistics.&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Focus on Mental Health (2001) An Uphill Struggle: Poverty and Mental Health. Final Report of the Focus on Mental Health Work Programme 2000/2001. London. &lt;A href="http://www.mentalhealth.org.uk/index.cfm" target="_blank"&gt;Mental Health Foundation&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Department of Health (2002) &lt;A href="http://www.dh.gov.uk/assetRoot/04/07/54/87/04075487.pdf" target="_blank"&gt;Women’s Mental Health:Into the Mainstream: Strategic Development of Mental Health Care for Women&lt;/A&gt; London. Department of Health&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Gorst-Unsworth C and Goldenberg EC (1998) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/172/1/90?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074074834184_363&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=172&amp;amp;firstpage=90&amp;amp;resourcetype=1" target="_blank"&gt;Psychological sequelae of torture and organised violence suffered by refugees from Iraq: Trauma-related factors compared with social factors in exile&lt;/A&gt;. British Journal of Psychiatry 172:90-94&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Burnett A and Peel M (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7285/544?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Burnett&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074074089125_1373&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=322&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Health needs of asylum seekers and refugees&lt;/A&gt; British Medical Journal 322:544-547 (link to &lt;A href="http://www.bmj.com/" target="_blank"&gt;www.bmj.com&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Health Education Authority (1997) Older People’s Mental Health: Fact Sheet. World Mental Health Day.&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Roberts E, Seymour L and Robinson J (2002) Old Habits Die Hard: Age Discrimination in Health and Social Care. London: &lt;A href="http://www.kingsfund.org.uk/index.cfm" target="_blank"&gt;Kings Fund&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;McCulloch A (2002) Mental Health in Later Life. Conference presentation. 4 December 2002.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>268318</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38651&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Spirituality and Mental Health Update</title>
    <publicationDate>2002-11-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on the Foundation's work exploring religion, spirituality and mental health.</description>
    <body>&lt;![CDATA[ Update briefing on the Foundation's work exploring religion, spirituality and mental health.This work has been informed by the views and experiences of service users and survivors as voiced in the Knowing Our Own Minds user-led survey, and the UK-wide user-led Strategies for Living qualitative research.]]&gt;</body>
  </document>
  <document>
    <id>278221</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://starwards.org.uk/]]&gt;</url>
    <title>Star Wards</title>
    <publicationDate>2008-01-30T00:00:00</publicationDate>
    <publisher>Star Wards</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Star Wards is a project which works with mental health trusts to enhance mental health inpatients’ daily experiences and treatment outcomes. We discover, celebrate, share, publicise and inspire excellence in acute care, and there is plenty of that all round the country. Our members use and adapt our resources to stimulate and structure therapeutic and enjoyable daily programmes for inpatients.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Star Wards is a project which works with mental health trusts to enhance mental health inpatients’ daily experiences and treatment outcomes. &lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We discover, celebrate, share, publicise and inspire excellence in acute care, and there is plenty of that all round the country. Our members use and adapt our resources to stimulate and structure therapeutic and enjoyable daily programmes for inpatients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;On this website you’ll find:&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;the Library, with it’s huge collection of Star Wards information and resources 
&lt;LI&gt;the &lt;A href="http://starwards.org.uk/?page_id=4" target="_blank"&gt;Star Wards blog&lt;/A&gt; with all the latest Star Wards news, reports of what members are doing around the country and other items of interest 
&lt;LI&gt;information on how to join Star Wards&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Get (and contribute to!) the regular e-newsletter, the Star Wards’ website and our regional and national networking events. Healthcare assistants are eligible for the Star Awards achievement scheme and wards who have got all relevant 75 ideas in place win the Full Monty Award. Make the Healthcare Commission and the Mental Health Act Commission happy. Make your finance people happy - it’s free to join!&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://starwards.org.uk/?page_id=7" target="_blank"&gt;Find out more information about joining Star Wards&lt;/A&gt; 
&lt;LI&gt;&lt;A href="mailto:info@starwards.org.uk" target="_blank"&gt;Email us if you’re interested&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Publication&lt;/H2&gt;
&lt;P&gt;The core of Star Wards is a 64pp resource packed with advice, research and based around 75 practical, yet inspiring ideas. Visit our &lt;A href="http://starwards.org.uk/?page_id=8" target="_blank"&gt;resources page&lt;/A&gt; where you can download a copy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268319</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=43590&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Strategies for Living Summary</title>
    <publicationDate>2000-01-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A summary report of user-led research into people’s strategies for living with mental distress.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A summary report of user-led research into people's strategies for living with mental distress.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268320</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38653&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Student Mental Health Update</title>
    <publicationDate>2001-01-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,EDUCATION,CAUSES OF HARM,ENVIRONMENTAL,OUTCOMES,EDUCATION,YOUNG PEOPLE,MENTAL &amp; BEHAVIOURAL DISORDERS,POLICY,POPULATION BASED &amp; PREVENTATIVE SERVICES,EDUCATIONAL SETTINGS,COLLEGES,UNIVERSITIES,DETERMINANTS,PUBLIC HEALTH,LIFESTYLE,SOCIAL DETERMINANTS,SOCIOECONOMIC FACTORS,MANAGEMENT &amp; INTERVENTIONS,PSYCHOLOGICAL DETERMINANTS,HEALTH SERVICES,CARE,HEALTHCARE &amp; HEALTH SERVICES,MANAGEMENT &amp; POLICY,SERVICES,GROUPS,POPULATIONS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on student mental health research commissioned by the Foundation.</description>
    <body>&lt;![CDATA[ Update briefing on student mental health research commissioned by the Foundation. It provides an overview of current mental health policy and practice initiatives related to student mental health. It also considers the views of student mental health held by students and university staff. This briefing summarises the main research findings and implications.]]&gt;</body>
  </document>
  <document>
    <id>395085</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/study-compares-drug-harms.aspx]]&gt;</url>
    <title>Study compares drug harms</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Alcohol is more harmful than crack or heroin,” reported &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; and many other newspapers today. The headlines stemmed from a study published in &lt;EM&gt;The Lancet&lt;/EM&gt; medical journal by Professor David J Nutt, the former head of the Advisory Council on the Misuse of Drugs. Professor Nutt was asked to resign&amp;nbsp;last year by the former home secretary for making similar claims.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386601</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=386601]]&gt;</url>
    <title>Study looks at reducing dementia</title>
    <publicationDate>2010-08-06T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Study looks at reducing dementia&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;“Keeping one's brain active, trying not to become depressed and eating a diet rich in fruit and vegetables are the best ways to ward off developing dementia,”&amp;nbsp;according to a report in&amp;nbsp;&lt;EM&gt;The Daily Telegraph.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This study was set up to estimate how eliminating specific risk factors for dementia could reduce the number of people developing the condition. The researchers followed 1,433 elderly adults over seven years, during which they regularly assessed cognitive performance and several known and suspected risk factors for dementia.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>111321</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111321]]&gt;</url>
    <title>Substance misuse</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DETERMINANTS,PUBLIC HEALTH,INDIVIDUAL BEHAVIOUR,ALCOHOL CONSUMPTION,SUBSTANCE MISUSE,SOCIETY,SOCIAL DETERMINANTS,LIFESTYLE,POPULATIONS,GENDER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Substance misuse&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111320:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111322:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Alcohol consumption has a significant effect on physical and mental health. It is also associated with a wide range of social issues such as criminal behaviour and violence. Alcohol use can pose particular problems for mental health service users. Over half the men who present to hospital after deliberate self-harm regularly drink excessive amounts of alcohol and 23% are alcohol dependent (ref 1). A study in south London found prevalence rates of 32% for alcohol abuse and 16% for the use of street drugs amongst mental health service users (ref 2). There is a considerably increased risk of acquiring HIV or hepatitis amongst service users who also abuse drugs. Research from America found an incidence of HIV five times higher than in the general population and that of hepatitis C up to ten times higher. A significant proportion of people with hepatitis C will develop hepatocellular carcinoma (a form of liver cancer) in later life (ref 3). &lt;/P&gt;
&lt;P&gt;Indian-born men have more than twice the prevalence rates of alcohol related disorders than White men and alcohol related admissions accounted for 25% of all psychiatric admissions in this group in 1981 (ref 4). There are known gender differences in alcohol and substance misuse. In the general population men are more likely to misuse both. There seems however to be greater social stigma attached to women misusing substances, particularly alcohol. This may lead to women’s problems being missed or ignored, with consequent difficulties in accessing services (ref 5). About 11% of dementia is related to alcohol use and is consequently preventable (ref 6). &lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111320:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111322:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;1.&amp;nbsp;Merrill J, Milner G, Owens J and Vale A (1992) Alcohol and attempted suicide. British Journal of Addictions. 87: 83-89.&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Took M (2001) Homeless People with a Severe Mental Illness. National Schizophrenia Fellowship Policy Statement&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Cohen A and Phelan M (2001) The Physical Health of Patients with Mental Illness: a neglected area. Mental Health Promotion Update 2:15-16&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Cochrane R and Bal S (1989) Mental Hospital admission rates of immigrants to England. Social Psychiatry and Psychiatric Epidemiology 24:2-12&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Department of Health (2002) &lt;A href="http://www.dh.gov.uk/assetRoot/04/07/54/87/04075487.pdf" target="_blank"&gt;Women’s Mental Health:Into the Mainstream: Strategic Development of Mental Health Care for Women &lt;/A&gt;London. Department of Health&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Audit Commission (2000) &lt;A href="http://www.audit-commission.gov.uk/reports/NATIONAL-REPORT.asp?CategoryID=&amp;amp;ProdID=4EEC12F0-AA9A-4CB0-90AE-7FC5CB6584CE" target="_blank"&gt;Forget me not&lt;/A&gt;. London: Audit Commission.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>111317</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111317]]&gt;</url>
    <title>Suicide</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION,OUTCOMES,EDUCATION,ENVIRONMENTAL,CAUSES OF HARM,UNEMPLOYMENT,MENTAL &amp; BEHAVIOURAL DISORDERS,SOCIAL SUPPORT,DISADVANTAGED GROUPS,POPULATION BASED &amp; PREVENTATIVE SERVICES,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SERVICES,POPULATIONS,GROUPS,COMMUNITIES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Suicide&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111306:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111318:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;Suicide is a significant cause of unexpected mortality worldwide. Between 800k - 1m people die internationally from suicide annually and for every one of these deaths, 10 to 20 times more people attempt suicide. This equates to one death every 40 seconds and one attempt every 3 seconds (ref 1).&lt;/P&gt;
&lt;P&gt;In England there are more than 5000 suicide deaths per annum. On average one person dies every two hours. In the last 20 years or so, suicide rates have fallen in older men and women, but risen in young men (ref 2).The majority of suicides now occur in young adult males and in men under the age of 35, suicide is the most common cause of death.&lt;/P&gt;
&lt;P&gt;Risk factors for suicide operate at individual and social levels. For example a history of attempted suicide (parasuicide) has been linked to completed suicide, even after an interval of many years. (ref 3,4).&lt;/P&gt;
&lt;P&gt;Clinically untreated deliberate self-harm can lead to suicide. A cross sectional anonymous survey with 15-16 yr olds in England found more common occurrence in females than males. Risk factors for girls were recent self-harm by friends or family members, drug misuse, depression, anxiety, impulsivity and low self-esteem. For boys risk factors included suicidal behaviour in family and friends, drug use and low self-esteem (ref 5). &lt;/P&gt;
&lt;P&gt;A systematic review of efficacy of psychosocial and pharmacological treatments in preventing repetition of self-harm concluded that there was considerable uncertainty about which forms of treatment might be most effective (ref 6). Promising results were found for problem solving therapy, provision of a card to allow patients to make emergency contact with services, depot flupenthixol for recurrent self-harm and long-term psychological therapy for female patients with borderline personality disorder and recurrent self-harm. However the included trials had too few patients to detect clinically significant effects.&lt;/P&gt;
&lt;P&gt;Relative deprivation, i.e. not absolute poverty or deprivation but where you are relative to others, is a risk factor both for mental health problems in general and also for suicide (ref 7).&amp;nbsp; Eroded ‘social capital’ undermines societal norms and networks that make up our individual and community interactions (ref 8, 9). Suicide is strongly associated with social fragmentation, characterised by neighbourhoods with high levels of private renting, single person households, unmarried persons and mobility (ref 10). &lt;/P&gt;
&lt;P&gt;Unemployed men are twice as likely to kill themselves as their employed counterparts, with low socio-economic status strongly associated with increased risk. For women, unemployment also increases the risk of suicide, with the association strengthening with length of unemployment. (ref 11).&lt;/P&gt;
&lt;P&gt;Suicidal behaviour, particularly deliberate self-harm, is much higher in manual occupational social groups and the unemployed (ref 6, 12) and is most strongly associated with socio-economic deprivation.&lt;/P&gt;
&lt;P&gt;Some commentators hold the view that there is insufficient knowledge about factors that are likely to protect against suicide, such as coping skills and problem-solving capabilities, social support and connectedness. (ref 7, 13). However evidence from a range of evidence does not support this view.&lt;/P&gt;
&lt;P&gt;For example, a qualitative study amongst people with severe and enduring mental health problems found that, in their view, social networks such as discussing their suicidal feelings with friends or relatives, were considered just as helpful as psychiatric services. Religious beliefs and affiliations were also helpful. Three-quarters of patients were in contact with psychiatric services when feeling at their lowest, and this contact was generally thought to be helpful. Negative influences included the media and the stigma of psychiatric illness.&lt;BR&gt;(ref 14).&lt;/P&gt;
&lt;P&gt;Efforts at suicide prevention might usefully focus on enhancing the social networks of people who use mental health services, increasing the likelihood of early contact with psychiatric services and decreasing the stigma attached to psychiatric illness.&lt;/P&gt;
&lt;P&gt;The importance of social support was highlighted in research amongst those in later life (ref 15). Significantly fewer suicide deaths occurred among elderly users of a telephone helpline than expected, despite an assumed overrepresentation of persons at increased risk. The service provided twice-weekly support and needs assessment telephone calls and a 24h emergency alarm service.&lt;/P&gt;
&lt;P&gt;A suicide prevention programme in Dorset, which was implemented in 1994, has seen a reduction in prevalence amongst young men from 25 per 100,000 to 10 per 100,000 (ref 16). Cross-agency working together with a willingness to explore gender issues have underpinned the success of the programme to date.&lt;/P&gt;
&lt;P&gt;At an individual level, there is a need to focus on the significance of socio-cultural factors in preventing suicide. It is important to examine risk and protective factors for suicide and also how they may vary in different localities and for different cultural groups (ref 17). An understanding of risk factors for poor mental health and protective factors for positive mental health underpin both mental health promotion and public mental health.&lt;/P&gt;
&lt;P&gt;At a community level, initiatives which aim to tackle inequalities and regenerate deprived communities will benefit from a greater awareness of how a range of factors combine cumulatively to increase suicide risk for individuals living in deprived localities. Local Strategic Partnerships, Neighbourhood Renewal and Community Safety Partnerships can all contribute to achieving suicide reduction targets.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111306:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111318:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;World Health Organisation (2001) &lt;A href="http://www.who.int/whr2001/2001/" target="_blank"&gt;World Health Report&lt;/A&gt;. Geneva: WHO&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Department of Health (2002) &lt;A href="http://www.dh.gov.uk/assetRoot/04/01/95/48/04019548.pdf" target="_blank"&gt;National Suicide Prevention Strategy&lt;/A&gt;. London: The Stationery Office.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Runeson B (2002) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/325/7373/1125/a" target="_blank"&gt;Suicide after parasuicide&lt;/A&gt;. BMJ 325: 1125-1126&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Jenkins et al (2002) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/325/7373/1155" target="_blank"&gt;Suicide rate 22 years after parasuicide: cohort study&lt;/A&gt;. BMJ 325: 1155&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Hawton et al (2002) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/325/7374/1207" target="_blank"&gt;Deliberate self-harm in adolescents: self report survey in schools in England&lt;/A&gt;. BMJ 325:1207-1211&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Hawton K, Arensman E, Townsend E et al (1998) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/317/7156/441?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=Deliberate%2Bself%2Bharm%3A%2Bsystematic%2Breview%2Bof%2Befficacy%2Bof%2Bpsychosocial%2Band%2Bpharmacological%2Btreatments%2Bi&amp;amp;searchid=1074004495430_7720&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;volume=317&amp;amp;issue=7156" target="_blank"&gt;Deliberate self harm: systematic review of efficacy of psychosocial and pharmacological treatments in preventing repetition &lt;/A&gt;British Medical Journal 317:441-447&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Gunnell et al (2003) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/182/2/164" target="_blank"&gt;Influence of cohort effects on patterns of suicide in England and Wales, 1950-1999&lt;/A&gt;. British Journal of Psychiatry 182:164-170&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Wilkinson R (1996) Unhealthy Societies: The afflictions of inequality. London: Routledge&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Cooper H, Arber S, Fee L and Ginn J (1999) The Influence of Social Support and Social Capital on Health. London: Health Education Authority&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Davey Smith G, Whitley E, Dorling D and Gunnell D (2001) Area based measures of social and economic circumstances: cause specific mortality patterns depend on the choice of index Journal of Epidemiology and Community Health 55:149-150&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Kposowa AJ (2001) Unemployment and suicide: a cohort analysis of social factors predicting suicide in the US National Longitudinal Mortality Study Psychological Medicine 31:127-138&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Hawton K and Fagg J (1992) Deliberate self-poisoning and self-injury in adolescents. A study of characteristics and trends in Oxford 1976-1989 British Journal of Psychiatry 161:816-823&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;De Leo D (2002) Why are we not getting any closer to preventing suicide? Br. J. Psychiatry 181:372-374&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Eagles JM, Carson DP, Begg A, and Naji SA (2003) &lt;A href="http://bjp.rcpsych.org/cgi/content/abstract/182/3/261" target="_blank"&gt;Suicide prevention: a study of patients' views&lt;/A&gt; British Journal of Psychiatry 182: 261-265&amp;nbsp;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;De Leo D, Dello Buono M and Dwyer J (2002) &lt;A href="http://bjp.rcpsych.org/cgi/content/full/181/3/226?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;title=Suicide%2Bamong%2Bthe%2Belderly&amp;amp;andorexacttitle=phrase&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074003888319_2649&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;journalcode=bjprcpsych" target="_blank"&gt;Suicide among the elderly: the long-term impact of a telephone support and assessment intervention in northern Italy &lt;/A&gt;Br. J. Psychiatry 181: 226 - 229.&lt;BR&gt;&lt;BR&gt;16.&amp;nbsp;&lt;A href="http://www.hda.nhs.uk/" target="_blank"&gt;Health Development Agency&lt;/A&gt;&amp;nbsp;(2002) Boys’ and young men’s health: what works?&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;DeLeo D (2003) Preventing suicide and Author’s replies. &lt;A href="http://bjp.rcpsych.org/" target="_blank"&gt;British Journal of Psychiatry&lt;/A&gt;. 182: 364-366.&lt;/P&gt;
&lt;P&gt;Office for National Statistics (1998) &lt;A href="http://www.statistics.gov.uk/CCI/article.asp?ID=622&amp;amp;Pos=&amp;amp;ColRank=1&amp;amp;Rank=224" target="_blank"&gt;Geographic variations in suicide mortality 1982-1996&lt;/A&gt; Population Trends HMSO&lt;/P&gt;
&lt;P&gt;Williams, J.M.G. &amp;amp; Pollock, L.R. (2001) Psychological aspects of the suicidal process. In K. van Heeringen (Ed.) Understanding Suicidal Behaviour. Chichester, John Wiley.pp. 76-93.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317734</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/entity/mental_health/resources/suicide_prevention_asia.pdf]]&gt;</url>
    <title>Suicide and Suicide Prevention in Asia PDF</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>WHO UK Collaborating Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=Times-Roman size=3&gt;&lt;FONT face=Times-Roman size=3&gt;
&lt;P align=left&gt;The research and policy attention that suicide prevention has received in Asia has been relatively small in comparison with the magnitude of the problem. More than half of the suicides that occur globally every year come from the South-East Asia and Western Pacific regions. Suicide is among the leading causes of death and, among young people, the leading cause of death in many Asian countries.&lt;/P&gt;
&lt;P align=left&gt;Suicide is a complex, yet preventable public health problem resulting from the interaction of psychological, social, biological, and environmental factors. The prevention of suicide is equally complex and, while feasible, is no easy task: it involves a whole series of activities, ranging from the environmental control of risk factors and means, through the early identification and effective treatment of people with mental and substance use disorders, to the responsible reporting of suicide in the media. Comprehensive public health action to prevent suicide addresses the population at large as well as particularly vulnerable groups, such as young people or those who attempted suicide. The involvement of various sectors (e.g., health,education, labour, agriculture) needs to be sought as well as the engagement of various partners (e.g., governments, nongovernmental organizations).&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>289772</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085969]]&gt;</url>
    <title>Support, time and recovery (STR) workers: a competence framework: best practice guidance</title>
    <publicationDate>2008-07-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This best practice guidance sets out the background, purpose, and development of the Competence Framework for Support, Time and Recovery (STR) workers employed across health and social care sectors of mental health.</description>
    <body>&lt;![CDATA[ This best practice guidance sets out the background, purpose, and development of the Competence Framework for Support, Time and Recovery (STR) workers employed across health and social care sectors of mental health. It supports the original STR guidance of 2003 and the STR handbook of 2007.]]&gt;</body>
  </document>
  <document>
    <id>268363</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=24693&amp;Rendition=Web]]&gt;</url>
    <title>Supporting women into the mainstream: Commissioning women-only community day services</title>
    <publicationDate>2006-03-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This best practice guidance is intended to support commissioners in delivering Section 6.1 of the implementation guidance 'Mainstream gender and women's mental health' on women-only community day services docetailing with the recommendations set out in the 'Mental health and social exclusion' report relating to day services.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This best practice guidance is intended to support commissioners in delivering Section 6.1 of the implementation guidance 'Mainstream gender and women's mental health' on women-only community day services docetailing with the recommendations set out in the 'Mental health and social exclusion' report relating to day services.&lt;/P&gt;
&lt;P&gt;Day services cover a range of services with women-only day support being primarily provided by the voluntary sector and mental health day centres being provided by the NHS and local authorities. This document uses the term 'day services' to cover this broad range of provision and therefore covers all sectors which provide day time support to women.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268508</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcarecommission.org.uk/_db/_documents/Community_mental_health_survey-2007.pdf]]&gt;</url>
    <title>Survey of users of mental health services 2007</title>
    <publicationDate>2007-09-03T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Healthcare Commission carried out this survey in 69 NHS trusts that provide secondary mental health services (including combined mental health and social care trusts and primary care trusts that provide mental health services). Secondary mental health services provide care to people, in psychiatric outpatient clinics or through a local community mental health team.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Healthcare Commission carried out this survey in 69 NHS trusts that provide secondary mental health services (including combined mental health and social care trusts and primary care trusts that provide mental health services). Secondary mental health services provide care to people, in psychiatric outpatient clinics or through a local community mental health team.&lt;/P&gt;
&lt;P&gt;This is the fourth survey of users of mental health services. Completed questionnaires were received from 21,047 service users, representing a national response rate of 37%.&lt;/P&gt;
&lt;P&gt;Although service users aged 16 years and older were included in the sample for the survey, only those aged 16 to 65 years are included in the briefing note, national spreadsheets and benchmark reports to enable fair comparison of the results with those from previous years. Questionnaires were returned by 15,986 service users aged 65 years and under, a response rate of 38%.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294235</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcarecommission.org.uk/yourviews/patientsurveys/mentalhealthservices.cfm]]&gt;</url>
    <title>Survey of users of mental health services 2008</title>
    <publicationDate>2008-09-12T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is the fifth annual survey of community mental health services carried out by the Healthcare Commission.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Survey of users of mental health services 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;This is the fifth annual survey of community mental health services carried out by the Healthcare Commission.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The survey included 68 NHS trusts that provide secondary mental health services (including combined mental health and social care trusts, and primary care trusts that provide mental health services). Secondary mental health services provide care to people in psychiatric outpatient clinics or through a local community mental health team.&lt;/P&gt;
&lt;P&gt;Over 14,000 service users took part in the 2008 survey, which is a response rate of 35%. The results of the survey offer a valuable insight into the experiences of service users, and can be used to improve the quality of the care they receive.&lt;/P&gt;
&lt;P&gt;Although service users aged 16 and above were included in the sample for the survey, only those aged 16 to 65 are included in the briefing note, the national spreadsheets and the benchmark reports, in order to enable a fair comparison of the results with those from previous years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;There are a number of supporting documents for the 2008 survey:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Press release on 2008 community mental health survey:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.healthcarecommission.org.uk/newsandevents/pressreleases.cfm?cit_id=6544&amp;amp;widCall1=customWidgets.content_view_1&amp;amp;usecache=false" target="_blank"&gt;Click here to view the press release&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Supporting briefing note highlighting key issues&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The briefing note is based on respondents aged 16 to 65.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.healthcarecommission.org.uk/_db/_documents/Supporting_briefing_note.pdf" target="_blank"&gt;Supporting briefing note&lt;/A&gt; (pdf 41kb) (opens new window)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Full 2008 results with historical comparisons&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;These tables show the national percentage results from the 2008 survey compared with previous years (where questions have been asked previously). The results are based on respondents aged 16 to 65.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.healthcarecommission.org.uk/_db/_documents/Full_2008_results_with_historical_comparisons.pdf" target="_blank"&gt;Full 2008 results with historical comparisons&lt;/A&gt; (pdf 1740kb) (opens new window)&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>268362</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=13535&amp;Rendition=Web]]&gt;</url>
    <title>Tackling the health and mental health effects of domestic and sexual violence and abuse</title>
    <publicationDate>2006-03-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ DOMESTIC VIOLENCE OR PARTNER ABUSE,LIFESTYLE AND SOCIAL ISSUES,DOMESTIC VIOLENCE,MENTAL HEALTH,ADULT CONDITIONS,DOMESTIC VIOLENCE,SEXUAL ASSAULT,POSTNATAL DISORDERS,ANTENATAL PROBLEMS,SEXUAL HEALTH,COMPLICATED PREGNANCY,DETERMINANTS,MATERNAL CARE,STANDARDS OF PRACTICE,WOMEN'S HEALTH,DOMESTIC VIOLENCE,PUBLIC HEALTH,GENERAL HEALTH CONCERNS,GOOD PRACTICE,SOCIAL DETERMINANTS,MONTHLY ADDITIONS,2009 SEPTEMBER,ABUSE,DOMESTIC VIOLENCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This document sets out a programme of work to equip services and professionals to identify and respond to the health and mental health needs of individuals affected by domestic violence, childhood sexual abuse, rape, oblique sexual assault and sexual exploitation including children, adolescents, and adults, both victims and abusers, male and female.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This document sets out a programme of work to equip services and professionals to identify and respond to the health and mental health needs of individuals affected by domestic violence, childhood sexual abuse, rape, oblique sexual assault and sexual exploitation including children, adolescents, and adults, both victims and abusers, male and female.&lt;/P&gt;
&lt;P&gt;This has been jointly produced by:&lt;/P&gt;
&lt;P&gt;Department of Health&lt;BR&gt;National Institute for Mental Health in England (NIMHE)&lt;BR&gt;Victims of Violence and Abuse Prevention Programme (VVAPP) Health and Mental Health Programme Implementation Guide In Partnership with the Home Office&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268327</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38655&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Talking Therapies Update</title>
    <publicationDate>2002-02-04T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on qualitative research undertaken to explore the treatments, therapies, and self-help strategies that people who experience mental distress find helpful.</description>
    <body>&lt;![CDATA[ Update briefing on qualitative research undertaken to explore the treatments, therapies, and self-help strategies that people who experience mental distress find helpful. People identified a number of ways in which talking therapies were helpful to them, most relating more to the ‘human relations’ elements of therapy than the type of therapeutic approach used.]]&gt;</body>
  </document>
  <document>
    <id>271013</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=271013]]&gt;</url>
    <title>The 2006/07 National Survey of Investment in Mental Health Services</title>
    <publicationDate>2007-10-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>An annual survey of planned investment in adult mental health services by independent consultants, Mental Health Strategies. It shows that in 2006-7, for the fifth year in a row, real investment in mental health services increased.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The 2006/07 National Survey of Investment in Mental Health Services&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;An annual survey of planned investment in adult mental health services by independent consultants, Mental Health Strategies. It shows that in 2006-7, for the fifth year in a row, real investment in mental health services increased.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>295142</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088701]]&gt;</url>
    <title>The 2007/08 national survey of investment in mental health services</title>
    <publicationDate>2008-09-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This is the sixth annual report presenting the results of the finance mapping exercise carried out as part of the autumn review process. It provides details of the level of  investment in adult mental health services in England  for  2007/08 and compares it with the reported  results in the five previous years.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the sixth annual report presenting the results of the finance mapping exercise carried out as part of the autumn review process. It provides details of the level of&amp;nbsp; investment in adult mental health services in England&amp;nbsp; for&amp;nbsp; 2007/08 and compares it with the reported&amp;nbsp; results in the five previous years.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The adult mental health analysis provides the following overall key findings:&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Total investment increased from £5.163 billion in 2006/7 to £5.530 billion in 2007/8, which is a 7.1% increase in amount, and 3.7% in real terms.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;In the last five years since 2002/03, total investment has increased by £1.276 billion which is 30% in real terms, from £4.253 billion to £5.530 billion in 2007/08. &lt;/LI&gt;
&lt;LI&gt;There was a 2% rise between 2006/07 and 2007/08 in the services reported directly delivered by the non-statutory sector, whose market share is now 21%, balanced by 1% falls in the share of services delivered by both NHS and Local Authority providers. &lt;/LI&gt;
&lt;LI&gt;The percentage of investment reported in direct services has again risen and stands at 81.4%. This is a part of a slight but steady improvement which has seen direct services rise by 6% from 75.4% in 2002/03. &lt;/LI&gt;
&lt;LI&gt;Investment in the three priority areas (crisis resolution, early intervention and assertive outreach) has risen in real terms by 15% in the last year 2006/07 to 2007/08 &lt;/LI&gt;
&lt;LI&gt;All SHAs reported increased levels of investment with most reporting real term increases, after inflation, ranging from 2.3% and 12%. Two SHAs reported small decreases&amp;nbsp; in&amp;nbsp; real term investment. &lt;/LI&gt;
&lt;LI&gt;London reported a small real term drop in investment since 2006/07 (-0.9%), but still spends the highest amount per weighted head (9.2% above the national average). &lt;/LI&gt;
&lt;LI&gt;The amount invested per weighted head varies between SHAs, by between 9.2% above and 6.5% below the national average (£169) &lt;/LI&gt;
&lt;LI&gt;Total investment in adult mental health services in 2007/08 was £5.530 billion, or £169 per head of weighted adult population (18-64).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088701?IdcService=GET_FILE&amp;amp;dID=149083&amp;amp;Rendition=Web" target="_blank"&gt;Download 2007/08 national survey of investment in mental health services (PDF, 1091K)&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296394</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ajp.psychiatryonline.org/index.dtl]]&gt;</url>
    <title>The American Journal of Psychiatry</title>
    <publicationDate></publicationDate>
    <publisher>American Psychiatric Publishing, Inc.</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The American Journal of Psychiatry&amp;nbsp;is published twelve times per year and features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Perspectives&lt;/LI&gt;
&lt;LI&gt;Treatment in Psychiatry&lt;/LI&gt;
&lt;LI&gt;New Research&lt;/LI&gt;
&lt;LI&gt;Communications and Updates&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;This journal is available from NLH with an Athens log-in:. &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;Click here to register for Athens&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332067</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.its-services.org.uk/silo/files/the-commissioning-friend-for-mental-health-services.pdf]]&gt;</url>
    <title>The Commissioning Friend for Mental Health Services</title>
    <publicationDate>2009-12-02T00:00:00</publicationDate>
    <publisher>Commissioning Support for London and the National Mental Health Development Unit</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Commissioning high quality modern mental health services presents real challenges - but help is at hand for commissioners with the publication of a new guide today. &amp;nbsp;‘The Commissioning Friend for Mental Health Services' is designed to support primary care trusts and local authorities and assist them in developing their mental health commissioning practice. &lt;/P&gt;
&lt;P&gt;Published jointly by Commissioning Support for London and the National Mental Health Development Unit, the guide, which covers mental health services across England, will act as a useful reference tool and up to date "friend" on key issues to support commissioners to carry out their day to day work.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The guide provides an invaluable insight into: &lt;/P&gt;
&lt;UL type=square&gt;
&lt;LI&gt;key challenges for mental health commissioners&lt;/LI&gt;
&lt;LI style="TEXT-ALIGN: justify"&gt;understanding the policy and legislative framework&lt;/LI&gt;
&lt;LI&gt;personalisation - giving people more choice over services and decision making control to individual service users&lt;/LI&gt;
&lt;LI&gt;the commissioning context&lt;/LI&gt;
&lt;LI&gt;co-production, partnership and integration&lt;/LI&gt;
&lt;LI&gt;effective mental health commissioning&lt;/LI&gt;
&lt;LI&gt;measuring effectiveness&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>282203</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scmh.org.uk/pdfs/scmh_mental_health_treatment_requirement_paper.pdf]]&gt;</url>
    <title>The Community Order and the Mental Health Treatment Requirement</title>
    <publicationDate>2008-01-09T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The report looks at the mental health treatment requirement and examines barriers to its use for offenders in the community.</description>
    <body>&lt;![CDATA[ &lt;P&gt;It is estimated that half of people on community orders have at least one mental health problem, yet fewer than one per cent of community orders issued in 2006 contained a requirement for mental health treatment.&lt;/P&gt;
&lt;P&gt;The report looks at the mental health treatment requirement and examines barriers to its use for offenders in the community.&lt;/P&gt;
&lt;P&gt;This marks the beginning of our research into the Community Order and the mental health treatment requirement as part of our criminal justice programme.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259581</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.iop.kcl.ac.uk/IoP/Departments/PsychMed/EDU/professionals/MentalHealthAct.shtml]]&gt;</url>
    <title>The Eating Disorders Unit: Mental Health Act</title>
    <publicationDate></publicationDate>
    <publisher>Institute of Psychiatry Eating Disorders Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Mental Health Act and Eating Disorders.]]&gt;</body>
  </document>
  <document>
    <id>324805</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103443.pdf]]&gt;</url>
    <title>The evidence base to guide development  of Tier 4 AMHS</title>
    <publicationDate>2009-07-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Until recently the idea of Tier 4 specialist CAMHS was synonymous with psychiatric inpatient provision, sometimes with day hospitals attached. Tier 4 has more recently come to be understood as multi-faceted with multi-agency services that can include inreach, outreach, intensive and crisis community initiatives, day provision, therapeutic fostering and other services that may be described as 'wrap around'. What we have seen over the past few years are innovative approaches in assessment and treatment of this most complex group of young people and the development of new intensive community focussed services.&lt;/P&gt;
&lt;P&gt;The purpose of this paper is to present the latest information on these new developments and share with commissioners and providers the evidence base for development of effective services in this area.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321543</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_103444?IdcService=GET_FILE&amp;dID=202273&amp;Rendition=Web]]&gt;</url>
    <title>The evidence base to guide development of Tier 4 CAMHS</title>
    <publicationDate>2009-07-29T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,COMMUNITY CHILD HEALTH,MENTAL HEALTH,HEALTH MANAGEMENT,SPECIALTIES,SERVICE SECTORS,MENTAL HEALTH SERVICES,MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Until recently the idea of Tier 4 specialist CAMHS was synonymous with psychiatric inpatient provision, sometimes with day hospitals attached. Tier 4 has more recently come to be understood as multi-faceted with multi-agency services that can include inreach, outreach, intensive and crisis community initiatives, day provision, therapeutic fostering and other services that may be described as 'wrap around'. What we have seen over the past few years are innovative approaches in assessment and treatment of this most complex group of young people and the development of new intensive community focussed services.&lt;/P&gt;
&lt;P&gt;The purpose of this paper is to present the latest information on these new developments and share with commissioners and providers the evidence base for development of effective services in this area.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291063</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.officefordisability.gov.uk/research/eedp.asp]]&gt;</url>
    <title>The Experiences and Expectations of Disabled People</title>
    <publicationDate>2008-07-25T00:00:00</publicationDate>
    <publisher>Office for Disability Issues</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A new research report commissioned by the Government shows that whilst progress is being made, disabled people in Britain are still more likely than non-disabled people to experience disadvantage in a variety of areas.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A new research report commissioned by the Government shows that whilst progress is being made, disabled people in Britain are still more likely than non-disabled people to experience disadvantage in a variety of areas.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Experiences and Expectations of Disabled People, the first comprehensive study of disability issues in six years, looked at key policy areas including employment, education, transport, health and discrimination across Great Britain in 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The research, which was commissioned by the Office for Disability Issues (ODI), provides a unique snapshot of the lives of nearly 2,000 disabled people. The study was ground-breaking in that it actively involved disabled people throughout the research process.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.officefordisability.gov.uk/research/pdfs/eedp-exec-summary.pdf" target="_blank"&gt;Executive summary&lt;/A&gt; (PDF, 1.85 MB, 48 pages)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.officefordisability.gov.uk/research/rtf/eedp-exec-summary.rtf" target="_blank"&gt;Executive summary&lt;/A&gt; (RTF, 73 kB, 48 pages)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.officefordisability.gov.uk/research/pdfs/eedp-easy-read.pdf" target="_blank"&gt;Easy Read version&lt;/A&gt; (PDF, 2.58 MB, 38 pages)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.officefordisability.gov.uk/research/pdfs/eedp-full-report.pdf" target="_blank"&gt;Full report&lt;/A&gt; (PDF, 4.39 MB, 248 pages)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.officefordisability.gov.uk/research/rtf/eedp-full-report.rtf" target="_blank"&gt;Full report&lt;/A&gt; (RTF, 1.25 MB, 248 pages)&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>291245</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_086478]]&gt;</url>
    <title>The first annual report of the Independent Mental Capacity Advocacy Service. Year 1,  April 2007 - March 2008</title>
    <publicationDate>2008-07-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Independent Mental Capacity Advocate (IMCA) service was established under the MCA in April 2007. This is the first annual report.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;SUMMARY&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;The Mental Capacity Act 2005 created the Independent Mental Capacity Advocate (IMCA) service as a safeguard for people without the capacity to make certain important decisions. 
&lt;LI&gt;The Act also introduced a legal duty on NHS and social care staff to refer eligible people to the IMCA service. The IMCA service started on 1st April 2007 and this is the report on its first year’s work. 
&lt;LI&gt;The Act envisaged the IMCA service being built on good practice in the independent advocacy sector. The Department of Health (DH) made a new grant available to Local Authorities working with PCTs to commission the new service from the advocacy sector; it also issued commissioning guidance. Commissioning was greatly assisted by the experience of seven pilot IMCA organisations and the Cambridge University report on the pilots. 
&lt;LI&gt;A large number of existing advocacy organisations were successfully commissioned, many at short notice, to develop the new service. National IMCA training was developed and IMCAs were trained in the three months prior to April 1st 2007. 
&lt;LI&gt;The role of the IMCA has been to represent and support people without capacity, and mainly without family or friends to support them, in important decisions. Five thousand, one hundred and seventy five (5,175) people received representation from the IMCA service in its first year. 
&lt;LI&gt;Three thousand and forty seven (3047) of the representations were for decisions on accommodation moves; 191 people were represented in care reviews; 671 represented in decisions about serious medical treatment and 675 were represented in adult protection proceedings. 
&lt;LI&gt;The Department of Health’s assessment of the first year was that a great deal had been achieved. 
&lt;LI&gt;Achievements for individual people included: better decision making for the most vulnerable people; a specialist service which has time for individuals who have limited capacity to communicate their wishes; a more holistic approach to decision making, particularly in the NHS; and a more rights based approach to looking at options. 
&lt;LI&gt;There were also achievements which went beyond the individuals. These are about the creation of: a new form of advocacy, a new profession and a new safeguard. 
&lt;LI&gt;Independent mental capacity advocacy is a specialist and very targeted, issue focussed form of advocacy. It works holistically with the whole person, but in relation to specific decisions that need to be made. Independent mental capacity advocates are a new profession with a statutory role. This role involves a duty to represent some of the most vulnerable people in society, vulnerable both due to their lack of capacity and due to their social isolation. The new profession has the right to question and to challenge and the power to identify and highlight poor individual and institutional practice, thereby providing new safeguards. 
&lt;LI&gt;At the same time the Department has concerns about the following three issues:&lt;BR&gt;i Referrals should be at a higher level for all decisions – suggesting that awareness of, or compliance with, the Act is insufficient. There are also wide geographical differences which raises concern.&lt;BR&gt;ii Referrals for Serious Medical Treatment are particularly low across the whole country, raising concerns about the extent to which the NHS is, at present, complying with the requirements of the Act.&lt;BR&gt;iii Gate-keeping by IMCA organisations needs to be reviewed. 
&lt;LI&gt;IMCAs have been created by the Act, as a specialist resource, a new statutory addition to the health and social care economy. They have had a strong first year, demonstrating that they are able to support and represent some of the most vulnerable people. In the next year their role will be increased by more referrals and extended in many places by the campus closure programme for people with learning disabilities and by the Deprivation of Liberty safeguards. They will be expected to grow in skills, in levels of confidence and in vision. They will play an increasing part in linking two challenging agendas: the personalisation agenda and the safeguarding agenda – a task that the whole of social and health care economy is struggling with.&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
  </document>
  <document>
    <id>263053</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38733&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>The impact of spirituality on mental health</title>
    <publicationDate>2006-07-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A literature review of the evidence linking spirituality and religious expression with different aspects of mental health and, in particular, different mental health problems. Written by Dr Deborah Cornah.</description>
    <body>&lt;![CDATA[ A literature review of the evidence linking spirituality and religious expression with different aspects of mental health and, in particular, different mental health problems. Written by Dr Deborah Cornah.]]&gt;</body>
  </document>
  <document>
    <id>283446</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.depressionalliance.org/documents/Inside-Story-Report.pdf]]&gt;</url>
    <title>The Inside Story: The impact of depression on daily life</title>
    <publicationDate>2008-04-21T00:00:00</publicationDate>
    <publisher>Depression Alliance (England)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,DEPRESSION,DETERMINANTS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,DEPRESSION,PUBLIC HEALTH,SOCIAL DETERMINANTS,PSYCHOLOGICAL DETERMINANTS,LIFESTYLE,IMPACT ASSESSMENT,ANALYSIS,METHODS,MONTHLY ADDITIONS,2008-AUGUST,ANALYSIS &amp; RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The development of this survey and the report into its findings were undertaken in partnership with and funded by Servier Laboratories Limited.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;This report reveals the inside story on depression at work.&lt;BR&gt;&lt;/H2&gt;
&lt;P&gt;People with depression are in need of more help and support from their employers and colleagues according to the results of new research revealed to coincide with Depression Awareness Week 2008 (21-26 April).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A report, published by Depression Alliance and funded by Servier Laboratories Limited, reveals the majority (79%) of people diagnosed with depression in the UK feel disclosing their condition to colleagues would have a detrimental impact on them, and nearly a third (32%) believe they have been turned down for a job.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381571</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealth.org.uk/EasySiteWeb/getresource.axd?AssetID=78999&amp;type=full&amp;servicetype=Attachment]]&gt;</url>
    <title>The lonely society?</title>
    <publicationDate>2010-05-25T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=oDataFormQuestion&gt;
&lt;DIV class=oDataFormLabel&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV class=oDataFormAnswerText&gt;
&lt;DIV class=oDataFormAnswerTextStyle&gt;&lt;SPAN style="COLOR: black" class=OneCE&gt;&lt;SPAN style="COLOR: black"&gt;This report examines how modern society has changed the way people connect. It aims to raise awareness of loneliness and its effect on our mental health, detailing steps we can take to reduce isolation. &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/DIV&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>317753</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.rcpsych.ac.uk/files/pdfversion/cr152.pdf]]&gt;</url>
    <title>The Management of patients with physical and psychological problems in primary care: a practical guide PDF</title>
    <publicationDate>2009-01-02T00:00:00</publicationDate>
    <publisher>Royal College of Psychiatrists</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal&gt;This report aims to highlight the importance of improving the management of individuals with both physical and psychological problems in primary care. Depression and anxiety are common in physical illness, yet, mental health services are separated from physical health services with separate commissioning processes, targets and service boundaries.&lt;/P&gt;
&lt;P class=MsoNormal&gt;As commissioning arrangements in England change, this report takes the opportunity to contribute positively to the provision of needs-led integrated services for people with both comorbid physical and mental health needs – as these individuals often fall through the funding gap between physical and mental health commissioners.&lt;/P&gt;
&lt;P class=MsoNormal&gt;Most liaison psychiatry has traditionally been hospital-based, but as health services in England change, with more individuals receiving their treatment in primary care, liaison services can provide valuable support to GPs and Tier 2 services, in addition to acute hospital work.&lt;/P&gt;
&lt;P class=MsoNormal&gt;A general practitioner (GP) is usually the first health professional to whom people turn when they develop symptoms. The report has been written as a practical guide to improve the detection and management of psychological issues and problems in the context of diagnosing and managing physical illness in the primary care setting. It is jargon-free, yet full of useful professional guidance and advice. Twelve overall recommendations and five action points are given. GP registrars and trainee psychiatrists should find it helpful.&lt;/P&gt;
&lt;P class=MsoNormal&gt;The report is divided into three sections: Person, Process and Practitioner. In all three, ‘patient-centred bio-psychosocial model’ of care is presented – it tries to move away from a mind/body dichotomy and present an approach based on successful clinical practice and supported by a strong body of research.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>269961</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/SocialCare/Deliveringadultsocialcare/MentalCapacity/MentalCapacityAct2005/DH_078733]]&gt;</url>
    <title>The Mental Capacity Act 2005 - Guide for Directors of Adult Social Services and Chief Executives of NHS Trusts</title>
    <publicationDate>2007-09-26T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Mental Capacity Act 2005 will be fully implemented on 1st October 2007. This document, aimed at Directors of Adult Social Services and Chief Executives of NHS Trusts, provides guidance and support for the implementation of the Act.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The Mental Capacity Act 2005 - Guide for Directors of Adult Social Services and Chief Executives of NHS Trusts&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The Mental Capacity Act 2005 will be fully implemented on 1st October 2007. This document, aimed at Directors of Adult Social Services and Chief Executives of NHS Trusts, provides guidance and support for the implementation of the Act.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>327431</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/SocialCare/Deliveringadultsocialcare/MentalCapacity/MentalCapacityAct2005/DH_078789]]&gt;</url>
    <title>The Mental Capacity Act and research</title>
    <publicationDate>2009-09-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;Research is an important way for us to understand illness and disability and to improve the care and support people receive. This could include testing how effective a certain type of care or treatment is in supporting those who may lack capacity, or finding out what caused a condition such as Alzheimer’s disease. Sometimes this research will only be useful if it involves people who lack the mental capacity to agree to take part, such as investigating what causes conditions like dementia.&lt;/P&gt;
&lt;P&gt;The Mental Capacity Act allows such research to take place but sets out strict rules to protect people who lack capacity to consent to take part in research and to make sure their current or previous wishes are taken into account.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The research provisions of the Mental Capacity Act 2005 will come into force in England and Wales on 1 October 2007.&lt;/P&gt;
&lt;P&gt;All research ethics committees established in England and Wales under the standards framework Governance arrangements for NHS Research Ethics Committees are appropriate bodies for the purposes of approving research under both section 30 of the Act and the Loss of Capacity Regulations made under section 34 of the Act.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267290</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mentalhealthalliance.org.uk/mentalhealthbill/Alliance_MHAct07_Final_Report.pdf]]&gt;</url>
    <title>The Mental Health Act 2007: the final report</title>
    <publicationDate>2007-07-16T00:00:00</publicationDate>
    <publisher>Mental Health Alliance</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This 'final report' from the Mental Health Alliance examines the Act in the light of the Alliance's values and concerns, and the impact that it is likely to have on the people who are most affected by the Act - service users, their families and carers.</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;The Mental Health Act 2007 comes at the end of eight years of controversy and debate. The Mental Health Alliance was at the forefront of the campaign to change the approach the government took to this legislation and achieve a better outcome for those who have to live with its consequences.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This ‘final report’ examines the Act in the light of the Alliance’s values and concerns: and the impact it is likely to have on the people who are affected most by the Act: service users and their families and carers.&lt;BR&gt;In assessing the 2007 Act, and the impact of the Alliance campaign, we need to ask three key questions:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Has the 2007 Act improved the 1983 Act for service users and their families and carers? 
&lt;LI&gt;Is the 2007 Act better or worse than the draft Bills of 2002 and 2004 (i.e. would we have been better off with the previous attempts at changing the law)? 
&lt;LI&gt;Is the 2007 Act an improvement on the Bill when it was published in 2006 (i.e. have the amendments to the Bill made a real difference)?&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;In brief, we conclude:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;On the first question, it is too early to gauge whether the new Act improves the 1983 Act. There are significant gains, such as the right to advocacy and some treatment safeguards, but there are also worrying developments, such as the creation of community treatment orders and the broader definition of mental disorder. Crucially, however, developments that could have yielded much better legislation, such as greater choice and rights to services, have been omitted.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;On the second question; there is little doubt that the abandonment of the 2004 Bill was a major and unprecedented victory for the Alliance. While some of its worst provisions were retained in the 2006 Bill, modifications were made to some of them – such as limiting CTOs to patients detained in hospital - and these were improvements from our point of view. The 2004 draft Bill would have been a significant and unprecedented worsening of the law for service users and their carers and families.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;On the question of whether the 2006 Bill has been improved as a result of the Alliance’s work, the answer is ‘yes’. Almost all of the benefits that will come from this legislation, such as preventing children from being admitted inappropriately to adult wards, are the result of amendments to the Bill: each had to be wrung from government through the hard work of Alliance members and their supporters. However this does not mean that the Mental Health Act 2007 is a satisfactory or adequate piece of legislation – and we are clear that new legislation fit for the 21st century remains an urgent necessity.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284089</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhac.org.uk/files/From%20Strength%20to%20Strength.pdf]]&gt;</url>
    <title>The Mental Health Act Commission: From Strength to Strength</title>
    <publicationDate>2008-04-25T00:00:00</publicationDate>
    <publisher>Mental Health Act Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,PATIENT AND PUBLIC INVOLVEMENT,ADULT CONDITIONS,HOW DO I INVOLVE...?,PEOPLE WITH MENTAL HEALTH ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report on the first two years of the Mental Health Act Commission Service User Involvement Strategy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Published by the Mental Health Act Commission (MHAC), this report shows that committed engagement of service users throughout the organisation can make a real difference to what an organisation does and achieves. &lt;/P&gt;
&lt;P&gt;It describes how the MHAC has involved service users, the methods used, and how service users have influenced and developed these methods. It also discusses the benefits of user involvement, the barriers to effective involvement, some of the challenges faced, and ways of overcoming these. It provides examples of some of the work that service users have been involved in with the Commission. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271147</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://inspectorates.homeoffice.gov.uk/hmiprisons/thematic-reports1/Mental_Health.pdf?view=Binary]]&gt;</url>
    <title>The mental health of prisoners - A thematic review of the care and support of prisoners with mental health needs</title>
    <publicationDate>2007-10-25T00:00:00</publicationDate>
    <publisher>HM Inspectorate of Prisons</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,DISADVANTAGED GROUPS,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,BUILDINGS,PRISONS,MONTHLY ADDITIONS,POPULATIONS,GROUPS,SETTINGS,2009 MAY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>HM Inspectorate of Prisons has published a report called 'The mental health of prisoners. A thematic review of the care and support of prisoners with mental health needs'. It identifies gaps in services and makes recommendations for improvements.</description>
    <body>&lt;![CDATA[ HM Inspectorate of Prisons has published a report called 'The mental health of prisoners. A thematic review of the care and support of prisoners with mental health needs'. It identifies gaps in services and makes recommendations for improvements.]]&gt;</body>
  </document>
  <document>
    <id>392227</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/news/new-edition-of-the-mental-wellbeing-impact-assessment-toolkit/]]&gt;</url>
    <title>The Mental Well-being Impact Assessment Toolkit</title>
    <publicationDate>2010-10-11T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This new edition of the Mental Well-being Impact Assessment (MWIA) toolkit has been published by the National Mental Health Development Unit in partnership with the English National MWIA Collaborative. &lt;STRONG&gt;Improving population mental health and well-being&amp;nbsp;will be&amp;nbsp;a key theme in the Government's forthcoming Mental Health Strategy and the Public Health White Paper. &lt;/STRONG&gt;The toolkit helps support national, regional and local services and systems across health, local government, the voluntary, community and private sector to embed mental well-being into their work. This version builds on the earlier MWIA Toolkit published in 2007.&lt;BR&gt;&lt;BR&gt;As before, we have made it as practical as possible with full instructions and resources to be used and adapted for your requirements. The Toolkit is presented in downloadable sections. The main new additions are: 
&lt;UL type=disc&gt;
&lt;LI&gt;a significantly strengthened evidence base on the population characteristics, determinants and protective factors for mental wellbeing &lt;/LI&gt;
&lt;LI&gt;a greater emphasis on social determinants of mental well-being such as socio-economic position, environment, transport, education, food, and the understanding of resilience, core economy, social justice and equity&lt;/LI&gt;
&lt;LI&gt;a refined and more user-friendly process for undertaking a Mental Wellbeing Impact Assessment &lt;/LI&gt;
&lt;LI&gt;a revised section on measuring mental well-being with practical explanations of how to identify suitable indicators for your proposal&lt;/LI&gt;
&lt;LI&gt;an improved set of resources including an extensive mental well-being bibliography.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NMHDU is supporting the dissemination of the toolkit and adoption of best practice in MWIA through a national capacity building programme in 2010/11. Details of the programme &lt;A href="http://www.nmhdu.org.uk/en/our-work/promoting-wellbeing-and-public-mental-health/" target="_blank"&gt;can be found here&lt;/A&gt;.&lt;A href="http://www.nmhdu.org.uk/" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recently, NMHDU also launched a Mental Well-being Checklist which can be &lt;/STRONG&gt;&lt;A href="http://www.nmhdu.org.uk/en/news/mental-wellbeing-checklist-available-to-download/" target="_blank"&gt;downloaded from here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260104</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nccmh.org.uk/index.php]]&gt;</url>
    <title>The National Collaborating Centre for Mental Health (NCCMH)</title>
    <publicationDate></publicationDate>
    <publisher>The National Collaborating Centre for Mental Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The NCCMH website provides a single point of access to all products developed by the NCCMH, as well as information about implementation resources and related events. &lt;/P&gt;
&lt;P&gt;The National Collaborating Centre for Mental Health (NCCMH) is one of seven centres established by the National Institute for Health and Clinical Excellence (NICE) to develop guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS in England and Wales. Established in 2001, the NCCMH is responsible for developing mental health guidelines, and is a partnership between the Royal College of Psychiatrists and the British Psychological Society.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314114</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/]]&gt;</url>
    <title>The National Mental Health Development Unit</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>The National Mental Health Development Unit</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NMHDU, launched in April 2009, consists of a small central team and a range of programmes funded by both the Department of Health and the NHS to provide national support for implementing mental health policy by advising on national and international best practice to improve mental health and mental health services. It will do this by commissioning or providing:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; * specialist expertise in priority areas of policy and delivery&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; * effective knowledge transfer on research, evidence and good practice&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; * translation of national policies into practical deliverables that achieve outcomes&lt;BR&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; * coordination of national activity to help regional and local implementation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The new body takes over some of the national activities previously carried out by the National Institute for Mental Health in England (NIMHE) while the ten Strategic Health Authorities (SHAs) will incorporate the resources of the former NIMHE Regional Development Centres to support regional and local delivery.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291244</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.healthcarecommission.org.uk/_db/_documents/The_pathway_to_recovery_A_review_of_NHS_acute_inpatient_mental_health_services.pdf]]&gt;</url>
    <title>The pathway to recovery: a review of the NHS acute inpatient mental health services</title>
    <publicationDate>2008-07-29T00:00:00</publicationDate>
    <publisher>Healthcare Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,PATIENT AND PUBLIC INVOLVEMENT,ADULT CONDITIONS,HOW DO I INVOLVE...?,PEOPLE WITH MENTAL HEALTH ISSUES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The report published by the Healthcare Commission says the quality of the services varies widely across the country. It also identifies areas for action, in particular improving the involvement of patients in their care. The Commission said that despite guidelines to include patients’ views in their care plans, this occurred in only 50% of cases. It concludes that better co-ordination is needed to ensure that service users do not spend any longer in hospital than necessary and are supported when they move from hospital to community services.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;The importance of acute inpatient mental health services&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A key aim of mental health care in England in recent years has been on supporting people to live more independent lives through better care and treatment in the community.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The emphasis placed on strengthening community services has meant that acute inpatient services have not always received the attention needed to ensure that service users are fully involved in planning their own care, and that care is safe and effective.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A number of reports have highlighted concerns about the quality of provision of acute inpatient services, with clear evidence of unmet needs. This has also led to public concern about the safety of these services. In response, the Government set out clear policy and objectives, along with capital investment, to ensure that appropriate acute services are available as part of the pathway of care. A range of national initiatives has been launched to support and coordinate improvement in the quality of these services.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;While this presented a timely opportunity to assess the extent to which the policy objectives have been implemented, it is also important that the findings are considered in the context of current policy objectives – personalised care, improved clinical pathways, and continued reduction in the barriers and stigma that people with mental health problems often face in our society.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327463</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nta.nhs.uk/publications/documents/nta_criminaljustice_0809.pdf]]&gt;</url>
    <title>The role of drug treatment in tackling crime</title>
    <publicationDate>2009-09-30T00:00:00</publicationDate>
    <publisher>National Treatment Agency for Substance Misuse</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The&amp;nbsp;report from&amp;nbsp;&lt;EM&gt;The National Treatment Agency for Substance Misuse&lt;/EM&gt;&amp;nbsp;examines the relationship between drug treatment and how best to tackle crime.]]&gt;</body>
  </document>
  <document>
    <id>328884</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.its-services.org.uk/silo/files/the-role-of-independent-mental-health-advocates.pdf]]&gt;</url>
    <title>The role of independent mental health advocates</title>
    <publicationDate>2009-05-29T00:00:00</publicationDate>
    <publisher>Mental Health Today</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=5 face=StoneSans&gt;&lt;FONT size=5 face=StoneSans&gt;
&lt;P align=left&gt;An independent mental health advocacy service was introduced in England in April as part of the changes to the Mental Health Act. Kay Steven and Jim Symington examine the implications.&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>395089</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/the-role-of-local-government-in-promoting-wellbeing.pdf]]&gt;</url>
    <title>The role of local government in promoting wellbeing</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHDU)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report presents the findings of a project commissioned by Local Government Improvement and Development and the National Mental Health Development Unit.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>345873</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bpsshop.org.uk/The-role-of-Psychology-in-end-of-life-care-P755.aspx]]&gt;</url>
    <title>The Role of Psychology in End of Life Care</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report aims to inform readers of the key issues in end of life care and highlights the role of psychologists within the settings where it takes place. The document is organised around three key domains: Contemporary Issues; Information about Legislation and Policy Issues; Clinical Practice.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>334283</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_110548.pdf]]&gt;</url>
    <title>The second year of the Independent Mental Capacity Advocacy Service: 2008/2009</title>
    <publicationDate>2010-12-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,MENTAL HEALTH SERVICES,MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=1 face=Arial&gt;&lt;FONT size=1 face=Arial&gt;
&lt;P align=left&gt;The Independent Mental Capacity Advocacy Service was created under the Mental Capacity Act 2005. It started in 2007 and this is the annual report of its second year in operation.&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>338976</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111203]]&gt;</url>
    <title>The standard NHS contracts for acute hospital, mental health, community and ambulance services and supporting guidance</title>
    <publicationDate>2010-01-18T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The NHS standard&amp;nbsp;contracts for Mental Health and Learning Disability and Ambulance Services are published today. The Acute Hospital and Community Services will be published later this week&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The contracts&amp;nbsp;support the&amp;nbsp; NHS Operating Framework for 20010-2011: The contracts should be read in conjunction with the&amp;nbsp; Principles and Rules for Co-operation and Competition and the PCT Procurement Guide.&lt;/P&gt;
&lt;P&gt;The NHS standard contracts cover agreements between PCTs and all types of provider delivering&amp;nbsp; NHS funded services.&amp;nbsp; The contract will apply to agreements from 2009-10 for:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS trusts 
&lt;LI&gt;NHS Foundation Trusts 
&lt;LI&gt;New agreements between PCTs and independent sector providers&lt;BR&gt;
&lt;LI&gt;New agreements between PCTs and third sector providers&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Guidance on each of the contracts are&amp;nbsp; published to support the implementation and interpretation of the contracts&lt;/P&gt;
&lt;P&gt;A model consortium agreement and its associated guidance has been updated and is published alongside the contracts&lt;/P&gt;
&lt;P&gt;A standard format national variation will be issued for use by PCTs and providers on existing contracts. The standard variation will reflect the policy priorities outlined in the 2010/2011 Operating Framework&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386829</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://its-services.org.uk/silo/files/triangle-of-care-carers-included.pdf]]&gt;</url>
    <title>The Triangle of Care - Carers included: a guide to best practice in acute mental health care</title>
    <publicationDate></publicationDate>
    <publisher>National Mental Health Development Unit, The Princess Royal Trust for Carers, Acute Care Declaration</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The guide emphasises the need for better local strategic involvement of carers and families in the care planning and treatment of people with mental ill-health and recommends better partnership working between service users and their carers, and organisations.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>388564</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.screening.nhs.uk/policydb_download.php?doc=52]]&gt;</url>
    <title>The UK NSC policy on Alzheimer's Disease screening in adults</title>
    <publicationDate>2010-09-16T00:00:00</publicationDate>
    <publisher>UK National Screening Committee</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,CAUSES AND PREVENTION,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Alzheimer's disease is the most common form of dementia, which describes the loss of mental abilities, such as memory and reasoning.&amp;nbsp;Alzheimer's disease is a progressive condition, meaning it will continue to get worse as it develops. Unfortunately, there is no cure for the condition, although there is treatment that can slow down the development.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Screening should not be offered.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This policy was reviewed in Jun 2010 but no significant changes were made. It is due to be considered again in 2013/14, or earlier if significant new evidence emerges. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302034</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/15]]&gt;</url>
    <title>Therapeutics -  Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alon</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective and safe is aripiprazole when added to antidepressants&lt;SUP&gt; &lt;/SUP&gt;in people with major depressive disorder and a history of incomplete&lt;SUP&gt; &lt;/SUP&gt;response?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;362 adults with major depressive disorder (DSM-IV-TR) whose&lt;SUP&gt; &lt;/SUP&gt;current episode had failed to show complete response to an 8-week&lt;SUP&gt; &lt;/SUP&gt;trial of standard antidepressant plus adjunctive placebo. Incomplete&lt;SUP&gt; &lt;/SUP&gt;response was defined as &amp;lt;50% reduction in 17-item Hamilton&lt;SUP&gt; &lt;/SUP&gt;Rating Scale for Depression (HAM-D17) total score, HAM-D17 score&lt;SUP&gt; &lt;/SUP&gt;&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;14, and a Clinical Global Impressions-Improvement scale score&lt;SUP&gt; &lt;/SUP&gt;&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;3. Participants enrolled in the 8-week trial had to have HAM-D17&lt;SUP&gt; &lt;/SUP&gt;total score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;18, and a history of inadequate response (&amp;lt;50%&lt;SUP&gt; &lt;/SUP&gt;reduction in Massachusetts General Hospital Antidepressant Treatment&lt;SUP&gt; &lt;/SUP&gt;Response Questionnaire (ATRQ)) to 1–3 adequate antidepressant&lt;SUP&gt; &lt;/SUP&gt;treatments (&amp;gt;6 weeks using adequate dose as specified in&lt;SUP&gt; &lt;/SUP&gt;the ATRQ) for their current depressive episode.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;24 sites in the USA; June 2004 to April &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;BR&gt;Andrea Cipriani, MD, Corrado Barbui, MD &lt;/P&gt;
&lt;P&gt;University of Verona, Verona, Italy &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/15" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383457</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/79.extract]]&gt;</url>
    <title>Therapeutics - A GP training package for the treatment of anxiety disorders is not cost-effective</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Is an optimised primary care model for anxiety disorders cost-effective?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;Participants were 389 people aged between 18 and 65 years who were screened positive for having an anxiety disorder on the Patient Health Questionnaire and recruited from 46 primary care practices. People who were terminally ill or suicidal, with cognitive impairment, or who did not have an adequate command of German, were excluded from the trial. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;General practice in Germany. Recruitment dates were not reported, but baseline questionnaires were sent between January and March 2006. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;A training package for general practitioners (GPs) based on a cognitive-behavioural therapy (CBT) approach used in psychiatry and current guidelines for treating anxiety disorders. Ten hours of training were provided over a 2-week period, and this included diagnosis, efficient pharmacotherapy guidelines, role play in counselling skills and information for the patient on diagnosis, treatment and relaxation. GPs were also offered a psychiatric consultation-liaison service for 6 months after the end of the training. This was a flexible service … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/79.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>224031</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/8/1/17]]&gt;</url>
    <title>Therapeutics - A joint crisis plan negotiated with mental health staff significantly reduces compulsory admission and treatment in people with severe mental illness</title>
    <publicationDate>2005-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Henderson C, Flood C, Leese M, et al. Effect of joint crisis plans on use of compulsory treatment in psychiatry: single blind randomised controlled trial. BMJ 2004;329:136.&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does a joint crisis plan reduce the use of inpatient services, and compulsory admission and treatment in people with severe mental illness?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blind (outcome assessor blinded).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Follow up period:&lt;/STRONG&gt; 15 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Seven community mental health teams, South London and Kent, UK; recruitment 2000 to 2001.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 160 people with psychotic illness, or bipolar affective disorder without psychotic symptoms. Exclusions: not admitted to hospital in the preceding two years; current inpatient, or unable to give informed consent.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Joint crisis plan: contained information on contact details, history of mental and physical illnesses, previous antidepressants and psychotherapies, signs predicting relapse, and instructions for care if a future relapse occurs. The plans were developed by negotiation and agreement between mental health staff and the person with severe mental illness. A carer, friend, or advocate was encouraged to help finalise the plan. Control: received information leaflets on mental illness and treatment, and local mental health services.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Admission to hospital; time spent in hospital; compulsory admission and treatment in mental health services.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient follow up:&lt;/STRONG&gt; 100%.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;At 15 months, people with a joint crisis plan were significantly less likely to experience compulsory admission and treatment (13% v 27%, RR 0.48, 95% Cl 0.24 to 0.95) and there was a trend towards fewer overall admissions compared with control (30% v 44%, RR 0.69, 95% Cl 0.45 to 1.04). The mean length of hospital stay after compulsory admission was significantly less for people with a joint crisis plan than controls (see &lt;A href="http://www.ebmentalhealth.com/supplemental" target="_blank"&gt;http://www.ebmentalhealth.com/supplemental&lt;/A&gt; for table). There was no significant difference in the time spent in hospital for each group after non-compulsory hospital admission. The reasons for compulsory admission were similar for both groups, but people with a joint treatment plan were more likely to be released from hospital early after compulsory admission than controls.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;A joint crisis plan made with the help of mental health staff and a carer, friend, or advocate significantly reduces compulsory hospital admission and treatment in people with severe mental illness.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306947</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/9]]&gt;</url>
    <title>Therapeutics - A nurse delivered management programme for depression in people with cancer reduces depressive symptoms compared with usual care</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;BR&gt;&lt;/STRONG&gt;In people with cancer, is a complex depression management intervention effective in reducing depressive symptoms compared with usual care?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;200 adult outpatients with both cancer (mean age 56.6 years; 71% women) and DSM-IV major depressive disorder (identified by screening using the Hospital Anxiety and Depression Scale; those scoring &amp;gt;=15 completed the Structured Clinical Interview for DSM-IV). Inclusion criteria: cancer prognosis of 6 months or more; major depressive disorder for &amp;gt;=1 month not associated with a change of cancer or cancer management; and a score of &amp;gt;=1.75 on the Symptom Checklist-20 (SCL-20) depression scale (score range 1–4, higher score indicating greater levels of depressive symptoms). Exclusions: intensive anticancer treatment, communication difficulties, poorly controlled comorbidities, and people needing or receiving specialist psychiatric care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Regional cancer centre, Scotland, UK; recruitment October 2003–December 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;The Depression Care for People with Cancer intervention plus usual care or usual care alone. Depression Care for People with . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Christina M Van der Feltz-Cornelis&lt;/P&gt;
&lt;P&gt;Trimbos Instituut/NIMHA Utrecht the Netherlands and VU University Medical Centre Institute of Extramural Research, Amsterdam, The Netherlands &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/9" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301869</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/119]]&gt;</url>
    <title>Therapeutics - A parenting programme does not affect behavioural problems in toddlers</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is a parenting programme in preventing behavioural problems in childhood?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;BR&gt;&lt;/STRONG&gt;Consecutive mothers (n = 733) of 6–7-month-old infants attending routine health visits.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;40 primary care nursing centres, Melbourne, Australia; recruitment 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Parenting programme of teaching, video, role play and written information focused upon key parental risk factors for childhood behavioural problems: harsh parenting, unreasonable expectations and lack of nurturing. Three sessions were conducted at 8, 12 and 15 months. The first involved literature on child development and ways to promote language development; the second, ways to develop a close, sensitive relationship with the toddler and promote desirable behaviour; and the third covered management of unwanted behaviour. The programme was delivered by a trained nurse and co-facilitator. Control group was usual maternal and child health care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Maternal report of externalising behavioural problems on the 99-item validated child behaviour checklist. Other outcomes: parenting styles on the parent behaviour checklist; child’s . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Professor Judy Hutchings&lt;/P&gt;
&lt;P&gt;School of Psychology, Bangor University, Gwynedd, Wales &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/119" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392780</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/128.extract]]&gt;</url>
    <title>Therapeutics - A psychosocial intervention in low birthweight term babies improves performance IQ, visual-spatial memory and behaviour</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Does early psychosocial stimulation benefit cognition and behaviour at 6 years of age in low birthweight term-born children?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;140 low birthweight term (LBW-T) infants born at the main public maternity hospital in Kingston, Jamaica. Low birthweight was defined as weight &amp;lt;2500 g, and term deliveries as gestational age =37 complete weeks at birth. For two in every three LBW-T infants, the next normal birthweight term (NBW-T) infant of the same gender born in the hospital was also enrolled; this gave a group of 94 NBW-T infants. &lt;EM&gt;Exclusion criteria:&lt;/EM&gt; mothers having =3 passes in national secondary level examinations; mothers with HIV; or infants who were twins, had congenital abnormalities or were admitted to special care nursery for &amp;gt;48 h. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;One hospital, Kingston, Jamaica; recruitment March to October 1999.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Psychosocial stimulation intervention or care as usual (control). The intervention focused on improving the mother's responsiveness to her child, and involved a 1-h session with mother and child once a week for … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/128.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is avilable for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328834</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/115]]&gt;</url>
    <title>Therapeutics - A stepped care intervention is effective for elderly people with subthreshold depression or anxiety</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Does an indicated prevention programme reduce the development&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of major depression and anxiety in an elderly population with&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;subthreshold symptoms?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;170 participants (aged x 75 years; 73.5% female) identified through&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;a database of participants in the Preventative Intervention&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;for Frail Elderly (PIKO) project. Those who scored x 16 on the&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;self-reported Centre for Epidemiologic Studies Depression Scale&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(CES-D) during the PIKO study (between October 2005 and October&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;2005), were aged 75 years or over and who did not meet the DSM-IV&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;criteria for depressive or anxiety disorder in the 12 months&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;prior to their PIKO questioning, were approached to participate&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in this study. Exclusions: DSM-IV depression or anxiety disorder&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;detected by the Mini International Neuropsychiatric Interview&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(MINI); serious cognitive disorder according to the self-rated&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Informant Questionnaire on Cognitive Decline in the Elderly.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;33 primary care practices in northwest Netherlands; October&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;2004–October 2005.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;A stepped care programme involving 3 month cognitive behavioural&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;&lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt;&lt;/I&gt;(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/115" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383507</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/87.extract]]&gt;</url>
    <title>Therapeutics - A stepped care programme for depressive or anxiety disorders offers good value for money</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Can cost-effective preventive strategies be developed to reduce the onset of mental disorders in an older population?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;170 patients over 75 years old presenting with subclinical depressive or anxiety symptoms; 74% were women. Patients had a score of 16 or higher on the Center for Epidemiologic Studies Depression (CES-D) scale but did not meet DSM-IV diagnostic criteria for depression or the Mini International Neuropsychiatric Interview criteria for anxiety disorders. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;The Netherlands; time unclear.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;The intervention was a stepped care programme with four interventions that could be used as necessary in cycles of 3 months: watchful waiting, bibliotherapy, problem-solving treatment and antidepressant medications. Depression symptom severity was monitored using CES-D. The control group received routine primary care. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;MINI/DSM-IV diagnostic status of depressive and anxiety disorders; proportion of patients who had a disorder free year; cost effectiveness (incremental cost-effectiveness ratios) from a societal perspective (costs in € at 2007 prices).&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Patient follow-up&lt;/H3&gt;
&lt;P id=p-6&gt;72% in the intervention group and 90% in the … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/87.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available via ATHENS login.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>224032</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/8/1/18]]&gt;</url>
    <title>Therapeutics - A structured needs assessment does not improve clinical outcomes for clients under the care programme approach</title>
    <publicationDate>2005-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Marshall M, Lockwood A, Green G, et al. Systematic assessments of need and care planning in severe mental illness: cluster randomised controlled trial. Br J Psychiatry 2004;185:163–8.&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Do clients benefit if formulation of their care plan is based on a formal, standardised assessment of need?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Not stated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blinded (assessor at 12 months was blind to group allocation).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Follow up period:&lt;/STRONG&gt; 12 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; National Health Service Trusts in urban areas of northwest England; October 1998 to October 2000.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 304 participants (in 72 clusters of up to six people under a given care coordinator); being cared for in the community under care programme approach (CPA); meeting Goldman’s criteria for severe mental disorder.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; The trial comprised two parallel experiments. In the first, clusters were randomised to structured assessment or control (experiment 1). In the second, individuals under a single care coordinator were randomised to structured assessment or control (experiment 2). Both groups received a baseline needs assessment. In intervention groups, the results were fed back to the care coordinator, detailing the interventions that would be appropriate for the client and how to obtain them in the locale. In the control group, the results of needs assessment were not made available to the care coordinator to guide management.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Mental state (Brief Psychiatric Rating Scale, BPRS); social functioning (World Health Organisation Psychiatric Disability Assessment Schedule, WHODAS); quality of life (Manchester Short Assessment of Quality of Life, MANSA); patient satisfaction (Client Satisfaction Index); met need (baseline needs that were no longer present at follow up).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient follow up:&lt;/STRONG&gt; 77% at 12 months.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Results were combined from both experiments. At 12 months there was no significant difference between intervention and control groups in mental state, social functioning, quality of life, or proportion of needs met (mean BPRS: 5.56 with intervention v 5.19 with control; difference 0.34, 95% CI –0.67 to 1.35; p = 0.51; mean WHODAS: 0.68 with intervention v 0.69 with control; difference 0.016, 95% CI –0.13 to 0.16; p = 0.83; mean MANSA: 4.66 with intervention v 4.58 with control; difference 0.032, 95% CI –0.147 to 0.210; p = 0.73; met needs 89% with intervention v 87% with control; OR 1.28, 95% CI 0.57 to 2.88; p = 0.52).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Standardised needs assessment does not improve clinical outcomes for clients under the care programme approach.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NOTES&lt;/STRONG&gt;&lt;BR&gt;In the individually randomised experiment (experiment 2), the care of participants may have been influenced by the coordinator’s knowledge of the structured assessment techniques. However, this hypothesis was tested statistically and the authors felt it was legitimate to combine results from the two experiments.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392769</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/122.extract]]&gt;</url>
    <title>Therapeutics - Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Does adjuvant aspirin benefit patients with schizophrenia spectrum disorders who are on antipsychotic therapy?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;70 adults (18–55 years of age) with DSM-IV schizophrenia spectrum disorder (schizophrenia, schizoactive disorder or schizophreniform disorder), who were at least moderately ill (score =60 on the Positive and Negative Syndrome Scale, PANSS, with score =4 on two items). There was a 2-week placebo run-in period, and only those who achieved over 80% compliance were randomised. Exclusion criteria: illness duration longer than 10 years (changed from 5 years because of slow recruitment), contraindications for aspirin or pantoprazole, significant somatic illness, chronic non-steroidal anti-inflammatory drug use, corticosteroid use, pregnancy or change in type or dose of antipsychotic drugs in the previous 2 weeks.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;10 psychiatric hospitals in The Netherlands; May 2004 to August 2007.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Adjuvant aspirin (1000 mg daily) or placebo (adjuvant to antipsychotic … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/122.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302032</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/13]]&gt;</url>
    <title>Therapeutics - Adding cognitive behavioural therapy to SSRIs does not improve outcomes in adolescents with major depression</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is cognitive behavioural therapy (CBT) an effective addition&lt;SUP&gt; &lt;/SUP&gt;to selective serotonin reuptake inhibitors (SSRIs) for adolescents&lt;SUP&gt; &lt;/SUP&gt;with major depression?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;208 adolescents (aged 11–17 years) diagnosed with moderate&lt;SUP&gt; &lt;/SUP&gt;to severe major or probable major depression who had not responded&lt;SUP&gt; &lt;/SUP&gt;to a brief initial intervention, or with active suicidal intent,&lt;SUP&gt; &lt;/SUP&gt;self-harm, conduct disorder or depressive psychosis. Exclusions:&lt;SUP&gt; &lt;/SUP&gt;adolescents who were immediately due to take, or were already&lt;SUP&gt; &lt;/SUP&gt;taking, antidepressants.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Six specialist child and adolescent mental health services in&lt;SUP&gt; &lt;/SUP&gt;Manchester and Cambridge, UK; recruitment 2000–4.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;An SSRI (fluoxetine) with or without CBT, received as part of&lt;SUP&gt; &lt;/SUP&gt;ongoing clinical care. Fluoxetine was started at 10 mg daily&lt;SUP&gt; &lt;/SUP&gt;for one week, increasing to 20 mg for 5 weeks, and increased&lt;SUP&gt; &lt;/SUP&gt;to a maximum of 60 mg daily if there was no response by 6 weeks.&lt;SUP&gt; &lt;/SUP&gt;CBT sessions were offered &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;H3&gt;commentator:&lt;/H3&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Glenn A Melvin, PhD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;New York State Psychiatric Institute, New York, USA &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/13" target="_blank"&gt;Full text of the article&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301981</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/78]]&gt;</url>
    <title>Therapeutics - Adding repetitive transcranial magnetic stimulation to antidepressants does not improve response in people with depression</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does repetitive transcranial magnetic stimulation (rTMS) alleviate&lt;SUP&gt; &lt;/SUP&gt;depression in people receiving antidepressants?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;127 adults experiencing a moderate to severe depressive episode&lt;SUP&gt; &lt;/SUP&gt;(DSM-IV and ICD-10 criteria, including bipolar depression),&lt;SUP&gt; &lt;/SUP&gt;with a score of &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;18 on at least two out of three depression rating&lt;SUP&gt; &lt;/SUP&gt;scales (Beck Depression Inventory, 21 item Hamilton Rating Scale&lt;SUP&gt; &lt;/SUP&gt;for Depression, Montgomery-Åsberg Depression Rating Scale).&lt;SUP&gt; &lt;/SUP&gt;Exclusions: psychiatric disorders other than depression, severe&lt;SUP&gt; &lt;/SUP&gt;medical disorders, neurological disorders, prior epileptic seizures,&lt;SUP&gt; &lt;/SUP&gt;heart pacemaker, brain lesions or neurosurgery, involuntary&lt;SUP&gt; &lt;/SUP&gt;hospitalisation.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Seven university clinics in Germany and Austria; time period&lt;SUP&gt; &lt;/SUP&gt;not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Real rTMS (10 Hz stimulation, 110% of motor threshold, 2000&lt;SUP&gt; &lt;/SUP&gt;stimuli a day to the left dorsolateral prefrontal cortex) or&lt;SUP&gt; &lt;/SUP&gt;sham rTMS (same stimulation protocol, but with electrodes placed&lt;SUP&gt; &lt;/SUP&gt;so that only a weak electromagnetic field reached the cortex)&lt;SUP&gt; &lt;/SUP&gt;for &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;José Luis R Martín &lt;/P&gt;
&lt;P&gt;Foundation for Health Research in Castilla la Mancha (FISCAM), Toledo, Spain &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/119" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344633</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/28.extract]]&gt;</url>
    <title>Therapeutics - Adding zolpidem to CBT produces limited benefits in persistent insomnia</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SLEEP PROBLEMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does the addition of zolpidem to cognitive behavioural therapy (CBT) improve persistent insomnia compared with CBT alone?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;160 adults (97 female; &amp;gt;30 years old) with chronic insomnia (DSM-IV and International Classification of Sleep Disorders).&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;University Hospital Sleep Centre, Quebec, Canada; January 2002-April 2005.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;&lt;EM&gt;Acute phase (6 weeks’ duration)&lt;/EM&gt;: CBT versus CBT plus zolpidem (10 mg/night). CBT involved one 90 min group session per week. &lt;EM&gt;Extended phase (6 months’ duration)&lt;/EM&gt;: The CBT alone group was randomised to either extended CBT (one individually tailored session per month) or no further treatment; the CBT plus zolpidem group was randomised to either CBT alone or CBT plus zolpidem as needed. &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-5&gt;&lt;EM&gt;Primary outcomes&lt;/EM&gt;: Sleep onset latency, time awake post sleep onset, total sleep time and sleep efficiency (total sleep time: time spent in bed) derived from self-report sleep diaries. &lt;EM&gt;Secondary outcomes&lt;/EM&gt;: the four sleep indices used as primary outcomes derived from laboratory sleep evaluations (polysomnography); response (defined as change from baseline &amp;gt;7 in the patient reported Insomnia Severity Index (ISI) total score) and remission (ISI score &amp;lt;8). &lt;/P&gt;
&lt;H3&gt;Patient follow-up:&lt;/H3&gt;
&lt;P id=p-6&gt;93.1% completed the acute phase, 88.1% completed … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/28.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298006</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/75]]&gt;</url>
    <title>Therapeutics - Adherence therapy does not improve quality of life in people with schizophrenia</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;BR&gt;&lt;/STRONG&gt;Gray R, Leese M, Bindman J, et al. Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. Br J Psychiatry 2006;189:508–14.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does adherence therapy improve quality of life in people with schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blind (assessors blinded).&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; One year (including 8-week treatment period).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Inpatient and community psychiatric services in four European cities (Amsterdam, London, Leipzig and Verona); recruitment June 2002 to October 2003.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 409 adults with ICD-10 schizophrenia and evidence of clinical instability in the preceding year (change in medication, increased contact with mental health services, psychiatric hospital admission, or reported clinical instability) needing antipsychotic medication. Exclusion criteria: alcohol or drug dependence; organic brain disorder or mental handicap; receiving forensic psychiatric services.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Adherence therapy (see &lt;A href="http://www.adherencetherapy.com/" target="_blank"&gt;http://www.adherencetherapy.com&lt;/A&gt;): 8 weekly sessions of individual cognitive-behavioural therapy, or health education: 8 weekly individual sessions on diet and lifestyle.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Qualify of life (Short Form Health Survey (SF-36) mental component summary (MCS)); medication adherence (Schedule of Assessment for Insight – Expanded version, keyworker adherence rating scale (SAI-C) and Medication Adherence Questionnaire (MAQ)); schizophrenic symptoms (Brief Psychiatric Rating Scale - Expanded (BPRS-E)).&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 81% in the adherence therapy group, 90% in the health education group (p = 0.01 for difference).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;There was no significant difference between adherence therapy and health education in quality of life at 1 year (mean SF-36 MCS score: 40.24 with adherence therapy vs 41.32 with health education, p = 0.38), nor was there significant difference between groups in adherence or symptoms (mean SAI-C score: 5.22 with adherence therapy vs 5.03 with health education, p = 0.24; mean MAQ score: 3.2 with adherence therapy vs 3.33 with health education, p = 0.23; mean BPRS-E score: 38.11 with adherence therapy vs 37.34 with health education, p = 0.48).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Adherence therapy does not improve quality of life, medication compliance or symptoms compared with health education in people with schizophrenia.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301701</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/111]]&gt;</url>
    <title>Therapeutics - Adjunctive aripiprazole improves symptoms in antidepressant refractory major depressive disorder</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective and safe is aripiprazole as an adjunctive treatment&lt;SUP&gt; &lt;/SUP&gt;for major depressive disorder (MDD) in people who have failed&lt;SUP&gt; &lt;/SUP&gt;to respond to one or more antidepressants?&lt;SUP&gt; &lt;/SUP&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;381 adult outpatients (aged 18–65 years) with a DSM-IV&lt;SUP&gt; &lt;/SUP&gt;diagnosis of MDD, who had inadequate response to an 8–week&lt;SUP&gt; &lt;/SUP&gt;single blind antidepressant trial, and had previously experienced&lt;SUP&gt; &lt;/SUP&gt;inadequate response to between one and three antidepressants&lt;SUP&gt; &lt;/SUP&gt;(assessed using the Antidepressant Treatment Response Questionnaire).&lt;SUP&gt; &lt;/SUP&gt;See online notes for details.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;36 sites in the USA; September 2004 to December 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Adjunctive aripiprazole (starting dose 5 mg/day, which could&lt;SUP&gt; &lt;/SUP&gt;be adjusted to a maximum of 20 mg/day as tolerated by week 4)&lt;SUP&gt; &lt;/SUP&gt;or placebo for 6 weeks. Type of antidepressant or dosage was&lt;SUP&gt; &lt;/SUP&gt;not changed during this period.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Change in symptoms from baseline (Montgomery-Åsberg Depression&lt;SUP&gt; &lt;/SUP&gt;Rating Scale (MADRS)); adverse events.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;85% completed treatment (97% analysed for efficacy using last&lt;SUP&gt; &lt;/SUP&gt;observation carried forward)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt;&lt;BR&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;BR&gt;&lt;/STRONG&gt;Anthony Cleare, Dr, MBBS, PhD, MRCPsych &lt;/P&gt;
&lt;P&gt;Reader in Affective Disorders, Institute of Psychiatry, King's College London, London, UK &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/111" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317831</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/55]]&gt;</url>
    <title>Therapeutics - Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does adjunctive transdermal oestradiol improve symptoms in women&lt;SUP&gt; &lt;/SUP&gt;with schizophrenia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;102 women who met the diagnostic criteria (DSM-IV) for schizophrenia,&lt;SUP&gt; &lt;/SUP&gt;schizoaffective disorder (bipolar subtype excluded) or schizophreniform&lt;SUP&gt; &lt;/SUP&gt;disorder. Main exclusions: currently in manic phase of illness;&lt;SUP&gt; &lt;/SUP&gt;currently using hormonal therapy; menopausal symptoms; pregnant&lt;SUP&gt; &lt;/SUP&gt;or breastfeeding; or serious medical illness.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Two general hospitals in Melbourne, Australia (inpatient and&lt;SUP&gt; &lt;/SUP&gt;outpatient clinics); recruitment 1 January 2001 to 30 April&lt;SUP&gt; &lt;/SUP&gt;2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Transdermal oestradiol (100 µg/day; n = 56) or transdermal&lt;SUP&gt; &lt;/SUP&gt;placebo (n = 46) for 28 days, in addition to usual antipsychotic&lt;SUP&gt; &lt;/SUP&gt;therapy. The majority of women (77%) were taking atypical antipsychotics,&lt;SUP&gt; &lt;/SUP&gt;17% took typical antipsychotics and data were missing for 4%.&lt;SUP&gt; &lt;/SUP&gt;There were no differences between the groups in antipsychotic&lt;SUP&gt; &lt;/SUP&gt;medication.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Positive, negative and general psychopathology symptoms (Positive&lt;SUP&gt; &lt;/SUP&gt;and Negative Syndrome Scale (PANSS)) and adverse events (Adverse&lt;SUP&gt; &lt;/SUP&gt;Symptoms Checklist). Symptoms were assessed at baseline and&lt;SUP&gt; &lt;/SUP&gt;every week thereafter. Outcomes were analysed using repeated&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;.&lt;/EM&gt; . (Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/55" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>301700</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/110]]&gt;</url>
    <title>Therapeutics - Adolescents with SSRI-resistant depression: CBT plus antidepressant switch more effective than medication switch alone</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the best strategy for adolescents with depression who&lt;SUP&gt; &lt;/SUP&gt;don’t respond to initial SSRIs?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;334 adolescents (12–18 years old) with a primary diagnosis&lt;SUP&gt; &lt;/SUP&gt;of major depressive disorder who had not responded to a 2-month&lt;SUP&gt; &lt;/SUP&gt;trial with an SSRI. Main exclusions: non-response to &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;2 trials&lt;SUP&gt; &lt;/SUP&gt;of an SSRI or to venlafaxine (&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;4 weeks at dose &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;150 mg) or CBT&lt;SUP&gt; &lt;/SUP&gt;(&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;7 sessions); already receiving CBT; taking psychoactive medications&lt;SUP&gt; &lt;/SUP&gt;(except those on stable doses of stimulants or hypnotics for&lt;SUP&gt; &lt;/SUP&gt;&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;12 weeks); bipolar spectrum disorder; psychosis; pervasive developmental&lt;SUP&gt; &lt;/SUP&gt;disorder or autism; eating disorders; or substance abuse or&lt;SUP&gt; &lt;/SUP&gt;dependence.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;US academic and community clinics; 2000–2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;One of four 12-week regimens: switch to a second, different&lt;SUP&gt; &lt;/SUP&gt;SSRI (paroxetine, fluoxetine or citalopram at 20–40 mg&lt;SUP&gt; &lt;/SUP&gt;daily); switch to venlafaxine (150–225 mg daily); switch&lt;SUP&gt; &lt;/SUP&gt;to second SSRI plus CBT; switch to venlafaxine plus CBT. CBT&lt;SUP&gt; &lt;/SUP&gt;was delivered by experienced therapists with at least master’s&lt;SUP&gt; &lt;/SUP&gt;level &lt;I&gt;&lt;NOBR&gt;. . (Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;NOBR&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/NOBR&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Bernadka Dubicka, Dr &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Locum Consultant in Adolescent Psychiatry, Lancaster, and Honorary Lecturer, University of Manchester, UK &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/110" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>235310</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/6/3/88]]&gt;</url>
    <title>Therapeutics - Advance directives about treatment preferences had little impact on compulsory readmissions for people with serious mental illness</title>
    <publicationDate>2003-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Papageorgiou A, King M, Janmohamed A et al. Advance directives for patients compulsorily admitted to hospital with serious mental illness. Randomised controlled trial. Br J Psychiatry 2002 Dec;181:513–9&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Do advance directives about a patient’s preferences for mental health treatment reduce compulsory readmission to hospital?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial with allocation concealed block design. Research assistants were not blind to treatment allocation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; 2 acute psychiatric services in inner London, United Kingdom; October 1997–October 1998.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants:&lt;/STRONG&gt; 156 adult inpatients discharged from compulsory psychiatric hospital treatment within the study period who were able to read in English. People treated under special sections of the Mental Health Act, about to be transferred to other hospitals, or with organic brain disease were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; All participants received standard community psychiatric care. In addition, one group received the advance directive initiative. Advance directives are descriptions of a person’s preferences for treatment, should they lose capacity to make decisions about treatment in future. In this study, guidelines about creating an advance directive were supplied in the booklet Preferences for Care. The booklet contained statements on future preferences for treatment. Participants were encouraged to complete these and sign the directive or to dictate their preferences to a researcher. Participants were asked to keep the booklet in a safe place. Copies were given to their key workers and general practitioners. Copies were also filed with the hospital and in general practice records.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main outcome measures:&lt;/STRONG&gt; The primary outcome was rate of compulsory readmission to psychiatric hospital.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main results&lt;/STRONG&gt;&lt;BR&gt;19% of the advance directive group and 21% of controls were compulsorily readmitted to psychiatric care within one year of discharge (P &amp;gt; 0.05). There was no significant difference between groups in the number of compulsory or voluntary readmissions, days spent in hospital or satisfaction with psychiatric services.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;Advance directives about treatment preferences did not reduce compulsory or voluntary readmissions for people with serious mental illness at 12 months.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317829</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/54]]&gt;</url>
    <title>Therapeutics - Agomelatine improves symptoms of generalised anxiety disorder</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Is agomelatine effective for people with generalised anxiety&lt;SUP&gt; &lt;/SUP&gt;disorder?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;121 people, aged 18–65 years, with DSM-IV generalised&lt;SUP&gt; &lt;/SUP&gt;anxiety disorder (69% female, mean age 42 years) (see online&lt;SUP&gt; &lt;/SUP&gt;notes for exclusion criteria).&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Five centres in Finland and six centres in South Africa; time&lt;SUP&gt; &lt;/SUP&gt;period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Agomelatine (n = 63; 25–50 mg/day) or placebo (n = 58)&lt;SUP&gt; &lt;/SUP&gt;for 12 weeks. Agomelatine dose was increased from 25 to 50 mg/day&lt;SUP&gt; &lt;/SUP&gt;if there was an insufficient response after 2 weeks. This was&lt;SUP&gt; &lt;/SUP&gt;done in a blinded fashion, using a dose adjustment algorithm.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;I&gt;Primary outcome&lt;/I&gt;: overall anxiety (HAM-A). &lt;I&gt;Secondary outcomes&lt;/I&gt;:&lt;SUP&gt; &lt;/SUP&gt;response (&lt;IMG border=0 alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif"&gt;50% reduction in HAM-A score); somatic anxiety, psychic&lt;SUP&gt; &lt;/SUP&gt;anxiety, severity of illness, sleep and disability symptoms&lt;SUP&gt; &lt;/SUP&gt;(HAM-A subscales, Clinical Global Impressions Scale, Leeds Sleep&lt;SUP&gt; &lt;/SUP&gt;Evaluation Questionnaire and Sheehan Disability Scale); discontinuation&lt;SUP&gt; &lt;/SUP&gt;effects in the week after discontinuation (Discontinuation Emergent&lt;SUP&gt; &lt;/SUP&gt;Signs and Symptoms scale (DESS)). Last observation carried forward&lt;SUP&gt; &lt;/SUP&gt;(LOCF) and &lt;NOBR&gt;&lt;EM&gt;. .&lt;/EM&gt; .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/54" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>224033</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/8/1/19]]&gt;</url>
    <title>Therapeutics - An individual placement and support programme is more effective than skills training and temporary employment for people with severe mental illness</title>
    <publicationDate>2005-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Mueser KT, Clark RE, Haines M, et al. The Hartford study of supported employment for persons with severe mental illness. J Consult Clin Psychol 2004;72:479–90.&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How does individual placement and support compare with a psychosocial rehabilitation programme or standard services for vocational rehabilitation in people with severe mental illness?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Unconcealed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Unblinded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Follow up period:&lt;/STRONG&gt; Two years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Hartford, Connecticut, USA; April 1996 to May 1998.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 204 people (46% African American, 30% Latino) with severe mental illness (DSM-IV Axis I diagnosis or borderline personality disorder and severe impairment of psychosocial functioning and self care) who were unemployed and lived in the inner city. Participants were required to have a desire for competitive work and be capable of giving informed consent.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Individual placement and support (IPS): employment specialists worked with case managers, psychiatrists and the client to integrate employment services with treatment. Services included vocational assessment and identifying job interests, job finding, and support, and were provided away from the mental health centre. Psychosocial rehabilitation programme (PSR): skills training was given followed by transitional employment and support for obtaining competitive work. PSR also gave social support and housing services, which were provided to all participants in the study. Standard services: access to local vocational services and a programme supplying sub-minimum wage employment in supervised janitorial positions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Employment: type of job, hours, wages, and tenure were assessed weekly by interview with participants or in logs written by support staff. Other outcomes: psychiatric symptoms were assessed using the PANSS, functioning with the Global Assessment Scale, and social and leisure functioning with the Social-Leisure subscale and global rating from the Social Adjustment Scale II. Interviews were held every 6 months for two years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient follow up:&lt;/STRONG&gt; 195/204 (96%) attended at least one interview; follow up at 6 months was 86%; at 12 months, 85%; at 18 months, 85%; at 24 months, 81%.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;At two years, IPS significantly improved employment outcomes compared with PSR or standard services (see &lt;A href="http://www.ebmentalhealth.com/supplemental" target="_blank"&gt;http://www.ebmentalhealth.com/supplemental&lt;/A&gt; for table). There were no significant differences among groups for the other outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Individual placement and support is more effective for finding competitive employment for people with serious mental illness than psychosocial rehabilitation or standard services.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377599</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/44.extract]]&gt;</url>
    <title>Therapeutics - Anticholinergic drugs increase the risk of cognitive decline and dementia in older people</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2&gt;Question:&amp;nbsp;&lt;/H2&gt;
&lt;P id=p-1&gt;What is the relationship between anticholinergic use, cognitive decline and onset of dementia in an older, community-dwelling population? &lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;6912 adults (4128 women, mean age 73.8 years; 2784 men, mean age 73.6 years) aged =65 years, living in the community and recruited from electoral rolls.&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Three cities in France, recruitment period: 1999–2001.&lt;/P&gt;
&lt;H3&gt;Prognostic factors:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Cognitive performance was measured using a battery of tests: Isaacs Set Test assessed verbal fluency, Benton Visual Retention Test (BVRT) assessed visual memory, Trail-Making Test A (TMT A) measured psychomotor speed, TMT B measured executive function, Mini-Mental State Examination (MMSE) provided a global measure of cognitive function and clinical diagnoses of dementia (&lt;EM&gt;Diagnostic and Statistical Manual of Mental Disorders&lt;/EM&gt;, fourth edition). The use of anticholinergic drugs was assessed by in-person interview; prescriptions and medications were checked where possible. Discontinuing anticholinergic treatment was defined as reporting anticholinergic drug use only at baseline but not at either the 2- or 4-year follow-up. Social and demographic variables were recorded using standardised interview questions. Fasting-blood samples were taken to determine cholesterol levels. Cognitive tests were administered at baseline and at 2- and 4-year follow-up. TMT A and B were administered only at the 4-year follow-up. Univariate and multivariate logistic regression analyses were performed to determine the association between anticholinergic drug use and cognitive decline. &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Cognitive decline (defined as being … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/2/44.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298043</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/109]]&gt;</url>
    <title>Therapeutics - Antidepressants are not an effective adjunct to mood stabilisers for bipolar depression</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,BIPOLAR DISORDER,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711–22.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Are antidepressants an effective adjunctive treatment to mood stabilisers in the treatment of bipolar depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Unclear.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Double blinded.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Sixteen weeks (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Part of STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder) trials, carried out in 22 centres in the USA; November 1999 to July 2005.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 366 adults (aged over 18 years) currently experiencing a DSM-IV major depressive episode associated with bipolar I or bipolar II disorder. Exclusions: history of intolerance or non-response to paroxetine and bupropion; receiving treatment for substance abuse disorder; or requiring addition of, or dose change of, antipsychotic medication.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Paroxetine (10 mg increased up to maximum 40 mg daily), sustained-release bupropion (150 mg increased up to maximum 375 mg daily) or placebo. All participants received a mood stabilising agent with dose adjustment according to the therapeutic range (initially lithium, valproate or carbamazepine; protocol amended in 2004 to allow any FDA-approved antimanic agent).&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Primary outcome: durable recovery by 16 weeks (according to DSM-IV definition of recovery: euthymia (&amp;lt;=2 depressive or manic symptoms) for at least 8 consecutive weeks). Secondary outcome: transient remission (defined as 1–7 consecutive weeks of euthymia with no DSM-IV hypomania or mania). Assessments used the Clinical Monitoring Form for mood disorders.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 34% completed treatment, 66.1% reached a study-defined outcome, 100% included in last observation carried forward analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Adding antidepressants to mood stabilisers was no more effective for producing durable recovery from bipolar depression than adding placebo (% achieving durable recovery: 23.5% with antidepressants vs 27.3% with placebo; p = 0.40). There was also no significant difference between antidepressants and placebo in the proportion of people achieving transient remission (17.9% with antidepressants vs 21.4% with placebo; p = 0.40).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Antidepressant therapy plus mood stabilisers for 16 weeks is no more effective than mood stabilisers alone for major depressive episodes in people with bipolar I or bipolar II disorder.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344617</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/13.extract]]&gt;</url>
    <title>Therapeutics - Antidepressants combined with self-management of pain improves outcomes in people with comorbid pain and depression</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the effect of a combined pharmacological and behavioural intervention on depression and pain symptoms in people with musculoskeletal pain and comorbid depression? &lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;250 adults (mean age 55.5 years, 53% female) with depression and musculoskeletal pain in the hip, low back or knee persisting for 3 months or more despite using &amp;gt;2 different analgesics. Pain scores had to be at least of moderate severity, scoring &amp;gt;5 on the Brief Pain Inventory Score (BPI). Severity of depression had to be at least moderate, scoring &amp;gt;10 on the Patient Health Questionnaire-9 (PHQ-9). Exclusions included bipolar disorder, severe cognitive impairment, substance use disorder or schizophrenia. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Six community based primary care clinics and five Veterans Affairs general medicine clinics, Indiana, USA; recruitment January 2005–June 2007.&lt;/P&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;The intervention consisted of three steps. &lt;EM&gt;Step 1:&lt;/EM&gt; 12 weeks of optimised antide press ant therapy, actively managed by a nurse care manager. Clinical response was assessed at 3 weeks and doses increased if a 5 point drop in the PHQ-9 score was … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/1/13.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301988</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/85]]&gt;</url>
    <title>Therapeutics - Antipsychotics for aggressive behaviour: no better than placebo for non-psychotic adults with learning difficulties</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=-1&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do risperidone or haloperidol reduce aggressive challenging&lt;SUP&gt; &lt;/SUP&gt;behaviour more than placebo in people with intellectual disability?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;86 adults with intellectual disability (intelligence quotient&lt;SUP&gt; &lt;/SUP&gt;&amp;lt;75) and aggressive challenging behaviour (&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;2 episodes of&lt;SUP&gt; &lt;/SUP&gt;aggressive behaviour, modified overt aggression scale (MOAS)&lt;SUP&gt; &lt;/SUP&gt;score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;4 in past 7 days), but who had not received a clinical&lt;SUP&gt; &lt;/SUP&gt;diagnosis of psychosis. Exclusions: depot or injected antipsychotics&lt;SUP&gt; &lt;/SUP&gt;in the past 3 months, oral antipsychotics in the past week;&lt;SUP&gt; &lt;/SUP&gt;currently sectioned under the Mental Health Act.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Ten centres in the UK and one centre in Australia; recruitment&lt;SUP&gt; &lt;/SUP&gt;2002–6.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Risperidone, haloperidol or placebo for 12 weeks, with the option&lt;SUP&gt; &lt;/SUP&gt;to continue to 26 weeks. Drug dosage could be adjusted by the&lt;SUP&gt; &lt;/SUP&gt;clinician (risperidone dose range: 0.5 mg to 2 mg daily; haloperidol&lt;SUP&gt; &lt;/SUP&gt;dose range: 1.25 mg to 5 mg &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;/P&gt;
&lt;P&gt;Anne D Hurley &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Tufts University School of Medicine, Boston, MA, USA &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/85" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302014</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/50]]&gt;</url>
    <title>Therapeutics - Antisocial behaviour: does a preventative intervention reduce cortisol levels in response to a social challenge?</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does an intervention to prevent antisocial behaviour also alter&lt;SUP&gt; &lt;/SUP&gt;cortisol levels in response to a social challenge?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;Seventy preschool children (aged 2–5 years) with risk&lt;SUP&gt; &lt;/SUP&gt;factors for psychiatric disorders (maternal depression, poverty,&lt;SUP&gt; &lt;/SUP&gt;poor birth environment or other parental issues). Participants&lt;SUP&gt; &lt;/SUP&gt;were identified from court records of their adjudicated siblings,&lt;SUP&gt; &lt;/SUP&gt;who had previously participated in an RCT of a preventative&lt;SUP&gt; &lt;/SUP&gt;intervention for antisocial behaviour. Exclusions: developmental&lt;SUP&gt; &lt;/SUP&gt;disorder or mental retardation, or caregiver with DSM-IV substance&lt;SUP&gt; &lt;/SUP&gt;abuse or psychiatric disorder. 64% of caregivers were African&lt;SUP&gt; &lt;/SUP&gt;American and 28% Latino.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;New York (location and study dates not given).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Parent/child group sessions and home visits over 22 weeks, aimed&lt;SUP&gt; &lt;/SUP&gt;at improving parenting practices and child’s social performance&lt;SUP&gt; &lt;/SUP&gt;(control condition not described). During parent group sessions,&lt;SUP&gt; &lt;/SUP&gt;the focus &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Richard E Tremblay &lt;/P&gt;
&lt;P&gt;International Laboratory for Child and Adolescent Mental Health Development, INSERM U669, Paris, France; University College Dublin, Ireland; University of Montreal, Canada &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/50" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392763</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/117.extract]]&gt;</url>
    <title>Therapeutics - Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,TREATMENT AND CARE,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Does atorvastatin improve cognition in patients with mild to moderate Alzheimer's disease (AD)?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;640 adults (age 50–90 years) patients with mild to moderate probable AD with a mini-mental state examination (MMSE) score 13–25, and taking donepezil 10 mg daily for =3 months before screening. The patients also had low-density lipoprotein cholesterol levels (LDL-C) between 95 and 195 mg/dl.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;87 sites in 10 countries (USA, Germany, Canada, UK, Australia, Spain, South Africa, Sweden, Austria and Denmark).&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Atorvastatin 80 mg daily or placebo for 72 weeks. Both groups also took donepezil 10 mg daily. After 72 weeks, the participants in the atorvastatin group were randomised to either continue atorvastatin or switch to placebo. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;(1) Primary outcomes: cognitive performance (Alzheimer's Disease Assessment Scale – cognitive subscale, ADAS-Cog, 11-item, 70-point scale) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, ADCS-CGIC). (2) Secondary outcomes: Neuropsychiatric Inventory (NPI), modified ADAS-Cog (13-item, 85-point scale), MMSE, Clinical Dementia Rating sum of boxes (CDR-SB) and Alzheimer's Disease Functional Assessment and Change Scale (ADFACS).&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Patient follow-up&lt;/H3&gt;
&lt;P id=p-6&gt;70.6% completed (65.9% in atorvastatin group, 75.2% in placebo group), 95.9% … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/117.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383474</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/85.extract]]&gt;</url>
    <title>Therapeutics - Bifrontal, bitemporal and right unilateral ECT electrode placement are similarly effective for reducing depressive symptoms</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;How does the efficacy of the new method of bifrontal electrode placement for electroconvulsive therapy (ECT) compare with standard bitemporal or right unilateral placement in people with depression? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;237 adults (age 20–87 years) with acute depression and a DSM-IV diagnosis of primary major depressive disorder or bipolar disorder, with or without psychosis, who had been referred for ECT.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Five Consortium for Research in ECT centres in the USA; 2001–2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;ECT three times a week using bifrontal, bitemporal or right unilateral placement of the electrodes. ECT was delivered using the Thymatron DGx ECT device, bifrontal and bitemporal at one and a half times seizure threshold, right unilateral at six times seizure threshold. Patients were treated until they achieved prespecified remission criteria (=60% decrease from baseline in HRSD-24 total score; HRSD-24 =10 on two consecutive ratings; and HRSD-24 not changing &amp;gt;3 points on the last two consecutive treatments). Participants were classed as non-remitters if they received at least 10 sessions without meeting remission criteria.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Depressive symptoms (Hamilton Rating … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/75.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>301870</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/120]]&gt;</url>
    <title>Therapeutics - Borderline personality disorder: STEPPS improves symptoms</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is the STEPPS programme for people with a borderline&lt;SUP&gt; &lt;/SUP&gt;personality disorder?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;165 people with DSM-IV borderline personality disorder (&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;18 years;&lt;SUP&gt; &lt;/SUP&gt;83% female). Main exclusions: psychotic or primary neurological&lt;SUP&gt; &lt;/SUP&gt;disorder; cognitive impairment; substance abuse or dependence;&lt;SUP&gt; &lt;/SUP&gt;recent suicidal thoughts or self-harm behaviour.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Outpatient setting, Iowa, USA; recruitment 2002–2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Systems Training for Emotional Predictability and Problem Solving&lt;SUP&gt; &lt;/SUP&gt;(STEPPS) plus usual care or usual care alone (including medication,&lt;SUP&gt; &lt;/SUP&gt;individual psychotherapy and case management). STEPPS is a manual-based&lt;SUP&gt; &lt;/SUP&gt;group treatment programme involving psychoeducation, and emotion&lt;SUP&gt; &lt;/SUP&gt;and behaviour management skills training, delivered in once&lt;SUP&gt; &lt;/SUP&gt;weekly 2-hour sessions over 20 weeks, which includes education&lt;SUP&gt; &lt;/SUP&gt;for a friend or relative.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Primary outcome: symptoms (Zanarini Rating Scale for Borderline&lt;SUP&gt; &lt;/SUP&gt;Personality Disorder Affective (ZRS-BPD), a scale which assesses&lt;SUP&gt; &lt;/SUP&gt;cognitive disturbance, disturbed relationships, and impulsivity).&lt;SUP&gt; &lt;/SUP&gt;Secondary outcomes: thoughts, feelings and behaviour (Borderline&lt;SUP&gt; &lt;/SUP&gt;Evaluation of Severity Over Time scale (BESOT)); positive and&lt;SUP&gt; &lt;/SUP&gt;negative disposition (Positive and Negative Affect &lt;I&gt;&lt;NOBR&gt;. . (Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;&lt;NOBR&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Professor of Clinical Psychology, Faculty of Medicine, University of Glasgow, Glasgow, UK &lt;BR&gt;&lt;/P&gt;&lt;/NOBR&gt;
&lt;P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/120" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/FONT&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328847</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/119]]&gt;</url>
    <title>Therapeutics - Both focused and enhanced cognitive behavioural therapy improve eating disorder symptom severity</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Is a complex cognitive behavioural therapy (CBT) package addressing&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;mood intolerance, clinical perfectionism, low self-esteem and&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;interpersonal difficulties more effective than CBT focused on&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;eating disorder symptoms alone?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;154 adults attending eating disorder clinics (95.5% female;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;mean age 26.1 years; 38.3% had bulimia nervosa). Participants&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;had to have a body mass index &amp;gt;17.5 and those who had received&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;similar previous CBT or with a psychiatric disorder were excluded.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Clinically warranted antidepressants were allowed during the&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;trial.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two eating disorder clinics in the UK (Oxfordshire and Leicester),&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;recruitment was March 2002–July 2005.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Enhanced CBT, focused CBT or waiting list control. Enhanced&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;CBT covered mood intolerance, clinical perfectionism, low self-esteem,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;interpersonal difficulties as well as aspects of eating disorders,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;while focused CBT covered only specific eating disorder features&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;such as shape and weight, binging and purging. Both CBT groups&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;received a 90 min initial session, then 20 sessions of 50 min&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;&lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/119" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317798</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/46]]&gt;</url>
    <title>Therapeutics - Brief behavioural intervention for infant sleep problems reduces depression in mothers</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does brief behavioural intervention aimed at modification of&lt;SUP&gt; &lt;/SUP&gt;infant sleep patterns at age 8 months improve maternal depression&lt;SUP&gt; &lt;/SUP&gt;and child sleep at age 2 years?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;328 mothers reporting infant sleep problems at age 7 months.&lt;SUP&gt; &lt;/SUP&gt;Mothers were recruited to the study when the infant was 4 months&lt;SUP&gt; &lt;/SUP&gt;old but were only allocated to intervention or usual care if&lt;SUP&gt; &lt;/SUP&gt;they reported infant sleep problems in a questionnaire administered&lt;SUP&gt; &lt;/SUP&gt;at 7 months of age. Exclusions: infants born before 32 weeks’&lt;SUP&gt; &lt;/SUP&gt;gestation; or mother’s English too poor to complete self-report&lt;SUP&gt; &lt;/SUP&gt;questionnaire.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Well child centres in six government areas (two low, two medium&lt;SUP&gt; &lt;/SUP&gt;and two highly disadvantaged), Melbourne, Australia. Recruitment&lt;SUP&gt; &lt;/SUP&gt;October to November 2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Brief behavioural sleep intervention (n = 174) or usual well&lt;SUP&gt; &lt;/SUP&gt;child care (n = 154). Sleep intervention was delivered by specially&lt;SUP&gt; &lt;/SUP&gt;trained nurses who taught parents two main strategies: either&lt;SUP&gt; &lt;/SUP&gt;"controlled crying", where parents respond to the infant’s&lt;SUP&gt; &lt;/SUP&gt;cries at &lt;NOBR&gt;&lt;EM&gt;.&lt;/EM&gt; . .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/46" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>297911</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/2/55]]&gt;</url>
    <title>Therapeutics - Brief cognitive-behavioural therapy reduces hospital readmission but does not reduce overall symptoms of schizophrenia</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;BR&gt;&lt;/STRONG&gt;Turkington D, Kingdon D, Rathod S, et al. Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. Br J Psychiatry 2006;189:36–40.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Is brief cognitive-behavioural therapy effective for people with schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blind (assessors blinded).&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; One year.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Six healthcare sites, UK; time period not stated.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 422 people with schizophrenia (ICD-10). Most participants had ongoing symptoms or were at risk of relapse. Exclusions: currently experiencing schizophrenia relapse, primary diagnosis of alcohol or substance abuse, organic brain disease, or learning disability.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Brief cognitive-behavioural therapy (CBT: 6 technique-based sessions over 2–3 months given by trained mental health nurses—including techniques for managing positive and negative symptoms and improving medication compliance) or usual care.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Primary outcomes: overall symptoms (Comprehensive Psychopathological Rating Scale (CPRS)); insight (Insight Rating Scale (IRS)); depression (Montgomery-Asberg Depression Rating Scale (MADRS)). Secondary outcomes: positive symptoms (Psychotic Symptom Rating Scales (PSYRATS)); negative symptoms (Negative Symptoms Rating Scales (NSRS)); readmission to hospital.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 87.5% of the CBT group and 77.6% of the usual care group completed treatment; 100% included in intention-to-treat analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;At 1 year, there were no significant differences between CBT and usual care groups in overall schizophrenia symptoms, depression or positive symptoms (mean difference in change scores for: CPRS –1.72, 95% CI –3.76 to +0.33, p = 0.10; MADRS –0.47, 95% CI –0.89 to +0.59, p = 0.13; PSYRATS voices +0.82, 95% CI –0.88 to +2.53, p = 0.342; PSYRATS delusions +0.57, 95% CI –0.57 to +1.72). CBT significantly improved insight and negative symptoms compared with usual care (mean difference in change scores for: IRS +0.71, 95% CI +0.11 to +1.31, p = 0.02; NSRS –0.77, 95% CI –1.27 to –0.28, p = 0.002). CBT significantly reduced readmission to hospital compared with usual care (14% with CBT v 23% with usual care; p&amp;lt;0.05).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;A brief course of CBT provided by trained mental health nurses does not reduce overall symptoms or depression in people with schizophrenia, but increases insight and reduces readmission to hospital.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298052</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/119]]&gt;</url>
    <title>Therapeutics - Brief motivational counselling does not reduce alcohol consumption in people with high alcohol intake</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Saitz R, Palfai TP, Cheng DM, et al. Brief intervention for medical inpatients with unhealthy alcohol use: a randomized, controlled trial. Ann Intern Med 2007;146:167–76.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does a brief motivational counselling session improve alcohol outcomes in hospitalised patients with unhealthy alcohol use?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Unblinded.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Twelve months.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Patient recruitment from an urban teaching hospital with out-patient follow-up; Massachusetts, USA; time period not stated.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 341 medical in-patients (&amp;gt;=18 years) with unhealthy alcohol intake over the past month (men: &amp;gt;14 standard drinks/week or &amp;gt;=5 drinks/occasion; women and those aged &amp;gt;=66 years: &amp;gt;11 standard drinks/week or &amp;gt;=4 drinks/occasion). Drinking habits were initially assessed using the Alcohol Use Disorders Identification Test (AUDIT). In the first 7 months, patients with AUDIT score &amp;gt;=8 were asked additional questions (drinking-days per week; drinks per day; maximum drinks per occasion) to determine eligibility; subsequently, any patient who drank in past 12 months was asked these questions, regardless of AUDIT score. &lt;STRONG&gt;Exclusions:&lt;/STRONG&gt; fewer than two contacts to assist with follow-up; planning to move from area within next year; Mini-Mental State score &amp;lt;21.&lt;BR&gt;Intervention: Brief motivational counselling or usual care. Counselling consisted of a single, 30-min session with feedback, discussion and development of an action plan, conducted by counselling and clinical psychology students. Usual care consisted of being informed of screening results, referral to specialist if requested, and opportunity to discuss condition with a physician.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Any alcohol assistance at 3 months (for example, out-patient or residential treatment, mutual-help groups, or employee assistance programmes; assessed using Treatment Services Review and Form 90) in participants with alcohol dependence; and change in mean number of drinks per day in all participants.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 80% at 3 months; 84% at 12 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;There was no significant difference between motivational counselling and usual care in mean drinks per day at 12 months (unadjusted reduction in drinks per day: 1.8 with counselling vs 2.6 with usual care; adjusted mean group difference: –1.5 drinks, 95% CI –3.7 to +0.6 drinks, p = 0.169). In the subgroup of participants with DSM-IV alcohol dependence at baseline, there was no significant difference between motivational counselling and usual care in the proportion receiving alcohol assistance at 3 months (204 of 341 randomised patients assessed (55% of counselling group; 65% of controls); adjusted absolute risk for receiving assistance: 49% with counselling vs 44% with usual care; adjusted difference: +5%, 95% CI –8% to +19%, p = 0.55).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;A single brief session of motivational counselling does not reduce alcohol consumption by 12 months, or the need for assistance for alcohol dependence at 3 months compared to usual care.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302041</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/22]]&gt;</url>
    <title>Therapeutics - Brief personalised motivational interviewing reduces frequency of marijuana use in regular users ambivalent to change</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DRUG USE DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is motivational interviewing effective for regular users of&lt;SUP&gt; &lt;/SUP&gt;marijuana who are ambivalent to stopping the drug?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;188 adults who used marijuana, who were identified via advertisements&lt;SUP&gt; &lt;/SUP&gt;offering objective, non-judgemental feedback about their marijuana&lt;SUP&gt; &lt;/SUP&gt;use and whether it was potentially harmful. Information about&lt;SUP&gt; &lt;/SUP&gt;marijuana use was obtained using the Marijuana Check-Up (MCU;&lt;SUP&gt; &lt;/SUP&gt;adapted from the Drinker’s Check-Up), and participants&lt;SUP&gt; &lt;/SUP&gt;were asked about whether they had intentions to change drug&lt;SUP&gt; &lt;/SUP&gt;use, and their stage of change classified. Most participants&lt;SUP&gt; &lt;/SUP&gt;reported that they did not plan to change their marijuana use&lt;SUP&gt; &lt;/SUP&gt;(pre-contemplation), or were thinking of changing their use,&lt;SUP&gt; &lt;/SUP&gt;but not in the next month (contemplation). Main exclusions:&lt;SUP&gt; &lt;/SUP&gt;use of marijuana on fewer than 15 days over the past month;&lt;SUP&gt; &lt;/SUP&gt;alcohol or other substance abuse; or severe psychiatric disorder.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;University of Washington Research Centre, Seattle, &lt;NOBR&gt;&lt;EM&gt;. . (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Jan Copeland &lt;BR&gt;National Cannabis Prevention and Information Centre, University of New South Wales, Sydney, Australia.&lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/22" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383460</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/82.extract]]&gt;</url>
    <title>Therapeutics - Brief, personality-targeted coping-skills intervention reduces onset and escalation of drug misuse</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Are targeted coping-skills interventions efficacious in preventing illicit drug use in adolescents with personality risk factors for substance misuse? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;Seven hundred and thirty-two students aged between 13 and 16 years with elevated scores on self-reported measures of hopelessness, anxiety sensitivity, impulsivity and sensation seeking (scores =1 SD above school mean on one or more of these four Substance Use Risk Profile Scale subscales). Participants were grouped on the basis of their highests score on a specific subscale. If more than one subscale score was elevated, they were placed in the group where they deviated most from the mean (based on z scores).&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Twenty-four state-run secondary schools in London, UK; time period not reported.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Personality-targeted coping-skills intervention or no intervention (control). The intervention consisted of two 90 min group sessions targeting each of the four personality profiles. The sessions were based on manuals, including psychoeducational, motivational, and cognitive behavioural therapy components and real-life scenarios. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Onset and frequency of illicit drug use, and number of drugs used (assessed using the … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/82.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>301964</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/121]]&gt;</url>
    <title>Therapeutics - Carers of people with dementia: no benefit of adding befriending initiative to usual care</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What effect does access to social support through a befriending&lt;SUP&gt; &lt;/SUP&gt;initiative have on psychological well-being and quality of life&lt;SUP&gt; &lt;/SUP&gt;for carers of people with dementia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;236 adult family carers of people with primary progressive dementia.&lt;SUP&gt; &lt;/SUP&gt;Carers were either cohabiting with patient or providing at least&lt;SUP&gt; &lt;/SUP&gt;20 h of care per week. Carers were recruited through participating&lt;SUP&gt; &lt;/SUP&gt;GPs; posters and leaflets in libraries, social services, mental&lt;SUP&gt; &lt;/SUP&gt;health services, pharmacies, day services, voluntary organisations&lt;SUP&gt; &lt;/SUP&gt;and supermarkets; through presentation to potential gatekeepers&lt;SUP&gt; &lt;/SUP&gt;(health, social and voluntary sector professionals) and through&lt;SUP&gt; &lt;/SUP&gt;radio and newspaper publicity. Exclusion criteria: carers with&lt;SUP&gt; &lt;/SUP&gt;terminal illness or congenital or acquired cognitive impairment&lt;SUP&gt; &lt;/SUP&gt;and patients who were in nursing or other permanent or long-stay&lt;SUP&gt; &lt;/SUP&gt;residential facilities.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;General community in Norfolk, Suffolk and the London Borough&lt;SUP&gt; &lt;/SUP&gt;of Havering; randomisation April 2000 to August 2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Access to a "befriender facilitator" and to a volunteer befriender&lt;SUP&gt; &lt;/SUP&gt;as well as usual care or usual &lt;I&gt;&lt;NOBR&gt;. . (Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;NOBR&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/NOBR&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Neena L Chappell, PhD, FRSC &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Centre on Aging, University of Victoria, Victoria, British Columbia, Canada &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/121" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306986</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/14]]&gt;</url>
    <title>Therapeutics - CBT does not improve relapse rates in people with recently relapsed psychosis</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the effect of cognitive behavioural therapy (CBT) and family intervention on relapse rates and symptoms in people with recently relapsed non-affective psychosis?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;301 people aged 18–65 years (218 without carers, 83 with carers) with non-affective psychosis (ICD-10 category F2 and DSM-IV) and a second or subsequent psychotic episode not more than 3 months before the trial began, plus a rating of at least 4 for one or more positive symptoms on the Positive and Negative Syndrome Scale (PANSS). Exclusion criteria: primary diagnosis of alcohol or substance dependency; intellectual disability or organic syndrome; unreliable residential arrangements; or limited spoken English.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;BR&gt;&lt;/STRONG&gt;Five local mental health services, UK; recruitment 2002–2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;BR&gt;&lt;/STRONG&gt;People with carers randomly allocated to: CBT for psychosis (12–20 sessions over 9 months, targeting key aspects of relapse prevention) plus treatment as usual (TAU), family intervention plus TAU or TAU only. People without carers randomly allocated to: the same CBT . . . [Full text of this article]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Robert C Durham&lt;/P&gt;
&lt;P&gt;University of Dundee, Dundee, UK &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/14" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317797</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/45]]&gt;</url>
    <title>Therapeutics - CBT improves maternal perinatal depression in rural Pakistan</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does a community health worker delivered cognitive behavioural&lt;SUP&gt; &lt;/SUP&gt;therapy (CBT) based intervention improve the health of perinatally&lt;SUP&gt; &lt;/SUP&gt;depressed women and their newborn infants in rural Pakistan?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;903 married women, aged 16–45 years, in their third trimester&lt;SUP&gt; &lt;/SUP&gt;of pregnancy and diagnosed with DSM-IV perinatal major depression&lt;SUP&gt; &lt;/SUP&gt;(CBT based intervention, 463; control, 440). Exclusions for&lt;SUP&gt; &lt;/SUP&gt;mothers: serious medical condition; pregnancy related illness;&lt;SUP&gt; &lt;/SUP&gt;disability; psychosis; and serious illness, death or moved residence&lt;SUP&gt; &lt;/SUP&gt;during the study. Exclusions for infants: born prematurely or&lt;SUP&gt; &lt;/SUP&gt;with congenital defect; aborted or stillborn; died within first&lt;SUP&gt; &lt;/SUP&gt;year of birth; and given up for adoption.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;40 Union Councils (administrative units) in Gujar Khan and Kallar&lt;SUP&gt; &lt;/SUP&gt;Syedan, rural Pakistan. Recruitment: April 2005 to March 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;CBT based intervention or enhanced routine care (control). Both&lt;SUP&gt; &lt;/SUP&gt;groups received visits from local female health visitors every&lt;SUP&gt; &lt;/SUP&gt;week during the last month of pregnancy, three times in the&lt;SUP&gt; &lt;/SUP&gt;month after birth and then once a &lt;NOBR&gt;. . (Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/45" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>344624</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/20.extract]]&gt;</url>
    <title>Therapeutics - CBT improves worry severity in older adults with GAD in primary care</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does cognitive behavioural therapy (CBT) improve generalised anxiety disorder (GAD) in older adults in primary care?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;134 older adults (&amp;gt;60 years) with a principal or co-principal diagnosis of GAD (Structured Diagnostic Interview for DSM-IV). Exclusion criteria: current substance abuse, psychotic illness or bipolar disorder; and Mini-Mental State Examination score &amp;lt;24. Current antidepressant or anxiolytic use was not considered an exclusion criterion. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Two primary care clinics, Texas, USA; March 2004–August 2006.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;CBT or enhanced usual care (EUC). CBT involved manualised treatment from trained therapists delivered individually for up to 10 sessions over 12 weeks. It focused on cognitive therapy, behavioural therapy (eg, exposure), education and awareness, problem solving skills and sleep management. EUC involved usual care plus twice weekly phone calls by therapists during the first 3 months of the study. &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-5&gt;&lt;EM&gt;Primary outcomes&lt;/EM&gt;: worry severity (self-report Penn State Worry Questionnaire (PSWQ)) and GAD severity (clinician rated Generalised Anxiety Disorder Severity Scale [GADSS]). &lt;EM&gt;Secondary outcomes&lt;/EM&gt;: anxiety severity (Structured Interview Guide for the Hamilton Anxiety Scale); depression severity … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/20.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392775</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/125.extract]]&gt;</url>
    <title>Therapeutics - CBT, SSRI or both are similarly effective for panic disorder 1-year post-treatment</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PANIC DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What is the long-term effectiveness of cognitive behavioural therapy (CBT), pharmacotherapy using a selective serotonin reuptake inhibitor (SSRI) or the combination of both for panic disorder with or without agoraphobia? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;150 adults with a primary diagnosis of DSM-IV panic disorder with or without DSM-III-R agoraphobia (based on Mini-International Neuropsychiatric Interview). The study excluded people who were pregnant, lactating, suicidal, psychotic or severely depressed. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;11 treatment centres in the Netherlands; enrolment April 2001 to September 2003.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;CBT, SSRI or both for 1 year. CBT consisted of up to 21 sessions lasting 50 min. Participants receiving SSRIs had up to 12 sessions with their therapist and tapered their medication over 3 months at the end of treatment. Participants were classed as completers, dropouts or no-tapers. Those who received a minimum of 15 CBT sessions and/or eight SSRI sessions and ended treatment with therapist consent were considered completers. Dropouts received less than 1 year's treatment. No-tapers did not taper off their SSRI medication. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;General aspects …&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/125.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>298014</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/80]]&gt;</url>
    <title>Therapeutics - Citalopram, but not interpersonal psychotherapy, improves major depression in people with coronary artery disease</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;297:367–79.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Are citalopram or interpersonal psychotherapy more effective than placebo or clinical management for major depression in people with coronary artery disease?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled 2x2 factorial trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Double blind for citalopram and placebo; single blind for interpersonal psychotherapy (IPT) or clinical management (assessors blind).&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Twelve weeks (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Nine academic centres, Canada; May 2002 to March 2006.&lt;BR&gt;Patients: 284 outpatients (&amp;gt;=18 years old) with DSM-IV major depression for &amp;gt;=4 weeks, Hamilton Depression rating scale (HAM-D) score &amp;gt;=20, and established coronary artery disease (previous myocardial infarction or revascularisation; or angiographic evidence of &amp;gt;=50% stenosis in &amp;gt;=1 major coronary artery). Main exclusions: depression with psychotic features; bipolar disorder; substance abuse; serious suicidal risk; taking antidepressants, anticonvulsants, lithium, or undergoing psychotherapy; previous non-response to citalopram or IPT; &amp;gt;=2 unsuccessful treatments for current depressive episode; previous early discontinuation of SSRIs due to adverse events; Mini-Mental State Examination score &amp;lt;24; worsening angina or congestive heart failure symptoms in previous week; severely limiting angina; cardiac admission within past week; or coronary artery bypass graft planned in next 4 months.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Citalopram (up to 40 mg daily) or placebo, plus IPT and clinical management or clinical management alone for 12 weeks (provided by trained IPT therapists). Clinical management sessions lasted 20–25 min and included information about depression and encouragement to comply with medication.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Depression symptoms (24-item Hamilton Depression rating scale (HAM-D)), remission (HAM-D score &amp;lt;=8), response (&amp;gt;=50% reduction from baseline in HAM-D).&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 81% completed treatment; 100% included in last observation carried forward analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Citalopram significantly improved symptoms of depression, and increased response and remission, compared with placebo at 12 weeks (mean difference in change in HAM-D score from baseline: 3.33, 95% CI 0.80 to 5.85; p = 0.005; remission: OR 1.93, 95% CI 1.14 to 3.25; response: OR 1.67, 95% CI 1.04 to 2.67). IPT added no benefit to clinical management alone in symptoms of depression, response, or remission at 12 weeks (mean difference in change in HAM-D score from baseline: –2.26, 95% CI –4.78 to +0.27; p = 0.06; remission: OR 0.90, 95% CI 0.54 to 1.51; response: OR 0.75, 95% CI 0.47 to 1.20).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt;&lt;BR&gt;When given in combination with clinical management, citalopram is more effective than placebo for treating depression in people with coronary artery disease. However, adding interpersonal psychotherapy to clinical management does not improve depressive symptoms.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302012</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/48]]&gt;</url>
    <title>Therapeutics - Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Cognitive therapy or pharmacotherapy as second-line for people&lt;SUP&gt; &lt;/SUP&gt;with citalopram-resistant depression—which is more effective?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;304 out-patients with non-psychotic major depressive disorder&lt;SUP&gt; &lt;/SUP&gt;(clinically established diagnosis verified through DSM-IV criteria)&lt;SUP&gt; &lt;/SUP&gt;enrolled in the Sequenced Treatment Alternatives to Relieve&lt;SUP&gt; &lt;/SUP&gt;Depression (STAR*D) study who did not achieve remission (remission&lt;SUP&gt; &lt;/SUP&gt;defined as Quick Inventory of Depressive Symptomatology score&lt;SUP&gt; &lt;/SUP&gt;&lt;IMG alt="&lt;=" src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID302012/nelhImp_0000_les.gif" border=0&gt;5) with first-line citalopram treatment. This analysis included&lt;SUP&gt; &lt;/SUP&gt;only those people who agreed to be randomised to treatment strategies&lt;SUP&gt; &lt;/SUP&gt;(augmentations, switches or both) which would allow cognitive&lt;SUP&gt; &lt;/SUP&gt;therapy to be compared with pharmacotherapy.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Primary care and psychiatric care practice settings across the&lt;SUP&gt; &lt;/SUP&gt;USA; recruitment July 2001 to April 2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Participants who did not achieve remission were randomised to&lt;SUP&gt; &lt;/SUP&gt;one of seven second-line treatments: ongoing citalopram with&lt;SUP&gt; &lt;/SUP&gt;sustained-release bupropion, buspirone, or cognitive therapy&lt;SUP&gt; &lt;/SUP&gt;(augmentation strategies; n = 182); or &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Sagar V Parikh &lt;BR&gt;University Health Network and University of Toronto, Toronto, Canada &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/48" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302031</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/12]]&gt;</url>
    <title>Therapeutics - Cognitive behavioural therapy and interpersonal therapy comparably effective for major depression</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Cognitive behavioural therapy (CBT) or interpersonal psychotherapy (IPT): which is more effective for depression? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;177 adults (aged over 18 years) with DSM-IV non-psychotic major depression. Main exclusions: history of mania, schizophrenia, major physical illness, moderate or severe current alcohol or drug dependence, antisocial personality disorder or failure to respond to a recent (within the last year) trial of either CBT or IPT. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Recruitment from various sources including mental health out-patient clinics, psychiatric emergency services, self-referral and general practitioners between August 1998 and February 2003; treatment delivered in a university-based outpatient research unit. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;CBT or IPT for up to 16 weeks. Both approaches were delivered as 50-minute weekly sessions. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Change in depression symptoms (% change in Montgomery-Asberg Depression Rating Scale (MADRS) score) between baseline and follow-up. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;89.8% of people completed . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Keith S Dobson, PhD &lt;BR&gt;University of Calgary, Calgary, Canada &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. Full text of the article is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224104</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/7/4/118]]&gt;</url>
    <title>Therapeutics - Cognitive behavioural therapy significantly improves hypochondriacal symptoms</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,UNEXPLAINED SOMATIC COMPLAINTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis; A randomized controlled trial. JAMA 2004;291:1464–70.&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Is cognitive behavioural therapy an effective treatment for hypochondriasis?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Assessors blinded to treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Follow up period:&lt;/STRONG&gt; 12 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Primary care practices, Boston, Mass., USA; September 1997 to November 2001.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 187 people aged 18 years or older, scoring &amp;gt;150 (range 52–258) on the hypochondriasis screening questionnaire, who had consulted a primary care physician in the preceding 12 months. People who were seriously ill, psychotic, suicidal, suffering from somatoform pain disorder, or undergoing disability related proceedings or litigation, were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Six 90 minute weekly sessions of individual cognitive behavioural therapy, specifically addressing hypochondriasis and including educational information, or usual care. To coordinate medical management with cognitive behavioural therapy, letters were sent to the participants’ practioners, advising them to be conservative in diagnosis and treatment, schedule regular appointments, make improved coping a treatment goal rather than symptom elimination, provide only limited reassurance, and explain symptoms using the model of cognitive and perceptual symptom amplification.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Hypochondriacal attitudes and beliefs (The Whitely Index); health related anxiety (Health Anxiety Inventory).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient follow up:&lt;/STRONG&gt; 86% at six months, 91% at 12 months.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;At 12 months, cognitive behavioural therapy significantly decreased hypochondriacal attitudes and beliefs (p&amp;lt;0.001) and health related anxiety (p&amp;lt;0.009) compared with usual care (see &lt;A href="http://www.ebmentalhealth.com/supplemental" target="_blank"&gt;http://www.ebmentalhealth.com/supplemental&lt;/A&gt; for table). Ability to function socially was significantly improved (p&amp;lt;0.05) as was the ability to perform normal daily activities (p&amp;lt;0.001). There were no significant differences in improvement of somatic symptoms between groups.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Cognitive behaviour therapy significantly improves the symptoms of hypochondriasis and may have long term benefits for sufferers.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302006</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/42]]&gt;</url>
    <title>Therapeutics - Cognitive improvements with antipsychotics: real or practice effect?</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do the effects of olanzapine and risperidone on cognition in&lt;SUP&gt; &lt;/SUP&gt;first-episode schizophrenia differ, and are the effects real&lt;SUP&gt; &lt;/SUP&gt;or the result of repeating the tests?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;104 people with DSM-IV first episode schizophrenia (76 with&lt;SUP&gt; &lt;/SUP&gt;schizophrenia, 10 with schizoaffective disorder, and 18 with&lt;SUP&gt; &lt;/SUP&gt;schizophreniform disorder) recruited through hospital-based&lt;SUP&gt; &lt;/SUP&gt;research units who were all actively psychotic on enrolment;&lt;SUP&gt; &lt;/SUP&gt;84 healthy controls were recruited through newspaper advertisements&lt;SUP&gt; &lt;/SUP&gt;and word of mouth. Exclusions: medical condition affecting the&lt;SUP&gt; &lt;/SUP&gt;central nervous system, and having neurological conditions or&lt;SUP&gt; &lt;/SUP&gt;taking drugs that affected cognition.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Hospitals in the USA; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;People with first-episode schizophrenia (FES) were randomised&lt;SUP&gt; &lt;/SUP&gt;to receive olanzapine (2.5–20 mg/d) or risperidone (1–6&lt;SUP&gt; &lt;/SUP&gt;mg/d) for 16 weeks. Healthy controls did not receive any medication.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Severity of illness (Schedule for Affective Disorders and Schizophrenia-Change&lt;SUP&gt; &lt;/SUP&gt;Version; Schedule &lt;NOBR&gt;&lt;EM&gt;. .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Corrado Barbui, Andrea Cipriani &lt;/P&gt;
&lt;P&gt;Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/42" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302037</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/18]]&gt;</url>
    <title>Therapeutics - Cognitive remediation therapy produces moderate improvements in working memory in people with schizophrenia</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is cognitive remediation therapy (CRT) effective for the cognitive&lt;SUP&gt; &lt;/SUP&gt;problems experienced by people with schizophrenia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;85 adults aged &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;17 years with DSM-IV schizophrenia and evidence&lt;SUP&gt; &lt;/SUP&gt;of social and cognitive dysfunction (poor scores on the Social&lt;SUP&gt; &lt;/SUP&gt;Behaviour Scale, Rivermead memory scale, Wisconsin Card Sorting&lt;SUP&gt; &lt;/SUP&gt;Test, and/or Hayling Sentence Completion Test). Participants&lt;SUP&gt; &lt;/SUP&gt;had to have been in contact with mental health services for&lt;SUP&gt; &lt;/SUP&gt;at least a year.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Community setting, London, UK; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;CRT or treatment as usual. CRT consisted of 40 face-to-face&lt;SUP&gt; &lt;/SUP&gt;sessions with trained psychologists on three days per week over&lt;SUP&gt; &lt;/SUP&gt;&lt;IMG alt=~ src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID302037/nelhImp_0000_sim.gif" border=0&gt;12 weeks. Sessions were based on teaching modules laid out in&lt;SUP&gt; &lt;/SUP&gt;a manual, and involved cognitive flexibility (tasks in engagement&lt;SUP&gt; &lt;/SUP&gt;activity), working memory (tasks involving holding information&lt;SUP&gt; &lt;/SUP&gt;sets in the mind) and planning (goal attainment). Treatment&lt;SUP&gt; &lt;/SUP&gt;as &lt;NOBR&gt;&lt;EM&gt;. . .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Gudrun Sartory, PhD &lt;BR&gt;Department of Psychology, University of Wuppertal, Wuppertal, Germany &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT face=""&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/18" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302044</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/25]]&gt;</url>
    <title>Therapeutics - Cognitive therapy improves post-traumatic stress disorder associated with civil conflict in Northern Ireland</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is cognitive therapy for post-traumatic stress&lt;SUP&gt; &lt;/SUP&gt;disorder (PTSD) associated with terrorism and civil conflict&lt;SUP&gt; &lt;/SUP&gt;in Northern Ireland?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;58 adults (60% male) with DSM-IV PTSD associated with terrorism&lt;SUP&gt; &lt;/SUP&gt;and civil conflict. Most participants (81%) had experienced&lt;SUP&gt; &lt;/SUP&gt;multiple traumas (median of 3 traumas), mainly associated with&lt;SUP&gt; &lt;/SUP&gt;the Northern Ireland "troubles" (84%), including bombings (40%).&lt;SUP&gt; &lt;/SUP&gt;The median duration of PTSD in participants was 5.2 years, and&lt;SUP&gt; &lt;/SUP&gt;most participants (72%) had axis I comorbidity, mainly major&lt;SUP&gt; &lt;/SUP&gt;depression (64%). Exclusion criterion: needing immediate treatment&lt;SUP&gt; &lt;/SUP&gt;for another disorder.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Northern Ireland Centre for Trauma and Transformation community&lt;SUP&gt; &lt;/SUP&gt;treatment centre, Omagh, Northern Ireland; enrolment August&lt;SUP&gt; &lt;/SUP&gt;2003 to September 2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Cognitive therapy or waiting list control for 12 weeks. Cognitive&lt;SUP&gt; &lt;/SUP&gt;therapy consisted of a maximum of one session a week for 12&lt;SUP&gt; &lt;/SUP&gt;weeks (average of 5.9 sessions received), plus additional &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;BR&gt;&lt;/STRONG&gt;Jonathan Bisson &lt;/P&gt;
&lt;P&gt;University Hospital of Wales, Cardiff, UK&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/25" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&amp;nbsp;&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301977</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/74]]&gt;</url>
    <title>Therapeutics - Collaborative consultation increases use of medication titration trials but not behaviour in children with ADHD</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does a collaborative consultation service in community paediatric&lt;SUP&gt; &lt;/SUP&gt;practices improve practice behaviours and symptoms in children&lt;SUP&gt; &lt;/SUP&gt;with attention-deficit/hyperactivity disorder (ADHD)?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;377 children with DSM-IV ADHD who had not previously received&lt;SUP&gt; &lt;/SUP&gt;treatment, and were registered at 12 paediatric practices which&lt;SUP&gt; &lt;/SUP&gt;agreed to participate. 146 of these children (mean age 7.8 years;&lt;SUP&gt; &lt;/SUP&gt;64% male) were selected at random to be assessed for behavioural&lt;SUP&gt; &lt;/SUP&gt;outcomes. Exclusions: practices with an on-site psychiatrist&lt;SUP&gt; &lt;/SUP&gt;or psychologist; practices that did not use computerised billing&lt;SUP&gt; &lt;/SUP&gt;systems.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;12 community-based paediatric practices, USA; time period not&lt;SUP&gt; &lt;/SUP&gt;stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Practices were randomised to collaborative consultation service&lt;SUP&gt; &lt;/SUP&gt;(6 practices, 25 healthcare professionals, 162 children with&lt;SUP&gt; &lt;/SUP&gt;ADHD) or control (6 practices, 27 healthcare professionals,&lt;SUP&gt; &lt;/SUP&gt;215 children with ADHD). Collaborative consultation involved&lt;SUP&gt; &lt;/SUP&gt;promotion of and assistance with blinded titration trials &lt;NOBR&gt;&lt;EM&gt;. . . (abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Thomas J Power, Heather A Jones &lt;/P&gt;
&lt;P&gt;University of Pennsylvania School of Medicine and The Children's Hospital of Philadelphia, Philadelphia, PA, USA&lt;BR&gt;The Children's Hospital of Philadelphia, Philadelphia, PA, USA &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/74" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298026</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/84]]&gt;</url>
    <title>Therapeutics - Combined fluoxetine plus cognitive behavioural therapy is more effective than monotherapy or placebo for adolescents with depression</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;March J, Silva S, Vitiello B. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006;45:1393–403.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What are the effects of fluoxetine plus cognitive behavioural therapy on depression and suicide ideation compared with either component alone or placebo?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Unclear.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt;&amp;nbsp;Double blind (fluoxetine and placebo), single blind (cognitive behavioural therapy (CBT) and combination treatment).&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Twelve weeks (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; US; enrolment 2000–3.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 439 adolescents (12–17 years) with major depressive disorder (DSM-IV) and a Children’s Depression Rating Scale-Revised (CDRS-R) total score &amp;gt;=45, demonstrating impairment due to depression in at least two settings (home, school or with friends) for at least 6 weeks. Exclusions: comorbid conditions requiring medication, previously failed CBT or two trials of selective serotonin reuptake inhibitor, currently receiving psychotherapy or psychotropic medication.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Fluoxetine, CBT (15 sessions), fluoxetine plus CBT, or placebo for 12 weeks. Fluoxetine and placebo started at 10 mg/day, increased up to 40 mg/day by week 8 as needed.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; CDRS-R and Reynolds Adolescent Depression Scale; achievement of CDRS-R score &amp;lt;28; Clinical Global Impression-Improvement scale score; time to first response; time to stable response; Suicidal Ideation Questionnaire endpoint score and slope; Children’s Global Assessment Scale; Health of the Nation Outcomes Scale; Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 82% completed their assigned treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;This paper summarises significant results for the 16 outcomes measured in the Treatment for Adolescents with Depression Study (TADS). Detailed results were presented in accompanying papers (see &lt;A href="http://ebmh.bmj.com/supplemental" target="_blank"&gt;http://ebmh.bmj.com/supplemental&lt;/A&gt; for references). Combining CBT with fluoxetine was significantly more effective than placebo on 15 of the 16 outcomes, more effective than fluoxetine alone on 8 outcomes, and more effective than CBT alone on 14 outcomes. Fluoxetine alone was more effective than placebo on 7 out of the 16 outcomes, while CBT alone was not superior to placebo on any of the 14 outcomes assessed. Fluoxetine alone was superior to CBT alone on 8 of the 14 outcomes assessed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;In treating adolescents with depression, a combination of fluoxetine plus CBT is more effective than fluoxetine alone, CBT alone, or placebo.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383461</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/83.extract]]&gt;</url>
    <title>Therapeutics - Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Do mirtazapine-based combinations of antidepressants increase remission of major depressive disorder compared with fluoxetine monotherapy? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;One hundred and five adults meeting &lt;EM&gt;DSM-IV&lt;/EM&gt; criteria for major depressive disorder (MDD), and with 17-item Hamilton Depression Rating Scale (HAM-D) score =18. Individuals who did not respond to fluoxetine in their index episode were excluded. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Two university sites and an associated clinic in the USA and Canada; time period not stated.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Fluoxetine monotherapy (20mg/day) was compared with fluoxetine, extended release venlafaxine (225mg/day titrated in 14 days) or bupropion (150mg/day) in combination with mirtazapine (30mg/day) for six weeks. Branded formulations of fluoxetine, extended release venlafaxine and mirtazapine were used, and a slow release capsule formulation of bupropion was prepared. After the initial six weeks, participants could enter a six-month prolongation period if they reached a score of 12 or less on the Montgomery-Å´sberg Depression Rating Scale (MADRS). In this period the fluoxetine monotherapy group continued their treatment, the fluoxetine … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/83.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>392768</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/121.extract]]&gt;</url>
    <title>Therapeutics - Coordinated multi-component treatment in primary care improves anxiety in adults with multiple anxiety disorders compared with usual care</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is a flexible treatment delivery model for anxiety disorders in primary care better than usual care?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;1004 primary care patients (18–75 years) with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition anxiety disorders, who scored =8 on the Overall Anxiety Severity and Impairment Scale. Participants could have one or more diagnoses of panic, generalised anxiety, social anxiety or post-traumatic stress disorder, with or without major depression. Exclusions: psychosis, bipolar I disorder, substance abuse or dependence (except marijuana and alcohol), unstable medical conditions, marked cognitive impairment, active suicidal intent or plan, already receiving cognitive behavioural therapy (CBT) or medication from a psychiatrist.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;17 primary care clinics in four US cities; June 2006 to April 2008.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Coordinated Anxiety Learning and Manage-ment (CALM) or usual care. CALM involved a blended package of treatment, which included the patient's preference out of CBT, medication or both for 10–12 weeks, plus web outcomes monitoring. Participants could switch from CBT to medication or combine the treatments …&lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/121.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302010</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/46]]&gt;</url>
    <title>Therapeutics - Depressed inpatients: treatment with psychotherapy plus pharmacotherapy superior to standard treatment</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is psychotherapy better than usual clinical management for inpatients&lt;SUP&gt; &lt;/SUP&gt;with depression who are also being treated with pharmacotherapy?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;130 people aged 18–65 years old with DSM-IV major depressive&lt;SUP&gt; &lt;/SUP&gt;disorder referred for psychiatric hospitalisation, who had a&lt;SUP&gt; &lt;/SUP&gt;score of &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;16 on the 17-item Hamilton Depression Rating Scale&lt;SUP&gt; &lt;/SUP&gt;(HAM-D). Exclusion criteria: bipolar I disorder, substance abuse&lt;SUP&gt; &lt;/SUP&gt;or dependency, other primary axis I disorders, organic mental&lt;SUP&gt; &lt;/SUP&gt;disorder, psychotic symptoms, severe cognitive impairment, active&lt;SUP&gt; &lt;/SUP&gt;suicide ideation.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Acute psychiatric hospital; enrolment November 2000 to August&lt;SUP&gt; &lt;/SUP&gt;2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Interpersonal psychotherapy (IPT) or clinical management (usual&lt;SUP&gt; &lt;/SUP&gt;care). IPT had been adapted for an inpatient setting and included&lt;SUP&gt; &lt;/SUP&gt;15 individual sessions (each about 50 minutes three times weekly&lt;SUP&gt; &lt;/SUP&gt;over 5 weeks), 8 IPT group sessions, some of which included&lt;SUP&gt; &lt;/SUP&gt;significant others in some of the sessions. Clinical management&lt;SUP&gt; &lt;/SUP&gt;&lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;H3&gt;Commentator:&lt;/H3&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Matthias Schwannauer &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;University of Edinburgh, Edinburgh, UK &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/46" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302008</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/44]]&gt;</url>
    <title>Therapeutics - Depression in older adults: collaborative care model seems effective</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is a collaborative care model an effective approach for the&lt;SUP&gt; &lt;/SUP&gt;management of depression in older people?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;105 males and females aged 60 years or older referred by their&lt;SUP&gt; &lt;/SUP&gt;general practitioner (GP) or a district, community or practice&lt;SUP&gt; &lt;/SUP&gt;nurse to the study. People were included if they scored 5 or&lt;SUP&gt; &lt;/SUP&gt;more on the Geriatric Depression Scale and 24 or more on the&lt;SUP&gt; &lt;/SUP&gt;Mini-Mental State Examination (MMSE).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;One primary care trust in Manchester; February 2004 to June&lt;SUP&gt; &lt;/SUP&gt;2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;A 12-week collaborative care intervention, delivering education&lt;SUP&gt; &lt;/SUP&gt;about depression, advice about antidepressants, provision of&lt;SUP&gt; &lt;/SUP&gt;a self-help manual (self-help manual for anxiety and depression&lt;SUP&gt; &lt;/SUP&gt;(SHADE)), and sign-posting to other services compared with usual&lt;SUP&gt; &lt;/SUP&gt;care. The intervention involved six face-to-face sessions in&lt;SUP&gt; &lt;/SUP&gt;the patient’s home and five sessions delivered via the&lt;SUP&gt; &lt;/SUP&gt;&lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted).&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Simon Gilbody &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Professor of Psychological Medicine and Health Services Research, University of York, York, USA&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/44" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377616</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/45.extract]]&gt;</url>
    <title>Therapeutics - Depressive symptoms highly prevalent after a musculoskeletal workplace injury</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Six months after a workplace injury to the back or upper extremity, what is the prevalence, incidience and course of depressive symptoms; how prevalent is mental health treatment, and is there an association between return-to-work trajectories (RTW) and depressive symptoms?&lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A total of 632 people (mean age 42.2 years, 55% male) lost their claim filed for working-time claim under the new Workplace Safety and Insurance Board of Ontario (WSIB), due to a work-related musculoskeletal disorder of the back or upper extremity. Eligibility criteria for enrolling participants in our study were as follows: absence from work for =5 days during the first 14 days after the injury, aged &amp;gt;15 years and passing the final eligibility screen conducted by a telephone interview. Exclusion criteria were severe injury (fracture or amputation), inability to speak English, receiving institutional care or a security problem.&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ontario, Canada; timeframe not stated.&lt;/P&gt;
&lt;H3&gt;Prognostic Factors:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Depressive symptoms at baseline and at 6 months postinjury were analysed using the Center for Epidemiologic Studies – Depression scale (CES-D). High-level depressive symptoms were defined so on the basis of a CES-D score of =16. Depression diagnosis at 6 months (self-reported … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/45.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298046</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/112]]&gt;</url>
    <title>Therapeutics - Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE Study. Am J Psychiatry 2007;164:428–36.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What are the effects of olanzapine, risperidone, quetiapine, perphenazine and ziprasidone on psychosocial functioning in people with schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Not clear.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Double blind.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Eighteen months (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Fifty seven clinical sites in the USA; January 2001 to December 2004.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 1493 adults with DSM-IV schizophrenia were randomised in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. This publication reports on the 455 participants who were assessed for the primary outcome measure at baseline and 12 months. Main exclusions: history of antipsychotic resistance, only one previous schizophrenic episode, schizoaffective disorder, mental retardation, other cognitive disorders, pregnant or breast feeding, or serious medical comorbidity.&lt;BR&gt;Intervention: Olanzapine (7.5–30 mg), quetiapine (200–800 mg), risperidone (1.5–6 mg), perphenazine (8–32 mg), or ziprasidone (40–160 mg) daily. Only participants without tardive dyskinesia could be randomised to perphenazine, and ziprasidone was only introduced as a study medication in January 2002. To account for this, comparisons involving perphenazine only included people without tardive dyskinesia, and comparisons involving ziprasidone only included people randomised after January 2002.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Psychosocial functioning (Quality of Life Scale: score range 0–6, higher scores indicate greater function).&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 30.5% at 12 months (see Notes).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Among people who continued to take their medication for one year, there were small improvements in psychosocial functioning from baseline with olanzapine, quetiapine, risperidone, perphenazine and ziprasidone (mean change in total Quality of Life Scale score from baseline: 0.26 with risperidone vs 0.26 with ziprasidone vs 0.19 with olanzapine vs 0.19 with perphenazine vs 0.09 with quetiapine; p&amp;lt;0.01 for within-group change from baseline with risperidone; p&amp;lt;0.05 for within-group change from baseline with olanzapine; other within-group changes not significant). There were no significant differences between the treatments in psychosocial functioning at one year (subgroup without tardive dyskinesia and not receiving ziprasidone: perphenazine vs olanzapine vs quetiapine vs risperidone: p = 0.62; subgroup with tardive dyskinesia not receiving ziprasidone: olanzapine vs quetiapine vs risperidone: p = 0.53). See &lt;A href="http://ebmh.bmj.com/supplemental" target="_blank"&gt;http://ebmh.bmj.com/supplemental&lt;/A&gt; for Notes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;There is no difference in psychosocial functioning between different antipsychotics in people with schizophrenia after one year.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298030</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/88]]&gt;</url>
    <title>Therapeutics - Dihydrocodeine as effective as methadone for maintenance of treatment for opiate dependence?</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Robertson JR, Raab GM, Bruce M, et al. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction 2006;101:1752–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How effective is dihydrocodeine compared with methadone in the maintenance treatment of opiate dependence?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled equivalence trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Unblinded.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Participants were followed up for a minimum of 6 months.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; A community drug service and two general practices in Edinburgh, Scotland; recruitment August 2003 to December 2003.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 235 people with opiate dependency and recommended for opiate substitution therapy. Those with coexisting conditions such as pregnancy or psychiatric problems were excluded.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Methadone (1 mg/ml) or dihydrocodeine (30 mg or 60 mg) at doses reflecting individual need. Starting doses for all participants were derived from agreed methadone doses (25 mg methadone = 30 mg dihydrocodeine) and stabilising doses were attained over a 3-week supervised induction phase.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Retention in treatment or abstinence from all opiates.&lt;BR&gt;Patient follow-up: 90% at 6 months and 77% at 12 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;BR&gt;&lt;/STRONG&gt;Retention in treatment or abstinence from all opiates was equivalent between groups receiving dihydrocodeine or methadone at 6 months (dihydrocodeine vs methadone: AR at 6 months: 90% (95/105) vs 87% (93/107), ARR: +3.6%, 95% CI –5.2% to +12.6%). At 12 months, although there was no significant difference between groups, the lower confidence interval for difference in treatment retention or abstinence from all opiates exceeded the 10% difference level required for equivalence (AR at 12 months: 85% (76/89) vs 86% (78/91), ARR –0.3%, 95% CI –10.8% to +10.3%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Dihydrocodeine may be similarly effective to methadone for maintenance of treatment for opiate dependence.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306988</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/21]]&gt;</url>
    <title>Therapeutics - Dimebon improves cognitive function in people with mild to moderate Alzheimer’s disease</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does dimebon improve cognitive function in people with mild to moderate Alzheimer’s disease?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;183 people over 50 years of age with Alzheimer’s disease (DSM-IV and National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders criteria); Mini-Mental State Examination (MMSE) score 10–24; modified Hachinski ischaemic score &amp;lt;=4; and CT/MRI scan consistent with Alzheimer’s within 12 months prior to enrolment. Main exclusion criteria: potential other cause of dementia (eg, thyroid disease); cholinesterase inhibitor or N-methyl-D-aspartate receptor antagonist use within 60 days prior to enrolment; schizophrenia; stroke; Parkinson’s disease; seizure disorder; unstable medical illness; or hepatic/renal disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;11 sites in Russia; recruitment September 2005–February 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;BR&gt;&lt;/STRONG&gt;Dimebon (10 mg three times a day for 7 days, increased to 20 mg three times a day for the remainder of the study) or placebo for 26 weeks. Blinded treatment could be continued for an additional 26 week extension period if the participant . . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Serge Gauthier&lt;/P&gt;
&lt;P&gt;McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Canada &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/21" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301987</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/84]]&gt;</url>
    <title>Therapeutics - Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEMENTIA,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is donepezil effective for behavioural disturbance in people&lt;SUP&gt; &lt;/SUP&gt;with Alzheimer’s disease that have not responded to psychosocial&lt;SUP&gt; &lt;/SUP&gt;treatment?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;250 adults (&amp;gt;39 years old; 85% female; 93% in residential&lt;SUP&gt; &lt;/SUP&gt;care) with Alzheimer’s disease (possible or probable according&lt;SUP&gt; &lt;/SUP&gt;to Neurological and Communication Disorders and Stroke-Alzheimer’s&lt;SUP&gt; &lt;/SUP&gt;disease and Related Disorders Association criteria) and distressing&lt;SUP&gt; &lt;/SUP&gt;agitation causing management problems for caregivers on &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;2 days&lt;SUP&gt; &lt;/SUP&gt;per week for 2 weeks and that had not responded to up to 4 weeks&lt;SUP&gt; &lt;/SUP&gt;of psychosocial treatment prior to randomisation. Other inclusion&lt;SUP&gt; &lt;/SUP&gt;criteria: Cohen-Mansfield Agitation Inventory (CMAI) score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;39;&lt;SUP&gt; &lt;/SUP&gt;living in residential care or with a permanent carer; were consenting&lt;SUP&gt; &lt;/SUP&gt;to treatment or were assenting and with a caregiver in agreement&lt;SUP&gt; &lt;/SUP&gt;with participation. Exclusions: treatment with neuroleptics&lt;SUP&gt; &lt;/SUP&gt;or cholinesterase inhibitors within past 4 &lt;NOBR&gt;&lt;EM&gt;. .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;BR&gt;&lt;/STRONG&gt;Anthony Pelosi &lt;/P&gt;
&lt;P&gt;Department of Psychiatry, Hairmyres Hospital, East Kilbride, UK &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/84" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392765</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/118.extract]]&gt;</url>
    <title>Therapeutics - Early school-based screening and intervention programmes for ADHD did not improve children's outcomes at age 10</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;How do early school-based screening and educational interventions affect the long-term outcomes for children at risk for attention deficit hyperactivity disorder (ADHD)? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;487 children (age 10–11) from 308 schools who had been screened for ADHD symptoms between 4 and 5 years of age. Initially 68 711 children aged 4–5 years old were screened in 2040 schools from 24 local education authority (LEA) areas in England; 7570 children were identified as having high teacher-rated hyperactivity/inattention scores (six or more ADHD symptoms as defined in Diagnostic and Statistical Manual, Fourth Edition criteria). These schools were randomised to receive one of four interventions (see Intervention below). The current study asked a sample of 549 schools from the 20 LEA areas with =20 participating schools, and 1662 children (and their parents) from these schools to participate in follow-up; parents of 487 (non-sibling) children from 308 schools agreed.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;308 schools in 20 LEA areas in England; initial screening took place September 2000 to July 2001.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Identification of children with high ADHD scores, educational intervention, both identification and educational intervention, or no intervention … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/118.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392757</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/114.extract]]&gt;</url>
    <title>Therapeutics - Employment rates for people with severe mental illness in the UK not improved by 1 year's individual placement and support</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Does individual placement and support (IPS) improve employment rates in people with severe mental illness?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;219 adults aged 18–65 with severe mental illness receiving out-patient or community psychiatric care from local mental health services. Severe mental illness was defined as a global assessment of functioning score =60; duration of illness &amp;gt;2 years and diagnosis of psychotic or chronic affective disorder (Structured Clinical Assessment in Neuropsychiatry). Participants had to have been unemployed for 3 months or more, wanting to work and be able to read and speak English. Main exclusion: referred for IPS in the last 6 months.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Community setting, two boroughs in South London, UK; recruitment November 2004 to September 2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;IPS or treatment as usual (TAU). For the IPS group, employment specialists attended community mental health team meetings and multidisciplinary care planning meetings, and met with participants and with their care coordinators. Employment specialists aimed to find employment which suited participants' skills, abilities and … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/114.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306958</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/10]]&gt;</url>
    <title>Therapeutics - Escitalopram and problem solving therapy reduce the incidence of post-stroke depression</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=-1&gt;
&lt;P&gt;&lt;FONT size=-1&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Can escitalopram or problem solving therapy prevent post-stroke depression? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;176 non-depressed participants within 3 months of haemorrhagic or ischaemic stroke. Exclusions were DSM-IV based major or minor depression (research criteria); &amp;gt;11 on the Hamilton-17 Depression Rating Scale; severe neuropsychological deficits; other life threatening medical conditions; neurodegenerative disorders; and DSM-IV alcohol or substance abuse or dependence within the past 12 months. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Two university hospitals, USA; enrolment 2003–2007. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;One of three 2 month regimens: escitalopram (10 mg/day if &amp;lt;65 years old, 5 mg/day if 65 years old; taken in the morning), placebo pill or problem solving therapy (PST) (six sessions over the first 12 weeks and six reinforcement sessions up to 12 months). PST was delivered by therapists who had completed training in the manual based intervention and all sessions were videotaped and assessed for adherence. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Major or minor depression (defined as meeting DSM-IV criteria for either of these diagnoses, as assessed . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Stefano Paolucci &lt;BR&gt;Fondazione Santa Lucia-IRCCS, Rome, Italy &lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/10" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383459</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/81.extract]]&gt;</url>
    <title>Therapeutics - Escitalopram may improve some cognitive functions after stroke in non-depressed patients</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,STROKE,REHABILITATION,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does the selective serotonin reuptake inhibitor escitalopram enhance performance on neuropsychological tests assessing memory and executive functions after stroke? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;129 nondepressed patients aged between 50 and 90 years with cerebral hemisphere, brainstem or cerebellar ischemic or haemorraghic stroke. Patients were randomised within 3 months of an index stroke. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;University of Iowa Stroke Center, USA; 2003 and 2007.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;Escitalopram versus placebo or problem-solving therapy (PST). Escitalopram was given at a dose of 10mg, once daily, for patients aged &amp;lt; 65 years and 5 mg for patients aged = 65 years. The placebo and PST groups were pooled for the main analyses, as the focus of the study was the effect of escitalopram.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-5&gt;Change from baseline status in cognitive function was assessed using a range of tests: immediate memory, visuospatial constructional, language, attention and delayed memory (Repeatable Battery for the Assessment of Neuropsychological Status, RBANS); psychomotor processing speed and cognitive flexibility (Trail-making test parts A and B); verbal fluency (Controlled Oral Word Association test); abstract thinking (Wechsler Adult Intelligence … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/81.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>321517</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/86]]&gt;</url>
    <title>Therapeutics - Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does high dose vitamin B supplementation have an effect on cognitive decline in people with Alzheimer’s disease?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;409 people with mild to moderate probable Alzheimer’s disease (NINCDS-ADRDA criteria; mean age 76 years; 56% female; 41% multivitamin users; 91% using cholinesterase inhibitors). Exclusions: &amp;lt;50 years old; medically unstable, Mini-Mental State Examination score &amp;lt;14 or &amp;gt;26; vitamin B12 or folate insufficiency (vitamin B12 &amp;lt;175 pg/ml; folate &amp;lt;4.2 ng/ml); renal insufficiency (serum creatine &amp;gt;=2.0 mg/dl); daily vitamin supplementation with &amp;gt;400 µg folic acid; used sedatives, anti-Parkinson’s or drugs with anticholinergic effects in the past 2 months; or recent investigational treatment for Alzheimer’s disease. Stable use of cholinesterase inhibitors or memantine was allowed if it had been ongoing for at least 3 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;40 sites across the USA; recruitment: February 2003 to December 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;High dose vitamin B supplementation (5 mg folic acid, 1 mg vitamin B12 (cyanocobalamin) and 25 mg vitamin B6 (pyridoxine . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/86" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306982</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/17]]&gt;</url>
    <title>Therapeutics - Exposure and ritual prevention reduces symptoms more than stress management training in OCD treated with SSRIs</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OBSESSIVE COMPULSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is exposure and ritual prevention more effective than stress management for controlling symptoms in people with obsessive–compulsive disorder (OCD) already taking adequate doses of serotonin reuptake inhibitors (SSRIs)?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;108 people with moderate to severe DSM-IV OCD (aged 18–70 years, 57% male) despite a therapeutic SSRI dose for at least 12 weeks. Exclusions: OCD not the primary diagnosis; psychosis, mania, suicidal, substance abuse or dependence in previous 6 months; subclinical OCD (Yale–Brown Obsessive Compulsive Scale score &amp;lt;16); taking SSRI but receiving no benefit; unstable medical condition; or prior cognitive behavioural therapy (CBT) or stress management training while taking SSRI.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Outpatient setting, Philadelphia, USA; recruitment November 2000–November 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Exposure and ritual prevention or stress management training CBT. Exposure and ritual prevention involved two treatment planning sessions and then 15 in vivo and imaginal exposure sessions in which participants faced their fears without ritualisation. Participants were asked to stop ritualising after the first . . . [Full text of this article]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Dean McKay&lt;/P&gt;
&lt;P&gt;New York University School of Medicine, New York, New York, USA &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/17" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377632</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/47.extract]]&gt;</url>
    <title>Therapeutics - Failure to improve during first 6 months of treatment and depression severity predict increased mortality in people with ACS and MDD</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;In people with acute coronary syndrome (ACS) and major depressive disorder (MDD), what features of MDD are associated with long-term mortality? &lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;369 adults with ACS meeting criteria for MDD who participated in the SADHART randomized controlled trial comparing safety and efficacy of sertraline versus placebo. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;SADHART study was conducted in 44 outpatient centres in 7 countries; study participants were recruited between April 1997 and December 1999 &lt;/P&gt;
&lt;H3&gt;Prognostic factors:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Baseline depression severity: Hamilton Depression Rating Scale (HAM-D) score of less than 18 &lt;EM&gt;vs&lt;/EM&gt; 18 or higher, onset of MDD before or after index ACS event, previous episodes of MDD; 8 months of sertraline treatment, mood improvement during 6-month placebo or setraline treatment (Clinical Global Impression-Improvement subscale, CGI-I) and left ventricular ejection fraction (LVEF &amp;lt;0.30 vs =0.30). Remission was defined as a CGI-I score of 1 (very much improved), which is similar to a Ham-D score of 7 or less. Cox proportional hazards regression models were used to analyse effects of risk factors at time of death and were controlled for age and sex. &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Vital status. Mortalities were collected 5 years after the final participant completed … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/47.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317811</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/48]]&gt;</url>
    <title>Therapeutics - Family focused therapy shortens recovery time from depression but not mania in adolescents with bipolar disorder</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does family focused therapy in combination with medication speed&lt;SUP&gt; &lt;/SUP&gt;up recovery and reduce time to recurrence in adolescents with&lt;SUP&gt; &lt;/SUP&gt;bipolar disorder?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;58 adolescents, aged 12–18 years, with DSM-IV bipolar&lt;SUP&gt; &lt;/SUP&gt;I (n = 38), bipolar II (n = 6) or bipolar disorder not otherwise&lt;SUP&gt; &lt;/SUP&gt;specified (n = 14), with a mood episode in the past 3 months&lt;SUP&gt; &lt;/SUP&gt;(see online notes for exclusion criteria).&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Colorado and Pittsburgh, USA; recruited October 2002 to September&lt;SUP&gt; &lt;/SUP&gt;2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Pharmacotherapy plus either family focused therapy for adolescents&lt;SUP&gt; &lt;/SUP&gt;(FFT-A) or enhanced care (EC). FFT-A involved 50 min sessions&lt;SUP&gt; &lt;/SUP&gt;with the patient, parent and available siblings for 9 months&lt;SUP&gt; &lt;/SUP&gt;(21 sessions in total: 12 weekly, six fortnightly and then 3&lt;SUP&gt; &lt;/SUP&gt;monthly). Sessions focused on education about bipolar disorder,&lt;SUP&gt; &lt;/SUP&gt;communication skills and problem solving skills. EC involved&lt;SUP&gt; &lt;/SUP&gt;three 50 min sessions of education with the patient, parent&lt;SUP&gt; &lt;/SUP&gt;and available siblings, with sessions focusing on planning to&lt;SUP&gt; &lt;/SUP&gt;prevent relapse, adherence to &lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/48" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>321513</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/85]]&gt;</url>
    <title>Therapeutics - Ginkgo biloba does not reduce incidence of dementia in elderly people</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does Ginkgo biloba reduce the incidence of dementia and Alzheimer’s disease (AD) in elderly people with normal cognition or mild cognitive impairment?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;3069 community volunteers aged 75 years or older (mean age 79.1 years, 46% women). Participants with mild cognitive impairment (MCI, n = 482) were included (see online notes for list of main exclusion criteria).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Five US academic medical centres; 2000–2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;BR&gt;&lt;/STRONG&gt;G biloba (120 mg extract EGb 761 twice daily) or placebo.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;All cause dementia and AD (DSM-IV), as determined by the consensus of an expert panel reviewing clinical assessments and scores on the Modified Mini-Mental State Examination, the Clinical Dementia Rating scale, the Alzheimer Disease Assessment Scale and the GEM Study Neuropsychological Battery (administered once scores in at least two of the other tests had declined by a specified number of points or the participant had been diagnosed with dementia or given anti-dementia drugs by their personal physician). .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/85" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344620</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/16.extract]]&gt;</url>
    <title>Therapeutics - Group CBT prevents depression in at-risk adolescents</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the effect of a group cognitive behavioural programme in preventing depression in at-risk adolescents?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;316 adolescents (aged 13–17 years; mean age 14.8 years; 58.5% female) with current subsyndromal depressive symptoms, identified by a score of &amp;gt;20 on the Center for Epidemiological Studies Depression Scale or a prior episode of depression (DSM-IV) from which they were in remission for a minimum of 2 months, or both, plus at least one parent or carer with current or prior depressive episodes (either a major depressive episode within the previous 3 years or three or more major depressive episodes within the adolescent's lifetime). Exclusions: diagnosis of bipolar 1 or schizophrenia (adolescent or parent); current mood disorder (DSM-IV); currently taking antidepressant medication or having received more than eight sessions of cognitive behavioural therapy (CBT).&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;four US cities; August 2003–February 2006.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;The group CBT prevention programme comprised eight weekly 90 min sessions for mixed sex groups of adolescents (mean group size 6.6). Sessions included cognitive restructuring techniques to challenge negative … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/16.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344622</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/18.extract]]&gt;</url>
    <title>Therapeutics - Group CBT reduces child anxiety diagnoses compared with nonspecific group support</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EMOTIONAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Is cognitive-behavioural therapy (CBT) more effective than group support and attention for reducing both mother and child reported anxiety? &lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;112 children aged between 7 and 16 years with DSM-IV anxiety disorder (mean age 10.2 years, 57% male) and their parents. Exclusion criteria were mental retardation, psychosis, receiving concurrent psychological treatment or with major depression. Children taking medication for anxiety or depression were included if the dose was stable. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Australia; recruitment period not reported.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;Group CBT or group support and attention (GSA). CBT used the Cool Kids programme which involves affect recognition, cognitive restructuring, child management, social skills training, assertiveness and gradual exposure. It was delivered in ten 2 h sessions once a week. Therapist time was divided equally between the children and parents together and separately. Exposure tasks were planned with the child's family and completed by the children as homework. GSA contained no aspects of CBT and aimed to provide a supportive environment to express emotions and build relationships. &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-5&gt;Principal anxiety or any anxiety diagnosis (diagnosis considered present if Clinical … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/18.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302036</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/17]]&gt;</url>
    <title>Therapeutics - Group interpersonal therapy reduces depression in adolescent survivors of war</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective are interventions for depression symptoms in displaced&lt;SUP&gt; &lt;/SUP&gt;adolescent survivors of war in northern Uganda?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;314 adolescents (14–17 years old) of the Acholi ethnic&lt;SUP&gt; &lt;/SUP&gt;group living in camps for internally displaced persons, who&lt;SUP&gt; &lt;/SUP&gt;had depression-like syndromes, defined using the Acholi Psychosocial&lt;SUP&gt; &lt;/SUP&gt;Assessment Instrument (APAI; a locally defined and validated&lt;SUP&gt; &lt;/SUP&gt;instrument assessing severity of 35 symptoms). For inclusion,&lt;SUP&gt; &lt;/SUP&gt;adolescents had to score at least 32 on the APAI (score range&lt;SUP&gt; &lt;/SUP&gt;0–105, higher score indicates greater severity of symptoms),&lt;SUP&gt; &lt;/SUP&gt;although 14 adolescents with scores between 28 and 31 were included&lt;SUP&gt; &lt;/SUP&gt;to achieve target sample size, and report some difficulties&lt;SUP&gt; &lt;/SUP&gt;in function on a gender-specific local function measure. Main&lt;SUP&gt; &lt;/SUP&gt;exclusion criteria: severe suicidal ideation or disability preventing&lt;SUP&gt; &lt;/SUP&gt;interview.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Two camps for internally displaced persons in &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Laura Mufson, PhD &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Department of Child Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, USA &lt;BR&gt;&lt;/P&gt;
&lt;H3&gt;
&lt;P&gt;&lt;FONT size=-1&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/17" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/H3&gt;]]&gt;</body>
  </document>
  <document>
    <id>328822</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/110]]&gt;</url>
    <title>Therapeutics - Group psychoeducation increases time to recurrence in stabilised bipolar disorders</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;What are the long term effects of group psychoeducation in people&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;with stabilised bipolar disorder?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;120 adults (aged 18–65 years) with a lifetime diagnosis&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of DSM-IV bipolar I and II disorders (diagnosed by a trained&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;psychiatrist) who were euthymic at enrolment (Young Mania Rating&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Scale (YMRS) score &amp;lt;6 and Hamilton Rating Scale for Depression&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(HRSD-17) score &amp;lt;8 for at least 6 months prior to study entry).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Main exclusions: current severe axis I comorbidity, substance&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;misuse, currently receiving psychotherapy or enrolment in any&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;pharmacological trial.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Hospital clinic, University of Barcelona, Spain (study date&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;not stated).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Group psychoeducation or control for 21 weeks. The group psychoeducation&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;intervention (n = 60) consisted of a weekly 90 min interactive/participative&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;sessions, aimed at improving illness awareness, treatment adherence,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;early detection of prodromal symptoms and recurrence, and lifestyle&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;regularity. Sessions were held in groups of 8–12, and&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;conducted by two experienced psychologists. The control group&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;&lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/110" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344621</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/17.extract]]&gt;</url>
    <title>Therapeutics - Group therapy does not reduce repeated deliberate self-harm in adolescents</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Using a method that replicates a previous trial,1 does group therapy prevent repeat deliberate self-harm in adolescents?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;72 adolescents aged 12–16 years (mean age 14 years, 91% female) with a minimum of two reported episodes of self-harm in the last year, with one in the last 3 months. All participants had been referred to child and adolescent mental health services. Self-harm included cutting (97%), head banging (71%), medication overdose (57%), smothering (36%), strangling (25%), other poisoning (19%), attempted drowning (19%), jumping from a height (17%) and other self-harm (35%). Main exclusions: unable to attend groups, acute psychosis, intensive treatment required due to danger of imminent self-harm or unlikely to benefit from group intervention.&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Community based adolescent mental health services in Newcastle, Brisbane North and Logan, Australia; time period not stated.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;The intervention comprises elements of cognitive-behavioural therapy (CBT), social skills training, interpersonal psychotherapy and group psychotherapy. Weekly group sessions lasting 1 h were held for 6 weeks. These initial sessions were oriented around family problems, anger management, depression and self-harm, … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/17.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344626</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/23.extract]]&gt;</url>
    <title>Therapeutics - Haloperidol plus promethazine effective for psychosis induced aggression</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Is haloperidol plus promethazine an effective treatment for aggressive episodes caused by psychotic illness?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-2&gt;Primary outcomes were not being tranquil or asleep within 30 min, another episode of aggression by 24 h, specific and serious adverse events by 24 h. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P id=p-4&gt;The Cochrane Schizophrenia Group Register was searched in January 2008 for this update of the review, and July 2004 for the original review. Reference lists of included and excluded studies and specific journals were hand searched. Study authors were also contacted. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P id=p-5&gt;Two reviewers independently selected randomised controlled trials of haloperidol plus promethazine, haloperidol alone, other antipsychotics, benzodi-azepine, anticonvulsive or haloperidol plus benzodiazepine, all given at any dose intramuscularly, compared with placebo or no intervention. &lt;EM&gt;Inclusion criteria:&lt;/EM&gt; studies of people currently in an aggressive episode due to psychotic illness reporting tranquillity or being asleep, overall improvement and adverse events. Two reviewers independently performed data extraction and quality assessment. Relative risks (RR) were calculated for dichotomous outcomes and mean differences for continuous outcomes. Numbers needed to harm (NNH) were calculated for adverse events. Where possible, results … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/23.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>298007</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/76]]&gt;</url>
    <title>Therapeutics - Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;McCue RE, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006;189:433–40.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How do second generation antipsychotics compare with haloperidol for the treatment of acute schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Unblinded (treating physician and participant aware of the treatment). Assessors of the Brief Psychiatric Rating Scale and side effects were blinded; the unblinded treating physician made the decision about discharge.&lt;BR&gt;&lt;STRONG&gt;Follow-up period&lt;/STRONG&gt; At least 3 weeks.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Six hospital adult psychiatric inpatient units, USA; recruitment January 2004 to February 2005.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 327 newly admitted adult inpatients (aged 18 years and over) with DSM-IV schizophrenia, schizoaffective disorder or schizophreniform disorder. Exclusions: substance-induced psychotic disorder, bipolar disorder, major depressive disorder, history of non-response to study drugs or response to non-study drugs, pregnancy or breastfeeding, or medical condition contraindicating study treatments.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Aripiprazole, haloperidol, olanzapine, quetiapine, risperidone or ziprasidone for at least 3 weeks (doses determined using manufacturer’s dose recommendations). Treatment could continue beyond 3 weeks to discharge if the treating physician decided that the participant was improving. Participants who did not improve by 3 weeks ceased study treatment and were withdrawn from the study.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Treatment failure (still needing acute inpatient care after at least 3 weeks’ treatment because of lack of significant improvement in mental status, or treatment discontinuation before 3 weeks because of deterioration of mental status or adverse effects); change in overall score on Brief Psychiatric Rating Scale (BPRS) from baseline; need for additional medication.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 92% completed treatment, 97% included in analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;The majority of participants (94%) received antipsychotics for at least three weeks. Haloperidol, olanzapine and risperidone significantly reduced treatment failure compared with aripiprazole, quetiapine and ziprasidone (p&amp;lt;=0.005 for these comparisons; AR of treatment failure: 11% with haloperidol vs 8% with olanzapine vs 12% with risperidone vs 36% with aripiprazole vs 36% with quetiapine vs 36% with ziprasidone). There were no significant differences in treatment failure between aripiprazole, quetiapine and ziprasidone or between haloperidol, olanzapine and risperidone (p&amp;gt;0.41 for all comparisons). There was no significant difference between treatments in change in BPRS score from baseline (mean change: 16.4 with haloperidol vs 14.9 with olanzapine vs 15.4 with risperidone vs 12.9 with aripiprazole vs 14.2 with quetiapine vs 14.2 with ziprasidone; p = 0.34 for overall comparison).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;After a minimum of 3 weeks’ treatment, haloperidol, olanzapine and risperidone reduce treatment failure (need for continued hospitalisation or treatment discontinuation) compared to aripiprazole, quetiapine and ziprasidone in inpatients with acute schizophrenia.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>297974</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/74]]&gt;</url>
    <title>Therapeutics - Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et al. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006;67:1511–21.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Are first and second generation antipsychotics equally effective and safe for people with first-episode non-affective psychosis?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Unclear.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Unclear.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Six weeks (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; One outpatient and one inpatient clinic at a university hospital, Cantabria, Spain; enrolment February 2001 to February 2005.&lt;BR&gt;Patients: 182 adults (15–60 years old; 93% antipsychotic naive) with non-affective psychotic disorder (DSM-IV) and psychotic symptoms of moderate severity or greater (Scale for the Assessment of Positive Symptoms). Exclusions: DSM-IV mental retardation, DSM-IV drug dependence, or &amp;gt;=6 weeks’ total lifetime adequate antipsychotic treatment.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Haloperidol (3–9 mg/day; mean modal dose 5.4 mg/day) risperidone (3–6 mg/day; mean modal dose 4 mg/day), or olanzapine (5–20 mg/day; mean modal dose 15.3 mg/day).&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Response (&amp;gt;=40% reduction in Brief Psychiatric Rating Scale score), adverse events including treatment-emergent parkinsonism (Simpson-Angus Scale &amp;gt;3) and akathisia (Barnes Akathisia Scale global score &amp;gt;=2).&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 95% included in last observation carried forward analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;All treatments showed similar effectiveness in inducing response by the sixth week (% responders: 57.1% with haloperidol vs 52.5% with risperidone vs 63.6% with olanzapine; p = 0.476). Haloperidol increased parkinsonism compared with the second generation antipsychotics (46.6% with haloperidol vs 5.5% with olanzapine vs 24.6% with risperidone; p&amp;lt;0.001). Haloperidol also increased akathisia (55.4% with haloperidol vs 26.2% with risperidone vs 5.5% with olanzapine; p&amp;lt;0.001). Olanzapine increased weight gain compared to the other antipsychotics (% people with &amp;gt;=4 kg weight gain: 47% with olanzapine vs 23% with risperidone vs 9% with haloperidol; p&amp;lt;0.001). Olanzapine and haloperidol increased somnolence compared with risperidone (46% with olanzapine vs 46% with haloperidol vs 23% with risperidone; p = 0.012).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis. Haloperidol increases parkinsonism and akathisia, while olanzapine increases weight gain. Both olanzapine and haloperidol increase somnolence.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344618</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/14.extract]]&gt;</url>
    <title>Therapeutics - Health visitor training reduces risk of postnatal depression 6 months after birth</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the effectiveness and costs effectiveness of training health visitors to identify and deliver psychologically informed interventions for postnatal depression? &lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;4084 women from participating general practices who were 36 weeks’ pregnant, had a live baby and remained on the health visitor's caseload for at least 4 months postna-tally. Exclusions: age &amp;lt;18 years; mental health issues (such as schizophrenia or bipolar disorder); moving away or temporary resident.&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;101 general practices in 29 Primary Care Trusts in the Trent Regional Health Authority, UK; randomisation February and March 2003. &lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;Specific health visitor training in postnatal depression or health visitor usual care. Health visitors in the training group were trained in assessing women and in providing psychological sessions. Heath visitors were also randomised to train to deliver either a cognitive behavioural approach (CBA) or a person centred approach (PCA) to … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/1/14.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321515</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/86]]&gt;</url>
    <title>Therapeutics - High dose vitamin B supplementation does not slow cognitive decline in mild to moderate alzheimer's disease</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;BR&gt;&lt;/STRONG&gt;Does high dose vitamin B supplementation have an effect on cognitive decline in people with Alzheimer’s disease?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;409 people with mild to moderate probable Alzheimer’s disease (NINCDS-ADRDA criteria; mean age 76 years; 56% female; 41% multivitamin users; 91% using cholinesterase inhibitors). Exclusions: &amp;lt;50 years old; medically unstable, Mini-Mental State Examination score &amp;lt;14 or &amp;gt;26; vitamin B12 or folate insufficiency (vitamin B12 &amp;lt;175 pg/ml; folate &amp;lt;4.2 ng/ml); renal insufficiency (serum creatine &amp;gt;=2.0 mg/dl); daily vitamin supplementation with &amp;gt;400 µg folic acid; used sedatives, anti-Parkinson’s or drugs with anticholinergic effects in the past 2 months; or recent investigational treatment for Alzheimer’s disease. Stable use of cholinesterase inhibitors or memantine was allowed if it had been ongoing for at least 3 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;40 sites across the USA; recruitment: February 2003 to December 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;BR&gt;&lt;/STRONG&gt;High dose vitamin B supplementation (5 mg folic acid, 1 mg vitamin B12 (cyanocobalamin) and 25 mg vitamin B6 (pyridoxine . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/86" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328820</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/108]]&gt;</url>
    <title>Therapeutics - In adolescents with SSRI resistant depression, CBT/combined treatment is most effective in those with comorbid disorders</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;What are the predictors and moderators of treatment response&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;among adolescents with selective serotonin reuptake inhibitor&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(SSRI) resistant depression?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;334 adolescents (aged 12–18 years) with a primary diagnosis&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of major depressive disorder in active treatment but who had&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;not responded to a 2 month trial with an SSRI. See online notes&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;for main exclusions.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;US academic and community clinics; 2000–2006.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;One of four 12 week regimens: switch to a second, different&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;SSRI (paroxetine, fluoxetine or citalopram at 20–40 mg&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;daily); switch to venlafaxine (150–225 mg daily); switch&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to second SSRI plus CBT; switch to venlafaxine plus CBT. Before&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;the switch, participants’ existing medication was tapered&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to discontinuation over up to 2 weeks. CBT was delivered by&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;experienced therapists with at least master’s level qualifications;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;up to 12 sessions of CBT (60–90 min each) were provided&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;during the first 12 weeks (3–6 of them were family sessions).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Predictor and moderator &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/108" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328850</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/121]]&gt;</url>
    <title>Therapeutics - Incentives increase enrolment in substance abuse treatment at community needle exchange site</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Do motivational interventions, with or without monetary incentive,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;increase uptake of substance abuse treatment compared with standard&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;referral to a needle exchange programme?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;281 opioid dependent individuals (DSM-IV criteria), newly registered&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to the Baltimore Needle Exchange Program (BNEP). Exclusions:&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;age &amp;gt;60 years; those currently receiving substance abuse&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;treatment; major mental illness or severe cognitive impairment.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two community locations in Baltimore, USA; time period unclear.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Motivational referral condition (MRC) or MRC plus monetary incentive&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(MRC+1). MRC involved 1 h individual motivational enhancement&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;therapy (MET) sessions (eight delivered twice weekly during&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;the first 2 months of treatment) and 1 h treatment readiness&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;groups (16 delivered twice weekly). Services are delivered through&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;a mobile medical van. MET aims to facilitate behaviour change&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;through building motivation, strengthening commitment and creating&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;a plan; treatment readiness involved use of a manual guided&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;protocol to promote an informed and positive view of the benefits&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of substance &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/121" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317828</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/53]]&gt;</url>
    <title>Therapeutics - Individual placement and support improves employment of young people with first episode psychosis</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EMOTIONAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;What is the effectiveness of individual placement and support&lt;SUP&gt; &lt;/SUP&gt;in young people with first episode psychosis?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;41 people (mean age 21 years, 80% male) with first episode psychosis&lt;SUP&gt; &lt;/SUP&gt;(Structured Clinical Interview for DSM-IV-TR Axis 1 disorders-Patient&lt;SUP&gt; &lt;/SUP&gt;Edition) wanting to find work and with at least 6 months of&lt;SUP&gt; &lt;/SUP&gt;treatment remaining at the Early Psychosis and Prevention Centre&lt;SUP&gt; &lt;/SUP&gt;(EPPIC) which provides 18 months of care in total. Exclusions:&lt;SUP&gt; &lt;/SUP&gt;lack of fluency in English language.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Melbourne, Australia; recruitment October 2005 to April 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Individual placement and support (IPS) plus treatment as usual&lt;SUP&gt; &lt;/SUP&gt;(TAU) versus TAU alone. IPS had the following principles: focus&lt;SUP&gt; &lt;/SUP&gt;on competitive employment as an outcome; open to anyone with&lt;SUP&gt; &lt;/SUP&gt;mental illness seeking work; job searching commences immediately&lt;SUP&gt; &lt;/SUP&gt;on entering the programme; the IPS programme is integrated with&lt;SUP&gt; &lt;/SUP&gt;the mental health treatment team; potential jobs are based on&lt;SUP&gt; &lt;/SUP&gt;participant’s preferences; support is unlimited by time&lt;SUP&gt; &lt;/SUP&gt;and continues after employment if &lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/53" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for suers with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>302016</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/52]]&gt;</url>
    <title>Therapeutics - Individual placement and support programme increases rates of obtaining employment in people with severe mental illness</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is an individual placement and support (IPS) programme effective&lt;SUP&gt; &lt;/SUP&gt;for helping people with severe mental health disorders gain&lt;SUP&gt; &lt;/SUP&gt;open employment in Europe?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;312 adults (aged between 18 years and local retirement age)&lt;SUP&gt; &lt;/SUP&gt;with psychotic illness or bipolar disorder, validated by structured&lt;SUP&gt; &lt;/SUP&gt;assessment of case notes. Inclusions: community dwelling, major&lt;SUP&gt; &lt;/SUP&gt;role dysfunction for &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;2 years, had not been in competitive employment&lt;SUP&gt; &lt;/SUP&gt;for the past year but wished to do so.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;UK, Germany, Italy, Switzerland, Bulgaria and the Netherlands;&lt;SUP&gt; &lt;/SUP&gt;April 2003 to November 2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Individual placement and support (IPS)—a supported employment&lt;SUP&gt; &lt;/SUP&gt;intervention, or standard rehabilitation and vocational services.&lt;SUP&gt; &lt;/SUP&gt;IPS involved a worker with an established network of employees&lt;SUP&gt; &lt;/SUP&gt;willing to accept people with mental health problems, helping&lt;SUP&gt; &lt;/SUP&gt;participants to develop realistic goals and seek appropriate&lt;SUP&gt; &lt;/SUP&gt;employment. Vocational service was the main alternative rehabilitation&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;. .(Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;BR&gt;Eric A Latimer &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Douglas Mental Health University Institute and Department of Psychiatry, McGill University, Montreal, Canada &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/52" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383458</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/80.extract]]&gt;</url>
    <title>Therapeutics - Injectable diacetylmorphine is more effective than oral methadone in the treatment of chronic relapsing opioid dependence</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is injectable diacetylmorphine more effective than oral methadone maintenance therapy in patients with opioid dependence that is refractory to treatment? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;Users of injectable heroin for at least 5 years, aged 25 years or older who had not responded to at least two previous attempts at treatment for addiction (including at least one methadone treatment, undertaken at least 6 months prior to the study). Exclusions: medical or psychiatric conditions that are contraindications for diacetylmorphine (diamorphine), pregnancy, involvement with the criminal justice system which may have resulted in incarceration during the study period. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Montreal, Quebec and Vancouver, British Columbia, from March 2005 to July 2008.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Oral methadone or injectable diacetylmorphine hydrochloride. Methadone was administered at a clinic or pharmacy on a daily basis; the dosage was based on best practices and current clinical practice guidelines. The diacetylmorphine (diamorphine) was self-administered under supervision in treatment clinics up to 3 times daily with a maximum daily dose of 1000 mg. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;The primary outcomes were the rate of retention … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/80.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>302039</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/20]]&gt;</url>
    <title>Therapeutics - Intensive family-based CBT similarly effective to weekly CBT for paediatric obsessive compulsive disorder</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OBSESSIVE COMPULSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is intensive cognitive behavioural therapy (CBT) more effective&lt;SUP&gt; &lt;/SUP&gt;than standard weekly CBT for children with obsessive compulsive&lt;SUP&gt; &lt;/SUP&gt;disorder (OCD)?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;40 children aged 7–17 with a primary diagnosis of DSM-IV-TR&lt;SUP&gt; &lt;/SUP&gt;OCD (Children’s Yale-Brown Obsessive-Compulsive Scale&lt;SUP&gt; &lt;/SUP&gt;(CY-BOCS) score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;16) who had one parent able to accompany them&lt;SUP&gt; &lt;/SUP&gt;to all treatment sessions. Exclusions: psychosis (current or&lt;SUP&gt; &lt;/SUP&gt;previous); psychotropic medication change within past 8 weeks;&lt;SUP&gt; &lt;/SUP&gt;bipolar disorder; pervasive developmental disorder; suicidal&lt;SUP&gt; &lt;/SUP&gt;ideation; mental retardation or other disorder that would prevent&lt;SUP&gt; &lt;/SUP&gt;understanding of CBT.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Participants self-presented to the OCD Program at University&lt;SUP&gt; &lt;/SUP&gt;of Florida, USA; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Intensive CBT (90-min sessions on 5 days per week for 3 weeks)&lt;SUP&gt; &lt;/SUP&gt;or standard weekly CBT (90 min on one day per week for 14 weeks)&lt;SUP&gt; &lt;/SUP&gt;given in the presence of a family member. Intensive sessions&lt;SUP&gt; &lt;/SUP&gt;were conducted by a &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Richard OâKearney, PhD &lt;/P&gt;
&lt;P&gt;School of Psychology, The Australia National University, Canberra, Australia &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/20" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377663</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/48.extract]]&gt;</url>
    <title>Therapeutics - Interpersonal therapy or guided self-help CBT improve remission from binge eating compared to a behavioural weight-loss programme at 2-year post-treatment</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;Is interpersonal therapy more effective than either behavioural weight-loss treatment (BWL) or guided self-help based on cognitive behavioural therapy (CBT) in patients with binge-eating disorder (BED), and is this influenced by negative affect? &lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Two hundred and five women and men who were overweight or obese (body mass index 27–45) who met &lt;EM&gt;DSM-IV&lt;/EM&gt; criteria for BED. Main exclusions are as follows: current psychosis or suicidality, bipolar disorder, alcohol or drug dependence in the past 6 months, taking medication or having medical disorders that would affect weight, already in weight-control programme and pregnancy. Randomisation was stratified by negative affect (low or high, Beck Depression Index score cut-off 18 points). &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Two university outpatient clinics, USA; time period not stated.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Interpersonal therapy (IPT) or BWL or guided self-help based on CBTgsh for 6 months. IPT consisted of 20 sessions and were manualised. The first session was 2 h long, and all other sessions were 50–60 min long. BWL involved moderate calorie restriction and exercise with a target weight loss … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/48.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301989</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/86]]&gt;</url>
    <title>Therapeutics - Intramuscular haloperidol plus promethazine is more effective and safer than haloperidol alone for rapid tranquillisation of agitated mentally ill patients</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is haloperidol alone more effective than haloperidol plus promethazine&lt;SUP&gt; &lt;/SUP&gt;for rapid tranquillisation of mentally ill patients?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;316 adults presenting to the psychiatric emergency room with&lt;SUP&gt; &lt;/SUP&gt;agitation or dangerous behaviour requiring intramuscular sedation,&lt;SUP&gt; &lt;/SUP&gt;for whom an attending doctor was available to record the diagnosis&lt;SUP&gt; &lt;/SUP&gt;and severity of the episode.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;One psychiatric emergency room, Rio de Janeiro, Brazil; January&lt;SUP&gt; &lt;/SUP&gt;2004 to July 2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Single intramuscular injection of haloperidol (5 or 10 mg) or&lt;SUP&gt; &lt;/SUP&gt;haloperidol (5 or 10 mg) plus promethazine (up to 50 mg). In&lt;SUP&gt; &lt;/SUP&gt;the haloperidol alone group, 29% received 5 mg and 71% received&lt;SUP&gt; &lt;/SUP&gt;10 mg. In the haloperidol plus promethazine group 50% received&lt;SUP&gt; &lt;/SUP&gt;5 mg haloperidol and 50% received 10 mg.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;&lt;I&gt;Primary outcome:&lt;/I&gt; proportion of patients tranquil (calm and non-agitated&lt;SUP&gt; &lt;/SUP&gt;with no threatening &lt;I&gt;&lt;NOBR&gt;. .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;/P&gt;
&lt;P&gt;Corrado Barbui &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/86" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/P&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301865</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/116]]&gt;</url>
    <title>Therapeutics - Little difference between haloperidol, risperidone and olanzapine in weight gain after 1 year of treatment</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What effects do haloperidol, risperidone and olanzapine have on weight gain in drug-naive psychotic patients after 1 year?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;164 drug-naive first episode psychotic patients (15 to 60 years old; mean age 27 years, mean body mass index (BMI) 23.1 kg/m2) with DSM IV brief psychotic disorder, schizophreniform disorder, schizophrenia or schizoaffective disorder who were consecutively referred to several psychiatric units in Spain. Exclusion criteria: drug dependence, mental retardation, serious medical comorbidity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Outpatient and inpatient psychiatric units of one university hospital, Cantabria, Spain; February 2001 to February 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;BR&gt;&lt;/STRONG&gt;Haloperidol (3–9 mg/day), olanzapine (5–20 mg/day) or risperidone (3–6 mg/day) for 12 months. Patients were switched to a different antipsychotic if they did not respond to 6 weeks of treatment or if they had significant side effects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Change in body weight and BMI. Measurements taken at 12 weeks and 1 year follow-up. Analyses were adjusted for baseline BMI, age and sex.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;90% . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Sahoo Saddichha, BA, MBBS, DPM&lt;/P&gt;
&lt;P&gt;Partner, Division of Clinical Research, Emergency Management and Research Institute (EMRI), Hyderabad, India &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/116" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302035</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/16]]&gt;</url>
    <title>Therapeutics - Managed depression care reduces mortality in older adults with major depression</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does managed care for depression reduce mortality in older adults?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;1226 older adults (&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;60 years) identified through depression screening&lt;SUP&gt; &lt;/SUP&gt;(Centers for Epidemiologic Studies Depression (CES-D) scale&lt;SUP&gt; &lt;/SUP&gt;score &amp;gt;20, or previous depressive episodes or treatment)&lt;SUP&gt; &lt;/SUP&gt;of a randomly selected age-stratified sample of people registered&lt;SUP&gt; &lt;/SUP&gt;in 20 primary care practices. Assessment with the Structured&lt;SUP&gt; &lt;/SUP&gt;Clinical Interview for DSM-IV Disorders Axis I (SCID-I) diagnosed&lt;SUP&gt; &lt;/SUP&gt;32% (396 people) with DSM-IV major depression, and 17% (203&lt;SUP&gt; &lt;/SUP&gt;people) with clinically significant minor depression (modified&lt;SUP&gt; &lt;/SUP&gt;DSM-IV criteria: 4 depression symptoms, Hamilton Depression&lt;SUP&gt; &lt;/SUP&gt;Rating Scale score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;10, symptoms lasting &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;4 weeks). Main exclusion&lt;SUP&gt; &lt;/SUP&gt;criteria: Mini-Mental State Examination score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;18, non-English&lt;SUP&gt; &lt;/SUP&gt;speaking.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;20 primary care practices in New York and Pennsylvania, USA;&lt;SUP&gt; &lt;/SUP&gt;May 1999 to August 2001.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Managed care &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;John W Williams Jr, MD, MHS&lt;/P&gt;
&lt;P&gt;Duke University Medical Center, Durham, NC, USA &lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/16" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301985</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/82]]&gt;</url>
    <title>Therapeutics - Metformin and lifestyle changes reduce antipsychotic-related weight gain in adults with schizophrenia</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective are a lifestyle intervention and metformin—alone&lt;SUP&gt; &lt;/SUP&gt;and in combination—at reducing antipsychotic-induced weight&lt;SUP&gt; &lt;/SUP&gt;gain in adults?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;128 people aged 18–45 years with a first psychotic episode&lt;SUP&gt; &lt;/SUP&gt;of schizophrenia (according to DSM-IV). Inclusions: weight gain&lt;SUP&gt; &lt;/SUP&gt;of more than 10% of their pre-drug body weight within the first&lt;SUP&gt; &lt;/SUP&gt;year of treatment with a targeted antipsychotic agent (clozapine,&lt;SUP&gt; &lt;/SUP&gt;olanzapine, risperidone, or sulpiride), documented weight and&lt;SUP&gt; &lt;/SUP&gt;treatment history, relatively stable improvement (PANSS &lt;IMG alt="&lt;=" src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID301985/nelhImp_0000_les.gif" border=0&gt;60),&lt;SUP&gt; &lt;/SUP&gt;taking only 1 antipsychotic at a stable dose (changed by &amp;lt;25%&lt;SUP&gt; &lt;/SUP&gt;in the past 3 months), under care of parent or guardian who&lt;SUP&gt; &lt;/SUP&gt;monitored food, exercise, medication intake. Exclusions: evidence&lt;SUP&gt; &lt;/SUP&gt;of liver or renal dysfunction, cardiovascular disease, diabetes&lt;SUP&gt; &lt;/SUP&gt;mellitus, substance abuse, psychiatric diagnosis other than&lt;SUP&gt; &lt;/SUP&gt;schizophrenia, or other conditions that limited ability to perform&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;. . .(Abstarcted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Mary Weber &lt;/P&gt;
&lt;P&gt;Assistant Professor, University of Texas at Arlington School of Nursing, Arlington, Texas, USA&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/82" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301699</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/109]]&gt;</url>
    <title>Therapeutics - Mood and anxiety disorders: differences between long- and short-term psychotherapies in work ability, but not employment</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective are short- and long-term psychotherapies for improving&lt;SUP&gt; &lt;/SUP&gt;work and functional capacity in people with depressive and anxiety&lt;SUP&gt; &lt;/SUP&gt;disorders?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;326 adult outpatients (20–45 years old) with DSM-IV mood&lt;SUP&gt; &lt;/SUP&gt;or anxiety disorders who were considered to have between neurosis&lt;SUP&gt; &lt;/SUP&gt;and higher level borderline disorder according to Kernberg’s&lt;SUP&gt; &lt;/SUP&gt;classification of personality organisation. Main exclusions:&lt;SUP&gt; &lt;/SUP&gt;psychotic disorder, severe personality disorder, adjustment&lt;SUP&gt; &lt;/SUP&gt;disorder, substance related disorder, serious physical disorders,&lt;SUP&gt; &lt;/SUP&gt;including organic brain disorder, mental retardation, having&lt;SUP&gt; &lt;/SUP&gt;psychotherapy in previous 2 years, or employed in psychiatric&lt;SUP&gt; &lt;/SUP&gt;health.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Outpatient psychiatric services in the Helsinki region, Finland;&lt;SUP&gt; &lt;/SUP&gt;recruitment June 1994 to June 2000.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Long-term psychodynamic psychotherapy (LPP), short-term psychodynamic&lt;SUP&gt; &lt;/SUP&gt;psychotherapy (SPP), or solution-focused therapy (SFT). See&lt;SUP&gt; &lt;/SUP&gt;online notes for further details.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Work ability (Work Ability Index (WAI) modified to apply to&lt;SUP&gt; &lt;/SUP&gt;the unemployed, students, and the employed, score range 7–49,&lt;SUP&gt; &lt;/SUP&gt;higher score indicates greater ability; work-subscale of the&lt;SUP&gt; &lt;/SUP&gt;Social Adjustment Scale (SAS)-Work; Perceived Psychological&lt;SUP&gt; &lt;/SUP&gt;Functioning Scale &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Falk Leichsenring, DSc &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Department of Psychosomatics and Psychotherapy, University of Giessen, Giessen, Germany &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/109" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298008</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/77]]&gt;</url>
    <title>Therapeutics - Music therapy improves symptoms in adults hospitalised with schizophrenia</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Talwar N, Crawford MJ, Maratos A, et al. Music therapy for in-patients with schizophrenia: exploratory randomised controlled trial. Br J Psychiatry 2006;189:405–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does music therapy improve symptoms in people hospitalised with schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blind (assessors blinded).&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Three months (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Four London hospitals, UK; time period not stated.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; Eighty one adult inpatients (&amp;gt;=18 years old) with a primary diagnosis of schizophrenia or schizophrenia-like psychosis. Exclusions: secondary diagnoses of dementia or organic psychosis.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Music therapy (access to a range of musical instruments and encouragement to express themselves accompanied by a trained music therapist during weekly individual sessions of up to 45 min) plus standard care (access to occupational, social and other activities and nursing care) versus standard care alone for up to 12 weeks.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Primary outcome measure: symptoms, total score on the Positive and Negative Syndrome Scale (PANSS); secondary outcome measures: satisfaction with care, Client Satisfaction Questionnaire (CSQ); global function, Global Assessment of Functioning Scale (GAF).&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 85%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;In people hospitalised with schizophrenia, adding music therapy to standard care lead to greater improvement in symptoms compared with standard care alone at 12 weeks (change in PANSS total score from baseline: –9.00 with music therapy plus standard care vs –2.96 with standard care alone; p = 0.045). There was no significant difference in patient satisfaction with care and global function between groups (change in CSQ score from baseline: +1.82 with music therapy plus standard care vs +0.33 with standard care alone; reported as non-significant; change in GAF score from baseline: +4.74 with music therapy plus standard care vs +4.60 with standard care; reported as non-significant).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Adding music therapy to standard care improves symptoms compared with standard care alone in people hospitalised with schizophrenia. Adding music therapy to standard care did not have a significant impact on overall patient satisfaction with care and global function.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344625</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/21.extract]]&gt;</url>
    <title>Therapeutics - Neurofeedback training improves ADHD symptoms more than attention skills training</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does neurofeedback training produce greater improvements in attention deficit hyperactivity disorder (ADHD) compared with attention skills training? &lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;102 children (8–12 years old) with DSM-IV ADHD based on a semi-structured clinical interview (CASCAP-D) and the Diagnostic Checklist for Hyperkinetic Disorders/ADHD.&lt;/P&gt;
&lt;P id=p-3&gt;&lt;EM&gt;Main exclusions&lt;/EM&gt;: gross neurological or organic disorders; medication or psychotherapy received within 6 weeks of beginning the intervention. Children with comorbid conduct disorder, emotional disorders, tic disorder and dyslexia were included in study. The majority of participants (87, 85.3%) were drug naive. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-4&gt;Outpatient clinics in three cities in Germany; May 2005–December 2007.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-5&gt;Neurofeedback training (NF) or attention skills training (AST). NF involved theta/beta training and slow cortical potential training using the computerised Self-regulation and Attention Management system. AST was based on the computerised program Skillies, which targets visual and auditory perception, vigilance, sustained attention and reactivity. Training was presented in two blocks of nine 50 min double sessions, two or three times a week. Each block lasted 3–4 weeks. Children trained in pairs and the administering psychologist discussed strategies for successful completion … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/1/21.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298010</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/79]]&gt;</url>
    <title>Therapeutics - No difference in depression relapse rates between maintenance electroconvulsive therapy and lithium plus nortriptyline</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006;63:1337–44.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How effective are electroconvulsive therapy or lithium carbonate plus nortriptyline hydrochloride as maintenance treatments in major depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Unconcealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Unblinded.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Six months (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Five academic medical centres (outpatient psychiatry clinics) in the US; 1997–2004.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; Phase 1 (acute non-randomised treatment): 531 people aged 18–85 years with primary DSM-IV major depression (24-item Hamilton Rating Scale for Depression (HRSD) total score &amp;gt;=21) referred for bilateral electroconvulsive therapy (ECT). Phase 2 (maintenance treatment): 201 people with remission in phase 1 (&amp;gt;=60% decrease from baseline in HRSD total score and HRSD score &amp;lt;=10 on two consecutive ratings), an HRSD score &amp;lt;=10 or less for 1 week without psychotropic medication, and modified Mini-Mental State Examination (mMMSE) score &amp;gt;=21. Exclusion criteria: ECT in 3 months before phase 1, medical conditions contraindicating study treatments, substance dependence in last 12 months, or disorders affecting cognition.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; ECT (10 sessions: once weekly for first 4 weeks, fortnightly for next 8 weeks, monthly for next 2 months) versus lithium carbonate plus nortriptyline hydrochloride (target blood levels 0.7 mEq/l lithium, 125 ng/m nortriptyline).&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Primary outcome: time to relapse (two consecutive HRSD total scores &amp;gt;=16, plus minimum increase of 10 points from phase 2 baseline). Secondary outcomes: rates of relapse, continued remission or dropout.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 74% completed treatment and all assessments; analyses included 92% with post-baseline measurements.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;There was no difference in relapse rates between maintenance ECT and medication (unadjusted HR 1.13, 95% CI 0.69 to 1.36; p = 0.62; HR adjusted for psychosis, sex and age: 1.18, 95% CI 0.71 to 1.94; p = 0.53). There was no difference between groups in the proportion of people experiencing relapse, continued remission, or withdrawing from the study (relapse: 37.1% with ECT vs 31.6% with medication; continued remission: 46.1% with ECT vs 46.3% with medication; withdrawals: 16.8% with ECT vs 22.1% with medication; p = 0.59 for overall comparison of categories).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;In people with major depression achieving remission with acute ECT, relapse rates do not differ between continued ECT and lithium carbonate plus nortriptyline hydrochloride.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377627</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/46.extract]]&gt;</url>
    <title>Therapeutics - No differences in mortality and suicide between treated and never-treated people with schizophrenia</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;Do the rates of all-cause mortality and suicide differ between treated and never-treated people with schizophrenia?&lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Participants were 510 people with schizophrenia (ICD-10), living in rural communities. Participants were identified from an epidemiological study of 123 572 people aged =15 years.&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Six townships in Xinjin County, Chengdu, China; time period studied March 1994 to May 2004.&lt;/P&gt;
&lt;H3&gt;Prognostic factors:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Participants, or one person familiar with the participant's circumstances (informant), or both, were interviewed in May 2004. If the participant had died, then the next kin or informant was interviewed. Trained psychiatrists used the Patients Follow-up Schedule for about 30 min. Psychiatric and medical treatment records were obtained from doctor's clinics, hospitals and traditional healers. Death certificates and suicide notes were also obtained as required. Treatment information was used to classify participants as never-treated or treated. Never-treated was defined as the participant or informant, or both, reporting that, … &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/2/46.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301978</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/75]]&gt;</url>
    <title>Therapeutics - No long-lasting effects of classroom-based cognitive behavioural and interpersonal prevention programmes on depressive symptoms in adolescents</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Are cognitive behavioural and interpersonal prevention programmes&lt;SUP&gt; &lt;/SUP&gt;effective for preventing depressive symptoms in adolescents?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;380 adolescents (average age 14.4 years) attending wellness&lt;SUP&gt; &lt;/SUP&gt;classes in high school. These adolescents were not selected&lt;SUP&gt; &lt;/SUP&gt;on the basis of having depressive symptoms or being at risk&lt;SUP&gt; &lt;/SUP&gt;for depression.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Three high schools, Tennessee, USA; 2004–5.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Cognitive behavioural programme (CB-P), interpersonal psychotherapy-adolescent&lt;SUP&gt; &lt;/SUP&gt;skills training programme (IPT-P), or no intervention (control).&lt;SUP&gt; &lt;/SUP&gt;The prevention programmes were given in small groups (8–15&lt;SUP&gt; &lt;/SUP&gt;students) as weekly 90 minute sessions for eight weeks as part&lt;SUP&gt; &lt;/SUP&gt;of wellness classes. Participants in the control group received&lt;SUP&gt; &lt;/SUP&gt;their standard wellness curriculum (details not given).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Depressive symptoms (Children’s Depression Inventory (CDI)&lt;SUP&gt; &lt;/SUP&gt;minus question about suicidal ideation, Center for Epidemiological&lt;SUP&gt; &lt;/SUP&gt;Studies Depression scale (CES-D)). A composite depression score&lt;SUP&gt; &lt;/SUP&gt;was obtained by &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;P Stallard &lt;/P&gt;
&lt;P&gt;University of Bath, Mental Health Research and Development Unit and the Avon and Wiltshire Mental Health Partnership NHS Trust, Bath, UK &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/75" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321519</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/89]]&gt;</url>
    <title>Therapeutics - No significant difference between olanzapine and placebo for improvement in borderline personality disorder symptoms</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the efficacy and safety of variable dose olanzapine in people with borderline personality disorder?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;314 outpatients (aged 18–65 years) with borderline personality disorder (DSM-IV) and scoring 9 on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) score at randomisation (see online notes for main exclusion criteria).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;52 sites in nine countries: Belgium, France, Germany, Norway, Portugal, Spain, Sweden, UK and USA; time period not stated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Olanzapine (2.5–20 mg/day) or placebo. Participants taking olanzapine started on 2.5 mg or 5 mg/day based on the investigator’s judgement. After 1 week, if needed, doses could be increased or decreased in 2.5 or 5 mg doses to a maximum of 20 mg/day. At week 4, participants without a &amp;gt;=30% reduction in the ZAN-BPD score were prescribed incremental dose increases (up to a maximum of 20 mg/day) unless precluded by adverse events. Participants on maximum dose and failing to achieve a reduction . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/89" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301986</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/83]]&gt;</url>
    <title>Therapeutics - Occupational therapy is cost-effective for older people with dementia and their caregivers</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How cost-effective is an occupational therapy intervention for&lt;SUP&gt; &lt;/SUP&gt;older patients with dementia and their caregivers?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;135 people aged 65 years and over with mild to moderate dementia&lt;SUP&gt; &lt;/SUP&gt;who were living in the community, plus their carers.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Memory clinic and day clinic of a department of geriatrics in&lt;SUP&gt; &lt;/SUP&gt;The Netherlands; recruitment April 2001 to January 2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Occupational therapy or usual care. Ten sessions of occupational&lt;SUP&gt; &lt;/SUP&gt;therapy were given over 5 weeks for both patients and their&lt;SUP&gt; &lt;/SUP&gt;carers. Sessions included cognitive and behavioural interventions;&lt;SUP&gt; &lt;/SUP&gt;in the first 4 sessions, participants were taught to define&lt;SUP&gt; &lt;/SUP&gt;and prioritise the problems they wanted to improve, in the final&lt;SUP&gt; &lt;/SUP&gt;6 sessions, participants were taught to optimise strategies&lt;SUP&gt; &lt;/SUP&gt;to address their issues. The intervention aimed &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Brian Draper &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Associate Professor, School of Psychiatry, University of NSW, Sydney, Australia &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/83" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/P&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302007</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/43]]&gt;</url>
    <title>Therapeutics - Ongoing pharmacotherapy maintains quality of life benefits in older adults with major depression</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does continuing treatment with combined paroxetine and interpersonal&lt;SUP&gt; &lt;/SUP&gt;psychotherapy sustain health-related quality of life benefits?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;116 people aged 70 years and older who had been diagnosed with&lt;SUP&gt; &lt;/SUP&gt;major depression, which had responded to treatment with paroxetine&lt;SUP&gt; &lt;/SUP&gt;and interpersonal psychotherapy. Initially 195 older adults&lt;SUP&gt; &lt;/SUP&gt;with non-psychotic DSM-IV major depression and 17-item Hamilton&lt;SUP&gt; &lt;/SUP&gt;Rating Scale for Depression (HRSD-17) score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;15 and Mini-Mental&lt;SUP&gt; &lt;/SUP&gt;State Examination score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;17 were recruited and treated with paroxetine&lt;SUP&gt; &lt;/SUP&gt;and interpersonal psychotherapy. The 151 people who responded&lt;SUP&gt; &lt;/SUP&gt;(3 consecutive weeks with HRSD-17 score &lt;IMG alt="&lt;=" src="https://rmsadmin.library.nhs.uk/libraryImages/Mental%20Health/contentID302007/nelhImp_0000_les.gif" border=0&gt;10) continued to received&lt;SUP&gt; &lt;/SUP&gt;open treatment for 16 weeks. The 116 people who did not relapse&lt;SUP&gt; &lt;/SUP&gt;during this period entered the maintenance phase.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;University-based clinic for treatment of major depression in&lt;SUP&gt; &lt;/SUP&gt;old age; recruitment March 1999 to February 2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Maintenance treatment with: paroxetine plus clinical &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Muthu K R Natarajan,, John R Geddes &lt;/P&gt;
&lt;P&gt;Speciality Registrar, General Adult Psychiatry, Warneford Hospital, Oxford, UK&lt;BR&gt;Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK &lt;/P&gt;
&lt;P class=MsoNormal&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/43" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377665</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/50.extract]]&gt;</url>
    <title>Therapeutics - Online cognitive behavioural therapy is effective for depression in primary care</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;Is cognitive behavioural therapy (CBT) delivered online in real time by a therapist effective for patients with depression in primary care? &lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;297 individuals with a score of =14 on the Beck Depression Inventory (BDI) and confirmed diagnosis of a new episode of depression within 4 weeks preceding referral. Individuals were from 55 general practices in Bristol, London and Warwickshire. Patients treated for depression in the 3 months before the present episode, patients with a history of bipolar disorder, alcohol or substance misuse and those already receiving psychotherapy were excluded.&lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Universities of Bristol and Warwick and the Department of Mental Health Sciences, Royal Free Campus London, UK. Recruitment took place between October 2005 and February 2008. &lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Usual care from general practitioner (GP) with or without ten 55-min sessions of online CBT (with a therapist online in real time) to be completed within 16 weeks of randomisation where possible. &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Primary: Recovery from depression 4 months after randomisation as assessed by BDI, where a score &amp;lt;10 … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/50.full" target="_blank"&gt;Full text of the article&lt;/A&gt; his available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306985</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/19]]&gt;</url>
    <title>Therapeutics - Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is osmotically released methylphenidate more effective than atomoxetine or placebo in children and adolescents with attention deficit hyperactivity disorder (ADHD)?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;516 children and adolescents with DSM-IV ADHD (aged 6–16 years; 26% female, mean age 10.2 years). Exclusions: ADHD symptom severity &amp;lt;1.5 standard deviations above average on the ADHD Rating Scale IV-parent version; seizures, bipolar disorder, psychotic illness, anxiety and tic disorders, or pervasive developmental disorder; use of psychoactive medications; or experienced intolerable adverse events or no improvement when previously treated with study drugs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;20 sites, USA; time period not stated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Osmotically released methylphenidate (n = 220; single morning dose of 18–54 mg/day), atomoxetine (n = 222; twice daily divided dose of 0.8–1.8 mg/kg/day) or placebo (n = 74) for 6 weeks. Washout of any psychoactive medication for at least 5 days was required prior to entry.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Response to treatment (40% decrease in total ADHD Rating Scale score).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;82% osmotically released . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Maggie E Toplak&lt;/P&gt;
&lt;P&gt;York University, Toronto, Canada &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/19" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298058</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/125]]&gt;</url>
    <title>Therapeutics - Parenting training improves problem behaviour in children at risk of conduct disorder</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,CONDUCT DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Hutchings J, Gardner F, Bywater T, et al. Parenting intervention in Sure Start services for children at risk of developing conduct disorder: pragmatic randomised controlled trial. BMJ 2007;334:678–82.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does Webster-Stratton Incredible Years basic parenting programme improve behavioural outcomes in preschool children at risk of developing conduct disorder when delivered in a community setting?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design&lt;/STRONG&gt;: Randomised controlled trial (block randomisation by area in a 2:1 ratio of intervention:control).&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Unclear.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blind (assessors blinded).&lt;BR&gt;&lt;STRONG&gt;Follow up period:&lt;/STRONG&gt; Unclear; described as "every six months until March 2005".&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Eleven Sure Start areas in north and mid-Wales; recruitment between January 2003 and September 2004.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 153 socially disadvantaged families with a child aged 3 or 4 years who were at risk of conduct disorder (score &amp;gt;11 on the Eyberg Child Behaviour Inventory (ECBI) problem scale, or &amp;gt;127 on the ECBI intensity scale).&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Webster-Stratton Incredible Years basic parenting programme (104 families) or waiting list control (49 families). The intervention consisted of weekly positive parenting group sessions (up to 12 parents per group) for 12 weeks. Each group lasted 2–2.5 hours and took a collaborative approach to promoting positive parenting, including role play, modeling, discussion and analysis of video material. Groups were run by two leaders (including family support workers, psychologists, social workers, health visitors and Barnardo’s project workers) who received three hours’ supervision a week from a certified trainer.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Primary outcome: child problem behaviour (ECBI problem and intensity scores). Secondary outcomes included: parental stress (Parenting Stress Index (PSI)), parental depression (Beck Depression Inventory (BDI)) and parental competency (Arnold parenting scale). Mean differences between groups were estimated using analysis of covariance, and adjusted for area and baseline scores.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 83% of the intervention group and 96% of the control group completed the trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Children of parents in the intervention group had fewer and less intense conduct disorder problems than children of parents in the control group (mean difference in ECBI problem score: 4.4, 95% CI 2.0 to 6.9, p&amp;lt;0.001; mean difference between groups in ECBI intensity rating: 25.1, 95% CI 14.9 to 35.2, p&amp;lt;0.001). Parents in the intervention group had reduced stress and depressive symptoms, and improved competency compared to parents in the control group (mean difference in PSI score: 12.92, 95% CI 6.09 to 19.75, p&amp;lt;0.001; mean difference in BDI score: 4.19, 95% CI 1.13 to 7.21, p = 0.008; mean difference in Arnold parenting score: 0.66 95% CI 0.42 to 0.91, p&amp;lt;0.001).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;A 12-week Webster-Stratton Incredible Years basic parenting course improves the incidence and intensity of conduct problems in preschool children at risk of conduct disorder when delivered in a socially disadvantaged community. It also improves parental competency, and reduces parental stress and depressive symptoms.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328849</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/120]]&gt;</url>
    <title>Therapeutics - Peer group support intervention reduces psychological distress in AIDS orphans</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Is peer group intervention effective in improving the psychosocial&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;well being of AIDS orphans?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;326 young AIDS orphans (aged 10–15 years; 50% male; 94.5%&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Bantu ethnic group and 42.6% "double" orphans), identified from&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;registers of 20 schools. AIDS orphan status was verified by&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;report by surviving parent or guardian.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Mbarara municipality, Mbarara District, southwest Uganda (study&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;dates not reported).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Peer group support programme including physical healthcare or&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;control (no support intervention). The peer group support programme&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(n = 159) is aimed at improving coping among AIDS orphans by&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;providing social support and sharing concerns, fears and worries&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;about orphanhood. It comprised 16 1 h psychosocial exercises,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;implemented over 10 weeks after school by teachers who were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;trained to facilitate the intervention. The exercises had originally&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;been designed for adults and were modified for children. Children&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in the intervention group also received monthly physical health&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;assessments and treatment (eg, antimicrobial &lt;I&gt;&lt;NOBR&gt;. . (Abstractes)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/120" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;BR&gt;&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302015</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/51]]&gt;</url>
    <title>Therapeutics - Personalised feedback on alcohol problems in young adults is more effective as part of a motivational interview</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does personalised feedback need to be combined with motivational&lt;SUP&gt; &lt;/SUP&gt;interviewing to reduce consumption and alcohol-related problems&lt;SUP&gt; &lt;/SUP&gt;in young adults?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;198 young adults aged 18–24 years who were positive for&lt;SUP&gt; &lt;/SUP&gt;alcohol use when they presented to the emergency department&lt;SUP&gt; &lt;/SUP&gt;(blood alcohol concentration &amp;gt;0.01%) or who met screening&lt;SUP&gt; &lt;/SUP&gt;criteria for alcohol problems (reporting drinking alcohol in&lt;SUP&gt; &lt;/SUP&gt;the previous 6 hours or score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;8 on the Alcohol Use Disorders&lt;SUP&gt; &lt;/SUP&gt;Identification Test).&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Trauma centre in Rhode Island, USA; recruitment January 2000&lt;SUP&gt; &lt;/SUP&gt;to June 2003.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Delivery of personalised feedback report through very brief&lt;SUP&gt; &lt;/SUP&gt;contact (1–3 minutes) with a counsellor, or delivery in&lt;SUP&gt; &lt;/SUP&gt;the context of a 30–45 minute long motivational interview&lt;SUP&gt; &lt;/SUP&gt;session. The personalised feedback report was based on an assessment&lt;SUP&gt; &lt;/SUP&gt;at baseline, which gave information on how much the patient&lt;SUP&gt; &lt;/SUP&gt;drank, &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted) &lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;/P&gt;
&lt;P&gt;Scott H Stewart &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC, USA &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/51" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317833</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/57]]&gt;</url>
    <title>Therapeutics - Physical activity improves cognitive function in people with memory impairment</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;Question:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does physical activity improve cognitive function in people&lt;SUP&gt; &lt;/SUP&gt;with self-reported memory impairment?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Patients:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;170 adults over 50 years old with self-reported memory difficulties.&lt;SUP&gt; &lt;/SUP&gt;Main exclusion criteria: dementia diagnosis; significant cognitive&lt;SUP&gt; &lt;/SUP&gt;impairment; significant depression symptoms; chronic mental&lt;SUP&gt; &lt;/SUP&gt;illness; inability to engage in physical activity; or potentially&lt;SUP&gt; &lt;/SUP&gt;fatal physical illness.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Setting:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Royal Perth Hospital, Australia; recruitment May 2004 to July&lt;SUP&gt; &lt;/SUP&gt;2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;Intervention:&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Physical activity programme (including behavioural adherence&lt;SUP&gt; &lt;/SUP&gt;package) plus usual care or usual care alone. &lt;I&gt;Physical activity&lt;SUP&gt; &lt;/SUP&gt;programme:&lt;/I&gt; 24 weeks of at least three 50 min moderate home based&lt;SUP&gt; &lt;/SUP&gt;exercise sessions. Physical activity was prescribed on an individualised&lt;SUP&gt; &lt;/SUP&gt;basis by trained physical activity staff during a 60 min initial&lt;SUP&gt; &lt;/SUP&gt;interview. After the initial 24 week programme, no further intervention&lt;SUP&gt; &lt;/SUP&gt;was delivered except for four reinforcing newsletters distributed&lt;SUP&gt; &lt;/SUP&gt;at 32, 40, 65 and 72 weeks. &lt;I&gt;Behavioural adherence package&lt;/I&gt;: information&lt;SUP&gt; &lt;/SUP&gt;on exercise programmes, goal setting, time management, barriers&lt;SUP&gt; &lt;/SUP&gt;to and safe exercise delivered via a &lt;NOBR&gt;&lt;EM&gt;.&lt;/EM&gt; . (Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/57" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>298016</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/82]]&gt;</url>
    <title>Therapeutics - Quetiapine more effective than placebo for depression in bipolar I and II disorder</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II study). J Clin Psychopharmacol 2006;26:600–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How effective is quetiapine monotherapy for depression in people with bipolar I or II disorder?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Double blind.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Eight weeks.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Forty one centres in the US; June 2004 to August 2005.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; 509 outpatients (18–65 years old) with DSM-IV bipolar I (n = 338) or II (n = 171) disorder experiencing a major depressive episode (17-item Hamilton Depression Rating Scale (HAM-D17) score &amp;gt;=20, HAM-D17 Item 1 score &amp;gt;=2; Young Mania Rating Scale score &amp;lt;=12). Participants were excluded if they had: been diagnosed with another Axis I disorder that had been treated within 6 months before the study; a current depressive episode lasting more than 12 months or less than 4 weeks; a history of non-response (over 6 weeks) to more than two classes of antidepressants during the current depressive episode; a diagnosis of DSM-IV substance dependence or substance use (other than nicotine) within 12 months before the study; significant clinical comorbidity, or a serious suicidal or homicidal risk.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Quetiapine (300 mg/day or 600 mg/day) or placebo. Quetiapine was initiated at 50 mg/day and increased to achieve a target dose of 300 mg/day by day 4 or 600 mg/day by week 1.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Change in depressive symptoms from baseline as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS; higher score indicates greater symptom severity).&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; Study completion rates by group: 65.5% for placebo; 58.7% for quetiapine 300 mg/day; 53.3% for quetiapine 600 mg/day. Last observation carried forward analyses included 91.7% of participants.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Quetiapine (at either 300 mg/day or 600 mg/day) improved depressive symptoms significantly more than placebo at 8 weeks (mean change in MADRS total score from baseline: –11.93 with placebo vs –16.94 with quetiapine 300 mg/day (p&amp;lt;0.001 vs placebo) vs –16.00 with quetiapine 600 mg/day (p = 0.001 vs placebo)).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Quetiapine at either 300 mg/day or 600 mg/day is more effective than placebo at treating depression in people with bipolar I or II disorder.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377598</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/43.extract]]&gt;</url>
    <title>Therapeutics - Recurrence of bipolar spectrum disorders—a common issue among the affected population of young people</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;What is the longitudinal symptom profile of young people with bipolar spectrum disorders?&lt;/P&gt;
&lt;H3&gt;Population:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;A total 413 young people aged between 7 and 17 years (mean age: 12.8 years, male: 53.5%, mean duration of bipolar disorder: 3.3 years, mean age at onset of mood symptoms: 8.4 years) who were participants of the Course and Outcome of Bipolar Youth programme that recruited young people with bipolar I or II disorders (59.1% bipolar I, 6.8% bipolar II and 34.1% bipolar disorder not specified) on the basis of criteria provided by &lt;EM&gt;Diagnostic and Statistical Manual of Mental Disorders&lt;/EM&gt; (DSM-IV). Study participants were recruited from outpatient clinics (67.6%), inpatient units (14.3%), advertisements (13.35%) and physician referral (4.8%). Young people with schizophrenia, mental retardation, autism or mood disorders secondary to substances, medication or medical conditions were excluded. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Interviews were conducted at universities in the USA; recruitment dates are not reported.&lt;/P&gt;
&lt;H3&gt;Prognostic factors:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Subtype of bipolar disorder, age, psychosis, age at bipolar onset, duration of bipolar disorder, presence of a co-morbid disorder and family history of mood disorders (measured using the Family History Screen). &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Time to recovery from the index episode defined as the current or most … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/content/13/2/43.full" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317823</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/51]]&gt;</url>
    <title>Therapeutics - Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does aripiprazole improve the antipsychotic effect of clozapine&lt;SUP&gt; &lt;/SUP&gt;without increasing the risk of major adverse events in people&lt;SUP&gt; &lt;/SUP&gt;with refractory schizophrenia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;61 Korean people, aged 18–65 years, with DSM-IV schizophrenia,&lt;SUP&gt; &lt;/SUP&gt;a history of treatment failure, partial responsiveness to long&lt;SUP&gt; &lt;/SUP&gt;term clozapine therapy (&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;1 year) and taking a stable clozapine&lt;SUP&gt; &lt;/SUP&gt;dose for at least 3 months. Treatment failure was defined as&lt;SUP&gt; &lt;/SUP&gt;persistent psychotic symptoms after at least two different antipsychotics&lt;SUP&gt; &lt;/SUP&gt;at equivalent to &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;600 mg/day chlorpromazine for &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;6 weeks. Participants&lt;SUP&gt; &lt;/SUP&gt;had to have a Brief Psychiatric Rating Scale (BPRS) score of&lt;SUP&gt; &lt;/SUP&gt;&lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;35 or &amp;gt;2 global rating items on the Schedule for Assessment&lt;SUP&gt; &lt;/SUP&gt;of Negative Symptoms (SANS) score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;3 (see online notes for exclusion&lt;SUP&gt; &lt;/SUP&gt;criteria).&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Refractory Schizophrenia Clinic, Seoul National University,&lt;SUP&gt; &lt;/SUP&gt;Republic of Korea. Recruitment 1 December 2005 to 10 December&lt;SUP&gt; &lt;/SUP&gt;2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Aripiprazole (5–30 mg/day) or placebo for 8 weeks. An&lt;SUP&gt; &lt;/SUP&gt;initial dose of 5 mg/day aripiprazole was administered and increased&lt;SUP&gt; &lt;/SUP&gt;&lt;NOBR&gt;&lt;EM&gt;.&lt;/EM&gt; . (Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/51" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>298009</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/78]]&gt;</url>
    <title>Therapeutics - Repetitive transcranial magnetic stimulation is not as effective as electroconvulsive therapy for major depression</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Eranti S, Mogg A, Pluck G, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry 2007;164:73–81.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Is repetitive transcranial magnetic stimulation equivalent to electroconvulsive therapy?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled equivalence trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blind (assessors blinded).&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Six months.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; South London and Maudsley National Health Service Trust, London, and Pembury Hospital, Invicta Mental Health Trust, Kent, UK; recruitment January 2002 to August 2004.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; Forty six right-handed adults (aged &amp;gt;=18 years) referred for electroconvulsive therapy (ECT) for major depression (Structured Clinical Interview for DSM-IV Axis I Disorders). Main exclusions: inability to receive repetitive transcranial magnetic stimulation (rTMS) or ECT (metallic plates in head, unfit for anaesthesia, history of seizures); rTMS or ECT in previous 6 months; dementia or other axis I diagnosis; substance misuse in previous 6 months.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; rTMS (15 sessions: daily for 5 days/week over 3 weeks) or ECT (bilateral or unilateral, twice weekly, number and duration dependent upon patient’s response, mean 6 sessions over 22 days).&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Depression symptoms (17 item Hamilton Depression Rating Scale [HAM-D17] score), remission (defined as HAM-D17 score &amp;lt;=8).&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 85% completed treatment, 80.4% completed follow-up. Analysis was by intention to treat.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;By the end of treatment, ECT reduced depressive symptoms significantly more than rTMS (mean reduction from baseline in HAM-D17 score: 58% with ECT vs 22% with rTMS; mean difference: 36%, 95% CI 14% to 58%). The upper CI for the difference lay outside the pre-specified level for equivalence (18.1%), therefore rTMS was not equivalent in efficacy to ECT. ECT also significantly increased remission (13/22 (59.1%) with ECT vs 4/24 (16.9%) with rTMS; p = 0.006). At six months follow-up, there was no significant difference between groups in HAM-D17 scores (mean difference not reported, 95% CI for the difference: –6.92 to +6.33; p = 0.93). Five participants in the rTMS group changed to ECT during follow-up.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;rTMS is not equivalently effective to ECT for major depression. ECT is more effective than rTMS for reducing depressive symptoms in the short term.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306978</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/15]]&gt;</url>
    <title>Therapeutics - Review: Adding psychosocial interventions to pharmacotherapy for opioid detoxification improves outcomes</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is adding psychosocial to pharmacological treatment for opioid detoxification?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Completion of treatment (the detoxification programme), use of opioid drugs (assessed by urinalysis during treatment) and abstinence from opioids at follow-up.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; The following databases were searched in February 2008: Cochrane Drugs and Alcohol Group trials register, Cochrane Central Register of Controlled Trials, PubMed (from 1996), EMBASE (from January 1980), CINAHL (from January 2003) and PsycINFO (from 1985 to April 2003). Conference proceedings and databases of ongoing trials were also searched and investigators contacted to obtain details of unpublished or ongoing trials. Reference lists of relevant articles were searched to identify additional citations.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Randomised controlled trials (RCTs) which compared psychosocial plus pharmacological treatment versus pharmacological treatment alone for opioid detoxification in adults (aged 18 years and over). RCTs in pregnant women were excluded. Three reviewers assessed trial quality and . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ed Day&lt;/P&gt;
&lt;P&gt;Senior Lecturer, University of Birmingham and Honorary Consultant in Addiction Psychiatry, Birmingham and Solihull Mental Health Foundation Trust, Birmingham, UK &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/15" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298045</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/111]]&gt;</url>
    <title>Therapeutics - Review: Adding second generation antipsychotics to mood stabilisers reduces acute mania symptoms</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,BIPOLAR DISORDER,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007;64:442–55.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What is the effect of second generation antipsychotics, alone or in combination with mood stabilisers, in people with acute mania?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PsiTri database and MEDLINE (search date May 2006), plus hand searches of references, contact with experts in the field.&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; The review included randomised controlled trials (RCTs) of second generation antipsychotics (aripiprazole, amisulpride, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, zotepine) for treatment of acute mania. Continuous data were presented as standardised mean differences with confidence intervals, which were calculated based on Hedges adjusted g (modified Cohen’s d corrected for samples sizes below 10). If standard deviations were not reported, values were derived from p values or mean standard deviation of other studies. Dichotomous data were presented as relative risks with confidence intervals. Random effects model was used in all meta-analyses. Assessment of heterogeneity involved visual inspection of forest plots and {chi}2 test comparing individual study relative risks versus the pooled relative risk, with a significance level of p&amp;lt;0.1. Assessment of publication bias involved funnel plots. Calculations were performed with MetaView software.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Mania symptoms: Young Mania Rating Scale (YMRS; lower score means fewer symptoms) or other scale scores; rate of response (as defined in individual studies); withdrawals for adverse events; mean weight gain; somnolence; extrapyramidal symptoms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;The review included 24 RCTs (5809 people with acute mania). Second generation antipsychotics (SGAs), including aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, reduced acute mania symptoms and increased response rate compared with placebo (see &lt;A href="http://ebmh.bmj.com/supplemental" target="_blank"&gt;http://ebmh.bmj.com/supplemental&lt;/A&gt; for table). In comparison with placebo, SGAs increased weight gain, somnolence and extrapyramidal symptoms. There was no significant difference in symptoms and response rate between SGAs and mood stabilisers. SGAs increased weight gain and somnolence compared with mood stabilisers. Adding SGAs to mood stabilisers reduced acute mania symptoms and increased response rate in comparison with adding placebo. Combination treatment increased weight gain, somnolence and extrapyramidal symptoms compared with mood stabilisers alone. There was no significant difference in symptoms and response rate between SGAs and haloperidol. SGAs increased somnolence compared with haloperidol, but extrapyramidal symptoms were lower with SGAs. There was heterogeneity in some of the meta-analysis results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Second generation antipsychotics, including aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, are effective in treatment of acute mania episodes compared with placebo. There is no difference between SGAs and mood stabilisers or haloperidol in symptoms or response. Adding second generation antipsychotics to mood stabilisers reduces symptoms and improves response in acute mania episodes.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298047</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/113]]&gt;</url>
    <title>Therapeutics - Review: Adding SSRIs to antipsychotics does not improve negative symptoms in people with schizophrenia</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does adding SSRIs to antipsychotics improve negative symptoms in people with schizophrenia-spectrum disorder?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007;68:604–10.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PsycINFO, MEDLINE (1967–2005), Current Contents (1993–2005), hand searching of reference lists, and contact with pharmaceutical companies.&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; The review included randomised, placebo-controlled, double-blind trials comparing the addition of SSRIs to antipsychotics versus adding placebo in people with schizophrenia-spectrum disorder. Main exclusions: comorbid obsessive-compulsive disorder; studies of monoamine oxidase inhibitors, tricyclic, dual action, or atypical antidepressants (for example, bupropion); incomplete or unavailable data; crossover RCTs. Data were extracted by two reviewers, with disagreement resolved by consensus. Hedges’ g effect sizes (which adjust for sample size) were calculated using a random effects model. Heterogeneity was assessed using the Q statistic, with the threshold for significance set at p&amp;lt;0.1. In addition, z scores were calculated for each study, and used in sensitivity analyses. These analyses were conducted using 2x2 factorial analysis of variance, to control for differences in outcome measures used and baseline differences between groups in symptoms.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Negative symptoms (Scale for the Assessment of Negative Symptoms (SANS) or the Positive and Negative Syndrome-negative subscale (PANSS-N)).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Eleven RCTs (393 people with schizophrenia-spectrum disorder) met inclusion criteria. The SSRIs assessed were: fluoxetine (5 RCTs), sertraline (2 RCTs), fluvoxamine (2 RCTs), paroxetine (1 RCT), and citalopram (1 RCT). Treatment duration ranged from 4–16 weeks. Studies also varied in types of patients enrolled (chronic or non-chronic), treatment setting (in-patient or out-patient), the type of antipsychotic used (typical, atypical, or mixed), outcome measure (SANS or PANSS-N), and how the data were analysed (completer, intention to treat, or last observation carried forward analysis). At baseline, there was a trend towards fewer negative symptoms in the placebo plus antipsychotic groups than in the SSRI plus antipsychotic groups (adjusted Hedges’ g –0.179, p = 0.072). After treatment, there was no significant difference in negative symptoms between SSRIs plus antipsychotic and placebo plus antipsychotic (adjusted Hedges’ g 0.178, p = 0.191). There was statistical heterogeneity in the meta-analysis (Q = 16.830, p = 0.078). The heterogeneity was removed when studies were divided according to illness severity. This analysis suggested that adding SSRIs to antipsychotics in people with "chronic" illness improved negative symptoms (adjusted Hedges’ g 0.386; p = 0.014). In sensitivity analyses, participants were found to improve over time (p&amp;lt;0.001), but this improvement did not differ significantly between SSRI and placebo (p = 0.112), even within the "chronic" illness group (p = 0.357).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;In people with schizophrenia-spectrum disorder, adding SSRIs to antipsychotics does not improve negative symptoms compared with antipsychotics alone.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377667</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/52.extract]]&gt;</url>
    <title>Therapeutics - Review: antidepressants associated with increased risk of suicidality in adults aged less than 25 years</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;What is the risk of suicidal behaviour within clinical trials of antidepressants in adults?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Primary outcome: definitive suicidal behaviour or ideation (completed suicide, attempted suicide or preparatory acts), secondary outcome: suicidal behaviour (preparatory actions). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Data requested from 8 industry sponsors of 12 marketed antidepressant products were used. FDA-specified data formats provided instructions for identifying and classifying events possibly related to suicidality and how events would be classified. The search date was not reported, and the majority of trials were unpublished. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Double-blind randomised placebo-controlled trials assessed the use of one of the 12 antidepressants in adults for any indication of suicidality. The antidepressants were bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluoxetine/olanzapine (ultimately excluded from the analysis), fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline and venlafaxine. A total of 372 trials (n=99 231) were included in the dataset. Trials limited to known drug responders, those with fewer than 20 participants, studies not providing patient level data and studies with non-antidepressant active control were excluded. Individual patient-level data were analysed using a conditional logistic regression model. Heterogeneity between studies was assessed. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/52.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>298048</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/115]]&gt;</url>
    <title>Therapeutics - Review: Antidepressants improve depression in people with Alzheimer’s disease</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer’s disease: a meta-analysis. Can J Psychiatry 2007;52:248–55.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Are antidepressants effective and safe for people with depression and Alzheimer’s disease?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE (January 1966 to June 2006), the Cochrane Database (search date not stated), and hand search of reference lists of relevant articles.&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Double-blind placebo controlled trials of antidepressants in adults with Alzheimer’s disease (DSM-III, DSM-III-R, DSM-IV, or National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease and Related Disorders criteria) and depression (major depressive disorder or episode, dysthymic disorder, or minor depression according to DSM-III, DSM-III-R, or DSM-IV criteria). Only English language studies were included, and studies of drugs not available in North America or studies not presenting sufficient data for inclusion in meta-analysis were excluded. Study quality appraisal and data extraction were carried out by two researchers. Analyses were conducted using Review Manager Version 4.2. Odds ratios and 95% confidence intervals (CI) were calculated using a random effects model. For continuous measures, the weighted mean difference (WMD) was calculated, using the larger standard deviation for the group scores (treatment or control group) as the standard deviation of the difference. Heterogeneity was assessed using {chi}2 analysis and the I2 statistic, and publication bias was assessed using funnel plots.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Response (&amp;gt;=50% reduction in a standardised depression measure, or other clinically valid or relevant definition), remission (score &amp;lt;8 on the 17 item Hamilton Depression rating scale, or other clinically valid or relevant definition), cognitive change (Mini-Mental State Examination (MMSE) score), withdrawals, adverse events.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Five RCTs met inclusion criteria (165 people). The antidepressants used were sertraline (2 RCTs, maximum 100 or 150 mg daily), imipramine (1 RCT, 84 mg daily), clomipramine (1 RCT, maximum 100 mg daily), and fluoxetine (1 RCT, maximum 40 mg daily). Study duration ranged from 6–12 weeks. Antidepressants significantly increased response and remission compared with placebo (response, 3 RCTs pooled: OR 2.32, 95% CI 1.04 to 5.16; remission, 3 RCTs pooled: OR 2.75, 95% CI 1.13 to 6.65). There was no significant difference in cognitive change between antidepressants and placebo (WMD in MMSE, 3 RCTs pooled: –0.71, 95% CI –3.20 to +1.79). There was no significant difference between treatments in overall withdrawals or withdrawals due to adverse events (overall withdrawals, 5 RCTs pooled: OR 0.70, 95% CI 0.29 to 1.66; withdrawals due to adverse events, 4 RCTs pooled: OR 1.41, 95% CI 0.36 to 5.54). There were insufficient data to analyse individual adverse events. None of the analyses had significant heterogeneity (p&amp;gt;0.3, I2&amp;lt;20% for all analyses), and there was no evidence of publication bias.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Antidepressants increase response and remission of depressive symptoms compared with placebo in people with Alzheimer’s disease and depression when used for 6–12 weeks.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298023</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/83]]&gt;</url>
    <title>Therapeutics - Review: Antipsychotic plus mood stabiliser co-therapy is more effective than mood stabiliser mono-therapy at reducing acute bipolar mania</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,BIPOLAR DISORDER,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007;115:12–20.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;: How effective is co-therapy (an antipsychotic plus a mood stabiliser) compared with monotherapy (mood stabiliser alone) for people with bipolar mania?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, PsycINFO and Cochrane Central Register of Controlled Trials (searched March 2006).&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Included studies were randomised controlled trials (RCTs) comparing co-therapy (an antipsychotic plus a mood stabiliser) versus monotherapy (mood-stabiliser alone) or another co-therapy for acute bipolar mania. Drugs had to be licensed in the UK or US for treatment of bipolar disorder (valproate semisodium, lithium, carbamazepine, lamotrigine, aripiprazole, olanzapine, risperidone, ziprasidone, quetiapine, haloperidol, chlorpromazine, flupentixol, fluphenazine, perphenazine, prochlorperazine and zuclopenthixol). Studies of mixed diagnostic groups were included if randomisation was stratified by bipolar type and data for people with bipolar disorder could be obtained. Meta-analyses were performed using the Mantel–Haenszel method for binary outcomes, and the inverse variance method for continuous outcomes. Treatment effects were expressed either as relative risks or differences in mean values.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Manic symptoms (using the Young Mania Rating Scale (YRMS); higher score indicates greater symptom severity), withdrawal from treatment, extrapyramidal symptoms and weight gain.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;BR&gt;&lt;/STRONG&gt;Eight RCTs met inclusion criteria (n = 1124). Atypical antipsychotic co-therapy significantly reduced manic symptoms compared with mood stabiliser monotherapy (see &lt;A href="http://ebmh.cmj.com/supplemental" target="_blank"&gt;http://ebmh.cmj.com/supplemental&lt;/A&gt; for table). There were no significant differences in overall treatment withdrawal rates (all causes) between atypical antipsychotic co-therapy and mood stabiliser monotherapy. Significantly more people receiving monotherapy withdrew from treatment because of a lack of efficacy compared with those receiving atypical antipsychotic co-therapy. Olanzapine co-therapy significantly increased withdrawal because of adverse events compared with mood stabiliser monotherapy. There were no significant differences in withdrawal because of adverse events with haloperidol, risperidone or quetiapine co-therapy compared with mood stabiliser monotherapy. Atypical antipsychotic co-therapy significantly increased weight gain compared with mood stabiliser monotherapy. Different studies used different measures of extrapyramidal side effects, and so meta-analyses were not performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Co-therapy with an antipsychotic and a mood stabiliser reduces manic symptoms compared with a mood stabiliser alone in people with acute bipolar mania.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377664</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/49.extract]]&gt;</url>
    <title>Therapeutics - Review: benefits of antidepressants over placebo limited except in very severe depression</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2 class=section&gt;Question:&lt;/H2&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1 class=section&gt;What are the effects of antidepressant medications across a range of initial symptoms severities in people with depression?&lt;/P&gt;
&lt;H3 class=section&gt;Outcomes:&lt;/H3&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2 class=section&gt;Depression severity measured using the Hamilton Depression Rating Scale (HDRS).&lt;/P&gt;
&lt;H2 class="section methods"&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 class="section methods"&gt;Methods&lt;/H2&gt;
&lt;H3 class="section methods"&gt;Design:&lt;/H3&gt;
&lt;P class="section methods"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3 class="section methods"&gt;Systematic review and individual patient data meta analysis.&lt;/P&gt;
&lt;H3 class="section methods"&gt;Data sources:&lt;/H3&gt;
&lt;P class="section methods"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4 class="section methods"&gt;PubMed, PsycINFO and the Cochrane Library were searched from January 1980 to March 2009. References from meta analyses and reviews were hand searched. &lt;/P&gt;
&lt;H2 class=section&gt;Study selection and analysis&lt;/H2&gt;
&lt;P id=p-5 class=section&gt;Placebo-controlled RCTs of US Food and Drug Association-approved antidepressants in adult outpatients with major or minor depressive disorders were included. Studies were excluded if they examined only patients with a specific subtype or severity of depression, compared medication versus placebo for less than 6 weeks, excluded patients on the basis of a placebo washout period, did not use the Hamilton Depression Rating Scale (HDRS), were not published in English, or study authors could not provide individual patient data. Study authors were contacted for individual patient data. Analyses of covariance were used to look at the effect of baseline symptom severity on symptom-change scores with … &lt;/P&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=section&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/49.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321522</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/91]]&gt;</url>
    <title>Therapeutics - Review: Brief interventions, gradual dose reduction and psychological interventions increase benzodiazepine cessation compared with routine care</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Are targeted interventions for benzodiazepine cessation more effective than routine care?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Cessation of benzodiazepine use.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; &lt;BR&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; &lt;BR&gt;PsycLIT, MEDLINE and EMBASE were searched from inception to January 2005 for randomised controlled trials (RCTs). A further search was performed in 2007. Reference lists of identified studies were hand searched.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; &lt;BR&gt;Two reviewers appraised studies and selected RCTs comparing: (1) routine care with: brief interventions, gradual dose reduction (GDR) or psychological interventions; (2) GDR with GDR plus psychological interventions or drug substitutions, and looking at the outcome of benzodiazepine cessation. Inclusion criteria: studies including outpatients who had been using benzodiazepines for 3 months or more, minimum of 10 participants in each group at baseline and sufficient information to enable calculation of cessation rates based on intention to treat. Benzodiazepine cessation rates were derived using intention to treat data at post-treatment (defined as first post-treatment . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/91" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344632</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/27.extract]]&gt;</url>
    <title>Therapeutics - Review: buprenorphine better than &amp;#945;2 adrenergic agonists for managing opioid withdrawal</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;How effective is buprenorphine for managing the symptoms of opioid withdrawal?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-2&gt;Primary outcomes were intensity of withdrawal, duration of withdrawal treatment or length of stay, adverse effects, treatment completion and completion of withdrawal. Adverse effects were defined as clinically significant signs and symptoms of opioid withdrawal (such as vomiting and diarrhoea) plus any events that were not typical components of the opioid withdrawal syndrome (such as hypotension and dry mouth). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P id=p-4&gt;The Cochrane Central Register of Controlled Trials (&lt;EM&gt;The Cochrane Library&lt;/EM&gt;, Issue 3, 2008), MEDLINE (January 1966–July 2008), EMBASE (January 1985–2008 week 31), PsycINFO (1967–7 August 2008) and hand searches of reference lists. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P id=p-5&gt;Randomised and quasi-randomised controlled trials of buprenorphine based regimens to manage the signs and symptoms of withdrawal in people who were primarily opioid dependent. Permitted comparator interventions were different buprenorphine based interventions, reducing doses of methadone, a&lt;SUB&gt;2&lt;/SUB&gt; adrenergic agonists, symptomatic medications or placebo. Risk ratios (RR) were calculated for dichotomous outcomes and standardised mean differences (SMD) for continuous outcomes. Heterogeneity was assessed using the ?&lt;SUP&gt;2&lt;/SUP&gt; statistic, … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/27.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>392767</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/120.extract]]&gt;</url>
    <title>Therapeutics - Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is bupropion safe and effective for achieving abstinence from smoking and reducing nicotine dependence in people with schizophrenia?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-2&gt;Smoking cessation at the end of treatment and at 6 months after the start of treatment: measured by self-report and/or biochemical verification (expired carbon monoxide (CO) level); reduction in nicotine dependence at the end of treatment and at 6 months (measured by change in expired CO level and self-reported number of cigarettes smoked, and other biochemical measurements such as serum cotinine levels); change in positive, negative and depressive symptoms at the end of treatment measured using validated tools; adverse events. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources&lt;/H3&gt;
&lt;P id=p-4&gt;Cochrane Central Register of Controlled trials, MEDLINE, EMBASE and PsycINFO, from inception to 7 March 2009. Reference lists of relevant studies were also searched to identify unpublished studies, conference abstracts and trial records held by GlaxoSmithKline (manufacturer of bupropion). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis&lt;/H3&gt;
&lt;P id=p-5&gt;Randomised clinical trials (RCTs) comparing bupropion, alone or combined with other pharmacological or non-pharmacological treatments, versus control in adult smokers with schizophrenia (ICD-10 or DSM-IV criteria) were included. Studies involving people with schizophrenia who had nicotine addiction and co-morbid substance abuse disorders were also included. One of the authors searched the databases; two of the authors reviewed the retrieved publications and independently abstracted data from included studies. Authors of the studies were contacted to obtain… &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/120.full" target="_blank"&gt;Full text of this article is available&lt;/A&gt;.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321497</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/77]]&gt;</url>
    <title>Therapeutics - Review: exercise may moderately improve depressive symptoms</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is exercise as a treatment for depression? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Symptoms of depression (continuous or dichotomous outcomes). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;BR&gt;Systematic review with meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;BR&gt;MEDLINE, EMBASE, PsycINFO, Sports Discus, Cochrane Controlled Trials Register, Cochrane Database of Systematic Reviews, hand search of BMJ, JAMA, Arch Intern Med, N Engl J Med, J R Soc Med, Compr Psychiatry, Br J Psychiatry, Acta Psychiatr Scand, Br J Sports Med and of bibliographies of all retrieved articles; search to March 2007. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;BR&gt;Two reviewers independently selected and appraised randomised controlled trials of any type of exercise as a treatment for depression. Inclusion criteria: adults aged 18 years and over with depression (any method of diagnosis and any severity), studies comparing exercise with no treatment (wait-list or placebo, such as social activity) or with any other intervention (including medication, psychotherapy or complementary therapies), or where exercise was an adjunct treatment compared against . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/77" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321505</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/80]]&gt;</url>
    <title>Therapeutics - Review: High frequency repetitive transcranial magnetic stimulation improves symptoms of major depression</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the clinical efficacy of high frequency repetitive transcranial magnetic stimulation in people with major depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Depressive symptoms measured using the Hamilton Depression Rating Scale (HAMD) or the Montgomery–Asberg Depression Rating Scale (MADRS).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; &lt;BR&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; &lt;BR&gt;PubMed and Web of Science were searched from January 1980 to November 2007 for randomised controlled trials (RCTs). Reference lists of six previous meta-analyses and six reviews were hand searched.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; &lt;BR&gt;English language studies from peer reviewed journals were appraised, and RCTs in adults with major depressive episodes without psychotic features (DSM-IV) that met the following criteria were selected: random allocation, double blind, sham controlled, parallel design, intention to treat analysis, minimum of five treatment sessions of high frequency (&amp;gt;5 Hz) repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex with an intensity &amp;gt;80% motor threshold (MT) and treatment sessions completed up to 6 . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/80" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321508</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/81]]&gt;</url>
    <title>Therapeutics - Review: High frequency repetitive transcranial magnetic stimulation improves symptoms of treatment resistant major depression</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the clinical efficacy of high frequency repetitive transcranial magnetic stimulation in people with treatment resistant depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;The primary outcome was clinical response defined using a global rating scale (eg, "much improved" or "very much improved" on the Clinical Global Impression Scale (CGI)) or a set level of improvement on a continuous depression rating scale (eg, improvement of 50% or greater from baseline to end of treatment on the Hamilton Depression Rating Scale (HAMD) or the Montgomery–Asberg Depression Rating Scale (MADRS)). Secondary outcomes included depressive symptoms (end point symptom scores) and remission (defined as a score on a depression rating scale within the normal range—eg, HAMD score &amp;lt;=7, MADRS score &amp;lt;=12 or a global rating of not depressed or equivalent on the CGI).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;BR&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;BR&gt;MEDLINE, EMBASE, PsycINFO and the Cochrane Central Register of Controlled Trials were searched from inception to May 2008 for randomised controlled trials . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/81" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306966</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/12]]&gt;</url>
    <title>Therapeutics - Review: Insufficient evidence to guide use of drugs for clozapine induced hypersalivation</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is drug therapy effective for reducing clozapine induced hypersalivation?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Measurement of salivation, measured as cure, no change, endpoint salivation score or change in salivation scores. Secondary outcomes included assessment of global state, service use, mental state, general functioning, behaviour, adverse effects, engagement, quality of life, satisfaction and costs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Cochrane Schizophrenia Group Trials Register; search to March 2007.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Six reviewers independently selected and appraised RCTs comparing treatment with any pharmacological intervention versus placebo or no treatment for any condition in populations, regardless of age and gender, all of whom had identified clozapine induced hypersalivation (identified by self, carer or clinician). Disagreements were resolved by consensus (see online notes for further methodological details). Reviewers performed several meta-analyses, pooling dichotomous results and continuous data for each outcome and comparator. Only some of these results are presented here.&lt;/P&gt;
&lt;P&gt;Main results Fifteen RCTs, including . . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Sanjeev Sockalingam, Gary Remington&lt;/P&gt;
&lt;P&gt;Assistant Professor, Faculty of Medicine, University of Toronto, Toronto General Hospital, University Health Network, Psychiatry, Health and Disease Program, Canada&lt;BR&gt;Professor, Faculty of Medicine, University of Toronto, Centre for Addiction and Mental Health, Schizophrenia and Continuing Care Program, Canada &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/12" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377666</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/51.extract]]&gt;</url>
    <title>Therapeutics - Review: Is aripiprazole as effective as risperidone in people with schizophrenia?</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2 class=section&gt;Question:&lt;/H2&gt;
&lt;P id=p-1 class=section&gt;What are the effects of aripiprazole compared with other atypical antipsychotics in people with schizophrenia and schizophrenia-like psychoses? &lt;/P&gt;
&lt;H3 class=section&gt;Outcomes:&lt;/H3&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2 class=section&gt;Efficacy (as defined by each study), adverse effects.&lt;/P&gt;
&lt;H2 class="section methods"&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 class="section methods"&gt;Methods&lt;/H2&gt;
&lt;H3 class="section methods"&gt;Design:&lt;/H3&gt;
&lt;P id=p-3 class="section methods"&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;P class="section methods"&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3 class="section methods"&gt;Data sources:&lt;/H3&gt;
&lt;P class="section methods"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4 class="section methods"&gt;Cochrane Schizophrenia Group's Specialised Register was searched from inception to March 2007 for randomised controlled trials (RCTs). Reference lists of identified studies were hand searched. First authors of included studies were contacted for missing information, and drug companies were contacted for additional data. &lt;/P&gt;
&lt;H3 class="section methods"&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P class="section methods"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5 class="section methods"&gt;Reviewers appraised studies and selected RCTs comparing oral aripiprazole with oral forms of risperidone, quetiapine, olanzapine, amisulpride, aripiprazole, clozapine, sertindole, ziprasidone or zotepine in people with schizophrenia and schizophrenia-like psychoses. Data were extracted independently. Weighted mean differences (MD) were calculated for continuous data. Dichotomous data were used to calculate RR using a random-effects model. Heterogeneity was investigated using the I&lt;SUP&gt;2&lt;/SUP&gt; statistic. &lt;/P&gt;
&lt;P class="section methods"&gt;&amp;nbsp;&lt;/P&gt;
&lt;DIV id=sec-8 class="section results"&gt;
&lt;H2&gt;Main results&lt;/H2&gt;
&lt;P id=p-6&gt;Four RCTs met inclusion criteria (&lt;EM&gt;n&lt;/EM&gt; = 1,404). Data were available that compared aripiprazole with olanzapine and risperidone. Overall, 38.5% of participants left the included studies prematurely, but there were no significant differences between groups. Aripiprazole was less effective than olanzapine in terms of positive … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/51.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>377676</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/56.extract]]&gt;</url>
    <title>Therapeutics - Review: lack of evidence for the optimal dose of risperidone for schizophrenia</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;What is the most effective dose of risperidone for treating schizophrenia and schizophrenia-like psychoses?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Primary: no clinically important change in short-term global state. Outcomes were classified as short (up to 12 weeks), medium (13–26 weeks) and long term (&amp;gt;26 weeks). Secondary: early study withdrawal for any reason, global state, relapse, need for additional medication, mental state, symptom scores, general functioning, social or life skill functioning, behaviour, quality of life, satisfaction with treatment, cognitive functioning, service use, adverse events and costs of treatment.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Systematic review and meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;The Cochrane Schizophrenia Group Trials Register was searched in July 2008. Reference lists of included and excluded studies and the FDA website were also searched, and a pharmaceutical company was also contacted to locate any additional studies. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Two reviewers independently selected potentially relevant studies. Inclusion criteria were randomised controlled trials (including quasi-randomised and crossover designs) evaluating risperidone in any oral form or dose in people with schizophrenia or other types of schizophrenia-like disorders. Doses were categorised as low (2 to &amp;lt;4 mg/day), standard-lower (4 to &amp;lt;6 mg/day), standard-high (6 to &amp;lt;10 mg/day) … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/56.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>328845</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/118]]&gt;</url>
    <title>Therapeutics - Review: limited evidence that psychological therapies are of benefit for adults with chronic pain</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Are psychological therapies effective for improving pain, disability&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and mood in adults with chronic pain?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Any measurement of pain, disability or mood.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review with meta-analysis.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;The Cochrane Central Register of Controlled Trials, MEDLINE,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;EMBASE and Psychlit (from database inception to January 2008;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;an update search was later made up to August 2008).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Published randomised controlled trials (RCTs) comparing any&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;psychological treatment with placebo, waiting list control,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;or medical or physical treatment for adults (aged &amp;gt;18 years)&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;with chronic pain (x3 months’ duration; any site of the&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;body). Exclusions: pain associated with malignancy; chronic&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;headache or migraine. Two reviewers independently assessed quality&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and included studies based on consensus agreement. Studies were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;classified as cognitive behavioural therapy (CBT) or behavioural&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;therapy (BT) compared with active control (AC) or treatment&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;as usual (TAU). Outcomes were assessed immediately post-treatment&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;or at follow-up (between 6 and 12 months post-treatment). Heterogeneity&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;was assessed &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/118" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;BR&gt;&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328836</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/117]]&gt;</url>
    <title>Therapeutics - Review: limited evidence to support specialist mental health services as alternatives to inpatient care for young people with severe mental health disorders</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Do community based specialist mental health services provide&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;effective alternatives to inpatient mental health care for children&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and young adults?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Disease specific symptoms and general psychological functioning&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(using various scales including the Global Severity Index (GSI)&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of brief symptoms, Child Behaviour Checklist (CBC), Family Adaptability&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and Cohesion Evaluation Scale (FACES)), acceptability and cost.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Cochrane Effective Practice and Organisation of Care Group Specialised&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Register (2007), the Cochrane Central Register of Controlled&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Trials, MEDLINE, EMBASE, CINAHL, PsycINFO, the British Nursing&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Index and RCN database; numerous other electronic resources&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(including SIGLE, King’s Fund); hand search of child mental&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;health journals and bibliographies of retrieved articles.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two independent reviewers assessed studies for inclusion and&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;extracted data. Inclusion criteria: randomised controlled trials,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;well designed controlled before–after studies and interrupted&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;time series comparing inpatient care for young people with one&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;or more alternative specialist mental health services (beyond&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;normal outpatient provision); only studies &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/117" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317832</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/56]]&gt;</url>
    <title>Therapeutics - Review: long term psychodynamic psychotherapy improves outcomes in people with complex mental disorders</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;How effective is long term psychodynamic psychotherapy (LTPP)&lt;SUP&gt; &lt;/SUP&gt;in people with complex mental disorders?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Overall outcome, target problems, general psychiatric symptoms,&lt;SUP&gt; &lt;/SUP&gt;personality and social functioning (see notes).&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, PsycINFO and Current Contents were searched from 1960&lt;SUP&gt; &lt;/SUP&gt;to May 2008 for randomised controlled trials (RCTs) and observational&lt;SUP&gt; &lt;/SUP&gt;studies. Reference lists of identified articles and textbooks&lt;SUP&gt; &lt;/SUP&gt;were hand searched, and authors and experts contacted for further&lt;SUP&gt; &lt;/SUP&gt;information.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Two reviewers appraised the studies and selected RCTs and observational&lt;SUP&gt; &lt;/SUP&gt;studies of LTPP. Inclusion criteria: studies in adults; &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;50 sessions&lt;SUP&gt; &lt;/SUP&gt;or 1 year of LTTP; reliable outcome measures used; mental disorders&lt;SUP&gt; &lt;/SUP&gt;of participants clearly described; and sufficient data to determine&lt;SUP&gt; &lt;/SUP&gt;effect sizes. Studies with concomitant treatments were included&lt;SUP&gt; &lt;/SUP&gt;but analysed separately to compare results of combined treatments&lt;SUP&gt; &lt;/SUP&gt;versus LTTP alone. Two reviewers independently rated study quality,&lt;SUP&gt; &lt;/SUP&gt;extracted data and assessed effect sizes. Point biserial &lt;NOBR&gt;&lt;EM&gt;. .&lt;/EM&gt; .(Abstracted)&lt;/NOBR&gt;&lt;/P&gt;
&lt;P&gt;&lt;NOBR&gt;This article has been abstracted at&amp;nbsp;150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/56" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317817</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/49]]&gt;</url>
    <title>Therapeutics - Review: long term use of antidepressants for bipolar disorder reduces depressive episodes but increases risk of mania</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;What is the effectiveness of long term antidepressants in people&lt;SUP&gt; &lt;/SUP&gt;with bipolar disorder?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;New episodes of depression or mania (DSM III, DSM IV, ICD 9,&lt;SUP&gt; &lt;/SUP&gt;ICD 10 or Research Diagnostic Criteria (RDC)).&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;SUP&gt;&lt;/SUP&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;Systematic review with meta-analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;MEDLINE, EMBASE, PsycINFO, HealthStar, Current Contents, CINAHL,&lt;SUP&gt; &lt;/SUP&gt;National Library of Medicine, DARE and Cochrane Library databases&lt;SUP&gt; &lt;/SUP&gt;were searched from inception to May 2008 for randomised controlled&lt;SUP&gt; &lt;/SUP&gt;trials (RCTs). Bibliographies of reports identified by computer&lt;SUP&gt; &lt;/SUP&gt;searching, reviews on treatment of bipolar disorder (BPD) and&lt;SUP&gt; &lt;/SUP&gt;abstracts or poster presentations from selected meetings were&lt;SUP&gt; &lt;/SUP&gt;hand searched. Experts and funding agencies were contacted to&lt;SUP&gt; &lt;/SUP&gt;find data from unpublished trials, and details of trials were&lt;SUP&gt; &lt;/SUP&gt;verified with the authors where necessary.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Two reviewers appraised the studies and selected RCTs of long&lt;SUP&gt; &lt;/SUP&gt;term use of antidepressant treatment in people with BPD. Inclusion&lt;SUP&gt; &lt;/SUP&gt;criteria: diagnosis of BPD according to DSM-III, DSM IV, ICD&lt;SUP&gt; &lt;/SUP&gt;9, &lt;NOBR&gt;. . (Abstracted)&lt;/NOBR&gt;&lt;/P&gt;
&lt;P&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;NOBR&gt;This article is abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/49" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321503</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/79]]&gt;</url>
    <title>Therapeutics - Review: Maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does the risk of relapse/recurrence of major depression following antidepressant treatment post-remission depend upon the duration of continuation/maintenance treatment, the number of previous depressive episodes or the mode of discontinuation of treatment?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Relapse (within 6 months of remission) and recurrence (after 6 months of remission).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design: &lt;BR&gt;&lt;/STRONG&gt;Systematic review with meta-regression analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; &lt;BR&gt;MEDLINE, EMBASE and the Cochrane Library were searched for randomised, placebo controlled trials (RCTs) published up to May 2007. Obtained articles were hand searched for further references. Authors were contacted if required information was not available in the article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; &lt;BR&gt;The reviewers included double blind RCTs in participants with major depressive disorder treated with a selective serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant (TCA) until remission, after which they had to be randomised to either the same antidepressant or placebo for continuation/maintenance therapy. Two reviewers assessed the studies. Data were analysed using random effects . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/79" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344629</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/26.extract]]&gt;</url>
    <title>Therapeutics - Review: methadone increases retention and reduces heroin use compared with non-pharmacological maintenance</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does methadone maintenance treatment (MMT) reduce opioid dependence more than treatments not involving opioid replacement therapy? &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-2&gt;&lt;EM&gt;Primary outcomes&lt;/EM&gt;: retention in treatment, mortality, proportion of urine or hair analysis results positive for heroin or morphine, self-reported heroin use, criminal activity. &lt;EM&gt;Secondary outcomes&lt;/EM&gt;: use of other drugs, physical health, psychological health. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P id=p-4&gt;Cochrane Drugs and Alcohol Group Register of Trials (issue 4, 2008), PUBMED, EMBASE, Current Contents, PsycLIT and CINAHL were searched to December 2008. Other drug specific databases, ongoing trial registers, drug and alcohol journals, conference proceedings and reference lists were also searched. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P id=p-5&gt;Two reviewers independently selected and quality assessed randomised controlled trials of MMT compared with placebo maintenance or other non-pharmacological therapy for the treatment of opioid dependence. &lt;EM&gt;Inclusion criteria&lt;/EM&gt;: people who were opioid dependent (heroin or methadone); trials of MMT alone or with behavioural therapies or outpatient rehabilitation compared with placebo, withdrawal or detoxification (with or without ancillary medication), drug free rehabilitation treatments (such as therapeutic communities) and … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/26.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>306984</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/1/18]]&gt;</url>
    <title>Therapeutics - Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER,CONDUCT DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective are short-acting methylphenidate and psychosocial treatments, alone or in combination, for school-aged children with attention deficit hyperactivity disorder (ADHD)?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;BR&gt;&lt;/STRONG&gt;Core ADHD or oppositional defiant disorder/conduct disorder (ODD/CD) symptoms, social behaviour and academic functioning.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PubMed, PsychInfo and ISI Web of Science were searched for randomised controlled trials (RCTs) published between 1 January 1985 and 30 September 2006. Reference lists were hand searched to identify other relevant RCTs.&lt;/P&gt;
&lt;P&gt;Study selection and analysis: Eligible studies included RCTs of short acting methylphenidate and psychosocial (behavioural/cognitive behavioural) treatments in school-aged children (aged 6–12 years) with ADHD. (See online notes for list of exclusions.) Within group effect sizes were calculated (Cohen’s d), with positive effect size indicating improvement. Effect sizes were defined as small, moderate and large based on Cohen’s guidelines (0.2, 0.5 and 0.8 thresholds, respectively). Mean weighted effect size was calculated separately for each informant . . . [Full text of this article]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Peter S Jensen&lt;/P&gt;
&lt;P&gt;The REACH Institute, New York, USA&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/1/18" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392761</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/116.extract]]&gt;</url>
    <title>Therapeutics - Review: mindfulness-based therapies effective for anxiety and depression</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Does mindfulness-based therapy (MBT) reduce anxiety and depression in people with psychiatric or medical conditions?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-2&gt;Pretreatment and post-treatment effect size (ES); ES in participants with elevated levels of anxiety and depression; controlled ESs. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources&lt;/H3&gt;
&lt;P id=p-4&gt;PubMed, PsycINFO and the Cochrane Library were searched from inception to April 2009 for controlled and uncontrolled treatment studies assessing mindfulness-based interventions for anxiety, depression, mood or stress. Reference lists of identified studies and reviews were hand searched. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis&lt;/H3&gt;
&lt;P id=p-5&gt;Two reviewers appraised studies and selected trials of MBT in adults (aged 18–65 years) with a diagnosed psychological or medical disorder. Inclusion criteria: reported measures of mood symptoms, or anxiety, or both, at preintervention and postintervention; ES analyses possible from reported data and MBT not coupled with treatments involving dialectical behaviour therapy or acceptance and commitment therapy. Study quality was rated using the Jadad score. ESs were calculated using Hodges's &lt;EM&gt;g&lt;/EM&gt; and its 95% CI. ESs were interpreted as small (0.2), medium (0.5) and large (0.8) according to Cohen's convention. Where participants were not diagnosed with anxiety and … &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/116.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392779</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/127.extract]]&gt;</url>
    <title>Therapeutics - Review: mood stabilisers monotherapy as effective as combination therapy for treatment of acute bipolar depression in studies with some limitations</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What are the effects of mood stabiliser monotherapy (MTM) compared with combination and antidepressant treatment in people with acute bipolar depression? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-2&gt;Clinical response measured by =50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) or =50% reduction in Hamilton Rating Scale for Depression (HRSD) or much, or very much, improved on the Clinical Global Impressions – Improvement scale; symptom remission: endpoint MADRS =12, endpoint score of &amp;lt;9 on the HRSD plus a 50% reduction; acceptability (all-cause discontinuation); affective switch (Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria); suicidal behaviour and clinically significant weight gain.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources&lt;/H3&gt;
&lt;P id=p-4&gt;MEDLINE, EMBASE, PsycINFO, CINAHL, the Cochrane Library and the clinical trial database (www.clinicaltrials.gov) were searched from inception to January 2008 for randomised controlled trials (RCTs). Reference lists of identified studies were reviewed. Eight key journals were hand searched till April 2008. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis&lt;/H3&gt;
&lt;P id=p-5&gt;Two reviewers appraised studies and selected RCTs comparing mood stabilisers with placebo, combination therapy (mood stabilisers plus augmenting agent) or antidepressant add-on or monotherapy in adults (aged 18–65 years) with bipolar disorder and acute major depression … &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/127.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377671</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/54.extract]]&gt;</url>
    <title>Therapeutics - Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;What is the incidence of hyperprolactinaemia and prolactin-related side effects in children and adolescents taking antipsychotic drugs? &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Prolactin level, incidence of hyperprolactinaemia (defined as &amp;gt;15 ng/ml); prolactin-related side effects (sex hormones, pubertal development, neuroendocrine and sexual side effects, bone-mineral density). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Systematic review.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;MEDLINE, EMBASE, PsycINFO and EBM databases were searched from 1965 to August 2008.&lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Open-label, observational and double-blind studies examining the effects of antipsychotic drugs in children (aged =12 years) and adolescents (aged 12–18 years) on prolactin levels and prolactin-related side effects were selected. There were no restrictions on diagnoses requiring antipsychotic medication. Studies with duration of &amp;lt;3 weeks, meeting abstracts and non-English-language articles were excluded. Weighted averages were calculated by multiplying the number of patients and the matching variable in each study, and then the sum of the amounts in the different studies was divided by the total number of patients. Seven studies did not report prolactin baseline measurements, and two did not report medication-free prolactin baseline measurements; these studies were excluded from the prolactin baseline weighted … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/54.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>344634</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/29.extract]]&gt;</url>
    <title>Therapeutics - Review: multiple session early psychological interventions after trauma do not prevent PTSD</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Do multiple session early psychological interventions starting within 3 months of a traumatic event prevent post-traumatic stress disorder (PTSD)? &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-2&gt;Rates of PTSD (measured by standard classification systems).&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P id=p-4&gt;MEDLINE, EMBASE, CLINPSYCH, PSYCHLIT, PILOTS, LILACS, SOCIOFILE, CINAHL and the Cochrane Depression, Anxiety and Neurosis Group Trials Registers were searched from inception to August 2008 for randomised controlled trials (RCTs). The &lt;EM&gt;Journal of Traumatic Stress&lt;/EM&gt; and the &lt;EM&gt;Journal of Consulting and Clinical Psychology&lt;/EM&gt; were hand searched, as were reference lists of identified studies. Experts in the field were also contacted. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P id=p-5&gt;Two reviewers appraised the studies and selected RCTs of multiple session (two or more treatments) early psychological interventions or treatments designed to prevent PTSD in adults who had suffered a traumatic event within 3 months. Traumatic events were defined as threatened death, serious injury or a threat to the physical integrity of the self or others (criterion … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/29.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>317826</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/52]]&gt;</url>
    <title>Therapeutics - Review: non-pharmacological interventions reduce antipsychotic induced weight gain</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Are non-pharmacological interventions effective in controlling&lt;SUP&gt; &lt;/SUP&gt;antipsychotic induced weight gain in people with schizophrenia&lt;SUP&gt; &lt;/SUP&gt;spectrum disorders?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;I&gt;Primary:&lt;/I&gt; change in body weight; change in body mass index (BMI)&lt;SUP&gt; &lt;/SUP&gt;post-treatment; &lt;I&gt;secondary:&lt;/I&gt; body weight and BMI at follow-up.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;The following databases were searched in May 2007: Cochrane&lt;SUP&gt; &lt;/SUP&gt;Central Register of Controlled Trials, Medline, EMBASE, PsycINFO,&lt;SUP&gt; &lt;/SUP&gt;CINAHL, UMI Proquest Digital Dissertations, Information Science&lt;SUP&gt; &lt;/SUP&gt;Citation Index Expanded Information Social Sciences Citation&lt;SUP&gt; &lt;/SUP&gt;Index, Information Arts and Humanities Citation Index, registers&lt;SUP&gt; &lt;/SUP&gt;of ongoing clinical trials, ISI Science and Technology proceedings&lt;SUP&gt; &lt;/SUP&gt;and ISI Information Social Science and Humanities proceedings.&lt;SUP&gt; &lt;/SUP&gt;Hand searching of reference lists and key journals (from January&lt;SUP&gt; &lt;/SUP&gt;2000 to May 2007) was used to identify additional articles.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; The review included randomised controlled trials (RCTs) comparing&lt;SUP&gt; &lt;/SUP&gt;the efficacy of non-pharmacological interventions to care as&lt;SUP&gt; &lt;/SUP&gt;usual or an active comparator in preventing or reducing weight&lt;SUP&gt; &lt;/SUP&gt;gain associated &lt;NOBR&gt;&lt;EM&gt;. .&lt;/EM&gt; .&lt;/NOBR&gt; (Abstracted)&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/52" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392771</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/124.extract]]&gt;</url>
    <title>Therapeutics - Review: pharmacological and psychological interventions decrease cannabis use in people with depressive and psychotic disorders in the short term</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ACUTE PSYCHOTIC DISORDERS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,DEPRESSION,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Do pharmacological or psychological interventions improve cannabis use outcomes in people with psychotic or depressive disorders?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-2&gt;Cannabis use.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources&lt;/H3&gt;
&lt;P id=p-4&gt;PubMed (from commencement) and PsycINFO (from commencement) to December 2008.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis&lt;/H3&gt;
&lt;P id=p-5&gt;Randomised controlled trials (RCTs) of pharmacological or psychological interventions reporting cannabis use outcomes in people with psychotic or depressive disorders were included in the review. Exclusions: non-English language studies. &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV id=sec-8 class="section results"&gt;
&lt;H2&gt;Main results&lt;/H2&gt;
&lt;P id=p-6&gt;Seven trials met inclusion criteria. Two RCTs reported cannabis use outcomes following pharmacological interventions: one in people with major depression, alcohol dependence and cannabis abuse diagnoses (n=22; fluoxetine vs placebo) and one in people with schizophrenia and cannabis and/or cocaine use disorders (n=28; olanzapine vs risperidone). Psychotherapy was included for all participants, and neither study assessed a pharmacological intervention specifically designed to reduce cannabis use. In the … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/124.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344623</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/19.extract]]&gt;</url>
    <title>Therapeutics - Review: pharmacotherapy increases response and reduces symptom severity in paediatric anxiety disorders</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EMOTIONAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;What is the efficacy and tolerability of pharmacotherapy for paediatric anxiety disorders?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-2&gt;Response (score of 1 or 2 (much or very much improved) on the Clinical Global Impressions-Improvement scale); symptom severity or investigator defined response on closely related measures; symptom severity (clinician rated DSM based anxiety scales such as the Child Yale-Brown Obsessive-Compulsive Scale); adverse events. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review and meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P id=p-4&gt;Cochrane Depression, Anxiety and Neurosis Group specialised register (CCDANCTR-Studies), MEDLINE (from 1966), EMBASE (from 1966) and PsycINFO (from 1972) were searched in August 2008. Reference lists of retrieved articles were hand searched; ongoing and unpublished studies were identified through electronic registers and contact with experts. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P id=p-5&gt;Placebo controlled randomised controlled trials (RCTs) of pharmacotherapy in children and adolescents (aged &amp;lt;18 years) with primary diagnoses of anxiety disorders (DSM-III or later). Studies where participants were receiving psychotherapy or pharmacotherapy for secondary psychiatric disorders were excluded. Authors were contacted if required. Two reviewers decided on the inclusion of studies. Meta-analyses were stratified by drug class and also by individual selective serotonin reuptake inhibitors (SSRIs). Random effects models were used for meta-analyses, and heterogeneity assessed using the ? … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/19.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>321486</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/76]]&gt;</url>
    <title>Therapeutics - Review: relaxation better than wait-list, minimal or no treatment for depression but not as good as psychological treatments</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do relaxation techniques have an effect on depressive symptoms and outcomes compared with other treatment approaches?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Symptoms of depression on a validated, reliable, self-rated and clinician rated depression symptoms scale (see online notes).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;BR&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;BR&gt;Cochrane Depression, Anxiety and Neurosis Group registers; search to February 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; &lt;BR&gt;Two reviewers independently selected and appraised randomised or quasi-randomised controlled trials (including crossover trials and cluster randomised trials). Inclusion criteria: patients of any age, primary diagnosis of depression (based on Feighner criteria, Research Diagnostic criteria, DSM-III or ICD 10 onwards, or depression symptoms), including those with depression comorbid to a secondary medical condition, studies comparing relaxation techniques (progressive muscle relaxation, relaxation imagery, autogenic training or combinations or enhancements of these) or adjunct relaxation therapies with control conditions (including wait-list, no treatment or minimal treatment, psychological treatment, lifestyle and complementary therapies or medication). Exclusion criteria: studies . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/76" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298015</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/3/81]]&gt;</url>
    <title>Therapeutics - Review: Response to SSRIs in unipolar depression occurs in the first week of treatment</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Taylor MJ, Freemantle N, Geddes JR, et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63:1217–23.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Is treatment response delayed for selective serotonin reuptake inhibitors in moderate to severe unipolar depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Cochrane CENTRAL; reference lists of RCTs; reference lists of other systematic reviews. Search date: Cochrane library, issue 1, 2005.&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Randomised controlled trials (RCTs) comparing UK licensed selective serotonin reuptake inhibitors (SSRIs) versus placebo for short-term treatment of moderate to severe unipolar depression, reporting outcomes for at least two time points in the first 4 weeks of treatment were included. Trials solely in adults aged over 65 years or with specific comorbidities were excluded. Standardised effect sizes on depressive symptom rating scales were calculated for each weekly time point for the first 6 weeks. Primary analyses were performed on scales reflecting primary outcomes. Five models of treatment effect were proposed: sudden onset response at week 4; step function response at week 4 and linearly increasing treatment effect; linearly increasing treatment effect; logarithmically increasing treatment effect defined as log (week); or treatment effect defined as a function of week. Autoregressive variance function and Akaike information criteria were used to select the model that best fit pooled results. The SAS9.12 Proc Mixed program was used for analyses.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Primary outcome: best fit model for effect on depressive symptoms. Secondary outcomes: Hamilton Depression Rating Scale (HDRS) score, Montgomery–Asberg Depression Rating Scale (MADRS) score.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Fifty RCTs met inclusion criteria (n = 10,121); only 28 RCTs had sufficient data for the primary analysis (n = 5872). The model best fitting the data on depression symptoms was logarithmically increasing treatment response—that is, the greatest absolute treatment response occurred in the first week, with absolute incremental response decreasing in subsequent weeks (p&amp;lt;=0.004 for comparisons with other models). In secondary analyses on the HDRS (25 RCTs) and MADRS scales (16 RCTs), treatment response to SSRIs was seen in week 1, with further decreases in symptom score by week 6 compared with placebo (weighted mean difference in HDRS score at week 1 (n = 1893): –1.07, 95% CI –1.69 to –0.44; at week 6 (n = 3432): –3.3, 95% CI –4.14 to –2.45; weighted mean difference in MADRS score at week 1 (n = 2062): –0.84, 95% CI –1.36 to –0.32; at week 6 (n = 3159): –3.25, 95% CI –4.11 to –2.39).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Onset of treatment response to SSRIs is not delayed in people with moderate to severe unipolar depression, with the greatest improvement in the first week and continued, but decreasing, improvements in subsequent weeks.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321520</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/90]]&gt;</url>
    <title>Therapeutics - Review: Second generation antipsychotics are a heterogeneous drug class</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Are second generation antipsychotic drugs more effective than first generation antipsychotic drugs for people with schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Overall efficacy (changes in Positive and Negative Syndrome Scale or in Brief Psychiatric Rating Scale), positive, negative and depressive symptoms, quality of life and relapse rates. Other outcomes were extrapyramidal side effects, weight gain and sedation property.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; &lt;BR&gt;Systematic review and meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; &lt;BR&gt;The Cochrane Schizophrenia Group Trials Register, FDA website and MEDLINE, from August 2005 to October 2006. Previous reviews were also used to identify additional references.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis: &lt;BR&gt;&lt;/STRONG&gt;Only double blind randomised controlled trials (RCTs), comparing first (FGA) and second (SGA) generation antipsychotic drugs in people with schizophrenia or related disorders were included. Main exclusions: single blind and open label trials and trials with inadequate randomisation. Data were independently extracted by two reviewers. Results of individual studies were combined and meta-analysed using a random effects model. Continuous data were . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/90" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298059</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/114]]&gt;</url>
    <title>Therapeutics - Review: Slow repetitive transcranial magnetic stimulation reduces auditory hallucinations in people with schizophrenia</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J Clin Psychiatry 2007;68:416–21.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does slow repetitive transcranial magnetic stimulation reduce auditory hallucinations in people with schizophrenia?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PubMed and Web of Science; search date February 2006.&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; Parallel or crossover randomised controlled trials (RCTs) of slow repetitive transcranial magnetic stimulation (rTMS) versus sham control in people with schizophrenia that used appropriate rating scales for auditory hallucination. As hallucinations were measured pre- and post-treatment and not all studies used the same hallucination rating scale, standardised mean gain effect sizes were calculated. In the meta-analysis, effect sizes were weighted according to sample size. Heterogeneity was assessed using Q statistic. Sensitivity analyses were performed if there was significant heterogeneity.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Auditory hallucinations (measured using scales such as Auditory Hallucinations Rating Scale, Hallucination Change Scale, or hallucination items from Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale); all positive symptoms (PANSS positive subscale or Scale for Assessment of Positive Symptoms).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;BR&gt;&lt;/STRONG&gt;The review included 10 RCTs (212 people), all of which used 1 Hz rTMS directed at the left temporoparietal cortex. In people with schizophrenia, the review found that rTMS reduced severity of auditory hallucinations compared with sham control (mean standardised gain effect size (d) 0.76, 95% CI 0.36 to 1.17; p = 0.0001; heterogeneity: Q = 21.4; p = 0.01). Sensitivity analysis revealed that excluding one study of insertion of multiple pauses between treatments (continuous simulation studies remaining) removed heterogeneity (d = 0.88, 95% CI 0.52 to 1.23; p&amp;lt;0.0001; Q = 12.2; p = 0.14). Similar results were found for parallel group design (five RCTs; 149 people; d = 0.63, 95% CI 0.3 to 0.97; p = 0.0001) and crossover design (five RCTs; 63 people; d = 0.93, 95% CI 0.17 to 1.69; p = 0.009). There was no significant difference in severity of all positive symptoms between rTMS and sham control (six RCTs; 134 people; d = +0.21, 95% CI –0.29 to +0.72; p = 0.20).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;In people with schizophrenia, rTMS reduces severity of auditory hallucinations compared with sham control. However, it does not affect severity of overall positive symptoms.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321500</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/78]]&gt;</url>
    <title>Therapeutics - Review: St John's wort superior to placebo and similar to antidepressants for major depression but with fewer side effects</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Is St John’s wort (hypericum) an effective treatment for major depression?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;Proportion of responders at end of treatment or at study endpoint if treatment was longer than 6 weeks (based on score improvements on Hamilton Rating Scale for Depression (HAMD), the Clinical Global Impression index (CGI), rating as at least "much improved" on global improvement subscale, Depression Scale von Zerssen (DS) or any other clinical response measure); safety (proportion of dropouts due to adverse events).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; &lt;BR&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; &lt;BR&gt;Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (search to July 2007), Cochrane Field for Complementary Medicine database, MEDLINE (1983–2008), EMBASE (1989–2008), PsycLIT and PsycINDEX (1987–1997), Phytodok (private database, Munich), hand search of bibliographies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; &lt;BR&gt;Two reviewers assessed studies. Inclusion criteria: randomised, controlled, double blind trials of hypericum extracts versus placebo or versus standard antidepressants in people with major depression (DSM-IV . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/78" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224365</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/6/4/126]]&gt;</url>
    <title>Therapeutics - Review: stress is a problem for mental health nurses but research on interventions is insufficient</title>
    <publicationDate>2003-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;BR&gt;&lt;/STRONG&gt;Edwards D, Burnard P.A systematic review of stress and stress management interventions for mental health nurses.J Adv Nurs 2003;42:169–200&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Do mental health nurses experience occupational stress? Are stress management interventions effective?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with narrative synthesis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Studies were identified using PUBMED, EMBASE, SCISearch, Pascal, CINAHL, ASSIA, PsychLit, Clin Psych, Heathstar, Cochrane Library, British Nursing Index, SIGLE, and the National Research Register. Reference lists and selected nursing journals were hand searched and key authors contacted.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection:&lt;/STRONG&gt; Eligible studies comprised primary research mainly conducted in the UK and published in English between 1966 and 2000. 7 studies completed after the search date were also included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data extraction:&lt;/STRONG&gt; Data were extracted on outcome measures and scales (stressors, burnout, coping, moderators, job satisfaction, psychological disturbance) and other study findings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main results:&lt;/STRONG&gt; 77 studies were included in the review. They suggested that sources of stress for mental health nurses included workload, poor resources, role conflict, job insecurity and client issues. Lower stress was associated with a good support network (including supervision at work, a good home life, or both) and external interests. Single studies suggested that beneficial interventions might include training in behavioural therapy techniques, therapeutic skills, psychosocial interventions, relaxation, and stress management. The review found a dearth of large, high quality studies and studies about organisational interventions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;There is insufficient good quality research about stress management interventions. Results cannot be generalised due to problems with the methods of existing research including heterogeneity and low power.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224361</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/6/4/122]]&gt;</url>
    <title>Therapeutics - Review: therapeutic relationship is modestly correlated with treatment outcome in child and adolescent psychotherapy</title>
    <publicationDate>2003-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Shirk S, Karver M.Prediction of treatment outcome from relationship variables in child and adolescent therapy: a meta-analytic review.J Consult Clin Psychol. 2003;71:452–464&lt;BR&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Do therapeutic relationship variables predict treatment outcomes in child and adolescent psychotherapy?&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; The reviewers searched PsychInfo, ERIC, Medline and Dissertation Abstracts. The Journal of Abnormal Child Psychology, Journal of Clinical Child Psychology, Journal of Consulting and Clinical Psychology, Journal of the Academy of Child and Adolescent Psychiatry, and reference lists of 2 previous reviews were hand searched.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection:&lt;/STRONG&gt; Clinical studies presenting a quantifiable measure of the association between therapeutic relationship variables and treatment outcomes in children or adolescents were eligible. Studies had to include at least 5 participants, and be presented in English. Treatments meeting inclusion criteria were parent management training, individual therapy and family therapy. Studies examining the association of relationship variables with session quality or impact were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data extraction:&lt;/STRONG&gt; Data on study design, treatment characteristics and participants’ age, gender and diagnosis, were extracted by two independent reviewers and coded for methodological quality. Most studies reported results as correlations. The product-moment correlation coefficient r was used to estimate effect size. Results were converted to Fisher’s Z equivalents and weighted in proportion to the number of participants in the study. These results were re-converted to r to aid comparison.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main results&lt;BR&gt;&lt;/STRONG&gt;23 studies met the inclusion criteria. Median sample size was 47, median length of treatment was 19 sessions. The product-moment correlation coefficient r for the association between therapeutic relationship variables and treatment outcomes was 0.24, giving a weighted effect size of 0.21 (a modest effect). This is similar to the effect size for the equivalent association in adult populations. This effect was not altered by the age of participants, the type of therapy (behavioural versus non-behavioural, or individual versus family versus parent), but was more marked among children and adolescents with externalising than internalising disorders (p&amp;lt;0.05).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;The therapeutic relationship has a fairly consistent, small effect as a non-specific contributing factor to the ultimate outcome of child and adolescent psychotherapy across age groups and type of therapy. However, the studies reviewed did not compare the size of this effect with the contribution of specific items of therapy, such as completion of therapy tasks, so the relative importance of each item is unknown.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377674</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/55.extract]]&gt;</url>
    <title>Therapeutics - Review: There is no evidence that psychosocial interventions prevent disability after traumatic physical injury</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POST-TRAUMATIC STRESS DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;Are psychosocial interventions effective in preventing physical, mental and social disability after a traumatic physical injury?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Primary: extent of physical disability, mental health status, quality of life and physical and social functioning, and measured using validated instruments. Secondary: social functioning such as social participation, employment status and healthcare utilisation. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Systematic review.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;The Cochrane Injuries Group Specialised Register, CENTRAL, MEDLINE (including PUBMED), EMBASE, PsycINFO, SSCI and the Controlled Trials metaRegister were searched up to January or February 2008. Reference lists of the selected papers were also searched, and there were no restrictions by date, language or publication status. &lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;Two reviewers independently selected potentially relevant studies. Inclusion criteria were randomised controlled trails (RCTs) of any design evaluating psychosocial interventions in people who had suffered a traumatic physical injury. Psychosocial interventions included therapies such as cognitive-behavioural therapy (CBT) or counselling and social interventions such as befriending or mentoring. Comparators were usual care, pharmacological treatments or physical interventions alone or in combination. Trials that involved the following types of subjects were excluded: people with traumatic brain injury who needed a physical, economic or complex … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/55.full" target="_blank"&gt;Full text of the article&lt;/A&gt; us available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>298044</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/110]]&gt;</url>
    <title>Therapeutics - Review: Training patients to recognise and manage early warning signs delays recurrence of bipolar disorder</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Morriss RK, Faizal MA, Jones AP, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007;1:CD004854.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; How effective are interventions aimed at training adults with bipolar disorder to recognise the early warning signs of recurrence?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD&lt;BR&gt;Design:&lt;/STRONG&gt; Systematic review with meta-analysis.&lt;BR&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (search date October 2005), UK National Research Register, hand searches of the journal Bipolar Disorders and reference lists, and contact with study authors.&lt;BR&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt; The review included randomised controlled trials (RCTs) comparing training to recognise and manage early warning signs (EWS) of bipolar disorder recurrence plus treatment as usual (TAU) versus TAU alone or TAU plus another psychological therapy (control) in adults with a primary diagnosis of bipolar disorder (diagnosed using standard criteria, such as ICD-10, DSM-IV, or Research Diagnostic Criteria). For inclusion, EWS interventions needed to include at least one hour of face-to-face clinical contact, and could be part of a larger package of interventions. Time to event outcomes were summarised using hazard ratios, and a random effects model was used if there was significant heterogeneity. Sources of heterogeneity were investigated using subgroup analysis and meta-regression.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Time to first recurrence (any episode).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;The review identified 11 RCTs, six of which reported on time to first recurrence (690 people). In the majority of these six RCTs the early warning signs training was the main focus of the intervention (five RCTs), was delivered to the patient only (five RCTs), and was delivered individually (three RCTs). Treatment as usual included visits to psychiatrist and medication in all RCTs, as well as non-specific group sessions in two RCTs as an attention control. Early warning signs interventions significantly increased time to first bipolar recurrence compared with control (HR 0.57, 95% CI 0.39 to 0.82, random effects analysis). There was significant heterogeneity in this analysis (p = 0.006; I2 = 69.2%), which was removed if analysis was restricted to only those RCTs which recruited people at least a month after the end of an acute episode, rather than recruiting during an episode. Other factors, such as the type of control group used, were not found to contribute significantly to this heterogeneity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Training adults to recognise and manage the early warning signs of bipolar disorder recurrence increases time to recurrence compared with treatment as usual (with or without a non-specific attention control).&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377668</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/53.extract]]&gt;</url>
    <title>Therapeutics - Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3 class=section&gt;Question:&lt;/H3&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1 class=section&gt;What are the effects of ziprasidone compared with other atypical antipsychotics in people with schizophrenia and schizophrenia-like psychoses? &lt;/P&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3 class=section&gt;Outcomes:&lt;/H3&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2 class=section&gt;Global state: no clinically important response (as defined by each study eg, &amp;lt;50% reduction on a rating scale, or global impression less than much improved); leaving study early (for any reason such as adverse events, inefficacy of treatment, weight gain etc.). &lt;/P&gt;
&lt;H3 class=section&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=section&gt;Methods&lt;/H2&gt;
&lt;H3 class=section&gt;Design:&lt;/H3&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3 class=section&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=section&gt;Data sources:&lt;/H2&gt;
&lt;P id=p-4 class=section&gt;Cochrane Schizophrenia Group's Specialised Register was searched from inception to April 2007 for randomised controlled trials (RCTs). Reference lists of identified studies were hand searched. The first authors of the included studies were contacted for missing information, and drug companies were contacted for additional data. &lt;/P&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 class=section&gt;Study selection and analysis:&lt;/H2&gt;
&lt;P class=section&gt;Reviewers appraised studies and selected RCTs that compared oral ziprasidone with oral forms of risperidone, quetiapine, olanzapine, amisulpride, aripiprazole, clozapine, sertindole or zotepine in people with schizophrenia and schizophrenia-like psychoses. There were no restrictions on dose and language. Data were extracted independently. Weighted mean differences (MDs) were calculated for continuous … &lt;/P&gt;
&lt;P class=section&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=section&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/53.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHES accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328817</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/107]]&gt;</url>
    <title>Therapeutics - Review:Clinically important differences between antidepressants</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;What are the effects of the 12 most commonly prescribed new&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;generation antidepressants for moderate to severe major depression&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in adults?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Response to treatment at 8 weeks, defined as the proportion&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of patients having a 50% or greater reduction from baseline&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in Hamilton Depression Rating Scale or Montgomery–Asberg&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;depression rating scale or those scoring "much improved" or&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;"very much improved" on the clinical global impression; discontinuation&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;as a measure of acceptability of treatment defined as the number&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of patients who terminated the study early for any reason during&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;the first 8 weeks of treatment.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review with meta-analysis (pairwise with random effects&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;model and mixed treatment meta-analysis).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Cochrane Collaboration Depression, Anxiety and Neurosis Controlled&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Trials registers (searched November 2007).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Randomised controlled trials comparing any of the following&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;new generation antidepressants being used as monotherapy to&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;treat adults with unipolar major depression: duloxetine, velanfaxine,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;sertraline, bupropion, citalopram, escitalopram, fluoxetine,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;minacipran, &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/107" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328823</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/111]]&gt;</url>
    <title>Therapeutics - Review:Lamotrigine may be an effective treatment for clozapine resistant schizophrenia</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Is lamotrigine an effective and safe augmentation treatment&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in schizophrenic patients who are resistant to clozapine?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Total symptom score, positive and negative subscales of the&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Rating Scale (BPRS), and adverse events.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review with meta-analysis.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;The Cochrane Schizophrenia Group’s PsiTri database was&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;searched without year or language limits. This database includes&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;trials identified from regular searches of MEDLINE, EMBASE,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;CENTRAL, CINAHL, PsycINFO and BIOSIS Inside as well as conference&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;proceedings and relevant journals. Clinical trials registers,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;relevant journals and reference lists of included studies were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;also searched and authors were contacted for further information.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Randomised controlled trials in people with schizophrenia receiving&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;clozapine, which compared lamotrigine with placebo, were included.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;It was not reported how many reviewers selected the studies.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Two reviewers independently extracted the data and assessed&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;study quality based on the level of allocation concealment;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;studies at &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/111" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&amp;nbsp;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328827</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/112]]&gt;</url>
    <title>Therapeutics - Review:Limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;What is the effect of adding antipsychotics to clozapine in&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;people with schizophrenia? Does absence of double blindness&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;exaggerate estimates of treatment effect?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Standardised mean difference of group mean changes in the Positive&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and Negative Symptoms Scale or the Brief Psychiatric Rating&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Scale score, either from baseline to endpoint or at the end&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of the trial; treatment failure, defined as the proportion of&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;people with no clinically significant response in global state.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review with meta-analysis.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Cochrane Schizophrenia Group Trials Register, MEDLINE and EMBASE&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;were searched from inception to November 2007 for randomised&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;controlled trials (RCTs). Reference lists of identified studies&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;were hand searched.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two reviewers appraised studies and selected RCTs comparing&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;clozapine plus placebo or clozapine alone with clozapine plus&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;another antipsychotic in adults (aged 18 years and over) with&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;a diagnosis of schizophrenia or related disorders. There were&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;no language restrictions. Participants had psychotic symptoms&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;that had &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/112" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328851</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/122]]&gt;</url>
    <title>Therapeutics - Review:Limited evidence to support pharmacological therapy for amphetamine withdrawal</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Is pharmacological therapy, alone or in combination with psychosocial&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;treatment, effective for amphetamine withdrawal?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Discontinuation rates, average global state score (eg, Clinical&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Global Impression), average score on withdrawal symptomatology&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;assessments (eg, Amphetamine Withdrawal Questionnaire), average&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;score in craving rating scales (eg, Questionnaire for Evaluating&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Cocaine Craving and Related Responses) and patient satisfaction&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;(measured by type and number of adverse events).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review with meta-analysis.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;The Cochrane Central Register of Controlled Trials, MEDLINE,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;PsycINFO and CINAHL (searched from inception to 1 May 2008).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Reference lists of identified studies and conference proceedings&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;were hand searched.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two independent reviewers appraised the studies and selected&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;randomised controlled trials comparing any kind of pharmacological&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;treatment, alone or in combination with a psychosocial treatment,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;placebo or any psychosocial treatment for amphetamine withdrawal.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Studies of other drugs in addition to amphetamine were included&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;provided &amp;gt;50% of participants were withdrawing from amphetamine&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and there was separate reporting &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/122" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;BR&gt;&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328832</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/113]]&gt;</url>
    <title>Therapeutics – Review:Rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer’s</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Is rivastigmine effective for the treatment of Alzheimer’s&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;disease?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Cognitive function (measured by psychometric tests); dependency;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;global impression; functional performance; behavioural disturbance;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;quality of life; rates of institutionalisation; effect on carer;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;acceptability of treatment as measured by withdrawal from trials;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;adverse effects; death.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review with meta-analysis.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;The Specialised Register of the Cochrane Dementia and Cognitive&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Improvement Group (searched from date of inception to December&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;2005). The Cochrane Library, MEDLINE, PsycINFO, EMBASE, CINAHL&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and LILACS were searched for records added after December 2005&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to March 2008; ongoing and other unpublished trials searched&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;through Novartis, FDA, EMEA, NICE, Google and Copernic websites.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Randomised, double blind, placebo controlled trials of rivastigmine&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;administered to patients with Alzheimer’s disease or probable&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Alzheimer’s disease (fulfilling DSM-IV or NINCDS-ADRDA)&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;for more than 2 weeks. Exclusions: non-randomised trials; no&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;allocation concealment. A single reviewer selected studies and&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;assessed the quality of included trials on the basis &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/113" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328835</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/116]]&gt;</url>
    <title>Therapeutics - Review:School based prevention and early intervention programmes reduce anxiety</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Do school based prevention and early intervention programmes&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;effectively reduce symptoms of anxiety?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Anxiety symptoms; diagnosis of anxiety.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;PsycINFO, Cochrane Library and PubMed were searched from 1987&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to February 2008 for randomised controlled trials (RCTs). Reference&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;lists of identified studies were hand searched.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;The primary author appraised studies and selected RCTs of structured&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;school based programmes with a primary outcome of building resilience&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to anxiety symptoms, reducing or preventing anxiety symptoms&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in children (aged 5–12 years) and adolescents (aged 13–19&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;years). Studies had to be published in English language peer&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;reviewed journals to be included. Two reviewers rated study&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;quality and extracted data. Standardised effect size (ES) estimates&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;were calculated using Cohen’s d or phi (for dichotomous&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;outcomes) to compare the efficacy and effectiveness of the early&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;intervention and prevention programmes. A Cohen’s d ES&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of 0.8 is considered large, 0.5 is considered moderate and 0.2&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;small. &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/116" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328833</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/114]]&gt;</url>
    <title>Therapeutics - Review:Statins do not protect against development of dementia</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Are statins effective for prevention of dementia?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Objective diagnosis of dementia, Alzheimer’s disease or&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;vascular dementia using standardised criteria; or change in&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Mini-Mental State Examination (MMSE), Alzheimer’s Disease&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Assessment Scale-Cognitive or other standardised tests of cognitive&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;performance in patients at risk of Alzheimer’s disease/vascular&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;dementia.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Systematic review.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;MEDLINE, EMBASE, The Specialised Register of the Cochrane Dementia&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;and Cognitive Improvement Group, The Cochrane Library, PsycINFO,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;CINAHL and LILACS (searched from inception to October 2007),&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;in addition to conference proceedings, theses and ongoing trials.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Study selection and analysis:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two reviewers independently selected and appraised double blind,&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;randomised, placebo controlled trials comparing any statin with&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;placebo (administered for a minimum of 12 months) in people&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;with normal cognitive function but of sufficient age to be at&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;risk of Alzheimer’s disease (including those at risk of&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;cerebrovascular disease). Exclusions: direct comparison trials&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;or those without a control group.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_one&gt;&lt;STRONG&gt;Main results&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Two randomised placebo controlled trials were eligible for inclusion:&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;&lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&lt;/I&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;NOBR&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/114" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298049</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/116]]&gt;</url>
    <title>Therapeutics - Rivastigmine three times daily improves cognition and response in Alzheimer’s disease</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEMENTIA,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Feldman HH, Lane R. Rivastigmine: a placebo–controlled trial of BID and TID regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007 Mar 12.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; What is the efficacy and safety of rapidly titrated rivastigmine compared to placebo, when administered twice or three times daily in people with mild to moderate Alzheimer’s disease?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design&lt;/STRONG&gt;: Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Unclear.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Double blinded.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Twenty six weeks (treatment period only).&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Thirty seven research centres, Australia, Canada, Ireland, Italy, South Africa, and the UK; time period not stated.&lt;BR&gt;Patients: 678 community dwelling adults aged &amp;gt;=50 years with Alzheimer’s disease (AD; meeting both DSM-IV criteria and criteria for "probable" Alzheimer’s disease of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders Association), and who had a Mini-Mental State Examination score of 10–26. Exclusions: severe obstructive pulmonary disease, cardiac disease, or other life threatening condition; use of anticholinergic drugs, insulin, psychotropics (with some exceptions), supplements containing acetylcholine precursors, or supposed memory enhancers.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Rivastigmine either twice (BID) or three times daily (TID) or placebo. Rivastigmine dose was titrated rapidly, starting at a dose of 2 mg/day and increased by 1 mg/day at weekly intervals, over 10–12 weeks, to 12 mg/day, or maximum dose tolerated. Mean dose at 26 weeks was 9.6 mg/day in the TID group and 8.9 mg/day in the BID group.&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Change in cognitive function (change from baseline in cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog); score range 0–70, higher score indicates greater impairment); global response (defined as Clinician Interview Based Impression of Change incorporating caregiver information scale (CIBIC-Plus) score &amp;lt;4; score range 1 (markedly improved) to 7 (markedly worsened)); adverse events.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 82% completed treatment (83% of TID rivastigmine group; 76% BID rivastigmine group; 85% placebo group); 100% included in intention to treat (ITT) analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Rivastigmine BID and TID significantly improved cognitive function compared to placebo at 26 weeks (mean ADAS-cog score change from baseline: –0.2 with rivastigmine TID vs +1.2 with rivastigmine BID vs +2.8 with placebo; p&amp;lt;=0.001 for TID vs placebo; p&amp;lt;0.05 for BID vs placebo; ITT analysis). Rivastigmine TID also significantly increased the proportion of people showing global response compared with placebo at 26 weeks (% responders: 31% with rivastigmine TID vs 19% with placebo; p&amp;lt;0.05). Both rivastigmine dose regimes increased adverse events, but only rivastigmine BID significantly increase withdrawals (adverse events: 91.6% with rivastigmine TID vs 91.2% with rivastigmine BID vs 76.1% with placebo; p&amp;lt;0.05; withdrawals due to adverse events: 10.6% with rivastigmine TID vs 16.7% with rivastigmine BID vs 9.0% with placebo; p&amp;lt;0.05 for rivastigmine BID vs placebo).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Rapidly titrated rivastigmine improves cognition in mild to moderate Alzheimer's disease, when administered either twice or three times daily compared to placebo. Rivastigmine three times daily, increases global response compared with placebo, while twice daily rivastigmine increases withdrawals due to adverse events.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317800</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/47]]&gt;</url>
    <title>Therapeutics - School based intervention improves PTSD symptoms in children affected by political violence</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ CHILD AND ADOLESCENT CONDITIONS,EMOTIONAL DISORDERS,MENTAL HEALTH,DETERMINANTS,OUTCOMES,AGE GROUPS,YOUNG PEOPLE,CHILDREN,POST TRAUMATIC STRESS,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,SOCIAL DETERMINANTS,MONTHLY ADDITIONS,POPULATIONS,GROUPS,2009 SEPTEMBER,ABUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;What is the efficacy of a school based intervention on the psychosocial&lt;SUP&gt; &lt;/SUP&gt;wellbeing of children in violence affected communities?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;495 children (mean age 9.9 years (range 7–15), 51% boys),&lt;SUP&gt; &lt;/SUP&gt;selected from 14 randomly selected schools within Poso, Indonesia,&lt;SUP&gt; &lt;/SUP&gt;an area affected by communal violence since 1998. For inclusion,&lt;SUP&gt; &lt;/SUP&gt;children had to have been exposed to at least one violent event&lt;SUP&gt; &lt;/SUP&gt;and show symptoms of post-traumatic stress disorder (PTSD) and&lt;SUP&gt; &lt;/SUP&gt;anxiety. Exclusions: children displaying violent behaviour,&lt;SUP&gt; &lt;/SUP&gt;unable to follow instructions, mutism, substance abuse, psychosis,&lt;SUP&gt; &lt;/SUP&gt;panic or phobic disorders, mental retardation, dissociative&lt;SUP&gt; &lt;/SUP&gt;disorders or epilepsy without medication.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;14 secondary schools in the Poso district, Central Sulawesi,&lt;SUP&gt; &lt;/SUP&gt;Indonesia; March to December 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;School based group psychosocial intervention (237 children from&lt;SUP&gt; &lt;/SUP&gt;seven schools) or wait-list control (258 children from seven&lt;SUP&gt; &lt;/SUP&gt;schools). The psychosocial intervention consisted of 15 group&lt;SUP&gt; &lt;/SUP&gt;sessions over 5 weeks (about 15 children per group) of a manual&lt;SUP&gt; &lt;/SUP&gt;classroom based intervention. The &lt;NOBR&gt;&lt;EM&gt;.&lt;/EM&gt; . (Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/47" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>344619</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/15.extract]]&gt;</url>
    <title>Therapeutics - School based prevention programme may reduce depressive episodes in adolescents at risk</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,DEPRESSIVE DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does participation in a prevention programme conducted in school reduce episodes of depressive disorders among adolescents?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;171 adolescents who were aged 14 or 15 years at the start of the study (52% female). Eligible students were those considered at risk for major depressive disorders (MDD), indicated by scoring between the 75th and 90th percentile on the Children's Depression Inventory (CDI) or on or over the 75th percentile of the negative component of the Children's Attributional Style Questionnaire (CASQ). Students with MDD, dysthymia or other psychiatric disorders or serious suicide ideation were excluded. &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Ninth grade classes in Icelandic schools; 2001–2005.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;Depression prevention programme or treatment as usual (TAU). The programme was delivered using a manual/homework book for the students over 14 or 15 sessions in the school setting but outside regular classes. The programme focused on adaptive and resilience coping strategies to enhance self-esteem and well being in order to prevent an episode of MDD. Handouts, comedy videos, posters and a relaxation tape were also used. Sessions were … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/15.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383469</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/84.extract]]&gt;</url>
    <title>Therapeutics - Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Are second generation antipsychotics superior to first generation antipsychotics for reducing family burden associated with schizophrenia? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;623 family caregivers of patients with schizophrenia (SCID diagnosed) enrolled in the CATIE trial. Main exclusions for patients: schizoaffective disorder, first episode schizophrenia, treatment resistant schizophrenia, mental retardation or other cognitive disorder. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;57 US sites; January 2001 to December 2004.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;First generation antipsychotic (FGA: perphenazine) or one of four second generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, or ziprasidone). Ziprasidone only became a treatment option after 40% of patients had been enrolled, and individuals with tardive dyskinesia (TD) were not eligible for randomisation to perphenazine. Analyses of four different datasets were carried out to ensure that participants had equal chance of being randomised to each of the groups being compared: perphenazine versus the three SGAs available at the start of the study (excluded participants with TD and those receiving ziprasidone); the three SGAs available at the start of the study versus each other; … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/84.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>383469</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/84.extract]]&gt;</url>
    <title>Therapeutics - Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Are second generation antipsychotics superior to first generation antipsychotics for reducing family burden associated with schizophrenia? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;623 family caregivers of patients with schizophrenia (SCID diagnosed) enrolled in the CATIE trial. Main exclusions for patients: schizoaffective disorder, first episode schizophrenia, treatment resistant schizophrenia, mental retardation or other cognitive disorder. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;57 US sites; January 2001 to December 2004.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;First generation antipsychotic (FGA: perphenazine) or one of four second generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, or ziprasidone). Ziprasidone only became a treatment option after 40% of patients had been enrolled, and individuals with tardive dyskinesia (TD) were not eligible for randomisation to perphenazine. Analyses of four different datasets were carried out to ensure that participants had equal chance of being randomised to each of the groups being compared: perphenazine versus the three SGAs available at the start of the study (excluded participants with TD and those receiving ziprasidone); the three SGAs available at the start of the study versus each other; … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/84.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>383473</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/84.extract]]&gt;</url>
    <title>Therapeutics - Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Are second generation antipsychotics superior to first generation antipsychotics for reducing family burden associated with schizophrenia? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;623 family caregivers of patients with schizophrenia (SCID diagnosed) enrolled in the CATIE trial. Main exclusions for patients: schizoaffective disorder, first episode schizophrenia, treatment resistant schizophrenia, mental retardation or other cognitive disorder. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;57 US sites; January 2001 to December 2004.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;First generation antipsychotic (FGA: perphenazine) or one of four second generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, or ziprasidone). Ziprasidone only became a treatment option after 40% of patients had been enrolled, and individuals with tardive dyskinesia (TD) were not eligible for randomisation to perphenazine. Analyses of four different datasets were carried out to ensure that participants had equal chance of being randomised to each of the groups being compared: perphenazine versus the three SGAs available at the start of the study (excluded participants with TD and those receiving ziprasidone); the three SGAs available at the start of the study versus each other; … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/84.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>383473</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/84.extract]]&gt;</url>
    <title>Therapeutics - Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Are second generation antipsychotics superior to first generation antipsychotics for reducing family burden associated with schizophrenia? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;623 family caregivers of patients with schizophrenia (SCID diagnosed) enrolled in the CATIE trial. Main exclusions for patients: schizoaffective disorder, first episode schizophrenia, treatment resistant schizophrenia, mental retardation or other cognitive disorder. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;57 US sites; January 2001 to December 2004.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;First generation antipsychotic (FGA: perphenazine) or one of four second generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, or ziprasidone). Ziprasidone only became a treatment option after 40% of patients had been enrolled, and individuals with tardive dyskinesia (TD) were not eligible for randomisation to perphenazine. Analyses of four different datasets were carried out to ensure that participants had equal chance of being randomised to each of the groups being compared: perphenazine versus the three SGAs available at the start of the study (excluded participants with TD and those receiving ziprasidone); the three SGAs available at the start of the study versus each other; … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/84.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>344627</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/24.extract]]&gt;</url>
    <title>Therapeutics - Second generation antipsychotics reduce dropout rates compared with first generation antipsychotics</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Do second generation medications for schizophrenic disorders result in similar dropout rates to first generation treatments?&lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-2&gt;Dropout, predictors of dropout rates (eg, trial duration, number of treatment groups, patient type, type of dosing, inpatients, dosage and study year). &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P id=p-4&gt;Pubmed and the Cochrane Central Register of Controlled Trials were searched from 1990 to 2006.&lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P id=p-5&gt;Double blind randomised controlled trials comparing second generation antipsychotic medications versus each other, first generation antipsychotics or placebo in any adult population with a diagnosis of schizophrenia, schizoaffective or schizophreniform disorder were included. Eligible second generation drugs were risperidone, olanzapine, clozapine, quetiapine, amisulpride, ziprasidone, sertindole and aripiprazole. The proportions of patients who dropped out from each study group were calculated as well as the odds ratios and 95% CI for those studies that compared first and second generation drugs. Random effects meta-analysis was used to compare dropout rates, firstly for all studies and then for subgroups by study size (at least 30, 50 and 100 patients), dose (removing high … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/24.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATEHNS accounts.&lt;/EM&gt; &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>301711</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/115]]&gt;</url>
    <title>Therapeutics - Second generation antipsychotics reduce treatment discontinuation rates compared with haloperidol</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the relative efficacy of low dose haloperidol and second&lt;SUP&gt; &lt;/SUP&gt;generation antipsychotic (SGA) drugs for first episode schizophrenia?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;498 adults (aged 18–40 years) with a first episode of&lt;SUP&gt; &lt;/SUP&gt;DSM-IV schizophrenia, schizophreniform disorder, or schizoaffective&lt;SUP&gt; &lt;/SUP&gt;disorder (assessed using the Mini International Neuropsychiatric&lt;SUP&gt; &lt;/SUP&gt;Interview plus). Main exclusions: positive symptoms starting&lt;SUP&gt; &lt;/SUP&gt;over 2 years previously; use of antipsychotic drugs for more&lt;SUP&gt; &lt;/SUP&gt;than 2 weeks in the preceding year, or for 6 weeks at any time;&lt;SUP&gt; &lt;/SUP&gt;or known intolerance or contraindication to study drugs.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;50 sites in 13 European countries and Israel; recruitment December&lt;SUP&gt; &lt;/SUP&gt;2002 to January 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Low dose haloperidol (1–4 mg/day) or one of four SGAs:&lt;SUP&gt; &lt;/SUP&gt;amisulpride (200–800 mg/day), olanzapine (5–20 mg/day),&lt;SUP&gt; &lt;/SUP&gt;quetiapine (200–750 mg/day), or ziprasidone (40–160&lt;SUP&gt; &lt;/SUP&gt;mg/day). All drugs were given orally.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;&lt;I&gt;Primary outcome&lt;/I&gt;: rate of treatment discontinuation for any cause&lt;SUP&gt; &lt;/SUP&gt;(defined as use of a dose of study drug either higher or lower&lt;SUP&gt; &lt;/SUP&gt;than the predefined range, &lt;I&gt;&lt;NOBR&gt;. . .(Abstracted)&lt;/NOBR&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Thomas W Weickert, PhD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;University of New South Wales School of Psychiatry and the Prince of Wales Medical Research Institute, Randwick, NSW, Australia &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;Vaughan J Carr, MD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Centre for Brain &amp;amp; Mental Health Research, University of Newcastle and the Schizophrenia Research Institute, Callaghan, NSW, Australia &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;Cynthia S Weickert, PhD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;University of New South Wales School of Psychiatry, the Prince of Wales Medical Research Institute and the Schizophrenia Research Institute, Randwick, NSW, Australia &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/115" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321518</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/88]]&gt;</url>
    <title>Therapeutics - Short term CBT and sertraline, alone or in combination, reduce anxiety in children and adolescents</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EMOTIONAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Do cognitive behavioural therapy (CBT) and sertraline, alone or in combination, reduce symptoms of anxiety disorder in children and adolescents?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;488 children, aged 7–17 years with DSM-IV moderate to severe separation anxiety (3.3%), generalised anxiety disorder (6.8%), social phobia (11.3%), or more than one (78.8%) of these disorders (51.4% male; mean age 10.7 years; 74% under 13 years; 78.9% white; 74.6% middle and upper class). Exclusions: unstable medical condition; refusing to attend school; no response to two adequate trials of selective serotonin reuptake inhibitors; no response to an adequate trial of CBT; receiving other psychoactive medications; current major depressive disorder; substance abuse; unmedicated attention deficit hyperactivity disorder; lifetime history of bipolar, psychotic or pervasive developmental disorder; pregnant or sexually active without using effective contraception; or presenting acute risk to themselves or others.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;6 clinical centres in New York, Durham, Baltimore, Philadelphia, Los Angeles and Pittsburgh, USA; recruitment December 2002 to . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/88" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301983</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/80]]&gt;</url>
    <title>Therapeutics - Six-month multicomponent intervention improves postnatal depression in low-income settings</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What is the optimum way to improve treatment and recognition&lt;SUP&gt; &lt;/SUP&gt;of postnatal depression in low-income settings?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;230 women who had given birth in the previous year, and who&lt;SUP&gt; &lt;/SUP&gt;had unrecognised and untreated postnatal depression. 922 women&lt;SUP&gt; &lt;/SUP&gt;were initially approached while they were waiting for health-related&lt;SUP&gt; &lt;/SUP&gt;consultations and screened for depression using the Edinburgh&lt;SUP&gt; &lt;/SUP&gt;postnatal depression scale (EPDS; maximum score 30, higher scores&lt;SUP&gt; &lt;/SUP&gt;indicate more severe symptoms) on two separate occasions two&lt;SUP&gt; &lt;/SUP&gt;weeks apart. Those with persistent depression (EPDS score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;10&lt;SUP&gt; &lt;/SUP&gt;on both occasions) were formally assessed and those with a clinical&lt;SUP&gt; &lt;/SUP&gt;diagnosis of major depression (DSM-IV criteria assessed through&lt;SUP&gt; &lt;/SUP&gt;Mini International Neuropsychiatry Interview) were included&lt;SUP&gt; &lt;/SUP&gt;in the study. Exclusions: receiving treatment for depression,&lt;SUP&gt; &lt;/SUP&gt;pregnancy, psychotic symptoms, suicide risk, or history of &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Luis H Zayas &lt;BR&gt;Shanti K Khinduka Distinguished Professor of Social Work and Professor of Psychiatry, Washington University in St Louis, St Louis, Missouri, USA &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/80" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328821</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/4/109]]&gt;</url>
    <title>Therapeutics – SSRI plus supportive care more effective than supportive care alone for mild to moderate depression</title>
    <publicationDate>2009-11-02T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_one&gt;&lt;STRONG&gt;Question&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;!-- null --&gt;&lt;/STRONG&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Are selective serotonin reuptake inhibitors (SSRIs), in addition&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;to supportive care, more effective and cost effective than supportive&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;care alone for treating mild to moderate depression?&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;220 adults (age x 18 years) potentially requiring treatment for&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;a new episode of depression. Inclusions: symptoms present for&lt;FONT size=2&gt;&lt;SUP&gt; x &lt;/SUP&gt;&lt;/FONT&gt;8 weeks; a score of 12–19 on the 17 item Hamilton Depression&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Rating Scale (HDRS); x 1 physical symptom on the Bradford Somatic&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Inventory; no antidepressant treatment within the previous 12&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;months; and not currently receiving counselling or psychological&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;therapy. Exclusions: severe depression (HDRS score &amp;gt;19);&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;subthreshold depression (HDRS score &amp;lt;12); suicidal intent;&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;significant substance misuse; score of x 13 on the Alcohol Use&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;Disorders Identification Test questionnaire; and spoken or written&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;language skills precluding participation.&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Primary care practices around three academic centres (University&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;of Southampton, University of Liverpool, Institute of Psychiatry&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;at King’s College London).&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;
&lt;P&gt;&lt;FONT size=2&gt;&lt;!-- null --&gt;&lt;/FONT&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;P&gt;Intervention group patients were prescribed an SSRI of the general&lt;SUP&gt;&lt;FONT size=2&gt; &lt;/FONT&gt;&lt;/SUP&gt;practitioner’s &lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/4/109" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302043</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/24]]&gt;</url>
    <title>Therapeutics - Structured outpatient treatments improve some aspects of borderline personality disorder</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;What are the effects of transference-focused psychotherapy,&lt;SUP&gt; &lt;/SUP&gt;dialectical behaviour therapy and dynamic supportive treatment&lt;SUP&gt; &lt;/SUP&gt;on borderline personality disorder?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;90 adults (aged 18–50 years) with DSM-IV borderline personality&lt;SUP&gt; &lt;/SUP&gt;disorder. Main exclusions: IQ&amp;lt;80, comorbid cognitive disorders,&lt;SUP&gt; &lt;/SUP&gt;bipolar I disorder, delusional disorders, psychotic disorders,&lt;SUP&gt; &lt;/SUP&gt;delirium or current substance dependence.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Community-based private outpatient practices, New York and adjacent&lt;SUP&gt; &lt;/SUP&gt;tri-state area, USA; time period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Transference-focused psychotherapy, dialectical behaviour therapy&lt;SUP&gt; &lt;/SUP&gt;or dynamic supportive treatment for one year. Transference-focused&lt;SUP&gt; &lt;/SUP&gt;psychotherapy (TFP): twice weekly individual sessions focusing&lt;SUP&gt; &lt;/SUP&gt;on dominant affect-laden themes developing between participant&lt;SUP&gt; &lt;/SUP&gt;and therapist. Dialectical behaviour therapy (DBT): weekly individual&lt;SUP&gt; &lt;/SUP&gt;and weekly group sessions plus telephone consultation as needed,&lt;SUP&gt; &lt;/SUP&gt;aimed at teaching emotional regulation skills. Dynamic supportive&lt;SUP&gt; &lt;/SUP&gt;treatment (ST): weekly sessions supplemented with extra sessions&lt;SUP&gt; &lt;/SUP&gt;as needed, providing &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentators:&lt;/STRONG&gt;&lt;BR&gt;Bauke Koekkoek1, Bea Tiemens2 &lt;/P&gt;
&lt;P&gt;Altrecht Mental Health Care &amp;amp; Gelderse Roos Mental Health Care, Utrecht, The Netherlands&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/24" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301991</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/89]]&gt;</url>
    <title>Therapeutics - Structured patient-clinician communication using DIALOG improves patient quality of life</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does the DIALOG computer based dialogue between patient and&lt;SUP&gt; &lt;/SUP&gt;clinician affect patients’ quality of life, need for care&lt;SUP&gt; &lt;/SUP&gt;and treatment satisfaction?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;507 adults (18–65 years) with schizophrenia or related&lt;SUP&gt; &lt;/SUP&gt;disorders who were part of the caseload of 134 key workers who&lt;SUP&gt; &lt;/SUP&gt;agreed to participate. Key workers had to have a professional&lt;SUP&gt; &lt;/SUP&gt;qualification in mental health or a minimum of 1 year’s&lt;SUP&gt; &lt;/SUP&gt;professional experience in an out-patient setting.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Community psychiatric services in urban and mixed urban-rural&lt;SUP&gt; &lt;/SUP&gt;areas in Spain, The Netherlands, UK, Sweden, Germany and Switzerland;&lt;SUP&gt; &lt;/SUP&gt;December 2002 to May 2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;DIALOG plus usual care or usual care alone. DIALOG was a computer-mediated&lt;SUP&gt; &lt;/SUP&gt;structured process facilitating clinician–patient communication&lt;SUP&gt; &lt;/SUP&gt;about patient needs, delivered every 2 months for a year during&lt;SUP&gt; &lt;/SUP&gt;meetings scheduled as &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Carma Bylund &lt;/P&gt;
&lt;P&gt;Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, USA&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/89" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344628</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/1/25.extract]]&gt;</url>
    <title>Therapeutics - Subcutaneous naltrexone implants reduce opioid use in opiate dependent patients</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Question:&lt;/H3&gt;
&lt;P id=p-1&gt;Does a 6 month naltrexone implant reduce opioid use after inpatient treatment compared with usual care?&lt;/P&gt;
&lt;H3&gt;Patients:&lt;/H3&gt;
&lt;P id=p-2&gt;56 opiate dependent patients (&amp;gt;18 years) who completed an inpatient treatment programme based on drug abstinence. Exclusion criteria: pregnant, psychotic or serious liver disease (except latent hepatitis C). &lt;/P&gt;
&lt;H3&gt;Setting:&lt;/H3&gt;
&lt;P id=p-3&gt;Two addiction treatment centres, Norway; 1 January 2006-1 July 2007.&lt;/P&gt;
&lt;H3&gt;Intervention:&lt;/H3&gt;
&lt;P id=p-4&gt;Subcutaneous naltrexone implant (2.2g naltrexone) versus usual care (counselling, access to maintenance programmes, hospital and community services, as needed). &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P id=p-5&gt;&lt;EM&gt;Primary outcomes&lt;/EM&gt;: self-reported opioid use (heroin, morphine, codeine, methadone, or buprenorphine; number of days of opioid use in previous 30 days; frequency of use within the 6 month trial period); number of overdoses. Primary outcomes were derived from the Addiction Severity Index and the timeline follow-back interview technique. &lt;EM&gt;Secondary outcomes included&lt;/EM&gt;: number of participants meeting DSM-IV opioid dependence and abuse (Mini International Neuropsychiatric Interview); other drug use; depression (Beck Depression Inventory and Hopkins Symptom Checklist-depression sub-scale); and life satisfaction (Temporal Satisfaction with Life Scale ‘present'). Satisfaction with treatment over the study period and craving were … &lt;BR&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/1/25.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317822</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/50]]&gt;</url>
    <title>Therapeutics - Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=st_two&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Does switching to aripiprazole from olanzapine improve metabolic&lt;SUP&gt; &lt;/SUP&gt;status in overweight people with schizophrenia or schizoaffective&lt;SUP&gt; &lt;/SUP&gt;disorder?&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Patients with schizophrenia or schizoaffective disorder (DSM-IV-TR)&lt;SUP&gt; &lt;/SUP&gt;treated with olanzapine only (10–20 mg/day for 1–24&lt;SUP&gt; &lt;/SUP&gt;months). Inclusion criteria: body mass index &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;27; Clinical Global&lt;SUP&gt; &lt;/SUP&gt;Impressions-Severity score &lt;IMG alt="&lt;=" src="/libraryImages/Mental%20Health/contentID317822/nelhImp_0000_les.gif" border=0&gt;4. Main exclusion criteria: other&lt;SUP&gt; &lt;/SUP&gt;axis I disorder; diabetes; neurological condition or mental&lt;SUP&gt; &lt;/SUP&gt;retardation; suicide risk; alcohol or drug dependence or electroconvulsive&lt;SUP&gt; &lt;/SUP&gt;therapy 3 months prior to study; previous failure to respond&lt;SUP&gt; &lt;/SUP&gt;to aripiprazole; clinically significant ECG, blood result or&lt;SUP&gt; &lt;/SUP&gt;vital sign; pregnant, breastfeeding or not reliably using contraception&lt;SUP&gt; &lt;/SUP&gt;for the duration of the study plus 4 weeks after study completion.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Multinational (countries not stated); recruitment 30 March 2004&lt;SUP&gt; &lt;/SUP&gt;to 8 August 2006.&lt;SUP&gt; &lt;/SUP&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;/P&gt;
&lt;DIV class=st_two&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;Switch to aripiprazole (n = 88) or continued olanzapine (n =&lt;SUP&gt; &lt;/SUP&gt;85) for 16 weeks. Switch participants received up to 15 mg/day&lt;SUP&gt; &lt;/SUP&gt;aripiprazole across 2 weeks while decreasing olanzapine dose&lt;SUP&gt; &lt;/SUP&gt;to nil, then 15 &lt;NOBR&gt;&lt;EM&gt;. .&lt;/EM&gt; .(Abstracted)&lt;/NOBR&gt;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;&lt;/NOBR&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=st_two&gt;&lt;NOBR&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/50" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with ATHENS accounts.&lt;/NOBR&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>321509</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/82]]&gt;</url>
    <title>Therapeutics - Telephone based peer support can reduce postnatal depression in women at high risk</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does telephone based mother to mother peer support help prevent postnatal depression in women who have recently given birth?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;701 women identified at high risk of postnatal depression 2 weeks after childbirth (defined as Edinburgh Postnatal Depression Scale (EPDS) score &amp;gt;9). Women were identified through web based screening after routine contact by a public health nurse 24–48 h after hospital discharge. Exclusions: &amp;lt;18 years age; unable to speak English; not live birth; mother or baby not discharged from hospital; or currently taking antipsychotics or antidepressants.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Seven large health regions, Ontario, Canada; recruited from November 2004 to September 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Telephone based peer support or standard community care (control). Telephone based peer support: new mothers were matched with a peer volunteer who was recruited from the community and had attended a 4 h training session to develop skills required to provide effective support and make referrals to health professionals when needed. Peer . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/82" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302011</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/2/47]]&gt;</url>
    <title>Therapeutics - Telephone treatment support improves outcomes for depressed employees</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does telephone management and support of treatment improve individual&lt;SUP&gt; &lt;/SUP&gt;and workplace outcomes for people with depression?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;604 employees aged 18 years and over with at least moderate&lt;SUP&gt; &lt;/SUP&gt;depression (Quick Inventory of Depressive Symptomatology Self&lt;SUP&gt; &lt;/SUP&gt;Report (QIDS-SR) score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;8). Participants were identified using&lt;SUP&gt; &lt;/SUP&gt;a two-stage screening process, involving an initial survey to&lt;SUP&gt; &lt;/SUP&gt;identify those with possible depression (score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;9 on the K-6&lt;SUP&gt; &lt;/SUP&gt;screen for psychological distress) followed by telephone screening&lt;SUP&gt; &lt;/SUP&gt;using the QIDS-SR. Exclusions: history of mania or substance&lt;SUP&gt; &lt;/SUP&gt;dependence, suicidal ideation or attempts in the previous week,&lt;SUP&gt; &lt;/SUP&gt;treatment by a mental health specialist in the previous year.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;16 companies covered by the United Behavioural Health Plan in&lt;SUP&gt; &lt;/SUP&gt;the USA; recruitment between January 2004 and February 2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Telephone care management intervention or &lt;NOBR&gt;&lt;EM&gt;. . (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;Simon Gilbody &lt;/P&gt;
&lt;P&gt;Professor of Psychological Medicine and Health Services Research, University of York, York, UK &lt;BR&gt;&lt;/NOBR&gt;&lt;FONT size=2&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/2/47" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392760</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/115.extract]]&gt;</url>
    <title>Therapeutics - The Family Bereavement Program reduces problematic grief in parentally bereaved youths</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,BEREAVEMENT AND LOSS,BEREAVEMENT AND LOSS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Does the Family Bereavement Program (FBP) reduce levels of grief in parentally bereaved youths?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;156 families including 244 children and adolescents (age 8–16 years) who had experienced the death of a parent between 4 and 30 months before the start of the study. Individuals already receiving other mental health or bereavement services were excluded.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;A Southwestern metropolitan area, USA; time period not stated.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;The FBP consisted of 12 group sessions and two individual sessions and delivered over 3 months with separate groups for children, adolescents and caregivers. The sessions involved teaching skills that are thought to improve outcomes for bereaved youths, such as effective parenting skills for the caregivers and effective coping skills for the youths. The intervention was compared with a 3-month self-study control group that received three books on dealing with grief for both the youth and their care giver. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Level of grief, clinical levels of problematic grief and prolonged grief disorder. Presence and severity of grief were assessed using the 13-item Present Feeling subscale of the Texas Revised Inventory of Grief (TRIG) and the 9-item Intrusive Grief Thoughts Scale (IGTS). Clinical levels of problematic grief...&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/115.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>321512</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/84]]&gt;</url>
    <title>Therapeutics - The focus on families intervention may reduce the risk of substance use among male but not female offspring of substance users</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS,DRUG USE DISORDERS,SUBSTANCE MISUSE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does the Focus on Families (FOF) intervention reduce the risk of children of parents in methadone treatment developing a substance use disorder once teenagers/young adults?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;177 children (average age 8.2 years) of 130 families with a parent (75% mothers, average age 35.5 years) who had been in methadone treatment for at least 90 days and with at least one child aged between 3 and 14 years who lived with them at least 50% of the time.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Two methadone clinics, the Pacific Northwest, USA; recruitment 1991–1993, follow-up 2005/2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;FOF intervention plus methadone clinic treatment as usual or methadone clinic treatment as usual alone (control). FOF centred on providing parenting skills and relapse prevention training for parents through a combination of day retreat (5 h), group counselling sessions (twice weekly sessions of 1.5 h for 16 weeks) and case manager home visits (average of 17 visits). Children were actively involved in the . .(Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;/EM&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/84" target="_blank"&gt;&lt;EM&gt;Full text of the article&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>302042</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/1/23]]&gt;</url>
    <title>Therapeutics - The internet-based My Body, My Life: Body Image Program for adolescent girls improves body image and disordered eating</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,EATING DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Can an internet-based group intervention improve body image&lt;SUP&gt; &lt;/SUP&gt;and eating problems in adolescent girls?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;73 adolescent girls aged 12–18 years (mean age 14.4 years)&lt;SUP&gt; &lt;/SUP&gt;who self-identified as having body image or eating problems&lt;SUP&gt; &lt;/SUP&gt;and who had access to the internet. Main exclusions: body mass&lt;SUP&gt; &lt;/SUP&gt;index (BMI) &amp;lt;5th percentile for age and gender, diagnosis&lt;SUP&gt; &lt;/SUP&gt;of anorexia nervosa, or receiving treatment for an eating or&lt;SUP&gt; &lt;/SUP&gt;other psychiatric disorder.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;High schools in Victoria and New South Wales in Australia; time&lt;SUP&gt; &lt;/SUP&gt;period not stated.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Immediate &lt;I&gt;My Body, My Life: Body Image Program&lt;/I&gt; for Adolescent&lt;SUP&gt; &lt;/SUP&gt;Girls (http://www.latrobe.edu.au/psy/projects/bodylife/index.html)&lt;SUP&gt; &lt;/SUP&gt;or delayed start of the same programme (waiting list control).&lt;SUP&gt; &lt;/SUP&gt;The programme consisted of a guided self-help manual supported&lt;SUP&gt; &lt;/SUP&gt;through six internet-based group sessions (delivered weekly).&lt;SUP&gt; &lt;/SUP&gt;The weekly group sessions included 4–8 participants, lasted&lt;SUP&gt; &lt;/SUP&gt;&lt;I&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;!--&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;&lt;/P&gt;
&lt;P&gt;Marion F Zabinski &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Sensei, Inc, Boca Raton, USA &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/1/23" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;REFERENCES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301965</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/122]]&gt;</url>
    <title>Therapeutics - Timely encouraging letters increase attendance at first consultations at outpatient psychiatric clinics</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Does an encouraging letter reduce non-attendance for first-time&lt;SUP&gt; &lt;/SUP&gt;consultations at psychiatric outpatient clinics?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;764 adults scheduled to attend their first appointment at a&lt;SUP&gt; &lt;/SUP&gt;psychiatric outpatient clinic.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Seven inner-city outpatient clinics, Leeds, UK; recruitment&lt;SUP&gt; &lt;/SUP&gt;May 2003 to July 2004.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;"Orientation statement" letter or standard care. The brief individualised&lt;SUP&gt; &lt;/SUP&gt;letter was delivered 1–2 days before the scheduled appointment.&lt;SUP&gt; &lt;/SUP&gt;It was based on a proforma and gave details about the appointment&lt;SUP&gt; &lt;/SUP&gt;(time, name of doctor, description of clinic and appointment&lt;SUP&gt; &lt;/SUP&gt;routine, map for finding clinic and request to bring a family&lt;SUP&gt; &lt;/SUP&gt;member and any medication). Both groups received standard care,&lt;SUP&gt; &lt;/SUP&gt;including an appointment card for the clinic within the following&lt;SUP&gt; &lt;/SUP&gt;13 weeks.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt;&lt;BR&gt;&lt;I&gt;Primary outcome&lt;/I&gt;: non-attendance at first appointment. &lt;I&gt;Secondary&lt;SUP&gt; &lt;/SUP&gt;outcomes&lt;/I&gt;: hospitalisation, transfer of care, continuing attendance,&lt;SUP&gt; &lt;/SUP&gt;discharge, presentation at A&amp;amp;E or death.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt;&lt;BR&gt;99.9% for primary outcome; 98.8% for secondary outcomes.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;SUP&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;/SUP&gt;&lt;BR&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Pragmatic randomised controlled trial.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Single blind ........(Abstracted)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;NOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;ABSTRACTED FROM&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;FONT FACE="arial,verdana,helvetica" SIZE=+1 COLOR=CC3300&gt;&lt;STRONG&gt;FOOTNOTES&lt;/STRONG&gt;&lt;/FONT&gt;&lt;BR&gt;--&gt;&lt;!--&lt;HR&gt;&amp;nbsp;&lt;BR&gt;--&gt;Cynthia A Dopke, PhD &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;FONT size=-1&gt;Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA&amp;nbsp;&lt;/FONT&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/122" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321511</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/3/83]]&gt;</url>
    <title>Therapeutics - Training health visitors to identify and treat depressive symptoms with psychological approaches reduces postnatal depression</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,POSTNATAL DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;Can health visitors with special training to enhance psychological care reduce depressive symptoms in postnatal women?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;4084 women registered at participating general practices. Exclusions: &amp;lt;18 years old; unable to give informed consent; or severe mental health problems.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;101 general practices in 29 primary care trusts, Trent region, UK; recruitment April 2003 to March 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Special training for health visitors, including training in either cognitive behavioural or person centred approaches to treatment (intervention, 89 health visitors at 63 general practitioner (GP) surgeries, 2749 women) or usual care (control, 49 health visitors at 38 GP surgeries, 1335 women). Intervention groups: health visitors were trained to identify symptoms of postnatal depression in women 6–8 weeks after giving birth (Edinburgh Postnatal Depression Scale (EPDS)) and to assess mood and deliver psychological interventions. The health visitors were randomly allocated to be trained in either cognitive behavioural or person centred approaches. Therapy was delivered for 1 . . (Abstracted)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/full/12/3/83" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301868</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/4/118]]&gt;</url>
    <title>Therapeutics - Transdermal methylphenidate more effective than placebo for treating ADHD</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective and safe is transdermal methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) compared with oral methyphenidate or placebo?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;282 children (6–12 years old) with ADHD who were either stimulant naive or responsive; who had IQ &amp;gt;=80, and ADHD Rating Scale-IV total score &amp;gt;=26. Main exclusions: comorbid psychiatric diagnosis (except oppositional defiant disorder); tic disorder; seizures in past 2 years; concurrent illness potentially compromising study safety; use of certain medications including antidepressants, antipsychotics, and anxiolytics in the 30 days prior to study entry. Children who did not respond (ie, &amp;lt;25% reduction in symptoms) to the 5-week dose optimisation phase, or who had an unacceptable safety profile, were withdrawn from the study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;BR&gt;&lt;/STRONG&gt;Community-based study in the USA; performed August 2004 to February 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Daily receipt of a patch and a capsule in one of the following three combinations: methylphenidate transdermal system (MTS) plus placebo capsule, osmotic-release oral system methylphenidate (OROSM) plus . . . (Abstracted).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;James M Swanson, PhD&lt;/P&gt;
&lt;P&gt;Professor of Pediatrics, University of California, Irvine, Irvine, California, USA &lt;/P&gt;
&lt;P&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/4/118" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392766</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/119.extract]]&gt;</url>
    <title>Therapeutics - Transference-focused psychotherapy reduces treatment drop-out and suicide attempters compared with community psychotherapist treatment in borderline personality disorder</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS,SELF-HARM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;How does transference-focused psychotherapy (TFP) compare with treatment by community psychotherapists for borderline personality disorder (BPD)? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;One hundred and four female outpatients aged between 18 and 45 years with Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) BPD. Main exclusions: antisocial personality disorder, schizophrenia, bipolar I or II disorder with an episode in the past 6 months, recent substance dependency, organic pathology or mental retardation. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Two outpatient units, Germany; recruitment October 2004 to August 2006.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;TFP or community psychotherapist treatment for a year. TFP was a manualised-modified psychodynamic psychotherapy delivered in two 50 min sessions per week by a specially trained therapist. Community psychotherapists were experienced and particularly interested in people with BPDs; however, none of the therapists had specific training in manualised borderline psychotherapy. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;(1) Primary outcomes included drop-out from treatment, suicide attempts (assessed using the Cornell Interview for Suicidal and Self Harming Behaviour – Self Report). (2) Secondary … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/119.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>301980</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/11/3/77]]&gt;</url>
    <title>Therapeutics - Treatment-resistant depression: adding low dose risperidone improves symptoms</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health/ BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,DEPRESSION,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt;&lt;BR&gt;How effective is augmentation with low-dose risperidone for&lt;SUP&gt; &lt;/SUP&gt;treatment-resistant depression in adults?&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt;&lt;BR&gt;274 outpatients aged 18–65 years with DSM-IV major depressive&lt;SUP&gt; &lt;/SUP&gt;disorder who did not respond to standard antidepressant monotherapy&lt;SUP&gt; &lt;/SUP&gt;during 4 weeks’ treatment prior to randomisation (non-response&lt;SUP&gt; &lt;/SUP&gt;defined as Clinical Global Impression-Severity of Illness (CGI-S)&lt;SUP&gt; &lt;/SUP&gt;score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;4 and Carroll Depression Scale score &lt;IMG alt="&gt;=" src="http://ebmh.bmj.com/math/ges.gif" border=0&gt;20). Exclusions:&lt;SUP&gt; &lt;/SUP&gt;pregnancy; substance or alcohol use disorder; current use of&lt;SUP&gt; &lt;/SUP&gt;tricyclic antidepressant, monoamine oxidase inhibitor, antiepileptic,&lt;SUP&gt; &lt;/SUP&gt;or mood stabiliser; suicidal risk; serious medical or neurological&lt;SUP&gt; &lt;/SUP&gt;illness; treatment for attention deficit/hyperactivity disorder&lt;SUP&gt; &lt;/SUP&gt;or narcolepsy.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt;&lt;BR&gt;Outpatient clinics in public and private care settings and psychiatric&lt;SUP&gt; &lt;/SUP&gt;centres in the USA; recruitment October 2004 to November 2005.&lt;SUP&gt; &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;!-- null --&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt;&lt;BR&gt;Six weeks’ treatment augmentation with low-dose risperidone&lt;SUP&gt; &lt;/SUP&gt;(0.25 mg for the first 3 days, 0.5 mg on days 4–15, &lt;EM&gt;&lt;NOBR&gt;. . .&lt;/NOBR&gt; (Abstracted)&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Commentator:&lt;/STRONG&gt;&lt;BR&gt;James G Barbee &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;LSU Health Sciences Center, New Orleans, LA, USA &lt;/P&gt;
&lt;P&gt;&lt;FONT size=2&gt;This article has been abstracted at 150 words. &lt;A href="http://ebmh.bmj.com/cgi/content/extract/11/3/77" target="_blank"&gt;Full text of the article &lt;/A&gt;is available for users with &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:City w:st="on"&gt;&lt;st1:place w:st="on"&gt;ATHENS&lt;/st1:place&gt;&lt;/st1:City&gt; accounts&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298053</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/full/10/4/120]]&gt;</url>
    <title>Therapeutics - Watching a video of themselves experiencing delirium tremens reduces relapse rates for up to three months in people with severe alcohol dependence</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ALCOHOL MISUSE,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;ORIGINAL ARTICLE&lt;/STRONG&gt;&lt;BR&gt;Mihai A, Damsa C, Allen M, et al. Viewing videotape of themselves while experiencing delirium tremens could reduce the relapse rate in alcohol-dependent patients. Addiction 2007;102:226–31.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Question:&lt;/STRONG&gt; Does watching a video of themselves experiencing delirium tremens reduce relapse among people with alcohol dependency?&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;BR&gt;Design:&lt;/STRONG&gt; Randomised controlled trial.&lt;BR&gt;&lt;STRONG&gt;Allocation:&lt;/STRONG&gt; Concealed.&lt;BR&gt;&lt;STRONG&gt;Blinding:&lt;/STRONG&gt; Not clear.&lt;BR&gt;&lt;STRONG&gt;Follow-up period:&lt;/STRONG&gt; Six months.&lt;BR&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; One in-patient crisis unit for people with alcohol dependence, country and time period not stated.&lt;BR&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; Sixty men admitted to hospital for suspected delirium tremens, who were diagnosed as having had DSM-IV severe alcohol dependence for at least three years, and an average daily consumption of 100 g (10 international units (IU)) alcohol (based on participant and family reports). Main exclusions: history of relapse (&amp;gt;=2 previous hospitalisations, or &amp;gt;=2 relapses after other psychiatric treatments), psychotic comorbidity, receiving other drug treatments or psychotherapy, cognitive deterioration, or absence of family to provide consent.&lt;BR&gt;&lt;STRONG&gt;Intervention:&lt;/STRONG&gt; Delirium tremens video exposure or usual care. Video exposure consisted of individual viewing a video of themselves experiencing delirium tremens, with a psychiatrist explaining how symptoms were linked to alcohol dependence. All participants received a hepato-protector medication (choline, methionine, alpha-tocopherol, thiamine, riboflavin, pyridoxine, cyanocobalamin, nicotinamide and calcium pantothenate), folic acid, cinnarizine (until 1 month after hospitalisation) and vitamins (until 2 weeks after hospitalisation).&lt;BR&gt;&lt;STRONG&gt;Outcomes:&lt;/STRONG&gt; Relapse (defined as any alcohol consumption), drinking days per week, number of drinks per drinking day. Outcomes were assessed monthly using participant report and verified by their family. Breath alcohol tests were also used during the monthly visit.&lt;BR&gt;&lt;STRONG&gt;Patient follow-up:&lt;/STRONG&gt; 100%&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN RESULTS&lt;/STRONG&gt;&lt;BR&gt;Video exposure significantly reduced relapse at up to 3 months after viewing the video, but this difference was not significant after 4 months (absolute risk of relapse at 1 month: 0% with video vs 20% with usual care, p = 0.01; at 2 months: 13% with video vs 47% with usual care, p = 0.005; at 3 months: 27% with video vs 53% with usual care, p = 0.04; at 4 months: 40% with video vs 60% with usual care; at 5 months: 43% with video vs 63% with usual care; at 6 months: 47% with video vs 70% with usual care; p = 0.12 for months 4 to 6). Time to relapse was significantly longer in the video exposure group (210 days with video vs 109 days with usual care, p = 0.04). Video exposure reduced number of drinking days per relapsed participant over 6 months (11 days with video vs 24 days with usual care, p = 0.0002). The number of units consumed weekly per relapsed participant was similar in the two groups by 6 months (33 IU with video vs 36 IU with usual care; p value not reported).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;&lt;BR&gt;Showing people admitted to hospital with severe alcohol dependence a video of themselves experiencing delirium tremens reduces relapse for up to 3 months, but not at 6 months, compared with usual care alone.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383629</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/88.extract]]&gt;</url>
    <title>Therapuetics - Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Are quetiapine and lithium monotherapy effective and well-tolerated treatments for a major depressive episode in bipolar disorder?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;802 adult (aged 18–65 years) outpatients with DSM-IV-defined bipolar disorder I or II (with or without rapid cycling; =4 episodes/year to =8 per year) who were experiencing an episode of depression (onset =4 weeks; duration =1 year), Hamilton Depression Rating Scale (HDRS) score =20 and an HDRS item 1 (depressed mood) score =2. See online notes for exclusion criteria.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Multicentre throughout Europe, Canada and Asia; August 2005 to May 2007.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;300 mg/day of quetiapine, 600 mg/day of quetiapine, 600–1800 mg/day of lithium or placebo. Treatment randomisation was stratified by bipolar diagnosis (I or II) and within strata in a 2:2:1:1 ratio to quetiapine 300 mg/day, quetiapine 600 mg/day, lithium 600–1800 mg/day or placebo.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-5&gt;Primary outcome was improvement in depression measured as a change in the total score on the Montgomery-Asberg Depression Rating Scale (MADRS) from baseline to week 8. Analysis of covariance was used with baseline MADRS total score as covariate, … &lt;/P&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/88.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is avaiklable for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>392777</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/4/126.extract]]&gt;</url>
    <title>Therpeutics - Supervised injectable heroin better at reducing street heroin use than supervised injectable methadone or optimised oral methadone</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;How effective is supervised injectable treatment with medicinal heroin or methadone compared with optimised oral methadone for people with chronic heroin addiction? &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Patients&lt;/H3&gt;
&lt;P id=p-2&gt;127 people (aged 18–65 years) with chronic heroin addiction (mean length of opiate use: 16.6 years (SD 7.0)), receiving continuous treatment with oral methadone for at least 6 months at supervised clinics and regularly injecting street heroin (50% or more days in preceding 3 months). Main exclusions include regular heroin use for &amp;lt;3 years; unable to attend clinics; not resident in catchment area; co-morbid alcohol dependence; other severe medical or psychiatric disorders; and unstable use of prescription drugs.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;H3&gt;Setting&lt;/H3&gt;
&lt;P id=p-3&gt;Supervised injecting clinics in London, Darlington and Brighton, UK.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Intervention&lt;/H3&gt;
&lt;P id=p-4&gt;Optimised oral methadone was compared with supervised injectable heroin and supervised injectable methadone. Oral methadone: single dose (=80 mg/day) under supervision on 5 or more days/week for a minimum of 3 months alongside psychosocial support (‘takeaway’ methadone provided on weekends and supervision reduced if clinically appropriate); supervised injectable heroin … &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/4/126.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts. &lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313657</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.audit-commission.gov.uk/Products/NATIONAL-REPORT/9F4E760A-70C4-47e6-80D0-E7B37AF237E4/tiredofhangingaround28jan09REP.pdf]]&gt;</url>
    <title>Tired of hanging around</title>
    <publicationDate>2009-01-28T00:00:00</publicationDate>
    <publisher>Audit Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,ATTENTION-DEFICIT / HYPERACTIVITY DISORDER,CONDUCT DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Abstract:&lt;/STRONG&gt;&amp;nbsp;This study focuses on the role of sport and leisure activities in preventing anti-social behaviour in young people aged 8 to 19 years. These activities are part of the actions that councils and their partners can use to tackle and prevent anti-social behaviour. This study recognises, but does not cover, local agencies' work with families and young children or the role of schools in helping to prevent or address anti-social behaviour.]]&gt;</body>
  </document>
  <document>
    <id>327461</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scotland.gov.uk/Resource/Doc/271822/0081031.pdf]]&gt;</url>
    <title>Towards a Mentally Flourishing Scotland: Policy and Action Plan 2009-2011</title>
    <publicationDate>2009-05-07T00:00:00</publicationDate>
    <publisher>The Scottish Government</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,MENTAL HEALTH PROMOTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This policy and action plan outlines the Government's plans for mental health improvement for the period 2009-2011.]]&gt;</body>
  </document>
  <document>
    <id>377683</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/2/64.extract]]&gt;</url>
    <title>Treatment - Limited evidence that antipsychotic drug treatment is associated with reduced brain volume</title>
    <publicationDate>2010-05-28T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHRONIC (PERSISTENT) PSYCHOTIC DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;H3&gt;Question:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-1&gt;What is the impact of antipsychotic medications on brain volume and are there differences in the brain volumes of antipsychotic-naïve patients and healthy controls? &lt;/P&gt;
&lt;H3&gt;Outcomes:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-2&gt;Overall brain volume, grey matter volume, lobar volumes, cerebrospinal fluid (CSF) volume and subcortical ventricular spaces, measured using MRI. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;H3&gt;Design:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-3&gt;Systematic review.&lt;/P&gt;
&lt;H3&gt;Data sources:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-4&gt;Medline searches for studies published between 1995 and April 2009.&lt;/P&gt;
&lt;H3&gt;Study selection and analysis:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P id=p-5&gt;To look at the effect of antipsychotic medication, longitudinal MRI studies were included that compared, at 6-month follow-up, brain-volume changes in patients with schizophrenia or psychosis and taking antipsychotics with that in healthy individuals. To look at whether there are baseline differences in brain-volume, studies looking at neuroleptic-naive patients or patients with minimal treatment (=4 weeks) compared with healthy controls were included. Research works that focused on people from ‘high-risk’ samples, who were considered to be at high risk of psychosis due to genetic loading or subclinical symptoms, were also included.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-8 class="section results"&gt;
&lt;H2&gt;Main results&lt;/H2&gt;
&lt;P id=p-6&gt;A total of 26 longitudinal studies were identified that satisfied inclusion criteria. The studies involved a … &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/2/64.full" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>383739</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/94.extract]]&gt;</url>
    <title>Treatment - Review: befriending modestly reduces depressive symptoms in varied populations</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;Is befriending effective in the treatment of depressive symptoms?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-2&gt;&lt;EM&gt;Primary outcome:&lt;/EM&gt; depressive symptoms; &lt;EM&gt;secondary outcome&lt;/EM&gt;: perceived social support. &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV id=methods class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review with meta-analysis.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources&lt;/H3&gt;
&lt;P id=p-4&gt;MEDLINE, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (nursing), Campbell Collaboration Register (SPECTR-C2 and SRPOC), Web of Knowledge, National Research Register, PsiTri (Register of Clinical Trials in Mental Health), International Standard Randomised Controlled Trial Registry, Meta Trials Register and the Department of Health Research Findings Register were searched in July-August 2007, with an update in April 2008. Hand searching of reference lists of relevant studies was also carried out. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis&lt;/H3&gt;
&lt;P id=p-5&gt;Randomised controlled trials looking at the effects of befriending on depressive symptoms on participants living in the community were included. Included studies could compare befriending with usual care, no treatment or active treatments (including other types of befriending, medications or psychological treatments). Participants were not required to have a diagnosis of depression or specific baseline levels of distress to be included in the study. Befriending was defined as the introduction of one or more volunteer or paid individuals … &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/94.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>383781</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/content/13/3/95.extract]]&gt;</url>
    <title>Treatment - Review: exercise programmes reduce anxiety symptoms in sedentary patients with chronic illnesses</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=sec-1 class=section&gt;
&lt;DIV id=sec-2 class=subsection&gt;
&lt;H3&gt;Question&lt;/H3&gt;
&lt;P id=p-1&gt;What is the effect of exercise training on anxiety in people with chronic illness, and what are the moderators of this effect?&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P id=p-2&gt;&lt;EM&gt;Primary outcome:&lt;/EM&gt; change in anxiety scores; &lt;EM&gt;primary moderators:&lt;/EM&gt; exercise session duration, programme length, fitness change, intervention type, comparator intervention type and time frame of anxiety report. &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV id=methods class="section methods"&gt;
&lt;H2&gt;Methods&lt;/H2&gt;
&lt;DIV id=sec-5 class=subsection&gt;
&lt;H3&gt;Design&lt;/H3&gt;
&lt;P id=p-3&gt;Systematic review and meta-analysis.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-6 class=subsection&gt;
&lt;H3&gt;Data sources&lt;/H3&gt;
&lt;P id=p-4&gt;The Physical Activity Guidelines for Americans Scientific Database (maintained by the US Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion) was searched for articles published between January 1995 and August 2007. Google Scholar, MEDLINE, PsycINFO, PubMed and Web of Science were searched in December 2008. Hand searches of relevant articles were also carried out. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-7 class=subsection&gt;
&lt;H3&gt;Study selection and analysis&lt;/H3&gt;
&lt;P id=p-5&gt;Randomised controlled trials (RCTs) comparing exercise intervention lasting at least three weeks versus no exercise intervention in sedentary adults with chronic illness. Other inclusion criteria: English language articles, anxiety outcome measured at baseline and after exercise training. Studies that included exercise as part of a multi-component intervention which did not use the non-exercise components as the comparator were excluded, … &lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;&lt;BR&gt;&lt;EM&gt;This article has been abstracted to 150 words. &lt;A href="http://ebmh.bmj.com/content/13/3/95.full" target="_blank"&gt;Full text of this article&lt;/A&gt; is available via ATHEN login.&lt;/EM&gt;]]&gt;</body>
  </document>
  <document>
    <id>268360</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=23153&amp;Rendition=Web]]&gt;</url>
    <title>Treatment choice in psychological therapies and counselling: Evidence based clinical practice guideline</title>
    <publicationDate>2001-02-19T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>These clinical practice guidelines were developed to aid decisions about which forms of psychological therapy are most appropriate for which patients.</description>
    <body>&lt;![CDATA[ &lt;P&gt;These clinical practice guidelines were developed to aid decisions about which forms of psychological therapy are most appropriate for which patients. They address who is likely to benefit from psychological treatment, and which of the main therapies available in the NHS is most appropriate for which patients. They also consider which other factors need to be taken into consideration. The guidelines have been produced by a multi-disciplinary guideline development group, led by the British Psychological Society, and they have undergone extensive independent scientific review.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;amp;dID=23153&amp;amp;Rendition=Web" target="_blank"&gt;Download full text of guideline &lt;/A&gt;(PDF)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;amp;dID=590&amp;amp;Rendition=Web" target="_blank"&gt;Treatment choice in psychological therapies and counselling: Evidence based clinical practice guideline&lt;/A&gt; (Download PDF leaflet)&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268330</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38732&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Turned Upside Down</title>
    <publicationDate>2001-01-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This report shows the results of a baseline research project which aimed to develop conceptual models of community-based crisis services for young people aged 16-25. A unique feature of this research was the involvement of 45 young people with experience of mental health crisis.</description>
    <body>&lt;![CDATA[ This report shows the results of a baseline research project which aimed to develop conceptual models of community-based crisis services for young people aged 16-25. A unique feature of this research was the involvement of 45 young people with experience of mental health crisis.]]&gt;</body>
  </document>
  <document>
    <id>388576</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.centreformentalhealth.org.uk/pdfs/under_the_radar.pdf]]&gt;</url>
    <title>Under the radar</title>
    <publicationDate>2010-09-14T00:00:00</publicationDate>
    <publisher>Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Women with borderline personality disorder in prison&lt;/H3&gt;
&lt;P&gt;Borderline personality disorder (BPD) is a serious condition characterized by pervasive instability in moods, relationships, self-image and behaviour. People suffering from this disorder often struggle with a mixture of emotions and engage in risky, impulsive behaviours.&lt;/P&gt;
&lt;P&gt;Under the Radar shows that women prisoners with borderline personality disorder often come from an unstable family environment. The report calls for better diversion from custodial sentences for women with a personality disorder and increased training for prison staff. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388587</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://download.bps.org.uk/downloadfile.asp?file_uuid=1A30EE9C-BD4C-43B0-2313-4D14F44EAA60&amp;ext=pdf&amp;fromServer=www.bps.org.uk&amp;randomID=4397C0F3-0B01-20D9-248962326B6C3F7A]]&gt;</url>
    <title>Understanding Bipolar Disorder - Why some people experience extreme mood states and what can help</title>
    <publicationDate>2010-09-16T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,BIPOLAR DISORDER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A tendency to extreme moods can have significant benefits as well as sometimes leading to problems, says a report published today, 15 September 2010, by the British Psychological Society’s Division of Clinical Psychology.&lt;/P&gt;
&lt;P&gt;The report, Understanding Bipolar Disorder, is the result of an in-depth review of recent research undertaken by a team of leading university academics and clinical psychologists, led by Professor Steven Jones of Lancaster University.&lt;/P&gt;
&lt;P&gt;Between one and two percent of the population have a diagnosis of bipolar disorder, which was previously known as manic depression. This diagnosis is made when someone experiences periods of extreme mood (highs and lows).&lt;/P&gt;
&lt;P&gt;Understanding Bipolar Disorder suggests that such experiences are more extreme forms of the mood variation we all experience. They can result from life experiences as well as from brain chemistry alone and it is not always helpful to think of them as an illness.&lt;/P&gt;
&lt;P&gt;Professor Richard Bentall, Professor of Clinical Psychology at the University of Bangor, says:&lt;/P&gt;
&lt;BLOCKQUOTE&gt;
&lt;P&gt;"This is a timely and clearly written report, which very neatly summarises our current understanding of bipolar disorder in a way that is authoritative, but very accessible to service users, carers and the general public. It will do much to promote a better understanding of a condition that can cause a great deal of distress and disability to sufferers and their families."&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;Understanding Bipolar Disorder can be &lt;A href="http://www.bps.org.uk/document-download-area/document-download$.cfm?file_uuid=1A30EE9C-BD4C-43B0-2313-4D14F44EAA60" target="_blank"&gt;downloaded from this website&lt;/A&gt; without charge until &lt;STRONG&gt;31 October 2010&lt;/STRONG&gt;.&lt;/P&gt;
&lt;P&gt;After that it will be sold through the BPS Shop.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347115</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.bpsshop.org.uk/BJEP-Monograph-Series-II-Part-7-Number-Development-and-Difficulties-non-institutional-use-P1130.aspx]]&gt;</url>
    <title>Understanding number development and difficulties</title>
    <publicationDate>2010-03-23T00:00:00</publicationDate>
    <publisher>The British Psychological Society</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS,SCHOOL REFUSAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2&gt;This is for No. 7 of the series: Understanding Number Development and Diffculties &lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;Edited by Vincent Connelly, Anna L. Barnett, Julie E. Dockrell and Andrew Tolmie&lt;/EM&gt; &lt;/P&gt;Proficiency with numbers is important for everyday life, employment, and the study of natural and social sciences. Understanding what promotes number development and why children differ are important for achieving national goals for primary education and because difficulties at primary school predict difficulties in adulthood. Differences between children in their mathematical attainment are not decreasing and some evidence suggests they are increasing. Understanding this diversity involves considerations of the roles of the environment, general cognitive factors and specific number skills. 
&lt;P&gt;This monograph features contributions from eminent developmental psychologists who have been concerned to make connections between developmental psycholgy and the theory and practice of education, particularly in mathematics. Their research is advancing understanding of the factors responsible for diversity in children's mathematical attainment and interventions that are effective in supporting mathematical development. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347124</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nmhdu.org.uk/silo/files/untold-problems-a-review-of-the-essential-issues-in-the-mental-health-of-men-and-boys.pdf]]&gt;</url>
    <title>Untold problems: A review of the essential issues in the mental health of men and boys</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>The National Mental Health Development Unit</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,INDIVIDUAL BEHAVIOUR,MENTAL &amp; BEHAVIOURAL DISORDERS,MALE,MONTHLY ADDITIONS,SERVICE PROVISION,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; POLICY,POPULATIONS,GENDER,APRIL 2010,ANTISOCIAL BEHAVIOUR]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This review is about the mental health of men and boys. It considers mental health from a male perspective and explores how good mental health can be achieved and maintained.&lt;BR&gt;&lt;BR&gt;It also looks the kinds of mental health problems that men and boys experience and asks how services can most effectively respond. To our knowledge this is the first time that the relevant evidence has been brought together and considered in this way.]]&gt;</body>
  </document>
  <document>
    <id>378416</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nepho.org.uk/securefiles/100622_1157//Microsoft%20Word%20-%20Use%20of%20mental%20health%20services%20by%20minority%20ethnic%20groups%20in%20England%20FINAL%20REVISED%20VERSION%20JUNE%202010.pdf]]&gt;</url>
    <title>Use of mental health services by minority ethnic groups in England</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>North East Public Health Observatory</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,PUBLIC HEALTH ORGANISATIONS,ETHNIC GROUPS,ETHNICITY,MENTAL &amp; BEHAVIOURAL DISORDERS,MONTHLY ADDITIONS,PUBLIC HEALTH,POPULATIONS,ORGANISATIONS,CULTURAL IDENTITY,GROUPS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=publication_markdown&gt;
&lt;P&gt;Over the last decade, four new types of mental health care have been introduced in the English NHS. This study examines how far these have been used in the care of minority ethnic groups.&lt;/P&gt;
&lt;P&gt;The study was based on specially collected surveys. All PCTs reported numbers of users of Crisis Resolution / Home Treatment (CRHT), Early Intervention in psychosis (EI) and Assertive Outreach (AO) teams as part of the NHS Information Centre 'Omnibus' returns for the final quarter of 2008/09. At the same time, the 13 PCTs with first wave services in the new Improving Access to Psychological Therapies (IAPT) programme supplied reports of numbers referred to and entering services and numbers finishing treatment and moving towards recovery.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>268332</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38663&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>User/ Survivor Research Update</title>
    <publicationDate>2003-11-03T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on the development of mental health user/survivor research on mental health in the UK, with reference to the work of the Strategies for Living programme.</description>
    <body>&lt;![CDATA[ Update briefing on the development of mental health user/survivor research on mental health in the UK, with reference to the work of the Strategies for Living programme.]]&gt;</body>
  </document>
  <document>
    <id>268333</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38662&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>User-centred Initiatives Update</title>
    <publicationDate>2003-04-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing reviewing the development of the service user phenomenon and implications for future action.</description>
    <body>&lt;![CDATA[ Update briefing reviewing the development of the service user phenomenon and implications for future action. In introducing Guiding Lights, a new project concentrating on user-centred initiatives, it suggests that a range of different formations and activities are now taking shape which will map out the as-yet unnamed territory beyond mere ‘user involvement’.]]&gt;</body>
  </document>
  <document>
    <id>317788</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://ebmh.bmj.com/cgi/content/extract/12/2/33]]&gt;</url>
    <title>Uses and abuses of the Hare psychopathy Checklist</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Evidence Based Mental Health / BMJ Publishing Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,PERSONALITY (BEHAVIOURAL) DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Notions of psychopathic personality and personality disorder&lt;SUP&gt; &lt;/SUP&gt;have a lengthy history within criminal justice and mental health&lt;SUP&gt; &lt;/SUP&gt;settings. Issues of how to assess and intervene with this group&lt;SUP&gt; &lt;/SUP&gt;of individuals also continue to present significant challenges&lt;SUP&gt; &lt;/SUP&gt;for both services. Those categorised as psychopathic or personality&lt;SUP&gt; &lt;/SUP&gt;disordered may behave in ways that are seriously damaging both&lt;SUP&gt; &lt;/SUP&gt;to themselves and to others. There has also been frequent criticism&lt;SUP&gt; &lt;/SUP&gt;and, at times, castigation of services for failing to engage&lt;SUP&gt; &lt;/SUP&gt;with these groups and protect the public effectively.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ebmh.bmj.com/cgi/content/extract/12/2/33" target="_blank"&gt;Full text of the article&lt;/A&gt; is available for users with ATHENS accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388532</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=388532]]&gt;</url>
    <title>Vitamin B clue to dementia</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Vitamin B clue to dementia&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;“Vitamin B tablets could slow and even halt the devastating march of Alzheimer's disease,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reported. According to the newspaper, large daily doses of vitamin B can halve the rate of brain shrinkage, a process that can precede Alzheimer’s disease and dementia.&lt;/P&gt;
&lt;P&gt;This story is based on a well-conducted two-year trial, which compared vitamin B pills with inactive placebo pills in 271 elderly people with mild memory problems. The study found that those given vitamin B experienced brain shrinkage (atrophy) 30% slower than those given inactive tablets. However, slower brain shrinkage may not necessarily lead to any improvement in symptoms. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>268355</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&amp;dID=3795&amp;Rendition=Web]]&gt;</url>
    <title>Vocational services for people with severe mental health problems: Commissioning guidance</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,COMMISSIONING,SERVICE SECTORS,MENTAL HEALTH SERVICES,POPULATIONS SERVED,SERVICE DEVELOPMENT,ASSESSMENT AND PLANNING,DISEASE/CONDITION GROUPS,PERFORMANCE MANAGEMENT,MENTAL HEALTH PROBLEMS,PEOPLE WITH MENTAL HEALTH PROBLEMS,OUTCOMES,COMMISSIONING PROCESS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This guidance provides commissioners of mental health services with a framework to commission evidence-based vocational services for people with severe mental health problems and provide the tools to monitor the effectiveness of such services.</description>
    <body>&lt;![CDATA[ This guidance provides commissioners of mental health services with a framework to commission evidence-based vocational services for people with severe mental health problems and provide the tools to monitor the effectiveness of such services.]]&gt;</body>
  </document>
  <document>
    <id>392201</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/walking-may-fight-dementia.aspx]]&gt;</url>
    <title>Walking and dementia studied</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>NHS Choices - Behind the Headlines</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Walking just one mile a day could keep dementia at bay,” according to the &lt;EM&gt;Daily Express.&lt;/EM&gt; The newspaper said that pensioners who walk between six and nine miles a week are 50% less likely to suffer from future memory problems.&lt;/P&gt;
&lt;P&gt;The story comes from a study which looked at how physical activity (measured by walking) in elderly adults might be associated with any brain volume and risk of cognitive decline. It found that elderly people who reported walking the most at the start of the study showed higher volumes of grey matter in particular areas of the brain when tested nine years later. This increased grey matter was also associated with a 50% reduction in cognitive impairment.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268334</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40847&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>We need to talk</title>
    <publicationDate>2006-10-02T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>We Need to Talk argues that evidence-based talking therapies such as cognitive behavioural therapy are as important for the nation’s health as any cancer drug or surgical procedure.</description>
    <body>&lt;![CDATA[ We Need to Talk argues that evidence-based talking therapies such as cognitive behavioural therapy are as important for the nation’s health as any cancer drug or surgical procedure. Evidence shows that they can help millions of people in the UK who experience common and severe mental health problems.]]&gt;</body>
  </document>
  <document>
    <id>268334</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40847&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>We need to talk</title>
    <publicationDate>2006-10-02T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>We Need to Talk argues that evidence-based talking therapies such as cognitive behavioural therapy are as important for the nation’s health as any cancer drug or surgical procedure.</description>
    <body>&lt;![CDATA[ We Need to Talk argues that evidence-based talking therapies such as cognitive behavioural therapy are as important for the nation’s health as any cancer drug or surgical procedure. Evidence shows that they can help millions of people in the UK who experience common and severe mental health problems.]]&gt;</body>
  </document>
  <document>
    <id>392215</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mind.org.uk/assets/0001/0027/Mind_We_need_to_talk_Report.pdf]]&gt;</url>
    <title>We need to talk</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>MIND</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P sizset="28" sizcache="50"&gt;A &lt;A class="popup pdf doclink ga_link" title="Report: We need to talk. Link opens in a new window." href="http://www.mind.org.uk/assets/0001/0027/Mind_We_need_to_talk_Report.pdf" target="_blank"&gt;new report released today&lt;/A&gt; by Mind for the &lt;A href="http://www.mind.org.uk/campaigns_and_issues/we_need_to_talk" target="_blank"&gt;We Need To Talk coalition &lt;/A&gt;has called on the Government to fulfil its promise to make psychological therapies available across the country to people who need them.&lt;/P&gt;
&lt;P sizset="28" sizcache="50"&gt;The report found that the &lt;A href="http://www.dh.gov.uk/en/Healthcare/Mentalhealth/Psychologicaltherapies/index.htm" target="_blank"&gt;Improving Access to Psychological Therapies (IAPT)&lt;/A&gt; scheme has had a dramatic impact on waiting times for people with depression and anxiety. However across England 1 in 5 people are still waiting over a year to access psychological therapies such as Cognitive Behavioural Therapy (CBT) or counselling. This is despite respondents to Mind’s survey reporting that access to the right therapy at the right time had a significant impact on their ability to return to work.&lt;/P&gt;
&lt;P&gt;Access to psychological therapies for children and for people with severe mental illnesses remains limited despite good evidence of their effectiveness. As the Government puts the final touches to the Comprehensive Spending Review, the coalition is urging investment in a full range of evidence based psychological therapies to all who need them, within 28 days of requesting referral.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392215</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mind.org.uk/assets/0001/0027/Mind_We_need_to_talk_Report.pdf]]&gt;</url>
    <title>We need to talk</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>MIND</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P sizset="28" sizcache="50"&gt;A &lt;A class="popup pdf doclink ga_link" title="Report: We need to talk. Link opens in a new window." href="http://www.mind.org.uk/assets/0001/0027/Mind_We_need_to_talk_Report.pdf" target="_blank"&gt;new report released today&lt;/A&gt; by Mind for the &lt;A href="http://www.mind.org.uk/campaigns_and_issues/we_need_to_talk" target="_blank"&gt;We Need To Talk coalition &lt;/A&gt;has called on the Government to fulfil its promise to make psychological therapies available across the country to people who need them.&lt;/P&gt;
&lt;P sizset="28" sizcache="50"&gt;The report found that the &lt;A href="http://www.dh.gov.uk/en/Healthcare/Mentalhealth/Psychologicaltherapies/index.htm" target="_blank"&gt;Improving Access to Psychological Therapies (IAPT)&lt;/A&gt; scheme has had a dramatic impact on waiting times for people with depression and anxiety. However across England 1 in 5 people are still waiting over a year to access psychological therapies such as Cognitive Behavioural Therapy (CBT) or counselling. This is despite respondents to Mind’s survey reporting that access to the right therapy at the right time had a significant impact on their ability to return to work.&lt;/P&gt;
&lt;P&gt;Access to psychological therapies for children and for people with severe mental illnesses remains limited despite good evidence of their effectiveness. As the Government puts the final touches to the Comprehensive Spending Review, the coalition is urging investment in a full range of evidence based psychological therapies to all who need them, within 28 days of requesting referral.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322813</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.audit-commission.gov.uk/localgov/nationalstudies/Pages/whenitcomestothecrunch12aug2009_copy.aspx]]&gt;</url>
    <title>When it comes to crunch - How councils are responding to the recession</title>
    <publicationDate>2009-08-12T00:00:00</publicationDate>
    <publisher>Audit Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DOMESTIC VIOLENCE OR PARTNER ABUSE,INNOVATION AND IMPROVEMENT,ORGANISATIONS,ADAPTIVE ORGANISATIONS,EVALUATION,ECONOMIC]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report is the second in a series of Audit Commission reports looking at how local authorities are responding to the 2008/09 recession. The report finds that local and national government have made a positive initial response to the recession, but it warns that councils should prepare for worsening social impact as unemployment rises. Demand for benefits, welfare and help with debt are growing, and social problems such as domestic violence and mental ill-health are expected to follow as the recession deepens.]]&gt;</body>
  </document>
  <document>
    <id>291052</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mind.org.uk/NR/rdonlyres/FBC70E3F-15E5-492D-8D53-D38397409DE6/0/WhilewearewaitingJul08.pdf]]&gt;</url>
    <title>While we are waiting: Experiences of waiting for and receiving psychological therapies on the NHS</title>
    <publicationDate>2008-07-25T00:00:00</publicationDate>
    <publisher>We Need to Talk</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DEPRESSION,GENERALIZED ANXIETY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A group of leading mental health charities has published a report which says that the lives of those stuck on long NHS waiting lists for psychological treatments are being damaged as a result. Mental health problems can worsen, relationships can break down and some people are forced to take time off from work - or give up a job completely - according to While we are waiting.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A group of leading mental health charities has published a report which says that the lives of those stuck on long NHS waiting lists for psychological treatments are being damaged as a result. Mental health problems can worsen, relationships can break down and some people are forced to take time off from work - or give up a job completely - according to While we are waiting.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;National clinical guidelines recommend that psychological treatments, such as cognitive behavioural therapy and psychotherapy, should be made available on the NHS. But such therapies remain difficult to access and the wait for patients is long – often more than six months, sometimes years.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;One participant who took part in the report's research said: "The assessment was incredible…I felt that someone finally understood. When I was told that the wait after assessment was two years it felt like a real let down, offering a life line and [then] snatching it away."&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The report comes ahead of the roll out of the Government's Improving Access to Psychological Therapies (IAPT) programme, which is expected to bring 3,600 extra therapists to half of England's primary care trusts (PCTs) in the next three years and to reduce waiting times in those areas dramatically.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333122</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2009/9789241563918_eng.pdf]]&gt;</url>
    <title>WHO Report on the global tobacco epidemic, 2009: Implementing smoke-free environments</title>
    <publicationDate>2009-12-09T00:00:00</publicationDate>
    <publisher>World Health Organization</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,DRUG USE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The report is the second in a series about the extent of the global tobacco epidemic and measures to stop it. It includes the latest global and country figures on the prevalence of tobacco use and on the measures' impacts.]]&gt;</body>
  </document>
  <document>
    <id>268335</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=40193&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Whose Life is it anyway?</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report on the effects of poor work-life balance on mental health.</description>
    <body>&lt;![CDATA[ A report on the effects of poor work-life balance on mental health.]]&gt;</body>
  </document>
  <document>
    <id>268336</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38665&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Women at the Crossroads Update</title>
    <publicationDate>2003-08-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on 'Women at the Crossroads: A literature review of the mental health risks facing women in midlife'. The review highlights the key dimensions of the lives of mid-life women which do - or might be expected to - have an impact on their emotional and psychological well-being.</description>
    <body>&lt;![CDATA[ Update briefing on 'Women at the Crossroads: A literature review of the mental health risks facing women in midlife'. The review highlights the key dimensions of the lives of mid-life women which do - or might be expected to - have an impact on their emotional and psychological well-being.]]&gt;</body>
  </document>
  <document>
    <id>268337</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38664&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Women's Mental Health Update</title>
    <publicationDate>2002-12-02T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,FEMALE,WOMEN,POLICY,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,SOCIOECONOMIC FACTORS,SOCIAL DETERMINANTS,INFORMATION,MANAGEMENT &amp; POLICY,GROUPS,GENDER,POPULATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on the Department of Health's (England) consultation document on women’s mental health care: 'Women’s Mental Health: Into the Mainstream'.</description>
    <body>&lt;![CDATA[ Update briefing on the Department of Health's (England) consultation document on women’s mental health care: 'Women’s Mental Health: Into the Mainstream'.]]&gt;</body>
  </document>
  <document>
    <id>346087</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.its-services.org.uk/silo/files/working-towards-womens-wellbeing-unfinished-business.pdf]]&gt;</url>
    <title>Working towards Women's Well-being: Unfinished business</title>
    <publicationDate>2010-03-17T00:00:00</publicationDate>
    <publisher>National Mental Health Development Unit (NMHU)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PREVENTATIVE HEALTHCARE,LIFESTYLE AND SOCIAL ISSUES,ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,MENTAL &amp; BEHAVIOURAL DISORDERS,MONTHLY ADDITIONS,SERVICE PROVISION,WOMEN'S HEALTH,PUBLIC HEALTH,DETERMINANTS,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,APRIL 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Working Towards Women's Well-being is a progress report measuring the extent of policy and mental health organisational progress since the publication of 'Into the Mainstream', women's mental health strategy in 2002 and implementation guide 'Mainstreaming Gender and Women's Mental Health' in 2003.]]&gt;</body>
  </document>
  <document>
    <id>317662</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.scie.org.uk/pmhcwg/index.asp]]&gt;</url>
    <title>Working with parents with mental health problems and their children</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>SCIE</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Welcome to the consultation on SCIE’s draft guidance for working with parents with mental health problems and their children. Please take time to read the guidance document before you answer the consultation questions.]]&gt;</body>
  </document>
  <document>
    <id>268341</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38667&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Work-Life Balance Update</title>
    <publicationDate>2003-04-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Update briefing on the Foundation's report 'Whose Life is it Anyway?' The survey asked people to record their working hours as well as travelling time and time outside work devoted to work-related thinking or problem solving.</description>
    <body>&lt;![CDATA[ Update briefing on the Foundation's report 'Whose Life is it Anyway?' The survey asked people to record their working hours as well as travelling time and time outside work devoted to work-related thinking or problem solving. It also asked them to describe their feelings when working long hours, what made them work long hours if they did so, and what activities they spend less time on when working more hours than usual.]]&gt;</body>
  </document>
  <document>
    <id>111334</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111334]]&gt;</url>
    <title>Workplaces</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,ENVIRONMENTAL,OUTCOMES,EDUCATION,MENTAL &amp; BEHAVIOURAL DISORDERS,POPULATION BASED &amp; PREVENTATIVE SERVICES,POLICY,DETERMINANTS,PUBLIC HEALTH,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,SERVICES,INFORMATION,MANAGEMENT &amp; POLICY,WORKPLACE,BUILDINGS,SETTINGS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Workplaces&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111333:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111326:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;The case for action&lt;/H2&gt;
&lt;P&gt;Many factors in the workplace influence the mental health of individual employees, of particular sections or departments and of the whole organisation. A positive working environment and appropriate support at work has a significant impact on stress related sickness absence and long term outcomes for employees experiencing mental distress (ref 1, 2).&lt;/P&gt;
&lt;P&gt;Workplace health promotion programmes ideally should not only focus on individual behaviour and threats arising from the chemical, physical and biological environments, but should also include a focus on the ‘newly recognised threats to health’ arising from the psycho-social environment (ref 3, 4).&lt;/P&gt;
&lt;P&gt;Overall, working has a positive effect on people’s mental health. In addition to financial benefits, work is an important source of support, providing social and information networks, a sense of purpose and personal identity. Enhancing social support within the workplace for people working in a stressful environment can help to reduce mental health problems among employees (ref 5). Clarity and consistency of information and emotional support have a significant impact on employee health and well-being (ref 2). Social support at work is a protective factor against the negative impact of excessive job demands, notably from managers to their staff (ref 6, 7, 8).&lt;/P&gt;
&lt;P&gt;Many of the factors that influence both the physical and mental health of staff are psycho-social and relate to style of management and working culture. For example, lack of job control is associated with alcohol dependence, poor mental health, poor health function and increased sickness absence (ref 2, 9, 10). In both men and women, high job demands and low social support at work have been found to be predictive of depression. (ref 11, 12).&lt;/P&gt;
&lt;P&gt;A study over 25 years showed that job strain (high job demands combined with low job control) and effort reward imbalance are associated with a doubling of risk of cardiovascular disease (ref 13). Bullying is linked to low job satisfaction, work related stress, depression and anxiety and research has found a link between bullying and increases in sickness absence (ref 14, 15).&lt;/P&gt;
&lt;P&gt;Although individuals can take steps to promote their own mental well-being, mental health issues need to be addressed systemically, at an organisational rather than an individual level (ref 2, 8, 16). For example consulting and listening to staff can make them feel more secure and valued, notably at times of organisational change which are associated with an increase in mental health problems and prevalence of smoking (ref 17).&lt;/P&gt;
&lt;P&gt;Consequently mental health promotion is relevant to many broader aspects of employment including health and safety, equal opportunities, bullying and harassment, work/life balance, terms and conditions of employment, performance management and pay. In addition, changes in employment legislation such as the Disability Discrimination Act mean that employers need to assess their practice in relation to people with mental health problems (ref 18). Implementing a workplace mental health promotion provides a framework which can facilitate a mentally healthy workplace (ref 19 , 20).&lt;/P&gt;
&lt;H2&gt;Evidence based priorities:&lt;/H2&gt;
&lt;P&gt;All the evidence suggests that an effective policy to improve health at work must tackle work organisation and management practice. Key elements of an effective mental health promotion strategy include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;redressing effort/reward imbalance&lt;/LI&gt;
&lt;LI&gt;improving communications and staff involvement&lt;/LI&gt;
&lt;LI&gt;enhancing social support, especially from managers to subordinates&lt;/LI&gt;
&lt;LI&gt;increasing job control and decision making latitude&lt;/LI&gt;
&lt;LI&gt;assessing job demands&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;(see &lt;A href="nelh:111308:1" name=internalLink&gt;making connections – the workplace&lt;/A&gt;)&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Workplace – summary of the evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Organisation wide approaches are most effective and should include support for staff, enhanced job control, increased staff involvement, workload assessment, effort/reward balance, role clarity and policies to tackle bullying and harassment.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Social support&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Clarity and consistency of information and emotional support have a significant impact on employee health and well-being (ref 2, 6, 7). Social support at work is a protective factor against the negative impact of excessive job demands, notably from managers to their staff.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Workplace trauma&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is a lack of evidence that debriefing following trauma in workplace settings is effective and some evidence which suggests that it is harmful (ref 21).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Stress&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Counselling can achieve a reduction in work related stress. It helps people who are stressed to cope better but does not prevent or identify the structural sources of workplace stress (ref 22). Consulting and listening to staff can make them feel more secure and valued, notably in times of organisational change, which are associated with an increase in mental health problems and prevalence of smoking (ref 17).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Job control and decision making latitude&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Lack of control is associated with alcohol dependence, poor mental health, poor health function and increased sickness absence (ref 2, 9, 10). &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bullying and harrassment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Explicit policies and procedures for dealing with bullying, support from line management, an understood grievances procedure and a workplace culture that challenges bullying behaviour. Bullying is linked to low job satisfaction, work related stress, depression and anxiety (ref 13, 14, 15) found a link between bullying and increases in sickness absence.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Effort/Reward imbalance&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Effort reward imbalance is associated with increased risk of alcohol dependence (especially in men), psychiatric disorders, sickness absence and poor overall health (ref 2). It may not be possible to reduce effort, but increasing rewards may include psychological, training, promotion and other options. Involving staff in addressing issues around effort/reward imbalance can help to identify what kinds of benefits/recognition they would value, if additional financial reward is not an option.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Improving the health of the NHS workforce&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A systematic review of the literature presented evidence on interventions aimed at improving employee health, six of which were conducted with healthcare staff. Seven interventions were aimed at improving general physical and psychological problems and the reviewers describe the findings from these programmes. Initiatives targeting the culture of the workplace, communications and job design were given precedence over those aiming to change individual employee behaviour. These points reflect a core principle of the review, that management style clearly affects employee health (ref 23).&lt;/P&gt;
&lt;P&gt;These findings were supported by primary quantitative and qualitative research on the health of NHS staff. Management style and good internal communications were identified by employees as crucial to their mental health and well-being (ref 6).&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111333:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111326:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Sainsbury Centre for Mental Health (1998) &lt;A href="http://www.scmh.org.uk/8025695100388752/GenerateFrameset1?OpenAgent&amp;amp;doc=wpASTN4SVFQN" target="_blank"&gt;Keys to Engagement: Review of Care for People with severe mental illness who are hard to engage with services&lt;/A&gt;. London: SCMH&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Stansfeld S, Head J and Marmot M (2000) Work Related Factors and Ill Health: the Whitehall II Study HSE: Suffolk&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Karasek R and Theorell T (1995) Health work: stress, productivity and thereconstruction of working life. London: Harper Collins&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Springett J and Dugdill L (1995) Workplace health promotion programmes: towards a framework for evaluation. Health Education Journal. 54: 88-98&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Heaney C, Price R &amp;amp; Rafferty J (1995) Increasing coping resources at work: a field experiment to increase social support, improve work team functioning and enhance employee mental health Journal of Organisational Behaviour 16:335-352&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Health Education Authority (1999) More to work than this: Evaluation of the Health at Work in the NHS Programme. London: Health Education Authority&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Holloway F, Szmukler G, Carson J (2000) Support Systems Advances in Psychiatric Treatment 6: 226-235&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Health and Safety Executive (2001) Tackling work-related stress. Norwich:&lt;A href="http://www.hse.gov.uk/" target="_blank"&gt;HSE&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Cheng Y, Kawachi I, Coakley E, Schwartz J, Colditz G (2000) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/320/7247/1432?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074852156120_1594&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=320&amp;amp;firstpage=1432&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Association between psychosocial work characteristics and health functioning in American Women&lt;/A&gt; British Medical Journal 320:1432-1436.&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Niedhammer I, Goldberg M et al (1998) Psychosocial work environment and cardiovascular risk factors in an occupational cohort in France J. Epidemiology &amp;amp; Community Health 52: 93-100.&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Paterniti S, Niedhammer I, Lang T and Consoli SM (2002) &lt;A href="http://bjp.rcpsych.org/cgi/content/full/181/2/111?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074852401161_804&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=181&amp;amp;firstpage=111&amp;amp;resourcetype=1" target="_blank"&gt;Psychosocial factors ar work, personality traits and depressive symptoms&lt;/A&gt;. The British Journal of Psychiatry 181: 111-117.&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Pattani S, Constantivovici N and Williams S (2001) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7280/208?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074852457008_1674&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=322&amp;amp;firstpage=208&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Who retires early from the NHS because of ill health and what does it cost?&lt;/A&gt; British Medical Journal 322: 208-209.&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Kivimaki M, Leino-Arjas P, Luukkonen R, Riihimaki H, Vahtera J and Kirjonen J (2000a) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/325/7369/857?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074852233103_1620&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=325&amp;amp;firstpage=857&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Work stress and risk of cardiovascular mortality: prospective cohort study of industrial employees&lt;/A&gt;. British Medical Journal 325: 857.&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Kivimaki M, Elovainio M, Vahtera J (2000b) Workplace Bullying and sickness absence in hospital staff Occupational and Environmental Medicine 57: 656-660.&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Quine L (1999) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/318/7178/228?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074852539556_1695&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=318&amp;amp;firstpage=228&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Workplace Bullying in NHS Community Trust: Staff Questionnaire&lt;/A&gt; BMJ 318:228-232.&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Cooper C and Cartwright S (1996) Mental Health and Stress in the Workplace. Norwich:HMSO.&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Ferrie JE, Shipley MJ, Marmot M et al (1998) An uncertain future: the health effects of threats to employment security in white collar men and women American Journal of Public Health 88:1030-6.&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Department of Health (2002) &lt;A href="http://www.dh.gov.uk/assetRoot/04/06/03/81/04060381.pdf" target="_blank"&gt;Mental health and employment in the NHS&lt;/A&gt;. London:The Stationery Office.&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;&lt;A href="http://www.mentality.org.uk/" target="_blank"&gt;mentality&lt;/A&gt; (2002) A Toolkit for Workplace Mental Health Promotion. Leicester: Trent Workforce Development Confederation.&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;&lt;A href="http://www.mentality.org.uk/" target="_blank"&gt;mentality&lt;/A&gt; (2003) Mental Health in the Workplace – finding the key to inclusion. London: Greater London Authority.&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Yamey G (2000) &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/320/7228/140?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1074852795663_1969&amp;amp;stored_search=&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=320&amp;amp;firstpage=140&amp;amp;resourcetype=1,2,3,4" target="_blank"&gt;Psychologists question ‘debriefing’ for traumatised employees&lt;/A&gt; British Medical Journal 320:140.&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;British Association for Counselling and Psychotherapy (2001) Counselling in the workplace: the facts Rugby:BACP.&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;Williams S, Michie S, Pattani S (1998) Improving the health of the NHS Workforce: report of the partnership on the health of the NHS Workforce Leeds: The Nuffield Trust.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Other &lt;/P&gt;
&lt;P&gt;Perkins R, Hardisty J et al (2001) User employment programme: progress report London: South West and St George’s Mental Health NHS Trust.&lt;/P&gt;
&lt;P&gt;Price RH, Van Ryn M, Vinokur AD (1992) Impact of a preventive job search intervention on the likelihood of depression among the unemployed Journal of health and social behaviour 33: 158-167.&lt;/P&gt;
&lt;P&gt;Smith AP et al (2000) The Scale of Occupational Stress: The Bristol Stress and Health at Work Study HSE.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>270341</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=270341]]&gt;</url>
    <title>World Mental Health Day October 10 2007 - Mental Health in a Changing World: The Impact of Culture and Diversity</title>
    <publicationDate>2007-10-10T00:00:00</publicationDate>
    <publisher>World Federation for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ ADULT CONDITIONS,MENTAL HEALTH,OUTCOMES,LANGUAGE,DISADVANTAGED GROUPS,ETHNIC GROUPS,RELIGION,HEALTH BELIEFS,ETHNICITY,MENTAL &amp; BEHAVIOURAL DISORDERS,PUBLIC HEALTH,DETERMINANTS,PSYCHOLOGICAL DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,HEALTH BELIEFS,SOCIETY,HEALTHCARE &amp; HEALTH SERVICES,HEALTH SERVICES,PROFESSIONAL PRACTICE,THERAPY,INTERNATIONAL ISSUES,GEOGRAPHY,POPULATIONS,CULTURAL IDENTITY,BELIEFS,SETTINGS,GROUPS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>A 51-page report on Mental Health in a Changing World.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;World Mental Health Day October 10 2007 - Mental Health in a Changing World: The Impact of Culture and Diversity&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Contents:&lt;/H2&gt;
&lt;UL&gt;
&lt;LI&gt;Introduction&lt;/LI&gt;
&lt;LI&gt;The Impact of Culture on Services and Public Understanding&lt;/LI&gt;
&lt;LI&gt;The Impact of Culture across the Life Span&lt;/LI&gt;
&lt;LI&gt;Special Aspects of Migrants and other Displaced Populations&lt;/LI&gt;
&lt;LI&gt;Best Practices in Transcultural Mental Health&lt;/LI&gt;
&lt;LI&gt;Mental Health in a Changing World: Call to Action&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;There are approximately 6.5 billion people living on planet Earth. Within that number, there are more people living outside their country of origin than at any other time in history. One person out of 35 is an international migrant — 3% of the global population. If we look at our world today, is there any single culture, race or religion that is 100% contained in one single country? We can find dramatically different languages, religions, family relationships and values, as well as views on health care and treatment wherever we go, including in our own respective countries. A female mental health professional born and trained in India may have moved to the United Kingdom and is seeing a male client born and raised in Ecuador — how do they communicate and how do each view the same mental illness?&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Culture may influence many aspects of mental health, including how individuals from a given culture communicate and manifest their symptoms, their style of coping, their family and community supports, and their willingness to seek treatment. Likewise, the cultures of the clinician and the service system influence diagnosis, treatment, and service delivery. Cultural and social influences are not the only determinants of mental illness and patterns of service use, but they do play important roles.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;In the mental health care setting, culture impacts how people:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Label and communicate distress&lt;/LI&gt;
&lt;LI&gt;Explain the causes of mental health problems&lt;/LI&gt;
&lt;LI&gt;Perceive mental health providers&lt;/LI&gt;
&lt;LI&gt;Utilize and respond to mental health treatment&lt;/LI&gt;&lt;/UL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388578</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.centreformentalhealth.org.uk/pdfs/Centre_for_MH_Healthcare_provision_YOTs.pdf]]&gt;</url>
    <title>You just get on and do it</title>
    <publicationDate>2010-09-07T00:00:00</publicationDate>
    <publisher>Centre for Mental Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;Healthcare provision in Youth Offending Teams&lt;/H3&gt;
&lt;P&gt;Children and young people in the youth justice system are at high risk of multiple health inequalities and poor life chances. Research indicates that these young people have their needs under identified and supported after entry into the Youth Justice System.&lt;/P&gt;
&lt;P&gt;This paper shows the results of our study of healthcare provision in YOTs in England. We also reviewed mental health diversion work along the youth justice pathway to look at how these services might be better developed to improve outcomes for young people and their families.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>111328</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//mentalHealth/ViewResource.aspx?resID=111328]]&gt;</url>
    <title>Young people</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>mentality</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH PROMOTION,MENTAL HEALTH,OUTCOMES,EDUCATION,ENVIRONMENTAL,EDUCATION,RISK FACTORS,CHILDREN,YOUNG PEOPLE,MENTAL &amp; BEHAVIOURAL DISORDERS,DEPRESSION,EATING DISORDERS,DISADVANTAGED GROUPS,DETERMINANTS,PUBLIC HEALTH,SOCIOECONOMIC FACTORS,SOCIETY,SOCIAL DETERMINANTS,INDIVIDUAL BEHAVIOUR,AGE GROUPS,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Young people&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;lt;&lt;A href="nelh:111327:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111329:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;H2&gt;The case for action&lt;/H2&gt;
&lt;P&gt;Mental health is about maintaining a good level of personal and social functioning. For children and young people, this means getting on with others, both peers and adults, participating in educative and other social activities, and having a sense of positive self-esteem. It is also about coping and adjusting to the demands of growing up (ref 1, 2).&lt;/P&gt;
&lt;P&gt;The social context which children and young people now inhabit has changed considerably in recent years. There has been a breakdown in communities and traditional patterns of employment, higher rates of parental separation and the emergence of more isolation and smaller family units. As a result of the increase in social fragmentation many young people do not have the same number of adult role models as in the past and a significant proportion grow up in one-parent families (ref 3).&lt;/P&gt;
&lt;P&gt;In parallel with these changes young people now face increased demands and challenges. They are exposed to more performance measurement within schools and are regularly targeted by the media and advertising. They no longer experience much of a protected stage of childhood. (ibid)&lt;/P&gt;
&lt;P&gt;These increased social pressures are taking their toll on the young who are now suffering from various forms of mental distress to a greater extent than previously. A House of Commons select committee estimated that 10-20 per cent of young people will experience a mental health problem serious enough to require professional help during their lifetime (ref 4). One-third of younger teenagers in the UK claim to feel ‘stressed’ or ‘depressed’ (ref 5).&lt;/P&gt;
&lt;P&gt;Although a significant proportion of mental health promotion for young people is delivered within schools there are a number of opportunities to promote the mental health of young people outside school and to work with networks of young people in the community. This is particularly important as children grow older and often spend more time with their friends than with their family (ref 6). Peer group pressure is particularly significant in early adolescence (ref 7).&lt;/P&gt;
&lt;P&gt;For older children, programmes to promote mental and social well-being are likely to improve the overall effectiveness of health promotion both within schools and in other settings. Work to address self-esteem, communication and negotiation skills, media influences, social, cultural and gendered norms will have a significant impact on the effectiveness of health promotion with young people.&lt;/P&gt;
&lt;P&gt;For example, findings from research with 15-16 year olds in the East Midlands indicate that for many young people, smoking has certain benefits in terms of coping with uncertain identities and being ‘in control’ of themselves and their lives (ref 8). This suggests the potential significance of addressing mental well-being as part of an overall strategy to tackle risk-taking behaviours.&lt;/P&gt;
&lt;P&gt;The growing gap between the health of young women and young men, and the apparent impact of gender roles on the experience and expression of mental distress, has led to calls for a much greater emphasis on different approaches for young men and young women (ref 9,10). Self esteem, peer pressure, identity and coping styles are all important influences on young people’s mental health and all have significant gender elements.&lt;/P&gt;
&lt;P&gt;Health risk behaviour is also an important aspect of expressing or acquiring gender identity (ref 11). For example, young men are three times more likely to be alcohol dependent than young women and twice as likely to be drug dependent (ref 12). There is a strong case for paying more attention to gender issues in developing interventions for young people.&lt;/P&gt;
&lt;P&gt;For young people with a range of risk factors, including young people in care and leaving care and young people in prisons, addressing mental health needs may be fundamental to improving overall health and well-being (ref 13). 67% of a sample of in-care adolescents had a diagnosable mental health problem (ref 14). Up to half of rough sleepers have some kind of mental health problem, with the majority becoming ill before they became homeless (ref 15) (see &lt;A href="nelh:111308:1" name=internalLink&gt;making connections – young people and schools&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Young people – summary of the evidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Effective programmes are most likely to be those that involve young people in their design and delivery as well as in their evaluation and monitoring.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Depression and young people&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Given that one third of people who have met the criteria for major depression in their lifetimes report that the first attack occurred before the age of 21 (ref 16), prevention must take place in young people if it is to be effective. Depression is usually caused by a combination of genetic vulnerability, negative early developmental experiences, and exposure to stresses. Physical illness may be another factor. Continuity between childhood and adult depression has been demonstrated, making recognition and treatment of childhood depression very important (ref 17).&lt;/P&gt;
&lt;P&gt;Systematic review level evidence demonstrated the efficacy of cognitive behavioural therapy (CBT) for moderate, but not severe, depression amongst children and adolescents (ref 18). However there seemed to be a significant amount of spontaneous remission in moderately severe juvenile depression and so the reviewers make a strong case for using brief supportive interventions as the first line of treatment and keeping CBT for patients who fail to respond. (see &lt;A href="nelh:111333:1" name=internalLink&gt;Schools&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anti-bullying programmes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A whole system approach to mental health promotion in young people is reflected in anti-bullying schemes developed in Norway. These programmes involve the whole school, parents and the community. For example a bullying/victimisation questionnaire was used both to assess the level of the problem and also as a catalyst to increase awareness and involvement. Additional components of the programme included a day conference to discuss questionnaire results, the creation of a bullying prevention coordinating committee and the development of a coordinated structure for monitoring student behaviour during periods of increased student interaction. Follow-up of participating students at 8 and 20 months found a 50% reduction in bully/victim problems for boys and girls across all grades with more marked effects after two years than after one year. There were also significant reductions in anti-social behaviour such as vandalism, fighting, truancy, theft and drunkenness (ref 19, 20)&lt;BR&gt;(See &lt;A href="nelh:111333:1" name=internalLink&gt;schools)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Early interventions with adolescents&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A systematic literature review on evidence-based early intervention programmes for youth mental health found insufficient good research from which to draw any conclusions about the types of programmes that might be most beneficial (ref 21). Studies targeting the 14-24 year old age range were considered if they aimed to prevent the development of mental health conditions relating to substance abuse, conduct disorder, mood, eating disorders or anxiety. The lack of research in this age range may reflect a focus by programmes on intervening in middle childhood rather than adolescence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Eating disorder prevention programmes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A systematic review of prevention research in eating disorders found only 20 studies, the majority of which were designed to target and measure change on an individual level (ref 22). Even though most publications on eating disorders make some reference to the wider social context, the role of socio-cultural factors in eating disorders is absent from the studies. This ignores the dominant cultural belief that the body is malleable and that one can and should strive to change the size and form of one’s body (ref 23).&lt;/P&gt;
&lt;P&gt;A more recent Cochrane review (ref 24) tried to determine whether eating disorder prevention programmes had a positive impact on children and adolescents. The results of the review, based on eight studies, did not allow for any firm conclusions to be drawn.&lt;BR&gt;Barriers to and facilitators of good mental health for young people&lt;BR&gt;A review on the effectiveness of intervention programmes that aim to prevent mental illness or promote mental health amongst young people age 11-21 yrs found little evidence of effective programmes (ref 25). The review included a review of systematic reviews, a review of outcome evaluations and a review of British qualitative studies on young people’s views on mental health promotion.&lt;/P&gt;
&lt;P&gt;Interventions to promote positive self-esteem are more likely to be effective if self-esteem is the main focus of the intervention, rather than just one component of a broad mental health initiative. There was some evidence that discussing suicide with young people could encourage some of them to consider it a viable option for resolving problems.&lt;/P&gt;
&lt;P&gt;The qualitative review demonstrated that asking young people about mental health was ineffective. They tended to equate mental health with mental illness - and so as a problem belonging to other people and not relevant to their own lives. Young people showed a good understanding of useful mental health coping strategies. Many traditional health promotion materials and approaches are out of step with young people's pragmatic, everyday worries and interests. Research and evaluation should involve young people in its design and delivery.&lt;/P&gt;
&lt;P&gt;&amp;lt;&lt;A href="nelh:111327:1" name=internalLink&gt;previous page&lt;/A&gt;&amp;gt; &amp;lt;&lt;A href="nelh:111329:1" name=internalLink&gt;next page&lt;/A&gt;&amp;gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;&lt;A href="http://www.dfes.gov.uk/mentalhealth" target="_blank"&gt;Department for Education and Skills&lt;/A&gt; (2001) Promoting children’s mental health within early years and school settings. London: The Stationery Office&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Mental Health Foundation (1999) Bright Futures – promoting children and young people’s mental health. London: &lt;A href="http://www.mentalhealth.org.uk/" target="_blank"&gt;Mental Health Foundation&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Weare K (2000) Developing Mental, Emotional and Social Health: A Whole School Approach. London: Routledge.&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Mind (1997) The Bird and the Word: Materials for Mental Health Education in Secondary Schools. London:&lt;A href="http://www.mind.org.uk/" target="_blank"&gt;Mind&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Gordon J and Grant G (1997) How We Feel. London: Jessica Kingsley.&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Morrow V (2002) Children’s experiences of community’:implications of social capital discourses. In Health Education Authority Social Capital and Health:Isights from Qualitative Research. London: Health Education Authority&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Heaven P (1994) Contemporary adolescence: a social psychological approach. London: MacMillan&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Denscombe M (2001) Uncertainties identities and health-risking behaviour: the case of young people and smoking in late modernity. British Journal of Sociology 52 (1): 157-177&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Health Development Agency (2001) Boys’ and Young Men’s Health: Literature and practice review. London: Health Development Agency&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Meryn S and Jadad AR (2001) The future of men and their health. &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/323/7320/1013" target="_blank"&gt;British Medical Journal&lt;/A&gt; 323: 1013-1014&lt;/P&gt;
&lt;P&gt;11. &lt;A href="http://www.workingwithmen.org/" target="_blank"&gt;Working with Men&lt;/A&gt;&amp;nbsp;(2001) (&lt;A href="http://www.workingwithmen.org/" target="_blank"&gt;www.workingwithmen.org&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Coleman J and Schofield J (2000) Key data on adolescence. Brighton: Trust for the Study of Adolescence&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Big Step (2002) The health of young people in care and leaving care in Glasgow. Glasgow: Big Step&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;McCann J, James A, Wilson S and Dunn G (1996) Prevalence of psychiatric disorders in young people in the care system. &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/313/7071/1529" target="_blank"&gt;British Medical Journal&lt;/A&gt; 313: 1529-1530.&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Social Exclusion Unit (1998) Rough Sleeping: &lt;A href="http://www.socialexclusionunit.gov.uk/downloaddoc.asp?id=240" target="_blank"&gt;A Report by the Social Exclusion Unit&lt;/A&gt; London: Social Exclusion Unit&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Andrews G (2001) Should depression be managed as a chronic disease? &lt;A href="http://bmj.bmjjournals.com/cgi/content/full/322/7283/419" target="_blank"&gt;British Medical Journal&lt;/A&gt; 322:419-421&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Birmaher B, Ryan ND, Williamson DE and Brent DA (1996) Childhood and adolescent depression: a review of the past ten years. Journal of American Academy for Child and Adolescent Psychiatry 35: 1427 - 1439&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Harrington R, Whittaker J, Shoebridge P and Campbell F (1998) Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. British Medical Journal 316: 1559-1563&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Olweus D (1993) Bullying at school: What we know and what we can do. London:Blackwell&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Olweus D (1995) Bullying or peer abuse at school: facts and interventions. Current Directions in Psychological Science. 4:196-200&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Nicholas B and Broadstock M (1999) Effectiveness of early interventions for preventing mental illness in young people: a critical appraisal of the literature. NZHTA Report 1999; 2(3). New Zealand Health Technology Assessment Clearing House&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;Bryn Austin S (2000) Prevention research in eating disorders: theory and new directions. Psychological Medicine 30: 1249-1262&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;Becker AE and Hamburg P (1996) Culture, the media and eating disorders. Harvard Review of Psychiatry 4: 163-167&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp;Pratt BM and Woolfenden SR (2002) &lt;A href="http://www.cochrane.org/cochrane/revabstr/AB002891.htm" target="_blank"&gt;Interventions for preventing eating disorders in children and adolescents&lt;/A&gt; (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;Harden A, Rees R, Shepherd J, Brunton G, Oliver S and Oakley A (2001) Young people and mental health: a systematic review of research on barriers and facilitators. London:&lt;A href="http://eppi.ioe.ac.uk/EPPIWeb/home.aspx?page=/hp/reports/mental_health/mental_health.htm" target="_blank"&gt;EPPI-Centre&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>268342</id>
    <name>&lt;![CDATA[ Mental Health]]&gt;</name>
    <rootDirectory>/mentalHealth</rootDirectory>
    <url>&lt;![CDATA[http://www.mhf.org.uk/EasysiteWeb/getresource.axd?AssetID=38742&amp;type=Full&amp;servicetype=Attachment]]&gt;</url>
    <title>Young people have a say!</title>
    <publicationDate>1999-01-01T00:00:00</publicationDate>
    <publisher>Mental Health Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,CHILD AND ADOLESCENT CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Report on the findings of a qualitative analysis of six focus groups held with young people aged 12-25, looking at their views about the services and professionals they had been in contact with.</description>
    <body>&lt;![CDATA[ Report on the findings of a qualitative analysis of six focus groups held with young people aged 12-25, looking at their views about the services and professionals they had been in contact with.]]&gt;</body>
  </document>
</documents>